Images	O

Figure	O
1	O

Figure	O
2	O

Figure	O
3	O

Figure	O
4	O

Immunostaining	O
and	O
confocal	O
analysis	O

DNA	O
labelling	O
and	O
staining	O
with	O
5	O
-	O
bromo	O
-	O
2	O
'	O
-	O
deoxyuridine	O
(	O
BrdU	O
labelling	O
and	O
detection	O
kit	O
I	O
;	O
Boehringer	O
Mannheim	O
,	O
Germany	O
)	O
was	O
performed	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

The	O
nucleoli	O
were	O
detected	O
with	O
an	O
anti	O
-	O
nucleolin	O
antibody	O
(	O
clone	O
3G4B2	O
;	O
Upstate	O
biotechnology	O
,	O
Lake	O
Placid	O
,	O
NY	O
)	O
on	O
cells	O
fixed	O
in	O
2	O
%	O
formalin	O
for	O
10	O
min	O
followed	O
by	O
permeabilization	O
with	O
ice	O
-	O
cold	O
methanol	O
for	O
30	O
min	O
.	O

The	O
secondary	O
antibody	O
used	O
for	O
both	O
BrdU	O
and	O
nucleoli	O
staining	O
was	O
a	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
-	O
conjugated	O
goat	O
anti	O
-	O
mouse	O
antibody	O
(	O
T	O
-	O
2762	O
)	O
from	O
Molecular	O
Probe	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O

The	O
cells	O
were	O
examined	O
in	O
a	O
Zeiss	O
LSM	O
510	O
laser	O
scanning	O
microscope	O
equipped	O
with	O
a	O
Plan	O
-	O
Apochromate	O
63x	O
/	O
1	O
.	O
4	O
oil	O
immersion	O
objective	O
.	O

We	O
used	O
the	O
488	O
nm	O
laser	O
line	O
for	O
excitation	O
of	O
EGFP	O
(	O
detected	O
at	O
505	O
nm	O
<	O
lambdaEGFP	O
<	O
530	O
nm	O
)	O
and	O
the	O
543	O
nm	O
laser	O
line	O
for	O
rhodamine	O
(	O
tetra	O
-	O
methyl	O
)	O
(	O
detected	O
at	O
lambdaRhodamine	O
>	O
560	O
nm	O
)	O
.	O

ECFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
458	O
nm	O
laser	O
line	O
(	O
detected	O
at	O
480	O
nm	O
<	O
lambdaECFP	O
<	O
520	O
nm	O
)	O
,	O
EYFP	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
514	O
nm	O
laser	O
line	O
(	O
lambdaEGFP	O
>	O
560	O
nm	O
)	O
and	O
HcRed	O
fusion	O
protein	O
was	O
excited	O
with	O
a	O
543	O
nm	O
laser	O
line	O
and	O
detected	O
at	O
>	O
585	O
or	O
650	O
nm	O
.	O

The	O
images	O
were	O
from	O
1	O
mum	O
thick	O
slices	O
of	O
the	O
cells	O
.	O

The	O
images	O
were	O
exported	O
into	O
Adobe	O
Photoshop	O
(	O
Adobe	O
Systems	O
Inc	O
.	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
.	O

(	O
a	O
)	O
Schematic	O
drawing	O
of	O
the	O
magnetic	O
tweezers	O
.	O

A	O
DNA	O
molecule	O
is	O
attached	O
at	O
one	O
end	O
to	O
the	O
bottom	O
of	O
the	O
flow	O
cell	O
and	O
at	O
the	O
other	O
end	O
to	O
a	O
magnetic	O
bead	O
.	O

This	O
molecule	O
can	O
be	O
pulled	O
and	O
twisted	O
using	O
small	O
magnets	O
placed	O
above	O
the	O
flow	O
cell	O
.	O

The	O
position	O
of	O
the	O
magnetic	O
bead	O
is	O
measured	O
using	O
an	O
inverted	O
microscope	O
placed	O
beneath	O
the	O
flow	O
cell	O
.	O

The	O
bead	O
position	O
and	O
thus	O
the	O
end	O
-	O
to	O
-	O
end	O
distance	O
of	O
the	O
DNA	O
molecule	O
is	O
determined	O
using	O
video	O
microscopy	O
and	O
image	O
analysis	O
.	O

(	O
b	O
)	O
Extension	O
of	O
a	O
DNA	O
molecule	O
versus	O
the	O
number	O
of	O
turns	O
applied	O
by	O
the	O
magnets	O
for	O
various	O
stretching	O
forces	O
.	O

At	O
low	O
force	O
,	O
contraction	O
of	O
the	O
molecule	O
is	O
symmetrical	O
under	O
positive	O
and	O
negative	O
applied	O
turns	O
.	O

At	O
higher	O
force	O
,	O
the	O
molecule	O
'	O
s	O
extension	O
initially	O
remains	O
constant	O
for	O
positive	O
applied	O
turns	O
.	O

The	O
induced	O
torque	O
increases	O
linearly	O
with	O
the	O
number	O
of	O
applied	O
turns	O
,	O
as	O
depicted	O
in	O
the	O
top	O
graph	O
until	O
a	O
buckling	O
transition	O
allows	O
the	O
system	O
to	O
saturate	O
its	O
torsional	O
constraint	O
through	O
the	O
formation	O
of	O
plectonemes	O
.	O

Effect	O
of	O
Trail	O
on	O
the	O
expression	O
of	O
endogenous	O
M2	O
.	O

(	O
A	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
level	O
of	O
endogenous	O
M2	O
protein	O
.	O

The	O
expression	O
level	O
of	O
endogenous	O
M2	O
protein	O
in	O
HeLa	B
cells	O
was	O
determined	O
using	O
western	O
blot	O
4	O
h	O
following	O
Trail	O
(	O
250	O
mug	O
/	O
ml	O
)	O
treatment	O
.	O

(	O
B	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
endogenous	O
M2	O
mRNA	O
.	O

The	O
expression	O
level	O
of	O
endogenous	O
M2	O
mRNA	O
in	O
HeLa	B
cells	O
was	O
detected	O
using	O
RNase	O
protection	O
assay	O
4	O
h	O
following	O
Trail	O
(	O
250	O
mug	O
/	O
ml	O
)	O
treatment	O
.	O

(	O
C	O
)	O
Effect	O
of	O
Trail	O
on	O
the	O
synthesis	O
of	O
endogenous	O
M2	O
protein	O
.	O

HeLa	B
cells	O
were	O
first	O
treated	O
with	O
250	O
mug	O
/	O
ml	O
Trail	O
followed	O
by	O
pulse	O
labeling	O
of	O
newly	O
synthesized	O
proteins	O
with	O
[	O
35S	O
]	O
methionine	O
.	O

M2	O
protein	O
was	O
then	O
immunoprecipitated	O
and	O
separated	O
by	O
SDS	O
-	O
PAGE	O
for	O
autoradiography	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

The	O
most	O
highly	O
represented	O
gene	O
ontology	O
themes	O
in	O
the	O
neurosphere	O
vs	O
.	O
differentiated	O
cells	O
comparison	O
(	O
F	O
-	O
G	O
)	O
.	O

Planning	O
for	O
the	O
Future	O
:	O
Disaster	O
Preparedness	O
and	O
Mitigation	O

It	O
is	O
often	O
believed	O
that	O
casualties	O
from	O
natural	O
disasters	O
are	O
unavoidable	O
,	O
but	O
this	O
belief	O
is	O
false	O
[	O
8	O
]	O
.	O

There	O
are	O
many	O
measures	O
that	O
can	O
reduce	O
morbidity	O
and	O
mortality	O
following	O
large	O
and	O
potentially	O
catastrophic	O
flooding	O
events	O
[	O
19	O
]	O
.	O

Early	O
warning	O
of	O
impending	O
floods	O
and	O
natural	O
events	O
such	O
as	O
hurricanes	O
allows	O
sufficient	O
time	O
for	O
communities	O
to	O
be	O
evacuated	O
to	O
safe	O
areas	O
.	O

Although	O
Florida	O
experienced	O
one	O
of	O
the	O
worst	O
hurricane	O
seasons	O
on	O
record	O
in	O
2004	O
,	O
the	O
number	O
of	O
fatalities	O
was	O
lower	O
than	O
expected	O
because	O
of	O
early	O
warning	O
and	O
evacuation	O
.	O

Early	O
warning	O
also	O
provides	O
sufficient	O
time	O
to	O
prepare	O
when	O
evacuation	O
is	O
not	O
possible	O
.	O

Hurricane	O
George	O
in	O
1998	O
caused	O
widespread	O
damage	O
and	O
several	O
fatalities	O
in	O
the	O
Dominican	O
Republic	O
,	O
where	O
residents	O
were	O
not	O
warned	O
.	O

In	O
contrast	O
,	O
Cuba	O
and	O
Puerto	O
Rico	O
experienced	O
relatively	O
limited	O
damage	O
and	O
loss	O
of	O
life	O
,	O
because	O
preparations	O
were	O
made	O
in	O
the	O
hours	O
before	O
the	O
storm	O
.	O

Disaster	O
preparedness	O
can	O
also	O
be	O
developed	O
for	O
communities	O
that	O
are	O
regularly	O
exposed	O
to	O
flooding	O
disasters	O
.	O

Cyclone	O
shelters	O
built	O
by	O
the	O
Red	O
Cross	O
in	O
Orissa	O
,	O
India	O
,	O
saved	O
many	O
thousands	O
of	O
lives	O
in	O
1999	O
when	O
two	O
cyclones	O
struck	O
.	O

In	O
the	O
region	O
of	O
the	O
Americas	O
,	O
the	O
Pan	O
American	O
Health	O
Organization	O
has	O
spent	O
many	O
years	O
promoting	O
and	O
integrating	O
disaster	O
preparedness	O
into	O
building	O
health	O
facilities	O
to	O
ensure	O
that	O
medical	O
services	O
needed	O
to	O
treat	O
victims	O
and	O
maintain	O
ongoing	O
care	O
for	O
patients	O
with	O
chronic	O
conditions	O
will	O
not	O
be	O
disrupted	O
by	O
disasters	O
.	O

A	O
recent	O
global	O
-	O
scale	O
review	O
of	O
health	O
risks	O
from	O
flooding	O
highlights	O
that	O
in	O
flood	O
-	O
prone	O
areas	O
,	O
disaster	O
preparedness	O
within	O
the	O
health	O
system	O
as	O
a	O
whole	O
is	O
particularly	O
important	O
[	O
20	O
]	O
.	O

In	O
addition	O
to	O
infrastructure	O
and	O
early	O
-	O
warning	O
systems	O
,	O
another	O
key	O
element	O
in	O
disaster	O
preparedness	O
is	O
education	O
and	O
raising	O
awareness	O
about	O
disaster	O
risks	O
and	O
response	O
plans	O
.	O

Had	O
there	O
been	O
greater	O
awareness	O
about	O
the	O
risk	O
of	O
tsunamis	O
,	O
perhaps	O
many	O
lives	O
could	O
have	O
been	O
saved	O
in	O
the	O
South	O
Asian	O
disaster	O
in	O
December	O
2004	O
.	O

Discussion	O

Among	O
adolescent	O
boys	O
in	O
Chapaevsk	O
,	O
Russia	O
,	O
higher	O
serum	O
levels	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
were	O
positively	O
associated	O
with	O
increased	O
age	O
,	O
consumption	O
of	O
fish	O
,	O
local	O
meats	O
other	O
than	O
chicken	O
,	O
and	O
inversely	O
with	O
weeks	O
of	O
gestation	O
.	O

The	O
age	O
association	O
was	O
found	O
despite	O
a	O
narrow	O
age	O
range	O
of	O
slightly	O
over	O
two	O
years	O
in	O
our	O
study	O
.	O

Although	O
not	O
statistically	O
significant	O
,	O
the	O
distance	O
the	O
boy	O
lived	O
from	O
the	O
Khimprom	O
factory	O
at	O
the	O
time	O
of	O
blood	O
draw	O
was	O
inversely	O
associated	O
with	O
serum	O
levels	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
.	O

As	O
expected	O
,	O
serum	O
PCBs	O
,	O
specifically	O
PCB	O
118	O
,	O
were	O
strongly	O
associated	O
with	O
both	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
sum	O
of	O
dioxin	O
TEQs	O
.	O

There	O
was	O
no	O
association	O
between	O
the	O
distance	O
of	O
the	O
residence	O
from	O
the	O
Khimprom	O
plant	O
during	O
the	O
pregnancy	O
and	O
subsequent	O
serum	O
dioxin	O
levels	O
.	O

One	O
potential	O
explanation	O
for	O
the	O
lack	O
of	O
association	O
may	O
include	O
misclassification	O
of	O
distance	O
since	O
the	O
mother	O
was	O
asked	O
to	O
recall	O
a	O
time	O
period	O
more	O
than	O
14	O
years	O
prior	O
to	O
the	O
study	O
.	O

However	O
,	O
we	O
would	O
expect	O
that	O
the	O
mother	O
would	O
be	O
able	O
to	O
recall	O
residential	O
history	O
at	O
the	O
time	O
of	O
the	O
birth	O
of	O
their	O
son	O
.	O

Mother	O
'	O
s	O
self	O
-	O
reported	O
estimates	O
of	O
current	O
residential	O
distance	O
from	O
Khimprom	O
was	O
generally	O
accurate	O
;	O
twenty	O
-	O
one	O
of	O
twenty	O
-	O
nine	O
mothers	O
correctly	O
categorized	O
their	O
current	O
residential	O
distance	O
from	O
the	O
Khimprom	O
plants	O
based	O
on	O
cross	O
-	O
referencing	O
using	O
GIS	O
mapping	O
.	O

Other	O
explanations	O
include	O
that	O
prenatal	O
exposure	O
14	O
or	O
more	O
years	O
prior	O
to	O
the	O
current	O
serum	O
sample	O
is	O
not	O
as	O
strong	O
a	O
predictor	O
as	O
are	O
exposures	O
resulting	O
from	O
present	O
residential	O
location	O
.	O

Although	O
there	O
was	O
no	O
association	O
of	O
case	O
status	O
(	O
cryptorchidism	O
or	O
hypospadias	O
)	O
with	O
dioxin	O
levels	O
,	O
we	O
did	O
not	O
have	O
sufficient	O
power	O
to	O
definitively	O
assess	O
this	O
relationship	O
.	O

Perinatal	O
history	O
(	O
e	O
.	O
g	O
.	O
weeks	O
of	O
breastfeeding	O
)	O
was	O
generally	O
not	O
associated	O
with	O
exposure	O
measures	O
in	O
this	O
population	O
;	O
this	O
may	O
be	O
a	O
function	O
of	O
older	O
age	O
of	O
the	O
children	O
.	O

However	O
,	O
there	O
are	O
limited	O
data	O
on	O
the	O
relationship	O
of	O
perinatal	O
factors	O
with	O
organochlorine	O
exposures	O
in	O
this	O
age	O
group	O
so	O
a	O
null	O
finding	O
is	O
of	O
interest	O
given	O
reports	O
that	O
differences	O
in	O
organochlorine	O
levels	O
among	O
breastfed	O
and	O
non	O
-	O
breastfed	O
are	O
generally	O
no	O
longer	O
discernable	O
by	O
early	O
school	O
age	O
[	O
24	O
,	O
25	O
]	O
and	O
,	O
furthermore	O
,	O
that	O
dietary	O
intake	O
after	O
this	O
age	O
contributes	O
significantly	O
to	O
total	O
dioxin	O
intake	O
[	O
26	O
]	O
.	O

In	O
prior	O
studies	O
,	O
substantial	O
emphasis	O
has	O
been	O
placed	O
on	O
pre	O
-	O
and	O
early	O
postnatal	O
(	O
via	O
breastfeeding	O
)	O
exposures	O
because	O
of	O
particular	O
vulnerability	O
during	O
fetal	O
and	O
early	O
infant	O
development	O
.	O

The	O
exposure	O
risk	O
factors	O
during	O
peri	O
-	O
adolescence	O
,	O
another	O
period	O
of	O
potential	O
developmental	O
vulnerability	O
,	O
has	O
not	O
been	O
studied	O
in	O
-	O
detail	O
,	O
therefore	O
,	O
the	O
identification	O
of	O
exposure	O
risk	O
factors	O
specific	O
to	O
this	O
period	O
will	O
enhance	O
our	O
understanding	O
of	O
this	O
critical	O
period	O
.	O

Although	O
data	O
on	O
levels	O
of	O
PCDD	O
/	O
PCDFs	O
in	O
children	O
is	O
limited	O
,	O
our	O
results	O
suggest	O
that	O
the	O
mean	O
total	O
TEQs	O
among	O
Chapaevsk	O
adolescents	O
were	O
higher	O
than	O
most	O
values	O
previously	O
reported	O
in	O
non	O
-	O
occupationally	O
exposed	O
populations	O
of	O
comparable	O
or	O
even	O
older	O
ages	O
.	O

Figure	O
2	O
shows	O
a	O
comparison	O
of	O
the	O
mean	O
PCDD	O
/	O
PCDFs	O
TEQ	O
levels	O
in	O
Chapaevsk	O
boys	O
with	O
other	O
populations	O
(	O
TEQ	O
from	O
dioxin	O
-	O
like	O
PCBs	O
was	O
not	O
included	O
,	O
since	O
some	O
of	O
these	O
studies	O
did	O
not	O
report	O
them	O
)	O
.	O

The	O
mean	O
TEQs	O
of	O
pooled	O
blood	O
samples	O
from	O
10	O
year	O
-	O
old	O
German	O
boys	O
in	O
rural	O
and	O
urban	O
settings	O
was	O
8	O
.	O
2	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
an	O
urban	O
industrial	O
area	O
,	O
9	O
.	O
0	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
an	O
industrial	O
area	O
within	O
a	O
rural	O
setting	O
,	O
and	O
10	O
.	O
1	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
a	O
rural	O
area	O
[	O
27	O
]	O
.	O

In	O
comparison	O
,	O
the	O
mean	O
TEQ	O
in	O
the	O
Chapevsk	O
boys	O
was	O
19	O
.	O
3	O
pg	O
TEQ	O
/	O
g	O
lipid	O
.	O

With	O
the	O
exception	O
of	O
children	O
described	O
by	O
Wuthe	O
et	O
al	O
.	O

[	O
27	O
]	O
,	O
subjects	O
in	O
the	O
other	O
studies	O
in	O
Figure	O
2	O
were	O
significantly	O
older	O
than	O
the	O
Chapaevsk	O
boys	O
.	O

Despite	O
age	O
differences	O
,	O
the	O
mean	O
TEQ	O
in	O
Chapaevsk	O
boys	O
was	O
comparable	O
to	O
or	O
even	O
higher	O
than	O
the	O
mean	O
TEQ	O
in	O
older	O
populations	O
from	O
other	O
countries	O
.	O

For	O
example	O
,	O
they	O
were	O
higher	O
than	O
mean	O
TEQs	O
of	O
18	O
.	O
4	O
pg	O
TEQ	O
/	O
g	O
lipid	O
in	O
adults	O
(	O
40	O
.	O
6	O
years	O
old	O
average	O
)	O
from	O
South	O
Germany	O
[	O
27	O
]	O
or	O
16	O
.	O
4	O
pg	O
TEQ	O
/	O
g	O
lipid	O
from	O
20	O
year	O
old	O
Japanese	O
women	O
[	O
28	O
]	O
or	O
pooled	O
samples	O
from	O
randomly	O
selected	O
males	O
and	O
females	O
18	O
-	O
69	O
years	O
of	O
age	O
from	O
the	O
Spanish	O
city	O
of	O
Mataro	O
[	O
29	O
]	O
,	O
which	O
were	O
12	O
.	O
5	O
and	O
14	O
.	O
7	O
pg	O
TEQ	O
/	O
g	O
lipid	O
respectively	O
.	O

The	O
mean	O
levels	O
in	O
adult	O
female	O
(	O
mean	O
age	O
41	O
years	O
)	O
non	O
-	O
factory	O
workers	O
in	O
the	O
Russian	O
city	O
of	O
Shelekhovo	O
were	O
also	O
lower	O
at	O
14	O
.	O
5	O
pg	O
TEQ	O
/	O
g	O
lipid	O
[	O
30	O
]	O
.	O

Mean	O
TEQs	O
for	O
the	O
general	O
population	O
(	O
mean	O
age	O
44	O
.	O
2	O
years	O
)	O
in	O
Germany	O
,	O
collected	O
in	O
1997	O
-	O
98	O
[	O
31	O
]	O
,	O
and	O
median	O
TEQs	O
for	O
long	O
-	O
term	O
workers	O
of	O
pulp	O
and	O
paper	O
mill	O
and	O
non	O
-	O
workers	O
in	O
the	O
U	O
.	O
S	O
.	O
in	O
1996	O
[	O
32	O
]	O
were	O
similar	O
to	O
levels	O
found	O
in	O
the	O
Chapaevsk	O
boys	O
.	O

The	O
mean	O
levels	O
in	O
the	O
study	O
in	O
Germany	O
were	O
20	O
.	O
71	O
pg	O
TEQ	O
/	O
g	O
lipid	O
and	O
in	O
the	O
U	O
.	O
S	O
.	O
the	O
median	O
levels	O
were	O
19	O
.	O
1	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
community	O
residents	O
and	O
21	O
.	O
2	O
pg	O
TEQ	O
/	O
g	O
lipid	O
for	O
low	O
exposure	O
workers	O
.	O

Figure	O
2	O

Mean	O
PCDD	O
/	O
PCDFs	O
TEQ	O
levels	O
in	O
Chapaevsk	O
boys	O
in	O
comparison	O
with	O
other	O
populations	O
.	O

Although	O
TCDD	O
was	O
largely	O
below	O
the	O
detection	O
limits	O
in	O
this	O
small	O
pilot	O
sample	O
,	O
the	O
two	O
boys	O
with	O
detectable	O
values	O
had	O
high	O
TCDD	O
levels	O
(	O
17	O
.	O
9	O
and	O
21	O
.	O
7	O
pg	O
/	O
g	O
lipid	O
)	O
,	O
suggesting	O
that	O
exposure	O
for	O
at	O
least	O
some	O
portion	O
of	O
this	O
population	O
is	O
substantially	O
higher	O
than	O
typical	O
of	O
this	O
age	O
group	O
.	O

In	O
comparison	O
,	O
in	O
a	O
cohort	O
of	O
adult	O
(	O
mean	O
age	O
of	O
58	O
years	O
)	O
fishermen	O
from	O
a	O
polluted	O
region	O
of	O
Finland	O
,	O
the	O
mean	O
TCDD	O
concentration	O
was	O
19	O
pg	O
/	O
g	O
lipid	O
[	O
33	O
]	O
.	O

In	O
adult	O
(	O
mean	O
age	O
of	O
53	O
years	O
)	O
residents	O
from	O
Calcasieu	O
Parish	O
,	O
Louisiana	O
,	O
which	O
is	O
near	O
a	O
chemical	O
industrial	O
complex	O
,	O
the	O
mean	O
TCDD	O
level	O
was	O
7	O
.	O
6	O
pg	O
/	O
g	O
lipid	O
[	O
34	O
]	O
.	O

Not	O
only	O
were	O
the	O
dioxin	O
levels	O
in	O
these	O
two	O
children	O
higher	O
than	O
those	O
found	O
in	O
these	O
studies	O
,	O
but	O
the	O
adults	O
in	O
the	O
previous	O
studies	O
were	O
several	O
decades	O
older	O
and	O
therefore	O
would	O
be	O
expected	O
to	O
have	O
higher	O
dioxin	O
body	O
burdens	O
than	O
younger	O
children	O
[	O
35	O
]	O
.	O

Potential	O
explanations	O
for	O
the	O
large	O
number	O
of	O
non	O
-	O
detectable	O
samples	O
for	O
TCDD	O
include	O
the	O
small	O
sample	O
volume	O
and	O
young	O
age	O
of	O
the	O
subjects	O
.	O

In	O
our	O
future	O
studies	O
in	O
this	O
population	O
,	O
we	O
will	O
collect	O
larger	O
volumes	O
of	O
serum	O
for	O
dioxin	O
analysis	O
.	O

In	O
one	O
of	O
the	O
few	O
studies	O
on	O
dioxin	O
-	O
like	O
compounds	O
in	O
which	O
children	O
were	O
included	O
,	O
Eskenazi	O
and	O
coworkers	O
[	O
36	O
]	O
evaluated	O
the	O
relationship	O
between	O
serum	O
TCDD	O
concentrations	O
and	O
age	O
at	O
exposure	O
of	O
female	O
residents	O
of	O
Seveso	O
,	O
Italy	O
.	O

Residents	O
near	O
the	O
ICMESA	O
chemical	O
plant	O
in	O
Seveso	O
were	O
exposed	O
to	O
some	O
of	O
the	O
highest	O
known	O
residential	O
levels	O
of	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
as	O
a	O
result	O
of	O
an	O
explosion	O
at	O
the	O
plant	O
.	O

Archived	O
serum	O
collected	O
near	O
the	O
time	O
of	O
the	O
accident	O
was	O
used	O
to	O
measure	O
exposures	O
.	O

Residents	O
closest	O
to	O
the	O
plant	O
had	O
a	O
median	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
level	O
of	O
272	O
ppt	O
(	O
IQR	O
92	O
-	O
883	O
ppt	O
)	O
.	O

Residential	O
proximity	O
to	O
the	O
plant	O
and	O
younger	O
age	O
(	O
up	O
to	O
13	O
years	O
old	O
)	O
were	O
the	O
strongest	O
predictors	O
of	O
an	O
individual	O
'	O
s	O
serum	O
2	O
,	O
3	O
,	O
7	O
,	O
8	O
-	O
TCDD	O
level	O
.	O

Other	O
predictors	O
included	O
being	O
outdoors	O
at	O
the	O
time	O
of	O
explosion	O
and	O
consumption	O
of	O
homegrown	O
food	O
.	O

The	O
higher	O
levels	O
found	O
in	O
children	O
were	O
most	O
likely	O
a	O
result	O
of	O
increased	O
exposure	O
as	O
a	O
result	O
of	O
activity	O
patterns	O
and	O
a	O
greater	O
proportionate	O
consumption	O
of	O
food	O
,	O
water	O
and	O
air	O
than	O
adults	O
[	O
37	O
]	O
.	O

Although	O
the	O
exposure	O
scenario	O
(	O
an	O
acute	O
high	O
exposure	O
event	O
)	O
is	O
different	O
than	O
the	O
chronic	O
low	O
/	O
moderate	O
exposure	O
occurring	O
in	O
Chapaevsk	O
,	O
the	O
results	O
from	O
Seveso	O
suggest	O
that	O
children	O
may	O
be	O
at	O
increased	O
risk	O
for	O
high	O
dioxin	O
exposure	O
from	O
environmental	O
contamination	O
.	O

In	O
our	O
study	O
,	O
although	O
distance	O
from	O
the	O
Khimprom	O
plants	O
was	O
a	O
weak	O
predictor	O
of	O
serum	O
dioxin	O
-	O
like	O
compounds	O
,	O
consumption	O
of	O
local	O
foods	O
(	O
specifically	O
meat	O
and	O
fish	O
)	O
,	O
as	O
in	O
the	O
Seveso	O
study	O
,	O
was	O
a	O
strong	O
predictor	O
of	O
sum	O
of	O
dioxin	O
-	O
like	O
compounds	O
and	O
dioxin	O
TEQs	O
.	O

This	O
finding	O
is	O
notable	O
given	O
concerns	O
regarding	O
environmental	O
dioxin	O
contamination	O
in	O
the	O
community	O
and	O
suggests	O
that	O
food	O
may	O
be	O
one	O
of	O
the	O
more	O
,	O
if	O
not	O
most	O
,	O
important	O
routes	O
of	O
environmental	O
contaminant	O
exposure	O
for	O
residents	O
in	O
this	O
setting	O
.	O

In	O
other	O
settings	O
,	O
contaminated	O
food	O
generally	O
contributes	O
much	O
more	O
substantially	O
to	O
human	O
organochlorine	O
burden	O
than	O
air	O
or	O
soil	O
(	O
which	O
may	O
be	O
related	O
to	O
residential	O
proximity	O
to	O
pollutant	O
sources	O
)	O
[	O
6	O
]	O
.	O

We	O
will	O
investigate	O
this	O
issue	O
in	O
more	O
detail	O
in	O
our	O
ongoing	O
study	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Allergen	O
and	O
particle	O
dose	O
-	O
response	O
experiments	O
in	O
BALB	O
/	O
cA	O
and	O
NIH	O
mice	O
Levels	O
of	O
serum	O
OVA	O
-	O
specific	O
IgE	O
(	O
A	O
,	O
D	O
)	O
,	O
IgG1	O
(	O
B	O
,	O
E	O
)	O
and	O
IgG2a	O
(	O
C	O
,	O
F	O
)	O
on	O
day	O
26	O
after	O
injection	O
into	O
one	O
hind	O
footpad	O
of	O
100	O
(	O
open	O
columns	O
)	O
,	O
50	O
(	O
gray	O
)	O
or	O
10	O
(	O
black	O
)	O
mug	O
OVA	O
combined	O
with	O
100	O
,	O
40	O
,	O
10	O
or	O
0	O
mug	O
PSP	O
,	O
or	O
buffer	O
(	O
HBSS	O
(	O
hatched	O
)	O
)	O
,	O
in	O
BALB	O
/	O
cA	O
(	O
A	O
,	O
B	O
,	O
C	O
)	O
and	O
NIH	O
(	O
D	O
,	O
E	O
,	O
F	O
)	O
mice	O
.	O

On	O
day	O
21	O
the	O
mice	O
were	O
boostered	O
with	O
the	O
same	O
OVA	O
dose	O
in	O
the	O
footpad	O
.	O

The	O
PSP	O
-	O
control	O
(	O
""""	O
PSP	O
ctr	O
""""	O
)	O
group	O
was	O
given	O
100	O
mug	O
PSP	O
on	O
day	O
0	O
,	O
followed	O
by	O
HBSS	O
injection	O
on	O
day	O
21	O
(	O
diamonds	O
)	O
.	O

Values	O
(	O
arbitrary	O
units	O
,	O
AU	O
)	O
for	O
individual	O
mice	O
(	O
circles	O
)	O
and	O
median	O
values	O
(	O
columns	O
)	O
for	O
groups	O
of	O
eight	O
mice	O
are	O
shown	O
.	O

Dotted	O
lines	O
indicate	O
the	O
lower	O
or	O
higher	O
detection	O
limits	O
for	O
the	O
ELISA	O
assays	O
.	O

Note	O
different	O
scales	O
for	O
the	O
two	O
strains	O
of	O
mice	O
.	O

Figure	O
2	O

The	O
adjuvant	O
effect	O
of	O
PSP	O
on	O
OVA	O
-	O
specific	O
IgE	O
and	O
IgG2a	O
responses	O
in	O
different	O
strains	O
of	O
mice	O
Levels	O
of	O
serum	O
OVA	O
-	O
specific	O
IgE	O
(	O
A	O
)	O
and	O
IgG2a	O
(	O
B	O
)	O
on	O
day	O
26	O
after	O
injection	O
into	O
one	O
hind	O
footpad	O
of	O
HBSS	O
(	O
open	O
columns	O
)	O
,	O
10	O
mug	O
OVA	O
(	O
gray	O
)	O
,	O
40	O
mug	O
PSP	O
(	O
hatched	O
)	O
or	O
10	O
mug	O
OVA	O
+	O
40	O
mug	O
PSP	O
(	O
black	O
)	O
in	O
different	O
mouse	O
strains	O
.	O

On	O
day	O
21	O
all	O
mice	O
were	O
boostered	O
with	O
10	O
mug	O
OVA	O
in	O
the	O
footpad	O
.	O

Vertical	O
straight	O
lines	O
indicate	O
separate	O
experiments	O
.	O

Values	O
(	O
arbitrary	O
units	O
,	O
AU	O
)	O
for	O
individual	O
mice	O
(	O
circles	O
)	O
and	O
median	O
values	O
(	O
columns	O
)	O
for	O
groups	O
of	O
mice	O
are	O
shown	O
.	O

Dotted	O
lines	O
indicate	O
the	O
lower	O
detection	O
limits	O
for	O
the	O
ELISA	O
assays	O
.	O

Brackets	O
indicate	O
statistically	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

All	O
experiments	O
were	O
performed	O
twice	O
with	O
similar	O
results	O
,	O
with	O
eight	O
mice	O
per	O
group	O
.	O

Figure	O
3	O

The	O
primary	O
cellular	O
response	O
in	O
the	O
draining	O
lymph	O
node	O
The	O
primary	O
cellular	O
response	O
in	O
the	O
draining	O
PLN	O
was	O
determined	O
five	O
days	O
after	O
a	O
single	O
injection	O
of	O
HBSS	O
(	O
open	O
columns	O
)	O
,	O
10	O
mug	O
OVA	O
(	O
gray	O
)	O
,	O
40	O
mug	O
PSP	O
(	O
hatched	O
)	O
or	O
10	O
mug	O
OVA	O
+	O
40	O
mug	O
PSP	O
(	O
black	O
)	O
into	O
both	O
hind	O
footpads	O
of	O
BALB	O
/	O
cA	O
,	O
NIH	O
and	O
C3H	O
/	O
HeN	O
mice	O
.	O

The	O
total	O
lymph	O
node	O
cell	O
numbers	O
(	O
A	O
)	O
and	O
IL	O
-	O
4	O
(	O
B	O
)	O
,	O
IFN	O
-	O
gamma	O
(	O
C	O
)	O
and	O
IL	O
-	O
10	O
(	O
D	O
)	O
secreted	O
from	O
the	O
PLN	O
cells	O
after	O
ex	O
vivo	O
stimulation	O
with	O
Con	O
A	O
were	O
determined	O
.	O

Values	O
for	O
individual	O
samples	O
(	O
circles	O
)	O
and	O
group	O
median	O
values	O
(	O
columns	O
)	O
are	O
shown	O
.	O

Dotted	O
lines	O
indicate	O
the	O
lower	O
detection	O
limits	O
for	O
the	O
cytokine	O
ELISA	O
assays	O
,	O
and	O
brackets	O
indicate	O
statistically	O
significant	O
differences	O
between	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Figures	O
and	O
Tables	O

Stages	O
in	O
the	O
life	O
cycle	O
of	O
Plasmodium	O
falciparum	O

(	O
Illustration	O
:	O
Coatney	O
GR	O
,	O
Collins	O
WE	O
,	O
Warren	O
M	O
,	O
Contacos	O
PG	O
(	O
1971	O
)	O

The	O
primate	O
malarias	O
.	O
(	O
Bethesda	O
)	O
:	O
U	O
.	O
S	O
.	O
Department	O
of	O
Health	O
,	O
Education	O
and	O
Welfare	O
.	O
)	O

Transcripts	O
Upregulated	O
in	O
ST	O
-	O
HSC	O
Compared	O
to	O
LT	O
-	O
HSC	O

(	O
181	O
KB	O
XLS	O
)	O

Results	O

OFTT	O
was	O
given	O
to	O
33	O
men	O
with	O
MetS	O
(	O
defined	O
by	O
the	O
Adult	O
Treatment	O
Panel	O
III	O
)	O
,	O
17	O
HTN	O
and	O
14	O
healthy	O
men	O
.	O

The	O
MetS	O
group	O
was	O
further	O
divided	O
according	O
to	O
fasting	O
triglycerides	O
(	O
TG	O
)	O
into	O
TG	O
>	O
=	O
150	O
[	O
MetS	O
+	O
TG	O
,	O
(	O
n	O
=	O
22	O
)	O
]	O
or	O
<	O
150	O
mg	O
/	O
dl	O
[	O
MetS	O
-	O
TG	O
(	O
n	O
=	O
11	O
)	O
]	O
,	O
and	O
into	O
those	O
with	O
or	O
without	O
hypertension	O
[	O
MetS	O
+	O
HTN	O
(	O
n	O
=	O
24	O
)	O
,	O
MetS	O
-	O
HTN	O
(	O
n	O
=	O
9	O
)	O
,	O
respectively	O
]	O
.	O

TG	O
concentrations	O
were	O
measured	O
before	O
and	O
at	O
4	O
,	O
6	O
and	O
8	O
h	O
after	O
OFTT	O
and	O
the	O
postprandial	O
response	O
was	O
quantified	O
using	O
the	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
TG	O
.	O

The	O
postprandial	O
response	O
was	O
significantly	O
higher	O
in	O
MetS	O
compared	O
to	O
HTN	O
and	O
healthy	O
men	O
[	O
AUC	O
(	O
SD	O
)	O
in	O
mg	O
/	O
dl	O
/	O
h	O
;	O
2534	O
+	O
/	O
-	O
1016	O
vs	O
.	O
1620	O
+	O
/	O
-	O
494	O
and	O
1019	O
+	O
/	O
-	O
280	O
,	O
respectively	O
,	O
p	O
<	O
=	O
0	O
.	O
001	O
]	O
.	O

The	O
TG	O
levels	O
were	O
increased	O
significantly	O
in	O
MetS	O
+	O
TG	O
compared	O
to	O
MetS	O
-	O
TG	O
subjects	O
at	O
4	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
,	O
6	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
8	O
hours	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
TG	O
were	O
increased	O
significantly	O
in	O
MetS	O
-	O
TG	O
compared	O
to	O
healthy	O
subjects	O
at	O
4	O
(	O
p	O
=	O
0	O
.	O
011	O
)	O
,	O
6	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
8	O
hours	O
(	O
p	O
=	O
0	O
.	O
015	O
)	O
.	O

In	O
linear	O
regression	O
analysis	O
only	O
fasting	O
TG	O
levels	O
were	O
a	O
significant	O
predictor	O
of	O
the	O
AUC	O
(	O
Coefficient	O
B	O
=	O
8	O
.	O
462	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Conclusions	O

Only	O
after	O
careful	O
consideration	O
of	O
the	O
biological	O
underpinnings	O
of	O
a	O
truly	O
beneficial	O
response	O
can	O
an	O
exposure	O
be	O
considered	O
for	O
the	O
general	O
population	O
,	O
such	O
as	O
the	O
addition	O
of	O
folic	O
acid	O
to	O
cereals	O
.	O

If	O
a	O
toxic	O
or	O
hazardous	O
pollutant	O
were	O
found	O
to	O
have	O
truly	O
beneficial	O
effects	O
at	O
low	O
dose	O
,	O
then	O
that	O
agent	O
should	O
be	O
tested	O
clinically	O
,	O
go	O
through	O
the	O
U	O
.	O
S	O
.	O

Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
approval	O
process	O
,	O
and	O
be	O
regulated	O
as	O
a	O
pharmaceutical	O
for	O
those	O
who	O
might	O
benefit	O
from	O
its	O
use	O
.	O

Certainly	O
,	O
the	O
general	O
population	O
should	O
not	O
be	O
exposed	O
to	O
chemotherapeutic	O
agents	O
that	O
benefit	O
cancer	O
patients	O
.	O

For	O
pharmaceuticals	O
,	O
it	O
is	O
understood	O
that	O
there	O
are	O
trade	O
offs	O
between	O
benefits	O
and	O
risks	O
.	O

For	O
example	O
,	O
although	O
aspirin	O
is	O
a	O
generally	O
well	O
-	O
tolerated	O
pain	O
reliever	O
and	O
is	O
increasingly	O
advocated	O
as	O
a	O
preventative	O
tool	O
for	O
heart	O
attacks	O
and	O
colorectal	O
cancer	O
(	O
Vainio	O
and	O
Miller	O
2003	O
;	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
it	O
is	O
also	O
linked	O
to	O
increased	O
risk	O
of	O
gastrointestinal	O
bleeding	O
,	O
cerebral	O
hemorrhage	O
(	O
Werner	O
et	O
al	O
.	O
2004	O
)	O
,	O
and	O
asthma	O
attacks	O
(	O
Jenkins	O
et	O
al	O
.	O
2004	O
)	O
.	O

In	O
addition	O
,	O
aspirin	O
is	O
not	O
recommended	O
for	O
children	O
or	O
teenagers	O
who	O
have	O
or	O
are	O
recovering	O
from	O
chicken	O
pox	O
or	O
flulike	O
symptoms	O
because	O
it	O
can	O
cause	O
debilitating	O
and	O
sometimes	O
lethal	O
Reyes	O
syndrome	O
(	O
U	O
.	O
S	O
.	O
FDA	O
2003	O
)	O
.	O

Individual	O
risks	O
to	O
pharmaceutical	O
agents	O
can	O
be	O
controlled	O
with	O
proper	O
usage	O
;	O
however	O
,	O
increased	O
exposure	O
to	O
environmental	O
toxins	O
presents	O
additional	O
involuntary	O
risks	O
for	O
the	O
general	O
population	O
.	O

Under	O
the	O
latter	O
condition	O
,	O
exposure	O
is	O
inadequately	O
controlled	O
,	O
and	O
there	O
is	O
no	O
mechanism	O
to	O
correct	O
for	O
individual	O
circumstances	O
(	O
e	O
.	O
g	O
.	O
,	O
medical	O
condition	O
or	O
age	O
)	O
that	O
may	O
result	O
in	O
harm	O
.	O

Although	O
hormetic	O
effects	O
may	O
occur	O
in	O
some	O
instances	O
,	O
it	O
is	O
indeed	O
rare	O
that	O
exposures	O
to	O
toxic	O
,	O
mutagenic	O
,	O
teratogenic	O
,	O
and	O
carcinogenic	O
chemicals	O
,	O
even	O
at	O
low	O
exposure	O
levels	O
,	O
would	O
be	O
risk	O
free	O
and	O
provide	O
health	O
benefits	O
for	O
the	O
general	O
public	O
.	O

Portraying	O
chemicals	O
with	O
numerous	O
adverse	O
effects	O
as	O
having	O
benefits	O
while	O
ignoring	O
their	O
hazards	O
is	O
irresponsible	O
and	O
does	O
not	O
provide	O
full	O
and	O
objective	O
disclosure	O
.	O

In	O
the	O
1950s	O
doctors	O
prescribed	O
DES	O
to	O
pregnant	O
women	O
to	O
prevent	O
miscarriage	O
and	O
premature	O
births	O
and	O
to	O
produce	O
""""	O
bigger	O
and	O
stronger	O
babies	O
""""	O
even	O
though	O
DES	O
had	O
been	O
shown	O
to	O
cause	O
damage	O
to	O
reproductive	O
tissues	O
in	O
animals	O
(	O
Dinusson	O
et	O
al	O
.	O
1948	O
;	O
Dunn	O
and	O
Green	O
1963	O
;	O
Takasugi	O
and	O
Bern	O
1964	O
)	O
.	O

Human	O
use	O
of	O
DES	O
was	O
banned	O
in	O
the	O
United	O
States	O
in	O
1971	O
after	O
the	O
discovery	O
of	O
high	O
rates	O
of	O
rare	O
,	O
clear	O
-	O
cell	O
adenocarcinomas	O
of	O
the	O
vagina	O
and	O
cervix	O
in	O
DES	O
-	O
exposed	O
daughters	O
(	O
Herbst	O
1981	O
)	O
,	O
and	O
later	O
studies	O
showed	O
elevated	O
breast	O
cancer	O
risk	O
in	O
women	O
who	O
took	O
DES	O
during	O
pregnancy	O
(	O
Titus	O
-	O
Ernstoff	O
et	O
al	O
.	O
2001	O
)	O
.	O

Certainly	O
,	O
health	O
policy	O
decisions	O
should	O
be	O
based	O
on	O
scientific	O
evidence	O
and	O
not	O
on	O
speculation	O
of	O
health	O
benefits	O
in	O
order	O
for	O
the	O
general	O
population	O
to	O
avoid	O
repeating	O
the	O
mistakes	O
of	O
the	O
past	O
similar	O
to	O
that	O
of	O
the	O
DES	O
tragedy	O
.	O

The	O
claims	O
and	O
projections	O
of	O
health	O
benefits	O
from	O
exposures	O
to	O
environmental	O
toxicants	O
and	O
carcinogens	O
are	O
based	O
on	O
untested	O
assumptions	O
and	O
disregard	O
numerous	O
well	O
-	O
established	O
scientific	O
principles	O
that	O
underpin	O
a	O
public	O
health	O
-	O
protective	O
approach	O
to	O
regulating	O
exposure	O
to	O
toxic	O
substances	O
.	O

If	O
hormesis	O
were	O
used	O
in	O
the	O
decision	O
-	O
making	O
process	O
to	O
allow	O
higher	O
exposures	O
to	O
toxic	O
and	O
carcinogenic	O
agents	O
,	O
this	O
would	O
substantially	O
increase	O
health	O
risks	O
for	O
many	O
,	O
if	O
not	O
most	O
,	O
segments	O
of	O
the	O
general	O
population	O
.	O

Measured	O
analytes	O
in	O
five	O
biologic	O
sample	O
matrices	O
.	O
a	O

Results	O

Competing	O
interests	O

None	O
declared	O
.	O

This	O
article	O
is	O
the	O
third	O
in	O
an	O
ongoing	O
,	O
educational	O
review	O
series	O
on	O
medical	O
statistics	O
in	O
critical	O
care	O
.	O

Previous	O
articles	O
have	O
covered	O
'	O
presenting	O
and	O
summarising	O
data	O
'	O
[	O
3	O
]	O
and	O
'	O
samples	O
and	O
populations	O
'	O
[	O
4	O
]	O
.	O

Future	O
topics	O
to	O
be	O
covered	O
include	O
power	O
calculations	O
,	O
comparison	O
of	O
means	O
,	O
comparison	O
of	O
proportions	O
,	O
and	O
analysis	O
of	O
survival	O
data	O
to	O
name	O
but	O
a	O
few	O
.	O

If	O
there	O
is	O
a	O
medical	O
statistics	O
topic	O
you	O
would	O
like	O
explained	O
contact	O
us	O
on	O
editorial	O
@	O
ccforum	O
.	O
com	O
.	O

Results	O

The	O
set	O
of	O
E	O
.	O
coli	O
expression	O
vectors	O
,	O
encode	O
for	O
either	O
a	O
hexa	O
-	O
histidine	O
tag	O
or	O
the	O
three	O
most	O
commonly	O
used	O
solubility	O
tags	O
(	O
GST	O
,	O
MBP	O
,	O
NusA	O
)	O
and	O
all	O
with	O
an	O
N	O
-	O
terminal	O
hexa	O
-	O
histidine	O
sequence	O
.	O

The	O
result	O
is	O
two	O
-	O
fold	O
:	O
the	O
His	O
-	O
tag	O
facilitates	O
purification	O
by	O
immobilised	O
metal	O
affinity	O
chromatography	O
,	O
whilst	O
the	O
fusion	O
domains	O
act	O
primarily	O
as	O
solubility	O
aids	O
during	O
expression	O
,	O
in	O
addition	O
to	O
providing	O
an	O
optional	O
purification	O
step	O
.	O

We	O
have	O
also	O
incorporated	O
a	O
TEV	O
recognition	O
sequence	O
following	O
the	O
solubility	O
tag	O
domain	O
,	O
which	O
allows	O
for	O
highly	O
specific	O
cleavage	O
(	O
using	O
TEV	O
protease	O
)	O
of	O
the	O
fusion	O
protein	O
to	O
yield	O
native	O
protein	O
.	O

These	O
vectors	O
are	O
also	O
designed	O
for	O
ligation	O
-	O
independent	O
cloning	O
and	O
they	O
possess	O
a	O
high	O
-	O
level	O
expressing	O
T7	O
promoter	O
,	O
which	O
is	O
suitable	O
for	O
auto	O
-	O
induction	O
.	O

To	O
validate	O
our	O
vector	O
system	O
,	O
we	O
have	O
cloned	O
four	O
different	O
genes	O
and	O
also	O
one	O
gene	O
into	O
all	O
four	O
vectors	O
and	O
used	O
small	O
-	O
scale	O
expression	O
and	O
purification	O
techniques	O
.	O

We	O
demonstrate	O
that	O
the	O
vectors	O
are	O
capable	O
of	O
high	O
levels	O
of	O
expression	O
and	O
that	O
efficient	O
screening	O
of	O
new	O
proteins	O
can	O
be	O
readily	O
achieved	O
at	O
the	O
laboratory	O
level	O
.	O

Images	O

FIGURE	O
2	O
.	O

A	O

FIGURE	O
2	O
.	O

B	O

FIGURE	O
3	O
.	O

Images	O

FIGURE	O
2	O
.	O

Inflammation	O
-	O
modulating	O
effect	O
of	O
antithrombin	O
on	O
the	O
endothelium	O
.	O

Ligation	O
of	O
heparan	O
sulfate	O
proteoglycans	O
(	O
HSPGs	O
)	O
of	O
endothelium	O
with	O
antithrombin	O
(	O
AT	O
)	O
induces	O
cellular	O
signalling	O
events	O
that	O
alter	O
the	O
cell	O
'	O
s	O
biochemical	O
and	O
functional	O
responses	O
to	O
inflammatory	O
stimuli	O
(	O
e	O
.	O
g	O
.	O
bacterial	O
lipopolysaccharide	O
[	O
LPS	O
]	O
)	O
.	O

Changes	O
include	O
reduced	O
release	O
of	O
inflammatory	O
and	O
procoagulatory	O
mediators	O
(	O
e	O
.	O
g	O
.	O
interleukin	O
[	O
IL	O
]	O
-	O
1	O
,	O
IL	O
-	O
6	O
,	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
[	O
TNF	O
]	O
)	O
,	O
tissue	O
factor	O
(	O
TF	O
)	O
,	O
adenosine	O
diphosphate	O
(	O
ADP	O
)	O
and	O
cellular	O
adhesion	O
molecules	O
(	O
not	O
shown	O
)	O
,	O
as	O
well	O
as	O
increased	O
release	O
of	O
anticoagulatory	O
prostacyclin	O
(	O
prostaglandin	O
[	O
PG	O
]	O
I	O
)	O
or	O
CD39	O
/	O
ATPDase	O
.	O

In	O
neuronal	O
tissue	O
,	O
protective	O
mechanisms	O
may	O
by	O
mediated	O
via	O
the	O
release	O
of	O
calcitonin	O
gene	O
-	O
related	O
peptide	O
and	O
nitric	O
oxide	O
with	O
the	O
potential	O
to	O
affect	O
prostacyclin	O
release	O
[	O
55	O
]	O
.	O

Background	O

Hallucinations	O
may	O
occur	O
in	O
any	O
sensory	O
modalities	O
.	O

Formed	O
musical	O
hallucinations	O
(	O
i	O
.	O
e	O
.	O
Perception	O
of	O
either	O
vocal	O
or	O
instrumental	O
melodies	O
)	O
reported	O
in	O
English	O
literature	O
to	O
date	O
have	O
typically	O
been	O
associated	O
with	O
marked	O
hearing	O
loss	O
,	O
advanced	O
age	O
,	O
female	O
sex	O
(	O
71	O
%	O
)	O
,	O
lack	O
of	O
response	O
to	O
treatment	O
and	O
associated	O
psychopathology	O
[	O
1	O
]	O
but	O
has	O
been	O
concluded	O
that	O
hearing	O
loss	O
is	O
neither	O
a	O
necessary	O
nor	O
sufficient	O
condition	O
for	O
the	O
occurrence	O
of	O
musical	O
hallucinations	O
[	O
1	O
]	O
.	O

Tumor	O
like	O
Astrocytoma	O
,	O
Temporal	O
lobe	O
epilepsy	O
,	O
raised	O
intra	O
cranial	O
tension	O
,	O
drug	O
induced	O
(	O
tricyclics	O
,	O
Propronolol	O
etc	O
;	O
)	O
,	O
meningitis	O
and	O
psychotic	O
illness	O
were	O
shown	O
to	O
cause	O
palinacousis	O
and	O
musical	O
hallucinations	O
[	O
2	O
,	O
3	O
]	O
.	O

Musical	O
hallucinations	O
are	O
pseudo	O
hallucinations	O
that	O
originate	O
in	O
memory	O
representations	O
and	O
they	O
may	O
undergo	O
a	O
transition	O
to	O
true	O
hallucination	O
.	O

In	O
musical	O
hallucination	O
spatial	O
projection	O
is	O
less	O
definite	O
.	O

Sometimes	O
they	O
are	O
perceived	O
like	O
the	O
tinnitus	O
in	O
patient	O
'	O
s	O
own	O
head	O
.	O

The	O
quality	O
is	O
usually	O
very	O
intense	O
and	O
distinct	O
often	O
very	O
loud	O
.	O

They	O
vary	O
from	O
elementary	O
sounds	O
to	O
instrumental	O
music	O
,	O
vocal	O
music	O
,	O
bird	O
songs	O
,	O
bells	O
,	O
pieces	O
of	O
melodies	O
or	O
sentences	O
,	O
religious	O
music	O
etc	O
:	O
-	O
We	O
report	O
an	O
unusual	O
presentation	O
of	O
an	O
elderly	O
lady	O
who	O
had	O
experienced	O
musical	O
hallucinations	O
whilst	O
being	O
treated	O
with	O
Electro	O
Convulsive	O
Therapy	O
.	O

Though	O
this	O
has	O
never	O
been	O
reported	O
earlier	O
,	O
there	O
seemed	O
to	O
have	O
a	O
good	O
association	O
between	O
the	O
initiation	O
of	O
Electro	O
convulsive	O
therapy	O
and	O
musical	O
hallucination	O
in	O
our	O
patient	O
.	O

Supporting	O
Information	O

Table	O
S1	O

Supplementary	O
Information	O
on	O
Genes	O
in	O
the	O
Three	O
Gene	O
Sets	O

(	O
219	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S2	O

UFW	O
Primers	O
for	O
Gene	O
Set	O
I	O

(	O
36	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S3	O

UFW	O
Primers	O
for	O
Gene	O
Set	O
II	O

(	O
44	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S4	O

UFW	O
Primers	O
for	O
Gene	O
Set	O
III	O

(	O
31	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S5	O

Transposable	O
Element	O
-	O
Specific	O
Primers	O
for	O
Additional	O
Screens	O

(	O
80	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S6	O

Primers	O
for	O
Intergenic	O
Regions	O

(	O
58	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Table	O
S7	O

P	O
Element	O
-	O
Specific	O
Primers	O
for	O
Orientation	O
and	O
Length	O
Determination	O

(	O
299	O
KB	O
PDF	O
)	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Correlation	O
between	O
sperm	O
morphology	O
and	O
seminal	O
plasma	O
NO	O
(	O
a	O
)	O
and	O
TBARS	O
(	O
b	O
)	O
levels	O
in	O
both	O
groups	O
.	O

Conclusion	O

The	O
survey	O
indicated	O
that	O
,	O
the	O
study	O
area	O
has	O
plenty	O
of	O
medicinal	O
plants	O
to	O
treat	O
a	O
wide	O
spectrum	O
of	O
human	O
ailments	O
.	O

Earlier	O
studies	O
on	O
traditional	O
medicinal	O
plants	O
also	O
revealed	O
that	O
the	O
economically	O
backward	O
local	O
and	O
tribal	O
people	O
of	O
Tamil	O
Nadu	O
prefer	O
folk	O
medicine	O
due	O
to	O
low	O
cost	O
and	O
sometimes	O
it	O
is	O
a	O
part	O
of	O
their	O
social	O
life	O
and	O
culture	O
[	O
40	O
-	O
45	O
]	O
.	O

It	O
is	O
evident	O
from	O
the	O
interviews	O
conducted	O
in	O
different	O
villages	O
,	O
knowledge	O
of	O
medicinal	O
plants	O
is	O
limited	O
to	O
traditional	O
healers	O
,	O
herbalists	O
and	O
elderly	O
persons	O
who	O
are	O
living	O
in	O
rural	O
areas	O
.	O

This	O
study	O
also	O
points	O
out	O
that	O
certain	O
species	O
of	O
medicinal	O
plants	O
are	O
being	O
exploited	O
by	O
the	O
local	O
residents	O
who	O
are	O
unaware	O
of	O
the	O
importance	O
of	O
medicinal	O
plants	O
in	O
the	O
ecosystem	O
.	O

This	O
study	O
concluded	O
that	O
even	O
though	O
the	O
accessibility	O
of	O
Western	O
medicine	O
for	O
simple	O
and	O
complicated	O
diseases	O
is	O
available	O
,	O
many	O
people	O
in	O
the	O
studied	O
parts	O
of	O
Kancheepuram	O
district	O
is	O
still	O
continue	O
to	O
depend	O
on	O
medicinal	O
plants	O
,	O
at	O
least	O
for	O
the	O
treatment	O
of	O
some	O
simple	O
diseases	O
such	O
as	O
,	O
cold	O
,	O
cough	O
,	O
fever	O
,	O
headache	O
,	O
poison	O
bites	O
,	O
skin	O
diseases	O
and	O
tooth	O
infections	O
.	O

Well	O
-	O
knowledged	O
healers	O
have	O
good	O
interactions	O
with	O
patients	O
and	O
this	O
would	O
improve	O
the	O
quality	O
of	O
healthcare	O
delivery	O
.	O

The	O
present	O
-	O
day	O
traditional	O
healers	O
are	O
very	O
old	O
.	O

Due	O
to	O
lack	O
of	O
interest	O
among	O
the	O
younger	O
generation	O
as	O
well	O
as	O
their	O
tendency	O
to	O
migrate	O
to	O
cities	O
for	O
lucrative	O
jobs	O
,	O
there	O
is	O
a	O
possibility	O
of	O
losing	O
this	O
wealth	O
of	O
knowledge	O
in	O
the	O
near	O
future	O
.	O

It	O
thus	O
becomes	O
necessary	O
to	O
acquire	O
and	O
preserve	O
this	O
traditional	O
system	O
of	O
medicine	O
by	O
proper	O
documentation	O
and	O
identification	O
of	O
specimens	O
.	O

Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
processively	O

The	O
results	O
presented	O
in	O
this	O
paper	O
clearly	O
indicate	O
that	O
Nf	O
and	O
GA	O
-	O
1	O
DNA	O
polymerases	O
can	O
account	O
for	O
their	O
genome	O
replication	O
without	O
the	O
assistance	O
of	O
unwinding	O
and	O
processivity	O
factors	O
,	O
in	O
contrast	O
to	O
most	O
replicative	O
DNA	O
polymerases	O
which	O
require	O
their	O
physical	O
association	O
to	O
processivity	O
factors	O
and	O
DNA	O
unwinding	O
proteins	O
(	O
1	O
,	O
70	O
)	O
.	O

Strand	O
displacement	O
capacity	O
has	O
also	O
been	O
shown	O
for	O
other	O
protein	O
-	O
primed	O
DNA	O
polymerases	O
as	O
those	O
of	O
bacteriophages	O
phi29	O
(	O
10	O
)	O
,	O
Cp	O
-	O
1	O
(	O
71	O
)	O
and	O
PRD1	O
(	O
72	O
,	O
73	O
)	O
.	O

On	O
the	O
contrary	O
,	O
adenovirus	O
DNA	O
polymerase	O
,	O
although	O
processive	O
,	O
can	O
not	O
couple	O
polymerization	O
to	O
strand	O
displacement	O
,	O
requiring	O
the	O
DNA	O
unwinding	O
activity	O
of	O
the	O
adenovirus	O
DBP	O
to	O
perform	O
strand	O
displacement	O
(	O
74	O
,	O
75	O
)	O
.	O

Whereas	O
it	O
was	O
possible	O
to	O
obtain	O
GA	O
-	O
1	O
DNA	O
replication	O
by	O
using	O
exclusively	O
the	O
GA	O
-	O
1	O
TP	O
and	O
DNA	O
polymerase	O
,	O
Nf	O
DNA	O
polymerase	O
,	O
although	O
provided	O
with	O
competent	O
strand	O
displacement	O
and	O
processivity	O
features	O
,	O
required	O
the	O
presence	O
of	O
Nf	O
DBP	O
for	O
an	O
effective	O
in	O
vitro	O
replication	O
of	O
Nf	O
TP	O
-	O
DNA	O
.	O

Results	O
presented	O
here	O
show	O
that	O
Nf	O
DBP	O
strongly	O
stimulates	O
the	O
formation	O
of	O
the	O
TP	O
-	O
dAMP	O
initiation	O
complex	O
by	O
decreasing	O
the	O
Km	O
for	O
dATP	O
and	O
facilitates	O
the	O
transition	O
from	O
initiation	O
to	O
elongation	O
,	O
as	O
it	O
occurs	O
in	O
phi29	O
(	O
76	O
)	O
.	O

These	O
results	O
point	O
to	O
either	O
a	O
specific	O
and	O
direct	O
contact	O
between	O
DBP	O
and	O
DNA	O
polymerase	O
that	O
promotes	O
conformational	O
changes	O
at	O
the	O
polymerization	O
active	O
site	O
or	O
to	O
an	O
effect	O
of	O
DBP	O
in	O
conferring	O
the	O
optimal	O
template	O
structure	O
to	O
direct	O
initiating	O
nucleotide	O
insertion	O
.	O

A	O
similar	O
role	O
has	O
been	O
proposed	O
for	O
adenovirus	O
DBP	O
,	O
a	O
DNA	O
unwinding	O
protein	O
(	O
77	O
)	O
.	O

As	O
in	O
the	O
case	O
of	O
phi29	O
and	O
Nf	O
DBP	O
,	O
this	O
protein	O
stimulates	O
the	O
rate	O
of	O
initiation	O
also	O
by	O
decreasing	O
the	O
Km	O
for	O
the	O
initiating	O
nucleotide	O
(	O
74	O
)	O
.	O

The	O
fact	O
that	O
an	O
adenovirus	O
DBP	O
mutant	O
defective	O
in	O
unwinding	O
can	O
still	O
stimulate	O
initiation	O
precludes	O
the	O
unwinding	O
role	O
as	O
the	O
one	O
responsible	O
for	O
such	O
an	O
activation	O
(	O
77	O
,	O
78	O
)	O
.	O

In	O
this	O
case	O
,	O
contacts	O
between	O
DBP	O
and	O
pTP	O
/	O
DNA	O
polymerase	O
complex	O
have	O
been	O
reported	O
(	O
77	O
)	O
.	O

The	O
effect	O
of	O
Nf	O
DBP	O
in	O
promoting	O
elongation	O
of	O
the	O
initiation	O
products	O
could	O
be	O
due	O
to	O
a	O
decrease	O
of	O
the	O
Km	O
also	O
for	O
the	O
incorporation	O
of	O
the	O
dNMPs	O
during	O
the	O
transition	O
stage	O
from	O
initiation	O
to	O
elongation	O
,	O
to	O
a	O
different	O
type	O
of	O
contact	O
with	O
the	O
DNA	O
polymerase	O
that	O
helps	O
transition	O
to	O
elongation	O
,	O
or	O
both	O
.	O

The	O
similarity	O
in	O
replication	O
rates	O
when	O
comparing	O
M13	O
DNA	O
replication	O
,	O
performed	O
in	O
the	O
absence	O
of	O
DBP	O
(	O
2400	O
nt	O
/	O
min	O
)	O
,	O
with	O
Nf	O
TP	O
-	O
DNA	O
replication	O
in	O
the	O
presence	O
of	O
DBP	O
(	O
2260	O
nt	O
/	O
min	O
)	O
,	O
suggests	O
that	O
the	O
DBP	O
stimulatory	O
role	O
is	O
restricted	O
to	O
the	O
first	O
phases	O
of	O
Nf	O
TP	O
-	O
DNA	O
replication	O
.	O

Figures	O
and	O
Tables	O

Figure	O
1	O

Modular	O
crosstalking	O
in	O
synthetic	O
gene	O
networks	O
.	O

A	O
promoter	O
with	O
binding	O
sites	O
for	O
lambda	O
cI	O
dimers	O
(	O
OR1	O
and	O
OR2	O
)	O
and	O
for	O
the	O
lac	O
repressor	O
(	O
Olac	O
)	O
controls	O
the	O
production	O
of	O
the	O
lac	O
repressor	O
(	O
encoded	O
by	O
lacI	O
)	O
in	O
module	O
1	O
and	O
lambda	O
cI	O
(	O
encoded	O
by	O
cI	O
)	O
in	O
module	O
2	O
.	O

The	O
lac	O
repressor	O
and	O
lambda	O
cI	O
dimers	O
are	O
represented	O
by	O
blue	O
ellipsoids	O
and	O
red	O
circles	O
,	O
respectively	O
.	O

When	O
the	O
two	O
modules	O
are	O
put	O
together	O
,	O
two	O
pairs	O
of	O
lambda	O
cI	O
dimers	O
bound	O
at	O
different	O
operators	O
can	O
loop	O
DNA	O
and	O
octamerize	O
,	O
forming	O
a	O
tetramer	O
of	O
dimers	O
.	O

2	O
-	O
Theory	O

Scanning	O
holography	O
is	O
a	O
two	O
-	O
pupil	O
interaction	O
method	O
[	O
8	O
]	O
by	O
which	O
incoherent	O
imaging	O
with	O
complex	O
point	O
-	O
spread	O
-	O
functions	O
(	O
PSF	O
)	O
is	O
possible	O
.	O

The	O
method	O
has	O
recently	O
been	O
applied	O
to	O
the	O
recording	O
of	O
high	O
resolution	O
holographic	O
images	O
of	O
incoherent	O
objects	O
and	O
fluorescent	O
biological	O
specimens	O
[	O
6	O
,	O
7	O
]	O
.	O

A	O
single	O
-	O
sideband	O
in	O
-	O
line	O
Fresnel	O
hologram	O
is	O
obtained	O
by	O
a	O
2D	O
raster	O
scan	O
of	O
the	O
object	O
with	O
the	O
superposed	O
3D	O
diffraction	O
distributions	O
of	O
two	O
pupils	O
,	O
as	O
sketched	O
in	O
fig	O
.	O

1	O
.	O

The	O
two	O
pupil	O
distributions	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
and	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3297	O
@	O
from	O
the	O
same	O
source	O
(	O
for	O
example	O
,	O
but	O
not	O
necessarily	O
,	O
a	O
laser	O
)	O
are	O
combined	O
by	O
a	O
beam	O
splitter	O
in	O
the	O
pupil	O
plane	O
of	O
the	O
objective	O
where	O
they	O
interfere	O
,	O
forming	O
a	O
Fresnel	O
pattern	O
with	O
a	O
depth	O
-	O
dependent	O
Fresnel	O
number	O
.	O

To	O
obtain	O
the	O
conventional	O
point	O
-	O
spread	O
function	O
of	O
wide	O
field	O
imaging	O
,	O
P1	O
is	O
chosen	O
as	O
a	O
point	O
source	O
,	O
and	O
P2	O
as	O
a	O
spherical	O
wave	O
with	O
appropriate	O
curvature	O
.	O

The	O
3D	O
specimen	O
is	O
placed	O
in	O
the	O
focal	O
region	O
of	O
the	O
objective	O
,	O
and	O
scattered	O
lights	O
(	O
transmitted	O
,	O
reflected	O
,	O
and	O
fluorescent	O
)	O
are	O
collected	O
by	O
non	O
-	O
imaging	O
detectors	O
.	O

The	O
hologram	O
data	O
can	O
be	O
obtained	O
by	O
heterodyne	O
detection	O
with	O
one	O
of	O
the	O
pupils	O
shifted	O
in	O
frequency	O
(	O
as	O
done	O
in	O
this	O
work	O
)	O
,	O
or	O
by	O
a	O
homodyne	O
method	O
requiring	O
the	O
capture	O
of	O
at	O
least	O
three	O
frames	O
with	O
different	O
relative	O
phases	O
between	O
the	O
two	O
pupils	O
[	O
9	O
]	O
.	O

The	O
amplitude	O
distribution	O
of	O
the	O
illuminating	O
beam	O
,	O
in	O
a	O
transverse	O
plane	O
at	O
an	O
axial	O
distance	O
z	O
from	O
the	O
focal	O
plane	O
of	O
the	O
objective	O
,	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
combined	O
pupil	O
distributions	O
[	O
10	O
]	O
.	O

Namely	O
:	O

Figure	O
1	O

Experimental	O
set	O
up	O
of	O
a	O
scanning	O
holographic	O
microscope	O
.	O

Sketch	O
of	O
the	O
experimental	O
setup	O
.	O

M	O
'	O
s	O
are	O
mirrors	O
,	O
BS	O
'	O
s	O
are	O
beam	O
splitters	O
,	O
EO	O
is	O
an	O
electro	O
-	O
optic	O
phase	O
modulator	O
.	O

Lens	O
L1	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
produces	O
the	O
desired	O
Fresnel	O
pattern	O
in	O
the	O
focal	O
plane	O
of	O
L2	O
(	O
achromat	O
doublet	O
16	O
cm	O
focal	O
length	O
)	O
.	O

L2	O
and	O
the	O
objective	O
form	O
a	O
4	O
-	O
f	O
system	O
projecting	O
a	O
reduced	O
image	O
of	O
the	O
Fresnel	O
pattern	O
onto	O
the	O
specimen	O
.	O

L3	O
(	O
achromat	O
doublet	O
12	O
cm	O
focal	O
length	O
)	O
projects	O
the	O
images	O
of	O
the	O
pupils	O
on	O
the	O
pinhole	O
detector	O
.	O

(	O
Not	O
shown	O
are	O
the	O
beam	O
expanders	O
used	O
to	O
illuminate	O
the	O
pupils	O
)	O
.	O

S	O
(	O
r	O
-	O
-	O
>	O
,	O
z	O
)	O
=	O
F	O
-	O
1	O
{	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
+	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
(	O
-	O
iOmegat	O
]	O
}	O
,	O
(	O
1a	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
@	O
5D95	O
@	O

where	O

P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
=	O
P	O
~	O
1	O
,	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
exp	O
(	O
ipilambdazrho2	O
)	O
(	O
1b	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGH9aqpcuWGqbaugaacamaaBaaaleaacqaIXaqmcqGGSaalcqaIYaGmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCcqGGOaakcqWGPbqAcqWFapaCcqWF7oaBcqWG6bGEcqWFbpGCdaahaaWcbeqaaiabikdaYaaakiabcMcaPiaaxMaacaWLjaWaaeWaaeaacqaIXaqmcqqGIbGyaiaawIcacaGLPaaaaaa	O
@	O
53A8	O
@	O

are	O
the	O
generalized	O
defocused	O
pupils	O
[	O
11	O
]	O
.	O

F	O
-	O
1	O
stands	O
for	O
inverse	O
Fourier	O
transform	O
,	O
and	O
Omega	O
is	O
the	O
frequency	O
shift	O
of	O
one	O
of	O
the	O
pupils	O
.	O

The	O
transverse	O
spatial	O
frequency	O
vector	O
rho	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaaiiGacuWFbpGCgaWcaaaa	O
@	O
2E85	O
@	O
=	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
/	O
lambdaf0	O
is	O
proportional	O
to	O
the	O
real	O
space	O
coordinate	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
P	O
in	O
the	O
pupil	O
plane	O
[	O
10	O
]	O
.	O
lambda	O
is	O
the	O
wavelength	O
of	O
the	O
illumination	O
,	O
and	O
f0	O
is	O
the	O
focal	O
length	O
of	O
the	O
objective	O
.	O

The	O
two	O
pupils	O
used	O
to	O
obtain	O
an	O
in	O
-	O
line	O
Fresnel	O
hologram	O
are	O
,	O
respectively	O
,	O
a	O
spherical	O
wave	O
filling	O
the	O
pupil	O
of	O
the	O
objective	O
,	O
and	O
a	O
point	O
at	O
the	O
center	O
of	O
that	O
pupil	O
:	O

P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkaaa	O
@	O
3295	O
@	O
=	O
exp	O
(	O
ipilambdaz0rho2	O
)	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O

P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
delta	O
(	O
rho	O
-	O
-	O
>	O
)	O
.	O

(	O
2	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGqbaugaacamaaBaaaleaacqaIYaGmaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpcqWF0oazcqGGOaakcuWFbpGCgaWcaiabcMcaPiabc6caUiaaxMaacaWLjaWaaeWaaeaacqaIYaGmaiaawIcacaGLPaaaaaa	O
@	O
3D5F	O
@	O

circ	O
(	O
x	O
)	O
is	O
a	O
disc	O
function	O
of	O
unit	O
radius	O
.	O

rhoMAX	O
=	O
sinalpha	O
/	O
lambda	O
is	O
the	O
cutoff	O
frequency	O
of	O
the	O
objective	O
,	O
where	O
sinalpha	O
=	O
NA	O
is	O
its	O
numerical	O
aperture	O
.	O

The	O
Fresnel	O
pattern	O
projected	O
on	O
the	O
object	O
is	O
the	O
interference	O
of	O
the	O
Fourier	O
transforms	O
of	O
the	O
two	O
pupils	O
,	O
namely	O
a	O
spherical	O
wave	O
and	O
a	O
plane	O
wave	O
in	O
the	O
paraxial	O
approximation	O
.	O

The	O
Fresnel	O
number	O
of	O
this	O
pattern	O
is	O
determined	O
by	O
the	O
free	O
parameter	O
z0	O
,	O
which	O
is	O
the	O
distance	O
from	O
the	O
objective	O
'	O
s	O
focal	O
plane	O
to	O
the	O
point	O
where	O
the	O
spherical	O
wave	O
comes	O
to	O
a	O
focus	O
.	O

There	O
are	O
two	O
possible	O
modes	O
of	O
operation	O
,	O
depending	O
on	O
the	O
detector	O
geometry	O
[	O
5	O
]	O
.	O

With	O
a	O
spatially	O
integrating	O
detector	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
with	O
the	O
desired	O
complex	O
PSF	O
(	O
namely	O
,	O
a	O
spherical	O
wave	O
with	O
a	O
radius	O
of	O
curvature	O
z0	O
+	O
z	O
,	O
and	O
a	O
radius	O
a	O
=	O
z0sinalpha	O
,	O
in	O
this	O
case	O
)	O
.	O

This	O
detection	O
mode	O
leads	O
to	O
a	O
hologram	O
from	O
which	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
scattering	O
intensity	O
,	O
absorption	O
,	O
and	O
fluorescence	O
intensity	O
can	O
be	O
reconstructed	O
.	O

With	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
pupil	O
plane	O
,	O
the	O
resulting	O
data	O
is	O
a	O
convolution	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
with	O
the	O
same	O
complex	O
PSF	O
.	O

The	O
reconstruction	O
of	O
this	O
hologram	O
gives	O
the	O
three	O
-	O
dimensional	O
distribution	O
of	O
the	O
specimen	O
'	O
s	O
complex	O
amplitude	O
transmittance	O
.	O

In	O
particular	O
,	O
assuming	O
that	O
multiple	O
scattering	O
can	O
be	O
ignored	O
,	O
the	O
phase	O
of	O
the	O
reconstruction	O
is	O
a	O
quantitative	O
measure	O
of	O
the	O
integrated	O
optical	O
path	O
length	O
through	O
the	O
specimen	O
.	O

These	O
two	O
modes	O
of	O
operation	O
are	O
similar	O
to	O
the	O
usual	O
coherent	O
/	O
incoherent	O
imaging	O
modes	O
of	O
a	O
conventional	O
system	O
,	O
which	O
are	O
obtained	O
by	O
using	O
,	O
respectively	O
,	O
a	O
point	O
source	O
,	O
or	O
a	O
large	O
spatially	O
incoherent	O
source	O
.	O

In	O
scanning	O
holography	O
,	O
the	O
detector	O
size	O
plays	O
a	O
similar	O
role	O
to	O
that	O
of	O
the	O
source	O
size	O
in	O
conventional	O
imaging	O
.	O

For	O
simplicity	O
,	O
let	O
'	O
s	O
assume	O
an	O
object	O
with	O
an	O
amplitude	O
transmittance	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
.	O

Note	O
that	O
for	O
an	O
incoherent	O
or	O
fluorescent	O
object	O
,	O
the	O
phase	O
of	O
the	O
transmitted	O
field	O
is	O
a	O
random	O
variable	O
,	O
and	O
only	O
the	O
intensity	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
is	O
measurable	O
.	O

For	O
a	O
quasi	O
transparent	O
object	O
,	O
the	O
phase	O
is	O
equal	O
to	O
the	O
integrated	O
optical	O
thickness	O
of	O
the	O
object	O
:	O
Phi	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
(	O
2pi	O
/	O
lambda	O
)	O
integraldzn	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
,	O
where	O
n	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
is	O
the	O
3D	O
distribution	O
of	O
refractive	O
index	O
.	O

The	O
amplitude	O
distribution	O
after	O
the	O
object	O
is	O
written	O
as	O

A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
=	O
integraldzS	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
T	O
[	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
-	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
,	O
z	O
]	O
,	O
(	O
3	O
)	O

where	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
S	O
(	O
t	O
)	O
is	O
the	O
instantaneous	O
position	O
of	O
the	O
2D	O
raster	O
scan	O
.	O

The	O
incoherent	O
imaging	O
mode	O
is	O
obtained	O
with	O
a	O
spatially	O
integrating	O
detector	O
,	O
leading	O
to	O
a	O
temporal	O
signal	O
proportional	O
to	O
the	O
integrated	O
intensity	O
,	O
integrald2r	O
|	O
A	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
t	O
)	O
|	O
2	O
,	O
which	O
is	O
stored	O
in	O
the	O
computer	O
.	O

The	O
data	O
corresponding	O
to	O
each	O
hologram	O
line	O
is	O
cut	O
from	O
the	O
signal	O
,	O
and	O
band	O
pass	O
filtered	O
to	O
extract	O
the	O
term	O
oscillating	O
at	O
Omega	O
.	O

The	O
lines	O
are	O
then	O
rearranged	O
in	O
a	O
2D	O
format	O
.	O

The	O
resulting	O
hologram	O
amplitude	O
is	O
found	O
to	O
be	O

HI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldzI	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
[	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
p	O
*	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
,	O
(	O
4	O
)	O

where	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
integral	O
,	O
I	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
=	O
|	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
|	O
2	O
,	O
and	O
p1	O
,	O
2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
are	O
the	O
inverse	O
Fourier	O
transforms	O
of	O
the	O
defocused	O
pupil	O
distributions	O
(	O
eq	O
.	O
1b	O
)	O
.	O

The	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O

The	O
hologram	O
is	O
thus	O
the	O
convolution	O
of	O
the	O
object	O
intensity	O
with	O
a	O
spherical	O
wave	O
,	O
i	O
.	O
e	O
.	O
an	O
in	O
-	O
line	O
single	O
-	O
sideband	O
Gabor	O
hologram	O
.	O

In	O
Fourier	O
space	O
,	O
the	O
hologram	O
can	O
be	O
written	O
as	O

H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
[	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
]	O
,	O
(	O
5	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkdaWadaqaaiqbdcfaqzaaiaWaaSbaaSqaaiabigdaXaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPiabgEPielqbdcfaqzaaiaWaaSbaaSqaaiabikdaYaqabaGccqGGOaakcuWFbpGCgaWcaiabcUda7iabdQha6jabcMcaPaGaay5waiaaw2faaiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI1aqnaiaawIcacaGLPaaaaaa	O
@	O
58FF	O
@	O

where	O
(	O
+	O
)	O
symbolizes	O
a	O
correlation	O
integral	O
.	O

With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O
,	O
in	O
the	O
paraxial	O
approximation	O
,	O

H	O
~	O
I	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzI	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
,	O
(	O
6	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGjbqsaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdMeajzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcyGGLbqzcqGG4baEcqGGWbaCdaWadaqaaiabdMgaPjab	O
=	O
b8aWjab	O
=	O
T7aSjabcIcaOiabdQha6naaBaaaleaacqaIWaamaeqaaOGaey4kaSIaemOEaONaeiykaKIae8xWdi3aaWbaaSqabeaacqaIYaGmaaaakiaawUfacaGLDbaacqWGJbWycqWGPbqAcqWGYbGCcqWGJbWycqGGOaakcqWFbpGCcqGGVaWlcqWFbpGCdaWgaaWcbaGaemyta0KaemyqaeKaemiwaGfabeaakiabcMcaPiabcYcaSiaaxMaacaWLjaWaaeWaaeaacqaI2aGnaiaawIcacaGLPaaaaaa	O
@	O
67E3	O
@	O

which	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
intensity	O
distribution	O
.	O

The	O
coherent	O
imaging	O
mode	O
is	O
obtained	O
by	O
using	O
a	O
pinhole	O
or	O
a	O
point	O
detector	O
at	O
the	O
center	O
of	O
a	O
conjugate	O
plane	O
of	O
the	O
pupil	O
of	O
the	O
objective	O
.	O

This	O
leads	O
to	O
the	O
hologram	O
amplitude	O

HC	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
)	O
=	O
integraldz	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p1	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
[	O
T	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
(	O
+	O
)	O
p2	O
(	O
r	O
-	O
-	O
>	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGYbGCgaWcaaaa	O
@	O
2E2B	O
@	O
,	O
z	O
)	O
]	O
*	O
.	O

(	O
7	O
)	O

Where	O
again	O
,	O
(	O
+	O
)	O
symbolizes	O
a	O
convolution	O
product	O
,	O
and	O
the	O
superscript	O
*	O
stands	O
for	O
complex	O
conjugate	O
.	O

In	O
Fourier	O
space	O
,	O

H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
1	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
(	O
*	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
P	O
~	O
2	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
.	O

(	O
8	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
vr0dc8meaabaqaciaacaGaaeqabaqabeGadaaakeaacuWGibasgaacamaaBaaaleaacqWGdbWqaeqaaOGaeiikaGccciGaf8xWdiNbaSaacqGGPaqkcqGH9aqpdaWdbaqaaiabdsgaKjabdQha6jqbdsfauzaaiaaaleqabeqdcqGHRiI8aOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcuWGqbaugaacamaaBaaaleaacqaIXaqmaeqaaOGaeiikaGIaf8xWdiNbaSaacqGG7aWocqWG6bGEcqGGPaqkcqGHxkcXcuWGubavgaacaiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIafmiuaaLbaGaadaWgaaWcbaGaeGOmaidabeaakiabcIcaOiqb	O
=	O
f8aYzaalaGaei4oaSJaemOEaONaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiIda4aGaayjkaiaawMcaaaaa	O
@	O
5E5B	O
@	O

With	O
the	O
pupils	O
of	O
eq	O
.	O
2	O
,	O
we	O
find	O

H	O
~	O
C	O
(	O
rho	O
-	O
-	O
>	O
)	O
=	O
integraldzT	O
~	O
*	O
(	O
0	O
;	O
z	O
)	O
T	O
~	O
(	O
rho	O
-	O
-	O
>	O
;	O
z	O
)	O
exp	O
[	O
ipilambda	O
(	O
z0	O
+	O
z	O
)	O
rho2	O
]	O
circ	O
(	O
rho	O
/	O
rhoMAX	O
)	O
.	O

(	O
9	O
)	O
MathType	O
@	O
MTEF	O
@	O
5	O
@	O
5	O
@	O
+	O
=	O
feaafiart1ev1aaatCvAUfKttLearuWrP9MDH5MBPbIqV92AaeXatLxBI9gBaebbnrfifHhDYfgasaacH8akY	O
=	O
wiFfYdH8Gipec8Eeeu0xXdbba9frFj0	O
=	O
OqFfea0dXdd9vqai	O
=	O
hGuQ8kuc9pgc9s8qqaq	O
=	O
dirpe0xb9q8qiLsFr0	O
=	O
vr0	O
=	O
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	O
=	O
f8aYjabc	O
+	O
caViab	O
=	O
f8aYnaaBaaaleaacqWGnbqtcqWGbbqqcqWGybawaeqaaOGaeiykaKIaeiOla4IaaCzcaiaaxMaadaqadaqaaiabiMda5aGaayjkaiaawMcaaaaa	O
@	O
6F41	O
@	O

Aside	O
from	O
an	O
inconsequential	O
complex	O
constant	O
(	O
the	O
first	O
term	O
under	O
the	O
integral	O
)	O
,	O
eq	O
.	O
9	O
is	O
the	O
Fourier	O
transform	O
of	O
the	O
Fresnel	O
hologram	O
of	O
the	O
object	O
'	O
s	O
complex	O
amplitude	O
distribution	O
.	O

Thus	O
,	O
the	O
reconstruction	O
of	O
the	O
hologram	O
recorded	O
in	O
the	O
coherent	O
mode	O
carries	O
a	O
quantitative	O
measure	O
of	O
the	O
object	O
'	O
s	O
phase	O
distribution	O
.	O

Comparison	O
of	O
the	O
Predicted	O
Irr	O
Regulon	O
and	O
ICE	O
Motifs	O
with	O
the	O
Published	O
Expression	O
Microarray	O
Data	O
for	O
Iron	O
-	O
and	O
Irr	O
-	O
Affected	O
Genes	O
in	O
Bradyrhizobium	O
japonicum	O

Background	O

HIV	O
-	O
1	O
infectivity	O
depends	O
on	O
free	O
cholesterol	O
incorporated	O
into	O
the	O
viral	O
envelope	O
.	O

Here	O
,	O
we	O
analyze	O
HIV	O
infectivity	O
in	O
the	O
presence	O
of	O
drugs	O
that	O
stimulate	O
cholesterol	O
efflux	O
.	O

Mass	O
casualty	O
estimation	O
on	O
a	O
geographic	O
basis	O

The	O
Defense	O
Threat	O
Reduction	O
Agency	O
(	O
DTRA	O
)	O
has	O
expended	O
considerable	O
effort	O
to	O
develop	O
models	O
for	O
calculating	O
mass	O
casualties	O
from	O
a	O
nuclear	O
detonation	O
.	O

In	O
order	O
to	O
specifically	O
evaluate	O
urban	O
medical	O
systems	O
vulnerability	O
we	O
are	O
employing	O
the	O
PC	O
based	O
Consequence	O
Assessment	O
Tool	O
Set	O
(	O
CATS	O
)	O
v6	O
,	O
with	O
ESRI	O
'	O
s	O
ArcGIS9	O
[	O
14	O
]	O
,	O
CATS	O
/	O
JACE	O
(	O
Joint	O
Assessment	O
of	O
Catastrophic	O
Events	O
)	O
v5	O
with	O
ESRI	O
'	O
s	O
ArcView	O
3	O
.	O
3	O
,	O
Hazard	O
Prediction	O
and	O
Assessment	O
Capability	O
(	O
HPAC	O
)	O
V4	O
.	O
04SP3	O
[	O
15	O
]	O
,	O
as	O
well	O
as	O
custom	O
GIS	O
and	O
database	O
software	O
applications	O
.	O

HPAC	O
does	O
excellent	O
Chemical	O
Biological	O
and	O
Nuclear	O
(	O
CBN	O
)	O
modeling	O
,	O
although	O
output	O
could	O
provide	O
more	O
flexibility	O
.	O

Additionally	O
,	O
results	O
can	O
be	O
exported	O
to	O
CATS	O
for	O
further	O
analysis	O
and	O
display	O
.	O

All	O
three	O
programs	O
can	O
access	O
the	O
current	O
weather	O
data	O
from	O
both	O
classified	O
and	O
unclassified	O
weather	O
servers	O
.	O

Examples	O
of	O
uses	O
of	O
CATS	O
/	O
HPAC	O
are	O
hurricane	O
,	O
tidal	O
surge	O
and	O
earthquake	O
damage	O
,	O
prediction	O
of	O
the	O
results	O
from	O
nuclear	O
,	O
biological	O
and	O
chemical	O
releases	O
,	O
assessment	O
of	O
persons	O
and	O
infrastructure	O
affected	O
and	O
at	O
risk	O
(	O
e	O
.	O
g	O
.	O
which	O
hospitals	O
and	O
pharmacies	O
are	O
under	O
a	O
CBN	O
plume	O
and	O
are	O
thus	O
out	O
of	O
commission	O
)	O
,	O
and	O
mobilization	O
of	O
surviving	O
and	O
nearby	O
infrastructure	O
outside	O
the	O
plume	O
that	O
would	O
be	O
needed	O
to	O
address	O
healthcare	O
and	O
other	O
emergency	O
response	O
needs	O
of	O
the	O
community	O
.	O

These	O
models	O
have	O
been	O
,	O
and	O
continue	O
to	O
be	O
,	O
developed	O
with	O
a	O
view	O
to	O
better	O
estimating	O
the	O
impact	O
of	O
WMD	O
weapons	O
in	O
an	O
offensive	O
setting	O
.	O

However	O
,	O
recent	O
DTRA	O
enhancements	O
and	O
our	O
modifications	O
have	O
facilitated	O
their	O
use	O
in	O
helping	O
estimate	O
potential	O
casualties	O
from	O
a	O
WMD	O
terrorist	O
incident	O
.	O

One	O
area	O
of	O
intense	O
interest	O
,	O
and	O
somewhat	O
of	O
a	O
vacuum	O
in	O
public	O
health	O
planning	O
,	O
has	O
been	O
the	O
utility	O
of	O
this	O
approach	O
in	O
estimating	O
medical	O
care	O
vulnerabilities	O
in	O
such	O
an	O
attack	O
,	O
and	O
for	O
the	O
calculation	O
of	O
the	O
distribution	O
of	O
surviving	O
medical	O
care	O
resources	O
.	O

While	O
much	O
work	O
has	O
already	O
occurred	O
in	O
estimating	O
the	O
impact	O
of	O
chemical	O
weapons	O
(	O
due	O
to	O
the	O
dual	O
use	O
in	O
chemical	O
spill	O
management	O
from	O
transportation	O
and	O
industrial	O
accidents	O
)	O
,	O
or	O
in	O
nuclear	O
power	O
plant	O
accident	O
management	O
,	O
much	O
less	O
research	O
and	O
development	O
has	O
gone	O
into	O
estimating	O
the	O
impact	O
on	O
our	O
civilian	O
population	O
of	O
a	O
nuclear	O
weapon	O
detonation	O
from	O
a	O
terrorist	O
incident	O
in	O
a	O
large	O
urban	O
area	O
.	O

The	O
models	O
already	O
calculate	O
such	O
factors	O
as	O
the	O
impact	O
of	O
blast	O
,	O
thermal	O
effects	O
and	O
fallout	O
,	O
but	O
results	O
are	O
often	O
not	O
available	O
at	O
the	O
detail	O
level	O
needed	O
for	O
civil	O
defense	O
purposes	O
,	O
casualty	O
management	O
,	O
and	O
planning	O
the	O
use	O
of	O
scarce	O
health	O
resources	O
in	O
response	O
to	O
a	O
nuclear	O
weapon	O
detonation	O
.	O

Furthermore	O
,	O
the	O
models	O
do	O
not	O
readily	O
facilitate	O
the	O
calculation	O
of	O
injuries	O
from	O
multiple	O
effects	O
such	O
as	O
burns	O
and	O
blast	O
with	O
fallout	O
or	O
prompt	O
radiation	O
.	O

The	O
complexity	O
of	O
the	O
urban	O
three	O
-	O
dimensional	O
landscape	O
and	O
its	O
local	O
impact	O
on	O
thermal	O
,	O
blast	O
and	O
radiation	O
is	O
also	O
poorly	O
understood	O
.	O

Additionally	O
,	O
given	O
their	O
traditional	O
world	O
-	O
wide	O
focus	O
,	O
and	O
the	O
increased	O
sensitivity	O
to	O
providing	O
information	O
on	O
the	O
U	O
.	O
S	O
.	O
A	O
.	O
of	O
use	O
to	O
terrorists	O
,	O
the	O
models	O
do	O
not	O
provide	O
detailed	O
or	O
current	O
data	O
that	O
exists	O
for	O
the	O
United	O
States	O
that	O
would	O
help	O
provide	O
better	O
casualty	O
estimates	O
and	O
response	O
.	O

The	O
models	O
can	O
be	O
customized	O
locally	O
and	O
data	O
updated	O
if	O
the	O
user	O
has	O
sufficient	O
expertise	O
.	O

However	O
,	O
there	O
is	O
often	O
a	O
significant	O
duplication	O
of	O
effort	O
due	O
to	O
overlapping	O
jurisdictions	O
and	O
the	O
lack	O
of	O
data	O
sharing	O
due	O
to	O
security	O
and	O
other	O
considerations	O
.	O

CATS	O
and	O
HPAC	O
are	O
also	O
useful	O
for	O
creating	O
realistic	O
scenarios	O
for	O
training	O
and	O
planning	O
before	O
a	O
disaster	O
strikes	O
,	O
thus	O
enabling	O
responders	O
to	O
drill	O
and	O
exercise	O
so	O
they	O
know	O
roughly	O
what	O
to	O
expect	O
and	O
how	O
to	O
react	O
.	O

Contingency	O
plans	O
can	O
be	O
created	O
using	O
comprehensive	O
national	O
and	O
more	O
detailed	O
population	O
and	O
infrastructure	O
data	O
.	O

Should	O
disaster	O
strike	O
,	O
the	O
affected	O
population	O
and	O
the	O
impact	O
on	O
critical	O
facilities	O
can	O
be	O
quickly	O
assessed	O
,	O
although	O
efforts	O
frequently	O
need	O
to	O
be	O
expended	O
to	O
ensure	O
regional	O
and	O
local	O
databases	O
are	O
current	O
and	O
useful	O
.	O

Case	O
Presentation	O

The	O
patient	O
is	O
an	O
80	O
year	O
old	O
male	O
with	O
diabetes	O
mellitus	O
and	O
hypertension	O
,	O
who	O
at	O
age	O
74	O
(	O
March	O
2001	O
)	O
had	O
received	O
a	O
living	O
non	O
-	O
related	O
donor	O
kidney	O
transplant	O
.	O

At	O
that	O
time	O
he	O
was	O
discharged	O
with	O
a	O
double	O
immunosuppressive	O
therapy	O
consisting	O
of	O
prednisone	O
20	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
1	O
.	O
5	O
gr	O
/	O
day	O
.	O

No	O
calcineurin	O
inhibitor	O
was	O
administered	O
.	O

His	O
prednisone	O
dose	O
was	O
further	O
decreased	O
to	O
5	O
mg	O
/	O
day	O
and	O
mophetil	O
mycophenolate	O
doses	O
sustained	O
.	O

In	O
November	O
2001	O
he	O
developed	O
cutaneous	O
purple	O
elevated	O
lesions	O
in	O
his	O
lower	O
limbs	O
that	O
were	O
diagnosed	O
as	O
KS	O
by	O
skin	O
biopsy	O
.	O

He	O
received	O
19	O
administrations	O
of	O
vincristine	O
(	O
1	O
mg	O
)	O
and	O
bleomycin	O
(	O
15	O
mg	O
)	O
weekly	O
that	O
resulted	O
in	O
flattening	O
and	O
fading	O
of	O
the	O
lesions	O
.	O

Treatment	O
was	O
discontinued	O
for	O
two	O
months	O
,	O
and	O
KS	O
recurred	O
,	O
with	O
pain	O
and	O
edema	O
in	O
both	O
legs	O
.	O

On	O
July	O
2002	O
,	O
with	O
an	O
almost	O
100	O
%	O
involvement	O
of	O
his	O
lower	O
limbs	O
skin	O
with	O
KS	O
but	O
no	O
visceral	O
involvement	O
he	O
received	O
50	O
mg	O
of	O
liposomal	O
-	O
adriamycin	O
.	O

In	O
addition	O
,	O
he	O
was	O
then	O
prescribed	O
valganciclovir	O
450	O
mg	O
BID	O
(	O
corrected	O
for	O
creatinine	O
clearance	O
)	O
[	O
7	O
]	O
and	O
three	O
additional	O
administrations	O
of	O
liposomal	O
-	O
adriamycin	O
,	O
up	O
to	O
December	O
2002	O
.	O

He	O
showed	O
40	O
%	O
response	O
again	O
with	O
early	O
relapse	O
.	O

On	O
January	O
2003	O
the	O
patient	O
developed	O
disseminated	O
herpes	O
zoster	O
,	O
which	O
was	O
treated	O
with	O
IV	O
acyclovir	O
.	O

In	O
May	O
2003	O
KS	O
progression	O
was	O
observed	O
and	O
received	O
radiotherapy	O
with	O
no	O
benefit	O
Figure	O
1	O
.	O

In	O
August	O
2003	O
he	O
started	O
oral	O
etoposide	O
at	O
50	O
mg	O
QD	O
for	O
two	O
weeks	O
followed	O
by	O
two	O
weeks	O
off	O
until	O
May	O
2004	O
achieving	O
a	O
very	O
slow	O
50	O
%	O
response	O
.	O

Tolerance	O
was	O
good	O
and	O
serum	O
creatinine	O
remain	O
stable	O
at	O
around	O
1	O
,	O
4	O
mg	O
/	O
dl	O
.	O

Mophetil	O
mycophenolate	O
dose	O
was	O
reduced	O
to	O
1	O
g	O
/	O
day	O
and	O
prednisone	O
to	O
2	O
.	O
5	O
mg	O
/	O
day	O
.	O

Figure	O
1	O

Kaposi	O
'	O
s	O
sarcoma	O
progressions	O
after	O
chemotherapy	O
withdrawal	O
,	O
both	O
lower	O
limbs	O
were	O
completely	O
covered	O
with	O
Kaposi	O
'	O
s	O
Sarcoma	O
(	O
June	O
2003	O
)	O
.	O

On	O
May	O
2004	O
the	O
patient	O
requested	O
a	O
second	O
opinion	O
and	O
was	O
prescribed	O
Imatinib	O
200	O
mg	O
qd	O
for	O
two	O
weeks	O
followed	O
by	O
400	O
mg	O
qd	O
.	O

After	O
four	O
weeks	O
of	O
Imatinib	O
,	O
his	O
health	O
deteriorated	O
rapidly	O
,	O
he	O
developed	O
anasarca	O
,	O
worsening	O
of	O
KS	O
,	O
his	O
serum	O
creatinine	O
increased	O
from	O
1	O
.	O
4	O
mg	O
/	O
dl	O
to	O
2	O
.	O
3	O
mg	O
/	O
dl	O
and	O
he	O
developed	O
grade	O
4	O
granulocytopenia	O
(	O
Figure	O
2	O
)	O
.	O

The	O
patient	O
was	O
hospitalized	O
with	O
fever	O
and	O
was	O
started	O
on	O
IV	O
antibiotics	O
and	O
daily	O
G	O
-	O
CSF	O
for	O
four	O
days	O
after	O
which	O
his	O
WBC	O
count	O
normalized	O
.	O

Two	O
weeks	O
later	O
the	O
creatinine	O
level	O
returned	O
to	O
1	O
.	O
5	O
mg	O
/	O
dl	O
.	O

On	O
February	O
2005	O
he	O
was	O
started	O
on	O
30	O
mg	O
of	O
paclitaxel	O
IV	O
every	O
three	O
weeks	O
.	O

After	O
three	O
courses	O
with	O
no	O
clinical	O
benefit	O
he	O
developed	O
a	O
skin	O
rash	O
that	O
prompted	O
discontinuation	O
.	O

Figure	O
2	O

Patient	O
developed	O
anasarca	O
with	O
rapid	O
progression	O
of	O
Kaposi	O
'	O
s	O
Sarcoma	O
after	O
four	O
weeks	O
of	O
taking	O
Imatinib	O
(	O
June	O
2004	O
)	O
.	O

On	O
April	O
2005	O
,	O
he	O
was	O
started	O
on	O
Sirolimus	O
2	O
mg	O
a	O
day	O
,	O
and	O
after	O
8	O
weeks	O
escalated	O
to	O
4	O
mg	O
a	O
day	O
.	O

Three	O
weeks	O
later	O
mophetil	O
mycophenolate	O
and	O
prednisone	O
were	O
discontinued	O
.	O

Sustained	O
and	O
significant	O
KS	O
regression	O
was	O
evident	O
after	O
16	O
weeks	O
,	O
but	O
he	O
developed	O
a	O
basal	O
cell	O
carcinoma	O
and	O
pneumonia	O
that	O
required	O
hospital	O
admission	O
;	O
Sirolimus	O
dose	O
was	O
lowered	O
to	O
2	O
mg	O
a	O
day	O
.	O

Thereafter	O
his	O
clinical	O
course	O
has	O
been	O
satisfactory	O
with	O
continuous	O
and	O
progressive	O
regression	O
of	O
KS	O
lesions	O
(	O
Figure	O
3	O
)	O
.	O

His	O
serum	O
creatinine	O
has	O
remained	O
under	O
1	O
.	O
6	O
mg	O
/	O
dl	O
and	O
he	O
has	O
not	O
developed	O
new	O
infectious	O
episodes	O
.	O

Figure	O
3	O

Extensive	O
regression	O
of	O
Kaposi	O
Sarcoma	O
after	O
immune	O
-	O
suppression	O
was	O
changed	O
to	O
Sirolimus	O
,	O
(	O
14	O
months	O
later	O
)	O
,	O
he	O
only	O
has	O
hyperpigmented	O
areas	O
at	O
knee	O
levels	O
,	O
skin	O
looks	O
thin	O
and	O
delicate	O
and	O
easily	O
bruised	O
(	O
July	O
2006	O
)	O
.	O

Step	O
-	O
wise	O
logistic	O
regression	O
(	O
STEPLOG	O
)	O

The	O
group	O
variable	O
was	O
considered	O
as	O
an	O
ordinal	O
(	O
or	O
binary	O
)	O
dependent	O
variable	O
and	O
the	O
feature	O
vector	O
(	O
multiple	O
marker	O
IBD	O
estimates	O
and	O
covariates	O
)	O
as	O
the	O
independent	O
variables	O
.	O

A	O
nonlinear	O
relationship	O
(	O
logit	O
)	O
between	O
the	O
dependent	O
and	O
independent	O
variables	O
was	O
taken	O
.	O

For	O
binary	O
data	O
(	O
collapsing	O
concordantly	O
affected	O
or	O
unaffected	O
sib	O
pair	O
into	O
one	O
group	O
)	O
,	O
a	O
conventional	O
logistic	O
regression	O
was	O
used	O
.	O

For	O
ordinal	O
data	O
,	O
the	O
SAS	O
LOGISTIC	O
[	O
8	O
]	O
procedure	O
fits	O
a	O
parallel	O
lines	O
regression	O
model	O
based	O
on	O
the	O
cumulative	O
distribution	O
probabilities	O
of	O
response	O
categories	O
,	O
rather	O
than	O
on	O
their	O
individual	O
probabilities	O
.	O

The	O
statistical	O
P	O
-	O
value	O
for	O
each	O
(	O
selected	O
)	O
independent	O
variable	O
was	O
obtained	O
from	O
the	O
final	O
model	O
fitting	O
with	O
only	O
selected	O
variables	O
included	O
via	O
an	O
asymptotic	O
chi	O
-	O
squared	O
statistic	O
.	O

Additional	O
File	O
1	O

Appendix	O
1	O
.	O

Indications	O
for	O
liver	O
function	O
tests	O
with	O
no	O
obvious	O
liver	O
disease	O
,	O
and	O
consequent	O
investigations	O

Hypothetical	O
distribution	O
patterns	O
of	O
the	O
meadow	O
brown	O
Maniola	O
jurtina	O
in	O
Europe	O
during	O
the	O
last	O
glacial	O
maximum	O
(	O
dark	O
hatched	O
areas	O
)	O
.	O

Postglacial	O
expansions	O
are	O
indicated	O
by	O
solid	O
arrows	O
.	O

The	O
postulated	O
actual	O
hybrid	O
zone	O
is	O
shown	O
by	O
the	O
hatched	O
area	O
.	O

Question	O
marks	O
indicate	O
lack	O
of	O
information	O
concerning	O
ancient	O
distribution	O
patterns	O
in	O
the	O
South	O
and	O
present	O
distribution	O
of	O
hybrid	O
populations	O
in	O
the	O
North	O
.	O

Redrawn	O
from	O
Schmitt	O
et	O
.	O

al	O
.	O

[	O
36	O
]	O
;	O
based	O
on	O
Thomson	O
[	O
37	O
]	O
and	O
Schmitt	O
et	O
al	O
.	O

[	O
36	O
]	O
.	O

Representative	O
PCR	O
/	O
LDR	O
results	O
for	O
HPTs	O
in	O
fimX	O
,	O
BP0059	O
,	O
BP0880	O
,	O
sphB2	O
,	O
ptxA	O
,	O
and	O
bhuR	O
.	O

Raw	O
capillary	O
electrophoresis	O
data	O
for	O
ligation	O
products	O
(	O
green	O
)	O
and	O
molecular	O
weight	O
standards	O
(	O
red	O
)	O
displayed	O
as	O
if	O
an	O
electrophoretic	O
gel	O
image	O
.	O

Assayed	O
locus	O
is	O
indicated	O
at	O
the	O
top	O
of	O
each	O
panel	O
;	O
strain	O
and	O
length	O
of	O
its	O
HPT	O
allele	O
are	O
noted	O
above	O
each	O
lane	O
.	O

Representative	O
LDR	O
results	O
are	O
depicted	O
here	O
;	O
for	O
complete	O
data	O
from	O
all	O
strains	O
see	O
Additional	O
files	O
8	O
,	O
9	O
,	O
10	O
,	O
11	O
,	O
12	O
,	O
and	O
13	O
.	O

BP0880	O
,	O
BP0059	O
,	O
fimX	O
,	O
and	O
sphB2	O
HPTs	O
were	O
screened	O
by	O
uniplex	O
LDR	O
reactions	O
containing	O
only	O
the	O
discriminating	O
oligonucleotide	O
that	O
targets	O
the	O
Tohama	O
I	O
sequence	O
.	O

The	O
ptxA	O
and	O
bhuR	O
HPTs	O
were	O
screened	O
by	O
multiplex	O
reactions	O
that	O
contain	O
all	O
three	O
discriminating	O
oligonucleotides	O
.	O

Letters	O
in	O
teal	O
indicate	O
molecular	O
weight	O
standards	O
as	O
labeled	O
in	O
the	O
corresponding	O
supplementary	O
figures	O
.	O

Ligation	O
products	O
(	O
arrows	O
)	O
are	O
labeled	O
using	O
the	O
notation	O
described	O
in	O
the	O
legend	O
to	O
Figure	O
1	O
.	O

The	O
open	O
arrowhead	O
indicates	O
a	O
synthesis	O
artifact	O
in	O
the	O
BP0059	O
common	O
oligonucleotide	O
preparation	O
.	O

Supporting	O
Information	O

Alternate	O
Language	O
Article	O
S1	O

Translation	O
of	O
the	O
manuscript	O
into	O
French	O
by	O
EL	O

(	O
201	O
KB	O
DOC	O
)	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Results	O

Here	O
we	O
include	O
data	O
obtained	O
from	O
active	O
,	O
oscillatory	O
brain	O
slices	O
as	O
well	O
as	O
from	O
recordings	O
during	O
cortical	O
slow	O
oscillations	O
in	O
anesthetized	O
animals	O
.	O

All	O
recordings	O
included	O
in	O
this	O
study	O
were	O
obtained	O
from	O
the	O
visual	O
cortex	O
of	O
the	O
ferret	O
(	O
in	O
vitro	O
)	O
,	O
cat	O
(	O
in	O
vivo	O
)	O
and	O
from	O
barrel	O
cortex	O
of	O
the	O
rat	O
(	O
in	O
vivo	O
)	O
.	O

Twenty	O
-	O
nine	O
neurons	O
recorded	O
from	O
ferret	O
cortical	O
slices	O
are	O
included	O
in	O
this	O
study	O
(	O
22	O
regular	O
spiking	O
(	O
RS	O
)	O
;	O
5	O
chattering	O
(	O
CH	O
)	O
and	O
2	O
intrinsic	O
bursting	O
(	O
IB	O
)	O
)	O
,	O
27	O
neurons	O
from	O
cat	O
visual	O
cortex	O
in	O
vivo	O
(	O
14	O
RS	O
;	O
5	O
CH	O
;	O
2	O
IB	O
;	O
3	O
fast	O
spiking	O
(	O
FS	O
)	O
;	O
plus	O
3	O
non	O
classified	O
)	O
and	O
14	O
neurons	O
from	O
rat	O
barrel	O
cortex	O
in	O
vivo	O
(	O
12	O
RS	O
;	O
1	O
CH	O
;	O
1	O
IB	O
)	O
.	O

Synaptic	O
potentials	O
were	O
evoked	O
by	O
electric	O
shocks	O
(	O
intracortical	O
or	O
thalamocortical	O
connections	O
)	O
or	O
by	O
means	O
of	O
sensory	O
(	O
visual	O
or	O
whisker	O
)	O
stimulation	O
.	O

The	O
main	O
results	O
are	O
:	O
1	O
)	O
Synaptic	O
potentials	O
show	O
more	O
paired	O
pulsed	O
facilitation	O
and	O
synaptic	O
augmentation	O
in	O
active	O
than	O
in	O
silent	O
cortical	O
networks	O
and	O
2	O
)	O
Synaptic	O
potentials	O
occurring	O
during	O
up	O
or	O
activated	O
states	O
of	O
the	O
cortex	O
increased	O
their	O
amplitude	O
with	O
respect	O
to	O
those	O
occurring	O
during	O
down	O
states	O
.	O

INTRODUCTION	O

Comparing	O
genomic	O
sequences	O
across	O
related	O
species	O
is	O
a	O
fruitful	O
source	O
of	O
biological	O
insight	O
.	O

Functional	O
elements	O
such	O
as	O
exons	O
tend	O
to	O
exhibit	O
significant	O
sequence	O
similarity	O
due	O
to	O
purifying	O
selection	O
,	O
whereas	O
regions	O
that	O
are	O
not	O
functional	O
tend	O
to	O
be	O
neutrally	O
evolving	O
and	O
thus	O
less	O
conserved	O
.	O

The	O
first	O
step	O
in	O
comparing	O
genomic	O
sequences	O
is	O
to	O
align	O
them	O
-	O
-	O
to	O
map	O
the	O
letters	O
of	O
the	O
sequences	O
to	O
each	O
other	O
.	O

After	O
an	O
alignment	O
is	O
computed	O
,	O
visualization	O
frameworks	O
become	O
essential	O
to	O
enable	O
users	O
to	O
interact	O
with	O
the	O
sequence	O
and	O
conservation	O
data	O
,	O
especially	O
in	O
the	O
context	O
of	O
longer	O
DNA	O
sequences	O
or	O
whole	O
genomes	O
.	O

Visualization	O
frameworks	O
should	O
be	O
easy	O
to	O
understand	O
by	O
a	O
biologist	O
and	O
provide	O
insight	O
into	O
the	O
mutations	O
that	O
a	O
particular	O
genomic	O
locus	O
has	O
undergone	O
.	O

The	O
VISTA	O
portal	O
is	O
a	O
comprehensive	O
comparative	O
genomics	O
resource	O
that	O
provides	O
biomedical	O
scientists	O
with	O
a	O
single	O
unified	O
framework	O
to	O
generate	O
and	O
download	O
multiple	O
sequence	O
alignments	O
,	O
visualize	O
the	O
results	O
in	O
the	O
context	O
of	O
existing	O
annotations	O
and	O
analyze	O
comparative	O
results	O
in	O
search	O
for	O
important	O
sequence	O
signals	O
in	O
alignments	O
.	O

The	O
VISTA	O
suite	O
of	O
programs	O
has	O
been	O
in	O
development	O
and	O
continued	O
use	O
since	O
2000	O
(	O
1	O
-	O
4	O
)	O
.	O

It	O
was	O
originally	O
developed	O
for	O
the	O
alignment	O
and	O
comparative	O
analysis	O
of	O
long	O
genomic	O
sequences	O
and	O
later	O
was	O
expanded	O
to	O
pair	O
-	O
wise	O
and	O
multiple	O
alignment	O
of	O
vertebrate	O
genomes	O
.	O

VISTA	O
has	O
popularized	O
the	O
visualization	O
of	O
the	O
level	O
of	O
conservation	O
in	O
the	O
format	O
of	O
a	O
continuous	O
curve	O
based	O
on	O
the	O
conservation	O
in	O
a	O
sliding	O
window	O
.	O

This	O
concept	O
proved	O
to	O
be	O
extremely	O
successful	O
due	O
to	O
the	O
easy	O
interpretation	O
of	O
the	O
resulting	O
plots	O
.	O

VISTA	O
was	O
built	O
through	O
a	O
close	O
collaboration	O
between	O
computational	O
and	O
biological	O
scientists	O
,	O
resulting	O
in	O
a	O
product	O
that	O
is	O
robust	O
,	O
efficient	O
and	O
powerful	O
,	O
yet	O
simple	O
to	O
use	O
for	O
a	O
person	O
without	O
extensive	O
computer	O
experience	O
,	O
as	O
is	O
illustrated	O
by	O
more	O
than	O
1000	O
citations	O
to	O
the	O
various	O
VISTA	O
-	O
associated	O
tools	O
(	O
according	O
to	O
http	O
:	O
/	O
/	O
scholar	O
.	O
google	O
.	O
com	O
)	O
.	O

In	O
the	O
last	O
2	O
years	O
the	O
VISTA	O
portal	O
has	O
seen	O
many	O
significant	O
improvements	O
.	O

In	O
addition	O
to	O
updating	O
the	O
whole	O
genome	O
alignments	O
,	O
computed	O
using	O
recent	O
assemblies	O
of	O
vertebrate	O
,	O
insect	O
,	O
plant	O
and	O
microbial	O
genomes	O
,	O
we	O
have	O
added	O
significant	O
new	O
functionality	O
and	O
resources	O
to	O
the	O
Genome	O
Browser	O
and	O
other	O
tools	O
,	O
including	O
:	O

A	O
novel	O
multiple	O
whole	O
genome	O
alignment	O
algorithm	O
.	O

A	O
new	O
server	O
for	O
whole	O
-	O
genome	O
alignment	O
of	O
bacterial	O
genomes	O
.	O

Base	O
-	O
pair	O
level	O
visualization	O
ability	O
within	O
the	O
VISTA	O
browser	O
.	O

Visual	O
access	O
to	O
the	O
results	O
of	O
the	O
prediction	O
of	O
potential	O
deleteriousness	O
of	O
non	O
-	O
synonymous	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
SNPs	O
)	O
by	O
the	O
algorithm	O
PolyPhen	O
(	O
5	O
)	O
.	O

A	O
novel	O
conservation	O
track	O
,	O
Rank	O
-	O
VISTA	O
,	O
to	O
show	O
the	O
statistical	O
significance	O
of	O
conserved	O
regions	O
computed	O
by	O
the	O
Gumby	O
algorithm	O
(	O
6	O
)	O
.	O

Whole	O
-	O
genome	O
rVISTA	O
,	O
that	O
allows	O
for	O
evaluation	O
of	O
which	O
conserved	O
transcription	O
factor	O
binding	O
sites	O
(	O
TFBS	O
)	O
are	O
over	O
-	O
represented	O
in	O
a	O
group	O
of	O
genes	O
.	O

Extrapyramidal	O
symptoms	O
based	O
on	O
Extrapyramidal	O
Symptoms	O
Rating	O
Scale	O

Images	O

Figure	O
5	O

Etiology	O

Anorectal	O
malformations	O
(	O
ARM	O
)	O
represent	O
a	O
spectrum	O
of	O
abnormalities	O
ranging	O
from	O
mild	O
anal	O
anomalies	O
to	O
complex	O
cloacal	O
malformations	O
.	O

The	O
etiology	O
of	O
such	O
malformations	O
remains	O
unclear	O
and	O
is	O
likely	O
multifactorial	O
.	O

There	O
are	O
however	O
reasons	O
to	O
believe	O
there	O
is	O
a	O
genetic	O
componenet	O
.	O

As	O
early	O
as	O
the	O
1950s	O
,	O
it	O
was	O
recognized	O
that	O
there	O
was	O
an	O
increased	O
risk	O
for	O
a	O
sibling	O
of	O
a	O
patient	O
with	O
ARM	O
to	O
be	O
born	O
with	O
a	O
malformation	O
,	O
as	O
much	O
as	O
1	O
in	O
100	O
,	O
compared	O
with	O
the	O
incidence	O
of	O
about	O
1	O
in	O
5000	O
in	O
the	O
general	O
population	O
.	O

Since	O
that	O
time	O
there	O
have	O
been	O
reports	O
of	O
families	O
with	O
2	O
or	O
more	O
affected	O
members	O
and	O
associations	O
of	O
ARMs	O
with	O
multisystem	O
syndromes	O
.	O

In	O
particular	O
,	O
mutations	O
in	O
specific	O
genes	O
encoding	O
transcription	O
factors	O
have	O
been	O
described	O
in	O
patients	O
having	O
Townes	O
-	O
Broks	O
syndrome	O
,	O
Currarino	O
'	O
s	O
syndrome	O
,	O
and	O
Pallister	O
-	O
Hall	O
syndrome	O
,	O
each	O
of	O
which	O
have	O
autosomal	O
dominant	O
modes	O
of	O
inheritance	O
.	O

In	O
addition	O
,	O
it	O
has	O
been	O
found	O
that	O
there	O
is	O
not	O
only	O
an	O
increased	O
incidence	O
of	O
ARM	O
in	O
patient	O
with	O
trisomy	O
21	O
(	O
Down	O
'	O
s	O
syndrome	O
)	O
,	O
but	O
that	O
95	O
%	O
of	O
patients	O
with	O
trisomy	O
21	O
and	O
ARM	O
have	O
imperforate	O
anus	O
without	O
fistula	O
,	O
compared	O
with	O
only	O
5	O
%	O
of	O
all	O
patients	O
with	O
ARM	O
.	O

Based	O
on	O
this	O
evidence	O
,	O
it	O
is	O
likely	O
that	O
the	O
mutation	O
of	O
a	O
variety	O
of	O
different	O
genes	O
can	O
result	O
in	O
ARM	O
,	O
or	O
that	O
the	O
etiology	O
of	O
ARM	O
is	O
multigenic	O
[	O
13	O
]	O
.	O

Images	O

Fig	O
.	O

1	O

Fig	O
.	O

2	O

Fig	O
.	O

3	O

Miscellaneous	O
Proteins	O

Apart	O
from	O
the	O
above	O
-	O
described	O
proteins	O
,	O
several	O
other	O
molecules	O
are	O
also	O
associated	O
with	O
the	O
pathological	O
lesions	O
of	O
AD	O
,	O
and	O
some	O
of	O
these	O
can	O
be	O
regarded	O
as	O
amateur	O
chaperones	O
.	O

Acute	O
phase	O
proteins	O
,	O
such	O
as	O
alpha1	O
-	O
antichymotrypsin	O
(	O
ACT	O
)	O
,	O
alpha2	O
-	O
macroglobulin	O
(	O
alpha2	O
M	O
)	O
,	O
and	O
SAP	O
,	O
are	O
all	O
associated	O
with	O
Abeta	O
deposition	O
[	O
129	O
-	O
132	O
]	O
.	O

ACT	O
is	O
a	O
serine	O
protease	O
inhibitor	O
of	O
the	O
serpin	O
family	O
,	O
and	O
in	O
AD	O
,	O
ACT	O
levels	O
are	O
upregulated	O
,	O
and	O
binding	O
of	O
ACT	O
with	O
Abeta	O
induces	O
Abeta	O
fibrillogenesis	O
[	O
133	O
-	O
135	O
]	O
.	O

Furthermore	O
,	O
when	O
ACT	O
is	O
overexpressed	O
in	O
transgenic	O
mice	O
,	O
an	O
increased	O
plaque	O
load	O
in	O
the	O
brains	O
of	O
these	O
mice	O
and	O
impaired	O
spatial	O
learning	O
is	O
observed	O
[	O
134	O
,	O
135	O
]	O
.	O

alpha2	O
M	O
also	O
binds	O
Abeta	O
,	O
although	O
in	O
contrast	O
to	O
ACT	O
,	O
this	O
binding	O
prevents	O
Abeta	O
fibril	O
formation	O
and	O
fibril	O
-	O
associated	O
neurotoxicity	O
[	O
136	O
,	O
137	O
]	O
.	O

alpha2	O
M	O
promotes	O
the	O
protease	O
-	O
mediated	O
degradation	O
of	O
alpha2	O
M	O
/	O
Abeta	O
complexes	O
and	O
contributes	O
to	O
clearance	O
of	O
Abeta	O
from	O
the	O
brain	O
(	O
discussed	O
in	O
paragraph	O
4	O
)	O
[	O
138	O
,	O
139	O
]	O
.	O

The	O
glycoprotein	O
SAP	O
belongs	O
to	O
the	O
pentraxin	O
family	O
and	O
is	O
a	O
common	O
component	O
of	O
all	O
known	O
types	O
of	O
amyloid	O
fibrils	O
.	O

SAP	O
is	O
upregulated	O
in	O
AD	O
and	O
protects	O
amyloid	O
fibrils	O
from	O
proteolysis	O
in	O
vitro	O
[	O
140	O
,	O
141	O
]	O
.	O

SAP	O
not	O
only	O
colocalizes	O
with	O
SPs	O
and	O
interacts	O
with	O
aggregated	O
Abeta	O
;	O
SAP	O
oligomers	O
also	O
bind	O
and	O
activate	O
C1	O
[	O
142	O
]	O
.	O

Both	O
C1	O
and	O
SAP	O
may	O
bind	O
to	O
fibrillar	O
Abeta	O
deposits	O
in	O
vivo	O
and	O
induce	O
microglial	O
activation	O
,	O
as	O
cultured	O
human	O
microglial	O
cells	O
show	O
an	O
increase	O
in	O
cytokine	O
production	O
after	O
co	O
-	O
stimulation	O
of	O
Abeta	O
with	O
C1q	O
and	O
SAP	O
[	O
104	O
]	O
.	O

These	O
observations	O
further	O
strengthen	O
the	O
above	O
-	O
noted	O
suggestion	O
that	O
not	O
only	O
Abeta	O
,	O
but	O
also	O
several	O
Abeta	O
-	O
binding	O
proteins	O
,	O
are	O
capable	O
of	O
activating	O
the	O
complement	O
system	O
,	O
and	O
thus	O
,	O
contribute	O
to	O
neuroinflammation	O
in	O
AD	O
.	O

In	O
addition	O
,	O
both	O
alpha2	O
M	O
and	O
ACT	O
,	O
in	O
contrast	O
to	O
SAP	O
,	O
can	O
be	O
regarded	O
as	O
amateur	O
chaperones	O
,	O
as	O
they	O
regulate	O
conformational	O
changes	O
of	O
Abeta	O
.	O

Tissue	O
-	O
type	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
regulates	O
activation	O
of	O
plasminogen	O
into	O
plasmin	O
and	O
is	O
expressed	O
in	O
various	O
regions	O
of	O
the	O
brain	O
especially	O
in	O
the	O
hippocampus	O
[	O
143	O
]	O
.	O

Several	O
reports	O
suggested	O
an	O
important	O
role	O
for	O
tPA	O
in	O
AD	O
,	O
as	O
the	O
tPA	O
system	O
is	O
involved	O
in	O
Abeta	O
turnover	O
[	O
144	O
,	O
145	O
]	O
.	O

Fibrillar	O
forms	O
of	O
Abeta	O
stimulate	O
tPA	O
activity	O
in	O
vitro	O
,	O
whereas	O
in	O
AD	O
patients	O
,	O
a	O
reduction	O
of	O
tPA	O
activity	O
is	O
observed	O
in	O
the	O
affected	O
areas	O
[	O
144	O
,	O
146	O
]	O
.	O

Although	O
tPA	O
has	O
no	O
effect	O
on	O
conformational	O
changes	O
of	O
Abeta	O
,	O
it	O
might	O
play	O
a	O
role	O
in	O
the	O
clearance	O
of	O
Abeta	O
from	O
the	O
brain	O
(	O
paragraph	O
4	O
]	O
.	O

The	O
actin	O
-	O
regulatory	O
protein	O
gelsolin	O
is	O
found	O
both	O
intracellularly	O
and	O
in	O
plasma	O
[	O
147	O
,	O
148	O
]	O
.	O

Plasma	O
gelsolin	O
can	O
be	O
considered	O
an	O
amateur	O
chaperone	O
,	O
as	O
it	O
binds	O
Abeta	O
and	O
not	O
only	O
inhibits	O
its	O
Abeta	O
fibrillization	O
but	O
is	O
also	O
capable	O
of	O
degrading	O
preformed	O
Abeta	O
fibrils	O
[	O
149	O
,	O
150	O
]	O
.	O

Furthermore	O
,	O
gelsolin	O
inhibits	O
Abeta	O
-	O
mediated	O
neurotoxicity	O
[	O
151	O
]	O
.	O

One	O
of	O
the	O
major	O
gangliosides	O
in	O
the	O
brain	O
is	O
GM1	O
.	O

Soluble	O
Abeta	O
binds	O
GM1	O
and	O
the	O
formed	O
complexes	O
accelerate	O
Abeta	O
fibrillogenesis	O
by	O
acting	O
as	O
a	O
seed	O
for	O
Abeta	O
[	O
152	O
]	O
.	O

In	O
the	O
presence	O
of	O
GM1	O
,	O
Abeta	O
is	O
more	O
neurotoxic	O
than	O
Abeta	O
alone	O
,	O
and	O
cholesterol	O
-	O
rich	O
membranes	O
demonstrate	O
accelerated	O
Abeta	O
binding	O
due	O
to	O
the	O
formation	O
of	O
GM1	O
clusters	O
[	O
153	O
,	O
154	O
]	O
.	O

As	O
GM1	O
is	O
a	O
major	O
component	O
of	O
lipid	O
rafts	O
and	O
recent	O
studies	O
suggest	O
that	O
Abeta	O
accumulation	O
in	O
these	O
lipid	O
rafts	O
is	O
an	O
early	O
event	O
in	O
AD	O
development	O
,	O
GM1	O
might	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
steps	O
in	O
AD	O
pathogenesis	O
[	O
155	O
,	O
156	O
]	O
.	O

In	O
summary	O
,	O
several	O
proteins	O
are	O
associated	O
with	O
Abeta	O
aggregates	O
in	O
the	O
AD	O
brain	O
and	O
contribute	O
to	O
the	O
aggregation	O
of	O
Abeta	O
and	O
should	O
,	O
therefore	O
,	O
be	O
considered	O
as	O
amateur	O
chaperones	O
.	O

In	O
addition	O
,	O
they	O
might	O
play	O
a	O
role	O
in	O
triggering	O
inflammation	O
.	O

Results	O

Images	O

Figure	O
1	O

Results	O

The	O
observation	O
that	O
AP	O
-	O
3	O
is	O
found	O
in	O
both	O
cytosolic	O
and	O
membrane	O
subcellular	O
fractions	O
,	O
and	O
that	O
membrane	O
-	O
associated	O
AP	O
-	O
3	O
can	O
be	O
extracted	O
with	O
salts	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
)	O
is	O
consistent	O
with	O
its	O
role	O
as	O
a	O
membrane	O
coat	O
that	O
can	O
be	O
recruited	O
from	O
a	O
cytosolic	O
pool	O
.	O

In	O
addition	O
,	O
the	O
punctate	O
staining	O
of	O
AP	O
-	O
3	O
by	O
immunofluorescence	O
microscopy	O
,	O
its	O
redistribution	O
to	O
the	O
cytosol	O
by	O
BFA	O
,	O
and	O
the	O
reversibility	O
of	O
the	O
BFA	O
effect	O
(	O
Dell	O
'	O
Angelica	O
et	O
al	O
.	O
,	O
1997a	O
;	O
Simpson	O
et	O
al	O
.	O
,	O
1997	O
)	O
also	O
indicate	O
that	O
AP	O
-	O
3	O
can	O
cycle	O
between	O
the	O
cytosol	O
and	O
membranes	O
.	O

The	O
sensitivity	O
of	O
AP	O
-	O
3	O
to	O
BFA	O
in	O
cells	O
suggests	O
that	O
its	O
membrane	O
association	O
may	O
be	O
regulated	O
by	O
ARF1	O
,	O
since	O
BFA	O
inhibits	O
ARF1	O
guanine	O
nucleotide	O
exchange	O
,	O
and	O
has	O
been	O
shown	O
to	O
prevent	O
ARF1	O
membrane	O
binding	O
in	O
vitro	O
(	O
Donaldson	O
et	O
al	O
.	O
,	O
1992	O
;	O
Helms	O
and	O
Rothman	O
,	O
1992	O
;	O
Randazzo	O
et	O
al	O
.	O
,	O
1993	O
)	O
.	O

Ca2	O
+	O
Dependence	O
of	O
Slob57	O
Modulation	O
of	O
the	O
Voltage	O
Dependence	O
of	O
Activation	O
of	O
dSlo	O

Ca2	O
+	O
plays	O
a	O
fundamental	O
role	O
in	O
regulating	O
the	O
dSlo	O
response	O
to	O
membrane	O
depolarization	O
.	O

One	O
of	O
the	O
three	O
known	O
Ca2	O
+	O
binding	O
sites	O
(	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
,	O
known	O
as	O
the	O
calcium	O
bowl	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
)	O
,	O
contributes	O
to	O
the	O
high	O
-	O
affinity	O
Ca2	O
+	O
sensitivity	O
of	O
the	O
channel	O
(	O
Schreiber	O
and	O
Salkoff	O
,	O
1997	O
;	O
Schreiber	O
et	O
al	O
.	O
,	O
1999	O
;	O
Braun	O
and	O
Sy	O
,	O
2001	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2002	O
;	O
Niu	O
and	O
Magleby	O
,	O
2002	O
;	O
Xia	O
et	O
al	O
.	O
,	O
2002	O
;	O
Bao	O
et	O
al	O
.	O
,	O
2004	O
;	O
Zeng	O
et	O
al	O
.	O
,	O
2005b	O
)	O
.	O

We	O
used	O
a	O
mutated	O
dSlo	O
channel	O
with	O
substitution	O
of	O
Asp966	O
-	O
Asp970	O
by	O
Asn966	O
-	O
Asn970	O
within	O
its	O
calcium	O
bowl	O
,	O
which	O
greatly	O
reduces	O
the	O
channel	O
'	O
s	O
calcium	O
sensitivity	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
to	O
determine	O
whether	O
Ca2	O
+	O
participates	O
in	O
Slob57	O
modulation	O
of	O
dSlo	O
.	O

This	O
mutated	O
channel	O
,	O
dSloD5N5	O
,	O
still	O
binds	O
to	O
full	O
-	O
length	O
and	O
truncated	O
Slobs	O
(	O
Fig	O
.	O
1	O
B	O
,	O
lanes	O
4	O
-	O
6	O
)	O
.	O

During	O
a	O
350	O
-	O
ms	O
test	O
pulse	O
(	O
Fig	O
.	O
7	O
E	O
)	O
,	O
Slob57	O
causes	O
dSloD5N5	O
inactivation	O
(	O
Fig	O
.	O
7	O
B	O
)	O
,	O
consistent	O
with	O
our	O
previous	O
finding	O
that	O
the	O
inactivation	O
caused	O
by	O
Slob57	O
is	O
Ca2	O
+	O
independent	O
(	O
Zeng	O
et	O
al	O
.	O
,	O
2005a	O
)	O
.	O

After	O
deletion	O
of	O
the	O
amino	O
-	O
terminal	O
residues	O
2	O
-	O
6	O
of	O
Slob57	O
,	O
the	O
inactivation	O
of	O
dSloD5N5	O
is	O
eliminated	O
(	O
Fig	O
.	O
7	O
C	O
)	O
,	O
and	O
further	O
truncation	O
of	O
Slob57	O
to	O
Arg16	O
also	O
eliminates	O
the	O
inactivation	O
(	O
Fig	O
.	O
7	O
D	O
)	O
,	O
just	O
as	O
observed	O
with	O
wild	O
-	O
type	O
dSlo	O
(	O
Fig	O
.	O
2	O
,	O
C	O
and	O
D	O
)	O
.	O

Figure	O
7	O
.	O

Slob57	O
causes	O
inactivation	O
of	O
dSloD5N5	O
.	O

Same	O
as	O
Fig	O
.	O

2	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
instead	O
of	O
wild	O
-	O
type	O
dSlo	O
.	O

(	O
A	O
)	O
dSloD5N5	O
alone	O
,	O
(	O
B	O
)	O
dSloD5N5	O
together	O
with	O
Slob57	O
,	O
(	O
C	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN5	O
,	O
(	O
D	O
)	O
dSloD5N5	O
together	O
with	O
Slob57DeltaN15	O
,	O
(	O
E	O
)	O
pulse	O
protocol	O
.	O

We	O
next	O
used	O
a	O
100	O
-	O
ms	O
test	O
pulse	O
(	O
during	O
which	O
no	O
inactivation	O
occurs	O
)	O
to	O
measure	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
dSloD5N5	O
in	O
the	O
presence	O
of	O
110	O
muM	O
free	O
Ca2	O
+	O
,	O
as	O
only	O
at	O
high	O
concentrations	O
of	O
free	O
Ca2	O
+	O
can	O
tail	O
current	O
saturation	O
be	O
achieved	O
with	O
the	O
mutant	O
channel	O
(	O
Fig	O
.	O
8	O
)	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

8	O
,	O
Slob57	O
does	O
not	O
rightward	O
shift	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
.	O

Because	O
dSloD5N5	O
can	O
still	O
respond	O
to	O
an	O
increment	O
of	O
free	O
Ca2	O
+	O
at	O
high	O
concentration	O
(	O
Bian	O
et	O
al	O
.	O
,	O
2001	O
)	O
,	O
we	O
then	O
increased	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
to	O
300	O
muM	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

8	O
,	O
the	O
conductance	O
-	O
voltage	O
relationship	O
of	O
dSloD5N5	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
110	O
to	O
300	O
muM	O
,	O
but	O
again	O
the	O
V1	O
/	O
2	O
is	O
not	O
modulated	O
by	O
Slob57	O
.	O

Figure	O
8	O
.	O

Conductance	O
-	O
voltage	O
relationships	O
for	O
dSloD5N5	O
.	O

Same	O
protocol	O
as	O
Fig	O
.	O

6	O
,	O
except	O
that	O
the	O
mutated	O
channel	O
dSloD5N5	O
was	O
used	O
in	O
the	O
presence	O
(	O
circles	O
)	O
or	O
absence	O
(	O
squares	O
)	O
of	O
Slob57	O
,	O
and	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
was	O
either	O
110	O
muM	O
(	O
filled	O
symbols	O
)	O
or	O
300	O
muM	O
(	O
open	O
symbols	O
)	O
.	O

We	O
next	O
measured	O
the	O
voltage	O
dependence	O
of	O
activation	O
of	O
wild	O
-	O
type	O
dSlo	O
,	O
in	O
the	O
presence	O
or	O
absence	O
of	O
Slob57	O
,	O
at	O
free	O
Ca2	O
+	O
concentrations	O
ranging	O
from	O
20	O
to	O
300	O
muM	O
.	O

As	O
shown	O
in	O
Fig	O
.	O

9	O
A	O
(	O
and	O
by	O
many	O
previous	O
investigators	O
)	O
,	O
in	O
the	O
absence	O
of	O
Slob57	O
,	O
the	O
voltage	O
-	O
conductance	O
relationship	O
of	O
dSlo	O
shifts	O
to	O
less	O
depolarized	O
voltages	O
as	O
the	O
free	O
Ca2	O
+	O
concentration	O
is	O
increased	O
in	O
this	O
range	O
.	O

The	O
V1	O
/	O
2	O
decreases	O
from	O
85	O
to	O
-	O
22	O
mV	O
,	O
a	O
change	O
of	O
107	O
mV	O
,	O
when	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
is	O
increased	O
from	O
20	O
to	O
300	O
muM	O
.	O

In	O
contrast	O
,	O
when	O
dSlo	O
is	O
coexpressed	O
with	O
Slob57	O
,	O
this	O
increment	O
of	O
free	O
Ca2	O
+	O
concentration	O
shifts	O
the	O
V1	O
/	O
2	O
to	O
a	O
much	O
lesser	O
extent	O
(	O
Fig	O
.	O
9	O
B	O
and	O
Fig	O
.	O
10	O
A	O
)	O
.	O

Note	O
also	O
that	O
the	O
effect	O
of	O
Slob57	O
on	O
the	O
V1	O
/	O
2	O
is	O
more	O
apparent	O
at	O
higher	O
free	O
Ca2	O
+	O
concentrations	O
(	O
Fig	O
.	O
10	O
A	O
)	O
.	O

To	O
illustrate	O
this	O
better	O
,	O
we	O
plotted	O
the	O
V1	O
/	O
2	O
change	O
evoked	O
by	O
Slob57	O
(	O
DeltaV1	O
/	O
2	O
)	O
as	O
a	O
function	O
of	O
the	O
free	O
Ca2	O
+	O
concentration	O
(	O
Fig	O
.	O
10	O
B	O
)	O
to	O
demonstrate	O
that	O
the	O
magnitude	O
of	O
the	O
modulatory	O
shift	O
in	O
V1	O
/	O
2	O
evoked	O
by	O
Slob57	O
itself	O
is	O
calcium	O
dependent	O
.	O

Figure	O
9	O
.	O

Effect	O
of	O
calcium	O
on	O
dSlo	O
voltage	O
dependence	O
of	O
activation	O
in	O
the	O
absence	O
or	O
presence	O
of	O
Slob57	O
.	O

Same	O
as	O
Fig	O
.	O

6	O
,	O
except	O
that	O
the	O
measurements	O
of	O
dSlo	O
expressed	O
alone	O
(	O
A	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
B	O
)	O
were	O
performed	O
in	O
the	O
presence	O
of	O
different	O
concentrations	O
of	O
free	O
Ca2	O
+	O
:	O
20	O
muM	O
(	O
diamonds	O
)	O
,	O
40	O
muM	O
(	O
inverted	O
triangles	O
)	O
,	O
80	O
muM	O
(	O
triangles	O
)	O
,	O
110	O
muM	O
(	O
squares	O
)	O
,	O
and	O
300	O
muM	O
(	O
circles	O
)	O
.	O

Figure	O
10	O
.	O

Interaction	O
between	O
Slob57	O
and	O
calcium	O
.	O

The	O
V1	O
/	O
2	O
(	O
A	O
)	O
of	O
the	O
conductance	O
-	O
voltage	O
relationship	O
for	O
dSlo	O
expressed	O
alone	O
(	O
O	O
)	O
or	O
together	O
with	O
Slob57	O
(	O
*	O
)	O
,	O
taken	O
from	O
Fig	O
.	O

9	O
,	O
and	O
the	O
difference	O
in	O
V1	O
/	O
2	O
(	O
DeltaV1	O
/	O
2	O
)	O
evoked	O
by	O
Slob57	O
(	O
B	O
)	O
are	O
plotted	O
as	O
a	O
function	O
of	O
the	O
concentration	O
of	O
free	O
Ca2	O
+	O
.	O

Immunocytochemistry	O

C2C12	B
cells	O
grown	O
in	O
8	O
-	O
chamber	O
slides	O
(	O
Nunc	O
)	O
were	O
fixed	O
in	O
4	O
%	O
PFA	O
/	O
PBS	O
for	O
10	O
min	O
and	O
permeabilized	O
in	O
0	O
.	O
1	O
%	O
Triton	O
X	O
-	O
100	O
for	O
20	O
min	O
.	O

In	O
some	O
cases	O
,	O
they	O
were	O
fixed	O
and	O
permeabilized	O
in	O
methanol	O
at	O
-	O
20degreesC	O
for	O
2	O
min	O
.	O

The	O
fixed	O
and	O
permeabilized	O
cells	O
were	O
blocked	O
in	O
PBS	O
containing	O
3	O
%	O
BSA	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
)	O
and	O
incubated	O
overnight	O
at	O
4degreesC	O
with	O
primary	O
antibodies	O
in	O
blocking	O
solution	O
.	O

Immunoreactivity	O
was	O
detected	O
with	O
either	O
Alexa	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Molecular	O
Probes	O
)	O
or	O
a	O
combination	O
of	O
biotin	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
Vector	O
Laboratories	O
)	O
and	O
Alexa	O
-	O
conjugated	O
streptavidin	O
(	O
Molecular	O
Probes	O
)	O
.	O

Cytology	O
and	O
Histology	O

For	O
semithin	O
sections	O
,	O
embryoid	O
bodies	O
were	O
washed	O
twice	O
in	O
PBS	O
,	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
at	O
4degreesC	O
overnight	O
,	O
and	O
after	O
dehydration	O
in	O
ethanol	O
were	O
embedded	O
in	O
JB	O
-	O
4	O
resin	O
(	O
Polysciences	O
,	O
Inc	O
.	O
)	O
.	O

1	O
-	O
4	O
-	O
mum	O
sections	O
were	O
cut	O
with	O
a	O
glass	O
knife	O
.	O

For	O
cytology	O
,	O
the	O
sections	O
were	O
stained	O
with	O
toluidine	O
blue	O
.	O

In	O
cell	O
mixing	O
experiments	O
,	O
the	O
embryoid	O
bodies	O
were	O
prefixed	O
and	O
stained	O
for	O
beta	O
-	O
galactosidase	O
and	O
the	O
sections	O
were	O
counterstained	O
with	O
neutral	O
red	O
.	O

Teratocarcinomas	O
were	O
fixed	O
in	O
Bouin	O
fixative	O
,	O
embedded	O
in	O
Paraplast	O
,	O
and	O
the	O
sections	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
.	O

Microphotography	O
was	O
with	O
a	O
ZEISS	O
Axiomat	O
microscope	O
.	O

Films	O
were	O
scanned	O
and	O
figures	O
were	O
prepared	O
with	O
Photoshop	O
5	O
.	O
5	O
software	O
.	O

Stimulation	O
/	O
Inhibition	O
of	O
iDC	O
Functions	O
by	O
Activated	O
NK	O
Cells	O
.	O

Two	O
previous	O
studies	O
have	O
shown	O
that	O
both	O
resting	O
and	O
activated	O
NK	O
cells	O
partially	O
kill	O
autologous	O
DCs	O
,	O
as	O
measured	O
by	O
3	O
-	O
4	O
-	O
h	O
chromium	O
release	O
assays	O
using	O
high	O
NK	O
/	O
DC	O
ratios	O
(	O
11	O
,	O
12	O
)	O
.	O

However	O
,	O
in	O
our	O
long	O
-	O
term	O
cultures	O
(	O
24	O
-	O
48	O
h	O
)	O
the	O
NK	O
cells	O
stimulated	O
the	O
iDCs	O
rather	O
than	O
lysing	O
them	O
.	O

Based	O
on	O
these	O
conflicting	O
results	O
,	O
we	O
examined	O
in	O
more	O
detail	O
the	O
apparent	O
stimulation	O
of	O
iDCs	O
after	O
contact	O
with	O
NK	O
cells	O
.	O

We	O
reasoned	O
that	O
activated	O
NK	O
cells	O
would	O
be	O
more	O
useful	O
for	O
these	O
experiments	O
because	O
(	O
i	O
)	O
an	O
encounter	O
in	O
vivo	O
between	O
NK	O
cells	O
that	O
normally	O
traffic	O
in	O
the	O
blood	O
(	O
4	O
)	O
and	O
iDCs	O
which	O
reside	O
in	O
the	O
tissues	O
(	O
1	O
,	O
3	O
)	O
,	O
should	O
only	O
occur	O
when	O
both	O
cells	O
are	O
activated	O
;	O
(	O
ii	O
)	O
activated	O
NK	O
cells	O
mediate	O
more	O
potent	O
lysis	O
of	O
iDCs	O
(	O
11	O
-	O
13	O
)	O
,	O
thereby	O
allowing	O
for	O
a	O
more	O
rigorous	O
examination	O
of	O
a	O
potential	O
cytotoxic	O
effect	O
;	O
and	O
(	O
iii	O
)	O
the	O
number	O
of	O
NK	O
cells	O
obtained	O
after	O
short	O
-	O
term	O
in	O
vitro	O
culture	O
would	O
be	O
far	O
greater	O
providing	O
more	O
cells	O
for	O
analysis	O
(	O
9	O
)	O
.	O

The	O
DC	O
maturation	O
induced	O
by	O
resting	O
NK	O
cells	O
we	O
observed	O
was	O
dependent	O
on	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O

Furthermore	O
,	O
TNF	O
-	O
alpha	O
and	O
other	O
proinflammatory	O
cytokines	O
are	O
important	O
amplifiers	O
of	O
immune	O
responses	O
(	O
14	O
)	O
.	O

Therefore	O
,	O
we	O
used	O
TNF	O
-	O
alpha	O
production	O
as	O
a	O
readout	O
for	O
DC	O
stimulation	O
in	O
our	O
culture	O
system	O
.	O

Culturing	O
activated	O
NK	O
cells	O
with	O
DCs	O
at	O
low	O
NK	O
/	O
DC	O
ratios	O
(	O
1	O
:	O
5	O
)	O
led	O
to	O
increases	O
in	O
TNF	O
-	O
alpha	O
production	O
,	O
which	O
were	O
augmented	O
dramatically	O
by	O
the	O
addition	O
of	O
suboptimal	O
doses	O
(	O
10	O
ng	O
/	O
ml	O
)	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
A	O
)	O
.	O

The	O
increased	O
TNF	O
-	O
alpha	O
production	O
was	O
dependent	O
on	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
because	O
when	O
the	O
two	O
cell	O
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
,	O
no	O
stimulation	O
was	O
observed	O
(	O
Fig	O
.	O
2	O
B	O
)	O
.	O

In	O
separate	O
experiments	O
we	O
observed	O
this	O
NK	O
-	O
stimulatory	O
effect	O
on	O
TNF	O
-	O
alpha	O
production	O
at	O
NK	O
/	O
DC	O
ratios	O
as	O
low	O
as	O
1	O
:	O
20	O
and	O
1	O
:	O
40	O
(	O
data	O
not	O
shown	O
)	O
.	O

Raising	O
the	O
NK	O
/	O
DC	O
ratio	O
to	O
5	O
:	O
1	O
changes	O
the	O
interaction	O
from	O
one	O
of	O
potent	O
DC	O
stimulation	O
to	O
that	O
of	O
complete	O
inhibition	O
in	O
the	O
presence	O
or	O
absence	O
of	O
LPS	O
(	O
Fig	O
.	O
2	O
C	O
)	O
.	O

An	O
identical	O
pattern	O
is	O
seen	O
for	O
IL	O
-	O
12	O
p40	O
production	O
(	O
Fig	O
.	O
2	O
D	O
)	O
.	O

No	O
IL	O
-	O
10	O
production	O
in	O
the	O
cultures	O
was	O
detected	O
under	O
any	O
of	O
the	O
conditions	O
tested	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
massive	O
production	O
of	O
TNF	O
-	O
alpha	O
in	O
the	O
cultures	O
at	O
the	O
lowest	O
ratios	O
was	O
mediated	O
primarily	O
by	O
DCs	O
in	O
the	O
culture	O
due	O
to	O
the	O
low	O
number	O
of	O
NK	O
cells	O
(	O
2	O
x	O
104	O
cells	O
per	O
well	O
)	O
used	O
in	O
these	O
experiments	O
.	O

In	O
addition	O
,	O
efforts	O
to	O
stimulate	O
NK	O
cells	O
directly	O
with	O
optimal	O
doses	O
of	O
anti	O
-	O
CD16	O
,	O
rIL	O
-	O
2	O
,	O
rIL	O
-	O
12	O
,	O
and	O
PMA	O
/	O
ionomycin	O
alone	O
or	O
in	O
combination	O
induced	O
only	O
moderate	O
(	O
<	O
500	O
pg	O
/	O
ml	O
)	O
TNF	O
-	O
alpha	O
production	O
by	O
the	O
NK	O
cells	O
alone	O
which	O
were	O
present	O
at	O
2	O
x	O
105	O
cells	O
per	O
well	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
2	O
.	O

Activated	O
/	O
cultured	O
NK	O
cell	O
-	O
mediated	O
amplification	O
/	O
inhibition	O
of	O
DC	O
cytokine	O
production	O
.	O

Results	O
are	O
presented	O
on	O
log	O
scales	O
.	O

Cultured	O
iDCs	O
were	O
incubated	O
alone	O
or	O
with	O
cultured	O
/	O
purified	O
NK	O
cells	O
for	O
24	O
h	O
(	O
A	O
and	O
B	O
)	O
or	O
48	O
h	O
(	O
C	O
-	O
E	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
indicated	O
concentrations	O
of	O
LPS	O
.	O

After	O
culture	O
the	O
supernatants	O
were	O
removed	O
and	O
analyzed	O
by	O
ELISA	O
for	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
.	O

(	O
A	O
)	O
TNF	O
-	O
alpha	O
production	O
was	O
measured	O
in	O
the	O
supernatants	O
from	O
cultures	O
of	O
:	O
DCs	O
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	O
+	O
DC	O
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
.	O

LPS	O
concentrations	O
used	O
were	O
:	O
0	O
,	O
10	O
,	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
(	O
DCs	O
alone	O
only	O
)	O
.	O

(	O
B	O
)	O
Contact	O
-	O
dependent	O
stimulation	O
of	O
iDC	O
TNF	O
-	O
alpha	O
production	O
by	O
NK	O
cells	O
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	O
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	O
+	O
DC	O
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	O
/	O
DC	O
(	O
1	O
:	O
5	O
)	O
trans	O
-	O
wells	O
(	O
striped	O
bars	O
)	O
.	O

LPS	O
concentrations	O
used	O
were	O
:	O
10	O
ng	O
/	O
ml	O
(	O
donor	O
1	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
donor	O
2	O
)	O
.	O

(	O
C	O
and	O
D	O
)	O
Effect	O
of	O
increasing	O
the	O
NK	O
/	O
DC	O
ratio	O
(	O
DCs	O
alone	O
;	O
NK	O
:	O
DC	O
-	O
1	O
:	O
5	O
;	O
1	O
:	O
1	O
;	O
5	O
:	O
1	O
)	O
on	O
(	O
C	O
)	O
TNF	O
-	O
alpha	O
and	O
(	O
D	O
)	O
IL	O
-	O
12	O
p40	O
production	O
.	O

LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
20	O
ng	O
/	O
ml	O
(	O
*	O
)	O
;	O
50	O
ng	O
/	O
ml	O
(	O
^	O
)	O
;	O
and	O
1	O
,	O
000	O
ng	O
/	O
ml	O
-	O
LPS	O
(	O
*	O
)	O
(	O
DCs	O
alone	O
only	O
)	O
.	O

(	O
E	O
)	O
The	O
effect	O
of	O
neutralizing	O
IFN	O
-	O
gamma	O
production	O
was	O
tested	O
under	O
the	O
following	O
conditions	O
:	O
DCs	O
alone	O
(	O
gray	O
bars	O
)	O
;	O
NK	O
+	O
DC	O
(	O
1	O
:	O
5	O
)	O
(	O
black	O
bars	O
)	O
;	O
NK	O
+	O
DC	O
(	O
1	O
:	O
5	O
)	O
and	O
10	O
mug	O
/	O
ml	O
of	O
blocking	O
anti	O
-	O
IFN	O
-	O
gamma	O
mAb	O
(	O
stippled	O
bars	O
)	O
.	O

LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
NO	O
LPS	O
)	O
and	O
20	O
ng	O
/	O
ml	O
(	O
LPS	O
20	O
)	O
.	O

Blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
or	O
IL	O
-	O
12	O
,	O
had	O
no	O
effect	O
on	O
the	O
NK	O
cell	O
-	O
induced	O
TNF	O
-	O
alpha	O
or	O
IL	O
-	O
12	O
p40	O
production	O
,	O
whereas	O
a	O
neutralizing	O
antibody	O
for	O
IFN	O
-	O
gamma	O
while	O
not	O
affecting	O
TNF	O
-	O
alpha	O
production	O
partially	O
blocked	O
(	O
<	O
20	O
%	O
)	O
IL	O
-	O
12	O
p40	O
production	O
induced	O
by	O
the	O
NK	O
cells	O
(	O
Fig	O
.	O
2	O
E	O
)	O
.	O

This	O
partial	O
inhibition	O
is	O
consistent	O
with	O
numerous	O
previous	O
reports	O
demonstrating	O
a	O
central	O
role	O
for	O
an	O
IL	O
-	O
12	O
/	O
IFN	O
-	O
gamma	O
positive	O
feedback	O
loop	O
active	O
between	O
NK	O
cells	O
and	O
IL	O
-	O
12	O
-	O
producing	O
cells	O
(	O
15	O
-	O
17	O
)	O
.	O

Clearly	O
,	O
however	O
,	O
this	O
well	O
-	O
described	O
cytokine	O
cross	O
-	O
talk	O
mechanism	O
is	O
secondary	O
to	O
the	O
contact	O
-	O
dependent	O
activation	O
of	O
DCs	O
by	O
NK	O
cells	O
described	O
here	O
.	O

Taken	O
together	O
these	O
results	O
indicate	O
that	O
novel	O
mechanisms	O
control	O
cognate	O
interactions	O
between	O
NK	O
cells	O
and	O
DCs	O
and	O
that	O
NK	O
-	O
DC	O
contact	O
has	O
the	O
potential	O
to	O
serve	O
as	O
an	O
important	O
control	O
switch	O
for	O
both	O
amplifying	O
and	O
attenuating	O
innate	O
immune	O
responses	O
in	O
vivo	O
.	O

We	O
next	O
tested	O
directly	O
whether	O
NK	O
cell	O
killing	O
was	O
active	O
in	O
our	O
system	O
using	O
both	O
short	O
-	O
term	O
(	O
4	O
-	O
h	O
)	O
chromium	O
release	O
assays	O
(	O
data	O
not	O
shown	O
)	O
and	O
a	O
flow	O
cytometric	O
assay	O
which	O
allowed	O
us	O
to	O
follow	O
the	O
survival	O
of	O
the	O
autologous	O
iDCs	O
in	O
the	O
presence	O
of	O
NK	O
cells	O
over	O
longer	O
periods	O
(	O
Fig	O
.	O
3	O
)	O
.	O

The	O
results	O
demonstrate	O
that	O
NK	O
cells	O
kill	O
autologous	O
iDCs	O
(	O
Fig	O
.	O
3	O
A	O
)	O
at	O
all	O
NK	O
/	O
DC	O
ratios	O
tested	O
after	O
4	O
h	O
and	O
the	O
level	O
of	O
killing	O
is	O
similar	O
to	O
the	O
lysis	O
of	O
K562	B
cells	O
over	O
the	O
same	O
time	O
(	O
Fig	O
.	O
3	O
B	O
)	O
.	O

After	O
24	O
h	O
,	O
however	O
,	O
the	O
presence	O
of	O
NK	O
cells	O
led	O
to	O
completely	O
divergent	O
effects	O
on	O
the	O
DCs	O
.	O

At	O
the	O
5	O
:	O
1	O
(	O
NK	O
/	O
DC	O
)	O
ratio	O
,	O
NK	O
cell	O
-	O
mediated	O
destruction	O
of	O
the	O
iDCs	O
was	O
the	O
dominant	O
feature	O
,	O
whereas	O
at	O
the	O
low	O
ratio	O
(	O
1	O
:	O
5	O
)	O
the	O
same	O
NK	O
cells	O
promoted	O
iDCs	O
survival	O
compared	O
with	O
iDCs	O
alone	O
over	O
the	O
same	O
period	O
(	O
Fig	O
.	O
3	O
A	O
)	O
.	O

The	O
equal	O
ratio	O
of	O
NK	O
/	O
DC	O
(	O
1	O
:	O
1	O
)	O
fell	O
between	O
these	O
two	O
extremes	O
.	O

The	O
NK	O
cell	O
-	O
mediated	O
lysis	O
of	O
the	O
K562	B
targets	O
increased	O
at	O
all	O
ratios	O
tested	O
after	O
the	O
24	O
-	O
h	O
incubation	O
.	O

These	O
striking	O
differences	O
between	O
death	O
and	O
survival	O
of	O
DCs	O
upon	O
encountering	O
NK	O
cells	O
correlate	O
precisely	O
with	O
our	O
previous	O
results	O
on	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
12	O
p40	O
production	O
where	O
increasing	O
numbers	O
of	O
NK	O
cells	O
in	O
the	O
culture	O
shifts	O
the	O
NK	O
effect	O
from	O
potent	O
stimulation	O
to	O
complete	O
inhibition	O
(	O
Fig	O
.	O
2	O
)	O
.	O

Figure	O
3	O
.	O

Activated	O
/	O
cultured	O
NK	O
cell	O
-	O
mediated	O
death	O
/	O
survival	O
of	O
DCs	O
and	O
NK	O
-	O
DC	O
conjugate	O
formation	O
.	O

NK	O
cell	O
mediated	O
killing	O
/	O
survival	O
of	O
CFDA	O
.	O
SE	O
-	O
loaded	O
iDCs	O
(	O
A	O
)	O
and	O
K562	B
cells	O
(	O
B	O
)	O
was	O
measured	O
by	O
flow	O
cytometry	O
over	O
4	O
h	O
(	O
*	O
)	O
or	O
24	O
h	O
(	O
*	O
)	O
at	O
the	O
indicated	O
NK	O
/	O
DC	O
ratios	O
as	O
described	O
in	O
Materials	O
and	O
Methods	O
.	O

Results	O
are	O
presented	O
as	O
percentage	O
of	O
specific	O
lysis	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
3	O
independent	O
experiments	O
)	O
.	O

NK	O
-	O
DC	O
(	O
C	O
-	O
E	O
)	O
or	O
NK	O
-	O
K562	B
(	O
F	O
-	O
H	O
)	O
conjugate	O
formation	O
was	O
measured	O
by	O
flow	O
cytometry	O
,	O
at	O
the	O
following	O
ratios	O
(	O
NK	O
/	O
DC	O
or	O
NK	O
/	O
K562	B
)	O
:	O
1	O
:	O
5	O
(	O
C	O
and	O
F	O
)	O
;	O
1	O
:	O
1	O
(	O
D	O
and	O
G	O
)	O
;	O
and	O
5	O
:	O
1	O
(	O
E	O
and	O
H	O
)	O
.	O

Snarf	O
-	O
1	O
(	O
FL3	O
)	O
-	O
labeled	O
iDCs	O
or	O
K562	B
cells	O
were	O
incubated	O
(	O
30	O
min	O
)	O
with	O
CFDA	O
.	O
SE	O
(	O
FL1	O
)	O
-	O
labeled	O
NK	O
cells	O
at	O
the	O
different	O
ratios	O
.	O

The	O
percentage	O
of	O
conjugates	O
formed	O
(	O
top	O
right	O
quadrant	O
)	O
was	O
calculated	O
by	O
determining	O
the	O
percentage	O
of	O
FL3	O
+	O
(	O
Snarf	O
-	O
1	O
)	O
events	O
which	O
were	O
also	O
positive	O
for	O
FL1	O
(	O
CFDA	O
.	O
SE	O
)	O
.	O

The	O
results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
with	O
activated	O
NK	O
cells	O
.	O

Resting	O
NK	O
cells	O
also	O
readily	O
formed	O
conjugates	O
with	O
autologous	O
iDCs	O
(	O
data	O
not	O
shown	O
)	O
.	O

NK	O
cells	O
can	O
both	O
efficiently	O
kill	O
and	O
potently	O
stimulate	O
DCs	O
in	O
our	O
model	O
system	O
and	O
each	O
of	O
these	O
opposing	O
effects	O
appear	O
dependent	O
on	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
.	O

To	O
quantify	O
these	O
apparent	O
cognate	O
interactions	O
we	O
measured	O
the	O
formation	O
of	O
NK	O
-	O
DC	O
conjugates	O
and	O
compared	O
them	O
to	O
conjugates	O
formed	O
by	O
NK	O
cells	O
and	O
tumor	O
targets	O
.	O

Our	O
analysis	O
revealed	O
that	O
NK	O
cells	O
bound	O
DC	O
(	O
Fig	O
.	O
3	O
C	O
-	O
E	O
)	O
with	O
an	O
efficiency	O
almost	O
equal	O
to	O
that	O
of	O
NK	O
cell	O
binding	O
to	O
the	O
classical	O
NK	O
-	O
target	O
,	O
K562	B
(	O
Fig	O
.	O
3	O
F	O
-	O
H	O
)	O
.	O

Binding	O
was	O
detectable	O
even	O
at	O
the	O
lowest	O
NK	O
/	O
DC	O
ratio	O
tested	O
(	O
1	O
:	O
5	O
)	O
indicating	O
that	O
NK	O
-	O
DC	O
conjugates	O
are	O
formed	O
in	O
our	O
other	O
experiments	O
measuring	O
cytokine	O
production	O
and	O
cell	O
killing	O
.	O

Our	O
initial	O
experiments	O
using	O
resting	O
NK	O
cells	O
(	O
Fig	O
.	O
1	O
)	O
demonstrated	O
a	O
contact	O
-	O
dependent	O
NK	O
effect	O
driving	O
iDCs	O
to	O
mature	O
.	O

Therefore	O
,	O
we	O
tested	O
what	O
effects	O
activated	O
NK	O
cells	O
mediated	O
on	O
DC	O
maturation	O
(	O
Fig	O
.	O
4	O
)	O
.	O

Similar	O
to	O
our	O
previous	O
results	O
with	O
activated	O
NK	O
cells	O
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
,	O
addition	O
of	O
NK	O
cells	O
to	O
the	O
culture	O
leads	O
to	O
opposing	O
effects	O
on	O
the	O
iDC	O
population	O
depending	O
on	O
the	O
NK	O
/	O
DC	O
ratio	O
.	O

Compared	O
with	O
the	O
untreated	O
DCs	O
(	O
Fig	O
.	O
4	O
A	O
-	O
C	O
)	O
,	O
low	O
NK	O
/	O
DC	O
ratios	O
(	O
1	O
:	O
5	O
or	O
1	O
:	O
1	O
)	O
consistently	O
augmented	O
expression	O
of	O
the	O
maturation	O
markers	O
:	O
CD86	O
(	O
Fig	O
.	O
4	O
D	O
-	O
I	O
)	O
,	O
CD83	O
,	O
and	O
HLA	O
-	O
DR	O
(	O
data	O
not	O
shown	O
)	O
.	O

At	O
a	O
5	O
:	O
1	O
ratio	O
(	O
NK	O
/	O
DC	O
)	O
most	O
of	O
the	O
DCs	O
are	O
nonviable	O
(	O
Fig	O
.	O
4	O
J	O
-	O
L	O
)	O
.	O

Addition	O
of	O
suboptimal	O
doses	O
of	O
LPS	O
(	O
Fig	O
.	O
4	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
augmented	O
the	O
NK	O
-	O
induced	O
maturation	O
at	O
NK	O
/	O
DC	O
ratios	O
of	O
1	O
:	O
5	O
and	O
1	O
:	O
1	O
,	O
but	O
had	O
no	O
effect	O
at	O
the	O
5	O
:	O
1	O
ratio	O
.	O

Again	O
,	O
DC	O
maturation	O
was	O
dependent	O
on	O
NK	O
cell	O
contact	O
and	O
endogenously	O
produced	O
TNF	O
-	O
alpha	O
,	O
because	O
it	O
did	O
not	O
occur	O
when	O
the	O
two	O
cell	O
types	O
were	O
separated	O
in	O
trans	O
-	O
wells	O
or	O
upon	O
the	O
addition	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
Fig	O
.	O
5	O
)	O
.	O

Moreover	O
,	O
addition	O
of	O
blocking	O
reagents	O
for	O
CD80	O
,	O
CD86	O
,	O
CD154	O
,	O
CD95	O
,	O
CD11a	O
,	O
CD50	O
,	O
IL	O
-	O
12	O
,	O
IFN	O
-	O
gamma	O
,	O
IFN	O
-	O
alpha	O
,	O
or	O
IFN	O
-	O
beta	O
had	O
no	O
effect	O
on	O
the	O
NK	O
-	O
induced	O
maturation	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
4	O
.	O

Activated	O
/	O
cultured	O
NK	O
cell	O
-	O
mediated	O
maturation	O
/	O
death	O
of	O
DCs	O
.	O

Cultured	O
iDCs	O
were	O
incubated	O
for	O
48	O
h	O
,	O
alone	O
(	O
A	O
-	O
C	O
)	O
,	O
or	O
with	O
NK	O
cells	O
at	O
the	O
following	O
ratios	O
(	O
NK	O
/	O
DC	O
)	O
,	O
1	O
:	O
5	O
(	O
D	O
-	O
F	O
)	O
,	O
1	O
:	O
1	O
(	O
G	O
-	O
I	O
)	O
,	O
and	O
5	O
:	O
1	O
(	O
J	O
-	O
L	O
)	O
.	O

Forward	O
versus	O
side	O
scatter	O
plots	O
(	O
A	O
,	O
D	O
,	O
G	O
,	O
and	O
J	O
)	O
show	O
the	O
gating	O
on	O
the	O
DC	O
subset	O
and	O
demonstrate	O
its	O
disappearance	O
at	O
the	O
5	O
:	O
1	O
(	O
NK	O
/	O
DC	O
)	O
ratio	O
(	O
J	O
)	O
.	O

Propidium	O
iodide	O
staining	O
of	O
the	O
NK	O
/	O
DC	O
(	O
5	O
:	O
1	O
)	O
cultures	O
confirmed	O
the	O
almost	O
complete	O
absence	O
of	O
viable	O
DCs	O
(	O
data	O
not	O
shown	O
)	O
.	O

Staining	O
for	O
CD86	O
expression	O
was	O
performed	O
as	O
described	O
in	O
Fig	O
.	O

1	O
and	O
the	O
histograms	O
are	O
shown	O
for	O
DCs	O
cultured	O
in	O
the	O
presence	O
(	O
C	O
,	O
F	O
,	O
I	O
,	O
and	O
L	O
)	O
or	O
absence	O
(	O
B	O
,	O
E	O
,	O
H	O
,	O
and	O
K	O
)	O
of	O
1	O
ng	O
/	O
ml	O
of	O
LPS	O
.	O

Results	O
are	O
representative	O
of	O
six	O
experiments	O
performed	O
.	O

Figure	O
5	O
.	O

Activated	O
/	O
cultured	O
NK	O
cell	O
-	O
induced	O
DC	O
maturation	O
is	O
dependent	O
on	O
cell	O
-	O
to	O
-	O
cell	O
contact	O
and	O
endogenous	O
TNF	O
-	O
alpha	O
production	O
.	O

Cultured	O
iDCs	O
were	O
incubated	O
alone	O
(	O
A	O
,	O
D	O
,	O
and	O
G	O
)	O
;	O
with	O
activated	O
NK	O
cells	O
at	O
an	O
NK	O
/	O
DC	O
ratio	O
of	O
1	O
:	O
5	O
(	O
B	O
,	O
E	O
,	O
and	O
H	O
)	O
;	O
with	O
activated	O
NK	O
cells	O
(	O
NK	O
/	O
DC	O
;	O
1	O
:	O
5	O
)	O
separated	O
in	O
trans	O
-	O
wells	O
(	O
C	O
and	O
F	O
)	O
;	O
or	O
with	O
activated	O
NK	O
cells	O
and	O
10	O
mug	O
/	O
ml	O
of	O
a	O
neutralizing	O
antibody	O
for	O
TNF	O
-	O
alpha	O
(	O
I	O
)	O
.	O

LPS	O
concentrations	O
used	O
were	O
:	O
0	O
ng	O
/	O
ml	O
(	O
A	O
-	O
C	O
)	O
;	O
10	O
ng	O
/	O
ml	O
(	O
D	O
-	O
F	O
)	O
and	O
50	O
ng	O
/	O
ml	O
(	O
G	O
-	O
I	O
)	O
.	O

CD86	O
staining	O
of	O
the	O
DC	O
subset	O
was	O
performed	O
as	O
in	O
Figs	O
.	O

1	O
and	O
4	O
.	O

Results	O
are	O
representative	O
of	O
four	O
experiments	O
performed	O
.	O

Acknowledgements	O

We	O
would	O
like	O
to	O
thank	O
our	O
colleague	O
Dr	O
.	O
Nikolaos	O
Papathanasiou	O
for	O
his	O
assistance	O
in	O
performing	O
the	O
statistical	O
analysis	O
.	O

Anion	O
to	O
cation	O
selectivity	O
ratio	O
determined	O
from	O
the	O
relative	O
rates	O
of	O
reaction	O
of	O
MTSES	O
-	O
and	O
MTSET	O
+	O
with	O
the	O
water	O
exposed	O
residues	O
in	O
the	O
M6	O
segment	O
.	O

The	O
anion	O
selectivity	O
ratio	O
is	O
calculated	O
as	O
described	O
in	O
Table	O
II	O
,	O
column	O
5	O
.	O

Note	O
the	O
marked	O
increase	O
in	O
anion	O
selectivity	O
at	O
the	O
residues	O
T351C	O
and	O
Q353C	O
.	O

A	O
ratio	O
of	O
1	O
indicates	O
no	O
selectivity	O
between	O
anions	O
and	O
cations	O
.	O

The	O
larger	O
the	O
ratio	O
the	O
greater	O
the	O
anion	O
selectivity	O
.	O

Mineralization	O
(	O
red	O
)	O
of	O
the	O
aorta	O
is	O
prevented	O
by	O
local	O
(	O
left	O
)	O
,	O
but	O
not	O
global	O
(	O
right	O
)	O
,	O
Mgp	O
expression	O
.	O

Loss	O
of	O
both	O
apical	O
pathways	O
(	O
bottom	O
)	O
allows	O
astral	O
microtubules	O
(	O
arrows	O
)	O
to	O
form	O
apically	O
and	O
basally	O
in	O
neuroblasts	O
.	O

Authors	O
'	O
contributions	O

All	O
authors	O
contributed	O
to	O
the	O
development	O
of	O
the	O
methodology	O
.	O

CY	O
and	O
NZ	O
led	O
method	O
conceptualization	O
and	O
prepared	O
the	O
original	O
draft	O
,	O
which	O
was	O
revised	O
by	O
JR	O
.	O

CY	O
and	O
VD	O
performed	O
most	O
implementations	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Determination	O
of	O
As	O
metabolites	O

We	O
assessed	O
As	O
metabolism	O
using	O
the	O
percentages	O
of	O
iAs	O
,	O
MMA	O
,	O
and	O
DMA	O
in	O
urine	O
,	O
as	O
well	O
as	O
two	O
methylation	O
indexes	O
[	O
i	O
.	O
e	O
.	O
,	O
primary	O
methylation	O
index	O
(	O
PMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
MMA	O
and	O
iAs	O
,	O
and	O
secondary	O
methylation	O
index	O
(	O
SMI	O
)	O
,	O
defined	O
as	O
the	O
ratio	O
between	O
DMA	O
and	O
MMA	O
.	O

We	O
used	O
total	O
urinary	O
As	O
[	O
U	O
-	O
As	O
;	O
the	O
sum	O
of	O
As	O
metabolites	O
(	O
iAs	O
+	O
MMA	O
+	O
DMA	O
)	O
in	O
urine	O
]	O
as	O
the	O
measure	O
of	O
iAs	O
exposure	O
.	O

Concentrations	O
of	O
As	O
metabolites	O
in	O
urine	O
were	O
measured	O
with	O
an	O
Agilent	O
1100	O
HPLC	O
system	O
(	O
Agilent	O
Technologies	O
,	O
Waldbronn	O
,	O
Germany	O
)	O
,	O
coupled	O
with	O
hydride	O
generation	O
(	O
HG	O
)	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
(	O
ICPMS	O
)	O
(	O
Agilent	O
7500ce	O
series	O
;	O
Agilent	O
Technologies	O
,	O
Japan	O
)	O
.	O

The	O
method	O
measures	O
metabolites	O
of	O
iAs	O
[	O
iAs	O
(	O
III	O
)	O
,	O
iAs	O
(	O
V	O
)	O
,	O
MMA	O
,	O
and	O
DMA	O
]	O
,	O
but	O
not	O
organic	O
As	O
species	O
(	O
e	O
.	O
g	O
.	O
,	O
arsenobetaine	O
,	O
arsenocholine	O
)	O
originating	O
from	O
the	O
diet	O
,	O
because	O
those	O
arsenicals	O
do	O
not	O
form	O
volatile	O
arsines	O
(	O
hydride	O
generation	O
)	O
like	O
iAs	O
and	O
its	O
metabolites	O
do	O
.	O

The	O
method	O
was	O
described	O
in	O
detail	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2006	O
)	O
.	O

Determination	O
limits	O
were	O
0	O
.	O
1	O
mug	O
/	O
L	O
for	O
arsenite	O
[	O
As	O
(	O
III	O
)	O
]	O
and	O
MMA	O
and	O
0	O
.	O
2	O
mug	O
/	O
L	O
for	O
DMA	O
and	O
arsenate	O
[	O
As	O
(	O
V	O
)	O
]	O
.	O

We	O
adjusted	O
As	O
concentrations	O
for	O
variations	O
in	O
dilution	O
by	O
specific	O
gravity	O
(	O
to	O
the	O
mean	O
value	O
of	O
1	O
.	O
012	O
g	O
/	O
mL	O
)	O
;	O
U	O
-	O
Cre	O
,	O
which	O
is	O
commonly	O
used	O
for	O
dilution	O
adjustment	O
,	O
was	O
influenced	O
more	O
by	O
age	O
and	O
nutrition	O
than	O
was	O
specific	O
gravity	O
,	O
and	O
U	O
-	O
Cre	O
was	O
also	O
associated	O
with	O
urinary	O
As	O
(	O
Nermell	O
et	O
al	O
.	O
2007	O
)	O
.	O

For	O
quality	O
control	O
purposes	O
,	O
we	O
analyzed	O
the	O
reference	O
material	O
(	O
CRM	O
No	O
.	O
18	O
;	O
National	O
Institute	O
for	O
Environmental	O
Studies	O
,	O
Ibaraki	O
,	O
Japan	O
)	O
with	O
a	O
certified	O
DMA	O
concentration	O
of	O
36	O
+	O
/	O
-	O
9	O
mug	O
/	O
L	O
together	O
with	O
the	O
collected	O
urine	O
samples	O
.	O

The	O
concentration	O
of	O
DMA	O
was	O
41	O
+	O
/	O
-	O
3	O
.	O
4	O
mug	O
/	O
L	O
(	O
mean	O
+	O
/	O
-	O
SD	O
;	O
n	O
=	O
18	O
)	O
.	O

Urine	O
samples	O
were	O
also	O
analyzed	O
for	O
As	O
metabolites	O
by	O
atomic	O
fluorescence	O
spectrometry	O
(	O
AFS	O
)	O
and	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
by	O
atomic	O
absorption	O
spectrometry	O
(	O
AAS	O
)	O
,	O
as	O
reported	O
by	O
Lindberg	O
et	O
al	O
.	O

(	O
2007a	O
)	O
.	O

The	O
results	O
of	O
ICPMS	O
and	O
AFS	O
showed	O
good	O
agreement	O
for	O
all	O
metabolites	O
;	O
for	O
iAs	O
[	O
As	O
(	O
III	O
)	O
+	O
As	O
(	O
V	O
)	O
]	O
,	O
MMA	O
,	O
and	O
DMA	O
,	O
R2	O
=	O
0	O
.	O
91	O
,	O
0	O
.	O
91	O
,	O
and	O
0	O
.	O
97	O
,	O
respectively	O
(	O
n	O
=	O
221	O
)	O
.	O

Further	O
,	O
we	O
obtained	O
good	O
agreement	O
for	O
the	O
sum	O
of	O
As	O
metabolites	O
between	O
the	O
three	O
different	O
methods	O
(	O
for	O
ICPMS	O
vs	O
.	O
AFS	O
,	O
R2	O
=	O
0	O
.	O
97	O
;	O
for	O
ICPMS	O
vs	O
.	O
AAS	O
,	O
R2	O
=	O
0	O
.	O
96	O
(	O
n	O
=	O
221	O
)	O
.	O

Background	O

Potato	O
late	O
blight	O
,	O
a	O
disease	O
caused	O
by	O
the	O
oomycete	O
pathogen	O
Phytophthora	O
infestans	O
,	O
is	O
one	O
of	O
the	O
world	O
'	O
s	O
most	O
devastating	O
crop	O
diseases	O
.	O

World	O
-	O
wide	O
losses	O
due	O
to	O
late	O
blight	O
exceed	O
several	O
billion	O
dollars	O
annually	O
[	O
1	O
]	O
.	O

Most	O
of	O
the	O
potato	O
cultivars	O
currently	O
grown	O
in	O
the	O
United	O
States	O
are	O
highly	O
susceptible	O
to	O
late	O
blight	O
and	O
control	O
of	O
this	O
disease	O
relies	O
almost	O
exclusively	O
on	O
fungicide	O
applications	O
.	O

The	O
most	O
effective	O
and	O
environmentally	O
sound	O
way	O
for	O
controlling	O
late	O
blight	O
is	O
to	O
incorporate	O
natural	O
resistance	O
into	O
potato	O
cultivars	O
.	O

The	O
pedigrees	O
of	O
many	O
potato	O
cultivars	O
currently	O
used	O
in	O
different	O
countries	O
include	O
late	O
blight	O
resistant	O
germplasm	O
derived	O
from	O
Solanum	O
demissum	O
,	O
Solanum	O
andigena	O
,	O
and	O
other	O
wild	O
species	O
.	O

However	O
,	O
most	O
of	O
the	O
resistance	O
derived	O
from	O
these	O
wild	O
species	O
is	O
controlled	O
by	O
single	O
dominant	O
resistance	O
genes	O
(	O
R	O
genes	O
)	O
.	O

These	O
R	O
genes	O
are	O
only	O
effective	O
in	O
preventing	O
the	O
development	O
of	O
late	O
blight	O
if	O
the	O
invading	O
P	O
.	O
infestans	O
race	O
contains	O
the	O
corresponding	O
avirulence	O
genes	O
.	O

This	O
R	O
gene	O
-	O
mediated	O
resistance	O
is	O
often	O
short	O
-	O
lived	O
and	O
is	O
rapidly	O
overcome	O
by	O
new	O
races	O
of	O
the	O
late	O
blight	O
pathogen	O
.	O

Solanum	O
bulbocastanum	O
(	O
2n	O
=	O
2x	O
=	O
24	O
)	O
is	O
a	O
diploid	O
species	O
that	O
has	O
adapted	O
in	O
the	O
same	O
environment	O
as	O
the	O
late	O
blight	O
pathogen	O
.	O

This	O
wild	O
species	O
was	O
characterized	O
as	O
possessing	O
durable	O
resistance	O
against	O
P	O
.	O
infestans	O
,	O
even	O
under	O
high	O
disease	O
pressure	O
[	O
2	O
,	O
3	O
]	O
.	O

Two	O
resistance	O
genes	O
,	O
RB	O
(	O
Rpi	O
-	O
blb1	O
)	O
and	O
Rpi	O
-	O
blb2	O
,	O
have	O
been	O
cloned	O
from	O
S	O
.	O
bulbocastanum	O
[	O
4	O
-	O
6	O
]	O
.	O

Both	O
genes	O
confer	O
broad	O
-	O
spectrum	O
resistance	O
against	O
a	O
wide	O
range	O
of	O
known	O
P	O
.	O
infestans	O
races	O
.	O

Transgenic	O
potato	O
lines	O
containing	O
a	O
single	O
RB	O
gene	O
showed	O
a	O
high	O
-	O
level	O
resistance	O
in	O
the	O
Toluca	O
Valley	O
,	O
Mexico	O
,	O
where	O
the	O
potato	O
fields	O
are	O
naturally	O
intensively	O
infested	O
with	O
the	O
most	O
diversified	O
P	O
.	O
infestans	O
populations	O
[	O
7	O
]	O
.	O

Most	O
interestingly	O
,	O
transgenic	O
RB	O
plants	O
did	O
not	O
show	O
total	O
immunity	O
to	O
late	O
blight	O
,	O
but	O
instead	O
showed	O
a	O
marked	O
delay	O
in	O
both	O
onset	O
of	O
symptoms	O
and	O
development	O
of	O
lesions	O
.	O

Such	O
rate	O
-	O
limiting	O
resistance	O
may	O
put	O
less	O
selection	O
pressure	O
on	O
the	O
P	O
.	O
infestans	O
populations	O
and	O
protect	O
the	O
durability	O
of	O
this	O
resistance	O
gene	O
.	O

The	O
RB	O
gene	O
therefore	O
provides	O
an	O
excellent	O
model	O
to	O
study	O
the	O
mechanism	O
of	O
broad	O
-	O
spectrum	O
and	O
rate	O
-	O
limiting	O
disease	O
resistances	O
.	O

An	O
understanding	O
of	O
the	O
underlying	O
mechanism	O
of	O
this	O
type	O
of	O
resistance	O
is	O
important	O
for	O
developing	O
strategies	O
to	O
breed	O
durable	O
and	O
sustainable	O
disease	O
resistance	O
.	O

Several	O
genes	O
have	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
R	O
gene	O
function	O
.	O

Of	O
these	O
genes	O
,	O
Rar1	O
and	O
Sgt1	O
are	O
among	O
the	O
most	O
extensively	O
studied	O
genes	O
.	O

The	O
Rar1	O
(	O
required	O
for	O
Mla12	O
resistance	O
)	O
gene	O
was	O
first	O
identified	O
for	O
its	O
essential	O
role	O
in	O
the	O
function	O
of	O
a	O
subset	O
of	O
Mla	O
genes	O
that	O
confer	O
resistance	O
to	O
barley	O
powdery	O
mildew	O
[	O
8	O
]	O
.	O

The	O
RAR1	O
protein	O
contains	O
two	O
highly	O
similar	O
but	O
distinct	O
cysteine	O
-	O
and	O
histidine	O
-	O
rich	O
(	O
CHORD	O
)	O
Zn2	O
+	O
-	O
binding	O
domains	O
and	O
was	O
proposed	O
to	O
play	O
a	O
role	O
in	O
stabilizing	O
R	O
proteins	O
in	O
a	O
confirmation	O
that	O
is	O
implicated	O
in	O
receiving	O
pathogen	O
signals	O
[	O
9	O
]	O
.	O

The	O
Sgt1	O
gene	O
(	O
suppressor	O
of	O
the	O
G2	O
allele	O
of	O
skp1	O
)	O
is	O
an	O
essential	O
gene	O
with	O
multiple	O
functions	O
in	O
yeast	O
.	O

SGT1	O
protein	O
was	O
initially	O
identified	O
as	O
a	O
RAR1	O
-	O
interacting	O
partner	O
in	O
a	O
yeast	O
two	O
-	O
hybrid	O
screen	O
[	O
10	O
]	O
.	O

SGT1	O
may	O
play	O
a	O
role	O
in	O
R	O
protein	O
accumulation	O
[	O
11	O
]	O
.	O

Rar1	O
and	O
Sgt1	O
genes	O
are	O
required	O
in	O
various	O
R	O
-	O
gene	O
mediated	O
resistance	O
against	O
viral	O
,	O
bacterial	O
,	O
oomycete	O
or	O
fungal	O
pathogens	O
[	O
12	O
]	O
.	O

However	O
,	O
none	O
of	O
the	O
previously	O
studied	O
R	O
genes	O
showed	O
a	O
race	O
-	O
non	O
-	O
specific	O
and	O
rate	O
-	O
limiting	O
resistance	O
phenotype	O
as	O
the	O
RB	O
gene	O
.	O

In	O
addition	O
,	O
the	O
role	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
are	O
not	O
universal	O
and	O
these	O
genes	O
are	O
not	O
essential	O
for	O
resistance	O
involving	O
some	O
R	O
genes	O
[	O
12	O
,	O
13	O
]	O
.	O

Besides	O
the	O
two	O
broad	O
-	O
spectrum	O
resistance	O
genes	O
RB	O
and	O
Rpi	O
-	O
blb2	O
,	O
several	O
race	O
-	O
specific	O
late	O
blight	O
resistance	O
genes	O
have	O
also	O
been	O
cloned	O
[	O
14	O
-	O
16	O
]	O
.	O

Numerous	O
late	O
blight	O
resistance	O
genes	O
have	O
recently	O
been	O
mapped	O
in	O
various	O
potato	O
species	O
or	O
populations	O
[	O
17	O
-	O
25	O
]	O
.	O

However	O
,	O
there	O
is	O
almost	O
no	O
information	O
available	O
about	O
the	O
resistance	O
pathways	O
mediated	O
by	O
any	O
of	O
these	O
genes	O
.	O

As	O
an	O
initial	O
effort	O
to	O
understand	O
the	O
RB	O
-	O
mediated	O
late	O
blight	O
resistance	O
pathway	O
,	O
we	O
silenced	O
the	O
Rar1	O
and	O
Sgt1	O
genes	O
using	O
an	O
RNAi	O
-	O
based	O
approach	O
in	O
a	O
potato	O
line	O
containing	O
the	O
RB	O
gene	O
.	O

We	O
demonstrated	O
that	O
SGT1	O
,	O
but	O
not	O
RAR1	O
,	O
is	O
essential	O
for	O
the	O
RB	O
-	O
mediated	O
broad	O
-	O
spectrum	O
resistance	O
to	O
potato	O
late	O
blight	O
.	O

Ovariectomy	O

Based	O
on	O
the	O
uterine	O
weight	O
,	O
we	O
determined	O
seven	O
unsuccessful	O
OVXs	O
.	O

The	O
rats	O
concerned	O
were	O
removed	O
from	O
further	O
analyses	O
,	O
which	O
left	O
nine	O
rats	O
in	O
the	O
control	O
group	O
,	O
five	O
in	O
the	O
OVX	O
group	O
,	O
seven	O
in	O
the	O
OVX	O
and	O
late	O
ZOL	O
group	O
,	O
and	O
eight	O
in	O
the	O
OVX	O
and	O
early	O
ZOL	O
group	O
.	O

For	O
each	O
animal	O
,	O
we	O
determined	O
the	O
percentage	O
change	O
in	O
structural	O
parameters	O
compared	O
to	O
the	O
values	O
at	O
week	O
0	O
.	O

Figure	O
1	O
shows	O
the	O
average	O
percentage	O
change	O
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
for	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
Tb	O
.	O
Th	O
,	O
and	O
Tb	O
.	O
Sp	O
.	O

The	O
OVX	O
group	O
without	O
treatment	O
showed	O
large	O
changes	O
in	O
structural	O
parameters	O
,	O
indicating	O
the	O
development	O
of	O
OVX	O
-	O
induced	O
bone	O
loss	O
(	O
Figs	O
.	O
1	O
and	O
2	O
)	O
.	O

Paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
indicated	O
significant	O
changes	O
within	O
2	O
weeks	O
after	O
OVX	O
for	O
all	O
structural	O
parameters	O
.	O

BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
and	O
Tb	O
.	O
N	O
decreased	O
during	O
the	O
experiment	O
and	O
SMI	O
and	O
Tb	O
.	O
Sp	O
increased	O
.	O

Both	O
Tb	O
.	O
Th	O
and	O
Tb	O
.	O
N	O
decreased	O
within	O
2	O
weeks	O
,	O
indicating	O
that	O
both	O
thinning	O
and	O
complete	O
resorption	O
of	O
trabeculae	O
started	O
directly	O
after	O
OVX	O
.	O

The	O
initial	O
rapid	O
loss	O
of	O
bone	O
and	O
connectivity	O
was	O
largely	O
accompanied	O
by	O
trabecular	O
thinning	O
,	O
while	O
secondary	O
,	O
slower	O
loss	O
of	O
bone	O
was	O
concomitant	O
with	O
a	O
decrease	O
in	O
Tb	O
.	O
N	O
.	O

While	O
BV	O
/	O
TV	O
,	O
Conn	O
.	O
D	O
,	O
SMI	O
,	O
Tb	O
.	O
N	O
,	O
and	O
Tb	O
.	O
Sp	O
showed	O
continuous	O
changes	O
in	O
the	O
same	O
direction	O
throughout	O
the	O
experiment	O
,	O
Tb	O
.	O
Th	O
initially	O
decreased	O
significantly	O
until	O
4	O
weeks	O
after	O
OVX	O
and	O
then	O
increased	O
again	O
until	O
after	O
16	O
weeks	O
Tb	O
.	O
Th	O
was	O
significantly	O
higher	O
than	O
in	O
the	O
control	O
group	O
.	O

Fig	O
.	O

1	O

Average	O
percentage	O
change	O
in	O
structural	O
parameters	O
in	O
the	O
metaphyseal	O
proximal	O
tibia	O
and	O
upper	O
standard	O
deviation	O
for	O
all	O
groups	O
at	O
all	O
time	O
points	O
.	O

Brackets	O
indicate	O
P	O
<	O
0	O
.	O
05	O
at	O
week	O
16	O

Fig	O
.	O

2	O

Same	O
slice	O
of	O
an	O
unprocessed	O
CT	O
scan	O
of	O
the	O
same	O
rat	O
in	O
the	O
OVX	O
group	O
taken	O
at	O
weeks	O
0	O
(	O
a	O
)	O
,	O
2	O
(	O
b	O
)	O
,	O
4	O
(	O
c	O
)	O
,	O
8	O
(	O
d	O
)	O
,	O
12	O
(	O
e	O
)	O
,	O
and	O
16	O
(	O
f	O
)	O
.	O

Images	O
show	O
typical	O
trabecular	O
bone	O
loss	O
due	O
to	O
OVX	O
in	O
the	O
metaphysis	O
.	O

Green	O
line	O
shows	O
the	O
analyzed	O
metaphyseal	O
bone	O

The	O
absolute	O
average	O
values	O
and	O
standard	O
deviations	O
for	O
all	O
structural	O
parameters	O
of	O
all	O
measurements	O
are	O
shown	O
in	O
Table	O
1	O
.	O

At	O
the	O
starting	O
point	O
,	O
some	O
differences	O
in	O
the	O
values	O
between	O
the	O
groups	O
were	O
present	O
.	O

This	O
was	O
due	O
to	O
the	O
fact	O
that	O
some	O
animals	O
,	O
which	O
mostly	O
had	O
a	O
relatively	O
low	O
BV	O
/	O
TV	O
,	O
were	O
removed	O
from	O
the	O
study	O
because	O
they	O
did	O
not	O
respond	O
to	O
the	O
OVX	O
.	O

However	O
,	O
since	O
we	O
compared	O
the	O
relative	O
changes	O
in	O
each	O
animal	O
,	O
the	O
results	O
were	O
most	O
likely	O
not	O
affected	O
by	O
the	O
difference	O
in	O
absolute	O
values	O
.	O

Table	O
1	O

Mean	O
values	O
and	O
standard	O
deviation	O
of	O
all	O
structural	O
parameters	O
of	O
all	O
groups	O
at	O
the	O
start	O
of	O
the	O
experiment	O

Group	O
BV	O
/	O
TV	O
(	O
1	O
)	O
Conn	O
.	O
D	O
(	O
1	O
/	O
mm	O
)	O
SMI	O
(	O
1	O
)	O
Tb	O
.	O
N	O
(	O
1	O
/	O
mm	O
)	O
Tb	O
.	O
Th	O
(	O
mum	O
)	O
Tb	O
.	O
Sp	O
(	O
mum	O
)	O

Control	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
41	O
(	O
47	O
)	O
1	O
.	O
52	O
(	O
0	O
.	O
53	O
)	O
1	O
.	O
89	O
(	O
1	O
.	O
38	O
)	O
105	O
(	O
49	O
)	O
613	O
(	O
368	O
)	O

OVX	O
0	O
.	O
26	O
(	O
0	O
.	O
055	O
)	O
141	O
(	O
76	O
)	O
1	O
.	O
22	O
(	O
0	O
.	O
39	O
)	O
3	O
.	O
77	O
(	O
1	O
.	O
66	O
)	O
84	O
(	O
10	O
)	O
335	O
(	O
174	O
)	O

OVX	O
+	O
late	O
ZOL	O
0	O
.	O
23	O
(	O
0	O
.	O
062	O
)	O
86	O
(	O
66	O
)	O
1	O
.	O
23	O
(	O
0	O
.	O
34	O
)	O
2	O
.	O
77	O
(	O
1	O
.	O
55	O
)	O
89	O
(	O
13	O
)	O
482	O
(	O
227	O
)	O

OVX	O
+	O
early	O
ZOL	O
0	O
.	O
17	O
(	O
0	O
.	O
056	O
)	O
38	O
(	O
21	O
)	O
1	O
.	O
70	O
(	O
0	O
.	O
39	O
)	O
1	O
.	O
86	O
(	O
0	O
.	O
80	O
)	O
95	O
(	O
7	O
)	O
647	O
(	O
207	O
)	O

Basilar	O
papilla	O

The	O
basilar	O
papilla	O
is	O
found	O
in	O
a	O
recess	O
that	O
opens	O
into	O
the	O
saccular	O
space	O
at	O
one	O
end	O
,	O
and	O
is	O
limited	O
by	O
a	O
thin	O
contact	O
membrane	O
at	O
the	O
other	O
.	O

The	O
contact	O
membrane	O
separates	O
the	O
endolymphatic	O
fluid	O
in	O
the	O
papillar	O
recess	O
from	O
the	O
perilymphatic	O
fluid	O
at	O
the	O
round	O
window	O
(	O
Lewis	O
and	O
Narins	O
1999	O
;	O
Wever	O
1985	O
)	O
.	O

The	O
recess	O
perimeter	O
is	O
roughly	O
oval	O
in	O
shape	O
;	O
in	O
the	O
bullfrog	O
,	O
Rana	O
catesbeiana	O
,	O
its	O
major	O
axis	O
is	O
approximately	O
200	O
mum	O
long	O
,	O
while	O
the	O
minor	O
axis	O
measures	O
approximately	O
150	O
mum	O
(	O
Van	O
Bergeijk	O
1957	O
)	O
.	O

In	O
the	O
leopard	O
frog	O
,	O
Rana	O
pipiens	O
pipiens	O
,	O
it	O
is	O
of	O
similar	O
size	O
(	O
personal	O
observation	O
,	O
RLMS	O
&	O
JMS	O
)	O
.	O

The	O
oval	O
perimeter	O
of	O
the	O
lumen	O
is	O
formed	O
from	O
limbic	O
tissue	O
;	O
a	O
substance	O
unique	O
to	O
the	O
inner	O
ear	O
,	O
and	O
similar	O
to	O
cartilage	O
(	O
Wever	O
1985	O
)	O
.	O

The	O
sensory	O
epithelium	O
is	O
approximately	O
100	O
mum	O
long	O
.	O

It	O
occupies	O
a	O
curved	O
area	O
that	O
is	O
symmetrical	O
in	O
the	O
major	O
axis	O
of	O
the	O
elliptical	O
lumen	O
.	O

It	O
contains	O
approximately	O
60	O
hair	O
cells	O
(	O
measured	O
in	O
Rana	O
catesbeiana	O
)	O
,	O
from	O
which	O
the	O
stereovilli	O
protrude	O
into	O
the	O
lumen	O
and	O
connect	O
to	O
the	O
tectorial	O
membrane	O
(	O
Frishkopf	O
and	O
Flock	O
1974	O
)	O
.	O

Typically	O
the	O
orientation	O
of	O
the	O
hair	O
cells	O
,	O
as	O
defined	O
by	O
the	O
direction	O
to	O
which	O
the	O
v	O
-	O
shape	O
of	O
the	O
stereovilli	O
bundle	O
points	O
(	O
Lewis	O
et	O
al	O
.	O
1985	O
)	O
,	O
is	O
away	O
from	O
the	O
sacculus	O
in	O
Ranidae	O
.	O

The	O
tectorial	O
membrane	O
spans	O
the	O
lumen	O
of	O
the	O
papillar	O
recess	O
.	O

It	O
occludes	O
about	O
half	O
the	O
lumen	O
,	O
and	O
consequently	O
takes	O
an	O
approximately	O
semi	O
-	O
circular	O
shape	O
when	O
viewed	O
from	O
the	O
saccular	O
side	O
(	O
Frishkopf	O
and	O
Flock	O
1974	O
;	O
Wever	O
1985	O
)	O
.	O

The	O
membrane	O
has	O
pores	O
at	O
the	O
surface	O
closest	O
to	O
the	O
epithelium	O
,	O
into	O
which	O
the	O
tips	O
of	O
the	O
hair	O
bundles	O
project	O
(	O
Lewis	O
and	O
Narins	O
1999	O
)	O
.	O
4	O

3	O
.	O

Results	O
and	O
discussion	O

AbsC	O
was	O
overexpressed	O
and	O
purified	O
with	O
a	O
final	O
yield	O
of	O
approximately	O
10	O
mg	O
of	O
protein	O
from	O
1	O
l	O
culture	O
and	O
was	O
judged	O
to	O
be	O
greater	O
than	O
98	O
%	O
pure	O
by	O
SDS	O
-	O
PAGE	O
analysis	O
.	O

The	O
DLS	O
analysis	O
after	O
gel	O
filtration	O
showed	O
a	O
monomodal	O
distribution	O
,	O
with	O
a	O
polydispersity	O
value	O
of	O
18	O
.	O
9	O
%	O
and	O
a	O
molecular	O
-	O
size	O
estimate	O
of	O
39	O
.	O
6	O
kDa	O
.	O

This	O
was	O
comparable	O
to	O
the	O
value	O
of	O
36	O
kDa	O
estimated	O
from	O
the	O
calibrated	O
gel	O
-	O
filtration	O
column	O
,	O
strongly	O
suggesting	O
that	O
AbsC	O
exists	O
as	O
a	O
homodimer	O
in	O
solution	O
(	O
calculated	O
molecular	O
weight	O
of	O
41	O
.	O
0	O
kDa	O
for	O
the	O
His	O
-	O
tagged	O
dimer	O
)	O
,	O
in	O
agreement	O
with	O
other	O
characterized	O
MarR	O
homologues	O
.	O

Preliminary	O
crystals	O
grew	O
within	O
24	O
h	O
at	O
293	O
K	O
from	O
several	O
different	O
crystallization	O
conditions	O
.	O

Improved	O
crystals	O
were	O
subsequently	O
obtained	O
with	O
a	O
precipitant	O
solution	O
consisting	O
of	O
1	O
M	O
ammonium	O
sulfate	O
,	O
0	O
.	O
55	O
M	O
potassium	O
sodium	O
tartrate	O
in	O
100	O
mM	O
citrate	O
pH	O
5	O
.	O
6	O
,	O
giving	O
crystals	O
with	O
approximate	O
dimensions	O
of	O
700	O
x	O
50	O
x	O
50	O
microm	O
(	O
Fig	O
.	O
1	O
>	O
)	O
.	O

Native	O
X	O
-	O
ray	O
data	O
were	O
collected	O
from	O
a	O
single	O
AbsC	O
crystal	O
:	O
a	O
total	O
of	O
214	O
x	O
0	O
.	O
4degrees	O
oscillation	O
images	O
were	O
recorded	O
in	O
a	O
continuous	O
sweep	O
to	O
a	O
maximum	O
resolution	O
of	O
2	O
.	O
25	O
A	O
.	O

Indexing	O
was	O
consistent	O
with	O
a	O
primitive	O
orthorhombic	O
lattice	O
,	O
with	O
unit	O
-	O
cell	O
parameters	O
a	O
=	O
43	O
.	O
53	O
,	O
b	O
=	O
121	O
.	O
30	O
,	O
c	O
=	O
143	O
.	O
75	O
A	O
.	O

After	O
processing	O
the	O
data	O
in	O
space	O
group	O
P222	O
,	O
pseudo	O
-	O
precession	O
plots	O
were	O
analysed	O
using	O
HKLVIEW	O
(	O
Collaborative	O
Computational	O
Project	O
,	O
Number	O
4	O
,	O
1994	O
>	O
)	O
and	O
the	O
systematic	O
absences	O
were	O
indicative	O
of	O
space	O
group	O
P212121	O
.	O

Reprocessing	O
in	O
this	O
space	O
group	O
yielded	O
a	O
data	O
set	O
that	O
was	O
95	O
.	O
6	O
%	O
complete	O
to	O
2	O
.	O
25	O
A	O
resolution	O
.	O

Data	O
-	O
collection	O
statistics	O
are	O
summarized	O
in	O
Table	O
1	O
>	O
.	O

Estimation	O
of	O
the	O
content	O
of	O
the	O
asymmetric	O
unit	O
(	O
ASU	O
)	O
suggested	O
that	O
three	O
or	O
four	O
His	O
-	O
tagged	O
AbsC	O
subunits	O
were	O
most	O
likely	O
,	O
giving	O
solvent	O
contents	O
of	O
60	O
.	O
3	O
%	O
or	O
47	O
.	O
0	O
%	O
and	O
crystal	O
-	O
packing	O
parameters	O
(	O
V	O
M	O
)	O
of	O
3	O
.	O
09	O
or	O
2	O
.	O
32	O
A3	O
Da	O
-	O
1	O
,	O
respectively	O
.	O

Given	O
that	O
both	O
DLS	O
and	O
gel	O
filtration	O
suggest	O
that	O
AbsC	O
is	O
dimeric	O
and	O
that	O
MarR	O
homologues	O
exist	O
as	O
homodimers	O
(	O
Wilkinson	O
&	O
Grove	O
,	O
2006	O
>	O
)	O
,	O
an	O
even	O
number	O
of	O
subunits	O
per	O
ASU	O
,	O
i	O
.	O
e	O
.	O
four	O
,	O
would	O
seem	O
to	O
be	O
the	O
most	O
probable	O
(	O
Matthews	O
,	O
1968	O
>	O
)	O
.	O

A	O
Patterson	O
function	O
calculated	O
on	O
data	O
in	O
the	O
resolution	O
range	O
10	O
.	O
0	O
-	O
3	O
.	O
0	O
A	O
revealed	O
a	O
significant	O
peak	O
(	O
at	O
24	O
%	O
of	O
the	O
origin	O
peak	O
)	O
with	O
a	O
vector	O
of	O
u	O
=	O
0	O
.	O
0	O
,	O
v	O
=	O
0	O
.	O
5	O
,	O
w	O
=	O
0	O
.	O
014	O
,	O
indicating	O
that	O
one	O
or	O
more	O
molecules	O
in	O
the	O
ASU	O
were	O
similarly	O
orientated	O
.	O

A	O
self	O
-	O
rotation	O
function	O
calculated	O
on	O
data	O
in	O
the	O
resolution	O
range	O
10	O
.	O
0	O
-	O
5	O
.	O
0	O
A	O
using	O
MOLREP	O
(	O
Vagin	O
&	O
Teplyakov	O
,	O
2000	O
>	O
)	O
did	O
not	O
show	O
any	O
clear	O
noncrystallographic	O
symmetry	O
(	O
NCS	O
)	O
,	O
perhaps	O
suggesting	O
that	O
if	O
NCS	O
axes	O
were	O
present	O
they	O
were	O
parallel	O
(	O
or	O
almost	O
parallel	O
)	O
to	O
crystallographic	O
axes	O
.	O

Fold	O
prediction	O
,	O
based	O
on	O
the	O
amino	O
-	O
acid	O
sequence	O
of	O
AbsC	O
,	O
was	O
performed	O
using	O
the	O
FUGUE	O
server	O
(	O
http	O
:	O
/	O
/	O
www	O
-	O
cryst	O
.	O
bioc	O
.	O
cam	O
.	O
ac	O
.	O
uk	O
/	O
~	O
fugue	O
/	O
prfsearch	O
.	O
html	O
;	O
Shi	O
et	O
al	O
.	O
,	O
2001	O
>	O
)	O
.	O

This	O
found	O
eight	O
'	O
certain	O
'	O
hits	O
,	O
with	O
the	O
top	O
three	O
being	O
MarR	O
(	O
PDB	O
code	O
1jgs	O
;	O
Z	O
score	O
21	O
.	O
4	O
;	O
18	O
%	O
sequence	O
identity	O
)	O
,	O
SlyA	O
(	O
PDB	O
code	O
1lj9	O
;	O
Z	O
score	O
18	O
.	O
4	O
;	O
16	O
%	O
sequence	O
identity	O
)	O
and	O
YusO	O
(	O
PDB	O
code	O
1s3j	O
;	O
Z	O
score	O
15	O
.	O
7	O
;	O
16	O
%	O
sequence	O
identity	O
)	O
.	O

All	O
three	O
hits	O
were	O
used	O
as	O
search	O
models	O
for	O
molecular	O
replacement	O
in	O
the	O
program	O
AMoRe	O
(	O
Navaza	O
,	O
1994	O
>	O
)	O
,	O
but	O
none	O
yielded	O
plausible	O
solutions	O
against	O
the	O
2	O
.	O
25	O
A	O
resolution	O
native	O
data	O
set	O
,	O
although	O
this	O
is	O
not	O
too	O
surprising	O
given	O
their	O
very	O
low	O
sequence	O
identities	O
.	O

Thus	O
,	O
we	O
will	O
need	O
to	O
solve	O
the	O
AbsC	O
structure	O
by	O
isomorphous	O
replacement	O
methods	O
.	O

To	O
this	O
end	O
,	O
we	O
are	O
preparing	O
selenomethionine	O
-	O
labelled	O
protein	O
;	O
there	O
are	O
a	O
total	O
of	O
seven	O
methionine	O
residues	O
present	O
in	O
the	O
158	O
-	O
amino	O
-	O
acid	O
sequence	O
of	O
AbsC	O
.	O

Mean	O
differences	O
of	O
scores	O
with	O
baseline	O
of	O
the	O
22	O
patients	O
who	O
competed	O
all	O
QLQ	O
-	O
C30	O
questionnaires	O
-	O
symptoms	O
scores	O
.	O

Click	O
here	O
for	O
file	O

Aim	O

This	O
study	O
reports	O
the	O
results	O
of	O
a	O
large	O
prospective	O
single	O
-	O
blinded	O
clinical	O
trial	O
of	O
3	O
SSRI	O
(	O
paroxetine	O
,	O
fluoxetine	O
and	O
escitalopram	O
)	O
in	O
PE	O
using	O
a	O
validated	O
questionnaire	O
.	O

Haplotype	O
block	O
structure	O
from	O
one	O
replicate	O
generated	O
by	O
the	O
block	O
method	O
(	O
ALS	O
)	O
.	O

CA	O
IX	O
and	O
response	O
to	O
PMRT	O

Kaplan	O
-	O
Meier	O
probability	O
plots	O
of	O
OS	O
after	O
PMRT	O
among	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
revealed	O
improved	O
survival	O
after	O
PMRT	O
in	O
both	O
subgroups	O
of	O
patients	O
(	O
Figure	O
2	O
)	O
.	O

Fifteen	O
-	O
year	O
OS	O
probabilities	O
were	O
improved	O
by	O
7	O
%	O
and	O
9	O
%	O
after	O
PMRT	O
for	O
the	O
subgroups	O
of	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
,	O
respectively	O
.	O

The	O
HR	O
of	O
overall	O
mortality	O
after	O
PMRT	O
was	O
0	O
.	O
87	O
(	O
95	O
%	O
CI	O
0	O
.	O
60	O
to	O
1	O
.	O
27	O
)	O
for	O
the	O
small	O
subgroup	O
of	O
151	O
CA	O
IX	O
positive	O
patients	O
and	O
0	O
.	O
82	O
(	O
95	O
%	O
CI	O
0	O
.	O
69	O
to	O
0	O
.	O
97	O
)	O
for	O
the	O
large	O
subgroup	O
of	O
813	O
CA	O
IX	O
negative	O
patients	O
.	O

HRs	O
and	O
95	O
%	O
CIs	O
after	O
PMRT	O
did	O
not	O
differ	O
significantly	O
between	O
CA	O
IX	O
positive	O
and	O
CA	O
IX	O
negative	O
patients	O
for	O
OS	O
,	O
DSS	O
,	O
DM	O
,	O
or	O
LRR	O
(	O
Table	O
4	O
)	O
.	O

In	O
multivariate	O
analysis	O
by	O
Cox	O
regression	O
,	O
no	O
significant	O
interaction	O
was	O
found	O
between	O
CA	O
IX	O
and	O
randomization	O
status	O
for	O
any	O
of	O
the	O
four	O
end	O
-	O
points	O
.	O

Similar	O
tendencies	O
were	O
observed	O
when	O
the	O
women	O
were	O
separated	O
into	O
premenopausal	O
and	O
postmenopausal	O
women	O
,	O
and	O
into	O
women	O
with	O
one	O
to	O
three	O
positive	O
nodes	O
and	O
those	O
with	O
more	O
than	O
three	O
positive	O
nodes	O
.	O

Table	O
4	O

Hazard	O
ratios	O

CA	O
IX	O
positive	O
(	O
n	O
=	O
151	O
)	O
CA	O
IX	O
negative	O
(	O
n	O
=	O
794	O
)	O

Overall	O
mortality	O
0	O
.	O
87	O
(	O
0	O
.	O
60	O
-	O
1	O
.	O
27	O
)	O
0	O
.	O
82	O
(	O
0	O
.	O
69	O
-	O
0	O
.	O
97	O
)	O

Disease	O
-	O
specific	O
mortality	O
0	O
.	O
83	O
(	O
0	O
.	O
55	O
-	O
1	O
.	O
27	O
)	O
0	O
.	O
76	O
(	O
0	O
.	O
63	O
-	O
0	O
.	O
93	O
)	O

Distant	O
metastases	O
0	O
.	O
83	O
(	O
0	O
.	O
54	O
-	O
1	O
.	O
25	O
)	O
0	O
.	O
76	O
(	O
0	O
.	O
63	O
-	O
0	O
.	O
91	O
)	O

Locoregional	O
recurrence	O
0	O
.	O
23	O
(	O
0	O
.	O
08	O
-	O
0	O
.	O
61	O
)	O
0	O
.	O
16	O
(	O
0	O
.	O
09	O
-	O
0	O
.	O
28	O
)	O

Presented	O
are	O
hazard	O
ratios	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
of	O
overall	O
mortality	O
,	O
disease	O
-	O
specific	O
mortality	O
,	O
distant	O
metastases	O
and	O
loco	O
-	O
regional	O
recurrence	O
probabilities	O
after	O
postmastectomy	O
radiotherapy	O
in	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
IX	O
positive	O
and	O
in	O
CA	O
IX	O
negative	O
high	O
-	O
risk	O
breast	O
cancer	O
patients	O
.	O

Figure	O
2	O

Overall	O
survival	O
in	O
high	O
-	O
risk	O
breast	O
cancer	O
patients	O
.	O

Shown	O
are	O
Kaplan	O
-	O
Meier	O
probability	O
plots	O
of	O
overall	O
survival	O
in	O
high	O
-	O
risk	O
breast	O
cancer	O
patients	O
as	O
a	O
function	O
of	O
randomization	O
to	O
postmastectomy	O
radiotherapy	O
(	O
RT	O
)	O
within	O
the	O
subgroups	O
of	O
carbonic	O
anhydrase	O
(	O
CA	O
)	O
IX	O
negative	O
and	O
CA	O
IX	O
positive	O
patients	O
.	O

The	O
values	O
given	O
in	O
parentheses	O
after	O
hazard	O
ratios	O
(	O
HRs	O
)	O
are	O
the	O
95	O
%	O
confidence	O
intervals	O
.	O

Changing	O
the	O
cutpoints	O
to	O
at	O
least	O
one	O
tumour	O
cell	O
,	O
or	O
>	O
=	O
20	O
%	O
or	O
>	O
=	O
30	O
%	O
invasive	O
tumour	O
staining	O
did	O
not	O
improve	O
the	O
predictive	O
value	O
of	O
positive	O
CA	O
IX	O
staining	O
(	O
data	O
not	O
presented	O
)	O
.	O

Competing	O
interests	O

The	O
authors	O
declare	O
that	O
they	O
have	O
no	O
competing	O
interests	O
.	O

Analysis	O
of	O
furAII	O
-	O
katGII	O
region	O

The	O
cDNA	O
from	O
M	O
.	O
fortuitum	O
under	O
the	O
different	O
stresses	O
was	O
analysed	O
by	O
PCR	O
using	O
the	O
primers	O
furAII	O
-	O
Fo	O
and	O
P1	O
.	O
1	O
(	O
Table	O
2	O
)	O
to	O
test	O
the	O
presence	O
of	O
furAII	O
and	O
katGII	O
cotranscripts	O
.	O

PCR	O
cycling	O
was	O
performed	O
as	O
follows	O
:	O
a	O
denaturizing	O
step	O
at	O
95degreesC	O
for	O
5	O
minutes	O
;	O
36	O
cycles	O
of	O
95degreesC	O
for	O
45	O
seconds	O
,	O
54degreesC	O
for	O
45	O
seconds	O
and	O
72degreesC	O
for	O
1	O
minute	O
;	O
and	O
a	O
final	O
extension	O
at	O
72degreesC	O
for	O
10	O
minutes	O
.	O

Background	O

Previous	O
publications	O
indicate	O
that	O
acupuncture	O
is	O
efficient	O
for	O
the	O
treatment	O
of	O
pelvic	O
girdle	O
pain	O
,	O
PGP	O
,	O
in	O
pregnant	O
women	O
.	O

However	O
,	O
the	O
use	O
of	O
acupuncture	O
for	O
PGP	O
is	O
rare	O
due	O
to	O
insufficient	O
documentation	O
of	O
adverse	O
effects	O
of	O
this	O
treatment	O
in	O
this	O
specific	O
condition	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
assess	O
adverse	O
effects	O
of	O
acupuncture	O
on	O
the	O
pregnancy	O
,	O
mother	O
,	O
delivery	O
and	O
the	O
fetus	O
/	O
neonate	O
in	O
comparison	O
with	O
women	O
that	O
received	O
stabilising	O
exercises	O
as	O
adjunct	O
to	O
standard	O
treatment	O
or	O
standard	O
treatment	O
alone	O
.	O

Summary	O
of	O
studies	O
reporting	O
comorbidities	O
with	O
diabetes	O
.	O

Authors	O
'	O
contributions	O

MP	O
prepared	O
the	O
first	O
draft	O
with	O
the	O
assistance	O
of	O
JLdR	O
.	O

Other	O
authors	O
reviewed	O
the	O
manuscript	O
,	O
provided	O
further	O
contributions	O
and	O
suggestions	O
.	O

All	O
of	O
the	O
authors	O
worked	O
collectively	O
to	O
develop	O
the	O
algorithms	O
and	O
methods	O
described	O
in	O
this	O
paper	O
.	O

Study	O
of	O
freeze	O
-	O
thaw	O
effects	O
and	O
CSF	O
pH	O
on	O
tissue	O
RNA	O
integrity	O

We	O
have	O
long	O
suspected	O
,	O
on	O
the	O
basis	O
of	O
our	O
tissue	O
banking	O
experience	O
,	O
that	O
most	O
of	O
the	O
molecular	O
degradation	O
that	O
occurs	O
in	O
banked	O
tissue	O
is	O
due	O
to	O
repeated	O
freeze	O
-	O
thaw	O
cycles	O
,	O
which	O
occur	O
due	O
to	O
improper	O
handling	O
during	O
dissection	O
for	O
tissue	O
retrieval	O
or	O
due	O
to	O
freezer	O
malfunctions	O
.	O

Our	O
freezers	O
are	O
currently	O
protected	O
by	O
temperature	O
-	O
sensitive	O
alarms	O
that	O
automatically	O
telephone	O
maintenance	O
and	O
tissue	O
banking	O
personnel	O
when	O
the	O
temperature	O
reaches	O
a	O
certain	O
level	O
.	O

More	O
protection	O
is	O
preferable	O
,	O
with	O
CO2	O
tanks	O
for	O
backup	O
cooling	O
the	O
optimum	O
(	O
but	O
expensive	O
)	O
approach	O
.	O

We	O
plan	O
to	O
systematically	O
investigate	O
the	O
effects	O
of	O
thawing	O
and	O
refreezing	O
on	O
RNA	O
integrity	O
,	O
by	O
deliberately	O
thawing	O
and	O
freezing	O
small	O
samples	O
of	O
brain	O
tissue	O
over	O
varying	O
time	O
intervals	O
and	O
temperatures	O
.	O

Acknowledgements	O

The	O
authors	O
would	O
like	O
to	O
express	O
their	O
gratitude	O
to	O
Dr	O
.	O
Mahasti	O
Alizadeh	O
for	O
her	O
assistance	O
in	O
the	O
data	O
analysis	O
and	O
designing	O
the	O
questionnaire	O
.	O

Methods	O

Printing	O
solution	O

Several	O
transfection	O
reagents	O
were	O
tested	O
(	O
data	O
not	O
shown	O
)	O
,	O
and	O
we	O
found	O
that	O
the	O
X	O
-	O
tremeGENE	O
siRNA	O
transfection	O
reagent	O
(	O
Roche	O
)	O
gave	O
good	O
transfection	O
efficiencies	O
both	O
for	O
plasmids	O
and	O
siRNAs	O
,	O
and	O
chose	O
to	O
use	O
this	O
reagent	O
for	O
all	O
transfected	O
cell	O
microarray	O
experiments	O
in	O
the	O
present	O
study	O
.	O

For	O
printing	O
the	O
arrays	O
,	O
one	O
major	O
challenge	O
is	O
to	O
find	O
a	O
good	O
balance	O
between	O
high	O
transfection	O
efficiency	O
and	O
spatially	O
confined	O
spots	O
to	O
avoid	O
cross	O
-	O
contamination	O
between	O
the	O
spots	O
.	O

In	O
order	O
to	O
optimize	O
the	O
reverse	O
transfection	O
protocol	O
for	O
HEK	O
293ind	O
-	O
ICER	O
IIgamma	O
cells	O
(	O
see	O
below	O
)	O
and	O
X	O
-	O
tremeGENE	O
transfection	O
reagent	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
varying	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
in	O
the	O
printing	O
solution	O
.	O

These	O
reagents	O
have	O
been	O
reported	O
to	O
influence	O
both	O
the	O
transfection	O
efficiency	O
and	O
spot	O
integrity	O
(	O
6	O
,	O
27	O
)	O
.	O

Sucrose	O
was	O
observed	O
to	O
be	O
specifically	O
beneficial	O
for	O
obtaining	O
high	O
transfection	O
efficiency	O
when	O
storing	O
the	O
arrays	O
for	O
several	O
weeks	O
before	O
use	O
(	O
data	O
not	O
shown	O
)	O
.	O

Figure	O
1A	O
and	O
B	O
show	O
representative	O
images	O
of	O
the	O
observed	O
effects	O
of	O
varying	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
.	O

We	O
observed	O
that	O
the	O
transfection	O
efficiency	O
increased	O
with	O
increasing	O
gelatine	O
concentration	O
(	O
tested	O
in	O
the	O
range	O
0	O
.	O
01	O
-	O
0	O
.	O
40	O
%	O
)	O
.	O

However	O
,	O
an	O
increased	O
disturbance	O
of	O
the	O
spatial	O
definition	O
of	O
the	O
spots	O
was	O
observed	O
with	O
increasing	O
concentrations	O
of	O
gelatine	O
or	O
sucrose	O
(	O
tested	O
in	O
the	O
range	O
0	O
-	O
100	O
mM	O
)	O
.	O

A	O
combined	O
effect	O
of	O
the	O
concentrations	O
of	O
gelatine	O
and	O
sucrose	O
was	O
also	O
observed	O
,	O
as	O
low	O
concentrations	O
of	O
gelatine	O
allowed	O
us	O
to	O
use	O
higher	O
concentrations	O
of	O
sucrose	O
than	O
with	O
higher	O
concentrations	O
of	O
gelatine	O
before	O
cells	O
spread	O
outside	O
the	O
spots	O
.	O

Based	O
on	O
several	O
optimizing	O
experiments	O
,	O
we	O
found	O
that	O
3	O
microl	O
X	O
-	O
tremeGENE	O
solution	O
per	O
microgram	O
nucleic	O
acid	O
,	O
25	O
mM	O
sucrose	O
and	O
0	O
.	O
1	O
%	O
gelatine	O
in	O
the	O
final	O
printing	O
solution	O
reproducibly	O
gave	O
spatial	O
restricted	O
transfection	O
with	O
high	O
transfection	O
efficiency	O
printing	O
the	O
arrays	O
with	O
both	O
a	O
pipette	O
tip	O
and	O
a	O
hand	O
-	O
held	O
arrayer	O
(	O
see	O
below	O
)	O
.	O

Figure	O
1	O
.	O

Effects	O
of	O
sucrose	O
and	O
gelatine	O
concentrations	O
on	O
spot	O
integrity	O
and	O
transfection	O
efficiency	O
.	O

(	O
A	O
)	O
Array	O
printed	O
with	O
pDsRed	O
(	O
50	O
ng	O
/	O
microl	O
)	O
in	O
a	O
printing	O
solution	O
with	O
different	O
gelatine	O
and	O
sucrose	O
concentrations	O
.	O

Scanning	O
image	O
of	O
the	O
whole	O
array	O
and	O
magnifications	O
of	O
specific	O
spots	O
.	O

(	O
B	O
)	O
Array	O
printed	O
with	O
pEGFP	O
(	O
50	O
ng	O
/	O
microl	O
)	O
in	O
a	O
printing	O
solution	O
with	O
25	O
mM	O
sucrose	O
and	O
four	O
different	O
concentrations	O
of	O
gelatine	O
.	O

Top	O
:	O
Box	O
plot	O
of	O
the	O
fluorescence	O
intensities	O
in	O
each	O
spot	O
(	O
n	O
=	O
32	O
-	O
34	O
)	O
.	O

Bottom	O
:	O
Scanning	O
image	O
showing	O
squares	O
of	O
seven	O
times	O
five	O
spots	O
for	O
the	O
four	O
gelatine	O
concentrations	O
.	O

From	O
left	O
to	O
right	O
:	O
0	O
.	O
01	O
,	O
0	O
.	O
05	O
,	O
0	O
.	O
1	O
and	O
0	O
.	O
2	O
%	O
gelatine	O
.	O

The	O
DNA	O
-	O
lipid	O
-	O
gelatine	O
-	O
sucrose	O
solutions	O
were	O
printed	O
manually	O
with	O
a	O
10	O
microl	O
pipette	O
tip	O
(	O
A	O
)	O
or	O
by	O
MicroCasterTM	O
manual	O
arrayer	O
system	O
(	O
B	O
)	O
.	O

In	O
a	O
1	O
.	O
5	O
ml	O
microcentrifuge	O
tube	O
,	O
plasmid	O
(	O
1	O
microg	O
/	O
microl	O
)	O
and	O
siRNA	O
were	O
mixed	O
with	O
growth	O
medium	O
without	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
,	O
0	O
.	O
5	O
microl	O
1	O
.	O
5	O
M	O
sucrose	O
and	O
3	O
microl	O
X	O
-	O
tremeGENE	O
per	O
microgram	O
nucleic	O
acid	O
to	O
a	O
final	O
volume	O
of	O
22	O
.	O
5	O
microl	O
.	O

After	O
15	O
-	O
20	O
min	O
of	O
incubation	O
,	O
7	O
.	O
5	O
microl	O
0	O
.	O
4	O
%	O
gelatine	O
(	O
Type	O
B	O
,	O
G9391	O
,	O
Sigma	O
)	O
was	O
added	O
to	O
give	O
30	O
microl	O
printing	O
solution	O
.	O

The	O
gelatine	O
solution	O
was	O
prepared	O
as	O
described	O
by	O
Ziauddin	O
and	O
Sabatini	O
(	O
1	O
)	O
.	O

To	O
achieve	O
sufficient	O
level	O
of	O
expression	O
from	O
the	O
transfected	O
plasmids	O
,	O
25	O
-	O
50	O
ng	O
/	O
microl	O
pEGFP	O
-	O
N1	O
or	O
pDsRed	O
-	O
express	O
-	O
N1	O
and	O
50	O
-	O
75	O
ng	O
/	O
microl	O
of	O
CRE	O
or	O
NFkappaB	O
reporter	O
plasmids	O
was	O
used	O
.	O

For	O
siRNA	O
studies	O
,	O
2	O
-	O
30	O
ng	O
/	O
microl	O
siRNA	O
in	O
the	O
final	O
printing	O
solution	O
was	O
used	O
.	O

Click	O
here	O
for	O
additional	O
data	O
file	O
.	O

Candle	O
wicks	O

Candles	O
with	O
a	O
lead	O
metal	O
core	O
contribute	O
to	O
lead	O
in	O
the	O
home	O
(	O
Nriagu	O
and	O
Kim	O
2000	O
;	O
van	O
Alphen	O
1999	O
)	O
.	O

Exposure	O
occurs	O
both	O
from	O
air	O
and	O
from	O
hand	O
-	O
to	O
-	O
mouth	O
activity	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
children	O
'	O
s	O
EBLs	O
traceable	O
to	O
candles	O
have	O
been	O
reported	O
.	O

In	O
2002	O
,	O
the	O
CPSC	O
banned	O
candlewicks	O
containing	O
>	O
0	O
.	O
06	O
%	O
lead	O
(	O
CPSC	O
2003	O
)	O
.	O

RESULTS	O

Forty	O
Caucasians	O
(	O
19	O
females	O
)	O
with	O
essential	O
hypertension	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Their	O
mean	O
age	O
was	O
57	O
years	O
.	O

Most	O
of	O
them	O
were	O
overweight	O
,	O
17	O
had	O
metabolic	O
syndrome	O
according	O
to	O
the	O
updated	O
AHA	O
NHLBI	O
statement	O
(	O
defined	O
as	O
3	O
or	O
more	O
of	O
the	O
following	O
:	O
waist	O
circumference	O
>	O
102	O
cm	O
in	O
men	O
and	O
>	O
88	O
cm	O
in	O
women	O
,	O
blood	O
pressure	O
>	O
=	O
130	O
/	O
85	O
mmHg	O
,	O
triglycerides	O
>	O
150	O
mg	O
/	O
dl	O
,	O
HDL	O
-	O
C	O
<	O
40	O
mg	O
/	O
dl	O
in	O
men	O
and	O
<	O
50	O
mg	O
/	O
dl	O
in	O
women	O
,	O
and	O
fasting	O
glucose	O
>	O
=	O
100	O
mg	O
/	O
dl	O
)	O
,	O
8	O
had	O
type	O
2	O
diabetes	O
and	O
18	O
were	O
smokers	O
(	O
Table	O
1	O
)	O
.	O

Eprosartan	O
reduced	O
SBP	O
by	O
8	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
DBP	O
by	O
13	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
it	O
had	O
a	O
neutral	O
effect	O
on	O
the	O
lipid	O
profile	O
and	O
apolipoprotein	O
levels	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
did	O
not	O
affect	O
plasma	O
8	O
-	O
epiPGF2a	O
levels	O
,	O
whereas	O
it	O
significantly	O
increased	O
by	O
24	O
%	O
the	O
lag	O
time	O
of	O
total	O
serum	O
oxidation	O
(	O
145	O
+	O
/	O
-	O
54	O
min	O
vs	O
180	O
+	O
/	O
-	O
58	O
min	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
reduced	O
by	O
14	O
%	O
the	O
aspartate	O
aminotransferase	O
(	O
form	O
21	O
to	O
18	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
by	O
21	O
%	O
the	O
alanine	O
aminotransferase	O
(	O
from	O
24	O
to	O
19	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
activity	O
(	O
Table2	O
)	O
.	O

The	O
administration	O
of	O
eprosartan	O
had	O
no	O
influence	O
on	O
glucose	O
homeostasis	O
,	O
as	O
well	O
as	O
on	O
creatinine	O
and	O
uric	O
acid	O
levels	O
(	O
Table2	O
)	O
.	O

In	O
addition	O
,	O
eprosartan	O
did	O
not	O
affect	O
clotting	O
or	O
fibrinolytic	O
activity	O
as	O
this	O
was	O
estimated	O
by	O
PAI	O
-	O
1	O
,	O
tPA	O
and	O
a2	O
-	O
antiplasmin	O
(	O
Table2	O
)	O
.	O

The	O
enzymatic	O
activity	O
of	O
Lp	O
-	O
PLA2	O
and	O
PON1	O
were	O
not	O
altered	O
significantly	O
following	O
eprosartan	O
treatment	O
(	O
Table2	O
)	O
.	O

Comparison	O
of	O
the	O
number	O
of	O
known	O
complexes	O
matched	O
by	O
the	O
predicted	O
clusters	O
generated	O
by	O
IPCA	O
and	O
other	O
previous	O
algorithms	O

Images	O

Figure	O
1	O

Figure	O
5	O

Figure	O
6	O

Characteristics	O
of	O
cases	O
with	O
childhood	O
leukaemia	O
(	O
n	O
=	O
162	O
)	O
and	O
matched	O
controls	O
(	O
n	O
=	O
2125	O
)	O
,	O
all	O
registered	O
within	O
3	O
months	O
of	O
birth	O

Authors	O
'	O
contributions	O

OK	O
and	O
MG	O
analyzed	O
and	O
interpreted	O
the	O
patient	O
data	O
regarding	O
his	O
hospitalization	O
.	O

SP	O
and	O
PK	O
performed	O
the	O
coronary	O
angiography	O
,	O
and	O
were	O
the	O
major	O
contributors	O
in	O
writing	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Appendix	O
Table	O

Detection	O
of	O
Nipah	O
virus	O
antibody	O
among	O
bat	O
serum	O
samples	O
collected	O
from	O
10	O
provinces	O
in	O
China	O
,	O
2004	O
-	O
2007	O
*	O

Whole	O
-	O
Body	O
gamma	O
-	O
Irradiation	O

To	O
evaluate	O
differential	O
sensitivity	O
to	O
irradiation	O
,	O
mice	O
were	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
(	O
4	O
-	O
10	O
Gy	O
,	O
single	O
dose	O
)	O
and	O
closely	O
monitored	O
throughout	O
the	O
experimentation	O
period	O
.	O

Animals	O
were	O
killed	O
at	O
the	O
first	O
appearance	O
of	O
signs	O
of	O
poor	O
health	O
.	O

Recipients	O
of	O
bone	O
marrow	O
transplants	O
were	O
pre	O
-	O
irradiated	O
with	O
a	O
total	O
dose	O
of	O
10	O
.	O
2	O
Gy	O
(	O
two	O
doses	O
of	O
5	O
.	O
1	O
Gy	O
,	O
3	O
h	O
apart	O
)	O
.	O

For	O
in	O
vivo	O
DNA	O
damage	O
experiments	O
,	O
mice	O
were	O
irradiated	O
with	O
a	O
single	O
dose	O
of	O
5Gy	O
and	O
killed	O
after	O
1	O
,	O
3	O
or	O
6	O
hours	O
.	O

All	O
irradiations	O
were	O
carried	O
out	O
in	O
a	O
Cesium	O
Mark1	O
irradiator	O
(	O
Shepherd	O
Associates	O
)	O
.	O

Variables	O

Our	O
study	O
used	O
the	O
following	O
9	O
HRQOL	O
questions	O
from	O
the	O
2004	O
Rhode	O
Island	O
BRFSS	O
:	O
1	O
)	O
self	O
-	O
rated	O
general	O
health	O
status	O
;	O
and	O
self	O
-	O
reported	O
number	O
of	O
healthy	O
and	O
unhealthy	O
days	O
in	O
the	O
previous	O
30	O
days	O
for	O
2	O
)	O
physical	O
health	O
,	O
3	O
)	O
mental	O
health	O
,	O
4	O
)	O
physical	O
or	O
mental	O
health	O
-	O
related	O
activity	O
limitation	O
,	O
5	O
)	O
pain	O
-	O
related	O
activity	O
limitation	O
,	O
6	O
)	O
sad	O
,	O
blue	O
,	O
or	O
depressed	O
,	O
7	O
)	O
worried	O
,	O
tense	O
,	O
or	O
anxious	O
,	O
8	O
)	O
lack	O
of	O
rest	O
or	O
sleep	O
,	O
and	O
9	O
)	O
lack	O
of	O
energy	O
(	O
1	O
,	O
2	O
,	O
15	O
)	O
.	O

We	O
created	O
9	O
dichotomous	O
indicator	O
variables	O
.	O

The	O
responses	O
to	O
the	O
self	O
-	O
rated	O
general	O
health	O
status	O
question	O
were	O
dichotomized	O
into	O
""""	O
poor	O
""""	O
(	O
poor	O
or	O
fair	O
)	O
health	O
or	O
""""	O
good	O
""""	O
(	O
good	O
,	O
very	O
good	O
,	O
or	O
excellent	O
)	O
health	O
.	O

The	O
indicators	O
measured	O
in	O
days	O
were	O
dichotomized	O
at	O
a	O
cutoff	O
value	O
of	O
14	O
or	O
more	O
days	O
of	O
poor	O
health	O
in	O
the	O
previous	O
month	O
compared	O
to	O
less	O
than	O
14	O
days	O
(	O
3	O
)	O
.	O

We	O
selected	O
the	O
14	O
-	O
day	O
minimum	O
period	O
because	O
most	O
of	O
the	O
publications	O
we	O
reviewed	O
that	O
use	O
the	O
BRFSS	O
HRQOL	O
indicators	O
(	O
outcomes	O
)	O
use	O
the	O
cutoff	O
of	O
14	O
or	O
more	O
days	O
compared	O
to	O
13	O
or	O
fewer	O
days	O
(	O
3	O
-	O
5	O
,	O
7	O
-	O
11	O
,	O
16	O
,	O
17	O
)	O
.	O

Adopting	O
this	O
precedent	O
ensured	O
comparability	O
.	O

In	O
addition	O
,	O
clinicians	O
and	O
clinical	O
researchers	O
often	O
use	O
this	O
period	O
as	O
a	O
marker	O
for	O
clinical	O
depression	O
and	O
anxiety	O
disorders	O
,	O
and	O
long	O
symptomatic	O
durations	O
are	O
associated	O
with	O
high	O
levels	O
of	O
activity	O
limitation	O
(	O
2	O
,	O
18	O
)	O
.	O

Detailed	O
definitions	O
of	O
the	O
9	O
indicators	O
are	O
available	O
in	O
our	O
previous	O
article	O
(	O
1	O
)	O
or	O
are	O
accessible	O
through	O
the	O
Centers	O
for	O
Disease	O
Control	O
and	O
Prevention	O
'	O
s	O
HRQOL	O
Web	O
site	O
(	O
2	O
)	O
.	O

We	O
chose	O
12	O
predictors	O
for	O
the	O
analysis	O
:	O
5	O
standard	O
demographic	O
measures	O
(	O
age	O
,	O
sex	O
,	O
race	O
/	O
Hispanic	O
ethnicity	O
,	O
annual	O
income	O
,	O
and	O
employment	O
status	O
)	O
;	O
4	O
health	O
conditions	O
(	O
asthma	O
,	O
diabetes	O
,	O
obesity	O
,	O
and	O
physical	O
disability	O
)	O
;	O
and	O
3	O
health	O
risk	O
behaviors	O
(	O
smoking	O
,	O
chronic	O
alcohol	O
use	O
,	O
and	O
no	O
leisure	O
-	O
time	O
physical	O
activity	O
)	O
.	O

These	O
predictors	O
paralleled	O
the	O
results	O
of	O
other	O
studies	O
that	O
have	O
examined	O
relationships	O
between	O
a	O
specific	O
HRQOL	O
indicator	O
and	O
various	O
predictors	O
(	O
17	O
,	O
19	O
)	O
,	O
or	O
that	O
have	O
examined	O
multiple	O
HRQOL	O
indicators	O
in	O
relation	O
to	O
demographics	O
(	O
4	O
,	O
20	O
)	O
,	O
health	O
risks	O
(	O
5	O
,	O
10	O
,	O
21	O
)	O
,	O
or	O
specific	O
health	O
conditions	O
(	O
6	O
-	O
9	O
,	O
12	O
,	O
22	O
)	O
.	O

We	O
dichotomized	O
some	O
predictors	O
for	O
the	O
analysis	O
(	O
ie	O
,	O
sex	O
,	O
current	O
smoking	O
,	O
alcohol	O
use	O
,	O
physical	O
activity	O
,	O
asthma	O
,	O
diabetes	O
,	O
obesity	O
,	O
and	O
disability	O
)	O
,	O
whereas	O
other	O
predictors	O
had	O
multiple	O
categories	O
(	O
ie	O
,	O
age	O
,	O
race	O
/	O
Hispanic	O
ethnicity	O
,	O
income	O
,	O
and	O
employment	O
status	O
)	O
.	O

The	O
definitions	O
of	O
the	O
12	O
predictors	O
are	O
available	O
in	O
our	O
previous	O
article	O
(	O
1	O
)	O
.	O

Reference	O
groups	O
chosen	O
for	O
the	O
IRT	O
model	O
were	O
those	O
having	O
the	O
lowest	O
risk	O
for	O
poor	O
or	O
fair	O
general	O
health	O
and	O
usually	O
the	O
lowest	O
risk	O
for	O
the	O
other	O
HRQOL	O
variables	O
as	O
well	O
.	O

Background	O

Sealant	O
application	O
criteria	O
for	O
molar	O
fissures	O

Power	O
(	O
Y	O
-	O
axis	O
)	O
as	O
a	O
function	O
of	O
main	O
effects	O
(	O
x	O
-	O
axis	O
)	O
.	O

For	O
a	O
pure	O
main	O
-	O
effects	O
model	O
(	O
x	O
-	O
axis	O
=	O
a1	O
>	O
0	O
;	O
interaction	O
effects	O
a2	O
=	O
a3	O
=	O
0	O
are	O
all	O
zero	O
)	O
,	O
Figure	O
1	O
shows	O
that	O
pattern	O
(	O
solid	O
red	O
line	O
)	O
and	O
single	O
-	O
locus	O
(	O
broken	O
blue	O
line	O
)	O
approaches	O
have	O
virtually	O
the	O
same	O
power	O
.	O

Results	O

Peptide	O
-	O
BSA	O
conjugates	O
as	O
diagnostic	O
antigens	O

To	O
analyse	O
the	O
potential	O
of	O
the	O
peptides	O
to	O
behave	O
as	O
antigen	O
mimics	O
,	O
their	O
ability	O
to	O
react	O
with	O
IgM	O
antibodies	O
from	O
individuals	O
infected	O
with	O
EBV	O
was	O
assessed	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
demonstrated	O
that	O
the	O
sensitivity	O
of	O
detection	O
was	O
greatly	O
improved	O
when	O
the	O
peptides	O
were	O
coupled	O
to	O
a	O
carrier	O
molecule	O
such	O
as	O
BSA	O
prior	O
to	O
immobilisation	O
onto	O
a	O
solid	O
surface	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

This	O
strategy	O
was	O
adopted	O
to	O
test	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
.	O

A	O
set	O
of	O
40	O
clinical	O
samples	O
that	O
were	O
classified	O
as	O
EBV	O
seropositive	O
(	O
n	O
=	O
16	O
)	O
,	O
seronegative	O
(	O
n	O
=	O
16	O
)	O
or	O
potentially	O
cross	O
-	O
reactive	O
sera	O
(	O
n	O
=	O
8	O
)	O
were	O
assessed	O
for	O
reactivity	O
with	O
Eb1	O
-	O
4	O
and	O
H1	O
peptides	O
individually	O
.	O

The	O
cut	O
-	O
off	O
level	O
was	O
defined	O
as	O
the	O
mean	O
optical	O
density	O
of	O
the	O
seronegative	O
samples	O
plus	O
3	O
standard	O
deviations	O
shown	O
as	O
a	O
line	O
on	O
the	O
graphs	O
in	O
Fig	O
.	O

5	O
.	O

Readings	O
above	O
this	O
level	O
were	O
defined	O
as	O
positive	O
and	O
below	O
this	O
level	O
negative	O
.	O

The	O
same	O
set	O
of	O
samples	O
were	O
analysed	O
on	O
BSA	O
alone	O
and	O
these	O
values	O
were	O
subtracted	O
from	O
the	O
peptide	O
-	O
BSA	O
conjugate	O
readings	O
and	O
the	O
corrected	O
absorbance	O
readings	O
were	O
plotted	O
individually	O
for	O
our	O
new	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
in	O
Fig	O
.	O

5	O
.	O

There	O
was	O
a	O
clear	O
difference	O
in	O
the	O
detection	O
of	O
seropositive	O
antibodies	O
by	O
all	O
the	O
peptides	O
(	O
Fig	O
.	O
5A	O
-	O
E	O
)	O
compared	O
with	O
the	O
analysis	O
of	O
BSA	O
alone	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
with	O
the	O
majority	O
of	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
.	O

We	O
compared	O
the	O
ability	O
of	O
our	O
panel	O
of	O
peptide	O
mimotopes	O
to	O
be	O
recognised	O
by	O
antibodies	O
in	O
the	O
same	O
set	O
of	O
seropositive	O
samples	O
in	O
Fig	O
.	O

6A	O
and	O
the	O
sensitivity	O
of	O
detection	O
is	O
shown	O
in	O
Fig	O
.	O

6B	O
.	O

We	O
also	O
included	O
F1	O
and	O
Gp125	O
mimotopes	O
specific	O
for	O
two	O
mAbs	O
in	O
our	O
previous	O
study	O
(	O
Casey	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

Of	O
the	O
peptides	O
identified	O
from	O
polyclonal	O
sera	O
Eb1	O
,	O
Gp125	O
and	O
F1	O
had	O
the	O
highest	O
sensitivity	O
(	O
94	O
%	O
)	O
.	O

Slightly	O
lower	O
sensitivity	O
was	O
observed	O
for	O
Eb2	O
,	O
3	O
and	O
4	O
(	O
88	O
%	O
)	O
and	O
H1	O
peptide	O
had	O
the	O
lowest	O
sensitivity	O
(	O
81	O
%	O
)	O
as	O
summarised	O
in	O
Fig	O
.	O

6B	O
.	O

The	O
sensitivity	O
of	O
F1	O
and	O
Gp125	O
was	O
similar	O
to	O
that	O
produced	O
by	O
the	O
mimotopes	O
selected	O
in	O
our	O
previous	O
study	O
,	O
95	O
%	O
for	O
F1	O
and	O
92	O
%	O
for	O
Gp125	O
.	O

Fig	O
.	O

5	O

Evaluation	O
of	O
peptides	O
Eb1	O
-	O
4	O
and	O
H1	O
coupled	O
to	O
BSA	O
as	O
EBV	O
diagnostic	O
reagents	O
.	O

Human	O
serum	O
(	O
n	O
=	O
40	O
)	O
previously	O
analysed	O
using	O
a	O
diagnostic	O
test	O
for	O
VCA	O
IgM	O
was	O
allowed	O
to	O
react	O
with	O
the	O
peptides	O
and	O
the	O
bound	O
IgM	O
antibodies	O
were	O
detected	O
using	O
anti	O
-	O
human	O
IgM	O
HRP	O
.	O

The	O
absorbance	O
readings	O
for	O
1	O
(	O
positive	O
)	O
,	O
2	O
(	O
negative	O
)	O
and	O
putative	O
cross	O
-	O
reactive	O
sera	O
for	O
3	O
(	O
Parvo	O
)	O
,	O
4	O
(	O
HSV	O
)	O
,	O
5	O
(	O
CMV	O
)	O
and	O
6	O
(	O
RF	O
)	O
are	O
plotted	O
for	O
(	O
A	O
)	O
Eb1	O
,	O
(	O
B	O
)	O
Eb2	O
,	O
(	O
C	O
)	O
Eb3	O
,	O
(	O
D	O
)	O
Eb4	O
,	O
(	O
E	O
)	O
H1	O
and	O
(	O
F	O
)	O
BSA	O
,	O
respectively	O
.	O

The	O
cut	O
-	O
off	O
value	O
is	O
defined	O
as	O
the	O
mean	O
of	O
the	O
negative	O
population	O
+	O
3SD	O
indicated	O
by	O
a	O
solid	O
horizontal	O
line	O
;	O
since	O
there	O
were	O
no	O
false	O
positives	O
,	O
the	O
specificity	O
for	O
each	O
mimotope	O
was	O
100	O
%	O
.	O

Fig	O
.	O

6	O

Comparison	O
of	O
the	O
reactivities	O
of	O
our	O
panel	O
of	O
mimotopes	O
Eb1	O
-	O
4	O
,	O
H1	O
,	O
F1	O
and	O
Gp125	O
conjugated	O
to	O
BSA	O
with	O
EBV	O
IgM	O
-	O
positive	O
sera	O
(	O
n	O
=	O
16	O
)	O
absorbance	O
values	O
are	O
plotted	O
and	O
the	O
cut	O
-	O
off	O
levels	O
are	O
depicted	O
by	O
a	O
horizontal	O
line	O
in	O
(	O
A	O
)	O
.	O

(	O
B	O
)	O
Summary	O
of	O
the	O
false	O
-	O
negative	O
results	O
from	O
the	O
5	O
/	O
16	O
serum	O
samples	O
seropositive	O
for	O
IgM	O
EBV	O
and	O
the	O
overall	O
sensitivity	O
for	O
each	O
mimotope	O
for	O
diagnosis	O
of	O
EBV	O
IgM	O
antibodies	O
.	O

We	O
also	O
considered	O
which	O
seropositive	O
EBV	O
samples	O
contained	O
antibodies	O
that	O
did	O
not	O
recognise	O
the	O
panel	O
of	O
peptides	O
,	O
i	O
.	O
e	O
.	O
false	O
-	O
negative	O
readings	O
,	O
listed	O
in	O
Fig	O
.	O

6B	O
.	O

The	O
antibodies	O
in	O
serum	O
1	O
(	O
s1	O
)	O
were	O
unreactive	O
with	O
all	O
of	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
,	O
s2	O
was	O
not	O
reactive	O
with	O
Eb3	O
,	O
Eb4	O
and	O
H1	O
and	O
s3	O
was	O
unreactive	O
with	O
H1	O
.	O

Gp125	O
and	O
F1	O
that	O
were	O
selected	O
in	O
our	O
previous	O
study	O
were	O
recognised	O
by	O
s1	O
,	O
2	O
and	O
3	O
;	O
however	O
,	O
two	O
different	O
serum	O
samples	O
(	O
s4	O
and	O
5	O
)	O
did	O
not	O
recognise	O
F1	O
or	O
Gp125	O
,	O
respectively	O
.	O

This	O
demonstrates	O
that	O
individual	O
peptides	O
are	O
not	O
recognised	O
by	O
all	O
EBV	O
antibodies	O
and	O
confirms	O
that	O
different	O
peptides	O
are	O
required	O
to	O
represent	O
different	O
epitopes	O
.	O

Therefore	O
,	O
a	O
combination	O
of	O
Eb1	O
peptide	O
F1	O
and	O
Gp125	O
peptides	O
could	O
be	O
recognised	O
by	O
antibodies	O
present	O
in	O
all	O
this	O
set	O
of	O
EBV	O
clinical	O
samples	O
resulting	O
in	O
100	O
%	O
sensitivity	O
.	O

For	O
the	O
samples	O
defined	O
as	O
EBV	O
-	O
seronegative	O
,	O
there	O
were	O
no	O
readings	O
above	O
the	O
cut	O
-	O
off	O
level	O
and	O
therefore	O
no	O
false	O
positives	O
,	O
resulting	O
in	O
100	O
%	O
specificity	O
.	O

In	O
addition	O
,	O
there	O
were	O
no	O
absorbance	O
readings	O
above	O
the	O
cut	O
-	O
off	O
levels	O
for	O
the	O
potentially	O
cross	O
-	O
reactive	O
serum	O
samples	O
,	O
inferring	O
that	O
the	O
peptides	O
identified	O
in	O
this	O
study	O
have	O
high	O
specificity	O
for	O
EBV	O
antibodies	O
.	O

Additional	O
File	O
2	O

Full	O
Model	O
Code	O
.	O

Full	O
model	O
code	O
plus	O
instructions	O
for	O
running	O
in	O
Berkeley	O
Madonna	O
(	O
TM	O
)	O
.	O

Fragmentation	O
of	O
the	O
parent	O
ion	O
/	O
TCE	O
-	O
sulfate	O
moiety	O

The	O
mass	O
spectrum	O
of	O
compound	O
5	O
displays	O
its	O
molecular	O
ion	O
5a	O
with	O
the	O
typical	O
isotope	O
pattern	O
[	O
18	O
]	O
of	O
a	O
pentachlorinated	O
compound	O
at	O
m	O
/	O
z	O
448	O
(	O
relative	O
abundance	O
,	O
15	O
%	O
)	O
(	O
Figure	O
2	O
)	O
.	O

Scheme	O
1	O
illustrates	O
the	O
various	O
fragmentation	O
pathways	O
of	O
this	O
precursor	O
ion	O
.	O

The	O
molecular	O
ion	O
5a	O
loses	O
a	O
PCB	O
sulfate	O
(	O
ArOSO3	O
-	O
)	O
group	O
,	O
thus	O
yielding	O
TCE	O
group	O
-	O
derived	O
fragment	O
ions	O
.	O

These	O
ions	O
,	O
[	O
CH2CCl3	O
]	O
+	O
and	O
[	O
CH	O
=	O
CCl2	O
]	O
+	O
,	O
are	O
observed	O
at	O
m	O
/	O
z	O
131	O
(	O
6	O
%	O
)	O
and	O
95	O
(	O
7	O
%	O
)	O
,	O
respectively	O
.	O

Scheme	O
1	O

Principal	O
EI	O
-	O
MS	O
fragmentation	O
pathways	O
of	O
sulfuric	O
acid	O
2	O
'	O
,	O
5	O
'	O
-	O
dichlorobiphenyl	O
-	O
4yl	O
ester	O
2	O
,	O
2	O
,	O
2	O
-	O
trichloroethyl	O
ester	O
5	O
.	O

More	O
complex	O
fragmentation	O
patterns	O
are	O
observed	O
for	O
the	O
fragmentation	O
of	O
the	O
-	O
OSO3	O
-	O
TCE	O
group	O
.	O

The	O
abundant	O
fragment	O
ion	O
5	O
g	O
(	O
m	O
/	O
z	O
237	O
,	O
28	O
%	O
)	O
can	O
be	O
formed	O
by	O
two	O
fragmentation	O
pathways	O
from	O
precursor	O
ion	O
5a	O
.	O

One	O
pathway	O
involves	O
the	O
release	O
of	O
HCl	O
and	O
Cl	O
from	O
precursor	O
ion	O
5a	O
,	O
leading	O
to	O
an	O
unstable	O
cyclic	O
fragment	O
ion	O
5b	O
(	O
m	O
/	O
z	O
377	O
,	O
5	O
%	O
)	O
.	O

In	O
turn	O
,	O
fragment	O
ion	O
5b	O
produces	O
the	O
fragment	O
ion	O
5	O
g	O
after	O
releasing	O
chloroethyne	O
and	O
SO3	O
.	O

The	O
other	O
pathway	O
resulting	O
in	O
the	O
formation	O
of	O
fragment	O
ion	O
5	O
g	O
involves	O
the	O
removal	O
of	O
two	O
neutral	O
molecules	O
,	O
HCHO	O
and	O
SO2	O
,	O
from	O
the	O
daughter	O
fragment	O
ion	O
5c	O
(	O
m	O
/	O
z	O
331	O
,	O
5	O
%	O
)	O
,	O
which	O
is	O
formed	O
by	O
releasing	O
the	O
free	O
radical	O
group	O
CCl3	O
from	O
fragment	O
ion	O
5a	O
.	O

Alternatively	O
,	O
the	O
fragment	O
ion	O
5c	O
can	O
also	O
produce	O
the	O
daughter	O
fragment	O
ion	O
5e	O
(	O
m	O
/	O
z	O
183	O
,	O
12	O
%	O
)	O
by	O
losing	O
one	O
molecule	O
of	O
SO3	O
.	O

In	O
addition	O
,	O
precursor	O
ion	O
5a	O
yields	O
the	O
daughter	O
ion	O
5d	O
by	O
losing	O
a	O
CHCCl3	O
fragment	O
.	O

The	O
basic	O
fragment	O
ion	O
5f	O
at	O
m	O
/	O
z	O
238	O
is	O
produced	O
from	O
the	O
daughter	O
ion	O
5d	O
(	O
m	O
/	O
z	O
318	O
,	O
20	O
%	O
)	O
by	O
releasing	O
one	O
molecule	O
of	O
SO3	O
.	O

Fragment	O
ions	O
5f	O
and	O
5	O
g	O
can	O
produce	O
the	O
important	O
fragment	O
ion	O
5h	O
at	O
m	O
/	O
z	O
209	O
with	O
a	O
relative	O
abundance	O
of	O
26	O
%	O
by	O
losing	O
a	O
CHO	O
or	O
CO	O
fragment	O
,	O
respectively	O
.	O

The	O
same	O
fragmentation	O
pathways	O
are	O
observed	O
for	O
the	O
TCE	O
PCB	O
sulfates	O
diesters	O
1	O
and	O
3	O
-	O
10	O
.	O

The	O
only	O
exception	O
is	O
compound	O
2	O
,	O
which	O
has	O
the	O
TCE	O
sulfate	O
group	O
in	O
ortho	O
position	O
to	O
the	O
other	O
phenyl	O
ring	O
.	O

The	O
mass	O
spectrum	O
of	O
compounds	O
2	O
is	O
distinctively	O
different	O
from	O
the	O
mass	O
spectrum	O
of	O
its	O
isomer	O
,	O
compound	O
3	O
(	O
Figures	O
3	O
and	O
4	O
)	O
.	O

As	O
shown	O
in	O
Scheme	O
2	O
,	O
the	O
basic	O
fragment	O
ion	O
of	O
compound	O
2	O
is	O
the	O
stable	O
dibenzofuran	O
ion	O
2f	O
.	O

Fragment	O
ion	O
2f	O
is	O
formed	O
from	O
the	O
parent	O
ion	O
2a	O
(	O
m	O
/	O
z	O
414	O
;	O
relative	O
abundance	O
,	O
21	O
%	O
)	O
by	O
sequential	O
loss	O
of	O
CHCCl3	O
(	O
2d	O
,	O
m	O
/	O
z	O
284	O
;	O
relative	O
abundance	O
,	O
10	O
%	O
)	O
,	O
SO3	O
(	O
2e	O
,	O
m	O
/	O
z	O
204	O
;	O
relative	O
abundance	O
,	O
28	O
%	O
)	O
and	O
HCl	O
(	O
2f	O
,	O
m	O
/	O
z	O
168	O
;	O
relative	O
abundance	O
,	O
100	O
%	O
)	O
.	O

The	O
stable	O
dibenzofuran	O
cation	O
2f	O
is	O
also	O
formed	O
as	O
the	O
base	O
peak	O
ion	O
in	O
the	O
fragmentation	O
pathways	O
of	O
corresponding	O
methoxylated	O
PCB	O
11	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
other	O
2	O
-	O
methoxy	O
PCB	O
derivatives	O
also	O
form	O
a	O
stable	O
dibenzofuran	O
cation	O
after	O
losing	O
chlorine	O
atom	O
and	O
methyl	O
group	O
[	O
19	O
]	O
.	O

Scheme	O
2	O

Principal	O
EI	O
-	O
MS	O
fragmentation	O
pathways	O
of	O
sulfuric	O
acid	O
4	O
'	O
-	O
dichlorobiphenyl	O
-	O
2	O
-	O
yl	O
ester	O
2	O
,	O
2	O
,	O
2	O
-	O
trichloroethyl	O
ester	O
2	O
.	O

The	O
relative	O
abundance	O
of	O
several	O
fragment	O
ions	O
depends	O
on	O
the	O
position	O
of	O
the	O
-	O
OSO3	O
-	O
TCE	O
group	O
and	O
the	O
chlorine	O
substitution	O
pattern	O
.	O

The	O
relative	O
abundance	O
of	O
the	O
[	O
M	O
-	O
HCl2	O
]	O
+	O
and	O
[	O
M	O
-	O
CCl3	O
]	O
+	O
fragment	O
ions	O
of	O
compound	O
2	O
,	O
9	O
and	O
10	O
are	O
lower	O
compared	O
to	O
all	O
other	O
TCE	O
PCB	O
sulfate	O
diesters	O
(	O
Table	O
1	O
)	O
.	O

This	O
lower	O
relative	O
abundance	O
is	O
due	O
to	O
steric	O
and	O
/	O
or	O
electronic	O
effects	O
resulting	O
from	O
the	O
ortho	O
phenyl	O
substituent	O
in	O
compound	O
2	O
or	O
the	O
two	O
ortho	O
chlorine	O
substituents	O
in	O
compounds	O
9	O
and	O
10	O
.	O

In	O
addition	O
,	O
the	O
relative	O
abundance	O
of	O
fragment	O
ion	O
[	O
ArOSO3H	O
]	O
+	O
of	O
the	O
TCE	O
PCB	O
sulfate	O
diesters	O
9	O
and	O
10	O
is	O
low	O
compared	O
to	O
the	O
corresponding	O
fragment	O
ion	O
of	O
the	O
other	O
TCE	O
PCB	O
sulfate	O
diesters	O
,	O
with	O
only	O
a	O
trace	O
of	O
the	O
respective	O
ions	O
being	O
observed	O
(	O
Table	O
1	O
)	O
.	O

For	O
example	O
,	O
the	O
relative	O
abundance	O
of	O
[	O
ArOSO3H	O
]	O
+	O
5d	O
is	O
20	O
%	O
,	O
whereas	O
the	O
abundance	O
of	O
the	O
corresponding	O
fragment	O
ions	O
of	O
compounds	O
9	O
and	O
10	O
is	O
<	O
<	O
1	O
%	O
.	O

Since	O
compounds	O
9	O
and	O
10	O
have	O
two	O
chlorine	O
substituents	O
in	O
the	O
phenyl	O
ring	O
with	O
the	O
-	O
OSO3TCE	O
group	O
,	O
the	O
low	O
relative	O
abundance	O
of	O
fragment	O
ion	O
[	O
ArOSO3H	O
]	O
+	O
suggests	O
that	O
the	O
sulfate	O
group	O
of	O
both	O
compounds	O
is	O
less	O
stable	O
,	O
possibly	O
because	O
of	O
the	O
comparatively	O
high	O
pKa	O
value	O
of	O
the	O
Ar	O
-	O
OH	O
group	O
[	O
20	O
]	O
.	O

This	O
observation	O
is	O
in	O
agreement	O
with	O
the	O
decreasing	O
chemical	O
stability	O
of	O
aryl	O
sulfate	O
monoesters	O
with	O
increasing	O
acidity	O
of	O
the	O
phenolic	O
aryl	O
group	O
[	O
21	O
]	O
.	O

Authors	O
'	O
contributions	O

CM	O
,	O
JRH	O
,	O
HJP	O
,	O
and	O
JH	O
carried	O
animal	O
studies	O
.	O

CM	O
performed	O
the	O
statistical	O
analysis	O
.	O

JLK	O
conceived	O
of	O
the	O
study	O
,	O
participated	O
in	O
its	O
design	O
and	O
coordination	O
,	O
and	O
drafted	O
and	O
edited	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Disk	O
preparation	O
phase	O

o	O
Adoption	O
of	O
a	O
two	O
-	O
stage	O
sampling	O
scheme	O
.	O

o	O
Careful	O
planning	O
and	O
choice	O
of	O
representative	O
sampling	O
groups	O
and	O
sites	O
according	O
to	O
the	O
adopted	O
network	O
sampling	O
technique	O
,	O
and	O
determining	O
certain	O
criteria	O
such	O
as	O
control	O
sites	O
where	O
major	O
sampling	O
groups	O
exist	O
(	O
i	O
.	O
e	O
.	O
surface	O
water	O
points	O
,	O
valleys	O
,	O
and	O
wells	O
)	O
,	O
impact	O
sites	O
where	O
contamination	O
is	O
expected	O
,	O
such	O
as	O
polygons	O
,	O
and	O
outlets	O
(	O
e	O
.	O
g	O
.	O
treated	O
water	O
discharges	O
site	O
)	O
to	O
maximise	O
understanding	O
the	O
quality	O
of	O
urban	O
water	O
sources	O
,	O
and	O
with	O
the	O
least	O
risk	O
of	O
missing	O
the	O
correct	O
representative	O
sampling	O
groups	O
and	O
sites	O
.	O

o	O
Attention	O
paid	O
to	O
ensure	O
inclusion	O
in	O
the	O
sampling	O
frame	O
of	O
all	O
groups	O
and	O
locations	O
(	O
sites	O
,	O
roads	O
,	O
venues	O
,	O
and	O
so	O
on	O
)	O
via	O
screening	O
,	O
browsing	O
,	O
and	O
delineation	O
from	O
a	O
satellite	O
digital	O
map	O
of	O
the	O
Khamis	O
Mushait	O
Governorate	O
zone	O
,	O
because	O
local	O
pre	O
-	O
knowledge	O
was	O
preferred	O
with	O
regard	O
to	O
accessibility	O
,	O
safety	O
,	O
and	O
permission	O
.	O

o	O
Approximation	O
of	O
the	O
number	O
of	O
the	O
target	O
study	O
population	O
in	O
each	O
group	O
and	O
sampling	O
location	O
.	O

o	O
Determination	O
of	O
the	O
proportional	O
allocation	O
of	O
samples	O
between	O
different	O
groups	O
and	O
locations	O
.	O

o	O
Training	O
of	O
interviewers	O
\	O
sample	O
collectors	O
to	O
follow	O
and	O
to	O
use	O
the	O
sampling	O
strategy	O
and	O
procedures	O
.	O

o	O
Implementation	O
of	O
ways	O
to	O
boost	O
participation	O
rates	O
in	O
the	O
screening	O
and	O
core	O
interviews	O
and	O
sample	O
collection	O
.	O

o	O
Planning	O
of	O
logistic	O
needs	O
of	O
timing	O
,	O
gathering	O
,	O
handling	O
samples	O
,	O
and	O
laboratory	O
.	O

o	O
Producing	O
sampling	O
cards	O
to	O
be	O
completed	O
to	O
record	O
observations	O
at	O
scene	O
(	O
sample	O
ID	O
and	O
data	O
/	O
information	O
:	O
date	O
,	O
time	O
,	O
temperature	O
,	O
group	O
,	O
locality	O
,	O
problems	O
in	O
the	O
area	O
,	O
sketch	O
map	O
)	O
.	O

o	O
Selection	O
of	O
an	O
appropriate	O
major	O
sampling	O
method	O
[	O
52	O
]	O
(	O
i	O
.	O
e	O
.	O
simple	O
random	O
sample	O
;	O
network	O
sampling	O
)	O
.	O

o	O
Planning	O
of	O
pilot	O
visits	O
to	O
samples	O
of	O
each	O
group	O
in	O
the	O
field	O
to	O
review	O
strategy	O
.	O

Secchi	O
depth	O
in	O
the	O
Baltic	O
Proper	O
,	O
June	O
-	O
August	O
,	O
1957	O
-	O
1998	O
.	O

Number	O
of	O
data	O
:	O
3	O
,	O
452	O
.	O

1	O
.	O

Introduction	O

Phase	O
I	O
clinical	O
trials	O
of	O
new	O
anticancer	O
agents	O
have	O
been	O
commonly	O
conducted	O
using	O
the	O
method	O
of	O
modified	O
Fibonacci	O
[	O
1	O
]	O
.	O

In	O
brief	O
,	O
3	O
patients	O
are	O
treated	O
at	O
a	O
starting	O
dose	O
which	O
is	O
typically	O
one	O
tenth	O
of	O
the	O
dose	O
that	O
is	O
lethal	O
to	O
10	O
%	O
of	O
animals	O
defined	O
in	O
preclinical	O
studies	O
.	O

If	O
none	O
of	O
the	O
3	O
patients	O
experiences	O
DLT	O
,	O
then	O
the	O
next	O
3	O
patients	O
will	O
be	O
treated	O
at	O
the	O
next	O
higher	O
dose	O
.	O

If	O
DLT	O
is	O
observed	O
,	O
additional	O
patients	O
will	O
be	O
treated	O
at	O
the	O
same	O
or	O
lower	O
dose	O
level	O
to	O
determine	O
MTD	O
according	O
to	O
a	O
predetermined	O
schema	O
.	O

The	O
MTD	O
is	O
defined	O
as	O
the	O
highest	O
dose	O
reached	O
for	O
which	O
the	O
incidence	O
of	O
DLT	O
occurs	O
in	O
less	O
than	O
33	O
%	O
of	O
the	O
subjects	O
.	O

Typically	O
,	O
intrapatient	O
dose	O
escalation	O
is	O
not	O
allowed	O
.	O

There	O
are	O
several	O
shortcomings	O
associated	O
with	O
the	O
modified	O
-	O
Fibonacci	O
design	O
.	O

It	O
has	O
long	O
been	O
recognized	O
that	O
a	O
substantial	O
number	O
of	O
patients	O
are	O
likely	O
to	O
be	O
treated	O
at	O
subtherapeutic	O
doses	O
[	O
2	O
,	O
3	O
]	O
.	O

This	O
is	O
particularly	O
true	O
for	O
drugs	O
with	O
potential	O
anticancer	O
activity	O
.	O

Since	O
the	O
primary	O
purpose	O
of	O
phase	O
I	O
trials	O
is	O
to	O
determine	O
DLT	O
and	O
MTD	O
,	O
the	O
efficacy	O
of	O
the	O
drug	O
may	O
not	O
be	O
evident	O
for	O
certain	O
tumor	O
types	O
as	O
there	O
are	O
only	O
a	O
small	O
number	O
of	O
patients	O
enrolled	O
into	O
the	O
trial	O
.	O

Furthermore	O
,	O
the	O
modified	O
-	O
Fibonacci	O
design	O
does	O
not	O
take	O
into	O
account	O
individual	O
variations	O
in	O
therapeutic	O
and	O
toxicologic	O
responses	O
due	O
to	O
genomic	O
polymorphisms	O
[	O
4	O
,	O
5	O
]	O
.	O

In	O
addition	O
,	O
since	O
there	O
is	O
a	O
limit	O
of	O
3	O
subjects	O
allowed	O
for	O
each	O
cohort	O
,	O
a	O
waiting	O
period	O
of	O
up	O
to	O
four	O
weeks	O
is	O
commonly	O
required	O
before	O
enrollment	O
of	O
the	O
next	O
cohort	O
of	O
subjects	O
.	O

This	O
latter	O
requirement	O
creates	O
anxiety	O
of	O
waiting	O
for	O
eligible	O
patients	O
.	O

Several	O
alternative	O
phase	O
I	O
designs	O
have	O
been	O
proposed	O
which	O
limit	O
the	O
number	O
of	O
patients	O
accrued	O
at	O
each	O
dose	O
level	O
and	O
accelerate	O
the	O
dose	O
escalation	O
process	O
[	O
1	O
,	O
6	O
]	O
.	O

There	O
has	O
also	O
been	O
an	O
increase	O
in	O
the	O
number	O
of	O
clinical	O
trials	O
that	O
include	O
a	O
component	O
of	O
intrapatient	O
dose	O
escalation	O
although	O
no	O
formal	O
validation	O
with	O
the	O
modified	O
-	O
Fibonacci	O
approach	O
has	O
been	O
reported	O
[	O
7	O
-	O
9	O
]	O
.	O

We	O
have	O
pioneered	O
a	O
population	O
-	O
based	O
design	O
to	O
maximize	O
therapeutic	O
efficacy	O
,	O
to	O
provide	O
preliminary	O
efficacy	O
information	O
and	O
to	O
allow	O
derivation	O
of	O
a	O
pMTD	O
for	O
subsequent	O
phase	O
II	O
trials	O
.	O

Irinotecan	O
and	O
cisplatin	O
have	O
been	O
shown	O
to	O
have	O
promising	O
efficacy	O
in	O
patients	O
with	O
small	O
-	O
cell	O
lung	O
cancer	O
in	O
phase	O
III	O
trial	O
where	O
irinotecan	O
was	O
given	O
on	O
a	O
weekly	O
schedule	O
[	O
10	O
]	O
.	O

We	O
wished	O
to	O
perform	O
a	O
population	O
-	O
based	O
phase	O
I	O
trial	O
of	O
irinotecan	O
,	O
given	O
every	O
3	O
weeks	O
,	O
and	O
carboplatin	O
,	O
a	O
platinated	O
anticancer	O
drug	O
which	O
is	O
generally	O
better	O
tolerated	O
than	O
its	O
cisplatin	O
analog	O
.	O

Nucleotide	O
features	O
of	O
free	O
-	O
standing	O
homing	O
-	O
endonucleases	O

Gene	O
control	O
elements	O
were	O
identified	O
for	O
several	O
members	O
of	O
each	O
type	O
of	O
intervening	O
homing	O
endonuclease	O
genes	O
described	O
in	O
this	O
study	O
.	O

In	O
15	O
out	O
of	O
16	O
,	O
5	O
'	O
untranslated	O
regions	O
of	O
the	O
endonucleases	O
we	O
identified	O
RNA	O
hairpin	O
structures	O
upstream	O
of	O
initiation	O
codons	O
(	O
Figures	O
1	O
and	O
4A	O
)	O
.	O

This	O
may	O
be	O
a	O
translational	O
regulatory	O
hairpin	O
structure	O
known	O
from	O
various	O
phage	O
genes	O
,	O
including	O
homing	O
endonucleases	O
(	O
22	O
,	O
47	O
-	O
49	O
)	O
.	O

The	O
hairpins	O
we	O
found	O
are	O
in	O
fractured	O
gene	O
loci	O
with	O
different	O
protein	O
host	O
types	O
,	O
including	O
gp41	O
,	O
IMPDH	O
,	O
DnaE	O
,	O
NrdJ	O
and	O
NrdA	O
.	O

Ten	O
of	O
these	O
hairpins	O
also	O
include	O
a	O
conserved	O
sequence	O
of	O
Aeh1	O
phage	O
late	O
promoter	O
element	O
(	O
TATAAATA	O
)	O
,	O
which	O
was	O
recently	O
shown	O
to	O
inhibit	O
the	O
translation	O
of	O
a	O
gene	O
-	O
fracturing	O
endonuclease	O
gene	O
,	O
by	O
sequestering	O
its	O
ribosome	O
binding	O
site	O
(	O
22	O
,	O
23	O
)	O
.	O

Analysis	O
of	O
the	O
endonuclease	O
5	O
'	O
untranslated	O
regions	O
revealed	O
two	O
conserved	O
motifs	O
(	O
Figures	O
4A	O
and	O
Supplementary	O
Figure	O
S4	O
)	O
,	O
which	O
usually	O
complement	O
each	O
other	O
on	O
the	O
stem	O
of	O
the	O
conserved	O
hairpin	O
structures	O
.	O

Figure	O
4	O
.	O

Nucleotide	O
features	O
of	O
endonuclease	O
genes	O
.	O

(	O
A	O
)	O
RNA	O
hairpin	O
structures	O
at	O
the	O
5	O
'	O
untranslated	O
region	O
of	O
endonuclease	O
ORFs	O
in	O
the	O
gp41	O
-	O
1	O
(	O
representing	O
the	O
very	O
similar	O
sequences	O
of	O
gp41	O
-	O
1	O
-	O
7	O
)	O
,	O
nrdA	O
-	O
5	O
and	O
DnaE	O
-	O
1	O
gene	O
loci	O
.	O

Initiator	O
codons	O
are	O
marked	O
by	O
arrows	O
,	O
conserved	O
putative	O
T4	O
late	O
promoter	O
elements	O
are	O
boxed	O
,	O
and	O
conserved	O
sequence	O
motifs	O
(	O
Supplementary	O
Figure	O
S4	O
)	O
are	O
highlighted	O
in	O
grey	O
.	O

The	O
expected	O
values	O
for	O
motifs	O
1	O
and	O
2	O
are	O
1	O
.	O
7	O
-	O
10	O
and	O
9	O
.	O
9	O
-	O
3	O
,	O
respectively	O
.	O

RNA	O
structures	O
were	O
calculated	O
using	O
the	O
Vienna	O
package	O
(	O
http	O
:	O
/	O
/	O
rna	O
.	O
tbi	O
.	O
univie	O
.	O
ac	O
.	O
at	O
/	O
cgi	O
-	O
bin	O
/	O
RNAfold	O
.	O
cgi	O
)	O
,	O
and	O
sequence	O
motifs	O
were	O
identified	O
using	O
the	O
MEME	O
program	O
.	O

(	O
B	O
)	O
Overlapping	O
#	O
protein	O
coding	O
regions	O
of	O
endonuclease	O
3	O
'	O
termini	O
and	O
the	O
5	O
'	O
termini	O
of	O
their	O
downstream	O
genes	O
.	O

Additionally	O
,	O
15	O
loci	O
included	O
an	O
overlapping	O
region	O
of	O
6	O
-	O
69	O
bp	O
between	O
the	O
coding	O
regions	O
of	O
the	O
probable	O
endonuclease	O
C	O
-	O
termini	O
and	O
the	O
downstream	O
N	O
-	O
termini	O
of	O
the	O
split	O
-	O
intein	O
part	O
(	O
Figures	O
1	O
and	O
4B	O
)	O
.	O

This	O
overlap	O
is	O
present	O
in	O
both	O
types	O
of	O
endonucleases	O
,	O
and	O
is	O
independent	O
on	O
the	O
presence	O
of	O
a	O
split	O
-	O
intein	O
part	O
in	O
the	O
fractured	O
gene	O
,	O
also	O
occurring	O
in	O
the	O
putative	O
sbcD	O
DNA	O
-	O
repair	O
gene	O
that	O
we	O
found	O
,	O
as	O
well	O
as	O
in	O
the	O
Aeh1	O
fractured	O
nrdA	O
found	O
by	O
Gibb	O
and	O
Edgell	O
(	O
22	O
)	O
.	O

Efficacy	O
of	O
MMF	O
in	O
current	O
immunosuppressive	O
regimens	O
after	O
kidney	O
transplantation	O

Current	O
established	O
immunosuppressive	O
strategies	O
in	O
kidney	O
transplantation	O
often	O
include	O
an	O
induction	O
agent	O
(	O
monoclonal	O
or	O
polyclonal	O
anti	O
-	O
T	O
-	O
cell	O
antibodies	O
)	O
based	O
on	O
the	O
immunologic	O
risk	O
of	O
the	O
recipient	O
,	O
followed	O
by	O
a	O
maintenance	O
regimen	O
combining	O
a	O
CNI	O
and	O
an	O
anti	O
-	O
proliferative	O
agent	O
,	O
with	O
or	O
without	O
corticosteroids	O
.	O
2	O
-	O
4	O
As	O
MMF	O
was	O
the	O
first	O
MPA	O
formulation	O
approved	O
in	O
clinical	O
kidney	O
transplantation	O
,	O
more	O
extensive	O
clinical	O
data	O
are	O
available	O
with	O
this	O
drug	O
in	O
comparison	O
to	O
EC	O
-	O
MPS	O
.	O

Results	O

In	O
the	O
established	O
adult	O
rat	O
NSC	O
culture	O
,	O
FGF	O
-	O
2	O
promotes	O
self	O
-	O
renewal	O
by	O
increasing	O
proliferation	O
and	O
inhibiting	O
spontaneous	O
differentiation	O
of	O
adult	O
NSCs	O
,	O
accompanied	O
with	O
activation	O
of	O
MAPK	O
and	O
PLC	O
pathways	O
.	O

Using	O
a	O
molecular	O
genetic	O
approach	O
,	O
we	O
demonstrate	O
that	O
activation	O
of	O
FGF	O
receptor	O
1	O
(	O
FGFR1	O
)	O
,	O
largely	O
through	O
two	O
key	O
cytoplasmic	O
amino	O
acid	O
residues	O
that	O
are	O
linked	O
to	O
MAPK	O
and	O
PLC	O
activation	O
,	O
suffices	O
to	O
promote	O
adult	O
NSC	B
self	O
-	O
renewal	O
.	O

The	O
canonical	O
MAPK	O
,	O
Erk1	O
/	O
2	O
activation	O
,	O
is	O
both	O
required	O
and	O
sufficient	O
for	O
the	O
NSC	B
expansion	O
and	O
anti	O
-	O
differentiation	O
effects	O
of	O
FGF	O
-	O
2	O
.	O

In	O
contrast	O
,	O
PLC	O
activation	O
is	O
integral	O
to	O
the	O
maintenance	O
of	O
adult	O
NSC	B
characteristics	O
,	O
including	O
the	O
full	O
capacity	O
for	O
neuronal	O
and	O
oligodendroglial	O
differentiation	O
.	O

2	O
.	O
2	O
.	O

Iris	O
and	O
Ciliary	O
Body	O

Serotonin	O
is	O
present	O
in	O
mammalian	O
iris	O
-	O
ciliary	O
body	O
complex	O
(	O
ICB	O
)	O
at	O
higher	O
concentration	O
that	O
in	O
non	O
-	O
mammalian	O
species	O
[	O
5	O
,	O
45	O
,	O
73	O
,	O
129	O
,	O
137	O
]	O
.	O

Moreover	O
,	O
the	O
presence	O
of	O
serotonergic	O
nerves	O
has	O
been	O
demonstrated	O
in	O
studies	O
conducted	O
on	O
the	O
ICB	O
of	O
various	O
species	O
[	O
102	O
,	O
137	O
,	O
138	O
]	O
.	O

Experimental	O
evidence	O
and	O
radioligand	O
analyses	O
have	O
defined	O
the	O
presence	O
at	O
this	O
level	O
of	O
three	O
different	O
types	O
of	O
serotonin	O
receptors	O
[	O
10	O
,	O
28	O
,	O
85	O
,	O
136	O
,	O
137	O
]	O
,	O
i	O
.	O
e	O
.	O
5	O
-	O
HT1A	O
,	O
5	O
-	O
HT2A	O
/	O
2C	O
and	O
5	O
-	O
HT7	O
[	O
98	O
]	O
,	O
one	O
linked	O
to	O
a	O
stimulation	O
of	O
inositol	O
phosphates	O
(	O
5	O
-	O
HT2	O
subtype	O
)	O
,	O
while	O
the	O
others	O
two	O
are	O
linked	O
to	O
cAMP	O
activity	O
.	O

The	O
plausibility	O
of	O
the	O
existence	O
of	O
more	O
than	O
one	O
5	O
-	O
HT	O
receptor	O
type	O
in	O
the	O
ciliary	O
body	O
is	O
confirmed	O
by	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
experiments	O
.	O

Topical	O
application	O
of	O
serotonin	O
has	O
been	O
reported	O
to	O
both	O
elevate	O
[	O
84	O
]	O
and	O
lower	O
[	O
88	O
]	O
IOP	O
in	O
rabbit	O
.	O

A	O
large	O
number	O
of	O
reports	O
have	O
shown	O
that	O
serotonin	O
agonists	O
and	O
antagonists	O
can	O
produce	O
increases	O
and	O
decreases	O
in	O
IOP	O
when	O
given	O
orally	O
,	O
topically	O
to	O
the	O
eye	O
or	O
when	O
they	O
are	O
directly	O
injected	O
in	O
the	O
anterior	O
chamber	O
[	O
10	O
,	O
26	O
,	O
34	O
,	O
35	O
,	O
64	O
,	O
75	O
,	O
84	O
,	O
87	O
,	O
88	O
,	O
112	O
,	O
113	O
,	O
126	O
,	O
136	O
,	O
137	O
]	O
.	O

A	O
rationale	O
for	O
such	O
apparently	O
contradictory	O
results	O
may	O
be	O
due	O
to	O
the	O
different	O
sites	O
of	O
action	O
,	O
i	O
.	O
e	O
.	O
which	O
class	O
of	O
serotonin	O
receptor	O
is	O
activated	O
.	O

In	O
fact	O
,	O
in	O
rabbit	O
the	O
administration	O
of	O
5	O
-	O
methyl	O
-	O
urapidil	O
(	O
a	O
combined	O
5	O
-	O
HT1A	O
agonist	O
/	O
alpha1	O
adrenoreceptor	O
antagonist	O
)	O
and	O
8	O
-	O
OH	O
-	O
DPAT	O
(	O
8	O
-	O
hydroxydypropylaminotetralin	O
,	O
a	O
5HT1A	O
agonist	O
)	O
reduces	O
IOP	O
,	O
while	O
the	O
administration	O
of	O
5	O
-	O
CT	O
(	O
5	O
-	O
carboxamidotryptamine	O
,	O
a	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
agonist	O
)	O
increases	O
IOP	O
[	O
36	O
,	O
84	O
,	O
99	O
]	O
.	O

Chidlow	O
,	O
Le	O
Corre	O
and	O
Osborne	O
[	O
28	O
]	O
have	O
recently	O
demonstrated	O
that	O
,	O
in	O
section	O
taken	O
through	O
the	O
whole	O
eye	O
and	O
ciliary	O
body	O
,	O
prominent	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
receptor	O
messenger	O
ribonucleic	O
acid	O
signals	O
were	O
obtained	O
.	O

These	O
signals	O
were	O
evident	O
in	O
both	O
the	O
pigmented	O
and	O
non	O
-	O
pigmented	O
epithelial	O
cell	O
layers	O
of	O
the	O
pars	O
plicata	O
region	O
of	O
the	O
ciliary	O
processes	O
,	O
but	O
not	O
in	O
the	O
pars	O
plana	O
or	O
in	O
the	O
ciliary	O
musculature	O
.	O

5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
signals	O
were	O
apparent	O
in	O
the	O
posterior	O
processes	O
but	O
not	O
in	O
the	O
iris	O
processes	O
.	O

The	O
presence	O
of	O
both	O
receptors	O
in	O
the	O
ciliary	O
body	O
would	O
certainly	O
provide	O
an	O
explanation	O
for	O
the	O
shallow	O
displacement	O
curves	O
observed	O
in	O
[	O
3H	O
]	O
5	O
-	O
HT	O
binding	O
studies	O
with	O
the	O
tissue	O
[	O
110	O
]	O
,	O
since	O
this	O
ligand	O
can	O
be	O
used	O
to	O
label	O
both	O
receptors	O
.	O

Because	O
the	O
ciliary	O
epithelium	O
of	O
the	O
pars	O
plicata	O
is	O
responsible	O
for	O
the	O
secretion	O
of	O
aqueous	O
humor	O
,	O
an	O
obvious	O
function	O
for	O
these	O
two	O
receptors	O
would	O
be	O
an	O
involvement	O
in	O
the	O
control	O
of	O
aqueous	O
production	O
and	O
,	O
consequently	O
,	O
of	O
the	O
IOP	O
level	O
.	O

Further	O
,	O
the	O
almost	O
identical	O
distribution	O
of	O
the	O
5	O
-	O
HT1A	O
and	O
5	O
-	O
HT7	O
messengers	O
ribonucleic	O
acid	O
indicate	O
that	O
the	O
receptors	O
may	O
be	O
co	O
-	O
localized	O
in	O
epithelial	O
cells	O
.	O

The	O
presence	O
of	O
two	O
serotonin	O
receptors	O
with	O
opposing	O
effects	O
on	O
cAMP	O
in	O
the	O
same	O
cell	O
layer	O
prompts	O
the	O
suggestion	O
that	O
they	O
could	O
act	O
antagonistically	O
.	O

The	O
agonism	O
of	O
5	O
-	O
HT1A	O
receptors	O
,	O
negatively	O
coupled	O
to	O
cAMP	O
,	O
reduces	O
IOP	O
by	O
decreasing	O
the	O
production	O
of	O
aqueous	O
humor	O
,	O
like	O
beta	O
-	O
receptor	O
antagonists	O
which	O
,	O
diminishing	O
the	O
content	O
of	O
cAMP	O
at	O
the	O
postjunctional	O
site	O
,	O
lowers	O
the	O
aqueous	O
humor	O
secretion	O
with	O
a	O
consequent	O
decrease	O
in	O
IOP	O
[	O
98	O
]	O
.	O

On	O
the	O
contrary	O
,	O
the	O
administration	O
of	O
5	O
-	O
CT	O
induces	O
a	O
rise	O
in	O
IOP	O
,	O
which	O
is	O
partly	O
or	O
entirely	O
caused	O
by	O
an	O
increase	O
in	O
aqueous	O
humor	O
secretion	O
mediated	O
by	O
5	O
-	O
HT7	O
receptors	O
[	O
84	O
]	O
.	O

The	O
other	O
type	O
of	O
serotonin	O
receptor	O
present	O
in	O
the	O
ICB	O
is	O
a	O
5	O
-	O
HT2	O
type	O
.	O

Serotonin	O
stimulates	O
the	O
accumulation	O
of	O
inositol	O
phosphates	O
in	O
the	O
ICB	O
and	O
this	O
effect	O
is	O
partially	O
counteracted	O
by	O
the	O
5	O
-	O
HT2	O
antagonists	O
ketanserin	O
,	O
methysergide	O
and	O
mianserin	O
[	O
98	O
]	O
.	O

Studies	O
with	O
ketanserin	O
have	O
demonstrated	O
that	O
,	O
when	O
orally	O
or	O
topically	O
applied	O
,	O
it	O
lowers	O
IOP	O
in	O
animals	O
,	O
healthy	O
volunteers	O
and	O
in	O
glaucomatous	O
patients	O
[	O
26	O
,	O
34	O
,	O
37	O
,	O
64	O
,	O
75	O
,	O
88	O
,	O
113	O
,	O
126	O
]	O
.	O

It	O
has	O
been	O
emphasized	O
that	O
ketanserin	O
also	O
possesses	O
an	O
affinity	O
for	O
alpha1	O
-	O
adrenoreceptors	O
[	O
27	O
,	O
36	O
,	O
139	O
]	O
,	O
and	O
for	O
this	O
reason	O
the	O
effects	O
of	O
ketanserin	O
on	O
IOP	O
may	O
not	O
be	O
entirely	O
caused	O
by	O
its	O
action	O
on	O
5	O
-	O
HT2	O
receptors	O
.	O

However	O
,	O
data	O
from	O
human	O
studies	O
conducted	O
after	O
oral	O
or	O
topical	O
administration	O
of	O
ketanserin	O
,	O
in	O
which	O
were	O
determined	O
the	O
variations	O
of	O
IOP	O
,	O
total	O
outflow	O
facility	O
and	O
pupil	O
diameter	O
,	O
demonstrated	O
that	O
the	O
alpha1	O
-	O
adrenoreceptor	O
blocking	O
effect	O
exerted	O
by	O
ketanserin	O
should	O
represent	O
a	O
further	O
aspect	O
of	O
its	O
mechanism	O
of	O
action	O
,	O
probably	O
due	O
to	O
a	O
functional	O
sharing	O
of	O
these	O
receptors	O
[	O
64	O
,	O
87	O
]	O
.	O

Lastly	O
,	O
already	O
in	O
1992	O
Martin	O
and	O
co	O
-	O
workers	O
showed	O
the	O
occurrence	O
of	O
a	O
significant	O
correlation	O
between	O
the	O
content	O
of	O
serotonin	O
in	O
the	O
aqueous	O
humor	O
and	O
IOP	O
in	O
the	O
human	O
eye	O
[	O
85	O
]	O
.	O

In	O
1981	O
,	O
Moro	O
and	O
his	O
collaborators	O
found	O
that	O
intravitreal	O
injection	O
of	O
5	O
,	O
6	O
-	O
dihydroxytryptamine	O
,	O
a	O
serotonergic	O
neurotoxin	O
,	O
causes	O
miosis	O
[	O
91	O
]	O
.	O

The	O
identification	O
of	O
5	O
-	O
HT7	O
,	O
but	O
not	O
of	O
5	O
-	O
HT1	O
receptors	O
in	O
the	O
rabbit	O
iris	O
,	O
suggests	O
that	O
this	O
population	O
of	O
serotonergic	O
receptors	O
is	O
involved	O
in	O
the	O
relaxation	O
of	O
the	O
sphincter	O
of	O
the	O
pupil	O
.	O

In	O
fact	O
,	O
one	O
of	O
the	O
function	O
correlate	O
to	O
5	O
-	O
HT7	O
receptor	O
activation	O
includes	O
smooth	O
muscle	O
relaxation	O
observed	O
in	O
a	O
variety	O
of	O
isolated	O
tissue	O
preparations	O
,	O
in	O
which	O
elevation	O
of	O
cAMP	O
concentration	O
was	O
also	O
detected	O
[	O
3	O
,	O
44	O
]	O
.	O

Further	O
evidence	O
for	O
the	O
mediation	O
of	O
the	O
relaxant	O
response	O
via	O
the	O
5	O
-	O
HT7	O
receptor	O
is	O
provided	O
by	O
the	O
localization	O
of	O
messenger	O
ribonucleic	O
acid	O
transcripts	O
encoding	O
the	O
5	O
-	O
HT7	O
receptor	O
in	O
many	O
blood	O
vessels	O
[	O
67	O
]	O
.	O

This	O
hypothesized	O
mechanism	O
of	O
action	O
is	O
also	O
supported	O
by	O
the	O
fact	O
that	O
various	O
other	O
receptor	O
types	O
,	O
also	O
positively	O
coupled	O
to	O
cAMP	O
,	O
in	O
the	O
iris	O
cause	O
relaxation	O
of	O
the	O
sphincter	O
muscle	O
[	O
1	O
,	O
28	O
]	O
.	O

Sex	O
and	O
age	O
distributions	O
of	O
confirmed	O
cases	O

Of	O
480	O
confirmed	O
cases	O
,	O
56	O
%	O
(	O
269	O
/	O
480	O
)	O
were	O
male	O
patients	O
and	O
44	O
%	O
(	O
211	O
/	O
480	O
)	O
were	O
female	O
,	O
respectively	O
.	O

The	O
percentage	O
of	O
male	O
cases	O
was	O
higher	O
than	O
that	O
of	O
females	O
in	O
all	O
groups	O
except	O
for	O
the	O
group	O
aged	O
31	O
-	O
40	O
(	O
chi2	O
=	O
42	O
.	O
4	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

278	O
(	O
57	O
.	O
9	O
%	O
)	O
cases	O
were	O
in	O
the	O
group	O
aged	O
21	O
-	O
50	O
,	O
followed	O
by	O
102	O
(	O
21	O
.	O
3	O
%	O
)	O
,	O
79	O
(	O
16	O
.	O
5	O
%	O
)	O
and	O
21	O
(	O
4	O
.	O
4	O
%	O
)	O
cases	O
in	O
the	O
group	O
aged	O
51	O
-	O
70	O
,	O
0	O
-	O
20	O
,	O
and	O
>	O
=	O
71	O
,	O
respectively	O
.	O

The	O
youngest	O
and	O
oldest	O
cases	O
were	O
1	O
.	O
5	O
and	O
81	O
years	O
old	O
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

Table	O
2	O

Age	O
and	O
occupational	O
distributions	O
and	O
activities	O
(	O
1	O
-	O
3	O
weeks	O
prior	O
to	O
symptom	O
appearance	O
)	O
of	O
confirmed	O
cases	O

Cases	O
(	O
%	O
)	O
(	O
Male	O
:	O
Female	O
,	O
%	O
)	O

Age	O
(	O
Years	O
)	O

0	O
-	O
10	O
46	O
(	O
9	O
.	O
6	O
)	O
(	O
76	O
:	O
24	O
)	O

11	O
-	O
20	O
33	O
(	O
6	O
.	O
9	O
)	O
(	O
79	O
:	O
21	O
)	O

21	O
-	O
30	O
78	O
(	O
16	O
.	O
3	O
)	O
(	O
51	O
:	O
49	O
)	O

31	O
-	O
40	O
99	O
(	O
20	O
.	O
6	O
)	O
(	O
46	O
:	O
54	O
)	O

41	O
-	O
50	O
101	O
(	O
21	O
.	O
0	O
)	O
(	O
56	O
:	O
44	O
)	O

51	O
-	O
60	O
47	O
(	O
9	O
.	O
8	O
)	O
(	O
55	O
:	O
45	O
)	O

61	O
-	O
70	O
55	O
(	O
11	O
.	O
5	O
)	O
(	O
53	O
:	O
47	O
)	O

>	O
=	O
71	O
21	O
(	O
4	O
.	O
4	O
)	O
(	O
52	O
:	O
48	O
)	O

Occupation	O

Children	O
at	O
preschool	O
age	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
75	O
:	O
25	O
)	O

Pupils	O
50	O
(	O
10	O
.	O
4	O
)	O
(	O
78	O
:	O
22	O
)	O

Farmers	O
408	O
(	O
85	O
.	O
0	O
)	O
(	O
52	O
:	O
48	O
)	O

Others	O
2	O
(	O
0	O
.	O
4	O
)	O
(	O
50	O
:	O
50	O
)	O

Activities	O

Farm	O
work	O
325	O
(	O
67	O
.	O
7	O
)	O
(	O
53	O
:	O
47	O
)	O

Play	O
on	O
grassland	O
65	O
(	O
13	O
.	O
5	O
)	O
(	O
75	O
:	O
25	O
)	O

Recreation	O
20	O
(	O
4	O
.	O
2	O
)	O
(	O
65	O
:	O
35	O
)	O

Housework	O
25	O
(	O
5	O
.	O
2	O
)	O
(	O
8	O
:	O
92	O
)	O

Unknown	O
45	O
(	O
9	O
.	O
4	O
)	O
(	O
71	O
:	O
29	O
)	O

Stochastic	O
models	O

Stochasticity	O
inevitably	O
emerges	O
when	O
molecular	O
components	O
are	O
present	O
at	O
low	O
cellular	O
concentrations	O
(	O
McAdams	O
&	O
Arkin	O
,	O
1997	O
;	O
Kierzek	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

This	O
physical	O
phenomenon	O
generates	O
noise	O
in	O
synthetic	O
and	O
natural	O
circuits	O
(	O
Paulsson	O
,	O
2004	O
;	O
Mettetal	O
et	O
al	O
.	O
,	O
2006	O
)	O
,	O
and	O
its	O
consequences	O
over	O
the	O
phenotype	O
are	O
starting	O
to	O
be	O
explored	O
(	O
Suel	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

For	O
example	O
,	O
noise	O
constitutes	O
the	O
driving	O
force	O
behind	O
differentiation	O
in	O
isogenetic	O
colonies	O
(	O
Colman	O
-	O
Lerner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Biological	O
and	O
theoretical	O
studies	O
have	O
aided	O
to	O
delineate	O
the	O
regulatory	O
mechanism	O
by	O
which	O
the	O
cell	O
handles	O
noise	O
efficiently	O
and	O
effectively	O
to	O
carry	O
out	O
its	O
biological	O
functions	O
(	O
Gardner	O
&	O
Collins	O
,	O
2000	O
;	O
Orrell	O
&	O
Bolouri	O
,	O
2004	O
;	O
Raser	O
&	O
O	O
'	O
Shea	O
,	O
2005	O
)	O
.	O

From	O
a	O
theoretical	O
point	O
of	O
view	O
,	O
stochastic	O
models	O
are	O
the	O
most	O
challenging	O
but	O
also	O
the	O
most	O
realistic	O
ones	O
:	O
there	O
is	O
a	O
precise	O
counting	O
of	O
how	O
,	O
through	O
individual	O
chemical	O
reactions	O
,	O
the	O
populations	O
of	O
every	O
chemical	O
species	O
change	O
.	O

The	O
milestone	O
to	O
simulate	O
stochastic	O
processes	O
is	O
the	O
Gillespie	O
algorithm	O
(	O
Gillespie	O
,	O
1992	O
)	O
.	O

Because	O
of	O
their	O
analytical	O
and	O
computational	O
complexity	O
,	O
the	O
present	O
models	O
do	O
not	O
surpass	O
a	O
handful	O
of	O
chemical	O
species	O
.	O

Two	O
immediate	O
problems	O
must	O
be	O
solved	O
to	O
model	O
systems	O
with	O
several	O
dozens	O
of	O
genetic	O
components	O
:	O
the	O
systematic	O
determination	O
of	O
kinetic	O
constants	O
and	O
the	O
efficient	O
computation	O
of	O
thousands	O
of	O
chemical	O
stochastic	O
equations	O
(	O
Kuwahara	O
et	O
al	O
.	O
,	O
2006	O
;	O
Sanchez	O
&	O
Kondev	O
,	O
2008	O
)	O
.	O

Luciferase	O
Assay	O

For	O
Fig	O
.	O

1	O
,	O
10	O
ng	O
of	O
TORC1	O
,	O
5	O
ng	O
of	O
TORC2	O
,	O
and	O
15	O
ng	O
of	O
PKAalpha	O
expression	O
plasmids	O
were	O
transfected	O
into	O
HEK293	B
cells	O
.	O

For	O
Fig	O
.	O

2	O
,	O
800	O
ng	O
of	O
total	O
DNA	O
consisted	O
of	O
200	O
ng	O
of	O
the	O
pMLHoxb1ARE	O
luciferase	O
reporter	O
and	O
100	O
ng	O
of	O
each	O
expression	O
plasmid	O
.	O

A	O
lacZ	O
reporter	O
was	O
co	O
-	O
transfected	O
to	O
normalize	O
transfection	O
efficiency	O
.	O

For	O
Fig	O
.	O

3A	O
,	O
the	O
amounts	O
of	O
pENTR	O
T2i	O
shRNA	O
(	O
TORC2	O
shRNA	O
)	O
are	O
given	O
within	O
the	O
panel	O
.	O

For	O
Fig	O
.	O

3B	O
,	O
25	O
,	O
000	O
cells	O
per	O
well	O
were	O
plated	O
in	O
48	O
-	O
well	O
plates	O
and	O
transfected	O
using	O
Lipofectamine	O
2000	O
with	O
the	O
following	O
vectors	O
:	O
40	O
ng	O
of	O
pML5xUAS	O
,	O
40	O
ng	O
of	O
pGAL	O
-	O
DBD	O
or	O
pGAL	O
-	O
MEIS1A	O
(	O
335	O
-	O
390	O
)	O
,	O
40	O
ng	O
of	O
pRSV	O
-	O
PBS	O
or	O
pRSV	O
-	O
PKA	O
,	O
40	O
ng	O
of	O
pENTR	O
U6	O
(	O
control	O
shRNA	O
)	O
or	O
pENTR	O
T2i	O
shRNA	O
(	O
TORC2	O
shRNA	O
)	O
,	O
and	O
100	O
ng	O
of	O
pRSV	O
-	O
beta	O
-	O
galactosidase	O
.	O

At	O
48	O
h	O
post	O
-	O
transfection	O
,	O
cell	O
lysates	O
were	O
prepared	O
using	O
100	O
mul	O
per	O
well	O
of	O
lysis	O
buffer	O
(	O
1	O
%	O
Triton	O
X	O
-	O
100	O
,	O
1	O
mm	O
dithiothreitol	O
,	O
92	O
.	O
8	O
mm	O
K2HPO4	O
,	O
pH	O
7	O
.	O
8	O
,	O
9	O
.	O
2	O
mm	O
KH2PO4	O
,	O
pH	O
7	O
.	O
8	O
)	O
and	O
centrifuged	O
for	O
5	O
min	O
at	O
4	O
degreesC	O
.	O

A	O
20	O
-	O
mul	O
aliquot	O
of	O
the	O
supernatant	O
was	O
added	O
to	O
12	O
.	O
5	O
mul	O
of	O
assay	O
buffer	O
(	O
20	O
mm	O
ATP	O
,	O
40	O
mm	O
MgCl2	O
,	O
0	O
.	O
4	O
m	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
8	O
)	O
.	O

The	O
mixture	O
was	O
immediately	O
quantified	O
for	O
luciferase	O
activity	O
using	O
a	O
Lumat	O
LB	O
9507	O
luminometer	O
(	O
EG	O
&	O
G	O
Berthold	O
)	O
that	O
dispensed	O
100	O
mul	O
per	O
reaction	O
of	O
luciferin	O
solution	O
,	O
which	O
contains	O
1	O
mm	O
d	O
-	O
(	O
-	O
)	O
-	O
luciferin	O
(	O
catalogue	O
number	O
11626353001	O
,	O
Roche	O
)	O
and	O
0	O
.	O
1	O
m	O
Tris	O
-	O
Cl	O
,	O
pH	O
7	O
.	O
8	O
.	O

Implications	O
for	O
Psychological	O
Models	O
of	O
Interval	O
Timing	O

Several	O
models	O
have	O
been	O
previously	O
applied	O
to	O
interpret	O
data	O
obtained	O
in	O
interval	O
-	O
timing	O
experiments	O
involving	O
gaps	O
(	O
retention	O
-	O
intervals	O
)	O
.	O

A	O
switch	O
model	O
,	O
assuming	O
that	O
during	O
the	O
gap	O
time	O
fails	O
to	O
accumulate	O
due	O
to	O
the	O
opening	O
of	O
a	O
stimulus	O
-	O
controlled	O
switch	O
,	O
predicts	O
that	O
,	O
irrespective	O
of	O
gap	O
and	O
criterion	O
durations	O
,	O
subjects	O
should	O
use	O
a	O
stop	O
rule	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
,	O
[	O
30	O
]	O
,	O
[	O
31	O
]	O
.	O

In	O
contrast	O
,	O
the	O
present	O
data	O
indicate	O
that	O
rats	O
flexibly	O
change	O
their	O
behavior	O
with	O
both	O
gap	O
and	O
criterion	O
duration	O
.	O

An	O
instructional	O
-	O
ambiguity	O
model	O
proposing	O
that	O
subjects	O
perceive	O
the	O
gap	O
as	O
an	O
ambiguous	O
,	O
ITI	O
-	O
like	O
event	O
,	O
predicts	O
that	O
manipulations	O
that	O
render	O
the	O
gap	O
similar	O
to	O
the	O
ITI	O
should	O
reset	O
the	O
clock	O
,	O
while	O
manipulations	O
that	O
render	O
the	O
gap	O
dissimilar	O
from	O
the	O
ITI	O
should	O
stop	O
the	O
clock	O
[	O
37	O
]	O
.	O

Because	O
in	O
our	O
experiment	O
the	O
gap	O
and	O
ITI	O
were	O
identical	O
(	O
dark	O
)	O
this	O
hypothesis	O
predicts	O
the	O
use	O
of	O
the	O
same	O
rule	O
(	O
reset	O
)	O
at	O
all	O
gap	O
and	O
criteria	O
durations	O
,	O
in	O
contrast	O
to	O
the	O
current	O
data	O
showing	O
the	O
use	O
of	O
different	O
rules	O
for	O
different	O
temporal	O
criteria	O
.	O

To	O
account	O
for	O
the	O
flexible	O
use	O
of	O
the	O
run	O
/	O
stop	O
/	O
reset	O
rules	O
by	O
rats	O
and	O
pigeons	O
,	O
Cabeza	O
de	O
Vaca	O
et	O
al	O
.	O

[	O
38	O
]	O
proposed	O
a	O
passive	O
memory	O
-	O
decay	O
model	O
which	O
assumes	O
that	O
subjective	O
time	O
-	O
-	O
stored	O
in	O
WM	O
-	O
-	O
decays	O
passively	O
during	O
the	O
gap	O
.	O

This	O
model	O
predicts	O
that	O
the	O
effect	O
of	O
a	O
gap	O
should	O
depend	O
solely	O
on	O
absolute	O
gap	O
duration	O
,	O
but	O
not	O
on	O
criterion	O
duration	O
,	O
as	O
found	O
here	O
(	O
Fig	O
.	O
1B	O
-	O
D	O
)	O
.	O

These	O
models	O
can	O
not	O
account	O
for	O
the	O
differential	O
effects	O
of	O
gaps	O
on	O
multiple	O
intervals	O
.	O

In	O
contrast	O
to	O
these	O
alternatives	O
,	O
the	O
present	O
resource	O
allocation	O
model	O
assumes	O
that	O
during	O
the	O
gaps	O
resources	O
are	O
re	O
-	O
allocated	O
(	O
diverted	O
away	O
from	O
timing	O
)	O
,	O
each	O
clock	O
is	O
unable	O
to	O
maintain	O
its	O
current	O
subjective	O
time	O
in	O
WM	O
,	O
and	O
the	O
response	O
is	O
delayed	O
[	O
16	O
]	O
,	O
[	O
17	O
]	O
,	O
[	O
27	O
]	O
in	O
proportion	O
to	O
the	O
perceived	O
salience	O
of	O
the	O
distracter	O
relative	O
to	O
the	O
times	O
signal	O
[	O
34	O
]	O
,	O
[	O
35	O
]	O
.	O

Indeed	O
,	O
the	O
effect	O
of	O
a	O
gap	O
is	O
affected	O
by	O
the	O
contrast	O
in	O
intensity	O
between	O
the	O
gap	O
and	O
the	O
timed	O
signal	O
[	O
27	O
]	O
,	O
[	O
34	O
]	O
,	O
[	O
39	O
]	O
and	O
by	O
the	O
perceptual	O
acuity	O
of	O
the	O
subjects	O
[	O
27	O
]	O
.	O

Importantly	O
,	O
the	O
predictions	O
of	O
this	O
resource	O
re	O
-	O
allocation	O
model	O
are	O
not	O
restricted	O
to	O
retention	O
-	O
intervals	O
(	O
i	O
.	O
e	O
.	O
,	O
gaps	O
)	O
,	O
but	O
extend	O
to	O
distracters	O
presented	O
during	O
the	O
continuous	O
presentation	O
of	O
a	O
timed	O
signal	O
.	O

Previous	O
data	O
were	O
quantitatively	O
accounted	O
for	O
by	O
assuming	O
that	O
during	O
a	O
gap	O
and	O
/	O
or	O
distracter	O
the	O
accumulated	O
time	O
decays	O
at	O
a	O
rate	O
that	O
varies	O
with	O
the	O
relative	O
salience	O
of	O
the	O
distracter	O
to	O
the	O
timed	O
signal	O
[	O
25	O
]	O
,	O
[	O
26	O
]	O
,	O
[	O
35	O
]	O
.	O

Here	O
we	O
found	O
that	O
the	O
comparison	O
between	O
the	O
gap	O
and	O
the	O
(	O
multiple	O
)	O
timed	O
signal	O
(	O
s	O
)	O
extends	O
to	O
the	O
temporal	O
domain	O
.	O

Simulations	O
indicate	O
that	O
both	O
the	O
differential	O
effect	O
of	O
the	O
gap	O
on	O
multiple	O
durations	O
,	O
and	O
the	O
gradual	O
hierarchical	O
reset	O
due	O
to	O
increasing	O
gap	O
duration	O
can	O
be	O
quantitatively	O
accounted	O
for	O
assuming	O
that	O
the	O
three	O
clocks	O
have	O
separate	O
resources	O
re	O
-	O
allocated	O
independently	O
during	O
a	O
gap	O
at	O
a	O
rate	O
proportional	O
to	O
the	O
ratio	O
g	O
/	O
Tk	O
between	O
the	O
duration	O
of	O
the	O
gap	O
and	O
each	O
criterion	O
duration	O
(	O
Fig	O
.	O
2A	O
:	O
D	O
-	O
Model	O
)	O
.	O

Discussion	O

Because	O
Netherton	O
syndrome	O
exhibits	O
allergic	O
phenotype	O
,	O
it	O
is	O
reasonable	O
to	O
speculate	O
that	O
SPINK5	O
,	O
which	O
is	O
mutated	O
in	O
Netherton	O
syndrome	O
,	O
may	O
act	O
as	O
a	O
candidate	O
gene	O
for	O
asthma	O
and	O
other	O
allergic	O
diseases	O
[	O
9	O
]	O
.	O

An	O
extensive	O
search	O
for	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
SPINK5	O
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
SNPs	O
,	O
including	O
six	O
nonsynonymous	O
SNPs	O
in	O
coding	O
region	O
that	O
might	O
perturb	O
its	O
immune	O
function	O
.	O

Subsequent	O
genotyping	O
of	O
three	O
nonsynonymous	O
SNPs	O
,	O
A1103	O
G	O
,	O
G1156A	O
and	O
G1258A	O
in	O
two	O
independent	O
panels	O
of	O
British	O
families	O
showed	O
a	O
significant	O
association	O
between	O
SNP	O
G1258A	O
(	O
Glu420Lys	O
)	O
and	O
atopy	O
,	O
atopic	O
dermatitis	O
,	O
elevated	O
serum	O
IgE	O
levels	O
and	O
asthma	O
[	O
10	O
]	O
.	O

This	O
association	O
was	O
confirmed	O
in	O
a	O
large	O
German	O
population	O
and	O
two	O
Japanese	O
populations	O
[	O
16	O
-	O
18	O
]	O
.	O

Kato	O
et	O
al	O
analyzed	O
eight	O
SNPs	O
in	O
exon	O
13	O
and	O
14	O
of	O
the	O
SPINK5	O
including	O
G1258A	O
(	O
Glu420Lys	O
)	O
,	O
and	O
found	O
a	O
positive	O
association	O
of	O
seven	O
SNPs	O
with	O
atopic	O
dermatitis	O
in	O
a	O
Japanese	O
study	O
sample	O
using	O
a	O
case	O
-	O
control	O
study	O
design	O
[	O
16	O
]	O
.	O

Nishio	O
et	O
al	O
surveyed	O
five	O
of	O
six	O
previously	O
reported	O
nonsynonymous	O
SPINK5	O
SNPs	O
in	O
Japanese	O
atopic	O
families	O
identified	O
through	O
asthmatic	O
children	O
or	O
subjects	O
with	O
atopic	O
dermatitis	O
and	O
found	O
that	O
SPINK5	O
was	O
associated	O
with	O
development	O
of	O
atopic	O
dermatitis	O
but	O
not	O
asthma	O
[	O
17	O
]	O
.	O

Kabesch	O
M	O
et	O
al	O
.	O
analyzed	O
G1258A	O
(	O
Glu420Lys	O
)	O
in	O
a	O
German	O
population	O
of	O
school	O
children	O
,	O
and	O
found	O
its	O
association	O
with	O
asthma	O
as	O
well	O
as	O
a	O
concomitant	O
occurrence	O
of	O
asthma	O
and	O
atopic	O
dermatitis	O
[	O
18	O
]	O
.	O

However	O
,	O
two	O
subsequent	O
studies	O
failed	O
to	O
replicate	O
the	O
original	O
SPINK5	O
findings	O
for	O
allergic	O
diseases	O
[	O
19	O
,	O
20	O
]	O
.	O

Folster	O
-	O
Holst	O
et	O
al	O
genotyped	O
four	O
nonsynonymous	O
SNPs	O
(	O
Asp106Asn	O
,	O
Asn368Ser	O
,	O
Asp386Asn	O
,	O
and	O
Glu420Lys	O
)	O
,	O
and	O
detected	O
no	O
association	O
between	O
SPINK5	O
and	O
atopic	O
dermatitis	O
in	O
populations	O
of	O
Northern	O
German	O
origin	O
[	O
20	O
]	O
.	O

Jongepier	O
H	O
et	O
al	O
.	O
failed	O
to	O
detect	O
any	O
association	O
between	O
SPINK5	O
and	O
asthma	O
,	O
atopic	O
phenotypes	O
and	O
atopic	O
dermatitis	O
in	O
a	O
Dutch	O
population	O
[	O
19	O
]	O
.	O

These	O
discordant	O
findings	O
probably	O
reflect	O
different	O
genetic	O
and	O
environmental	O
backgrounds	O
in	O
various	O
populations	O
.	O

To	O
determine	O
whether	O
nonsynonymous	O
SNPs	O
of	O
the	O
SPINK5	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
in	O
the	O
Chinese	O
Han	O
population	O
,	O
we	O
performed	O
a	O
case	O
-	O
control	O
study	O
by	O
genotyping	O
four	O
nonsynonymous	O
SNPs	O
in	O
the	O
SPINK5	O
.	O

We	O
did	O
not	O
detect	O
any	O
significant	O
association	O
between	O
these	O
nonsynonymous	O
SNPs	O
and	O
asthma	O
in	O
our	O
Chinese	O
samples	O
.	O

With	O
our	O
sample	O
size	O
,	O
we	O
expected	O
a	O
power	O
of	O
at	O
least	O
80	O
%	O
in	O
detecting	O
an	O
effect	O
of	O
OR	O
>	O
=	O
1	O
.	O
3	O
for	O
each	O
of	O
these	O
SNPs	O
.	O

Therefore	O
,	O
our	O
failure	O
to	O
detect	O
an	O
association	O
for	O
these	O
4	O
SNPs	O
was	O
not	O
due	O
to	O
the	O
sample	O
size	O
.	O

These	O
results	O
suggest	O
that	O
the	O
polymorphisms	O
in	O
the	O
coding	O
region	O
of	O
the	O
SPINK5	O
are	O
unlikely	O
to	O
contribute	O
to	O
asthma	O
risk	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

However	O
,	O
because	O
our	O
patients	O
were	O
ascertained	O
for	O
asthma	O
,	O
we	O
could	O
not	O
exclude	O
a	O
role	O
of	O
the	O
coding	O
SNPs	O
of	O
the	O
SPINK5	O
in	O
atopic	O
dermatitis	O
in	O
our	O
population	O
.	O

The	O
variations	O
in	O
the	O
regulatory	O
sequences	O
of	O
genes	O
may	O
determine	O
risks	O
to	O
common	O
diseases	O
by	O
causing	O
different	O
levels	O
of	O
expression	O
.	O

Therefore	O
,	O
the	O
identification	O
and	O
functional	O
evaluation	O
of	O
polymorphisms	O
in	O
promoter	O
region	O
are	O
of	O
great	O
value	O
in	O
understanding	O
the	O
genetic	O
susceptibility	O
to	O
asthma	O
.	O

In	O
order	O
to	O
determine	O
the	O
role	O
of	O
the	O
SPINK5	O
promoter	O
polymorphism	O
in	O
the	O
pathogenesis	O
of	O
asthma	O
,	O
we	O
genotyped	O
a	O
promoter	O
polymorphism	O
,	O
-	O
206	O
G	O
>	O
A	O
,	O
in	O
422	O
asthma	O
patients	O
and	O
410	O
controls	O
,	O
and	O
found	O
a	O
marginal	O
association	O
.	O

The	O
frequency	O
of	O
allele	O
G	O
was	O
significantly	O
higher	O
in	O
asthmatic	O
patients	O
than	O
that	O
in	O
controls	O
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O

To	O
confirm	O
the	O
association	O
,	O
additional	O
267	O
asthma	O
patients	O
and	O
301	O
controls	O
newly	O
recruited	O
from	O
the	O
same	O
hospital	O
were	O
genotyped	O
,	O
and	O
the	O
-	O
206	O
G	O
>	O
A	O
polymorphism	O
remained	O
significantly	O
associated	O
with	O
asthma	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
even	O
after	O
Bonferroni	O
correction	O
(	O
adjusted	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
an	O
association	O
of	O
-	O
206	O
G	O
>	O
A	O
polymorphism	O
with	O
asthma	O
.	O

We	O
further	O
examined	O
the	O
potential	O
functional	O
role	O
of	O
this	O
promoter	O
polymorphism	O
,	O
and	O
found	O
that	O
the	O
G	O
to	O
A	O
substitution	O
at	O
-	O
206	O
generated	O
a	O
GATA	O
-	O
3	O
transcription	O
factor	O
binding	O
site	O
.	O

Major	O
transcription	O
factors	O
controlling	O
Th1	O
and	O
Th2	O
development	O
,	O
such	O
as	O
T	O
-	O
box	O
transcription	O
factor	O
and	O
GATA3	O
,	O
are	O
possibly	O
involved	O
in	O
asthma	O
and	O
atopic	O
diseases	O
.	O

GATA	O
-	O
3	O
,	O
a	O
transcription	O
factor	O
specifically	O
expressed	O
in	O
T	O
helper	O
2	O
(	O
Th2	O
)	O
cells	O
,	O
plays	O
a	O
critical	O
role	O
in	O
the	O
differentiation	O
of	O
Th2	O
cells	O
from	O
uncommitted	O
CD4	O
+	O
lymphocytes	O
.	O

In	O
addition	O
,	O
GATA	O
-	O
3	O
is	O
essential	O
for	O
the	O
expression	O
of	O
the	O
cytokines	O
IL	O
-	O
4	O
,	O
IL	O
-	O
5	O
and	O
IL	O
-	O
13	O
that	O
mediate	O
allergic	O
inflammation	O
[	O
23	O
]	O
.	O

Our	O
luciferase	O
reporter	O
assay	O
confirmed	O
that	O
SNP	O
-	O
206	O
G	O
>	O
A	O
is	O
associated	O
with	O
the	O
transcriptional	O
activity	O
of	O
SPINK5	O
.	O

The	O
G	O
allele	O
was	O
associated	O
with	O
decreased	O
transcriptional	O
activity	O
of	O
the	O
SPINK5	O
.	O

The	O
mechanism	O
by	O
which	O
the	O
-	O
206	O
G	O
>	O
A	O
SNP	O
affects	O
SPINK5	O
expression	O
may	O
be	O
explained	O
by	O
the	O
potential	O
differential	O
transcription	O
factor	O
binding	O
of	O
GATA	O
binding	O
factor	O
,	O
since	O
-	O
206	O
G	O
>	O
A	O
is	O
located	O
at	O
the	O
core	O
sequence	O
of	O
GATA	O
binding	O
factor	O
binding	O
site	O
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
confirmed	O
that	O
the	O
A	O
to	O
G	O
substitution	O
at	O
-	O
206	O
significantly	O
reduced	O
the	O
binding	O
efficiency	O
of	O
nuclear	O
proteins	O
to	O
this	O
element	O
.	O

Our	O
data	O
suggest	O
that	O
loss	O
of	O
GATA	O
transcription	O
factor	O
regulation	O
with	O
the	O
-	O
206	O
G	O
may	O
decrease	O
the	O
SPINK5	O
expression	O
and	O
thereby	O
potentially	O
perturb	O
the	O
immunosuppressive	O
function	O
of	O
LEKTI	O
.	O

SUMMARY	O

This	O
is	O
a	O
prospective	O
study	O
carried	O
out	O
to	O
determine	O
the	O
outcome	O
of	O
patients	O
who	O
refuse	O
cystectomy	O
after	O
receiving	O
neoadjuvant	O
chemotherapy	O
for	O
muscle	O
-	O
invasive	O
bladder	O
cancer	O
.	O

Sixty	O
-	O
three	O
patients	O
were	O
evaluated	O
between	O
1995	O
and	O
2001	O
who	O
declined	O
to	O
undergo	O
a	O
planned	O
cystectomy	O
because	O
they	O
achieved	O
a	O
complete	O
clinical	O
response	O
to	O
neoadjuvant	O
cisplatin	O
-	O
based	O
chemotherapy	O
.	O

Herr	O
assessed	O
patient	O
,	O
tumor	O
and	O
treatment	O
features	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
86	O
months	O
,	O
all	O
patients	O
being	O
followed	O
-	O
up	O
for	O
more	O
than	O
5	O
years	O
.	O

Forty	O
patients	O
(	O
64	O
%	O
)	O
survived	O
,	O
with	O
54	O
%	O
of	O
them	O
having	O
an	O
intact	O
functioning	O
bladder	O
.	O

The	O
number	O
and	O
size	O
of	O
invasive	O
tumors	O
were	O
strongly	O
associated	O
with	O
the	O
overall	O
survival	O
.	O

The	O
most	O
significant	O
treatment	O
variable	O
predicting	O
better	O
survival	O
was	O
complete	O
resection	O
of	O
the	O
invasive	O
tumor	O
on	O
restaging	O
transurethral	O
resection	O
(	O
TUR	O
)	O
before	O
starting	O
chemotherapy	O
.	O

Of	O
23	O
patients	O
(	O
36	O
%	O
)	O
who	O
subsequently	O
died	O
of	O
disease	O
,	O
19	O
(	O
30	O
%	O
)	O
relapsed	O
with	O
invasive	O
cancer	O
in	O
the	O
bladder	O
.	O

Over	O
90	O
%	O
of	O
the	O
surviving	O
patients	O
had	O
solitary	O
,	O
small	O
and	O
low	O
-	O
stage	O
invasive	O
tumors	O
completely	O
resected	O
and	O
83	O
%	O
survived	O
without	O
relapses	O
in	O
the	O
bladder	O
.	O
[	O
1	O
]	O

Statistical	O
Analysis	O

Mitochondrial	O
DNA	O
haplogroup	O
frequencies	O
were	O
calculated	O
by	O
counting	O
from	O
the	O
observed	O
genotypes	O
.	O

The	O
Pearson	O
chi	O
-	O
square	O
test	O
and	O
the	O
chi	O
-	O
square	O
test	O
for	O
linear	O
-	O
by	O
-	O
linear	O
association	O
were	O
used	O
to	O
analyze	O
the	O
significances	O
between	O
the	O
prevalence	O
of	O
haplogroups	O
and	O
different	O
age	O
groups	O
.	O

SPSS	O
software	O
(	O
version	O
10	O
.	O
0	O
)	O
was	O
used	O
.	O

Duplicated	O
HGT	O
candidates	O
in	O
K	O
.	O
thermotolerans	O
.	O

(	O
A	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0C07700	O
g	O
and	O
KLTH0C07722	O
g	O
tandem	O
genes	O
.	O

Same	O
legend	O
as	O
Figure	O
3A	O
.	O

(	O
B	O
)	O
Part	O
of	O
the	O
conserved	O
synteny	O
block	O
surrounding	O
KLTH0F12276	O
g	O
gene	O
.	O

Same	O
legend	O
as	O
Figure	O
3A	O
.	O

(	O
C	O
)	O
Sequence	O
alignment	O
of	O
proteins	O
from	O
K	O
.	O
thermotolerans	O
and	O
K	O
.	O
waltii	O
.	O

(	O
D	O
)	O
Phylogenetic	O
tree	O
reconstructed	O
from	O
sequence	O
alignment	O
of	O
100	O
sites	O
of	O
K	O
.	O
thermotolerans	O
protein	O
family	O
members	O
,	O
K	O
.	O
waltii	O
gene	O
,	O
bacterial	O
(	O
green	O
)	O
and	O
amoebal	O
(	O
blue	O
)	O
proteins	O
.	O

Bootstrap	O
values	O
are	O
indicated	O
next	O
to	O
the	O
nodes	O
and	O
branch	O
length	O
scale	O
is	O
shown	O
at	O
bottom	O
left	O
.	O

Quantitative	O
reverse	O
transcription	O
PCR	O

Reverse	O
transcription	O
was	O
performed	O
using	O
0	O
.	O
2	O
mug	O
of	O
total	O
RNA	O
from	O
muscle	O
of	O
10	O
week	O
-	O
old	O
and	O
19	O
month	O
-	O
old	O
C57Bl6	O
mice	O
(	O
five	O
animals	O
per	O
group	O
)	O
,	O
a	O
Core	O
kit	O
(	O
RT	O
-	O
RTCK	O
-	O
03	O
,	O
Eurogentec	O
)	O
according	O
to	O
manufacturer	O
'	O
s	O
instruction	O
and	O
a	O
mix	O
of	O
random	O
primers	O
(	O
9	O
mers	O
)	O
and	O
oligodT	O
.	O

qPCR	O
was	O
performed	O
on	O
SDS7900HT	O
(	O
Applied	O
Biosystem	O
)	O
using	O
Mesagreen	O
qPCR	O
kit	O
for	O
SYBR	O
(	O
Eurogentec	O
)	O
and	O
the	O
following	O
primers	O
:	O

PPARbeta	O
:	O
5	O
'	O
-	O
AGATGGTGGCAGAGCTATGACC	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TCCTCCTGTGGCTGTTCC	O
-	O
3	O
'	O
.	O

Catalase	O
:	O
5	O
'	O
-	O
GGATCCTGACATGGTCTGGG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
TGGAGAGACTCGGGACGAAG	O
-	O
3	O
'	O
.	O

PDK4	O
:	O
5	O
'	O
-	O
GCATTTCTACTCGGATGCTCAATG	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CCAATGTGGCTTGGGTTTCC	O
-	O
3	O
'	O
.	O

36B4	O
:	O
5	O
'	O
-	O
TCCAGGCTTTGGGCATCA	O
-	O
3	O
'	O
;	O
5	O
'	O
-	O
CTTTATCAGCTGCACATCACTCAGA	O
-	O
3	O
'	O
.	O

Data	O
were	O
all	O
normalised	O
using	O
36B4	O
as	O
housekeeping	O
gene	O
.	O

Chicken	O
CCN3	O
expression	O
in	O
embryonic	O
and	O
extraembryonic	O
tissues	O

Expression	O
of	O
CCN3	O
in	O
axial	O
structure	O
becomes	O
visible	O
in	O
the	O
presegmentation	O
stage	O
and	O
reaches	O
to	O
the	O
highest	O
level	O
at	O
the	O
beginning	O
of	O
somitogenesis	O
(	O
HH	O
stage	O
7	O
,	O
Fig	O
.	O
1a	O
)	O
.	O

Strong	O
similarity	O
between	O
CCN3	O
and	O
Sonic	O
Hedgehog	O
was	O
observed	O
for	O
the	O
expression	O
pattern	O
in	O
axial	O
structure	O
(	O
notochord	O
and	O
floor	O
plate	O
)	O
,	O
in	O
which	O
the	O
left	O
-	O
right	O
asymmetrical	O
pattern	O
in	O
the	O
node	O
area	O
is	O
also	O
conserved	O
(	O
Fig	O
.	O
1b	O
)	O
.	O

However	O
,	O
Sonic	O
Hedgehog	O
expression	O
is	O
slightly	O
broader	O
than	O
that	O
of	O
CCN3	O
.	O

Since	O
CCN3	O
stimulates	O
Notch	O
signaling	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
Notch	O
signal	O
genes	O
.	O

Among	O
them	O
,	O
Serrate1	O
,	O
a	O
ligand	O
of	O
Notch	O
is	O
unique	O
because	O
its	O
expression	O
is	O
apparently	O
a	O
right	O
deviated	O
pattern	O
in	O
the	O
node	O
area	O
(	O
Fig	O
.	O
1c	O
)	O
.	O

Another	O
Notch	O
ligand	O
,	O
Delta1	O
shows	O
a	O
right	O
deviated	O
pattern	O
,	O
but	O
is	O
more	O
caudal	O
area	O
of	O
the	O
node	O
extending	O
to	O
the	O
primitive	O
streak	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
expression	O
of	O
CCN3	O
in	O
axial	O
structure	O
was	O
followed	O
by	O
the	O
presomitic	O
mesoderm	O
although	O
it	O
is	O
diminished	O
(	O
Sakamoto	O
et	O
al	O
.	O
2002	O
)	O
.	O

Fig	O
.	O

1	O

Expression	O
of	O
mRNA	O
in	O
early	O
stage	O
chicken	O
embryo	O
;	O
CCN3	O
(	O
a	O
)	O
,	O
Sonic	O
Hedgehog	O
(	O
b	O
)	O
and	O
Serrate1	O
(	O
c	O
)	O
at	O
the	O
beginning	O
stage	O
of	O
somitogenesis	O
(	O
Hamburger	O
and	O
Hamilton	O
(	O
HH	O
)	O
Stage	O
7	O
)	O
.	O

Arrowheads	O
indicate	O
Hensen	O
'	O
s	O
node	O
.	O

Demonstrates	O
the	O
schematic	O
view	O
of	O
tissue	O
organization	O
at	O
this	O
stage	O
(	O
d	O
)	O
.	O

Expression	O
of	O
CCN3	O
mRNA	O
in	O
blood	O
islands	O
of	O
chicken	O
extraembryonic	O
tissue	O
(	O
HH	O
stage	O
10	O
)	O
(	O
e	O
)	O
.	O

Ventral	O
part	O
of	O
the	O
endothelial	O
precursor	O
cells	O
in	O
blood	O
islands	O
is	O
positive	O
for	O
CCN3	O
expression	O
.	O

Coloration	O
was	O
stopped	O
before	O
the	O
background	O
staining	O
started	O
in	O
sense	O
probes	O
(	O
negative	O
control	O
)	O

There	O
is	O
accumulating	O
evidence	O
of	O
CCN3	O
commitment	O
to	O
hematopoiesis	O
and	O
therefore	O
we	O
investigated	O
the	O
CCN3	O
expression	O
in	O
extraembryonic	O
tissues	O
.	O

Blood	O
islands	O
are	O
formed	O
in	O
the	O
yolk	O
sac	O
mesodermal	O
area	O
just	O
between	O
the	O
visceral	O
endodermal	O
and	O
ectodermal	O
layers	O
,	O
which	O
supply	O
the	O
red	O
blood	O
cells	O
at	O
the	O
primary	O
stage	O
.	O

The	O
cells	O
in	O
blood	O
islands	O
are	O
called	O
hemangioblasts	O
since	O
they	O
also	O
differentiate	O
into	O
the	O
endothelial	O
cells	O
of	O
extraembryonic	O
blood	O
vessel	O
structure	O
.	O

In	O
chicken	O
embryo	O
,	O
differentiating	O
endothelial	O
cells	O
in	O
the	O
ventral	O
part	O
of	O
blood	O
islands	O
express	O
CCN3	O
from	O
the	O
initial	O
stage	O
(	O
Fig	O
.	O
1e	O
)	O
.	O

Erythroblasts	O
in	O
the	O
center	O
of	O
blood	O
islands	O
(	O
spherical	O
cells	O
in	O
Fig	O
.	O
1e	O
)	O
weakly	O
express	O
CCN3	O
and	O
their	O
expression	O
is	O
mildly	O
enhanced	O
in	O
later	O
stage	O
(	O
data	O
not	O
shown	O
)	O
.	O

COMMENTS	O

Recurrent	O
anterior	O
vaginal	O
wall	O
prolapse	O
can	O
develop	O
in	O
more	O
than	O
20	O
%	O
of	O
patients	O
undergoing	O
traditional	O
anterior	O
colporrhaphy	O
.	O

In	O
light	O
of	O
this	O
high	O
recurrence	O
rate	O
many	O
surgeons	O
have	O
been	O
incorporating	O
synthetic	O
or	O
allograft	O
mesh	O
to	O
augment	O
the	O
repair	O
.	O

In	O
this	O
study	O
there	O
are	O
some	O
shortcomings	O
,	O
including	O
retrospective	O
design	O
,	O
short	O
follow	O
-	O
up	O
for	O
a	O
study	O
spanning	O
almost	O
six	O
years	O
and	O
a	O
lack	O
of	O
validated	O
questionnaires	O
.	O

Authors	O
report	O
a	O
negative	O
experience	O
with	O
porcine	O
dermis	O
,	O
both	O
in	O
terms	O
of	O
success	O
and	O
extrusion	O
rate	O
.	O

However	O
,	O
others	O
have	O
reported	O
better	O
outcome	O
[	O
1	O
]	O
which	O
may	O
be	O
due	O
to	O
different	O
follow	O
-	O
up	O
times	O
and	O
outcome	O
measures	O
.	O

Apart	O
from	O
this	O
,	O
biological	O
grafts	O
are	O
also	O
associated	O
with	O
allergic	O
reactions	O
and	O
disease	O
transmission	O
.	O

There	O
is	O
paucity	O
of	O
data	O
regarding	O
prospective	O
randomized	O
trials	O
on	O
the	O
use	O
of	O
these	O
biomaterials	O
prior	O
to	O
their	O
widespread	O
human	O
need	O
which	O
might	O
help	O
in	O
reducing	O
such	O
type	O
of	O
experiences	O
.	O

Unless	O
such	O
data	O
are	O
available	O
surgeons	O
should	O
give	O
serious	O
thought	O
prior	O
to	O
embarking	O
on	O
the	O
use	O
of	O
such	O
biological	O
materials	O
.	O
[	O
2	O
]	O

Background	O

Opioid	O
analgesics	O
are	O
generally	O
used	O
to	O
combat	O
the	O
pain	O
associated	O
with	O
cancerous	O
conditions	O
.	O

These	O
agents	O
not	O
only	O
inhibit	O
respiratory	O
function	O
and	O
cause	O
constipation	O
,	O
but	O
also	O
induce	O
other	O
significant	O
side	O
effects	O
such	O
as	O
addiction	O
and	O
tolerance	O
,	O
all	O
of	O
which	O
further	O
contribute	O
to	O
a	O
reduced	O
quality	O
of	O
life	O
for	O
cancer	O
patients	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
electro	O
-	O
acupuncture	O
treatment	O
(	O
EA	O
)	O
on	O
mechanical	O
allodynia	O
were	O
examined	O
in	O
a	O
cancer	O
pain	O
mouse	O
model	O
.	O

2	O
.	O
1	O
.	O

Biological	O
samples	O

Placental	O
tissues	O
from	O
the	O
first	O
trimester	O
legally	O
induced	O
abortions	O
(	O
8	O
-	O
12	O
weeks	O
of	O
gestation	O
)	O
were	O
obtained	O
from	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
at	O
the	O
Broussais	O
,	O
Saint	O
Vincent	O
de	O
Paul	O
and	O
Cochin	O
Hospitals	O
.	O

Second	O
trimester	O
placental	O
tissues	O
were	O
collected	O
at	O
the	O
time	O
of	O
termination	O
of	O
pregnancy	O
at	O
15	O
and	O
25	O
weeks	O
of	O
gestation	O
(	O
in	O
weeks	O
of	O
amenorrhea	O
)	O
in	O
trisomy	O
21	O
-	O
affected	O
pregnancies	O
.	O

Fetal	O
Down	O
syndrome	O
was	O
diagnosed	O
by	O
karyotyping	O
of	O
amniotic	O
fluid	O
cells	O
.	O

The	O
indication	O
of	O
amniocentesis	O
was	O
the	O
maternal	O
age	O
.	O

Term	O
placentas	O
were	O
obtained	O
after	O
elective	O
cesarean	O
section	O
from	O
healthy	O
mothers	O
near	O
term	O
with	O
uncomplicated	O
pregnancies	O
.	O

With	O
written	O
informed	O
consent	O
of	O
the	O
pregnant	O
woman	O
,	O
the	O
following	O
samples	O
were	O
collected	O
at	O
term	O
:	O
a	O
fragment	O
of	O
the	O
placenta	O
,	O
umbilical	O
cord	O
fetal	O
blood	O
and	O
maternal	O
blood	O
.	O

The	O
placenta	O
biopsy	O
sample	O
was	O
collected	O
at	O
a	O
depth	O
of	O
1	O
cm	O
and	O
at	O
a	O
distance	O
of	O
8	O
cm	O
from	O
the	O
edge	O
of	O
the	O
placenta	O
,	O
with	O
the	O
maternal	O
side	O
facing	O
upward	O
.	O

The	O
use	O
of	O
these	O
biological	O
samples	O
was	O
approved	O
by	O
local	O
ethical	O
committee	O
.	O

Villous	O
cytotrophoblastic	O
cells	O
were	O
isolated	O
by	O
sequential	O
enzymatic	O
digestion	O
of	O
chorionic	O
villi	O
from	O
the	O
first	O
trimester	O
,	O
second	O
trimester	O
and	O
term	O
placenta	O
and	O
purified	O
on	O
a	O
discontinuous	O
percoll	O
gradient	O
,	O
as	O
described	O
previously	O
.	O
47	O
-	O
49	O
These	O
cells	O
were	O
positively	O
stained	O
for	O
cytokeratin	O
7	O
at	O
95	O
%	O
,	O
indicating	O
the	O
cytotrophoblastic	O
origin	O
of	O
the	O
cells	O
.	O

Placental	O
fibroblasts	O
were	O
isolated	O
by	O
prolonged	O
enzymatic	O
digestion	O
from	O
first	O
trimester	O
chorionic	O
villi	O
as	O
in	O
Malassine	O
et	O
al	O
.	O
50	O
Fibroblastic	O
cells	O
(	O
1	O
.	O
25	O
x	O
105	O
cells	O
/	O
mL	O
)	O
were	O
plated	O
on	O
35	O
-	O
mm	O
plastic	O
dishes	O
(	O
TPP	O
,	O
Switzerland	O
)	O
and	O
cultured	O
for	O
48	O
h	O
,	O
and	O
the	O
culture	O
medium	O
was	O
changed	O
daily	O
.	O

These	O
cultured	O
fibroblasts	O
were	O
characterized	O
using	O
immunocytochemistry	O
.	O

It	O
was	O
found	O
that	O
98	O
%	O
of	O
the	O
cells	O
were	O
vimentin	O
positive	O
and	O
also	O
positive	O
for	O
a	O
monoclonal	O
antibody	O
against	O
specific	O
fibroblast	O
antigen	O
(	O
clone	O
ASO2	O
,	O
Dianova	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

Owing	O
to	O
the	O
limited	O
amount	O
of	O
cells	O
,	O
only	O
DNA	O
was	O
extracted	O
.	O

Conclusions	O
and	O
policy	O
implications	O

Early	O
postnatal	O
home	O
visit	O
is	O
one	O
strategy	O
for	O
providing	O
critical	O
interventions	O
to	O
improve	O
newborn	O
survival	O
.	O

Given	O
the	O
compelling	O
data	O
in	O
this	O
study	O
,	O
we	O
recommend	O
that	O
in	O
developing	O
countries	O
,	O
especially	O
those	O
where	O
home	O
delivery	O
with	O
unskilled	O
attendants	O
is	O
the	O
norm	O
,	O
all	O
newborns	O
should	O
receive	O
a	O
home	O
visit	O
and	O
undergo	O
assessment	O
by	O
a	O
trained	O
worker	O
as	O
soon	O
as	O
possible	O
,	O
preferably	O
on	O
the	O
day	O
of	O
birth	O
but	O
no	O
later	O
than	O
48	O
hours	O
after	O
birth	O
.	O

The	O
impact	O
of	O
this	O
approach	O
is	O
likely	O
to	O
be	O
dependent	O
on	O
the	O
content	O
,	O
quality	O
,	O
and	O
coverage	O
of	O
the	O
technical	O
interventions	O
included	O
.	O

Reaching	O
neonates	O
within	O
first	O
day	O
or	O
first	O
two	O
days	O
of	O
life	O
is	O
a	O
challenge	O
.	O

Given	O
that	O
the	O
community	O
health	O
workers	O
in	O
this	O
study	O
were	O
not	O
skilled	O
birth	O
attendants	O
and	O
attended	O
only	O
about	O
5	O
%	O
of	O
deliveries	O
,	O
a	O
complementary	O
strategy	O
will	O
be	O
to	O
ensure	O
skilled	O
attendance	O
at	O
delivery	O
that	O
is	O
linked	O
to	O
essential	O
obstetric	O
care	O
.	O
31	O
32	O
Further	O
operational	O
research	O
will	O
be	O
needed	O
to	O
develop	O
context	O
specific	O
strategies	O
to	O
reach	O
all	O
newborns	O
as	O
soon	O
as	O
possible	O
after	O
birth	O
.	O

Model	O
of	O
how	O
estrogen	O
induces	O
DNA	O
damage	O
.	O

Estrogen	O
enters	O
the	O
cell	O
and	O
is	O
bound	O
by	O
the	O
ER	O
.	O

The	O
dimeric	O
ER	O
-	O
estrogen	O
complex	O
enters	O
the	O
nucleus	O
and	O
induces	O
AID	O
expression	O
.	O

This	O
leads	O
to	O
an	O
increase	O
in	O
mutations	O
and	O
translocations	O
,	O
and	O
potentially	O
cancer	O

Assessment	O
of	O
various	O
forms	O
of	O
bevavioural	O
addictions	O

A	O
first	O
approach	O
for	O
the	O
comprehensive	O
and	O
standardized	O
assessment	O
of	O
different	O
forms	O
of	O
behavioural	O
addictions	O
(	O
e	O
.	O
g	O
.	O
,	O
pathological	O
gambling	O
,	O
workaholism	O
,	O
compulsive	O
buying	O
)	O
is	O
the	O
German	O
self	O
-	O
assessment	O
questionnaire	O
""""	O
Fragebogen	O
zur	O
Differenzierten	O
Anamnese	O
exzessiver	O
Verhaltensweisen	O
""""	O
(	O
FDAV	O
,	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Excessive	O
Behaviours	O
)	O
[	O
96	O
]	O
.	O

The	O
FDAV	O
is	O
based	O
on	O
the	O
criteria	O
of	O
substance	O
-	O
related	O
addictions	O
,	O
pathological	O
gambling	O
and	O
impulse	O
control	O
disorders	O
of	O
the	O
ICD	O
-	O
10	O
[	O
3	O
]	O
and	O
the	O
DSM	O
-	O
IV	O
-	O
TR	O
[	O
2	O
]	O
.	O

The	O
FDAV	O
is	O
a	O
modified	O
version	O
of	O
the	O
""""	O
Fragebogen	O
zur	O
Differenzierten	O
Drogenanamnese	O
""""	O
(	O
FDDA	O
;	O
Questionnaire	O
on	O
Differentiated	O
Assessment	O
of	O
Addiction	O
,	O
QDAA	O
)	O
[	O
97	O
]	O
.	O

Its	O
seven	O
modules	O
obtain	O
""""	O
sociodemographic	O
information	O
""""	O
(	O
e	O
.	O
g	O
.	O
,	O
age	O
,	O
profession	O
,	O
marital	O
status	O
)	O
,	O
""""	O
history	O
of	O
excessive	O
behaviour	O
""""	O
(	O
e	O
.	O
g	O
.	O
,	O
diagnostic	O
criteria	O
for	O
addictions	O
and	O
impulse	O
control	O
disorder	O
,	O
individual	O
patterns	O
of	O
behaviour	O
,	O
craving	O
symptoms	O
)	O
,	O
""""	O
critical	O
life	O
events	O
""""	O
(	O
stress	O
caused	O
by	O
traumatic	O
events	O
)	O
,	O
""""	O
legal	O
situation	O
""""	O
,	O
""""	O
medical	O
history	O
""""	O
,	O
""""	O
physical	O
and	O
psychological	O
complaints	O
""""	O
,	O
and	O
""""	O
emotional	O
state	O
""""	O
(	O
triggering	O
psychological	O
conditions	O
,	O
or	O
consequences	O
of	O
the	O
addictive	O
behaviour	O
,	O
respectively	O
)	O
.	O

Every	O
module	O
can	O
be	O
administered	O
separately	O
according	O
to	O
the	O
suspected	O
behavioural	O
addiction	O
,	O
thereby	O
making	O
the	O
FDAV	O
an	O
economical	O
tool	O
in	O
assessing	O
behavioural	O
addictions	O
.	O

The	O
FDAV	O
is	O
suitable	O
for	O
diagnostics	O
,	O
evaluation	O
of	O
therapy	O
and	O
follow	O
-	O
up	O
in	O
clinical	O
practice	O
and	O
research	O
.	O

Currently	O
,	O
the	O
FDAV	O
is	O
being	O
validated	O
in	O
clinical	O
and	O
non	O
-	O
clinical	O
samples	O
.	O

Click	O
here	O
for	O
file	O

Authors	O
'	O
contributions	O

PM	O
carried	O
out	O
and	O
analyzed	O
molecular	O
assay	O
and	O
sequencing	O
data	O
and	O
drafted	O
the	O
manuscript	O
.	O

NS	O
participated	O
in	O
study	O
design	O
and	O
in	O
the	O
local	O
coordination	O
during	O
the	O
study	O
.	O

She	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

MD	O
has	O
made	O
substantial	O
contributions	O
to	O
the	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O

He	O
participated	O
in	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

MO	O
has	O
made	O
substantial	O
contributions	O
to	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O

GB	O
has	O
made	O
substantial	O
contributions	O
to	O
acquisition	O
and	O
analysis	O
of	O
data	O
.	O

GP	O
carried	O
out	O
microscopy	O
and	O
microbiology	O
analyses	O
in	O
Italy	O
and	O
contributed	O
in	O
drafting	O
the	O
manuscript	O
.	O

GBM	O
has	O
made	O
substantial	O
contributions	O
in	O
conceiving	O
,	O
analysing	O
and	O
writing	O
the	O
manuscript	O
.	O

AM	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
helped	O
to	O
draft	O
the	O
manuscript	O
.	O

DMC	O
participated	O
in	O
the	O
design	O
of	O
the	O
study	O
and	O
conceived	O
,	O
and	O
analysed	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Method	O

Results	O
:	O

All	O
fractures	O
united	O
.	O

Individual	O
movement	O
of	O
dorsiflexion	O
,	O
palmar	O
flexion	O
,	O
supination	O
,	O
pronation	O
and	O
radial	O
-	O
ulnar	O
deviation	O
were	O
all	O
significantly	O
better	O
in	O
the	O
dorsiflexed	O
-	O
immobilized	O
group	O
as	O
compared	O
with	O
the	O
palmar	O
flexed	O
immobilized	O
group	O
.	O

Grip	O
strength	O
recovery	O
with	O
subjective	O
assessment	O
was	O
better	O
in	O
the	O
dorsiflexed	O
group	O
(	O
77	O
%	O
)	O
as	O
compared	O
to	O
the	O
palmar	O
flexed	O
group	O
(	O
23	O
%	O
)	O
.	O

Radiological	O
parameters	O
were	O
markedly	O
better	O
in	O
the	O
dorsiflexed	O
group	O
.	O

Ninety	O
-	O
one	O
per	O
cent	O
of	O
patients	O
in	O
the	O
dorsiflexed	O
group	O
had	O
excellent	O
to	O
good	O
results	O
as	O
compared	O
to	O
66	O
%	O
in	O
the	O
palmar	O
flexed	O
group	O
.	O

Methods	O

Therefore	O
,	O
we	O
developed	O
a	O
reciprocal	O
system	O
of	O
a	O
full	O
-	O
length	O
HIV	O
packaging	O
cell	O
line	O
and	O
a	O
shortened	O
HI	O
-	O
viral	O
shuttle	O
vector	O
.	O

The	O
Tat	O
-	O
deficient	O
packaging	O
construct	O
is	O
stably	O
integrated	O
in	O
a	O
VSVG	O
-	O
pseudotyped	O
cell	O
line	O
and	O
transactivated	O
by	O
the	O
shuttle	O
vector	O
by	O
expression	O
of	O
TATGFP	O
from	O
a	O
heterologous	O
promoter	O
which	O
also	O
indicates	O
positive	O
cells	O
.	O

Expression	O
of	O
the	O
HI	O
-	O
viral	O
structure	O
proteins	O
is	O
driven	O
by	O
a	O
natural	O
5	O
'	O
LTR	O
promoter	O
and	O
a	O
3	O
'	O
polyadenylation	O
signal	O
,	O
whereas	O
the	O
envelope	O
expression	O
out	O
of	O
the	O
shuttle	O
vector	O
is	O
achieved	O
by	O
an	O
IRES	O
.	O

This	O
system	O
of	O
two	O
vectors	O
is	O
tightly	O
controllable	O
and	O
bypasses	O
the	O
problem	O
of	O
limited	O
packaging	O
capacity	O
into	O
HIV	O
-	O
1	O
virions	O
.	O

8	O
.	O
2	O
.	O

Species	O
Differences	O
in	O
PPARalpha	O
-	O
Associated	O
Signaling	O

The	O
PPARalpha	O
isotype	O
has	O
prime	O
importance	O
for	O
studies	O
with	O
animal	O
models	O
to	O
predict	O
the	O
effects	O
of	O
hepatic	O
PPs	O
in	O
humans	O
,	O
because	O
PPARalpha	O
agonists	O
induce	O
seemingly	O
quite	O
different	O
actions	O
in	O
rodents	O
and	O
humans	O
[	O
53	O
]	O
.	O

Originally	O
,	O
as	O
the	O
name	O
indicates	O
,	O
PPARs	O
were	O
studied	O
because	O
of	O
their	O
ability	O
to	O
bind	O
PPs	O
and	O
consequently	O
induce	O
PP	O
-	O
metabolizing	O
enzymes	O
.	O

In	O
rats	O
and	O
mice	O
,	O
but	O
not	O
in	O
humans	O
,	O
PPs	O
such	O
as	O
hypolipidemic	O
drugs	O
,	O
industrial	O
plasticizers	O
,	O
and	O
herbicides	O
are	O
non	O
-	O
genotoxic	O
carcinogens	O
that	O
cause	O
liver	O
tumors	O
[	O
54	O
]	O
.	O

In	O
humans	O
,	O
these	O
drugs	O
function	O
to	O
maintain	O
lipid	O
homeostasis	O
and	O
do	O
not	O
induce	O
peroxisome	O
proliferation	O
.	O

Thus	O
,	O
the	O
toxicity	O
and	O
carcinogenicity	O
of	O
PPs	O
are	O
highly	O
species	O
specific	O
[	O
55	O
]	O
.	O

The	O
species	O
differences	O
may	O
be	O
attributable	O
to	O
lower	O
PPAR	O
mRNA	O
expression	O
levels	O
in	O
h	O
-	O
hepatocytes	O
compared	O
with	O
rodent	O
cells	O
[	O
56	O
,	O
57	O
]	O
.	O

Alternatively	O
,	O
or	O
additionally	O
,	O
species	O
differences	O
may	O
be	O
the	O
result	O
of	O
different	O
sensitivities	O
of	O
the	O
genes	O
associated	O
with	O
the	O
peroxisome	O
proliferation	O
response	O
to	O
low	O
levels	O
of	O
PPs	O
,	O
owing	O
to	O
structural	O
differences	O
in	O
PPARalpha	O
[	O
54	O
]	O
.	O

There	O
are	O
both	O
similarities	O
and	O
differences	O
in	O
responses	O
to	O
xenobiotics	O
among	O
not	O
only	O
different	O
species	O
(	O
interspecies	O
)	O
but	O
also	O
individuals	O
of	O
the	O
same	O
species	O
(	O
intraspecies	O
)	O
.	O

Interspecific	O
PPARalpha	O
diversity	O
between	O
rodents	O
and	O
humans	O
is	O
well	O
known	O
and	O
has	O
been	O
studied	O
with	O
respect	O
to	O
drug	O
metabolism	O
.	O

NR	O
subfamily	O
1	O
members	O
have	O
at	O
least	O
two	O
functions	O
in	O
mammals	O
.	O

One	O
is	O
to	O
regulate	O
peroxisome	O
proliferation	O
through	O
binding	O
to	O
PPAR	O
response	O
elements	O
(	O
PPREs	O
)	O
in	O
the	O
promoters	O
of	O
genes	O
such	O
as	O
ACO	O
[	O
58	O
,	O
59	O
]	O
,	O
bifunctional	O
dehydrogenase	O
/	O
hydratase	O
(	O
BFE	O
)	O
[	O
60	O
]	O
,	O
and	O
microsomal	O
CYP4A1	O
[	O
61	O
]	O
.	O

The	O
other	O
is	O
to	O
modulate	O
the	O
serum	O
cholesterol	O
level	O
by	O
targeting	O
genes	O
such	O
as	O
the	O
lipoprotein	O
lipase	O
gene	O
[	O
62	O
]	O
and	O
the	O
apolipoprotein	O
regulating	O
genes	O
AI	O
,	O
AII	O
,	O
and	O
CII	O
[	O
63	O
]	O
.	O

The	O
former	O
mechanism	O
appears	O
to	O
function	O
in	O
rodents	O
,	O
but	O
not	O
in	O
humans	O
,	O
and	O
is	O
responsible	O
for	O
the	O
induction	O
of	O
peroxisome	O
proliferation	O
and	O
hepatocarcinogenesis	O
,	O
whereas	O
the	O
latter	O
mechanism	O
controls	O
basic	O
lipid	O
metabolism	O
in	O
both	O
rodents	O
and	O
humans	O
[	O
56	O
]	O
.	O

This	O
species	O
difference	O
in	O
xenobiotic	O
receptor	O
/	O
ligand	O
signaling	O
may	O
be	O
attributable	O
to	O
differences	O
in	O
the	O
expression	O
level	O
of	O
a	O
receptor	O
,	O
or	O
to	O
differences	O
in	O
receptor	O
/	O
ligand	O
binding	O
affinity	O
,	O
and	O
causes	O
difficulty	O
in	O
determining	O
responses	O
in	O
humans	O
based	O
on	O
rodent	O
data	O
[	O
56	O
]	O
.	O

Results	O
:	O

In	O
the	O
total	O
population	O
(	O
N	O
=	O
95	O
)	O
,	O
median	O
OS	O
was	O
significantly	O
longer	O
in	O
patients	O
with	O
baseline	O
CA	O
19	O
-	O
9	O
values	O
at	O
or	O
below	O
the	O
median	O
than	O
in	O
those	O
with	O
values	O
above	O
it	O
(	O
12	O
.	O
2	O
months	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
5	O
.	O
0	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
9	O
-	O
5	O
.	O
7	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

This	O
also	O
reached	O
significance	O
in	O
the	O
Gem	O
+	O
A	O
arm	O
(	O
median	O
OS	O
,	O
12	O
.	O
5	O
months	O
[	O
95	O
%	O
CI	O
,	O
8	O
.	O
6	O
-	O
16	O
.	O
6	O
%	O
]	O
vs	O
4	O
.	O
9	O
months	O
[	O
95	O
%	O
CI	O
,	O
3	O
.	O
6	O
-	O
5	O
.	O
6	O
%	O
]	O
;	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Patients	O
with	O
any	O
dBP	O
>	O
90	O
mmHg	O
had	O
significantly	O
longer	O
OS	O
than	O
those	O
who	O
did	O
not	O
.	O

However	O
,	O
there	O
was	O
no	O
predictive	O
significance	O
of	O
CA	O
19	O
-	O
9	O
.	O

3	O
.	O
2	O
.	O

Cell	O
line	O
and	O
culture	O

DU145	B
(	O
prostate	O
cancer	O
)	O
cell	O
line	O
was	O
used	O
in	O
this	O
assay	O
.	O

DU145	B
was	O
grown	O
in	O
DMEM	O
/	O
F	O
-	O
12	O
medium	O
(	O
Gibco	O
BRL	O
Life	O
Technologies	O
,	O
San	O
Diego	O
,	O
CA	O
.	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
and	O
kept	O
in	O
a	O
humidified	O
37	O
degreesC	O
,	O
5	O
%	O
CO2	O
incubator	O
.	O

Reagents	O

CNQX	O
,	O
colchicine	O
,	O
forskolin	O
,	O
and	O
carbenoxolone	O
were	O
purchased	O
from	O
Sigma	O
.	O

DCG	O
-	O
IV	O
,	O
ZD7288	O
,	O
CGP55845	O
and	O
DPCPX	O
were	O
obtained	O
from	O
Tocris	O
Cookson	O
(	O
Ellisville	O
,	O
MO	O
)	O
.	O

Percutaneous	O
coronary	O
intervention	O
for	O
the	O
very	O
late	O
stent	O
thrombosis	O
in	O
right	O
coronary	O
artery	O
.	O

A	O
:	O
a	O
balloon	O
angioplasty	O
was	O
performed	O
to	O
treat	O
total	O
occlusion	O
of	O
the	O
stented	O
right	O
coronary	O
artery	O
.	O

B	O
:	O
final	O
coronary	O
angiogram	O
showed	O
good	O
distal	O
flow	O
without	O
residual	O
stenosis	O
.	O

Target	O
volumes	O
'	O
coverage	O

The	O
mean	O
PTV1	O
and	O
PTV2	O
volumes	O
were	O
452	O
cm3	O
(	O
range	O
276	O
-	O
1074	O
cm3	O
)	O
and	O
300	O
cm3	O
(	O
range	O
137	O
-	O
567	O
cm3	O
)	O
respectively	O
.	O

A	O
mean	O
of	O
>	O
98	O
%	O
(	O
range	O
92	O
-	O
100	O
%	O
)	O
of	O
the	O
PTV1	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
in	O
all	O
planning	O
methods	O
.	O

A	O
mean	O
of	O
95	O
.	O
5	O
%	O
and	O
95	O
.	O
7	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
TOMO	O
and	O
IMRT	O
plans	O
respectively	O
.	O

A	O
mean	O
of	O
94	O
%	O
and	O
92	O
%	O
of	O
the	O
PTV2	O
received	O
100	O
%	O
of	O
the	O
prescribed	O
dose	O
with	O
IB	O
and	O
3D	O
treatment	O
plans	O
,	O
respectively	O
.	O

The	O
mean	O
IB	O
and	O
3D	O
plans	O
PTV2	O
coverage	O
was	O
significantly	O
inferior	O
then	O
the	O
IMRT	O
and	O
TOMO	O
plans	O
(	O
p	O
<	O
0	O
.	O
02	O
,	O
for	O
all	O
comparisons	O
)	O
.	O

The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
was	O
significantly	O
lower	O
(	O
better	O
)	O
with	O
the	O
TOMO	O
plans	O
,	O
compared	O
to	O
all	O
other	O
plans	O
for	O
both	O
PTV1	O
and	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
0003	O
for	O
all	O
comparisons	O
)	O
(	O
figure	O
3	O
)	O
.	O

The	O
mean	O
IC	O
of	O
the	O
IMRT	O
plans	O
was	O
significantly	O
higher	O
(	O
worse	O
)	O
than	O
the	O
mean	O
IC	O
of	O
the	O
3D	O
plans	O
regarding	O
PTV	O
1	O
(	O
p	O
<	O
0	O
.	O
02	O
)	O
and	O
higher	O
(	O
worse	O
)	O
then	O
the	O
mean	O
IC	O
of	O
the	O
IB	O
plans	O
regarding	O
PTV2	O
(	O
p	O
<	O
0	O
.	O
03	O
)	O
(	O
figure	O
3	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
means	O
of	O
the	O
IC	O
of	O
the	O
3D	O
and	O
IB	O
plans	O
.	O

Figure	O
3	O

The	O
mean	O
Inhomogeneity	O
Coefficient	O
(	O
IC	O
)	O
achieved	O
by	O
the	O
different	O
planning	O
methods	O
.	O

The	O
mean	O
of	O
the	O
Inhomogeneity	O
Coefficient	O
is	O
a	O
measure	O
of	O
dose	O
inhomogeneity	O
in	O
the	O
target	O
volumes	O
.	O

The	O
closer	O
the	O
IC	O
to	O
zero	O
,	O
the	O
more	O
homogenous	O
the	O
dose	O
is	O
.	O

All	O
-	O
cause	O
mortality	O
in	O
RALES	O
and	O
EPHESUS	O
(	O
adapted	O
from	O
[	O
4	O
]	O
and	O
[	O
5	O
]	O
)	O
.	O

Mean	O
follow	O
-	O
up	O
period	O
is	O
24	O
months	O
in	O
RALES	O
and	O
16	O
months	O
in	O
EPHESUS	O

Pre	O
-	O
publication	O
history	O

The	O
pre	O
-	O
publication	O
history	O
for	O
this	O
paper	O
can	O
be	O
accessed	O
here	O
:	O

http	O
:	O
/	O
/	O
www	O
.	O
biomedcentral	O
.	O
com	O
/	O
1471	O
-	O
2377	O
/	O
9	O
/	O
57	O
/	O
prepub	O

RESEARCH	O
DESIGN	O
AND	O
METHODS	O

For	O
this	O
study	O
,	O
20	O
individuals	O
(	O
mean	O
age	O
39	O
.	O
5	O
+	O
/	O
-	O
11	O
.	O
1	O
years	O
)	O
with	O
long	O
-	O
standing	O
type	O
1	O
diabetes	O
(	O
21	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
7	O
years	O
)	O
were	O
enrolled	O
in	O
this	O
prospective	O
open	O
-	O
label	O
crossover	O
trial	O
.	O

After	O
achieving	O
optimal	O
blood	O
glucose	O
control	O
,	O
16	O
subjects	O
were	O
randomized	O
to	O
exenatide	O
with	O
or	O
without	O
daclizumab	O
.	O

Endogenous	O
insulin	O
production	O
was	O
determined	O
by	O
repeatedly	O
measuring	O
serum	O
C	O
-	O
peptide	O
.	O

Subjects	O
and	O
Methods	O

ABPM	O
was	O
conducted	O
for	O
60	O
selected	O
patients	O
who	O
had	O
visited	O
Sunlin	O
Hospital	O
between	O
January	O
2008	O
and	O
August	O
2008	O
.	O

Patients	O
were	O
classified	O
into	O
3	O
groups	O
;	O
an	O
obese	O
group	O
whose	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
>	O
the	O
95th	O
percentile	O
,	O
an	O
overweight	O
group	O
whose	O
BMI	O
was	O
>	O
the	O
85th	O
percentile	O
but	O
less	O
than	O
the	O
95th	O
percentile	O
,	O
and	O
a	O
normal	O
group	O
whose	O
BMI	O
was	O
below	O
the	O
85th	O
percentile	O
.	O

Overall	O
mean	O
BP	O
,	O
day	O
and	O
night	O
BP	O
and	O
BP	O
load	O
were	O
measured	O
by	O
ABPM	O
.	O

Results	O

Contrary	O
to	O
previous	O
reports	O
that	O
PON1	O
activities	O
plateau	O
by	O
2	O
years	O
of	O
age	O
,	O
we	O
observed	O
an	O
age	O
-	O
dependent	O
increase	O
in	O
all	O
three	O
PON1	O
measures	O
from	O
birth	O
through	O
7	O
years	O
of	O
age	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
PON1192	O
genotype	O
significantly	O
modified	O
the	O
effect	O
of	O
age	O
on	O
paraoxonase	O
(	O
POase	O
)	O
activity	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
such	O
that	O
increases	O
in	O
enzyme	O
activity	O
with	O
age	O
were	O
influenced	O
by	O
the	O
number	O
of	O
R	O
alleles	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Children	O
with	O
the	O
PON1	O
-	O
108CC192RR	O
diplotype	O
had	O
significantly	O
higher	O
mean	O
PON1	O
activities	O
and	O
also	O
experienced	O
steeper	O
increases	O
of	O
POase	O
activity	O
over	O
time	O
compared	O
with	O
children	O
with	O
the	O
PON1	O
-	O
108TT192QQ	O
diplotype	O
.	O

Surgery	O

Trabeculectomy	O
should	O
be	O
considered	O
in	O
all	O
patients	O
,	O
when	O
the	O
'	O
target	O
IOP	O
'	O
is	O
not	O
achieved	O
with	O
glaucoma	O
medications	O
and	O
if	O
the	O
expected	O
rate	O
of	O
visual	O
loss	O
could	O
affect	O
the	O
patient	O
during	O
their	O
lifetime	O
.	O

In	O
this	O
procedure	O
,	O
an	O
opening	O
is	O
made	O
in	O
the	O
trabecular	O
meshwork	O
,	O
so	O
that	O
aqueous	O
humor	O
can	O
drain	O
into	O
the	O
sclera	O
.	O

Many	O
patients	O
can	O
discontinue	O
glaucoma	O
medications	O
after	O
surgery	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
trabeculectomy	O
patients	O
develop	O
cataract	O
within	O
five	O
years	O
.	O

If	O
trabeculectomy	O
fails	O
,	O
another	O
type	O
of	O
surgery	O
places	O
a	O
drainage	O
tube	O
(	O
Molteno	O
tube	O
)	O
in	O
the	O
eye	O
,	O
between	O
the	O
cornea	O
and	O
iris	O
,	O
which	O
exits	O
at	O
the	O
junction	O
of	O
the	O
cornea	O
and	O
sclera	O
.	O

Cyclodestructive	O
procedures	O
,	O
which	O
lower	O
IOP	O
by	O
destroying	O
the	O
ciliary	O
body	O
,	O
are	O
typically	O
reserved	O
for	O
eyes	O
,	O
which	O
are	O
refractory	O
to	O
all	O
other	O
forms	O
of	O
therapy	O
.	O

These	O
procedures	O
include	O
cyclocryotherapy	O
,	O
cylcodiathermy	O
and	O
laser	O
cyclophotocoagulation	O
.	O
[	O
91	O
-	O
93	O
]	O

Follow	O
-	O
up	O

Patients	O
were	O
followed	O
up	O
at	O
the	O
outpatient	O
clinic	O
at	O
1	O
,	O
4	O
,	O
and	O
7	O
months	O
after	O
the	O
ablation	O
procedure	O
and	O
every	O
6	O
months	O
thereafter	O
.	O

Routine	O
24	O
or	O
48	O
h	O
Holter	O
monitoring	O
was	O
performed	O
before	O
each	O
appointment	O
,	O
and	O
a	O
12	O
-	O
lead	O
electrocardiogram	O
was	O
obtained	O
at	O
each	O
visit	O
.	O

Patients	O
were	O
asked	O
to	O
report	O
to	O
the	O
emergency	O
room	O
or	O
our	O
arrhythmia	O
unit	O
for	O
an	O
ECG	O
if	O
any	O
symptom	O
suggestive	O
of	O
recurrence	O
occurred	O
between	O
scheduled	O
visits	O
.	O

After	O
the	O
ablation	O
procedure	O
,	O
all	O
patients	O
received	O
anti	O
-	O
arrhythmic	O
treatment	O
for	O
at	O
least	O
1	O
month	O
to	O
protect	O
against	O
early	O
recurrences	O
and	O
continued	O
oral	O
anticoagulation	O
for	O
a	O
minimum	O
of	O
2	O
months	O
to	O
maintain	O
an	O
international	O
normalized	O
ratio	O
between	O
2	O
.	O
0	O
and	O
3	O
.	O
0	O
.	O

Additionally	O
,	O
magnetic	O
resonance	O
angiography	O
was	O
repeated	O
at	O
3	O
-	O
6	O
months	O
after	O
the	O
procedure	O
to	O
evaluate	O
the	O
presence	O
of	O
PV	O
stenosis	O
.	O

Arrhythmia	O
recurrence	O
was	O
defined	O
as	O
a	O
documented	O
AF	O
or	O
atrial	O
flutter	O
episode	O
of	O
>	O
30	O
s	O
.	O

Arrhythmic	O
episodes	O
within	O
the	O
first	O
3	O
months	O
after	O
the	O
CPVA	O
(	O
healing	O
period	O
)	O
were	O
not	O
considered	O
in	O
the	O
evaluation	O
of	O
final	O
success	O
rates	O
because	O
they	O
are	O
often	O
described	O
as	O
transient	O
recurrences	O
related	O
to	O
atrial	O
inflammatory	O
processes	O
following	O
RF	O
lesions	O
.	O
26	O

The	O
endpoint	O
of	O
the	O
study	O
was	O
freedom	O
from	O
arrhythmia	O
recurrence	O
after	O
a	O
single	O
CPVA	O
procedure	O
,	O
without	O
anti	O
-	O
arrhythmic	O
medication	O
.	O

A	O
minimum	O
follow	O
-	O
up	O
of	O
3	O
months	O
was	O
required	O
.	O

Background	O

Refractive	O
outcomes	O
have	O
become	O
an	O
increasingly	O
important	O
part	O
of	O
cataract	O
surgery	O
and	O
the	O
limbal	O
relaxing	O
incision	O
(	O
LRI	O
)	O
has	O
been	O
shown	O
to	O
be	O
a	O
safe	O
and	O
effective	O
procedure	O
to	O
reduce	O
astigmatism	O
[	O
1	O
-	O
4	O
]	O
.	O

Currently	O
,	O
ophthalmic	O
surgeons	O
have	O
only	O
two	O
material	O
choices	O
for	O
knives	O
to	O
perform	O
limbal	O
relaxing	O
incision	O
,	O
diamond	O
and	O
metal	O
.	O

BD	O
(	O
Becton	O
,	O
Dickinson	O
and	O
Company	O
)	O
,	O
Franklin	O
Lakes	O
,	O
NJ	O
has	O
developed	O
a	O
safety	O
engineered	O
,	O
single	O
use	O
,	O
uni	O
-	O
directional	O
cutting	O
silicon	O
knife	O
for	O
these	O
incisions	O
.	O

Previous	O
research	O
has	O
suggested	O
that	O
the	O
silicon	O
BD	O
Atomic	O
Edge	O
(	O
TM	O
)	O
knife	O
has	O
superior	O
performance	O
characteristics	O
when	O
compared	O
to	O
a	O
metal	O
knife	O
and	O
performance	O
similar	O
to	O
diamond	O
knife	O
when	O
making	O
various	O
incisions	O
[	O
5	O
,	O
6	O
]	O
.	O

This	O
study	O
was	O
designed	O
to	O
determine	O
the	O
performance	O
characteristics	O
of	O
silicon	O
accurate	O
depth	O
knives	O
in	O
comparison	O
to	O
diamond	O
LRI	O
knives	O
and	O
steel	O
accurate	O
depth	O
knives	O
in	O
five	O
performance	O
characteristics	O
.	O

Electrostatic	O
interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
fusing	O
membranes	O
.	O

(	O
A	O
)	O
Schematic	O
diagram	O
and	O
definitions	O
of	O
intermolecular	O
interaction	O
energies	O
presented	O
in	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
.	O

In	O
(	O
A	O
)	O
through	O
(	O
C	O
)	O
,	O
only	O
the	O
SNARE	O
core	O
complex	O
is	O
considered	O
.	O

Interaction	O
free	O
energies	O
are	O
calculated	O
for	O
(	O
B	O
)	O
a	O
series	O
of	O
SNARE	O
/	O
membrane	O
distances	O
and	O
(	O
C	O
)	O
different	O
membrane	O
lipid	O
compositions	O
.	O

Arrow	O
in	O
(	O
B	O
)	O
indicates	O
the	O
most	O
physiologically	O
relevant	O
distance	O
when	O
the	O
closest	O
points	O
between	O
SNARE	O
and	O
membranes	O
are	O
3	O
A	O
,	O
the	O
thickness	O
of	O
a	O
layer	O
of	O
water	O
.	O
[	O
19	O
]	O
In	O
(	O
D	O
)	O
through	O
(	O
F	O
)	O
,	O
TMDs	O
of	O
VAMP	O
and	O
syntaxin	O
are	O
present	O
and	O
embedded	O
in	O
membranes	O
.	O

Furthermore	O
,	O
the	O
C	O
-	O
terminus	O
of	O
the	O
SNARE	O
motif	O
is	O
partially	O
unraveled	O
into	O
individual	O
alpha	O
-	O
helices	O
by	O
molecular	O
dynamics	O
simulations	O
to	O
represent	O
trans	O
-	O
SNARE	O
complex	O
.	O

Interaction	O
free	O
energies	O
are	O
then	O
calculated	O
for	O
(	O
E	O
)	O
a	O
series	O
of	O
SNARE	O
motif	O
C	O
-	O
terminus	O
separation	O
distances	O
and	O
(	O
F	O
)	O
different	O
lipid	O
compositions	O
of	O
the	O
membranes	O
.	O

Conclusions	O
drawn	O
from	O
both	O
groups	O
of	O
studies	O
are	O
essentially	O
the	O
same	O
.	O

V	O
(	O
circles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
SNARE	O
complex	O
and	O
the	O
v	O
-	O
membrane	O
.	O

T	O
(	O
squares	O
)	O
:	O
Interaction	O
energies	O
between	O
SNARE	O
and	O
the	O
t	O
-	O
membrane	O
.	O

VT	O
(	O
triangles	O
)	O
:	O
Interaction	O
energies	O
between	O
the	O
v	O
-	O
and	O
the	O
t	O
-	O
membranes	O
if	O
the	O
SNARE	O
complex	O
were	O
extracted	O
.	O

Percentage	O
reported	O
purchasing	O
intentions	O
,	O
comparing	O
ITN	O
-	O
owning	O
to	O
non	O
-	O
owning	O
households	O

Demographic	O
data	O
of	O
subjects	O

School	O
environment	O

At	O
the	O
majority	O
of	O
the	O
schools	O
a	O
soft	O
drink	O
vending	O
machine	O
(	O
91	O
%	O
,	O
n	O
=	O
446	O
)	O
and	O
/	O
or	O
a	O
vending	O
machine	O
containing	O
sweets	O
and	O
candy	O
bars	O
(	O
81	O
%	O
,	O
n	O
=	O
413	O
)	O
is	O
present	O
(	O
Table	O
2	O
)	O
.	O

At	O
78	O
%	O
(	O
n	O
=	O
393	O
)	O
of	O
the	O
schools	O
there	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
or	O
a	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
(	O
within	O
1	O
km	O
of	O
the	O
school	O
)	O
.	O

At	O
68	O
%	O
(	O
n	O
=	O
345	O
)	O
of	O
the	O
schools	O
there	O
are	O
facilities	O
at	O
or	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
,	O
for	O
example	O
a	O
soccer	O
field	O
or	O
a	O
basketball	O
field	O
.	O

Table	O
2	O

The	O
school	O
environment	O

Total	O
School	O
level	O

Vocational	O
education	O
schools	O
Mixed	O
schools	O
Higher	O
education	O
schools	O
Vocational	O
education	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O
Mixed	O
schools	O
versus	O
higher	O
education	O
schools	O
#	O

n	O
=	O
515	O
n	O
=	O
216	O
n	O
=	O
232	O
n	O
=	O
67	O

%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
%	O
(	O
n	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O
OR	O
(	O
95	O
%	O
CI	O
)	O

Soft	O
drink	O
vending	O
machine	O
present	O
at	O
school	O
91	O
.	O
4	O
(	O
466	O
)	O
90	O
.	O
2	O
(	O
194	O
)	O
91	O
.	O
3	O
(	O
209	O
)	O
95	O
.	O
5	O
(	O
63	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
0	O
)	O

Percentage	O
of	O
soft	O
drink	O
vending	O
machines	O
present	O
at	O
school	O
that	O
contain	O
light	O
soft	O
drinks	O
79	O
.	O
8	O
(	O
372	O
)	O
75	O
.	O
4	O
(	O
147	O
)	O
82	O
.	O
2	O
(	O
171	O
)	O
85	O
.	O
7	O
(	O
54	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O
1	O
.	O
0	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
1	O
)	O

Soft	O
drink	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
drinks	O
than	O
healthy	O
drinks	O
57	O
.	O
9	O
(	O
268	O
)	O
61	O
.	O
9	O
(	O
120	O
)	O
58	O
.	O
5	O
(	O
121	O
)	O
43	O
.	O
6	O
(	O
27	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
1	O
.	O
4	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
9	O
)	O
*	O

Vending	O
machine	O
present	O
at	O
school	O
that	O
contains	O
sweets	O
/	O
candy	O
bars	O
80	O
.	O
7	O
(	O
413	O
)	O
75	O
.	O
6	O
(	O
161	O
)	O
84	O
.	O
9	O
(	O
197	O
)	O
82	O
.	O
1	O
(	O
55	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
1	O
.	O
0	O
;	O
1	O
.	O
2	O
)	O

Sweets	O
/	O
candy	O
bars	O
vending	O
machines	O
contain	O
more	O
unhealthy	O
than	O
healthy	O
foods	O
63	O
.	O
7	O
(	O
260	O
)	O
70	O
.	O
6	O
(	O
113	O
)	O
64	O
.	O
4	O
(	O
125	O
)	O
40	O
.	O
7	O
(	O
22	O
)	O
1	O
.	O
7	O
(	O
1	O
.	O
2	O
;	O
2	O
.	O
4	O
)	O
*	O
1	O
.	O
6	O
(	O
1	O
.	O
1	O
;	O
2	O
.	O
3	O
)	O
*	O

There	O
is	O
a	O
supermarket	O
,	O
gas	O
station	O
,	O
or	O
fast	O
food	O
restaurant	O
in	O
the	O
neighbourhood	O
of	O
the	O
school	O
78	O
.	O
3	O
(	O
393	O
)	O
76	O
.	O
7	O
(	O
161	O
)	O
79	O
.	O
7	O
(	O
181	O
)	O
78	O
.	O
5	O
(	O
51	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O
1	O
.	O
1	O
(	O
0	O
.	O
9	O
;	O
1	O
.	O
2	O
)	O

The	O
students	O
are	O
allowed	O
to	O
leave	O
the	O
school	O
property	O
during	O
school	O
hours	O
57	O
.	O
4	O
(	O
295	O
)	O
42	O
.	O
6	O
(	O
92	O
)	O
65	O
.	O
8	O
(	O
152	O
)	O
76	O
.	O
1	O
(	O
51	O
)	O
0	O
.	O
6	O
(	O
0	O
.	O
5	O
;	O
0	O
.	O
8	O
)	O
*	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
0	O
)	O

There	O
are	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
where	O
the	O
students	O
can	O
be	O
physically	O
active	O
68	O
.	O
1	O
(	O
345	O
)	O
63	O
.	O
1	O
(	O
135	O
)	O
70	O
.	O
3	O
(	O
161	O
)	O
76	O
.	O
6	O
(	O
49	O
)	O
0	O
.	O
8	O
(	O
0	O
.	O
7	O
;	O
1	O
.	O
0	O
)	O
0	O
.	O
9	O
(	O
0	O
.	O
8	O
;	O
1	O
.	O
1	O
)	O

#	O
Associations	O
are	O
adjusted	O
for	O
school	O
size	O

*	O
p	O
<	O
0	O
.	O
05	O

The	O
vocational	O
education	O
schools	O
did	O
not	O
differ	O
from	O
the	O
higher	O
education	O
schools	O
with	O
regard	O
to	O
the	O
presence	O
of	O
vending	O
machines	O
and	O
a	O
canteen	O
,	O
but	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
a	O
less	O
favourable	O
selection	O
of	O
foods	O
and	O
drinks	O
.	O

The	O
vocational	O
education	O
schools	O
indicated	O
more	O
often	O
that	O
the	O
vending	O
machines	O
and	O
the	O
canteen	O
contained	O
more	O
unhealthy	O
foods	O
and	O
drinks	O
than	O
healthy	O
foods	O
and	O
drinks	O
.	O

Vocational	O
education	O
schools	O
had	O
fewer	O
facilities	O
at	O
and	O
around	O
the	O
school	O
property	O
to	O
be	O
physical	O
than	O
the	O
higher	O
education	O
schools	O
.	O

Most	O
associations	O
were	O
attenuated	O
after	O
adjustment	O
for	O
school	O
size	O
.	O

For	O
example	O
,	O
the	O
association	O
between	O
school	O
level	O
and	O
content	O
of	O
the	O
soft	O
drink	O
vending	O
machines	O
was	O
OR	O
=	O
1	O
.	O
42	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
05	O
-	O
1	O
.	O
93	O
in	O
the	O
crude	O
analysis	O
and	O
OR	O
=	O
1	O
.	O
35	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
99	O
-	O
1	O
.	O
85	O
in	O
the	O
adjusted	O
analysis	O
.	O

Behavior	O

Across	O
all	O
participants	O
,	O
50	O
%	O
+	O
/	O
-	O
13	O
of	O
studied	O
high	O
-	O
complexity	O
scene	O
were	O
later	O
recognized	O
as	O
""""	O
old	O
""""	O
(	O
hit	O
rate	O
)	O
,	O
and	O
52	O
%	O
+	O
/	O
-	O
18	O
of	O
studied	O
low	O
-	O
complexity	O
scenes	O
were	O
later	O
recognized	O
as	O
""""	O
old	O
""""	O
.	O

For	O
new	O
scenes	O
presented	O
at	O
test	O
(	O
foils	O
)	O
,	O
22	O
%	O
+	O
/	O
-	O
16	O
of	O
high	O
-	O
complexity	O
scenes	O
were	O
falsely	O
categorized	O
as	O
""""	O
old	O
""""	O
(	O
false	O
alarm	O
rate	O
)	O
,	O
and	O
22	O
%	O
+	O
/	O
-	O
14	O
of	O
low	O
-	O
complexity	O
scenes	O
were	O
falsely	O
categorized	O
as	O
""""	O
old	O
""""	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
hit	O
rate	O
(	O
hit	O
rate	O
-	O
false	O
alarm	O
rate	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
(	O
28	O
%	O
+	O
/	O
-	O
13	O
)	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
30	O
%	O
+	O
/	O
-	O
14	O
)	O
(	O
t	O
(	O
45	O
)	O
=	O
1	O
.	O
02	O
,	O
p	O
=	O
0	O
.	O
31	O
)	O
.	O

Critically	O
,	O
the	O
adjusted	O
hit	O
rate	O
increased	O
with	O
age	O
for	O
high	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
40	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
but	O
not	O
for	O
low	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
11	O
,	O
p	O
=	O
0	O
.	O
46	O
)	O
scenes	O
.	O

Thus	O
,	O
overall	O
participants	O
had	O
similar	O
memory	O
accuracy	O
for	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
but	O
memory	O
accuracy	O
improved	O
with	O
age	O
only	O
for	O
high	O
-	O
complexity	O
scenes	O
.	O

Participants	O
categorized	O
as	O
""""	O
remembered	O
""""	O
(	O
RHIT	O
)	O
,	O
28	O
%	O
+	O
/	O
-	O
12	O
of	O
the	O
studied	O
high	O
-	O
complexity	O
scenes	O
,	O
and	O
29	O
%	O
+	O
/	O
-	O
15	O
of	O
the	O
studied	O
low	O
-	O
complexity	O
scenes	O
.	O

Participants	O
had	O
similar	O
rates	O
of	O
falsely	O
categorizing	O
as	O
""""	O
remembered	O
""""	O
(	O
RFA	O
)	O
high	O
(	O
5	O
%	O
+	O
/	O
-	O
6	O
)	O
and	O
low	O
(	O
5	O
%	O
+	O
/	O
-	O
6	O
)	O
complexity	O
foils	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
R	O
rates	O
(	O
RHIT	O
-	O
RFA	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
t	O
(	O
45	O
)	O
=	O
1	O
.	O
41	O
,	O
p	O
=	O
0	O
.	O
17	O
)	O
.	O

Adjusted	O
R	O
rates	O
increased	O
with	O
age	O
for	O
high	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
but	O
not	O
for	O
low	O
-	O
complexity	O
(	O
r	O
=	O
0	O
.	O
16	O
,	O
p	O
=	O
0	O
.	O
30	O
)	O
,	O
scenes	O
(	O
Figures	O
1C	O
,	O
D	O
)	O
.	O

The	O
difference	O
between	O
the	O
adjusted	O
R	O
rates	O
of	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
increased	O
with	O
age	O
(	O
r	O
=	O
0	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
03	O
;	O
1	O
-	O
tailed	O
)	O
,	O
suggesting	O
that	O
the	O
age	O
-	O
related	O
improvements	O
in	O
memory	O
performance	O
were	O
more	O
robust	O
for	O
recollected	O
high	O
-	O
complexity	O
scenes	O
.	O

Thus	O
,	O
overall	O
,	O
participants	O
had	O
similar	O
memory	O
accuracy	O
for	O
recollected	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
but	O
accuracy	O
for	O
recollected	O
high	O
-	O
complexity	O
scenes	O
improved	O
with	O
age	O
,	O
whereas	O
accuracy	O
for	O
recollected	O
low	O
-	O
complexity	O
scenes	O
did	O
not	O
change	O
with	O
age	O
.	O

Participants	O
categorized	O
as	O
""""	O
familiar	O
""""	O
(	O
KHIT	O
)	O
,	O
22	O
%	O
+	O
/	O
-	O
9	O
of	O
studied	O
high	O
-	O
complexity	O
scenes	O
,	O
and	O
22	O
%	O
+	O
/	O
-	O
10	O
of	O
studied	O
low	O
-	O
complexity	O
scenes	O
.	O

Participants	O
falsely	O
categorized	O
as	O
""""	O
familiar	O
""""	O
(	O
KFA	O
)	O
17	O
%	O
+	O
/	O
-	O
11	O
of	O
high	O
-	O
complexity	O
,	O
and	O
17	O
%	O
+	O
/	O
-	O
12	O
of	O
low	O
-	O
complexity	O
foils	O
.	O

Across	O
all	O
participants	O
,	O
adjusted	O
K	O
rates	O
(	O
KHIT	O
-	O
KFA	O
)	O
for	O
high	O
-	O
complexity	O
scenes	O
did	O
not	O
differ	O
from	O
that	O
for	O
low	O
-	O
complexity	O
scenes	O
(	O
t	O
(	O
45	O
)	O
=	O
0	O
.	O
06	O
,	O
p	O
=	O
0	O
.	O
95	O
)	O
.	O

Adjusted	O
K	O
rates	O
did	O
not	O
change	O
with	O
age	O
for	O
either	O
high	O
-	O
complexity	O
or	O
low	O
-	O
complexity	O
scenes	O
(	O
|	O
r	O
|	O
s	O
<	O
0	O
.	O
09	O
,	O
ps	O
>	O
0	O
.	O
56	O
)	O
(	O
Figures	O
1C	O
,	O
D	O
)	O
.	O

During	O
the	O
encoding	O
task	O
,	O
participants	O
were	O
overall	O
faster	O
to	O
respond	O
to	O
low	O
-	O
complexity	O
scenes	O
(	O
1072	O
+	O
/	O
-	O
275	O
ms	O
)	O
than	O
to	O
high	O
-	O
complexity	O
scenes	O
(	O
1093	O
+	O
/	O
-	O
287	O
ms	O
)	O
(	O
t	O
(	O
45	O
)	O
=	O
2	O
.	O
31	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

Response	O
times	O
decreased	O
with	O
age	O
for	O
low	O
-	O
(	O
r	O
=	O
-	O
0	O
.	O
37	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
and	O
high	O
-	O
(	O
r	O
=	O
-	O
0	O
.	O
33	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
complexity	O
scenes	O
.	O

The	O
difference	O
between	O
the	O
response	O
times	O
for	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
,	O
however	O
,	O
did	O
not	O
change	O
with	O
age	O
(	O
r	O
=	O
0	O
.	O
14	O
,	O
p	O
=	O
0	O
.	O
35	O
)	O
.	O

Response	O
times	O
decreased	O
with	O
age	O
for	O
R	O
,	O
K	O
and	O
F	O
trial	O
types	O
for	O
both	O
high	O
-	O
and	O
low	O
-	O
complexity	O
scenes	O
(	O
-	O
0	O
.	O
36	O
<	O
r	O
<	O
-	O
0	O
.	O
30	O
,	O
ps	O
<	O
0	O
.	O
04	O
)	O
.	O

The	O
difference	O
between	O
response	O
times	O
for	O
R	O
and	O
F	O
trial	O
types	O
,	O
however	O
,	O
did	O
not	O
change	O
with	O
age	O
for	O
either	O
high	O
(	O
r	O
=	O
0	O
.	O
12	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
or	O
low	O
complexity	O
scenes	O
(	O
r	O
=	O
0	O
.	O
08	O
,	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O

1	O
.	O

Background	O

The	O
United	O
Republic	O
of	O
Tanzania	O
,	O
is	O
among	O
the	O
many	O
countries	O
in	O
sub	O
-	O
Saharan	O
Africa	O
facing	O
a	O
human	O
resources	O
crisis	O
in	O
its	O
health	O
sector	O
,	O
with	O
a	O
small	O
and	O
inequitably	O
distributed	O
health	O
workforce	O
[	O
1	O
]	O
that	O
shoulders	O
a	O
disproportionately	O
high	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O

Although	O
all	O
poor	O
countries	O
in	O
the	O
world	O
face	O
a	O
severe	O
human	O
resource	O
crisis	O
in	O
their	O
health	O
sectors	O
[	O
3	O
,	O
4	O
]	O
,	O
the	O
problem	O
is	O
most	O
acute	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
,	O
in	O
which	O
an	O
estimated	O
workforce	O
of	O
750	O
000	O
health	O
workers	O
in	O
the	O
region	O
serves	O
682	O
million	O
people	O
[	O
2	O
]	O
.	O

By	O
comparison	O
,	O
the	O
ratio	O
is	O
10	O
to	O
15	O
times	O
higher	O
in	O
developed	O
countries	O
.	O

Moreover	O
,	O
this	O
estimated	O
workforce	O
of	O
doctors	O
,	O
nurses	O
and	O
allied	O
health	O
workers	O
in	O
Sub	O
-	O
Saharan	O
Africa	O
constitutes	O
1	O
.	O
3	O
%	O
of	O
the	O
world	O
'	O
s	O
health	O
workforce	O
,	O
while	O
Africa	O
suffers	O
from	O
25	O
%	O
of	O
the	O
world	O
'	O
s	O
burden	O
of	O
disease	O
[	O
2	O
]	O
.	O

A	O
minimum	O
level	O
of	O
a	O
health	O
workforce	O
of	O
2	O
.	O
5	O
health	O
workers	O
per	O
1000	O
people	O
is	O
required	O
to	O
achieve	O
the	O
Millennium	O
Development	O
Goals	O
[	O
5	O
]	O
.	O

Africa	O
is	O
far	O
from	O
this	O
level	O
with	O
a	O
health	O
workforce	O
density	O
that	O
only	O
averages	O
0	O
.	O
8	O
worker	O
per	O
1000	O
people	O
,	O
while	O
the	O
world	O
median	O
density	O
of	O
health	O
personnel	O
is	O
5	O
per	O
1000	O
people	O
[	O
5	O
]	O
.	O

There	O
is	O
a	O
positive	O
correlation	O
between	O
health	O
worker	O
density	O
and	O
various	O
health	O
indices	O
,	O
most	O
notably	O
infant	O
mortality	O
rate	O
,	O
maternal	O
mortality	O
rates	O
,	O
and	O
various	O
disease	O
specific	O
mortality	O
and	O
morbidity	O
rates	O
[	O
6	O
,	O
7	O
]	O
.	O

An	O
increase	O
in	O
the	O
number	O
of	O
health	O
workers	O
per	O
capita	O
is	O
associated	O
with	O
a	O
notable	O
decline	O
in	O
the	O
rates	O
mentioned	O
above	O
.	O

As	O
a	O
consequence	O
,	O
it	O
has	O
been	O
argued	O
that	O
health	O
worker	O
shortages	O
have	O
impeded	O
the	O
implementation	O
of	O
development	O
goals	O
in	O
many	O
poor	O
countries	O
[	O
8	O
]	O
.	O

CASE	O
:	O

Here	O
for	O
the	O
first	O
time	O
a	O
case	O
of	O
CDLS	O
from	O
Iran	O
,	O
a	O
15	O
-	O
week	O
-	O
old	O
male	O
infant	O
who	O
was	O
refereed	O
as	O
a	O
case	O
of	O
multiple	O
congenital	O
anomalies	O
.	O

Clinical	O
investigation	O
showed	O
that	O
the	O
child	O
was	O
a	O
case	O
of	O
CDLS	O
.	O

NSPCs	O
protect	O
against	O
30	O
minute	O
MCAO	O
.	O

(	O
A	O
-	O
D	O
)	O
Coronal	O
histological	O
sections	O
through	O
the	O
ischemic	O
striatum	O
3	O
days	O
following	O
MCAO	O
,	O
stained	O
for	O
TUNEL	O
(	O
A	O
,	O
B	O
)	O
or	O
NeuN	O
(	O
C	O
,	O
D	O
)	O
.	O

Mice	O
received	O
intrastriatal	O
injections	O
of	O
exogenous	O
PBS	O
(	O
A	O
,	O
C	O
)	O
or	O
EGFP	O
+	O
NSPCs	O
(	O
B	O
,	O
D	O
,	O
E	O
)	O
72	O
hr	O
prior	O
to	O
MCAO	O
.	O

Inset	O
in	O
(	O
B	O
)	O
shows	O
40x	O
magnified	O
view	O
of	O
the	O
injection	O
site	O
.	O

(	O
E	O
)	O
Monochrome	O
conversion	O
of	O
image	O
shown	O
in	O
B	O
to	O
demonstrate	O
concentric	O
ring	O
structures	O
used	O
for	O
Sholl	O
analysis	O
.	O

(	O
F	O
)	O
Quantification	O
of	O
TUNEL	O
+	O
cells	O
using	O
Sholl	O
analysis	O
performed	O
on	O
fluorescent	O
images	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
n	O
=	O
5	O
mice	O
per	O
group	O
.	O

Scale	O
bar	O
:	O
A	O
,	O
B	O
=	O
20	O
microm	O
;	O
C	O
,	O
D	O
=	O
10	O
microm	O
.	O

Magnetic	O
resonance	O
imaging	O
of	O
axial	O
plan	O
with	O
intravenous	O
contrast	O
gadolinium	O
-	O
BOPTA	O
demonstrating	O
a	O
mass	O
adherent	O
to	O
the	O
right	O
ventricular	O
wall	O
.	O

Applying	O
A1C	O
cut	O
offs	O
to	O
the	O
AusDiab	O
population	O
(	O
4	O
.	O
6	O
%	O
undiagnosed	O
diabetes	O
)	O

Applying	O
the	O
same	O
cut	O
offs	O
,	O
a	O
total	O
75	O
.	O
9	O
%	O
of	O
the	O
AusDiab	O
population	O
had	O
diabetes	O
ruled	O
in	O
or	O
ruled	O
out	O
(	O
Fig	O
.	O
1B	O
)	O
,	O
while	O
the	O
remaining	O
24	O
.	O
1	O
%	O
had	O
impaired	O
A1C	O
.	O

From	O
those	O
with	O
impaired	O
A1C	O
,	O
69	O
.	O
3	O
%	O
had	O
abnormal	O
glucose	O
status	O
.	O

For	O
diabetes	O
,	O
A1C	O
at	O
5	O
.	O
5	O
%	O
provided	O
moderate	O
sensitivity	O
(	O
83	O
.	O
5	O
%	O
)	O
but	O
high	O
NPV	O
(	O
99	O
.	O
0	O
%	O
)	O
,	O
since	O
diabetes	O
prevalence	O
was	O
lower	O
in	O
the	O
AusDiab	O
than	O
in	O
the	O
MP	O
population	O
.	O

A1C	O
at	O
7	O
.	O
0	O
%	O
gave	O
100	O
%	O
specificity	O
and	O
100	O
%	O
PPV	O
.	O

By	O
dropping	O
the	O
cut	O
off	O
to	O
6	O
.	O
5	O
%	O
,	O
specificity	O
remained	O
99	O
.	O
9	O
%	O
,	O
with	O
PPV	O
near	O
100	O
%	O
.	O

Background	O

Over	O
the	O
past	O
decades	O
,	O
extensive	O
comparative	O
mapping	O
research	O
has	O
been	O
performed	O
in	O
the	O
plant	O
family	O
Solanaceae	O
.	O

The	O
recent	O
identification	O
of	O
a	O
large	O
set	O
of	O
single	O
-	O
copy	O
conserved	O
orthologous	O
(	O
COSII	O
)	O
markers	O
has	O
greatly	O
accelerated	O
comparative	O
mapping	O
studies	O
among	O
major	O
solanaceous	O
species	O
including	O
tomato	O
,	O
potato	O
,	O
eggplant	O
,	O
pepper	O
and	O
diploid	O
Nicotiana	O
species	O
(	O
as	O
well	O
as	O
tetraploid	O
tobacco	O
)	O
.	O

The	O
large	O
amount	O
of	O
comparative	O
data	O
now	O
available	O
for	O
these	O
species	O
provides	O
the	O
opportunity	O
to	O
describe	O
the	O
overall	O
patterns	O
of	O
chromosomal	O
evolution	O
in	O
this	O
important	O
plant	O
family	O
.	O

The	O
results	O
of	O
this	O
investigation	O
are	O
described	O
herein	O
.	O

Calcium	O
intake	O
and	O
effects	O
on	O
QUS	O
T	O
-	O
score	O

Figure	O
5	O
shows	O
the	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
according	O
to	O
menopausal	O
status	O
.	O

Calcium	O
consumption	O
in	O
most	O
groups	O
,	O
like	O
that	O
in	O
the	O
study	O
population	O
as	O
a	O
whole	O
,	O
was	O
inadequate	O
.	O

Fewer	O
than	O
one	O
third	O
of	O
premenopausal	O
and	O
postmenopausal	O
women	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
,	O
and	O
fewer	O
than	O
16	O
%	O
of	O
premenopausal	O
women	O
in	O
the	O
50	O
-	O
59	O
age	O
decade	O
(	O
n	O
=	O
38	O
)	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
.	O

Figure	O
5	O

Daily	O
calcium	O
intake	O
in	O
premenopausal	O
and	O
postmenopausal	O
women	O
.	O

This	O
figure	O
depicts	O
the	O
daily	O
amounts	O
of	O
dietary	O
calcium	O
intake	O
(	O
and	O
percent	O
)	O
according	O
to	O
menopausal	O
status	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
.	O

QUS	O
T	O
-	O
score	O
were	O
then	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
calcium	O
as	O
cutoff	O
point	O
.	O

As	O
shown	O
in	O
Tables	O
3	O
and	O
4	O
and	O
Figure	O
6	O
,	O
premenopausal	O
women	O
who	O
were	O
systematically	O
active	O
and	O
consumed	O
more	O
than	O
800	O
mg	O
calcium	O
daily	O
had	O
significantly	O
higher	O
QUS	O
T	O
-	O
scores	O
compared	O
with	O
all	O
other	O
activity	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Among	O
systematically	O
active	O
premenopausal	O
women	O
who	O
received	O
more	O
than	O
800	O
mg	O
calcium	O
per	O
day	O
,	O
this	O
difference	O
was	O
separately	O
significant	O
verses	O
sedentary	O
(	O
p	O
=	O
0	O
.	O
028	O
)	O
and	O
moderately	O
active	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
women	O
.	O

In	O
contrast	O
,	O
postmenopausal	O
women	O
showed	O
no	O
difference	O
in	O
QUS	O
T	O
-	O
scores	O
regardless	O
of	O
the	O
amount	O
of	O
daily	O
calcium	O
intake	O
.	O

Figure	O
6	O

Synergy	O
between	O
physical	O
activity	O
and	O
dietary	O
calcium	O
intake	O
in	O
women	O
consuming	O
calcium	O
amounts	O
greater	O
than	O
800	O
mg	O
/	O
day	O
.	O

This	O
graphic	O
depicts	O
mean	O
QUS	O
T	O
-	O
score	O
values	O
calculated	O
according	O
to	O
daily	O
calcium	O
intake	O
in	O
all	O
premenopausal	O
and	O
postmenopausal	O
activity	O
groups	O
using	O
800	O
mg	O
daily	O
as	O
cut	O
off	O
point	O
(	O
for	O
statistical	O
significant	O
values	O
see	O
text	O
)	O
.	O

CONCLUSIONS	O

The	O
lack	O
of	O
association	O
between	O
depression	O
and	O
glycemic	O
control	O
is	O
not	O
due	O
to	O
the	O
use	O
of	O
a	O
binary	O
measure	O
of	O
depression	O
.	O

Findings	O
further	O
clarify	O
the	O
significant	O
association	O
between	O
distress	O
and	O
A1C	O
.	O

Additional	O
file	O
3	O

Primers	O
used	O
in	O
this	O
study	O
.	O

All	O
of	O
the	O
primers	O
used	O
for	O
generating	O
PCR	O
products	O
for	O
microinjection	O
and	O
site	O
-	O
direct	O
mutagenesis	O
are	O
listed	O
.	O

Discussion	O

This	O
is	O
the	O
first	O
study	O
to	O
employ	O
such	O
a	O
large	O
number	O
of	O
replicated	O
samples	O
in	O
order	O
to	O
assess	O
the	O
bacterial	O
communities	O
of	O
healthy	O
and	O
diseased	O
corals	O
,	O
and	O
the	O
first	O
culture	O
-	O
independent	O
assessment	O
of	O
bacterial	O
communities	O
on	O
Acroporid	O
WS	O
corals	O
on	O
the	O
GBR	O
.	O

Despite	O
the	O
potential	O
of	O
not	O
capturing	O
rare	O
or	O
very	O
low	O
abundance	O
bacterial	O
ribotypes	O
,	O
the	O
DGGE	O
analysis	O
used	O
in	O
this	O
study	O
indicated	O
similar	O
results	O
of	O
captured	O
bacterial	O
ribotypes	O
and	O
tentative	O
bacterial	O
species	O
replacement	O
in	O
unhealthy	O
corals	O
to	O
that	O
of	O
less	O
replicated	O
studies	O
using	O
other	O
non	O
-	O
culture	O
based	O
techniques	O
(	O
e	O
.	O
g	O
.	O
[	O
3	O
]	O
,	O
[	O
54	O
]	O
,	O
[	O
69	O
]	O
;	O
Figure	O
4	O
)	O
.	O

The	O
results	O
from	O
this	O
research	O
reinforce	O
,	O
with	O
statistically	O
relevant	O
data	O
,	O
that	O
corals	O
harbour	O
bacterial	O
communities	O
different	O
to	O
the	O
water	O
column	O
[	O
7	O
]	O
,	O
[	O
9	O
]	O
,	O
[	O
42	O
]	O
,	O
corroborate	O
findings	O
that	O
corals	O
associate	O
only	O
with	O
certain	O
specific	O
bacterial	O
groups	O
,	O
and	O
that	O
these	O
coral	O
-	O
associated	O
bacterial	O
communities	O
are	O
'	O
host	O
'	O
species	O
-	O
specific	O
[	O
2	O
]	O
.	O

The	O
data	O
presented	O
here	O
highlight	O
a	O
cluster	O
of	O
bacterial	O
ribotypes	O
frequently	O
associated	O
with	O
corals	O
,	O
and	O
the	O
distribution	O
of	O
these	O
bacterial	O
ribotypes	O
on	O
healthy	O
and	O
diseased	O
corals	O
,	O
which	O
allows	O
for	O
further	O
targeted	O
research	O
into	O
a	O
tentative	O
link	O
between	O
these	O
common	O
coral	O
associates	O
and	O
coral	O
health	O
.	O

This	O
study	O
indicates	O
that	O
coral	O
bacterial	O
community	O
assessments	O
require	O
a	O
number	O
of	O
replicates	O
per	O
coral	O
species	O
and	O
site	O
to	O
accurately	O
describe	O
the	O
diversity	O
present	O
across	O
the	O
population	O
and	O
in	O
order	O
to	O
draw	O
inferences	O
on	O
health	O
-	O
related	O
changes	O
in	O
the	O
community	O
composition	O
.	O

In	O
addition	O
,	O
the	O
comparisons	O
of	O
healthy	O
and	O
diseased	O
Acropora	O
hyacinthus	O
samples	O
showed	O
that	O
bacterial	O
communities	O
can	O
change	O
dramatically	O
in	O
diseased	O
individuals	O
.	O

The	O
DGGE	O
profiles	O
observed	O
for	O
corals	O
displaying	O
signs	O
of	O
White	O
Syndrome	O
comprised	O
a	O
range	O
of	O
bacterial	O
ribotypes	O
not	O
generally	O
found	O
on	O
healthy	O
corals	O
,	O
including	O
close	O
relatives	O
of	O
bacteria	O
previously	O
found	O
on	O
Black	O
Band	O
Diseased	O
corals	O
.	O

However	O
the	O
community	O
profiles	O
across	O
the	O
samples	O
taken	O
from	O
diseased	O
coral	O
colonies	O
were	O
inconsistent	O
and	O
not	O
indicative	O
of	O
a	O
single	O
bacterial	O
causative	O
agent	O
.	O

2	O
.	O

Methods	O

We	O
conducted	O
a	O
systematic	O
study	O
of	O
patients	O
hospitalized	O
from	O
August	O
2006	O
until	O
September	O
2007	O
at	O
the	O
Yerevan	O
City	O
and	O
the	O
Republican	O
Dispensaries	O
,	O
the	O
two	O
reference	O
TB	O
hospitals	O
in	O
Armenia	O
.	O

Following	O
focus	O
group	O
discussions	O
and	O
pilot	O
testing	O
to	O
refine	O
the	O
survey	O
instrument	O
,	O
patient	O
interviews	O
began	O
in	O
the	O
fall	O
of	O
2006	O
and	O
were	O
conducted	O
by	O
trained	O
students	O
in	O
the	O
public	O
health	O
program	O
of	O
the	O
American	O
University	O
of	O
Armenia	O
.	O

Students	O
received	O
training	O
by	O
the	O
study	O
designer	O
(	O
SO	O
)	O
on	O
principles	O
of	O
interview	O
ethics	O
and	O
interviewing	O
processes	O
.	O

Most	O
patient	O
interviews	O
were	O
conducted	O
at	O
the	O
Republican	O
Dispensary	O
in	O
Abovian	O
Marz	O
,	O
the	O
national	O
TB	O
diagnostic	O
and	O
treatment	O
facility	O
to	O
which	O
all	O
suspected	O
cases	O
throughout	O
the	O
country	O
are	O
referred	O
for	O
diagnostic	O
confirmation	O
.	O

In	O
the	O
past	O
several	O
years	O
,	O
strong	O
financial	O
support	O
has	O
been	O
provided	O
to	O
Armenia	O
by	O
a	O
number	O
of	O
international	O
organizations	O
,	O
such	O
as	O
the	O
German	O
Gesellschaft	O
fur	O
Technische	O
Zusammenarbeit	O
(	O
GTZ	O
)	O
,	O
the	O
Global	O
Fund	O
to	O
Fight	O
AIDS	O
,	O
Tuberculosis	O
and	O
Malaria	O
,	O
and	O
the	O
Red	O
Cross	O
,	O
which	O
has	O
enabled	O
both	O
microscopic	O
and	O
culture	O
examinations	O
for	O
each	O
TB	O
case	O
to	O
be	O
performed	O
at	O
the	O
National	O
Reference	O
Laboratory	O
located	O
at	O
the	O
Republican	O
TB	O
Dispensary	O
.	O

All	O
culture	O
-	O
confirmed	O
TB	O
cases	O
are	O
admitted	O
as	O
in	O
-	O
patients	O
while	O
undergoing	O
the	O
initial	O
phase	O
of	O
therapy	O
.	O

Because	O
all	O
confirmed	O
TB	O
patients	O
in	O
Armenia	O
are	O
referred	O
to	O
one	O
of	O
these	O
dispensaries	O
for	O
treatment	O
,	O
this	O
population	O
represents	O
all	O
known	O
TB	O
cases	O
in	O
the	O
country	O
.	O

Therefore	O
,	O
all	O
culture	O
-	O
confirmed	O
TB	O
in	O
-	O
patients	O
present	O
at	O
the	O
time	O
of	O
the	O
interviewer	O
visits	O
were	O
eligible	O
for	O
inclusion	O
in	O
the	O
study	O
(	O
the	O
study	O
group	O
included	O
both	O
new	O
and	O
relapsed	O
patients	O
)	O
.	O

Our	O
systematic	O
sample	O
of	O
the	O
inpatient	O
TB	O
population	O
-	O
-	O
in	O
which	O
interviewers	O
visited	O
every	O
hospital	O
room	O
to	O
identify	O
patients	O
willing	O
to	O
participate	O
-	O
-	O
yielded	O
a	O
participation	O
rate	O
of	O
approximately	O
80	O
%	O
(	O
a	O
total	O
of	O
240	O
patients	O
)	O
.	O

Interviewers	O
collected	O
demographic	O
information	O
and	O
asked	O
each	O
patient	O
to	O
recall	O
when	O
they	O
first	O
began	O
to	O
feel	O
ill	O
,	O
what	O
symptoms	O
they	O
experienced	O
,	O
how	O
long	O
after	O
symptom	O
onset	O
they	O
waited	O
to	O
see	O
a	O
doctor	O
,	O
their	O
reasons	O
for	O
delaying	O
medical	O
evaluation	O
,	O
the	O
type	O
of	O
facility	O
at	O
which	O
they	O
first	O
sought	O
care	O
,	O
the	O
initial	O
diagnosis	O
,	O
if	O
they	O
had	O
been	O
referred	O
for	O
further	O
evaluation	O
,	O
and	O
their	O
adherence	O
to	O
treatment	O
once	O
diagnosed	O
with	O
TB	O
.	O

In	O
2006	O
,	O
129	O
of	O
the	O
planned	O
250	O
surveys	O
were	O
completed	O
.	O

Data	O
collection	O
resumed	O
in	O
the	O
fall	O
of	O
2007	O
and	O
a	O
total	O
of	O
240	O
interviews	O
were	O
conducted	O
.	O

Summary	O

Kindt	O
et	O
al	O
.	O
1	O
published	O
a	O
report	O
entitled	O
""""	O
Intestinal	O
immune	O
activation	O
in	O
presumed	O
post	O
-	O
infectious	O
functional	O
syspepsia	O
""""	O
in	O
the	O
August	O
issue	O
of	O
Neurogastroenterology	O
and	O
Motility	O
in	O
2009	O
.	O

By	O
comparing	O
the	O
signs	O
of	O
inflammation	O
and	O
the	O
degree	O
of	O
hyperplasia	O
of	O
the	O
enterochromaffin	O
cells	O
(	O
EC	O
)	O
in	O
duodenal	O
biopsies	O
obtained	O
from	O
patients	O
with	O
presumed	O
post	O
-	O
infectious	O
functional	O
dyspepsia	O
(	O
PI	O
-	O
FD	O
)	O
and	O
unspecified	O
-	O
onset	O
functional	O
dyspepsia	O
(	O
U	O
-	O
FD	O
)	O
,	O
they	O
showed	O
that	O
PI	O
-	O
FD	O
is	O
associated	O
with	O
persistence	O
of	O
focal	O
T	O
-	O
cell	O
aggregates	O
,	O
decrease	O
in	O
CD4	O
+	O
cells	O
and	O
increased	O
macrophage	O
counts	O
surrounding	O
the	O
crypts	O
,	O
without	O
any	O
significant	O
differences	O
in	O
the	O
numbers	O
of	O
EC	O
or	O
chromogranin	O
A	O
(	O
CA	O
)	O
-	O
positive	O
cells	O
(	O
mast	O
cells	O
)	O
.	O

This	O
finding	O
may	O
indicate	O
impaired	O
ability	O
of	O
the	O
immune	O
system	O
in	O
these	O
cases	O
to	O
terminate	O
the	O
inflammatory	O
response	O
after	O
an	O
acute	O
insult	O
.	O

Temporary	O
migration	O
module	O

A	O
temporary	O
migration	O
census	O
module	O
was	O
conducted	O
in	O
2002	O
and	O
2007	O
.	O

People	O
who	O
were	O
identified	O
as	O
temporary	O
migrants	O
were	O
entered	O
into	O
the	O
module	O
,	O
and	O
a	O
household	O
respondent	O
answered	O
questions	O
about	O
the	O
migration	O
.	O

Key	O
areas	O
included	O
the	O
duration	O
of	O
migration	O
,	O
destination	O
,	O
reasons	O
for	O
migration	O
,	O
return	O
pattern	O
,	O
communication	O
pattern	O
,	O
remittances	O
,	O
linked	O
moves	O
and	O
child	O
care	O
arrangements	O
.	O

Introduction	O

Tea	O
(	O
Camellia	O
sinensis	O
L	O
.	O
)	O
is	O
one	O
of	O
the	O
most	O
widely	O
consumed	O
beverages	O
in	O
the	O
world	O
.	O

(	O
-	O
)	O
-	O
Epigallocatechin	O
-	O
3	O
-	O
O	O
-	O
gallate	O
(	O
EGCG	O
)	O
,	O
which	O
is	O
the	O
major	O
green	O
tea	O
catechin	O
present	O
in	O
the	O
leaves	O
,	O
is	O
believed	O
to	O
the	O
compound	O
most	O
responsible	O
for	O
the	O
health	O
benefits	O
attributed	O
to	O
tea	O
.	O

EGCG	O
was	O
reported	O
to	O
have	O
antioxidative	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
,	O
antimutagenic	O
[	O
3	O
]	O
,	O
anti	O
-	O
inflammatory	O
[	O
4	O
]	O
,	O
and	O
anticarcinogenic	O
activities	O
[	O
5	O
]	O
.	O

Although	O
the	O
EGCG	O
concentrations	O
required	O
to	O
elicit	O
the	O
anticancer	O
activity	O
have	O
been	O
shown	O
to	O
be	O
more	O
than	O
1	O
microM	O
,	O
the	O
blood	O
level	O
of	O
EGCG	O
after	O
consuming	O
the	O
equivalent	O
of	O
2	O
-	O
3	O
cups	O
of	O
green	O
tea	O
was	O
0	O
.	O
1	O
-	O
0	O
.	O
6	O
microM	O
and	O
for	O
an	O
equivalent	O
of	O
7	O
-	O
9	O
cups	O
was	O
still	O
lower	O
than	O
1	O
microM	O
[	O
6	O
]	O
,	O
[	O
7	O
]	O
.	O

In	O
a	O
cohort	O
study	O
,	O
daily	O
consumption	O
of	O
ten	O
cups	O
of	O
green	O
tea	O
was	O
required	O
for	O
the	O
cancer	O
preventive	O
effect	O
[	O
8	O
]	O
.	O

Moreover	O
,	O
adverse	O
effects	O
of	O
green	O
tea	O
,	O
mainly	O
hepatitis	O
,	O
by	O
consumption	O
of	O
high	O
doses	O
of	O
green	O
tea	O
have	O
been	O
reported	O
[	O
9	O
]	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
enhance	O
the	O
pharmacologic	O
effect	O
of	O
EGCG	O
to	O
obtain	O
the	O
health	O
benefit	O
in	O
reasonable	O
concentration	O
in	O
daily	O
life	O
.	O

We	O
have	O
reported	O
that	O
the	O
cell	O
-	O
surface	O
binding	O
of	O
EGCG	O
and	O
its	O
derivatives	O
is	O
involved	O
in	O
their	O
biological	O
activities	O
[	O
10	O
]	O
-	O
[	O
15	O
]	O
.	O

We	O
have	O
identified	O
the	O
67	O
-	O
kDa	O
laminin	O
receptor	O
(	O
67LR	O
)	O
as	O
a	O
cell	O
surface	O
receptor	O
for	O
EGCG	O
that	O
mediates	O
the	O
anticancer	O
activity	O
of	O
EGCG	O
[	O
16	O
]	O
.	O

67LR	O
has	O
been	O
shown	O
to	O
be	O
overexpressed	O
on	O
the	O
cell	O
surface	O
of	O
various	O
tumor	O
cells	O
[	O
17	O
]	O
.	O

It	O
was	O
postulated	O
that	O
67LR	O
plays	O
a	O
significant	O
role	O
in	O
the	O
tumor	O
progression	O
and	O
speculated	O
that	O
studies	O
conducted	O
to	O
define	O
the	O
function	O
of	O
67LR	O
could	O
provide	O
a	O
new	O
approach	O
to	O
cancer	O
prevention	O
.	O

Indeed	O
,	O
expression	O
of	O
67	O
LR	O
confers	O
EGCG	O
responsiveness	O
to	O
tumor	O
cells	O
in	O
vivo	O
[	O
18	O
]	O
.	O

Vitamin	O
A	O
,	O
also	O
known	O
as	O
retinol	O
,	O
participates	O
in	O
physiological	O
activities	O
related	O
to	O
the	O
immune	O
system	O
,	O
maintenance	O
of	O
epithelial	O
and	O
mucosa	O
tissues	O
,	O
growth	O
,	O
reproduction	O
,	O
and	O
bone	O
development	O
.	O

It	O
comes	O
from	O
animal	O
sources	O
,	O
such	O
as	O
eggs	O
,	O
meat	O
,	O
milk	O
,	O
cheese	O
,	O
cream	O
,	O
liver	O
,	O
kidney	O
,	O
cod	O
and	O
halibut	O
fish	O
oil	O
.	O

In	O
vitro	O
and	O
in	O
animal	O
models	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
vitamin	O
A	O
is	O
involved	O
in	O
the	O
regulation	O
and	O
promotion	O
of	O
growth	O
and	O
differentiation	O
of	O
many	O
cells	O
[	O
19	O
]	O
.	O

The	O
visual	O
function	O
of	O
vitamin	O
A	O
depends	O
on	O
its	O
natural	O
and	O
synthetic	O
derivatives	O
,	O
retinoids	O
[	O
20	O
]	O
.	O

All	O
-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
,	O
the	O
active	O
derivative	O
of	O
vitamin	O
A	O
,	O
has	O
been	O
well	O
documented	O
as	O
a	O
growth	O
and	O
differentiation	O
factor	O
in	O
many	O
tissues	O
and	O
cells	O
,	O
and	O
proved	O
to	O
be	O
an	O
effective	O
treatment	O
to	O
many	O
diseases	O
including	O
cancers	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

Retinoids	O
exert	O
their	O
physiological	O
activities	O
through	O
retinoid	O
receptor	O
nuclear	O
proteins	O
that	O
belong	O
to	O
the	O
superfamily	O
of	O
steroid	O
/	O
thyroid	O
hormone	O
receptors	O
,	O
of	O
which	O
there	O
are	O
two	O
classes	O
,	O
retinoic	O
acid	O
receptors	O
(	O
RARs	O
)	O
and	O
the	O
retinoic	O
-	O
X	O
receptors	O
(	O
RXRs	O
)	O
,	O
each	O
of	O
which	O
has	O
three	O
subtypes	O
,	O
alpha	O
,	O
beta	O
,	O
and	O
gamma	O
[	O
23	O
]	O
,	O
[	O
24	O
]	O
.	O

The	O
natural	O
ligands	O
for	O
the	O
RARs	O
are	O
ATRA	O
and	O
its	O
stereoisomers	O
9	O
-	O
cis	O
-	O
RA	O
and	O
13	O
-	O
cis	O
-	O
RA	O
,	O
whereas	O
RXRs	O
are	O
activated	O
by	O
9	O
-	O
cis	O
-	O
RA	O
only	O
.	O

ATRA	O
acts	O
through	O
RAR	O
to	O
transcriptionally	O
activate	O
target	O
genes	O
,	O
such	O
as	O
cytochrome	O
P450	O
and	O
CRABI	O
[	O
24	O
]	O
.	O

This	O
study	O
was	O
designed	O
to	O
identify	O
a	O
food	O
component	O
that	O
could	O
be	O
effectively	O
used	O
in	O
combination	O
with	O
EGCG	O
and	O
to	O
investigate	O
the	O
mechanism	O
of	O
action	O
of	O
this	O
combination	O
.	O

By	O
using	O
in	O
vitro	O
and	O
in	O
vivo	O
systems	O
involving	O
a	O
highly	O
metastatic	O
mouse	O
B16	B
melanoma	O
cell	O
line	O
[	O
25	O
]	O
,	O
we	O
found	O
that	O
ATRA	O
enhances	O
the	O
antitumor	O
activity	O
of	O
EGCG	O
by	O
upregulating	O
the	O
67	O
LR	O
expression	O
through	O
RAR	O
.	O

Comparison	O
of	O
the	O
molecular	O
organisation	O
of	O
the	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
(	O
A	O
)	O
,	O
C	O
.	O
capitata	O
(	O
B	O
)	O
and	O
D	O
.	O
melanogaster	O
(	O
C	O
)	O
and	O
their	O
proteins	O
.	O

Exons	O
(	O
boxes	O
)	O
and	O
introns	O
(	O
dashed	O
lines	O
)	O
are	O
not	O
drawn	O
to	O
scale	O
.	O

The	O
numbers	O
inside	O
the	O
boxes	O
indicate	O
the	O
number	O
of	O
the	O
exon	O
.	O

The	O
beginning	O
and	O
the	O
end	O
of	O
the	O
ORF	O
are	O
indicated	O
by	O
ATG	O
and	O
TAA	O
respectively	O
.	O

AAA	O
stands	O
for	O
poly	O
-	O
A	O
(	O
+	O
)	O
.	O

(	O
D	O
)	O
Expression	O
of	O
gene	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
.	O

RT	O
-	O
PCR	O
analyses	O
of	O
total	O
RNA	O
from	O
ovaries	O
(	O
O	O
)	O
,	O
embryos	O
(	O
E	O
)	O
,	O
from	O
male	O
and	O
female	O
larvae	O
(	O
L	O
)	O
,	O
male	O
soma	O
(	O
head	O
plus	O
thorax	O
,	O
MS	O
)	O
and	O
female	O
soma	O
(	O
head	O
plus	O
thorax	O
,	O
FS	O
)	O
.	O

(	O
E	O
)	O
Expression	O
of	O
gene	O
tra	O
-	O
2	O
of	O
A	O
.	O
obliqua	O
.	O

RT	O
-	O
PCR	O
analysis	O
of	O
total	O
RNA	O
from	O
A	O
.	O
obliqua	O
testis	O
.	O

Lane	O
1	O
corresponds	O
to	O
PCR	O
with	O
primers	O
PM1	O
and	O
P2	O
;	O
lane	O
2	O
corresponds	O
to	O
PCR	O
with	O
primers	O
P1	O
and	O
P2	O
(	O
see	O
location	O
of	O
primers	O
in	O
Figure	O
1A	O
)	O
.	O

(	O
F	O
)	O
Southern	O
-	O
blot	O
corresponding	O
to	O
the	O
gel	O
shown	O
in	O
(	O
E	O
)	O
and	O
hybridisation	O
with	O
a	O
probe	O
specific	O
for	O
intron	O
3	O
of	O
A	O
.	O
obliqua	O
.	O

The	O
arrow	O
marks	O
the	O
hybridisation	O
to	O
the	O
higher	O
band	O
in	O
lane	O
1	O
of	O
Figure	O
1E	O
.	O

The	O
size	O
of	O
the	O
mRNAs	O
encoding	O
the	O
proteins	O
shown	O
in	O
this	O
figure	O
are	O
:	O
1923	O
bp	O
for	O
A	O
.	O
obliqua	O
mRNA	O
,	O
1113	O
bp	O
for	O
C	O
.	O
capitata	O
mRNA	O
,	O
and	O
960	O
,	O
1583	O
and	O
1391	O
bp	O
for	O
D	O
.	O
melanogaster	O
mRNAs	O
tra2	O
-	O
179	O
,	O
tra2	O
-	O
226	O
and	O
tra2	O
-	O
264	O
,	O
respectively	O
.	O

The	O
eukaryotic	O
parasite	O
Trypanosoma	O
brucei	O
is	O
able	O
to	O
import	O
inositol	O
from	O
the	O
environment	O
or	O
synthesize	O
it	O
de	O
novo	O
.	O

However	O
,	O
according	O
to	O
the	O
current	O
model	O
,	O
inositol	O
imported	O
from	O
the	O
environment	O
is	O
utilized	O
primarily	O
in	O
bulk	O
phosphatidylinositol	O
(	O
red	O
and	O
yellow	O
phospholipid	O
)	O
production	O
via	O
a	O
phosphatidylinositol	O
synthase	O
(	O
PIS	O
)	O
localized	O
to	O
the	O
Golgi	O
complex	O
.	O

Inositol	O
synthesized	O
de	O
novo	O
is	O
primarily	O
used	O
to	O
generate	O
phosphatidylinositol	O
that	O
is	O
used	O
for	O
production	O
of	O
glycosylphosphatidylinositols	O
(	O
GPIs	O
)	O
.	O

The	O
de	O
novo	O
-	O
synthesized	O
inositol	O
is	O
believed	O
to	O
be	O
utilized	O
mostly	O
for	O
GPI	O
production	O
because	O
the	O
IMPase	O
that	O
dephosphorylates	O
inositol	O
3	O
-	O
phosphate	O
to	O
inositol	O
is	O
localized	O
to	O
the	O
ER	O
,	O
where	O
GPI	O
synthesis	O
occurs	O
.	O

Mutants	O
lacking	O
TbINO1	O
are	O
inviable	O
because	O
of	O
diminished	O
GPI	O
production	O
.	O

2	O
.	O

CLINICAL	O
PROTEOMICS	O
AT	O
THE	O
BEDSIDE	O

Clinically	O
-	O
based	O
proteomics	O
has	O
a	O
large	O
potential	O
for	O
the	O
development	O
of	O
strategies	O
which	O
aim	O
to	O
alleviate	O
risk	O
associated	O
with	O
cardiac	O
disease	O
.	O

Biomarkers	O
that	O
are	O
used	O
in	O
clinical	O
practice	O
are	O
highly	O
useful	O
in	O
that	O
they	O
support	O
medical	O
decision	O
making	O
,	O
by	O
complementing	O
other	O
diagnostic	O
tests	O
,	O
such	O
as	O
the	O
medical	O
history	O
,	O
physical	O
examination	O
,	O
and	O
various	O
other	O
special	O
tests	O
.	O

Theoretically	O
,	O
there	O
are	O
three	O
criteria	O
that	O
,	O
if	O
satisfied	O
,	O
would	O
provide	O
an	O
optimal	O
biomarker	O
of	O
the	O
disease	O
state	O
.	O

First	O
,	O
the	O
potential	O
biomarkers	O
must	O
be	O
easily	O
measurable	O
in	O
a	O
short	O
time	O
period	O
at	O
a	O
cost	O
that	O
is	O
practical	O
.	O

Second	O
,	O
elevation	O
of	O
this	O
protein	O
would	O
offer	O
diagnostic	O
information	O
that	O
was	O
not	O
previously	O
present	O
in	O
the	O
absence	O
of	O
the	O
protein	O
.	O

Third	O
,	O
the	O
information	O
obtained	O
would	O
aid	O
in	O
the	O
medical	O
decision	O
making	O
process	O
performed	O
by	O
the	O
clinician	O
[	O
11	O
]	O
.	O

Fulfillment	O
of	O
such	O
criteria	O
encourages	O
follow	O
-	O
up	O
of	O
such	O
a	O
biomarker	O
in	O
other	O
model	O
systems	O
or	O
patient	O
cohort	O
samples	O
.	O

For	O
instance	O
,	O
cardiac	O
troponin	O
I	O
has	O
been	O
previously	O
shown	O
to	O
fulfill	O
such	O
criteria	O
,	O
and	O
further	O
follow	O
-	O
up	O
in	O
patient	O
cohorts	O
is	O
underway	O
.	O

Recently	O
,	O
this	O
approach	O
was	O
utilized	O
to	O
ascertain	O
whether	O
Cardiac	O
Troponin	O
I	O
(	O
CTN	O
I	O
)	O
or	O
Creatine	O
Kinase	O
-	O
Myoglobin	O
(	O
CK	O
-	O
MB	O
)	O
could	O
be	O
used	O
as	O
short	O
-	O
term	O
or	O
long	O
-	O
term	O
markers	O
of	O
risk	O
associated	O
with	O
cardiac	O
surgery	O
[	O
12	O
]	O
.	O

In	O
this	O
study	O
,	O
a	O
patient	O
cohort	O
of	O
252	O
individuals	O
who	O
had	O
undergone	O
cardiac	O
surgery	O
was	O
used	O
to	O
analyze	O
levels	O
of	O
these	O
two	O
proteins	O
in	O
blood	O
.	O

Not	O
only	O
was	O
CTN	O
-	O
I	O
shown	O
to	O
be	O
a	O
strong	O
predictor	O
of	O
mortality	O
,	O
but	O
increases	O
in	O
the	O
levels	O
of	O
this	O
protein	O
also	O
correlated	O
well	O
with	O
increases	O
in	O
mortality	O
.	O

Findings	O
from	O
this	O
study	O
support	O
the	O
utilization	O
of	O
patient	O
cohorts	O
as	O
a	O
means	O
to	O
ease	O
the	O
transition	O
from	O
bench	O
to	O
bedside	O
.	O

Titration	O
of	O
Ab	O
-	O
01	O
inhibition	O
of	O
ex	O
vivo	O
response	O
to	O
rhIL21	O

Samples	O
from	O
4	O
individual	O
healthy	O
human	O
donors	O
were	O
pre	O
-	O
incubated	O
for	O
2	O
hours	O
at	O
the	O
indicated	O
concentration	O
of	O
Ab	O
-	O
01	O
or	O
the	O
control	O
IgG1TM	O
prior	O
to	O
addition	O
of	O
10	O
ng	O
/	O
mL	O
rhIL21	O
and	O
2	O
hr	O
incubation	O
,	O
and	O
the	O
effect	O
on	O
the	O
6	O
biomarkers	O
was	O
then	O
assessed	O
(	O
Figures	O
4	O
and	O
5	O
)	O
.	O

For	O
the	O
first	O
2	O
donors	O
tested	O
,	O
even	O
the	O
lowest	O
concentration	O
of	O
Ab	O
-	O
01	O
(	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
66	O
nM	O
)	O
resulted	O
in	O
complete	O
inhibition	O
of	O
the	O
rhIL21	O
response	O
,	O
therefore	O
the	O
two	O
subsequent	O
donors	O
were	O
tested	O
at	O
increasing	O
concentrations	O
of	O
Ab	O
-	O
01	O
starting	O
at	O
0	O
.	O
003	O
mug	O
/	O
mL	O
.	O

Ab	O
-	O
01	O
inhibited	O
the	O
response	O
of	O
all	O
6	O
genes	O
in	O
all	O
4	O
donors	O
.	O

IC50	O
values	O
ranged	O
between	O
0	O
.	O
003	O
and	O
0	O
.	O
015	O
mug	O
/	O
mL	O
Ab	O
-	O
01	O
(	O
Figure	O
5	O
)	O
.	O

Control	O
IgG1TM	O
had	O
no	O
significant	O
effect	O
on	O
rhIL21	O
response	O
(	O
Figure4B	O
)	O
.	O

Figure	O
4	O

Average	O
percent	O
inhibition	O
of	O
the	O
expression	O
level	O
of	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O

Percent	O
inhibition	O
values	O
were	O
calculated	O
based	O
on	O
RQ	O
(	O
relative	O
quantification	O
)	O
values	O
of	O
untreated	O
control	O
and	O
rhIL21	O
-	O
treated	O
samples	O
for	O
each	O
of	O
the	O
4	O
donors	O
,	O
and	O
subsequently	O
the	O
mean	O
and	O
standard	O
deviation	O
were	O
determined	O
for	O
each	O
gene	O
shown	O
.	O

A	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
Ab	O
-	O
01	O
.	O

B	O
:	O
Percent	O
inhibition	O
in	O
presence	O
of	O
control	O
IgG1TM	O
.	O

Data	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O

Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
.	O

Figure	O
5	O

Inhibition	O
by	O
Ab	O
-	O
01	O
at	O
the	O
indicated	O
concentration	O
is	O
shown	O
for	O
6	O
IL21	O
-	O
responsive	O
genes	O
.	O

IC50	O
values	O
of	O
inhibition	O
curves	O
shown	O
in	O
Figure	O
4A	O
were	O
calculated	O
using	O
curve	O
fit	O
(	O
XLfit	O
)	O
program	O
for	O
each	O
of	O
the	O
referred	O
biomarker	O
genes	O
.	O

Values	O
for	O
the	O
0	O
.	O
1	O
mug	O
/	O
mL	O
,	O
0	O
.	O
3	O
mug	O
/	O
mL	O
and	O
1	O
mug	O
/	O
mL	O
concentrations	O
were	O
generated	O
using	O
4	O
donors	O
.	O

Data	O
for	O
the	O
higher	O
and	O
the	O
lower	O
concentrations	O
were	O
generated	O
using	O
2	O
donors	O
each	O
.	O

Large	O
nodular	O
hepatic	O
flexure	O
lesions	O
as	O
seen	O
on	O
Colonoscopy	O
.	O

MOR1	O
K	O
expression	O
and	O
binding	O
pattern	O
.	O

(	O
A	O
)	O
The	O
schematic	O
diagram	O
illustrates	O
the	O
exonic	O
composition	O
and	O
relative	O
positions	O
of	O
PCR	O
primers	O
designed	O
to	O
amplify	O
the	O
major	O
MOR1	O
isoform	O
and	O
the	O
newly	O
identified	O
alternative	O
MOR1	O
K	O
isoform	O
.	O

The	O
relative	O
positions	O
of	O
translation	O
initiation	O
start	O
and	O
stop	O
codons	O
are	O
designated	O
by	O
ATG	O
and	O
TGA	O
,	O
respectively	O
.	O

The	O
predicted	O
protein	O
structure	O
of	O
MOR1	O
and	O
MOR1	O
K	O
isoforms	O
is	O
schematically	O
presented	O
.	O

Translation	O
of	O
the	O
MOR1	O
K	O
variant	O
results	O
in	O
a	O
6TM	O
receptor	O
,	O
truncated	O
at	O
the	O
N	O
-	O
terminus	O
.	O

(	O
B	O
)	O
Real	O
-	O
time	O
PCR	O
was	O
performed	O
on	O
total	O
RNA	O
samples	O
from	O
the	O
human	O
brain	O
regions	O
known	O
to	O
express	O
MOR1	O
.	O

Primers	O
specific	O
for	O
exons	O
1	O
and	O
2	O
were	O
used	O
to	O
measure	O
MOR1	O
and	O
primers	O
specific	O
for	O
exons	O
13	O
and	O
exon	O
2	O
were	O
used	O
to	O
measure	O
MOR1	O
K	O
[	O
32	O
]	O
.	O

GAP3DH	O
was	O
used	O
as	O
a	O
control	O
for	O
cDNA	O
loading	O
and	O
PCR	O
efficiency	O
.	O

(	O
C	O
)	O
Confocal	O
images	O
of	O
C	O
-	O
terminally	O
MYC	O
-	O
tagged	O
MOR1	O
or	O
FLAG	O
-	O
tagged	O
MOR1	O
K	O
overexpressed	O
in	O
HEK293	B
cells	O
and	O
stained	O
with	O
either	O
Anti	O
-	O
MYC	O
-	O
Tag	O
Antibody	O
(	O
Alexa	O
Fluor	O
647	O
Conjugate	O
)	O
or	O
Anti	O
-	O
DYKDDDDK	O
Tag	O
Antibody	O
(	O
Alexa	O
Fluor	O
555	O
conjugate	O
)	O
.	O

Cells	O
transfected	O
with	O
MOR1	O
showed	O
membrane	O
expression	O
of	O
receptor	O
,	O
while	O
cell	O
transfected	O
with	O
MOR1	O
K	O
express	O
receptor	O
only	O
intracellular	O
.	O

(	O
D	O
)	O
Confocal	O
images	O
of	O
C	O
-	O
terminally	O
FLAG	O
-	O
tagged	O
MOR1	O
K	O
overexpressed	O
in	O
Be2C	B
cells	O
and	O
stained	O
with	O
either	O
Anti	O
-	O
FLAG	O
M2	O
Antibody	O
Alexa	O
Fluor	O
Conjugate	O
or	O
fluorescent	O
-	O
labeled	O
naloxone	O
(	O
FNAL	O
)	O
.	O

Cells	O
transfected	O
with	O
MOR1	O
K	O
showed	O
intracellular	O
retention	O
of	O
FNAL	O
that	O
co	O
-	O
localized	O
with	O
antibody	O
-	O
labeled	O
receptor	O
.	O

(	O
E	O
)	O
The	O
binding	O
of	O
naloxone	O
to	O
MOR1	O
K	O
was	O
assessed	O
using	O
flow	O
cytometry	O
to	O
measure	O
FNAL	O
retention	O
.	O

Be2C	B
cells	O
transfected	O
with	O
either	O
MOR1	O
or	O
MOR1	O
K	O
isoforms	O
showed	O
increased	O
retention	O
of	O
FNAL	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
and	O
1	O
muM	O
.	O

FNAL	O
retention	O
was	O
abolished	O
in	O
the	O
presence	O
of	O
10	O
muM	O
unlabelled	O
naloxone	O
(	O
Nal	O
)	O
.	O

In	O
panel	O
E	O
,	O
data	O
are	O
presented	O
as	O
mean	O
+	O
SEM	O
.	O

*	O
P	O
<	O
0	O
.	O
05	O
different	O
from	O
controls	O
)	O
.	O

Water	O
emerging	O
from	O
the	O
yoke	O
adapter	O
of	O
the	O
nitrous	O
oxide	O
hose	O

Treatment	O
for	O
patients	O
with	O
diabetes	O

It	O
is	O
notable	O
that	O
treatment	O
of	O
diabetes	O
has	O
not	O
been	O
directly	O
monitored	O
by	O
OECD	O
indicators	O
,	O
largely	O
due	O
to	O
complexity	O
in	O
data	O
collection	O
.	O

Treatment	O
is	O
tailored	O
for	O
individuals	O
depending	O
on	O
the	O
patient	O
'	O
s	O
disease	O
status	O
,	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
diabetes	O
management	O
.	O

Clinical	O
trials	O
have	O
found	O
that	O
a	O
one	O
percentage	O
point	O
reduction	O
in	O
HbA1c	O
levels	O
would	O
reduce	O
micro	O
-	O
vascular	O
complications	O
by	O
25	O
%	O
to	O
30	O
%	O
[	O
49	O
,	O
50	O
]	O
and	O
a	O
10	O
mmHg	O
reduction	O
in	O
blood	O
pressure	O
would	O
decrease	O
macro	O
-	O
and	O
micro	O
-	O
vascular	O
complications	O
and	O
death	O
rates	O
by	O
32	O
%	O
[	O
51	O
]	O
.	O

Improved	O
control	O
of	O
blood	O
lipids	O
can	O
reduce	O
risk	O
of	O
coronary	O
heart	O
disease	O
by	O
39	O
%	O
and	O
risk	O
of	O
death	O
by	O
43	O
%	O
[	O
52	O
]	O
.	O

RAND	O
'	O
s	O
Quality	O
Assessment	O
Tools	O
System	O
offers	O
indicators	O
relating	O
to	O
diabetes	O
treatment	O
[	O
53	O
]	O
,	O
and	O
application	O
of	O
these	O
indicators	O
in	O
a	O
national	O
study	O
in	O
the	O
US	O
has	O
provided	O
insight	O
into	O
adherence	O
to	O
recommended	O
treatment	O
regimens	O
.	O

For	O
people	O
with	O
newly	O
diagnosed	O
diabetes	O
56	O
%	O
received	O
dietary	O
and	O
exercise	O
counselling	O
.	O

In	O
type	O
2	O
diabetes	O
patients	O
,	O
use	O
of	O
oral	O
hypoglycaemic	O
agents	O
for	O
those	O
inadequately	O
controlled	O
on	O
dietary	O
therapy	O
was	O
38	O
%	O
and	O
use	O
of	O
insulin	O
for	O
those	O
inadequately	O
controlled	O
on	O
oral	O
hypoglycaemics	O
was	O
39	O
%	O
.	O

Fifty	O
-	O
five	O
percent	O
of	O
diabetics	O
were	O
offered	O
an	O
ACE	O
inhibitor	O
within	O
3	O
months	O
of	O
the	O
notation	O
of	O
proteinuria	O
unless	O
contraindicated	O
.	O

The	O
AusDiab	O
study	O
reported	O
the	O
treatment	O
pattern	O
among	O
Australian	O
adults	O
with	O
type	O
2	O
diabetes	O
[	O
37	O
]	O
.	O

While	O
32	O
%	O
of	O
diabetes	O
patients	O
were	O
on	O
diet	O
regimen	O
only	O
,	O
58	O
%	O
used	O
oral	O
hypoglycaemic	O
agents	O
and	O
diet	O
only	O
,	O
and	O
another	O
10	O
%	O
took	O
insulin	O
.	O

Bailie	O
and	O
colleagues	O
reported	O
pharmaceutical	O
interventions	O
for	O
diabetes	O
patients	O
in	O
remote	O
Aboriginal	O
communities	O
in	O
the	O
Northern	O
Territory	O
[	O
54	O
]	O
.	O

During	O
the	O
3	O
-	O
years	O
study	O
period	O
,	O
75	O
-	O
79	O
%	O
of	O
Aboriginal	O
patients	O
took	O
oral	O
hypoglycaemic	O
agents	O
,	O
and	O
4	O
-	O
7	O
%	O
used	O
insulin	O
.	O

The	O
pedigree	O
of	O
a	O
Korean	O
family	O
with	O
macular	O
dystrophy	O
demonstrating	O
the	O
characteristics	O
of	O
an	O
autosomal	O
dominant	O
inheritance	O
trait	O
.	O

Histological	O
analysis	O

A	O
cross	O
-	O
section	O
of	O
the	O
distal	O
colon	O
(	O
2	O
cm	O
)	O
was	O
fixed	O
in	O
10	O
%	O
paraformaldehyde	O
solution	O
.	O

Afterwards	O
,	O
it	O
was	O
cut	O
into	O
small	O
fragments	O
,	O
dehydrated	O
through	O
an	O
ethanol	O
series	O
(	O
70	O
%	O
-	O
100	O
%	O
)	O
,	O
cleared	O
in	O
xylol	O
and	O
embedded	O
in	O
paraffin	O
.	O

The	O
fragments	O
were	O
sliced	O
into	O
5	O
mum	O
thick	O
sections	O
and	O
stained	O
with	O
hematoxylin	O
-	O
eosin	O
.	O

Histological	O
evaluation	O
was	O
done	O
by	O
a	O
pathologist	O
who	O
was	O
blinded	O
to	O
the	O
experimental	O
groups	O
,	O
and	O
it	O
was	O
based	O
on	O
the	O
intensity	O
of	O
mononuclear	O
and	O
polymorphonuclear	O
infiltrates	O
in	O
the	O
lamina	O
propria	O
,	O
crypt	O
dilation	O
,	O
cellular	O
destruction	O
and	O
mucosal	O
ulceration	O
.	O

Histopathological	O
changes	O
were	O
graded	O
according	O
to	O
the	O
degree	O
of	O
inflammation	O
using	O
the	O
following	O
scale	O
:	O
absent	O
(	O
0	O
)	O
,	O
light	O
(	O
1	O
)	O
,	O
moderate	O
(	O
2	O
)	O
and	O
intense	O
(	O
3	O
)	O
,	O
and	O
the	O
numbers	O
represented	O
the	O
inflammation	O
score	O
(	O
IS	O
)	O
.	O

Results	O
were	O
expressed	O
as	O
mean	O
values	O
of	O
IS	O
+	O
/	O
-	O
standard	O
error	O
of	O
the	O
mean	O
(	O
SEM	O
)	O
for	O
each	O
experimental	O
group	O
.	O

Authors	O
'	O
contributions	O

MBH	O
made	O
the	O
pathological	O
diagnosis	O
and	O
was	O
responsible	O
for	O
conception	O
and	O
final	O
approval	O
of	O
the	O
manuscript	O
.	O

MB	O
carried	O
out	O
the	O
literature	O
search	O
and	O
drafted	O
the	O
manuscript	O
.	O

IC	O
carried	O
out	O
the	O
surgical	O
procedure	O
and	O
reviewed	O
the	O
manuscript	O
.	O

RM	O
carried	O
out	O
the	O
surgical	O
procedure	O
,	O
provided	O
clinical	O
details	O
,	O
followed	O
up	O
our	O
patient	O
and	O
obtained	O
her	O
consent	O
to	O
publish	O
this	O
case	O
report	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

The	O
effect	O
of	O
PCL	O
elevation	O

Our	O
hypothesis	O
that	O
the	O
dynamics	O
of	O
the	O
flexion	O
gap	O
depend	O
on	O
the	O
orientation	O
of	O
the	O
PCL	O
was	O
confirmed	O
.	O

Distraction	O
of	O
the	O
knee	O
with	O
a	O
low	O
PCL	O
elevation	O
angle	O
(	O
i	O
.	O
e	O
.	O
a	O
flat	O
PCL	O
)	O
resulted	O
in	O
greater	O
increase	O
in	O
gap	O
height	O
than	O
distraction	O
of	O
a	O
knee	O
with	O
a	O
steep	O
PCL	O
.	O

This	O
result	O
was	O
to	O
be	O
expected	O
;	O
when	O
the	O
gap	O
between	O
the	O
tibia	O
and	O
femur	O
was	O
increased	O
,	O
the	O
increase	O
in	O
PCL	O
tension	O
resulted	O
in	O
the	O
tibia	O
pivoting	O
around	O
the	O
femoral	O
insertion	O
of	O
the	O
PCL	O
.	O

Thus	O
,	O
the	O
greatest	O
increase	O
in	O
gap	O
height	O
will	O
occur	O
when	O
the	O
PCL	O
is	O
flat	O
.	O

Taking	O
this	O
finding	O
into	O
consideration	O
,	O
the	O
surgeon	O
should	O
be	O
aware	O
of	O
the	O
strong	O
effect	O
of	O
PCL	O
elevation	O
on	O
the	O
relationship	O
between	O
gap	O
height	O
increase	O
and	O
tibial	O
translation	O
.	O

A	O
flat	O
PCL	O
will	O
lead	O
to	O
a	O
mean	O
anterior	O
tibial	O
translation	O
of	O
1	O
.	O
7	O
mm	O
when	O
the	O
gap	O
is	O
distracted	O
1	O
mm	O
.	O

A	O
knee	O
with	O
a	O
steep	O
PCL	O
will	O
even	O
translate	O
2	O
.	O
3	O
mm	O
on	O
average	O
with	O
1	O
mm	O
of	O
gap	O
distraction	O
.	O

If	O
the	O
PCL	O
were	O
the	O
only	O
structure	O
that	O
was	O
tensioned	O
with	O
distraction	O
of	O
the	O
flexion	O
gap	O
,	O
then	O
at	O
100	O
N	O
it	O
would	O
be	O
oriented	O
vertically	O
.	O

This	O
is	O
not	O
the	O
case	O
,	O
and	O
therefore	O
other	O
structures	O
such	O
as	O
the	O
collateral	O
ligaments	O
must	O
have	O
restrained	O
the	O
translation	O
.	O

From	O
an	O
anatomical	O
point	O
of	O
view	O
,	O
the	O
collateral	O
structures	O
are	O
the	O
only	O
structures	O
that	O
could	O
have	O
had	O
a	O
restraining	O
function	O
on	O
vertical	O
movements	O
.	O

For	O
obvious	O
reasons	O
,	O
in	O
this	O
in	O
vivo	O
study	O
we	O
could	O
not	O
test	O
what	O
would	O
have	O
happened	O
to	O
the	O
orientation	O
of	O
the	O
PCL	O
when	O
the	O
collateral	O
structures	O
were	O
resected	O
.	O

In	O
addition	O
,	O
the	O
PCL	O
elevation	O
angle	O
at	O
100	O
N	O
influenced	O
the	O
increase	O
in	O
PCL	O
elevation	O
angle	O
between	O
100	O
N	O
and	O
200	O
N	O
(	O
DeltaPCLe	O
)	O
.	O

This	O
seems	O
logical	O
:	O
a	O
flat	O
PCL	O
can	O
be	O
recruited	O
more	O
easily	O
whereas	O
knees	O
with	O
a	O
steep	O
PCL	O
might	O
already	O
be	O
tensioned	O
at	O
100	O
N	O
so	O
that	O
a	O
further	O
increase	O
in	O
PCL	O
elevation	O
angle	O
would	O
be	O
hard	O
to	O
achieve	O
.	O

However	O
,	O
steep	O
PCLs	O
are	O
not	O
necessarily	O
recruited	O
more	O
than	O
flat	O
PCLs	O
.	O

Furthermore	O
,	O
the	O
situation	O
during	O
implantation	O
of	O
a	O
TKR	O
is	O
quite	O
unnatural	O
:	O
we	O
investigated	O
the	O
PCL	O
elevation	O
after	O
the	O
tibia	O
was	O
cut	O
.	O

Breast	O
cancer	O

The	O
incidence	O
of	O
breast	O
cancer	O
is	O
no	O
higher	O
than	O
in	O
the	O
rest	O
of	O
the	O
population	O
.	O

Tamoxifen	O
should	O
not	O
be	O
used	O
as	O
it	O
may	O
worsen	O
symptoms	O
[	O
43	O
]	O
.	O

Women	O
need	O
also	O
specific	O
management	O
for	O
treatment	O
of	O
HAE	O
.	O

Short	O
term	O
prophylaxis	O
:	O
three	O
options	O
are	O
available	O
:	O
attenuated	O
androgens	O
,	O
tranexamic	O
acid	O
or	O
C1Inh	O
concentrate	O
.	O

There	O
is	O
no	O
specific	O
problem	O
for	O
the	O
use	O
of	O
theses	O
drugs	O
for	O
short	O
course	O
in	O
female	O
patients	O
.	O

In	O
case	O
of	O
short	O
term	O
prophylaxis	O
with	O
attenuated	O
androgens	O
,	O
no	O
virilisation	O
has	O
been	O
observed	O
[	O
44	O
,	O
45	O
]	O
.	O

Acute	O
attack	O
treatment	O
:	O
there	O
is	O
no	O
specific	O
problem	O
for	O
the	O
use	O
of	O
C1inh	O
concentrate	O
,	O
tranexamic	O
acid	O
,	O
icatibant	O
;	O
or	O
ecallantide	O
in	O
female	O
patients	O
.	O

Pteris	O
vittata	O

RNA	O
extraction	O
and	O
reverse	O
transcription	O

Total	O
RNA	O
were	O
extracted	O
from	O
cells	O
using	O
either	O
Trizol	O
reagent	O
(	O
Invitrogen	O
)	O
or	O
RNeasy	O
kit	O
(	O
Qiagen	O
)	O
and	O
treated	O
with	O
DNaseI	O
reagent	O
(	O
Macherey	O
-	O
Nagel	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Reverse	O
transcriptions	O
were	O
performed	O
using	O
1microg	O
total	O
RNA	O
and	O
the	O
High	O
capacity	O
cDNA	O
reverse	O
transcription	O
kit	O
with	O
RNase	O
Inhibitor	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Intervention	O

Patients	O
'	O
initial	O
introduction	O
to	O
the	O
Wrist	O
Extension	O
Dynasplint	O
(	O
WED	O
)	O
system	O
,	O
[	O
Dynasplint	O
Systems	O
,	O
Inc	O
.	O
,	O
Severna	O
Park	O
,	O
MD	O
,	O
USA	O
]	O
included	O
customized	O
fitting	O
(	O
wrist	O
length	O
,	O
width	O
,	O
and	O
girth	O
so	O
that	O
the	O
force	O
and	O
counter	O
force	O
straps	O
could	O
be	O
properly	O
aligned	O
)	O
and	O
training	O
on	O
donning	O
and	O
doffing	O
of	O
the	O
device	O
.	O

(	O
See	O
figure	O
1	O
.	O
)	O
Verbal	O
and	O
written	O
instructions	O
were	O
provided	O
throughout	O
the	O
duration	O
of	O
treatment	O
for	O
safety	O
,	O
general	O
wear	O
and	O
care	O
,	O
and	O
tension	O
setting	O
goals	O
based	O
on	O
patient	O
tolerance	O
.	O

Figure	O
1	O

Wrist	O
Extension	O
Dynasplint	O
.	O

Each	O
patient	O
initially	O
wore	O
the	O
WED	O
for	O
4	O
-	O
6	O
continuous	O
hours	O
at	O
an	O
initial	O
tension	O
setting	O
of	O
#	O
2	O
(	O
0	O
.	O
1	O
foot	O
pounds	O
of	O
torque	O
)	O
.	O

This	O
duration	O
was	O
for	O
acclimatization	O
to	O
the	O
system	O
;	O
then	O
patients	O
were	O
instructed	O
to	O
wear	O
the	O
WED	O
system	O
at	O
night	O
while	O
sleeping	O
for	O
6	O
-	O
8	O
hours	O
of	O
continuous	O
wear	O
.	O

After	O
each	O
patient	O
was	O
comfortable	O
wearing	O
the	O
unit	O
for	O
one	O
week	O
at	O
tension	O
level	O
#	O
2	O
,	O
they	O
were	O
instructed	O
to	O
increase	O
the	O
tension	O
level	O
to	O
#	O
3	O
(	O
0	O
.	O
3	O
ft	O
lbs	O
.	O
)	O
and	O
make	O
continual	O
increases	O
every	O
two	O
weeks	O
.	O

If	O
prolonged	O
soreness	O
followed	O
a	O
session	O
(	O
soreness	O
for	O
more	O
than	O
15	O
minutes	O
)	O
the	O
patient	O
was	O
instructed	O
to	O
decrease	O
the	O
tension	O
one	O
half	O
a	O
setting	O
for	O
two	O
days	O
until	O
they	O
were	O
comfortable	O
wearing	O
it	O
for	O
6	O
-	O
8	O
hours	O
at	O
the	O
new	O
tension	O
setting	O
.	O

The	O
majority	O
of	O
all	O
patients	O
reached	O
level	O
#	O
5	O
(	O
0	O
.	O
8	O
foot	O
pounds	O
of	O
torque	O
)	O
by	O
the	O
end	O
of	O
two	O
months	O
.	O

All	O
range	O
of	O
motion	O
measurements	O
were	O
recorded	O
by	O
the	O
prescribing	O
clinician	O
.	O

Differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O

Integrating	O
4849	O
CMap	O
arrays	O
with	O
40	O
,	O
656	O
drug	O
target	O
relations	O
from	O
STITCH	O
resulted	O
in	O
a	O
set	O
of	O
1	O
,	O
290	O
drug	O
-	O
target	O
relations	O
for	O
which	O
a	O
genome	O
-	O
wide	O
cellular	O
response	O
is	O
available	O
.	O

We	O
found	O
that	O
thirteen	O
out	O
of	O
167	O
distinct	O
drug	O
targets	O
in	O
this	O
set	O
(	O
8	O
%	O
;	O
86	O
drug	O
target	O
relations	O
)	O
are	O
subjected	O
to	O
significant	O
differential	O
expression	O
upon	O
drug	O
treatment	O
(	O
Figure	O
3	O
)	O
by	O
comparing	O
the	O
drug	O
-	O
induced	O
expression	O
changes	O
of	O
the	O
drug	O
target	O
against	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
(	O
see	O
methods	O
)	O
.	O

We	O
found	O
supporting	O
evidence	O
in	O
the	O
literature	O
for	O
seven	O
out	O
of	O
thirteen	O
(	O
q	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
significant	O
differential	O
regulations	O
of	O
drug	O
targets	O
shown	O
in	O
Figure	O
3	O
,	O
confirming	O
the	O
rationale	O
and	O
predictive	O
power	O
of	O
our	O
systematic	O
approach	O
.	O

For	O
the	O
remaining	O
six	O
targets	O
we	O
can	O
predict	O
a	O
hitherto	O
unknown	O
drug	O
-	O
induced	O
differential	O
regulation	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pcbi	O
.	O
1000925	O
.	O
g003	O
Figure	O
3	O

Drug	O
-	O
induced	O
differentially	O
regulated	O
drug	O
targets	O
.	O

Anova	O
is	O
used	O
to	O
assess	O
the	O
significance	O
of	O
the	O
differential	O
expression	O
of	O
drug	O
-	O
induced	O
drug	O
targets	O
against	O
the	O
mRNA	O
changes	O
of	O
the	O
same	O
gene	O
in	O
the	O
population	O
of	O
heterogeneous	O
drug	O
treatments	O
from	O
CMap	O
.	O

The	O
genes	O
are	O
mainly	O
ordered	O
based	O
on	O
their	O
q	O
-	O
values	O
as	O
provided	O
in	O
Table	O
S1	O
.	O

In	O
the	O
scatter	O
plots	O
,	O
inhibitors	O
/	O
activators	O
are	O
labeled	O
in	O
red	O
/	O
green	O
respectively	O
and	O
grey	O
represents	O
all	O
other	O
treatments	O
present	O
in	O
CMap	O
.	O

The	O
identified	O
,	O
differentially	O
regulated	O
drug	O
targets	O
are	O
enriched	O
in	O
G	O
-	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
(	O
Figure	O
S4	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
reports	O
that	O
members	O
of	O
the	O
GPCR	O
family	O
are	O
generally	O
regulated	O
by	O
several	O
mechanisms	O
including	O
receptor	O
desensitization	O
,	O
endocytosis	O
at	O
the	O
protein	O
level	O
and	O
regulation	O
of	O
the	O
cellular	O
receptor	O
content	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

In	O
the	O
three	O
cancer	O
cell	O
lines	O
used	O
,	O
we	O
observe	O
agonist	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
GPCR	O
mRNAs	O
for	O
beta	O
-	O
2	O
adrenergic	O
receptor	O
(	O
ADRB2	O
)	O
,	O
prostaglandin	O
E2	O
receptor	O
subtype	O
EP2	O
and	O
prostaglandin	O
E4	O
receptor	O
subtype	O
EP4	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
4	O
,	O
12	O
)	O
,	O
which	O
were	O
previously	O
reported	O
in	O
DDT1	B
MF	I
-	I
2	I
smooth	O
muscle	O
cells	O
(	O
ADRB2	O
)	O
and	O
293	B
-	I
EBNA	I
human	O
embryonic	O
kidney	O
cells	O
(	O
prostaglandin	O
E2	O
/	O
E4	O
receptor	O
subtypes	O
EP2	O
/	O
EP4	O
)	O
[	O
20	O
]	O
,	O
[	O
21	O
]	O
.	O

This	O
indicates	O
that	O
drugs	O
can	O
induce	O
similar	O
feedback	O
loops	O
in	O
a	O
wide	O
variety	O
of	O
cell	O
types	O
.	O

However	O
,	O
we	O
can	O
not	O
rule	O
out	O
that	O
cross	O
-	O
regulation	O
among	O
signaling	O
pathways	O
may	O
be	O
responsible	O
for	O
the	O
regulation	O
of	O
GPCR	O
mRNAs	O
as	O
it	O
has	O
been	O
described	O
before	O
[	O
22	O
]	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
a	O
beta	O
adrenergic	O
mRNA	O
-	O
binding	O
protein	O
,	O
ELAV	O
-	O
like	O
protein	O
1	O
(	O
ELAVL1	O
)	O
can	O
be	O
induced	O
by	O
ADRB2	O
agonist	O
or	O
elevated	O
levels	O
of	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	O
)	O
[	O
22	O
]	O
,	O
[	O
23	O
]	O
and	O
destabilizes	O
ADRB2	O
mRNA	O
.	O

The	O
ELAVL1	O
protein	O
binds	O
to	O
GPCR	O
mRNAs	O
and	O
recognizes	O
a	O
cognate	O
sequence	O
located	O
at	O
the	O
3	O
'	O
-	O
UTR	O
of	O
ADRB2	O
,	O
proteinase	O
-	O
activated	O
receptor	O
and	O
M2	O
,	O
M3	O
muscarinic	O
acetylcholine	O
receptor	O
mRNAs	O
[	O
24	O
]	O
,	O
[	O
25	O
]	O
.	O

Therefore	O
cAMP	O
provides	O
cross	O
-	O
talk	O
among	O
GPCR	O
regulatory	O
networks	O
.	O

However	O
,	O
it	O
is	O
shown	O
that	O
intracellular	O
cAMP	O
accumulation	O
is	O
not	O
the	O
only	O
factor	O
contributing	O
to	O
the	O
reduction	O
of	O
ADRB2	O
mRNA	O
levels	O
[	O
20	O
]	O
.	O

Moreover	O
,	O
we	O
find	O
that	O
GPCR	O
-	O
targeting	O
drugs	O
regulate	O
the	O
transcription	O
of	O
their	O
specific	O
targets	O
(	O
Figure	O
S5	O
)	O
.	O

We	O
conclude	O
that	O
in	O
addition	O
to	O
the	O
cross	O
-	O
regulation	O
of	O
G	O
-	O
protein	O
signaling	O
pathways	O
drug	O
target	O
-	O
specific	O
feedback	O
loops	O
are	O
also	O
responsible	O
for	O
the	O
regulation	O
of	O
drug	O
target	O
mRNAs	O
.	O

In	O
addition	O
to	O
cross	O
-	O
regulation	O
of	O
multiple	O
drugs	O
through	O
the	O
same	O
signaling	O
pathways	O
,	O
promiscuous	O
drugs	O
targeting	O
multiple	O
proteins	O
may	O
cause	O
complex	O
regulatory	O
networks	O
.	O

In	O
order	O
to	O
explore	O
the	O
cross	O
-	O
regulation	O
of	O
drug	O
targets	O
induced	O
by	O
a	O
promiscuous	O
drug	O
,	O
we	O
searched	O
and	O
found	O
that	O
259	O
out	O
of	O
466	O
total	O
drugs	O
are	O
multi	O
-	O
target	O
drugs	O
and	O
4	O
of	O
these	O
drugs	O
act	O
on	O
multiple	O
differentially	O
regulated	O
drug	O
targets	O
upon	O
drug	O
treatment	O
.	O

For	O
example	O
,	O
Podophyllotoxin	O
used	O
in	O
various	O
chemotherapies	O
is	O
known	O
to	O
target	O
both	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
.	O

The	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
both	O
down	O
-	O
regulated	O
upon	O
drug	O
treatment	O
in	O
three	O
cell	O
lines	O
(	O
Figure	O
3	O
,	O
Genes	O
8	O
,	O
13	O
)	O
.	O

Tubulin	O
beta	O
2C	O
inhibitors	O
induce	O
microtubule	O
depolymerization	O
that	O
leads	O
to	O
the	O
specific	O
down	O
-	O
regulation	O
of	O
tubulin	O
beta	O
2C	O
mRNAs	O
preventing	O
the	O
translational	O
synthesis	O
and	O
thus	O
the	O
further	O
accumulation	O
of	O
abundant	O
tubulin	O
monomers	O
[	O
26	O
]	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
mRNAs	O
are	O
not	O
down	O
-	O
regulated	O
upon	O
treatment	O
of	O
other	O
tubulin	O
inhibitors	O
(	O
Figure	O
S5	O
)	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
feedback	O
loops	O
of	O
tubulin	O
beta	O
2C	O
and	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
are	O
not	O
cross	O
-	O
regulated	O
.	O

Two	O
other	O
examples	O
of	O
multi	O
-	O
target	O
drugs	O
are	O
vorinostat	O
used	O
for	O
the	O
treatment	O
of	O
cutaneous	O
T	O
cell	O
lymphoma	O
and	O
trichostatin	O
A	O
that	O
serves	O
as	O
an	O
antifungal	O
antibiotic	O
.	O

Vorinostat	O
and	O
trichostatin	O
A	O
are	O
considered	O
to	O
be	O
nonspecific	O
histone	O
deacetylase	O
inhibitors	O
.	O

These	O
drugs	O
lead	O
to	O
the	O
up	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
3	O
(	O
HDAC3	O
)	O
and	O
down	O
-	O
regulation	O
of	O
histone	O
deacetylase	O
7	O
(	O
HDAC7	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
1	O
,	O
5	O
)	O
.	O

In	O
this	O
case	O
it	O
is	O
unclear	O
whether	O
there	O
is	O
cross	O
-	O
regulation	O
,	O
although	O
HDAC7	O
siRNA	O
experiments	O
failed	O
to	O
induce	O
the	O
up	O
-	O
regulation	O
of	O
HDAC3	O
mRNAs	O
[	O
27	O
]	O
,	O
a	O
result	O
that	O
is	O
disfavoring	O
the	O
cross	O
-	O
regulation	O
.	O

While	O
the	O
above	O
cases	O
only	O
confirm	O
literature	O
reports	O
in	O
other	O
cell	O
lines	O
or	O
tissues	O
,	O
we	O
also	O
identified	O
new	O
cases	O
of	O
drug	O
-	O
induced	O
expression	O
regulation	O
of	O
drug	O
targets	O
.	O

The	O
significant	O
novel	O
findings	O
are	O
the	O
inhibitor	O
-	O
induced	O
down	O
-	O
regulation	O
of	O
calmodulin	O
1	O
,	O
DNA	O
topoisomerase	O
2	O
-	O
alpha	O
and	O
up	O
-	O
regulation	O
of	O
endoplasmin	O
,	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
and	O
cAMP	O
-	O
specific	O
phosphodiesterase	O
4D	O
(	O
Figure	O
3	O
,	O
Genes	O
9	O
,	O
8	O
,	O
2	O
,	O
7	O
,	O
10	O
)	O
.	O

Lanosterol	O
14	O
-	O
alpha	O
demethylase	O
is	O
actually	O
an	O
off	O
-	O
target	O
of	O
antifungal	O
drugs	O
that	O
bind	O
the	O
mammalian	O
version	O
with	O
lower	O
affinity	O
than	O
the	O
fungal	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
.	O

Probably	O
,	O
the	O
up	O
-	O
regulation	O
of	O
the	O
mammalian	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
compensates	O
for	O
the	O
undesired	O
inhibition	O
and	O
modulates	O
the	O
adverse	O
effects	O
.	O

On	O
the	O
contrary	O
,	O
we	O
observed	O
a	O
feedback	O
loop	O
that	O
accelerates	O
the	O
down	O
regulation	O
of	O
calmodulin	O
1	O
mRNA	O
induced	O
by	O
calmodulin	O
inhibitors	O
.	O

Calmodulin	O
targeting	O
drugs	O
can	O
provide	O
a	O
rapid	O
and	O
effective	O
therapeutic	O
effect	O
,	O
while	O
at	O
the	O
same	O
time	O
small	O
variations	O
of	O
drug	O
concentrations	O
can	O
increase	O
adverse	O
effects	O
.	O

Therefore	O
,	O
it	O
would	O
be	O
interesting	O
to	O
study	O
further	O
the	O
functional	O
effects	O
upon	O
target	O
inhibition	O
of	O
lanosterol	O
14	O
-	O
alpha	O
demethylase	O
,	O
endoplasmin	O
and	O
calmodulin	O
1	O
to	O
elucidate	O
the	O
roles	O
of	O
feedback	O
loops	O
in	O
drug	O
mode	O
of	O
action	O
and	O
adverse	O
effects	O
.	O

Drug	O
-	O
induced	O
target	O
regulation	O
might	O
be	O
implicated	O
in	O
tolerance	O
development	O
and	O
thus	O
identifying	O
potential	O
target	O
regulation	O
should	O
be	O
an	O
integral	O
part	O
of	O
drug	O
discovery	O
to	O
prevent	O
failures	O
in	O
later	O
stages	O
of	O
clinical	O
trials	O
.	O

For	O
example	O
,	O
we	O
have	O
observed	O
the	O
inhibitor	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
thymidylate	O
synthetase	O
(	O
TYMS	O
)	O
(	O
Figure	O
3	O
,	O
Genes	O
3	O
,	O
11	O
)	O
[	O
28	O
]	O
.	O

TYMS	O
is	O
an	O
essential	O
enzyme	O
for	O
DNA	O
replication	O
/	O
repair	O
and	O
an	O
important	O
drug	O
target	O
in	O
cancerous	O
cells	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
shown	O
that	O
inhibitor	O
-	O
induced	O
TYMS	O
over	O
-	O
expression	O
obstructs	O
the	O
clinical	O
efficiency	O
by	O
inducing	O
tumor	O
drug	O
resistance	O
[	O
29	O
]	O
.	O

In	O
addition	O
to	O
over	O
-	O
expression	O
,	O
down	O
-	O
regulation	O
of	O
drug	O
targets	O
upon	O
agonist	O
treatment	O
may	O
also	O
cause	O
treatment	O
tolerance	O
as	O
observed	O
for	O
ADRB2	O
long	O
-	O
acting	O
agonist	O
treatment	O
.	O

ADRB2	O
is	O
a	O
therapeutic	O
target	O
activated	O
to	O
treat	O
the	O
symptoms	O
of	O
asthma	O
.	O

We	O
observe	O
the	O
agonist	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
ADRB2	O
and	O
already	O
in	O
2005	O
,	O
the	O
FDA	O
warned	O
patients	O
that	O
ADRB2	O
might	O
be	O
down	O
-	O
regulated	O
(	O
desensitization	O
)	O
and	O
be	O
unresponsive	O
for	O
asthma	O
treatment	O
due	O
to	O
long	O
-	O
acting	O
agonist	O
exposure	O
[	O
20	O
]	O
,	O
[	O
30	O
]	O
.	O

Thus	O
,	O
robustness	O
in	O
biological	O
systems	O
could	O
prevent	O
the	O
applicability	O
of	O
the	O
long	O
-	O
term	O
treatments	O
via	O
positive	O
/	O
negative	O
feedback	O
loops	O
of	O
the	O
drug	O
target	O
affecting	O
the	O
clinical	O
efficiency	O
of	O
drugs	O
in	O
trial	O
and	O
on	O
the	O
market	O
.	O

Drug	O
-	O
induced	O
regulation	O
of	O
drug	O
targets	O
can	O
thus	O
be	O
linked	O
to	O
tolerance	O
development	O
,	O
which	O
restricts	O
the	O
efficiency	O
of	O
clinical	O
treatments	O
where	O
the	O
drug	O
concentration	O
is	O
limited	O
to	O
avoid	O
an	O
excess	O
of	O
adverse	O
drug	O
reactions	O
.	O

Taken	O
together	O
,	O
we	O
have	O
identified	O
drug	O
-	O
induced	O
differential	O
regulation	O
of	O
drug	O
targets	O
.	O

Due	O
to	O
the	O
limited	O
signal	O
to	O
noise	O
ratio	O
in	O
the	O
data	O
at	O
hand	O
,	O
the	O
identified	O
8	O
%	O
of	O
all	O
drug	O
targets	O
that	O
show	O
feedback	O
loops	O
has	O
to	O
be	O
seen	O
as	O
a	O
lower	O
limit	O
,	O
i	O
.	O
e	O
.	O
target	O
-	O
regulation	O
appears	O
as	O
a	O
wide	O
-	O
spread	O
biological	O
phenomenon	O
that	O
has	O
to	O
be	O
taken	O
into	O
account	O
during	O
drug	O
development	O
.	O

Study	O
Population	O

This	O
prospective	O
longitudinal	O
study	O
was	O
conducted	O
at	O
the	O
University	O
of	O
British	O
Columbia	O
and	O
was	O
approved	O
by	O
the	O
human	O
research	O
ethics	O
board	O
at	O
that	O
institution	O
.	O

All	O
subjects	O
who	O
received	O
a	O
renal	O
transplant	O
from	O
January	O
2005	O
to	O
December	O
2007	O
were	O
invited	O
to	O
participate	O
,	O
and	O
those	O
who	O
agreed	O
and	O
signed	O
consent	O
forms	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Patients	O
were	O
followed	O
routinely	O
at	O
the	O
transplant	O
center	O
,	O
and	O
blood	O
and	O
urine	O
samples	O
were	O
obtained	O
prior	O
to	O
and	O
serially	O
post	O
-	O
transplant	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
26	O
weeks	O
;	O
then	O
every	O
6	O
months	O
through	O
year	O
3	O
;	O
and	O
also	O
at	O
the	O
time	O
of	O
suspected	O
rejection	O
.	O

Graft	O
biopsy	O
tissue	O
was	O
obtained	O
pretransplant	O
and	O
at	O
the	O
time	O
of	O
all	O
biopsies	O
performed	O
post	O
-	O
transplant	O
.	O

Blood	O
samples	O
from	O
normal	O
healthy	O
controls	O
served	O
as	O
reference	O
samples	O
.	O

Samples	O
from	O
cases	O
,	O
controls	O
,	O
and	O
comparators	O
were	O
treated	O
identically	O
.	O

All	O
rejection	O
episodes	O
were	O
diagnosed	O
by	O
conventional	O
clinical	O
and	O
laboratory	O
parameters	O
,	O
confirmed	O
by	O
biopsy	O
,	O
and	O
graded	O
according	O
to	O
the	O
Banff	O
97	O
working	O
classification	O
of	O
renal	O
allograft	O
pathology	O
(	O
28	O
)	O
.	O

Banff	O
categories	O
2	O
and	O
4	O
(	O
antibody	O
-	O
mediated	O
or	O
acute	O
/	O
active	O
cellular	O
rejection	O
)	O
were	O
considered	O
significant	O
.	O

Category	O
3	O
(	O
borderline	O
change	O
)	O
was	O
only	O
considered	O
significant	O
if	O
associated	O
with	O
graft	O
dysfunction	O
and	O
treated	O
for	O
rejection	O
.	O

All	O
baseline	O
demographic	O
and	O
follow	O
-	O
up	O
data	O
were	O
recorded	O
in	O
the	O
transplant	O
program	O
electronic	O
database	O
,	O
and	O
there	O
was	O
no	O
loss	O
to	O
follow	O
-	O
up	O
during	O
the	O
period	O
of	O
study	O
.	O

Statistical	O
results	O
showing	O
significant	O
differences	O
between	O
habitats	O
.	O

Animals	O

STOP	O
null	O
mice	O
and	O
their	O
WT	O
littermates	O
were	O
generated	O
on	O
a	O
mixed	O
BALBc	O
/	O
129	O
SvPas	O
and	O
on	O
a	O
pure	O
129	O
SvPas	O
background	O
as	O
previously	O
reported	O
by	O
Andrieux	O
et	O
al	O
.	O

[	O
4	O
]	O
.	O

All	O
animals	O
used	O
in	O
the	O
study	O
underwent	O
immunohistochemistry	O
for	O
the	O
detection	O
of	O
STOP	O
protein	O
,	O
resulting	O
in	O
no	O
staining	O
in	O
STOP	O
null	O
mice	O
,	O
and	O
genotyping	O
by	O
PCR	O
as	O
described	O
by	O
Andrieux	O
et	O
al	O
.	O

[	O
4	O
]	O
.	O

All	O
mice	O
were	O
kept	O
under	O
standard	O
housing	O
conditions	O
with	O
a	O
12	O
-	O
hour	O
/	O
12	O
-	O
hour	O
dark	O
-	O
light	O
cycle	O
.	O

The	O
experiments	O
were	O
carried	O
out	O
in	O
accordance	O
with	O
the	O
European	O
Communities	O
Council	O
Directive	O
of	O
24	O
November	O
1986	O
(	O
86	O
/	O
609	O
/	O
EEC	O
)	O
,	O
and	O
the	O
French	O
Department	O
of	O
Agriculture	O
(	O
License	O
Ndegrees	O
67	O
-	O
95	O
)	O
.	O

The	O
protocol	O
was	O
approved	O
by	O
the	O
ethical	O
Animal	O
Research	O
Committee	O
of	O
Louis	O
Pasteur	O
University	O
(	O
CREMEAS	O
#	O
AL	O
/	O
01	O
/	O
19	O
/	O
10	O
/	O
07	O
)	O
.	O

In	O
a	O
first	O
experiment	O
,	O
we	O
searched	O
for	O
differences	O
in	O
glomerular	O
ultrastructure	O
and	O
peripheral	O
neurogenesis	O
between	O
WT	O
and	O
STOP	O
null	O
mice	O
:	O
a	O
first	O
group	O
of	O
24	O
mice	O
,	O
3	O
-	O
to	O
6	O
-	O
month	O
-	O
old	O
,	O
was	O
used	O
for	O
ultrastructural	O
study	O
of	O
the	O
OBs	O
;	O
a	O
second	O
group	O
of	O
13	O
animals	O
was	O
used	O
to	O
analyse	O
proliferation	O
and	O
apoptosis	O
in	O
the	O
OE	O
and	O
VNE	O
on	O
paraffin	O
sections	O
in	O
3	O
-	O
month	O
-	O
old	O
mice	O
.	O

In	O
a	O
second	O
experiment	O
we	O
analysed	O
,	O
in	O
WT	O
and	O
STOP	O
null	O
mice	O
,	O
the	O
effect	O
of	O
OE	O
regeneration	O
on	O
glomeruli	O
structure	O
and	O
ultrastructure	O
and	O
on	O
peripheral	O
neurogenesis	O
at	O
two	O
age	O
times	O
(	O
3	O
and	O
10	O
months	O
)	O
.	O

INTRODUCTION	O

For	O
several	O
years	O
now	O
,	O
virtual	O
microscopy	O
has	O
been	O
utilized	O
in	O
medical	O
teaching	O
,	O
research	O
,	O
proficiency	O
testing	O
,	O
American	O
Board	O
of	O
Pathology	O
examinations	O
,	O
pathology	O
meetings	O
and	O
conferences	O
,	O
and	O
quality	O
assurance	O
programs	O
.	O

In	O
diagnostic	O
practice	O
,	O
it	O
is	O
most	O
widely	O
and	O
routinely	O
used	O
in	O
image	O
analysis	O
.	O

Some	O
practices	O
are	O
beginning	O
to	O
use	O
it	O
internally	O
(	O
within	O
their	O
group	O
)	O
for	O
frozen	O
section	O
intraoperative	O
consultations	O
and	O
subspecialty	O
consultations	O
due	O
to	O
geographic	O
and	O
time	O
constrains	O
.	O

Although	O
diagnostic	O
consultation	O
for	O
expert	O
second	O
opinion	O
is	O
a	O
well	O
-	O
established	O
practice	O
in	O
pathology	O
for	O
glass	O
slides	O
,	O
similar	O
consultation	O
via	O
virtual	O
microscopy	O
poses	O
multiple	O
controversial	O
issues	O
such	O
as	O
licensing	O
,	O
liability	O
,	O
security	O
,	O
reimbursement	O
,	O
and	O
scanning	O
quality	O
and	O
its	O
validation	O
.	O

Regulations	O
and	O
standardization	O
are	O
not	O
yet	O
in	O
place	O
that	O
pathologists	O
can	O
use	O
to	O
allay	O
these	O
fears	O
.	O

Nevertheless	O
,	O
if	O
the	O
virtual	O
microscopy	O
scans	O
are	O
of	O
optimal	O
quality	O
,	O
these	O
can	O
be	O
simply	O
substituted	O
for	O
glass	O
slides	O
and	O
a	O
microscope	O
while	O
maintaining	O
all	O
other	O
practice	O
guidelines	O
for	O
second	O
opinion	O
consultation	O
.	O

Additionally	O
,	O
the	O
cost	O
and	O
maintenance	O
of	O
scanning	O
equipment	O
is	O
not	O
currently	O
affordable	O
to	O
most	O
practitioners	O
and	O
consultants	O
.	O

A	O
practice	O
model	O
that	O
offers	O
tertiary	O
consultation	O
in	O
gastrointestinal	O
(	O
GI	O
)	O
and	O
liver	O
pathology	O
is	O
presented	O
that	O
eliminates	O
the	O
cost	O
and	O
maintenance	O
of	O
scanners	O
by	O
the	O
consultants	O
and	O
clients	O
,	O
minimizes	O
the	O
need	O
for	O
review	O
of	O
glass	O
slides	O
,	O
facilitates	O
clinicopathological	O
and	O
radiological	O
correlation	O
and	O
serves	O
the	O
need	O
of	O
clients	O
who	O
need	O
timely	O
help	O
with	O
challenging	O
liver	O
and	O
GI	O
cases	O
and	O
to	O
obtain	O
expert	O
opinion	O
for	O
dysplasia	O
in	O
Barrett	O
'	O
s	O
and	O
ulcerative	O
colitis	O
surveillance	O
biopsies	O
required	O
by	O
the	O
American	O
Gastroenterology	O
Association	O
(	O
AGA	O
)	O
.	O

This	O
model	O
has	O
been	O
practiced	O
for	O
3	O
years	O
and	O
applied	O
to	O
over	O
2000	O
cases	O
by	O
small	O
pathology	O
practices	O
in	O
the	O
50	O
United	O
States	O
and	O
a	O
single	O
consultant	O
GI	O
and	O
liver	O
pathologist	O
.	O

Definition	O
of	O
pathogens	O

It	O
remains	O
difficult	O
to	O
determine	O
whether	O
the	O
organisms	O
detected	O
by	O
the	O
DNA	O
Detection	O
Kit	O
are	O
true	O
pathogens	O
.	O

This	O
also	O
applies	O
,	O
although	O
to	O
a	O
much	O
lesser	O
degree	O
,	O
to	O
conventional	O
blood	O
culture	O
analysis	O
.	O

However	O
,	O
detected	O
organisms	O
were	O
considered	O
to	O
be	O
pathogens	O
if	O
the	O
results	O
of	O
culture	O
tests	O
from	O
samples	O
of	O
the	O
suspected	O
infectious	O
sites	O
coincided	O
with	O
the	O
results	O
of	O
DNA	O
Detection	O
Kit	O
or	O
blood	O
culture	O
analysis	O
.	O

The	O
culture	O
data	O
of	O
sputum	O
,	O
urine	O
,	O
pus	O
and	O
drainage	O
fluid	O
were	O
used	O
to	O
define	O
the	O
pathogens	O
.	O

A	O
decision	O
as	O
to	O
whether	O
an	O
identified	O
organism	O
was	O
a	O
pathogen	O
was	O
taken	O
based	O
on	O
the	O
decision	O
tree	O
shown	O
in	O
Figure	O
1	O
.	O

Thus	O
,	O
when	O
the	O
same	O
organism	O
was	O
detected	O
by	O
both	O
DNA	O
Detection	O
Kit	O
and	O
blood	O
culture	O
analysis	O
,	O
the	O
detected	O
organism	O
was	O
considered	O
an	O
infectious	O
pathogen	O
.	O

If	O
there	O
was	O
a	O
discrepancy	O
between	O
the	O
organism	O
that	O
was	O
detected	O
by	O
SeptiFast	O
analysis	O
and	O
that	O
detected	O
by	O
blood	O
culture	O
analysis	O
,	O
or	O
if	O
an	O
organism	O
was	O
only	O
detected	O
in	O
one	O
of	O
these	O
tests	O
,	O
then	O
other	O
samples	O
taken	O
from	O
the	O
infection	O
site	O
were	O
analyzed	O
.	O

If	O
this	O
second	O
culture	O
test	O
of	O
the	O
suspected	O
infectious	O
site	O
revealed	O
the	O
presence	O
of	O
the	O
same	O
organism	O
,	O
this	O
organism	O
was	O
considered	O
to	O
be	O
a	O
pathogen	O
.	O

If	O
the	O
microbial	O
strain	O
was	O
only	O
detected	O
once	O
for	O
a	O
sample	O
,	O
we	O
then	O
checked	O
the	O
second	O
culture	O
results	O
in	O
the	O
suspected	O
infectious	O
sites	O
.	O

If	O
this	O
result	O
identified	O
the	O
same	O
strain	O
as	O
that	O
identified	O
by	O
SeptiFast	O
analysis	O
then	O
it	O
was	O
decided	O
that	O
this	O
strain	O
was	O
a	O
pathogen	O
.	O

However	O
,	O
if	O
the	O
strain	O
was	O
still	O
only	O
detected	O
in	O
some	O
of	O
the	O
assays	O
,	O
we	O
next	O
determined	O
if	O
the	O
patient	O
involved	O
suffered	O
from	O
sepsis	O
.	O

Sepsis	O
is	O
defined	O
as	O
SIRS	O
caused	O
by	O
infection	O
.	O

The	O
definition	O
of	O
sepsis	O
that	O
we	O
used	O
was	O
based	O
on	O
the	O
International	O
Sepsis	O
Forum	O
Definition	O
of	O
Infection	O
at	O
the	O
ICU	O
Consensus	O
Conference	O
[	O
7	O
]	O
.	O

However	O
,	O
if	O
the	O
underlying	O
disease	O
is	O
acute	O
lymphoma	O
leukemia	O
(	O
ALL	O
)	O
,	O
malignant	O
lymphoma	O
(	O
ML	O
)	O
,	O
or	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
the	O
definition	O
of	O
infection	O
is	O
defined	O
as	O
the	O
ability	O
to	O
detect	O
infectious	O
organisms	O
by	O
blood	O
culture	O
analysis	O
.	O

If	O
the	O
patient	O
was	O
not	O
defined	O
as	O
having	O
sepsis	O
when	O
whole	O
blood	O
was	O
administered	O
to	O
the	O
patient	O
,	O
we	O
decided	O
that	O
the	O
strain	O
detected	O
by	O
subsequent	O
DNA	O
Detection	O
Kit	O
or	O
blood	O
culture	O
analysis	O
was	O
not	O
a	O
pathogen	O
.	O

Figure	O
1	O

Flowchart	O
for	O
pathogen	O
decision	O
.	O

Samples	O
were	O
defined	O
as	O
negative	O
for	O
pathogens	O
if	O
a	O
pathogen	O
could	O
not	O
be	O
detected	O
by	O
any	O
method	O
of	O
analysis	O
within	O
seven	O
days	O
,	O
and	O
if	O
another	O
type	O
of	O
culture	O
test	O
did	O
not	O
detect	O
this	O
pathogen	O
but	O
could	O
detect	O
other	O
organisms	O
.	O

CoNS	O
bacteria	O
,	O
which	O
are	O
represented	O
by	O
the	O
Staphylococcus	O
epidermidis	O
(	O
S	O
.	O
epidermidis	O
)	O
and	O
Streptococcus	O
spp	O
.	O
are	O
indigenous	O
bacteria	O
and	O
often	O
cause	O
contamination	O
in	O
assays	O
of	O
pathogens	O
.	O

Therefore	O
,	O
when	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
by	O
blood	O
culture	O
and	O
SeptiFast	O
analysis	O
,	O
the	O
following	O
criteria	O
were	O
applied	O
to	O
define	O
whether	O
these	O
strains	O
represented	O
a	O
pathogenic	O
infection	O
:	O
(	O
1	O
)	O
Tests	O
were	O
performed	O
at	O
least	O
twice	O
within	O
48	O
hours	O
before	O
and	O
after	O
CoNS	O
were	O
detected	O
by	O
blood	O
culture	O
or	O
SeptiFast	O
analysis	O
;	O
(	O
2	O
)	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
in	O
two	O
different	O
blood	O
culture	O
tests	O
that	O
were	O
separately	O
performed	O
twice	O
within	O
48	O
hours	O
;	O
and	O
,	O
(	O
3	O
)	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
twice	O
or	O
more	O
in	O
tests	O
that	O
were	O
performed	O
three	O
times	O
[	O
11	O
-	O
15	O
]	O
.	O

If	O
a	O
sample	O
'	O
s	O
results	O
met	O
any	O
of	O
these	O
three	O
criteria	O
,	O
then	O
the	O
sample	O
was	O
evaluated	O
as	O
a	O
pathogen	O
.	O

The	O
distinction	O
between	O
pathogen	O
and	O
contamination	O
was	O
also	O
determined	O
for	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
from	O
the	O
crossing	O
point	O
(	O
Cp	O
)	O
obtained	O
using	O
the	O
LightCycler	O
analysis	O
software	O
v4	O
.	O
05	O
.	O

The	O
Cp	O
represents	O
the	O
point	O
in	O
the	O
amplification	O
cycle	O
where	O
the	O
amplification	O
curve	O
crosses	O
the	O
detection	O
threshold	O
.	O

When	O
CoNS	O
or	O
Streptococcus	O
spp	O
.	O
were	O
detected	O
using	O
the	O
LightCycler	O
analysis	O
software	O
v4	O
.	O
05	O
,	O
a	O
Cp	O
of	O
less	O
than	O
20	O
was	O
defined	O
as	O
indicating	O
a	O
pathogen	O
and	O
a	O
Cp	O
of	O
over	O
20	O
was	O
defined	O
as	O
contamination	O
by	O
checking	O
the	O
amplification	O
curve	O
.	O

Effect	O
of	O
the	O
deletion	O
of	O
IRE1alpha	O
on	O
the	O
liver	O
.	O

(	O
A	O
)	O
HE	O
-	O
stained	O
sections	O
of	O
the	O
liver	O
tissue	O
(	O
scale	O
bar	O
:	O
50	O
mum	O
)	O
.	O

(	O
B	O
)	O
Comparison	O
of	O
the	O
serum	O
AST	O
and	O
ALT	O
levels	O
between	O
the	O
IRE1alpha	O
CKO	O
mice	O
and	O
the	O
control	O
mice	O
.	O

Data	O
are	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
5	O
)	O
.	O

(	O
C	O
)	O
Quantitative	O
PCR	O
analysis	O
of	O
lipid	O
synthesis	O
genes	O
in	O
the	O
liver	O
of	O
mice	O
fed	O
normal	O
or	O
high	O
-	O
fructose	O
feed	O
.	O

Columns	O
indicate	O
mean	O
and	O
error	O
bars	O
denote	O
S	O
.	O
E	O
.	O
M	O
(	O
n	O
=	O
3	O
)	O
.	O

All	O
the	O
data	O
were	O
obtained	O
from	O
20	O
weeks	O
old	O
male	O
mice	O
.	O

2	O
.	O

Methods	O

Conclusion	O
:	O

This	O
study	O
demonstrates	O
that	O
surgery	O
plus	O
chemotherapy	O
and	O
radiation	O
therapy	O
is	O
helpful	O
for	O
treating	O
patients	O
with	O
pelvic	O
Ewing	O
'	O
s	O
sarcoma	O
,	O
particularly	O
in	O
achieving	O
local	O
control	O
.	O

Historical	O
Background	O
of	O
PTSD	O

PTSD	O
gained	O
acceptance	O
in	O
the	O
medical	O
and	O
psychiatric	O
community	O
after	O
a	O
number	O
of	O
studies	O
appeared	O
in	O
prominent	O
medical	O
and	O
psychiatric	O
journals	O
describing	O
the	O
psychiatric	O
symptoms	O
of	O
soldiers	O
who	O
had	O
served	O
and	O
fought	O
in	O
the	O
Vietnam	O
War	O
(	O
Fox	O
1972	O
;	O
Goldsmith	O
and	O
Cretekos	O
1969	O
)	O
.	O

Subsequent	O
publications	O
described	O
the	O
profound	O
psychological	O
and	O
emotional	O
sequelae	O
secondary	O
to	O
being	O
exposed	O
to	O
extremely	O
traumatic	O
events	O
such	O
as	O
fires	O
,	O
explosions	O
,	O
floods	O
,	O
torture	O
,	O
serious	O
motor	O
vehicle	O
accidents	O
(	O
MVAs	O
)	O
,	O
violent	O
crimes	O
,	O
and	O
sexual	O
assault	O
(	O
e	O
.	O
g	O
.	O
,	O
Horowitz	O
1976	O
)	O
.	O

These	O
publications	O
posited	O
that	O
individuals	O
with	O
PTSD	O
no	O
longer	O
felt	O
in	O
control	O
of	O
their	O
lives	O
,	O
viewed	O
the	O
world	O
as	O
an	O
unpredictable	O
and	O
dangerous	O
place	O
,	O
lived	O
in	O
fear	O
,	O
and	O
reported	O
a	O
loss	O
of	O
trust	O
in	O
a	O
""""	O
just	O
world	O
.	O
""""	O
These	O
studies	O
also	O
reported	O
that	O
individuals	O
with	O
PTSD	O
avoided	O
thoughts	O
or	O
situations	O
that	O
might	O
trigger	O
traumatic	O
memories	O
,	O
complained	O
of	O
feelings	O
of	O
emotional	O
numbness	O
,	O
and	O
exhibited	O
symptoms	O
of	O
blunted	O
affect	O
.	O

The	O
conceptual	O
refinements	O
coupled	O
with	O
the	O
empirical	O
information	O
generated	O
by	O
these	O
studies	O
significantly	O
advanced	O
our	O
understanding	O
of	O
individuals	O
who	O
have	O
been	O
exposed	O
to	O
a	O
traumatic	O
stressor	O
.	O

This	O
led	O
in	O
1980	O
to	O
the	O
inclusion	O
of	O
the	O
diagnostic	O
criteria	O
for	O
PTSD	O
in	O
the	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	O
Disorders	O
III	O
(	O
DSM	O
-	O
III	O
;	O
American	O
Psychiatric	O
Association	O
1980	O
)	O
.	O

At	O
that	O
time	O
,	O
PTSD	O
was	O
defined	O
as	O
a	O
syndrome	O
that	O
developed	O
in	O
response	O
to	O
a	O
""""	O
stressor	O
that	O
would	O
evoke	O
significant	O
symptoms	O
of	O
distress	O
in	O
almost	O
everyone	O
""""	O
(	O
p	O
.	O
238	O
)	O
.	O

The	O
DSM	O
-	O
III	O
criteria	O
also	O
required	O
that	O
the	O
individual	O
who	O
developed	O
PTSD	O
had	O
to	O
have	O
been	O
directly	O
exposed	O
to	O
a	O
traumatic	O
event	O
.	O

The	O
DSM	O
-	O
IV	O
criteria	O
(	O
APA	O
1994	O
)	O
significantly	O
broadened	O
the	O
definition	O
of	O
PTSD	O
to	O
include	O
(	O
a	O
)	O
a	O
""""	O
personal	O
experience	O
of	O
an	O
event	O
that	O
involves	O
actual	O
or	O
threatened	O
death	O
or	O
serious	O
injury	O
,	O
or	O
other	O
threat	O
to	O
one	O
'	O
s	O
physical	O
integrity	O
""""	O
(	O
p	O
.	O
463	O
)	O
or	O
(	O
b	O
)	O
witnessing	O
a	O
comparable	O
traumatic	O
event	O
or	O
even	O
""""	O
learning	O
about	O
unexpected	O
or	O
violent	O
death	O
,	O
serious	O
harm	O
,	O
or	O
threat	O
of	O
death	O
or	O
injury	O
experienced	O
by	O
a	O
family	O
member	O
or	O
a	O
close	O
associate	O
""""	O
(	O
p	O
.	O
462	O
)	O
.	O

As	O
a	O
consequence	O
of	O
these	O
modifications	O
,	O
the	O
DSM	O
-	O
IV	O
diagnostic	O
criteria	O
for	O
PTSD	O
have	O
been	O
criticized	O
for	O
failing	O
to	O
discriminate	O
between	O
symptoms	O
of	O
PTSD	O
and	O
normal	O
stress	O
reactions	O
(	O
e	O
.	O
g	O
.	O
,	O
learning	O
about	O
the	O
9	O
/	O
11	O
disaster	O
;	O
Wakefield	O
and	O
Spitzer	O
2002	O
)	O
.	O

Summary	O
of	O
instrument	O
characteristics	O

Click	O
here	O
for	O
file	O

The	O
right	O
eye	O
of	O
a	O
50	O
-	O
year	O
-	O
old	O
patient	O
with	O
severe	O
hypertension	O
at	O
the	O
first	O
visit	O
.	O

(	O
a	O
)	O
Fundus	O
photograph	O
shows	O
serous	O
retinal	O
detachment	O
.	O

The	O
optic	O
disc	O
is	O
pale	O
at	O
the	O
temporal	O
side	O
.	O

(	O
b	O
)	O
Optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
shows	O
retinal	O
detachment	O
involving	O
the	O
fovea	O
and	O
cystic	O
change	O
of	O
inner	O
retina	O
.	O

(	O
c	O
)	O
Early	O
phase	O
images	O
of	O
fluorescein	O
angiography	O
(	O
FA	O
)	O
(	O
left	O
)	O
and	O
indocyanine	O
green	O
angiography	O
(	O
IA	O
)	O
(	O
right	O
)	O
.	O

(	O
d	O
)	O
Late	O
phase	O
images	O
of	O
FA	O
(	O
left	O
)	O
and	O
IA	O
(	O
right	O
)	O
.	O

FA	O
shows	O
window	O
defect	O
associated	O
with	O
macular	O
cystic	O
change	O
.	O

Note	O
that	O
no	O
active	O
leakage	O
is	O
observed	O
in	O
the	O
area	O
with	O
serous	O
retinal	O
detachment	O
or	O
cystoid	O
edema	O
.	O

IA	O
shows	O
decreased	O
perfusion	O
of	O
the	O
choroid	O
at	O
the	O
macula	O
and	O
window	O
defect	O
with	O
the	O
damaged	O
RPE	O
.	O

Hypofluorescence	O
(	O
arrow	O
)	O
along	O
the	O
retinal	O
artery	O
are	O
observed	O
.	O

These	O
are	O
unique	O
findings	O
.	O

Additional	O
file	O
2	O

Video	O
S2	O
TTE	O
apical	O
4	O
-	O
chamber	O
view	O
.	O

The	O
vegetation	O
seems	O
located	O
just	O
above	O
the	O
tricuspid	O
septal	O
valve	O
without	O
causing	O
obstruction	O
on	O
it	O
.	O

Histology	O
of	O
the	O
lung	O

The	O
left	O
lung	O
was	O
fixed	O
by	O
gentle	O
infusion	O
of	O
fixative	O
(	O
4	O
%	O
paraformaldehyde	O
)	O
through	O
the	O
tracheal	O
cannula	O
[	O
24	O
]	O
.	O

After	O
excision	O
,	O
the	O
lung	O
was	O
immersed	O
in	O
a	O
fresh	O
fixative	O
for	O
2	O
h	O
.	O

The	O
lung	O
lobe	O
was	O
embedded	O
in	O
paraffin	O
and	O
cut	O
into	O
3	O
mum	O
transverse	O
sections	O
,	O
followed	O
by	O
immunohistochemical	O
and	O
chemical	O
staining	O
.	O

Photomicrographs	O
were	O
captured	O
using	O
KS400	O
image	O
analyze	O
platform	O
(	O
Zeiss	O
,	O
Oberkochen	O
,	O
Germany	O
)	O
and	O
analyzed	O
quantitatively	O
.	O

Fractional	O
atomic	O
coordinates	O
and	O
isotropic	O
or	O
equivalent	O
isotropic	O
displacement	O
parameters	O
(	O
A2	O
)	O

x	O
y	O
z	O
Uiso	O
*	O
/	O
Ueq	O

C1	O
0	O
.	O
3043	O
(	O
3	O
)	O
0	O
.	O
1779	O
(	O
4	O
)	O
0	O
.	O
79280	O
(	O
13	O
)	O
0	O
.	O
0445	O
(	O
6	O
)	O

C2	O
0	O
.	O
4358	O
(	O
4	O
)	O
0	O
.	O
1697	O
(	O
5	O
)	O
0	O
.	O
84058	O
(	O
17	O
)	O
0	O
.	O
0604	O
(	O
8	O
)	O

H2	O
0	O
.	O
4201	O
0	O
.	O
1476	O
0	O
.	O
8809	O
0	O
.	O
072	O
*	O

C3	O
0	O
.	O
5911	O
(	O
4	O
)	O
0	O
.	O
1953	O
(	O
6	O
)	O
0	O
.	O
8269	O
(	O
2	O
)	O
0	O
.	O
0783	O
(	O
12	O
)	O

H3	O
0	O
.	O
6811	O
0	O
.	O
1914	O
0	O
.	O
8584	O
0	O
.	O
094	O
*	O

C4	O
0	O
.	O
6130	O
(	O
4	O
)	O
0	O
.	O
2267	O
(	O
6	O
)	O
0	O
.	O
7670	O
(	O
2	O
)	O
0	O
.	O
0773	O
(	O
11	O
)	O

H4	O
0	O
.	O
7180	O
0	O
.	O
2427	O
0	O
.	O
7582	O
0	O
.	O
093	O
*	O

C5	O
0	O
.	O
4818	O
(	O
5	O
)	O
0	O
.	O
2344	O
(	O
5	O
)	O
0	O
.	O
7202	O
(	O
2	O
)	O
0	O
.	O
0746	O
(	O
10	O
)	O

H5	O
0	O
.	O
4980	O
0	O
.	O
2547	O
0	O
.	O
6798	O
0	O
.	O
090	O
*	O

C6	O
0	O
.	O
3257	O
(	O
4	O
)	O
0	O
.	O
2121	O
(	O
4	O
)	O
0	O
.	O
73293	O
(	O
15	O
)	O
0	O
.	O
0562	O
(	O
7	O
)	O

H6	O
0	O
.	O
2360	O
0	O
.	O
2200	O
0	O
.	O
7015	O
0	O
.	O
067	O
*	O

C7	O
0	O
.	O
1252	O
(	O
3	O
)	O
0	O
.	O
3838	O
(	O
4	O
)	O
0	O
.	O
90059	O
(	O
11	O
)	O
0	O
.	O
0400	O
(	O
6	O
)	O

C8	O
0	O
.	O
2051	O
(	O
4	O
)	O
0	O
.	O
5522	O
(	O
4	O
)	O
0	O
.	O
90920	O
(	O
13	O
)	O
0	O
.	O
0484	O
(	O
6	O
)	O

H8	O
0	O
.	O
2132	O
0	O
.	O
6288	O
0	O
.	O
8758	O
0	O
.	O
058	O
*	O

C9	O
0	O
.	O
2725	O
(	O
4	O
)	O
0	O
.	O
6041	O
(	O
4	O
)	O
0	O
.	O
96827	O
(	O
15	O
)	O
0	O
.	O
0558	O
(	O
7	O
)	O

C10	O
0	O
.	O
2645	O
(	O
4	O
)	O
0	O
.	O
4935	O
(	O
4	O
)	O
1	O
.	O
01861	O
(	O
14	O
)	O
0	O
.	O
0590	O
(	O
8	O
)	O

H10	O
0	O
.	O
3122	O
0	O
.	O
5293	O
1	O
.	O
0582	O
0	O
.	O
071	O
*	O

C11	O
0	O
.	O
1830	O
(	O
4	O
)	O
0	O
.	O
3278	O
(	O
4	O
)	O
1	O
.	O
00819	O
(	O
13	O
)	O
0	O
.	O
0534	O
(	O
7	O
)	O

C12	O
0	O
.	O
1118	O
(	O
3	O
)	O
0	O
.	O
2699	O
(	O
4	O
)	O
0	O
.	O
95062	O
(	O
12	O
)	O
0	O
.	O
0480	O
(	O
6	O
)	O

H12	O
0	O
.	O
0561	O
0	O
.	O
1577	O
0	O
.	O
9451	O
0	O
.	O
058	O
*	O

N1	O
0	O
.	O
0494	O
(	O
3	O
)	O
0	O
.	O
3297	O
(	O
3	O
)	O
0	O
.	O
84009	O
(	O
10	O
)	O
0	O
.	O
0441	O
(	O
5	O
)	O

H1N	O
0	O
.	O
038	O
(	O
4	O
)	O
0	O
.	O
418	O
(	O
3	O
)	O
0	O
.	O
8138	O
(	O
12	O
)	O
0	O
.	O
053	O
*	O

O1	O
-	O
0	O
.	O
0021	O
(	O
3	O
)	O
0	O
.	O
1298	O
(	O
3	O
)	O
0	O
.	O
74998	O
(	O
9	O
)	O
0	O
.	O
0527	O
(	O
5	O
)	O

O2	O
0	O
.	O
1112	O
(	O
3	O
)	O
-	O
0	O
.	O
0066	O
(	O
3	O
)	O
0	O
.	O
85135	O
(	O
10	O
)	O
0	O
.	O
0574	O
(	O
6	O
)	O

Cl1	O
0	O
.	O
37237	O
(	O
16	O
)	O
0	O
.	O
81541	O
(	O
13	O
)	O
0	O
.	O
97944	O
(	O
5	O
)	O
0	O
.	O
0927	O
(	O
4	O
)	O

Cl2	O
0	O
.	O
16462	O
(	O
15	O
)	O
0	O
.	O
18752	O
(	O
15	O
)	O
1	O
.	O
07089	O
(	O
4	O
)	O
0	O
.	O
0834	O
(	O
4	O
)	O

S1	O
0	O
.	O
10584	O
(	O
7	O
)	O
0	O
.	O
14095	O
(	O
9	O
)	O
0	O
.	O
80800	O
(	O
3	O
)	O
0	O
.	O
0412	O
(	O
3	O
)	O

Data	O
collection	O
:	O
CrystalClear	O
(	O
Rigaku	O
/	O
MSC	O
,	O
2005	O
>	O
)	O
;	O
cell	O
refinement	O
:	O
CrystalClear	O
;	O
data	O
reduction	O
:	O
CrystalClear	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
solve	O
structure	O
:	O
SHELXS97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
program	O
(	O
s	O
)	O
used	O
to	O
refine	O
structure	O
:	O
SHELXL97	O
(	O
Sheldrick	O
,	O
2008	O
>	O
)	O
;	O
molecular	O
graphics	O
:	O
ORTEPII	O
(	O
Johnson	O
,	O
1976	O
>	O
)	O
;	O
software	O
used	O
to	O
prepare	O
material	O
for	O
publication	O
:	O
SHELXL97	O
.	O

Experimental	O

The	O
molecular	O
structure	O
of	O
(	O
I	O
)	O
,	O
showing	O
displacement	O
ellipsoids	O
at	O
the	O
30	O
%	O
probability	O
level	O
for	O
non	O
-	O
H	O
atoms	O
.	O

Crystal	O
data	O

C16H20N4	O

M	O
r	O
=	O
268	O
.	O
36	O

Monoclinic	O
,	O

a	O
=	O
12	O
.	O
819	O
(	O
4	O
)	O
A	O

b	O
=	O
8	O
.	O
441	O
(	O
3	O
)	O
A	O

c	O
=	O
13	O
.	O
310	O
(	O
4	O
)	O
A	O

beta	O
=	O
95	O
.	O
462	O
(	O
5	O
)	O
degrees	O

V	O
=	O
1433	O
.	O
7	O
(	O
8	O
)	O
A3	O

Z	O
=	O
4	O

Mo	O
Kalpha	O
radiation	O

mu	O
=	O
0	O
.	O
08	O
mm	O
-	O
1	O

T	O
=	O
298	O
(	O
2	O
)	O
K	O

0	O
.	O
33	O
x	O
0	O
.	O
28	O
x	O
0	O
.	O
21	O
mm	O

Crystal	O
data	O

C15H12ClN3O2S2	O
F	O
(	O
000	O
)	O
=	O
752	O

Mr	O
=	O
365	O
.	O
85	O
Dx	O
=	O
1	O
.	O
507	O
Mg	O
m	O
-	O
3	O

Monoclinic	O
,	O
P21	O
/	O
n	O
Mo	O
Kalpha	O
radiation	O
,	O
lambda	O
=	O
0	O
.	O
71073	O
A	O

Hall	O
symbol	O
:	O
-	O
P	O
2yn	O
Cell	O
parameters	O
from	O
25	O
reflections	O

a	O
=	O
10	O
.	O
175	O
(	O
2	O
)	O
A	O
theta	O
=	O
9	O
-	O
12degrees	O

b	O
=	O
8	O
.	O
4958	O
(	O
17	O
)	O
A	O
micro	O
=	O
0	O
.	O
51	O
mm	O
-	O
1	O

c	O
=	O
19	O
.	O
318	O
(	O
4	O
)	O
A	O
T	O
=	O
293	O
K	O

beta	O
=	O
105	O
.	O
01	O
(	O
3	O
)	O
degrees	O
Block	O
,	O
yellow	O

V	O
=	O
1613	O
.	O
0	O
(	O
6	O
)	O
A3	O
0	O
.	O
25	O
x	O
0	O
.	O
15	O
x	O
0	O
.	O
15	O
mm	O

Z	O
=	O
4	O

Discussion	O

Our	O
results	O
indicate	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
performance	O
and	O
alleviating	O
effects	O
on	O
cognitive	O
decline	O
.	O

These	O
beneficial	O
effects	O
were	O
evident	O
in	O
healthy	O
young	O
and	O
older	O
adults	O
and	O
in	O
patients	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O

Young	O
adults	O
showed	O
improved	O
antisaccade	O
preparation	O
when	O
a	O
reward	O
was	O
at	O
stake	O
;	O
older	O
adults	O
and	O
PD	O
patients	O
could	O
utilize	O
reward	O
prospect	O
to	O
improve	O
their	O
impaired	O
antisaccade	O
preparation	O
.	O

Elderly	O
participants	O
and	O
PD	O
patients	O
were	O
not	O
only	O
better	O
prepared	O
by	O
means	O
of	O
commonly	O
used	O
preparatory	O
aids	O
(	O
i	O
.	O
e	O
.	O
,	O
more	O
preparation	O
time	O
and	O
advance	O
information	O
on	O
the	O
upcoming	O
response	O
)	O
but	O
also	O
by	O
means	O
of	O
motivational	O
incentives	O
.	O

These	O
beneficial	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
action	O
preparation	O
in	O
healthy	O
and	O
pathological	O
aging	O
further	O
support	O
views	O
that	O
question	O
the	O
notion	O
of	O
monotonic	O
deterioration	O
of	O
cognitive	O
function	O
with	O
age	O
(	O
Allen	O
et	O
al	O
.	O
,	O
2001	O
)	O
.	O

They	O
indicate	O
that	O
age	O
-	O
related	O
declines	O
can	O
be	O
modulated	O
by	O
emotion	O
-	O
cognition	O
interactions	O
.	O

In	O
line	O
with	O
the	O
predominant	O
view	O
that	O
cognitive	O
control	O
deteriorates	O
in	O
aging	O
and	O
Parkinson	O
'	O
s	O
disease	O
,	O
and	O
in	O
line	O
with	O
previous	O
findings	O
on	O
age	O
-	O
related	O
changes	O
in	O
antisaccade	O
control	O
specifically	O
(	O
Eenshuistra	O
et	O
al	O
.	O
,	O
2004	O
;	O
Chan	O
et	O
al	O
.	O
,	O
2005	O
;	O
Amador	O
et	O
al	O
.	O
,	O
2006	O
;	O
Abel	O
and	O
Douglas	O
,	O
2007	O
)	O
,	O
the	O
current	O
results	O
showed	O
decline	O
in	O
antisaccade	O
preparation	O
in	O
PD	O
patients	O
with	O
severe	O
motor	O
symptoms	O
as	O
compared	O
to	O
healthy	O
seniors	O
.	O

Mild	O
-	O
symptom	O
patients	O
and	O
healthy	O
elderly	O
did	O
not	O
differ	O
in	O
antisaccade	O
preparation	O
.	O

Healthy	O
seniors	O
showed	O
declining	O
antisaccade	O
preparation	O
as	O
compared	O
to	O
young	O
adults	O
.	O

Decline	O
was	O
evident	O
on	O
several	O
oculomotor	O
parameters	O
and	O
most	O
pronounced	O
on	O
antisaccade	O
onset	O
latencies	O
.	O

In	O
line	O
with	O
the	O
notion	O
that	O
in	O
general	O
,	O
elderly	O
tend	O
to	O
prefer	O
accuracy	O
over	O
speed	O
,	O
elderly	O
showed	O
no	O
decreased	O
antisaccade	O
accuracy	O
as	O
compared	O
to	O
young	O
adults	O
.	O

As	O
compared	O
to	O
the	O
young	O
group	O
,	O
elderly	O
and	O
PD	O
patients	O
exhibited	O
slightly	O
,	O
but	O
not	O
significantly	O
more	O
premature	O
eye	O
movements	O
.	O

Premature	O
eye	O
movements	O
,	O
however	O
significantly	O
increased	O
in	O
elderly	O
and	O
PD	O
patients	O
but	O
only	O
slightly	O
in	O
the	O
young	O
,	O
when	O
more	O
specific	O
information	O
on	O
the	O
upcoming	O
movement	O
was	O
available	O
in	O
advance	O
.	O

Presumably	O
,	O
this	O
increase	O
in	O
premature	O
eye	O
movements	O
reflects	O
difficulties	O
with	O
the	O
inhibition	O
of	O
externally	O
guided	O
movement	O
and	O
/	O
or	O
the	O
suppression	O
of	O
strongly	O
activated	O
prepotent	O
action	O
plans	O
.	O

On	O
the	O
one	O
hand	O
,	O
the	O
choice	O
for	O
medicated	O
PD	O
patients	O
represents	O
a	O
limitation	O
of	O
the	O
current	O
study	O
as	O
we	O
can	O
not	O
exclude	O
differential	O
effects	O
of	O
medication	O
on	O
behavior	O
.	O

On	O
the	O
other	O
hand	O
,	O
PD	O
patients	O
generally	O
take	O
medication	O
in	O
their	O
daily	O
routine	O
,	O
such	O
that	O
the	O
results	O
can	O
be	O
generalized	O
to	O
clinical	O
practice	O
.	O

Exploratory	O
analysis	O
within	O
the	O
PD	O
patient	O
group	O
revealed	O
that	O
patients	O
with	O
more	O
severe	O
motoric	O
symptoms	O
(	O
as	O
indexed	O
by	O
their	O
motoric	O
subscore	O
on	O
the	O
UPDRS	O
)	O
displayed	O
more	O
signs	O
of	O
antisaccade	O
decline	O
,	O
such	O
as	O
longer	O
antisaccade	O
latencies	O
and	O
lower	O
accuracy	O
compared	O
to	O
mildly	O
affected	O
patients	O
,	O
who	O
initiated	O
saccades	O
equally	O
fast	O
as	O
healthy	O
adults	O
.	O

This	O
suggests	O
that	O
dopaminergic	O
medication	O
was	O
not	O
sufficient	O
to	O
raise	O
the	O
patient	O
'	O
s	O
antisaccadic	O
preparation	O
up	O
to	O
the	O
level	O
of	O
the	O
healthy	O
older	O
adults	O
.	O

One	O
intriguing	O
observation	O
was	O
that	O
despite	O
the	O
different	O
extents	O
of	O
observed	O
antisaccade	O
performance	O
decline	O
in	O
elderly	O
and	O
PD	O
patients	O
,	O
reward	O
prospect	O
led	O
to	O
beneficial	O
effects	O
on	O
antisaccade	O
latency	O
and	O
accuracy	O
in	O
young	O
,	O
elderly	O
,	O
and	O
PD	O
patients	O
alike	O
.	O

Young	O
,	O
elderly	O
and	O
PD	O
patients	O
benefited	O
from	O
reward	O
prospect	O
to	O
the	O
same	O
extent	O
,	O
confirming	O
that	O
the	O
expectancy	O
of	O
reward	O
is	O
a	O
powerful	O
mediator	O
of	O
cognitive	O
control	O
,	O
even	O
if	O
cognitive	O
control	O
suffers	O
from	O
decline	O
.	O

The	O
expectation	O
of	O
rewarding	O
incentives	O
thus	O
seems	O
to	O
support	O
older	O
adults	O
'	O
and	O
PD	O
patients	O
'	O
ability	O
to	O
anticipate	O
,	O
prepare	O
and	O
initiate	O
goal	O
-	O
directed	O
behavior	O
.	O

These	O
findings	O
imply	O
that	O
despite	O
a	O
general	O
decline	O
in	O
the	O
action	O
preparation	O
system	O
as	O
indexed	O
by	O
increased	O
antisaccade	O
latency	O
,	O
action	O
preparation	O
processes	O
remain	O
susceptible	O
to	O
the	O
prospect	O
of	O
future	O
reward	O
.	O

It	O
could	O
thus	O
be	O
argued	O
that	O
the	O
neural	O
representations	O
of	O
upcoming	O
rewards	O
influence	O
neural	O
systems	O
concerned	O
with	O
action	O
preparation	O
and	O
oculomotor	O
control	O
.	O

Although	O
the	O
current	O
behavioral	O
results	O
can	O
not	O
exclude	O
or	O
confirm	O
neural	O
links	O
between	O
reward	O
anticipation	O
and	O
action	O
preparation	O
systems	O
in	O
the	O
brain	O
,	O
they	O
suggest	O
intact	O
cross	O
-	O
talk	O
among	O
subcortical	O
circuits	O
that	O
allow	O
goal	O
-	O
directed	O
action	O
to	O
be	O
modified	O
by	O
motivational	O
factors	O
.	O

The	O
motivational	O
neural	O
reward	O
anticipation	O
signal	O
presumably	O
activates	O
the	O
reward	O
network	O
including	O
the	O
amygdala	O
,	O
orbitofrontal	O
cortex	O
,	O
the	O
more	O
ventral	O
and	O
dorsal	O
striatum	O
(	O
nucleus	O
accumbens	O
,	O
putamen	O
,	O
and	O
caudate	O
)	O
,	O
leading	O
to	O
an	O
release	O
of	O
caudate	O
/	O
SNr	O
inhibition	O
on	O
the	O
executive	O
oculomotor	O
structure	O
superior	O
colliculus	O
.	O

This	O
transiently	O
decreased	O
inhibitory	O
force	O
on	O
superior	O
colliculus	O
may	O
improve	O
goal	O
-	O
directed	O
oculomotor	O
control	O
.	O

Thus	O
reward	O
anticipation	O
might	O
compensate	O
for	O
the	O
age	O
-	O
and	O
disease	O
-	O
related	O
dopaminergic	O
loss	O
in	O
the	O
SNc	O
projections	O
to	O
the	O
caudate	O
/	O
SNr	O
and	O
may	O
thus	O
play	O
a	O
compensatory	O
role	O
in	O
""""	O
boosting	O
""""	O
the	O
efficiency	O
of	O
interactions	O
between	O
motivational	O
and	O
impaired	O
cognitive	O
control	O
processes	O
.	O

However	O
the	O
reward	O
-	O
related	O
modulation	O
of	O
the	O
oculomotor	O
control	O
system	O
may	O
not	O
only	O
apply	O
to	O
the	O
basal	O
ganglia	O
part	O
of	O
the	O
oculomotor	O
network	O
.	O

Although	O
speculative	O
,	O
it	O
could	O
extend	O
to	O
the	O
cortical	O
eyefields	O
(	O
frontal	O
,	O
supplementary	O
,	O
and	O
parietal	O
eyefields	O
)	O
and	O
to	O
parts	O
of	O
the	O
visual	O
cortex	O
.	O

Human	O
research	O
shows	O
that	O
more	O
preparatory	O
activation	O
in	O
the	O
frontal	O
eyefields	O
leads	O
to	O
a	O
faster	O
antisaccade	O
latency	O
(	O
Connolly	O
et	O
al	O
.	O
,	O
2002	O
,	O
2005	O
)	O
.	O

The	O
compensatory	O
effect	O
on	O
the	O
antisaccade	O
latency	O
,	O
therefore	O
,	O
could	O
theoretically	O
stem	O
from	O
a	O
propagation	O
of	O
reward	O
anticipation	O
signal	O
in	O
the	O
caudate	O
to	O
the	O
frontal	O
eyefields	O
.	O

Complex	O
structural	O
connections	O
enable	O
the	O
striatum	O
to	O
exert	O
a	O
controlling	O
influence	O
over	O
the	O
cerebral	O
cortex	O
via	O
a	O
series	O
of	O
reentrant	O
corticobasal	O
ganglia	O
circuits	O
.	O

Thus	O
reward	O
anticipation	O
may	O
increase	O
the	O
level	O
of	O
preparation	O
in	O
the	O
intact	O
cortical	O
eyefields	O
and	O
thereby	O
compensate	O
for	O
age	O
-	O
and	O
disease	O
-	O
related	O
subcortical	O
decrements	O
in	O
the	O
oculomotor	O
network	O
.	O

Taken	O
together	O
,	O
it	O
seems	O
plausible	O
that	O
motivational	O
reward	O
processes	O
in	O
the	O
caudate	O
enhance	O
preparatory	O
activation	O
in	O
subcortical	O
as	O
well	O
as	O
in	O
cortical	O
nodes	O
of	O
the	O
oculomotor	O
network	O
.	O

Several	O
neurotransmission	O
mechanisms	O
may	O
underlie	O
the	O
remedial	O
effect	O
of	O
positive	O
incentives	O
on	O
declining	O
antisaccadic	O
control	O
.	O

Given	O
the	O
convergence	O
of	O
dopamine	O
and	O
glutamate	O
inputs	O
at	O
the	O
spiny	O
projection	O
neurons	O
in	O
the	O
striatum	O
(	O
Burns	O
et	O
al	O
.	O
,	O
1994	O
)	O
,	O
an	O
interaction	O
between	O
dopamine	O
and	O
glutamate	O
might	O
underlie	O
striatal	O
processes	O
of	O
reward	O
anticipation	O
and	O
action	O
preparation	O
.	O

However	O
,	O
it	O
can	O
not	O
be	O
fully	O
excluded	O
that	O
alterations	O
in	O
other	O
neurotransmitter	O
systems	O
may	O
also	O
have	O
an	O
effect	O
on	O
declining	O
oculomotor	O
control	O
and	O
on	O
remediating	O
incentive	O
effects	O
.	O

Non	O
-	O
dopaminergic	O
changes	O
such	O
as	O
noradrenergic	O
,	O
serotonergic	O
,	O
and	O
cholinergic	O
deafferentation	O
of	O
the	O
cortex	O
also	O
occur	O
in	O
PD	O
and	O
can	O
inflict	O
cognitive	O
deficits	O
(	O
Agid	O
et	O
al	O
.	O
,	O
1987	O
)	O
.	O

Evidence	O
from	O
non	O
-	O
human	O
primates	O
suggests	O
that	O
basal	O
ganglia	O
dopamine	O
acts	O
to	O
speed	O
motor	O
responding	O
in	O
response	O
to	O
rewarding	O
cues	O
(	O
Niv	O
,	O
2007	O
;	O
Niv	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

Among	O
at	O
least	O
five	O
types	O
of	O
DA	O
receptors	O
,	O
mainly	O
D1	O
and	O
D2	O
receptors	O
are	O
expressed	O
in	O
caudate	O
projection	O
neurons	O
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O

Tendencies	O
to	O
speed	O
responses	O
to	O
obtain	O
large	O
rewards	O
have	O
been	O
found	O
to	O
be	O
dependent	O
on	O
striatal	O
D1	O
receptors	O
(	O
Dalley	O
et	O
al	O
.	O
,	O
2005	O
;	O
Berridge	O
,	O
2007	O
)	O
.	O

In	O
contrast	O
to	O
this	O
D1	O
modulated	O
speeding	O
in	O
reward	O
-	O
motor	O
tasks	O
,	O
evidence	O
from	O
saccade	O
tasks	O
in	O
non	O
-	O
human	O
primates	O
suggests	O
D2	O
receptor	O
modulation	O
of	O
reward	O
dependent	O
improvements	O
of	O
performance	O
(	O
Nakamura	O
and	O
Hikosaka	O
,	O
2006	O
)	O
.	O

Injections	O
of	O
a	O
D1	O
antagonist	O
and	O
a	O
D2	O
antagonist	O
into	O
the	O
region	O
of	O
the	O
caudate	O
where	O
saccade	O
-	O
related	O
neurons	O
are	O
clustered	O
while	O
the	O
monkey	O
performed	O
a	O
reward	O
-	O
biased	O
saccade	O
task	O
showed	O
that	O
D1	O
antagonists	O
attenuate	O
the	O
reward	O
modulation	O
of	O
saccade	O
behavior	O
whereas	O
D2	O
antagonists	O
into	O
the	O
same	O
region	O
enhanced	O
the	O
reward	O
-	O
dependent	O
changes	O
.	O

Future	O
studies	O
of	O
Parkinson	O
patients	O
on	O
versus	O
off	O
medication	O
,	O
could	O
provide	O
some	O
information	O
on	O
the	O
role	O
of	O
dopaminergic	O
mechanisms	O
in	O
the	O
remedial	O
effects	O
on	O
antisaccadic	O
performance	O
.	O

A	O
recent	O
study	O
of	O
reward	O
learning	O
in	O
Parkinson	O
patients	O
on	O
/	O
off	O
dopaminergic	O
medication	O
showed	O
that	O
patients	O
adapted	O
their	O
behavior	O
to	O
maximize	O
expected	O
reward	O
value	O
dependent	O
on	O
their	O
medication	O
status	O
(	O
Moustafa	O
et	O
al	O
.	O
,	O
2008	O
)	O
.	O

Whilst	O
off	O
dopaminergic	O
medication	O
,	O
patients	O
slowed	O
their	O
responses	O
to	O
avoid	O
low	O
expected	O
values	O
,	O
but	O
succeeded	O
less	O
well	O
in	O
speeding	O
responses	O
when	O
a	O
reward	O
was	O
at	O
stake	O
.	O

The	O
opposite	O
pattern	O
emerged	O
when	O
the	O
same	O
patients	O
were	O
on	O
medication	O
;	O
patients	O
showed	O
better	O
response	O
speeding	O
,	O
and	O
worse	O
response	O
slowing	O
,	O
to	O
maximize	O
expected	O
value	O
.	O

The	O
current	O
behavioral	O
findings	O
are	O
in	O
line	O
with	O
neuroimaging	O
research	O
showing	O
intact	O
neural	O
representations	O
of	O
future	O
reward	O
in	O
the	O
aging	O
striatum	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
observation	O
however	O
that	O
older	O
adults	O
and	O
PD	O
patients	O
can	O
use	O
this	O
intact	O
neural	O
representation	O
of	O
reward	O
anticipation	O
(	O
a	O
positive	O
motivational	O
incentive	O
)	O
to	O
optimize	O
their	O
preparatory	O
processes	O
,	O
can	O
not	O
necessarily	O
be	O
generalized	O
to	O
cognitive	O
contexts	O
with	O
negative	O
motivational	O
incentives	O
.	O

Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
(	O
2010	O
)	O
recently	O
showed	O
that	O
older	O
adults	O
were	O
not	O
able	O
to	O
optimally	O
use	O
their	O
intact	O
neural	O
reward	O
anticipation	O
system	O
in	O
risky	O
financial	O
decision	O
making	O
.	O

Elderly	O
made	O
more	O
suboptimal	O
choices	O
when	O
they	O
were	O
to	O
choose	O
risky	O
assets	O
.	O

The	O
authors	O
deemed	O
it	O
likely	O
that	O
these	O
decrements	O
in	O
value	O
-	O
based	O
decision	O
making	O
are	O
explained	O
by	O
the	O
fact	O
that	O
value	O
-	O
based	O
decision	O
making	O
requires	O
the	O
weighting	O
of	O
behavioral	O
alternatives	O
,	O
that	O
may	O
lead	O
to	O
either	O
gain	O
or	O
loss	O
.	O

During	O
anticipation	O
of	O
rewards	O
older	O
adults	O
show	O
similar	O
neural	O
responses	O
as	O
young	O
adults	O
but	O
they	O
show	O
reduced	O
neural	O
activation	O
during	O
the	O
anticipation	O
of	O
losses	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
.	O

The	O
latter	O
,	O
together	O
with	O
the	O
observation	O
that	O
older	O
adults	O
tend	O
to	O
shift	O
their	O
attention	O
away	O
from	O
negative	O
stimuli	O
and	O
attend	O
to	O
positive	O
information	O
instead	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
,	O
2005	O
)	O
,	O
may	O
have	O
led	O
to	O
the	O
underestimation	O
of	O
loss	O
and	O
therefore	O
to	O
more	O
risky	O
and	O
suboptimal	O
decisions	O
.	O

In	O
this	O
respect	O
,	O
one	O
limitation	O
of	O
the	O
current	O
task	O
is	O
that	O
it	O
built	O
solely	O
on	O
reward	O
prospect	O
and	O
not	O
on	O
the	O
prospect	O
of	O
loss	O
,	O
such	O
that	O
the	O
question	O
of	O
how	O
the	O
anticipation	O
of	O
loss	O
influences	O
action	O
preparation	O
was	O
not	O
tested	O
.	O

The	O
impact	O
of	O
negative	O
incentives	O
might	O
be	O
an	O
intriguing	O
question	O
for	O
future	O
research	O
,	O
as	O
due	O
to	O
the	O
decreased	O
activation	O
of	O
the	O
neural	O
loss	O
anticipation	O
system	O
(	O
Samanez	O
-	O
Larkin	O
et	O
al	O
.	O
,	O
2007	O
)	O
together	O
with	O
the	O
observed	O
differential	O
attentional	O
bias	O
for	O
negative	O
and	O
positive	O
information	O
(	O
Mather	O
and	O
Carstensen	O
,	O
2003	O
)	O
,	O
it	O
seems	O
likely	O
that	O
negative	O
motivational	O
incentives	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
prospect	O
of	O
loss	O
,	O
might	O
have	O
a	O
different	O
impact	O
on	O
action	O
preparation	O
in	O
older	O
adults	O
than	O
in	O
the	O
young	O
.	O

Future	O
approaches	O
to	O
the	O
effect	O
of	O
loss	O
anticipation	O
on	O
declining	O
antisaccade	O
control	O
may	O
ideally	O
contain	O
a	O
sequence	O
of	O
experiments	O
,	O
starting	O
with	O
a	O
separate	O
(	O
punishment	O
only	O
)	O
approach	O
before	O
moving	O
to	O
combined	O
reward	O
-	O
punishment	O
designs	O
.	O

This	O
might	O
be	O
necessary	O
as	O
previous	O
evidence	O
(	O
from	O
healthy	O
young	O
adults	O
)	O
suggests	O
that	O
the	O
reward	O
effect	O
on	O
oculomotor	O
control	O
disappears	O
in	O
the	O
presence	O
of	O
punishment	O
trials	O
.	O

The	O
authors	O
deemed	O
it	O
likely	O
that	O
the	O
participants	O
increased	O
caution	O
to	O
all	O
incentive	O
(	O
reward	O
and	O
punishment	O
)	O
trials	O
(	O
Blaukopf	O
and	O
DiGirolamo	O
,	O
2006	O
)	O
.	O

As	O
of	O
yet	O
,	O
age	O
-	O
related	O
changes	O
in	O
neural	O
reward	O
anticipation	O
have	O
mainly	O
been	O
studied	O
in	O
isolation	O
.	O

Recently	O
however	O
,	O
the	O
interaction	O
of	O
neural	O
reward	O
processing	O
with	O
other	O
cognitive	O
functions	O
and	O
their	O
underlying	O
neural	O
systems	O
,	O
such	O
as	O
the	O
action	O
control	O
system	O
,	O
has	O
gained	O
increasing	O
interest	O
(	O
Haber	O
and	O
Knutson	O
,	O
2010	O
)	O
.	O

Initial	O
evidence	O
suggests	O
coordinated	O
activity	O
between	O
distant	O
brain	O
regions	O
responsible	O
for	O
reward	O
processing	O
(	O
Cohen	O
et	O
al	O
.	O
,	O
2009	O
)	O
.	O

The	O
current	O
results	O
encourage	O
further	O
neural	O
network	O
investigations	O
on	O
the	O
role	O
of	O
coordinated	O
brain	O
network	O
activity	O
in	O
motivated	O
behavior	O
.	O

Behavioral	O
benefits	O
from	O
motivation	O
might	O
be	O
associated	O
with	O
changes	O
in	O
functional	O
brain	O
connectivity	O
on	O
a	O
larger	O
scale	O
,	O
e	O
.	O
g	O
.	O
,	O
between	O
frontostriatal	O
reward	O
and	O
action	O
preparation	O
structures	O
.	O

Another	O
important	O
factor	O
that	O
emerges	O
from	O
the	O
present	O
and	O
previous	O
results	O
,	O
is	O
the	O
importance	O
of	O
the	O
training	O
of	O
the	O
motivational	O
aspects	O
of	O
the	O
instructions	O
that	O
need	O
to	O
be	O
kept	O
in	O
working	O
memory	O
when	O
performing	O
a	O
cognitive	O
task	O
.	O

Samanez	O
-	O
Larkin	O
et	O
al	O
.	O

(	O
2007	O
)	O
found	O
intact	O
neural	O
reward	O
anticipation	O
processes	O
specifically	O
in	O
the	O
absence	O
of	O
learning	O
(	O
after	O
the	O
learning	O
process	O
of	O
reward	O
cue	O
-	O
reward	O
associations	O
was	O
completed	O
)	O
.	O

Therefore	O
it	O
might	O
be	O
important	O
for	O
researchers	O
doing	O
experiments	O
with	O
motivation	O
based	O
instructions	O
to	O
keep	O
in	O
mind	O
that	O
,	O
compared	O
to	O
young	O
adults	O
,	O
elderly	O
and	O
PD	O
patients	O
are	O
generally	O
hampered	O
on	O
stimulus	O
-	O
response	O
learning	O
(	O
Shohamy	O
et	O
al	O
.	O
,	O
2004	O
;	O
Marschner	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Reward	O
instruction	O
cues	O
,	O
as	O
they	O
were	O
used	O
in	O
the	O
current	O
study	O
require	O
participants	O
to	O
form	O
reward	O
cue	O
-	O
reward	O
associations	O
.	O

Impairments	O
in	O
the	O
learning	O
of	O
associations	O
between	O
the	O
cue	O
signaling	O
reward	O
and	O
the	O
actual	O
reward	O
might	O
conceal	O
intact	O
reward	O
anticipation	O
processes	O
.	O

When	O
the	O
formation	O
of	O
associations	O
is	O
weakened	O
,	O
it	O
could	O
appear	O
as	O
a	O
failure	O
to	O
capitalize	O
on	O
the	O
neural	O
reward	O
anticipation	O
system	O
,	O
whereas	O
it	O
represents	O
an	O
indirect	O
effect	O
of	O
non	O
-	O
available	O
reward	O
associations	O
in	O
working	O
memory	O
when	O
preparing	O
the	O
response	O
.	O

Hence	O
,	O
one	O
might	O
circumvent	O
the	O
effect	O
of	O
potential	O
learning	O
impairments	O
on	O
reward	O
anticipation	O
processes	O
by	O
the	O
training	O
of	O
abstract	O
reward	O
cues	O
(	O
as	O
in	O
the	O
current	O
and	O
in	O
Samanez	O
-	O
Larkin	O
'	O
s	O
study	O
)	O
or	O
by	O
using	O
explicit	O
and	O
concrete	O
rewards	O
.	O

Once	O
the	O
learning	O
of	O
reward	O
cues	O
is	O
accomplished	O
the	O
intact	O
reward	O
anticipation	O
processes	O
might	O
become	O
evident	O
.	O

In	O
sum	O
,	O
the	O
results	O
confirmed	O
that	O
the	O
preparation	O
of	O
goal	O
-	O
directed	O
actions	O
declined	O
in	O
PD	O
patients	O
compared	O
to	O
healthy	O
seniors	O
,	O
and	O
in	O
healthy	O
seniors	O
compared	O
to	O
young	O
adults	O
.	O

Due	O
perhaps	O
to	O
deterioration	O
in	O
dopaminergic	O
striatal	O
circuitry	O
,	O
antisaccade	O
performance	O
is	O
subject	O
to	O
decline	O
in	O
healthy	O
seniors	O
,	O
and	O
even	O
more	O
in	O
individuals	O
with	O
Parkinson	O
'	O
s	O
disease	O
.	O

The	O
prospect	O
of	O
future	O
reward	O
however	O
provided	O
a	O
motivational	O
incentive	O
for	O
optimizing	O
oculomotor	O
preparation	O
in	O
all	O
groups	O
alike	O
.	O

These	O
results	O
suggest	O
that	O
reward	O
-	O
processing	O
networks	O
and	O
oculomotor	O
-	O
control	O
networks	O
in	O
the	O
brain	O
are	O
connected	O
in	O
such	O
a	O
way	O
(	O
presumably	O
with	O
the	O
dorsal	O
striatum	O
as	O
a	O
common	O
nexus	O
)	O
that	O
reward	O
anticipation	O
can	O
facilitate	O
oculomotor	O
control	O
and	O
alleviate	O
the	O
deficiencies	O
experienced	O
by	O
healthy	O
seniors	O
and	O
PD	O
patients	O
.	O

Future	O
investigations	O
should	O
examine	O
whether	O
the	O
observed	O
effects	O
are	O
specific	O
for	O
the	O
current	O
task	O
or	O
generalize	O
to	O
other	O
tasks	O
that	O
show	O
age	O
-	O
and	O
PD	O
-	O
related	O
cognitive	O
decrements	O
(	O
e	O
.	O
g	O
.	O
,	O
in	O
task	O
switching	O
)	O
and	O
have	O
been	O
related	O
to	O
dopaminergic	O
denervation	O
in	O
the	O
caudate	O
(	O
e	O
.	O
g	O
.	O
,	O
impaired	O
verbal	O
episodic	O
memory	O
,	O
attention	O
,	O
and	O
response	O
inhibition	O
;	O
Rinne	O
et	O
al	O
.	O
,	O
2000	O
;	O
Bruck	O
et	O
al	O
.	O
,	O
2005	O
)	O
.	O

Future	O
studies	O
on	O
network	O
processes	O
may	O
help	O
to	O
localize	O
the	O
neural	O
link	O
between	O
reward	O
prospect	O
and	O
action	O
preparation	O
that	O
enables	O
alleviating	O
effects	O
of	O
motivational	O
incentives	O
on	O
cognitive	O
decline	O
.	O

Atomic	O
displacement	O
parameters	O
(	O
A2	O
)	O

U11	O
U22	O
U33	O
U12	O
U13	O
U23	O

Br	O
0	O
.	O
03555	O
(	O
15	O
)	O
0	O
.	O
05091	O
(	O
17	O
)	O
0	O
.	O
03161	O
(	O
14	O
)	O
-	O
0	O
.	O
01198	O
(	O
11	O
)	O
0	O
.	O
01077	O
(	O
10	O
)	O
-	O
0	O
.	O
00502	O
(	O
11	O
)	O

S	O
0	O
.	O
0273	O
(	O
3	O
)	O
0	O
.	O
0176	O
(	O
2	O
)	O
0	O
.	O
0338	O
(	O
3	O
)	O
0	O
.	O
0016	O
(	O
2	O
)	O
-	O
0	O
.	O
0020	O
(	O
2	O
)	O
0	O
.	O
0026	O
(	O
2	O
)	O

F	O
0	O
.	O
0514	O
(	O
10	O
)	O
0	O
.	O
0486	O
(	O
9	O
)	O
0	O
.	O
0464	O
(	O
9	O
)	O
0	O
.	O
0068	O
(	O
8	O
)	O
0	O
.	O
0279	O
(	O
8	O
)	O
-	O
0	O
.	O
0001	O
(	O
7	O
)	O

O1	O
0	O
.	O
0293	O
(	O
8	O
)	O
0	O
.	O
0186	O
(	O
7	O
)	O
0	O
.	O
0251	O
(	O
7	O
)	O
-	O
0	O
.	O
0030	O
(	O
6	O
)	O
0	O
.	O
0028	O
(	O
6	O
)	O
0	O
.	O
0004	O
(	O
6	O
)	O

O2A	O
0	O
.	O
0417	O
(	O
12	O
)	O
0	O
.	O
0238	O
(	O
9	O
)	O
0	O
.	O
0326	O
(	O
10	O
)	O
-	O
0	O
.	O
0001	O
(	O
8	O
)	O
-	O
0	O
.	O
0051	O
(	O
8	O
)	O
0	O
.	O
0102	O
(	O
7	O
)	O

O2B	O
0	O
.	O
036	O
(	O
11	O
)	O
0	O
.	O
010	O
(	O
7	O
)	O
0	O
.	O
025	O
(	O
9	O
)	O
-	O
0	O
.	O
003	O
(	O
7	O
)	O
0	O
.	O
003	O
(	O
7	O
)	O
0	O
.	O
007	O
(	O
6	O
)	O

C1	O
0	O
.	O
0228	O
(	O
11	O
)	O
0	O
.	O
0192	O
(	O
9	O
)	O
0	O
.	O
0233	O
(	O
10	O
)	O
0	O
.	O
0001	O
(	O
8	O
)	O
-	O
0	O
.	O
0023	O
(	O
8	O
)	O
0	O
.	O
0019	O
(	O
8	O
)	O

C2	O
0	O
.	O
0258	O
(	O
11	O
)	O
0	O
.	O
0199	O
(	O
10	O
)	O
0	O
.	O
0193	O
(	O
9	O
)	O
0	O
.	O
0000	O
(	O
8	O
)	O
-	O
0	O
.	O
0033	O
(	O
8	O
)	O
0	O
.	O
0016	O
(	O
7	O
)	O

C3	O
0	O
.	O
0263	O
(	O
11	O
)	O
0	O
.	O
0229	O
(	O
10	O
)	O
0	O
.	O
0177	O
(	O
9	O
)	O
-	O
0	O
.	O
0020	O
(	O
8	O
)	O
-	O
0	O
.	O
0031	O
(	O
8	O
)	O
0	O
.	O
0008	O
(	O
8	O
)	O

C4	O
0	O
.	O
0294	O
(	O
12	O
)	O
0	O
.	O
0228	O
(	O
10	O
)	O
0	O
.	O
0277	O
(	O
11	O
)	O
-	O
0	O
.	O
0014	O
(	O
9	O
)	O
-	O
0	O
.	O
0008	O
(	O
9	O
)	O
0	O
.	O
0027	O
(	O
8	O
)	O

C5	O
0	O
.	O
0323	O
(	O
13	O
)	O
0	O
.	O
0297	O
(	O
11	O
)	O
0	O
.	O
0285	O
(	O
11	O
)	O
-	O
0	O
.	O
0081	O
(	O
10	O
)	O
-	O
0	O
.	O
0003	O
(	O
9	O
)	O
0	O
.	O
0042	O
(	O
9	O
)	O

C6	O
0	O
.	O
0257	O
(	O
12	O
)	O
0	O
.	O
0389	O
(	O
13	O
)	O
0	O
.	O
0207	O
(	O
10	O
)	O
-	O
0	O
.	O
0049	O
(	O
10	O
)	O
0	O
.	O
0013	O
(	O
8	O
)	O
0	O
.	O
0001	O
(	O
9	O
)	O

C7	O
0	O
.	O
0320	O
(	O
13	O
)	O
0	O
.	O
0304	O
(	O
11	O
)	O
0	O
.	O
0218	O
(	O
10	O
)	O
0	O
.	O
0015	O
(	O
9	O
)	O
0	O
.	O
0009	O
(	O
9	O
)	O
-	O
0	O
.	O
0005	O
(	O
9	O
)	O

C8	O
0	O
.	O
0298	O
(	O
12	O
)	O
0	O
.	O
0257	O
(	O
10	O
)	O
0	O
.	O
0178	O
(	O
9	O
)	O
0	O
.	O
0006	O
(	O
9	O
)	O
-	O
0	O
.	O
0012	O
(	O
8	O
)	O
0	O
.	O
0001	O
(	O
8	O
)	O

C9	O
0	O
.	O
0392	O
(	O
14	O
)	O
0	O
.	O
0205	O
(	O
10	O
)	O
0	O
.	O
0219	O
(	O
10	O
)	O
0	O
.	O
0034	O
(	O
9	O
)	O
0	O
.	O
0031	O
(	O
9	O
)	O
-	O
0	O
.	O
0010	O
(	O
8	O
)	O

C10	O
0	O
.	O
0378	O
(	O
13	O
)	O
0	O
.	O
0184	O
(	O
10	O
)	O
0	O
.	O
0234	O
(	O
10	O
)	O
-	O
0	O
.	O
0017	O
(	O
9	O
)	O
0	O
.	O
0014	O
(	O
9	O
)	O
0	O
.	O
0006	O
(	O
8	O
)	O

C11	O
0	O
.	O
0254	O
(	O
11	O
)	O
0	O
.	O
0227	O
(	O
10	O
)	O
0	O
.	O
0198	O
(	O
10	O
)	O
-	O
0	O
.	O
0024	O
(	O
8	O
)	O
0	O
.	O
0004	O
(	O
8	O
)	O
0	O
.	O
0006	O
(	O
8	O
)	O

C12	O
0	O
.	O
0254	O
(	O
11	O
)	O
0	O
.	O
0187	O
(	O
10	O
)	O
0	O
.	O
0222	O
(	O
10	O
)	O
-	O
0	O
.	O
0003	O
(	O
8	O
)	O
-	O
0	O
.	O
0032	O
(	O
8	O
)	O
-	O
0	O
.	O
0007	O
(	O
7	O
)	O

C13	O
0	O
.	O
0237	O
(	O
11	O
)	O
0	O
.	O
0220	O
(	O
10	O
)	O
0	O
.	O
0222	O
(	O
10	O
)	O
0	O
.	O
0012	O
(	O
8	O
)	O
-	O
0	O
.	O
0008	O
(	O
8	O
)	O
0	O
.	O
0030	O
(	O
8	O
)	O

C14	O
0	O
.	O
0298	O
(	O
12	O
)	O
0	O
.	O
0241	O
(	O
10	O
)	O
0	O
.	O
0286	O
(	O
11	O
)	O
-	O
0	O
.	O
0009	O
(	O
9	O
)	O
-	O
0	O
.	O
0007	O
(	O
9	O
)	O
-	O
0	O
.	O
0006	O
(	O
9	O
)	O

C15	O
0	O
.	O
0408	O
(	O
14	O
)	O
0	O
.	O
0267	O
(	O
11	O
)	O
0	O
.	O
0269	O
(	O
11	O
)	O
0	O
.	O
0049	O
(	O
10	O
)	O
0	O
.	O
0028	O
(	O
10	O
)	O
-	O
0	O
.	O
0031	O
(	O
9	O
)	O

C16	O
0	O
.	O
0353	O
(	O
14	O
)	O
0	O
.	O
0326	O
(	O
12	O
)	O
0	O
.	O
0294	O
(	O
12	O
)	O
0	O
.	O
0094	O
(	O
10	O
)	O
0	O
.	O
0094	O
(	O
10	O
)	O
0	O
.	O
0058	O
(	O
9	O
)	O

C17	O
0	O
.	O
0255	O
(	O
12	O
)	O
0	O
.	O
0281	O
(	O
11	O
)	O
0	O
.	O
0349	O
(	O
12	O
)	O
-	O
0	O
.	O
0001	O
(	O
9	O
)	O
0	O
.	O
0015	O
(	O
9	O
)	O
0	O
.	O
0082	O
(	O
9	O
)	O

C18	O
0	O
.	O
0271	O
(	O
12	O
)	O
0	O
.	O
0231	O
(	O
10	O
)	O
0	O
.	O
0250	O
(	O
11	O
)	O
0	O
.	O
0002	O
(	O
9	O
)	O
-	O
0	O
.	O
0032	O
(	O
9	O
)	O
0	O
.	O
0011	O
(	O
8	O
)	O

C19	O
0	O
.	O
0353	O
(	O
14	O
)	O
0	O
.	O
0251	O
(	O
11	O
)	O
0	O
.	O
0375	O
(	O
13	O
)	O
-	O
0	O
.	O
0045	O
(	O
10	O
)	O
-	O
0	O
.	O
0070	O
(	O
10	O
)	O
-	O
0	O
.	O
0012	O
(	O
9	O
)	O

Different	O
ROC	O
analysis	O

When	O
the	O
true	O
positive	O
peptides	O
are	O
not	O
known	O
a	O
priori	O
,	O
there	O
exist	O
various	O
strategies	O
in	O
classifying	O
hits	O
into	O
true	O
or	O
false	O
positives	O
when	O
making	O
a	O
ROC	O
plot	O
.	O

These	O
strategies	O
,	O
unfortunately	O
,	O
will	O
make	O
a	O
notable	O
difference	O
in	O
retrieval	O
assessment	O
.	O

For	O
example	O
,	O
in	O
a	O
cell	O
lysate	O
experiment	O
of	O
a	O
certain	O
organism	O
,	O
it	O
is	O
customary	O
to	O
estimate	O
the	O
number	O
of	O
false	O
positive	O
hits	O
by	O
introducing	O
a	O
decoy	O
database	O
during	O
the	O
data	O
analysis	O
.	O

The	O
main	O
idea	O
there	O
is	O
to	O
first	O
sort	O
the	O
peptide	O
hits	O
according	O
to	O
their	O
scores	O
.	O

Then	O
for	O
each	O
decoy	O
hit	O
,	O
one	O
assumes	O
that	O
there	O
is	O
just	O
one	O
corresponding	O
false	O
hit	O
in	O
the	O
target	O
database	O
.	O

This	O
strategy	O
has	O
been	O
used	O
extensively	O
[	O
24	O
]	O
.	O

ROC	O
analyses	O
done	O
this	O
way	O
generally	O
count	O
false	O
positives	O
,	O
which	O
are	O
highly	O
homologous	O
to	O
the	O
target	O
peptides	O
,	O
towards	O
true	O
positives	O
.	O

This	O
has	O
two	O
effects	O
:	O
an	O
overcount	O
of	O
true	O
positives	O
and	O
a	O
undercount	O
of	O
false	O
positives	O
.	O

As	O
a	O
consequence	O
,	O
the	O
ROC	O
curves	O
will	O
appear	O
more	O
impressive	O
.	O

To	O
mimick	O
this	O
situation	O
,	O
we	O
used	O
BLAST	O
to	O
find	O
in	O
the	O
NCBI	O
'	O
s	O
nr	O
database	O
highly	O
homologous	O
proteins	O
to	O
the	O
target	O
proteins	O
used	O
in	O
the	O
experiment	O
and	O
include	O
those	O
proteins	O
in	O
our	O
true	O
positive	O
set	O
.	O

This	O
strategy	O
produces	O
ROC	O
curves	O
shown	O
as	O
the	O
solid	O
curves	O
of	O
Figure	O
S8	O
.	O

When	O
compared	O
to	O
Figure	O
6	O
and	O
Figure	O
S6	O
,	O
the	O
ROC	O
curves	O
produced	O
by	O
this	O
strategy	O
seem	O
much	O
more	O
impressive	O
.	O

Not	O
counting	O
highly	O
homologous	O
proteins	O
as	O
false	O
positives	O
would	O
probably	O
be	O
agreeable	O
.	O

However	O
,	O
counting	O
those	O
peptides	O
/	O
proteins	O
as	O
true	O
positives	O
could	O
be	O
exaggerating	O
.	O

Therefore	O
one	O
may	O
use	O
a	O
slightly	O
different	O
strategy	O
:	O
removing	O
from	O
consideration	O
proteins	O
homologous	O
to	O
the	O
target	O
proteins	O
,	O
which	O
is	O
called	O
the	O
cluster	O
removal	O
strategy	O
[	O
11	O
]	O
.	O

The	O
dashed	O
curves	O
of	O
Figure	O
S9	O
are	O
ROC	O
curves	O
obtained	O
this	O
way	O
.	O

This	O
strategy	O
also	O
produces	O
slightly	O
more	O
impressive	O
ROC	O
curves	O
than	O
in	O
Figure	O
6	O
and	O
Figure	O
S6	O
.	O

Apparently	O
,	O
this	O
indicates	O
the	O
highly	O
homologous	O
false	O
positive	O
hits	O
are	O
the	O
ones	O
that	O
degrade	O
the	O
retrieval	O
performance	O
.	O

Thus	O
,	O
it	O
can	O
be	O
useful	O
to	O
remove	O
those	O
false	O
positives	O
from	O
consideration	O
.	O

Keeping	O
only	O
the	O
best	O
hit	O
per	O
spectrum	O
turns	O
out	O
to	O
be	O
one	O
way	O
to	O
achieve	O
this	O
goal	O
.	O

Crystal	O
data	O

C24H21ClN4O2S	O

M	O
r	O
=	O
464	O
.	O
96	O

Triclinic	O
,	O

a	O
=	O
8	O
.	O
6798	O
(	O
18	O
)	O
A	O

b	O
=	O
11	O
.	O
078	O
(	O
2	O
)	O
A	O

c	O
=	O
11	O
.	O
372	O
(	O
2	O
)	O
A	O

alpha	O
=	O
78	O
.	O
984	O
(	O
7	O
)	O
degrees	O

beta	O
=	O
81	O
.	O
867	O
(	O
10	O
)	O
degrees	O

gamma	O
=	O
81	O
.	O
718	O
(	O
11	O
)	O
degrees	O

V	O
=	O
1054	O
.	O
8	O
(	O
4	O
)	O
A3	O

Z	O
=	O
2	O

Cu	O
Kalpha	O
radiation	O

mu	O
=	O
2	O
.	O
78	O
mm	O
-	O
1	O

T	O
=	O
113	O
K	O

0	O
.	O
28	O
x	O
0	O
.	O
24	O
x	O
0	O
.	O
20	O
mm	O

Characteristics	O
of	O
fistula	O
lesions	O

Selective	O
SMA	O
angiography	O
was	O
performed	O
5	O
h	O
from	O
onset	O
.	O

Before	O
therapy	O
,	O
the	O
SMA	O
was	O
completely	O
occluded	O
by	O
an	O
embolus	O
at	O
the	O
proximal	O
portion	O
(	O
a	O
)	O
,	O
and	O
after	O
the	O
bolus	O
infusion	O
of	O
urokinase	O
(	O
600	O
,	O
000	O
IU	O
)	O
into	O
the	O
SMA	O
,	O
peripheral	O
blood	O
flow	O
was	O
improved	O
.	O

However	O
,	O
the	O
thrombus	O
decreased	O
in	O
size	O
,	O
but	O
remained	O
(	O
b	O
)	O
.	O

Asterisks	O
indicate	O
thrombus	O
.	O

Measurement	O
of	O
IgA1	O
content	O

IgA1	O
content	O
in	O
the	O
supernatant	O
from	O
each	O
culture	O
well	O
was	O
measured	O
in	O
duplicate	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

All	O
incubations	O
were	O
performed	O
at	O
room	O
temperature	O
except	O
for	O
capture	O
antibody	O
coating	O
.	O

Briefly	O
,	O
96	O
-	O
well	O
immunoplates	O
(	O
Thermo	O
Fisher	O
Scientific	O
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
were	O
coated	O
with	O
5	O
microg	O
/	O
mL	O
of	O
F	O
(	O
ab	O
'	O
)	O
2	O
fragment	O
goat	O
anti	O
-	O
human	O
IgA	O
antibody	O
(	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
,	O
USA	O
)	O
,	O
in	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
)	O
at	O
4degreesC	O
overnight	O
.	O

After	O
three	O
washes	O
with	O
PBS	O
containing	O
0	O
.	O
05	O
%	O
Tween	O
-	O
20	O
(	O
PBST	O
)	O
,	O
plates	O
were	O
blocked	O
by	O
adding	O
PBS	O
containing	O
1	O
%	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
to	O
the	O
wells	O
for	O
90	O
min	O
.	O

Next	O
,	O
50	O
microL	O
of	O
supernatant	O
sample	O
or	O
standard	O
human	O
IgA1	O
(	O
CALBIOCHEM	O
,	O
La	O
Jolla	O
,	O
CA	O
,	O
USA	O
)	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O

After	O
three	O
washes	O
,	O
0	O
.	O
75	O
microg	O
/	O
mL	O
alkaline	O
phosphatase	O
conjugated	O
goat	O
anti	O
-	O
human	O
IgA	O
(	O
Southern	O
Biotechnology	O
Associates	O
,	O
Birmingham	O
,	O
AL	O
,	O
USA	O
)	O
in	O
1	O
%	O
BSA	O
/	O
PBS	O
was	O
added	O
to	O
the	O
reaction	O
wells	O
and	O
then	O
incubated	O
for	O
90	O
min	O
.	O

Plates	O
were	O
washed	O
three	O
times	O
and	O
developed	O
with	O
a	O
substrate	O
solution	O
of	O
1	O
mg	O
/	O
mL	O
p	O
-	O
nitrophenyl	O
phosphate	O
disodium	O
salt	O
(	O
SIGMA	O
,	O
St	O
.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
in	O
0	O
.	O
1	O
M	O
glycine	O
buffer	O
containing	O
1	O
mM	O
MgCl2	O
,	O
1	O
mM	O
ZnCl2	O
,	O
pH	O
10	O
.	O
4	O
.	O

The	O
optical	O
density	O
at	O
405	O
nm	O
was	O
determined	O
in	O
a	O
microplate	O
reader	O
(	O
Benchmark	O
PlusTM	O
Bio	O
-	O
Rad	O
Laboratories	O
,	O
Hercules	O
,	O
CA	O
,	O
USA	O
)	O
.	O

IgA1	O
concentration	O
in	O
unknown	O
duplicate	O
samples	O
was	O
determined	O
by	O
interpolation	O
of	O
the	O
respective	O
optical	O
density	O
into	O
the	O
appropriate	O
standard	O
curve	O
.	O

IgG	O
and	O
IgM	O
contents	O
in	O
the	O
supernatant	O
were	O
measured	O
using	O
sandwich	O
ELISA	O
(	O
IMMUNOtek	O
(	O
R	O
)	O
,	O
ZeptoMetrix	O
Corporation	O
,	O
Buffalo	O
,	O
NY	O
,	O
USA	O
)	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

Results	O
and	O
Discussion	O

Figure	O
4	O
shows	O
the	O
frequency	O
response	O
of	O
the	O
device	O
before	O
and	O
after	O
plating	O
cells	O
.	O

In	O
the	O
frequency	O
range	O
measured	O
(	O
4	O
-	O
600	O
Hz	O
)	O
,	O
only	O
two	O
clear	O
peaks	O
can	O
be	O
seen	O
in	O
the	O
bare	O
device	O
.	O

After	O
cells	O
had	O
adhered	O
to	O
the	O
surface	O
,	O
there	O
is	O
a	O
shift	O
in	O
both	O
the	O
resonant	O
frequency	O
and	O
the	O
height	O
of	O
these	O
peaks	O
.	O

Table	O
1	O
shows	O
the	O
results	O
for	O
this	O
trial	O
and	O
a	O
second	O
trial	O
where	O
the	O
experiment	O
was	O
repeated	O
to	O
confirm	O
the	O
initial	O
results	O
.	O

At	O
a	O
plating	O
density	O
of	O
1300	O
cells	O
/	O
mm2	O
,	O
there	O
were	O
approximately	O
140	O
cells	O
on	O
the	O
portion	O
of	O
the	O
cantilever	O
free	O
to	O
vibrate	O
(	O
dimensions	O
shown	O
in	O
Figure	O
1	O
)	O
.	O

Table	O
1	O

Cantilever	O
response	O
data	O
from	O
two	O
trials	O

Experiment	O
#	O
1	O
Experiment	O
#	O
2	O

Freq	O
.	O

1	O
(	O
kHz	O
)	O
Amp	O
.	O

1	O
(	O
deg	O
)	O
Freq	O
.	O

2	O
(	O
kHz	O
)	O
Amp	O
.	O

2	O
(	O
deg	O
)	O
Freq	O
.	O

1	O
(	O
kHz	O
)	O
Amp	O
.	O

1	O
(	O
deg	O
)	O
Freq	O
.	O

2	O
(	O
kHz	O
)	O
Amp	O
.	O

2	O
(	O
deg	O
)	O

Initial	O
313	O
.	O
0	O
.	O
086	O
375	O
.	O
5	O
.	O
055	O
313	O
.	O
9	O
.	O
091	O
376	O
.	O
5	O
.	O
071	O

With	O
cells	O
307	O
.	O
5	O
.	O
031	O
371	O
.	O
0	O
.	O
018	O
308	O
.	O
052	O
370	O
.	O
5	O
.	O
043	O

Change	O
5	O
.	O
5	O
.	O
055	O
4	O
.	O
5	O
.	O
037	O
5	O
.	O
9	O
.	O
039	O
6	O
.	O
0	O
.	O
028	O

Figure	O
4	O

Phase	O
angle	O
vs	O
.	O
frequency	O
.	O

(	O
left	O
)	O
Phase	O
angle	O
of	O
impedance	O
with	O
linear	O
regression	O
line	O
.	O

(	O
right	O
)	O
To	O
provide	O
an	O
easier	O
comparison	O
,	O
phase	O
angles	O
have	O
been	O
levelled	O
with	O
respect	O
to	O
the	O
linear	O
regression	O
line	O
that	O
passes	O
through	O
each	O
set	O
of	O
data	O
.	O

The	O
addition	O
of	O
cells	O
causes	O
the	O
peaks	O
to	O
shift	O
to	O
lower	O
frequencies	O
and	O
decrease	O
in	O
amplitude	O
.	O

The	O
two	O
peaks	O
shown	O
were	O
the	O
only	O
detectable	O
resonances	O
despite	O
the	O
relatively	O
wide	O
frequency	O
range	O
measured	O
.	O

The	O
electrical	O
detection	O
of	O
resonances	O
is	O
critically	O
compromised	O
by	O
the	O
strong	O
damping	O
imposed	O
by	O
the	O
cell	O
media	O
,	O
making	O
these	O
measurements	O
more	O
challenging	O
than	O
those	O
carried	O
out	O
in	O
air	O
or	O
in	O
a	O
vacuum	O
where	O
resonance	O
peaks	O
show	O
much	O
larger	O
amplitude	O
[	O
18	O
]	O
.	O

In	O
the	O
desired	O
in	O
vivo	O
application	O
for	O
this	O
work	O
,	O
as	O
a	O
sensor	O
for	O
stent	O
healing	O
,	O
it	O
can	O
be	O
expected	O
that	O
in	O
the	O
course	O
of	O
normal	O
healing	O
the	O
stent	O
will	O
be	O
fully	O
populated	O
with	O
a	O
significantly	O
thicker	O
layer	O
of	O
endothelial	O
cells	O
.	O

In	O
the	O
case	O
of	O
restenosis	O
,	O
this	O
lining	O
would	O
be	O
even	O
thicker	O
.	O

This	O
may	O
hamper	O
any	O
movement	O
of	O
the	O
cantilever	O
and	O
cause	O
the	O
peaks	O
to	O
eventually	O
become	O
undetectable	O
.	O

Frequent	O
measurements	O
of	O
the	O
resonant	O
frequencies	O
will	O
differentiate	O
this	O
end	O
state	O
with	O
the	O
possibility	O
of	O
device	O
failure	O
.	O

The	O
noninvasive	O
nature	O
of	O
these	O
measurements	O
that	O
can	O
be	O
transmitted	O
wirelessly	O
to	O
an	O
external	O
device	O
make	O
this	O
an	O
attractive	O
and	O
low	O
risk	O
option	O
for	O
monitoring	O
healing	O
.	O

The	O
thickness	O
of	O
the	O
inner	O
retina	O
was	O
established	O
as	O
the	O
distance	O
between	O
retinal	O
nerve	O
fiber	O
layer	O
and	O
inner	O
nuclear	O
layer	O
and	O
was	O
measured	O
using	O
the	O
1	O
,	O
000	O
mum	O
caliper	O
available	O
in	O
the	O
OCT	O
-	O
SLO	O
Spectralis	O
.	O

Ten	O
age	O
-	O
matched	O
normal	O
eyes	O
were	O
used	O
as	O
controls	O
.	O

Observe	O
the	O
decrease	O
in	O
the	O
nasal	O
and	O
temporal	O
inner	O
retinal	O
thickness	O
in	O
the	O
right	O
eye	O
in	O
comparison	O
to	O
the	O
left	O
and	O
normal	O
control	O
eyes	O
.	O

2	O
.	O
1	O
.	O

Genome	O
sequencing	O
,	O
assembly	O
and	O
validation	O

DNA	O
shotgun	O
libraries	O
with	O
average	O
insert	O
sizes	O
of	O
1	O
.	O
6	O
and	O
6	O
.	O
5	O
kb	O
were	O
constructed	O
in	O
pUC118	O
(	O
TaKaRa	O
)	O
,	O
whereas	O
a	O
fosmid	O
library	O
with	O
average	O
insert	O
size	O
of	O
37	O
kb	O
was	O
constructed	O
in	O
pCC1FOS	O
(	O
EPICENTRE	O
)	O
as	O
described	O
previously	O
.	O
18	O
,	O
19	O
A	O
total	O
of	O
50	O
400	O
clones	O
(	O
34	O
560	O
,	O
10	O
752	O
and	O
5088	O
clones	O
from	O
libraries	O
with	O
1	O
.	O
6	O
,	O
6	O
.	O
5	O
and	O
37	O
kb	O
inserts	O
,	O
respectively	O
)	O
were	O
subjected	O
to	O
sequencing	O
from	O
both	O
ends	O
of	O
the	O
inserts	O
on	O
either	O
ABI	O
3730xl	O
DNA	O
Analyzer	O
(	O
Applied	O
Biosystems	O
)	O
or	O
Base	O
Station	O
DNA	O
Fragment	O
Analyzer	O
BST	O
-	O
0100	O
(	O
MJ	O
Research	O
,	O
Inc	O
.	O
)	O
.	O

Sequence	O
reads	O
were	O
trimmed	O
at	O
a	O
threshold	O
quality	O
value	O
of	O
20	O
by	O
Phred	O
and	O
assembled	O
by	O
Phrap	O
and	O
CONSED	O
assembly	O
tools	O
.	O
20	O
,	O
21	O
For	O
alignment	O
and	O
validation	O
of	O
contigs	O
,	O
Optical	O
Mapping	O
(	O
OpGen	O
)	O
was	O
used	O
.	O

Gaps	O
between	O
contigs	O
were	O
closed	O
by	O
sequencing	O
PCR	O
products	O
,	O
which	O
bridge	O
two	O
neighboring	O
contigs	O
.	O

Finally	O
,	O
each	O
base	O
of	O
K	O
.	O
setae	O
NBRC	O
14216	O
T	O
genome	O
was	O
ensured	O
to	O
be	O
sequenced	O
from	O
multiple	O
clones	O
and	O
from	O
both	O
directions	O
with	O
Phrap	O
quality	O
score	O
>	O
=	O
70	O
or	O
from	O
one	O
direction	O
with	O
Phrap	O
quality	O
score	O
>	O
=	O
40	O
.	O

Chromosomal	O
terminus	O
was	O
determined	O
after	O
attaching	O
adenine	O
and	O
thymine	O
homopolymers	O
to	O
the	O
naked	O
3	O
'	O
ends	O
of	O
the	O
chromosome	O
as	O
described	O
previously	O
.	O
5	O

Sensitivity	O
of	O
intervention	O
cost	O
-	O
effectiveness	O
to	O
rates	O
of	O
decay	O
in	O
intervention	O
effectiveness	O
between	O
0	O
%	O
(	O
life	O
-	O
long	O
health	O
benefits	O
from	O
one	O
-	O
off	O
intervention	O
)	O
and	O
100	O
%	O
(	O
no	O
health	O
benefits	O
beyond	O
the	O
end	O
of	O
intervention	O
)	O
.	O

Real	O
time	O
RT	O
-	O
PCR	O

RNA	O
extraction	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
performed	O
as	O
we	O
described	O
previously	O
[	O
22	O
]	O
.	O

The	O
sequences	O
of	O
ABCG2	O
primers	O
are	O
5	O
'	O
-	O
GGCTTTCTACCTGCACGAAAACCAGTTGAG	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
ATGGCGTTGAGACCAG	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O

The	O
sequences	O
of	O
GAPDH	O
primers	O
are	O
5	O
'	O
-	O
AAGGACTCATGACCACAGTCCAT	O
-	O
3	O
'	O
(	O
forward	O
)	O
and	O
5	O
'	O
-	O
CCATCACGCCACAGTTTCC	O
-	O
3	O
'	O
(	O
reverse	O
)	O
.	O

The	O
relative	O
ABCG2	O
RNA	O
level	O
(	O
2DeltaCT	O
)	O
treated	O
with	O
inhibitors	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
control	O
(	O
in	O
the	O
presence	O
of	O
0	O
.	O
1	O
%	O
DMSO	O
)	O
where	O
DeltaCT	O
(	O
threshold	O
cycle	O
)	O
=	O
(	O
CTABCG2	O
-	O
CTGAPDH	O
)	O
.	O

Introduction	O

Adipose	O
tissue	O
,	O
once	O
viewed	O
as	O
simply	O
a	O
storage	O
and	O
release	O
depot	O
for	O
lipids	O
,	O
is	O
now	O
considered	O
an	O
endocrine	O
tissue	O
[	O
1	O
,	O
2	O
]	O
that	O
secretes	O
various	O
substances	O
(	O
adipokines	O
)	O
,	O
including	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
interleukin	O
(	O
IL	O
)	O
-	O
6	O
,	O
leptin	O
,	O
adiponectin	O
,	O
resistin	O
,	O
visfatin	O
,	O
and	O
omenetin	O
[	O
3	O
,	O
4	O
]	O
.	O

Among	O
these	O
adipokines	O
,	O
much	O
attention	O
has	O
been	O
paid	O
to	O
adiponectin	O
'	O
s	O
relationship	O
with	O
insulin	O
sensitivity	O
and	O
glucose	O
and	O
lipid	O
metabolism	O
in	O
the	O
past	O
10	O
years	O
.	O

In	O
addition	O
,	O
adiponectin	O
is	O
known	O
to	O
exhibit	O
potent	O
anti	O
-	O
inflammatory	O
[	O
5	O
]	O
,	O
atheroprotective	O
[	O
6	O
]	O
,	O
and	O
antidiabetic	O
[	O
7	O
]	O
effects	O
.	O

Recent	O
findings	O
suggest	O
that	O
adiponectin	O
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Levels	O
of	O
adiponectin	O
in	O
synovial	O
fluid	O
and	O
sera	O
were	O
elevated	O
in	O
patients	O
with	O
RA	O
[	O
8	O
,	O
9	O
]	O
.	O

Adiponectin	O
also	O
induces	O
the	O
production	O
of	O
proinflammatory	O
cytokines	O
,	O
IL	O
-	O
6	O
,	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
-	O
1	O
,	O
and	O
IL	O
-	O
8	O
from	O
RA	O
synovial	O
fibroblasts	O
in	O
vitro	O
[	O
10	O
,	O
11	O
]	O
.	O

Thus	O
,	O
it	O
was	O
suggested	O
that	O
adiponectin	O
can	O
also	O
exert	O
significant	O
proinflammatory	O
and	O
matrix	O
-	O
degrading	O
effects	O
.	O

However	O
,	O
the	O
role	O
of	O
adiponectin	O
in	O
the	O
pathogenesis	O
of	O
RA	O
is	O
still	O
controversial	O
because	O
of	O
conflicting	O
reports	O
about	O
its	O
function	O
[	O
10	O
,	O
12	O
-	O
15	O
]	O
.	O

In	O
particular	O
,	O
adiponectin	O
seems	O
to	O
play	O
an	O
anti	O
-	O
inflammatory	O
role	O
because	O
it	O
significantly	O
inhibited	O
IL	O
-	O
1beta	O
-	O
stimulated	O
synovial	O
cell	O
proliferation	O
in	O
collagen	O
-	O
induced	O
arthritic	O
mice	O
,	O
despite	O
increased	O
IL	O
-	O
6	O
expression	O
[	O
16	O
]	O
.	O

In	O
contrast	O
,	O
high	O
-	O
grade	O
inflammation	O
in	O
RA	O
patients	O
was	O
negatively	O
correlated	O
with	O
circulating	O
adiponectin	O
concentrations	O
[	O
17	O
]	O
.	O

Rather	O
,	O
it	O
was	O
suggested	O
that	O
circulating	O
adiponectin	O
may	O
be	O
involved	O
in	O
cardiovascular	O
disease	O
in	O
RA	O
patients	O
.	O

Although	O
this	O
contradiction	O
was	O
partly	O
explained	O
by	O
the	O
induction	O
of	O
tolerance	O
to	O
inflammatory	O
stimuli	O
by	O
adiponectin	O
[	O
18	O
]	O
,	O
the	O
pro	O
-	O
or	O
anti	O
-	O
inflammatory	O
effects	O
of	O
adiponectin	O
on	O
the	O
pathogenesis	O
of	O
RA	O
remain	O
unknown	O
.	O

With	O
regard	O
to	O
adiponectin	O
'	O
s	O
proinflammatory	O
effects	O
,	O
we	O
wondered	O
whether	O
adiponectin	O
might	O
stimulate	O
the	O
production	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
MMPs	O
as	O
well	O
as	O
proinflammatory	O
mediators	O
like	O
IL	O
-	O
1beta	O
and	O
TNF	O
-	O
alpha	O
do	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
stimulatory	O
effect	O
of	O
adiponectin	O
on	O
the	O
production	O
of	O
IL	O
-	O
6	O
,	O
IL	O
-	O
8	O
,	O
prostaglandin	O
E2	O
(	O
PGE2	O
)	O
,	O
VEGF	O
,	O
and	O
MMPs	O
.	O

In	O
addition	O
,	O
the	O
correlation	O
between	O
adiponectin	O
and	O
VEGF	O
or	O
MMPs	O
was	O
investigated	O
by	O
measuring	O
the	O
levels	O
of	O
these	O
three	O
proteins	O
in	O
the	O
joint	O
fluid	O
of	O
patients	O
with	O
RA	O
or	O
osteoarthritis	O
(	O
OA	O
)	O
.	O

Correlation	O
matrix	O
for	O
ear	O
(	O
E	O
)	O
traits	O
in	O
2006	O
;	O
data	O
from	O
water	O
stress	O
plots	O
(	O
lower	O
left	O
)	O
and	O
well	O
-	O
watered	O
plots	O
(	O
upper	O
right	O
)	O
of	O
350	O
maize	O
inbreds	O

Refinement	O

The	O
H	O
-	O
atoms	O
were	O
positioned	O
geometrically	O
(	O
O	O
-	O
H	O
=	O
0	O
.	O
82	O
,	O
C	O
-	O
H	O
=	O
0	O
.	O
93	O
A	O
)	O
and	O
were	O
included	O
in	O
the	O
refinement	O
in	O
the	O
riding	O
model	O
approximation	O
,	O
with	O
Uiso	O
(	O
H	O
)	O
=	O
xUeq	O
(	O
C	O
,	O
O	O
)	O
,	O
where	O
x	O
=	O
1	O
.	O
2	O
for	O
all	O
H	O
-	O
atoms	O
.	O

Reagents	O
and	O
antibodies	O

Maxisorp	O
strips	O
(	O
NunC	O
,	O
Roskilde	O
,	O
Denmark	O
)	O
,	O
GST	O
-	O
PNMA2	O
recombinant	O
protein	O
(	O
Abnova	O
,	O
Taipei	O
,	O
Taiwan	O
)	O
;	O
3	O
,	O
3	O
'	O
,	O
5	O
,	O
5	O
-	O
tetramethylbenzidine	O
(	O
TMB	O
)	O
+	O
substrate	O
(	O
Dako	O
,	O
Glostrup	O
,	O
Denmark	O
)	O
,	O
Peroxidase	O
with	O
dakocytomation	O
peroxidase	O
block	O
(	O
Dako	O
)	O
,	O
Dakocytomation	O
envision	O
(	O
R	O
)	O
system	O
labeled	O
polymer	O
-	O
HRP	O
anti	O
-	O
rabbit	O
kit	O
and	O
3	O
-	O
3	O
'	O
-	O
diaminobenzidine	O
(	O
Dako	O
)	O
,	O
Mayer	O
'	O
s	O
hematoxylin	O
(	O
Histolab	O
Product	O
AB	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Graded	O
alcohol	O
(	O
Kemetyl	O
,	O
Vestby	O
,	O
Norway	O
)	O
,	O
Xylen	O
(	O
Solveco	O
,	O
Rosersberg	O
,	O
Sweden	O
)	O
,	O
Pertex	O
(	O
R	O
)	O
(	O
Histolab	O
,	O
Gothenburg	O
,	O
Sweden	O
)	O
,	O
Tris	O
-	O
Glycine	O
blotting	O
buffer	O
(	O
Amresco	O
,	O
Solon	O
,	O
OH	O
)	O
,	O
Western	O
blotting	O
(	O
WB	O
)	O
reagent	O
and	O
Lumi	O
-	O
Light	O
WB	O
substrate	O
(	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
,	O
EasyTag	O
Methionine	O
-	O
L	O
-	O
35S	O
,	O
NEG709A005MC	O
(	O
PerkinElmer	O
,	O
Waltham	O
,	O
MA	O
)	O
,	O
Full	O
-	O
length	O
cDNA	O
clone	O
for	O
human	O
PNMA2	O
,	O
ID6580976	O
(	O
BioScience	O
Geneservice	O
,	O
Cambridge	O
,	O
UK	O
)	O
,	O
TnT	O
(	O
R	O
)	O
SP6	O
Quick	O
Coupled	O
Transcription	O
/	O
Translation	O
System	O
(	O
Promega	O
,	O
Madison	O
,	O
WI	O
)	O
,	O
Protein	O
G	O
-	O
Sepharose	O
beads	O
(	O
GE	O
Healthcare	O
,	O
Little	O
Chalfont	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
,	O
Peroxidase	O
(	O
HRP	O
)	O
-	O
conjugated	O
rabbit	O
anti	O
human	O
IgG	O
(	O
anti	O
-	O
IgG	O
)	O
(	O
Dako	O
)	O
,	O
rabbit	O
polyclonal	O
antibody	O
anti	O
-	O
PNMA2	O
(	O
Atlas	O
Antibodies	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
,	O
monoclonal	O
mouse	O
anti	O
-	O
GST	O
,	O
sc	O
-	O
138	O
,	O
polyclonal	O
goat	O
anti	O
-	O
human	O
Ma2	O
,	O
sc	O
-	O
68099	O
,	O
HRP	O
-	O
donkey	O
anti	O
-	O
goat	O
,	O
sc	O
-	O
2020	O
,	O
(	O
Santa	O
Cruz	O
Biotechnology	O
,	O
Santa	O
Cruz	O
,	O
CA	O
)	O
,	O
HRP	O
-	O
goat	O
anti	O
-	O
rabbit	O
,	O
P0448	O
,	O
(	O
Dako	O
)	O
and	O
Ravo	O
PNS	O
-	O
Blot	O
,	O
(	O
Ravo	O
Diagnostika	O
GmbH	O
,	O
Freiburg	O
,	O
Germany	O
)	O
.	O

FUNDING	O

National	O
Institutes	O
of	O
Health	O
grants	O
,	O
National	O
Institute	O
of	O
Environmental	O
Health	O
Sciences	O
and	O
the	O
National	O
Library	O
of	O
Medicine	O
(	O
R01	O
ES014065	O
and	O
R01	O
ES014065	O
-	O
04S1	O
to	O
CTD	O
)	O
;	O
INBRE	O
program	O
of	O
the	O
National	O
Center	O
for	O
Research	O
Resources	O
(	O
P20	O
RR016463	O
)	O
.	O

Funding	O
for	O
open	O
access	O
charge	O
:	O
NIEHS	O
grant	O
(	O
R01	O
ES014065	O
)	O
.	O

Conflict	O
of	O
interest	O
statement	O
.	O

None	O
declared	O
.	O

Tarsoconjunctival	O
flap	O
after	O
division	O

Statistical	O
analysis	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
SPSS13	O
.	O
0	O
software	O
.	O

The	O
differences	O
between	O
groups	O
were	O
compared	O
using	O
Student	O
'	O
s	O
t	O
-	O
test	O
,	O
and	O
data	O
were	O
expressed	O
as	O
mean	O
+	O
/	O
-	O
SD	O
.	O

Statistical	O
difference	O
was	O
accepted	O
at	O
P	O
<	O
0	O
.	O
05	O
.	O

The	O
importance	O
in	O
identifying	O
genes	O
involved	O
in	O
spinal	O
curvature	O

Spinal	O
curvature	O
is	O
a	O
prevalent	O
and	O
costly	O
deformity	O
among	O
humans	O
and	O
teleosts	O
.	O

The	O
estimated	O
annual	O
cost	O
of	O
treating	O
children	O
hospitalized	O
with	O
idiopathic	O
scoliosis	O
(	O
IS	O
)	O
in	O
the	O
United	O
States	O
alone	O
is	O
over	O
$	O
3	O
billion	O
.	O

This	O
cost	O
estimate	O
does	O
not	O
consider	O
Scheuermann	O
kyphosis	O
,	O
or	O
adults	O
with	O
idiopathic	O
-	O
type	O
spinal	O
curvature	O
who	O
suffer	O
from	O
chronic	O
back	O
pain	O
,	O
contributing	O
to	O
the	O
estimated	O
$	O
849	O
billion	O
cost	O
of	O
treatment	O
and	O
lost	O
wages	O
associated	O
with	O
musculoskeletal	O
disease	O
[	O
24	O
]	O
.	O

Among	O
teleosts	O
,	O
spinal	O
column	O
deformities	O
reduce	O
total	O
production	O
in	O
the	O
aquaculture	O
industry	O
substantially	O
[	O
12	O
]	O
.	O

In	O
contrast	O
to	O
humans	O
,	O
teleost	O
curve	O
phenotypes	O
are	O
less	O
well	O
characterized	O
;	O
although	O
heritable	O
curves	O
are	O
acknowledged	O
to	O
account	O
for	O
many	O
cases	O
among	O
cultured	O
stocks	O
,	O
whether	O
these	O
cases	O
are	O
from	O
congenital	O
defects	O
or	O
are	O
idiopathic	O
-	O
type	O
is	O
often	O
not	O
known	O
.	O

Despite	O
the	O
prevalence	O
and	O
impact	O
of	O
this	O
type	O
of	O
deformity	O
,	O
the	O
genetic	O
architecture	O
and	O
specific	O
genes	O
involved	O
are	O
unknown	O
.	O

The	O
current	O
view	O
is	O
that	O
human	O
idiopathic	O
-	O
type	O
scoliosis	O
is	O
a	O
complex	O
genetic	O
disorder	O
with	O
multiple	O
genes	O
segregating	O
in	O
the	O
population	O
exhibiting	O
complex	O
genotype	O
by	O
environment	O
interactions	O
[	O
25	O
-	O
30	O
]	O
.	O

In	O
aquaculture	O
stocks	O
,	O
inheritance	O
for	O
spinal	O
curvature	O
has	O
been	O
described	O
as	O
Mendelian	O
recessive	O
or	O
dominant	O
,	O
as	O
well	O
as	O
polygenic	O
,	O
depending	O
on	O
how	O
well	O
the	O
phenotype	O
is	O
characterized	O
and	O
what	O
stock	O
is	O
considered	O
(	O
reviewed	O
in	O
[	O
13	O
]	O
,	O
[	O
16	O
]	O
)	O
.	O

The	O
guppy	O
curveback	O
phenotype	O
has	O
been	O
extensively	O
characterized	O
so	O
that	O
the	O
lineage	O
can	O
be	O
applied	O
as	O
a	O
model	O
for	O
understanding	O
the	O
biological	O
context	O
of	O
heritable	O
spinal	O
curvature	O
[	O
1	O
,	O
7	O
-	O
9	O
]	O
.	O

Future	O
studies	O
can	O
use	O
approaches	O
to	O
map	O
QTL	O
affecting	O
shape	O
based	O
on	O
digital	O
photos	O
[	O
31	O
,	O
32	O
]	O
,	O
rather	O
than	O
the	O
qualitative	O
scale	O
used	O
in	O
the	O
present	O
study	O
.	O

The	O
identification	O
of	O
QTL	O
in	O
this	O
study	O
is	O
a	O
first	O
step	O
in	O
understanding	O
the	O
genetics	O
of	O
this	O
type	O
of	O
deformity	O
and	O
will	O
lead	O
to	O
the	O
identification	O
of	O
biological	O
pathways	O
associated	O
with	O
spinal	O
integrity	O
.	O

MoClo	O
cloning	O
protocol	O

Restriction	O
-	O
ligations	O
were	O
set	O
up	O
by	O
pipetting	O
in	O
one	O
tube	O
approximately	O
40	O
fmol	O
(	O
~	O
100	O
ng	O
of	O
DNA	O
for	O
a	O
4	O
kb	O
plasmid	O
)	O
of	O
each	O
DNA	O
component	O
(	O
PCR	O
product	O
or	O
plasmid	O
)	O
,	O
10	O
U	O
of	O
the	O
required	O
restriction	O
enzyme	O
(	O
BsaI	O
or	O
BpiI	O
)	O
and	O
10	O
U	O
T4	O
DNA	O
ligase	O
(	O
using	O
high	O
concentration	O
ligase	O
,	O
20	O
U	O
/	O
microl	O
)	O
in	O
Promega	O
ligation	O
buffer	O
in	O
a	O
final	O
reaction	O
volume	O
of	O
20	O
microl	O
.	O

The	O
reaction	O
was	O
incubated	O
in	O
a	O
thermocycler	O
for	O
5	O
hours	O
at	O
37degreesC	O
,	O
5	O
min	O
at	O
50degreesC	O
and	O
10	O
min	O
at	O
80degreesC	O
.	O

The	O
reaction	O
mix	O
was	O
then	O
added	O
to	O
100	O
microl	O
chemically	O
competent	O
DH10b	B
cells	O
,	O
incubated	O
for	O
15	O
-	O
30	O
min	O
on	O
ice	O
and	O
transformed	O
by	O
heat	O
shock	O
.	O

800	O
microl	O
of	O
liquid	O
LB	O
was	O
then	O
added	O
to	O
the	O
transformation	O
,	O
and	O
the	O
cells	O
were	O
let	O
to	O
recover	O
45	O
min	O
at	O
37degreesC	O
.	O

Different	O
aliquots	O
of	O
the	O
transformation	O
were	O
plated	O
on	O
LB	O
plates	O
containing	O
the	O
appropriate	O
antibiotic	O
.	O

The	O
number	O
of	O
colonies	O
was	O
counted	O
for	O
one	O
or	O
two	O
selected	O
plates	O
(	O
containing	O
countable	O
number	O
of	O
colonies	O
)	O
,	O
or	O
from	O
a	O
section	O
of	O
the	O
plates	O
when	O
very	O
high	O
number	O
of	O
colonies	O
were	O
obtained	O
even	O
for	O
the	O
lowest	O
volume	O
plated	O
.	O

The	O
number	O
of	O
colonies	O
was	O
then	O
extrapolated	O
for	O
the	O
entire	O
transformation	O
.	O

For	O
level	O
2	O
-	O
2	O
cloning	O
,	O
two	O
type	O
IIS	O
enzymes	O
were	O
required	O
,	O
BpiI	O
and	O
BsaI	O
.	O

The	O
same	O
protocol	O
was	O
used	O
as	O
described	O
above	O
except	O
that	O
10	O
U	O
and	O
2	O
.	O
5	O
U	O
were	O
used	O
for	O
the	O
enzymes	O
BpiI	O
and	O
BsaI	O
,	O
respectively	O
.	O

To	O
optimize	O
efficiency	O
of	O
the	O
restriction	O
-	O
ligation	O
for	O
the	O
final	O
construct	O
containing	O
11	O
transcription	O
units	O
(	O
cL2	O
-	O
13	O
*	O
)	O
,	O
a	O
variation	O
of	O
this	O
protocol	O
was	O
used	O
as	O
follows	O
.	O

The	O
reaction	O
mix	O
was	O
set	O
up	O
containing	O
20	O
U	O
ligase	O
,	O
5	O
U	O
BpiI	O
and	O
5	O
U	O
BsaI	O
,	O
in	O
a	O
total	O
reaction	O
volume	O
of	O
20	O
microl	O
.	O

The	O
mix	O
was	O
incubated	O
in	O
a	O
thermocycler	O
with	O
the	O
following	O
parameters	O
:	O
incubation	O
for	O
2	O
minutes	O
at	O
37degreesC	O
,	O
5	O
minutes	O
at	O
16degreesC	O
,	O
both	O
steps	O
repeated	O
45	O
times	O
,	O
followed	O
by	O
incubation	O
for	O
5	O
minutes	O
at	O
50degreesC	O
and	O
10	O
minutes	O
at	O
80degreesC	O
.	O

The	O
reaction	O
mix	O
was	O
transformed	O
in	O
E	O
.	O
coli	O
chemically	O
competent	O
cells	O
as	O
described	O
above	O
.	O

Intact	O
mass	O
analysis	O
of	O
a	O
mixed	O
population	O
of	O
proteins	O
.	O

A	O
mixture	O
of	O
the	O
membrane	O
protein	O
KCNJ12	O
,	O
the	O
soluble	O
TEV	O
protease	O
used	O
to	O
cleave	O
the	O
fusion	O
tag	O
,	O
and	O
the	O
membrane	O
protein	O
HVCN1	O
,	O
which	O
occurred	O
as	O
a	O
contaminant	O
from	O
an	O
earlier	O
analysis	O
on	O
the	O
same	O
LC	O
column	O
.	O

Observed	O
type	O
I	O
error	O
for	O
datasets	O
simulated	O
under	O
the	O
null	O
hypothesis	O

DNA	O
isolation	O

All	O
solutions	O
used	O
for	O
DNA	O
isolation	O
are	O
purged	O
with	O
nitrogen	O
(	O
immediately	O
prior	O
to	O
use	O
)	O
and	O
supplemented	O
with	O
50	O
muM	O
phenyl	O
-	O
tert	O
-	O
butyl	O
nitrone	O
to	O
minimise	O
oxidative	O
damage	O
to	O
DNA	O
[	O
31	O
]	O
.	O

Qiagen	O
DNAeasy	O
Kit	O
(	O
#	O
69506	O
)	O

includes	O
:	O
Proteinase	O
K	O
,	O
AW1	O
,	O
AW2	O
,	O
AE	O
and	O
Spin	O
-	O
columns	O

Dithiothreitol	O
(	O
DTT	O
;	O
Sigma	O
)	O

Ethanol	O
(	O
Ajax	O
Finechem	O
#	O
214	O
-	O
2	O
.	O
5L	O
)	O

Nitrogen	O
(	O
for	O
purging	O
of	O
buffers	O
)	O

Genes	O
related	O
to	O
signal	O
transduction	O

On	O
day	O
7	O
,	O
the	O
up	O
-	O
regulated	O
genes	O
related	O
to	O
signal	O
transduction	O
were	O
PDE1A	O
,	O
MYO10	O
,	O
APOB	O
,	O
and	O
so	O
on	O
,	O
and	O
down	O
-	O
regulated	O
genes	O
were	O
CYTL1	O
and	O
IL6	O
.	O

On	O
day	O
14	O
,	O
the	O
up	O
-	O
regulated	O
genes	O
were	O
ANGPTL4	O
,	O
EPHA3	O
,	O
RASL10B	O
,	O
etc	O
.	O
,	O
and	O
the	O
down	O
-	O
regulated	O
genes	O
were	O
CXCL12	O
,	O
CCL8	O
and	O
VLDLR	O
.	O

The	O
genes	O
up	O
-	O
regulated	O
on	O
both	O
days	O
were	O
LEP	O
,	O
RAC3	O
,	O
and	O
RASL11B	O
,	O
and	O
those	O
down	O
-	O
regulated	O
both	O
days	O
were	O
MX1	O
and	O
WISP2	O
.	O

Notably	O
,	O
up	O
-	O
and	O
down	O
-	O
regulated	O
genes	O
PDE1A	O
,	O
APOB	O
,	O
ALCAM	O
,	O
PSCD4	O
,	O
CYTL1	O
,	O
and	O
IL6	O
were	O
more	O
strongly	O
expressed	O
on	O
day	O
7	O
than	O
on	O
day	O
14	O
,	O
while	O
ANGPTL4	O
,	O
EPHA3	O
,	O
RAB12	O
,	O
CXCL12	O
,	O
CCL8	O
,	O
and	O
VLDLR	O
were	O
more	O
strongly	O
expressed	O
on	O
day	O
14	O
than	O
on	O
day	O
7	O
.	O

The	O
asymmetric	O
unit	O
of	O
the	O
title	O
compound	O
with	O
the	O
atomic	O
labelling	O
scheme	O
.	O
Displacement	O
are	O
drawn	O
at	O
the	O
50	O
%	O
probability	O
level	O
.	O

H	O
atoms	O
are	O
represented	O
as	O
small	O
spheres	O
of	O
arbitrary	O
radii	O
.	O

Hydrogen	O
bonds	O
are	O
shown	O
as	O
dashed	O
lines	O
.	O

Modified	O
radiology	O
-	O
guided	O
percutaneous	O
gastrostomy	O
technique	O
.	O

A	O
.	O

21	O
G	O
fine	O
needle	O
punctured	O
localized	O
collection	O
of	O
air	O
,	O
which	O
was	O
visible	O
in	O
collapsed	O
stomach	O
under	O
fluoroscopy	O
-	O
guided	O
gastrostomy	O
.	O

Needle	O
tip	O
is	O
then	O
gradually	O
withdrawn	O
while	O
injecting	O
small	O
amounts	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
.	O

Location	O
of	O
stomach	O
is	O
confirmed	O
by	O
visualization	O
of	O
opacified	O
gastric	O
rugae	O
.	O

B	O
.	O

Stomach	O
was	O
inflated	O
with	O
approximately	O
600	O
-	O
800	O
mL	O
of	O
room	O
air	O
through	O
21	O
G	O
fine	O
needle	O
.	O

C	O
.	O

100	O
-	O
cm	O
stainless	O
steel	O
guide	O
wire	O
is	O
inserted	O
through	O
needle	O
,	O
and	O
gastro	O
-	O
percutaneous	O
tract	O
is	O
gradually	O
dilated	O
.	O

D	O
.	O

Insertion	O
of	O
14	O
-	O
Fr	O
pigtail	O
gastrostomy	O
catheter	O
and	O
injection	O
of	O
small	O
amount	O
of	O
water	O
-	O
soluble	O
contrast	O
medium	O
via	O
pigtail	O
catheter	O
confirmed	O
that	O
gastrostomy	O
catheter	O
is	O
correctly	O
placed	O
within	O
stomach	O
.	O

SUMMARY	O

Both	O
the	O
innate	O
and	O
adaptive	O
immune	O
subsystems	O
are	O
necessary	O
to	O
provide	O
an	O
effective	O
immune	O
response	O
whether	O
to	O
an	O
actual	O
pathogenic	O
agent	O
or	O
to	O
an	O
immunization	O
.	O

Further	O
,	O
effective	O
immunizations	O
must	O
induce	O
long	O
-	O
term	O
stimulation	O
of	O
both	O
the	O
humoral	O
and	O
cell	O
-	O
mediated	O
arms	O
of	O
the	O
adaptive	O
system	O
by	O
the	O
production	O
of	O
effector	O
cells	O
for	O
the	O
current	O
infection	O
and	O
memory	O
cells	O
for	O
future	O
infections	O
with	O
the	O
pathogenic	O
agent	O
.	O

At	O
least	O
seven	O
different	O
types	O
of	O
vaccines	O
are	O
currently	O
in	O
use	O
or	O
in	O
development	O
that	O
produce	O
this	O
effective	O
immunity	O
and	O
have	O
contributed	O
greatly	O
to	O
the	O
prevention	O
of	O
infectious	O
disease	O
around	O
the	O
world	O
.	O

Encoding	O
methods	O
of	O
SOLiDzipper	O
.	O

Notes	O
:	O
A	O
)	O
The	O
quality	O
value	O
in	O
QV	O
files	O
from	O
ABI	O
SOLiD	O
system	O
ranges	O
from	O
-	O
1	O
to	O
40	O
,	O
which	O
requires	O
6	O
bit	O
space	O
.	O

The	O
remaining	O
2	O
bit	O
space	O
out	O
of	O
1	O
byte	O
can	O
be	O
used	O
for	O
storing	O
another	O
quality	O
value	O
in	O
part	O
.	O

B	O
)	O
Csfasta	O
files	O
contain	O
the	O
sequence	O
information	O
in	O
four	O
digits	O
,	O
'	O
0123	O
'	O
,	O
which	O
require	O
2	O
bit	O
space	O
.	O

Provided	O
that	O
'	O
0	O
'	O
,	O
1	O
byte	O
character	O
in	O
csfasta	O
files	O
,	O
is	O
mapped	O
as	O
binary	O
data	O
'	O
00	O
'	O
,	O
'	O
1	O
'	O
as	O
'	O
01	O
'	O
,	O
'	O
2	O
'	O
as	O
'	O
10	O
'	O
,	O
'	O
3	O
'	O
as	O
'	O
11	O
'	O
,	O
4	O
byte	O
data	O
'	O
0113	O
'	O
can	O
be	O
encoded	O
into	O
1	O
byte	O
character	O
0x17	O
(	O
00010111	O
)	O
through	O
shift	O
operation	O
.	O

C	O
)	O
Sequence	O
IDs	O
are	O
extracted	O
from	O
QV	O
and	O
csfasta	O
files	O
,	O
combined	O
,	O
and	O
compressed	O
using	O
the	O
general	O
purpose	O
compression	O
methods	O
.	O

D	O
)	O
Encoded	O
data	O
are	O
stored	O
as	O
data	O
blocks	O
of	O
fixed	O
size	O
.	O

This	O
allows	O
for	O
selective	O
decoding	O
.	O

Western	O
blots	O
showing	O
C	O
/	O
EBPalpha	O
(	O
top	O
)	O
,	O
adiponectin	O
(	O
middle	O
)	O
,	O
and	O
GAPDH	O
(	O
bottom	O
)	O
protein	O
bands	O
in	O
confluent	O
GO	O
orbital	O
fibroblast	O
cultures	O
exposed	O
throughout	O
10	O
days	O
in	O
culture	O
to	O
the	O
indicated	O
treatments	O
.	O

Lane	O
1	O
)	O
no	O
treatment	O
;	O
2	O
)	O
LY294002	O
(	O
10	O
muM	O
)	O
;	O
3	O
)	O
M22	O
(	O
10	O
ng	O
/	O
ml	O
)	O
;	O
4	O
)	O
M22	O
plus	O
LY294002	O
.	O

Loss	O
of	O
body	O
weight	O
after	O
challenge	O
-	O
infection	O
with	O
WNV	O
.	O

Mice	O
(	O
n	O
=	O
8	O
)	O
were	O
vaccinated	O
intranasally	O
with	O
Flu	O
-	O
NA	O
-	O
DIII	O
(	O
*	O
)	O
or	O
Flu	O
-	O
NA	O
-	O
GFP	O
(	O
o	O
)	O
or	O
by	O
the	O
subcutaneous	O
route	O
(	O
^	O
and	O
^	O
,	O
respectively	O
)	O
.	O

The	O
daily	O
weights	O
of	O
each	O
animal	O
were	O
calculated	O
compared	O
to	O
their	O
respective	O
weight	O
on	O
the	O
day	O
of	O
challenge	O
,	O
and	O
data	O
are	O
shown	O
as	O
the	O
average	O
percentage	O
of	O
initial	O
weight	O
for	O
each	O
group	O
.	O

Error	O
bars	O
represent	O
the	O
standard	O
error	O
for	O
all	O
samples	O
available	O
at	O
that	O
time	O
point	O
.	O

Subsequently	O
,	O
the	O
mice	O
were	O
challenged	O
subcutaneously	O
with	O
106	O
TCID50	O
WNV	O
-	O
NY99	O
and	O
weighed	O
daily	O
.	O

The	O
mean	O
body	O
weight	O
is	O
expressed	O
as	O
the	O
percentage	O
of	O
the	O
body	O
weight	O
before	O
challenge	O
infection	O
(	O
A	O
)	O
.	O

The	O
survival	O
rates	O
of	O
mice	O
after	O
challenge	O
infection	O
with	O
WNV	O
-	O
NY99	O
are	O
depicted	O
as	O
Kaplan	O
-	O
Meier	O
survival	O
curves	O
(	O
B	O
)	O
.	O

The	O
difference	O
in	O
survival	O
rate	O
between	O
Flu	O
-	O
NA	O
-	O
DIII	O
and	O
Flu	O
-	O
NA	O
-	O
GFP	O
vaccinated	O
mice	O
was	O
statistically	O
significant	O
as	O
determined	O
by	O
the	O
logrank	O
test	O
.	O

The	O
symbols	O
for	O
the	O
respective	O
groups	O
are	O
the	O
same	O
as	O
in	O
panel	O
A	O
.	O

CONCLUSION	O

Intra	O
-	O
operative	O
monitoring	O
of	O
partial	O
pressure	O
of	O
tissue	O
oxygen	O
(	O
PtiO2	O
)	O
is	O
a	O
very	O
sensitive	O
method	O
of	O
detecting	O
the	O
decrease	O
of	O
oxygen	O
for	O
cell	O
utilization	O
,	O
due	O
to	O
decreased	O
blood	O
flow	O
,	O
during	O
temporary	O
clipping	O
and	O
after	O
definitive	O
clipping	O
,	O
in	O
middle	O
cerebral	O
artery	O
incidental	O
unruptured	O
aneurysm	O
surgery	O
.	O

""""	O
Basal	O
values	O
""""	O
,	O
obtained	O
without	O
the	O
influence	O
of	O
subarachnoid	O
blood	O
,	O
were	O
lower	O
than	O
expected	O
in	O
""""	O
uninjured	O
""""	O
brain	O
,	O
and	O
this	O
fact	O
,	O
although	O
unexplained	O
,	O
should	O
be	O
kept	O
in	O
mind	O
in	O
future	O
investigation	O
in	O
this	O
field	O
.	O

Although	O
values	O
that	O
could	O
be	O
predictive	O
of	O
brain	O
ischemia	O
could	O
not	O
be	O
established	O
,	O
an	O
incomplete	O
recovery	O
or	O
continuous	O
decrease	O
in	O
PtiO2	O
values	O
after	O
definitive	O
clipping	O
should	O
be	O
considered	O
an	O
indicator	O
of	O
high	O
risk	O
for	O
the	O
development	O
of	O
post	O
-	O
operative	O
brain	O
infarction	O
,	O
and	O
,	O
therefore	O
,	O
an	O
indication	O
for	O
verification	O
of	O
the	O
position	O
of	O
the	O
clip	O
.	O

Representative	O
time	O
histories	O
of	O
the	O
estimated	O
SatO2	O
levels	O
of	O
normal	O
cortex	O
(	O
black	O
)	O
and	O
tumor	O
(	O
grey	O
)	O
from	O
all	O
six	O
patients	O
.	O

Etymology	O
.	O

Professor	O
Stephen	O
Lane	O
Wood	O
worked	O
extensively	O
on	O
collections	O
of	O
Scolytinae	O
preserved	O
in	O
Indian	O
museums	O
,	O
and	O
described	O
a	O
number	O
of	O
new	O
Scolytinae	O
species	O
from	O
India	O
.	O

In	O
this	O
paper	O
we	O
describe	O
one	O
more	O
new	O
bark	O
-	O
beetle	O
species	O
from	O
India	O
kept	O
in	O
the	O
Natural	O
History	O
Museum	O
in	O
Vienna	O
(	O
NHMW	O
)	O
and	O
dedicate	O
this	O
species	O
to	O
the	O
late	O
Professor	O
Stephen	O
Lane	O
Wood	O
.	O

View	O
of	O
the	O
structure	O
of	O
the	O
title	O
compound	O
along	O
the	O
a	O
axis	O
displaying	O
chains	O
alternating	O
with	O
amine	O
groups	O
.	O

Results	O

Statistics	O

The	O
survival	O
of	O
mice	O
was	O
analyzed	O
using	O
Kaplan	O
-	O
Meier	O
survival	O
analysis	O
.	O

All	O
other	O
data	O
were	O
analyzed	O
by	O
one	O
-	O
way	O
ANOVA	O
,	O
followed	O
by	O
the	O
Student	O
-	O
Newman	O
-	O
Keuls	O
test	O
for	O
all	O
pairwise	O
comparisons	O
.	O

Prior	O
to	O
ANOVA	O
,	O
Levene	O
'	O
s	O
Test	O
for	O
Equality	O
of	O
Variances	O
was	O
performed	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
MedCalc	O
software	O
,	O
version	O
11	O
.	O
2	O
.	O
1	O
.	O
0	O
.	O

5	O
.	O

Conclusion	O

RLs	O
are	O
new	O
actors	O
in	O
animal	O
and	O
plant	O
defense	O
and	O
their	O
low	O
toxicity	O
and	O
biodegradability	O
make	O
them	O
promising	O
molecules	O
to	O
be	O
used	O
against	O
pathogens	O
.	O

In	O
this	O
respect	O
,	O
there	O
are	O
some	O
clues	O
now	O
available	O
for	O
the	O
success	O
of	O
RL	O
applications	O
in	O
greenhouses	O
to	O
fight	O
phytopathogens	O
.	O

A	O
better	O
understanding	O
of	O
RL	O
mode	O
of	O
action	O
,	O
especially	O
their	O
perception	O
and	O
the	O
signaling	O
pathways	O
activated	O
,	O
will	O
be	O
very	O
important	O
to	O
potentiate	O
their	O
beneficial	O
effects	O
in	O
plants	O
.	O

RLs	O
have	O
a	O
dual	O
mode	O
of	O
action	O
:	O
they	O
are	O
antimicrobial	O
and	O
also	O
stimulate	O
plant	O
defense	O
responses	O
.	O

This	O
dual	O
property	O
is	O
probably	O
very	O
important	O
for	O
the	O
efficiency	O
of	O
new	O
biopesticides	O
.	O

In	O
animals	O
,	O
the	O
use	O
of	O
RLs	O
is	O
also	O
at	O
an	O
advanced	O
stage	O
.	O

RLs	O
are	O
successfully	O
used	O
as	O
antimicrobial	O
agents	O
,	O
especially	O
for	O
skin	O
disease	O
treatment	O
.	O

Deep	O
insight	O
into	O
the	O
physiochemical	O
effects	O
of	O
RLs	O
and	O
their	O
biological	O
importance	O
would	O
reveal	O
new	O
dimensions	O
in	O
the	O
fields	O
of	O
research	O
like	O
agriculture	O
and	O
medicine	O
,	O
precisely	O
in	O
plant	O
defense	O
,	O
disease	O
control	O
and	O
pathogenesis	O
.	O

An	O
understanding	O
of	O
bacterial	O
genera	O
producing	O
RLs	O
that	O
are	O
not	O
yet	O
well	O
studied	O
would	O
provide	O
light	O
on	O
these	O
fascinating	O
aspects	O
.	O

(	O
a	O
)	O
Sequence	O
alignment	O
of	O
PY	O
-	O
NLSs	O
.	O

The	O
homologous	O
regions	O
of	O
C	O
-	O
NLS	O
of	O
the	O
EWS	O
protein	O
,	O
NLS	O
of	O
Sam68	O
and	O
FUS	O
/	O
TLS	O
protein	O
and	O
M9	O
NLS	O
of	O
hnRNP	O
A1	O
and	O
hnRNP	O
M	O
,	O
classified	O
as	O
PY	O
-	O
NLS	O
are	O
in	O
yellow	O
boxes	O
.	O

Phosphorylated	O
Y656	O
of	O
the	O
EWS	O
protein	O
and	O
Y440	O
of	O
Sam68	O
are	O
indicated	O
(	O
in	O
red	O
)	O
.	O

Positions	O
of	O
identical	O
residues	O
in	O
SAM68	O
and	O
EWS	O
C	O
-	O
NLS	O
are	O
indicated	O
in	O
bold	O
and	O
residues	O
with	O
identical	O
charges	O
are	O
underlined	O
.	O

Known	O
positions	O
of	O
the	O
FUS	O
/	O
TLS	O
mutations	O
in	O
ALS	O
are	O
in	O
bold	O
.	O

(	O
b	O
)	O
Subcellular	O
localization	O
of	O
YFP	O
,	O
the	O
C	O
-	O
terminally	O
tagged	O
EWS	O
-	O
YFP	O
,	O
EWS	O
(	O
Y656A	O
)	O
-	O
YFP	O
,	O
EWS	O
(	O
Y656F	O
)	O
-	O
YFP	O
,	O
and	O
EWS	O
(	O
Y656D	O
)	O
-	O
YFP	O
(	O
in	O
green	O
)	O
.	O

Nuclei	O
are	O
shown	O
by	O
DAPI	O
staining	O
(	O
in	O
blue	O
)	O
.	O

Bars	O
,	O
15	O
mum	O
.	O

Background	O

Inflammation	O
plays	O
a	O
critical	O
role	O
in	O
plaque	O
initiation	O
,	O
progression	O
,	O
and	O
disruption	O
.	O

As	O
such	O
,	O
inflammation	O
represents	O
an	O
emerging	O
target	O
for	O
the	O
treatment	O
of	O
atherosclerosis	O
.	O

Conclusions	O

Myocardial	O
ischaemia	O
during	O
DCMR	O
is	O
independently	O
predictive	O
of	O
cardiac	O
events	O
among	O
patients	O
with	O
previous	O
myocardial	O
revascularisation	O
.	O

Acknowledgements	O

The	O
authors	O
gratefully	O
acknowledge	O
the	O
support	O
of	O
DRUID	O
study	O
participants	O
,	O
study	O
staff	O
,	O
members	O
of	O
the	O
Indigenous	O
Steering	O
Group	O
,	O
and	O
partner	O
organisations	O
.	O

The	O
DRUID	O
Study	O
was	O
funded	O
by	O
the	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
Project	O
Grant	O
#	O
236207	O
)	O
,	O
with	O
additional	O
support	O
from	O
the	O
Australian	O
Government	O
Department	O
of	O
Employment	O
and	O
Workplace	O
Relations	O
,	O
the	O
Clive	O
and	O
Vera	O
Ramaciotti	O
Foundation	O
,	O
the	O
Vincent	O
Fairfax	O
Family	O
Foundation	O
,	O
the	O
International	O
Diabetes	O
Institute	O
(	O
AusDiab	O
Partnership	O
)	O
,	O
and	O
Bayer	O
HealthCare	O
.	O

The	O
DRUID	O
Study	O
is	O
an	O
in	O
-	O
kind	O
project	O
of	O
the	O
Cooperative	O
Research	O
Centre	O
for	O
Aboriginal	O
Health	O
.	O

LMB	O
had	O
a	O
NHMRC	O
Scholarship	O
2003	O
-	O
5	O
and	O
is	O
supported	O
by	O
NHMRC	O
Training	O
Fellowship	O
(	O
#	O
605837	O
)	O
,	O
NHMRC	O
#	O
320860	O
and	O
the	O
Centre	O
of	O
Clinical	O
Research	O
Excellence	O
in	O
Clinical	O
Science	O
in	O
Diabetes	O
,	O
University	O
of	O
Melbourne	O
.	O

JC	O
was	O
supported	O
by	O
a	O
NHMRC	O
Career	O
Development	O
Award	O
(	O
#	O
283310	O
)	O
and	O
a	O
NHMRC	O
Research	O
Fellowship	O
(	O
#	O
545200	O
)	O
.	O

AH	O
is	O
supported	O
by	O
NHMRC	O
Fellowship	O
(	O
#	O
520316	O
)	O
.	O

Thank	O
you	O
to	O
Dr	O
Jaquelyne	O
Hughes	O
for	O
comments	O
on	O
the	O
manuscript	O
.	O

Funding	O
sources	O
played	O
no	O
role	O
in	O
the	O
study	O
design	O
,	O
in	O
the	O
collection	O
,	O
analysis	O
and	O
interpretation	O
of	O
the	O
data	O
,	O
in	O
the	O
writing	O
of	O
the	O
manuscript	O
,	O
or	O
in	O
the	O
decision	O
to	O
submit	O
the	O
manuscript	O
for	O
publication	O
.	O

Importing	O
citations	O
in	O
different	O
formats	O
using	O
Google	O
Scholar	O

Acknowledgements	O

We	O
thank	O
Dr	O
.	O
Neva	O
Meyer	O
for	O
confocal	O
imaging	O
and	O
generation	O
of	O
Z	O
-	O
stack	O
projection	O
,	O
and	O
the	O
following	O
members	O
of	O
the	O
Seaver	O
lab	O
for	O
their	O
continued	O
support	O
of	O
this	O
project	O
:	O
Dr	O
.	O
Neva	O
Meyer	O
,	O
Dr	O
.	O
Aldine	O
Amiel	O
,	O
and	O
Tyler	O
Smith	O
.	O

This	O
work	O
was	O
supported	O
by	O
the	O
National	O
Science	O
Foundation	O
(	O
REU	O
Supplement	O
of	O
10B05	O
-	O
44869	O
to	O
E	O
.	O
C	O
.	O
S	O
.	O
)	O
.	O

Concurrent	O
disease	O
in	O
33	O
cows	O
with	O
LDA	O
.	O

Subject	O
disposition	O
.	O

Data	O
from	O
110	O
enrolled	O
subjects	O
were	O
eligible	O
for	O
analysis	O
.	O

The	O
demographics	O
of	O
the	O
study	O
subjects	O
,	O
by	O
site	O
,	O
are	O
recorded	O
in	O
Table	O
1	O
.	O

The	O
population	O
studied	O
was	O
predominantly	O
not	O
HIV	O
infected	O
(	O
92	O
%	O
)	O
,	O
and	O
by	O
the	O
study	O
entry	O
criteria	O
,	O
their	O
probability	O
of	O
infection	O
was	O
considered	O
to	O
be	O
low	O
.	O

The	O
risk	O
categories	O
assigned	O
at	O
the	O
time	O
of	O
study	O
entry	O
were	O
combined	O
into	O
groups	O
for	O
analysis	O
,	O
based	O
on	O
the	O
predisposition	O
for	O
PCP	O
.	O

The	O
analysis	O
groups	O
were	O
as	O
follows	O
:	O
(	O
i	O
)	O
HIV	O
/	O
AIDS	O
,	O
(	O
ii	O
)	O
lung	O
transplant	O
(	O
one	O
subject	O
with	O
a	O
dual	O
organ	O
transplant	O
[	O
lung	O
/	O
kidney	O
]	O
was	O
included	O
in	O
this	O
category	O
)	O
,	O
(	O
iii	O
)	O
all	O
other	O
organ	O
transplants	O
and	O
allogeneic	O
hematopoietic	O
stem	O
cell	O
transplants	O
(	O
HSCT	O
)	O
,	O
(	O
iv	O
)	O
leukemia	O
,	O
other	O
hematological	O
disorders	O
,	O
and	O
autologous	O
HSCT	O
,	O
(	O
v	O
)	O
other	O
solid	O
tumors	O
,	O
and	O
(	O
vi	O
)	O
other	O
nonmalignant	O
conditions	O
.	O

Table	O
1	O
.	O

Subject	O
enrollment	O
,	O
disposition	O
,	O
and	O
demographics	O
by	O
sitea	O

Characteristic	O
Valueb	O

Site	O
1	O
Site	O
2	O
Site	O
3	O
Site	O
4	O

Enrollment	O

Unique	O
subjects	O
18	O
29	O
22	O
62	O

Subjects	O
entering	O
into	O
primary	O
analysisc	O
18	O
22	O
22	O
48	O

Subjects	O
with	O
repeat	O
visits	O
0	O
0	O
0	O
16	O

No	O
.	O
of	O
samples	O
assayed	O
18	O
22	O
22	O
70	O

Gender	O

Male	O
7	O
10	O
13	O
29	O

Female	O
11	O
12	O
9	O
19	O

Race	O

Caucasian	O
12	O
4	O
0	O
48	O

Black	O
6	O
13	O
0	O
0	O

Other	O
(	O
nonwhite	O
)	O
0	O
5	O
0	O
0	O

No	O
data	O
0	O
0	O
22	O
0	O

Mean	O
(	O
range	O
)	O
age	O
(	O
yr	O
)	O
57	O
(	O
26	O
-	O
78	O
)	O
54	O
(	O
21	O
-	O
75	O
)	O
52	O
(	O
26	O
-	O
74	O
)	O
56	O
(	O
23	O
-	O
73	O
)	O

Pretest	O
probability	O
of	O
PCP	O

Moderate	O
0	O
3	O
4	O
0	O

Low	O
18	O
19	O
18	O
48	O

Sample	O
type	O

BAL	O
18	O
20	O
20	O
43	O

Sputum	O
0	O
1	O
1	O
0	O

Other	O
LRT	O
0	O
1	O
1	O
5	O

At	O
-	O
risk	O
group	O

HIV	O
/	O
AIDS	O
0	O
3	O
6	O
0	O

Lung	O
transplant	O
8	O
0	O
1	O
31	O

Other	O
transplants	O
1	O
7	O
3	O
0	O

Leukemia	O
1	O
1	O
7	O
0	O

Other	O
solid	O
tumors	O
2	O
1	O
1	O
7	O

Other	O
nonmalignant	O
conditions	O
6	O
10	O
4	O
10	O

a	O

The	O
testing	O
and	O
enrollment	O
sites	O
for	O
the	O
study	O
were	O
Duke	O
University	O
School	O
of	O
Medicine	O
,	O
Durham	O
,	O
NC	O
;	O
Albert	O
Einstein	O
College	O
of	O
Medicine	O
and	O
Montefiore	O
Medical	O
Center	O
,	O
Bronx	O
,	O
NY	O
;	O
Centre	O
Hospitalier	O
Universitaire	O
Vaudois	O
and	O
University	O
of	O
Lausanne	O
,	O
Lausanne	O
,	O
Switzerland	O
;	O
and	O
Medizinische	O
Universitat	O
and	O
Landeskrankenhaus	O
Natters	O
,	O
Innsbruck	O
,	O
Austria	O
.	O

b	O

Except	O
where	O
otherwise	O
indicated	O
,	O
values	O
are	O
numbers	O
of	O
patients	O
.	O

c	O

Subjects	O
were	O
excluded	O
from	O
analysis	O
if	O
they	O
withdrew	O
consent	O
or	O
if	O
there	O
was	O
inadequate	O
sample	O
left	O
for	O
PCR	O
testing	O
.	O

Parkin	O
regulates	O
the	O
proteasomal	O
degradation	O
of	O
PARIS	O
and	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
mitochondrial	O
biogenesis	O
.	O

(	O
A	O
)	O
Normal	O
physiological	O
conditions	O
that	O
maintain	O
mitochondrial	O
homeostasis	O
:	O
PINK1	O
recruits	O
parkin	O
to	O
the	O
mitochondria	O
,	O
where	O
these	O
two	O
proteins	O
interact	O
to	O
eliminate	O
abnormal	O
mitochondria	O
through	O
mitophagy	O
.	O

Alterations	O
in	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsim	O
;	O
a	O
key	O
indicator	O
of	O
mitochondrial	O
physiology	O
and	O
cell	O
viability	O
)	O
initiate	O
the	O
PINK1	O
-	O
parkin	O
cascade	O
of	O
events	O
that	O
lead	O
to	O
mitophagy	O
.	O

Furthermore	O
,	O
parkin	O
ubiquitylates	O
and	O
thereby	O
promotes	O
proteasomal	O
degradation	O
of	O
PARIS	O
.	O

Because	O
PARIS	O
represses	O
the	O
expression	O
of	O
PGC	O
-	O
1alpha	O
,	O
degradation	O
of	O
PARIS	O
by	O
parkin	O
allows	O
PGC	O
-	O
1alpha	O
-	O
dependent	O
gene	O
expression	O
and	O
enables	O
mitochondrial	O
biogenesis	O
.	O

Parkin	O
seems	O
to	O
be	O
an	O
integral	O
regulator	O
of	O
mitochondrial	O
homeostasis	O
,	O
controlling	O
both	O
degradation	O
and	O
biogenesis	O
.	O

(	O
B	O
)	O
Loss	O
of	O
parkin	O
function	O
as	O
a	O
result	O
of	O
familial	O
mutations	O
(	O
in	O
the	O
case	O
of	O
AR	O
-	O
PD	O
)	O
or	O
aging	O
,	O
environmental	O
or	O
cellular	O
stress	O
(	O
in	O
the	O
case	O
of	O
sporadic	O
PD	O
)	O
leads	O
to	O
the	O
accumulation	O
of	O
abnormal	O
mitochondria	O
,	O
owing	O
to	O
faulty	O
mitophagy	O
.	O

In	O
addition	O
,	O
PARIS	O
accumulates	O
and	O
represses	O
PGC	O
-	O
1alpha	O
,	O
preventing	O
mitochondrial	O
biogenesis	O
.	O

Loss	O
of	O
parkin	O
function	O
does	O
not	O
tip	O
the	O
balance	O
between	O
mitochondrial	O
biogenesis	O
and	O
degradation	O
to	O
either	O
side	O
,	O
but	O
leads	O
to	O
a	O
general	O
breakdown	O
of	O
mitochondrial	O
homeostasis	O
that	O
can	O
ultimately	O
lead	O
to	O
PD	O
.	O

Acknowledgments	O
and	O
Funding	O

The	O
authors	O
thank	O
CRB	O
GADIE	O
(	O
Diane	O
Esquerre	O
)	O
for	O
BAC	O
clones	O
handling	O
and	O
Brian	O
Smith	O
,	O
Renee	O
Fincham	O
and	O
Kristy	O
Shewbridge	O
for	O
microsatellites	O
genotyping	O
.	O

We	O
are	O
grateful	O
to	O
Yann	O
Guiguen	O
for	O
help	O
and	O
precious	O
contribution	O
to	O
fund	O
raising	O
for	O
this	O
study	O
.	O

This	O
work	O
was	O
made	O
possible	O
by	O
financial	O
support	O
of	O
Genoscope	O
.	O

We	O
acknowledge	O
Rene	O
Guyomard	O
for	O
his	O
initial	O
contribution	O
in	O
BAC	O
library	O
procurement	O
.	O

The	O
microsatellites	O
genotyping	O
was	O
supported	O
by	O
NRI	O
Grant	O
No	O
.	O
2007	O
-	O
35616	O
-	O
17875	O
from	O
the	O
USDA	O
National	O
Institute	O
of	O
Food	O
and	O
Agriculture	O
.	O

Confocal	O
and	O
scanning	O
microscopic	O
images	O
of	O
mammoth	O
'	O
s	O
and	O
human	O
hair	O
.	O

Taphonomic	O
changes	O
,	O
indicated	O
by	O
arrow	O
-	O
heads	O
and	O
straight	O
white	O
arrow	O
in	O
the	O
confocal	O
image	O
.	O

Bacterial	O
-	O
fungal	O
colonies	O
are	O
shown	O
by	O
broken	O
arrows	O
.	O

Red	O
arrow	O
indicates	O
space	O
between	O
cuticle	O
and	O
hair	O
shaft	O
due	O
to	O
shrinkage	O
.	O

Extensive	O
taphonomic	O
changes	O
in	O
YUK	O
are	O
evident	O
.	O

Note	O
the	O
preservation	O
of	O
the	O
cuticle	O
in	O
the	O
human	O
hair	O
in	O
contrast	O
to	O
the	O
craters	O
in	O
the	O
cuticles	O
of	O
the	O
mammoth	O
'	O
s	O
hair	O
.	O

Bacterial	O
biofilms	O
are	O
a	O
feature	O
of	O
human	O
hair	O
;	O
mammoth	O
'	O
s	O
hair	O
was	O
protected	O
from	O
bacterial	O
invasion	O
in	O
permafrost	O
.	O

Scheme	O
of	O
the	O
activity	O
of	O
5	O
-	O
HT	O
(	O
A	O
)	O
and	O
norepinephrine	O
(	O
NE	O
)	O
(	O
B	O
)	O
neurotransmission	O
during	O
treatment	O
with	O
milnacipran	O
.	O

A	O
)	O
5	O
-	O
HT	O
system	O
.	O

Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
decreased	O
firing	O
of	O
5	O
-	O
HT	O
neurons	O
from	O
the	O
raphe	O
nucleus	O
possibly	O
due	O
in	O
part	O
to	O
increased	O
stimulation	O
of	O
somatodendritic	O
autoreceptors	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
full	O
recovery	O
in	O
the	O
firing	O
rate	O
of	O
5	O
-	O
HT	O
neurons	O
in	O
the	O
presence	O
of	O
milnacipran	O
thereby	O
leading	O
to	O
a	O
net	O
increase	O
in	O
5	O
-	O
HT	O
neurotransmission	O
.	O

Contributing	O
to	O
this	O
enhancement	O
are	O
:	O
1	O
)	O
the	O
normalized	O
firing	O
rate	O
of	O
5	O
-	O
HT	O
neurons	O
in	O
the	O
presence	O
of	O
milnacipran	O
2	O
)	O
the	O
desensitization	O
of	O
the	O
terminal	O
5	O
-	O
HT1B	O
autoreceptor	O
,	O
and	O
3	O
)	O
the	O
desensitization	O
of	O
the	O
alpha2	O
-	O
adrenergic	O
heteroreceptors	O
on	O
5	O
-	O
HT	O
terminals	O
.	O

B	O
)	O
NE	O
system	O
.	O

Acute	O
treatment	O
with	O
milnacipran	O
results	O
in	O
increased	O
synaptic	O
concentrations	O
of	O
NE	O
but	O
decreased	O
firing	O
of	O
the	O
NE	O
neurons	O
of	O
the	O
locus	O
coeruleus	O
due	O
to	O
increased	O
stimulation	O
of	O
the	O
somatodendritic	O
alpha2	O
-	O
adrenergic	O
autoreceptors	O
.	O

Long	O
-	O
term	O
treatment	O
with	O
milnacipran	O
results	O
in	O
a	O
further	O
increase	O
in	O
synaptic	O
concentrations	O
of	O
NE	O
due	O
to	O
desensitization	O
of	O
presynaptic	O
autoreceptors	O
.	O

The	O
somatodendritic	O
alpha2	O
-	O
adrenergic	O
autoreceptors	O
do	O
not	O
desensitize	O
.	O

3	O
.	O
1	O
.	O

Glucose	O
Tolerance	O
Test	O
at	O
Various	O
Times	O
following	O
Dosing	O

DIO	O
mice	O
were	O
treated	O
with	O
a	O
single	O
IV	O
dose	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
metabolism	O
was	O
monitored	O
using	O
an	O
intraperitoneal	O
glucose	O
tolerance	O
test	O
(	O
IPGTT	O
)	O
at	O
various	O
times	O
following	O
dosing	O
(	O
day	O
1	O
to	O
35	O
)	O
.	O

CNTO	O
530	O
did	O
not	O
influence	O
glucose	O
tolerance	O
24	O
hours	O
after	O
dosing	O
.	O

However	O
,	O
a	O
significant	O
improvement	O
was	O
observed	O
in	O
both	O
fasting	O
glucose	O
(	O
179	O
+	O
/	O
-	O
29	O
versus	O
133	O
+	O
/	O
-	O
19	O
mg	O
/	O
dL	O
for	O
untreated	O
versus	O
treated	O
)	O
and	O
overall	O
glucose	O
tolerance	O
seven	O
days	O
after	O
a	O
single	O
dose	O
of	O
CNTO	O
530	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

In	O
a	O
separate	O
study	O
,	O
the	O
activity	O
of	O
CNTO	O
530	O
was	O
compared	O
to	O
a	O
control	O
protein	O
that	O
lacked	O
the	O
EMP	O
-	O
1	O
peptides	O
to	O
ensure	O
that	O
the	O
observed	O
effects	O
were	O
due	O
to	O
the	O
peptide	O
and	O
not	O
the	O
Fc	O
.	O

The	O
glucose	O
lowering	O
effect	O
was	O
not	O
observed	O
in	O
the	O
mice	O
treated	O
with	O
the	O
protein	O
lacking	O
the	O
EMP	O
-	O
1	O
peptides	O
(	O
data	O
not	O
shown	O
)	O
.	O

Fasting	O
blood	O
glucose	O
remained	O
improved	O
in	O
the	O
treated	O
animals	O
14	O
and	O
21	O
days	O
after	O
CNTO530	O
treatment	O
,	O
but	O
was	O
similar	O
to	O
the	O
untreated	O
group	O
after	O
35	O
days	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
for	O
the	O
glucose	O
tolerance	O
tests	O
showed	O
a	O
significant	O
improvement	O
with	O
CNTO	O
530	O
treatment	O
on	O
days	O
7	O
,	O
14	O
,	O
20	O
,	O
and	O
28	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

The	O
most	O
dramatic	O
effect	O
on	O
glucose	O
tolerance	O
following	O
CNTO	O
530	O
-	O
treatment	O
was	O
observed	O
on	O
day	O
14	O
where	O
glucose	O
was	O
cleared	O
from	O
circulation	O
by	O
the	O
15	O
-	O
minute	O
time	O
point	O
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
.	O

CNTO	O
530	O
-	O
mediated	O
acceleration	O
of	O
glucose	O
utilization	O
was	O
diminished	O
but	O
still	O
significant	O
by	O
day	O
28	O
and	O
not	O
seen	O
by	O
day	O
35	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

Hemoglobin	O
levels	O
followed	O
a	O
similar	O
time	O
-	O
dependent	O
change	O
,	O
showing	O
an	O
increase	O
that	O
peaked	O
on	O
day	O
22	O
and	O
returned	O
to	O
normal	O
levels	O
by	O
day	O
29	O
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
.	O

Similar	O
studies	O
were	O
completed	O
in	O
lean	O
littermate	O
mice	O
fed	O
a	O
normal	O
chow	O
diet	O
.	O

Mice	O
(	O
n	O
=	O
7	O
)	O
were	O
given	O
a	O
single	O
administration	O
of	O
CNTO	O
530	O
(	O
0	O
.	O
01	O
-	O
0	O
.	O
3	O
mg	O
/	O
kg	O
)	O
,	O
and	O
glucose	O
tolerance	O
tests	O
were	O
completed	O
after	O
1	O
and	O
14	O
days	O
.	O

As	O
we	O
observed	O
in	O
the	O
diabetic	O
rodents	O
,	O
no	O
significant	O
changes	O
were	O
seen	O
in	O
glucose	O
clearance	O
24	O
hours	O
after	O
dosing	O
.	O

However	O
,	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
area	O
under	O
the	O
curve	O
in	O
the	O
glucose	O
tolerance	O
test	O
in	O
animals	O
dosed	O
with	O
0	O
.	O
3	O
and	O
0	O
.	O
1	O
mg	O
/	O
kg	O
CNTO	O
530	O
as	O
compared	O
to	O
PBS	O
(	O
22865	O
.	O
4	O
+	O
/	O
-	O
1900	O
.	O
2	O
,	O
24478	O
.	O
9	O
+	O
/	O
-	O
1093	O
.	O
4	O
,	O
and	O
28773	O
.	O
2	O
+	O
/	O
-	O
1368	O
.	O
3	O
,	O
resp	O
.	O
,	O
mean	O
+	O
/	O
-	O
SEM	O
)	O
.	O

There	O
were	O
no	O
dose	O
-	O
dependent	O
changes	O
in	O
the	O
fasting	O
blood	O
glucose	O
.	O

Cone	O
beam	O
geometry	O

Calculation	O
of	O
male	O
mating	O
success	O

In	O
order	O
to	O
compare	O
whether	O
males	O
'	O
access	O
to	O
receptive	O
females	O
followed	O
the	O
predictions	O
of	O
the	O
PoA	O
model	O
,	O
we	O
calculated	O
mating	O
success	O
as	O
follows	O
.	O

For	O
all	O
the	O
mating	O
partners	O
a	O
female	O
had	O
during	O
the	O
receptive	O
period	O
of	O
her	O
conceptive	O
cycle	O
,	O
mating	O
success	O
of	O
each	O
mating	O
partner	O
was	O
calculated	O
as	O
the	O
number	O
of	O
mating	O
series	O
a	O
male	O
was	O
involved	O
in	O
divided	O
by	O
the	O
total	O
number	O
of	O
mating	O
series	O
the	O
female	O
was	O
involved	O
in	O
.	O

Overall	O
mating	O
success	O
of	O
each	O
male	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
all	O
mating	O
successes	O
calculated	O
for	O
this	O
male	O
as	O
described	O
above	O
.	O

4	O
.	O
2	O
.	O

Histological	O
Findings	O

Microscopy	O
revealed	O
features	O
of	O
a	O
diffusely	O
growing	O
discohesive	O
carcinoma	O
,	O
exclusively	O
growing	O
in	O
the	O
alveolar	O
interstitium	O
,	O
thus	O
expanding	O
it	O
,	O
while	O
leaving	O
the	O
original	O
alveolar	O
architecture	O
intact	O
(	O
Figure	O
2	O
)	O
.	O

There	O
was	O
local	O
ulceration	O
of	O
the	O
pleura	O
,	O
while	O
,	O
beyond	O
this	O
ulcer	O
,	O
the	O
tumor	O
formed	O
a	O
thick	O
cake	O
of	O
discohesive	O
tumor	O
cells	O
lining	O
the	O
pleural	O
membrane	O
(	O
Figure	O
2	O
(	O
c	O
)	O
)	O
,	O
with	O
only	O
focal	O
,	O
microscopic	O
invasion	O
into	O
the	O
fatty	O
tissue	O
of	O
the	O
parietal	O
pleura	O
.	O

The	O
tumor	O
consisted	O
of	O
atypical	O
,	O
moderately	O
polymorphous	O
,	O
and	O
irregularly	O
shaped	O
tumor	O
cells	O
with	O
marked	O
discohesiveness	O
.	O

They	O
featured	O
scant	O
eosinophilic	O
cytoplasm	O
and	O
irregularly	O
contoured	O
and	O
hyperchromatic	O
nuclei	O
,	O
often	O
containing	O
one	O
or	O
more	O
prominent	O
nucleoli	O
(	O
Figure	O
2	O
(	O
b	O
)	O
)	O
.	O

There	O
were	O
many	O
mitoses	O
and	O
apoptoses	O
present	O
,	O
but	O
necrosis	O
was	O
not	O
observed	O
.	O

No	O
squamous	O
or	O
glandular	O
differentiation	O
was	O
observed	O
,	O
and	O
mucin	O
stains	O
(	O
PAS	O
-	O
D	O
and	O
alcian	O
blue	O
)	O
were	O
negative	O
.	O

Within	O
the	O
tumor	O
,	O
there	O
were	O
multiple	O
small	O
blood	O
-	O
filled	O
clefts	O
and	O
blood	O
lakes	O
.	O

Angioinvasion	O
in	O
medium	O
-	O
sized	O
vessels	O
,	O
including	O
an	O
artery	O
,	O
was	O
demonstrated	O
(	O
Figure	O
2	O
(	O
d	O
)	O
)	O
.	O

Of	O
note	O
,	O
the	O
broadened	O
alveolar	O
septa	O
were	O
lined	O
by	O
markedly	O
atypical	O
epithelial	O
cells	O
,	O
yet	O
less	O
atypical	O
than	O
the	O
interstitial	O
carcinoma	O
(	O
Figures	O
2	O
(	O
a	O
)	O
and	O
2	O
(	O
b	O
)	O
)	O
.	O

The	O
atypia	O
of	O
the	O
lining	O
cells	O
extended	O
beyond	O
the	O
tumor	O
front	O
,	O
showing	O
a	O
sharp	O
demarcation	O
with	O
normal	O
type	O
I	O
pneumocytes	O
(	O
Figure	O
2	O
(	O
a	O
)	O
)	O
,	O
a	O
feature	O
characteristic	O
to	O
nonmucinous	O
adenocarcinoma	O
in	O
situ	O
with	O
lepidic	O
growth	O
pattern	O
(	O
former	O
bronchioloalveolar	O
carcinoma	O
,	O
BAC	O
)	O
[	O
3	O
]	O
.	O

Tail	O
flick	O
test	O

CSLE	O
did	O
not	O
show	O
any	O
difference	O
compared	O
with	O
control	O
,	O
at	O
all	O
the	O
tested	O
doses	O
[	O
Figure	O
4	O
]	O
.	O

Morphine	O
showed	O
a	O
significant	O
increase	O
of	O
latency	O
time	O
at	O
45	O
,	O
60	O
and	O
75	O
min	O
.	O

Figure	O
4	O

Effect	O
of	O
CSLE	O
(	O
100	O
,	O
200	O
and	O
500	O
mg	O
/	O
kg	O
)	O
and	O
morphine	O
on	O
the	O
latency	O
response	O
of	O
mice	O
in	O
the	O
tail	O
flick	O
test	O
.	O

Values	O
are	O
presented	O
as	O
the	O
mean	O
+	O
/	O
-	O
SEM	O
(	O
n	O
=	O
5	O
)	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
significant	O
increase	O
from	O
control	O

Details	O
of	O
treatment	O
programs	O
A	O
and	O
B	O
in	O
respect	O
to	O
visits	O
to	O
different	O
health	O
care	O
professionals	O
and	O
treatment	O
activities	O

Paederus	O
dermatitis	O
involving	O
the	O
neck	O

Genes	O
associated	O
with	O
nonsegmental	O
vitiligo	O
.	O

a	O
,	O
b	O
Radiographs	O
of	O
the	O
left	O
elbow	O
and	O
forearm	O
5	O
months	O
after	O
the	O
surgery	O

Introduction	O

During	O
the	O
weaning	O
period	O
and	O
transition	O
to	O
solid	O
foods	O
in	O
the	O
first	O
year	O
of	O
life	O
,	O
infants	O
take	O
a	O
critical	O
step	O
in	O
their	O
eating	O
behavior	O
and	O
need	O
to	O
meet	O
high	O
nutrient	O
requirements	O
[	O
1	O
,	O
2	O
]	O
.	O

They	O
are	O
exposed	O
to	O
new	O
foods	O
and	O
food	O
combinations	O
,	O
which	O
should	O
ensure	O
a	O
smooth	O
transition	O
to	O
the	O
family	O
diet	O
later	O
in	O
life	O
.	O

At	O
this	O
stage	O
,	O
either	O
homemade	O
or	O
commercially	O
prepared	O
foods	O
may	O
be	O
fed	O
.	O

It	O
is	O
worth	O
noting	O
that	O
in	O
prosperous	O
countries	O
the	O
modern	O
diet	O
differs	O
considerably	O
from	O
that	O
of	O
previous	O
generations	O
,	O
now	O
dominated	O
by	O
products	O
that	O
have	O
been	O
processed	O
,	O
stored	O
,	O
and	O
transported	O
over	O
great	O
distances	O
.	O

Traditional	O
,	O
cold	O
-	O
pressed	O
vegetable	O
oils	O
of	O
the	O
highest	O
nutritional	O
quality	O
,	O
e	O
.	O
g	O
.	O
extra	O
virgin	O
olive	O
oil	O
,	O
may	O
therefore	O
constitute	O
an	O
important	O
part	O
of	O
the	O
modern	O
diet	O
[	O
3	O
,	O
4	O
]	O
.	O

In	O
Poland	O
,	O
many	O
infants	O
do	O
not	O
receive	O
any	O
traditional	O
homemade	O
foods	O
and	O
even	O
fruits	O
come	O
from	O
purchased	O
jars	O
.	O

Commercial	O
baby	O
foods	O
are	O
regarded	O
by	O
some	O
parents	O
and	O
medical	O
professionals	O
to	O
be	O
more	O
appropriate	O
for	O
several	O
reasons	O
:	O
they	O
undergo	O
intense	O
screening	O
for	O
contaminants	O
in	O
comparison	O
to	O
foods	O
sold	O
for	O
the	O
general	O
population	O
,	O
contain	O
no	O
additives	O
of	O
certain	O
types	O
,	O
and	O
are	O
thought	O
to	O
be	O
designed	O
to	O
help	O
infants	O
meet	O
nutrient	O
requirements	O
[	O
5	O
]	O
.	O

The	O
process	O
of	O
peeling	O
,	O
however	O
,	O
was	O
identified	O
as	O
the	O
most	O
effective	O
,	O
and	O
simple	O
,	O
procedure	O
in	O
reducing	O
residues	O
,	O
e	O
.	O
g	O
.	O
pesticides	O
,	O
in	O
fruits	O
and	O
vegetables	O
[	O
6	O
]	O
.	O

Moreover	O
,	O
contrary	O
to	O
homemade	O
food	O
,	O
which	O
does	O
not	O
contain	O
furan	O
,	O
the	O
highest	O
average	O
content	O
of	O
this	O
chemical	O
was	O
found	O
in	O
ready	O
-	O
to	O
-	O
eat	O
baby	O
foods	O
with	O
pasta	O
meals	O
,	O
followed	O
by	O
vegetable	O
meals	O
and	O
meals	O
with	O
meat	O
[	O
7	O
]	O
.	O

Furan	O
is	O
considered	O
to	O
be	O
potentially	O
hazardous	O
chemical	O
and	O
is	O
classified	O
as	O
a	O
possible	O
carcinogen	O
.	O

The	O
problem	O
of	O
this	O
chemical	O
in	O
homemade	O
food	O
may	O
only	O
arise	O
if	O
meals	O
with	O
potatoes	O
are	O
stored	O
and	O
then	O
hardly	O
re	O
-	O
heated	O
[	O
7	O
]	O
.	O

There	O
is	O
a	O
growing	O
body	O
of	O
evidence	O
that	O
flavor	O
experiences	O
and	O
dietary	O
patterns	O
in	O
childhood	O
influence	O
these	O
patterns	O
later	O
in	O
life	O
[	O
1	O
,	O
8	O
,	O
9	O
]	O
.	O

It	O
is	O
most	O
likely	O
early	O
in	O
life	O
that	O
culture	O
-	O
specific	O
flavor	O
preferences	O
are	O
initiated	O
[	O
10	O
,	O
11	O
]	O
.	O

Consequently	O
,	O
exposure	O
to	O
flavors	O
and	O
smells	O
of	O
transitory	O
foods	O
may	O
serve	O
to	O
heighten	O
preferences	O
for	O
""""	O
known	O
tastes	O
""""	O
in	O
the	O
family	O
diet	O
later	O
in	O
adulthood	O
.	O

Moreover	O
,	O
adopting	O
elements	O
of	O
childhood	O
dinner	O
patterns	O
was	O
recognized	O
to	O
be	O
an	O
important	O
part	O
of	O
the	O
social	O
reproduction	O
of	O
family	O
identities	O
across	O
generations	O
[	O
12	O
]	O
.	O

Processing	O
industries	O
have	O
been	O
successful	O
in	O
manufacturing	O
and	O
marketing	O
jarred	O
baby	O
foods	O
on	O
a	O
commercial	O
scale	O
.	O

Available	O
products	O
contain	O
different	O
ingredients	O
and	O
depend	O
on	O
the	O
manufacturer	O
,	O
country	O
,	O
traditional	O
cuisine	O
,	O
income	O
rate	O
,	O
and	O
lastly	O
,	O
personal	O
beliefs	O
and	O
values	O
of	O
parents	O
[	O
9	O
,	O
11	O
]	O
.	O

Jarred	O
foods	O
with	O
vegetables	O
,	O
meats	O
,	O
and	O
desserts	O
may	O
contain	O
added	O
fat	O
from	O
a	O
variety	O
of	O
sources	O
:	O
vegetable	O
oils	O
,	O
cow	O
milk	O
butter	O
,	O
or	O
cream	O
.	O

Manufacturer	O
advertising	O
makes	O
the	O
majority	O
of	O
consumers	O
feel	O
safe	O
,	O
causing	O
them	O
to	O
believe	O
that	O
they	O
are	O
doing	O
the	O
best	O
possible	O
in	O
buying	O
given	O
products	O
[	O
11	O
]	O
.	O

A	O
noteworthy	O
fact	O
is	O
that	O
many	O
types	O
of	O
baby	O
foods	O
produced	O
by	O
international	O
manufacturers	O
are	O
,	O
in	O
essence	O
,	O
the	O
same	O
mixtures	O
with	O
different	O
names	O
;	O
this	O
procedure	O
aims	O
to	O
exploit	O
the	O
specifics	O
of	O
local	O
markets	O
without	O
delivering	O
any	O
new	O
,	O
real	O
value	O
[	O
11	O
]	O
.	O

In	O
the	O
book	O
,	O
How	O
to	O
Eat	O
Well	O
and	O
Stay	O
Well	O
the	O
Mediterranean	O
Way	O
by	O
Keys	O
[	O
13	O
]	O
first	O
used	O
the	O
term	O
""""	O
good	O
Mediterranean	O
diet	O
""""	O
to	O
describe	O
the	O
eating	O
patterns	O
of	O
populations	O
dwelling	O
in	O
southern	O
Europe	O
,	O
where	O
the	O
olive	O
tree	O
(	O
Olea	O
europaea	O
)	O
is	O
an	O
emblematic	O
species	O
[	O
4	O
,	O
14	O
]	O
.	O

There	O
is	O
variation	O
between	O
the	O
exact	O
diet	O
in	O
different	O
parts	O
of	O
the	O
Mediterranean	O
region	O
.	O

However	O
,	O
generalized	O
and	O
distinctive	O
dietary	O
patterns	O
do	O
exist	O
,	O
including	O
olive	O
oil	O
as	O
the	O
main	O
source	O
of	O
visible	O
fat	O
,	O
employed	O
both	O
in	O
cooking	O
and	O
as	O
a	O
dressing	O
,	O
moderate	O
fish	O
and	O
poultry	O
but	O
low	O
red	O
meat	O
consumption	O
,	O
high	O
intake	O
of	O
vegetables	O
,	O
fruits	O
,	O
legumes	O
,	O
nuts	O
,	O
and	O
whole	O
-	O
grain	O
cereals	O
[	O
4	O
,	O
14	O
-	O
16	O
]	O
.	O

When	O
dietary	O
fats	O
are	O
added	O
,	O
in	O
accordance	O
with	O
the	O
traditional	O
Mediterranean	O
diet	O
,	O
olive	O
oil	O
is	O
the	O
choice	O
for	O
children	O
[	O
17	O
]	O
.	O

It	O
has	O
been	O
repeatedly	O
observed	O
that	O
individuals	O
applying	O
the	O
Mediterranean	O
diet	O
have	O
reduced	O
risks	O
of	O
type	O
2	O
diabetes	O
and	O
other	O
diseases	O
associated	O
with	O
the	O
metabolic	O
syndrome	O
,	O
autoimmunological	O
diseases	O
,	O
and	O
certain	O
forms	O
of	O
cancer	O
[	O
18	O
]	O
.	O

Moreover	O
,	O
considerable	O
evidence	O
exists	O
that	O
the	O
Mediterranean	O
diet	O
increases	O
quality	O
of	O
life	O
in	O
the	O
course	O
of	O
ageing	O
,	O
as	O
well	O
as	O
longevity	O
[	O
13	O
,	O
19	O
]	O
.	O

The	O
health	O
benefits	O
of	O
olive	O
oil	O
have	O
been	O
attributed	O
to	O
two	O
main	O
constituents	O
:	O
a	O
high	O
oleic	O
acid	O
(	O
monounsaturated	O
fatty	O
acid	O
,	O
18	O
:	O
1n	O
-	O
9	O
)	O
content	O
(	O
70	O
-	O
85	O
%	O
)	O
and	O
a	O
large	O
amount	O
of	O
antioxidant	O
compounds	O
,	O
which	O
also	O
possess	O
antiviral	O
,	O
antibacterial	O
,	O
and	O
immunomodulating	O
effects	O
[	O
3	O
,	O
4	O
,	O
14	O
,	O
16	O
]	O
.	O

Polyphenols	O
found	O
in	O
virgin	O
olive	O
oil	O
are	O
linked	O
to	O
both	O
its	O
flavor	O
and	O
its	O
remarkable	O
stability	O
[	O
3	O
]	O
.	O

The	O
introduction	O
of	O
solid	O
foods	O
in	O
infancy	O
is	O
one	O
of	O
the	O
primary	O
matters	O
often	O
discussed	O
by	O
parents	O
with	O
their	O
child	O
'	O
s	O
pediatrician	O
.	O

However	O
,	O
many	O
parents	O
do	O
not	O
feel	O
that	O
the	O
diet	O
of	O
their	O
child	O
may	O
be	O
linked	O
to	O
poor	O
health	O
outcomes	O
in	O
the	O
future	O
.	O

Parents	O
should	O
be	O
educated	O
about	O
the	O
interplay	O
of	O
environmental	O
and	O
genetic	O
influences	O
on	O
children	O
,	O
specifically	O
during	O
the	O
early	O
years	O
of	O
development	O
when	O
the	O
child	O
is	O
maturing	O
and	O
taking	O
control	O
of	O
its	O
own	O
diet	O
[	O
11	O
]	O
.	O

Nutrition	O
educators	O
should	O
increase	O
the	O
critical	O
awareness	O
of	O
parents	O
in	O
relation	O
to	O
their	O
child	O
'	O
s	O
solid	O
food	O
choices	O
.	O

It	O
is	O
important	O
to	O
emphasize	O
to	O
parents	O
the	O
fundamental	O
role	O
that	O
the	O
Mediterranean	O
diet	O
and	O
consumption	O
of	O
foods	O
with	O
olive	O
oil	O
play	O
in	O
a	O
healthy	O
life	O
style	O
[	O
14	O
,	O
20	O
]	O
.	O

Parental	O
management	O
of	O
the	O
family	O
food	O
environment	O
may	O
be	O
complicated	O
by	O
numerous	O
mitigating	O
factors	O
,	O
e	O
.	O
g	O
.	O
health	O
literacy	O
,	O
time	O
availability	O
,	O
and	O
financial	O
resources	O
.	O

Considering	O
the	O
role	O
baby	O
food	O
manufacturers	O
play	O
in	O
the	O
infant	O
'	O
s	O
contextual	O
environment	O
,	O
their	O
products	O
,	O
as	O
well	O
as	O
the	O
manufacturers	O
themselves	O
,	O
should	O
also	O
be	O
viewed	O
as	O
key	O
players	O
and	O
central	O
agents	O
in	O
establishing	O
dietary	O
habits	O
.	O

Consequently	O
,	O
we	O
attempted	O
to	O
survey	O
manufacturer	O
claims	O
concerning	O
added	O
fat	O
in	O
jarred	O
infant	O
foods	O
supplied	O
to	O
the	O
Polish	O
market	O
.	O

Materials	O
and	O
Methods	O

Discussion	O

The	O
two	O
most	O
important	O
factors	O
leading	O
to	O
the	O
development	O
of	O
hypoxia	O
are	O
biological	O
processes	O
that	O
determine	O
the	O
amount	O
of	O
organic	O
matter	O
available	O
to	O
be	O
degraded	O
and	O
physical	O
factors	O
creating	O
stratification	O
.	O

Stratification	O
in	O
most	O
areas	O
of	O
the	O
coastal	O
zone	O
of	O
the	O
Baltic	O
Sea	O
is	O
due	O
to	O
seasonal	O
temperature	O
changes	O
,	O
although	O
stratification	O
by	O
occasional	O
inflowing	O
saltier	O
water	O
does	O
occur	O
in	O
some	O
estuaries	O
.	O
(	O
14	O
)	O
Hypoxia	O
is	O
common	O
in	O
estuaries	O
located	O
in	O
the	O
Danish	O
Straits	O
due	O
to	O
the	O
large	O
load	O
of	O
nutrients	O
sustaining	O
algal	O
production	O
and	O
the	O
strong	O
stratification	O
caused	O
by	O
large	O
differences	O
in	O
surface	O
and	O
bottom	O
water	O
salinity	O
.	O
(	O
5	O
)	O
Hypoxia	O
in	O
the	O
Swedish	O
and	O
Finnish	O
archipelagos	O
are	O
influenced	O
by	O
phytoplankton	O
growth	O
stimulated	O
by	O
nutrient	O
loads	O
from	O
urban	O
and	O
agricultural	O
sources	O
,	O
but	O
also	O
by	O
restricted	O
water	O
circulation	O
.	O

The	O
Finnish	O
Archipelago	O
Sea	O
is	O
impacted	O
by	O
drifting	O
algal	O
mats	O
that	O
consume	O
oxygen	O
during	O
their	O
decomposition	O
when	O
they	O
sink	O
to	O
the	O
bottom	O
.	O
(	O
15	O
)	O
By	O
contrast	O
,	O
hypoxia	O
is	O
rare	O
in	O
the	O
northern	O
Baltic	O
Sea	O
estuaries	O
located	O
in	O
the	O
Bothnian	O
Sea	O
coastal	O
zone	O
where	O
nutrient	O
loads	O
are	O
lower	O
.	O

Hypoxia	O
is	O
uncommon	O
along	O
the	O
eastern	O
shore	O
from	O
Estonia	O
to	O
Poland	O
due	O
to	O
enhanced	O
circulation	O
of	O
water	O
in	O
open	O
areas	O
along	O
the	O
coastline	O
(	O
Figure	O
1	O
)	O
.	O

There	O
are	O
very	O
limited	O
data	O
available	O
to	O
examine	O
how	O
far	O
back	O
in	O
time	O
hypoxia	O
has	O
occurred	O
.	O

A	O
key	O
question	O
in	O
this	O
ecosystem	O
affected	O
daily	O
by	O
over	O
85	O
million	O
people	O
could	O
be	O
""""	O
Is	O
hypoxia	O
a	O
natural	O
phenomenon	O
?	O
""""	O
.	O
(	O
16	O
)	O
The	O
large	O
numbers	O
of	O
enclosed	O
areas	O
,	O
in	O
many	O
cases	O
with	O
shallow	O
sills	O
that	O
restrict	O
the	O
exchange	O
of	O
bottom	O
water	O
and	O
often	O
in	O
combination	O
with	O
large	O
irregular	O
changes	O
in	O
salinity	O
,	O
might	O
mean	O
that	O
hypoxia	O
has	O
always	O
been	O
present	O
in	O
the	O
coastal	O
zone	O
.	O

However	O
,	O
sediment	O
laminations	O
from	O
Stockholm	O
Archipelago	O
,	O
an	O
indicator	O
of	O
past	O
hypoxia	O
,	O
(	O
17	O
)	O
have	O
been	O
shown	O
to	O
be	O
a	O
recent	O
phenomenon	O
with	O
very	O
few	O
areas	O
with	O
laminated	O
sediments	O
prior	O
to	O
1900	O
.	O
17	O
,	O
18	O
The	O
long	O
-	O
term	O
millennial	O
trends	O
in	O
coastal	O
hypoxia	O
remain	O
unknown	O
,	O
although	O
hypoxia	O
has	O
occurred	O
intermittently	O
throughout	O
the	O
last	O
8000	O
years	O
in	O
offshore	O
deep	O
waters	O
of	O
the	O
Baltic	O
Sea	O
.	O
(	O
10	O
)	O
Further	O
sediment	O
studies	O
are	O
necessary	O
,	O
similar	O
to	O
those	O
carried	O
out	O
in	O
the	O
open	O
Baltic	O
Sea	O
,	O
(	O
10	O
)	O
to	O
ascertain	O
how	O
far	O
back	O
in	O
time	O
hypoxia	O
was	O
observed	O
in	O
the	O
coastal	O
zone	O
.	O

Key	O
uncertainties	O
remain	O
including	O
how	O
have	O
the	O
driving	O
forces	O
for	O
hypoxia	O
,	O
e	O
.	O
g	O
.	O
,	O
climate	O
(	O
19	O
)	O
and	O
nutrient	O
loading	O
,	O
changed	O
through	O
time	O
in	O
the	O
Baltic	O
Sea	O
coastal	O
zone	O
,	O
and	O
do	O
they	O
vary	O
during	O
the	O
same	O
time	O
periods	O
that	O
hypoxia	O
varies	O
in	O
the	O
open	O
waters	O
?	O
(	O
16	O
)	O

An	O
important	O
consideration	O
in	O
determining	O
the	O
number	O
of	O
ecosystems	O
experiencing	O
hypoxia	O
is	O
the	O
size	O
of	O
the	O
assessment	O
unit	O
.	O

We	O
combined	O
numerous	O
monitoring	O
points	O
and	O
sites	O
to	O
form	O
a	O
coherent	O
coastal	O
unit	O
when	O
bottom	O
waters	O
were	O
physically	O
connected	O
to	O
each	O
other	O
.	O

This	O
means	O
that	O
assessment	O
units	O
considered	O
hypoxic	O
might	O
occur	O
in	O
the	O
same	O
geographical	O
region	O
and	O
could	O
be	O
in	O
close	O
proximately	O
to	O
each	O
other	O
,	O
if	O
their	O
bottom	O
waters	O
were	O
physically	O
disconnected	O
.	O

The	O
Baltic	O
Sea	O
archipelagos	O
have	O
a	O
complex	O
topography	O
with	O
many	O
basins	O
disjoined	O
by	O
shallow	O
sills	O
resulting	O
in	O
many	O
distinct	O
sites	O
,	O
although	O
they	O
are	O
all	O
affected	O
by	O
similar	O
mechanisms	O
.	O

In	O
fact	O
,	O
the	O
Stockholm	O
and	O
Finnish	O
archipelagos	O
contributed	O
21	O
%	O
of	O
the	O
total	O
assessment	O
units	O
,	O
a	O
relatively	O
large	O
share	O
compared	O
to	O
the	O
total	O
Baltic	O
Sea	O
coastal	O
zone	O
,	O
but	O
>	O
40	O
%	O
of	O
the	O
hypoxic	O
sites	O
.	O

The	O
coastal	O
stretches	O
of	O
the	O
Western	O
Gotland	O
Basin	O
and	O
Gulf	O
of	O
Finland	O
that	O
have	O
a	O
substantial	O
number	O
of	O
hypoxic	O
sites	O
are	O
also	O
archipelagos	O
,	O
which	O
are	O
more	O
prone	O
to	O
hypoxia	O
because	O
of	O
the	O
complex	O
topography	O
,	O
proximity	O
to	O
development	O
,	O
and	O
consequently	O
more	O
sensitive	O
to	O
enhanced	O
nutrient	O
inputs	O
from	O
land	O
.	O

Surprisingly	O
only	O
4	O
.	O
0	O
%	O
of	O
all	O
sites	O
were	O
classified	O
as	O
seasonally	O
hypoxic	O
according	O
to	O
our	O
definition	O
when	O
>	O
50	O
%	O
and	O
<	O
80	O
%	O
of	O
profiles	O
during	O
the	O
stratified	O
period	O
have	O
oxygen	O
concentrations	O
less	O
than	O
2	O
mg	O
L	O
-	O
1	O
.	O

A	O
statistically	O
rigorous	O
definition	O
of	O
what	O
constitutes	O
seasonal	O
hypoxia	O
does	O
not	O
currently	O
exist	O
and	O
in	O
fact	O
should	O
be	O
linked	O
to	O
ecological	O
consequences	O
for	O
it	O
to	O
be	O
ecologically	O
relevant	O
and	O
not	O
just	O
connected	O
to	O
absolute	O
concentrations	O
.	O
(	O
3	O
)	O
Currently	O
coastal	O
marine	O
ecosystems	O
that	O
experience	O
hypoxia	O
for	O
a	O
period	O
of	O
days	O
to	O
months	O
every	O
year	O
are	O
often	O
considered	O
to	O
be	O
seasonally	O
hypoxic	O
,	O
although	O
we	O
have	O
categorized	O
them	O
here	O
as	O
being	O
episodic	O
,	O
because	O
we	O
required	O
the	O
monitoring	O
units	O
to	O
be	O
hypoxic	O
for	O
most	O
of	O
the	O
stratified	O
period	O
.	O

However	O
,	O
in	O
Limfjorden	O
,	O
Denmark	O
,	O
bottom	O
water	O
oxygen	O
concentrations	O
can	O
vary	O
greatly	O
between	O
weekly	O
samplings	O
(	O
SI	O
Figure	O
S6	O
)	O
,	O
although	O
nearly	O
every	O
year	O
hypoxic	O
conditions	O
are	O
observed	O
somewhere	O
in	O
the	O
Limfjorden	O
.	O

Our	O
statistical	O
estimation	O
is	O
that	O
Limfjorden	O
is	O
episodically	O
hypoxic	O
.	O

Diaz	O
and	O
Rosenberg	O
(	O
1	O
)	O
would	O
classify	O
Limfjorden	O
as	O
periodically	O
hypoxic	O
,	O
although	O
we	O
have	O
found	O
it	O
difficult	O
to	O
create	O
a	O
statistically	O
robust	O
indicator	O
that	O
would	O
classify	O
systems	O
as	O
periodically	O
hypoxic	O
.	O

Periodic	O
hypoxia	O
is	O
problematic	O
because	O
it	O
never	O
allows	O
for	O
re	O
-	O
establishment	O
of	O
benthic	O
communities	O
.	O
(	O
20	O
)	O

Currently	O
,	O
there	O
are	O
416	O
areas	O
in	O
the	O
world	O
with	O
reported	O
coastal	O
hypoxia	O
with	O
about	O
30	O
previously	O
reported	O
sites	O
in	O
the	O
Baltic	O
Sea	O
region	O
,	O
which	O
includes	O
both	O
coastal	O
zone	O
hypoxia	O
and	O
deep	O
water	O
sites	O
in	O
the	O
Baltic	O
Sea	O
.	O
(	O
1	O
)	O
We	O
have	O
identified	O
an	O
additional	O
96	O
sites	O
that	O
have	O
experienced	O
hypoxia	O
,	O
increasing	O
the	O
global	O
total	O
to	O
nearly	O
500	O
sites	O
.	O

Of	O
all	O
the	O
known	O
sites	O
around	O
the	O
world	O
,	O
around	O
20	O
%	O
of	O
the	O
sites	O
are	O
found	O
in	O
the	O
Baltic	O
Sea	O
region	O
.	O

Most	O
sites	O
experienced	O
episodic	O
hypoxia	O
,	O
which	O
is	O
a	O
precursor	O
to	O
development	O
of	O
seasonal	O
hypoxia	O
.	O
(	O
20	O
)	O
The	O
large	O
number	O
of	O
sites	O
partially	O
reflects	O
the	O
fact	O
that	O
the	O
Baltic	O
Sea	O
is	O
one	O
of	O
the	O
most	O
data	O
rich	O
regions	O
of	O
the	O
world	O
with	O
no	O
tidal	O
mixing	O
and	O
complex	O
bottom	O
topography	O
creating	O
conditions	O
favorable	O
for	O
hypoxia	O
,	O
although	O
these	O
are	O
only	O
the	O
""""	O
monitored	O
areas	O
""""	O
and	O
many	O
more	O
hypoxic	O
sites	O
probably	O
exist	O
in	O
the	O
Baltic	O
Sea	O
coastal	O
zone	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
evidence	O
of	O
hypoxia	O
at	O
95	O
stations	O
in	O
estuarine	O
and	O
coastal	O
waters	O
around	O
Ireland	O
due	O
to	O
sufficient	O
tidal	O
mixing	O
.	O
(	O
21	O
)	O
If	O
such	O
detailed	O
data	O
existed	O
for	O
other	O
coastal	O
regions	O
around	O
the	O
world	O
,	O
it	O
is	O
likely	O
that	O
the	O
number	O
of	O
areas	O
would	O
increase	O
globally	O
.	O

Oxygen	O
is	O
an	O
important	O
parameter	O
in	O
water	O
quality	O
assessments	O
since	O
sufficient	O
oxygen	O
is	O
essential	O
to	O
aquatic	O
life	O
and	O
is	O
necessary	O
to	O
support	O
healthy	O
biological	O
communities	O
.	O
(	O
3	O
)	O
For	O
example	O
,	O
oxygen	O
concentration	O
is	O
a	O
supporting	O
element	O
to	O
the	O
biological	O
quality	O
elements	O
in	O
the	O
European	O
Water	O
Framework	O
Directive	O
,	O
(	O
21	O
)	O
is	O
one	O
of	O
the	O
ecological	O
objectives	O
in	O
the	O
Helsinki	O
Commission	O
'	O
s	O
(	O
HELCOM	O
)	O
eutrophication	O
assessment	O
of	O
the	O
Baltic	O
Sea	O
,	O
and	O
is	O
included	O
in	O
the	O
European	O
Marine	O
Strategy	O
Framework	O
Directive	O
as	O
an	O
effect	O
parameter	O
of	O
eutrophication	O
.	O

Accurate	O
data	O
for	O
the	O
concentration	O
of	O
dissolved	O
oxygen	O
are	O
essential	O
for	O
documenting	O
environmental	O
changes	O
in	O
water	O
resources	O
resulting	O
from	O
natural	O
phenomena	O
and	O
human	O
activities	O
.	O

Reports	O
of	O
hypoxia	O
globally	O
are	O
increasing1	O
,	O
22	O
both	O
due	O
to	O
the	O
recognition	O
of	O
the	O
seriousness	O
of	O
hypoxia	O
on	O
ecosystem	O
functioning	O
and	O
as	O
decades	O
-	O
long	O
monitoring	O
records	O
become	O
available	O
in	O
databases	O
.	O

How	O
the	O
large	O
number	O
of	O
newly	O
identified	O
hypoxic	O
areas	O
influences	O
nutrient	O
biogeochemical	O
cycles	O
and	O
ecosystem	O
services	O
in	O
the	O
coastal	O
zone	O
in	O
the	O
Baltic	O
Sea	O
is	O
currently	O
unknown	O
,	O
although	O
the	O
functioning	O
of	O
the	O
coastal	O
filter	O
certainly	O
plays	O
an	O
important	O
role	O
in	O
how	O
adjacent	O
marine	O
systems	O
respond	O
to	O
changes	O
in	O
nutrient	O
loading	O
.	O

Presently	O
about	O
40	O
%	O
of	O
the	O
world	O
'	O
s	O
population	O
lives	O
within	O
100	O
km	O
of	O
the	O
coastal	O
zone	O
strongly	O
impacting	O
ocean	O
health	O
,	O
(	O
24	O
)	O
including	O
increasing	O
the	O
occurrence	O
of	O
hypoxic	O
areas	O
.	O
1	O
,	O
2	O
What	O
is	O
currently	O
lacking	O
is	O
the	O
link	O
to	O
the	O
driving	O
factors	O
of	O
hypoxia	O
including	O
nutrient	O
enrichment	O
,	O
organic	O
carbon	O
loading	O
and	O
climate	O
change	O
,	O
(	O
25	O
)	O
and	O
a	O
determination	O
of	O
appropriate	O
nutrient	O
loading	O
targets	O
for	O
guidance	O
to	O
managers	O
to	O
ameliorate	O
the	O
devastating	O
impact	O
of	O
hypoxia	O
.	O
(	O
24	O
)	O

2	O
.	O
1	O
.	O
3	O

Pixel	O
Classification	O

The	O
feature	O
vector	O
of	O
a	O
grid	O
,	O
which	O
consists	O
of	O
nine	O
features	O
,	O
is	O
normalized	O
to	O
[	O
0	O
,	O
1	O
]	O
,	O
and	O
the	O
position	O
features	O
are	O
scaled	O
by	O
the	O
weighting	O
coefficient	O
wpos	O
.	O

Then	O
,	O
taking	O
the	O
nine	O
dimensional	O
vector	O
of	O
each	O
grid	O
as	O
the	O
input	O
of	O
the	O
classifier	O
,	O
the	O
ROI	O
and	O
non	O
-	O
ROI	O
background	O
in	O
ultrasonic	O
breast	O
tumor	O
images	O
can	O
be	O
distinguished	O
.	O

In	O
this	O
section	O
,	O
the	O
self	O
-	O
organizing	O
feature	O
map	O
neural	O
network	O
(	O
SOMNN	O
)	O
[	O
25	O
]	O
,	O
proposed	O
by	O
Kohonen	O
according	O
to	O
characteristics	O
of	O
the	O
nervous	O
system	O
,	O
is	O
used	O
for	O
the	O
classification	O
of	O
these	O
grids	O
to	O
detect	O
the	O
ROI	O
automatically	O
.	O

The	O
SOM	O
is	O
trained	O
by	O
the	O
unsupervised	O
learning	O
to	O
produce	O
a	O
low	O
-	O
dimensional	O
discretized	O
representation	O
of	O
the	O
input	O
space	O
of	O
the	O
training	O
samples	O
,	O
and	O
it	O
uses	O
a	O
neighborhood	O
function	O
to	O
preserve	O
the	O
topological	O
properties	O
of	O
the	O
input	O
space	O
,	O
which	O
makes	O
it	O
different	O
from	O
other	O
artificial	O
neural	O
networks	O
.	O

In	O
this	O
way	O
,	O
the	O
SOM	O
is	O
able	O
to	O
classify	O
the	O
sub	O
-	O
blocks	O
into	O
n	O
clusters	O
only	O
by	O
the	O
unsupervised	O
learning	O
.	O

In	O
our	O
study	O
,	O
the	O
output	O
layer	O
number	O
n	O
is	O
set	O
to	O
2	O
(	O
ROI	O
and	O
non	O
-	O
ROI	O
output	O
)	O
and	O
the	O
feature	O
vector	O
extracted	O
from	O
each	O
grid	O
is	O
taken	O
as	O
the	O
input	O
.	O

To	O
map	O
the	O
sorted	O
sub	O
-	O
blocks	O
back	O
to	O
the	O
size	O
of	O
the	O
original	O
ultrasonic	O
images	O
,	O
the	O
initial	O
result	O
of	O
ROI	O
detection	O
can	O
be	O
represented	O
by	O
a	O
binary	O
image	O
as	O
shown	O
in	O
Fig	O
.	O

(	O
2d	O
)	O
,	O
where	O
white	O
areas	O
indicate	O
the	O
ROI	O
candidates	O
while	O
black	O
areas	O
the	O
non	O
-	O
ROIs	O
.	O

Materials	O
and	O
Methods	O
:	O

A	O
total	O
of	O
75	O
brain	O
abscess	O
pus	O
specimens	O
were	O
collected	O
during	O
neurosurgery	O
,	O
either	O
by	O
burr	O
hole	O
or	O
by	O
craniotomy	O
.	O

These	O
specimens	O
were	O
further	O
subjected	O
to	O
Gram	O
stain	O
,	O
Ziehl	O
-	O
Neelsen	O
(	O
ZN	O
)	O
stain	O
,	O
and	O
conventional	O
microbiological	O
culture	O
.	O

Only	O
those	O
cases	O
which	O
showed	O
presence	O
of	O
AFB	O
on	O
ZN	O
stain	O
along	O
with	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
were	O
considered	O
as	O
TBAs	O
.	O

Such	O
TBA	O
cases	O
were	O
further	O
presented	O
along	O
with	O
their	O
In	O
vitro	O
Proton	O
Magnetic	O
Resonance	O
(	O
MR	O
)	O
Spectroscopic	O
findings	O
.	O

Rate	O
of	O
distraction	O
calculation	O
(	O
Figs	O
.	O
6	O
,	O
7	O
and	O
8	O
)	O

Ideal	O
rate	O
for	O
new	O
bone	O
formation	O
by	O
distraction	O
osteogenesis	O
is	O
known	O
as	O
1	O
mm	O
/	O
day	O
.	O
5	O
,	O
6	O
The	O
slower	O
rates	O
may	O
lead	O
to	O
premature	O
consolidation	O
,	O
whereas	O
the	O
faster	O
rates	O
may	O
result	O
in	O
poor	O
regenerate	O
bone	O
formation	O
.	O

In	O
simple	O
longitudinal	O
lengthening	O
,	O
the	O
rate	O
of	O
distraction	O
is	O
equal	O
at	O
any	O
point	O
of	O
the	O
corticotomy	O
,	O
however	O
,	O
the	O
rate	O
of	O
distraction	O
at	O
any	O
given	O
portion	O
of	O
the	O
corticotomy	O
varies	O
during	O
angular	O
correction	O
.	O

Usually	O
,	O
the	O
gap	O
between	O
corticotomized	O
bone	O
ends	O
is	O
larger	O
on	O
the	O
concave	O
side	O
,	O
therefore	O
,	O
the	O
rate	O
of	O
angular	O
correction	O
should	O
be	O
adjusted	O
so	O
that	O
the	O
rate	O
of	O
distraction	O
of	O
the	O
concave	O
side	O
is	O
closer	O
to	O
1	O
mm	O
/	O
day	O
.	O

In	O
cases	O
with	O
passive	O
hinge	O
system	O
,	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
can	O
easily	O
be	O
calculated	O
by	O
the	O
geometric	O
methods	O
using	O
the	O
rule	O
of	O
similar	O
triangles	O
and	O
the	O
rule	O
of	O
concentric	O
circles	O
,	O
and	O
can	O
be	O
expressed	O
as	O
the	O
amount	O
of	O
daily	O
lengthening	O
of	O
motor	O
system	O
.	O

In	O
passive	O
hinge	O
system	O
,	O
the	O
ACA	O
is	O
fixed	O
on	O
the	O
frame	O
in	O
Ilizarov	O
system	O
or	O
on	O
the	O
convex	O
side	O
of	O
corticotomy	O
in	O
unilateral	O
fixator	O
system	O
,	O
and	O
angular	O
correction	O
is	O
achieved	O
by	O
changing	O
the	O
length	O
of	O
the	O
motor	O
(	O
Ilizarov	O
system	O
)	O
or	O
the	O
lengthener	O
(	O
unilateral	O
fixator	O
)	O
which	O
rotates	O
the	O
passive	O
hinge	O
.	O

However	O
,	O
in	O
active	O
hinge	O
system	O
,	O
angulator	O
directly	O
corrects	O
angular	O
deformity	O
,	O
and	O
the	O
lengthener	O
and	O
translator	O
adjust	O
secondary	O
displacement	O
.	O

Therefore	O
,	O
the	O
rate	O
of	O
angular	O
correction	O
can	O
not	O
be	O
determined	O
by	O
the	O
simple	O
geometric	O
methods	O
used	O
for	O
passive	O
hinge	O
system	O
.	O

Regardless	O
of	O
types	O
of	O
fixators	O
,	O
the	O
gap	O
opens	O
larger	O
on	O
the	O
concave	O
side	O
of	O
the	O
deformity	O
after	O
realignment	O
.	O

The	O
rate	O
of	O
angular	O
correction	O
also	O
should	O
be	O
adjusted	O
so	O
that	O
the	O
rate	O
of	O
distraction	O
of	O
concave	O
side	O
is	O
1	O
mm	O
/	O
day	O
.	O

Theoretically	O
,	O
after	O
realignment	O
by	O
Dyna	O
-	O
ATC	O
with	O
adjustment	O
of	O
secondary	O
displacement	O
,	O
the	O
convex	O
side	O
of	O
the	O
corticotomy	O
does	O
not	O
change	O
in	O
length	O
,	O
but	O
the	O
cocave	O
side	O
opens	O
to	O
correct	O
angular	O
deformity	O
.	O

The	O
amount	O
of	O
lengthening	O
on	O
the	O
concave	O
side	O
can	O
be	O
calculated	O
with	O
the	O
thickness	O
of	O
the	O
bone	O
at	O
the	O
corticotomy	O
site	O
and	O
the	O
amount	O
of	O
angular	O
deformity	O
(	O
Fig	O
.	O
6	O
)	O
.	O

If	O
the	O
corticotomy	O
is	O
performed	O
on	O
the	O
CORA	O
,	O
no	O
translation	O
deformity	O
happens	O
,	O
however	O
,	O
if	O
not	O
,	O
translation	O
results	O
at	O
the	O
corticotomy	O
site	O
after	O
realignment	O
is	O
achieved	O
.	O

The	O
amount	O
of	O
translation	O
can	O
be	O
calculated	O
with	O
the	O
distance	O
from	O
the	O
CORA	O
to	O
the	O
corticotomy	O
over	O
the	O
longitudinal	O
bisecting	O
line	O
(	O
lBL	O
)	O
(	O
Fig	O
.	O
6	O
)	O
.	O

On	O
the	O
immediate	O
post	O
-	O
operative	O
radiographs	O
,	O
the	O
gap	O
distance	O
of	O
concave	O
side	O
after	O
realignment	O
can	O
be	O
calculated	O
with	O
the	O
expected	O
change	O
in	O
length	O
and	O
translation	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
using	O
the	O
Pythaorean	O
theorem	O
.	O

The	O
rate	O
of	O
angular	O
correction	O
should	O
be	O
given	O
as	O
the	O
amount	O
of	O
daily	O
correction	O
angle	O
,	O
but	O
not	O
as	O
the	O
amount	O
of	O
length	O
change	O
of	O
the	O
fixator	O
.	O

The	O
angular	O
change	O
of	O
angulator	O
determines	O
the	O
secondary	O
change	O
of	O
length	O
and	O
translation	O
of	O
the	O
corticotomy	O
site	O
.	O

The	O
amount	O
of	O
secondary	O
deformity	O
during	O
angular	O
correction	O
can	O
be	O
calculated	O
with	O
the	O
thickness	O
of	O
bone	O
at	O
the	O
corticotomy	O
site	O
,	O
the	O
distance	O
between	O
the	O
ACA	O
and	O
the	O
corticotomy	O
,	O
and	O
tan	O
(	O
a	O
/	O
2	O
)	O
(	O
a	O
is	O
the	O
amount	O
of	O
angular	O
correction	O
)	O
(	O
Fig	O
.	O
6	O
)	O
.	O

The	O
thickness	O
of	O
the	O
bone	O
at	O
the	O
corticotomy	O
site	O
and	O
the	O
distance	O
between	O
the	O
ACA	O
and	O
the	O
corticotomy	O
do	O
not	O
change	O
,	O
once	O
the	O
corticotomy	O
is	O
performed	O
after	O
Dyna	O
-	O
ATC	O
is	O
applied	O
.	O

Therefore	O
,	O
the	O
amount	O
of	O
secondary	O
deformities	O
changes	O
only	O
with	O
tan	O
(	O
a	O
/	O
2	O
)	O
value	O
.	O

If	O
tangent	O
value	O
varies	O
proportionally	O
with	O
changes	O
of	O
angle	O
,	O
the	O
gap	O
distance	O
increases	O
constantly	O
with	O
the	O
given	O
amount	O
of	O
daily	O
correction	O
angle	O
during	O
angular	O
correction	O
.	O

If	O
not	O
,	O
the	O
gap	O
distance	O
varies	O
continuously	O
with	O
changes	O
of	O
the	O
angle	O
,	O
therefore	O
,	O
the	O
amount	O
of	O
correction	O
angle	O
should	O
be	O
readjusted	O
everyday	O
to	O
maintain	O
1	O
mm	O
/	O
day	O
of	O
distraction	O
rate	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
.	O

Fortunately	O
,	O
while	O
the	O
value	O
of	O
tangent	O
angle	O
increases	O
exponentially	O
especially	O
over	O
45	O
degrees	O
,	O
tangent	O
function	O
curve	O
is	O
nearly	O
straight	O
,	O
less	O
than	O
30	O
degrees	O
(	O
Fig	O
.	O
7	O
)	O
.	O

Therefore	O
,	O
in	O
cases	O
with	O
less	O
than	O
60	O
degrees	O
of	O
angular	O
deformity	O
,	O
the	O
amount	O
of	O
daily	O
correction	O
angle	O
which	O
permits	O
1	O
mm	O
/	O
day	O
of	O
distraction	O
rate	O
on	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
can	O
be	O
obtained	O
as	O
the	O
rate	O
of	O
angular	O
correction	O
without	O
daily	O
adjustment	O
during	O
angular	O
correction	O
.	O

Once	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
is	O
determined	O
,	O
the	O
amount	O
of	O
daily	O
length	O
and	O
translation	O
compensation	O
can	O
also	O
be	O
calculated	O
with	O
the	O
amount	O
of	O
daily	O
angular	O
correction	O
.	O

Exact	O
adjustment	O
of	O
secondary	O
changes	O
in	O
length	O
and	O
translation	O
at	O
each	O
angular	O
correction	O
opens	O
the	O
concave	O
side	O
of	O
the	O
corticotomy	O
1	O
mm	O
per	O
day	O
,	O
but	O
allows	O
minimal	O
gap	O
on	O
the	O
corticotomy	O
of	O
convex	O
side	O
especially	O
in	O
the	O
early	O
stage	O
of	O
angular	O
correction	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
the	O
corticotomized	O
bone	O
ends	O
of	O
convex	O
side	O
,	O
may	O
abut	O
each	O
other	O
and	O
prevent	O
angular	O
correction	O
or	O
adjustment	O
of	O
secondary	O
translation	O
.	O

For	O
the	O
cases	O
where	O
the	O
concomitant	O
lengthening	O
is	O
required	O
,	O
longitudinal	O
lengthening	O
prior	O
to	O
angular	O
correction	O
is	O
recommended	O
.	O

Otherwise	O
,	O
about	O
5	O
mm	O
pre	O
-	O
lengthening	O
and	O
re	O
-	O
shortening	O
after	O
angular	O
correction	O
could	O
be	O
helpful	O
in	O
avoiding	O
abutment	O
on	O
the	O
convex	O
side	O
of	O
the	O
corticotomy	O
site	O
.	O

Inappropriate	O
sequence	O
of	O
angular	O
correction	O
and	O
adjustment	O
of	O
secondary	O
deformities	O
could	O
be	O
one	O
of	O
the	O
causes	O
of	O
the	O
impingement	O
.	O

Appropriate	O
sequence	O
of	O
correction	O
is	O
lengthening	O
-	O
translation	O
-	O
angulation	O
with	O
Dyna	O
-	O
ATC	O
on	O
the	O
concave	O
side	O
and	O
angulation	O
-	O
translation	O
-	O
shortening	O
with	O
Dyna	O
-	O
ATC	O
on	O
the	O
convex	O
side	O
.	O

Pharmacokinetic	O
-	O
pharmacodynamic	O
analysis	O
.	O

The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
R	O
-	O
R	O
interval	O
analysis	O
was	O
-	O
0	O
.	O
0017	O
(	O
-	O
0	O
.	O
0022	O
to	O
-	O
0	O
.	O
0011	O
)	O
ms	O
/	O
ng	O
/	O
ml	O
.	O

This	O
translates	O
to	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
decreases	O
in	O
heart	O
rate	O
of	O
approximately	O
1	O
.	O
5	O
(	O
1	O
.	O
0	O
to	O
2	O
.	O
0	O
)	O
and	O
3	O
.	O
0	O
(	O
2	O
.	O
1	O
to	O
4	O
.	O
1	O
)	O
beats	O
/	O
min	O
at	O
the	O
mean	O
Cmax	O
following	O
the	O
administration	O
of	O
600	O
-	O
and	O
1	O
,	O
200	O
-	O
mg	O
linezolid	O
doses	O
,	O
respectively	O
.	O

The	O
study	O
-	O
specific	O
mean	O
correction	O
factor	O
estimated	O
from	O
baseline	O
data	O
was	O
0	O
.	O
278	O
,	O
which	O
is	O
slightly	O
less	O
than	O
Fridericia	O
'	O
s	O
correction	O
(	O
0	O
.	O
333	O
)	O
.	O

Evaluation	O
of	O
the	O
various	O
correction	O
factors	O
showed	O
that	O
QTcF	O
most	O
appropriately	O
resolves	O
the	O
relationship	O
between	O
the	O
QT	O
interval	O
and	O
the	O
heart	O
rate	O
in	O
the	O
baseline	O
data	O
from	O
the	O
present	O
study	O
.	O

This	O
is	O
evident	O
upon	O
inspection	O
of	O
Fig	O
.	O

4	O
,	O
since	O
the	O
slope	O
between	O
the	O
QTcF	O
interval	O
and	O
the	O
R	O
-	O
R	O
interval	O
is	O
closest	O
to	O
zero	O
when	O
this	O
correction	O
is	O
applied	O
.	O

Fig	O
.	O

4	O
.	O

Evaluation	O
of	O
various	O
heart	O
rate	O
correction	O
factors	O
for	O
the	O
QT	O
interval	O
versus	O
the	O
R	O
-	O
R	O
interval	O
.	O

The	O
predicted	O
line	O
in	O
each	O
figure	O
represents	O
the	O
fit	O
from	O
a	O
linear	O
mixed	O
-	O
effect	O
model	O
with	O
R	O
-	O
R	O
interval	O
as	O
a	O
fixed	O
effect	O
and	O
subject	O
-	O
specific	O
random	O
effects	O
for	O
intercept	O
and	O
slope	O
.	O

The	O
results	O
from	O
the	O
concentration	O
-	O
QTcF	O
analysis	O
are	O
graphically	O
depicted	O
in	O
Fig	O
.	O

5	O
.	O

The	O
mean	O
(	O
90	O
%	O
CI	O
)	O
slope	O
estimate	O
from	O
the	O
linezolid	O
concentration	O
-	O
QTcF	O
analysis	O
was	O
-	O
0	O
.	O
0145	O
(	O
-	O
0	O
.	O
0768	O
to	O
0	O
.	O
0477	O
)	O
ms	O
/	O
mug	O
/	O
ml	O
.	O

At	O
the	O
geometric	O
mean	O
Cmax	O
following	O
the	O
infusion	O
of	O
linezolid	O
at	O
600	O
mg	O
(	O
14	O
.	O
9	O
mug	O
/	O
ml	O
)	O
and	O
1	O
,	O
200	O
mg	O
(	O
30	O
.	O
5	O
mug	O
/	O
ml	O
)	O
,	O
the	O
mean	O
(	O
90	O
%	O
CI	O
)	O
predicted	O
placebo	O
-	O
adjusted	O
changes	O
from	O
the	O
baseline	O
QTcF	O
were	O
-	O
0	O
.	O
217	O
(	O
-	O
1	O
.	O
14	O
to	O
0	O
.	O
710	O
)	O
and	O
-	O
0	O
.	O
444	O
(	O
-	O
2	O
.	O
34	O
to	O
1	O
.	O
45	O
)	O
ms	O
,	O
respectively	O
,	O
thus	O
confirming	O
a	O
lack	O
of	O
a	O
relationship	O
between	O
linezolid	O
concentrations	O
and	O
QTc	O
interval	O
.	O

Fig	O
.	O

5	O
.	O

QTcF	O
interval	O
versus	O
plasma	O
linezolid	O
concentrations	O
.	O

Results	O

primary	O
pancreatic	O
sarcomas	O
are	O
extremely	O
rare	O
.	O

Pancreatic	O
sarcomas	O
are	O
more	O
aggressive	O
than	O
other	O
pancreatic	O
neoplasms	O
.	O

Challenges	O
to	O
creating	O
and	O
implementing	O
a	O
perioperative	O
glycemic	O
control	O
protocol	O
.	O

Introduction	O

Hip	O
fractures	O
in	O
the	O
aged	O
constitute	O
a	O
major	O
health	O
problem	O
with	O
substantial	O
morbidity	O
[	O
1	O
]	O
,	O
mortality	O
[	O
2	O
,	O
3	O
]	O
,	O
and	O
,	O
as	O
the	O
ageing	O
population	O
increases	O
,	O
an	O
increasing	O
burden	O
on	O
the	O
health	O
care	O
system	O
[	O
4	O
]	O
.	O

Fracture	O
risk	O
varies	O
markedly	O
between	O
countries	O
[	O
5	O
]	O
.	O

In	O
a	O
study	O
by	O
Kanis	O
et	O
al	O
.	O

[	O
6	O
]	O
,	O
comparing	O
10	O
-	O
year	O
probability	O
of	O
hip	O
fracture	O
,	O
all	O
countries	O
except	O
Norway	O
had	O
lower	O
risk	O
than	O
Sweden	O
.	O

Other	O
countries	O
categorized	O
at	O
very	O
high	O
risk	O
(	O
>	O
75	O
%	O
of	O
the	O
risk	O
of	O
Sweden	O
)	O
were	O
Iceland	O
,	O
Denmark	O
and	O
the	O
US	O
.	O

At	O
the	O
age	O
of	O
80	O
,	O
the	O
estimated	O
probability	O
of	O
sustaining	O
a	O
hip	O
fracture	O
the	O
next	O
10	O
years	O
is	O
8	O
.	O
6	O
%	O
and	O
17	O
.	O
7	O
%	O
in	O
Norwegian	O
men	O
and	O
women	O
,	O
respectively	O
[	O
7	O
]	O
,	O
and	O
a	O
report	O
from	O
the	O
Norwegian	O
capital	O
Oslo	O
calculated	O
an	O
overall	O
annual	O
fracture	O
rate	O
of	O
118	O
.	O
0	O
in	O
women	O
and	O
44	O
.	O
0	O
in	O
men	O
per	O
10	O
,	O
000	O
[	O
8	O
]	O
.	O

Several	O
recent	O
studies	O
are	O
reporting	O
declining	O
fracture	O
incidence	O
[	O
9	O
-	O
14	O
]	O
.	O

Although	O
the	O
Norwegian	O
hip	O
fracture	O
rates	O
remain	O
the	O
highest	O
reported	O
in	O
the	O
world	O
,	O
data	O
from	O
Oslo	O
in	O
1996	O
-	O
1997	O
indicated	O
no	O
increasing	O
incidence	O
rates	O
compared	O
to	O
the	O
1988	O
-	O
1989	O
[	O
8	O
]	O
.	O
Within	O
Norway	O
,	O
considerable	O
geographic	O
differences	O
have	O
been	O
reported	O
,	O
with	O
substantially	O
lower	O
rates	O
in	O
smaller	O
cities	O
and	O
rural	O
areas	O
compared	O
to	O
Oslo	O
[	O
7	O
,	O
15	O
]	O
.	O

However	O
,	O
these	O
are	O
reports	O
based	O
on	O
sporadic	O
studies	O
in	O
few	O
regions	O
and	O
in	O
limited	O
time	O
periods	O
[	O
16	O
,	O
17	O
]	O
.	O

From	O
1985	O
to	O
2003	O
,	O
the	O
Norwegian	O
Institute	O
of	O
Public	O
Health	O
commissioned	O
four	O
Norwegian	O
hospitals	O
,	O
representing	O
10	O
%	O
of	O
the	O
population	O
,	O
to	O
run	O
a	O
national	O
injury	O
registry	O
[	O
18	O
]	O
.	O

The	O
registry	O
collected	O
a	O
variety	O
of	O
data	O
connected	O
to	O
the	O
actual	O
injury	O
itself	O
and	O
the	O
event	O
leading	O
to	O
the	O
injury	O
.	O

In	O
the	O
city	O
of	O
Harstad	O
in	O
Northern	O
Norway	O
,	O
the	O
registration	O
continued	O
and	O
has	O
been	O
running	O
for	O
more	O
than	O
23	O
years	O
.	O

Throughout	O
the	O
years	O
of	O
the	O
National	O
Injury	O
Registry	O
,	O
the	O
injury	O
rates	O
in	O
Harstad	O
closely	O
resembled	O
the	O
rates	O
of	O
the	O
national	O
registry	O
[	O
18	O
]	O
.	O

With	O
reference	O
to	O
the	O
recent	O
reports	O
suggesting	O
stabilizing	O
hip	O
fracture	O
incidence	O
internationally	O
as	O
well	O
as	O
nationally	O
,	O
and	O
regional	O
differences	O
within	O
Norway	O
,	O
we	O
have	O
used	O
the	O
hip	O
fracture	O
data	O
in	O
the	O
Harstad	O
Injury	O
Registry	O
to	O
:	O

Describe	O
age	O
-	O
and	O
sex	O
-	O
specific	O
incidence	O
of	O
hip	O
fractures	O
in	O
Harstad	O
,	O
Northern	O
Norway	O
and	O
make	O
comparison	O
with	O
rates	O
from	O
the	O
Norwegian	O
capital	O
Oslo	O

Describe	O
time	O
trends	O
in	O
hip	O
fracture	O
incidence	O
in	O
Harstad	O
from	O
1994	O
to	O
2008	O

Describe	O
place	O
of	O
injury	O
and	O
seasonal	O
variations	O
in	O
hip	O
fracture	O
incidence	O
in	O
Harstad	O

Compare	O
3	O
-	O
month	O
,	O
6	O
-	O
month	O
,	O
and	O
1	O
-	O
year	O
mortality	O
after	O
hip	O
fracture	O
between	O
women	O
and	O
men	O
in	O
Harstad	O

(	O
a	O
)	O
The	O
Tn6087	O
target	O
site	O
within	O
S	O
.	O
oralis	O
F	O
.	O
MI	O
.	O
5	O
.	O

(	O
b	O
)	O
The	O
left	O
end	O
and	O
(	O
c	O
)	O
right	O
end	O
of	O
Tn6087	O
are	O
shown	O
in	O
bold	O
.	O

(	O
d	O
)	O
The	O
joint	O
of	O
the	O
circular	O
intermediate	O
of	O
Tn6087	O
is	O
shown	O
.	O

The	O
transposon	O
'	O
s	O
coupling	O
sequences	O
are	O
shown	O
in	O
bold	O
italics	O
.	O

As	O
can	O
be	O
seen	O
in	O
(	O
d	O
)	O
,	O
the	O
coupling	O
sequence	O
at	O
the	O
joint	O
of	O
the	O
circular	O
form	O
is	O
a	O
heteroduplex	O
.	O

Parameters	O
derived	O
from	O
normalized	O
averaged	O
data	O
across	O
participants	O

Results	O

Table	O
1	O
shows	O
the	O
predicted	O
new	O
case	O
detection	O
rates	O
at	O
25	O
years	O
after	O
the	O
initiation	O
of	O
the	O
interventions	O
.	O

Under	O
the	O
baseline	O
control	O
program	O
,	O
the	O
different	O
mechanisms	O
that	O
determined	O
susceptibility	O
showed	O
up	O
to	O
three	O
-	O
fold	O
differences	O
in	O
the	O
predicted	O
number	O
of	O
cases	O
per	O
100	O
,	O
000	O
people	O
.	O

In	O
Figure	O
1	O
,	O
the	O
trends	O
in	O
the	O
new	O
case	O
detection	O
rates	O
over	O
50	O
years	O
are	O
shown	O
for	O
all	O
seven	O
interventions	O
.	O

All	O
susceptibility	O
mechanisms	O
give	O
qualitatively	O
comparable	O
trends	O
.	O

When	O
the	O
intervention	O
scenarios	O
were	O
ordered	O
after	O
50	O
years	O
by	O
the	O
amount	O
of	O
reduction	O
in	O
new	O
case	O
detection	O
rates	O
,	O
the	O
order	O
was	O
as	O
good	O
as	O
identical	O
for	O
all	O
mechanisms	O
;	O
i	O
.	O
e	O
.	O
early	O
diagnosis	O
lowest	O
;	O
then	O
no	O
BCG	O
&	O
early	O
diagnosis	O
;	O
then	O
chemoprophylaxis	O
;	O
then	O
baseline	O
;	O
then	O
no	O
BCG	O
&	O
chemoprophylaxis	O
together	O
with	O
no	O
contact	O
tracing	O
;	O
and	O
finally	O
no	O
BCG	O
had	O
the	O
highest	O
new	O
case	O
detection	O
rate	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g001	O
Figure	O
1	O

Predicted	O
decline	O
of	O
the	O
new	O
case	O
detection	O
rate	O
with	O
seven	O
intervention	O
scenarios	O
and	O
six	O
mechanisms	O
of	O
leprosy	O
susceptiblity	O
since	O
start	O
of	O
intervention	O
strategy	O
.	O

The	O
baseline	O
program	O
(	O
black	O
line	O
)	O
included	O
passive	O
detection	O
,	O
multidrug	O
therapy	O
,	O
contact	O
tracing	O
,	O
and	O
an	O
infant	O
leprosy	O
-	O
preventative	O
BCG	O
vaccination	O
given	O
at	O
the	O
population	O
level	O
.	O

The	O
other	O
six	O
intervention	O
strategies	O
included	O
the	O
baseline	O
program	O
and	O
,	O
introduction	O
of	O
a	O
new	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
leprosy	O
replacing	O
BCG	O
(	O
red	O
)	O
;	O
no	O
tracing	O
of	O
household	O
contacts	O
(	O
orange	O
)	O
;	O
a	O
single	O
chemoprophylactic	O
dose	O
of	O
rifampicin	O
that	O
cured	O
50	O
%	O
of	O
subclinically	O
infected	O
contacts	O
(	O
yellow	O
)	O
;	O
early	O
diagnosis	O
of	O
70	O
%	O
of	O
subclinically	O
infected	O
contacts	O
in	O
each	O
of	O
3	O
consecutive	O
annual	O
examinations	O
(	O
green	O
)	O
;	O
chemoprophylaxis	O
plus	O
introduction	O
of	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
leprosy	O
(	O
blue	O
)	O
;	O
and	O
detection	O
of	O
subclinically	O
infected	O
contacts	O
plus	O
introduction	O
of	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
against	O
le	O
-	O
pro	O
-	O
sy	O
(	O
purple	O
)	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
for	O
each	O
scenario	O
and	O
susceptibilty	O
mechanism	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
t001	O
Table	O
1	O

Predicted	O
new	O
case	O
detection	O
rates	O
(	O
per	O
100	O
,	O
000	O
)	O
at	O
25	O
years	O
after	O
the	O
introduction	O
of	O
the	O
indicated	O
intervention	O
scenario	O
for	O
six	O
mechanisms	O
of	O
leprosy	O
susceptibility	O
as	O
described	O
in	O
[	O
9	O
]	O
.	O

Intervention	O
Mechanism	O
determining	O
susceptibilty	O

Random	O
Household	O
Dominant	O
Recessive	O
Household	O
&	O
dominant	O
Household	O
&	O
recessive	O

Baseline	O
control	O
3	O
.	O
4	O
4	O
.	O
0	O
10	O
.	O
4	O
8	O
.	O
2	O
5	O
.	O
6	O
4	O
.	O
6	O

No	O
BCG	O
4	O
.	O
6	O
5	O
.	O
5	O
15	O
.	O
0	O
11	O
.	O
9	O
7	O
.	O
6	O
6	O
.	O
4	O

No	O
contact	O
tracing	O
3	O
.	O
8	O
4	O
.	O
1	O
10	O
.	O
5	O
8	O
.	O
5	O
5	O
.	O
5	O
4	O
.	O
8	O

Chemoprophylaxis	O
2	O
.	O
8	O
3	O
.	O
2	O
6	O
.	O
9	O
5	O
.	O
9	O
4	O
.	O
1	O
3	O
.	O
4	O

Early	O
diagnosis	O
1	O
.	O
1	O
2	O
.	O
1	O
2	O
.	O
7	O
2	O
.	O
6	O
2	O
.	O
1	O
2	O
.	O
0	O

No	O
BCG	O
&	O
chemoprophylaxis	O
3	O
.	O
6	O
4	O
.	O
0	O
10	O
.	O
5	O
8	O
.	O
5	O
5	O
.	O
9	O
5	O
.	O
1	O

No	O
BCG	O
&	O
early	O
diagnosis	O
1	O
.	O
2	O
2	O
.	O
5	O
3	O
.	O
7	O
3	O
.	O
7	O
2	O
.	O
9	O
2	O
.	O
8	O

The	O
results	O
are	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Both	O
the	O
cessation	O
of	O
contact	O
tracing	O
and	O
the	O
replacement	O
of	O
BCG	O
vaccine	O
by	O
a	O
tuberculosis	O
vaccine	O
ineffective	O
for	O
leprosy	O
(	O
no	O
BCG	O
)	O
would	O
have	O
detrimental	O
effects	O
on	O
the	O
rate	O
of	O
decline	O
in	O
leprosy	O
(	O
Figure	O
2	O
)	O
.	O

Twenty	O
-	O
five	O
years	O
after	O
introduction	O
of	O
the	O
ineffective	O
vaccine	O
(	O
no	O
BCG	O
)	O
,	O
the	O
new	O
case	O
detection	O
of	O
leprosy	O
was	O
approximately	O
1	O
.	O
5	O
times	O
higher	O
than	O
the	O
baseline	O
(	O
Table	O
1	O
)	O
.	O

The	O
cessation	O
of	O
contact	O
tracing	O
was	O
predicted	O
to	O
have	O
a	O
smaller	O
impact	O
,	O
with	O
a	O
marked	O
drop	O
in	O
detection	O
of	O
new	O
leprosy	O
cases	O
during	O
the	O
first	O
few	O
years	O
.	O

This	O
sudden	O
drop	O
was	O
due	O
to	O
the	O
reduced	O
number	O
of	O
examinations	O
of	O
people	O
in	O
contact	O
with	O
patients	O
;	O
thus	O
,	O
these	O
cases	O
would	O
not	O
be	O
detected	O
until	O
later	O
,	O
through	O
passive	O
detection	O
(	O
self	O
-	O
reporting	O
)	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g002	O
Figure	O
2	O

Predicted	O
new	O
case	O
detection	O
rates	O
for	O
six	O
intervention	O
scenarios	O
relative	O
to	O
the	O
baseline	O
control	O
program	O
.	O

For	O
each	O
intervention	O
scenario	O
simulations	O
with	O
different	O
mechanisms	O
of	O
susceptibility	O
to	O
leprosy	O
,	O
as	O
defined	O
in	O
our	O
previous	O
paper	O
[	O
9	O
]	O
are	O
performed	O
.	O

For	O
each	O
intervention	O
scenario	O
,	O
the	O
two	O
dotted	O
lines	O
show	O
the	O
smallest	O
and	O
largest	O
deviations	O
from	O
the	O
baseline	O
control	O
program	O
.	O

The	O
solid	O
line	O
shows	O
the	O
median	O
of	O
all	O
susceptibility	O
mechanisms	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Both	O
chemoprophylaxis	O
and	O
early	O
diagnosis	O
were	O
predicted	O
to	O
have	O
substantial	O
effects	O
on	O
the	O
new	O
case	O
detection	O
of	O
leprosy	O
(	O
Figure	O
2	O
)	O
.	O

With	O
no	O
BCG	O
,	O
chemoprophylaxis	O
would	O
partially	O
compensate	O
for	O
the	O
predicted	O
increase	O
in	O
new	O
case	O
detection	O
rates	O
.	O

Furthermore	O
,	O
early	O
diagnosis	O
was	O
predicted	O
to	O
more	O
than	O
compensate	O
for	O
the	O
adverse	O
effects	O
of	O
a	O
leprosy	O
-	O
ineffective	O
tuberculosis	O
vaccine	O
,	O
and	O
reduce	O
the	O
rate	O
of	O
new	O
case	O
detection	O
compared	O
to	O
the	O
baseline	O
.	O

The	O
effects	O
were	O
more	O
promising	O
with	O
the	O
ongoing	O
presence	O
of	O
the	O
BCG	O
vaccine	O
.	O

Under	O
those	O
conditions	O
,	O
at	O
25	O
years	O
after	O
the	O
introduction	O
of	O
chemoprophylaxis	O
,	O
the	O
new	O
case	O
detection	O
rate	O
was	O
predicted	O
to	O
be	O
25	O
%	O
lower	O
than	O
baseline	O
control	O
.	O

Moreover	O
,	O
with	O
the	O
introduction	O
of	O
early	O
diagnosis	O
,	O
the	O
new	O
case	O
detection	O
rate	O
was	O
predicted	O
to	O
halve	O
the	O
baseline	O
incidence	O
after	O
25	O
years	O
(	O
Table	O
1	O
)	O
.	O

Early	O
diagnosis	O
of	O
infection	O
allows	O
the	O
detection	O
of	O
subclinical	O
cases	O
,	O
of	O
which	O
part	O
would	O
be	O
detected	O
later	O
or	O
never	O
at	O
all	O
.	O

These	O
subclinical	O
cases	O
are	O
added	O
to	O
the	O
number	O
of	O
detected	O
cases	O
.	O

This	O
is	O
seen	O
in	O
the	O
results	O
of	O
this	O
intervention	O
.	O

The	O
introduction	O
of	O
early	O
diagnosis	O
would	O
increase	O
the	O
total	O
number	O
of	O
detected	O
cases	O
in	O
the	O
first	O
18	O
years	O
,	O
simply	O
because	O
of	O
the	O
detection	O
of	O
previously	O
undetectable	O
subclinical	O
cases	O
.	O

Over	O
time	O
however	O
,	O
the	O
total	O
number	O
of	O
new	O
cases	O
(	O
subclinical	O
and	O
clinical	O
)	O
would	O
finally	O
drop	O
below	O
the	O
number	O
detected	O
in	O
the	O
baseline	O
control	O
program	O
(	O
Figure	O
3	O
)	O
.	O

In	O
Figure	O
3	O
,	O
we	O
show	O
that	O
the	O
new	O
cases	O
detected	O
under	O
the	O
chemoprophylaxis	O
intervention	O
strategy	O
drop	O
immediately	O
below	O
the	O
level	O
of	O
the	O
baseline	O
control	O
program	O
.	O

The	O
additional	O
effect	O
of	O
chemoprophylaxis	O
is	O
that	O
additional	O
new	O
infections	O
are	O
prevented	O
on	O
top	O
of	O
the	O
cure	O
of	O
subclinical	O
infections	O
.	O

These	O
additional	O
prevented	O
infections	O
are	O
due	O
to	O
a	O
shorter	O
infectious	O
period	O
of	O
the	O
cured	O
subclinical	O
infections	O
.	O

To	O
illustrate	O
this	O
effect	O
we	O
show	O
in	O
Figure	O
3	O
the	O
clinical	O
and	O
the	O
subclinical	O
cases	O
that	O
were	O
cured	O
by	O
the	O
chemoprophylactic	O
intervention	O
.	O

During	O
the	O
first	O
10	O
years	O
,	O
this	O
total	O
number	O
of	O
newly	O
detected	O
cases	O
plus	O
cured	O
cases	O
is	O
equal	O
to	O
the	O
number	O
of	O
newly	O
detected	O
cases	O
under	O
the	O
baseline	O
control	O
program	O
,	O
but	O
afterwards	O
the	O
number	O
of	O
cases	O
plus	O
cured	O
subclinical	O
cases	O
in	O
the	O
chemoprophylaxis	O
intervention	O
group	O
drops	O
under	O
the	O
baseline	O
control	O
program	O
,	O
indicating	O
the	O
prevention	O
of	O
new	O
infections	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pntd	O
.	O
0001330	O
.	O
g003	O
Figure	O
3	O

Cumulative	O
New	O
cases	O
detected	O
of	O
leprosy	O
per	O
person	O
-	O
year	O
since	O
start	O
of	O
the	O
interventions	O
.	O

Results	O
are	O
the	O
average	O
of	O
100	O
runs	O
of	O
the	O
simulation	O
model	O
.	O

Breeding	O
of	O
p53	O
mice	O
with	O
BCCIP	O
conditional	O
knockdown	O
mice	O

The	O
heterozygous	O
p53	O
knockout	O
mice	O
[	O
36	O
]	O
were	O
crossed	O
with	O
LoxPshBCCIP	O
+	O
/	O
+	O
-	O
4	O
mouse	O
and	O
EIIaCre	O
+	O
/	O
+	O
mouse	O
respectively	O
to	O
generate	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
,	O
and	O
p53	O
+	O
/	O
-	O
;	O
EIIaCre	O
+	O
/	O
-	O
mice	O
.	O

The	O
PCR	O
primers	O
used	O
to	O
genotype	O
p53	O
are	O
:	O
p53ex6F	O
:	O
5	O
'	O
-	O
GTATCCCGAGTATCTGGAAGACAG	O
-	O
3	O
'	O
,	O
p53neoF	O
:	O
5	O
'	O
-	O
GCCTTCTATCGCCTTCTTGACG	O
-	O
3	O
'	O
,	O
p53ex7RN	O
:	O
5	O
'	O
-	O
AAGGATAGGTCGGCGGTTCATGC	O
-	O
3	O
'	O
.	O

The	O
same	O
PCR	O
primer	O
pairs	O
as	O
described	O
earlier	O
in	O
this	O
report	O
were	O
used	O
for	O
BCCIPshRNA	O
and	O
EIIaCre	O
genotyping	O
.	O

The	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
+	O
mice	O
were	O
obtained	O
by	O
crossing	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
females	O
with	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
males	O
.	O

The	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
+	O
or	O
p53	O
+	O
/	O
-	O
;	O
LoxPshBCCIP	O
+	O
/	O
-	O
mice	O
were	O
crossed	O
with	O
p53	O
+	O
/	O
-	O
;	O
EIIaCre	O
+	O
/	O
-	O
mice	O
respectively	O
.	O

ACKNOWLEDGEMENTS	O

The	O
authors	O
thank	O
Mr	O
.	O
C	O
.	O

Roberto	O
for	O
providing	O
animal	O
care	O
.	O

This	O
research	O
was	O
supported	O
by	O
the	O
State	O
of	O
Rio	O
de	O
Janeiro	O
Carlos	O
Chagas	O
Filho	O
Research	O
Foundation	O
(	O
FAPERJ	O
)	O
and	O
the	O
Coordination	O
for	O
the	O
Enhancement	O
of	O
Higher	O
Education	O
Personnel	O
(	O
CAPES	O
)	O
.	O

Absolute	O
responder	O
rates	O
for	O
medical	O
management	O
recommendations	O
.	O

Biochemical	O
traits	O

ERK	O
signaling	O
is	O
involved	O
in	O
decreasing	O
BDNF	O
-	O
induced	O
gene	O
activity	O
via	O
Eph	O
receptors	O

Data	O
provided	O
so	O
far	O
suggest	O
that	O
ephrin	O
-	O
A5	O
might	O
counteract	O
BDNF	O
-	O
mediated	O
gene	O
expression	O
and	O
growth	O
cone	O
responses	O
via	O
decreasing	O
ERK	O
activity	O
and	O
nuclear	O
localization	O
(	O
Figs	O
.	O
2	O
and	O
3	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
more	O
directly	O
,	O
we	O
analyzed	O
whether	O
Eph	O
forward	O
signaling	O
can	O
still	O
suppress	O
BDNF	O
-	O
stimulated	O
IEG	O
induction	O
and	O
growth	O
cone	O
collapse	O
when	O
ERK	O
kinase	O
activity	O
was	O
experimentally	O
raised	O
.	O

For	O
this	O
,	O
ERK	O
activity	O
was	O
elevated	O
by	O
expressing	O
constitutively	O
-	O
active	O
MEK1	O
(	O
CA	O
-	O
MEK1	O
)	O
,	O
an	O
ERK	O
upstream	O
activator	O
,	O
in	O
cortical	O
neurons	O
(	O
Fig	O
.	O
S3	O
)	O
.	O

Subsequently	O
,	O
neurons	O
were	O
subjected	O
to	O
either	O
an	O
ephrin	O
-	O
A5	O
mediated	O
growth	O
cone	O
collapse	O
assay	O
(	O
Fig	O
.	O
5	O
)	O
or	O
stimulated	O
with	O
guidance	O
cues	O
for	O
20	O
minutes	O
and	O
IEG	O
mRNA	O
levels	O
were	O
quantified	O
via	O
qRT	O
-	O
PCR	O
(	O
Fig	O
.	O
6	O
)	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026089	O
.	O
g005	O
Figure	O
5	O

Constitutively	O
-	O
active	O
MEK1	O
blocks	O
ephrin	O
-	O
A5	O
mediated	O
growth	O
cone	O
collapse	O
.	O

Wild	O
-	O
type	O
neurons	O
were	O
electroporated	O
with	O
vectors	O
expressing	O
GFP	O
(	O
control	O
;	O
A	O
,	O
C	O
,	O
E	O
)	O
or	O
expressing	O
a	O
FLAG	O
-	O
tagged	O
constitutively	O
-	O
active	O
MEK1	O
(	O
CA	O
-	O
MEK1	O
;	O
B	O
,	O
D	O
,	O
F	O
)	O
.	O

Neurons	O
were	O
treated	O
with	O
ephrin	O
-	O
A5	O
-	O
Fc	O
for	O
30	O
min	O
followed	O
by	O
visualization	O
of	O
GFP	O
(	O
A	O
,	O
C	O
,	O
E	O
)	O
or	O
CA	O
-	O
MEK	O
-	O
1	O
(	O
green	O
in	O
B	O
,	O
D	O
,	O
F	O
)	O
,	O
F	O
-	O
actin	O
and	O
betaIII	O
tubulin	O
.	O

(	O
A	O
,	O
B	O
)	O
Overexpression	O
of	O
CA	O
-	O
MEK1	O
(	O
B	O
)	O
reduces	O
mean	O
neurite	O
length	O
compared	O
to	O
a	O
control	O
GFP	O
-	O
expressing	O
neuron	O
(	O
A	O
)	O
.	O

(	O
C	O
-	O
F	O
)	O
A	O
control	O
growth	O
cone	O
without	O
ephrin	O
-	O
A5	O
application	O
(	O
C	O
)	O
typically	O
protrudes	O
multiple	O
filopodia	O
(	O
arrow	O
)	O
.	O

CA	O
-	O
MEK	O
-	O
1	O
expressing	O
growth	O
cones	O
(	O
D	O
)	O
were	O
indistinguishable	O
from	O
a	O
GFP	O
-	O
expressing	O
growth	O
cone	O
.	O

Note	O
that	O
CA	O
-	O
MEK1	O
was	O
expressed	O
in	O
a	O
dot	O
-	O
like	O
pattern	O
in	O
the	O
growth	O
cone	O
(	O
arrowheads	O
in	O
D	O
and	O
F	O
)	O
.	O

Upon	O
ephrin	O
-	O
A5	O
application	O
,	O
a	O
control	O
growth	O
cone	O
(	O
E	O
)	O
collapsed	O
resulting	O
in	O
only	O
few	O
filopodia	O
.	O

In	O
contrast	O
,	O
a	O
CA	O
-	O
MEK1	O
expressing	O
growth	O
cone	O
(	O
F	O
)	O
was	O
only	O
partially	O
collapsed	O
and	O
many	O
filopodia	O
structures	O
were	O
preserved	O
after	O
ephrin	O
-	O
A5	O
induction	O
.	O

(	O
G	O
)	O
Quantification	O
of	O
average	O
neurite	O
length	O
.	O

(	O
H	O
,	O
I	O
)	O
Quantification	O
of	O
growth	O
cone	O
area	O
(	O
H	O
)	O
and	O
filopodia	O
number	O
/	O
growth	O
cone	O
(	O
I	O
)	O
in	O
the	O
four	O
conditions	O
.	O

Ephrin	O
-	O
A5	O
induces	O
a	O
growth	O
cone	O
collapse	O
,	O
resulting	O
in	O
reduced	O
growth	O
cone	O
area	O
and	O
filopodia	O
number	O
in	O
GFP	O
but	O
not	O
CA	O
-	O
MEK1	O
expressing	O
neurons	O
.	O

Scale	O
-	O
bar	O
(	O
A	O
,	O
B	O
)	O
=	O
10	O
microm	O
;	O
(	O
C	O
-	O
F	O
)	O
=	O
2	O
microm	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026089	O
.	O
g006	O
Figure	O
6	O

Ephrin	O
-	O
A5	O
suppresses	O
BDNF	O
-	O
induced	O
IEG	O
responses	O
via	O
MAP	O
kinase	O
signaling	O
.	O

Wild	O
-	O
type	O
cortical	O
neurons	O
,	O
mock	O
-	O
electroporated	O
(	O
black	O
bars	O
)	O
or	O
with	O
a	O
vector	O
expressing	O
constitutively	O
-	O
active	O
MEK1	O
(	O
white	O
bars	O
)	O
,	O
were	O
treated	O
with	O
guidance	O
cues	O
for	O
20	O
minutes	O
as	O
depicted	O
,	O
followed	O
by	O
mRNA	O
quantification	O
.	O

In	O
mock	O
-	O
electroporated	O
neurons	O
,	O
BDNF	O
induced	O
an	O
IEG	O
response	O
of	O
c	O
-	O
fos	O
(	O
A	O
)	O
,	O
Egr1	O
(	O
B	O
)	O
,	O
Egr2	O
(	O
C	O
)	O
and	O
Arc	O
(	O
D	O
)	O
.	O

Co	O
-	O
application	O
of	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
reduced	O
mRNA	O
levels	O
of	O
all	O
four	O
IEGs	O
in	O
mock	O
-	O
electroporated	O
neurons	O
(	O
A	O
-	O
D	O
)	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
constitutively	O
-	O
active	O
MEK1	O
prevented	O
Eph	O
forward	O
signaling	O
from	O
suppressing	O
BDNF	O
-	O
evoked	O
IEG	O
responses	O
.	O

This	O
was	O
most	O
evident	O
for	O
the	O
IEGs	O
Egr1	O
(	O
B	O
)	O
and	O
Egr2	O
(	O
C	O
)	O
.	O

First	O
of	O
all	O
,	O
we	O
analyzed	O
the	O
impact	O
of	O
CA	O
-	O
MEK1	O
on	O
neurite	O
outgrowth	O
and	O
ephrin	O
-	O
A5	O
mediated	O
growth	O
cone	O
responses	O
(	O
Fig	O
.	O
5	O
)	O
.	O

The	O
average	O
neurite	O
length	O
of	O
neurons	O
overexpressing	O
CA	O
-	O
MEK1	O
(	O
Fig	O
.	O
5B	O
)	O
was	O
clearly	O
reduced	O
compared	O
to	O
control	O
GFP	O
expressing	O
neurons	O
(	O
Fig	O
.	O
5A	O
;	O
see	O
quantification	O
in	O
(	O
G	O
)	O
)	O
.	O

Growth	O
cones	O
of	O
GFP	O
(	O
C	O
)	O
and	O
CA	O
-	O
MEK1	O
expressing	O
neurons	O
were	O
similar	O
and	O
protruded	O
many	O
filopodia	O
(	O
arrows	O
in	O
Fig	O
.	O
5C	O
-	O
F	O
)	O
.	O

CA	O
-	O
MEK1	O
expression	O
in	O
growth	O
cones	O
was	O
confined	O
to	O
individual	O
dot	O
-	O
like	O
structures	O
(	O
arrowheads	O
in	O
Fig	O
.	O
5D	O
,	O
F	O
)	O
.	O

Ephrin	O
-	O
A5	O
application	O
on	O
a	O
GFP	O
expressing	O
control	O
growth	O
cone	O
(	O
Fig	O
.	O
5E	O
)	O
resulted	O
in	O
a	O
growth	O
cone	O
collapse	O
as	O
revealed	O
by	O
reduced	O
overall	O
growth	O
cone	O
area	O
and	O
filopodia	O
number	O
(	O
quantified	O
in	O
Fig	O
.	O
5H	O
,	O
I	O
)	O
.	O

In	O
contrast	O
,	O
in	O
neurons	O
overexpressing	O
CA	O
-	O
MEK1	O
(	O
Fig	O
.	O
5F	O
)	O
,	O
ephrin	O
-	O
A5	O
induced	O
only	O
a	O
partial	O
growth	O
cone	O
collapse	O
.	O

Thus	O
,	O
growth	O
cone	O
area	O
and	O
filopodia	O
number	O
were	O
not	O
reduced	O
(	O
see	O
Fig	O
.	O
5H	O
,	O
I	O
)	O
.	O

This	O
result	O
suggests	O
that	O
an	O
ephrin	O
-	O
A5	O
induced	O
signaling	O
cascade	O
targets	O
MAP	O
kinase	O
signaling	O
to	O
exert	O
a	O
full	O
growth	O
cone	O
collapse	O
.	O

This	O
result	O
is	O
in	O
contrast	O
to	O
a	O
recent	O
report	O
[	O
46	O
]	O
which	O
excluded	O
ERK	O
signaling	O
downstream	O
of	O
an	O
ephrin	O
-	O
A5	O
mediated	O
growth	O
cone	O
collapse	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
ephrin	O
-	O
A5	O
signaling	O
suppresses	O
ERK	O
kinase	O
signaling	O
also	O
to	O
interfere	O
with	O
BDNF	O
-	O
mediated	O
gene	O
expression	O
(	O
Fig	O
.	O
6	O
)	O
.	O

In	O
agreement	O
with	O
previous	O
results	O
(	O
Fig	O
.	O
4	O
)	O
,	O
in	O
mock	O
-	O
electroporated	O
neurons	O
,	O
ephrin	O
-	O
A5	O
incubation	O
reduced	O
the	O
BDNF	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
c	O
-	O
fos	O
(	O
Fig	O
.	O
6A	O
)	O
,	O
Egr1	O
(	O
Fig	O
.	O
6B	O
)	O
,	O
Egr2	O
(	O
Fig	O
.	O
6C	O
)	O
and	O
Arc	O
(	O
Fig	O
.	O
6D	O
)	O
mRNA	O
.	O

In	O
contrast	O
,	O
in	O
neurons	O
over	O
-	O
expressing	O
CA	O
-	O
MEK1	O
,	O
ephrin	O
-	O
A5	O
could	O
not	O
suppress	O
BDNF	O
-	O
induced	O
IEG	O
responses	O
to	O
the	O
same	O
degree	O
.	O

Particularly	O
Egr1	O
(	O
Fig	O
.	O
6B	O
)	O
and	O
Egr2	O
(	O
Fig	O
.	O
6C	O
)	O
mRNA	O
levels	O
were	O
almost	O
identical	O
when	O
comparing	O
neurons	O
treated	O
with	O
BDNF	O
alone	O
and	O
neurons	O
with	O
BDNF	O
and	O
ephrin	O
-	O
A5	O
together	O
.	O

Thus	O
,	O
ephrin	O
-	O
A5	O
represses	O
gene	O
activity	O
elicited	O
by	O
BDNF	O
at	O
least	O
in	O
part	O
via	O
MAP	O
kinases	O
.	O

Besides	O
IEGs	O
,	O
we	O
inspected	O
the	O
influence	O
of	O
both	O
guidance	O
cues	O
on	O
cytoskeletal	O
genes	O
,	O
whose	O
gene	O
products	O
might	O
modulate	O
cytoskeletal	O
dynamics	O
evoked	O
by	O
ephrin	O
-	O
As	O
and	O
/	O
or	O
neurotrophins	O
(	O
Fig	O
.	O
S4	O
)	O
.	O

Therefore	O
,	O
the	O
filamentous	O
actin	O
(	O
F	O
-	O
actin	O
)	O
stabilizing	O
tropomyosins	O
(	O
Tpm1	O
and	O
Tpm2	O
)	O
,	O
the	O
F	O
-	O
actin	O
cross	O
-	O
linker	O
alpha	O
-	O
actinin	O
1	O
(	O
Actn1	O
)	O
and	O
the	O
motor	O
protein	O
dynein	O
light	O
chain	O
1	O
(	O
Dnal1	O
)	O
were	O
analyzed	O
.	O

mRNA	O
levels	O
of	O
other	O
cytoskeletal	O
genes	O
were	O
not	O
altered	O
by	O
any	O
of	O
the	O
guidance	O
cues	O
(	O
i	O
.	O
e	O
.	O
cofilin	O
,	O
filamin	O
A	O
,	O
mena	O
,	O
vinculin	O
and	O
smooth	O
muscle	O
actin	O
;	O
data	O
not	O
shown	O
)	O
.	O

Short	O
-	O
term	O
stimulation	O
with	O
guidance	O
cues	O
did	O
not	O
result	O
in	O
major	O
alterations	O
of	O
cytoskeletal	O
mRNA	O
levels	O
except	O
for	O
upregulation	O
of	O
Tpm1	O
by	O
ephrin	O
-	O
A5	O
(	O
Fig	O
.	O
S4A	O
)	O
.	O

At	O
16h	O
of	O
incubation	O
,	O
both	O
tropomyosin	O
genes	O
were	O
induced	O
by	O
BDNF	O
and	O
ephrin	O
-	O
A5	O
alone	O
and	O
both	O
together	O
(	O
Fig	O
.	O
S4B	O
,	O
D	O
)	O
.	O

Actn1	O
levels	O
were	O
induced	O
by	O
individual	O
application	O
of	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
and	O
by	O
co	O
-	O
application	O
of	O
both	O
(	O
Fig	O
.	O
S4F	O
)	O
.	O

A	O
similar	O
profile	O
was	O
observed	O
for	O
the	O
dynein	O
light	O
chain	O
(	O
Fig	O
.	O
S4H	O
)	O
.	O

Taken	O
together	O
,	O
cytoskeletal	O
gene	O
expression	O
was	O
modulated	O
by	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
.	O

In	O
contrast	O
to	O
the	O
antagonistic	O
impact	O
on	O
the	O
IEG	O
gene	O
response	O
(	O
Figs	O
.	O
4	O
and	O
6	O
)	O
,	O
ephrin	O
-	O
A5	O
and	O
BDNF	O
resulted	O
in	O
rather	O
synergistic	O
action	O
on	O
cytoskeletal	O
gene	O
expression	O
.	O

This	O
difference	O
might	O
be	O
due	O
to	O
short	O
-	O
term	O
(	O
i	O
.	O
e	O
.	O
20	O
minutes	O
)	O
vs	O
.	O
long	O
-	O
term	O
(	O
i	O
.	O
e	O
.	O
16h	O
)	O
exposure	O
of	O
both	O
guidance	O
cues	O
in	O
the	O
IEG	O
and	O
cytoskeletal	O
gene	O
response	O
,	O
respectively	O
.	O

Introduction	O

Yeast	O
infections	O
cause	O
significant	O
mortality	O
in	O
critically	O
ill	O
and	O
immunocompromised	O
patients	O
.	O

In	O
particular	O
,	O
Candida	O
species	O
are	O
the	O
4th	O
most	O
common	O
cause	O
of	O
nosocomial	O
bloodstream	O
infections	O
in	O
the	O
United	O
States	O
,	O
and	O
Cryptococcus	O
neoformans	O
,	O
the	O
commonest	O
cause	O
of	O
fungal	O
meningitis	O
worldwide	O
[	O
1	O
]	O
,	O
[	O
2	O
]	O
.	O

Whilst	O
Candida	O
albicans	O
remains	O
the	O
leading	O
pathogenic	O
yeast	O
,	O
infections	O
due	O
to	O
non	O
-	O
C	O
.	O
albicans	O
species	O
such	O
as	O
Candida	O
glabrata	O
,	O
as	O
well	O
as	O
previously	O
rare	O
opportunists	O
such	O
as	O
Trichosporon	O
and	O
Geotrichum	O
species	O
,	O
are	O
increasingly	O
reported	O
[	O
1	O
]	O
,	O
[	O
3	O
]	O
-	O
[	O
6	O
]	O
.	O

Novel	O
pathogenic	O
Candida	O
species	O
such	O
as	O
Candida	O
nivariensis	O
and	O
Candida	O
bracarensis	O
have	O
also	O
been	O
described	O
[	O
7	O
]	O
.	O

Since	O
many	O
non	O
-	O
C	O
.	O
albicans	O
Candida	O
and	O
non	O
-	O
Candida	O
yeasts	O
are	O
resistant	O
or	O
less	O
susceptible	O
to	O
antifungal	O
agents	O
,	O
rapid	O
accurate	O
species	O
identification	O
is	O
central	O
to	O
timely	O
,	O
effective	O
antifungal	O
therapy	O
[	O
3	O
]	O
-	O
[	O
6	O
]	O
,	O
[	O
8	O
]	O
,	O
[	O
9	O
]	O
.	O

Conventional	O
phenotypic	O
-	O
based	O
methods	O
for	O
yeast	O
identification	O
,	O
however	O
,	O
are	O
slow	O
(	O
24	O
-	O
72	O
h	O
)	O
,	O
insensitive	O
and	O
often	O
unable	O
to	O
identify	O
more	O
unusual	O
species	O
.	O

Various	O
molecular	O
techniques	O
including	O
real	O
-	O
time	O
PCR	O
,	O
DNA	O
sequence	O
analysis	O
,	O
microarray	O
analysis	O
,	O
and	O
fluorescence	O
in	O
-	O
situ	O
hybridization	O
provide	O
accurate	O
identification	O
[	O
10	O
]	O
,	O
[	O
11	O
]	O
but	O
are	O
expensive	O
,	O
require	O
substantial	O
specimen	O
processing	O
time	O
(	O
hours	O
to	O
a	O
day	O
)	O
and	O
are	O
not	O
easily	O
implemented	O
as	O
routine	O
techniques	O
in	O
the	O
clinical	O
laboratory	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
-	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
MS	O
)	O
has	O
emerged	O
as	O
a	O
powerful	O
and	O
rapid	O
tool	O
for	O
the	O
identification	O
of	O
bacterial	O
and	O
yeast	O
pathogens	O
[	O
12	O
]	O
-	O
[	O
17	O
]	O
.	O

Using	O
MALDI	O
-	O
TOF	O
MS	O
,	O
the	O
protein	O
spectral	O
""""	O
fingerprint	O
""""	O
of	O
an	O
isolate	O
is	O
compared	O
to	O
a	O
reference	O
spectral	O
database	O
for	O
identification	O
[	O
18	O
]	O
.	O

Previous	O
studies	O
have	O
reported	O
species	O
identification	O
rates	O
of	O
92	O
-	O
99	O
%	O
amongst	O
collections	O
of	O
yeasts	O
and	O
yeast	O
-	O
like	O
organisms	O
[	O
14	O
]	O
-	O
[	O
17	O
]	O
,	O
[	O
19	O
]	O
,	O
[	O
20	O
]	O
.	O

However	O
,	O
taken	O
collectively	O
,	O
the	O
results	O
may	O
not	O
be	O
directly	O
comparable	O
since	O
these	O
studies	O
have	O
used	O
different	O
approaches	O
to	O
assign	O
species	O
-	O
from	O
comparing	O
spectra	O
from	O
test	O
organisms	O
to	O
reference	O
spectra	O
in	O
MALDI	O
-	O
TOF	O
MS	O
databases	O
[	O
16	O
]	O
,	O
[	O
20	O
]	O
,	O
to	O
enhancing	O
these	O
databases	O
,	O
and	O
in	O
some	O
instances	O
developing	O
study	O
-	O
specific	O
databases	O
,	O
with	O
""""	O
in	O
-	O
house	O
""""	O
spectral	O
signatures	O
[	O
14	O
]	O
,	O
[	O
15	O
]	O
.	O

There	O
also	O
is	O
a	O
continuing	O
need	O
to	O
extend	O
the	O
repository	O
of	O
reference	O
spectra	O
in	O
MALDI	O
-	O
TOF	O
MS	O
databases	O
.	O

We	O
therefore	O
undertook	O
the	O
present	O
study	O
to	O
evaluate	O
the	O
utility	O
of	O
the	O
MALDI	O
Biotyper	O
2	O
.	O
0	O
Microflex	O
LT	O
spectrometer	O
(	O
Bruker	O
Daltonik	O
GmbH	O
;	O
Bremen	O
,	O
Germany	O
)	O
with	O
its	O
current	O
spectral	O
database	O
in	O
comparison	O
with	O
phenotypic	O
-	O
based	O
methods	O
for	O
the	O
identification	O
of	O
a	O
broad	O
range	O
of	O
yeasts	O
in	O
a	O
diagnostic	O
laboratory	O
.	O

The	O
first	O
part	O
of	O
the	O
study	O
comprised	O
testing	O
of	O
reference	O
and	O
clinical	O
strains	O
from	O
our	O
culture	O
collection	O
.	O

The	O
second	O
was	O
a	O
blinded	O
prospective	O
analysis	O
of	O
freshly	O
-	O
collected	O
yeast	O
isolates	O
recovered	O
during	O
routine	O
laboratory	O
work	O
flow	O
;	O
discrepant	O
results	O
between	O
MALDI	O
TOF	O
MS	O
and	O
phenotypic	O
methods	O
were	O
resolved	O
using	O
sequence	O
analysis	O
of	O
the	O
fungal	O
internal	O
transcribed	O
spacer	O
(	O
ITS	O
)	O
regions	O
[	O
21	O
]	O
,	O
[	O
22	O
]	O
.	O

Results	O
obtained	O
by	O
preparation	O
of	O
yeasts	O
by	O
extraction	O
of	O
fungal	O
proteins	O
and	O
by	O
direct	O
application	O
of	O
yeast	O
colonies	O
onto	O
the	O
MALDI	O
TOF	O
MS	O
plate	O
were	O
also	O
compared	O
.	O

Conclusions	O

This	O
is	O
the	O
first	O
prospective	O
evaluation	O
of	O
parents	O
'	O
preferences	O
in	O
newly	O
diagnosed	O
juvenile	O
idiopathic	O
arthritis	O
patients	O
participating	O
in	O
the	O
BeSt	O
for	O
Kids	O
trial	O
.	O

Within	O
the	O
limitations	O
of	O
the	O
small	O
amounts	O
,	O
patients	O
clearly	O
preferred	O
initial	O
combination	O
therapy	O
with	O
etanercept	O
and	O
disliked	O
taking	O
prednisone	O
.	O

After	O
actual	O
exposure	O
and	O
follow	O
up	O
,	O
this	O
questionnaire	O
will	O
be	O
repeated	O
to	O
see	O
if	O
preferences	O
remain	O
the	O
same	O
.	O

Classification	O
result	O
.	O

Effects	O
of	O
rule	O
-	O
breakers	O
on	O
intermediary	O
-	O
based	O
networks	O
.	O

Individuals	O
using	O
rule	O
-	O
breaking	O
strategy	O
primarily	O
affected	O
(	O
A	O
)	O
their	O
own	O
social	O
position	O
(	O
H	O
(	O
2	O
)	O
=	O
213	O
.	O
18	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
but	O
also	O
made	O
an	O
impact	O
on	O
the	O
other	O
aspects	O
of	O
the	O
social	O
system	O
,	O
affecting	O
(	O
B	O
)	O
the	O
social	O
position	O
of	O
others	O
(	O
H	O
(	O
2	O
)	O
=	O
6	O
.	O
79	O
,	O
p	O
=	O
0	O
.	O
034	O
)	O
and	O
(	O
C	O
)	O
group	O
organization	O
(	O
H	O
(	O
2	O
)	O
=	O
125	O
.	O
3	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
as	O
their	O
frequency	O
in	O
a	O
population	O
increased	O
.	O

The	O
boxes	O
show	O
medians	O
,	O
quartiles	O
,	O
minima	O
and	O
maxima	O
.	O

Results	O
significantly	O
different	O
from	O
a	O
relevant	O
uniform	O
network	O
with	O
no	O
rule	O
-	O
breaking	O
behavior	O
(	O
p	O
<	O
0	O
.	O
05	O
in	O
Dunn	O
'	O
s	O
multiple	O
comparison	O
test	O
for	O
comparing	O
each	O
group	O
with	O
control	O
)	O
are	O
designated	O
with	O
*	O
.	O

Patients	O
and	O
Study	O
Design	O

A	O
prospective	O
evaluation	O
of	O
the	O
different	O
CMR	O
parameters	O
for	O
predicting	O
LV	O
segmental	O
and	O
global	O
functional	O
recovery	O
was	O
performed	O
in	O
46	O
patients	O
(	O
63	O
+	O
/	O
-	O
10	O
years	O
old	O
,	O
3	O
with	O
previous	O
CABG	O
,	O
35	O
with	O
three	O
-	O
vessel	O
disease	O
,	O
3	O
with	O
one	O
-	O
vessel	O
disease	O
)	O
with	O
LV	O
systolic	O
dysfunction	O
(	O
LVEF	O
35	O
+	O
/	O
-	O
8	O
%	O
)	O
before	O
they	O
underwent	O
surgical	O
(	O
n	O
=	O
34	O
)	O
or	O
percutaneous	O
(	O
n	O
=	O
12	O
)	O
revascularisation	O
.	O

Sixty	O
patients	O
without	O
contraindications	O
for	O
CMR	O
were	O
screened	O
for	O
the	O
following	O
inclusion	O
criteria	O
:	O
(	O
1	O
)	O
CAD	O
(	O
>	O
70	O
%	O
stenosis	O
in	O
one	O
or	O
more	O
major	O
epicardial	O
vessels	O
)	O
,	O
scheduled	O
for	O
a	O
revascularisation	O
procedure	O
;	O
(	O
2	O
)	O
LVEF	O
<	O
=	O
45	O
%	O
;	O
(	O
3	O
)	O
at	O
least	O
two	O
adjacent	O
segments	O
with	O
wall	O
motion	O
abnormalities	O
at	O
rest	O
;	O
and	O
(	O
4	O
)	O
no	O
infarction	O
or	O
revascularisation	O
within	O
the	O
last	O
two	O
months	O
.	O

Patients	O
were	O
included	O
in	O
the	O
study	O
only	O
after	O
a	O
successful	O
and	O
complete	O
coronary	O
revascularisation	O
.	O

Of	O
the	O
14	O
patients	O
who	O
did	O
not	O
complete	O
the	O
study	O
,	O
3	O
decided	O
not	O
to	O
undergo	O
the	O
repeated	O
CMR	O
scan	O
or	O
were	O
lost	O
during	O
follow	O
-	O
up	O
;	O
7	O
had	O
significant	O
periprocedural	O
injury	O
(	O
new	O
LGE	O
zones	O
on	O
repeated	O
CMR	O
scans	O
and	O
clinically	O
proven	O
periprocedural	O
myocardial	O
infarction	O
(	O
MI	O
)	O
or	O
MI	O
between	O
both	O
scans	O
)	O
;	O
3	O
had	O
pacemakers	O
or	O
defibrillators	O
implanted	O
in	O
the	O
period	O
between	O
the	O
MR	O
scans	O
;	O
and	O
1	O
was	O
excluded	O
because	O
of	O
dilated	O
cardiomyopathy	O
with	O
secondary	O
CAD	O
.	O

None	O
of	O
the	O
patients	O
were	O
excluded	O
from	O
the	O
study	O
for	O
technical	O
reasons	O
or	O
image	O
quality	O
.	O

The	O
mean	O
interval	O
between	O
CMR	O
and	O
revascularisation	O
was	O
12	O
+	O
/	O
-	O
13	O
days	O
,	O
and	O
none	O
of	O
the	O
patients	O
presented	O
clinical	O
evidence	O
of	O
infarction	O
during	O
this	O
period	O
.	O

The	O
mean	O
interval	O
between	O
MI	O
and	O
the	O
first	O
CMR	O
was	O
3	O
.	O
6	O
years	O
.	O

In	O
46	O
patients	O
,	O
the	O
extent	O
of	O
regional	O
contractility	O
and	O
LGE	O
were	O
determined	O
repeatedly	O
by	O
CMR	O
28	O
+	O
/	O
-	O
4	O
weeks	O
(	O
6	O
months	O
)	O
after	O
revascularisation	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Lithuanian	O
Bioethics	O
Committee	O
(	O
Nr	O
.	O
17	O
)	O
,	O
and	O
informed	O
written	O
consent	O
was	O
obtained	O
from	O
each	O
patient	O
prior	O
to	O
inclusion	O
in	O
the	O
study	O
.	O

3	O
.	O
2	O
.	O

Molecular	O
Mechanisms	O
Mediating	O
the	O
Perinatal	O
Beta	O
-	O
Cell	O
Adaptive	O
Response	O
to	O
Early	O
-	O
Life	O
Stressors	O

Molecular	O
mechanisms	O
responsible	O
for	O
impaired	O
beta	O
-	O
cell	O
mass	O
formation	O
after	O
IUCR	O
or	O
IUPR	O
have	O
come	O
under	O
investigation	O
.	O

First	O
,	O
it	O
has	O
been	O
proposed	O
that	O
IUCR	O
can	O
result	O
in	O
a	O
reduction	O
of	O
the	O
embryonic	O
beta	O
-	O
cell	O
progenitor	O
pool	O
leading	O
to	O
inappropriate	O
postnatal	O
beta	O
-	O
cell	O
formation	O
.	O

Stanger	O
et	O
al	O
.	O

[	O
108	O
]	O
demonstrated	O
that	O
selective	O
genetic	O
reduction	O
in	O
the	O
size	O
of	O
PDX	O
-	O
1	O
+	O
pancreatic	O
progenitors	O
during	O
the	O
fetal	O
period	O
results	O
in	O
impaired	O
beta	O
-	O
cell	O
formation	O
during	O
the	O
postnatal	O
period	O
with	O
consequent	O
development	O
of	O
glucose	O
intolerance	O
during	O
adulthood	O
.	O

Consistent	O
with	O
this	O
,	O
maternal	O
food	O
restriction	O
leads	O
to	O
significant	O
reduction	O
in	O
PDX	O
-	O
1	O
+	O
and	O
neurogenin	O
-	O
3	O
+	O
pancreatic	O
precursors	O
during	O
embryonic	O
development	O
in	O
rats	O
,	O
diminished	O
postnatal	O
beta	O
-	O
cell	O
formation	O
,	O
and	O
inability	O
to	O
expand	O
beta	O
-	O
cell	O
mass	O
in	O
response	O
to	O
pregnancy	O
[	O
47	O
,	O
94	O
]	O
.	O

The	O
UPI	O
model	O
is	O
also	O
characterized	O
by	O
a	O
permanent	O
decrease	O
in	O
islet	O
PDX	O
-	O
1	O
mRNA	O
expression	O
.	O

This	O
decrease	O
has	O
recently	O
been	O
shown	O
to	O
be	O
due	O
to	O
progressive	O
epigenetic	O
silencing	O
of	O
the	O
Pdx1	O
gene	O
locus	O
secondary	O
to	O
proximal	O
promoter	O
methylation	O
[	O
69	O
,	O
109	O
]	O
,	O
and	O
it	O
may	O
be	O
responsible	O
for	O
the	O
decreased	O
rate	O
of	O
beta	O
-	O
cell	O
replication	O
and	O
inappropriate	O
postnatal	O
beta	O
-	O
cell	O
mass	O
development	O
[	O
69	O
,	O
110	O
]	O
.	O

In	O
the	O
same	O
way	O
of	O
thinking	O
,	O
studies	O
have	O
demonstrated	O
that	O
the	O
maintenance	O
of	O
methylated	O
histone	O
H3	O
Lys4	O
by	O
Set7	O
/	O
9	O
,	O
a	O
member	O
of	O
the	O
SET	O
methyltransferase	O
family	O
,	O
is	O
crucial	O
to	O
Pdx1	O
activity	O
in	O
beta	O
-	O
cell	O
lines	O
[	O
111	O
-	O
113	O
]	O
.	O

This	O
led	O
to	O
the	O
hypothesis	O
that	O
Set7	O
/	O
9	O
may	O
represent	O
a	O
novel	O
chromatin	O
-	O
modifying	O
protein	O
that	O
functions	O
in	O
part	O
through	O
its	O
recruitment	O
to	O
target	O
genes	O
by	O
cell	O
-	O
specific	O
transcription	O
factors	O
such	O
as	O
Pdx1	O
.	O

Since	O
then	O
,	O
a	O
role	O
of	O
histone	O
methyl	O
transferases	O
,	O
particularly	O
set7	O
,	O
has	O
also	O
been	O
demonstrated	O
in	O
the	O
sustained	O
deleterious	O
effects	O
of	O
chronic	O
hyperglycemia	O
on	O
human	O
microvascular	O
endothelial	O
cells	O
[	O
114	O
]	O
.	O

Such	O
an	O
epigenetic	O
change	O
could	O
potentially	O
be	O
involved	O
in	O
the	O
deleterious	O
effect	O
of	O
high	O
glucose	O
upon	O
the	O
fetal	O
pancreas	O
in	O
the	O
IUED	O
models	O
.	O

Another	O
mechanism	O
proposed	O
to	O
explain	O
reduced	O
beta	O
-	O
cell	O
formation	O
after	O
IUCR	O
is	O
related	O
to	O
prenatal	O
glucocorticoid	O
exposure	O
.	O

Administration	O
of	O
either	O
dexamethasone	O
or	O
carbenoxolone	O
(	O
to	O
inhibit	O
11	O
beta	O
-	O
hydroxysteroid	O
dehydrogenase	O
type	O
2	O
)	O
to	O
normal	O
pregnant	O
rats	O
also	O
causes	O
fetal	O
growth	O
retardation	O
and	O
the	O
adult	O
offspring	O
are	O
hypertensive	O
and	O
hyperglycemic	O
,	O
with	O
hyperactive	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
[	O
115	O
]	O
.	O

Maternal	O
undernutrition	O
significantly	O
increased	O
both	O
fetal	O
and	O
maternal	O
corticosterone	O
concentrations	O
in	O
rats	O
[	O
116	O
]	O
.	O

Subsequently	O
,	O
maternal	O
and	O
/	O
or	O
fetal	O
overexposure	O
to	O
glucocorticoids	O
(	O
via	O
administration	O
of	O
dexamethasone	O
)	O
impairs	O
both	O
fetal	O
and	O
postnatal	O
beta	O
-	O
cell	O
formation	O
in	O
rodents	O
and	O
nonhuman	O
primates	O
[	O
94	O
,	O
117	O
-	O
119	O
]	O
.	O

Seckl	O
et	O
al	O
.	O

[	O
115	O
]	O
have	O
shown	O
that	O
fetal	O
corticosterone	O
concentrations	O
are	O
inversely	O
correlated	O
with	O
fetal	O
insulin	O
content	O
and	O
postnatal	O
beta	O
-	O
cell	O
formation	O
in	O
rats	O
.	O

Evidence	O
suggests	O
that	O
glucocorticoids	O
can	O
exert	O
a	O
direct	O
effect	O
on	O
the	O
developing	O
fetal	O
pancreas	O
via	O
transcriptional	O
modulation	O
of	O
transcription	O
factors	O
involved	O
in	O
beta	O
-	O
cell	O
formation	O
and	O
differentiation	O
[	O
117	O
]	O
.	O

Glucocorticoid	O
receptors	O
are	O
present	O
in	O
the	O
pancreas	O
during	O
embryonic	O
development	O
of	O
rodents	O
and	O
humans	O
[	O
117	O
]	O
,	O
and	O
glucocorticoids	O
can	O
bind	O
to	O
the	O
Pdx1	O
promoter	O
and	O
thus	O
suppress	O
fetal	O
endocrine	O
cell	O
differentiation	O
[	O
117	O
]	O
.	O

Glucocorticoid	O
treatment	O
has	O
been	O
shown	O
to	O
significantly	O
reduce	O
fetal	O
expression	O
of	O
key	O
endocrine	O
transcription	O
factors	O
such	O
as	O
Pdx1	O
and	O
Pax6	O
but	O
simultaneously	O
increase	O
expression	O
of	O
transcription	O
factors	O
that	O
regulate	O
development	O
of	O
the	O
exocrine	O
pancreas	O
[	O
119	O
]	O
.	O

It	O
has	O
also	O
been	O
demonstrated	O
that	O
the	O
UPI	O
or	O
the	O
low	O
-	O
protein	O
IUPR	O
offspring	O
experience	O
increased	O
oxidative	O
stress	O
and	O
impaired	O
mitochondrial	O
function	O
[	O
96	O
,	O
120	O
]	O
.	O

The	O
mitochondrial	O
dysfunction	O
was	O
not	O
limited	O
to	O
just	O
the	O
beta	O
cell	O
,	O
as	O
mitochondria	O
from	O
both	O
the	O
liver	O
and	O
skeletal	O
muscle	O
exhibit	O
decreased	O
oxidation	O
of	O
pyruvate	O
,	O
subsequently	O
leading	O
to	O
the	O
development	O
of	O
features	O
commonly	O
found	O
in	O
T2D	O
[	O
100	O
,	O
121	O
]	O
.	O

Also	O
exposure	O
to	O
a	O
Western	O
-	O
style	O
diet	O
before	O
and	O
during	O
pregnancy	O
(	O
an	O
IUEO	O
model	O
)	O
alters	O
the	O
redox	O
state	O
as	O
early	O
as	O
preimplantation	O
development	O
,	O
leading	O
to	O
mild	O
oxidative	O
stress	O
associated	O
with	O
inflammation	O
.	O

The	O
finding	O
that	O
administration	O
of	O
antioxidants	O
to	O
the	O
dam	O
reverses	O
oxidative	O
stress	O
and	O
completely	O
prevents	O
the	O
development	O
of	O
glucose	O
intolerance	O
and	O
increased	O
adiposity	O
in	O
the	O
adult	O
offspring	O
suggests	O
that	O
oxidative	O
stress	O
plays	O
an	O
important	O
role	O
in	O
the	O
development	O
of	O
adiposity	O
in	O
this	O
case	O
[	O
122	O
]	O
.	O

Some	O
studies	O
in	O
the	O
low	O
-	O
protein	O
IUPR	O
model	O
have	O
demonstrated	O
that	O
oxidative	O
stress	O
is	O
not	O
limited	O
to	O
just	O
mitochondrial	O
DNA	O
damage	O
,	O
but	O
also	O
to	O
genomic	O
DNA	O
,	O
impacting	O
cell	O
-	O
cycle	O
regulation	O
and	O
gene	O
expression	O
[	O
123	O
]	O
.	O

While	O
DNA	O
is	O
being	O
targeted	O
throughout	O
by	O
ROS	O
,	O
there	O
are	O
particular	O
regions	O
that	O
are	O
known	O
to	O
be	O
more	O
sensitive	O
to	O
ROS	O
-	O
mediated	O
damage	O
,	O
for	O
example	O
,	O
telomeres	O
.	O

Telomeres	O
comprise	O
GC	O
-	O
rich	O
repeats	O
and	O
are	O
found	O
at	O
the	O
ends	O
of	O
each	O
chromosome	O
.	O

They	O
are	O
known	O
to	O
shorten	O
with	O
each	O
cellular	O
division	O
and	O
,	O
hence	O
,	O
can	O
act	O
as	O
a	O
mitotic	O
clock	O
,	O
registering	O
the	O
number	O
of	O
replicative	O
divisions	O
to	O
have	O
taken	O
place	O
within	O
the	O
cell	O
.	O

Investigations	O
using	O
an	O
IUPR	O
model	O
have	O
indeed	O
reported	O
a	O
decrease	O
in	O
longevity	O
in	O
the	O
offspring	O
[	O
123	O
,	O
124	O
]	O
accompanied	O
by	O
reduction	O
in	O
mitochondrial	O
antioxidant	O
defences	O
[	O
96	O
,	O
125	O
]	O
and	O
telomere	O
length	O
in	O
islets	O
[	O
125	O
]	O
.	O

Pancreatic	O
islet	O
development	O
has	O
been	O
shown	O
to	O
be	O
influenced	O
by	O
a	O
number	O
of	O
growth	O
factors	O
including	O
the	O
insulin	O
-	O
like	O
growth	O
factors	O
,	O
IGF	O
-	O
I	O
and	O
IGF	O
-	O
II	O
whose	O
expression	O
in	O
utero	O
is	O
regulated	O
by	O
nutrient	O
and	O
hormone	O
concentrations	O
.	O

IUPR	O
modifies	O
expression	O
of	O
both	O
IGF	O
genes	O
in	O
a	O
variety	O
of	O
fetal	O
tissues	O
.	O

In	O
an	O
IUPR	O
rat	O
model	O
with	O
a	O
decreased	O
beta	O
-	O
cell	O
mass	O
and	O
beta	O
-	O
cell	O
replication	O
and	O
an	O
increased	O
rate	O
of	O
beta	O
-	O
cell	O
apoptosis	O
,	O
gene	O
expression	O
for	O
IGF	O
-	O
II	O
but	O
not	O
IGF	O
-	O
I	O
was	O
found	O
reduced	O
in	O
the	O
fetal	O
pancreas	O
[	O
126	O
]	O
.	O

In	O
a	O
different	O
IUPR	O
model	O
with	O
more	O
severe	O
global	O
food	O
restriction	O
which	O
induced	O
hyperinsulinemia	O
and	O
an	O
increase	O
in	O
beta	O
-	O
cell	O
mass	O
in	O
their	O
fetuses	O
[	O
90	O
]	O
,	O
the	O
fetal	O
phenotype	O
was	O
unexpectedly	O
associated	O
with	O
an	O
increase	O
in	O
pancreatic	O
IGF	O
-	O
I	O
expression	O
,	O
islet	O
IGF	O
-	O
1R	O
[	O
91	O
]	O
,	O
and	O
IRS	O
-	O
2	O
[	O
92	O
]	O
.	O

In	O
the	O
fetal	O
GK	O
/	O
Par	O
rat	O
exposed	O
to	O
mild	O
hyperglycemia	O
during	O
gestation	O
(	O
a	O
model	O
of	O
IUED	O
)	O
,	O
data	O
from	O
our	O
group	O
suggest	O
that	O
the	O
beta	O
-	O
cell	O
deficit	O
(	O
reduced	O
by	O
more	O
than	O
50	O
%	O
)	O
starts	O
as	O
early	O
as	O
fetal	O
age	O
E16	O
and	O
reflects	O
decreased	O
beta	O
-	O
cell	O
proliferation	O
,	O
a	O
limitation	O
of	O
beta	O
-	O
cell	O
neogenesis	O
from	O
precursors	O
,	O
and	O
increased	O
apoptosis	O
of	O
both	O
beta	O
cells	O
and	O
their	O
precursors	O
[	O
86	O
]	O
.	O

Notably	O
,	O
Pdx1	O
and	O
Neurogenin3	O
expression	O
were	O
decreased	O
on	O
E18	O
but	O
normally	O
expressed	O
on	O
E13	O
[	O
86	O
]	O
.	O

Defective	O
signalling	O
through	O
the	O
Igf2	O
/	O
Igf1	O
-	O
R	O
pathway	O
may	O
represent	O
the	O
primary	O
instrumental	O
anomaly	O
since	O
Igf2	O
and	O
Igf1	O
-	O
R	O
protein	O
expressions	O
are	O
already	O
decreased	O
within	O
the	O
GK	O
/	O
Par	O
pancreatic	O
rudiment	O
at	O
E13	O
,	O
at	O
a	O
time	O
when	O
beta	O
-	O
cell	O
mass	O
(	O
first	O
wave	O
of	O
beta	O
-	O
cell	O
expansion	O
)	O
is	O
in	O
fact	O
normal	O
[	O
31	O
]	O
.	O

Low	O
levels	O
of	O
pancreatic	O
Igf2	O
associated	O
with	O
beta	O
-	O
cell	O
mass	O
deficiency	O
are	O
maintained	O
thereafter	O
within	O
the	O
fetal	O
pancreas	O
[	O
87	O
]	O
.	O

Crossbreeding	O
protocols	O
between	O
nondiabetic	O
W	O
and	O
diabetic	O
GK	O
rats	O
showed	O
that	O
,	O
in	O
late	O
gestation	O
(	O
E18	O
)	O
,	O
pancreatic	O
Igf2	O
protein	O
expression	O
was	O
as	O
low	O
in	O
GKmother	O
/	O
GKfather	O
and	O
Wmother	O
/	O
GKfather	O
crosses	O
as	O
in	O
GKmother	O
/	O
GKfather	O
crosses	O
[	O
87	O
]	O
.	O

These	O
findings	O
rather	O
support	O
the	O
hypothesis	O
that	O
the	O
pancreatic	O
Igf2	O
anomaly	O
in	O
the	O
GK	O
diabetic	O
model	O
is	O
linked	O
to	O
a	O
genetic	O
determinism	O
.	O

This	O
view	O
is	O
also	O
consistent	O
with	O
the	O
results	O
of	O
genetic	O
analyses	O
that	O
linked	O
a	O
locus	O
containing	O
the	O
gene	O
encoding	O
Igf2	O
to	O
diabetes	O
in	O
the	O
GK	O
rat	O
[	O
127	O
]	O
.	O

The	O
Igf2	O
gene	O
is	O
subjected	O
to	O
paternal	O
genomic	O
imprinting	O
.	O

However	O
,	O
because	O
the	O
Igf2	O
expression	O
is	O
similarly	O
affected	O
in	O
fetuses	O
,	O
regardless	O
of	O
whether	O
the	O
father	O
is	O
W	O
or	O
GK	O
[	O
87	O
]	O
,	O
we	O
can	O
not	O
conclude	O
with	O
a	O
simple	O
change	O
of	O
Igf2	O
gene	O
imprinting	O
in	O
the	O
GK	O
rat	O
.	O

Finally	O
,	O
our	O
understanding	O
of	O
the	O
underlying	O
mechanisms	O
for	O
reduced	O
BCM	O
in	O
response	O
to	O
inappropriate	O
perinatal	O
nutrition	O
is	O
growing	O
rapidly	O
.	O

However	O
,	O
the	O
relative	O
contribution	O
of	O
the	O
many	O
intrinsic	O
and	O
extrinsic	O
factors	O
which	O
contribute	O
to	O
the	O
adaptive	O
response	O
of	O
the	O
developing	O
endocrine	O
pancreas	O
is	O
still	O
to	O
be	O
established	O
.	O

4	O
.	O

The	O
kinetochore	O

The	O
arguments	O
built	O
in	O
the	O
previous	O
section	O
lead	O
to	O
the	O
conclusion	O
that	O
it	O
is	O
essential	O
to	O
understand	O
error	O
correction	O
and	O
spindle	O
checkpoint	O
signalling	O
in	O
the	O
context	O
of	O
the	O
complex	O
structural	O
organization	O
of	O
the	O
kinetochore	O
.	O

A	O
complete	O
account	O
of	O
kinetochore	O
organization	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	O
and	O
several	O
reviews	O
on	O
this	O
topic	O
have	O
been	O
made	O
available	O
recently	O
[	O
21	O
,	O
22	O
]	O
.	O

Suffice	O
to	O
say	O
that	O
kinetochores	O
are	O
thought	O
to	O
consist	O
of	O
an	O
inner	O
plate	O
hosting	O
an	O
interface	O
between	O
the	O
15	O
-	O
subunit	O
constitutive	O
centromere	O
-	O
associated	O
network	O
(	O
CCAN	O
)	O
and	O
specialized	O
centromeric	O
chromatin	O
;	O
and	O
an	O
outer	O
plate	O
containing	O
the	O
10	O
-	O
subunit	O
KMN	O
network	O
(	O
from	O
the	O
initials	O
of	O
its	O
Knl1	O
,	O
Mis12	O
and	O
Ndc80	O
subcomplexes	O
)	O
implicated	O
in	O
microtubule	O
binding	O
.	O

The	O
CCAN	O
and	O
KMN	O
networks	O
are	O
tightly	O
connected	O
.	O

An	O
interaction	O
between	O
CENP	O
-	O
C	O
(	O
CCAN	O
)	O
and	O
the	O
Mis12	O
complex	O
(	O
KMN	O
network	O
)	O
provides	O
an	O
important	O
point	O
of	O
contact	O
[	O
81	O
-	O
83	O
]	O
.	O

The	O
existence	O
of	O
additional	O
points	O
of	O
contact	O
,	O
including	O
one	O
between	O
CENP	O
-	O
T	O
(	O
CCAN	O
)	O
and	O
the	O
Ndc80	O
subcomplex	O
(	O
KMN	O
network	O
)	O
[	O
83	O
,	O
84	O
]	O
,	O
is	O
supported	O
by	O
extensive	O
analyses	O
of	O
localization	O
dependencies	O
of	O
kinetochore	O
proteins	O
and	O
from	O
initial	O
experiments	O
of	O
biochemical	O
reconstitution	O
.	O

Biochemical	O
and	O
structural	O
studies	O
,	O
including	O
super	O
-	O
resolution	O
investigations	O
of	O
kinetochore	O
organization	O
by	O
fluorescence	O
microscopy	O
,	O
have	O
finally	O
resulted	O
in	O
rather	O
precise	O
maps	O
of	O
the	O
relative	O
position	O
of	O
many	O
structural	O
kinetochore	O
proteins	O
and	O
of	O
several	O
checkpoint	O
components	O
[	O
85	O
-	O
88	O
]	O
.	O

For	O
instance	O
,	O
these	O
studies	O
clarified	O
that	O
the	O
highly	O
elongated	O
4	O
-	O
subunit	O
Ndc80	O
complex	O
,	O
conserved	O
in	O
all	O
eukaryotes	O
,	O
orients	O
its	O
approximately	O
60	O
nm	O
long	O
axis	O
at	O
a	O
relatively	O
small	O
angle	O
with	O
the	O
inter	O
-	O
kinetochore	O
axis	O
[	O
85	O
-	O
87	O
]	O
.	O

The	O
kinetochore	O
-	O
binding	O
end	O
of	O
the	O
Ndc80	O
complex	O
was	O
predicted	O
to	O
be	O
positioned	O
near	O
the	O
Mis12	O
and	O
Knl1	O
complexes	O
[	O
87	O
,	O
88	O
]	O
,	O
and	O
this	O
prediction	O
was	O
fully	O
confirmed	O
in	O
experiments	O
of	O
biochemical	O
reconstitution	O
[	O
89	O
]	O
.	O

In	O
prophase	O
Drosophila	O
melanogaster	O
S2	B
cells	O
,	O
the	O
C	O
-	O
terminal	O
region	O
of	O
the	O
Ndc80	O
subunit	O
is	O
located	O
approximately	O
65	O
nm	O
outward	O
(	O
i	O
.	O
e	O
.	O
towards	O
the	O
microtubule	O
)	O
relative	O
to	O
CENP	O
-	O
A	O
,	O
the	O
histone	O
H3	O
variant	O
that	O
marks	O
centromeres	O
from	O
yeast	O
to	O
humans	O
[	O
40	O
]	O
.	O

Remarkably	O
,	O
it	O
was	O
shown	O
that	O
this	O
distance	O
increases	O
to	O
approximately	O
100	O
nm	O
when	O
kinetochores	O
experience	O
microtubule	O
-	O
dependent	O
tension	O
at	O
metaphase	O
[	O
40	O
]	O
.	O

This	O
phenomenon	O
is	O
now	O
known	O
as	O
intra	O
-	O
kinetochore	O
stretch	O
or	O
tension	O
[	O
40	O
,	O
90	O
]	O
.	O

A	O
major	O
task	O
for	O
the	O
future	O
is	O
to	O
understand	O
how	O
intra	O
-	O
kinetochore	O
stretch	O
is	O
generated	O
when	O
microtubules	O
bind	O
the	O
kinetochore	O
.	O

At	O
one	O
extreme	O
,	O
intra	O
-	O
kinetochore	O
stretching	O
might	O
be	O
the	O
result	O
of	O
a	O
discreet	O
conformational	O
change	O
in	O
the	O
kinetochore	O
caused	O
by	O
microtubule	O
binding	O
[	O
22	O
,	O
91	O
]	O
.	O

While	O
this	O
is	O
possible	O
,	O
it	O
seems	O
unlikely	O
when	O
considering	O
the	O
great	O
structural	O
complexity	O
of	O
kinetochores	O
.	O

Each	O
microtubule	O
-	O
binding	O
site	O
contains	O
six	O
to	O
eight	O
copies	O
of	O
the	O
approximately	O
30	O
structural	O
kinetochore	O
components	O
[	O
85	O
]	O
.	O

Furthermore	O
,	O
in	O
most	O
species	O
,	O
kinetochores	O
are	O
designed	O
to	O
bind	O
multiple	O
microtubules	O
.	O

Plausibly	O
,	O
each	O
microtubule	O
-	O
binding	O
site	O
becomes	O
engaged	O
at	O
a	O
different	O
time	O
.	O

Thus	O
,	O
it	O
may	O
be	O
more	O
sensible	O
to	O
interpret	O
intra	O
-	O
kinetochore	O
stretching	O
as	O
a	O
progressive	O
,	O
continuous	O
distortion	O
of	O
the	O
kinetochore	O
when	O
microtubules	O
are	O
added	O
.	O

In	O
agreement	O
with	O
this	O
idea	O
,	O
intermediate	O
levels	O
of	O
stretching	O
are	O
observed	O
when	O
microtubule	O
end	O
dynamics	O
are	O
inhibited	O
through	O
addition	O
of	O
taxol	O
[	O
40	O
]	O
.	O

Importantly	O
,	O
intra	O
-	O
kinetochore	O
stretch	O
was	O
shown	O
to	O
correlate	O
with	O
the	O
status	O
of	O
checkpoint	O
activation	O
,	O
with	O
high	O
stretch	O
being	O
correlated	O
with	O
checkpoint	O
satisfaction	O
.	O

This	O
idea	O
of	O
checkpoint	O
control	O
is	O
alternative	O
to	O
a	O
previous	O
idea	O
that	O
tension	O
might	O
be	O
monitored	O
at	O
the	O
centromere	O
,	O
i	O
.	O
e	O
.	O
between	O
sister	O
kinetochores	O
(	O
inter	O
-	O
kinetochore	O
tension	O
)	O
[	O
46	O
]	O
.	O

A	O
significant	O
theoretical	O
limitation	O
of	O
the	O
idea	O
that	O
the	O
checkpoint	O
sensor	O
monitors	O
tension	O
between	O
sister	O
kinetochores	O
is	O
that	O
it	O
is	O
not	O
applicable	O
to	O
meiosis	O
I	O
,	O
when	O
the	O
sisters	O
co	O
-	O
orient	O
and	O
the	O
homologues	O
pair	O
through	O
the	O
chiasmata	O
.	O

Conversely	O
,	O
the	O
intra	O
-	O
kinetochore	O
tension	O
idea	O
is	O
also	O
applicable	O
to	O
checkpoint	O
control	O
in	O
meiosis	O
I	O
.	O

Discussion	O

In	O
our	O
previous	O
work	O
,	O
we	O
considered	O
in	O
CD	O
families	O
the	O
risk	O
to	O
develop	O
the	O
disease	O
according	O
to	O
a	O
specific	O
HLA	O
haplotypes	O
,	O
obtaining	O
a	O
risk	O
range	O
from	O
0	O
.	O
01	O
to	O
>	O
=	O
0	O
.	O
20	O
[	O
1	O
]	O
.	O

In	O
the	O
present	O
study	O
we	O
evaluated	O
the	O
role	O
of	O
3	O
non	O
-	O
HLA	O
genetic	O
markers	O
to	O
influence	O
the	O
CD	O
risk	O
in	O
first	O
relatives	O
of	O
CD	O
affected	O
children	O
.	O

We	O
collected	O
data	O
on	O
families	O
with	O
at	O
least	O
one	O
CD	O
-	O
affected	O
among	O
offspring	O
.	O

This	O
family	O
set	O
helped	O
to	O
evaluate	O
the	O
association	O
between	O
SNPs	O
and	O
CD	O
(	O
TDT	O
on	O
parents	O
-	O
offspring	O
trios	O
)	O
and	O
to	O
estimate	O
the	O
risk	O
of	O
CD	O
in	O
the	O
other	O
sibs	O
.	O

The	O
TDT	O
design	O
provides	O
robustness	O
to	O
population	O
stratification	O
and	O
mitigation	O
of	O
the	O
possible	O
confounding	O
effect	O
of	O
environmental	O
factors	O
,	O
because	O
all	O
family	O
members	O
share	O
the	O
same	O
environment	O
[	O
16	O
]	O
.	O

Ten	O
SNPs	O
,	O
selected	O
from	O
those	O
previously	O
found	O
to	O
be	O
associated	O
with	O
CD	O
by	O
GWAS	O
[	O
13	O
]	O
,	O
were	O
successfully	O
genotyped	O
.	O

In	O
our	O
population	O
three	O
SNPs	O
resulted	O
significantly	O
associated	O
with	O
CD	O
(	O
those	O
in	O
LPP	O
,	O
RGS1	O
and	O
REL	O
genes	O
)	O
and	O
the	O
other	O
seven	O
investigated	O
SNPs	O
,	O
even	O
if	O
not	O
statistically	O
associated	O
with	O
CD	O
,	O
showed	O
always	O
an	O
higher	O
frequency	O
of	O
the	O
previously	O
reported	O
risk	O
alleles	O
[	O
13	O
]	O
in	O
affected	O
subjects	O
than	O
in	O
controls	O
.	O

The	O
three	O
genes	O
selected	O
appear	O
to	O
be	O
appealing	O
for	O
the	O
pathogenesis	O
of	O
CD	O
.	O

LPP	O
(	O
OR	O
=	O
2	O
.	O
36	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
was	O
reported	O
to	O
be	O
highly	O
expressed	O
in	O
small	O
intestinal	O
mucosa	O
and	O
may	O
have	O
a	O
structural	O
role	O
at	O
sites	O
of	O
cell	O
adhesion	O
in	O
maintaining	O
cell	O
shape	O
and	O
motility	O
[	O
7	O
]	O
.	O

RGS1	O
(	O
OR	O
=	O
1	O
.	O
75	O
;	O
p	O
=	O
0	O
.	O
025	O
)	O
belongs	O
to	O
a	O
family	O
of	O
RGS	O
genes	O
.	O

It	O
attenuates	O
the	O
signaling	O
activity	O
of	O
G	O
-	O
proteins	O
,	O
blocking	O
the	O
homing	O
of	O
Intra	O
Epithelial	O
Lymphocytes	O
(	O
IELs	O
)	O
,	O
and	O
it	O
is	O
specifically	O
expressed	O
both	O
in	O
human	O
small	O
intestinal	O
mucosa	O
and	O
in	O
murine	O
IELs	O
,	O
key	O
players	O
in	O
the	O
development	O
of	O
human	O
CD	O
villous	O
atrophy	O
[	O
7	O
]	O
,	O
[	O
17	O
]	O
.	O

REL	O
(	O
OR	O
=	O
1	O
.	O
66	O
;	O
p	O
=	O
0	O
.	O
034	O
)	O
is	O
a	O
subunit	O
of	O
NF	O
-	O
kB	O
complex	O
,	O
implicated	O
in	O
T	O
cell	O
differentiation	O
[	O
18	O
]	O
and	O
it	O
appears	O
to	O
be	O
a	O
key	O
molecule	O
regulating	O
inflammation	O
and	O
the	O
switch	O
from	O
tolerance	O
to	O
autoimmunity	O
[	O
19	O
]	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
our	O
data	O
confirm	O
previous	O
pathogenetic	O
implications	O
reported	O
in	O
literature	O
of	O
these	O
SNPs	O
with	O
CD	O
as	O
well	O
as	O
with	O
other	O
autoimmune	O
diseases	O
[	O
20	O
]	O
.	O

By	O
the	O
Bayesian	O
approach	O
we	O
calculated	O
a	O
ranking	O
score	O
(	O
BS	O
)	O
among	O
the	O
sibs	O
.	O

However	O
,	O
it	O
should	O
be	O
considered	O
that	O
BS	O
is	O
not	O
a	O
plain	O
disease	O
risk	O
,	O
rather	O
a	O
method	O
to	O
rank	O
different	O
genotypes	O
according	O
to	O
their	O
contribution	O
to	O
make	O
an	O
individual	O
susceptible	O
to	O
CD	O
.	O

For	O
instance	O
,	O
some	O
of	O
our	O
BS	O
are	O
very	O
near	O
to	O
1	O
,	O
nevertheless	O
none	O
of	O
the	O
considered	O
genotypes	O
could	O
give	O
a	O
100	O
%	O
risk	O
to	O
develop	O
the	O
disease	O
.	O

In	O
other	O
terms	O
,	O
we	O
considered	O
the	O
BS	O
as	O
a	O
ranking	O
measure	O
,	O
only	O
stating	O
that	O
a	O
given	O
genotype	O
could	O
assign	O
a	O
higher	O
risk	O
than	O
another	O
genotype	O
but	O
does	O
not	O
allow	O
a	O
quantitative	O
measure	O
of	O
the	O
risk	O
difference	O
(	O
2	O
-	O
fold	O
,	O
3	O
-	O
fold	O
,	O
etc	O
)	O
.	O

However	O
,	O
even	O
if	O
the	O
addition	O
of	O
only	O
3	O
SNPs	O
to	O
HLA	O
could	O
be	O
considered	O
at	O
""""	O
minor	O
effect	O
""""	O
[	O
13	O
]	O
,	O
we	O
demonstrated	O
that	O
they	O
could	O
significantly	O
improve	O
the	O
prediction	O
of	O
CD	O
risk	O
in	O
sibs	O
,	O
in	O
terms	O
of	O
diagnostic	O
sensitivity	O
and	O
negative	O
predictive	O
value	O
.	O

So	O
,	O
in	O
a	O
cohort	O
of	O
CD	O
families	O
,	O
our	O
data	O
confirm	O
that	O
non	O
-	O
HLA	O
SNPs	O
evaluation	O
is	O
an	O
usefull	O
diagnostic	O
tool	O
in	O
CD	O
risk	O
evaluation	O
as	O
a	O
previous	O
study	O
showed	O
in	O
CD	O
unrelated	O
subjects	O
[	O
14	O
]	O
.	O

CD	O
,	O
on	O
the	O
basis	O
of	O
the	O
actual	O
knowledge	O
,	O
can	O
not	O
be	O
exactly	O
predicted	O
by	O
genetic	O
testing	O
,	O
but	O
a	O
reliable	O
probabilistic	O
method	O
might	O
be	O
associated	O
to	O
careful	O
surveillance	O
of	O
infants	O
carrying	O
the	O
higher	O
risk	O
.	O

This	O
will	O
help	O
to	O
significantly	O
reduce	O
the	O
heavy	O
load	O
of	O
anxiety	O
and	O
pain	O
associated	O
with	O
the	O
appearance	O
of	O
symptoms	O
of	O
CD	O
,	O
by	O
anticipating	O
,	O
with	O
simple	O
serological	O
tests	O
,	O
the	O
clinical	O
appearance	O
of	O
the	O
disease	O
.	O

To	O
improve	O
the	O
possibility	O
to	O
identify	O
high	O
risk	O
patients	O
in	O
CD	O
families	O
we	O
propose	O
in	O
alternative	O
to	O
the	O
classical	O
HLA	O
classification	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
A	O
)	O
a	O
slight	O
improved	O
flow	O
-	O
chart	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
:	O
1	O
)	O
HLA	O
genotyping	O
:	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
1	O
and	O
2	O
will	O
be	O
classified	O
as	O
at	O
high	O
CD	O
risk	O
;	O
2	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
groups	O
3	O
and	O
4	O
,	O
will	O
be	O
further	O
investigated	O
for	O
our	O
SNPs	O
combination	O
(	O
LPP	O
,	O
REL	O
,	O
RGS1	O
)	O
in	O
order	O
to	O
calculate	O
their	O
BS	O
(	O
Fig	O
.	O
4	O
,	O
panel	O
B	O
)	O
.	O

Among	O
these	O
latter	O
subjects	O
those	O
with	O
a	O
BS	O
>	O
=	O
the	O
median	O
value	O
will	O
be	O
classified	O
at	O
high	O
risk	O
;	O
3	O
)	O
subjects	O
belonging	O
to	O
the	O
HLA	O
risk	O
group	O
5	O
will	O
be	O
considered	O
at	O
low	O
CD	O
risk	O
.	O

All	O
CD	O
familials	O
belonging	O
to	O
the	O
above	O
high	O
risk	O
groups	O
(	O
HLA	O
group	O
1	O
-	O
2	O
and	O
HLA	O
group	O
3	O
-	O
4	O
with	O
BS	O
>	O
=	O
median	O
)	O
will	O
be	O
undergo	O
a	O
strict	O
surveillance	O
.	O

10	O
.	O
1371	O
/	O
journal	O
.	O
pone	O
.	O
0026920	O
.	O
g004	O
Figure	O
4	O

Classification	O
flow	O
-	O
chart	O
.	O

In	O
panel	O
A	O
the	O
classical	O
HLA	O
-	O
based	O
classification	O
.	O

In	O
panel	O
B	O
the	O
proposed	O
BS	O
-	O
based	O
classification	O
considering	O
the	O
genotypes	O
of	O
HLA	O
plus	O
LPP	O
,	O
RGS1	O
and	O
REL	O
SNPs	O
.	O

One	O
of	O
the	O
limitation	O
of	O
our	O
cohort	O
family	O
study	O
could	O
be	O
the	O
sample	O
size	O
,	O
which	O
may	O
have	O
not	O
allowed	O
to	O
explore	O
genes	O
at	O
smaller	O
effect	O
,	O
so	O
explaining	O
the	O
lack	O
of	O
association	O
between	O
SNPs	O
in	O
TAGAP	O
,	O
IL2	O
/	O
IL21	O
,	O
OLIG3	O
,	O
CCR	O
,	O
SH2B3	O
,	O
IL12A	O
and	O
IL12A	O
/	O
SCHIP1	O
genes	O
with	O
CD	O
although	O
the	O
trend	O
observed	O
in	O
previous	O
studies	O
in	O
unrelated	O
CD	O
patients	O
was	O
confirmed	O
[	O
13	O
]	O
.	O

In	O
the	O
main	O
time	O
the	O
homogeneity	O
of	O
the	O
genetic	O
and	O
environmental	O
domains	O
in	O
the	O
tested	O
families	O
allows	O
to	O
explore	O
risk	O
factors	O
within	O
a	O
controlled	O
cohort	O
.	O

A	O
second	O
limit	O
of	O
the	O
study	O
is	O
the	O
relatively	O
short	O
(	O
6	O
years	O
)	O
follow	O
up	O
of	O
the	O
sibship	O
,	O
which	O
could	O
cause	O
an	O
underestimation	O
of	O
the	O
disease	O
development	O
at	O
later	O
ages	O
.	O

Our	O
aim	O
is	O
to	O
go	O
on	O
with	O
the	O
monitoring	O
of	O
these	O
families	O
in	O
the	O
next	O
years	O
.	O

In	O
conclusion	O
,	O
the	O
estimate	O
of	O
the	O
CD	O
risk	O
by	O
HLA	O
+	O
SNPs	O
approach	O
,	O
even	O
if	O
not	O
applicable	O
to	O
prevention	O
,	O
could	O
be	O
a	O
precious	O
tool	O
improving	O
CD	O
diagnosis	O
respect	O
to	O
the	O
only	O
HLA	O
(	O
NPV	O
:	O
95	O
%	O
vs	O
91	O
%	O
,	O
and	O
DS	O
:	O
79	O
%	O
vs	O
45	O
%	O
)	O
,	O
in	O
the	O
cohort	O
of	O
first	O
degree	O
relatives	O
.	O

In	O
fact	O
in	O
clinical	O
practice	O
the	O
absence	O
of	O
HLA	O
risk	O
groups	O
1	O
or	O
2	O
,	O
allows	O
to	O
exclude	O
the	O
disease	O
with	O
high	O
probability	O
,	O
while	O
testing	O
the	O
three	O
SNPs	O
in	O
HLA	O
groups	O
3	O
or	O
4	O
could	O
represent	O
a	O
further	O
tool	O
to	O
identify	O
less	O
frequent	O
CD	O
cases	O
.	O

So	O
,	O
an	O
infant	O
with	O
high	O
HLA	O
+	O
SNPs	O
score	O
even	O
if	O
belonging	O
to	O
HLA	O
low	O
risk	O
groups	O
,	O
shall	O
undergo	O
a	O
simple	O
surveillance	O
system	O
to	O
allow	O
proper	O
diagnosis	O
and	O
treatment	O
before	O
the	O
full	O
blow	O
disease	O
appears	O
.	O

Refinement	O

R	O
[	O
F	O
2	O
>	O
2sigma	O
(	O
F	O
2	O
)	O
]	O
=	O
0	O
.	O
052	O

wR	O
(	O
F	O
2	O
)	O
=	O
0	O
.	O
132	O

S	O
=	O
1	O
.	O
02	O

3804	O
reflections	O

229	O
parameters	O

67	O
restraints	O

H	O
-	O
atom	O
parameters	O
constrained	O

Deltarhomax	O
=	O
0	O
.	O
56	O
e	O
A	O
-	O
3	O

Deltarhomin	O
=	O
-	O
0	O
.	O
38	O
e	O
A	O
-	O
3	O

Objectives	O

Evaluate	O
relationships	O
between	O
MRI	O
and	O
clinical	O
/	O
laboratory	O
/	O
radiographic	O
findings	O
in	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
.	O

Authors	O
'	O
contributions	O

EEKN	O
was	O
responsible	O
for	O
data	O
collection	O
,	O
statistical	O
analysis	O
and	O
drafting	O
the	O
manuscript	O
.	O

SAGN	O
and	O
YW	O
involved	O
in	O
data	O
collection	O
and	O
helped	O
with	O
the	O
data	O
analysis	O
.	O

AS	O
helped	O
in	O
data	O
analysis	O
.	O

EST	O
and	O
JL	O
directed	O
the	O
study	O
and	O
helped	O
in	O
revising	O
the	O
manuscript	O
.	O

RMVD	O
helped	O
in	O
data	O
analysis	O
,	O
interpretation	O
of	O
the	O
results	O
and	O
led	O
writing	O
of	O
the	O
manuscript	O
.	O

All	O
authors	O
read	O
and	O
approved	O
the	O
final	O
manuscript	O
.	O

Outcomes	O

The	O
primary	O
outcomes	O
of	O
this	O
study	O
are	O
smoking	O
abstinence	O
rates	O
post	O
release	O
as	O
well	O
as	O
number	O
of	O
days	O
to	O
first	O
cigarette	O
after	O
release	O
.	O

Seven	O
day	O
point	O
-	O
prevalence	O
abstinence	O
will	O
be	O
determined	O
by	O
combining	O
self	O
-	O
reported	O
tobacco	O
use	O
over	O
the	O
prior	O
seven	O
days	O
and	O
urine	O
cotinine	O
assays	O
(	O
below	O
200	O
ng	O
/	O
ml	O
versus	O
200	O
or	O
above	O
)	O
.	O

Participants	O
with	O
self	O
-	O
reported	O
abstinence	O
and	O
cotinine	O
levels	O
below	O
the	O
cut	O
-	O
off	O
will	O
be	O
classified	O
as	O
abstinent	O
.	O

Participants	O
lost	O
to	O
follow	O
-	O
up	O
will	O
be	O
considered	O
non	O
-	O
abstinent	O
.	O

A	O
secondary	O
analysis	O
will	O
examine	O
the	O
effect	O
of	O
length	O
of	O
forced	O
abstinence	O
on	O
quit	O
rates	O
.	O

Abbreviations	O

ARDS	O
:	O
acute	O
respiratory	O
distress	O
syndrome	O
;	O
CMV	O
:	O
conventional	O
mechanical	O
ventilation	O
;	O
HFOV	O
:	O
high	O
-	O
frequency	O
oscillation	O
ventilation	O
;	O
LPS	O
:	O
lipopolysaccharide	O
;	O
PEEP	O
:	O
positive	O
end	O
-	O
expiratory	O
pressure	O
;	O
VILI	O
:	O
ventilator	O
-	O
induced	O
lung	O
injury	O
.	O

TxA2	O
,	O
generated	O
from	O
arachidonic	O
acid	O
by	O
cyclooxygenase	O
1	O
(	O
COX	O
-	O
1	O
)	O
and	O
Tx	O
synthase	O
,	O
further	O
amplifies	O
platelet	O
activation	O
.	O

COX	O
-	O
1	O
converts	O
arachidonic	O
acid	O
into	O
prostaglandin	O
endoperoxides	O
PGG2	O
and	O
PGH2	O
,	O
the	O
latter	O
being	O
,	O
in	O
turn	O
,	O
transformed	O
by	O
Tx	O
synthase	O
into	O
TxA2	O
,	O
a	O
potent	O
amplifier	O
of	O
platelet	O
aggregation	O
with	O
vasoconstrictive	O
properties	O
.	O

At	O
the	O
site	O
of	O
the	O
atheroma	O
rupture	O
,	O
platelet	O
-	O
released	O
TxA2	O
leads	O
to	O
downstream	O
micro	O
-	O
vessel	O
contraction	O
and	O
thrombus	O
propagation	O
(	O
7	O
)	O
.	O

In	O
addition	O
to	O
its	O
role	O
in	O
coagulation	O
,	O
thrombin	O
at	O
extremely	O
low	O
concentrations	O
is	O
one	O
of	O
the	O
major	O
platelet	O
activators	O
(	O
8	O
)	O
.	O

Human	O
platelets	O
express	O
two	O
cell	O
surface	O
G	O
-	O
protein	O
-	O
coupled	O
protease	O
-	O
activated	O
receptors	O
(	O
PARs	O
)	O
for	O
thrombin	O
:	O
PAR	O
-	O
1	O
and	O
PAR	O
-	O
4	O
.	O

By	O
binding	O
the	O
hirudin	O
-	O
like	O
extracellular	O
amino	O
terminal	O
domain	O
(	O
the	O
so	O
-	O
called	O
thrombin	O
receptor	O
)	O
,	O
thrombin	O
activates	O
platelets	O
and	O
smooth	O
muscle	O
cells	O
,	O
thus	O
promoting	O
platelet	O
pro	O
-	O
coagulant	O
activity	O
,	O
shape	O
change	O
,	O
secretion	O
and	O
release	O
of	O
agonists	O
(	O
ADP	O
and	O
TxA2	O
)	O
,	O
expression	O
of	O
P	O
-	O
selectin	O
,	O
activation	O
of	O
the	O
alphaIIbbeta3	O
integrin	O
receptor	O
,	O
and	O
aggregation	O
.	O

Thrombin	O
also	O
binds	O
to	O
GpIbalpha	O
on	O
the	O
surface	O
of	O
platelets	O
,	O
thought	O
to	O
act	O
as	O
a	O
co	O
-	O
factor	O
that	O
localizes	O
the	O
enzyme	O
on	O
the	O
platelet	O
surface	O
and	O
accelerates	O
the	O
hydrolysis	O
of	O
PAR	O
-	O
1	O
(	O
9	O
)	O
.	O

PAR	O
-	O
1	O
and	O
P2Y12	O
cross	O
-	O
react	O
in	O
platelet	O
activation	O
,	O
and	O
Galphaq	O
and	O
Galphai	O
-	O
coupled	O
receptors	O
are	O
involved	O
in	O
this	O
process	O
.	O

Thrombin	O
-	O
dependent	O
platelet	O
aggregation	O
is	O
mediated	O
in	O
part	O
by	O
secreted	O
ADP	O
,	O
acting	O
on	O
the	O
Galphai	O
-	O
linked	O
ADP	O
receptor	O
.	O

By	O
blocking	O
Galphaq	O
via	O
PAR	O
-	O
1	O
and	O
Gbetai	O
via	O
P2Y12	O
,	O
combined	O
inhibition	O
of	O
thrombin	O
and	O
P2Y12	O
receptors	O
leads	O
to	O
a	O
synergistic	O
inhibitory	O
effect	O
on	O
thrombin	O
-	O
induced	O
platelet	O
aggregation	O
(	O
10	O
)	O
.	O

5	O
-	O
HT	O
is	O
a	O
vasoconstrictor	O
agent	O
that	O
binds	O
to	O
5HT	O
-	O
2A	O
receptors	O
and	O
amplifies	O
the	O
platelet	O
response	O
by	O
stimulating	O
shape	O
change	O
and	O
enhancing	O
platelet	O
recruitment	O
at	O
sites	O
of	O
injury	O
(	O
3	O
)	O
.	O

It	O
may	O
also	O
play	O
a	O
pro	O
-	O
coagulant	O
role	O
by	O
promoting	O
the	O
retention	O
of	O
fibrinogen	O
and	O
thrombospondin	O
on	O
the	O
platelet	O
surface	O
.	O

Intraplatelet	O
5	O
-	O
HT	O
stores	O
are	O
implicated	O
in	O
shear	O
-	O
induced	O
platelet	O
aggregation	O
and	O
thrombus	O
propagation	O
(	O
3	O
)	O
.	O

Assessment	O
instruments	O

The	O
SCID	O
-	O
I	O
/	O
P	O
was	O
administered	O
by	O
psychiatrists	O
trained	O
and	O
certified	O
in	O
the	O
use	O
of	O
all	O
instruments	O
in	O
this	O
study	O
.	O

The	O
ICG	O
is	O
a	O
self	O
-	O
report	O
instrument	O
that	O
can	O
be	O
used	O
to	O
identify	O
CG	O
when	O
the	O
total	O
score	O
is	O
>	O
25	O
,	O
that	O
demonstrated	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
94	O
)	O
,	O
and	O
convergent	O
and	O
criterion	O
validity	O
[	O
27	O
]	O
.	O

The	O
ICG	O
total	O
score	O
also	O
showed	O
a	O
fairly	O
high	O
association	O
with	O
the	O
Beck	O
Depression	O
Inventory	O
(	O
BDI	O
)	O
[	O
32	O
]	O
total	O
score	O
(	O
r	O
=	O
0	O
.	O
67	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
the	O
Texas	O
Revised	O
Inventory	O
of	O
Grief	O
(	O
TRIG	O
)	O
[	O
33	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
87	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
Grief	O
Measurement	O
Scale	O
(	O
GMS	O
)	O
[	O
34	O
]	O
score	O
(	O
r	O
=	O
0	O
.	O
70	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
ASA	O
-	O
27	O
is	O
a	O
self	O
-	O
report	O
measure	O
developed	O
to	O
rate	O
separation	O
anxiety	O
symptoms	O
in	O
adult	O
life	O
(	O
from	O
18	O
years	O
of	O
age	O
)	O
.	O

Principal	O
components	O
analysis	O
revealed	O
a	O
coherent	O
construct	O
of	O
adult	O
separation	O
anxiety	O
with	O
high	O
internal	O
consistency	O
(	O
Cronbach	O
'	O
s	O
alpha	O
=	O
0	O
.	O
95	O
)	O
and	O
sound	O
test	O
-	O
retest	O
reliability	O
(	O
r	O
=	O
0	O
.	O
86	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Further	O
,	O
a	O
receiver	O
operation	O
characteristic	O
(	O
ROC	O
)	O
analysis	O
against	O
the	O
semistructured	O
interview	O
yielded	O
a	O
high	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
index	O
of	O
0	O
.	O
9	O
,	O
suggesting	O
that	O
the	O
questionnaire	O
is	O
an	O
adequate	O
alternative	O
measure	O
of	O
adult	O
separation	O
anxiety	O
[	O
29	O
]	O
.	O

The	O
WSAS	O
is	O
a	O
self	O
-	O
report	O
scale	O
of	O
functional	O
impairment	O
that	O
includes	O
five	O
questions	O
rating	O
interference	O
of	O
psychiatric	O
symptoms	O
in	O
work	O
,	O
home	O
management	O
,	O
social	O
or	O
private	O
leisure	O
activities	O
,	O
and	O
ability	O
to	O
form	O
and	O
maintain	O
close	O
relationships	O
with	O
others	O
.	O

Each	O
question	O
is	O
rated	O
on	O
a	O
0	O
to	O
8	O
scale	O
with	O
0	O
indicating	O
no	O
impairment	O
at	O
all	O
and	O
8	O
indicating	O
very	O
severe	O
impairment	O
.	O

The	O
Cronbach	O
'	O
s	O
alpha	O
measure	O
of	O
internal	O
scale	O
consistency	O
ranged	O
from	O
0	O
.	O
70	O
to	O
0	O
.	O
94	O
,	O
the	O
test	O
-	O
retest	O
correlation	O
was	O
0	O
.	O
73	O
,	O
and	O
the	O
WSAS	O
interactive	O
voice	O
response	O
administrations	O
gave	O
correlations	O
of	O
0	O
.	O
81	O
and	O
0	O
.	O
86	O
with	O
clinician	O
interviews	O
[	O
30	O
]	O
.	O

Correlations	O
of	O
WSAS	O
with	O
severity	O
of	O
depression	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
symptoms	O
were	O
0	O
.	O
76	O
and	O
0	O
.	O
61	O
,	O
respectively	O
,	O
and	O
the	O
scores	O
were	O
sensitive	O
to	O
patient	O
differences	O
in	O
disorder	O
severity	O
and	O
treatment	O
-	O
related	O
change	O
[	O
30	O
]	O
.	O

The	O
MOODS	O
-	O
SR	O
is	O
an	O
instrument	O
developed	O
and	O
validated	O
to	O
assess	O
lifetime	O
mood	O
spectrum	O
symptoms	O
[	O
35	O
]	O
,	O
including	O
manic	O
and	O
depressive	O
features	O
,	O
rhythmicity	O
and	O
vegetative	O
functions	O
.	O

The	O
manic	O
and	O
depressive	O
components	O
are	O
subtyped	O
into	O
mood	O
,	O
energy	O
and	O
cognition	O
domains	O
,	O
focusing	O
on	O
manic	O
or	O
depressive	O
symptoms	O
,	O
respectively	O
.	O

The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
include	O
changes	O
in	O
energy	O
,	O
physical	O
wellbeing	O
,	O
mental	O
and	O
physical	O
efficiency	O
,	O
related	O
to	O
the	O
weather	O
and	O
season	O
,	O
and	O
changes	O
in	O
appetite	O
,	O
sleep	O
and	O
sexual	O
activities	O
.	O

The	O
sum	O
of	O
the	O
scores	O
on	O
the	O
3	O
manic	O
domains	O
(	O
mood	O
,	O
energy	O
,	O
cognition	O
)	O
constitutes	O
the	O
'	O
manic	O
component	O
'	O
(	O
62	O
items	O
)	O
and	O
that	O
of	O
the	O
3	O
depressive	O
domains	O
the	O
'	O
depressive	O
component	O
'	O
(	O
63	O
items	O
)	O
.	O

The	O
rhythmicity	O
and	O
vegetative	O
functions	O
domain	O
includes	O
29	O
items	O
.	O

The	O
instrument	O
can	O
be	O
downloaded	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
spectrum	O
-	O
project	O
.	O
org	O
.	O

Figures	O

Fig	O
.	O

1	O
.	O

A	O
view	O
of	O
(	O
I	O
)	O
with	O
displacement	O
ellipsoids	O
drawn	O
at	O
the	O
30	O
%	O
probability	O
level	O
.	O

Fig	O
.	O

2	O
.	O

Stereoview	O
of	O
the	O
sheet	O
formed	O
by	O
C	O
-	O
-	O
H	O
.	O
.	O
.	O
pi	O
interactions	O
.	O

Hydrogen	O
atoms	O
not	O
involved	O
in	O
the	O
motifs	O
are	O
not	O
included	O
.	O

Background	O

Eucalyptus	O
globulus	O
is	O
the	O
most	O
widely	O
planted	O
species	O
for	O
pulpwood	O
production	O
in	O
temperate	O
regions	O
of	O
the	O
world	O
and	O
there	O
are	O
breeding	O
programs	O
in	O
numerous	O
countries	O
.	O

There	O
is	O
interest	O
in	O
molecular	O
approaches	O
to	O
breeding	O
,	O
particularly	O
marker	O
assisted	O
selection	O
of	O
wood	O
properties	O
.	O

QTL	O
analysis	O
has	O
an	O
important	O
role	O
in	O
identifying	O
positional	O
candidate	O
genes	O
responsible	O
for	O
variation	O
in	O
wood	O
properties	O
.	O

This	O
is	O
one	O
approach	O
to	O
targeting	O
genes	O
which	O
may	O
harbour	O
functional	O
allelic	O
variants	O
(	O
SNPs	O
)	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
detect	O
and	O
validate	O
QTL	O
across	O
multiple	O
sites	O
and	O
pedigrees	O
,	O
in	O
order	O
to	O
identify	O
genomic	O
regions	O
and	O
genes	O
affecting	O
growth	O
and	O
wood	O
properties	O
with	O
wide	O
applicability	O
in	O
the	O
species	O
.	O

We	O
also	O
aimed	O
to	O
determine	O
the	O
proportion	O
of	O
QTL	O
which	O
were	O
stable	O
in	O
their	O
expression	O
across	O
sites	O
of	O
contrasting	O
productivity	O
.	O

Such	O
information	O
will	O
be	O
important	O
to	O
exploit	O
the	O
full	O
potential	O
of	O
the	O
impending	O
Eucalyptus	O
genome	O
sequences	O
.	O

Methods	O

We	O
studied	O
3	O
,	O
574	O
Canadian	O
children	O
,	O
aged	O
7	O
-	O
8	O
yr	O
,	O
enrolled	O
in	O
a	O
population	O
-	O
based	O
birth	O
cohort	O
.	O

Standardized	O
questionnaires	O
were	O
completed	O
by	O
the	O
children	O
'	O
s	O
parents	O
,	O
and	O
data	O
were	O
analyzed	O
by	O
multivariate	O
logistic	O
regression	O
.	O

The	O
growth	O
in	O
the	O
number	O
of	O
database	O
publications	O
per	O
year	O
.	O

Each	O
bar	O
shows	O
the	O
number	O
of	O
research	O
articles	O
with	O
the	O
keyword	O
'	O
database	O
'	O
appearing	O
in	O
the	O
article	O
title	O
in	O
the	O
given	O
year	O
.	O

The	O
count	O
only	O
covers	O
articles	O
indexed	O
in	O
PubMed	O
.	O

The	O
increase	O
shows	O
an	O
exponential	O
trend	O
that	O
will	O
produce	O
nearly	O
2000	O
database	O
publications	O
per	O
year	O
by	O
2015	O
.	O

(	O
iii	O
)	O
HIV	O
testing	O
response	O
rate	O
by	O
educational	O
attainment	O
and	O
gender	O
.	O

Cation	O
binding	O
to	O
yolk	O
platelet	O
phosvitin	O

In	O
addition	O
to	O
non	O
-	O
heme	O
iron	O
[	O
23	O
]	O
,	O
yolk	O
phosvitin	O
also	O
contains	O
Ca2	O
+	O
,	O
Mg2	O
+	O
,	O
Na	O
+	O
and	O
K	O
+	O
[	O
11	O
]	O
.	O

Partially	O
relaxed	O
23Na	O
Fourier	O
transform	O
NMR	O
spectra	O
revealed	O
the	O
existence	O
of	O
at	O
least	O
two	O
major	O
intracellular	O
compartments	O
of	O
NMR	O
-	O
visible	O
Na	O
+	O
[	O
35	O
]	O
.	O

A	O
large	O
fraction	O
of	O
the	O
Rana	O
oocyte	O
Na	O
+	O
was	O
NMR	O
-	O
invisible	O
and	O
could	O
be	O
recovered	O
in	O
the	O
yolk	O
platelets	O
[	O
35	O
]	O
.	O

During	O
the	O
first	O
meiotic	O
division	O
there	O
is	O
a	O
net	O
increase	O
in	O
NMR	O
-	O
visible	O
Na	O
+	O
;	O
by	O
completion	O
of	O
the	O
second	O
meiotic	O
division	O
(	O
following	O
fertilization	O
)	O
,	O
about	O
70	O
%	O
of	O
the	O
total	O
Na	O
+	O
becomes	O
NMR	O
-	O
visible	O
.	O

Thus	O
,	O
phosvitin	O
not	O
only	O
serves	O
as	O
a	O
site	O
for	O
energy	O
storage	O
,	O
but	O
also	O
as	O
a	O
storage	O
site	O
for	O
iron	O
and	O
other	O
ions	O
essential	O
for	O
embryonic	O
development	O
in	O
ponds	O
and	O
streams	O
that	O
contain	O
little	O
dissolved	O
salts	O
and	O
minerals	O
.	O

Predicted	O
methylation	O
level	O
of	O
C	O
.	O
gigas	O
genes	O
categorized	O
by	O
biological	O
processes	O
compared	O
to	O
measured	O
level	O
of	O
DNA	O
methylation	O
.	O

Mean	O
CpG	O
O	O
/	O
E	O
for	O
10	O
,	O
699	O
C	O
.	O
gigas	O
genes	O
categorized	O
according	O
to	O
Biological	O
Process	O
Gene	O
Ontology	O
(	O
GO	O
)	O
Slim	O
terms	O
are	O
plotted	O
on	O
the	O
x	O
-	O
axis	O
(	O
modified	O
from	O
Gavery	O
and	O
Roberts	O
,	O
2010	O
)	O
.	O

DNA	O
methylation	O
was	O
empirically	O
measured	O
by	O
performing	O
MBD	O
-	O
seq	O
on	O
the	O
SOLiD	O
4	O
platform	O
(	O
Applied	O
Biosystems	O
)	O
.	O

Genes	O
identified	O
in	O
the	O
MBD	O
-	O
library	O
were	O
associated	O
with	O
respective	O
GO	O
terms	O
and	O
enrichment	O
analysis	O
was	O
performed	O
based	O
on	O
the	O
entire	O
transcriptome	O
(	O
Fleury	O
et	O
al	O
.	O
,	O
2009	O
)	O
using	O
DAVID	O
(	O
Huang	O
et	O
al	O
.	O
,	O
2009a	O
,	O
b	O
)	O
.	O

Results	O
indicate	O
the	O
most	O
underrepresented	O
genes	O
in	O
the	O
library	O
are	O
involved	O
in	O
cell	O
adhesion	O
and	O
genes	O
involved	O
in	O
DNA	O
and	O
protein	O
metabolism	O
were	O
most	O
prevalent	O
in	O
the	O
MBD	O
-	O
library	O
.	O

Methods	O

Thirteen	O
focus	O
group	O
discussions	O
with	O
first	O
-	O
time	O
parents	O
and	O
female	O
and	O
male	O
informal	O
supporters	O
were	O
analysed	O
by	O
discourse	O
analysis	O
.	O

Mitochondria	O
in	O
Cardiac	O
Myocyte	O
Apoptosis	O

It	O
has	O
been	O
suggested	O
that	O
activation	O
of	O
the	O
mitochondrial	O
apoptotic	O
pathway	O
leading	O
to	O
executioner	O
casp	O
activation	O
is	O
relevant	O
in	O
heart	O
injury	O
.	O
1	O
The	O
notion	O
of	O
participation	O
of	O
casp	O
activation	O
in	O
adult	O
cardiac	O
myocyte	O
apoptosis	O
emerged	O
from	O
studies	O
using	O
immunofluorescence	O
microscopy16	O
and	O
casp	O
inhibitors	O
.	O
37	O
Bahi	O
et	O
al	O
.	O
38	O
demonstrated	O
that	O
cardiomyocyte	O
levels	O
of	O
all	O
casps	O
decrease	O
with	O
age	O
,	O
and	O
they	O
are	O
very	O
low	O
in	O
adult	O
cardiac	O
cells	O
.	O

Recently	O
,	O
Bae	O
et	O
al	O
.	O
39	O
reported	O
that	O
apoptosis	O
can	O
be	O
induced	O
in	O
the	O
heart	O
lacking	O
casp	O
activation	O
via	O
casp	O
-	O
independent	O
pathways	O
,	O
probably	O
through	O
apoptosis	O
-	O
inducing	O
factor	O
(	O
AIF	O
)	O
.	O

Both	O
the	O
intrinsic	O
and	O
extrinsic	O
pathways	O
can	O
be	O
inhibited	O
by	O
the	O
cytoprotective	O
protein	O
apoptosis	O
repressor	O
with	O
caspase	O
recruitment	O
domain	O
(	O
ARC	O
)	O
.	O

ARC	O
inhibits	O
the	O
extrinsic	O
pathway	O
by	O
interacting	O
with	O
casp	O
8	O
and	O
components	O
of	O
the	O
death	O
-	O
inducing	O
signaling	O
complex	O
,	O
such	O
as	O
FADD	O
,	O
whereas	O
inhibition	O
of	O
the	O
intrinsic	O
pathway	O
is	O
mediated	O
by	O
blocking	O
BAX	O
activation	O
and	O
mitochondria	O
translocation	O
.	O
40	O

AIF	O
is	O
anchored	O
by	O
its	O
N	O
terminus	O
to	O
the	O
mitochondrial	O
inner	O
membrane	O
,	O
with	O
its	O
C	O
terminus	O
oriented	O
toward	O
the	O
intermembrane	O
space	O
.	O

AIF	O
is	O
required	O
for	O
oxidative	O
phosphorylation	O
and	O
for	O
the	O
assembly	O
and	O
/	O
or	O
stabilization	O
of	O
respiratory	O
complex	O
I	O
.	O
41	O
Upon	O
induction	O
of	O
apoptosis	O
,	O
AIF	O
is	O
cleaved	O
and	O
released	O
into	O
the	O
cytosol	O
,	O
where	O
it	O
translocates	O
to	O
the	O
nucleus	O
and	O
mediates	O
chromatin	O
condensation	O
and	O
large	O
-	O
scale	O
DNA	O
fragmentation	O
.	O
41	O
However	O
,	O
this	O
well	O
-	O
known	O
pro	O
-	O
apoptotic	O
action	O
of	O
AIF	O
is	O
in	O
conflict	O
with	O
the	O
observation	O
that	O
AIF	O
is	O
essential	O
for	O
the	O
maintenance	O
of	O
normal	O
heart	O
function	O
and	O
its	O
inactivation	O
results	O
in	O
dilated	O
C	O
.	O
42	O
Moreover	O
,	O
cardiac	O
myocytes	O
isolated	O
from	O
a	O
mouse	O
model	O
with	O
80	O
%	O
reduction	O
in	O
AIF	O
levels	O
manifested	O
increased	O
cell	O
death	O
induced	O
by	O
oxidative	O
stress	O
,	O
and	O
the	O
hearts	O
of	O
these	O
mice	O
displayed	O
enhanced	O
ischemic	O
damage	O
after	O
in	O
vivo	O
I	O
/	O
R	O
.	O
43	O
Although	O
it	O
has	O
been	O
described	O
that	O
AIF	O
is	O
released	O
from	O
cardiac	O
myocyte	O
mitochondria	O
during	O
I	O
/	O
R	O
,	O
its	O
contribution	O
to	O
I	O
/	O
R	O
-	O
induced	O
apoptosis	O
was	O
discounted	O
.	O
38	O
However	O
,	O
AIF	O
has	O
been	O
implicated	O
in	O
cardiac	O
myocyte	O
death	O
induced	O
by	O
oxidative	O
stress	O
and	O
HF	O
.	O
44	O

Endonuclease	O
G	O
(	O
Endo	O
G	O
)	O
is	O
a	O
nuclear	O
-	O
encoded	O
endonuclease	O
localized	O
to	O
the	O
intermembrane	O
space	O
of	O
mitochondria	O
.	O

In	O
cardiac	O
myocyte	O
apoptosis	O
,	O
Endo	O
G	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
cleaves	O
DNA	O
.	O

In	O
heart	O
and	O
cultured	O
cardiac	O
myocytes	O
,	O
Endo	O
G	O
has	O
a	O
role	O
in	O
I	O
/	O
R	O
-	O
mediated	O
cell	O
death	O
.	O
38	O
Activation	O
of	O
the	O
intrinsic	O
pathway	O
by	O
the	O
extrinsic	O
apoptotic	O
pathway	O
can	O
take	O
place	O
through	O
casp	O
-	O
8	O
-	O
dependent	O
cleavage	O
of	O
BCL2	O
-	O
interacting	O
protein	O
(	O
BID	O
)	O
to	O
truncated	O
BID	O
(	O
t	O
-	O
BID	O
)	O
.	O

The	O
C	O
-	O
terminal	O
fragment	O
of	O
t	O
-	O
BID	O
subsequently	O
translocates	O
to	O
the	O
mitochondrial	O
outer	O
membrane	O
,	O
where	O
it	O
presumably	O
activates	O
the	O
intrinsic	O
pathway	O
.	O

This	O
pathway	O
is	O
operative	O
in	O
the	O
heart	O
.	O
1	O

Discussion	O

We	O
estimated	O
the	O
future	O
acceptability	O
of	O
PrEP	O
,	O
examining	O
the	O
attitudes	O
and	O
preferences	O
of	O
potential	O
user	O
groups	O
from	O
different	O
countries	O
towards	O
hypothetical	O
and	O
known	O
PrEP	O
attributes	O
.	O

Our	O
results	O
show	O
that	O
participants	O
were	O
generally	O
willing	O
to	O
accept	O
PrEP	O
and	O
adopt	O
it	O
as	O
soon	O
as	O
it	O
becomes	O
available	O
.	O

Surprisingly	O
,	O
participants	O
were	O
also	O
willing	O
to	O
take	O
PrEP	O
even	O
when	O
reminded	O
of	O
potential	O
side	O
effects	O
,	O
cost	O
,	O
condom	O
use	O
,	O
and	O
frequent	O
HIV	O
testing	O
.	O

These	O
findings	O
indicate	O
participants	O
'	O
motivation	O
to	O
overcome	O
barriers	O
which	O
can	O
have	O
a	O
considerable	O
impact	O
on	O
uptake	O
.	O

In	O
contrast	O
,	O
participants	O
mentioned	O
that	O
the	O
thought	O
of	O
taking	O
PrEP	O
made	O
them	O
feel	O
anxious	O
,	O
although	O
they	O
also	O
indicated	O
that	O
taking	O
PrEP	O
would	O
not	O
be	O
embarrassing	O
and	O
they	O
would	O
want	O
their	O
partner	O
or	O
partners	O
to	O
know	O
.	O

Participants	O
'	O
anxiety	O
may	O
be	O
explained	O
by	O
the	O
hypothetical	O
nature	O
of	O
most	O
of	O
the	O
presented	O
PrEP	O
characteristics	O
,	O
the	O
stigma	O
associated	O
with	O
HIV	O
[	O
34	O
]	O
,	O
and	O
in	O
some	O
settings	O
,	O
the	O
criminalization	O
of	O
sex	O
work	O
,	O
injected	O
drug	O
use	O
and	O
homosexuality	O
[	O
35	O
]	O
.	O

Most	O
participants	O
,	O
nonetheless	O
,	O
subsequently	O
indicated	O
that	O
PrEP	O
would	O
give	O
them	O
hope	O
,	O
which	O
suggests	O
that	O
their	O
initial	O
willingness	O
to	O
take	O
it	O
remained	O
largely	O
unscathed	O
.	O

Female	O
participants	O
indicated	O
a	O
higher	O
level	O
of	O
willingness	O
to	O
take	O
PrEP	O
than	O
male	O
participants	O
,	O
which	O
may	O
be	O
explained	O
by	O
women	O
'	O
s	O
difficulty	O
negotiating	O
the	O
use	O
of	O
condoms	O
and	O
awareness	O
of	O
their	O
and	O
/	O
or	O
their	O
partners	O
'	O
risk	O
of	O
becoming	O
infected	O
with	O
HIV	O
[	O
36	O
]	O
.	O

We	O
also	O
found	O
that	O
younger	O
participants	O
and	O
those	O
with	O
fewer	O
children	O
,	O
those	O
who	O
reported	O
adherence	O
to	O
past	O
medication	O
,	O
more	O
frequent	O
condom	O
usage	O
,	O
having	O
been	O
tested	O
for	O
HIV	O
in	O
the	O
past	O
and	O
never	O
injecting	O
drugs	O
,	O
reported	O
greater	O
willingness	O
to	O
take	O
PrEP	O
.	O

These	O
promising	O
findings	O
suggest	O
that	O
those	O
who	O
are	O
currently	O
bearing	O
the	O
brunt	O
of	O
HIV	O
[	O
1	O
]	O
,	O
have	O
higher	O
perceived	O
risk	O
,	O
and	O
are	O
most	O
likely	O
to	O
adhere	O
to	O
a	O
comprehensive	O
PrEP	O
program	O
,	O
are	O
also	O
the	O
most	O
motivated	O
to	O
enroll	O
.	O

Yet	O
,	O
while	O
participants	O
stated	O
not	O
being	O
interested	O
in	O
selling	O
PrEP	O
,	O
the	O
majority	O
reported	O
intentions	O
to	O
share	O
it	O
.	O

Therefore	O
,	O
information	O
and	O
counseling	O
about	O
the	O
risks	O
of	O
sharing	O
PrEP	O
should	O
be	O
readily	O
available	O
as	O
part	O
of	O
any	O
implementation	O
program	O
.	O

Results	O
from	O
the	O
conjoint	O
analysis	O
reveal	O
trends	O
in	O
participants	O
'	O
preferences	O
which	O
deserve	O
consideration	O
.	O

PrEP	O
route	O
of	O
administration	O
was	O
the	O
most	O
important	O
attribute	O
,	O
and	O
bi	O
-	O
monthly	O
and	O
monthly	O
injections	O
were	O
the	O
preferred	O
alternatives	O
.	O

This	O
finding	O
is	O
encouraging	O
from	O
a	O
policy	O
perspective	O
if	O
such	O
modalities	O
become	O
available	O
;	O
since	O
it	O
may	O
reduce	O
users	O
'	O
likelihood	O
of	O
sharing	O
,	O
selling	O
or	O
forgetting	O
to	O
take	O
PrEP	O
,	O
but	O
it	O
also	O
raises	O
questions	O
regarding	O
participants	O
'	O
willingness	O
to	O
take	O
oral	O
PrEP	O
.	O

HIV	O
testing	O
was	O
the	O
second	O
most	O
important	O
attribute	O
,	O
and	O
a	O
test	O
every	O
six	O
months	O
was	O
,	O
as	O
expected	O
,	O
the	O
preferred	O
alternative	O
.	O

Interestingly	O
,	O
dispensing	O
sites	O
were	O
more	O
important	O
than	O
any	O
other	O
attribute	O
for	O
some	O
groups	O
,	O
particularly	O
in	O
Africa	O
.	O

This	O
may	O
indicate	O
concerns	O
about	O
social	O
stigma	O
and	O
access	O
[	O
37	O
]	O
.	O

However	O
,	O
it	O
is	O
encouraging	O
that	O
most	O
participants	O
were	O
willing	O
to	O
receive	O
PrEP	O
at	O
a	O
healthcare	O
facility	O
,	O
which	O
can	O
facilitate	O
synergies	O
between	O
PrEP	O
and	O
other	O
existing	O
prevention	O
services	O
.	O

Time	O
spent	O
obtaining	O
PrEP	O
and	O
frequency	O
of	O
pick	O
up	O
,	O
which	O
we	O
used	O
as	O
a	O
proxy	O
measure	O
for	O
cost	O
-	O
opportunity	O
,	O
were	O
generally	O
less	O
important	O
,	O
consistent	O
with	O
participants	O
'	O
willingness	O
to	O
pay	O
for	O
PrEP	O
.	O

Our	O
findings	O
are	O
broadly	O
consistent	O
with	O
the	O
work	O
of	O
Guest	O
et	O
al	O
.	O
and	O
Galea	O
et	O
al	O
[	O
18	O
]	O
,	O
[	O
19	O
]	O
.	O

However	O
,	O
specific	O
comparisons	O
are	O
not	O
advisable	O
as	O
the	O
composition	O
and	O
size	O
of	O
the	O
samples	O
,	O
recruitment	O
methods	O
,	O
measures	O
and	O
statistical	O
analyses	O
differ	O
greatly	O
.	O

Previous	O
work	O
on	O
PrEP	O
implementation	O
suggests	O
that	O
delivery	O
programs	O
will	O
need	O
to	O
meet	O
a	O
number	O
of	O
requirements	O
in	O
order	O
to	O
be	O
effective	O
,	O
including	O
:	O
prioritization	O
of	O
groups	O
at	O
higher	O
risk	O
of	O
infection	O
;	O
delivery	O
of	O
PrEP	O
in	O
combination	O
with	O
other	O
prevention	O
services	O
,	O
including	O
risk	O
reduction	O
and	O
medication	O
adherence	O
counseling	O
,	O
condoms	O
provision	O
,	O
diagnosis	O
and	O
treatment	O
of	O
other	O
sexually	O
transmitted	O
infections	O
,	O
and	O
frequent	O
HIV	O
testing	O
;	O
and	O
monitoring	O
of	O
side	O
effects	O
,	O
adherence	O
and	O
risk	O
behaviors	O
[	O
8	O
]	O
,	O
[	O
38	O
]	O
,	O
[	O
39	O
]	O
,	O
[	O
40	O
]	O
,	O
[	O
41	O
]	O
,	O
[	O
42	O
]	O
.	O

Our	O
results	O
provide	O
valuable	O
clues	O
that	O
can	O
help	O
countries	O
to	O
deliver	O
PrEP	O
more	O
effectively	O
,	O
should	O
they	O
decide	O
to	O
implement	O
it	O
,	O
by	O
focusing	O
their	O
efforts	O
on	O
the	O
aspects	O
that	O
need	O
more	O
attention	O
.	O

This	O
is	O
the	O
first	O
multinational	O
study	O
,	O
to	O
our	O
knowledge	O
,	O
that	O
integrates	O
different	O
disciplines	O
to	O
shed	O
light	O
on	O
a	O
question	O
that	O
we	O
believe	O
is	O
of	O
global	O
importance	O
.	O

Our	O
study	O
complements	O
previous	O
work	O
on	O
PrEP	O
by	O
examining	O
potential	O
users	O
'	O
perspective	O
and	O
offering	O
insights	O
into	O
their	O
attitudes	O
and	O
preferences	O
.	O

We	O
note	O
that	O
it	O
may	O
not	O
be	O
possible	O
to	O
generalize	O
the	O
observed	O
PrEP	O
acceptability	O
to	O
other	O
settings	O
and	O
our	O
results	O
should	O
be	O
considered	O
within	O
the	O
context	O
of	O
this	O
study	O
'	O
s	O
limitations	O
.	O

Given	O
the	O
sensitive	O
nature	O
of	O
the	O
addressed	O
questions	O
,	O
and	O
despite	O
all	O
our	O
efforts	O
to	O
reduce	O
social	O
desirability	O
bias	O
,	O
there	O
is	O
an	O
unavoidable	O
risk	O
that	O
participants	O
may	O
have	O
felt	O
at	O
times	O
compelled	O
to	O
provide	O
what	O
they	O
felt	O
was	O
the	O
""""	O
right	O
""""	O
answer	O
.	O

Additionally	O
,	O
our	O
data	O
collection	O
took	O
place	O
in	O
urban	O
areas	O
,	O
where	O
HIV	O
incidence	O
is	O
normally	O
higher	O
,	O
thus	O
current	O
findings	O
may	O
not	O
be	O
generalizable	O
to	O
rural	O
settings	O
.	O

Finally	O
,	O
examining	O
acceptability	O
among	O
users	O
enrolled	O
in	O
pilot	O
programs	O
is	O
much	O
deserving	O
,	O
as	O
actual	O
acceptability	O
may	O
differ	O
from	O
potential	O
willingness	O
to	O
take	O
PrEP	O
,	O
especially	O
if	O
relevant	O
attributes	O
of	O
a	O
product	O
or	O
program	O
are	O
modified	O
,	O
as	O
observed	O
in	O
other	O
comparable	O
interventions	O
[	O
43	O
]	O
.	O

Origins	O
of	O
Acquired	O
Antibiotic	O
Resistance	O
Mechanisms	O

Recently	O
,	O
D	O
'	O
Costa	O
et	O
al	O
.	O

(	O
2011	O
)	O
have	O
reported	O
a	O
metagenomic	O
analysis	O
of	O
the	O
Beringian	O
permafrost	O
,	O
which	O
is	O
30	O
,	O
000	O
years	O
old	O
.	O

They	O
showed	O
molecular	O
evidences	O
of	O
the	O
ancient	O
origins	O
of	O
antibiotic	O
resistances	O
,	O
detecting	O
beta	O
-	O
lactamases	O
genes	O
,	O
vanX	O
-	O
like	O
,	O
component	O
of	O
the	O
vancomycin	O
resistance	O
operon	O
,	O
and	O
tetM	O
,	O
coding	O
for	O
a	O
protein	O
protecting	O
the	O
ribosomal	O
target	O
from	O
tetracycline	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
the	O
beta	O
-	O
lactamases	O
genes	O
recovered	O
from	O
the	O
permafrost	O
demonstrated	O
an	O
amino	O
-	O
acid	O
homology	O
(	O
53	O
-	O
84	O
%	O
)	O
to	O
known	O
beta	O
-	O
lactamases	O
from	O
beta	O
-	O
lactams	O
producing	O
Streptomyces	O
.	O

The	O
tetM	O
sequences	O
revealed	O
a	O
high	O
similarity	O
to	O
the	O
genes	O
coding	O
for	O
the	O
ribosomal	O
protection	O
protein	O
of	O
actinomycetes	O
.	O

The	O
vanX	O
sequence	O
showed	O
a	O
similarity	O
to	O
the	O
vanX	O
gene	O
recovered	O
in	O
pathogenic	O
vancomycin	O
resistant	O
enterococci	O
(	O
VRE	O
)	O
and	O
to	O
the	O
vanX	O
gene	O
from	O
Amycolatopsis	O
orientalis	O
.	O

This	O
environmental	O
species	O
,	O
belonging	O
to	O
the	O
actinobacteria	O
phylum	O
,	O
is	O
a	O
natural	O
producer	O
of	O
vancomycin	O
,	O
and	O
very	O
likely	O
the	O
progenitor	O
of	O
the	O
van	O
genes	O
operons	O
,	O
responsible	O
for	O
resistance	O
to	O
vancomycin	O
.	O

The	O
integration	O
of	O
the	O
van	O
operons	O
on	O
transposons	O
and	O
on	O
conjugative	O
plasmids	O
has	O
enhanced	O
their	O
spread	O
(	O
Courvalin	O
,	O
2006	O
)	O
.	O

Reports	O
of	O
VRE	O
in	O
freshwater	O
have	O
been	O
provided	O
by	O
several	O
authors	O
(	O
Talebi	O
et	O
al	O
.	O
,	O
2008	O
;	O
Lata	O
et	O
al	O
.	O
,	O
2009	O
;	O
Luczkiewicz	O
et	O
al	O
.	O
,	O
2010	O
)	O
.	O

Interestingly	O
,	O
Schwartz	O
et	O
al	O
.	O

(	O
2003	O
)	O
detected	O
vanA	O
genes	O
in	O
the	O
biofilm	O
of	O
drinking	O
water	O
supplies	O
,	O
in	O
the	O
absence	O
of	O
enterococci	O
,	O
demonstrating	O
the	O
lateral	O
transfer	O
of	O
this	O
gene	O
.	O

Notably	O
,	O
the	O
progenitors	O
of	O
these	O
resistance	O
genes	O
are	O
soil	O
bacteria	O
thus	O
most	O
likely	O
,	O
a	O
shuttle	O
has	O
been	O
responsible	O
for	O
the	O
introduction	O
of	O
these	O
genes	O
into	O
the	O
commensal	O
bacterial	O
community	O
and	O
afterward	O
into	O
the	O
pathogenic	O
species	O
.	O

Results	O

Supplementary	O
Material	O

Crystal	O
structure	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
global	O
,	O
I	O
.	O

DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166sup1	O
.	O
cif	O

Structure	O
factors	O
:	O
contains	O
datablock	O
(	O
s	O
)	O
I	O
.	O

DOI	O
:	O
10	O
.	O
1107	O
/	O
S1600536812002796	O
/	O
hg5166Isup2	O
.	O
hkl	O

Additional	O
supplementary	O
materials	O
:	O
crystallographic	O
information	O
;	O
3D	O
view	O
;	O
checkCIF	O
report	O

Relative	O
phage	O
haplotype	O
frequencies	O
in	O
PAO1	O
samples	O
,	O
(	O
A	O
)	O
planktonic	O
,	O
(	O
B	O
)	O
biofilm	O
4	O
days	O
,	O
(	O
C	O
)	O
biofilm	O
11	O
days	O
.	O

Collaxa	O
BPEL	O
Server	O
Screenshot	O
of	O
Collaxa	O
'	O
s	O
bpelz	O
design	O
tool	O
,	O
building	O
a	O
choreography	O
of	O
GetHAPI	O
and	O
GetUMLS	O
web	O
services	O

Abbreviations	O

Ac	O
-	O
DEVD	O
-	O
AMC	O
=	O
N	O
-	O
acetyl	O
-	O
Asp	O
-	O
Glu	O
-	O
Val	O
-	O
Asp	O
-	O
7	O
-	O
amino	O
-	O
4	O
-	O
methylcoumarin	O
;	O
Ac	O
-	O
DEVD	O
-	O
CHO	O
=	O
N	O
-	O
acetyl	O
-	O
Asp	O
-	O
Glu	O
-	O
Val	O
-	O
Asp	O
-	O
aldehyde	O
;	O
COX	O
=	O
cyclooxygenase	O
;	O
Deltapsim	O
=	O
mitochondrial	O
membrane	O
potential	O
;	O
DAPI	O
=	O
4	O
'	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
;	O
DMEM	O
=	O
Dulbecco	O
'	O
s	O
modified	O
Eagle	O
'	O
s	O
medium	O
;	O
ELISA	O
=	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
;	O
FCS	O
=	O
fetal	O
calf	O
serum	O
;	O
FLS	O
=	O
fibroblast	O
-	O
like	O
synoviocytes	O
;	O
IL	O
=	O
interleukin	O
;	O
JC	O
-	O
1	O
=	O
5	O
,	O
5	O
'	O
,	O
6	O
,	O
6	O
'	O
-	O
tetrachloro	O
-	O
1	O
,	O
1	O
'	O
,	O
3	O
,	O
3	O
'	O
-	O
tetraethylbenzimidazole	O
carbocyanide	O
iodide	O
;	O
MTT	O
=	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
;	O
PBS	O
=	O
phosphate	O
-	O
buffered	O
saline	O
;	O
PGE2	O
=	O
prostaglandin	O
E2	O
;	O
RA	O
=	O
rheumatoid	O
arthritis	O
.	O

Results	O

Authors	O
'	O
contributions	O

FR	O
initiated	O
and	O
designed	O
the	O
research	O
,	O
collected	O
and	O
analyzed	O
the	O
data	O
and	O
wrote	O
the	O
paper	O
.	O

FO	O
was	O
the	O
main	O
supervisor	O
,	O
helped	O
in	O
analysis	O
,	O
and	O
revised	O
and	O
edited	O
the	O
drafts	O
.	O

MN	O
was	O
co	O
-	O
supervisor	O
and	O
revised	O
the	O
drafts	O
.	O

Conclusion	O

Artificial	O
addition	O
of	O
siderophores	O
and	O
HSLs	O
may	O
be	O
a	O
possible	O
method	O
to	O
aid	O
in	O
the	O
identification	O
and	O
isolation	O
of	O
marine	O
bacterial	O
species	O
which	O
are	O
thought	O
to	O
be	O
unknown	O
.	O

Ventricular	O
fibrillation	O
due	O
to	O
long	O
QT	O
syndrome	O
probably	O
caused	O
by	O
clindamycin	O
.	O

Prolongation	O
of	O
QT	O
time	O
interval	O
may	O
be	O
provoked	O
by	O
a	O
limited	O
number	O
of	O
drugs	O
,	O
especially	O
macrolide	O
antibiotics	O
.	O

We	O
describe	O
a	O
case	O
of	O
QT	O
time	O
interval	O
prolongation	O
induced	O
by	O
clindamycin	O
with	O
subsequent	O
repeated	O
ventricular	O
fibrillation	O
and	O
resuscitation	O
;	O
there	O
is	O
no	O
previous	O
report	O
in	O
the	O
literature	O
of	O
QT	O
time	O
prolongation	O
caused	O
by	O
lincosamides	O
.	O

[	O
Epidemiology	O
of	O
respiratory	O
allergy	O
in	O
children	O
]	O
.	O

Epidemiology	O
of	O
paediatric	O
respiratory	O
allergic	O
disorders	O
allows	O
the	O
approach	O
to	O
causal	O
and	O
preventive	O
risk	O
factors	O
by	O
studying	O
groups	O
or	O
sub	O
groups	O
of	O
children	O
in	O
different	O
locations	O
and	O
under	O
different	O
conditions	O
.	O

This	O
is	O
,	O
however	O
,	O
complicated	O
by	O
the	O
lack	O
of	O
consensus	O
on	O
disease	O
definitions	O
,	O
which	O
renders	O
comparisons	O
between	O
studies	O
difficult	O
.	O

Atopy	O
is	O
usually	O
defined	O
by	O
the	O
presence	O
of	O
positive	O
skin	O
tests	O
(	O
wheal	O
size	O
of	O
at	O
least	O
a	O
mean	O
diameter	O
>	O
or	O
=	O
3	O
mm	O
)	O
,	O
by	O
the	O
presence	O
of	O
specific	O
IgE	O
,	O
or	O
by	O
the	O
presence	O
of	O
increased	O
total	O
IgE	O
(	O
>	O
or	O
=	O
100	O
UI	O
/	O
mL	O
)	O
.	O

Infantile	O
asthma	O
is	O
not	O
well	O
defined	O
,	O
complicated	O
by	O
the	O
high	O
prevalence	O
of	O
bronchiolitis	O
;	O
one	O
thus	O
questions	O
between	O
wheezing	O
or	O
wheezy	O
bronchitis	O
.	O

Prevalence	O
is	O
high	O
:	O
among	O
early	O
wheezers	O
,	O
two	O
populations	O
will	O
be	O
defined	O
by	O
the	O
medium	O
term	O
evolution	O
:	O
transient	O
wheezers	O
and	O
persistent	O
wheezers	O
.	O

Risk	O
factors	O
for	O
these	O
two	O
conditions	O
are	O
different	O
.	O

Childhood	O
asthma	O
may	O
be	O
defined	O
by	O
the	O
diagnosis	O
of	O
asthma	O
(	O
specific	O
but	O
fairly	O
non	O
-	O
sensitive	O
)	O
,	O
by	O
asthmatic	O
symptoms	O
(	O
wheezing	O
,	O
waking	O
by	O
an	O
attack	O
of	O
shortness	O
of	O
breath	O
)	O
(	O
sensitive	O
but	O
not	O
very	O
specific	O
)	O
,	O
or	O
by	O
the	O
combination	O
of	O
symptoms	O
and	O
airway	O
hyperresponsiveness	O
.	O

The	O
ISAAC	O
study	O
has	O
standardised	O
a	O
questionnaire	O
to	O
assess	O
the	O
prevalence	O
of	O
asthma	O
.	O

The	O
preliminary	O
results	O
show	O
that	O
there	O
are	O
wide	O
variations	O
across	O
the	O
world	O
.	O

The	O
prevalence	O
is	O
low	O
in	O
Africa	O
and	O
Asia	O
,	O
intermediate	O
in	O
Europe	O
,	O
and	O
high	O
in	O
Anglo	O
-	O
Saxon	O
countries	O
.	O

The	O
prevalence	O
of	O
asthma	O
has	O
gradually	O
increased	O
over	O
the	O
past	O
20	O
years	O
in	O
developed	O
countries	O
.	O

Asthma	O
and	O
atopy	O
are	O
closely	O
associated	O
in	O
children	O
.	O

Risk	O
factors	O
are	O
genetic	O
,	O
associated	O
with	O
sex	O
and	O
environmental	O
factors	O
.	O

Among	O
these	O
,	O
allergic	O
sensitisation	O
is	O
associated	O
with	O
the	O
degree	O
of	O
exposure	O
to	O
allergens	O
.	O

Westernization	O
of	O
way	O
of	O
life	O
is	O
associated	O
with	O
increased	O
prevalence	O
of	O
atopy	O
,	O
allergic	O
rhinitis	O
and	O
asthma	O
.	O

Atopy	O
seems	O
inversely	O
correlated	O
to	O
certain	O
infections	O
.	O

Passive	O
smoking	O
is	O
clearly	O
associated	O
with	O
early	O
wheezing	O
.	O

This	O
and	O
atmospheric	O
pollution	O
aggravate	O
childhood	O
asthma	O
.	O

However	O
,	O
the	O
inducing	O
role	O
of	O
pollution	O
on	O
asthma	O
is	O
still	O
controversial	O
.	O

The	O
TGF	O
-	O
beta	O
type	O
II	O
receptor	O
in	O
chronic	O
myeloid	O
leukemia	O
:	O
analysis	O
of	O
microsatellite	O
regions	O
and	O
gene	O
expression	O
.	O

Genomic	O
instability	O
is	O
one	O
mechanism	O
proposed	O
to	O
play	O
a	O
role	O
in	O
the	O
disease	O
progression	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

Microsatellite	O
regions	O
in	O
the	O
type	O
II	O
transforming	O
growth	O
factor	O
-	O
beta	O
receptor	O
(	O
TGF	O
-	O
beta	O
RII	O
)	O
gene	O
appear	O
to	O
be	O
targets	O
for	O
mutation	O
in	O
some	O
cancers	O
displaying	O
microsatellite	O
instability	O
(	O
replication	O
error	O
phenotype	O
,	O
RER	O
+	O
)	O
.	O

Furthermore	O
,	O
TGF	O
-	O
beta	O
RII	O
mutations	O
in	O
RER	O
+	O
tumors	O
have	O
been	O
associated	O
with	O
decreased	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
levels	O
.	O

As	O
TGF	O
-	O
beta	O
is	O
a	O
potent	O
negative	O
growth	O
regulator	O
of	O
hematopoietic	O
cells	O
,	O
investigations	O
were	O
undertaken	O
to	O
determine	O
whether	O
inactivation	O
of	O
the	O
receptor	O
by	O
microsatellite	O
alteration	O
might	O
be	O
involved	O
in	O
the	O
progression	O
of	O
CML	O
.	O

Analysis	O
of	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
expression	O
by	O
RNase	O
protection	O
,	O
with	O
comparison	O
of	O
cells	O
from	O
the	O
chronic	O
,	O
accelerated	O
and	O
blast	O
phases	O
of	O
CML	O
,	O
showed	O
no	O
change	O
in	O
TGF	O
-	O
beta	O
RII	O
transcript	O
levels	O
during	O
disease	O
progression	O
.	O

However	O
,	O
during	O
each	O
phase	O
of	O
the	O
disease	O
,	O
low	O
levels	O
of	O
TGF	O
-	O
beta	O
RII	O
were	O
detected	O
when	O
compared	O
with	O
the	O
hematopoietic	O
cells	O
of	O
normal	O
donors	O
.	O

Furthermore	O
,	O
this	O
decreased	O
expression	O
was	O
also	O
observed	O
in	O
the	O
other	O
myeloproliferative	O
disorders	O
,	O
polycythemia	O
rubra	O
vera	O
(	O
PRV	O
)	O
and	O
essential	O
thrombocythemia	O
(	O
ET	O
)	O
.	O

The	O
leukemia	O
cell	O
lines	O
K562	B
and	O
HL	B
-	I
60	I
had	O
no	O
detectable	O
TGF	O
-	O
beta	O
RII	O
mRNA	O
.	O

Two	O
microsatellite	O
regions	O
found	O
altered	O
in	O
RER	O
+	O
colon	O
cancers	O
were	O
analyzed	O
to	O
establish	O
if	O
these	O
sequences	O
were	O
aberrant	O
in	O
CML	O
.	O

No	O
alteration	O
was	O
detected	O
in	O
either	O
of	O
these	O
regions	O
in	O
any	O
phase	O
of	O
the	O
disease	O
.	O

These	O
results	O
suggest	O
that	O
alterations	O
of	O
the	O
microsatellite	O
regions	O
in	O
the	O
TGF	O
-	O
beta	O
RII	O
gene	O
are	O
not	O
involved	O
in	O
the	O
progression	O
of	O
CML	O
.	O

Decreased	O
expression	O
of	O
TGF	O
-	O
beta	O
RII	O
in	O
CML	O
cells	O
and	O
leukemia	O
cell	O
lines	O
raises	O
the	O
possibility	O
that	O
altered	O
expression	O
of	O
the	O
receptor	O
may	O
play	O
a	O
role	O
in	O
the	O
initiation	O
and	O
/	O
or	O
maintenance	O
of	O
the	O
disease	O
state	O
.	O

N	O
-	O
glycosylation	O
of	O
glucose	O
transporter	O
-	O
1	O
(	O
Glut	O
-	O
1	O
)	O
is	O
associated	O
with	O
increased	O
transporter	O
affinity	O
for	O
glucose	O
in	O
human	O
leukemic	O
cells	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
N	O
-	O
glycosylation	O
in	O
the	O
functional	O
activity	O
of	O
the	O
universal	O
glucose	O
transporter	O
,	O
Glut	O
-	O
1	O
,	O
we	O
investigated	O
effects	O
of	O
the	O
N	O
-	O
glycosylation	O
inhibitor	O
,	O
tunicamycin	O
,	O
on	O
glucose	O
transport	O
by	O
human	O
leukemic	O
cell	O
lines	O
K562	B
,	O
U937	B
and	O
HL60	B
.	O

Treatment	O
with	O
tunicamycin	O
produced	O
a	O
40	O
-	O
50	O
%	O
inhibition	O
of	O
2	O
-	O
deoxyglucose	O
uptake	O
and	O
this	O
was	O
associated	O
with	O
a	O
2	O
-	O
2	O
.	O
5	O
-	O
fold	O
decrease	O
in	O
transporter	O
affinity	O
for	O
glucose	O
(	O
Km	O
)	O
without	O
a	O
change	O
in	O
Vmax	O
.	O

Leukemic	O
K562	B
,	O
U937	B
and	O
HL60	B
cells	O
expressed	O
Glut	O
-	O
1	O
transporter	O
protein	O
.	O

With	O
K562	B
cells	O
Glut	O
-	O
1	O
appeared	O
as	O
a	O
broad	O
band	O
of	O
50	O
-	O
60	O
kDa	O
,	O
whereas	O
with	O
U937	B
and	O
HL60	B
cells	O
a	O
diffuse	O
band	O
was	O
observed	O
at	O
approximately	O
55	O
kDa	O
.	O

Treatment	O
of	O
K562	B
cells	O
with	O
tunicamycin	O
for	O
18	O
h	O
,	O
resulted	O
in	O
extensive	O
loss	O
of	O
the	O
50	O
-	O
60	O
kDa	O
glycoprotein	O
,	O
appearance	O
of	O
a	O
30	O
-	O
40	O
kDa	O
band	O
and	O
increased	O
staining	O
of	O
a	O
45	O
kDa	O
band	O
.	O

With	O
U937	B
cells	O
,	O
tunicamycin	O
treatment	O
resulted	O
in	O
the	O
appearance	O
of	O
a	O
30	O
-	O
40	O
kDa	O
band	O
and	O
increased	O
staining	O
of	O
a	O
45	O
kDa	O
band	O
.	O

With	O
HL60	B
cells	O
loss	O
of	O
the	O
55	O
kDa	O
Glut	O
-	O
1	O
band	O
was	O
observed	O
and	O
a	O
band	O
of	O
45	O
kDa	O
appeared	O
.	O

Tunicamycin	O
-	O
treatment	O
resulted	O
in	O
75	O
-	O
90	O
%	O
inhibition	O
in	O
[	O
3H	O
]	O
mannose	O
incorporation	O
but	O
only	O
20	O
-	O
25	O
%	O
inhibition	O
in	O
[	O
3H	O
]	O
thymidine	O
and	O
[	O
3H	O
]	O
leucine	O
incorporation	O
.	O

In	O
contrast	O
,	O
tunicamycin	O
had	O
little	O
effect	O
on	O
the	O
viability	O
and	O
MTT	O
responses	O
of	O
the	O
cells	O
used	O
.	O

These	O
results	O
suggest	O
that	O
in	O
leukemic	O
cells	O
N	O
-	O
glycosylation	O
of	O
Glut	O
-	O
1	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
its	O
structure	O
and	O
functional	O
integration	O
.	O

Decontamination	O
of	O
medical	O
equipment	O
-	O
-	O
manufacturer	O
'	O
s	O
problems	O
.	O

1	O
.	O

Small	O
items	O
sent	O
via	O
the	O
post	O
present	O
a	O
much	O
greater	O
hidden	O
hazard	O
and	O
a	O
higher	O
potential	O
for	O
catching	O
people	O
unawares	O
.	O

2	O
.	O

Large	O
items	O
accompanied	O
by	O
a	O
Decontamination	O
Certificate	O
need	O
to	O
be	O
treated	O
with	O
caution	O
because	O
only	O
those	O
surfaces	O
which	O
are	O
accessible	O
will	O
have	O
been	O
cleaned	O
;	O
as	O
soon	O
as	O
engineers	O
start	O
dismantling	O
equipment	O
,	O
areas	O
which	O
are	O
still	O
soiled	O
become	O
exposed	O
.	O

3	O
.	O

Total	O
co	O
-	O
operation	O
between	O
hospital	O
staff	O
and	O
service	O
engineers	O
is	O
necessary	O
to	O
resolve	O
these	O
problems	O
-	O
neither	O
can	O
work	O
safely	O
without	O
the	O
assistance	O
of	O
the	O
other	O
.	O

4	O
.	O

Many	O
products	O
in	O
use	O
in	O
hospitals	O
may	O
be	O
up	O
to	O
20	O
years	O
old	O
and	O
clearly	O
were	O
not	O
designed	O
to	O
facilitate	O
decontamination	O
and	O
therefore	O
present	O
far	O
greater	O
risk	O
to	O
all	O
concerned	O
.	O

5	O
.	O

For	O
the	O
future	O
there	O
a	O
clearly	O
a	O
responsibility	O
with	O
manufacturers	O
to	O
give	O
more	O
thought	O
to	O
the	O
design	O
of	O
their	O
equipment	O
so	O
that	O
decontamination	O
can	O
be	O
achieved	O
more	O
effectively	O
.	O

Positron	O
emission	O
tomography	O
in	O
a	O
case	O
of	O
intracranial	O
hemangiopericytoma	O
.	O

Due	O
to	O
the	O
low	O
prevalence	O
of	O
hemangiopericytomas	O
(	O
HPCs	O
)	O
,	O
data	O
on	O
the	O
biophysiological	O
characteristics	O
of	O
this	O
tumor	O
are	O
rare	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
demonstrated	O
a	O
sixfold	O
increased	O
uptake	O
of	O
[	O
11C	O
]	O
methionine	O
and	O
hyperperfusion	O
in	O
the	O
HPC	O
,	O
whereas	O
glucose	O
utilization	O
was	O
decreased	O
in	O
this	O
area	O
.	O

This	O
low	O
glucose	O
utilization	O
is	O
in	O
contrast	O
to	O
the	O
high	O
[	O
11C	O
]	O
methionine	O
uptake	O
and	O
the	O
malignancy	O
of	O
these	O
tumors	O
.	O

The	O
characteristics	O
of	O
HPCs	O
in	O
PET	O
described	O
herein	O
for	O
the	O
first	O
time	O
offer	O
additional	O
diagnostic	O
criteria	O
and	O
may	O
help	O
especially	O
to	O
differentiate	O
these	O
tumors	O
from	O
meningiomas	O
.	O

Novel	O
mechanism	O
for	O
the	O
impairment	O
of	O
cell	O
proliferation	O
in	O
HIV	O
-	O
1	O
infection	O
.	O

The	O
synthesis	O
of	O
ribonucleotides	O
is	O
essential	O
to	O
cell	O
proliferation	O
.	O

Defects	O
in	O
the	O
relevant	O
metabolic	O
pathways	O
have	O
been	O
demonstrated	O
in	O
stimulated	O
T	O
cells	O
from	O
AIDS	O
patients	O
and	O
are	O
associated	O
with	O
lymphocyte	O
necrotic	O
death	O
.	O

Here	O
,	O
Margarita	O
Bofill	O
and	O
colleagues	O
discuss	O
the	O
possibility	O
that	O
an	O
impaired	O
ribonucleotide	O
metabolism	O
might	O
be	O
common	O
to	O
all	O
rapidly	O
dividing	O
cells	O
and	O
thus	O
contribute	O
to	O
other	O
recognized	O
symptoms	O
of	O
HIV	O
-	O
1	O
infection	O
.	O

Enterococci	O
at	O
the	O
crossroads	O
of	O
food	O
safety	O
?	O

Enterococci	O
are	O
gram	O
-	O
positive	O
bacteria	O
and	O
fit	O
within	O
the	O
general	O
definition	O
of	O
lactic	O
acid	O
bacteria	O
.	O

Modern	O
classification	O
techniques	O
resulted	O
in	O
the	O
transfer	O
of	O
some	O
members	O
of	O
the	O
genus	O
Streptococcus	O
,	O
notably	O
some	O
of	O
the	O
Lancefield	O
'	O
s	O
group	O
D	O
streptococci	O
,	O
to	O
the	O
new	O
genus	O
Enterococcus	O
.	O

Enterococci	O
can	O
be	O
used	O
as	O
indicators	O
of	O
faecal	O
contamination	O
.	O

They	O
have	O
been	O
implicated	O
in	O
outbreaks	O
of	O
foodborne	O
illness	O
,	O
and	O
they	O
have	O
been	O
ascribed	O
a	O
beneficial	O
or	O
detrimental	O
role	O
in	O
foods	O
.	O

In	O
processed	O
meats	O
,	O
enterococci	O
may	O
survive	O
heat	O
processing	O
and	O
cause	O
spoilage	O
,	O
though	O
in	O
certain	O
cheeses	O
the	O
growth	O
of	O
enterococci	O
contributes	O
to	O
ripening	O
and	O
development	O
of	O
product	O
flavour	O
.	O

Some	O
enterococci	O
of	O
food	O
origin	O
produce	O
bacteriocins	O
that	O
exert	O
anti	O
-	O
Listeria	O
activity	O
.	O

Enterococci	O
are	O
used	O
as	O
probiotics	O
to	O
improve	O
the	O
microbial	O
balance	O
of	O
the	O
intestine	O
,	O
or	O
as	O
a	O
treatment	O
for	O
gastroenteritis	O
in	O
humans	O
and	O
animals	O
.	O

On	O
the	O
other	O
hand	O
,	O
enterococci	O
have	O
become	O
recognised	O
as	O
serious	O
nosocomial	O
pathogens	O
causing	O
bacteraemia	O
,	O
endocarditis	O
,	O
urinary	O
tract	O
and	O
other	O
infections	O
.	O

This	O
is	O
in	O
part	O
explained	O
by	O
the	O
resistance	O
of	O
some	O
of	O
these	O
bacteria	O
to	O
most	O
antibiotics	O
that	O
are	O
currently	O
in	O
use	O
.	O

Resistance	O
is	O
acquired	O
by	O
gene	O
transfer	O
systems	O
,	O
such	O
as	O
conjugative	O
or	O
nonconjugative	O
plasmids	O
or	O
transposons	O
.	O

Virulence	O
of	O
enterococci	O
is	O
not	O
well	O
understood	O
but	O
adhesins	O
,	O
haemolysin	O
,	O
hyaluronidase	O
,	O
aggregation	O
substance	O
and	O
gelatinase	O
are	O
putative	O
virulence	O
factors	O
.	O

It	O
appears	O
that	O
foods	O
could	O
be	O
a	O
source	O
of	O
vancomycin	O
-	O
resistant	O
enterococci	O
.	O

This	O
review	O
addresses	O
the	O
issue	O
of	O
the	O
health	O
risk	O
of	O
foods	O
containing	O
enterococci	O
.	O

Thyrotropin	O
receptor	O
:	O
a	O
role	O
for	O
thyroid	O
tumourigenesis	O
?	O

Human	O
thyroid	O
tumours	O
represent	O
an	O
example	O
of	O
the	O
interplay	O
of	O
genetic	O
and	O
non	O
genetic	O
carcinogenesis	O
.	O

Recently	O
,	O
genetic	O
abnormalities	O
in	O
the	O
elements	O
of	O
the	O
Thyrotropin	O
receptor	O
(	O
TSH	O
-	O
R	O
)	O
dependent	O
cAMP	O
regulatory	O
cascade	O
have	O
been	O
found	O
to	O
be	O
involved	O
both	O
in	O
benign	O
and	O
malignant	O
thyroid	O
tumours	O
.	O

The	O
presence	O
of	O
activating	O
mutations	O
has	O
been	O
demonstrated	O
in	O
the	O
TSH	O
-	O
R	O
gene	O
as	O
well	O
as	O
in	O
the	O
Gs	O
alpha	O
protein	O
gene	O
in	O
thyroid	O
toxic	O
adenoma	O
resulting	O
in	O
the	O
constitutive	O
activation	O
of	O
the	O
cAMP	O
pathway	O
and	O
it	O
has	O
been	O
hypothesised	O
that	O
these	O
genetic	O
alterations	O
may	O
play	O
a	O
causative	O
role	O
in	O
the	O
disease	O
.	O

However	O
,	O
recent	O
observations	O
suggest	O
more	O
caution	O
in	O
accepting	O
such	O
a	O
hypothesis	O
.	O

The	O
presence	O
of	O
activating	O
TSH	O
-	O
R	O
mutations	O
has	O
also	O
been	O
demonstrated	O
in	O
differentiated	O
thyroid	O
carcinomas	O
.	O

At	O
present	O
,	O
the	O
percentage	O
of	O
such	O
a	O
modification	O
is	O
low	O
,	O
unless	O
referred	O
to	O
selected	O
series	O
of	O
tumours	O
.	O

Activating	O
mutations	O
of	O
the	O
TSH	O
-	O
R	O
gene	O
have	O
been	O
detected	O
in	O
a	O
group	O
of	O
differentiated	O
carcinomas	O
with	O
high	O
basal	O
adenylyl	O
cyclase	O
activity	O
,	O
and	O
in	O
a	O
few	O
cases	O
of	O
hyperfunctioning	O
thyroid	O
carcinoma	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
TSH	O
-	O
R	O
-	O
related	O
cAMP	O
pathway	O
alterations	O
in	O
thyroid	O
transformation	O
remains	O
to	O
be	O
elucidated	O
.	O

In	O
this	O
review	O
,	O
the	O
role	O
of	O
TSH	O
-	O
R	O
gene	O
alterations	O
in	O
benign	O
and	O
malignant	O
thyroid	O
neoplasia	O
is	O
examined	O
.	O

Immunohistochemical	O
analysis	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
node	O
-	O
positive	O
lung	O
cancer	O
and	O
lymph	O
nodes	O
.	O

The	O
nm23	O
-	O
H1	O
gene	O
product	O
has	O
been	O
considered	O
as	O
an	O
anti	O
-	O
metastatic	O
protein	O
and	O
the	O
level	O
of	O
its	O
expression	O
has	O
been	O
reported	O
to	O
correlate	O
inversely	O
with	O
metastatic	O
potential	O
in	O
some	O
cancers	O
.	O

However	O
,	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
the	O
metastatic	O
sites	O
have	O
not	O
been	O
studied	O
in	O
detail	O
.	O

We	O
examined	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
surgically	O
resected	O
46	O
pairs	O
of	O
primary	O
lung	O
cancers	O
and	O
metastatic	O
lymph	O
nodes	O
by	O
immunohistochemistry	O
.	O

The	O
positive	O
staining	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
primary	O
cancers	O
and	O
metastatic	O
lymph	O
nodes	O
were	O
observed	O
in	O
56	O
.	O
5	O
and	O
67	O
.	O
4	O
%	O
,	O
respectively	O
.	O

The	O
heterogeneity	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
between	O
primary	O
cancers	O
and	O
metastatic	O
lymph	O
nodes	O
was	O
observed	O
in	O
41	O
.	O
3	O
%	O
.	O

No	O
correlations	O
were	O
found	O
between	O
the	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
in	O
lung	O
cancers	O
and	O
the	O
patients	O
survival	O
.	O

No	O
significant	O
association	O
was	O
also	O
observed	O
between	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
in	O
lymph	O
nodes	O
and	O
the	O
patients	O
survival	O
.	O

There	O
was	O
,	O
furthermore	O
,	O
no	O
correlation	O
between	O
the	O
heterogeneity	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
and	O
the	O
patients	O
survival	O
.	O

In	O
conclusion	O
,	O
the	O
level	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
expression	O
does	O
not	O
significantly	O
reveal	O
prognostic	O
value	O
in	O
node	O
-	O
positive	O
lung	O
cancers	O
.	O

Expression	O
of	O
nm23	O
-	O
H1	O
gene	O
product	O
in	O
metastatic	O
lymph	O
nodes	O
was	O
also	O
unrelated	O
to	O
patients	O
survival	O
.	O

Bradycardia	O
-	O
induced	O
coronary	O
angiogenesis	O
is	O
dependent	O
on	O
vascular	O
endothelial	O
growth	O
factor	O
.	O

A	O
marked	O
coronary	O
angiogenesis	O
is	O
known	O
to	O
occur	O
with	O
chronic	O
bradycardia	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
an	O
endothelial	O
cell	O
mitogen	O
and	O
a	O
major	O
regulator	O
of	O
angiogenesis	O
,	O
is	O
upregulated	O
in	O
response	O
to	O
low	O
heart	O
rate	O
and	O
consequential	O
increased	O
stroke	O
volume	O
.	O

Bradycardia	O
was	O
induced	O
in	O
rats	O
by	O
administering	O
the	O
bradycardic	O
drug	O
alinidine	O
(	O
3	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
daily	O
.	O

Heart	O
rate	O
decreased	O
by	O
32	O
%	O
for	O
20	O
to	O
40	O
minutes	O
after	O
injection	O
and	O
was	O
chronically	O
reduced	O
by	O
10	O
%	O
,	O
14	O
%	O
,	O
and	O
18	O
.	O
5	O
%	O
after	O
1	O
,	O
2	O
,	O
and	O
3	O
weeks	O
of	O
treatment	O
,	O
respectively	O
.	O

Arterial	O
pressure	O
and	O
cardiac	O
output	O
were	O
unchanged	O
.	O

Left	O
ventricular	O
capillary	O
length	O
density	O
(	O
mm	O
/	O
mm	O
(	O
3	O
)	O
)	O
increased	O
gradually	O
with	O
alinidine	O
administration	O
;	O
a	O
15	O
%	O
increase	O
after	O
2	O
weeks	O
and	O
a	O
40	O
%	O
increase	O
after	O
3	O
weeks	O
of	O
alinidine	O
treatment	O
were	O
documented	O
.	O

Left	O
ventricular	O
weight	O
,	O
body	O
weight	O
,	O
and	O
their	O
ratio	O
were	O
not	O
significantly	O
altered	O
by	O
alinidine	O
treatment	O
.	O

After	O
1	O
week	O
of	O
treatment	O
,	O
before	O
an	O
increase	O
in	O
capillary	O
length	O
density	O
,	O
VEGF	O
mRNA	O
increased	O
greater	O
than	O
2	O
-	O
fold	O
and	O
then	O
declined	O
to	O
control	O
levels	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

VEGF	O
protein	O
was	O
higher	O
in	O
alinidine	O
-	O
treated	O
rats	O
than	O
in	O
controls	O
after	O
2	O
weeks	O
and	O
increased	O
further	O
after	O
3	O
weeks	O
of	O
treatment	O
.	O

Injection	O
of	O
VEGF	O
-	O
neutralizing	O
antibodies	O
over	O
a	O
2	O
-	O
week	O
period	O
completely	O
blocked	O
alinidine	O
-	O
stimulated	O
angiogenesis	O
.	O

In	O
contrast	O
,	O
bFGF	O
mRNA	O
was	O
not	O
altered	O
by	O
alinidine	O
treatment	O
.	O

These	O
data	O
suggest	O
that	O
VEGF	O
plays	O
a	O
key	O
role	O
in	O
the	O
angiogenic	O
response	O
that	O
occurs	O
with	O
chronic	O
bradycardia	O
.	O

The	O
mechanism	O
underlying	O
this	O
VEGF	O
-	O
associated	O
angiogenesis	O
may	O
be	O
an	O
increase	O
in	O
stretch	O
due	O
to	O
enhanced	O
diastolic	O
filling	O
.	O

[	O
Histopathologic	O
examination	O
of	O
rectal	O
carcinoma	O
]	O
.	O

In	O
patients	O
with	O
rectal	O
carcinoma	O
,	O
the	O
histopathological	O
evaluation	O
of	O
the	O
surgical	O
specimen	O
provides	O
pivotal	O
prognostic	O
and	O
therapeutic	O
information	O
.	O

Important	O
parameters	O
are	O
tumor	O
site	O
,	O
depth	O
of	O
invasion	O
,	O
histological	O
type	O
and	O
grade	O
,	O
pattern	O
of	O
invasion	O
(	O
diffusely	O
infiltrating	O
versus	O
expanding	O
margin	O
)	O
,	O
degree	O
of	O
peritumoral	O
lymphocytic	O
infiltration	O
,	O
and	O
tumor	O
involvement	O
of	O
surgical	O
margins	O
and	O
lymph	O
nodes	O
.	O

Evaluation	O
of	O
the	O
circumferential	O
(	O
deep	O
,	O
lateral	O
)	O
margin	O
is	O
of	O
utmost	O
importance	O
.	O

It	O
should	O
be	O
labeled	O
with	O
ink	O
in	O
the	O
gross	O
specimen	O
and	O
should	O
be	O
examined	O
histologically	O
using	O
several	O
tissue	O
blocks	O
.	O

The	O
number	O
of	O
lymph	O
node	O
metastases	O
and	O
the	O
total	O
number	O
of	O
lymph	O
nodes	O
examined	O
should	O
be	O
reported	O
.	O

A	O
histological	O
evaluation	O
of	O
the	O
distal	O
mesorectum	O
in	O
its	O
entirety	O
is	O
recommended	O
to	O
detect	O
discontinuous	O
distal	O
mesorectal	O
tumor	O
spread	O
.	O

The	O
histopathological	O
findings	O
should	O
be	O
summarized	O
using	O
the	O
TNM	O
-	O
classification	O
.	O

Cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	O
-	O
catenin	O
and	O
overexpression	O
of	O
p53	O
is	O
a	O
predictor	O
of	O
lymph	O
node	O
metastasis	O
in	O
early	O
gastric	O
cancer	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Even	O
though	O
the	O
pathological	O
background	O
contributes	O
to	O
lymph	O
node	O
metastasis	O
,	O
the	O
biological	O
characteristics	O
of	O
tumors	O
have	O
also	O
gained	O
wide	O
attention	O
.	O

In	O
this	O
study	O
,	O
the	O
expression	O
of	O
the	O
cadherin	O
-	O
catenin	O
complex	O
and	O
p53	O
was	O
studied	O
in	O
early	O
gastric	O
cancer	O
.	O

Their	O
correlation	O
with	O
lymph	O
node	O
metastasis	O
and	O
the	O
predictability	O
of	O
lymph	O
node	O
metastases	O
,	O
by	O
combining	O
these	O
factors	O
,	O
were	O
also	O
discussed	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
one	O
specimens	O
obtained	O
from	O
surgery	O
were	O
studied	O
by	O
immunohistochemistry	O
using	O
monoclonal	O
anti	O
-	O
E	O
-	O
cadherin	O
,	O
anti	O
-	O
alpha	O
-	O
catenin	O
and	O
anti	O
-	O
p53	O
antibodies	O
.	O

RESULTS	O
:	O
Expression	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
catenin	O
was	O
reduced	O
in	O
50	O
.	O
5	O
and	O
64	O
.	O
4	O
%	O
,	O
respectively	O
.	O

p53	O
protein	O
staining	O
was	O
positive	O
in	O
29	O
.	O
7	O
%	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
catenin	O
expression	O
,	O
but	O
no	O
correlation	O
was	O
found	O
between	O
p53	O
expression	O
and	O
E	O
-	O
cadherin	O
or	O
alpha	O
-	O
catenin	O
expression	O
.	O

A	O
reduction	O
in	O
alpha	O
-	O
catenin	O
expression	O
and	O
p53	O
overexpression	O
correlated	O
to	O
lymph	O
node	O
metastases	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
cooccurrence	O
of	O
reduced	O
expression	O
of	O
alpha	O
-	O
catenin	O
and	O
overexpression	O
of	O
p53	O
was	O
an	O
independent	O
factor	O
indicating	O
lymph	O
node	O
metastases	O
.	O

CONCLUSION	O
:	O
A	O
study	O
of	O
both	O
alpha	O
-	O
catenin	O
and	O
p53	O
expression	O
may	O
be	O
helpful	O
to	O
predict	O
lymph	O
node	O
metastases	O
in	O
early	O
gastric	O
cancer	O
.	O

Antisense	O
technologies	O
have	O
a	O
future	O
fighting	O
neurodegenerative	O
diseases	O
.	O

Our	O
growing	O
understanding	O
of	O
the	O
role	O
that	O
unfavorable	O
patterns	O
of	O
gene	O
expression	O
play	O
in	O
the	O
etiology	O
of	O
neurodegenerative	O
disease	O
emphasizes	O
the	O
need	O
for	O
strategies	O
to	O
selectively	O
block	O
the	O
biosynthesis	O
of	O
harmful	O
proteins	O
in	O
the	O
brain	O
.	O

Antisense	O
technologies	O
are	O
ideally	O
suited	O
to	O
this	O
purpose	O
.	O

Tailor	O
-	O
designed	O
to	O
target	O
specific	O
RNA	O
,	O
antisense	O
oligonucleotides	O
and	O
ribozymes	O
offer	O
tools	O
to	O
suppress	O
the	O
production	O
of	O
proteins	O
mediating	O
neurodegeneration	O
.	O

Although	O
technical	O
limitations	O
must	O
still	O
be	O
overcome	O
,	O
the	O
antisense	O
approach	O
represents	O
a	O
novel	O
and	O
exciting	O
strategy	O
for	O
intervention	O
in	O
diseases	O
of	O
the	O
central	O
nervous	O
system	O
.	O

Proto	O
-	O
oncogene	O
N	O
-	O
myc	O
promoter	O
is	O
down	O
regulated	O
by	O
the	O
Wilms	O
'	O
tumor	O
suppressor	O
gene	O
WT1	O
.	O

The	O
Wilms	O
'	O
tumor	O
1	O
(	O
WT1	O
)	O
gene	O
is	O
a	O
tumor	O
suppressor	O
gene	O
that	O
encodes	O
a	O
zinc	O
-	O
finger	O
transcription	O
factor	O
.	O

WT1	O
represses	O
transcription	O
of	O
several	O
growth	O
factors	O
and	O
growth	O
factor	O
receptors	O
.	O

The	O
N	O
-	O
myc	O
proto	O
-	O
oncogene	O
encodes	O
a	O
transcription	O
factor	O
which	O
regulates	O
cell	O
growth	O
and	O
differentiation	O
.	O

N	O
-	O
myc	O
is	O
coexpressed	O
with	O
WT1	O
in	O
the	O
developing	O
kidney	O
and	O
is	O
overexpressed	O
in	O
many	O
Wilms	O
'	O
tumors	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
proto	O
-	O
oncogene	O
N	O
-	O
myc	O
promoter	O
was	O
down	O
-	O
regulated	O
by	O
WT1	O
in	O
transient	O
transfection	O
assays	O
.	O

However	O
,	O
mutant	O
WT1	O
(	O
R394W	O
)	O
which	O
has	O
a	O
mutation	O
in	O
the	O
DNA	O
binding	O
domain	O
could	O
not	O
repress	O
the	O
N	O
-	O
myc	O
promoter	O
.	O

Electrophoretic	O
mobility	O
shift	O
assays	O
showed	O
that	O
the	O
oligonucleotides	O
containing	O
the	O
WT1	O
motifs	O
could	O
bind	O
recombinant	O
WT1	O
proteins	O
.	O

This	O
suggests	O
that	O
the	O
repression	O
of	O
the	O
N	O
-	O
myc	O
promoter	O
is	O
mediated	O
through	O
the	O
WT1	O
binding	O
sites	O
.	O

This	O
finding	O
may	O
help	O
to	O
elucidate	O
the	O
relationship	O
of	O
WT1	O
and	O
N	O
-	O
myc	O
in	O
tumorigenesis	O
and	O
renal	O
development	O
.	O

UFT	O
and	O
its	O
metabolites	O
inhibit	O
the	O
angiogenesis	O
induced	O
by	O
murine	O
renal	O
cell	O
carcinoma	O
,	O
as	O
determined	O
by	O
a	O
dorsal	O
air	O
sac	O
assay	O
in	O
mice	O
.	O

UFT	O
,	O
an	O
anticancer	O
agent	O
that	O
is	O
composed	O
of	O
tegafur	O
(	O
FT	O
)	O
and	O
uracil	O
at	O
a	O
molar	O
ratio	O
of	O
1	O
:	O
4	O
,	O
is	O
widely	O
used	O
in	O
clinical	O
practice	O
in	O
Japan	O
to	O
treat	O
cancer	O
patients	O
requiring	O
a	O
long	O
-	O
term	O
chemotherapy	O
,	O
and	O
it	O
is	O
associated	O
with	O
few	O
side	O
effects	O
,	O
if	O
any	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
evaluated	O
the	O
inhibitory	O
effect	O
of	O
UFT	O
against	O
RENCA	B
cell	O
-	O
induced	O
angiogenesis	O
by	O
a	O
dorsal	O
air	O
sac	O
assay	O
.	O

Marked	O
angiogenesis	O
is	O
induced	O
by	O
implantation	O
of	O
a	O
chamber	O
containing	O
RENCA	B
cells	O
into	O
mice	O
.	O

In	O
this	O
model	O
,	O
UFT	O
showed	O
a	O
strong	O
angiogenesis	O
-	O
inhibitory	O
effect	O
,	O
whereas	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
and	O
doxifluridine	O
were	O
less	O
effective	O
.	O

Additional	O
experiments	O
revealed	O
FT	O
to	O
be	O
effective	O
component	O
of	O
UFT	O
;	O
uracil	O
remained	O
ineffective	O
in	O
the	O
inhibition	O
of	O
angiogenesis	O
.	O

Moreover	O
,	O
we	O
have	O
found	O
that	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
the	O
metabolites	O
of	O
FT	O
,	O
possess	O
a	O
potent	O
angiogenesis	O
inhibitory	O
effect	O
that	O
is	O
amplified	O
when	O
the	O
compounds	O
are	O
administered	O
by	O
a	O
continuous	O
infusion	O
.	O

This	O
may	O
reflect	O
a	O
transition	O
in	O
blood	O
concentration	O
of	O
each	O
metabolite	O
resulting	O
from	O
the	O
administration	O
of	O
UFT	O
.	O

Similar	O
results	O
were	O
also	O
obtained	O
with	O
respect	O
to	O
5	O
-	O
FU	O
.	O

It	O
was	O
suggested	O
that	O
UFT	O
has	O
a	O
stronger	O
angiogenesis	O
-	O
inhibitory	O
effect	O
than	O
did	O
other	O
fluorinated	O
pyrimidines	O
,	O
partly	O
due	O
to	O
its	O
pharmacokinetic	O
properties	O
characterized	O
by	O
maintaining	O
of	O
higher	O
and	O
long	O
-	O
lasting	O
blood	O
levels	O
of	O
5	O
-	O
FU	O
and	O
partly	O
due	O
the	O
inhibitory	O
effects	O
derived	O
from	O
gamma	O
-	O
hydroxybutyric	O
acid	O
and	O
gamma	O
-	O
butyrolactone	O
,	O
UFT	O
-	O
specific	O
metabolites	O
.	O

External	O
beam	O
radiotherapy	O
for	O
subretinal	O
neovascularization	O
in	O
age	O
-	O
related	O
macular	O
degeneration	O
:	O
is	O
this	O
treatment	O
efficient	O
?	O

PURPOSE	O
:	O
Control	O
of	O
the	O
natural	O
course	O
of	O
subretinal	O
neovascularization	O
(	O
SRNV	O
)	O
in	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
is	O
difficult	O
.	O

Only	O
a	O
subset	O
of	O
patients	O
is	O
suitable	O
for	O
laser	O
coagulation	O
.	O

This	O
prospective	O
study	O
aimed	O
to	O
determine	O
the	O
efficacy	O
and	O
individual	O
benefit	O
of	O
external	O
beam	O
radiotherapy	O
(	O
EBRT	O
)	O
.	O

METHODS	O
AND	O
MATERIALS	O
:	O
The	O
prospective	O
trial	O
included	O
287	O
patients	O
with	O
subfoveal	O
neovascularization	O
due	O
to	O
AMD	O
which	O
was	O
verified	O
by	O
fluorescein	O
angiography	O
.	O

Patients	O
have	O
been	O
treated	O
between	O
January	O
1996	O
and	O
October	O
1997	O
.	O

All	O
patients	O
received	O
a	O
total	O
dose	O
of	O
16	O
Gy	O
in	O
2	O
-	O
Gy	O
daily	O
fractions	O
with	O
5	O
-	O
6	O
MeV	O
photons	O
based	O
on	O
computerized	O
treatment	O
planning	O
in	O
individual	O
head	O
mask	O
fixation	O
.	O

This	O
first	O
analysis	O
is	O
based	O
on	O
73	O
patients	O
(	O
50	O
women	O
,	O
23	O
men	O
,	O
median	O
age	O
74	O
.	O
3	O
years	O
)	O
,	O
with	O
a	O
median	O
follow	O
-	O
up	O
of	O
13	O
.	O
3	O
months	O
and	O
a	O
minimum	O
follow	O
-	O
up	O
of	O
11	O
months	O
.	O

RESULTS	O
:	O
All	O
patients	O
completed	O
therapy	O
and	O
tolerability	O
was	O
good	O
.	O

First	O
clinical	O
control	O
with	O
second	O
angiography	O
was	O
performed	O
6	O
weeks	O
after	O
irradiation	O
,	O
then	O
in	O
3	O
-	O
month	O
intervals	O
.	O

Eighteen	O
patients	O
with	O
SRNV	O
refusing	O
radiotherapy	O
served	O
as	O
a	O
control	O
group	O
and	O
were	O
matched	O
with	O
18	O
irradiated	O
patients	O
.	O

After	O
7	O
months	O
median	O
visual	O
acuity	O
(	O
VA	O
)	O
was	O
20	O
/	O
160	O
for	O
the	O
irradiated	O
and	O
20	O
/	O
400	O
for	O
the	O
untreated	O
patients	O
.	O

One	O
year	O
after	O
radiotherapy	O
final	O
median	O
VA	O
was	O
20	O
/	O
400	O
in	O
both	O
groups	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
16	O
Gy	O
of	O
conventionally	O
fractionated	O
external	O
beam	O
irradiation	O
slows	O
down	O
the	O
visual	O
loss	O
in	O
exudative	O
AMD	O
for	O
only	O
a	O
few	O
months	O
.	O

Patients	O
'	O
reading	O
vision	O
could	O
not	O
be	O
saved	O
for	O
a	O
long	O
-	O
term	O
run	O
.	O

Increased	O
serum	O
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
in	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
.	O

Neovascularization	O
,	O
an	O
essential	O
event	O
for	O
the	O
growth	O
of	O
solid	O
tumors	O
,	O
is	O
regulated	O
by	O
a	O
number	O
of	O
angiogenic	O
factors	O
.	O

One	O
such	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
is	O
considered	O
to	O
exert	O
a	O
potent	O
angiogenic	O
activity	O
,	O
as	O
indicated	O
by	O
immunohistochemical	O
and	O
molecular	O
evidence	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
serum	O
VEGF	O
level	O
(	O
s	O
-	O
VEGF	O
)	O
in	O
patients	O
with	O
renal	O
cell	O
carcinoma	O
(	O
RCC	O
)	O
.	O

s	O
-	O
VEGF	O
in	O
peripheral	O
blood	O
samples	O
was	O
analyzed	O
in	O
40	O
RCC	O
patients	O
and	O
40	O
patients	O
without	O
cancer	O
(	O
controls	O
)	O
using	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunoassay	O
.	O

In	O
20	O
RCC	O
patients	O
,	O
serum	O
samples	O
were	O
obtained	O
separately	O
from	O
the	O
bilateral	O
renal	O
veins	O
.	O

s	O
-	O
VEGF	O
was	O
also	O
measured	O
before	O
,	O
4	O
and	O
8	O
weeks	O
after	O
nephrectomy	O
in	O
11	O
patients	O
.	O

There	O
were	O
significant	O
differences	O
in	O
s	O
-	O
VEGF	O
between	O
the	O
RCC	O
patients	O
and	O
the	O
controls	O
(	O
207	O
.	O
3	O
+	O
/	O
-	O
32	O
.	O
9	O
vs	O
.	O
71	O
.	O
5	O
+	O
/	O
-	O
9	O
.	O
1	O
pg	O
/	O
ml	O
,	O
mean	O
+	O
/	O
-	O
SE	O
)	O
(	O
P	O
less	O
than	O
0	O
.	O
005	O
)	O
,	O
between	O
the	O
tumor	O
-	O
bearing	O
renal	O
veins	O
and	O
the	O
contralateral	O
ones	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
between	O
the	O
pre	O
-	O
and	O
post	O
-	O
nephrectomy	O
situations	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
among	O
the	O
various	O
parameters	O
of	O
tumor	O
status	O
such	O
as	O
tumor	O
extent	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
existence	O
of	O
metastasis	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

s	O
-	O
VEGF	O
significantly	O
correlated	O
with	O
the	O
tumor	O
volume	O
obtained	O
by	O
a	O
three	O
-	O
dimensional	O
measurement	O
(	O
r	O
=	O
0	O
.	O
802	O
,	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
s	O
-	O
VEGF	O
at	O
the	O
cut	O
-	O
off	O
level	O
of	O
100	O
pg	O
/	O
ml	O
,	O
as	O
determined	O
by	O
the	O
receiver	O
-	O
operating	O
-	O
characteristics	O
curve	O
,	O
were	O
80	O
.	O
0	O
%	O
and	O
72	O
.	O
5	O
%	O
,	O
respectively	O
.	O

The	O
results	O
indicate	O
that	O
tumor	O
tissue	O
of	O
RCC	O
liberates	O
VEGF	O
into	O
the	O
systemic	O
blood	O
flow	O
and	O
that	O
s	O
-	O
VEGF	O
is	O
a	O
possible	O
marker	O
for	O
RCC	O
.	O

Insulin	O
-	O
induced	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
retina	O
.	O

PURPOSE	O
:	O
Clinical	O
studies	O
have	O
demonstrated	O
that	O
intensive	O
insulin	O
therapy	O
causes	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
.	O

The	O
mechanisms	O
underlying	O
the	O
initial	O
insulin	O
-	O
induced	O
deterioration	O
of	O
retinal	O
status	O
in	O
patients	O
with	O
diabetes	O
remain	O
unknown	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
known	O
to	O
be	O
operative	O
in	O
the	O
pathogenesis	O
of	O
diabetic	O
retinopathy	O
.	O

The	O
current	O
study	O
was	O
conducted	O
to	O
characterize	O
the	O
effect	O
of	O
insulin	O
on	O
retinal	O
VEGF	O
gene	O
expression	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

METHODS	O
:	O
The	O
effect	O
of	O
insulin	O
on	O
VEGF	O
expression	O
in	O
vivo	O
was	O
examined	O
by	O
in	O
situ	O
hybridization	O
studies	O
of	O
rat	O
retinal	O
VEGF	O
transcripts	O
.	O

To	O
examine	O
the	O
mechanisms	O
by	O
which	O
insulin	O
regulates	O
VEGF	O
expression	O
,	O
human	O
retinal	O
pigment	O
epithelial	O
(	O
RPE	O
)	O
cells	O
were	O
exposed	O
to	O
insulin	O
,	O
and	O
VEGF	O
mRNA	O
levels	O
were	O
quantified	O
with	O
RNase	O
protection	O
assays	O
(	O
RPAs	O
)	O
.	O

Conditioned	O
media	O
from	O
insulin	O
-	O
treated	O
RPE	O
cells	O
were	O
assayed	O
for	O
VEGF	O
protein	O
and	O
capillary	O
endothelial	O
cell	O
proliferation	O
.	O

The	O
capacity	O
of	O
insulin	O
to	O
stimulate	O
the	O
VEGF	O
promoter	O
linked	O
to	O
a	O
luciferase	O
reporter	O
gene	O
was	O
characterized	O
in	O
transient	O
transfection	O
assays	O
.	O

RESULTS	O
:	O
Insulin	O
increased	O
VEGF	O
mRNA	O
levels	O
in	O
the	O
ganglion	O
,	O
inner	O
nuclear	O
,	O
and	O
RPE	O
cell	O
layers	O
.	O

In	O
vitro	O
,	O
insulin	O
increased	O
VEGF	O
mRNA	O
levels	O
in	O
human	O
RPE	O
cells	O
and	O
enhanced	O
VEGF	O
promoter	O
activity	O
without	O
affecting	O
transcript	O
stability	O
.	O

Insulin	O
treatment	O
also	O
increased	O
VEGF	O
protein	O
levels	O
in	O
conditioned	O
RPE	O
cell	O
media	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
a	O
median	O
effective	O
concentration	O
of	O
5	O
nM	O
.	O

The	O
insulin	O
-	O
conditioned	O
RPE	O
cell	O
media	O
stimulated	O
capillary	O
endothelial	O
cell	O
proliferation	O
,	O
an	O
effect	O
that	O
was	O
completely	O
blocked	O
by	O
anti	O
-	O
VEGF	O
neutralizing	O
antibody	O
.	O

CONCLUSIONS	O
:	O
Insulin	O
increases	O
VEGF	O
mRNA	O
and	O
secreted	O
protein	O
levels	O
in	O
RPE	O
cells	O
through	O
enhanced	O
transcription	O
of	O
the	O
VEGF	O
gene	O
.	O

Intensive	O
insulin	O
therapy	O
may	O
cause	O
a	O
transient	O
worsening	O
of	O
retinopathy	O
in	O
patients	O
with	O
diabetes	O
through	O
increased	O
retinal	O
VEGF	O
gene	O
expression	O
.	O

The	O
antiangiogenic	O
agent	O
linomide	O
inhibits	O
the	O
growth	O
rate	O
of	O
von	O
Hippel	O
-	O
Lindau	O
paraganglioma	O
xenografts	O
to	O
mice	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
ascertain	O
the	O
potential	O
usefulness	O
of	O
the	O
antiangiogenic	O
compound	O
linomide	O
for	O
treatment	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
-	O
related	O
tumors	O
.	O

Paraganglioma	O
tissue	O
fragments	O
obtained	O
at	O
surgery	O
from	O
a	O
VHL	O
type	O
2a	O
patient	O
were	O
transplanted	O
s	O
.	O
c	O
.	O
to	O
male	O
BALB	O
/	O
c	O
nu	O
/	O
nu	O
(	O
nude	O
)	O
mice	O
:	O
(	O
a	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	O
for	O
""""	O
prevention	O
""""	O
experiments	O
;	O
and	O
(	O
b	O
)	O
2	O
-	O
3	O
-	O
mm	O
fragments	O
allowed	O
to	O
grow	O
to	O
1	O
cm	O
for	O
""""	O
intervention	O
""""	O
studies	O
.	O

Both	O
groups	O
received	O
either	O
0	O
.	O
5	O
mg	O
/	O
ml	O
linomide	O
in	O
drinking	O
water	O
or	O
acidified	O
water	O
and	O
were	O
followed	O
until	O
tumor	O
diameter	O
reached	O
3	O
cm	O
or	O
for	O
4	O
weeks	O
.	O

In	O
both	O
the	O
prevention	O
and	O
intervention	O
experiments	O
,	O
a	O
significant	O
diminution	O
of	O
tumor	O
size	O
and	O
weight	O
was	O
observed	O
in	O
the	O
drug	O
-	O
treated	O
animals	O
.	O

In	O
vivo	O
nuclear	O
magnetic	O
resonance	O
analysis	O
of	O
tumor	O
blood	O
flow	O
in	O
linomide	O
-	O
treated	O
animals	O
showed	O
localization	O
of	O
blood	O
vessels	O
almost	O
exclusively	O
to	O
the	O
periphery	O
of	O
the	O
poorly	O
vascularized	O
tumors	O
with	O
a	O
significant	O
reduction	O
of	O
both	O
vascular	O
functionality	O
and	O
vasodilation	O
.	O

Histological	O
examination	O
of	O
tumors	O
from	O
linomide	O
-	O
treated	O
animals	O
revealed	O
marked	O
avascularity	O
.	O

Treated	O
animals	O
also	O
displayed	O
a	O
2	O
.	O
4	O
-	O
fold	O
reduction	O
of	O
tumor	O
vascular	O
endothelial	O
growth	O
factor	O
mRNA	O
levels	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
in	O
VHL	O
disease	O
,	O
therapy	O
directed	O
at	O
inhibition	O
of	O
constitutively	O
expressed	O
VEGF	O
induction	O
of	O
angiogenesis	O
by	O
VHL	O
tumors	O
may	O
constitute	O
an	O
effective	O
medical	O
treatment	O
.	O

Spacing	O
effects	O
on	O
the	O
memory	O
for	O
faces	O
.	O

25	O
undergraduate	O
women	O
studied	O
12	O
stimulus	O
pictures	O
of	O
female	O
faces	O
successively	O
presented	O
in	O
spaced	O
or	O
massed	O
conditions	O
and	O
made	O
affective	O
judgments	O
for	O
the	O
pictures	O
along	O
a	O
dimension	O
of	O
like	O
to	O
dislike	O
.	O

One	O
week	O
after	O
the	O
exposure	O
(	O
study	O
)	O
period	O
,	O
subjects	O
were	O
given	O
an	O
identification	O
test	O
comprised	O
of	O
photographs	O
of	O
the	O
same	O
female	O
faces	O
with	O
different	O
expressions	O
.	O

Analysis	O
showed	O
that	O
the	O
pictures	O
presented	O
in	O
the	O
spaced	O
condition	O
were	O
more	O
frequently	O
and	O
accurately	O
identified	O
than	O
those	O
presented	O
under	O
the	O
massed	O
condition	O
and	O
that	O
affective	O
judgment	O
was	O
unrelated	O
to	O
conditions	O
of	O
presentation	O
.	O

Phosphatidyl	O
serine	O
exposure	O
during	O
apoptosis	O
precedes	O
release	O
of	O
cytochrome	O
c	O
and	O
decrease	O
in	O
mitochondrial	O
transmembrane	O
potential	O
.	O

Time	O
kinetics	O
of	O
phosphatidyl	O
serine	O
(	O
PS	O
)	O
exposure	O
were	O
compared	O
to	O
other	O
apoptotic	O
parameters	O
following	O
different	O
apoptotic	O
stimuli	O
.	O

Our	O
data	O
indicate	O
that	O
anti	O
-	O
Fas	O
treatment	O
of	O
L929sAhFas	B
cells	O
results	O
in	O
rapid	O
exposure	O
of	O
PS	O
,	O
which	O
precedes	O
decrease	O
in	O
mitochondrial	O
transmembrane	O
potential	O
(	O
DeltaPsi	O
(	O
m	O
)	O
)	O
and	O
release	O
of	O
cytochrome	O
c	O
,	O
indicating	O
that	O
PS	O
exposure	O
occurs	O
independently	O
of	O
these	O
mitochondrial	O
events	O
.	O

Also	O
during	O
TNF	O
-	O
,	O
etoposide	O
-	O
or	O
staurosporine	O
-	O
mediated	O
apoptosis	O
in	O
PC60	B
RI	O
/	O
RII	O
cells	O
,	O
PS	O
-	O
positive	O
cells	O
were	O
observed	O
before	O
they	O
had	O
a	O
decreased	O
DeltaPsi	O
(	O
m	O
)	O
.	O

However	O
,	O
during	O
growth	O
factor	O
depletion	O
-	O
induced	O
death	O
of	O
32D	B
cells	O
,	O
both	O
phenomena	O
seemed	O
to	O
occur	O
at	O
the	O
same	O
time	O
.	O

LMP1	O
of	O
Epstein	O
-	O
Barr	O
virus	O
induces	O
proliferation	O
of	O
primary	O
mouse	O
embryonic	O
fibroblasts	O
and	O
cooperatively	O
transforms	O
the	O
cells	O
with	O
a	O
p16	O
-	O
insensitive	O
CDK4	O
oncogene	O
.	O

The	O
latent	O
membrane	O
protein	O
LMP1	O
of	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
is	O
often	O
present	O
in	O
EBV	O
-	O
associated	O
malignancies	O
including	O
nasopharyngeal	O
carcinoma	O
and	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Previous	O
work	O
demonstrates	O
that	O
the	O
LMP1	O
gene	O
of	O
EBV	O
is	O
sufficient	O
to	O
transform	O
certain	O
established	O
rodent	O
fibroblast	O
cell	O
lines	O
and	O
to	O
induce	O
the	O
tumorigenicity	O
of	O
some	O
human	O
epithelial	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
LMP1	O
plays	O
pleiotropic	O
roles	O
in	O
cell	O
growth	O
arrest	O
,	O
differentiation	O
,	O
and	O
apoptosis	O
,	O
depending	O
on	O
the	O
background	O
of	O
the	O
target	O
cells	O
.	O

To	O
examine	O
the	O
roles	O
of	O
LMP1	O
in	O
cell	O
proliferation	O
and	O
growth	O
regulation	O
in	O
primary	O
culture	O
cells	O
,	O
we	O
constructed	O
a	O
recombinant	O
retrovirus	O
containing	O
an	O
LMP1	O
gene	O
.	O

With	O
this	O
retrovirus	O
,	O
LMP1	O
was	O
shown	O
to	O
stimulate	O
the	O
proliferation	O
of	O
primary	O
mouse	O
embryonic	O
fibroblasts	O
(	O
MEF	O
cells	O
)	O
.	O

It	O
has	O
a	O
mitogenic	O
activity	O
for	O
MEF	O
cells	O
,	O
as	O
demonstrated	O
by	O
an	O
immediate	O
induction	O
of	O
cell	O
doubling	O
time	O
.	O

In	O
addition	O
,	O
it	O
significantly	O
extends	O
the	O
passage	O
number	O
of	O
MEF	O
cells	O
to	O
more	O
than	O
30	O
after	O
retroviral	O
infection	O
,	O
compared	O
with	O
less	O
than	O
5	O
for	O
uninfected	O
MEF	O
cells	O
.	O

Furthermore	O
,	O
LMP1	O
cooperates	O
with	O
a	O
p16	O
-	O
insensitive	O
CDK4	O
(	O
R24C	O
)	O
oncogene	O
in	O
transforming	O
MEF	O
cells	O
.	O

Our	O
results	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
abilities	O
of	O
the	O
LMP1	O
gene	O
,	O
acting	O
alone	O
,	O
to	O
effectively	O
induce	O
the	O
proliferation	O
of	O
primary	O
MEF	O
cells	O
and	O
of	O
its	O
cooperativity	O
with	O
another	O
cellular	O
oncogene	O
in	O
transforming	O
primary	O
cells	O
.	O

Obstructive	O
nephropathy	O
:	O
lessons	O
from	O
cystic	O
kidney	O
disease	O
.	O

Obstructive	O
nephropathy	O
is	O
one	O
of	O
the	O
most	O
important	O
causes	O
of	O
renal	O
failure	O
in	O
infants	O
and	O
children	O
,	O
while	O
polycystic	O
kidney	O
disease	O
(	O
PKD	O
)	O
is	O
a	O
major	O
cause	O
of	O
renal	O
failure	O
in	O
the	O
adult	O
population	O
.	O

This	O
review	O
summarizes	O
the	O
evidence	O
that	O
there	O
may	O
be	O
a	O
number	O
of	O
mechanisms	O
common	O
to	O
the	O
pathophysiology	O
of	O
both	O
conditions	O
.	O

In	O
animal	O
models	O
of	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
the	O
renal	O
tubular	O
expression	O
of	O
epidermal	O
growth	O
factor	O
is	O
suppressed	O
,	O
and	O
expression	O
of	O
clusterin	O
is	O
increased	O
,	O
both	O
of	O
which	O
suggest	O
arrested	O
maturation	O
or	O
dedifferentiation	O
of	O
the	O
tubular	O
cell	O
.	O

There	O
is	O
a	O
marked	O
increase	O
in	O
apoptosis	O
of	O
epithelial	O
cells	O
in	O
dilated	O
tubules	O
,	O
associated	O
with	O
an	O
increase	O
in	O
apoptotic	O
stimuli	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
is	O
activated	O
in	O
both	O
obstructive	O
nephropathy	O
and	O
PKD	O
,	O
which	O
may	O
contribute	O
to	O
tubular	O
atrophy	O
and	O
interstitial	O
fibrosis	O
,	O
which	O
characterize	O
the	O
progression	O
of	O
both	O
conditions	O
.	O

Focal	O
cystic	O
dilatation	O
of	O
the	O
tubule	O
is	O
found	O
in	O
obstructive	O
nephropathy	O
,	O
while	O
tubular	O
obstruction	O
is	O
present	O
in	O
cystic	O
kidney	O
disease	O
.	O

It	O
is	O
therefore	O
likely	O
that	O
elucidation	O
of	O
the	O
effects	O
of	O
mechanical	O
stretch	O
on	O
renal	O
tubular	O
epithelial	O
cells	O
will	O
contribute	O
to	O
our	O
understanding	O
of	O
both	O
conditions	O
.	O

Autotaxin	O
(	O
ATX	O
)	O
,	O
a	O
potent	O
tumor	O
motogen	O
,	O
augments	O
invasive	O
and	O
metastatic	O
potential	O
of	O
ras	O
-	O
transformed	O
cells	O
.	O

Autotaxin	O
(	O
ATX	O
)	O
,	O
an	O
exo	O
-	O
nucleotide	O
pyrophosphatase	O
and	O
phosphodiesterase	O
,	O
was	O
originally	O
isolated	O
as	O
a	O
potent	O
stimulator	O
of	O
tumor	O
cell	O
motility	O
.	O

In	O
order	O
to	O
study	O
whether	O
ATX	O
expression	O
affects	O
motility	O
-	O
dependent	O
processes	O
such	O
as	O
invasion	O
and	O
metastasis	O
,	O
we	O
stably	O
transfected	O
full	O
-	O
length	O
ATX	O
cDNA	O
into	O
two	O
non	O
-	O
expressing	O
cell	O
lines	O
,	O
parental	O
and	O
ras	O
-	O
transformed	O
NIH3T3	B
(	O
clone7	O
)	O
cells	O
.	O

The	O
effect	O
of	O
ATX	O
secretion	O
on	O
in	O
vitro	O
cell	O
motility	O
was	O
variable	O
.	O

The	O
ras	O
-	O
transformed	O
,	O
ATX	O
-	O
secreting	O
subclones	O
had	O
enhanced	O
motility	O
to	O
ATX	O
as	O
chemoattractant	O
,	O
but	O
there	O
was	O
little	O
difference	O
in	O
the	O
motility	O
responses	O
of	O
NIH3T3	B
cells	O
transfected	O
with	O
atx	O
,	O
an	O
inactive	O
mutant	O
gene	O
,	O
or	O
empty	O
vector	O
.	O

In	O
MatrigelTM	O
invasion	O
assays	O
,	O
all	O
subclones	O
,	O
which	O
secreted	O
enzymatically	O
active	O
ATX	O
,	O
demonstrated	O
greater	O
spontaneous	O
and	O
ATX	O
-	O
stimulated	O
invasion	O
than	O
appropriate	O
controls	O
.	O

This	O
difference	O
in	O
invasiveness	O
was	O
not	O
caused	O
by	O
differences	O
in	O
gelatinase	O
production	O
,	O
which	O
was	O
constant	O
within	O
each	O
group	O
of	O
transfectants	O
.	O

In	O
vivo	O
studies	O
with	O
athymic	O
nude	O
mice	O
demonstrated	O
that	O
injection	O
of	O
atx	O
-	O
transfected	O
NIH3T3	B
cells	O
resulted	O
in	O
a	O
weak	O
tumorigenic	O
capacity	O
with	O
few	O
experimental	O
metastases	O
.	O

Combination	O
of	O
ATX	O
expression	O
with	O
ras	O
transformation	O
produced	O
cells	O
with	O
greatly	O
amplified	O
tumorigenesis	O
and	O
metastatic	O
potential	O
compared	O
to	O
ras	O
-	O
transformed	O
controls	O
.	O

Thus	O
,	O
ATX	O
appears	O
to	O
augment	O
cellular	O
characteristics	O
necessary	O
for	O
tumor	O
aggressiveness	O
.	O

Tumour	O
-	O
specific	O
distribution	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
supports	O
a	O
pathogenetic	O
role	O
in	O
breast	O
and	O
ovarian	O
cancer	O
.	O

The	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
breast	O
and	O
ovarian	O
cancers	O
remains	O
elusive	O
.	O

Direct	O
involvement	O
of	O
BRCA1	O
in	O
the	O
development	O
of	O
breast	O
and	O
ovarian	O
cancer	O
is	O
suggested	O
by	O
the	O
finding	O
that	O
the	O
BRCA1	O
promoter	O
region	O
CpG	O
island	O
is	O
methylated	O
in	O
a	O
proportion	O
of	O
breast	O
and	O
ovarian	O
cancers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
incidence	O
of	O
BRCA1	O
promoter	O
region	O
methylation	O
in	O
tumours	O
in	O
which	O
loss	O
of	O
BRCA1	O
has	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
(	O
breast	O
and	O
ovarian	O
carcinomas	O
)	O
with	O
the	O
incidence	O
in	O
tumours	O
in	O
which	O
BRCA1	O
is	O
unlikely	O
to	O
play	O
a	O
role	O
in	O
pathogenesis	O
.	O

Promoter	O
region	O
hypermethylation	O
was	O
significantly	O
more	O
common	O
(	O
P	O
<	O
0	O
.	O
008	O
)	O
in	O
breast	O
and	O
ovarian	O
cancer	O
(	O
6	O
/	O
38	O
tumours	O
methylated	O
)	O
than	O
in	O
colon	O
cancer	O
(	O
0	O
/	O
35	O
tumours	O
methylated	O
)	O
or	O
in	O
leukaemias	O
(	O
0	O
/	O
19	O
samples	O
methylated	O
)	O
.	O

The	O
restriction	O
of	O
BRCA1	O
promoter	O
region	O
hypermethylation	O
to	O
breast	O
and	O
ovarian	O
cancer	O
is	O
consistent	O
with	O
a	O
pathogenetic	O
role	O
of	O
BRCA1	O
promoter	O
methylation	O
in	O
these	O
tumours	O
.	O

We	O
suggest	O
that	O
the	O
rarity	O
of	O
observed	O
BRCA1	O
mutations	O
in	O
sporadic	O
breast	O
and	O
ovarian	O
cancer	O
is	O
due	O
to	O
the	O
greater	O
likelihood	O
of	O
BRCA1	O
inactivation	O
by	O
non	O
-	O
mutational	O
mechanisms	O
such	O
as	O
methylation	O
.	O

Regulation	O
of	O
the	O
resident	O
chromosomal	O
copy	O
of	O
c	O
-	O
myc	O
by	O
c	O
-	O
Myb	O
is	O
involved	O
in	O
myeloid	O
leukemogenesis	O
.	O

c	O
-	O
myb	O
is	O
a	O
frequent	O
target	O
of	O
retroviral	O
insertional	O
mutagenesis	O
in	O
murine	O
leukemia	O
virus	O
-	O
induced	O
myeloid	O
leukemia	O
.	O

Induction	O
of	O
the	O
leukemogenic	O
phenotype	O
is	O
generally	O
associated	O
with	O
inappropriate	O
expression	O
of	O
this	O
transcriptional	O
regulator	O
.	O

Despite	O
intensive	O
investigations	O
,	O
the	O
target	O
genes	O
of	O
c	O
-	O
myb	O
that	O
are	O
specifically	O
involved	O
in	O
development	O
of	O
these	O
myeloid	O
lineage	O
neoplasms	O
are	O
still	O
unknown	O
.	O

In	O
vitro	O
assays	O
have	O
indicated	O
that	O
c	O
-	O
myc	O
may	O
be	O
a	O
target	O
gene	O
of	O
c	O
-	O
Myb	O
;	O
however	O
,	O
regulation	O
of	O
the	O
resident	O
chromosomal	O
gene	O
has	O
not	O
yet	O
been	O
demonstrated	O
.	O

To	O
address	O
this	O
question	O
further	O
,	O
we	O
analyzed	O
the	O
expression	O
of	O
c	O
-	O
myc	O
in	O
a	O
myeloblastic	O
cell	O
line	O
,	O
M1	B
,	O
expressing	O
a	O
conditionally	O
active	O
c	O
-	O
Myb	O
-	O
estrogen	O
receptor	O
fusion	O
protein	O
(	O
MybER	O
)	O
.	O

Activation	O
of	O
MybER	O
both	O
prevented	O
the	O
growth	O
arrest	O
induced	O
by	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
and	O
rapidly	O
restored	O
c	O
-	O
myc	O
expression	O
in	O
nearly	O
terminal	O
differentiated	O
cells	O
that	O
had	O
been	O
exposed	O
to	O
IL	O
-	O
6	O
for	O
3	O
days	O
.	O

Restoration	O
occurred	O
in	O
the	O
presence	O
of	O
a	O
protein	O
synthesis	O
inhibitor	O
but	O
not	O
after	O
a	O
transcriptional	O
block	O
,	O
indicating	O
that	O
c	O
-	O
myc	O
is	O
a	O
direct	O
,	O
transcriptionally	O
regulated	O
target	O
of	O
c	O
-	O
Myb	O
.	O

c	O
-	O
myc	O
is	O
a	O
major	O
target	O
that	O
transduces	O
Myb	O
'	O
s	O
proliferative	O
signal	O
,	O
as	O
shown	O
by	O
the	O
ability	O
of	O
a	O
c	O
-	O
Myc	O
-	O
estrogen	O
receptor	O
fusion	O
protein	O
alone	O
to	O
also	O
reverse	O
growth	O
arrest	O
in	O
this	O
system	O
.	O

To	O
investigate	O
the	O
possibility	O
that	O
this	O
regulatory	O
connection	O
contributes	O
to	O
Myb	O
'	O
s	O
oncogenicity	O
,	O
we	O
expressed	O
a	O
dominant	O
negative	O
Myb	O
in	O
the	O
myeloid	O
leukemic	O
cell	O
line	O
RI	B
-	I
4	I
-	I
11	I
.	O

In	O
this	O
cell	O
line	O
,	O
c	O
-	O
myb	O
is	O
activated	O
by	O
insertional	O
mutagenesis	O
and	O
can	O
not	O
be	O
effectively	O
down	O
regulated	O
by	O
cytokine	O
.	O

Myb	O
'	O
s	O
ability	O
to	O
regulate	O
c	O
-	O
myc	O
'	O
s	O
expression	O
was	O
also	O
demonstrated	O
in	O
these	O
cells	O
,	O
showing	O
a	O
mechanism	O
through	O
which	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
myb	O
can	O
exert	O
its	O
oncogenic	O
potential	O
in	O
myeloid	O
lineage	O
hematopoietic	O
cells	O
.	O

Oncogenic	O
epidermal	O
growth	O
factor	O
receptor	O
mutants	O
with	O
tandem	O
duplication	O
:	O
gene	O
structure	O
and	O
effects	O
on	O
receptor	O
function	O
.	O

A	O
number	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
deletion	O
mutants	O
have	O
been	O
identified	O
in	O
gliomas	O
,	O
in	O
which	O
the	O
EGFR	O
gene	O
is	O
frequently	O
amplified	O
and	O
rearranged	O
.	O

We	O
have	O
previously	O
characterized	O
the	O
structure	O
of	O
a	O
gene	O
in	O
A	B
-	I
172	I
human	O
glioma	O
cells	O
that	O
encodes	O
a	O
190	O
-	O
kDa	O
EGFR	O
mutant	O
with	O
tandem	O
duplication	O
of	O
the	O
tyrosine	O
kinase	O
(	O
TK	O
)	O
and	O
calcium	O
-	O
mediated	O
internalization	O
(	O
CAIN	O
)	O
domains	O
.	O

Here	O
we	O
describe	O
a	O
185	O
-	O
kDa	O
tandem	O
duplication	O
mutant	O
(	O
TDM	O
)	O
that	O
is	O
expressed	O
in	O
KE	O
and	O
A	B
-	I
1235	I
glioma	O
cells	O
,	O
along	O
with	O
certain	O
functional	O
characteristics	O
of	O
the	O
mutants	O
.	O

The	O
corresponding	O
transcripts	O
in	O
KE	O
and	O
A	B
-	I
1235	I
cells	O
contain	O
1053	O
additional	O
nucleotides	O
representing	O
an	O
in	O
-	O
frame	O
duplication	O
of	O
exons	O
18	O
through	O
25	O
which	O
encode	O
the	O
entire	O
TK	O
region	O
and	O
a	O
portion	O
of	O
the	O
CAIN	O
domain	O
.	O

As	O
with	O
duplication	O
of	O
the	O
entire	O
TK	O
/	O
CAIN	O
region	O
(	O
exons	O
18	O
-	O
26	O
)	O
in	O
A	B
-	I
172	I
cells	O
,	O
duplication	O
of	O
exons	O
18	O
-	O
25	O
is	O
associated	O
with	O
a	O
specific	O
genomic	O
rearrangement	O
between	O
flanking	O
introns	O
.	O

Involved	O
introns	O
contain	O
homology	O
to	O
recombination	O
signal	O
sequence	O
(	O
RSS	O
)	O
heptamers	O
present	O
in	O
the	O
V	O
(	O
D	O
)	O
J	O
region	O
of	O
the	O
T	O
lymphocyte	O
receptor	O
gene	O
.	O

In	O
defined	O
medium	O
,	O
both	O
oncogenic	O
TDM	O
are	O
constitutively	O
autophosphorylated	O
and	O
inefficiently	O
downregulated	O
.	O

High	O
-	O
affinity	O
binding	O
is	O
reduced	O
in	O
EGFR	O
.	O
TDM	O
/	O
18	O
-	O
26	O
,	O
although	O
the	O
t1	O
/	O
2	O
of	O
receptor	O
internalization	O
is	O
not	O
prolonged	O
.	O

Ciprofloxacin	O
mediated	O
cell	O
growth	O
inhibition	O
,	O
S	O
/	O
G2	O
-	O
M	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
in	O
a	O
human	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
cell	O
line	O
.	O

The	O
second	O
most	O
prevalent	O
urological	O
malignancy	O
in	O
middle	O
aged	O
and	O
elderly	O
men	O
is	O
bladder	O
cancer	O
,	O
with	O
90	O
%	O
of	O
the	O
cases	O
being	O
transitional	O
cell	O
carcinomas	O
.	O

The	O
success	O
of	O
current	O
systemic	O
and	O
intravesical	O
therapeutic	O
agents	O
,	O
such	O
as	O
cisplatin	O
,	O
thiotepa	O
,	O
Adriamycin	O
,	O
mitomycin	O
C	O
,	O
and	O
bacillus	O
Calmette	O
-	O
Guerin	O
,	O
is	O
limited	O
with	O
recurrence	O
rates	O
reduced	O
to	O
17	O
-	O
44	O
%	O
.	O

In	O
addition	O
,	O
most	O
of	O
these	O
agents	O
require	O
instrumentation	O
of	O
the	O
urinary	O
tract	O
and	O
are	O
delivered	O
at	O
a	O
significant	O
cost	O
and	O
potential	O
morbidity	O
to	O
the	O
patient	O
.	O

Fluroquinolone	O
antibiotics	O
such	O
as	O
ciprofloxacin	O
,	O
which	O
can	O
be	O
administered	O
p	O
.	O
o	O
.	O
,	O
may	O
have	O
a	O
profound	O
effect	O
in	O
bladder	O
cancer	O
management	O
.	O

This	O
is	O
primarily	O
based	O
on	O
limited	O
in	O
vitro	O
studies	O
on	O
tumor	O
cells	O
derived	O
from	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
that	O
revealed	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibition	O
of	O
cell	O
growth	O
by	O
ciprofloxacin	O
at	O
concentrations	O
that	O
are	O
easily	O
attainable	O
in	O
the	O
urine	O
of	O
patients	O
.	O

However	O
,	O
the	O
mechanism	O
(	O
s	O
)	O
by	O
which	O
ciprofloxacin	O
elicits	O
its	O
biological	O
effects	O
on	O
bladder	O
cancer	O
cells	O
is	O
not	O
well	O
documented	O
.	O

Our	O
experimental	O
data	O
confirm	O
previous	O
studies	O
showing	O
the	O
in	O
vitro	O
cell	O
growth	O
inhibition	O
of	O
the	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
cell	O
line	O
HTB9	B
and	O
further	O
showed	O
the	O
induction	O
of	O
cell	O
cycle	O
arrest	O
at	O
the	O
S	O
/	O
G2	O
-	O
M	O
checkpoints	O
.	O

In	O
addition	O
,	O
we	O
found	O
down	O
-	O
regulation	O
of	O
cyclin	O
B	O
,	O
cyclin	O
E	O
,	O
and	O
dephosphorylation	O
of	O
cdk2	O
in	O
ciprofloxacin	O
-	O
treated	O
bladder	O
tumor	O
cells	O
.	O

There	O
was	O
also	O
an	O
up	O
-	O
regulation	O
of	O
Bax	O
,	O
which	O
altered	O
the	O
Bax	O
:	O
Bcl	O
-	O
2	O
ratio	O
,	O
which	O
may	O
be	O
responsible	O
for	O
mitochondrial	O
depolarization	O
reported	O
to	O
be	O
involved	O
prior	O
to	O
the	O
induction	O
of	O
apoptosis	O
.	O

The	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitor	O
p21WAF1	O
level	O
was	O
found	O
to	O
be	O
decreased	O
within	O
12	O
h	O
of	O
ciprofloxacin	O
treatment	O
and	O
disappeared	O
completely	O
when	O
HTB9	B
cells	O
were	O
treated	O
with	O
200	O
microg	O
/	O
ml	O
ciprofloxacin	O
for	O
24	O
h	O
.	O

The	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
closely	O
correlated	O
with	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
and	O
CPP32	O
activation	O
.	O

Recent	O
studies	O
revealed	O
that	O
p21WAF1	O
protects	O
cells	O
from	O
apoptosis	O
by	O
arresting	O
them	O
in	O
G1	O
and	O
further	O
binds	O
to	O
pro	O
-	O
caspase	O
-	O
3	O
,	O
preventing	O
its	O
activation	O
and	O
thus	O
,	O
inhibiting	O
the	O
apoptotic	O
cascade	O
.	O

Hence	O
,	O
the	O
down	O
-	O
regulation	O
of	O
p21WAF1	O
,	O
together	O
with	O
the	O
alterations	O
in	O
Bax	O
and	O
cdk2	O
as	O
observed	O
in	O
our	O
studies	O
,	O
may	O
define	O
a	O
novel	O
mechanism	O
by	O
which	O
ciprofloxacin	O
inhibits	O
tumor	O
cell	O
growth	O
and	O
induces	O
apoptotic	O
cell	O
death	O
.	O

The	O
results	O
of	O
our	O
current	O
studies	O
provide	O
strong	O
experimental	O
evidence	O
for	O
the	O
use	O
of	O
ciprofloxacin	O
as	O
a	O
potential	O
preventive	O
and	O
/	O
or	O
therapeutic	O
agent	O
for	O
the	O
management	O
of	O
transitional	O
cell	O
carcinoma	O
of	O
the	O
bladder	O
.	O

Genuine	O
monovalent	O
ligands	O
of	O
TrkA	O
nerve	O
growth	O
factor	O
receptors	O
reveal	O
a	O
novel	O
pharmacological	O
mechanism	O
of	O
action	O
.	O

Developing	O
small	O
molecule	O
agonistic	O
ligands	O
for	O
tyrosine	O
kinase	O
receptors	O
has	O
been	O
difficult	O
,	O
and	O
it	O
is	O
generally	O
thought	O
that	O
such	O
ligands	O
require	O
bivalency	O
.	O

Moreover	O
,	O
multisubunit	O
receptors	O
are	O
difficult	O
to	O
target	O
,	O
because	O
each	O
subunit	O
contributes	O
to	O
ligand	O
affinity	O
,	O
and	O
each	O
subunit	O
may	O
have	O
distinct	O
and	O
sometimes	O
opposing	O
functions	O
.	O

Here	O
,	O
the	O
nerve	O
growth	O
factor	O
receptor	O
subunits	O
p75	O
and	O
the	O
tyrosine	O
kinase	O
TrkA	O
were	O
studied	O
using	O
artificial	O
ligands	O
that	O
bind	O
specifically	O
to	O
their	O
extracellular	O
domain	O
.	O

Bivalent	O
TrkA	O
ligands	O
afford	O
robust	O
signals	O
.	O

However	O
,	O
genuine	O
monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
afford	O
partial	O
agonism	O
,	O
activate	O
the	O
tyrosine	O
kinase	O
activity	O
,	O
cause	O
receptor	O
internalization	O
,	O
and	O
induce	O
survival	O
and	O
differentiation	O
in	O
cell	O
lines	O
and	O
primary	O
neurons	O
.	O

Monomeric	O
and	O
monovalent	O
TrkA	O
ligands	O
can	O
synergize	O
with	O
ligands	O
that	O
bind	O
the	O
p75	O
subunit	O
.	O

However	O
,	O
the	O
p75	O
ligands	O
used	O
in	O
this	O
study	O
must	O
be	O
bivalent	O
,	O
and	O
monovalent	O
p75	O
ligands	O
have	O
no	O
effect	O
.	O

These	O
findings	O
will	O
be	O
useful	O
in	O
designing	O
and	O
developing	O
screens	O
of	O
small	O
molecules	O
selective	O
for	O
tyrosine	O
kinase	O
receptors	O
and	O
indicate	O
that	O
strategies	O
for	O
designing	O
agonists	O
of	O
multisubunit	O
receptors	O
require	O
consideration	O
of	O
the	O
role	O
of	O
each	O
subunit	O
.	O

Last	O
,	O
the	O
strategy	O
of	O
using	O
anti	O
-	O
receptor	O
mAbs	O
and	O
small	O
molecule	O
hormone	O
mimics	O
as	O
receptor	O
ligands	O
could	O
be	O
applied	O
to	O
the	O
study	O
of	O
many	O
other	O
heteromeric	O
cell	O
surface	O
receptors	O
.	O

Vascular	O
proliferation	O
and	O
enhanced	O
expression	O
of	O
endothelial	O
nitric	O
oxide	O
synthase	O
in	O
human	O
peritoneum	O
exposed	O
to	O
long	O
-	O
term	O
peritoneal	O
dialysis	O
.	O

Long	O
-	O
term	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
is	O
associated	O
with	O
alterations	O
in	O
peritoneal	O
permeability	O
and	O
loss	O
of	O
ultrafiltration	O
.	O

These	O
changes	O
originate	O
from	O
increased	O
peritoneal	O
surface	O
area	O
,	O
but	O
the	O
morphologic	O
and	O
molecular	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O

The	O
hypothesis	O
that	O
modifications	O
of	O
activity	O
and	O
/	O
or	O
expression	O
of	O
nitric	O
oxide	O
synthase	O
(	O
NOS	O
)	O
isozymes	O
might	O
play	O
a	O
role	O
in	O
these	O
modifications	O
,	O
via	O
enhanced	O
local	O
production	O
of	O
nitric	O
oxide	O
,	O
was	O
tested	O
in	O
this	O
study	O
.	O

NOS	O
activities	O
were	O
measured	O
by	O
the	O
L	O
-	O
citrulline	O
assay	O
in	O
peritoneal	O
biopsies	O
from	O
seven	O
control	O
subjects	O
,	O
eight	O
uremic	O
patients	O
immediately	O
before	O
the	O
onset	O
of	O
PD	O
,	O
and	O
13	O
uremic	O
patients	O
on	O
short	O
-	O
term	O
(	O
less	O
than	O
18	O
mo	O
,	O
n	O
=	O
6	O
)	O
or	O
long	O
-	O
term	O
(	O
greater	O
than	O
18	O
mo	O
,	O
n	O
=	O
7	O
)	O
PD	O
.	O

Peritoneal	O
NOS	O
activity	O
is	O
increased	O
fivefold	O
in	O
long	O
-	O
term	O
PD	O
patients	O
compared	O
with	O
control	O
subjects	O
.	O

In	O
uremic	O
patients	O
,	O
NOS	O
activity	O
is	O
positively	O
correlated	O
with	O
the	O
duration	O
of	O
PD	O
.	O

Increased	O
NOS	O
activity	O
is	O
mediated	O
solely	O
by	O
Ca	O
(	O
2	O
+	O
)	O
-	O
dependent	O
NOS	O
and	O
,	O
as	O
shown	O
by	O
immunoblotting	O
,	O
an	O
upregulation	O
of	O
endothelial	O
NOS	O
.	O

The	O
biologic	O
relevance	O
of	O
increased	O
NOS	O
in	O
long	O
-	O
term	O
PD	O
was	O
demonstrated	O
by	O
enhanced	O
nitrotyrosine	O
immunoreactivity	O
and	O
a	O
significant	O
increase	O
in	O
vascular	O
density	O
and	O
endothelial	O
area	O
in	O
the	O
peritoneum	O
.	O

Immunoblotting	O
and	O
immunostaining	O
studies	O
demonstrated	O
an	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mostly	O
along	O
the	O
endothelium	O
lining	O
peritoneal	O
blood	O
vessels	O
in	O
long	O
-	O
term	O
PD	O
patients	O
.	O

In	O
the	O
latter	O
,	O
VEGF	O
colocalized	O
with	O
the	O
advanced	O
glycation	O
end	O
product	O
pentosidine	O
deposits	O
.	O

These	O
data	O
provide	O
a	O
morphologic	O
(	O
angiogenesis	O
and	O
increased	O
endothelial	O
area	O
)	O
and	O
molecular	O
(	O
enhanced	O
NOS	O
activity	O
and	O
endothelial	O
NOS	O
upregulation	O
)	O
basis	O
for	O
explaining	O
the	O
permeability	O
changes	O
observed	O
in	O
long	O
-	O
term	O
PD	O
.	O

They	O
also	O
support	O
the	O
implication	O
of	O
local	O
advanced	O
glycation	O
end	O
product	O
deposits	O
and	O
liberation	O
of	O
VEGF	O
in	O
that	O
process	O
.	O

Adenovirus	O
-	O
mediated	O
gene	O
transfer	O
of	O
endostatin	O
in	O
vivo	O
results	O
in	O
high	O
level	O
of	O
transgene	O
expression	O
and	O
inhibition	O
of	O
tumor	O
growth	O
and	O
metastases	O
.	O

Inhibition	O
of	O
angiogenesis	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
strategy	O
in	O
cancer	O
therapy	O
in	O
mice	O
.	O

However	O
,	O
its	O
widespread	O
application	O
has	O
been	O
hampered	O
by	O
difficulties	O
in	O
the	O
large	O
-	O
scale	O
production	O
of	O
the	O
antiangiogenic	O
proteins	O
.	O

This	O
limitation	O
may	O
be	O
resolved	O
by	O
in	O
vivo	O
delivery	O
and	O
expression	O
of	O
the	O
antiangiogenic	O
genes	O
.	O

We	O
have	O
constructed	O
a	O
recombinant	O
adenovirus	O
that	O
expresses	O
murine	O
endostatin	O
that	O
is	O
biologically	O
active	O
both	O
in	O
vitro	O
,	O
as	O
determined	O
in	O
endothelial	O
cell	O
proliferation	O
assays	O
,	O
and	O
in	O
vivo	O
,	O
by	O
suppression	O
of	O
angiogenesis	O
induced	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
165	O
.	O

Persistent	O
high	O
serum	O
levels	O
of	O
endostatin	O
(	O
605	O
-	O
1740	O
ng	O
/	O
ml	O
;	O
mean	O
,	O
936	O
ng	O
/	O
ml	O
)	O
were	O
achieved	O
after	O
systemic	O
administration	O
of	O
the	O
vector	O
to	O
nude	O
mice	O
,	O
which	O
resulted	O
in	O
significant	O
reduction	O
of	O
the	O
growth	O
rates	O
and	O
the	O
volumes	O
of	O
JC	O
breast	O
carcinoma	O
and	O
Lewis	O
lung	O
carcinoma	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
and	O
P	O
less	O
than	O
0	O
.	O
05	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
endostatin	O
vector	O
treatment	O
completely	O
prevented	O
the	O
formation	O
of	O
pulmonary	O
micrometastases	O
in	O
Lewis	O
lung	O
carcinoma	O
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
.	O

Immunohistochemical	O
staining	O
of	O
the	O
tumors	O
demonstrated	O
a	O
decreased	O
number	O
of	O
blood	O
vessels	O
in	O
the	O
treatment	O
group	O
versus	O
the	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
present	O
study	O
clearly	O
demonstrates	O
the	O
potential	O
of	O
vector	O
-	O
mediated	O
antiangiogenic	O
gene	O
therapy	O
as	O
a	O
component	O
in	O
cancer	O
therapy	O
.	O

Active	O
hair	O
growth	O
(	O
anagen	O
)	O
is	O
associated	O
with	O
angiogenesis	O
.	O

After	O
the	O
completion	O
of	O
skin	O
development	O
,	O
angiogenesis	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
growth	O
of	O
new	O
capillaries	O
from	O
pre	O
-	O
existing	O
blood	O
vessels	O
,	O
is	O
held	O
to	O
occur	O
in	O
the	O
skin	O
only	O
under	O
pathologic	O
conditions	O
.	O

It	O
has	O
long	O
been	O
noted	O
,	O
however	O
,	O
that	O
hair	O
follicle	O
cycling	O
is	O
associated	O
with	O
prominent	O
changes	O
in	O
skin	O
perfusion	O
,	O
that	O
the	O
epithelial	O
hair	O
bulbs	O
of	O
anagen	O
follicles	O
display	O
angiogenic	O
properties	O
,	O
and	O
that	O
the	O
follicular	O
dermal	O
papilla	O
can	O
produce	O
angiogenic	O
factors	O
.	O

Despite	O
these	O
suggestive	O
observations	O
,	O
no	O
formal	O
proof	O
is	O
as	O
yet	O
available	O
for	O
the	O
concept	O
that	O
angiogenesis	O
is	O
a	O
physiologic	O
event	O
that	O
occurs	O
all	O
over	O
the	O
mature	O
mammalian	O
integument	O
whenever	O
hair	O
follicles	O
switch	O
from	O
resting	O
(	O
telogen	O
)	O
to	O
active	O
growth	O
(	O
anagen	O
)	O
.	O

This	O
study	O
uses	O
quantitative	O
histomorphometry	O
and	O
double	O
-	O
immunohistologic	O
detection	O
techniques	O
for	O
the	O
demarcation	O
of	O
proliferating	O
endothelial	O
cells	O
,	O
to	O
show	O
that	O
synchronized	O
hair	O
follicle	O
cycling	O
in	O
adolescent	O
C57BL	O
/	O
6	O
mice	O
is	O
associated	O
with	O
substantial	O
angiogenesis	O
,	O
and	O
that	O
inhibiting	O
angiogenesis	O
in	O
vivo	O
by	O
the	O
intraperitoneal	O
application	O
of	O
a	O
fumagillin	O
derivative	O
retards	O
experimentally	O
induced	O
anagen	O
development	O
in	O
these	O
mice	O
.	O

Thus	O
,	O
angiogenesis	O
is	O
a	O
physiologic	O
event	O
in	O
normal	O
postnatal	O
murine	O
skin	O
,	O
apparently	O
is	O
dictated	O
by	O
the	O
hair	O
follicle	O
,	O
and	O
appears	O
to	O
be	O
required	O
for	O
normal	O
anagen	O
development	O
.	O

Anagen	O
-	O
associated	O
angiogenesis	O
offers	O
an	O
attractive	O
model	O
for	O
identifying	O
the	O
physiologic	O
controls	O
of	O
cutaneous	O
angiogenesis	O
,	O
and	O
an	O
interesting	O
system	O
for	O
screening	O
the	O
effects	O
of	O
potential	O
antiangiogenic	O
drugs	O
in	O
vivo	O
.	O

Abdominal	O
approach	O
for	O
the	O
ligation	O
of	O
bleeding	O
oesophageal	O
varices	O
.	O

The	O
conventional	O
surgical	O
treatment	O
of	O
bleeding	O
oesophageal	O
varices	O
in	O
the	O
emergency	O
situation	O
is	O
based	O
upon	O
the	O
Boerema	O
-	O
Crile	O
operation	O
of	O
transthoracic	O
oesophagotomy	O
and	O
ligation	O
of	O
the	O
varices	O
.	O

This	O
and	O
the	O
other	O
methods	O
of	O
treatment	O
of	O
this	O
condition	O
in	O
current	O
practice	O
are	O
discussed	O
.	O

Two	O
cases	O
are	O
reported	O
in	O
which	O
a	O
transabdominal	O
oesophagogastrotomy	O
was	O
used	O
to	O
approach	O
the	O
site	O
of	O
bleeding	O
.	O

This	O
operation	O
is	O
described	O
and	O
the	O
theoretical	O
and	O
practical	O
advantages	O
it	O
appears	O
to	O
offer	O
over	O
the	O
standard	O
approach	O
are	O
considered	O
.	O

Neuroblastoma	O
and	O
hepatocyte	O
coculture	O
conditioned	O
media	O
alter	O
apoptosis	O
.	O

BACKGROUND	O
:	O
Neuroblastoma	O
is	O
a	O
childhood	O
tumor	O
that	O
often	O
displays	O
unusual	O
biological	O
behavior	O
.	O

The	O
tumor	O
may	O
present	O
with	O
widespread	O
metastases	O
that	O
are	O
unresponsive	O
to	O
aggressive	O
treatment	O
.	O

At	O
other	O
times	O
,	O
both	O
the	O
metastases	O
and	O
the	O
primary	O
tumor	O
may	O
spontaneously	O
regress	O
without	O
treatment	O
.	O

Apoptosis	O
,	O
or	O
programmed	O
cell	O
death	O
,	O
is	O
thought	O
to	O
play	O
a	O
role	O
in	O
the	O
dichotomous	O
behavior	O
of	O
neuroblastoma	O
.	O

We	O
hypothesize	O
that	O
neuroblastoma	O
cells	O
will	O
interact	O
with	O
host	O
tissues	O
to	O
release	O
mediators	O
that	O
affect	O
apoptosis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Human	O
neuroblastoma	O
cells	O
and	O
human	O
Chang	O
hepatocytes	O
are	O
grown	O
in	O
a	O
noncontact	O
,	O
coculture	O
system	O
.	O

After	O
incubation	O
for	O
4	O
days	O
,	O
the	O
medium	O
from	O
the	O
coculture	O
system	O
is	O
collected	O
.	O

Neuroblastoma	O
cells	O
and	O
Chang	O
hepatocytes	O
are	O
then	O
plated	O
separately	O
with	O
the	O
conditioned	O
medium	O
and	O
their	O
own	O
standard	O
growth	O
medium	O
as	O
controls	O
.	O

After	O
4	O
days	O
,	O
these	O
cells	O
are	O
harvested	O
and	O
cytospins	O
made	O
for	O
immunostaining	O
.	O

Tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
,	O
Fas	O
ligand	O
,	O
and	O
Bcl	O
-	O
2	O
,	O
are	O
measured	O
with	O
immunohistochemistry	O
.	O

Apoptosis	O
is	O
detected	O
with	O
the	O
TUNEL	O
method	O
.	O

Immunostaining	O
data	O
are	O
interpreted	O
with	O
computer	O
image	O
analysis	O
and	O
reported	O
as	O
stain	O
index	O
.	O

TUNEL	O
data	O
are	O
reported	O
as	O
percentage	O
apoptotic	O
cells	O
.	O

All	O
data	O
are	O
reported	O
as	O
means	O
+	O
/	O
-	O
SEM	O
.	O

Statistical	O
analysis	O
is	O
performed	O
and	O
P	O
<	O
0	O
.	O
05	O
considered	O
significant	O
.	O

RESULTS	O
:	O
Chang	O
hepatocytes	O
grown	O
in	O
the	O
coculture	O
conditioned	O
media	O
have	O
an	O
increase	O
in	O
TNF	O
-	O
alpha	O
and	O
Fas	O
ligand	O
.	O

The	O
neuroblastoma	O
cells	O
have	O
a	O
significant	O
decrease	O
in	O
Fas	O
ligand	O
.	O

There	O
is	O
a	O
significant	O
increase	O
in	O
the	O
number	O
of	O
apoptotic	O
hepatocytes	O
when	O
they	O
are	O
cultured	O
in	O
the	O
conditioned	O
media	O
.	O

In	O
contrast	O
,	O
the	O
neuroblastoma	O
cells	O
grown	O
in	O
the	O
coculture	O
conditioned	O
media	O
show	O
no	O
increase	O
in	O
apoptosis	O
.	O

Finally	O
,	O
Bcl	O
-	O
2	O
is	O
significantly	O
increased	O
in	O
the	O
neuroblastoma	O
cells	O
cultured	O
in	O
the	O
conditioned	O
media	O
.	O

CONCLUSIONS	O
:	O
Neuroblastoma	O
cells	O
grown	O
in	O
coculture	O
conditioned	O
media	O
show	O
increased	O
expression	O
of	O
Bcl	O
-	O
2	O
and	O
decreased	O
Fas	O
ligand	O
levels	O
.	O

These	O
changes	O
should	O
diminish	O
apoptosis	O
activity	O
in	O
the	O
tumor	O
cells	O
.	O

In	O
contrast	O
,	O
the	O
conditioned	O
media	O
induce	O
elevated	O
levels	O
of	O
proapoptotic	O
mediators	O
in	O
the	O
Chang	O
hepatocytes	O
.	O

A	O
tumor	O
'	O
s	O
ability	O
to	O
successfully	O
metastasize	O
may	O
be	O
dependent	O
on	O
mediators	O
generated	O
in	O
the	O
tumor	O
-	O
host	O
interaction	O
,	O
and	O
may	O
not	O
be	O
just	O
an	O
independent	O
characteristic	O
of	O
the	O
tumor	O
itself	O
.	O

Neoplastic	O
transformation	O
by	O
Notch	O
requires	O
nuclear	O
localization	O
.	O

Notch	O
proteins	O
are	O
plasma	O
membrane	O
-	O
spanning	O
receptors	O
that	O
mediate	O
important	O
cell	O
fate	O
decisions	O
such	O
as	O
differentiation	O
,	O
proliferation	O
,	O
and	O
apoptosis	O
.	O

The	O
mechanism	O
of	O
Notch	O
signaling	O
remains	O
poorly	O
understood	O
.	O

However	O
,	O
it	O
is	O
clear	O
that	O
the	O
Notch	O
signaling	O
pathway	O
mediates	O
its	O
effects	O
through	O
intercellular	O
contact	O
between	O
neighboring	O
cells	O
.	O

The	O
prevailing	O
model	O
for	O
Notch	O
signaling	O
suggests	O
that	O
ligand	O
,	O
presented	O
on	O
a	O
neighboring	O
cell	O
,	O
triggers	O
proteolytic	O
processing	O
of	O
Notch	O
.	O

Following	O
proteolysis	O
,	O
it	O
is	O
thought	O
that	O
the	O
intracellular	O
portion	O
of	O
Notch	O
(	O
N	O
(	O
ic	O
)	O
)	O
translocates	O
to	O
the	O
nucleus	O
,	O
where	O
it	O
is	O
involved	O
in	O
regulating	O
gene	O
expression	O
.	O

There	O
is	O
considerable	O
debate	O
concerning	O
where	O
in	O
the	O
cell	O
Notch	O
functions	O
and	O
what	O
proteins	O
serve	O
as	O
effectors	O
of	O
the	O
Notch	O
signal	O
.	O

Several	O
Notch	O
genes	O
have	O
clearly	O
been	O
shown	O
to	O
be	O
proto	O
-	O
oncogenes	O
in	O
mammalian	O
cells	O
.	O

Activation	O
of	O
Notch	O
proto	O
-	O
oncogenes	O
has	O
been	O
associated	O
with	O
tumorigenesis	O
in	O
several	O
human	O
and	O
other	O
mammalian	O
cancers	O
.	O

Transforming	O
alleles	O
of	O
Notch	O
direct	O
the	O
expression	O
of	O
truncated	O
proteins	O
that	O
primarily	O
consist	O
of	O
N	O
(	O
ic	O
)	O
and	O
are	O
not	O
tethered	O
to	O
the	O
plasma	O
membrane	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
Notch	O
oncoproteins	O
(	O
generically	O
termed	O
here	O
as	O
N	O
(	O
ic	O
)	O
)	O
induce	O
neoplastic	O
transformation	O
is	O
not	O
known	O
.	O

Previously	O
we	O
demonstrated	O
that	O
N1	O
(	O
ic	O
)	O
and	O
N2	O
(	O
ic	O
)	O
could	O
transform	O
E1A	O
immortalized	O
baby	O
rat	O
kidney	O
cells	O
(	O
RKE	O
)	O
in	O
vitro	O
.	O

We	O
now	O
report	O
direct	O
evidence	O
that	O
N1	O
(	O
ic	O
)	O
must	O
accumulate	O
in	O
the	O
nucleus	O
to	O
induce	O
transformation	O
of	O
RKE	O
cells	O
.	O

In	O
addition	O
,	O
we	O
define	O
the	O
minimal	O
domain	O
of	O
N1	O
(	O
ic	O
)	O
required	O
to	O
induce	O
transformation	O
and	O
present	O
evidence	O
that	O
transformation	O
of	O
RKE	O
cells	O
by	O
N1	O
(	O
ic	O
)	O
is	O
likely	O
to	O
be	O
through	O
a	O
CBF1	O
-	O
independent	O
pathway	O
.	O

High	O
frequency	O
of	O
hypermethylation	O
at	O
the	O
14	O
-	O
3	O
-	O
3	O
sigma	O
locus	O
leads	O
to	O
gene	O
silencing	O
in	O
breast	O
cancer	O
.	O

Expression	O
of	O
14	O
-	O
3	O
-	O
3	O
final	O
sigma	O
(	O
final	O
sigma	O
)	O
is	O
induced	O
in	O
response	O
to	O
DNA	O
damage	O
,	O
and	O
causes	O
cells	O
to	O
arrest	O
in	O
G	O
(	O
2	O
)	O
.	O

By	O
SAGE	O
(	O
serial	O
analysis	O
of	O
gene	O
expression	O
)	O
analysis	O
,	O
we	O
identified	O
final	O
sigma	O
as	O
a	O
gene	O
whose	O
expression	O
is	O
7	O
-	O
fold	O
lower	O
in	O
breast	O
carcinoma	O
cells	O
than	O
in	O
normal	O
breast	O
epithelium	O
.	O

We	O
verified	O
this	O
finding	O
by	O
Northern	O
blot	O
analysis	O
.	O

Remarkably	O
,	O
final	O
sigma	O
mRNA	O
was	O
undetectable	O
in	O
45	O
of	O
48	O
primary	O
breast	O
carcinomas	O
.	O

Genetic	O
alterations	O
at	O
final	O
sigma	O
such	O
as	O
loss	O
of	O
heterozygosity	O
were	O
rare	O
(	O
1	O
/	O
20	O
informative	O
cases	O
)	O
,	O
and	O
no	O
mutations	O
were	O
detected	O
(	O
0	O
/	O
34	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
hypermethylation	O
of	O
CpG	O
islands	O
in	O
the	O
final	O
sigma	O
gene	O
was	O
detected	O
in	O
91	O
%	O
(	O
75	O
/	O
82	O
)	O
of	O
breast	O
tumors	O
and	O
was	O
associated	O
with	O
lack	O
of	O
gene	O
expression	O
.	O

Hypermethylation	O
of	O
final	O
sigma	O
is	O
functionally	O
important	O
,	O
because	O
treatment	O
of	O
final	O
sigma	O
-	O
non	O
-	O
expressing	O
breast	O
cancer	O
cell	O
lines	O
with	O
the	O
drug	O
5	O
-	O
aza	O
-	O
2	O
'	O
-	O
deoxycytidine	O
resulted	O
in	O
demethylation	O
of	O
the	O
gene	O
and	O
synthesis	O
of	O
final	O
sigma	O
mRNA	O
.	O

Breast	O
cancer	O
cells	O
lacking	O
final	O
sigma	O
expression	O
showed	O
increased	O
number	O
of	O
chromosomal	O
breaks	O
and	O
gaps	O
when	O
exposed	O
to	O
gamma	O
-	O
irradiation	O
.	O

Therefore	O
,	O
it	O
is	O
possible	O
that	O
loss	O
of	O
final	O
sigma	O
expression	O
contributes	O
to	O
malignant	O
transformation	O
by	O
impairing	O
the	O
G	O
(	O
2	O
)	O
cell	O
cycle	O
checkpoint	O
function	O
,	O
thus	O
allowing	O
an	O
accumulation	O
of	O
genetic	O
defects	O
.	O

Hypermethylation	O
and	O
loss	O
of	O
final	O
sigma	O
expression	O
are	O
the	O
most	O
consistent	O
molecular	O
alterations	O
in	O
breast	O
cancer	O
identified	O
so	O
far	O
.	O

Alpha	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
modulates	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
and	O
secretion	O
of	O
interleukin	O
-	O
8	O
in	O
human	O
dermal	O
fibroblasts	O
.	O

Alpha	O
-	O
melanocyte	O
-	O
stimulating	O
hormone	O
(	O
alpha	O
-	O
MSH	O
)	O
has	O
evolved	O
as	O
a	O
mediator	O
of	O
diverse	O
biological	O
activities	O
in	O
an	O
ever	O
-	O
growing	O
number	O
of	O
non	O
-	O
melanocytic	O
cell	O
types	O
.	O

One	O
mechanism	O
by	O
which	O
alpha	O
-	O
MSH	O
exerts	O
its	O
effects	O
is	O
modulation	O
of	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
.	O

These	O
two	O
transcription	O
factors	O
also	O
play	O
an	O
important	O
role	O
in	O
fibroblasts	O
,	O
in	O
extracellular	O
matrix	O
composition	O
,	O
and	O
in	O
cytokine	O
expression	O
.	O

By	O
use	O
of	O
electric	O
mobility	O
shift	O
assays	O
,	O
we	O
demonstrate	O
that	O
alpha	O
-	O
MSH	O
(	O
10	O
(	O
-	O
6	O
)	O
to	O
10	O
(	O
-	O
14	O
)	O
M	O
)	O
activates	O
AP	O
-	O
1	O
in	O
human	O
dermal	O
fibroblasts	O
,	O
whereas	O
coincubation	O
with	O
interleukin	O
-	O
1	O
beta	O
(	O
IL	O
-	O
1	O
beta	O
)	O
results	O
in	O
suppression	O
of	O
its	O
activation	O
.	O

alpha	O
-	O
MSH	O
also	O
induces	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
but	O
does	O
not	O
modulate	O
DNA	O
binding	O
on	O
costimulation	O
with	O
IL	O
-	O
1	O
beta	O
.	O

Since	O
AP	O
-	O
1	O
and	O
NF	O
-	O
kappa	O
B	O
are	O
key	O
elements	O
in	O
controlling	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
transcription	O
,	O
human	O
fibroblasts	O
were	O
treated	O
with	O
alpha	O
-	O
MSH	O
and	O
IL	O
-	O
1	O
beta	O
for	O
24	O
hours	O
,	O
and	O
cytokine	O
levels	O
in	O
the	O
supernatants	O
were	O
measured	O
by	O
ELISA	O
.	O

alpha	O
-	O
MSH	O
alone	O
had	O
little	O
effect	O
,	O
whereas	O
coincubation	O
with	O
IL	O
-	O
1	O
beta	O
led	O
to	O
marked	O
downregulation	O
of	O
IL	O
-	O
8	O
secretion	O
(	O
at	O
most	O
288	O
+	O
/	O
-	O
152	O
ng	O
/	O
mL	O
)	O
when	O
compared	O
to	O
treatment	O
with	O
IL	O
-	O
1	O
beta	O
alone	O
(	O
919	O
+	O
/	O
-	O
157	O
ng	O
/	O
mL	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
alpha	O
-	O
MSH	O
exerts	O
modulatory	O
effects	O
on	O
the	O
activation	O
of	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
,	O
and	O
that	O
it	O
can	O
regulate	O
chemokine	O
secretion	O
in	O
human	O
dermal	O
fibroblasts	O
.	O

These	O
effects	O
of	O
alpha	O
-	O
MSH	O
may	O
have	O
important	O
regulatory	O
functions	O
in	O
extracellular	O
matrix	O
composition	O
,	O
wound	O
healing	O
,	O
or	O
angiogenesis	O
.	O

Application	O
of	O
microsatellite	O
PCR	O
techniques	O
in	O
the	O
identification	O
of	O
mixed	O
up	O
tissue	O
specimens	O
in	O
surgical	O
pathology	O
.	O

A	O
fragment	O
of	O
tumour	O
was	O
erroneously	O
mixed	O
up	O
with	O
an	O
endometrial	O
biopsy	O
.	O

Micro	O
-	O
satellite	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
clearly	O
demonstrated	O
the	O
extraneous	O
nature	O
of	O
the	O
fragment	O
.	O

Micro	O
-	O
satellite	O
PCR	O
may	O
be	O
useful	O
for	O
the	O
identification	O
of	O
mis	O
-	O
labelled	O
or	O
mismatched	O
tissue	O
fragments	O
in	O
surgical	O
pathology	O
specimens	O
.	O

CD40	O
expression	O
on	O
human	O
lung	O
cancer	O
correlates	O
with	O
metastatic	O
spread	O
.	O

PURPOSE	O
:	O
The	O
poor	O
prognosis	O
associated	O
with	O
lung	O
cancer	O
is	O
related	O
to	O
the	O
high	O
incidence	O
of	O
regional	O
and	O
distant	O
metastasis	O
.	O

There	O
is	O
a	O
crucial	O
need	O
to	O
identify	O
parameters	O
that	O
can	O
predict	O
a	O
tendancy	O
to	O
metastatic	O
spread	O
to	O
allow	O
better	O
prognostic	O
evaluation	O
and	O
therapeutic	O
approach	O
.	O

METHODS	O
:	O
Using	O
flow	O
cytometry	O
we	O
evaluated	O
18	O
human	O
lung	O
cancer	O
cell	O
lines	O
for	O
the	O
expression	O
of	O
different	O
surface	O
markers	O
on	O
lung	O
cancers	O
suggested	O
to	O
be	O
possible	O
prognostic	O
parameters	O
,	O
including	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
intercellular	O
adhesion	O
molecule	O
1	O
(	O
ICAM	O
-	O
1	O
)	O
,	O
Fas	O
and	O
CD40	O
.	O

RESULTS	O
:	O
No	O
correlation	O
was	O
found	O
between	O
tumor	O
prognosis	O
and	O
EGFR	O
,	O
ICAM	O
-	O
1	O
or	O
Fas	O
.	O

However	O
,	O
a	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
the	O
surface	O
expression	O
of	O
CD40	O
and	O
the	O
metastatic	O
spread	O
of	O
the	O
tumor	O
.	O

In	O
this	O
study	O
,	O
14	O
of	O
18	O
lung	O
cancer	O
cell	O
lines	O
(	O
78	O
%	O
)	O
expressed	O
CD40	O
on	O
their	O
surface	O
.	O

All	O
of	O
the	O
4	O
tumors	O
that	O
were	O
CD40	O
-	O
negative	O
,	O
were	O
stage	O
I	O
tumors	O
,	O
without	O
any	O
evidence	O
of	O
regional	O
or	O
distant	O
metastasis	O
.	O

Of	O
the	O
14	O
tumors	O
that	O
expressed	O
CD40	O
,	O
all	O
but	O
1	O
(	O
93	O
%	O
)	O
had	O
either	O
nodal	O
or	O
systemic	O
metastasis	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

Patients	O
whose	O
tumors	O
were	O
CD40	O
-	O
negative	O
showed	O
a	O
significantly	O
better	O
N	O
stage	O
,	O
overall	O
stage	O
at	O
presentation	O
and	O
survival	O
than	O
those	O
patients	O
with	O
CD40	O
-	O
positive	O
patients	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
in	O
tumor	O
size	O
,	O
gender	O
,	O
age	O
,	O
histology	O
,	O
differentiation	O
or	O
preoperative	O
therapy	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
CD40	O
expression	O
on	O
lung	O
cancer	O
may	O
play	O
a	O
role	O
in	O
metastatic	O
spread	O
,	O
and	O
also	O
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
and	O
an	O
indicator	O
of	O
advanced	O
disease	O
.	O

Specific	O
subgroup	O
B	O
adenovirus	O
diagnosis	O
by	O
PCR	O
of	O
the	O
fibre	O
gene	O
.	O

OBJECTIVE	O
:	O

A	O
highly	O
sensitive	O
and	O
specific	O
PCR	O
assay	O
targeting	O
regions	O
of	O
the	O
fibre	O
gene	O
was	O
developed	O
for	O
the	O
identification	O
of	O
subgroup	O
B	O
adenovirus	O
strains	O
.	O

This	O
is	O
critical	O
,	O
since	O
these	O
adenovirus	O
strains	O
are	O
frequently	O
associated	O
with	O
severe	O
respiratory	O
infections	O
in	O
infants	O
and	O
new	O
-	O
borns	O
.	O

METHODS	O
:	O

Clinical	O
samples	O
from	O
nasopharyngeal	O
aspirates	O
were	O
analysed	O
by	O
PCR	O
using	O
several	O
sets	O
of	O
primers	O
corresponding	O
to	O
sequences	O
of	O
the	O
gene	O
coding	O
for	O
the	O
fibre	O
protein	O
.	O

RESULTS	O
:	O

The	O
assay	O
allowed	O
the	O
detection	O
and	O
identification	O
of	O
all	O
the	O
genotypes	O
of	O
adenovirus	O
subgroup	O
B	O
,	O
based	O
on	O
the	O
size	O
of	O
the	O
amplified	O
product	O
when	O
analysed	O
on	O
polyacrilamide	O
gel	O
electrophoresis	O
.	O

Specifically	O
,	O
one	O
set	O
of	O
primers	O
was	O
able	O
to	O
amplify	O
DNA	O
of	O
subgroup	O
B	O
but	O
not	O
subgroup	O
C	O
and	O
E	O
viruses	O
.	O

CONCLUSION	O
:	O

The	O
detection	O
of	O
adenovirus	O
and	O
the	O
genotyping	O
can	O
be	O
done	O
on	O
a	O
routine	O
basis	O
by	O
a	O
PCR	O
assay	O
using	O
the	O
fibre	O
gene	O
as	O
a	O
target	O
.	O

The	O
assay	O
allows	O
the	O
identification	O
of	O
ADV	O
subgroup	O
B	O
,	O
including	O
genotype	O
7h	O
,	O
which	O
is	O
the	O
single	O
most	O
important	O
viral	O
pathogen	O
associated	O
with	O
respiratory	O
diseases	O
in	O
infants	O
and	O
young	O
children	O
in	O
the	O
southern	O
part	O
of	O
South	O
America	O
.	O

Stimulation	O
of	O
the	O
sodium	O
pump	O
by	O
azide	O
and	O
high	O
internal	O
sodium	O
:	O
changes	O
in	O
the	O
number	O
of	O
pumping	O
sites	O
and	O
turnover	O
rate	O
.	O

1	O
.	O

The	O
effects	O
of	O
5	O
mM	O
azide	O
on	O
[	O
3H	O
]	O
ouabain	O
uptake	O
and	O
22Na	O
efflux	O
were	O
determined	O
.	O

Both	O
glycoside	O
uptake	O
and	O
22Na	O
efflux	O
were	O
enhanced	O
by	O
azide	O
.	O

2	O
.	O

Azide	O
stimulated	O
the	O
Na	O
pump	O
in	O
muscles	O
whose	O
pumping	O
sites	O
had	O
been	O
inhibited	O
by	O
ouabain	O
and	O
then	O
transferred	O
to	O
a	O
glycoside	O
-	O
free	O
solution	O
.	O

This	O
stimulation	O
was	O
observed	O
before	O
detecting	O
any	O
recovery	O
of	O
the	O
initial	O
pumping	O
activity	O
.	O

3	O
.	O

When	O
both	O
the	O
resting	O
and	O
the	O
azide	O
-	O
stimulated	O
22Na	O
efflux	O
had	O
been	O
blocked	O
by	O
ouabain	O
,	O
an	O
additional	O
exposure	O
to	O
azide	O
,	O
in	O
a	O
ouabain	O
-	O
free	O
solution	O
,	O
had	O
no	O
further	O
effects	O
on	O
22Na	O
efflux	O
.	O

4	O
.	O

It	O
is	O
concluded	O
that	O
the	O
increase	O
in	O
Na	O
pumping	O
caused	O
by	O
azide	O
is	O
due	O
in	O
part	O
to	O
an	O
increase	O
in	O
the	O
number	O
of	O
pumping	O
sites	O
.	O

5	O
.	O

[	O
3H	O
]	O
ouabain	O
binding	O
was	O
measured	O
in	O
muscles	O
with	O
different	O
intracellular	O
alkali	O
cation	O
concentrations	O
.	O

Variations	O
in	O
[	O
Na	O
]	O
i	O
from	O
15	O
up	O
to	O
50	O
mM	O
did	O
not	O
significantly	O
affect	O
the	O
amount	O
of	O
glycoside	O
bound	O
.	O

A	O
substantial	O
increase	O
in	O
binding	O
occurred	O
when	O
[	O
Na	O
]	O
i	O
reached	O
70	O
mM	O
.	O

6	O
.	O

It	O
is	O
proposed	O
that	O
the	O
increase	O
in	O
Na	O
extrusion	O
that	O
occurs	O
during	O
the	O
recovery	O
of	O
Na	O
loaded	O
muscles	O
mostly	O
results	O
from	O
an	O
increased	O
turnover	O
rate	O
of	O
the	O
pump	O
rather	O
than	O
from	O
an	O
increase	O
in	O
number	O
of	O
pumping	O
sites	O
.	O

The	O
value	O
of	O
serum	O
S	O
-	O
100beta	O
and	O
interleukins	O
as	O
tumour	O
markers	O
in	O
advanced	O
melanoma	O
.	O

Recently	O
serum	O
S	O
-	O
100beta	O
has	O
shown	O
promise	O
as	O
a	O
tumour	O
marker	O
in	O
melanoma	O
;	O
however	O
,	O
its	O
use	O
as	O
a	O
prognostic	O
marker	O
in	O
the	O
advanced	O
stage	O
needs	O
to	O
be	O
confirmed	O
.	O

Interleukins	O
(	O
ILs	O
)	O
may	O
mediate	O
regression	O
or	O
progression	O
of	O
cancer	O
.	O

In	O
order	O
to	O
study	O
their	O
relation	O
to	O
the	O
metastatic	O
profile	O
and	O
survival	O
,	O
we	O
evaluated	O
the	O
association	O
between	O
pretreatment	O
serum	O
levels	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
10	O
and	O
IL	O
-	O
12	O
and	O
metastatic	O
site	O
and	O
survival	O
in	O
50	O
patients	O
with	O
advanced	O
melanoma	O
who	O
were	O
to	O
receive	O
chemoimmunotherapy	O
.	O

Patients	O
with	O
liver	O
and	O
/	O
or	O
bone	O
metastases	O
had	O
significantly	O
higher	O
median	O
concentrations	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
10	O
than	O
those	O
with	O
only	O
skin	O
,	O
nodal	O
and	O
/	O
or	O
lung	O
involvement	O
.	O

The	O
differences	O
in	O
IL	O
-	O
12	O
levels	O
were	O
unremarkable	O
.	O

Using	O
univariate	O
analysis	O
,	O
the	O
S	O
-	O
100beta	O
level	O
and	O
metastatic	O
profile	O
were	O
found	O
to	O
be	O
statistically	O
significant	O
prognostic	O
factors	O
for	O
survival	O
.	O

Using	O
multivariate	O
analysis	O
the	O
S	O
-	O
100beta	O
level	O
was	O
the	O
most	O
powerful	O
prognostic	O
indicator	O
,	O
while	O
the	O
metastatic	O
profile	O
was	O
found	O
to	O
be	O
significant	O
after	O
exclusion	O
of	O
S	O
-	O
100beta	O
.	O

The	O
findings	O
suggest	O
that	O
elevated	O
serum	O
levels	O
of	O
S	O
-	O
100beta	O
,	O
IL	O
-	O
6	O
and	O
IL	O
-	O
10	O
reflect	O
concurrent	O
liver	O
or	O
bone	O
metastases	O
in	O
melanoma	O
.	O

S	O
-	O
100beta	O
is	O
also	O
an	O
independent	O
prognostic	O
marker	O
.	O

Pretreatment	O
IL	O
levels	O
were	O
not	O
associated	O
with	O
outcome	O
.	O

TEL	O
,	O
a	O
putative	O
tumor	O
suppressor	O
,	O
modulates	O
cell	O
growth	O
and	O
cell	O
morphology	O
of	O
ras	O
-	O
transformed	O
cells	O
while	O
repressing	O
the	O
transcription	O
of	O
stromelysin	O
-	O
1	O
.	O

TEL	O
is	O
a	O
member	O
of	O
the	O
ETS	O
family	O
of	O
transcription	O
factors	O
that	O
interacts	O
with	O
the	O
mSin3	O
and	O
SMRT	O
corepressors	O
to	O
regulate	O
transcription	O
.	O

TEL	O
is	O
biallelically	O
disrupted	O
in	O
acute	O
leukemia	O
,	O
and	O
loss	O
of	O
heterozygosity	O
at	O
the	O
TEL	O
locus	O
has	O
been	O
observed	O
in	O
various	O
cancers	O
.	O

Here	O
we	O
show	O
that	O
expression	O
of	O
TEL	O
in	O
Ras	O
-	O
transformed	O
NIH	B
3T3	I
cells	O
inhibits	O
cell	O
growth	O
in	O
soft	O
agar	O
and	O
in	O
normal	O
cultures	O
.	O

Unexpectedly	O
,	O
cells	O
expressing	O
both	O
Ras	O
and	O
TEL	O
grew	O
as	O
aggregates	O
.	O

To	O
begin	O
to	O
explain	O
the	O
morphology	O
of	O
Ras	O
-	O
plus	O
TEL	O
-	O
expressing	O
cells	O
,	O
we	O
demonstrated	O
that	O
the	O
endogenous	O
matrix	O
metalloproteinase	O
stromelysin	O
-	O
1	O
was	O
repressed	O
by	O
TEL	O
.	O

TEL	O
bound	O
sequences	O
in	O
the	O
stromelysin	O
-	O
1	O
promoter	O
and	O
repressed	O
the	O
promoter	O
in	O
transient	O
-	O
expression	O
assays	O
,	O
suggesting	O
that	O
it	O
is	O
a	O
direct	O
target	O
for	O
TEL	O
-	O
mediated	O
regulation	O
.	O

Mutants	O
of	O
TEL	O
that	O
removed	O
a	O
binding	O
site	O
for	O
the	O
mSin3A	O
corepressor	O
but	O
retained	O
the	O
ETS	O
domain	O
failed	O
to	O
repress	O
stromelysin	O
-	O
1	O
.	O

When	O
BB	O
-	O
94	O
,	O
a	O
matrix	O
metalloproteinase	O
inhibitor	O
,	O
was	O
added	O
to	O
the	O
culture	O
medium	O
of	O
Ras	O
-	O
expressing	O
cells	O
,	O
it	O
caused	O
a	O
cell	O
aggregation	O
phenotype	O
similar	O
to	O
that	O
caused	O
by	O
TEL	O
expression	O
.	O

In	O
addition	O
,	O
TEL	O
inhibited	O
the	O
invasiveness	O
of	O
Ras	O
-	O
transformed	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Our	O
results	O
suggest	O
that	O
TEL	O
acts	O
as	O
a	O
tumor	O
suppressor	O
,	O
in	O
part	O
,	O
by	O
transcriptional	O
repression	O
of	O
stromelysin	O
-	O
1	O
.	O

Caspase	O
-	O
3	O
is	O
essential	O
for	O
procaspase	O
-	O
9	O
processing	O
and	O
cisplatin	O
-	O
induced	O
apoptosis	O
of	O
MCF	B
-	I
7	I
breast	O
cancer	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
investigate	O
in	O
more	O
detail	O
the	O
role	O
of	O
caspase	O
-	O
3	O
in	O
apoptotic	O
processes	O
in	O
cultured	O
cells	O
and	O
in	O
cell	O
-	O
free	O
extracts	O
of	O
breast	O
cancer	O
cells	O
.	O

We	O
present	O
evidence	O
that	O
apoptosis	O
of	O
caspase	O
-	O
3	O
-	O
deficient	O
MCF	B
-	I
7	I
breast	O
cancer	O
cells	O
is	O
defective	O
in	O
response	O
to	O
cisplatin	O
treatment	O
,	O
as	O
determined	O
by	O
chromatin	O
condensation	O
,	O
nuclear	O
fragmentation	O
,	O
DNA	O
fragmentation	O
,	O
and	O
release	O
of	O
cytochrome	O
c	O
from	O
the	O
mitochondria	O
.	O

Reconstitution	O
of	O
MCF	B
-	I
7	I
cells	O
by	O
stable	O
transfection	O
of	O
CASP	O
-	O
3	O
cDNA	O
restores	O
all	O
these	O
defects	O
and	O
results	O
in	O
an	O
extensive	O
apoptosis	O
after	O
cisplatin	O
treatment	O
.	O

We	O
further	O
show	O
that	O
in	O
extracts	O
from	O
caspase	O
-	O
3	O
-	O
deficient	O
MCF	B
-	I
7	I
cells	O
,	O
procaspase	O
-	O
9	O
processing	O
is	O
strongly	O
impaired	O
after	O
stimulation	O
with	O
either	O
cytochrome	O
c	O
or	O
recombinant	O
caspase	O
-	O
8	O
.	O

Reconstitution	O
of	O
MCF	B
-	I
7	I
cell	O
extracts	O
with	O
procaspase	O
-	O
3	O
corrects	O
this	O
defect	O
,	O
resulting	O
in	O
an	O
efficient	O
and	O
complete	O
processing	O
of	O
procaspase	O
-	O
9	O
.	O

Together	O
,	O
our	O
data	O
define	O
caspase	O
-	O
3	O
as	O
an	O
important	O
integrator	O
of	O
the	O
apoptotic	O
process	O
in	O
MCF	B
-	I
7	I
breast	O
cancer	O
cells	O
and	O
reveal	O
an	O
essential	O
function	O
of	O
caspase	O
-	O
3	O
for	O
procaspase	O
-	O
9	O
processing	O
.	O

Vasodilator	O
-	O
stimulated	O
phosphoprotein	O
is	O
involved	O
in	O
stress	O
-	O
fiber	O
and	O
membrane	O
ruffle	O
formation	O
in	O
endothelial	O
cells	O
.	O

Vasodilator	O
-	O
stimulated	O
phosphoprotein	O
(	O
VASP	O
)	O
is	O
highly	O
expressed	O
in	O
vascular	O
endothelial	O
cells	O
,	O
where	O
it	O
has	O
been	O
implicated	O
in	O
cellular	O
reorganization	O
during	O
angiogenesis	O
,	O
as	O
well	O
as	O
in	O
endothelial	O
retraction	O
and	O
changes	O
in	O
vessel	O
permeability	O
.	O

However	O
,	O
the	O
cellular	O
functions	O
of	O
VASP	O
are	O
not	O
known	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
expressed	O
wild	O
-	O
type	O
and	O
mutant	O
forms	O
of	O
VASP	O
in	O
endothelial	O
cells	O
to	O
determine	O
in	O
what	O
aspects	O
of	O
cytoskeletal	O
behavior	O
this	O
protein	O
participates	O
.	O

Expression	O
of	O
wild	O
-	O
type	O
VASP	O
induces	O
marked	O
membrane	O
ruffling	O
and	O
formation	O
of	O
prominent	O
stress	O
fibers	O
in	O
bovine	O
aortic	O
endothelial	O
cells	O
.	O

Deletion	O
of	O
the	O
proline	O
-	O
rich	O
domain	O
of	O
VASP	O
abolishes	O
its	O
ability	O
to	O
bind	O
profilin	O
but	O
does	O
not	O
affect	O
ruffling	O
or	O
stress	O
fiber	O
formation	O
.	O

Further	O
deletions	O
reveal	O
a	O
sequence	O
within	O
the	O
carboxy	O
-	O
terminal	O
domain	O
that	O
is	O
responsible	O
for	O
in	O
vivo	O
bundle	O
formation	O
.	O

Ruffling	O
occurs	O
only	O
on	O
the	O
expression	O
of	O
forms	O
of	O
VASP	O
that	O
possess	O
bundling	O
activity	O
and	O
the	O
capacity	O
to	O
bind	O
zyxin	O
/	O
vinculin	O
-	O
derived	O
peptide	O
.	O

The	O
ability	O
of	O
distinct	O
subdomains	O
within	O
VASP	O
to	O
bind	O
adhesion	O
proteins	O
and	O
induce	O
F	O
-	O
actin	O
bundling	O
in	O
vivo	O
suggests	O
that	O
this	O
protein	O
could	O
function	O
in	O
the	O
aggregation	O
and	O
tethering	O
of	O
actin	O
filaments	O
during	O
the	O
formation	O
of	O
endothelial	O
cell	O
-	O
substrate	O
and	O
cell	O
-	O
cell	O
contacts	O
.	O

These	O
data	O
provide	O
a	O
mechanism	O
whereby	O
VASP	O
can	O
influence	O
endothelial	O
migration	O
and	O
organization	O
during	O
capillary	O
formation	O
and	O
modulate	O
vascular	O
permeability	O
via	O
effects	O
on	O
endothelial	O
cell	O
contractility	O
.	O

Urokinase	O
receptor	O
:	O
a	O
molecular	O
organizer	O
in	O
cellular	O
communication	O
.	O

In	O
a	O
variety	O
of	O
cell	O
types	O
,	O
the	O
glycolipid	O
-	O
anchored	O
urokinase	O
receptor	O
(	O
uPAR	O
)	O
is	O
colocalized	O
pericellularly	O
with	O
components	O
of	O
the	O
plasminogen	O
activation	O
system	O
and	O
endocytosis	O
receptors	O
.	O

uPAR	O
is	O
also	O
coexpressed	O
with	O
caveolin	O
and	O
members	O
of	O
the	O
integrin	O
adhesion	O
receptor	O
superfamily	O
.	O

The	O
formation	O
of	O
functional	O
units	O
with	O
these	O
various	O
proteins	O
allows	O
the	O
uPAR	O
to	O
mediate	O
the	O
focused	O
proteolysis	O
required	O
for	O
cell	O
migration	O
and	O
invasion	O
and	O
to	O
contribute	O
both	O
directly	O
and	O
indirectly	O
to	O
cell	O
adhesive	O
processes	O
in	O
a	O
non	O
-	O
proteolytic	O
fashion	O
.	O

This	O
dual	O
activity	O
,	O
together	O
with	O
the	O
initiation	O
of	O
signal	O
transduction	O
pathways	O
by	O
uPAR	O
,	O
is	O
believed	O
to	O
influence	O
cellular	O
behaviour	O
in	O
angiogenesis	O
,	O
inflammation	O
,	O
wound	O
repair	O
and	O
tumor	O
progression	O
/	O
metastasis	O
and	O
open	O
up	O
the	O
way	O
for	O
uPAR	O
-	O
based	O
therapeutic	O
approaches	O
.	O

Reduced	O
oncogenicity	O
of	O
p190	O
Bcr	O
/	O
Abl	O
F	O
-	O
actin	O
-	O
binding	O
domain	O
mutants	O
.	O

The	O
deregulated	O
Bcr	O
/	O
Abl	O
tyrosine	O
kinase	O
is	O
responsible	O
for	O
the	O
development	O
of	O
Philadelphia	O
(	O
Ph	O
)	O
-	O
positive	O
leukemia	O
in	O
humans	O
.	O

To	O
investigate	O
the	O
significance	O
of	O
the	O
C	O
-	O
terminal	O
Abl	O
actin	O
-	O
binding	O
domain	O
within	O
Bcr	O
/	O
Abl	O
p190	O
in	O
the	O
development	O
of	O
leukemia	O
/	O
lymphoma	O
in	O
vivo	O
,	O
mutant	O
p190	O
DNA	O
constructs	O
were	O
used	O
to	O
generate	O
transgenic	O
mice	O
.	O

Eight	O
founder	O
and	O
progeny	O
mice	O
of	O
5	O
different	O
lines	O
were	O
monitored	O
for	O
leukemogenesis	O
.	O

Latency	O
was	O
markedly	O
increased	O
and	O
occurrence	O
decreased	O
in	O
the	O
p190	O
del	O
C	O
lines	O
as	O
compared	O
with	O
nonmutated	O
p190	O
BCR	O
/	O
ABL	O
transgenics	O
.	O

Western	O
blot	O
analysis	O
of	O
involved	O
hematologic	O
tissues	O
of	O
the	O
p190	O
del	O
C	O
transgenics	O
with	O
end	O
-	O
stage	O
disease	O
showed	O
high	O
-	O
level	O
expression	O
of	O
the	O
transgene	O
and	O
tyrosine	O
phosphorylation	O
of	O
Cbl	O
and	O
Hef1	O
/	O
Cas	O
,	O
proteins	O
previously	O
shown	O
to	O
be	O
affected	O
by	O
Bcr	O
/	O
Abl	O
.	O

These	O
results	O
show	O
that	O
the	O
actin	O
-	O
binding	O
domain	O
of	O
Abl	O
enhances	O
leukemia	O
development	O
but	O
does	O
not	O
appear	O
to	O
be	O
an	O
absolute	O
requirement	O
for	O
leukemogenesis	O
.	O

Building	O
the	O
vertebrate	O
vasculature	O
:	O
research	O
is	O
going	O
swimmingly	O
.	O

The	O
vertebrate	O
vasculature	O
develops	O
in	O
remarkably	O
similar	O
fashion	O
in	O
all	O
vertebrates	O
.	O

A	O
cohort	O
of	O
unspecified	O
mesodermal	O
cells	O
differentiates	O
into	O
primitive	O
endothelial	O
cells	O
,	O
which	O
migrate	O
to	O
and	O
occupy	O
positions	O
within	O
the	O
stereotypical	O
blueprint	O
of	O
the	O
primitive	O
vasculature	O
.	O

Once	O
in	O
position	O
,	O
these	O
cells	O
coalesce	O
and	O
form	O
cords	O
,	O
which	O
lumenize	O
and	O
become	O
ensheathed	O
by	O
supporting	O
pericytes	O
and	O
smooth	O
muscle	O
cells	O
.	O

This	O
primitive	O
vascular	O
network	O
is	O
extensively	O
remodeled	O
in	O
some	O
places	O
,	O
and	O
expanded	O
by	O
sprouting	O
in	O
others	O
.	O

Various	O
studies	O
using	O
the	O
mouse	O
,	O
quail	O
/	O
chick	O
,	O
and	O
frog	O
have	O
uncovered	O
a	O
number	O
of	O
signals	O
that	O
guide	O
these	O
complex	O
processes	O
but	O
many	O
gaps	O
still	O
exist	O
in	O
our	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
the	O
embryonic	O
vasculature	O
is	O
built	O
.	O

Because	O
many	O
questions	O
will	O
require	O
in	O
vivo	O
studies	O
to	O
be	O
properly	O
addressed	O
,	O
the	O
zebrafish	O
,	O
with	O
its	O
unique	O
accessibility	O
to	O
analysis	O
by	O
combined	O
embryological	O
,	O
molecular	O
,	O
and	O
genetic	O
methods	O
,	O
should	O
prove	O
invaluable	O
in	O
identifying	O
new	O
molecules	O
involved	O
in	O
blood	O
vessel	O
development	O
and	O
integrating	O
pathways	O
that	O
influence	O
embryonic	O
blood	O
vessel	O
formation	O
.	O

Nitric	O
oxide	O
synthase	O
inhibition	O
results	O
in	O
synergistic	O
anti	O
-	O
tumour	O
activity	O
with	O
melphalan	O
and	O
tumour	O
necrosis	O
factor	O
alpha	O
-	O
based	O
isolated	O
limb	O
perfusions	O
.	O

Nitric	O
oxide	O
(	O
NO	O
)	O
is	O
an	O
important	O
molecule	O
in	O
regulating	O
tumour	O
blood	O
flow	O
and	O
stimulating	O
tumour	O
angiogenesis	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
by	O
L	O
-	O
NAME	O
might	O
induce	O
an	O
anti	O
-	O
tumour	O
effect	O
by	O
limiting	O
nutrients	O
and	O
oxygen	O
to	O
reach	O
tumour	O
tissue	O
or	O
affecting	O
vascular	O
growth	O
.	O

The	O
anti	O
-	O
tumour	O
effect	O
of	O
L	O
-	O
NAME	O
after	O
systemic	O
administration	O
was	O
studied	O
in	O
a	O
renal	O
subcapsular	O
CC531	B
adenocarcinoma	O
model	O
in	O
rats	O
.	O

Moreover	O
,	O
regional	O
administration	O
of	O
L	O
-	O
NAME	O
,	O
in	O
combination	O
with	O
TNF	O
and	O
melphalan	O
,	O
was	O
studied	O
in	O
an	O
isolated	O
limb	O
perfusion	O
(	O
ILP	O
)	O
model	O
using	O
BN175	O
soft	O
-	O
tissue	O
sarcomas	O
.	O

Systemic	O
treatment	O
with	O
L	O
-	O
NAME	O
inhibited	O
growth	O
of	O
adenocarcinoma	O
significantly	O
but	O
was	O
accompanied	O
by	O
impaired	O
renal	O
function	O
.	O

In	O
ILP	O
,	O
reduced	O
tumour	O
growth	O
was	O
observed	O
when	O
L	O
-	O
NAME	O
was	O
used	O
alone	O
.	O

In	O
combination	O
with	O
TNF	O
or	O
melphalan	O
,	O
L	O
-	O
NAME	O
increased	O
response	O
rates	O
significantly	O
compared	O
to	O
perfusions	O
without	O
L	O
-	O
NAME	O
(	O
0	O
-	O
64	O
%	O
and	O
0	O
-	O
63	O
%	O
respectively	O
)	O
.	O

An	O
additional	O
anti	O
-	O
tumour	O
effect	O
was	O
demonstrated	O
when	O
L	O
-	O
NAME	O
was	O
added	O
to	O
the	O
synergistic	O
combination	O
of	O
melphalan	O
and	O
TNF	O
(	O
responses	O
increased	O
from	O
70	O
to	O
100	O
%	O
)	O
.	O

Inhibition	O
of	O
NO	O
synthase	O
reduces	O
tumour	O
growth	O
both	O
after	O
systemic	O
and	O
regional	O
(	O
ILP	O
)	O
treatment	O
.	O

A	O
synergistic	O
anti	O
-	O
tumour	O
effect	O
of	O
L	O
-	O
NAME	O
is	O
observed	O
in	O
combination	O
with	O
melphalan	O
and	O
/	O
or	O
TNF	O
using	O
ILP	O
.	O

These	O
results	O
indicate	O
a	O
possible	O
role	O
of	O
L	O
-	O
NAME	O
for	O
the	O
treatment	O
of	O
solid	O
tumours	O
in	O
a	O
systemic	O
or	O
regional	O
setting	O
.	O

p75	O
mediated	O
apoptosis	O
in	O
neuroblastoma	O
cells	O
is	O
inhibited	O
by	O
expression	O
of	O
TrkA	O
.	O

BACKGROUND	O
:	O
Neurotrophins	O
mediate	O
their	O
effects	O
by	O
binding	O
to	O
members	O
of	O
the	O
Trk	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
and	O
to	O
the	O
low	O
-	O
affinity	O
nerve	O
growth	O
factor	O
receptor	O
p75	O
.	O

Nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
has	O
been	O
demonstrated	O
to	O
support	O
survival	O
and	O
differentiation	O
of	O
neuroblastoma	O
(	O
NB	O
)	O
cells	O
by	O
activation	O
of	O
the	O
TrkA	O
receptor	O
.	O

The	O
p75	O
receptor	O
belongs	O
to	O
the	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
family	O
of	O
death	O
receptors	O
and	O
has	O
been	O
suggested	O
as	O
a	O
receptor	O
that	O
mediates	O
apoptosis	O
in	O
neuronal	O
and	O
NB	O
cells	O
.	O

PROCEDURE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
p75	O
expression	O
in	O
NB	O
,	O
we	O
transfected	O
the	O
p75	O
cDNA	O
into	O
SH	B
-	I
SY5Y	I
cells	O
,	O
an	O
NB	O
cell	O
line	O
lacking	O
expression	O
of	O
both	O
p75	O
and	O
TrkA	O
.	O

RESULTS	O
:	O
Cell	O
clones	O
expressing	O
elevated	O
levels	O
of	O
p75	O
showed	O
a	O
high	O
degree	O
of	O
apoptosis	O
even	O
in	O
10	O
%	O
serum	O
-	O
supplemented	O
medium	O
.	O

Apoptotic	O
signaling	O
by	O
p75	O
was	O
ligand	O
-	O
independent	O
and	O
only	O
partly	O
caspase	O
-	O
dependent	O
.	O

The	O
level	O
of	O
apoptosis	O
correlated	O
directly	O
with	O
the	O
expression	O
level	O
of	O
the	O
receptor	O
,	O
indicating	O
that	O
p75	O
may	O
activate	O
the	O
cell	O
death	O
program	O
directly	O
.	O

However	O
,	O
additional	O
transfection	O
of	O
TrkA	O
into	O
SY5Y	B
-	O
p75	O
cells	O
resulted	O
in	O
a	O
significantly	O
reduced	O
rate	O
of	O
apoptosis	O
even	O
in	O
the	O
absence	O
of	O
NGF	O
.	O

CONCLUSIONS	O
:	O
Thus	O
,	O
expression	O
of	O
the	O
TrkA	O
receptor	O
itself	O
inhibits	O
p75	O
mediated	O
apoptosis	O
in	O
NB	O
cells	O
.	O

[	O
Interleukin	O
-	O
18	O
and	O
new	O
drugs	O
.	O
Protective	O
effect	O
against	O
tumor	O
growth	O
and	O
infections	O
]	O
.	O

IL	O
-	O
18	O
,	O
originally	O
identified	O
as	O
interferon	O
-	O
gamma	O
inducing	O
factor	O
(	O
IGIF	O
)	O
,	O
is	O
related	O
to	O
the	O
IL	O
-	O
1	O
family	O
in	O
terms	O
of	O
its	O
structure	O
as	O
well	O
as	O
its	O
processing	O
,	O
receptor	O
,	O
signal	O
transduction	O
pathway	O
and	O
pro	O
-	O
inflammatory	O
properties	O
.	O

IL	O
-	O
18	O
is	O
also	O
functionally	O
related	O
to	O
IL	O
-	O
12	O
,	O
as	O
it	O
induces	O
the	O
production	O
of	O
Th1	O
cytokines	O
and	O
participates	O
in	O
cell	O
-	O
mediated	O
immune	O
cytotoxicity	O
.	O

A	O
summary	O
is	O
made	O
of	O
recent	O
advances	O
in	O
the	O
understanding	O
of	O
IL	O
-	O
18	O
structure	O
,	O
processing	O
,	O
receptor	O
expression	O
and	O
immunoregulatory	O
functions	O
.	O

It	O
focuses	O
on	O
the	O
role	O
of	O
IL	O
-	O
18	O
modulation	O
in	O
tumours	O
,	O
infections	O
and	O
autoimmune	O
and	O
inflammatory	O
diseases	O
.	O

RNA	O
damage	O
and	O
inhibition	O
of	O
neoplastic	O
endothelial	O
cell	O
growth	O
:	O
effects	O
of	O
human	O
and	O
amphibian	O
ribonucleases	O
.	O

Angiogenesis	O
defines	O
the	O
many	O
steps	O
involved	O
in	O
the	O
growth	O
and	O
migration	O
of	O
endothelial	O
cell	O
-	O
derived	O
blood	O
vessels	O
.	O

This	O
process	O
is	O
necessary	O
for	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	O
,	O
and	O
considerable	O
effort	O
is	O
being	O
expended	O
to	O
find	O
inhibitors	O
of	O
tumor	O
angiogenesis	O
.	O

This	O
usually	O
involves	O
screening	O
of	O
potential	O
anti	O
-	O
angiogenic	O
compounds	O
on	O
endothelial	O
cells	O
.	O

To	O
this	O
end	O
,	O
two	O
candidate	O
anti	O
-	O
angiogenic	O
RNA	O
-	O
damaging	O
agents	O
,	O
onconase	O
and	O
(	O
-	O
4	O
)	O
rhEDN	O
,	O
were	O
screened	O
for	O
their	O
effects	O
on	O
endothelial	O
cell	O
proliferation	O
using	O
three	O
distinct	O
types	O
of	O
endothelial	O
cells	O
in	O
culture	O
:	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
-	O
immortalized	O
human	B
umbilical	I
vein	I
endothelial	I
cells	I
(	O
HUVECs	B
)	O
,	O
a	O
Kras	O
-	O
transformed	O
HPV	O
-	O
16	O
E6	O
/	O
E7	O
HUVEC	B
(	O
Rhim	O
et	O
al	O
.	O
,	O
Carcinogenesis	O
4	O
,	O
673	O
-	O
681	O
,	O
1998	O
)	O
,	O
and	O
primary	O
HUVECs	O
.	O

Onconase	O
similarly	O
inhibited	O
proliferation	O
in	O
all	O
three	O
cell	O
lines	O
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
3	O
-	O
1	O
.	O
0	O
microM	O
)	O
while	O
(	O
-	O
4	O
)	O
rhEDN	O
was	O
more	O
effective	O
on	O
immortalized	O
HUVEC	B
cell	O
lines	O
(	O
IC	O
(	O
50	O
)	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
06	O
microM	O
)	O
than	O
on	O
primary	O
HUVECs	O
(	O
IC	O
(	O
50	O
)	O
>	O
0	O
.	O
1	O
microM	O
)	O
.	O

Differential	O
sensitivity	O
to	O
these	O
agents	O
implies	O
that	O
more	O
than	O
one	O
endothelial	O
cell	O
type	O
must	O
be	O
used	O
in	O
proliferation	O
assays	O
to	O
screen	O
for	O
novel	O
anti	O
-	O
angiogenic	O
compounds	O
.	O

Apoptosis	O
induced	O
by	O
1	O
'	O
-	O
acetoxychavicol	O
acetate	O
in	O
Ehrlich	O
ascites	O
tumor	O
cells	O
is	O
associated	O
with	O
modulation	O
of	O
polyamine	O
metabolism	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

The	O
efficacy	O
of	O
the	O
antitumor	O
activity	O
of	O
1	O
'	O
-	O
acetoxychavicol	O
acetate	O
(	O
ACA	O
)	O
,	O
reported	O
to	O
be	O
a	O
suppressor	O
of	O
chemically	O
induced	O
carcinogenesis	O
,	O
was	O
evaluated	O
in	O
Ehrlich	O
ascites	O
tumor	O
cells	O
.	O

ACA	O
treatment	O
resulted	O
in	O
changes	O
in	O
morphology	O
and	O
a	O
dose	O
-	O
dependent	O
suppression	O
of	O
cell	O
viability	O
.	O

Apoptosis	O
,	O
characterized	O
by	O
nuclear	O
condensation	O
,	O
membrane	O
blebbing	O
,	O
cell	O
shrinkage	O
and	O
a	O
significant	O
induction	O
of	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
at	O
8	O
h	O
in	O
a	O
time	O
-	O
course	O
study	O
were	O
observed	O
.	O

Formation	O
of	O
apoptotic	O
bodies	O
was	O
preceded	O
by	O
lowering	O
of	O
intracellular	O
polyamines	O
,	O
particularly	O
putrescine	O
,	O
and	O
both	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
inhibitory	O
and	O
activation	O
effect	O
by	O
ACA	O
on	O
ornithine	O
decarboxylase	O
(	O
ODC	O
)	O
and	O
spermidine	O
/	O
spermine	O
N	O
(	O
1	O
)	O
-	O
acetyltransferase	O
(	O
SSAT	O
)	O
,	O
respectively	O
.	O

Administration	O
of	O
exogenous	O
polyamines	O
prevented	O
ACA	O
-	O
induced	O
apoptosis	O
represented	O
by	O
a	O
reduction	O
in	O
the	O
number	O
of	O
apoptotic	O
bodies	O
and	O
also	O
caused	O
reduction	O
in	O
the	O
induced	O
caspase	O
-	O
3	O
-	O
like	O
protease	O
activity	O
at	O
8	O
h	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
anticarcinogenic	O
effects	O
of	O
ACA	O
might	O
be	O
partly	O
due	O
to	O
perturbation	O
of	O
the	O
polyamine	O
metabolic	O
pathway	O
and	O
triggering	O
of	O
caspase	O
-	O
3	O
-	O
like	O
activity	O
,	O
which	O
result	O
in	O
apoptosis	O
.	O

Focal	O
congenital	O
alveolar	O
proteinosis	O
associated	O
with	O
abnormal	O
surfactant	O
protein	O
B	O
messenger	O
RNA	O
.	O

Two	O
siblings	O
presented	O
with	O
typical	O
clinical	O
features	O
of	O
congenital	O
pulmonary	O
alveolar	O
proteinosis	O
(	O
PAP	O
)	O
.	O

Necropsy	O
of	O
one	O
sibling	O
revealed	O
scattered	O
foci	O
of	O
the	O
diagnostic	O
histologic	O
changes	O
in	O
the	O
lung	O
tissue	O
.	O

In	O
contrast	O
to	O
infantile	O
and	O
adult	O
PAP	O
,	O
focal	O
distribution	O
is	O
uncommon	O
in	O
congenital	O
PAP	O
.	O

Defective	O
expression	O
of	O
the	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
receptor	O
was	O
ruled	O
out	O
.	O

The	O
surfactant	O
protein	O
B	O
(	O
SP	O
-	O
B	O
)	O
content	O
in	O
the	O
lung	O
tissue	O
of	O
the	O
autopsied	O
patient	O
was	O
low	O
,	O
and	O
a	O
deletion	O
in	O
the	O
SP	O
-	O
B	O
messenger	O
RNA	O
was	O
detected	O
.	O

We	O
speculate	O
that	O
the	O
PAP	O
in	O
our	O
patients	O
was	O
related	O
to	O
the	O
reduced	O
quantity	O
and	O
/	O
or	O
to	O
the	O
altered	O
quality	O
of	O
SP	O
-	O
B	O
.	O

TRADD	O
domain	O
of	O
Epstein	O
-	O
Barr	O
virus	O
transforming	O
protein	O
LMP1	O
is	O
essential	O
for	O
inducing	O
immortalization	O
and	O
suppressing	O
senescence	O
of	O
primary	O
rodent	O
fibroblasts	O
.	O

Mutation	O
analysis	O
of	O
latent	O
membrane	O
protein	O
1	O
(	O
LMP1	O
)	O
in	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
-	O
induced	O
B	O
-	O
cell	O
immortalization	O
revealed	O
two	O
transformation	O
effector	O
sites	O
,	O
TES1	O
and	O
TES2	O
.	O

TES2	O
mediates	O
the	O
interaction	O
with	O
tumor	O
necrosis	O
factor	O
receptor	O
-	O
associated	O
death	O
domain	O
protein	O
(	O
TRADD	O
)	O
and	O
plays	O
a	O
key	O
role	O
in	O
transactivating	O
NF	O
-	O
kappa	O
B	O
and	O
AP	O
-	O
1	O
.	O

Recombinant	O
EBV	O
containing	O
LMP1	O
with	O
TES2	O
deleted	O
induces	O
a	O
limited	O
proliferation	O
of	O
B	O
cells	O
.	O

The	O
present	O
study	O
shows	O
that	O
a	O
mutant	O
with	O
an	O
LMP1	O
site	O
-	O
specific	O
mutation	O
at	O
TES2	O
,	O
LMP1	O
(	O
TRADD	O
)	O
,	O
initially	O
stimulates	O
cell	O
growth	O
and	O
significantly	O
extends	O
the	O
life	O
span	O
of	O
MEF	O
.	O

However	O
,	O
it	O
is	O
not	O
sufficient	O
for	O
the	O
immortalization	O
of	O
MEF	O
,	O
and	O
MEF	O
-	O
LMP1	O
(	O
TRADD	O
)	O
cells	O
eventually	O
enter	O
growth	O
arrest	O
.	O

Further	O
analysis	O
reveals	O
that	O
although	O
LMP1	O
(	O
TRADD	O
)	O
promotes	O
cell	O
growth	O
,	O
it	O
does	O
not	O
prevent	O
the	O
eventual	O
onset	O
of	O
senescence	O
and	O
the	O
expression	O
of	O
tumor	O
suppressor	O
p16	O
(	O
Ink4a	O
)	O
.	O

IL	O
-	O
12	O
inhibition	O
of	O
endothelial	O
cell	O
functions	O
and	O
angiogenesis	O
depends	O
on	O
lymphocyte	O
-	O
endothelial	O
cell	O
cross	O
-	O
talk	O
.	O

In	O
vivo	O
IL	O
-	O
12	O
-	O
dependent	O
tumor	O
inhibition	O
rests	O
on	O
the	O
ability	O
of	O
IL	O
-	O
12	O
to	O
activate	O
a	O
CD8	O
-	O
mediated	O
cytotoxicity	O
,	O
inhibit	O
angiogenesis	O
,	O
and	O
cause	O
vascular	O
injury	O
.	O

Although	O
in	O
vivo	O
studies	O
have	O
shown	O
that	O
such	O
inhibition	O
stems	O
from	O
complex	O
interactions	O
of	O
immune	O
cells	O
and	O
the	O
production	O
of	O
IFN	O
-	O
gamma	O
and	O
other	O
downstream	O
angiostatic	O
chemokines	O
,	O
the	O
mechanisms	O
involved	O
are	O
still	O
poorly	O
defined	O
.	O

Here	O
we	O
show	O
that	O
IL	O
-	O
12	O
activates	O
an	O
anti	O
-	O
angiogenic	O
program	O
in	O
Con	O
A	O
-	O
activated	O
mouse	O
spleen	O
cells	O
(	O
activated	O
spc	O
)	O
or	O
human	O
PBMC	O
(	O
activated	O
PBMC	O
)	O
.	O

The	O
soluble	O
factors	O
they	O
release	O
in	O
its	O
presence	O
arrest	O
the	O
cycle	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
,	O
inhibit	O
in	O
vitro	O
angiogenesis	O
,	O
negatively	O
modulate	O
the	O
production	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
and	O
the	O
ability	O
of	O
EC	O
to	O
adhere	O
to	O
vitronectin	O
and	O
up	O
-	O
regulate	O
ICAM	O
-	O
1	O
and	O
VCAM	O
-	O
1	O
expression	O
.	O

These	O
effects	O
do	O
not	O
require	O
direct	O
cell	O
-	O
cell	O
contact	O
,	O
yet	O
result	O
from	O
continuous	O
interaction	O
between	O
activated	O
lymphoid	O
cells	O
and	O
EC	O
.	O

We	O
used	O
neutralizing	O
Abs	O
to	O
show	O
that	O
the	O
IFN	O
-	O
inducible	O
protein	O
-	O
10	O
and	O
monokine	O
-	O
induced	O
by	O
IFN	O
-	O
gamma	O
chemokines	O
are	O
pivotal	O
in	O
inducing	O
these	O
effects	O
.	O

Experiments	O
with	O
nu	O
/	O
nu	O
mice	O
,	O
nonobese	O
diabetic	O
-	O
SCID	O
mice	O
,	O
or	O
activated	O
spc	O
enriched	O
in	O
specific	O
cell	O
subpopulations	O
demonstrated	O
that	O
CD4	O
(	O
+	O
)	O
,	O
CD8	O
(	O
+	O
)	O
,	O
and	O
NK	O
cells	O
are	O
all	O
needed	O
to	O
mediate	O
the	O
full	O
anti	O
-	O
angiogenetic	O
effect	O
of	O
IL	O
-	O
12	O
.	O

[	O
Study	O
of	O
fungus	O
polysaccharides	O
compounds	O
(	O
FPC	O
)	O
in	O
inducing	O
the	O
apoptosis	O
of	O
liver	O
cancer	O
cell	O
Bel	B
-	I
7402	I
]	O
.	O

To	O
observe	O
the	O
influence	O
of	O
fungus	O
polysaccharides	O
compounds	O
(	O
FPC	O
)	O
in	O
inducing	O
human	O
liver	O
cancer	O
cell	O
Bel	B
-	I
7402	I
apoptosis	O
in	O
cell	O
cultivating	O
in	O
vitro	O
,	O
the	O
authors	O
analyzed	O
tumor	O
inhibitive	O
gene	O
P53	O
expression	O
in	O
Bel	B
-	I
7402	I
apoptosis	O
by	O
applying	O
double	O
immuno	O
-	O
marker	O
.	O

The	O
result	O
showed	O
that	O
the	O
multilevel	O
of	O
FPC	O
could	O
all	O
apparently	O
induce	O
Bel	B
-	I
7402	I
apoptosis	O
.	O

With	O
the	O
enhancement	O
of	O
FPC	O
concentration	O
,	O
the	O
authors	O
observed	O
chromatin	O
condensation	O
in	O
some	O
phases	O
companying	O
with	O
the	O
characteristic	O
apoptosis	O
.	O

In	O
the	O
meantime	O
,	O
it	O
could	O
also	O
greatly	O
reduce	O
the	O
G1	O
and	O
S	O
,	O
with	O
obviously	O
dose	O
-	O
response	O
relationship	O
.	O

The	O
percentage	O
of	O
cell	O
apoptosis	O
increased	O
with	O
the	O
enhancing	O
of	O
concentration	O
.	O

In	O
the	O
high	O
-	O
level	O
group	O
the	O
authors	O
found	O
typical	O
DNA	O
ladder	O
eletrophoresis	O
stripe	O
.	O

The	O
result	O
showed	O
that	O
the	O
mechanism	O
of	O
the	O
FPC	O
antineoplastic	O
effect	O
had	O
an	O
intimate	O
relation	O
with	O
its	O
induction	O
to	O
apoptosis	O
and	O
that	O
the	O
result	O
of	O
FPC	O
inducing	O
tumor	O
cell	O
apoptosis	O
had	O
the	O
character	O
of	O
P53	O
independence	O
.	O

Tonometry	O
in	O
normal	O
and	O
scarred	O
corneas	O
,	O
and	O
in	O
postkeratoplasty	O
eyes	O
:	O
a	O
comparative	O
study	O
of	O
the	O
Goldmann	O
,	O
the	O
ProTon	O
and	O
the	O
Schiotz	O
tonometers	O
.	O

PURPOSE	O
:	O

Clinical	O
comparison	O
of	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
measured	O
with	O
the	O
Goldmann	O
applanation	O
tonometer	O
(	O
GAT	O
)	O
,	O
the	O
ProTon	O
tonometer	O
(	O
PT	O
)	O
,	O
and	O
the	O
Schiotz	O
tonometer	O
(	O
ST	O
)	O
,	O
in	O
normal	O
eyes	O
,	O
eyes	O
with	O
scarred	O
corneas	O
and	O
postkeratoplasty	O
eyes	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O

The	O
IOP	O
readings	O
with	O
GAT	O
,	O
PT	O
,	O
and	O
ST	O
were	O
compared	O
in	O
125	O
eyes	O
with	O
normal	O
corneas	O
(	O
Group	O
A	O
)	O
,	O
17	O
eyes	O
with	O
scarred	O
corneas	O
(	O
Group	O
B	O
)	O
,	O
and	O
in	O
21	O
postkeratoplasty	O
eyes	O
(	O
Group	O
C	O
)	O
.	O

The	O
data	O
were	O
statistically	O
analysed	O
at	O
95	O
%	O
confidence	O
interval	O
;	O
linear	O
regression	O
analysis	O
and	O
paired	O
t	O
-	O
test	O
were	O
done	O
.	O

RESULTS	O
:	O

The	O
mean	O
differences	O
and	O
their	O
standard	O
deviation	O
[	O
SD	O
]	O
between	O
GAT	O
and	O
PT	O
readings	O
,	O
and	O
GAT	O
and	O
ST	O
readings	O
respectively	O
were	O
:	O
[	O
1	O
]	O
in	O
Group	O
A	O
:	O
-	O
0	O
.	O
23	O
[	O
SD	O
2	O
.	O
75	O
]	O
mmHg	O
and	O
+	O
0	O
.	O
24	O
[	O
SD	O
3	O
.	O
18	O
]	O
mmHg	O
respectively	O
;	O
[	O
2	O
]	O
in	O
Group	O
B	O
:	O
-	O
1	O
.	O
8	O
[	O
SD	O
12	O
.	O
67	O
]	O
mmHg	O
and	O
-	O
4	O
.	O
5	O
[	O
SD	O
9	O
.	O
95	O
mmHg	O
;	O
and	O
[	O
3	O
]	O
in	O
Group	O
C	O
:	O
+	O
0	O
.	O
24	O
[	O
SD	O
8	O
.	O
72	O
]	O
mmHg	O
and	O
-	O
0	O
.	O
12	O
[	O
SD	O
8	O
.	O
7	O
]	O
mmHg	O
.	O

They	O
were	O
not	O
statistically	O
significant	O
.	O

In	O
Group	O
A	O
the	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
readings	O
was	O
-	O
5	O
.	O
27	O
mmHg	O
to	O
5	O
.	O
73	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
readings	O
,	O
-	O
6	O
.	O
12	O
mmHg	O
to	O
6	O
.	O
59	O
mmHg	O
.	O

Ninety	O
six	O
[	O
77	O
%	O
]	O
eyes	O
with	O
the	O
PT	O
and	O
84	O
[	O
69	O
%	O
]	O
eyes	O
with	O
ST	O
measurements	O
were	O
within	O
3	O
mmHg	O
of	O
GAT	O
pressure	O
.	O

The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
PT	O
and	O
ST	O
were	O
0	O
.	O
93	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
and	O
0	O
.	O
88	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
respectively	O
.	O

In	O
Group	O
B	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
readings	O
was	O
-	O
27	O
.	O
17	O
mmHg	O
to	O
23	O
.	O
51	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
measurement	O
,	O
-	O
24	O
.	O
37	O
mmHg	O
to	O
15	O
.	O
44	O
mmHg	O
.	O

The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
the	O
PT	O
and	O
ST	O
were	O
0	O
.	O
112	O
[	O
P	O
=	O
0	O
.	O
660	O
]	O
and	O
0	O
.	O
630	O
[	O
P	O
=	O
0	O
.	O
006	O
]	O
respectively	O
.	O

In	O
group	O
C	O
,	O
the	O
95	O
%	O
confidence	O
interval	O
between	O
GAT	O
and	O
PT	O
measurements	O
was	O
-	O
17	O
.	O
20	O
mmHg	O
to	O
17	O
.	O
67	O
mmHg	O
,	O
and	O
between	O
GAT	O
and	O
ST	O
measurements	O
,	O
-	O
17	O
.	O
51	O
mmHg	O
to	O
17	O
.	O
27	O
mmHg	O
.	O

The	O
correlation	O
coefficients	O
[	O
r	O
]	O
for	O
the	O
PT	O
and	O
the	O
ST	O
were	O
0	O
.	O
780	O
[	O
P	O
=	O
0	O
.	O
0000	O
]	O
and	O
0	O
.	O
740	O
[	O
P	O
=	O
0	O
.	O
0001	O
]	O
respectively	O
.	O

CONCLUSIONS	O
:	O

In	O
clinical	O
practice	O
PT	O
appears	O
to	O
have	O
a	O
higher	O
level	O
of	O
accuracy	O
than	O
ST	O
in	O
normal	O
corneas	O
.	O

In	O
scarred	O
corneas	O
and	O
post	O
-	O
penetrating	O
keratoplasty	O
eyes	O
,	O
because	O
of	O
high	O
SD	O
for	O
mean	O
differences	O
and	O
wide	O
confidence	O
interval	O
of	O
95	O
%	O
,	O
both	O
PT	O
and	O
ST	O
are	O
inaccurate	O
in	O
measuring	O
IOP	O
as	O
compared	O
to	O
GAT	O
in	O
such	O
eyes	O
.	O

A	O
pancreatic	O
beta	O
-	O
cell	O
-	O
specific	O
enhancer	O
in	O
the	O
human	O
PDX	O
-	O
1	O
gene	O
is	O
regulated	O
by	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SPs	O
transcription	O
factors	O
.	O

The	O
PDX	O
-	O
1	O
transcription	O
factor	O
plays	O
a	O
key	O
role	O
in	O
pancreas	O
development	O
.	O

Although	O
expressed	O
in	O
all	O
cells	O
at	O
the	O
early	O
stages	O
,	O
in	O
the	O
adult	O
it	O
is	O
mainly	O
restricted	O
to	O
the	O
beta	O
-	O
cell	O
.	O

To	O
characterize	O
the	O
regulatory	O
elements	O
and	O
potential	O
transcription	O
factors	O
necessary	O
for	O
human	O
PDX	O
-	O
1	O
gene	O
expression	O
in	O
beta	O
-	O
cells	O
,	O
we	O
constructed	O
a	O
series	O
of	O
5	O
'	O
and	O
3	O
'	O
deletion	O
fragments	O
of	O
the	O
5	O
'	O
-	O
flanking	O
region	O
of	O
the	O
gene	O
,	O
fused	O
to	O
the	O
luciferase	O
reporter	O
gene	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
by	O
transient	O
transfections	O
in	O
beta	O
-	O
and	O
non	O
-	O
beta	O
-	O
cells	O
a	O
novel	O
beta	O
-	O
cell	O
-	O
specific	O
distal	O
enhancer	O
element	O
located	O
between	O
-	O
3	O
.	O
7	O
and	O
-	O
3	O
.	O
45	O
kilobases	O
.	O

DNase	O
I	O
footprinting	O
analysis	O
revealed	O
two	O
protected	O
regions	O
,	O
one	O
binding	O
the	O
transcription	O
factors	O
SP1	O
and	O
SP3	O
and	O
the	O
other	O
hepatocyte	O
nuclear	O
factor	O
3beta	O
(	O
HNF	O
-	O
3beta	O
)	O
and	O
HNF	O
-	O
1alpha	O
.	O

Cotransfection	O
experiments	O
suggest	O
that	O
HNF	O
-	O
3beta	O
,	O
HNF	O
-	O
1alpha	O
,	O
and	O
SP1	O
are	O
positive	O
regulators	O
of	O
the	O
herein	O
-	O
described	O
human	O
PDX	O
-	O
1	O
enhancer	O
element	O
.	O

Furthermore	O
,	O
mutations	O
within	O
each	O
motif	O
abolished	O
the	O
binding	O
of	O
the	O
corresponding	O
factor	O
(	O
s	O
)	O
and	O
dramatically	O
impaired	O
the	O
enhancer	O
activity	O
,	O
therefore	O
suggesting	O
cooperativity	O
between	O
these	O
factors	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
-	O
B	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
expression	O
in	O
renal	O
cell	O
carcinomas	O
:	O
regulation	O
by	O
the	O
von	O
Hippel	O
-	O
Lindau	O
gene	O
and	O
hypoxia	O
.	O

Angiogenesis	O
is	O
essential	O
for	O
tumor	O
growth	O
and	O
metastasis	O
.	O

It	O
is	O
regulated	O
by	O
numerous	O
angiogenic	O
factors	O
,	O
one	O
of	O
the	O
most	O
important	O
being	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

Recently	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
,	O
two	O
new	O
VEGF	O
family	O
members	O
,	O
have	O
been	O
identified	O
that	O
bind	O
to	O
the	O
tyrosine	O
kinase	O
receptors	O
flt	O
-	O
1	O
(	O
VEGFR1	O
)	O
,	O
KDR	O
(	O
VEGFR2	O
)	O
,	O
and	O
flt	O
-	O
4	O
(	O
VEGFR3	O
)	O
.	O

Although	O
the	O
importance	O
of	O
VEGF	O
-	O
A	O
has	O
been	O
shown	O
in	O
renal	O
carcinomas	O
,	O
the	O
contribution	O
of	O
these	O
new	O
ligands	O
in	O
kidney	O
tumors	O
is	O
not	O
clear	O
.	O

We	O
have	O
,	O
therefore	O
,	O
measured	O
the	O
mRNA	O
level	O
of	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
together	O
with	O
their	O
receptors	O
by	O
RNase	O
protection	O
assay	O
(	O
RPA	O
)	O
in	O
26	O
normal	O
kidney	O
samples	O
and	O
45	O
renal	O
cell	O
cancers	O
.	O

We	O
observed	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
VEGF	O
-	O
B	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
but	O
not	O
VEGF	O
-	O
C	O
(	O
P	O
=	O
0	O
.	O
3	O
)	O
in	O
neoplastic	O
kidney	O
compared	O
with	O
normal	O
tissues	O
.	O

In	O
addition	O
,	O
although	O
VEGF	O
receptors	O
were	O
higher	O
in	O
tumors	O
than	O
normal	O
kidney	O
,	O
there	O
was	O
a	O
significant	O
up	O
-	O
regulation	O
of	O
only	O
flt	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
003	O
)	O
but	O
not	O
KDR	O
(	O
P	O
=	O
0	O
.	O
12	O
)	O
or	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

There	O
was	O
also	O
a	O
significant	O
correlation	O
between	O
VEGF	O
-	O
C	O
and	O
both	O
of	O
its	O
receptors	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
and	O
KDR	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
but	O
no	O
association	O
between	O
VEGF	O
-	O
B	O
and	O
its	O
receptor	O
flt	O
-	O
1	O
(	O
P	O
=	O
0	O
.	O
23	O
)	O
.	O

A	O
significant	O
increase	O
was	O
observed	O
in	O
flt	O
-	O
1	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
KDR	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
flt	O
-	O
4	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
but	O
not	O
VEGF	O
-	O
B	O
(	O
P	O
=	O
0	O
.	O
82	O
)	O
or	O
VEGF	O
-	O
C	O
(	O
P	O
=	O
0	O
.	O
52	O
)	O
expression	O
in	O
clear	O
cell	O
compared	O
with	O
chromophil	O
(	O
papillary	O
)	O
carcinomas	O
.	O

No	O
significant	O
association	O
was	O
demonstrated	O
between	O
VEGF	O
-	O
B	O
,	O
VEGF	O
-	O
C	O
,	O
flt	O
-	O
1	O
,	O
KDR	O
,	O
and	O
flt	O
-	O
4	O
with	O
patient	O
sex	O
,	O
patient	O
age	O
,	O
or	O
tumor	O
size	O
(	O
P	O
greater	O
than	O
0	O
.	O
05	O
)	O
.	O

The	O
effect	O
of	O
von	O
Hippel	O
-	O
Lindau	O
(	O
VHL	O
)	O
gene	O
and	O
hypoxia	O
on	O
VEGF	O
-	O
B	O
and	O
VEGF	O
-	O
C	O
expression	O
in	O
the	O
renal	O
carcinoma	O
cell	O
line	O
786	B
-	I
0	I
transfected	O
with	O
wild	O
-	O
type	O
and	O
mutant	O
VHL	O
was	O
determined	O
by	O
growing	O
cells	O
under	O
21	O
%	O
O2	O
-	O
and	O
0	O
.	O
1	O
%	O
O2	O
.	O

In	O
wild	O
-	O
type	O
VHL	O
cells	O
,	O
whereas	O
VEGF	O
-	O
A	O
was	O
significantly	O
up	O
-	O
regulated	O
under	O
hypoxic	O
compared	O
with	O
normoxic	O
conditions	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
expression	O
of	O
VEGF	O
-	O
C	O
was	O
reduced	O
(	O
P	O
less	O
than	O
0	O
.	O
002	O
)	O
.	O

Nevertheless	O
,	O
the	O
repression	O
of	O
VEGF	O
-	O
C	O
was	O
lost	O
in	O
mutant	O
VHL	O
cell	O
lines	O
under	O
hypoxia	O
.	O

In	O
contrast	O
VEGF	O
-	O
B	O
was	O
not	O
regulated	O
by	O
VHL	O
despite	O
clear	O
up	O
-	O
regulation	O
in	O
vivo	O
.	O

These	O
findings	O
strongly	O
support	O
an	O
enhanced	O
role	O
for	O
this	O
pathway	O
in	O
clear	O
cell	O
carcinomas	O
by	O
regulating	O
angiogenesis	O
and	O
/	O
or	O
lymphangiogenesis	O
.	O

The	O
study	O
shows	O
that	O
clear	O
cell	O
tumors	O
are	O
able	O
to	O
up	O
-	O
regulate	O
angiogenic	O
growth	O
factor	O
receptors	O
more	O
efficiently	O
than	O
chromophil	O
(	O
papillary	O
)	O
,	O
that	O
clear	O
cell	O
tumors	O
can	O
use	O
pathways	O
independent	O
of	O
VHL	O
to	O
regulate	O
angiogenesis	O
,	O
and	O
that	O
this	O
combined	O
regulation	O
may	O
account	O
for	O
their	O
more	O
aggressive	O
phenotype	O
,	O
which	O
suggests	O
that	O
targeting	O
VEGFR1	O
(	O
flt	O
-	O
l	O
)	O
may	O
be	O
particularly	O
effective	O
in	O
these	O
tumor	O
types	O
.	O

A	O
small	O
peptide	O
derived	O
from	O
Flt	O
-	O
1	O
(	O
VEGFR	O
-	O
1	O
)	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
an	O
angiogenic	O
stimulator	O
which	O
functions	O
through	O
two	O
endothelial	O
specific	O
tyrosine	O
kinase	O
receptors	O
,	O
Flt	O
-	O
1	O
and	O
Flk	O
-	O
1	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
an	O
11	O
-	O
amino	O
acid	O
peptide	O
derived	O
from	O
the	O
second	O
immunoglobulin	O
-	O
like	O
domain	O
of	O
Flt	O
-	O
1	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
in	O
chick	O
chorioallantoic	O
membrane	O
and	O
inhibited	O
VEGF	O
-	O
induced	O
vascular	O
permeability	O
in	O
Miles	O
'	O
assay	O
without	O
binding	O
to	O
VEGF	O
directly	O
.	O

Circular	O
dichroism	O
and	O
nuclear	O
magnetic	O
resonance	O
analyses	O
indicate	O
that	O
this	O
peptide	O
forms	O
a	O
stable	O
extended	O
structure	O
in	O
solution	O
,	O
presumably	O
beta	O
-	O
sheet	O
structure	O
and	O
is	O
most	O
likely	O
existing	O
as	O
a	O
dimer	O
.	O

Our	O
results	O
suggest	O
that	O
this	O
small	O
peptide	O
functions	O
as	O
an	O
angiogenic	O
inhibitor	O
by	O
inhibiting	O
VEGF	O
function	O
through	O
a	O
non	O
-	O
VEGF	O
binding	O
mechanism	O
.	O

[	O
H	O
.	O
pylori	O
infection	O
.	O
Our	O
experience	O
with	O
the	O
quadruple	O
and	O
triple	O
therapy	O
as	O
first	O
pharmacologic	O
approach	O
]	O
.	O

For	O
now	O
the	O
most	O
used	O
pharmacological	O
treatment	O
of	O
first	O
instance	O
to	O
eradication	O
of	O
Hp	O
foresees	O
utilization	O
of	O
triple	O
therapy	O
(	O
PPI	O
+	O
two	O
antibiotics	O
)	O
.	O

In	O
our	O
study	O
we	O
have	O
compared	O
this	O
kind	O
of	O
treatment	O
with	O
the	O
quadruple	O
therapy	O
(	O
PPI	O
+	O
three	O
antibiotics	O
)	O
,	O
that	O
have	O
showed	O
a	O
taller	O
percentage	O
of	O
eradication	O
at	O
the	O
end	O
of	O
first	O
therapeutical	O
cycle	O
with	O
a	O
shorter	O
time	O
and	O
lower	O
price	O
of	O
treatment	O
.	O

Effects	O
of	O
morphological	O
patterning	O
on	O
endothelial	O
cell	O
migration	O
.	O

The	O
migration	O
of	O
vascular	O
endothelial	O
cells	O
(	O
ECs	O
)	O
plays	O
an	O
important	O
role	O
in	O
vascular	O
remodeling	O
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
cell	O
morphology	O
on	O
the	O
migration	O
of	O
bovine	O
aortic	O
ECs	O
by	O
culturing	O
cells	O
on	O
micropatterned	O
strips	O
of	O
collagen	O
matrix	O
(	O
60	O
-	O
,	O
30	O
-	O
,	O
and	O
15	O
-	O
microm	O
wide	O
)	O
.	O

The	O
spreading	O
areas	O
of	O
the	O
cells	O
on	O
15	O
-	O
and	O
30	O
-	O
microm	O
wide	O
strips	O
were	O
30	O
%	O
lower	O
than	O
those	O
on	O
60	O
-	O
microm	O
wide	O
strips	O
and	O
unpatterned	O
collagen	O
.	O

The	O
cells	O
on	O
15	O
-	O
microm	O
wide	O
strips	O
completely	O
aligned	O
in	O
the	O
direction	O
of	O
the	O
strip	O
,	O
and	O
had	O
significantly	O
lower	O
shape	O
index	O
than	O
those	O
in	O
all	O
other	O
groups	O
.	O

On	O
strips	O
of	O
all	O
widths	O
,	O
ECs	O
tended	O
to	O
migrate	O
in	O
the	O
direction	O
of	O
strips	O
.	O

ECs	O
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
highest	O
speed	O
,	O
particularly	O
in	O
the	O
direction	O
of	O
the	O
strip	O
.	O

Vinculin	O
staining	O
showed	O
that	O
the	O
leading	O
edge	O
of	O
ECs	O
on	O
15	O
-	O
microm	O
wide	O
strips	O
had	O
focal	O
adhesions	O
that	O
were	O
oriented	O
with	O
their	O
lamellipodial	O
protrusion	O
and	O
the	O
direction	O
of	O
cell	O
migration	O
;	O
this	O
arrangement	O
of	O
the	O
focal	O
adhesions	O
may	O
promote	O
EC	O
migration	O
.	O

The	O
present	O
study	O
provides	O
direct	O
evidence	O
on	O
the	O
role	O
of	O
cell	O
morphology	O
in	O
EC	O
migration	O
,	O
and	O
will	O
help	O
us	O
to	O
understand	O
the	O
mechanisms	O
of	O
EC	O
migration	O
during	O
angiogenesis	O
and	O
wound	O
healing	O
.	O

Thrombospondin	O
-	O
2	O
plays	O
a	O
protective	O
role	O
in	O
multistep	O
carcinogenesis	O
:	O
a	O
novel	O
host	O
anti	O
-	O
tumor	O
defense	O
mechanism	O
.	O

The	O
angiogenic	O
switch	O
during	O
tumorigenesis	O
is	O
thought	O
to	O
be	O
induced	O
by	O
a	O
change	O
in	O
the	O
balance	O
of	O
pro	O
-	O
angiogenic	O
and	O
anti	O
-	O
angiogenic	O
factors	O
.	O

To	O
elucidate	O
the	O
biological	O
role	O
of	O
the	O
endogenous	O
angiogenesis	O
inhibitor	O
thrombospondin	O
-	O
2	O
(	O
TSP	O
-	O
2	O
)	O
during	O
multistep	O
carcinogenesis	O
,	O
we	O
subjected	O
TSP	O
-	O
2	O
-	O
deficient	O
and	O
wild	O
-	O
type	O
mice	O
to	O
a	O
chemical	O
skin	O
carcinogenesis	O
regimen	O
.	O

Surprisingly	O
,	O
TSP	O
-	O
2	O
expression	O
was	O
strongly	O
upregulated	O
in	O
the	O
mesenchymal	O
stroma	O
of	O
wild	O
-	O
type	O
mice	O
throughout	O
the	O
consecutive	O
stages	O
of	O
tumorigenesis	O
whereas	O
the	O
angiogenesis	O
factor	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
was	O
induced	O
predominantly	O
in	O
tumor	O
cells	O
.	O

TSP	O
-	O
2	O
deficiency	O
dramatically	O
enhanced	O
susceptibility	O
to	O
skin	O
carcinogenesis	O
and	O
resulted	O
in	O
accelerated	O
and	O
increased	O
tumor	O
formation	O
.	O

The	O
angiogenic	O
switch	O
occurred	O
in	O
early	O
stages	O
of	O
pre	O
-	O
malignant	O
tumor	O
formation	O
,	O
and	O
tumor	O
angiogenesis	O
was	O
significantly	O
enhanced	O
in	O
TSP	O
-	O
2	O
-	O
deficient	O
mice	O
.	O

While	O
TSP	O
-	O
2	O
deficiency	O
did	O
not	O
affect	O
tumor	O
differentiation	O
or	O
proliferation	O
,	O
tumor	O
cell	O
apoptosis	O
was	O
significantly	O
reduced	O
.	O

These	O
results	O
reveal	O
upregulation	O
of	O
an	O
endogenous	O
angiogenesis	O
inhibitor	O
during	O
multi	O
step	O
tumorigenesis	O
and	O
identify	O
enhanced	O
stromal	O
TSP	O
-	O
2	O
expression	O
as	O
a	O
novel	O
host	O
anti	O
-	O
tumor	O
defense	O
mechanism	O
.	O

Relationship	O
of	O
p53	O
and	O
Helicobacter	O
pylori	O
to	O
clinicopathological	O
features	O
of	O
human	O
remnant	O
stomach	O
cancer	O
after	O
gastric	O
surgery	O
for	O
primary	O
gastric	O
cancer	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
biological	O
features	O
of	O
gastric	O
cancer	O
of	O
the	O
remnant	O
stomach	O
(	O
RSC	O
)	O
.	O

Twenty	O
-	O
one	O
patients	O
underwent	O
resection	O
of	O
the	O
remnant	O
stomach	O
for	O
RSC	O
and	O
were	O
divided	O
into	O
two	O
groups	O
:	O
the	O
RSCB	O
group	O
consisted	O
of	O
11	O
patients	O
who	O
underwent	O
distal	O
gastrectomy	O
for	O
benign	O
disease	O
and	O
the	O
RSCM	O
group	O
consisted	O
of	O
10	O
patients	O
who	O
underwent	O
gastrectomy	O
for	O
primary	O
gastric	O
cancer	O
.	O

The	O
interval	O
between	O
primary	O
surgery	O
and	O
the	O
appearance	O
of	O
gastric	O
cancer	O
in	O
the	O
remnant	O
stomach	O
was	O
significantly	O
shorter	O
in	O
the	O
RSCM	O
group	O
than	O
in	O
the	O
RSCB	O
group	O
.	O

Invasion	O
of	O
adjacent	O
organs	O
was	O
more	O
frequent	O
in	O
the	O
RSCM	O
group	O
than	O
in	O
the	O
RSCB	O
group	O
and	O
the	O
Ki	O
-	O
67	O
labeling	O
index	O
of	O
the	O
tumors	O
was	O
significantly	O
higher	O
in	O
the	O
former	O
group	O
.	O

Furthermore	O
,	O
p53	O
overexpression	O
by	O
tumors	O
was	O
almost	O
twice	O
as	O
common	O
in	O
the	O
RSCM	O
group	O
as	O
in	O
the	O
RSCB	O
group	O
.	O

Although	O
there	O
was	O
no	O
significant	O
difference	O
of	O
the	O
H	O
.	O
pylori	O
positivity	O
between	O
the	O
two	O
groups	O
,	O
the	O
rate	O
for	O
both	O
groups	O
was	O
higher	O
than	O
reported	O
in	O
previous	O
studies	O
.	O

Mutation	O
of	O
p53	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
high	O
proliferative	O
activity	O
of	O
tumors	O
in	O
the	O
RSCM	O
group	O
and	O
H	O
.	O
pylori	O
infection	O
may	O
be	O
closely	O
related	O
to	O
carcinogenesis	O
in	O
patients	O
with	O
RSC	O
.	O

Coexpression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
p53	O
protein	O
in	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
esophagus	O
.	O

OBJECTIVE	O
:	O
p53	O
plays	O
a	O
role	O
in	O
tumor	O
angiogenesis	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
plays	O
a	O
key	O
role	O
in	O
tumor	O
angiogenesis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
how	O
expression	O
of	O
p53	O
protein	O
participates	O
in	O
angiogenesis	O
,	O
and	O
whether	O
the	O
coexpression	O
of	O
VEGF	O
and	O
p53	O
protein	O
has	O
a	O
significance	O
for	O
angiogenesis	O
and	O
the	O
clinicopathological	O
features	O
in	O
esophageal	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
.	O

METHODS	O
:	O
Tissues	O
samples	O
were	O
taken	O
from	O
60	O
patients	O
with	O
esophageal	O
SCC	O
after	O
surgery	O
.	O

The	O
expression	O
of	O
VEGF	O
and	O
p53	O
protein	O
in	O
these	O
SCC	O
was	O
examined	O
immunohistochemically	O
.	O

Microvessel	O
density	O
(	O
MVD	O
)	O
was	O
determined	O
by	O
counting	O
microvessels	O
in	O
tumor	O
sections	O
stained	O
for	O
Factor	O
VIII	O
-	O
related	O
antigen	O
.	O

Ki	O
-	O
67	O
labeling	O
index	O
(	O
LI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
Ki	O
-	O
67	O
antigen	O
immunostaining	O
,	O
as	O
a	O
proliferative	O
marker	O
.	O

Apoptotic	O
index	O
(	O
AI	O
)	O
was	O
calculated	O
,	O
based	O
on	O
the	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
deoxyuridine	O
triphosphate	O
biotin	O
nick	O
end	O
labeling	O
,	O
to	O
evaluate	O
apoptosis	O
.	O

RESULTS	O
:	O
VEGF	O
expression	O
was	O
observed	O
in	O
58	O
.	O
3	O
%	O
,	O
and	O
p53	O
protein	O
expression	O
was	O
observed	O
in	O
61	O
.	O
7	O
%	O
of	O
the	O
60	O
patients	O
.	O

VEGF	O
and	O
p53	O
protein	O
were	O
significantly	O
coexpressed	O
in	O
26	O
(	O
43	O
.	O
4	O
%	O
)	O
.	O

Histological	O
venous	O
invasion	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
and	O
distant	O
metastasis	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
)	O
were	O
significantly	O
correlated	O
with	O
p53	O
protein	O
expression	O
.	O

The	O
two	O
parameters	O
were	O
more	O
frequently	O
observed	O
in	O
the	O
SCC	O
with	O
VEGF	O
/	O
p53	O
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O

The	O
MVD	O
and	O
Ki	O
-	O
67	O
LI	O
were	O
significantly	O
higher	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
and	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
and	O
the	O
AI	O
was	O
significantly	O
lower	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
in	O
the	O
SCC	O
with	O
p53	O
protein	O
expression	O
than	O
in	O
the	O
SCC	O
without	O
it	O
.	O

The	O
MVD	O
and	O
Ki	O
-	O
67	O
LI	O
were	O
higher	O
,	O
and	O
the	O
AI	O
was	O
lower	O
in	O
the	O
SCC	O
with	O
VEGF	O
/	O
p53	O
coexpression	O
than	O
in	O
those	O
without	O
the	O
coexpression	O
.	O

The	O
5	O
-	O
yr	O
survival	O
rate	O
in	O
patients	O
with	O
the	O
coexpression	O
was	O
poorer	O
than	O
in	O
the	O
other	O
patients	O
.	O

CONCLUSION	O
:	O
These	O
results	O
suggest	O
that	O
mutant	O
p53	O
expression	O
is	O
associated	O
with	O
angiogenesis	O
and	O
distant	O
metastasis	O
in	O
esophageal	O
SCC	O
,	O
and	O
that	O
the	O
coexpression	O
of	O
p53	O
and	O
VEGF	O
may	O
play	O
an	O
important	O
role	O
in	O
angiogenesis	O
,	O
and	O
have	O
important	O
clinical	O
significance	O
.	O

Current	O
prospects	O
for	O
controlling	O
cancer	O
growth	O
with	O
non	O
-	O
cytotoxic	O
agents	O
-	O
-	O
nutrients	O
,	O
phytochemicals	O
,	O
herbal	O
extracts	O
,	O
and	O
available	O
drugs	O
.	O

In	O
animal	O
or	O
cell	O
culture	O
studies	O
,	O
the	O
growth	O
and	O
spread	O
of	O
cancer	O
can	O
be	O
slowed	O
by	O
many	O
nutrients	O
,	O
food	O
factors	O
,	O
herbal	O
extracts	O
,	O
and	O
well	O
-	O
tolerated	O
,	O
available	O
drugs	O
that	O
are	O
still	O
rarely	O
used	O
in	O
the	O
clinical	O
management	O
of	O
cancer	O
,	O
in	O
part	O
because	O
they	O
seem	O
unlikely	O
to	O
constitute	O
definitive	O
therapies	O
in	O
themselves	O
.	O

However	O
,	O
it	O
is	O
reasonable	O
to	O
expect	O
that	O
mechanistically	O
complementary	O
combinations	O
of	O
these	O
measures	O
could	O
have	O
a	O
worthwhile	O
impact	O
on	O
survival	O
times	O
and	O
,	O
when	O
used	O
as	O
adjuvants	O
,	O
could	O
improve	O
the	O
cure	O
rates	O
achievable	O
with	O
standard	O
therapies	O
.	O

The	O
therapeutic	O
options	O
available	O
in	O
this	O
regard	O
include	O
measures	O
that	O
:	O
down	O
-	O
regulate	O
serum	O
free	O
IGF	O
-	O
I	O
;	O
suppress	O
the	O
synthesis	O
of	O
mevalonic	O
acid	O
and	O
/	O
or	O
certain	O
derivatives	O
thereof	O
;	O
modulate	O
arachidonate	O
metabolism	O
by	O
inhibiting	O
5	O
-	O
lipoxygenase	O
,	O
12	O
-	O
lipoxygenase	O
,	O
or	O
COX	O
-	O
2	O
;	O
antagonize	O
the	O
activation	O
of	O
AP	O
-	O
1	O
transcription	O
factors	O
;	O
promote	O
the	O
activation	O
of	O
PPAR	O
-	O
gamma	O
transcription	O
factors	O
;	O
and	O
that	O
suppress	O
angiogenesis	O
by	O
additional	O
mechanisms	O
.	O

Many	O
of	O
these	O
measures	O
appear	O
suitable	O
for	O
use	O
in	O
cancer	O
prevention	O
.	O

[	O
mRNA	O
expression	O
of	O
metastasis	O
-	O
suppressor	O
gene	O
nm23	O
in	O
carcinoma	O
of	O
buccal	O
mucosa	O
.	O
II	O
.	O
Quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
]	O
.	O

The	O
nm23	O
gene	O
is	O
a	O
conspicuous	O
metastasis	O
-	O
suppressor	O
gene	O
.	O

The	O
authors	O
detected	O
both	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
levels	O
in	O
47	O
tissues	O
samples	O
of	O
patients	O
with	O
carcinoma	O
of	O
buccal	O
mucosa	O
(	O
CBM	O
)	O
by	O
quantitative	O
reverse	O
transcription	O
PCR	O
amplification	O
.	O

The	O
results	O
showed	O
that	O
expression	O
levels	O
of	O
both	O
nm23	O
-	O
H1	O
and	O
nm23	O
-	O
H2	O
mRNA	O
varied	O
in	O
normal	O
buccal	O
mucosa	O
,	O
leukoplakia	O
,	O
adjacent	O
nontumorous	O
mucosa	O
,	O
submandibular	O
gland	O
,	O
CBM	O
and	O
lymph	O
nodes	O
with	O
or	O
without	O
metastasis	O
.	O

The	O
nm23	O
-	O
H1	O
mRNA	O
expression	O
levels	O
in	O
CBM	O
with	O
lymph	O
nodes	O
metastases	O
were	O
lower	O
than	O
those	O
in	O
CBM	O
without	O
metastases	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
no	O
significance	O
of	O
nm23	O
-	O
H2	O
mRNA	O
expression	O
levels	O
was	O
found	O
between	O
CBM	O
with	O
and	O
CBM	O
without	O
metastasis	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
results	O
were	O
comparative	O
to	O
those	O
of	O
Northern	O
blotting	O
of	O
the	O
same	O
cases	O
.	O

The	O
authors	O
concluded	O
that	O
,	O
as	O
also	O
in	O
the	O
study	O
of	O
Northern	O
blotting	O
,	O
the	O
expression	O
of	O
nm23	O
-	O
H1	O
mRNA	O
significantly	O
correlated	O
inversely	O
with	O
lymph	O
node	O
metastasis	O
in	O
CBM	O
,	O
while	O
the	O
expression	O
of	O
nm23	O
-	O
H2	O
mRNA	O
not	O
.	O

Q	O
-	O
RT	O
-	O
PCR	O
was	O
a	O
useful	O
method	O
to	O
detect	O
the	O
mRNA	O
levels	O
of	O
nm23	O
gene	O
in	O
buccal	O
carcinoma	O
.	O

Glucose	O
catabolism	O
in	O
cancer	O
cells	O
:	O
identification	O
and	O
characterization	O
of	O
a	O
marked	O
activation	O
response	O
of	O
the	O
type	O
II	O
hexokinase	O
gene	O
to	O
hypoxic	O
conditions	O
.	O

One	O
of	O
the	O
most	O
common	O
signatures	O
of	O
highly	O
malignant	O
tumors	O
is	O
their	O
capacity	O
to	O
metabolize	O
more	O
glucose	O
to	O
lactic	O
acid	O
than	O
their	O
tissues	O
of	O
origin	O
.	O

Hepatomas	O
exhibiting	O
this	O
phenotype	O
are	O
dependent	O
on	O
the	O
high	O
expression	O
of	O
type	O
II	O
hexokinase	O
,	O
which	O
supplies	O
such	O
tumors	O
with	O
abundant	O
amounts	O
of	O
glucose	O
6	O
-	O
phosphate	O
,	O
a	O
significant	O
carbon	O
and	O
energy	O
source	O
especially	O
under	O
hypoxic	O
conditions	O
.	O

Here	O
we	O
report	O
that	O
the	O
distal	O
region	O
of	O
the	O
hepatoma	O
type	O
II	O
hexokinase	O
promoter	O
displays	O
consensus	O
motifs	O
for	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
-	O
1	O
)	O
that	O
overlap	O
E	O
-	O
box	O
sequences	O
known	O
to	O
be	O
related	O
in	O
other	O
gene	O
promoters	O
to	O
glucose	O
response	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
subjecting	O
transfected	O
hepatoma	O
cells	O
to	O
hypoxic	O
conditions	O
activates	O
the	O
type	O
II	O
hexokinase	O
promoter	O
almost	O
3	O
-	O
fold	O
,	O
a	O
value	O
that	O
approaches	O
7	O
-	O
fold	O
in	O
the	O
presence	O
of	O
glucose	O
.	O

Consistent	O
with	O
these	O
findings	O
is	O
the	O
induction	O
under	O
hypoxic	O
conditions	O
of	O
the	O
HIF	O
-	O
1	O
protein	O
.	O

Reporter	O
gene	O
analyses	O
with	O
a	O
series	O
of	O
nested	O
deletion	O
mutants	O
of	O
the	O
hepatoma	O
type	O
II	O
hexokinase	O
promoter	O
show	O
that	O
a	O
significant	O
fraction	O
of	O
the	O
total	O
activation	O
observed	O
under	O
hypoxic	O
conditions	O
localizes	O
to	O
the	O
distal	O
region	O
where	O
the	O
overlapping	O
HIF	O
-	O
1	O
/	O
E	O
-	O
box	O
sequences	O
are	O
located	O
.	O

Finally	O
,	O
DNase	O
I	O
footprint	O
analysis	O
with	O
a	O
segment	O
of	O
the	O
promoter	O
containing	O
these	O
elements	O
reveals	O
the	O
binding	O
of	O
several	O
nuclear	O
proteins	O
.	O

In	O
summary	O
,	O
these	O
novel	O
studies	O
identify	O
and	O
characterize	O
a	O
marked	O
glucose	O
-	O
modulated	O
activation	O
response	O
of	O
the	O
type	O
II	O
hexokinase	O
gene	O
to	O
hypoxic	O
conditions	O
within	O
highly	O
glycolytic	O
hepatoma	O
cells	O
,	O
a	O
property	O
that	O
may	O
help	O
assure	O
that	O
such	O
cells	O
exhibit	O
a	O
growth	O
and	O
survival	O
advantage	O
over	O
their	O
parental	O
cells	O
of	O
origin	O
.	O

Neoplastic	O
transformation	O
and	O
tumorigenesis	O
associated	O
with	O
overexpression	O
of	O
phospholipase	O
D	O
isozymes	O
in	O
cultured	O
murine	O
fibroblasts	O
.	O

Phospholipase	O
D	O
(	O
PLD	O
)	O
has	O
been	O
suggested	O
to	O
play	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

PLD	O
activity	O
has	O
been	O
shown	O
to	O
be	O
significantly	O
elevated	O
in	O
many	O
tumours	O
and	O
transformed	O
cells	O
,	O
suggesting	O
the	O
possibility	O
that	O
PLD	O
might	O
be	O
involved	O
in	O
tumorigenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
established	O
stable	O
cell	O
lines	O
overexpressing	O
PLD1	O
and	O
PLD2	O
from	O
fibroblast	O
cells	O
.	O

These	O
cells	O
,	O
but	O
not	O
control	O
cells	O
,	O
showed	O
altered	O
growth	O
properties	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
soft	O
agar	O
.	O

Both	O
PLD1	O
and	O
PLD2	O
also	O
induced	O
an	O
up	O
-	O
regulation	O
of	O
the	O
activity	O
of	O
matrix	O
metalloprotease	O
-	O
9	O
as	O
detected	O
by	O
zymograms	O
.	O

Furthermore	O
,	O
both	O
PLD1	O
and	O
PLD2	O
transformants	O
,	O
but	O
not	O
vector	O
-	O
transfectants	O
,	O
induced	O
undifferentiated	O
sarcoma	O
when	O
transplanted	O
into	O
nude	O
mice	O
.	O

Both	O
PLD1	O
-	O
and	O
PLD2	O
-	O
mediated	O
cell	O
cycle	O
distributions	O
in	O
stable	O
cell	O
lines	O
revealed	O
an	O
increased	O
fraction	O
of	O
cells	O
in	O
the	O
S	O
phase	O
compared	O
with	O
control	O
cells	O
.	O

Interestingly	O
,	O
the	O
level	O
of	O
cyclin	O
D3	O
protein	O
,	O
known	O
as	O
an	O
activator	O
of	O
G	O
(	O
1	O
)	O
to	O
S	O
phase	O
transition	O
in	O
the	O
cell	O
cycle	O
,	O
was	O
aberrantly	O
high	O
in	O
cells	O
overexpressing	O
PLD1	O
and	O
PLD2	O
compared	O
with	O
control	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
overexpression	O
of	O
PLD	O
isozymes	O
may	O
play	O
an	O
important	O
role	O
in	O
neoplastic	O
transformation	O
.	O

Oncogenic	O
mechanisms	O
of	O
Evi	O
-	O
1	O
protein	O
.	O

Although	O
Evi	O
-	O
1	O
is	O
thought	O
to	O
promote	O
growth	O
or	O
block	O
differentiation	O
in	O
some	O
cell	O
types	O
,	O
its	O
biological	O
functions	O
have	O
not	O
been	O
elucidated	O
.	O

To	O
explore	O
the	O
mechanisms	O
underlying	O
Evi	O
-	O
1	O
-	O
induced	O
oncogenesis	O
,	O
we	O
investigated	O
whether	O
Evi	O
-	O
1	O
affects	O
the	O
signaling	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
which	O
inhibits	O
proliferation	O
of	O
a	O
wide	O
range	O
of	O
cell	O
types	O
and	O
is	O
one	O
of	O
the	O
most	O
studied	O
growth	O
regulatory	O
factors	O
.	O

We	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
TGF	O
-	O
beta	O
signaling	O
and	O
antagonizes	O
its	O
growth	O
-	O
inhibitory	O
effects	O
.	O

Two	O
separate	O
regions	O
of	O
Evi	O
-	O
1	O
are	O
responsible	O
for	O
this	O
repression	O
,	O
one	O
of	O
which	O
is	O
the	O
first	O
zinc	O
-	O
finger	O
domain	O
.	O

Through	O
this	O
domain	O
,	O
Evi	O
-	O
1	O
physically	O
interacts	O
with	O
Smad3	O
,	O
an	O
intracellular	O
mediator	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
thereby	O
suppressing	O
the	O
transcriptional	O
activity	O
of	O
Smad3	O
.	O

These	O
results	O
define	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
repressor	O
of	O
signaling	O
components	O
of	O
TGF	O
-	O
beta	O
.	O

We	O
also	O
demonstrated	O
that	O
Evi	O
-	O
1	O
represses	O
Smad	O
-	O
induced	O
transcriptional	O
activation	O
by	O
recruiting	O
CtBP	O
as	O
a	O
corepressor	O
.	O

Evi	O
-	O
1	O
associates	O
with	O
CtBP1	O
through	O
one	O
of	O
the	O
CtBP	O
-	O
binding	O
consensus	O
motifs	O
within	O
the	O
region	O
from	O
amino	O
acid	O
544	O
to	O
607	O
,	O
and	O
this	O
association	O
is	O
required	O
for	O
the	O
efficient	O
inhibition	O
of	O
TGF	O
-	O
beta	O
signaling	O
.	O

A	O
specific	O
histone	O
deacetylase	O
(	O
HDAc	O
)	O
inhibitor	O
,	O
trichostatin	O
A	O
(	O
TSA	O
)	O
,	O
alleviates	O
Evi	O
-	O
1	O
-	O
mediated	O
repression	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
suggesting	O
that	O
HDAc	O
is	O
involved	O
in	O
transcriptional	O
repression	O
by	O
Evi	O
-	O
1	O
.	O

This	O
identifies	O
a	O
novel	O
function	O
of	O
Evi	O
-	O
1	O
as	O
a	O
member	O
of	O
corepressor	O
complexes	O
and	O
suggests	O
that	O
aberrant	O
recruitment	O
of	O
corepressors	O
is	O
one	O
of	O
the	O
mechanisms	O
involved	O
in	O
Evi	O
-	O
1	O
-	O
induced	O
leukemogenesis	O
.	O

These	O
results	O
indicate	O
that	O
specific	O
HDAc	O
inhibitors	O
may	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
Evi	O
-	O
1	O
-	O
induced	O
neoplastic	O
tumors	O
,	O
including	O
myeloid	O
leukemias	O
.	O

Antibodies	O
to	O
PAI	O
-	O
1	O
alter	O
the	O
invasive	O
and	O
migratory	O
properties	O
of	O
human	O
tumour	O
cells	O
in	O
vitro	O
.	O

Recent	O
reports	O
suggest	O
that	O
elevated	O
levels	O
of	O
plasminogen	O
activator	O
inhibitor	O
-	O
1	O
(	O
PAI	O
-	O
1	O
)	O
may	O
contribute	O
to	O
tumour	O
progression	O
.	O

The	O
studies	O
reported	O
here	O
were	O
designed	O
to	O
help	O
elucidate	O
PAI	O
-	O
1	O
'	O
s	O
contribution	O
to	O
the	O
invasive	O
and	O
migratory	O
phenotype	O
.	O

Antibodies	O
to	O
PA	O
-	O
1	O
dose	O
-	O
dependently	O
,	O
and	O
significantly	O
,	O
inhibited	O
the	O
invasive	O
and	O
migratory	O
potential	O
of	O
human	O
HT1080	B
fibrosarcoma	O
cells	O
,	O
as	O
did	O
an	O
antibody	O
to	O
uPA	O
and	O
the	O
plasmin	O
inhibitor	O
aprotinin	O
.	O

Invasion	O
of	O
the	O
human	O
melanoma	O
cell	O
line	O
,	O
BLM	B
,	O
was	O
also	O
attenuated	O
by	O
the	O
anti	O
-	O
PAI	O
-	O
1	O
monoclonal	O
antibody	O
MAI	O
-	O
12	O
.	O

The	O
non	O
-	O
invasive	O
human	O
melanoma	O
cell	O
line	O
,	O
IF6	B
,	O
which	O
does	O
not	O
express	O
uPA	O
,	O
provided	O
further	O
confirmation	O
of	O
PAI	O
-	O
1	O
and	O
uPA	O
'	O
s	O
role	O
as	O
,	O
upon	O
transfection	O
with	O
uPA	O
,	O
this	O
cell	O
line	O
attained	O
an	O
invasive	O
phenotype	O
,	O
which	O
was	O
again	O
attenuated	O
by	O
MAI	O
-	O
12	O
.	O

Although	O
antibodies	O
to	O
PAI	O
-	O
1	O
did	O
not	O
affect	O
the	O
adhesion	O
of	O
HT1080	B
cells	O
to	O
vitronectin	O
,	O
the	O
antibody	O
to	O
uPA	O
reduced	O
their	O
attachment	O
.	O

Addition	O
of	O
exogenous	O
PAI	O
-	O
1	O
,	O
however	O
,	O
prevented	O
HT1080	B
cell	O
adhesion	O
(	O
IC50	O
180	O
nM	O
)	O
and	O
promoted	O
cell	O
detachment	O
from	O
vitronectin	O
.	O

Furthermore	O
melanoma	O
cells	O
transfected	O
with	O
a	O
uPA	O
variant	O
,	O
which	O
had	O
an	O
impaired	O
interaction	O
with	O
PAI	O
-	O
1	O
,	O
were	O
not	O
invasive	O
and	O
had	O
impaired	O
binding	O
to	O
vitronectin	O
.	O

These	O
data	O
highlight	O
the	O
importance	O
of	O
a	O
balanced	O
proteolysis	O
and	O
suggest	O
an	O
additional	O
role	O
for	O
PAI	O
-	O
1	O
distinct	O
from	O
its	O
role	O
in	O
proteolysis	O
.	O

These	O
data	O
also	O
suggest	O
that	O
uPA	O
and	O
PAI	O
-	O
1	O
may	O
co	O
-	O
operate	O
in	O
the	O
migratory	O
process	O
by	O
respectively	O
facilitating	O
the	O
attachment	O
to	O
,	O
and	O
subsequent	O
detachment	O
from	O
,	O
vitronectin	O
in	O
the	O
extracellular	O
matrix	O
.	O

These	O
results	O
support	O
the	O
clinical	O
findings	O
and	O
indicate	O
that	O
modulation	O
of	O
PAI	O
-	O
1	O
activity	O
may	O
be	O
of	O
therapeutic	O
benefit	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

[	O
Anesthetic	O
management	O
of	O
a	O
patient	O
with	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
]	O
.	O

The	O
Dyggve	O
-	O
Melchior	O
-	O
Clausen	O
syndrome	O
(	O
DMCS	O
)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
skeletal	O
dysplasia	O
characterized	O
by	O
short	O
-	O
trunk	O
dwarfism	O
and	O
mental	O
retardation	O
.	O

A	O
49	O
-	O
year	O
-	O
old	O
male	O
with	O
DMCS	O
underwent	O
resection	O
arthroplasty	O
for	O
contracture	O
of	O
the	O
right	O
hip	O
joint	O
under	O
general	O
anesthesia	O
using	O
thiamylal	O
,	O
nitrous	O
oxide	O
,	O
sevoflurane	O
,	O
and	O
vecuronium	O
.	O

Although	O
he	O
was	O
assumed	O
to	O
have	O
difficult	O
airway	O
due	O
to	O
short	O
neck	O
,	O
macroglossia	O
,	O
and	O
disturbance	O
of	O
neck	O
flexion	O
,	O
tracheal	O
intubation	O
was	O
not	O
difficult	O
.	O

No	O
complications	O
including	O
malignant	O
hyperthermia	O
were	O
observed	O
during	O
the	O
95	O
min	O
of	O
the	O
operation	O
.	O

Assembly	O
strategies	O
and	O
GTPase	O
regulation	O
of	O
the	O
eukaryotic	O
and	O
Escherichia	O
coil	O
translocons	O
.	O

The	O
translocation	O
of	O
most	O
proteins	O
across	O
the	O
endoplasmic	O
reticulum	O
or	O
bacterial	O
inner	O
membrane	O
occurs	O
through	O
an	O
aqueous	O
pore	O
that	O
spans	O
the	O
membrane	O
.	O

Substrates	O
that	O
are	O
translocated	O
co	O
-	O
translationally	O
across	O
the	O
membrane	O
are	O
directed	O
to	O
the	O
translocation	O
pore	O
via	O
an	O
interaction	O
between	O
the	O
cytosolic	O
signal	O
recognition	O
particle	O
and	O
its	O
membrane	O
-	O
bound	O
receptor	O
.	O

Together	O
the	O
translocation	O
pore	O
and	O
the	O
receptor	O
are	O
referred	O
to	O
as	O
a	O
translocon	O
.	O

By	O
studying	O
the	O
biogenesis	O
of	O
the	O
translocon	O
a	O
number	O
of	O
alternate	O
targeting	O
and	O
membrane	O
-	O
integration	O
pathways	O
have	O
been	O
discovered	O
that	O
operate	O
independently	O
of	O
the	O
signal	O
recognition	O
particle	O
(	O
SRP	O
)	O
pathway	O
.	O

The	O
novel	O
assembly	O
strategies	O
of	O
the	O
translocon	O
and	O
the	O
ways	O
in	O
which	O
these	O
components	O
interact	O
to	O
ensure	O
the	O
fidelity	O
and	O
unidirectionality	O
of	O
the	O
targeting	O
and	O
translocation	O
process	O
are	O
reviewed	O
here	O
.	O

[	O
Decreased	O
stimulation	O
of	O
glycosaminoglycan	O
synthesis	O
by	O
human	O
skin	O
fibroblasts	O
by	O
interleukin	O
6	O
within	O
the	O
scope	O
of	O
in	O
vitro	O
aging	O
]	O
.	O

Addition	O
of	O
human	O
recombinant	O
interleukin	O
6	O
(	O
IL	O
-	O
6	O
)	O
to	O
culture	O
medium	O
(	O
supplemented	O
MEM	O
without	O
or	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
)	O
of	O
human	O
skin	O
fibroblasts	O
exerted	O
a	O
stimulating	O
effect	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
on	O
glycosaminoglycan	O
(	O
GAG	O
)	O
synthesis	O
,	O
including	O
hyaluronic	O
acid	O
(	O
hyaluronan	O
)	O
synthesis	O
,	O
of	O
young	O
(	O
phase	O
-	O
II	O
)	O
skin	O
fibroblasts	O
in	O
concentrations	O
of	O
1	O
ng	O
/	O
ml	O
and	O
10	O
ng	O
/	O
ml	O
.	O

Stimulation	O
was	O
mainly	O
due	O
to	O
an	O
increase	O
in	O
extracellular	O
GAGs	O
(	O
secreted	O
into	O
culture	O
medium	O
)	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
to	O
an	O
increase	O
in	O
peri	O
-	O
and	O
intracellular	O
GAGs	O
.	O

Stimulation	O
with	O
1	O
ng	O
/	O
ml	O
and	O
10	O
ng	O
/	O
ml	O
IL	O
-	O
6	O
led	O
to	O
an	O
increase	O
in	O
hyaluronic	O
acid	O
from	O
48	O
%	O
to	O
61	O
%	O
(	O
-	O
FCS	O
)	O
and	O
from	O
77	O
%	O
to	O
90	O
%	O
(	O
+	O
10	O
%	O
FCS	O
)	O
,	O
respectively	O
.	O

Maximum	O
stimulation	O
,	O
with	O
and	O
without	O
FCS	O
,	O
was	O
achieved	O
by	O
10	O
ng	O
/	O
ml	O
IL	O
-	O
6	O
.	O

Compared	O
to	O
young	O
(	O
phase	O
-	O
II	O
)	O
cells	O
,	O
senescent	O
(	O
phase	O
-	O
III	O
)	O
cells	O
,	O
showed	O
no	O
significant	O
stimulation	O
of	O
total	O
GAG	O
(	O
including	O
hyaluronic	O
acid	O
)	O
synthesis	O
by	O
IL	O
-	O
6	O
.	O

The	O
diminished	O
response	O
of	O
GAG	O
-	O
and	O
hyaluronic	O
acid	O
synthesis	O
during	O
aging	O
of	O
these	O
in	O
vitro	O
cultured	O
fibroblasts	O
should	O
motivate	O
further	O
research	O
if	O
similar	O
processes	O
occur	O
during	O
aging	O
in	O
an	O
organism	O
.	O

Renormalization	O
group	O
analysis	O
of	O
autoregressive	O
processes	O
and	O
fractional	O
noise	O
.	O

A	O
renormalization	O
group	O
analysis	O
is	O
applied	O
to	O
autoregressive	O
processes	O
with	O
an	O
infinite	O
series	O
of	O
coefficients	O
.	O

A	O
simple	O
fixed	O
point	O
is	O
given	O
by	O
a	O
random	O
walk	O
,	O
and	O
a	O
second	O
class	O
is	O
found	O
that	O
is	O
proportional	O
to	O
the	O
high	O
order	O
coefficients	O
of	O
fractional	O
autoregressive	O
integrated	O
moving	O
average	O
(	O
ARIMA	O
)	O
processes	O
.	O

The	O
approach	O
might	O
be	O
useful	O
to	O
detect	O
nonstationarity	O
in	O
autoregressive	O
processes	O
.	O

Troponin	O
I	O
inhibits	O
capillary	O
endothelial	O
cell	O
proliferation	O
by	O
interaction	O
with	O
the	O
cell	O
'	O
s	O
bFGF	O
receptor	O
.	O

Troponin	O
I	O
(	O
TnI	O
)	O
is	O
a	O
novel	O
cartilage	O
-	O
derived	O
angiogenesis	O
inhibitor	O
,	O
first	O
demonstrated	O
by	O
Moses	O
et	O
al	O
.	O

(	O
1999	O
,	O
Proc	O
.	O
Natl	O
.	O
Acad	O
.	O
Sci	O
.	O
USA	O
2645	O
-	O
2650	O
)	O
to	O
inhibit	O
endothelial	O
cell	O
proliferation	O
and	O
angiogenesis	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
to	O
inhibit	O
metastasis	O
of	O
a	O
wide	O
variety	O
of	O
tumors	O
in	O
vivo	O
.	O

Despite	O
convincing	O
evidence	O
of	O
its	O
efficacy	O
,	O
little	O
is	O
known	O
about	O
the	O
mechanism	O
of	O
action	O
of	O
TnI	O
as	O
an	O
anti	O
-	O
proliferative	O
and	O
anti	O
-	O
angiogenic	O
agent	O
.	O

In	O
the	O
current	O
article	O
we	O
demonstrate	O
that	O
TnI	O
inhibits	O
both	O
bFGF	O
-	O
stimulated	O
and	O
basal	O
levels	O
of	O
endothelial	O
cell	O
proliferation	O
,	O
and	O
we	O
hypothesize	O
that	O
this	O
inhibition	O
is	O
occurring	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
an	O
interaction	O
of	O
TnI	O
with	O
the	O
cell	O
-	O
surface	O
bFGF	O
receptor	O
on	O
capillary	O
endothelial	O
cells	O
.	O

We	O
further	O
support	O
this	O
hypothesis	O
by	O
providing	O
the	O
first	O
evidence	O
that	O
TnI	O
can	O
act	O
on	O
nonendothelial	O
as	O
well	O
as	O
endothelial	O
cells	O
and	O
by	O
demonstrating	O
that	O
this	O
inhibitory	O
action	O
is	O
specific	O
for	O
the	O
bFGF	O
receptor	O
on	O
the	O
target	O
cells	O
.	O

Preliminary	O
data	O
suggest	O
that	O
TnI	O
may	O
be	O
competing	O
with	O
bFGF	O
for	O
interaction	O
with	O
the	O
bFGF	O
receptor	O
on	O
responsive	O
cells	O
.	O

RhoA	O
activation	O
promotes	O
transformation	O
and	O
loss	O
of	O
thyroid	O
cell	O
differentiation	O
interfering	O
with	O
thyroid	O
transcription	O
factor	O
-	O
1	O
activity	O
.	O

Highly	O
specialized	O
cells	O
,	O
the	O
thyrocytes	O
,	O
express	O
a	O
thyroid	O
-	O
specific	O
set	O
of	O
genes	O
for	O
thyroglobulin	O
(	O
Tg	O
)	O
,	O
thyroperoxidase	O
,	O
and	O
the	O
transcription	O
factors	O
TTF	O
-	O
1	O
,	O
TTF	O
-	O
2	O
,	O
and	O
Pax	O
-	O
8	O
.	O

The	O
implication	O
of	O
the	O
small	O
GTPase	O
RhoA	O
in	O
TSH	O
-	O
mediated	O
proliferation	O
of	O
FRTL	B
-	I
5	I
rat	O
thyroid	O
cells	O
has	O
been	O
previously	O
demonstrated	O
.	O

To	O
further	O
analyze	O
RhoA	O
function	O
in	O
thyroid	O
cell	O
proliferation	O
and	O
differentiation	O
patterns	O
,	O
we	O
combined	O
transient	O
and	O
stable	O
transfection	O
assays	O
to	O
express	O
different	O
mutant	O
RhoA	O
forms	O
in	O
FRTL	B
-	I
5	I
cells	O
.	O

Constitutively	O
active	O
RhoA	O
(	O
FRTL	B
-	I
5	I
-	O
RhoA	O
QL	O
cells	O
)	O
exhibited	O
a	O
fibroblast	O
-	O
like	O
phenotype	O
with	O
organized	O
actin	O
fibers	O
,	O
whereas	O
cells	O
expressing	O
the	O
RhoA	O
negative	O
dominant	O
phenotype	O
(	O
FRTL	B
-	I
5	I
-	O
RhoA	O
N19	O
cells	O
)	O
present	O
a	O
rounded	O
morphology	O
and	O
lose	O
normal	O
cytoskeletal	O
architecture	O
.	O

In	O
addition	O
,	O
expression	O
of	O
the	O
constitutively	O
active	O
form	O
of	O
RhoA	O
results	O
in	O
TSH	O
-	O
independent	O
proliferation	O
and	O
anchorage	O
-	O
independent	O
growth	O
and	O
induces	O
tumors	O
when	O
inoculated	O
in	O
nude	O
mice	O
.	O

Interestingly	O
,	O
FRTL	B
-	I
5	I
-	O
RhoA	O
QL	O
cells	O
express	O
less	O
Tg	O
and	O
TTF	O
-	O
1	O
than	O
wild	O
-	O
type	O
FRTL	B
-	I
5	I
(	O
FRTL	B
-	I
5	I
-	O
vector	O
)	O
or	O
FRTL	B
-	I
5	I
-	O
RhoA	O
N19	O
,	O
suggesting	O
a	O
loss	O
at	O
the	O
differentiation	O
stage	O
.	O

This	O
effect	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
a	O
decrease	O
in	O
TTF	O
-	O
1	O
activity	O
,	O
since	O
transient	O
or	O
stable	O
expression	O
of	O
RhoA	O
QL	O
results	O
in	O
a	O
reduction	O
in	O
the	O
activity	O
of	O
the	O
wild	O
-	O
type	O
Tg	O
promoter	O
as	O
well	O
as	O
an	O
artificial	O
promoter	O
the	O
activation	O
of	O
which	O
depends	O
exclusively	O
on	O
TTF	O
-	O
1	O
.	O

The	O
similarity	O
between	O
RhoA	O
effects	O
and	O
thyroid	O
transformation	O
by	O
Ras	O
suggests	O
that	O
RhoA	O
may	O
act	O
as	O
a	O
downstream	O
effector	O
of	O
Ras	O
;	O
in	O
fact	O
,	O
the	O
dominant	O
negative	O
RhoA	O
N19	O
abolished	O
the	O
down	O
-	O
regulatory	O
effect	O
of	O
Ras	O
V12	O
over	O
the	O
Tg	O
promoter	O
.	O

Taken	O
together	O
,	O
these	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
active	O
RhoA	O
is	O
able	O
to	O
transform	O
FRTL	B
-	I
5	I
cells	O
and	O
that	O
this	O
effect	O
is	O
coupled	O
to	O
a	O
loss	O
of	O
thyroid	O
differentiation	O
due	O
to	O
impaired	O
TTF	O
-	O
1	O
activity	O
.	O

Phonology	O
:	O
a	O
review	O
and	O
proposals	O
from	O
a	O
connectionist	O
perspective	O
.	O

A	O
parallel	O
distributed	O
processing	O
(	O
PDP	O
)	O
model	O
of	O
phonological	O
processing	O
is	O
developed	O
,	O
including	O
components	O
to	O
support	O
repetition	O
,	O
auditory	O
processing	O
,	O
comprehension	O
,	O
and	O
language	O
production	O
.	O

From	O
the	O
performance	O
of	O
the	O
PDP	O
reading	O
model	O
of	O
Plaut	O
,	O
McClelland	O
,	O
Seidenberg	O
,	O
and	O
Patterson	O
(	O
1996	O
)	O
,	O
it	O
is	O
inferred	O
that	O
the	O
acoustic	O
-	O
articulatory	O
motor	O
pattern	O
associator	O
that	O
supports	O
repetition	O
provides	O
the	O
basis	O
for	O
phonological	O
sequence	O
knowledge	O
.	O

From	O
the	O
observation	O
that	O
many	O
patients	O
make	O
phonemic	O
paraphasic	O
errors	O
in	O
language	O
production	O
,	O
as	O
in	O
repetition	O
,	O
it	O
is	O
argued	O
that	O
there	O
must	O
be	O
a	O
direct	O
link	O
between	O
distributed	O
concept	O
representations	O
(	O
lexical	O
semantic	O
knowledge	O
)	O
and	O
this	O
network	O
representation	O
of	O
sequence	O
knowledge	O
.	O

In	O
this	O
way	O
,	O
both	O
lexical	O
semantic	O
and	O
phonotactic	O
constraints	O
are	O
brought	O
to	O
bear	O
on	O
language	O
production	O
.	O

The	O
literature	O
on	O
phonological	O
function	O
in	O
normal	O
subjects	O
(	O
slip	O
-	O
of	O
-	O
the	O
-	O
tongue	O
corpora	O
)	O
and	O
in	O
patients	O
with	O
aphasia	O
is	O
critically	O
reviewed	O
from	O
this	O
perspective	O
.	O

The	O
relationship	O
between	O
acoustic	O
and	O
articulatory	O
motor	O
representations	O
in	O
the	O
process	O
of	O
phonetic	O
perception	O
is	O
considered	O
.	O

Repetition	O
and	O
reproduction	O
conduction	O
aphasia	O
are	O
reviewed	O
in	O
detail	O
and	O
extended	O
consideration	O
is	O
given	O
to	O
the	O
representation	O
of	O
auditory	O
verbal	O
short	O
-	O
term	O
memory	O
in	O
the	O
model	O
.	O

Finally	O
,	O
the	O
PDP	O
model	O
is	O
reconciled	O
with	O
information	O
processing	O
models	O
of	O
phonological	O
processing	O
,	O
including	O
that	O
of	O
Lichtheim	O
,	O
and	O
with	O
current	O
knowledge	O
of	O
the	O
anatomic	O
localization	O
of	O
phonological	O
processing	O
.	O

Although	O
no	O
simulations	O
of	O
the	O
model	O
were	O
run	O
,	O
a	O
number	O
of	O
simulation	O
studies	O
are	O
proposed	O
.	O

Clinical	O
significance	O
of	O
plasma	O
endostatin	O
in	O
acute	O
myeloid	O
leukemia	O
/	O
myelodysplastic	O
syndrome	O
.	O

BACKGROUND	O
:	O
Endostatin	O
,	O
a	O
C	O
-	O
terminal	O
fragment	O
of	O
collagen	O
XVIII	O
,	O
is	O
an	O
endogenous	O
angiogenesis	O
inhibitor	O
.	O

While	O
endostatin	O
is	O
being	O
investigated	O
for	O
its	O
usefulness	O
in	O
treating	O
solid	O
tumors	O
,	O
its	O
significance	O
in	O
hematologic	O
malignancies	O
is	O
unknown	O
.	O

METHODS	O
:	O
The	O
authors	O
evaluated	O
plasma	O
endostatin	O
(	O
PE	O
)	O
levels	O
using	O
an	O
enzyme	O
linked	O
immunoassay	O
in	O
71	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
and	O
43	O
patients	O
with	O
myelodysplastic	O
syndrome	O
(	O
MDS	O
)	O
,	O
and	O
correlated	O
PE	O
with	O
various	O
clinical	O
parameters	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
median	O
PE	O
level	O
between	O
AML	O
/	O
MDS	O
patients	O
and	O
the	O
normal	O
controls	O
.	O

Nevertheless	O
,	O
patients	O
who	O
achieved	O
complete	O
remission	O
(	O
CR	O
)	O
had	O
a	O
significantly	O
lower	O
median	O
PE	O
level	O
compared	O
to	O
those	O
who	O
did	O
not	O
.	O

In	O
multivariate	O
analysis	O
,	O
PE	O
was	O
found	O
to	O
be	O
a	O
significant	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
predictor	O
of	O
overall	O
survival	O
(	O
OS	O
)	O
with	O
adjustment	O
of	O
the	O
other	O
baseline	O
covariates	O
,	O
including	O
patient	O
age	O
,	O
history	O
of	O
antecedent	O
hematologic	O
disorders	O
,	O
and	O
the	O
use	O
of	O
protective	O
environments	O
.	O

The	O
prognostic	O
value	O
of	O
PE	O
was	O
also	O
evaluated	O
by	O
dividing	O
MDS	O
/	O
AML	O
patients	O
into	O
high	O
and	O
low	O
PE	O
groups	O
using	O
the	O
median	O
PE	O
level	O
of	O
normal	O
controls	O
as	O
the	O
cut	O
-	O
off	O
.	O

The	O
authors	O
found	O
that	O
patients	O
in	O
the	O
high	O
PE	O
group	O
survived	O
for	O
a	O
significantly	O
shorter	O
time	O
than	O
those	O
patients	O
in	O
the	O
low	O
PE	O
group	O
.	O

CONCLUSIONS	O
:	O
PE	O
is	O
a	O
useful	O
prognostic	O
predictor	O
of	O
CR	O
and	O
OS	O
for	O
AML	O
/	O
MDS	O
patients	O
.	O

The	O
mechanism	O
underlying	O
the	O
association	O
between	O
high	O
PE	O
and	O
poor	O
clinical	O
outcome	O
is	O
unclear	O
,	O
although	O
it	O
may	O
be	O
related	O
to	O
the	O
possible	O
PE	O
reflection	O
of	O
tumor	O
burden	O
.	O

Modulation	O
of	O
angiogenesis	O
and	O
progelatinase	O
a	O
by	O
thrombin	O
receptor	O
mimetics	O
and	O
antagonists	O
.	O

The	O
angiogenic	O
action	O
of	O
thrombin	O
has	O
been	O
shown	O
to	O
be	O
mediated	O
by	O
activation	O
of	O
the	O
thrombin	O
receptor	O
.	O

In	O
this	O
report	O
we	O
studied	O
the	O
effects	O
of	O
SFLLR	O
,	O
an	O
agonist	O
of	O
the	O
activated	O
thrombin	O
receptor	O
and	O
thrombin	O
receptor	O
peptide	O
and	O
non	O
peptide	O
antagonists	O
on	O
angiogenesis	O
in	O
the	O
chick	O
chorioallantoic	O
membrane	O
(	O
CAM	O
)	O
system	O
.	O

As	O
antagonists	O
were	O
used	O
the	O
tripeptide	O
FPR	O
and	O
non	O
-	O
peptide	O
1	O
,	O
4	O
-	O
disubstituted	O
piperazine	O
derivatives	O
.	O

The	O
pentapeptide	O
SFLLR	O
,	O
like	O
thrombin	O
,	O
caused	O
a	O
marked	O
stimulation	O
of	O
angiogenesis	O
in	O
the	O
CAM	O
.	O

FPR	O
and	O
the	O
piperazine	O
derivatives	O
caused	O
suppression	O
of	O
angiogenesis	O
and	O
in	O
combination	O
with	O
thrombin	O
antagonized	O
its	O
angiogenic	O
effect	O
.	O

Thrombin	O
and	O
SFLLR	O
activated	O
progelatinase	O
A	O
(	O
MMP	O
-	O
2	O
)	O
in	O
the	O
culture	O
medium	O
of	O
human	O
umbilical	O
cord	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
.	O

MMP	O
-	O
2	O
is	O
involved	O
in	O
the	O
early	O
steps	O
of	O
angiogenesis	O
leading	O
to	O
local	O
dissolution	O
of	O
basement	O
membrane	O
collagen	O
and	O
migration	O
of	O
the	O
activated	O
endothelial	O
cells	O
.	O

FPR	O
and	O
the	O
piperazine	O
derivatives	O
inhibited	O
the	O
activation	O
of	O
this	O
enzyme	O
.	O

They	O
also	O
antagonised	O
the	O
effects	O
of	O
both	O
thrombin	O
and	O
SFLLR	O
on	O
MMP	O
-	O
2	O
activation	O
.	O

These	O
results	O
suggest	O
that	O
non	O
-	O
thrombogenic	O
agonists	O
or	O
antagonists	O
of	O
the	O
activated	O
thrombin	O
receptor	O
can	O
be	O
used	O
as	O
modulators	O
of	O
angiogenesis	O
.	O

Inhibition	O
of	O
PDGF	O
-	O
stimulated	O
and	O
matrix	O
-	O
mediated	O
proliferation	O
of	O
human	O
vascular	O
smooth	O
muscle	O
cells	O
by	O
SPARC	O
is	O
independent	O
of	O
changes	O
in	O
cell	O
shape	O
or	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
.	O

Interactions	O
among	O
growth	O
factors	O
,	O
cells	O
,	O
and	O
extracellular	O
matrix	O
regulate	O
proliferation	O
during	O
normal	O
development	O
and	O
in	O
pathologies	O
such	O
as	O
atherosclerosis	O
.	O

SPARC	O
(	O
secreted	O
protein	O
,	O
acidic	O
,	O
and	O
rich	O
in	O
cysteine	O
)	O
is	O
a	O
matrix	O
-	O
associated	O
glycoprotein	O
that	O
modulates	O
the	O
adhesion	O
and	O
proliferation	O
of	O
vascular	O
cells	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
SPARC	O
inhibits	O
human	O
arterial	O
smooth	O
muscle	O
cell	O
proliferation	O
stimulated	O
by	O
platelet	O
-	O
derived	O
growth	O
factor	O
or	O
by	O
adhesion	O
to	O
monomeric	O
type	O
I	O
collagen	O
.	O

Binding	O
studies	O
with	O
SPARC	O
and	O
SPARC	O
peptides	O
indicate	O
specific	O
and	O
saturable	O
interaction	O
with	O
smooth	O
muscle	O
cells	O
that	O
involves	O
the	O
C	O
-	O
terminal	O
Ca2	O
+	O
-	O
binding	O
region	O
of	O
the	O
protein	O
.	O

We	O
also	O
report	O
that	O
SPARC	O
arrests	O
monomeric	O
collagen	O
-	O
supported	O
smooth	O
muscle	O
cell	O
proliferation	O
in	O
the	O
late	O
G1	O
-	O
phase	O
of	O
the	O
cell	O
cycle	O
in	O
the	O
absence	O
of	O
an	O
effect	O
on	O
cell	O
shape	O
or	O
on	O
levels	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
.	O

Cyclin	O
-	O
dependent	O
kinase	O
-	O
2	O
activity	O
,	O
p107	O
and	O
cyclin	O
A	O
levels	O
,	O
and	O
retinoblastoma	O
protein	O
phosphorylation	O
are	O
markedly	O
reduced	O
in	O
response	O
to	O
the	O
addition	O
of	O
exogenous	O
SPARC	O
and	O
/	O
or	O
peptides	O
derived	O
from	O
specific	O
domains	O
of	O
SPARC	O
.	O

Thus	O
,	O
SPARC	O
,	O
previously	O
characterized	O
as	O
an	O
inhibitor	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
binding	O
to	O
its	O
receptor	O
,	O
also	O
antagonizes	O
smooth	O
muscle	O
cell	O
proliferation	O
mediated	O
by	O
monomeric	O
collagen	O
at	O
the	O
level	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
-	O
2	O
activity	O
.	O

Prognostic	O
significance	O
of	O
heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
)	O
in	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Heat	O
shock	O
proteins	O
(	O
HSPs	O
)	O
have	O
been	O
defined	O
as	O
proteins	O
induced	O
by	O
heat	O
shock	O
and	O
other	O
environmental	O
and	O
pathophysiologic	O
stress	O
.	O

Heat	O
shock	O
protein	O
27	O
(	O
HSP27	O
)	O
is	O
one	O
of	O
the	O
small	O
heat	O
shock	O
proteins	O
.	O

HSP27	O
is	O
implicated	O
in	O
protein	O
-	O
protein	O
interactions	O
such	O
as	O
folding	O
,	O
translocation	O
,	O
and	O
prevention	O
of	O
inappropriate	O
protein	O
aggregation	O
.	O

Many	O
of	O
their	O
functions	O
suggest	O
that	O
they	O
play	O
important	O
roles	O
in	O
cancers	O
.	O

Archival	O
tissues	O
from	O
40	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinoma	O
who	O
received	O
primary	O
surgical	O
resection	O
were	O
examined	O
for	O
HSP27	O
by	O
immunohistochemistry	O
and	O
correlated	O
with	O
clinical	O
stage	O
,	O
lymph	O
node	O
metastasis	O
,	O
histological	O
grade	O
and	O
survival	O
period	O
.	O

HSP27	O
expression	O
was	O
positive	O
staining	O
(	O
+	O
)	O
in	O
20	O
(	O
50	O
%	O
)	O
,	O
weak	O
or	O
negative	O
staining	O
(	O
-	O
)	O
in	O
20	O
(	O
50	O
%	O
)	O
of	O
total	O
40	O
cases	O
.	O

There	O
was	O
no	O
correlation	O
between	O
HSP27	O
expression	O
and	O
clinical	O
stage	O
,	O
lymph	O
node	O
metastasis	O
and	O
histological	O
grade	O
.	O

However	O
,	O
when	O
compared	O
with	O
clinicopathological	O
features	O
,	O
the	O
expression	O
of	O
HSP27	O
correlated	O
inversely	O
with	O
survival	O
period	O
.	O

This	O
study	O
suggests	O
that	O
the	O
expression	O
of	O
HSP27	O
is	O
frequently	O
promoted	O
in	O
patients	O
with	O
oral	O
squamous	O
cell	O
carcinoma	O
and	O
should	O
be	O
considered	O
an	O
independent	O
prognostic	O
factor	O
of	O
oral	O
squamous	O
cell	O
carcinoma	O
patients	O
.	O

Abnormal	O
expression	O
of	O
E	O
-	O
cadherin	O
and	O
beta	O
-	O
catenin	O
may	O
be	O
a	O
molecular	O
marker	O
of	O
submucosal	O
invasion	O
and	O
lymph	O
node	O
metastasis	O
in	O
early	O
gastric	O
cancer	O
.	O

BACKGROUND	O
:	O
Impaired	O
expression	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
is	O
frequently	O
observed	O
in	O
several	O
human	O
cancers	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
immunohistochemical	O
expression	O
of	O
these	O
adhesion	O
molecules	O
,	O
focusing	O
on	O
early	O
gastric	O
carcinomas	O
,	O
and	O
to	O
investigate	O
differences	O
between	O
differentiated	O
and	O
undifferentiated	O
gastric	O
cancer	O
at	O
the	O
early	O
phase	O
of	O
carcinogenesis	O
.	O

METHODS	O
:	O
Immunohistochemical	O
staining	O
of	O
E	O
-	O
cadherin	O
and	O
alpha	O
-	O
and	O
beta	O
-	O
catenin	O
was	O
performed	O
using	O
specimens	O
from	O
143	O
patients	O
with	O
early	O
gastric	O
cancer	O
.	O

RESULTS	O
:	O
Abnormal	O
E	O
-	O
cadherin	O
and	O
beta	O
-	O
catenin	O
staining	O
correlated	O
with	O
depth	O
of	O
tumour	O
invasion	O
in	O
differentiated	O
-	O
type	O
tumours	O
.	O

In	O
contrast	O
,	O
abnormal	O
staining	O
was	O
frequently	O
found	O
even	O
in	O
intramucosal	O
carcinoma	O
of	O
undifferentiated	O
-	O
type	O
tumours	O
,	O
suggesting	O
an	O
apparent	O
difference	O
in	O
the	O
onset	O
of	O
E	O
-	O
cadherin	O
-	O
catenin	O
complex	O
abnormality	O
between	O
the	O
two	O
cancer	O
types	O
.	O

Absent	O
staining	O
of	O
beta	O
-	O
catenin	O
was	O
associated	O
with	O
lymph	O
node	O
metastasis	O
.	O

Multivariate	O
analysis	O
revealed	O
abnormal	O
E	O
-	O
cadherin	O
expression	O
as	O
an	O
independent	O
factor	O
that	O
correlated	O
with	O
submucosal	O
invasion	O
in	O
early	O
gastric	O
cancer	O
.	O

CONCLUSION	O
:	O
Abnormal	O
E	O
-	O
cadherin	O
expression	O
is	O
a	O
possible	O
marker	O
of	O
submucosal	O
invasion	O
in	O
differentiated	O
-	O
type	O
early	O
gastric	O
cancer	O
and	O
absent	O
beta	O
-	O
catenin	O
staining	O
could	O
be	O
used	O
as	O
a	O
predictor	O
of	O
lymph	O
node	O
metastasis	O
in	O
both	O
types	O
.	O

Dominant	O
negative	O
interference	O
of	O
transcription	O
factor	O
AP	O
-	O
2	O
causes	O
inhibition	O
of	O
ErbB	O
-	O
3	O
expression	O
and	O
suppresses	O
malignant	O
cell	O
growth	O
.	O

ErbB	O
-	O
3	O
(	O
HER3	O
)	O
is	O
a	O
member	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
family	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
elevated	O
expression	O
of	O
ErbB	O
-	O
3	O
is	O
important	O
for	O
malignancy	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
elevated	O
levels	O
of	O
ErbB	O
-	O
3	O
expression	O
did	O
not	O
occur	O
in	O
the	O
absence	O
of	O
AP	O
-	O
2gamma	O
in	O
a	O
panel	O
of	O
human	O
mammary	O
epithelial	O
and	O
fibroblasts	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
there	O
was	O
no	O
association	O
between	O
the	O
expression	O
of	O
AP	O
-	O
2alpha	O
or	O
AP	O
-	O
2beta	O
and	O
the	O
level	O
of	O
ErbB	O
-	O
3	O
,	O
or	O
between	O
AP	O
-	O
2alpha	O
and	O
AP	O
-	O
2gamma	O
double	O
positivity	O
and	O
ErbB	O
-	O
3	O
expression	O
.	O

In	O
co	O
-	O
transfection	O
experiments	O
,	O
exogenous	O
expression	O
of	O
AP	O
-	O
2gamma	O
robustly	O
activated	O
ErbB	O
-	O
3	O
promoter	O
activity	O
.	O

Moreover	O
,	O
expression	O
of	O
a	O
dominant	O
negative	O
AP	O
-	O
2	O
protein	O
,	O
AP	O
-	O
2delta	O
(	O
deleted	O
residues	O
31	O
-	O
117	O
)	O
,	O
not	O
only	O
repressed	O
the	O
ErbB	O
-	O
3	O
promoter	O
activity	O
but	O
also	O
suppressed	O
endogenous	O
ErbB	O
-	O
3	O
transcription	O
in	O
the	O
ErbB	O
-	O
3	O
overexpressing	O
cell	O
line	O
MRC	B
-	I
5VA	I
.	O

Overexpression	O
of	O
AP	O
-	O
2A	O
resulted	O
in	O
a	O
decreased	O
proliferation	O
rate	O
and	O
inhibitin	O
of	O
colony	O
formation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
strongly	O
support	O
a	O
role	O
for	O
the	O
AP	O
-	O
2	O
gene	O
family	O
,	O
in	O
particular	O
,	O
AP	O
-	O
2gamma	O
,	O
in	O
the	O
control	O
of	O
ErbB	O
-	O
3	O
expression	O
.	O

Interference	O
with	O
the	O
function	O
of	O
transcription	O
factor	O
AP	O
-	O
2	O
might	O
provide	O
a	O
potential	O
strategy	O
for	O
modulation	O
of	O
the	O
malignant	O
phenotype	O
.	O

Membrane	O
-	O
anchored	O
Cbl	O
suppresses	O
Hck	O
protein	O
-	O
tyrosine	O
kinase	O
mediated	O
cellular	O
transformation	O
.	O

The	O
mammalian	O
proto	O
-	O
oncogene	O
Cbl	O
and	O
its	O
cellular	O
homologues	O
in	O
Caenorhabditis	O
elegans	O
(	O
Sli	O
-	O
1	O
)	O
and	O
Drosophila	O
(	O
D	O
-	O
Cbl	O
)	O
are	O
negative	O
regulators	O
of	O
some	O
growth	O
factor	O
receptor	O
signaling	O
pathways	O
.	O

Herein	O
we	O
show	O
that	O
Cbl	O
can	O
negatively	O
regulate	O
another	O
signaling	O
molecule	O
,	O
namely	O
theSrc	O
-	O
family	O
kinase	O
Hck	O
by	O
targeting	O
it	O
for	O
degradation	O
.	O

Hck	O
-	O
mediated	O
cellular	O
transformation	O
of	O
murine	O
fibroblasts	O
is	O
reverted	O
by	O
ectopic	O
expression	O
of	O
a	O
membrane	O
-	O
anchored	O
allele	O
of	O
Cbl	O
as	O
assessed	O
by	O
the	O
cellular	O
morphology	O
,	O
suppression	O
of	O
anchorage	O
independent	O
growth	O
,	O
and	O
an	O
overall	O
reduction	O
in	O
the	O
total	O
tyrosine	O
phosphorylation	O
levels	O
within	O
the	O
cells	O
.	O

The	O
expression	O
of	O
Cbl	O
at	O
the	O
plasma	O
membrane	O
targets	O
both	O
Hck	O
and	O
itself	O
for	O
ubiquitination	O
and	O
degradation	O
,	O
requiring	O
an	O
intact	O
RING	O
finger	O
.	O

Pharmacological	O
inhibition	O
of	O
the	O
proteasome	O
prevents	O
the	O
degradation	O
of	O
Hck	O
correlating	O
with	O
an	O
increase	O
in	O
the	O
phosphotyrosine	O
levels	O
within	O
the	O
cells	O
.	O

Activated	O
Hck	O
and	O
membrane	O
-	O
anchored	O
Cbl	O
are	O
present	O
in	O
similar	O
subcellular	O
localizations	O
and	O
co	O
-	O
immunoprecipitate	O
,	O
suggesting	O
that	O
their	O
interaction	O
is	O
required	O
for	O
subsequent	O
ubiquitination	O
and	O
degradation	O
.	O

Interestingly	O
,	O
both	O
constitutively	O
active	O
and	O
kinase	O
-	O
inactive	O
Hck	O
interact	O
with	O
and	O
are	O
targeted	O
for	O
degradation	O
by	O
Cbl	O
.	O

This	O
work	O
illustrates	O
alternate	O
means	O
to	O
regulate	O
Src	O
-	O
family	O
kinases	O
,	O
and	O
suggests	O
that	O
Cbl	O
may	O
be	O
able	O
to	O
suppress	O
many	O
signaling	O
pathways	O
that	O
are	O
activated	O
in	O
various	O
proliferative	O
syndromes	O
including	O
cancer	O
.	O

Novel	O
method	O
for	O
multiturn	O
extraction	O
:	O
trapping	O
charged	O
particles	O
in	O
islands	O
of	O
phase	O
space	O
.	O

A	O
novel	O
method	O
for	O
multiturn	O
extraction	O
from	O
a	O
circular	O
particle	O
accelerator	O
is	O
presented	O
,	O
based	O
on	O
trapping	O
particles	O
into	O
islands	O
of	O
phase	O
space	O
generated	O
by	O
nonlinear	O
resonances	O
.	O

By	O
appropriate	O
use	O
of	O
sextupoles	O
and	O
octupoles	O
,	O
stable	O
islands	O
can	O
be	O
created	O
at	O
small	O
amplitude	O
in	O
phase	O
space	O
.	O

By	O
varying	O
the	O
linear	O
tune	O
,	O
particles	O
can	O
be	O
trapped	O
inside	O
these	O
islands	O
and	O
then	O
transported	O
towards	O
higher	O
amplitudes	O
for	O
extraction	O
.	O

Results	O
of	O
numerical	O
simulations	O
are	O
discussed	O
.	O

Upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptors	O
is	O
associated	O
with	O
advanced	O
neuroblastoma	O
.	O

BACKGROUND	O
:	O
Angiogenesis	O
is	O
essential	O
for	O
tumor	O
growth	O
and	O
relies	O
on	O
the	O
production	O
of	O
angiogenic	O
factors	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
major	O
regulator	O
of	O
angiogenesis	O
that	O
binds	O
to	O
tyrosine	O
kinase	O
receptors	O
Flt	O
-	O
1	O
and	O
KDR	O
.	O

The	O
interaction	O
of	O
VEGF	O
and	O
its	O
receptors	O
at	O
gene	O
and	O
protein	O
levels	O
in	O
neuroblastoma	O
remains	O
widely	O
unknown	O
.	O

METHODS	O
:	O
Tumor	O
biopsy	O
specimens	O
and	O
serum	O
were	O
obtained	O
from	O
37	O
neuroblastoma	O
patients	O
;	O
adrenal	O
biopsy	O
sections	O
and	O
sera	O
of	O
7	O
normal	O
children	O
served	O
as	O
controls	O
.	O

Biopsy	O
specimens	O
were	O
examined	O
by	O
real	O
-	O
time	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
Western	O
blotting	O
;	O
serum	O
was	O
analyzed	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
.	O

VEGF	O
-	O
A	O
(	O
165	O
)	O
,	O
B	O
,	O
C	O
,	O
Flt	O
-	O
1	O
,	O
and	O
KDR	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
VEGF	O
isoforms	O
and	O
its	O
receptors	O
'	O
mRNA	O
were	O
expressed	O
in	O
neuroblastoma	O
and	O
control	O
tissues	O
.	O

Whereas	O
the	O
ligands	O
were	O
increased	O
in	O
stages	O
III	O
and	O
IV	O
,	O
the	O
receptors	O
were	O
upregulated	O
in	O
stage	O
III	O
only	O
.	O

At	O
protein	O
level	O
,	O
VEGF	O
-	O
B	O
and	O
C	O
,	O
Flt	O
-	O
1	O
,	O
and	O
KDR	O
were	O
not	O
detectable	O
in	O
tissue	O
lysates	O
,	O
whereas	O
VEGF	O
-	O
A	O
was	O
increased	O
in	O
stages	O
III	O
and	O
IV	O
.	O

Serum	O
VEGF	O
protein	O
levels	O
were	O
upregulated	O
in	O
stage	O
III	O
.	O

CONCLUSIONS	O
:	O
VEGF	O
-	O
A	O
(	O
165	O
)	O
is	O
one	O
of	O
the	O
major	O
angiogenesis	O
regulators	O
among	O
the	O
ligands	O
'	O
family	O
of	O
VEGF	O
,	O
whereas	O
its	O
receptors	O
KDR	O
,	O
and	O
most	O
probably	O
Flt	O
-	O
1	O
,	O
may	O
contribute	O
to	O
a	O
poor	O
prognosis	O
(	O
angiogenic	O
)	O
phenotype	O
,	O
as	O
indicated	O
by	O
their	O
upregulated	O
MRNA	O
levels	O
in	O
stage	O
III	O
neuroblastoma	O
.	O

VEGF	O
-	O
A	O
(	O
165	O
)	O
mainly	O
contributes	O
to	O
increased	O
serum	O
VEGF	O
levels	O
and	O
may	O
serve	O
as	O
a	O
diagnostic	O
tool	O
in	O
advanced	O
-	O
stage	O
neuroblastoma	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
1	O
activation	O
by	O
aerobic	O
glycolysis	O
implicates	O
the	O
Warburg	O
effect	O
in	O
carcinogenesis	O
.	O

Cancer	O
cells	O
display	O
high	O
rates	O
of	O
aerobic	O
glycolysis	O
,	O
a	O
phenomenon	O
known	O
historically	O
as	O
the	O
Warburg	O
effect	O
.	O

Lactate	O
and	O
pyruvate	O
,	O
the	O
end	O
products	O
of	O
glycolysis	O
,	O
are	O
highly	O
produced	O
by	O
cancer	O
cells	O
even	O
in	O
the	O
presence	O
of	O
oxygen	O
.	O

Hypoxia	O
-	O
induced	O
gene	O
expression	O
in	O
cancer	O
cells	O
has	O
been	O
linked	O
to	O
malignant	O
transformation	O
.	O

Here	O
we	O
provide	O
evidence	O
that	O
lactate	O
and	O
pyruvate	O
regulate	O
hypoxia	O
-	O
inducible	O
gene	O
expression	O
independently	O
of	O
hypoxia	O
by	O
stimulating	O
the	O
accumulation	O
of	O
hypoxia	O
-	O
inducible	O
Factor	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O

In	O
human	O
gliomas	O
and	O
other	O
cancer	O
cell	O
lines	O
,	O
the	O
accumulation	O
of	O
HIF	O
-	O
1alpha	O
protein	O
under	O
aerobic	O
conditions	O
requires	O
the	O
metabolism	O
of	O
glucose	O
to	O
pyruvate	O
that	O
prevents	O
the	O
aerobic	O
degradation	O
of	O
HIF	O
-	O
1alpha	O
protein	O
,	O
activates	O
HIF	O
-	O
1	O
DNA	O
binding	O
activity	O
,	O
and	O
enhances	O
the	O
expression	O
of	O
several	O
HIF	O
-	O
1	O
-	O
activated	O
genes	O
including	O
erythropoietin	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
glucose	O
transporter	O
3	O
,	O
and	O
aldolase	O
A	O
.	O

Our	O
findings	O
support	O
a	O
novel	O
role	O
for	O
pyruvate	O
in	O
metabolic	O
signaling	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
high	O
rates	O
of	O
aerobic	O
glycolysis	O
can	O
promote	O
the	O
malignant	O
transformation	O
and	O
survival	O
of	O
cancer	O
cells	O
.	O

VEGF165	O
mediates	O
formation	O
of	O
complexes	O
containing	O
VEGFR	O
-	O
2	O
and	O
neuropilin	O
-	O
1	O
that	O
enhance	O
VEGF165	O
-	O
receptor	O
binding	O
.	O

Co	O
-	O
expression	O
of	O
NRP1	O
and	O
(	O
VEGFR	O
-	O
2	O
)	O
KDR	O
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
(	O
EC	O
)	O
enhances	O
VEGF165	O
binding	O
to	O
KDR	O
and	O
EC	O
chemotaxis	O
in	O
response	O
to	O
VEGF165	O
.	O

Overexpression	O
of	O
NRP1	O
by	O
prostate	O
tumor	O
cells	O
in	O
vivo	O
results	O
in	O
increased	O
tumor	O
angiogenesis	O
and	O
growth	O
.	O

We	O
investigated	O
the	O
molecular	O
mechanisms	O
underlying	O
NRP1	O
-	O
mediated	O
angiogenesis	O
by	O
analyzing	O
the	O
association	O
of	O
NRP1	O
and	O
KDR	O
.	O

An	O
intracellular	O
complex	O
containing	O
NRP1	O
and	O
KDR	O
was	O
immunoprecipitated	O
from	O
EC	O
by	O
anti	O
-	O
NRP1	O
antibodies	O
only	O
in	O
the	O
presence	O
of	O
VEGF165	O
.	O

In	O
contrast	O
,	O
VEGF121	O
,	O
which	O
does	O
not	O
bind	O
to	O
NRP1	O
,	O
did	O
not	O
support	O
complex	O
formation	O
.	O

Complexes	O
containing	O
VEGF165	O
,	O
NRP1	O
,	O
and	O
KDR	O
were	O
also	O
formed	O
in	O
an	O
intercellular	O
fashion	O
by	O
co	O
-	O
culture	O
of	O
EC	O
expressing	O
KDR	O
only	O
,	O
with	O
cells	O
expressing	O
NRP1	O
only	O
,	O
for	O
example	O
,	O
breast	O
carcinoma	O
cells	O
.	O

VEGF165	O
also	O
mediated	O
the	O
binding	O
of	O
a	O
soluble	O
NRP1	O
dimer	O
to	O
cells	O
expressing	O
KDR	O
only	O
,	O
confirming	O
the	O
formation	O
of	O
such	O
complexes	O
.	O

Furthermore	O
,	O
the	O
formation	O
of	O
complexes	O
containing	O
KDR	O
and	O
NRP1	O
markedly	O
increased	O
125I	O
-	O
VEGF165	O
binding	O
to	O
KDR	O
.	O

Our	O
results	O
suggest	O
that	O
formation	O
of	O
a	O
ternary	O
complex	O
of	O
VEGF165	O
,	O
KDR	O
,	O
and	O
NRP1	O
potentiates	O
VEGF165	O
binding	O
to	O
KDR	O
.	O

These	O
complexes	O
are	O
formed	O
on	O
the	O
surface	O
of	O
EC	O
and	O
in	O
a	O
juxtacrine	O
manner	O
via	O
association	O
of	O
tumor	O
cell	O
NRP1	O
and	O
EC	O
KDR	O
.	O

Risk	O
of	O
myelodysplastic	O
syndrome	O
and	O
acute	O
myeloid	O
leukemia	O
in	O
congenital	O
neutropenias	O
.	O

Granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
has	O
had	O
a	O
major	O
impact	O
on	O
the	O
management	O
of	O
""""	O
severe	O
chronic	O
neutropenia	O
""""	O
(	O
SCN	O
)	O
,	O
a	O
collective	O
term	O
referring	O
to	O
congenital	O
,	O
idiopathic	O
,	O
or	O
cyclic	O
neutropenia	O
.	O

Almost	O
all	O
patients	O
respond	O
to	O
G	O
-	O
CSF	O
with	O
increased	O
neutrophils	O
,	O
reduced	O
infections	O
,	O
and	O
improved	O
survival	O
.	O

Some	O
responders	O
with	O
congenital	O
neutropenia	O
and	O
Shwachman	O
-	O
Diamond	O
syndrome	O
(	O
SDS	O
)	O
have	O
developed	O
myelodysplastic	O
syndrome	O
and	O
acute	O
myeloid	O
leukemia	O
(	O
MDS	O
/	O
AML	O
)	O
,	O
which	O
raises	O
the	O
question	O
of	O
the	O
role	O
of	O
G	O
-	O
CSF	O
in	O
pathogenesis	O
.	O

The	O
issue	O
is	O
complicated	O
because	O
both	O
disorders	O
have	O
a	O
propensity	O
for	O
MDS	O
or	O
AML	O
as	O
part	O
of	O
their	O
natural	O
history	O
.	O

To	O
address	O
this	O
,	O
the	O
Severe	O
Chronic	O
Neutropenia	O
International	O
Registry	O
(	O
SCNIR	O
)	O
used	O
its	O
large	O
database	O
of	O
chronic	O
neutropenia	O
patients	O
treated	O
with	O
G	O
-	O
CSF	O
to	O
determine	O
the	O
incidence	O
of	O
malignant	O
myeloid	O
transformation	O
in	O
the	O
two	O
disorders	O
,	O
and	O
its	O
relationship	O
to	O
treatment	O
and	O
to	O
other	O
patient	O
characteristics	O
.	O

No	O
statistically	O
significant	O
relationships	O
were	O
found	O
between	O
age	O
at	O
onset	O
of	O
MDS	O
or	O
AML	O
and	O
patient	O
gender	O
,	O
G	O
-	O
CSF	O
dose	O
,	O
or	O
duration	O
of	O
G	O
-	O
CSF	O
therapy	O
.	O

What	O
was	O
observed	O
,	O
however	O
,	O
was	O
the	O
multistep	O
acquisition	O
of	O
aberrant	O
cellular	O
genetic	O
changes	O
in	O
marrow	O
cells	O
from	O
patients	O
who	O
transformed	O
,	O
including	O
activating	O
ras	O
oncogene	O
mutations	O
,	O
clonal	O
cytogenetic	O
abnormalities	O
,	O
and	O
G	O
-	O
CSF	O
receptor	O
mutations	O
.	O

In	O
murine	O
models	O
,	O
the	O
latter	O
produces	O
a	O
hyperproliferative	O
response	O
to	O
G	O
-	O
CSF	O
,	O
confers	O
resistance	O
to	O
apoptosis	O
,	O
and	O
enhances	O
cell	O
survival	O
.	O

Since	O
congenital	O
neutropenia	O
and	O
SDS	O
are	O
inherited	O
forms	O
of	O
bone	O
marrow	O
failure	O
,	O
G	O
-	O
CSF	O
may	O
accelerate	O
the	O
propensity	O
for	O
MDS	O
/	O
AML	O
in	O
the	O
genetically	O
altered	O
stem	O
and	O
progenitor	O
cells	O
,	O
especially	O
in	O
those	O
with	O
G	O
-	O
CSF	O
receptor	O
and	O
ras	O
mutations	O
(	O
82	O
%	O
and	O
50	O
%	O
of	O
patients	O
who	O
transform	O
,	O
respectively	O
)	O
.	O

Alternatively	O
,	O
and	O
equally	O
plausible	O
,	O
G	O
-	O
CSF	O
may	O
simply	O
be	O
an	O
""""	O
innocent	O
bystander	O
""""	O
that	O
corrects	O
neutropenia	O
,	O
prolongs	O
patient	O
survival	O
,	O
and	O
allows	O
time	O
for	O
the	O
malignant	O
predisposition	O
to	O
declare	O
itself	O
.	O

In	O
patients	O
who	O
transform	O
to	O
overt	O
MDS	O
or	O
AML	O
,	O
hematopoietic	O
stem	O
cell	O
transplantation	O
is	O
the	O
only	O
chance	O
for	O
cure	O
.	O

In	O
those	O
with	O
""""	O
soft	O
""""	O
signs	O
of	O
MDS	O
,	O
such	O
as	O
an	O
isolated	O
clonal	O
cytogenetic	O
change	O
but	O
without	O
other	O
evidence	O
of	O
MDS	O
,	O
or	O
with	O
an	O
isolated	O
G	O
-	O
CSF	O
receptor	O
mutation	O
,	O
there	O
is	O
room	O
for	O
conservative	O
management	O
.	O

One	O
option	O
is	O
to	O
reduce	O
the	O
G	O
-	O
CSF	O
dosage	O
as	O
much	O
as	O
possible	O
,	O
and	O
observe	O
the	O
tempo	O
of	O
progression	O
,	O
if	O
any	O
,	O
to	O
more	O
overt	O
signs	O
of	O
malignancy	O
.	O

Stimulation	O
of	O
beta	O
-	O
adrenergic	O
receptors	O
in	O
the	O
pineal	O
gland	O
increases	O
the	O
noradrenaline	O
stores	O
of	O
its	O
sympathetic	O
nerves	O
.	O

The	O
administration	O
of	O
isoproterenol	O
decreases	O
the	O
level	O
of	O
serotonin	O
in	O
the	O
rat	O
pineal	O
gland	O
and	O
at	O
the	O
same	O
time	O
it	O
increases	O
pineal	O
noradrenaline	O
.	O

These	O
effects	O
depend	O
on	O
the	O
stimulation	O
of	O
a	O
beta	O
-	O
adrenergic	O
receptor	O
because	O
they	O
are	O
blocked	O
by	O
pretreatment	O
of	O
the	O
animals	O
with	O
propranolol	O
;	O
this	O
drug	O
by	O
itself	O
does	O
not	O
modify	O
either	O
serotonin	O
or	O
noradrenaline	O
levels	O
in	O
the	O
pineal	O
.	O

The	O
elevation	O
of	O
noradrenaline	O
produced	O
by	O
isoproterenol	O
is	O
selective	O
for	O
the	O
pineal	O
because	O
it	O
is	O
not	O
observed	O
in	O
the	O
salivary	O
gland	O
innervated	O
by	O
postganglionic	O
adrenergic	O
fibers	O
from	O
the	O
same	O
origin	O
as	O
pineal	O
nerves	O
.	O

Pineal	O
serotonin	O
is	O
stored	O
in	O
equilibrium	O
in	O
two	O
compartments	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
parenchymal	O
cells	O
and	O
the	O
adrenergic	O
nerves	O
and	O
thus	O
is	O
most	O
probably	O
reduced	O
in	O
both	O
sites	O
.	O

Since	O
noradrenaline	O
and	O
serotonin	O
are	O
detected	O
in	O
pineal	O
nerve	O
vesicles	O
and	O
may	O
coexist	O
in	O
them	O
,	O
the	O
diminution	O
of	O
intravesicular	O
serotonin	O
,	O
by	O
making	O
more	O
storage	O
sites	O
available	O
,	O
probably	O
determines	O
the	O
selective	O
increase	O
of	O
pineal	O
noradrenaline	O
.	O

A	O
similar	O
modification	O
in	O
the	O
ratio	O
of	O
intravesicular	O
amines	O
as	O
a	O
result	O
of	O
the	O
physiological	O
stimulation	O
of	O
pineal	O
beta	O
-	O
adrenergic	O
receptors	O
by	O
the	O
adrenergic	O
neurotransmitter	O
may	O
explain	O
some	O
of	O
the	O
changes	O
observed	O
in	O
the	O
content	O
of	O
pineal	O
amines	O
.	O

Hypoxic	O
induction	O
of	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
lines	O
is	O
mediated	O
by	O
stress	O
activated	O
protein	O
kinases	O
.	O

Solid	O
tumors	O
must	O
establish	O
a	O
blood	O
supply	O
in	O
order	O
to	O
proliferate	O
and	O
grow	O
.	O

Cancer	O
cells	O
secrete	O
soluble	O
factors	O
which	O
can	O
induce	O
proliferation	O
and	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
.	O

Among	O
the	O
most	O
potent	O
of	O
the	O
angiogenic	O
factors	O
is	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

Increased	O
VEGF	O
expression	O
by	O
malignant	O
tumors	O
has	O
been	O
associated	O
with	O
high	O
vascularity	O
,	O
increased	O
cancer	O
cell	O
growth	O
,	O
and	O
lymph	O
node	O
metastasis	O
.	O

Reduced	O
oxygen	O
tension	O
has	O
been	O
shown	O
to	O
increase	O
VEGF	O
production	O
by	O
induction	O
of	O
the	O
transcription	O
factor	O
hypoxia	O
inducible	O
factor	O
1	O
alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
.	O

The	O
mechanisms	O
by	O
which	O
hypoxic	O
tumor	O
environments	O
induce	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
are	O
largely	O
unknown	O
.	O

Jun	O
N	O
terminal	O
kinase	O
(	O
JNK1	O
)	O
and	O
p38	O
kinase	O
are	O
activated	O
by	O
a	O
variety	O
of	O
stress	O
stimuli	O
.	O

To	O
determine	O
if	O
hypoxic	O
activation	O
of	O
these	O
stress	O
activated	O
protein	O
kinases	O
regulated	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
,	O
we	O
assayed	O
JNK1	O
and	O
p38	O
activity	O
in	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
lines	O
grown	O
under	O
normoxic	O
or	O
hypoxic	O
conditions	O
.	O

Hypoxia	O
rapidly	O
induced	O
both	O
JNK1	O
and	O
p38	O
activity	O
in	O
these	O
cells	O
.	O

This	O
activation	O
correlated	O
with	O
induction	O
of	O
HIF	O
-	O
1alpha	O
expression	O
and	O
DNA	O
binding	O
activity	O
which	O
was	O
blocked	O
by	O
the	O
p38	O
inhibitor	O
SB203580	O
.	O

Hypoxia	O
also	O
increased	O
VEGF	O
production	O
by	O
SCC	O
lines	O
,	O
which	O
was	O
inhibited	O
by	O
treatment	O
with	O
SB203580	O
.	O

Overexpression	O
of	O
JNK1	O
or	O
p38	O
was	O
sufficient	O
to	O
induce	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
.	O

These	O
results	O
indicate	O
that	O
induction	O
of	O
SAPKs	O
by	O
hypoxia	O
regulates	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
expression	O
in	O
head	O
and	O
neck	O
carcinoma	O
cell	O
lines	O
.	O

In	O
vitro	O
cytotoxic	O
potential	O
and	O
mechanism	O
of	O
action	O
of	O
selected	O
coumarins	O
,	O
using	O
human	O
renal	O
cell	O
lines	O
.	O

This	O
study	O
determined	O
the	O
selective	O
cytotoxicity	O
of	O
eight	O
coumarin	O
compounds	O
to	O
human	O
renal	O
carcinoma	O
cells	O
,	O
relative	O
to	O
non	O
-	O
carcinoma	O
proximal	O
tubular	O
cells	O
.	O

Selectivity	O
cytotoxicity	O
was	O
observed	O
following	O
exposure	O
to	O
6	O
-	O
nitro	O
-	O
7	O
-	O
hydroxycoumarin	O
(	O
6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
)	O
and	O
7	O
,	O
8	O
-	O
dihydroxycoumarin	O
(	O
7	O
,	O
8	O
-	O
OHC	O
)	O
.	O

6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
induced	O
cytotoxicity	O
was	O
irreversible	O
in	O
both	O
cell	O
lines	O
,	O
unlike	O
7	O
,	O
8	O
-	O
OHC	O
,	O
which	O
was	O
reversible	O
in	O
the	O
carcinoma	O
cells	O
only	O
.	O

Mobility	O
shift	O
and	O
BrdU	O
incorporation	O
assays	O
showed	O
that	O
both	O
compounds	O
did	O
not	O
intercalate	O
DNA	O
but	O
had	O
a	O
concentration	O
-	O
dependent	O
inhibitory	O
effect	O
on	O
its	O
synthesis	O
.	O

All	O
coumarins	O
studied	O
were	O
found	O
to	O
be	O
non	O
-	O
mutagenic	O
using	O
the	O
standard	O
Ames	O
test	O
.	O

These	O
results	O
would	O
suggest	O
that	O
6	O
-	O
NO	O
(	O
2	O
)	O
-	O
7	O
-	O
OHC	O
and	O
7	O
,	O
8	O
-	O
OHC	O
might	O
have	O
a	O
therapeutic	O
role	O
to	O
play	O
in	O
the	O
treatment	O
of	O
renal	O
cell	O
carcinoma	O
.	O

[	O
Radiologic	O
-	O
pathologic	O
correlations	O
in	O
breast	O
diseases	O
]	O

The	O
objective	O
of	O
this	O
article	O
is	O
to	O
explain	O
radiologic	O
patterns	O
of	O
benign	O
and	O
malignant	O
breast	O
lesions	O
(	O
masses	O
,	O
microcalcifications	O
)	O
based	O
on	O
histological	O
correlations	O
.	O

The	O
stromal	O
fibrous	O
reaction	O
associated	O
to	O
infiltrating	O
carcinomas	O
is	O
responsible	O
of	O
focal	O
increased	O
density	O
,	O
and	O
architectural	O
distorsion	O
,	O
ultrasound	O
acoustic	O
shadowing	O
;	O
abnormal	O
neoangiogenesis	O
can	O
be	O
detected	O
by	O
Doppler	O
,	O
CT	O
or	O
MR	O
imaging	O
.	O

Invasive	O
carcinomas	O
without	O
spiculated	O
margins	O
are	O
poorly	O
differentiated	O
tumors	O
.	O

Mammographic	O
patterns	O
of	O
microcalcifications	O
depend	O
on	O
their	O
physiopathological	O
process	O
(	O
necrosis	O
,	O
secretion	O
)	O
,	O
and	O
the	O
shape	O
of	O
clusters	O
(	O
round	O
,	O
triangular	O
)	O
typifies	O
their	O
anatomical	O
site	O
of	O
origin	O
(	O
lobular	O
,	O
ductal	O
)	O
.	O

Less	O
frequent	O
lesions	O
(	O
invasive	O
lobular	O
,	O
mucinous	O
,	O
and	O
medullary	O
carcinomas	O
,	O
radial	O
scar	O
)	O
will	O
be	O
also	O
explained	O
based	O
on	O
radiopathological	O
correlations	O
.	O

Knowledge	O
of	O
radiopathological	O
correlations	O
in	O
breast	O
diseases	O
helps	O
the	O
radiologists	O
to	O
analyze	O
and	O
characterize	O
breast	O
lesions	O
.	O

Multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	O
cells	O
modelled	O
by	O
co	O
-	O
expression	O
of	O
telomerase	O
reverse	O
transcriptase	O
,	O
SV40	O
T	O
antigen	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

We	O
have	O
modelled	O
multiple	O
stages	O
of	O
malignant	O
transformation	O
of	O
human	O
endothelial	O
cells	O
(	O
ECs	O
)	O
by	O
overexpressing	O
the	O
catalytic	O
subunit	O
of	O
human	O
telomerase	O
(	O
hTERT	O
)	O
,	O
together	O
with	O
SV40	O
T	O
antigen	O
(	O
SV40	O
T	O
)	O
and	O
oncogenic	O
N	O
-	O
ras	O
.	O

Transfection	O
with	O
hTERT	O
alone	O
,	O
led	O
to	O
the	O
immortalization	O
of	O
two	O
out	O
of	O
three	O
cultures	O
of	O
bone	O
marrow	O
-	O
derived	O
ECs	O
(	O
BMECs	O
)	O
.	O

One	O
hTERT	O
transduced	O
BMEC	O
culture	O
underwent	O
a	O
long	O
proliferative	O
lag	O
before	O
resuming	O
proliferation	O
.	O

BMECs	O
transfected	O
with	O
hTERT	O
alone	O
were	O
functionally	O
and	O
phenotypically	O
normal	O
.	O

BMECs	O
transfected	O
with	O
SV40	O
T	O
(	O
BMSVTs	O
)	O
had	O
an	O
extended	O
lifespan	O
,	O
but	O
eventually	O
succumbed	O
to	O
crisis	O
.	O

BMSVTs	O
exhibited	O
a	O
partially	O
transformed	O
phenotype	O
,	O
demonstrating	O
growth	O
factor	O
independence	O
,	O
altered	O
antigen	O
expression	O
and	O
forming	O
tiny	O
,	O
infrequent	O
colonies	O
in	O
vitro	O
.	O

Transduction	O
of	O
BMSVTs	O
with	O
hTERT	O
resulted	O
in	O
immortalization	O
of	O
4	O
out	O
of	O
4	O
cultures	O
.	O

BMSVTs	O
immortalized	O
with	O
hTERT	O
formed	O
large	O
colonies	O
in	O
vitro	O
and	O
small	O
transient	O
tumours	O
in	O
vivo	O
.	O

BMECs	O
co	O
-	O
expressing	O
SV40	O
T	O
,	O
hTERT	O
and	O
N	O
-	O
ras	O
exhibited	O
an	O
overtly	O
transformed	O
phenotype	O
;	O
forming	O
very	O
large	O
colonies	O
with	O
an	O
altered	O
morphology	O
and	O
generating	O
rapidly	O
growing	O
tumours	O
in	O
vivo	O
.	O

These	O
investigations	O
demonstrate	O
transformation	O
of	O
human	O
ECs	O
to	O
an	O
overtly	O
malignant	O
phenotype	O
.	O

This	O
model	O
will	O
be	O
useful	O
for	O
understanding	O
mechanisms	O
underlying	O
vascular	O
and	O
angiogenic	O
neoplasias	O
,	O
as	O
well	O
as	O
for	O
testing	O
drugs	O
designed	O
to	O
curtail	O
aberrant	O
EC	O
growth	O
.	O

Pten	O
signaling	O
in	O
gliomas	O
.	O

In	O
1997	O
,	O
the	O
PTEN	O
gene	O
(	O
phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
)	O
was	O
identified	O
as	O
a	O
tumor	O
suppressor	O
gene	O
on	O
the	O
long	O
arm	O
of	O
chromosome	O
10	O
.	O

Since	O
then	O
,	O
important	O
progress	O
has	O
been	O
made	O
with	O
respect	O
to	O
the	O
understanding	O
of	O
the	O
role	O
of	O
the	O
Pten	O
protein	O
in	O
the	O
normal	O
development	O
of	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
human	O
gliomas	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
state	O
of	O
the	O
art	O
concerning	O
the	O
involvement	O
of	O
aberrant	O
Pten	O
function	O
in	O
the	O
development	O
of	O
different	O
biologic	O
features	O
of	O
malignant	O
gliomas	O
,	O
such	O
as	O
loss	O
of	O
cell	O
-	O
cycle	O
control	O
and	O
uncontrolled	O
cell	O
proliferation	O
,	O
escape	O
from	O
apoptosis	O
,	O
brain	O
invasion	O
,	O
and	O
aberrant	O
neoangiogenesis	O
.	O

Most	O
of	O
the	O
tumor	O
-	O
suppressive	O
properties	O
of	O
Pten	O
are	O
dependent	O
on	O
its	O
lipid	O
phosphatase	O
activity	O
,	O
which	O
inhibits	O
the	O
phosphatidylinositol	O
-	O
3	O
'	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
/	O
Akt	O
signaling	O
pathway	O
through	O
dephosphorylation	O
of	O
phosphatidylinositol	O
-	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
-	O
triphosphate	O
.	O

The	O
additional	O
function	O
of	O
Pten	O
as	O
a	O
dual	O
-	O
specificity	O
protein	O
phosphatase	O
may	O
also	O
play	O
a	O
role	O
in	O
glioma	O
pathogenesis	O
.	O

Besides	O
the	O
wealth	O
of	O
data	O
elucidating	O
the	O
functional	O
roles	O
of	O
Pten	O
,	O
recent	O
studies	O
suggest	O
a	O
diagnostic	O
significance	O
of	O
PTEN	O
gene	O
alterations	O
as	O
a	O
molecular	O
marker	O
for	O
poor	O
prognosis	O
in	O
anaplastic	O
astrocytomas	O
and	O
anaplastic	O
oligodendrogliomas	O
.	O

Furthermore	O
,	O
the	O
possibility	O
of	O
selective	O
targeting	O
of	O
PTEN	O
mutant	O
tumor	O
cells	O
by	O
specific	O
pharmacologic	O
inhibitors	O
of	O
members	O
of	O
the	O
Pten	O
/	O
PI3	O
K	O
/	O
Akt	O
pathway	O
opens	O
up	O
new	O
perspectives	O
for	O
a	O
targeted	O
molecular	O
therapy	O
of	O
malignant	O
gliomas	O
.	O

[	O
A	O
case	O
report	O
of	O
advanced	O
gastric	O
cancer	O
responding	O
to	O
TS	O
-	O
1	O
,	O
a	O
novel	O
oral	O
fluorouracil	O
derivative	O
]	O
.	O

TS	O
-	O
1	O
is	O
a	O
new	O
,	O
oral	O
anticancer	O
agent	O
composed	O
of	O
two	O
modulators	O
,	O
gimeracil	O
(	O
CDHP	O
)	O
and	O
oteracil	O
potassium	O
(	O
Oxo	O
)	O
are	O
mixed	O
with	O
tegafur	O
in	O
a	O
ratio	O
of	O
1	O
:	O
0	O
.	O
4	O
:	O
1	O
.	O

We	O
report	O
one	O
case	O
of	O
advanced	O
gastric	O
cancer	O
with	O
lung	O
and	O
lymph	O
node	O
metastases	O
that	O
completely	O
responded	O
to	O
TS	O
-	O
1	O
.	O

A	O
71	O
-	O
year	O
-	O
old	O
woman	O
was	O
admitted	O
to	O
our	O
hospital	O
because	O
of	O
breathlessness	O
.	O

A	O
diagnosis	O
of	O
advanced	O
gastric	O
cancer	O
with	O
extensive	O
lymph	O
node	O
metastases	O
and	O
multiple	O
pulmonary	O
metastases	O
was	O
made	O
.	O

One	O
hundred	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
was	O
orally	O
administrated	O
for	O
4	O
weeks	O
.	O

A	O
partial	O
response	O
(	O
PR	O
)	O
was	O
obtained	O
after	O
the	O
first	O
course	O
with	O
regression	O
of	O
multiple	O
pulmonary	O
metastases	O
.	O

After	O
1	O
drug	O
-	O
free	O
week	O
,	O
the	O
second	O
course	O
was	O
administered	O
with	O
120	O
mg	O
/	O
body	O
/	O
day	O
of	O
TS	O
-	O
1	O
for	O
4	O
weeks	O
.	O

After	O
two	O
courses	O
,	O
the	O
primary	O
tumor	O
was	O
reduced	O
to	O
an	O
ulcer	O
scar	O
with	O
pathological	O
confirmation	O
of	O
a	O
complete	O
disappearance	O
of	O
the	O
cancer	O
tissue	O
.	O

Moreover	O
,	O
computed	O
tomography	O
(	O
CT	O
)	O
showed	O
a	O
complete	O
regression	O
of	O
the	O
extensive	O
lymph	O
node	O
and	O
diffuse	O
lung	O
metastases	O
,	O
for	O
a	O
complete	O
response	O
(	O
CR	O
)	O
.	O

The	O
serum	O
level	O
of	O
CEA	O
was	O
reduced	O
from	O
172	O
.	O
7	O
ng	O
/	O
ml	O
to	O
8	O
.	O
1	O
ng	O
/	O
ml	O
after	O
TS	O
-	O
1	O
treatment	O
.	O

As	O
for	O
adverse	O
events	O
,	O
only	O
pigmentation	O
of	O
the	O
skin	O
and	O
Grade	O
2	O
oral	O
aphta	O
were	O
observed	O
.	O

Systemic	O
regulation	O
of	O
distraction	O
osteogenesis	O
:	O
a	O
cascade	O
of	O
biochemical	O
factors	O
.	O

This	O
study	O
investigates	O
the	O
systemic	O
biochemical	O
regulation	O
of	O
fracture	O
healing	O
in	O
distraction	O
osteogenesis	O
compared	O
with	O
rigid	O
osteotomy	O
in	O
a	O
prospective	O
in	O
vivo	O
study	O
in	O
humans	O
.	O

To	O
further	O
clarify	O
the	O
influence	O
of	O
mechanical	O
strain	O
on	O
the	O
regulation	O
of	O
bone	O
formation	O
,	O
bone	O
growth	O
factors	O
(	O
insulin	O
-	O
like	O
growth	O
factor	O
[	O
IGF	O
]	O
I	O
,	O
IGF	O
binding	O
protein	O
[	O
IGFBP	O
]	O
3	O
,	O
transforming	O
growth	O
factor	O
[	O
TGF	O
]	O
beta1	O
,	O
and	O
basic	O
FGF	O
[	O
bFGF	O
]	O
)	O
,	O
bone	O
matrix	O
degrading	O
enzymes	O
(	O
matrix	O
-	O
metalloproteinases	O
[	O
MMPs	O
]	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
,	O
human	O
growth	O
hormone	O
(	O
hGH	O
)	O
,	O
and	O
bone	O
formation	O
markers	O
(	O
ALP	O
,	O
bone	O
-	O
specific	O
ALP	O
[	O
BAP	O
]	O
,	O
and	O
osteocalcin	O
[	O
OC	O
]	O
)	O
have	O
been	O
analyzed	O
in	O
serum	O
samples	O
from	O
10	O
patients	O
in	O
each	O
group	O
pre	O
-	O
and	O
postoperatively	O
.	O

In	O
the	O
distraction	O
group	O
,	O
a	O
significant	O
postoperative	O
increase	O
in	O
MMP	O
-	O
1	O
,	O
bFGF	O
,	O
ALP	O
,	O
and	O
BAP	O
could	O
be	O
observed	O
during	O
the	O
lengthening	O
and	O
the	O
consolidation	O
period	O
when	O
compared	O
with	O
the	O
baseline	O
levels	O
.	O

Osteotomy	O
fracture	O
healing	O
without	O
the	O
traction	O
stimulus	O
failed	O
to	O
induce	O
a	O
corresponding	O
increase	O
in	O
these	O
factors	O
.	O

In	O
addition	O
,	O
comparison	O
of	O
both	O
groups	O
revealed	O
a	O
significantly	O
higher	O
increase	O
in	O
TGF	O
-	O
beta1	O
,	O
IGF	O
-	O
I	O
,	O
IGFBP	O
-	O
3	O
,	O
and	O
hGH	O
in	O
the	O
lengthening	O
group	O
during	O
the	O
distraction	O
period	O
,	O
indicating	O
key	O
regulatory	O
functions	O
in	O
mechanotransduction	O
.	O

The	O
time	O
courses	O
of	O
changes	O
in	O
MMP	O
-	O
1	O
,	O
bone	O
growth	O
factors	O
(	O
TGF	O
-	O
beta1	O
and	O
bFGF	O
)	O
,	O
and	O
hGH	O
,	O
respectively	O
,	O
correlated	O
significantly	O
during	O
the	O
lengthening	O
phase	O
,	O
indicating	O
common	O
regulatory	O
pathways	O
for	O
these	O
factors	O
in	O
distraction	O
osteogenesis	O
.	O

Significant	O
correlation	O
between	O
the	O
osteoblastic	O
marker	O
BAP	O
,	O
TGF	O
-	O
beta1	O
,	O
and	O
bFGF	O
suggests	O
strain	O
-	O
activated	O
osteoblastic	O
cells	O
as	O
a	O
major	O
source	O
of	O
systemically	O
increased	O
bone	O
growth	O
factors	O
during	O
callus	O
distraction	O
.	O

The	O
systemic	O
increase	O
in	O
bFGF	O
and	O
MMP	O
-	O
1	O
might	O
reflect	O
an	O
increased	O
local	O
stimulation	O
of	O
angiogenesis	O
during	O
distraction	O
osteogenesis	O
.	O

Simian	O
virus	O
40	O
large	O
T	O
antigen	O
and	O
two	O
independent	O
T	O
-	O
antigen	O
segments	O
sensitize	O
cells	O
to	O
apoptosis	O
following	O
genotoxic	O
damage	O
.	O

The	O
simian	O
virus	O
40	O
(	O
SV40	O
)	O
large	O
tumor	O
(	O
T	O
)	O
antigen	O
is	O
sufficient	O
to	O
transform	O
cells	O
in	O
cultures	O
and	O
induce	O
tumors	O
in	O
experimental	O
animals	O
.	O

Transformation	O
of	O
primary	O
cells	O
in	O
cultures	O
requires	O
both	O
overcoming	O
growth	O
arrest	O
by	O
stimulating	O
the	O
cell	O
cycle	O
and	O
blocking	O
cell	O
death	O
activities	O
presumably	O
activated	O
by	O
oncogene	O
-	O
mediated	O
hyperproliferation	O
signals	O
.	O

The	O
study	O
presented	O
here	O
examined	O
the	O
ability	O
of	O
specific	O
regions	O
and	O
activities	O
of	O
T	O
antigen	O
to	O
modulate	O
apoptosis	O
in	O
cells	O
treated	O
with	O
the	O
genotoxic	O
agent	O
5	O
-	O
fluorouracil	O
(	O
5	O
-	O
FU	O
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
expression	O
of	O
full	O
-	O
length	O
T	O
antigen	O
rendered	O
rat	O
embryo	O
fibroblasts	O
(	O
REF	O
)	O
sensitive	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O

Thus	O
,	O
neither	O
the	O
p53	O
-	O
binding	O
region	O
nor	O
the	O
Bcl	O
-	O
2	O
homology	O
region	O
of	O
T	O
antigen	O
was	O
sufficient	O
to	O
prevent	O
cell	O
death	O
induced	O
by	O
the	O
DNA	O
-	O
damaging	O
agent	O
.	O

T	O
-	O
antigen	O
-	O
mediated	O
sensitization	O
occurred	O
independently	O
of	O
retinoblastoma	O
protein	O
or	O
p53	O
and	O
p300	O
binding	O
.	O

An	O
N	O
-	O
terminal	O
segment	O
containing	O
the	O
first	O
127	O
T	O
-	O
antigen	O
amino	O
acids	O
(	O
T1	O
-	O
127	O
)	O
was	O
sufficient	O
to	O
sensitize	O
cells	O
.	O

A	O
C	O
-	O
terminal	O
segment	O
consisting	O
of	O
T	O
-	O
antigen	O
amino	O
acids	O
251	O
to	O
708	O
(	O
T251	O
-	O
708	O
)	O
also	O
sensitized	O
cells	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O

This	O
sensitization	O
did	O
not	O
occur	O
when	O
T251	O
-	O
708	O
was	O
targeted	O
to	O
the	O
nucleus	O
by	O
inclusion	O
of	O
the	O
SV40	O
nuclear	O
localization	O
signal	O
.	O

The	O
introduction	O
of	O
mutations	O
into	O
the	O
T	O
-	O
antigen	O
J	O
domain	O
resulted	O
in	O
mutation	O
-	O
specific	O
and	O
variable	O
inhibition	O
of	O
apoptosis	O
.	O

This	O
result	O
suggested	O
that	O
either	O
the	O
structural	O
or	O
the	O
functional	O
integrity	O
of	O
the	O
J	O
domain	O
is	O
required	O
to	O
sensitize	O
cells	O
to	O
apoptosis	O
.	O

Treatment	O
of	O
REF	O
or	O
REF	O
expressing	O
full	O
-	O
length	O
T	O
antigen	O
,	O
an	O
N	O
-	O
terminal	O
segment	O
,	O
or	O
T251	O
-	O
708	O
resulted	O
in	O
increased	O
expression	O
of	O
the	O
p53	O
-	O
responsive	O
MDM2	O
gene	O
;	O
apoptosis	O
occurred	O
through	O
a	O
p53	O
-	O
dependent	O
pathway	O
,	O
as	O
p53	O
-	O
null	O
cells	O
expressing	O
these	O
T	O
antigens	O
were	O
resistant	O
to	O
5	O
-	O
FU	O
-	O
induced	O
apoptosis	O
.	O

Possible	O
mechanisms	O
involved	O
in	O
sensitizing	O
cells	O
to	O
a	O
p53	O
-	O
dependent	O
apoptosis	O
pathway	O
in	O
spite	O
of	O
the	O
ability	O
of	O
T	O
antigen	O
to	O
bind	O
and	O
inactivate	O
the	O
transcriptional	O
transactivating	O
activity	O
of	O
p53	O
are	O
discussed	O
.	O

Human	O
papillomavirus	O
oncoprotein	O
E6	O
inactivates	O
the	O
transcriptional	O
coactivator	O
human	O
ADA3	O
.	O

High	O
-	O
risk	O
human	O
papillomaviruses	O
(	O
HPVs	O
)	O
are	O
associated	O
with	O
carcinomas	O
of	O
the	O
cervix	O
and	O
other	O
genital	O
tumors	O
.	O

The	O
HPV	O
oncoprotein	O
E6	O
is	O
essential	O
for	O
oncogenic	O
transformation	O
.	O

We	O
identify	O
here	O
hADA3	O
,	O
human	O
homologue	O
of	O
the	O
yeast	O
transcriptional	O
coactivator	O
yADA3	O
,	O
as	O
a	O
novel	O
E6	O
-	O
interacting	O
protein	O
and	O
a	O
target	O
of	O
E6	O
-	O
induced	O
degradation	O
.	O

hADA3	O
binds	O
selectively	O
to	O
the	O
high	O
-	O
risk	O
HPV	O
E6	O
proteins	O
and	O
only	O
to	O
immortalization	O
-	O
competent	O
E6	O
mutants	O
.	O

hADA3	O
functions	O
as	O
a	O
coactivator	O
for	O
p53	O
-	O
mediated	O
transactivation	O
by	O
stabilizing	O
p53	O
protein	O
.	O

Notably	O
,	O
three	O
immortalizing	O
E6	O
mutants	O
that	O
do	O
not	O
induce	O
direct	O
p53	O
degradation	O
but	O
do	O
interact	O
with	O
hADA3	O
induced	O
the	O
abrogation	O
of	O
p53	O
-	O
mediated	O
transactivation	O
and	O
G	O
(	O
1	O
)	O
cell	O
cycle	O
arrest	O
after	O
DNA	O
damage	O
,	O
comparable	O
to	O
wild	O
-	O
type	O
E6	O
.	O

These	O
findings	O
reveal	O
a	O
novel	O
strategy	O
of	O
HPV	O
E6	O
-	O
induced	O
loss	O
of	O
p53	O
function	O
that	O
is	O
independent	O
of	O
direct	O
p53	O
degradation	O
.	O

Given	O
the	O
likely	O
role	O
of	O
the	O
evolutionarily	O
conserved	O
hADA3	O
in	O
multiple	O
coactivator	O
complexes	O
,	O
inactivation	O
of	O
its	O
function	O
may	O
allow	O
E6	O
to	O
perturb	O
numerous	O
cellular	O
pathways	O
during	O
HPV	O
oncogenesis	O
.	O

Optimizing	O
treatment	O
of	O
choroidal	O
neovascularization	O
feeder	O
vessels	O
associated	O
with	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

PURPOSE	O
:	O
To	O
optimize	O
the	O
method	O
of	O
treating	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
associated	O
with	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
.	O

DESIGN	O
:	O
Experimental	O
study	O
and	O
interventional	O
case	O
series	O
.	O

METHODS	O
:	O
The	O
parameters	O
associated	O
with	O
locating	O
and	O
then	O
photocoagulating	O
CNV	O
feeder	O
vessels	O
were	O
identified	O
and	O
optimized	O
using	O
published	O
data	O
and	O
data	O
derived	O
from	O
modeling	O
the	O
choroidal	O
vasculature	O
.	O

Based	O
on	O
these	O
optimized	O
parameters	O
,	O
a	O
prototype	O
diagnostic	O
/	O
treatment	O
system	O
was	O
designed	O
that	O
captures	O
high	O
-	O
speed	O
indocyanine	O
green	O
(	O
ICG	O
)	O
angiogram	O
images	O
and	O
facilitates	O
analysis	O
of	O
the	O
images	O
by	O
enhancing	O
visualization	O
of	O
dye	O
movement	O
through	O
CNV	O
feeder	O
vessels	O
(	O
FVs	O
)	O
.	O

The	O
system	O
also	O
permits	O
precise	O
aiming	O
and	O
delivery	O
of	O
810	O
-	O
nm	O
wavelength	O
photocoagulation	O
laser	O
energy	O
to	O
target	O
FVs	O
on	O
a	O
real	O
-	O
time	O
ICG	O
angiogram	O
image	O
of	O
the	O
choroidal	O
vasculature	O
.	O

Target	O
FVs	O
are	O
tracked	O
by	O
a	O
joy	O
-	O
stick	O
controlled	O
laser	O
aiming	O
beam	O
until	O
an	O
intravenously	O
-	O
injected	O
high	O
-	O
concentration	O
ICG	O
dye	O
bolus	O
is	O
observed	O
to	O
enter	O
the	O
target	O
vessel	O
,	O
at	O
which	O
time	O
the	O
laser	O
is	O
fired	O
.	O

Proof	O
of	O
principle	O
of	O
the	O
combined	O
diagnosis	O
/	O
treatment	O
system	O
design	O
for	O
performing	O
dye	O
-	O
enhanced	O
photocoagulation	O
(	O
DEP	O
)	O
in	O
the	O
clinical	O
setting	O
and	O
determination	O
of	O
the	O
minimum	O
DEP	O
laser	O
energy	O
needed	O
to	O
close	O
CNV	O
FVs	O
was	O
made	O
in	O
11	O
AMD	O
patients	O
requiring	O
treatment	O
of	O
CNV	O
,	O
but	O
for	O
whom	O
other	O
treatment	O
was	O
not	O
appropriate	O
.	O

RESULTS	O
:	O
Using	O
ICG	O
-	O
DEP	O
,	O
CNV	O
feeder	O
vessels	O
were	O
closed	O
with	O
single	O
pulse	O
laser	O
energy	O
,	O
delivering	O
as	O
little	O
as	O
0	O
.	O
6	O
to	O
1	O
.	O
8	O
J	O
of	O
energy	O
to	O
the	O
fundus	O
,	O
producing	O
no	O
visible	O
change	O
in	O
the	O
fundus	O
.	O

Successful	O
FV	O
closure	O
was	O
usually	O
indicated	O
immediately	O
by	O
presence	O
of	O
incarcerated	O
ICG	O
dye	O
in	O
the	O
vessel	O
adjacent	O
to	O
the	O
burn	O
site	O
.	O

The	O
prototype	O
system	O
proved	O
relatively	O
easy	O
to	O
operate	O
.	O

After	O
acquiring	O
and	O
interpreting	O
diagnostic	O
angiograms	O
and	O
repositioning	O
a	O
patient	O
in	O
front	O
of	O
the	O
device	O
,	O
feeder	O
vessel	O
DEP	O
and	O
treatment	O
evaluation	O
required	O
15	O
to	O
20	O
minutes	O
.	O

CONCLUSIONS	O
:	O
Indocyanine	O
green	O
dye	O
-	O
enhanced	O
photocoagulation	O
of	O
CNV	O
feeder	O
vessels	O
,	O
facilitated	O
by	O
use	O
of	O
a	O
device	O
that	O
permits	O
real	O
-	O
time	O
visualization	O
of	O
the	O
choroidal	O
circulation	O
while	O
aiming	O
the	O
treatment	O
laser	O
beam	O
,	O
appears	O
to	O
minimize	O
the	O
amount	O
of	O
energy	O
applied	O
to	O
the	O
fundus	O
and	O
the	O
volume	O
of	O
fundus	O
tissue	O
affected	O
by	O
treatment	O
,	O
compared	O
with	O
other	O
treatment	O
modalities	O
.	O

The	O
combination	O
diagnosis	O
/	O
treatment	O
device	O
should	O
be	O
useful	O
in	O
optimizing	O
FV	O
treatment	O
and	O
in	O
refining	O
and	O
evaluating	O
the	O
efficacy	O
of	O
DEP	O
in	O
future	O
clinical	O
trials	O
.	O

Immunohistochemical	O
staining	O
for	O
thyroid	O
transcription	O
factor	O
-	O
1	O
:	O
a	O
helpful	O
aid	O
in	O
discerning	O
primary	O
site	O
of	O
tumor	O
origin	O
in	O
patients	O
with	O
brain	O
metastases	O
.	O

Metastatic	O
carcinoma	O
of	O
unknown	O
primary	O
origin	O
is	O
a	O
perplexing	O
but	O
common	O
problem	O
,	O
accounting	O
for	O
up	O
to	O
10	O
%	O
to	O
15	O
%	O
of	O
all	O
solid	O
tumors	O
at	O
presentation	O
.	O

Many	O
of	O
these	O
metastases	O
presumably	O
arise	O
from	O
primary	O
lung	O
carcinomas	O
,	O
but	O
the	O
morphologic	O
features	O
and	O
immunohistochemical	O
profile	O
of	O
lung	O
cancer	O
is	O
often	O
too	O
nonspecific	O
to	O
permit	O
unequivocal	O
confirmation	O
.	O

Thyroid	O
transcription	O
factor	O
-	O
1	O
(	O
TTF	O
-	O
1	O
)	O
is	O
expressed	O
in	O
lung	O
adenocarcinomas	O
and	O
thyroid	O
carcinomas	O
but	O
not	O
in	O
adenocarcinomas	O
arising	O
from	O
other	O
sites	O
.	O

For	O
patients	O
with	O
adenocarcinomas	O
in	O
the	O
lung	O
,	O
TTF	O
-	O
1	O
staining	O
is	O
now	O
routinely	O
used	O
to	O
distinguish	O
a	O
primary	O
lung	O
cancer	O
from	O
a	O
lung	O
metastasis	O
.	O

Along	O
these	O
same	O
lines	O
,	O
TTF	O
-	O
1	O
staining	O
might	O
prove	O
useful	O
in	O
localizing	O
the	O
tumor	O
origin	O
of	O
adenocarcinomas	O
encountered	O
outside	O
of	O
the	O
lung	O
.	O

The	O
archival	O
surgical	O
pathology	O
files	O
of	O
The	O
Johns	O
Hopkins	O
Hospital	O
were	O
searched	O
for	O
cases	O
of	O
brain	O
metastases	O
biopsied	O
between	O
1990	O
and	O
2000	O
.	O

Tissue	O
blocks	O
were	O
obtained	O
and	O
immunoperoxidase	O
staining	O
was	O
performed	O
using	O
the	O
TTF	O
-	O
1	O
antibody	O
.	O

The	O
medical	O
records	O
were	O
reviewed	O
independent	O
of	O
the	O
staining	O
results	O
to	O
determine	O
site	O
of	O
tumor	O
origin	O
.	O

Seventy	O
-	O
five	O
patients	O
underwent	O
biopsies	O
of	O
carcinomas	O
metastatic	O
to	O
the	O
brain	O
.	O

At	O
the	O
time	O
of	O
brain	O
biopsy	O
,	O
the	O
primary	O
site	O
of	O
tumor	O
origin	O
was	O
known	O
in	O
45	O
cases	O
and	O
unknown	O
in	O
30	O
cases	O
.	O

Ultimately	O
,	O
the	O
primary	O
site	O
was	O
established	O
on	O
clinical	O
and	O
radiographic	O
grounds	O
in	O
71	O
cases	O
(	O
95	O
%	O
)	O
.	O

These	O
included	O
40	O
(	O
56	O
%	O
)	O
metastases	O
from	O
a	O
primary	O
lung	O
carcinoma	O
and	O
31	O
(	O
44	O
%	O
)	O
metastases	O
from	O
some	O
nonpulmonary	O
carcinoma	O
.	O

TTF	O
-	O
1	O
staining	O
was	O
present	O
in	O
31	O
of	O
the	O
40	O
(	O
78	O
%	O
)	O
metastatic	O
lung	O
carcinomas	O
,	O
but	O
in	O
only	O
1	O
of	O
the	O
31	O
(	O
3	O
%	O
)	O
metastatic	O
nonpulmonary	O
carcinomas	O
(	O
a	O
small	O
-	O
cell	O
carcinoma	O
of	O
the	O
sinonasal	O
tract	O
)	O
.	O

When	O
the	O
metastatic	O
lung	O
carcinomas	O
were	O
subtyped	O
,	O
TTF	O
-	O
1	O
staining	O
was	O
noted	O
in	O
11	O
of	O
11	O
(	O
100	O
%	O
)	O
adenocarcinomas	O
,	O
in	O
6	O
of	O
7	O
(	O
86	O
%	O
)	O
small	O
-	O
cell	O
carcinomas	O
,	O
in	O
15	O
of	O
19	O
(	O
79	O
%	O
)	O
large	O
-	O
cell	O
carcinomas	O
,	O
and	O
in	O
none	O
of	O
3	O
(	O
0	O
%	O
)	O
squamous	O
cell	O
carcinomas	O
.	O

TTF	O
-	O
1	O
staining	O
is	O
very	O
reliable	O
in	O
discerning	O
whether	O
a	O
brain	O
metastasis	O
has	O
arisen	O
from	O
a	O
pulmonary	O
or	O
nonpulmonary	O
site	O
,	O
particularly	O
when	O
dealing	O
with	O
adenocarcinomas	O
and	O
large	O
-	O
cell	O
carcinomas	O
.	O

TTF	O
-	O
1	O
immunohistochemistry	O
could	O
focus	O
the	O
search	O
for	O
the	O
primary	O
tumor	O
for	O
patients	O
presenting	O
with	O
brain	O
metastasis	O
as	O
the	O
initial	O
manifestation	O
.	O

Inhibition	O
of	O
angiogenesis	O
by	O
the	O
cancer	O
chemopreventive	O
agent	O
conjugated	O
linoleic	O
acid	O
.	O

Dietary	O
conjugated	O
linoleic	O
acid	O
(	O
CLA	O
)	O
has	O
been	O
shown	O
previously	O
to	O
inhibit	O
rat	O
mammary	O
carcinogenesis	O
.	O

In	O
addition	O
to	O
direct	O
effects	O
on	O
mammary	O
epithelial	O
cells	O
,	O
including	O
decreased	O
proliferation	O
and	O
induction	O
of	O
apoptosis	O
,	O
CLA	O
may	O
exert	O
its	O
effects	O
indirectly	O
by	O
inhibiting	O
the	O
differentiation	O
of	O
mammary	O
stromal	O
cells	O
to	O
an	O
endothelial	O
cell	O
type	O
.	O

Specifically	O
,	O
CLA	O
was	O
found	O
to	O
decrease	O
the	O
ability	O
of	O
mammary	O
stromal	O
cells	O
to	O
form	O
complex	O
anastomosing	O
microcapillary	O
networks	O
in	O
vitro	O
on	O
Engelbreth	O
-	O
Holm	O
-	O
Swarm	O
-	O
derived	O
reconstituted	O
basement	O
membrane	O
.	O

This	O
suggested	O
that	O
CLA	O
might	O
inhibit	O
angiogenesis	O
in	O
vivo	O
.	O

To	O
test	O
this	O
possibility	O
,	O
CD2	O
/	O
F	O
(	O
1	O
)	O
mice	O
were	O
placed	O
on	O
synthetic	O
diets	O
containing	O
0	O
,	O
1	O
,	O
or	O
2	O
%	O
CLA	O
for	O
6	O
weeks	O
,	O
before	O
angiogenic	O
challenge	O
by	O
s	O
.	O
c	O
.	O
injection	O
with	O
an	O
angiogenic	O
gel	O
substrate	O
(	O
Matrigel	O
pellet	O
assay	O
)	O
.	O

After	O
7	O
days	O
,	O
the	O
pellets	O
from	O
animals	O
fed	O
the	O
control	O
diet	O
were	O
infiltrated	O
by	O
abundant	O
branching	O
networks	O
of	O
blood	O
vessels	O
with	O
patent	O
lumen	O
-	O
containing	O
RBCs	O
.	O

In	O
contrast	O
,	O
pellets	O
from	O
the	O
CLA	O
-	O
fed	O
animals	O
contained	O
fewer	O
infiltrating	O
cells	O
,	O
which	O
formed	O
limited	O
branching	O
cellular	O
networks	O
,	O
the	O
majority	O
of	O
which	O
had	O
collapsed	O
lumen	O
and	O
no	O
RBCs	O
.	O

Both	O
levels	O
of	O
dietary	O
CLA	O
showed	O
similar	O
effects	O
,	O
with	O
the	O
number	O
of	O
RBC	O
-	O
containing	O
vessels	O
per	O
20x	O
field	O
decreased	O
to	O
a	O
third	O
of	O
that	O
seen	O
in	O
control	O
.	O

Dietary	O
CLA	O
decreased	O
serum	O
levels	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
whole	O
mammary	O
gland	O
levels	O
of	O
VEGF	O
and	O
its	O
receptor	O
Flk	O
-	O
1	O
.	O

Both	O
cis	O
-	O
9	O
,	O
trans	O
-	O
11	O
and	O
trans	O
-	O
10	O
,	O
cis	O
-	O
12	O
CLA	O
isomers	O
were	O
effective	O
in	O
inhibiting	O
angiogenesis	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
ability	O
of	O
CLA	O
to	O
inhibit	O
angiogenesis	O
may	O
contribute	O
to	O
its	O
efficacy	O
as	O
a	O
chemopreventive	O
agent	O
.	O

Molecular	O
characterization	O
of	O
angiogenic	O
properties	O
of	O
human	O
oral	O
squamous	O
cell	O
carcinoma	O
cells	O
.	O

Little	O
is	O
known	O
about	O
the	O
specificity	O
of	O
angiogenic	O
properties	O
of	O
oral	O
cancer	O
cells	O
and	O
the	O
possible	O
mechanisms	O
.	O

Stimulatory	O
effects	O
on	O
proliferation	O
and	O
migration	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
characterized	O
the	O
angiogenic	O
properties	O
of	O
oral	O
cancer	O
cells	O
but	O
not	O
normal	O
oral	O
keratinocytes	O
(	O
NOK	O
)	O
.	O

ELISA	O
found	O
the	O
presence	O
of	O
vascular	O
endothelial	O
growth	O
factors	O
(	O
VEGF	O
)	O
both	O
in	O
the	O
tested	O
oral	O
cancer	O
cells	O
and	O
NOK	O
.	O

Attenuation	O
of	O
the	O
proangiogenic	O
effects	O
by	O
neutralizing	O
VEGF	O
antibodies	O
suggests	O
VEGF	O
play	O
a	O
key	O
role	O
in	O
the	O
acquisition	O
of	O
the	O
angiogenic	O
phenotype	O
in	O
oral	O
cancer	O
cells	O
.	O

Western	O
blotting	O
of	O
p53	O
and	O
murine	O
double	O
mutant	O
2	O
(	O
Mdm2	O
)	O
together	O
with	O
p53	O
DNA	O
sequencing	O
analysis	O
indicate	O
that	O
p53	O
function	O
loss	O
by	O
mutation	O
or	O
overexpression	O
of	O
Mdm2	O
occurred	O
in	O
all	O
tested	O
oral	O
cancer	O
cells	O
regardless	O
of	O
their	O
etiology	O
.	O

In	O
summary	O
,	O
the	O
angiogenic	O
property	O
of	O
oral	O
cancer	O
cells	O
is	O
mediated	O
by	O
many	O
factors	O
in	O
addition	O
to	O
VEGF	O
and	O
the	O
functional	O
status	O
of	O
p53	O
.	O

Prenatal	O
hypoxia	O
decreases	O
lung	O
extracellular	O
superoxide	O
dismutase	O
expression	O
and	O
activity	O
.	O

Extracellular	O
superoxide	O
dismutase	O
(	O
EC	O
-	O
SOD	O
)	O
,	O
which	O
scavenges	O
extracellular	O
superoxide	O
(	O
O	O
.	O
)	O
,	O
is	O
highly	O
regulated	O
in	O
the	O
developing	O
lung	O
.	O

In	O
the	O
prenatal	O
rabbit	O
,	O
EC	O
-	O
SOD	O
is	O
predominantly	O
intracellular	O
and	O
inactive	O
,	O
and	O
postnatally	O
,	O
active	O
EC	O
-	O
SOD	O
is	O
secreted	O
.	O

We	O
hypothesized	O
that	O
prenatal	O
hypoxia	O
would	O
delay	O
the	O
normal	O
postnatal	O
secretion	O
of	O
active	O
EC	O
-	O
SOD	O
in	O
the	O
lung	O
.	O

Pregnant	O
New	O
Zealand	O
White	O
rabbits	O
were	O
exposed	O
to	O
hypobaric	O
hypoxia	O
(	O
15	O
,	O
000	O
ft	O
x	O
36	O
h	O
)	O
to	O
alter	O
fetal	O
O	O
(	O
2	O
)	O
tension	O
or	O
were	O
maintained	O
in	O
room	O
air	O
.	O

Lungs	O
were	O
harvested	O
from	O
preterm	O
(	O
28	O
days	O
)	O
,	O
term	O
(	O
30	O
+	O
/	O
-	O
1	O
day	O
)	O
,	O
and	O
1	O
-	O
wk	O
-	O
old	O
kits	O
.	O

After	O
prenatal	O
hypobaric	O
hypoxia	O
,	O
EC	O
-	O
SOD	O
mRNA	O
expression	O
was	O
significantly	O
decreased	O
in	O
lungs	O
of	O
full	O
-	O
term	O
kits	O
,	O
whereas	O
EC	O
-	O
SOD	O
protein	O
decreased	O
at	O
all	O
ages	O
.	O

Immunohistochemical	O
staining	O
for	O
EC	O
-	O
SOD	O
showed	O
that	O
hypoxia	O
delayed	O
secretion	O
of	O
the	O
isoenzyme	O
in	O
the	O
airways	O
and	O
pulmonary	O
vasculature	O
.	O

Furthermore	O
,	O
pulmonary	O
EC	O
-	O
SOD	O
enzyme	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
1	O
-	O
wk	O
-	O
old	O
kits	O
exposed	O
to	O
prenatal	O
hypoxia	O
.	O

We	O
conclude	O
that	O
prenatal	O
hypoxia	O
downregulates	O
EC	O
-	O
SOD	O
expression	O
at	O
both	O
the	O
transcriptional	O
and	O
posttranslational	O
levels	O
.	O

Furthermore	O
,	O
prenatal	O
hypoxia	O
delays	O
secretion	O
of	O
active	O
EC	O
-	O
SOD	O
enzyme	O
.	O

These	O
findings	O
have	O
important	O
implications	O
for	O
the	O
effects	O
of	O
prenatal	O
asphyxia	O
on	O
postnatal	O
response	O
to	O
oxidant	O
stress	O
.	O

Impacts	O
of	O
water	O
management	O
options	O
on	O
flows	O
in	O
the	O
Condamine	O
River	O
in	O
Southern	O
Queensland	O
.	O

This	O
paper	O
examines	O
the	O
implications	O
for	O
river	O
flows	O
of	O
a	O
number	O
of	O
water	O
practices	O
and	O
potential	O
management	O
options	O
in	O
the	O
alluvial	O
plains	O
of	O
the	O
Upper	O
Condamine	O
River	O
.	O

It	O
is	O
an	O
intensively	O
cultivated	O
area	O
where	O
irrigation	O
is	O
limited	O
by	O
the	O
availability	O
of	O
water	O
resources	O
.	O

The	O
practice	O
of	O
capturing	O
overland	O
flows	O
was	O
investigated	O
by	O
the	O
development	O
of	O
a	O
model	O
that	O
simulates	O
the	O
performance	O
of	O
clusters	O
of	O
offstream	O
storages	O
up	O
to	O
sub	O
-	O
catchment	O
scale	O
.	O

Management	O
options	O
examined	O
included	O
improvement	O
to	O
on	O
-	O
farm	O
water	O
use	O
efficiency	O
,	O
the	O
suppression	O
of	O
evaporation	O
from	O
open	O
water	O
storages	O
,	O
increasing	O
the	O
depth	O
of	O
those	O
storages	O
,	O
decreasing	O
their	O
number	O
,	O
and	O
improved	O
tailwater	O
return	O
from	O
irrigated	O
land	O
.	O

Impacts	O
of	O
management	O
options	O
were	O
analysed	O
using	O
a	O
catchment	O
scale	O
water	O
allocation	O
model	O
.	O

Retinal	O
microangiopathies	O
overlying	O
pigment	O
epithelial	O
detachment	O
in	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

PURPOSE	O
:	O
To	O
evaluate	O
alterations	O
in	O
the	O
retinal	O
vasculature	O
overlying	O
pigment	O
epithelial	O
detachments	O
(	O
PED	O
)	O
in	O
exudative	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
ARMD	O
)	O
using	O
indocyanine	O
green	O
and	O
fluorescein	O
angiography	O
.	O

METHODS	O
:	O
Forty	O
-	O
one	O
patients	O
(	O
41	O
eyes	O
)	O
with	O
a	O
clinical	O
diagnosis	O
of	O
exudative	O
ARMD	O
with	O
PED	O
underwent	O
simultaneous	O
fluorescein	O
and	O
indocyanine	O
green	O
angiography	O
,	O
also	O
under	O
high	O
(	O
10	O
degrees	O
)	O
magnification	O
.	O

Vascular	O
abnormalities	O
in	O
the	O
retina	O
were	O
compared	O
between	O
patients	O
with	O
vascularized	O
(	O
n	O
=	O
34	O
,	O
group	O
1	O
)	O
and	O
nonvascularized	O
(	O
n	O
=	O
7	O
,	O
group	O
2	O
)	O
PED	O
on	O
indocyanine	O
green	O
angiography	O
and	O
correlated	O
with	O
the	O
size	O
of	O
the	O
PED	O
and	O
the	O
presence	O
of	O
serous	O
retinal	O
detachment	O
.	O

RESULTS	O
:	O
In	O
all	O
,	O
67	O
vascular	O
abnormalities	O
were	O
found	O
by	O
indocyanine	O
green	O
angiography	O
and	O
only	O
22	O
by	O
fluorescein	O
angiography	O
;	O
this	O
finding	O
was	O
statistically	O
significant	O
(	O
P	O
less	O
than	O
0	O
.	O
0001	O
)	O
.	O

The	O
finding	O
of	O
retinal	O
vasculopathy	O
(	O
32	O
patients	O
in	O
group	O
1	O
and	O
two	O
patients	O
in	O
group	O
2	O
)	O
was	O
directly	O
correlated	O
with	O
the	O
presence	O
of	O
choroidal	O
neovascularizations	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
.	O

There	O
was	O
also	O
a	O
direct	O
correlation	O
between	O
the	O
presence	O
of	O
choroidal	O
neovascularization	O
and	O
size	O
of	O
the	O
PED	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

The	O
number	O
of	O
retinal	O
vascular	O
findings	O
was	O
not	O
significantly	O
correlated	O
with	O
serous	O
elevation	O
of	O
the	O
retina	O
.	O

CONCLUSIONS	O
:	O
Retinal	O
vasculopathies	O
may	O
be	O
observed	O
in	O
eyes	O
with	O
PED	O
and	O
are	O
detectable	O
by	O
indocyanine	O
green	O
and	O
fluorescein	O
angiography	O
.	O

Protein	O
expression	O
profile	O
of	O
primary	O
human	O
squamous	O
cell	O
lung	O
carcinomas	O
indicative	O
of	O
the	O
incidence	O
of	O
metastases	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
evaluate	O
firstly	O
whether	O
different	O
protein	O
expression	O
patterns	O
exist	O
in	O
primary	O
squamous	O
cell	O
lung	O
carcinomas	O
of	O
patients	O
with	O
and	O
without	O
lymph	O
node	O
involvement	O
and	O
secondly	O
,	O
whether	O
or	O
not	O
different	O
patterns	O
exist	O
in	O
tumours	O
with	O
positive	O
lymph	O
nodes	O
.	O

For	O
this	O
reason	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
specimens	O
from	O
130	O
patients	O
with	O
squamous	O
cell	O
lung	O
carcinomas	O
were	O
analyzed	O
by	O
immunohistochemistry	O
.	O

In	O
a	O
first	O
step	O
,	O
proteins	O
were	O
selected	O
which	O
showed	O
a	O
relationship	O
to	O
lymph	O
node	O
involvement	O
.	O

The	O
expression	O
of	O
JUN	O
,	O
ERBB2	O
,	O
MYC	O
,	O
cyclin	O
D	O
,	O
PCNA	O
,	O
bFGF	O
,	O
VEGF	O
and	O
Hsp70	O
proteins	O
revealed	O
a	O
positive	O
correlation	O
to	O
lymph	O
node	O
involvement	O
.	O

In	O
contrast	O
,	O
caspase	O
-	O
3	O
,	O
Fas	O
ligand	O
,	O
Fas	O
/	O
CD95	O
,	O
and	O
PAI	O
showed	O
an	O
inverse	O
correlation	O
to	O
lymph	O
node	O
involvement	O
.	O

In	O
a	O
second	O
step	O
,	O
these	O
parameters	O
were	O
further	O
analyzed	O
by	O
hierarchical	O
cluster	O
analyses	O
.	O

The	O
resulting	O
clusters	O
were	O
correlated	O
to	O
patients	O
with	O
or	O
without	O
lymph	O
node	O
involvement	O
.	O

The	O
data	O
show	O
that	O
different	O
protein	O
expression	O
patterns	O
exist	O
between	O
primary	O
squamous	O
cell	O
lung	O
carcinomas	O
with	O
and	O
without	O
lymph	O
node	O
involvement	O
and	O
within	O
carcinomas	O
with	O
lymph	O
node	O
involvement	O
.	O

The	O
data	O
suggest	O
that	O
various	O
metastasis	O
profiles	O
exist	O
.	O

Antiangiogenic	O
and	O
antitumor	O
effects	O
of	O
a	O
protein	O
kinase	O
Cbeta	O
inhibitor	O
in	O
human	O
breast	O
cancer	O
and	O
ovarian	O
cancer	O
xenografts	O
.	O

In	O
cell	O
culture	O
,	O
the	O
compound	O
317615	O
2HCl	O
,	O
a	O
potent	O
inhibitor	O
of	O
VEGF	O
-	O
stimulated	O
HUVEC	O
proliferation	O
,	O
was	O
not	O
very	O
effective	O
against	O
MX	B
-	I
1	I
breast	O
cancer	O
cells	O
(	O
IC50	O
=	O
8	O
.	O
1	O
microM	O
)	O
or	O
SKOV	B
-	I
3	I
ovarian	O
carcinoma	O
cells	O
(	O
IC50	O
=	O
9	O
.	O
5	O
microM	O
)	O
.	O

Exposure	O
to	O
combinations	O
of	O
paclitaxel	O
or	O
carboplatin	O
and	O
317615	O
x	O
2HCl	O
with	O
MX	B
-	I
1	I
cells	O
in	O
culture	O
resulted	O
in	O
cell	O
survival	O
that	O
reflected	O
primarily	O
additivity	O
of	O
the	O
two	O
agents	O
.	O

Exposure	O
of	O
SKOV	B
-	I
3	I
cells	O
to	O
paclitaxel	O
or	O
carboplatin	O
along	O
with	O
317615	O
2HCl	O
resulted	O
in	O
cell	O
survivals	O
that	O
reflected	O
additivity	O
of	O
317615	O
x	O
2HCl	O
with	O
paclitaxel	O
and	O
greater	O
-	O
than	O
-	O
additive	O
cytotoxicity	O
with	O
carboplatin	O
.	O

Administration	O
of	O
317615	O
x	O
2HCI	O
orally	O
twice	O
daily	O
to	O
nude	O
mice	O
bearing	O
subcutaneous	O
MX	B
-	I
1	I
tumors	O
or	O
SKOV	B
-	I
3	I
tumors	O
resulted	O
in	O
a	O
decreased	O
number	O
of	O
intratumoral	O
vessels	O
as	O
determined	O
by	O
CD31	O
and	O
CD105	O
staining	O
with	O
decreases	O
of	O
35	O
%	O
and	O
43	O
%	O
in	O
MX	B
-	I
1	I
tumors	O
and	O
60	O
%	O
and	O
75	O
%	O
in	O
SKOV	B
-	I
3	I
tumors	O
,	O
respectively	O
.	O

317615	O
x	O
2HCl	O
was	O
an	O
active	O
antitumor	O
agent	O
against	O
the	O
MX	B
-	I
1	I
xenograft	O
and	O
increased	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
paclitaxel	O
by	O
1	O
.	O
7	O
-	O
fold	O
and	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
carboplatin	O
by	O
3	O
.	O
8	O
-	O
fold	O
.	O

Administration	O
of	O
317615	O
x	O
2HCl	O
also	O
increased	O
the	O
tumor	O
growth	O
delay	O
produced	O
by	O
fractionated	O
radiation	O
therapy	O
in	O
the	O
MX	B
-	I
1	I
tumor	O
.	O

Treatment	O
with	O
317615	O
x	O
2HCl	O
alone	O
increased	O
the	O
lifespan	O
of	O
animals	O
bearing	O
intraperitoneal	O
SKOV	B
-	I
3	I
xenografts	O
by	O
1	O
.	O
9	O
fold	O
compared	O
with	O
untreated	O
control	O
animals	O
.	O

The	O
combination	O
of	O
paclitaxel	O
and	O
317615	O
x	O
2HCl	O
resulted	O
in	O
100	O
%	O
120	O
-	O
day	O
survival	O
of	O
SKOV	B
-	I
3	I
bearing	O
animals	O
.	O

Administration	O
of	O
317615	O
x	O
2HCl	O
along	O
with	O
carboplatin	O
to	O
animals	O
bearing	O
the	O
SKOV	B
-	I
3	I
tumor	O
produced	O
a	O
1	O
.	O
8	O
-	O
fold	O
increase	O
in	O
lifespan	O
compared	O
with	O
carboplatin	O
alone	O
.	O

317615	O
x	O
2HCl	O
is	O
a	O
promising	O
new	O
antiangiogenic	O
agent	O
that	O
is	O
in	O
early	O
phase	O
clinical	O
testing	O
.	O

Expression	O
of	O
CD154	O
on	O
renal	O
cell	O
carcinomas	O
and	O
effect	O
on	O
cell	O
proliferation	O
,	O
motility	O
and	O
platelet	O
-	O
activating	O
factor	O
synthesis	O
.	O

CD40	O
activation	O
by	O
CD154	O
may	O
trigger	O
diverse	O
cellular	O
responses	O
,	O
ranging	O
from	O
proliferation	O
and	O
differentiation	O
to	O
growth	O
suppression	O
and	O
cell	O
death	O
,	O
in	O
normal	O
and	O
malignant	O
cells	O
.	O

However	O
,	O
the	O
pathophysiologic	O
role	O
of	O
CD154	O
expressed	O
by	O
tumor	O
cells	O
remains	O
unclear	O
.	O

We	O
have	O
investigated	O
the	O
expression	O
of	O
the	O
CD40	O
-	O
CD154	O
system	O
in	O
24	O
primary	O
cultures	O
derived	O
from	O
renal	O
cell	O
carcinomas	O
,	O
its	O
correlation	O
with	O
tumor	O
stage	O
and	O
its	O
potential	O
functional	O
significance	O
.	O

We	O
found	O
coexpression	O
of	O
CD40	O
and	O
CD154	O
in	O
most	O
of	O
the	O
renal	O
carcinoma	O
cell	O
lines	O
.	O

CD154	O
,	O
but	O
not	O
CD40	O
expression	O
,	O
significantly	O
correlated	O
with	O
tumor	O
stage	O
.	O

Moreover	O
,	O
renal	O
carcinoma	O
cell	O
lines	O
also	O
released	O
the	O
soluble	O
form	O
of	O
CD154	O
into	O
the	O
supernatant	O
.	O

CD40	O
engagement	O
by	O
CD154	O
did	O
not	O
affect	O
apoptosis	O
or	O
survival	O
.	O

On	O
the	O
contrary	O
,	O
CD154	O
stimulated	O
cell	O
proliferation	O
,	O
motility	O
and	O
production	O
of	O
PAF	O
,	O
a	O
phospholipid	O
mediator	O
of	O
inflammation	O
with	O
angiogenic	O
properties	O
.	O

Furthermore	O
,	O
the	O
renal	O
carcinoma	O
cell	O
lines	O
expressed	O
PAF	O
-	O
R	O
.	O

Blockade	O
of	O
PAF	O
-	O
R	O
by	O
WEB	O
-	O
2170	O
,	O
a	O
PAF	O
-	O
R	O
antagonist	O
,	O
abolished	O
the	O
CD154	O
-	O
dependent	O
motility	O
,	O
indicating	O
a	O
role	O
for	O
PAF	O
synthesized	O
after	O
CD154	O
stimulation	O
in	O
renal	O
carcinoma	O
cell	O
motility	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
identifies	O
new	O
functional	O
properties	O
for	O
CD154	O
,	O
which	O
are	O
potentially	O
relevant	O
for	O
the	O
growth	O
and	O
dissemination	O
of	O
renal	O
carcinoma	O
cells	O
.	O

Fas	O
-	O
Fas	O
ligand	O
signaling	O
pathway	O
mediates	O
an	O
interleukin	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
a	O
murine	O
prostate	O
tumor	O
system	O
.	O

BACKGROUND	O
:	O
Recent	O
data	O
suggest	O
that	O
anti	O
-	O
tumor	O
activities	O
of	O
interleukin	O
-	O
12	O
(	O
IL	O
-	O
12	O
)	O
involve	O
the	O
induction	O
of	O
apoptosis	O
.	O

Fas	O
(	O
APO	O
-	O
1	O
/	O
CD95	O
)	O
is	O
a	O
type	O
I	O
membrane	O
protein	O
that	O
is	O
capable	O
of	O
initiating	O
an	O
apoptosis	O
signaling	O
pathway	O
when	O
bound	O
to	O
its	O
ligand	O
(	O
FasL	O
)	O
.	O

We	O
undertook	O
this	O
study	O
to	O
test	O
the	O
hypothesis	O
that	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
plays	O
a	O
role	O
in	O
IL	O
-	O
12	O
-	O
induced	O
tumor	O
regression	O
.	O

METHODS	O
:	O
An	O
mIL	O
-	O
12	O
expression	O
vector	O
driven	O
by	O
cytomegalovirus	O
promoter	O
was	O
used	O
to	O
express	O
murine	O
IL	O
-	O
12	O
cDNA	O
in	O
the	O
RM	B
-	I
9	I
murine	O
prostate	O
carcinoma	O
cell	O
line	O
.	O

Control	O
RM	B
-	I
9	I
cells	O
and	O
RM	B
-	I
9	I
cells	O
stably	O
transfected	O
with	O
IL	O
-	O
12	O
gene	O
(	O
RM	B
-	I
9	I
-	O
IL12	O
)	O
were	O
inoculated	O
subcutaneously	O
in	O
4	O
-	O
to	O
6	O
-	O
week	O
-	O
old	O
male	O
C57BL	O
/	O
J6	O
mice	O
.	O

Tumor	O
size	O
was	O
measured	O
every	O
3	O
days	O
.	O

Western	O
blot	O
and	O
immunohistochemical	O
assays	O
were	O
used	O
to	O
evaluate	O
Fas	O
and	O
FasL	O
protein	O
expression	O
.	O

In	O
situ	O
fluorescent	O
end	O
labeling	O
was	O
used	O
to	O
label	O
apoptotic	O
cells	O
.	O

RESULTS	O
:	O
IL	O
-	O
12	O
-	O
expressing	O
RM	B
-	I
9	I
prostate	O
carcinoma	O
cells	O
transplanted	O
into	O
C57BL	O
/	O
J6	O
mice	O
grew	O
more	O
slowly	O
than	O
control	O
RM	B
-	I
9	I
cells	O
and	O
vector	O
control	O
RM	B
-	I
9	I
-	O
Luc	O
cells	O
.	O

The	O
average	O
survival	O
time	O
of	O
the	O
RM	B
-	I
9	I
-	O
IL12	O
mice	O
was	O
longer	O
than	O
53	O
days	O
,	O
whereas	O
the	O
mean	O
survival	O
for	O
mice	O
transplanted	O
with	O
control	O
RM	B
-	I
9	I
cells	O
was	O
only	O
16	O
days	O
.	O

Apoptotic	O
cells	O
were	O
more	O
numerous	O
in	O
RM	B
-	I
9	I
-	O
IL12	O
tumors	O
:	O
10	O
.	O
3	O
%	O
vs	O
.	O
1	O
.	O
5	O
%	O
in	O
control	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Fas	O
and	O
FasL	O
proteins	O
were	O
increased	O
approximately	O
twofold	O
in	O
the	O
RM	B
-	I
9	I
-	O
IL12	O
tumors	O
compared	O
with	O
the	O
RM	B
-	I
9	I
control	O
tumors	O
as	O
determined	O
by	O
Western	O
blot	O
and	O
immunohistochemical	O
analyses	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
Fas	O
-	O
FasL	O
-	O
mediated	O
apoptosis	O
pathway	O
may	O
contribute	O
to	O
the	O
IL	O
-	O
12	O
-	O
induced	O
rejection	O
of	O
prostate	O
carcinoma	O
.	O

DNA	O
damage	O
induces	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
regulating	O
cell	O
cycle	O
and	O
apoptosis	O
in	O
acute	O
lymphoblastic	O
leukemia	O
cells	O
.	O

Survivin	O
is	O
a	O
novel	O
member	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
(	O
IAP	O
)	O
family	O
.	O

Here	O
we	O
report	O
that	O
the	O
chemotherapeutic	O
drug	O
doxorubicin	O
,	O
a	O
DNA	O
-	O
damaging	O
agent	O
,	O
activates	O
a	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
inducing	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
childhood	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
.	O

Treatment	O
of	O
wild	O
-	O
type	O
(	O
wt	O
)	O
p53	O
ALL	O
cells	O
(	O
EU	B
-	I
3	I
cell	O
line	O
)	O
with	O
doxorubicin	O
caused	O
accumulation	O
of	O
p53	O
,	O
resulting	O
in	O
dramatic	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
depletion	O
of	O
cells	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
and	O
apoptosis	O
(	O
increased	O
sub	O
-	O
G	O
(	O
1	O
)	O
compartment	O
)	O
.	O

In	O
contrast	O
,	O
doxorubicin	O
treatment	O
of	O
mutant	O
(	O
mut	O
)	O
p53	O
cells	O
(	O
EU	B
-	I
6	I
/	O
ALL	O
line	O
)	O
up	O
-	O
regulated	O
survivin	O
and	O
induced	O
G	O
(	O
2	O
)	O
/	O
M	O
arrest	O
without	O
inducing	O
apoptosis	O
.	O

However	O
,	O
treating	O
EU	B
-	I
6	I
with	O
anti	O
-	O
survivin	O
antisense	O
resensitized	O
these	O
cells	O
to	O
doxorubicin	O
,	O
resulting	O
in	O
apoptosis	O
.	O

With	O
a	O
p53	O
-	O
null	O
cell	O
line	O
(	O
EU	B
-	I
4	I
)	O
,	O
although	O
doxorubicin	O
treatment	O
arrested	O
cells	O
in	O
G	O
(	O
2	O
)	O
/	O
M	O
,	O
survivin	O
expression	O
was	O
unchanged	O
,	O
and	O
cells	O
underwent	O
only	O
limited	O
apoptosis	O
.	O

However	O
,	O
re	O
-	O
expression	O
of	O
wt	O
-	O
p53	O
in	O
EU	B
-	I
4	I
cells	O
could	O
restore	O
the	O
doxorubicin	O
-	O
p53	O
-	O
survivin	O
pathway	O
,	O
resulting	O
in	O
significantly	O
decreased	O
survivin	O
expression	O
and	O
increased	O
apoptosis	O
in	O
these	O
cells	O
after	O
doxorubicin	O
treatment	O
.	O

Following	O
cotransfection	O
of	O
p53	O
-	O
null	O
EU	B
-	I
4	I
cells	O
with	O
survivin	O
promoter	O
-	O
luciferase	O
constructs	O
and	O
either	O
wt	O
-	O
p53	O
or	O
different	O
mut	O
-	O
p53	O
expression	O
vectors	O
,	O
wt	O
-	O
p53	O
inhibited	O
survivin	O
promoter	O
activity	O
;	O
p53	O
-	O
mediated	O
inhibition	O
could	O
be	O
abrogated	O
by	O
overexpression	O
of	O
murine	O
double	O
minute2	O
(	O
MDM2	O
)	O
protein	O
.	O

Together	O
,	O
these	O
studies	O
define	O
a	O
novel	O
p53	O
-	O
survivin	O
signaling	O
pathway	O
activated	O
by	O
DNA	O
damage	O
that	O
results	O
in	O
down	O
-	O
regulation	O
of	O
survivin	O
,	O
cell	O
cycle	O
arrest	O
,	O
and	O
apoptosis	O
.	O

Furthermore	O
,	O
our	O
data	O
indicate	O
that	O
loss	O
of	O
wt	O
-	O
p53	O
function	O
in	O
tumor	O
cells	O
may	O
contribute	O
to	O
up	O
-	O
regulation	O
of	O
survivin	O
and	O
resistance	O
to	O
DNA	O
-	O
damaging	O
agents	O
.	O

Male	O
role	O
in	O
fertility	O
decisions	O
in	O
Robertsport	O
,	O
Liberia	O
:	O
an	O
experimental	O
exercise	O
for	O
policy	O
formulation	O
.	O

There	O
is	O
a	O
tendency	O
to	O
believe	O
that	O
in	O
African	O
societies	O
men	O
are	O
the	O
dominant	O
decision	O
makers	O
in	O
the	O
family	O
.	O

In	O
Robertsport	O
,	O
Liberia	O
,	O
there	O
are	O
indications	O
that	O
,	O
with	O
respect	O
to	O
fertility	O
regulation	O
,	O
the	O
dominance	O
of	O
the	O
husband	O
in	O
fertility	O
decisions	O
exists	O
,	O
but	O
it	O
is	O
also	O
apparent	O
that	O
many	O
of	O
these	O
decisions	O
are	O
made	O
jointly	O
by	O
both	O
husband	O
and	O
wife	O
.	O

Education	O
is	O
particularly	O
influential	O
in	O
the	O
joint	O
fertility	O
decision	O
-	O
making	O
process	O
.	O

The	O
100	O
husbands	O
sampled	O
in	O
1982	O
desired	O
a	O
large	O
number	O
of	O
children	O
and	O
had	O
experience	O
with	O
infant	O
and	O
child	O
mortality	O
.	O

If	O
family	O
planning	O
programs	O
should	O
attain	O
their	O
goals	O
,	O
men	O
should	O
be	O
more	O
involved	O
,	O
than	O
at	O
present	O
,	O
in	O
every	O
aspect	O
of	O
the	O
programs	O
.	O

Equally	O
important	O
is	O
the	O
urgency	O
for	O
studies	O
related	O
to	O
the	O
role	O
of	O
men	O
in	O
fertility	O
regulation	O
,	O
using	O
adequately	O
large	O
samples	O
.	O

Genetic	O
differences	O
in	O
susceptibility	O
to	O
ulcerative	O
enteritis	O
in	O
Japanese	O
quail	O
.	O

Six	O
lines	O
of	O
Japanese	O
quail	O
were	O
derived	O
from	O
a	O
single	O
foundation	O
population	O
.	O

Four	O
of	O
the	O
lines	O
were	O
selected	O
on	O
the	O
basis	O
of	O
family	O
mean	O
three	O
week	O
body	O
weight	O
,	O
two	O
were	O
unselected	O
and	O
all	O
lines	O
were	O
randomly	O
mated	O
.	O

Quail	O
were	O
housed	O
in	O
wire	O
batteries	O
during	O
the	O
brooding	O
,	O
rearing	O
and	O
laying	O
periods	O
.	O

During	O
the	O
brooding	O
period	O
,	O
hover	O
temperature	O
and	O
floor	O
space	O
per	O
chick	O
were	O
similar	O
from	O
line	O
to	O
line	O
.	O

For	O
the	O
rearing	O
and	O
laying	O
periods	O
,	O
floor	O
space	O
per	O
chick	O
was	O
approximately	O
the	O
same	O
from	O
line	O
to	O
line	O
.	O

During	O
an	O
outbreak	O
of	O
ulcerative	O
enteritis	O
(	O
diagnosed	O
on	O
the	O
basis	O
of	O
gross	O
and	O
histopathology	O
)	O
in	O
generation	O
31	O
and	O
again	O
in	O
generation	O
34	O
,	O
mortality	O
ranged	O
from	O
zero	O
for	O
males	O
of	O
one	O
control	O
line	O
to	O
approximately	O
50	O
percent	O
for	O
females	O
of	O
one	O
selected	O
line	O
.	O

Analysis	O
of	O
variance	O
showed	O
that	O
incidence	O
of	O
mortality	O
differed	O
significantly	O
among	O
lines	O
and	O
between	O
sexes	O
.	O

Mortality	O
was	O
generally	O
higher	O
in	O
selected	O
than	O
in	O
control	O
lines	O
and	O
in	O
females	O
than	O
in	O
males	O
.	O

It	O
is	O
suggested	O
that	O
susceptibility	O
to	O
ulcerative	O
enteritis	O
in	O
quail	O
may	O
be	O
a	O
polygenically	O
inherited	O
trait	O
and	O
that	O
the	O
breeding	O
which	O
accompanied	O
selection	O
for	O
body	O
size	O
may	O
have	O
made	O
some	O
loci	O
homozygous	O
for	O
susceptibility	O
alleles	O
.	O

[	O
A	O
decline	O
in	O
the	O
French	O
demographic	O
situation	O
in	O
the	O
context	O
of	O
a	O
Europe	O
also	O
in	O
demographic	O
decline	O
]	O
.	O

The	O
author	O
analyzes	O
the	O
decline	O
in	O
French	O
fertility	O
which	O
has	O
occurred	O
over	O
the	O
past	O
two	O
years	O
using	O
data	O
from	O
official	O
sources	O
.	O

Some	O
comparisons	O
are	O
made	O
with	O
fertility	O
trends	O
in	O
other	O
European	O
countries	O
.	O

On	O
the	O
relationship	O
between	O
the	O
population	O
structure	O
and	O
national	O
economic	O
development	O
in	O
China	O
.	O

The	O
authors	O
examine	O
the	O
relationship	O
between	O
population	O
reproduction	O
and	O
the	O
production	O
of	O
material	O
goods	O
,	O
with	O
particular	O
reference	O
to	O
the	O
effect	O
of	O
changes	O
in	O
the	O
age	O
composition	O
of	O
the	O
population	O
on	O
the	O
national	O
economy	O
and	O
national	O
income	O
.	O

An	O
analysis	O
of	O
the	O
population	O
structure	O
of	O
China	O
is	O
presented	O
,	O
with	O
consideration	O
given	O
to	O
age	O
characteristics	O
,	O
occupation	O
,	O
and	O
urban	O
and	O
rural	O
population	O
.	O

Suggestions	O
for	O
improving	O
the	O
population	O
structure	O
to	O
achieve	O
maximum	O
rates	O
of	O
economic	O
development	O
are	O
presented	O
.	O

Regional	O
differences	O
in	O
population	O
structure	O
are	O
also	O
discussed	O
.	O

The	O
patterns	O
of	O
internal	O
migration	O
in	O
Maharashtra	O
:	O
an	O
analysis	O
of	O
1971	O
census	O
data	O
.	O

Patterns	O
of	O
internal	O
migration	O
in	O
the	O
state	O
of	O
Maharashtra	O
,	O
India	O
,	O
for	O
the	O
period	O
1961	O
-	O
1971	O
are	O
analyzed	O
using	O
1971	O
census	O
data	O
.	O

The	O
nature	O
,	O
volume	O
,	O
and	O
direction	O
of	O
migration	O
are	O
examined	O
.	O

Migrants	O
are	O
characterized	O
according	O
to	O
factors	O
including	O
age	O
,	O
sex	O
,	O
marital	O
status	O
,	O
occupation	O
,	O
and	O
areas	O
of	O
origin	O
and	O
destination	O
.	O

Act	O
No	O
.	O
16	O
.	O
045	O
of	O
2	O
June	O
1989	O
prohibiting	O
all	O
discrimination	O
that	O
violates	O
the	O
principle	O
of	O
equality	O
of	O
treatment	O
and	O
opportunities	O
for	O
both	O
sexes	O
in	O
all	O
sectors	O
of	O
labor	O
activity	O
.	O

This	O
Uruguayan	O
Act	O
prohibits	O
discrimination	O
in	O
employment	O
with	O
respect	O
to	O
the	O
following	O
areas	O
,	O
among	O
others	O
:	O
1	O
)	O
advertising	O
for	O
the	O
provision	O
of	O
positions	O
;	O
2	O
)	O
selection	O
criteria	O
;	O
3	O
)	O
recruitment	O
and	O
hiring	O
;	O
4	O
)	O
evaluation	O
of	O
performance	O
criteria	O
;	O
5	O
)	O
the	O
right	O
to	O
advancement	O
and	O
promotion	O
;	O
6	O
)	O
labour	O
stability	O
;	O
7	O
)	O
social	O
benefits	O
;	O
8	O
)	O
suspension	O
and	O
dismissal	O
,	O
particularly	O
in	O
cases	O
involving	O
a	O
change	O
of	O
civil	O
status	O
,	O
pregnancy	O
,	O
or	O
nursing	O
;	O
9	O
)	O
possibilities	O
for	O
professional	O
and	O
technical	O
education	O
or	O
retraining	O
;	O
and	O
10	O
)	O
remuneration	O
criteria	O
.	O

Reserving	O
places	O
for	O
one	O
sex	O
because	O
of	O
the	O
presence	O
of	O
activities	O
in	O
which	O
the	O
sex	O
of	O
the	O
employee	O
is	O
essential	O
for	O
performance	O
or	O
to	O
comply	O
with	O
international	O
labor	O
treaties	O
does	O
not	O
constitute	O
discrimination	O
.	O

Nor	O
do	O
compensatory	O
acts	O
designed	O
to	O
promote	O
equality	O
of	O
opportunities	O
and	O
treatment	O
of	O
both	O
sexes	O
in	O
concrete	O
situations	O
.	O

In	O
cases	O
where	O
the	O
provisions	O
of	O
this	O
Act	O
have	O
been	O
violated	O
,	O
specially	O
designated	O
judges	O
will	O
call	O
the	O
parties	O
together	O
and	O
may	O
adopt	O
measures	O
designed	O
to	O
end	O
the	O
situation	O
complained	O
of	O
.	O

If	O
they	O
deem	O
it	O
necessary	O
,	O
the	O
judges	O
may	O
institute	O
more	O
formal	O
proceedings	O
.	O

If	O
the	O
measures	O
adopted	O
are	O
not	O
carried	O
out	O
,	O
the	O
person	O
violating	O
the	O
law	O
is	O
subject	O
to	O
a	O
daily	O
fine	O
,	O
as	O
well	O
as	O
administrative	O
penalties	O
set	O
out	O
in	O
Act	O
15	O
.	O
903	O
of	O
10	O
November	O
1987	O
.	O

Adverse	O
decisions	O
may	O
be	O
appealed	O
.	O

The	O
state	O
is	O
also	O
to	O
undertake	O
educative	O
campaigns	O
to	O
create	O
interest	O
in	O
and	O
understanding	O
of	O
the	O
problems	O
affecting	O
women	O
workers	O
,	O
thus	O
promoting	O
awareness	O
in	O
such	O
workers	O
and	O
their	O
employers	O
of	O
their	O
situation	O
.	O

No	O
evidence	O
for	O
an	O
influence	O
of	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
polymorphism	O
on	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O

This	O
study	O
investigated	O
the	O
hypothesis	O
that	O
the	O
human	O
platelet	O
antigen	O
-	O
1	O
(	O
HPA	O
-	O
1	O
)	O
polymorphism	O
may	O
influence	O
the	O
antiplatelet	O
effects	O
of	O
glycoprotein	O
(	O
GP	O
)	O
IIb	O
/	O
IIIa	O
inhibitors	O
.	O

Adenosine	O
diphosphate	O
(	O
30	O
micro	O
mol	O
)	O
-	O
induced	O
fibrinogen	O
binding	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O

Abciximab	O
(	O
0	O
.	O
03	O
-	O
3	O
micro	O
g	O
/	O
ml	O
)	O
,	O
tirofiban	O
(	O
0	O
.	O
3	O
-	O
30	O
nmol	O
/	O
l	O
)	O
or	O
eptifibatide	O
(	O
0	O
.	O
01	O
-	O
1	O
micro	O
g	O
/	O
ml	O
)	O
were	O
incubated	O
for	O
15	O
min	O
with	O
the	O
samples	O
prior	O
to	O
stimulation	O
.	O

IC	O
(	O
50	O
)	O
values	O
for	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
were	O
determined	O
from	O
each	O
experiment	O
.	O

All	O
subjects	O
were	O
genotyped	O
by	O
GALIOS	O
and	O
automated	O
fluorescence	O
correlation	O
spectroscopy	O
.	O

Although	O
a	O
marked	O
variability	O
in	O
the	O
inhibitory	O
effects	O
of	O
all	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
was	O
confirmed	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
genotypes	O
with	O
respect	O
to	O
the	O
inhibition	O
of	O
fibrinogen	O
binding	O
.	O

Thus	O
,	O
the	O
present	O
study	O
does	O
not	O
provide	O
evidence	O
for	O
an	O
effect	O
of	O
HPA	O
-	O
1	O
polymorphism	O
on	O
the	O
inter	O
-	O
individual	O
variability	O
in	O
the	O
platelet	O
inhibitory	O
effects	O
of	O
the	O
three	O
GPIIb	O
/	O
IIIa	O
inhibitors	O
approved	O
for	O
clinical	O
use	O
.	O

Effects	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	B
leukaemia	O
cells	O
.	O

The	O
main	O
purpose	O
of	O
the	O
present	O
investigation	O
was	O
to	O
study	O
the	O
effect	O
of	O
the	O
homologous	O
series	O
of	O
4	O
-	O
alkylmorpholine	O
N	O
-	O
oxides	O
on	O
ATP	O
-	O
producing	O
processes	O
in	O
Ehrlich	O
ascites	O
and	O
L1210	B
murine	O
leukaemia	O
cells	O
.	O

The	O
effects	O
on	O
aerobic	O
glucose	O
consumption	O
,	O
lactic	O
acid	O
formation	O
,	O
content	O
of	O
total	O
(	O
T	O
-	O
SH	O
)	O
and	O
non	O
-	O
protein	O
thiol	O
groups	O
(	O
NP	O
-	O
SH	O
)	O
,	O
endogenous	O
and	O
exogenous	O
respiration	O
and	O
the	O
level	O
of	O
ATP	O
in	O
tumour	O
cells	O
incubated	O
in	O
vitro	O
were	O
investigated	O
.	O

4	O
-	O
Dodecylmorpholine	O
N	O
-	O
oxide	O
(	O
DMNO	O
)	O
,	O
one	O
of	O
the	O
most	O
active	O
compounds	O
,	O
decreased	O
the	O
level	O
of	O
ATP	O
immediately	O
after	O
addition	O
to	O
the	O
suspension	O
of	O
Ehrlich	O
cells	O
in	O
an	O
ice	O
bath	O
.	O

After	O
2	O
h	O
incubation	O
at	O
37	O
degrees	O
C	O
the	O
drop	O
in	O
the	O
ATP	O
level	O
was	O
much	O
lower	O
.	O

A	O
possible	O
explanation	O
for	O
the	O
decrease	O
in	O
the	O
ATP	O
level	O
might	O
be	O
interaction	O
of	O
the	O
amine	O
oxide	O
with	O
the	O
cell	O
membrane	O
.	O

The	O
Acute	O
Dialysis	O
Quality	O
Initiative	O
-	O
-	O
part	O
IV	O
:	O
membranes	O
for	O
CRRT	O
.	O

The	O
extracorporeal	O
membrane	O
used	O
in	O
a	O
continuous	O
renal	O
replacement	O
therapy	O
(	O
CRRT	O
)	O
for	O
the	O
treatment	O
of	O
a	O
critically	O
ill	O
patient	O
with	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
is	O
vitally	O
important	O
for	O
several	O
reasons	O
,	O
including	O
its	O
influence	O
on	O
biocompatibility	O
and	O
filter	O
performance	O
.	O

The	O
clinical	O
relevance	O
of	O
membrane	O
-	O
related	O
biocompatibility	O
markers	O
traditionally	O
used	O
in	O
chronic	O
hemodialysis	O
remains	O
unclear	O
in	O
CRRT	O
.	O

Numerous	O
approaches	O
may	O
be	O
used	O
to	O
assess	O
membrane	O
and	O
filter	O
performance	O
in	O
CRRT	O
,	O
but	O
no	O
specific	O
methodology	O
is	O
accepted	O
widely	O
at	O
present	O
.	O

Although	O
a	O
potential	O
benefit	O
of	O
certain	O
membranes	O
used	O
for	O
CRRT	O
is	O
adsorptive	O
removal	O
of	O
inflammatory	O
mediators	O
,	O
this	O
issue	O
has	O
not	O
been	O
assessed	O
carefully	O
in	O
well	O
-	O
designed	O
clinical	O
trials	O
.	O

These	O
and	O
other	O
issues	O
should	O
be	O
the	O
subject	O
of	O
future	O
clinical	O
research	O
efforts	O
.	O

Enforced	O
expression	O
of	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
-	O
3	O
affects	O
functional	O
capillary	O
morphogenesis	O
and	O
inhibits	O
tumor	O
growth	O
in	O
a	O
murine	O
tumor	O
model	O
.	O

Homeostasis	O
of	O
the	O
extracellular	O
matrix	O
is	O
a	O
delicate	O
balance	O
between	O
degradation	O
and	O
remodeling	O
,	O
the	O
balance	O
being	O
maintained	O
by	O
the	O
interaction	O
of	O
activated	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
and	O
specific	O
tissue	O
inhibitors	O
of	O
matrix	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O

Up	O
-	O
regulation	O
of	O
MMP	O
activity	O
,	O
favoring	O
proteolytic	O
degradation	O
of	O
the	O
basement	O
membrane	O
and	O
extracellular	O
matrix	O
,	O
has	O
been	O
linked	O
to	O
tumor	O
growth	O
and	O
metastasis	O
,	O
as	O
well	O
as	O
tumor	O
-	O
associated	O
angiogenesis	O
,	O
whereas	O
inhibition	O
of	O
MMP	O
activity	O
appears	O
to	O
restrict	O
these	O
processes	O
.	O

We	O
have	O
used	O
retroviral	O
-	O
mediated	O
gene	O
delivery	O
to	O
effect	O
sustained	O
autocrine	O
expression	O
of	O
TIMP	O
-	O
3	O
in	O
murine	O
neuroblastoma	O
and	O
melanoma	O
tumor	O
cells	O
in	O
order	O
to	O
further	O
examine	O
the	O
ability	O
of	O
TIMPs	O
to	O
inhibit	O
angiogenesis	O
in	O
vivo	O
.	O

Growth	O
of	O
both	O
histologic	O
types	O
of	O
gene	O
-	O
modified	O
tumor	O
cells	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
was	O
significantly	O
restricted	O
when	O
compared	O
with	O
controls	O
.	O

Grossly	O
,	O
these	O
tumors	O
were	O
small	O
and	O
had	O
few	O
feeding	O
vessels	O
.	O

Histologic	O
evaluation	O
revealed	O
that	O
although	O
tumors	O
overexpressing	O
TIMP	O
-	O
3	O
had	O
an	O
increased	O
number	O
of	O
CD31	O
(	O
+	O
)	O
endothelial	O
cells	O
,	O
these	O
endothelial	O
cells	O
had	O
not	O
formed	O
functional	O
tubules	O
,	O
as	O
evidenced	O
by	O
decreased	O
vessel	O
continuity	O
and	O
minimal	O
pericyte	O
recruitment	O
.	O

This	O
effect	O
appears	O
to	O
be	O
mediated	O
,	O
in	O
part	O
,	O
by	O
decreased	O
expression	O
of	O
vascular	O
endothelial	O
(	O
VE	O
)	O
-	O
cadherin	O
by	O
endothelial	O
cells	O
in	O
the	O
presence	O
of	O
TIMP	O
-	O
3	O
as	O
seen	O
both	O
in	O
an	O
in	O
vitro	O
assay	O
and	O
in	O
TIMP	O
-	O
3	O
-	O
overexpressing	O
tumors	O
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrate	O
that	O
overexpression	O
of	O
TIMP	O
-	O
3	O
can	O
inhibit	O
angiogenesis	O
and	O
associated	O
tumor	O
growth	O
,	O
and	O
that	O
the	O
antiangiogenic	O
effects	O
of	O
TIMP	O
-	O
3	O
appear	O
to	O
be	O
mediated	O
through	O
the	O
inhibition	O
of	O
functional	O
capillary	O
morphogenesis	O
.	O

Fibroblast	O
growth	O
factor	O
2	O
promotes	O
microvessel	O
formation	O
from	O
mouse	O
embryonic	O
aorta	O
.	O

To	O
delineate	O
the	O
roles	O
that	O
oxygen	O
and	O
fibroblast	O
growth	O
factors	O
(	O
FGFs	O
)	O
play	O
in	O
the	O
process	O
of	O
angiogenesis	O
from	O
the	O
embryonic	O
aorta	O
,	O
we	O
cultured	O
mouse	O
embryonic	O
aorta	O
explants	O
(	O
thoracic	O
level	O
to	O
lateral	O
vessels	O
supplying	O
the	O
mesonephros	O
and	O
metanephros	O
)	O
in	O
a	O
three	O
-	O
dimensional	O
type	O
I	O
collagen	O
gel	O
matrix	O
.	O

During	O
8	O
days	O
of	O
culture	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
,	O
but	O
not	O
room	O
air	O
,	O
the	O
addition	O
of	O
FGF2	O
to	O
explants	O
stimulated	O
the	O
formation	O
of	O
Gs	O
-	O
IB	O
(	O
4	O
-	O
)	O
positive	O
,	O
CD31	O
-	O
positive	O
,	O
and	O
Flk	O
-	O
1	O
-	O
positive	O
microvessels	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

FGF2	O
-	O
stimulated	O
microvessel	O
formation	O
was	O
inhibited	O
by	O
sequestration	O
of	O
FGF2	O
via	O
addition	O
of	O
soluble	O
FGF	O
receptor	O
(	O
FGFR	O
)	O
chimera	O
protein	O
or	O
anti	O
-	O
FGF2	O
antibodies	O
.	O

FGFR1	O
and	O
FGFR2	O
were	O
present	O
on	O
explants	O
.	O

Levels	O
of	O
FGFR1	O
,	O
but	O
not	O
FGFR2	O
,	O
were	O
increased	O
in	O
embryonic	O
aorta	O
cultured	O
under	O
5	O
%	O
O	O
(	O
2	O
)	O
relative	O
to	O
room	O
air	O
.	O

Our	O
data	O
suggest	O
that	O
low	O
oxygen	O
upregulates	O
FGFR1	O
expression	O
in	O
embryonic	O
aorta	O
in	O
vitro	O
and	O
renders	O
it	O
more	O
responsive	O
to	O
FGF2	O
.	O

Brn	O
-	O
3a	O
,	O
a	O
neuronal	O
transcription	O
factor	O
of	O
the	O
POU	O
gene	O
family	O
:	O
indications	O
for	O
its	O
involvement	O
in	O
cancer	O
and	O
angiogenesis	O
.	O

Brn	O
-	O
3a	O
,	O
a	O
member	O
of	O
the	O
POU	O
gene	O
family	O
(	O
so	O
-	O
called	O
because	O
of	O
the	O
similarity	O
with	O
the	O
group	O
of	O
transcription	O
factors	O
Pit	O
,	O
Oct	O
,	O
and	O
Unc	O
)	O
,	O
was	O
found	O
in	O
neuronal	O
cells	O
engaged	O
in	O
the	O
transcription	O
activity	O
of	O
the	O
p1	O
and	O
p2	O
promoters	O
of	O
the	O
most	O
powerful	O
antiapoptotic	O
gene	O
,	O
namely	O
,	O
Bcl	O
-	O
2	O
.	O

The	O
alternative	O
splicing	O
of	O
Brn	O
-	O
3a	O
mRNA	O
produces	O
two	O
molecular	O
forms	O
:	O
a	O
longer	O
,	O
Bcl	O
-	O
2	O
transactivating	O
form	O
,	O
and	O
a	O
shorter	O
inactive	O
form	O
,	O
lacking	O
84	O
AA	O
in	O
the	O
aminoterminus	O
.	O

In	O
neuronal	O
cells	O
,	O
following	O
Brn	O
-	O
3a	O
gene	O
transfection	O
and	O
superexpression	O
,	O
an	O
increase	O
of	O
30	O
fold	O
of	O
the	O
Bcl	O
-	O
2	O
protein	O
occurs	O
,	O
leading	O
to	O
apoptosis	O
protection	O
.	O

However	O
,	O
recent	O
works	O
demonstrate	O
that	O
Brn	O
-	O
3a	O
expression	O
is	O
not	O
restricted	O
to	O
neuronal	O
cells	O
,	O
as	O
its	O
activity	O
was	O
detected	O
also	O
in	O
cancer	O
cells	O
of	O
non	O
-	O
neuronal	O
nature	O
.	O

Looking	O
for	O
mechanisms	O
linking	O
Brn	O
-	O
3a	O
to	O
carcinogenesis	O
,	O
we	O
discuss	O
the	O
role	O
of	O
this	O
transcription	O
factor	O
in	O
influencing	O
Bcl	O
-	O
2	O
/	O
p53	O
antagonism	O
and	O
Bcl	O
-	O
2	O
/	O
VEGF	O
induction	O
of	O
tumor	O
angiogenesis	O
,	O
concluding	O
this	O
review	O
with	O
a	O
proposal	O
for	O
the	O
oncogenic	O
nature	O
of	O
Brn	O
-	O
3a	O
.	O

Roles	O
of	O
cell	O
adhesion	O
molecules	O
in	O
tumor	O
angiogenesis	O
induced	O
by	O
cotransplantation	O
of	O
cancer	O
and	O
endothelial	O
cells	O
to	O
nude	O
rats	O
.	O

Roles	O
of	O
cell	O
adhesion	O
molecules	O
mediating	O
the	O
interaction	O
of	O
cancer	O
and	O
endothelial	O
cells	O
in	O
tumor	O
angiogenesis	O
were	O
investigated	O
using	O
new	O
in	O
vitro	O
and	O
in	O
vivo	O
model	O
systems	O
with	O
a	O
cultured	O
murine	O
endothelial	O
cell	O
line	O
(	O
F	B
-	I
2	I
)	O
and	O
human	O
cultured	O
epidermoid	O
cancer	O
cells	O
(	O
A431	B
)	O
.	O

The	O
A431	B
cells	O
exhibited	O
typical	O
in	O
vitro	O
cell	O
adhesion	O
to	O
the	O
endothelial	O
F	B
-	I
2	I
cells	O
.	O

The	O
initial	O
step	O
of	O
adhesion	O
was	O
mediated	O
by	O
sialyl	O
Lewis	O
(	O
x	O
)	O
(	O
Le	O
(	O
x	O
)	O
)	O
and	O
sialyl	O
Le	O
(	O
a	O
)	O
,	O
the	O
carbohydrate	O
determinants	O
expressed	O
on	O
the	O
cancer	O
cells	O
,	O
and	O
E	O
-	O
selectin	O
expressed	O
constitutively	O
on	O
F	B
-	I
2	I
cells	O
.	O

Prolonged	O
culture	O
led	O
to	O
the	O
implantation	O
of	O
cancer	O
cells	O
into	O
the	O
monolayer	O
of	O
the	O
F	B
-	I
2	I
cells	O
,	O
which	O
was	O
mediated	O
mainly	O
by	O
alpha	O
(	O
3	O
)	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
.	O

F	B
-	I
2	I
cells	O
cultured	O
on	O
Matrigel	O
showed	O
evident	O
tube	O
formation	O
,	O
and	O
coculture	O
of	O
F	B
-	I
2	I
cells	O
with	O
A431	B
cells	O
led	O
to	O
the	O
formation	O
of	O
A431	B
cell	O
nests	O
constantly	O
surrounded	O
by	O
tube	O
-	O
like	O
networks	O
consisting	O
of	O
F	B
-	I
2	I
cells	O
.	O

This	O
in	O
vitro	O
morphogenesis	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
anti	O
-	O
sialyl	O
Le	O
(	O
x	O
)	O
/	O
Le	O
(	O
a	O
)	O
or	O
anti	O
-	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
antibodies	O
,	O
which	O
led	O
to	O
the	O
formation	O
of	O
cancer	O
cell	O
aggregates	O
that	O
were	O
independent	O
from	O
the	O
F	B
-	I
2	I
cell	O
networks	O
.	O

This	O
in	O
vitro	O
morphological	O
appearance	O
was	O
exactly	O
reproduced	O
in	O
the	O
in	O
vivo	O
tumors	O
,	O
which	O
were	O
formed	O
when	O
the	O
mixture	O
of	O
A431	B
and	O
F	B
-	I
2	I
cells	O
at	O
the	O
ratio	O
of	O
10	O
:	O
1	O
were	O
cotransplanted	O
s	O
.	O
c	O
.	O
into	O
the	O
back	O
of	O
nude	O
rats	O
.	O

The	O
tumors	O
of	O
A431	B
supplemented	O
with	O
F	B
-	I
2	I
cells	O
were	O
profoundly	O
vascularized	O
throughout	O
by	O
the	O
tubular	O
structures	O
formed	O
by	O
F	B
-	I
2	I
cells	O
,	O
the	O
lumen	O
of	O
which	O
contained	O
the	O
host	O
rat	O
blood	O
cells	O
.	O

The	O
tumor	O
mass	O
thus	O
formed	O
was	O
an	O
average	O
5	O
.	O
8	O
-	O
fold	O
as	O
large	O
as	O
control	O
A431	B
tumors	O
that	O
were	O
grown	O
without	O
F	B
-	I
2	I
cells	O
.	O

The	O
co	O
-	O
injection	O
of	O
anti	O
-	O
Le	O
(	O
x	O
)	O
/	O
Le	O
(	O
a	O
)	O
or	O
anti	O
-	O
beta	O
(	O
1	O
)	O
-	O
integrin	O
antibodies	O
produced	O
a	O
marked	O
reduction	O
in	O
the	O
size	O
of	O
A431	B
tumors	O
,	O
which	O
were	O
not	O
vascularized	O
and	O
accompanied	O
an	O
independent	O
tiny	O
remnant	O
clump	O
of	O
F	B
-	I
2	I
cells	O
.	O

The	O
size	O
of	O
these	O
A431	B
tumors	O
did	O
not	O
differ	O
significantly	O
from	O
those	O
of	O
control	O
A431	B
tumors	O
raised	O
without	O
F	B
-	I
2	I
cells	O
.	O

These	O
results	O
indicate	O
that	O
the	O
interaction	O
of	O
tumor	O
cells	O
and	O
endothelial	O
cells	O
in	O
orderly	O
tumor	O
angiomorphogenesis	O
is	O
highly	O
dependent	O
on	O
the	O
action	O
of	O
cell	O
adhesion	O
molecules	O
mediating	O
the	O
adhesion	O
of	O
cancer	O
cells	O
to	O
endothelial	O
cells	O
,	O
inhibition	O
of	O
which	O
remarkably	O
retards	O
tumor	O
growth	O
and	O
angiogenesis	O
.	O

Identification	O
of	O
Dss1	O
as	O
a	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
-	O
responsive	O
gene	O
expressed	O
in	O
keratinocyte	O
progenitor	O
cells	O
,	O
with	O
possible	O
involvement	O
in	O
early	O
skin	O
tumorigenesis	O
.	O

This	O
study	O
identifies	O
genes	O
expressed	O
early	O
in	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
)	O
-	O
induced	O
skin	O
carcinogenesis	O
in	O
genetically	O
initiated	O
Tg	O
.	O
AC	O
v	O
-	O
Ha	O
-	O
ras	O
transgenic	O
mice	O
.	O

Keratinocyte	O
progenitor	O
cells	O
from	O
TPA	O
-	O
treated	O
Tg	O
.	O
AC	O
mice	O
were	O
isolated	O
with	O
fluorescence	O
-	O
activated	O
cell	O
sorting	O
and	O
expression	O
was	O
analyzed	O
using	O
cDNA	O
microarray	O
technology	O
.	O

Eleven	O
genes	O
were	O
identified	O
whose	O
expression	O
changed	O
significantly	O
in	O
response	O
to	O
carcinogen	O
treatment	O
.	O

Deleted	O
in	O
split	O
hand	O
/	O
split	O
foot	O
1	O
(	O
Dss1	O
)	O
is	O
a	O
gene	O
associated	O
with	O
a	O
heterogeneous	O
limb	O
developmental	O
disorder	O
called	O
split	O
hand	O
/	O
split	O
foot	O
malformation	O
.	O

cDNA	O
microarray	O
expression	O
analysis	O
showed	O
that	O
the	O
mouse	O
homologue	O
of	O
Dss1	O
is	O
induced	O
by	O
TPA	O
.	O

Dss1	O
overexpression	O
was	O
detected	O
by	O
Northern	O
blot	O
analysis	O
in	O
early	O
TPA	O
-	O
treated	O
hyperplastic	O
skins	O
and	O
in	O
JB6	O
Cl	O
41	O
-	O
5a	O
epidermal	O
cells	O
.	O

Interestingly	O
,	O
Dss1	O
expression	O
was	O
also	O
shown	O
to	O
be	O
elevated	O
in	O
skin	O
papillomas	O
relative	O
to	O
normal	O
skins	O
,	O
and	O
further	O
increased	O
in	O
squamous	O
cell	O
malignancies	O
.	O

Functional	O
studies	O
by	O
ectopically	O
constitutive	O
expression	O
of	O
Dss1	O
in	O
JB6	O
Cl	O
41	O
-	O
5a	O
preneoplastic	O
cells	O
strongly	O
increased	O
focus	O
formation	O
and	O
proliferation	O
of	O
these	O
cells	O
and	O
enhanced	O
efficiency	O
of	O
neoplastic	O
transformation	O
of	O
the	O
cells	O
in	O
soft	O
agar	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
Dss1	O
is	O
a	O
TPA	O
-	O
inducible	O
gene	O
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
early	O
stages	O
of	O
skin	O
carcinogenesis	O
.	O

Downregulation	O
of	O
c	O
-	O
FLIP	O
sensitizes	O
DU145	B
prostate	O
cancer	O
cells	O
to	O
Fas	O
-	O
mediated	O
apoptosis	O
.	O

Although	O
DU145	B
prostate	O
cancer	O
cells	O
are	O
resistant	O
to	O
exogenously	O
applied	O
Fas	O
agonist	O
CH	O
-	O
11	O
(	O
anti	O
-	O
Fas	O
monoclonal	O
antibody	O
)	O
,	O
Fas	O
-	O
resistance	O
can	O
be	O
overcome	O
using	O
a	O
FasL	O
expressing	O
adenovirus	O
(	O
AdGFPFasL	O
(	O
TET	O
)	O
)	O
[	O
Hyer	O
et	O
al	O
.	O
,	O
Molecular	O
Therapy	O
,	O
2000	O
;	O
2	O
:	O
348	O
-	O
58	O
(	O
ref	O
.	O
12	O
)	O
]	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
try	O
to	O
understand	O
why	O
DU145	B
cells	O
are	O
resistant	O
to	O
CH	O
-	O
11	O
and	O
determine	O
the	O
signaling	O
pathway	O
utilized	O
by	O
AdGFPFasL	O
(	O
TET	O
)	O
to	O
induce	O
apoptosis	O
in	O
these	O
Fas	O
-	O
resistant	O
cells	O
.	O

Using	O
immunoblot	O
analysis	O
,	O
we	O
show	O
that	O
AdGFPFasL	O
(	O
TET	O
)	O
is	O
capable	O
of	O
initiating	O
the	O
classic	O
Fas	O
-	O
mediated	O
apoptotic	O
pathway	O
in	O
DU145	B
cells	O
,	O
which	O
includes	O
activation	O
of	O
caspases	O
-	O
8	O
,	O
-	O
3	O
,	O
-	O
7	O
,	O
and	O
-	O
9	O
,	O
BID	O
cleavage	O
,	O
cytochrome	O
c	O
release	O
from	O
mitochondria	O
,	O
and	O
PARP	O
cleavage	O
.	O

In	O
contrast	O
,	O
CH	O
-	O
11	O
binds	O
to	O
Fas	O
,	O
but	O
is	O
unable	O
to	O
transmit	O
the	O
death	O
signal	O
beyond	O
the	O
plasma	O
membrane	O
suggesting	O
a	O
block	O
at	O
the	O
DISC	O
(	O
death	O
inducing	O
signaling	O
complex	O
)	O
.	O

The	O
anti	O
-	O
apoptotic	O
protein	O
c	O
-	O
FLIP	O
(	O
cellular	O
Flice	O
-	O
like	O
inhibitory	O
protein	O
)	O
,	O
which	O
has	O
been	O
shown	O
to	O
inhibit	O
Fas	O
-	O
mediated	O
apoptosis	O
at	O
the	O
DISC	O
,	O
was	O
down	O
-	O
regulated	O
following	O
AdGFPFasL	O
(	O
TET	O
)	O
treatment	O
prompting	O
us	O
to	O
investigate	O
its	O
role	O
in	O
inhibiting	O
CH	O
-	O
11	O
-	O
induced	O
cell	O
death	O
.	O

Using	O
c	O
-	O
FLIP	O
anti	O
-	O
sense	O
oligonucleotides	O
to	O
down	O
-	O
regulate	O
c	O
-	O
FLIP	O
we	O
sensitized	O
DU145	B
cells	O
to	O
CH	O
-	O
11	O
-	O
induced	O
apoptosis	O
.	O

These	O
data	O
suggest	O
that	O
c	O
-	O
FLIP	O
may	O
play	O
a	O
critical	O
role	O
in	O
regulating	O
Fas	O
-	O
mediated	O
apoptosis	O
in	O
prostate	O
cancer	O
cells	O
and	O
that	O
modulation	O
of	O
c	O
-	O
FLIP	O
may	O
enhance	O
Fas	O
signaling	O
based	O
therapies	O
.	O

Topoisomerase	O
I	O
protein	O
expression	O
in	O
primary	O
colorectal	O
cancer	O
and	O
lymph	O
node	O
metastases	O
.	O

Topoisomerase	O
I	O
(	O
topo	O
I	O
)	O
is	O
an	O
important	O
target	O
for	O
the	O
treatment	O
of	O
malignant	O
disease	O
,	O
especially	O
colorectal	O
cancer	O
.	O

Because	O
there	O
is	O
little	O
information	O
on	O
the	O
expression	O
of	O
topo	O
I	O
in	O
colorectal	O
tumors	O
,	O
this	O
study	O
evaluated	O
and	O
characterized	O
topo	O
I	O
protein	O
expression	O
in	O
primary	O
colorectal	O
cancer	O
and	O
lymph	O
node	O
metastases	O
and	O
studied	O
the	O
association	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
clinicopathologic	O
data	O
,	O
p53	O
status	O
,	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
status	O
.	O

Immunohistochemistry	O
assay	O
was	O
performed	O
for	O
topo	O
I	O
protein	O
expression	O
in	O
249	O
primary	O
human	O
colorectal	O
cancer	O
and	O
42	O
paired	O
lymph	O
node	O
metastasis	O
samples	O
.	O

Topo	O
I	O
expression	O
was	O
described	O
as	O
the	O
percentage	O
of	O
cells	O
staining	O
positive	O
for	O
topo	O
I	O
,	O
along	O
with	O
the	O
intensity	O
and	O
localization	O
of	O
the	O
staining	O
.	O

Clinicopathologic	O
data	O
(	O
sex	O
,	O
age	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
)	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
were	O
statistically	O
analyzed	O
for	O
association	O
with	O
topo	O
I	O
protein	O
expression	O
.	O

Topo	O
I	O
expression	O
in	O
paired	O
primary	O
lymph	O
node	O
metastases	O
were	O
studied	O
for	O
concordance	O
.	O

Topo	O
I	O
protein	O
expression	O
was	O
detected	O
in	O
127	O
(	O
51	O
%	O
)	O
samples	O
,	O
including	O
24	O
.	O
4	O
%	O
with	O
>	O
50	O
%	O
positive	O
tumor	O
cells	O
.	O

The	O
majority	O
had	O
nuclear	O
(	O
70	O
.	O
1	O
%	O
)	O
or	O
nuclear	O
and	O
cytoplasmic	O
staining	O
(	O
17	O
.	O
3	O
%	O
)	O
.	O

A	O
higher	O
percentage	O
of	O
cells	O
expressing	O
topo	O
I	O
in	O
primary	O
colorectal	O
cancer	O
was	O
significantly	O
associated	O
with	O
advanced	O
age	O
(	O
P	O
=	O
.	O
040	O
)	O
.	O

Patients	O
with	O
rectal	O
cancer	O
had	O
greater	O
topo	O
I	O
expression	O
than	O
those	O
with	O
colon	O
tumors	O
(	O
P	O
=	O
.	O
029	O
)	O
.	O

No	O
significant	O
correlation	O
was	O
found	O
between	O
topo	O
I	O
protein	O
expression	O
and	O
sex	O
,	O
Dukes	O
'	O
stage	O
,	O
differentiation	O
grade	O
,	O
survival	O
status	O
,	O
p53	O
status	O
,	O
and	O
PCNA	O
status	O
.	O

Concordance	O
in	O
topo	O
I	O
staining	O
between	O
primary	O
and	O
lymph	O
node	O
metastases	O
was	O
observed	O
in	O
33	O
of	O
42	O
cases	O
(	O
P	O
=	O
.	O
029	O
)	O
.	O

This	O
suggests	O
that	O
the	O
activity	O
of	O
topo	O
I	O
inhibitors	O
will	O
not	O
differ	O
across	O
various	O
tumor	O
stages	O
,	O
pathology	O
,	O
and	O
patient	O
gender	O
.	O

p53	O
and	O
PCNA	O
status	O
do	O
not	O
appear	O
to	O
influence	O
topo	O
I	O
expression	O
,	O
and	O
topo	O
I	O
has	O
no	O
apparent	O
association	O
with	O
the	O
acquisition	O
of	O
a	O
metastatic	O
phenotype	O
.	O

Topo	O
I	O
expression	O
now	O
needs	O
to	O
be	O
evaluated	O
in	O
patients	O
undergoing	O
topo	O
I	O
-	O
inhibitor	O
therapy	O
,	O
to	O
better	O
define	O
the	O
role	O
of	O
this	O
protein	O
as	O
a	O
predictive	O
marker	O
.	O

Adaptor	O
protein	O
Crk	O
is	O
required	O
for	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	O
ruffling	O
and	O
focal	O
complex	O
assembly	O
of	O
human	O
aortic	O
endothelial	O
cells	O
.	O

Endothelial	O
cell	O
migration	O
is	O
an	O
essential	O
step	O
in	O
vasculogenesis	O
and	O
angiogenesis	O
,	O
in	O
which	O
receptor	O
tyrosine	O
kinases	O
play	O
a	O
pivotal	O
role	O
.	O

We	O
investigated	O
the	O
mechanism	O
by	O
which	O
ephrin	O
-	O
B1	O
promotes	O
membrane	O
ruffling	O
in	O
human	O
aortic	O
endothelial	O
cells	O
,	O
because	O
membrane	O
ruffling	O
heralds	O
cell	O
body	O
migration	O
.	O

We	O
especially	O
focused	O
on	O
the	O
role	O
of	O
Crk	O
adaptor	O
protein	O
in	O
EphB	O
-	O
mediated	O
signaling	O
.	O

Using	O
DsRed	O
-	O
tagged	O
Crk	O
and	O
a	O
fluorescent	O
time	O
-	O
lapse	O
microscope	O
,	O
we	O
showed	O
that	O
Crk	O
was	O
recruited	O
to	O
the	O
nascent	O
focal	O
complex	O
after	O
ephrin	O
-	O
B1	O
stimulation	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
p130	O
(	O
Cas	O
)	O
,	O
but	O
not	O
paxillin	O
,	O
recruited	O
Crk	O
to	O
the	O
nascent	O
focal	O
complex	O
.	O

The	O
necessity	O
of	O
Crk	O
in	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	O
ruffling	O
was	O
shown	O
both	O
by	O
the	O
overexpression	O
of	O
dominant	O
negative	O
Crk	O
mutants	O
and	O
by	O
the	O
depletion	O
of	O
Crk	O
by	O
using	O
RNA	O
interference	O
.	O

Then	O
,	O
we	O
examined	O
the	O
role	O
of	O
two	O
major	O
downstream	O
molecules	O
of	O
Crk	O
,	O
Rac1	O
and	O
Rap1	O
.	O

The	O
dominant	O
negative	O
mutant	O
of	O
Rac1	O
completely	O
inhibited	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	O
ruffling	O
and	O
focal	O
complex	O
assembly	O
.	O

In	O
contrast	O
,	O
rap1GAPII	O
,	O
a	O
negative	O
regulator	O
of	O
Rap1	O
,	O
did	O
not	O
inhibit	O
ephrin	O
-	O
B1	O
-	O
induced	O
membrane	O
ruffling	O
.	O

However	O
,	O
in	O
rap1GAPII	O
-	O
expressing	O
cells	O
,	O
ephrin	O
-	O
B1	O
did	O
not	O
induce	O
membrane	O
spreading	O
,	O
probably	O
due	O
to	O
instability	O
of	O
the	O
focal	O
complex	O
.	O

These	O
results	O
indicated	O
that	O
Crk	O
plays	O
a	O
critical	O
role	O
in	O
Rac1	O
-	O
induced	O
membrane	O
ruffling	O
and	O
Rap1	O
-	O
mediated	O
nascent	O
focal	O
complex	O
stabilization	O
contributing	O
to	O
ephrin	O
-	O
B1	O
-	O
induced	O
human	O
aortic	O
endothelial	O
cells	O
migration	O
.	O

CXC	O
chemokine	O
receptors	O
in	O
the	O
central	O
nervous	O
system	O
:	O
Role	O
in	O
cerebellar	O
neuromodulation	O
and	O
development	O
.	O

Chemokines	O
and	O
their	O
receptors	O
are	O
constitutively	O
present	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
expressed	O
in	O
neurons	O
and	O
glial	O
cells	O
.	O

Much	O
evidence	O
suggests	O
that	O
,	O
beyond	O
their	O
involvement	O
in	O
neuroinflammation	O
,	O
these	O
proteins	O
play	O
a	O
role	O
in	O
neurodevelopment	O
and	O
neurophysiological	O
signaling	O
.	O

The	O
goal	O
of	O
this	O
review	O
is	O
to	O
summarize	O
recent	O
information	O
concerning	O
expression	O
,	O
signaling	O
,	O
and	O
function	O
of	O
CXC	O
chemokine	O
receptor	O
in	O
the	O
CNS	O
,	O
with	O
the	O
main	O
focus	O
on	O
the	O
developmental	O
and	O
neuromodulatory	O
actions	O
of	O
chemokines	O
in	O
the	O
cerebellum	O
.	O

Combined	O
tracheal	O
and	O
esophageal	O
stenting	O
for	O
palliation	O
of	O
tracheoesophageal	O
symptoms	O
from	O
mediastinal	O
lymphoma	O
.	O

Mediastinal	O
lymphoma	O
as	O
a	O
cause	O
of	O
tracheobronchial	O
obstruction	O
is	O
uncommon	O
,	O
and	O
a	O
malignant	O
tracheoesophageal	O
fistula	O
in	O
the	O
setting	O
of	O
mediastinal	O
lymphoma	O
is	O
rare	O
.	O

Malignant	O
tracheoesophageal	O
fistulas	O
are	O
associated	O
with	O
pronounced	O
morbidity	O
and	O
mortality	O
.	O

We	O
describe	O
a	O
patient	O
with	O
mediastinal	O
lymphomatous	O
infiltration	O
resulting	O
in	O
tracheal	O
obstruction	O
,	O
esophageal	O
obstruction	O
,	O
and	O
tracheoesophageal	O
fistula	O
that	O
were	O
successfully	O
palliated	O
with	O
combined	O
airway	O
and	O
esophageal	O
stent	O
placement	O
.	O

Regulation	O
of	O
transforming	O
growth	O
factor	O
-	O
beta	O
signaling	O
and	O
vascular	O
diseases	O
.	O

PURPOSE	O
:	O
Members	O
of	O
the	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
beta	O
superfamily	O
play	O
critical	O
roles	O
in	O
regulation	O
of	O
various	O
cellular	O
functions	O
.	O

Dysregulation	O
of	O
the	O
signaling	O
mechanisms	O
of	O
the	O
TGF	O
-	O
beta	O
superfamily	O
proteins	O
is	O
associated	O
with	O
clinical	O
diseases	O
such	O
as	O
cancer	O
,	O
fibrotic	O
diseases	O
,	O
and	O
vascular	O
disorders	O
.	O

Therefore	O
,	O
understanding	O
these	O
signaling	O
mechanisms	O
may	O
provide	O
us	O
with	O
novel	O
ways	O
to	O
develop	O
strategies	O
for	O
treating	O
clinical	O
diseases	O
induced	O
by	O
these	O
cytokines	O
.	O

METHODS	O
:	O
This	O
review	O
discusses	O
our	O
current	O
understanding	O
of	O
the	O
mechanisms	O
of	O
TGF	O
-	O
beta	O
signaling	O
,	O
focusing	O
on	O
the	O
roles	O
of	O
TGF	O
-	O
beta	O
in	O
regulation	O
of	O
vascular	O
wall	O
cells	O
and	O
on	O
the	O
regulation	O
of	O
TGF	O
-	O
beta	O
superfamily	O
signals	O
by	O
inhibitory	O
Smads	O
.	O

[	O
Expression	O
and	O
mutation	O
of	O
c	O
-	O
kit	O
gene	O
in	O
gastrointestinal	O
stromal	O
tumor	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effect	O
of	O
the	O
expression	O
and	O
mutation	O
of	O
c	O
-	O
kit	O
gene	O
and	O
its	O
relationship	O
with	O
clinical	O
pathology	O
and	O
prognosis	O
of	O
gastrointestinal	O
stromal	O
tumor	O
(	O
GIST	O
)	O
.	O

METHODS	O
:	O
Immunohistochemical	O
and	O
PCR	O
-	O
SSCP	O
techniques	O
were	O
used	O
to	O
detect	O
c	O
-	O
kit	O
protein	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
exon	O
11	O
mutation	O
in	O
82	O
patients	O
with	O
GIST	O
.	O

RESULTS	O
:	O
The	O
positive	O
c	O
-	O
kit	O
protein	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
mutation	O
rates	O
were	O
97	O
.	O
6	O
%	O
(	O
80	O
/	O
82	O
)	O
and	O
41	O
.	O
5	O
%	O
(	O
34	O
/	O
82	O
)	O
.	O

Correlating	O
the	O
results	O
of	O
these	O
two	O
methods	O
and	O
clinicopathological	O
factors	O
,	O
the	O
c	O
-	O
kit	O
expression	O
and	O
c	O
-	O
kit	O
gene	O
mutation	O
rates	O
were	O
95	O
.	O
0	O
%	O
(	O
19	O
/	O
20	O
)	O
and	O
0	O
in	O
benign	O
GIST	O
,	O
and	O
were	O
98	O
.	O
4	O
%	O
(	O
61	O
/	O
62	O
)	O
,	O
54	O
.	O
8	O
%	O
(	O
34	O
/	O
62	O
)	O
in	O
malignant	O
GIST	O
.	O

Mutation	O
positive	O
GIST	O
showed	O
higher	O
frequency	O
of	O
adjacent	O
tissue	O
invasion	O
,	O
metastasis	O
and	O
recurrence	O
as	O
compared	O
with	O
mutation	O
negative	O
ones	O
.	O

CONCLUSION	O
:	O
c	O
-	O
kit	O
protein	O
is	O
an	O
important	O
diagnostic	O
marker	O
of	O
gastrointestinal	O
stromal	O
tumor	O
.	O

c	O
-	O
kit	O
gene	O
mutation	O
may	O
play	O
a	O
significant	O
role	O
in	O
the	O
pathogenesis	O
of	O
GIST	O
and	O
also	O
may	O
be	O
a	O
prognostic	O
marker	O
.	O

Insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
receptor	O
-	O
mediated	O
vasculogenesis	O
/	O
angiogenesis	O
in	O
human	O
lung	O
development	O
.	O

The	O
structural	O
and	O
functional	O
development	O
of	O
the	O
pulmonary	O
system	O
is	O
dependent	O
upon	O
appropriate	O
early	O
vascularization	O
of	O
the	O
embryonic	O
lung	O
.	O

Our	O
previous	O
in	O
vitro	O
studies	O
in	O
a	O
rat	O
model	O
indicated	O
that	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
I	O
(	O
IGF	O
-	O
I	O
)	O
is	O
a	O
potent	O
angiogenic	O
agent	O
for	O
fetal	O
lung	O
endothelial	O
cells	O
.	O

To	O
assess	O
its	O
role	O
on	O
human	O
vascular	O
lung	O
development	O
,	O
we	O
first	O
examined	O
the	O
expression	O
of	O
IGF	O
-	O
I	O
/	O
II	O
and	O
IGF	O
receptor	O
type	O
I	O
(	O
IGF	O
-	O
IR	O
)	O
in	O
human	O
embryonic	O
and	O
fetal	O
lung	O
tissues	O
at	O
4	O
-	O
12	O
wk	O
of	O
gestation	O
.	O

Immunohistochemical	O
and	O
in	O
situ	O
hybridization	O
studies	O
revealed	O
the	O
presence	O
of	O
IGF	O
-	O
I	O
/	O
II	O
-	O
IGF	O
-	O
IR	O
ligands	O
and	O
mRNA	O
transcripts	O
in	O
embryonic	O
lungs	O
as	O
early	O
as	O
4	O
wk	O
gestation	O
.	O

Immunotargeting	O
using	O
an	O
anti	O
-	O
IGF	O
-	O
IR	O
neutralizing	O
antibody	O
on	O
human	O
fetal	O
lung	O
explants	O
demonstrated	O
a	O
significant	O
blockade	O
of	O
IGF	O
-	O
IR	O
signaling	O
.	O

Inactivation	O
of	O
IGF	O
-	O
IR	O
resulted	O
in	O
a	O
loss	O
of	O
endothelial	O
cells	O
,	O
accompanied	O
by	O
dramatic	O
changes	O
in	O
fetal	O
lung	O
explant	O
morphology	O
.	O

Terminal	O
transferase	O
dUTP	O
end	O
-	O
labeling	O
assay	O
and	O
TEM	O
studies	O
of	O
anti	O
-	O
IGF	O
-	O
IR	O
-	O
treated	O
lungs	O
demonstrated	O
numerous	O
apoptotic	O
mesenchymal	O
cells	O
.	O

Rat	O
embryonic	O
lung	O
explant	O
studies	O
further	O
validated	O
the	O
importance	O
of	O
the	O
IGF	O
-	O
IGF	O
-	O
IR	O
system	O
for	O
lung	O
vascular	O
development	O
.	O

These	O
data	O
provide	O
the	O
first	O
demonstration	O
of	O
IGF	O
-	O
I	O
/	O
II	O
expression	O
in	O
the	O
human	O
lung	O
in	O
early	O
gestation	O
and	O
indicate	O
that	O
the	O
IGF	O
family	O
of	O
growth	O
factors	O
,	O
acting	O
through	O
the	O
IGF	O
-	O
IR	O
,	O
is	O
required	O
as	O
a	O
survival	O
factor	O
during	O
normal	O
human	O
lung	O
vascularization	O
.	O

Inhibition	O
of	O
glucose	O
metabolism	O
sensitizes	O
tumor	O
cells	O
to	O
death	O
receptor	O
-	O
triggered	O
apoptosis	O
through	O
enhancement	O
of	O
death	O
-	O
inducing	O
signaling	O
complex	O
formation	O
and	O
apical	O
procaspase	O
-	O
8	O
processing	O
.	O

Tumors	O
display	O
a	O
high	O
rate	O
of	O
glucose	O
uptake	O
and	O
glycolysis	O
.	O

We	O
investigated	O
how	O
inhibition	O
of	O
glucose	O
metabolism	O
could	O
affect	O
death	O
receptor	O
-	O
mediated	O
apoptosis	O
in	O
human	O
tumor	O
cells	O
of	O
diverse	O
origin	O
.	O

We	O
show	O
that	O
both	O
substitution	O
of	O
glucose	O
for	O
pyruvate	O
and	O
treatment	O
with	O
2	O
-	O
deoxyglucose	O
enhanced	O
apoptosis	O
induced	O
by	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-	O
alpha	O
,	O
CD95	O
agonistic	O
antibody	O
,	O
and	O
TNF	O
-	O
related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
.	O

Inhibition	O
of	O
glucose	O
metabolism	O
enhanced	O
killing	O
of	O
myeloid	O
leukemia	O
U937	B
,	O
cervical	O
carcinoma	O
HeLa	B
,	O
and	O
breast	O
carcinoma	O
MCF	B
-	I
7	I
cells	O
upon	O
death	O
receptor	O
ligation	O
.	O

Caspase	O
activation	O
,	O
mitochondrial	O
depolarization	O
,	O
and	O
cytochrome	O
c	O
release	O
were	O
increased	O
under	O
these	O
conditions	O
.	O

Glucose	O
deprivation	O
-	O
mediated	O
sensitization	O
to	O
apoptosis	O
was	O
prevented	O
in	O
MCF	B
-	I
7	I
cells	O
overexpressing	O
BCL	O
-	O
2	O
.	O

Interestingly	O
,	O
the	O
human	O
B	O
-	O
lymphoblastoid	O
cell	O
line	B
SKW6	I
.	I
4	I
,	O
a	O
prototype	O
for	O
mitochondria	O
-	O
independent	O
death	O
receptor	O
-	O
induced	O
apoptosis	O
,	O
was	O
also	O
sensitized	O
to	O
anti	O
-	O
CD95	O
and	O
TRAIL	O
-	O
induced	O
apoptosis	O
under	O
glucose	O
-	O
free	O
conditions	O
.	O

Changes	O
in	O
c	O
-	O
FLIP	O
(	O
L	O
)	O
and	O
cFLIPs	O
levels	O
were	O
observed	O
in	O
some	O
but	O
not	O
all	O
the	O
cell	O
lines	O
studied	O
following	O
glucose	O
deprivation	O
.	O

Glucose	O
deprivation	O
enhanced	O
death	O
receptor	O
-	O
triggered	O
formation	O
of	O
death	O
-	O
inducing	O
signaling	O
complex	O
and	O
early	O
processing	O
of	O
procaspase	O
-	O
8	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
the	O
glycolytic	O
pathway	O
may	O
be	O
an	O
important	O
target	O
for	O
therapeutic	O
intervention	O
to	O
sensitize	O
tumor	O
cells	O
to	O
selectively	O
toxic	O
soluble	O
death	O
ligands	O
or	O
death	O
ligand	O
-	O
expressing	O
cells	O
of	O
the	O
immune	O
system	O
by	O
facilitating	O
the	O
activation	O
of	O
initiator	O
caspase	O
-	O
8	O
.	O

Enhanced	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
by	O
periodontal	O
pathogens	O
in	O
gingival	O
fibroblasts	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
has	O
recently	O
attracted	O
attention	O
as	O
a	O
potent	O
inducer	O
of	O
vascular	O
permeability	O
and	O
angiogenesis	O
.	O

Aberrant	O
angiogenesis	O
is	O
often	O
associated	O
with	O
lesion	O
formation	O
in	O
chronic	O
periodontitis	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
properties	O
of	O
VEGF	O
expression	O
in	O
human	O
gingival	O
fibroblasts	O
(	O
HGF	O
)	O
culture	O
.	O

HGF	O
were	O
stimulated	O
with	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
vesicle	O
(	O
Ve	O
)	O
and	O
outer	O
membrane	O
protein	O
(	O
OMP	O
)	O
from	O
Actinobacillus	O
actinomycetemcomitans	O
and	O
Porphyromonas	O
gingivalis	O
.	O

HGF	O
constitutively	O
produced	O
VEGF	O
and	O
levels	O
were	O
significantly	O
enhanced	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
by	O
stimulation	O
with	O
Ve	O
and	O
OMP	O
from	O
A	O
.	O
actinomycetemcomitans	O
and	O
P	O
.	O
gingivalis	O
at	O
concentrations	O
of	O
10	O
microg	O
/	O
ml	O
or	O
higher	O
.	O

On	O
the	O
other	O
hand	O
,	O
VEGF	O
levels	O
were	O
not	O
increased	O
by	O
LPS	O
stimulation	O
.	O

VEGF	O
mRNA	O
expression	O
was	O
also	O
observed	O
in	O
Ve	O
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	O
.	O

A	O
vascular	O
permeability	O
enhancement	O
(	O
VPE	O
)	O
assay	O
was	O
performed	O
using	O
guinea	O
pigs	O
to	O
ascertain	O
whether	O
supernatant	O
from	O
cultures	O
of	O
Ve	O
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	O
enhance	O
vascular	O
permeability	O
in	O
vivo	O
.	O

Supernatant	O
from	O
cultures	O
of	O
Ve	O
-	O
and	O
OMP	O
-	O
stimulated	O
HGF	O
strongly	O
induced	O
VPE	O
.	O

This	O
was	O
markedly	O
suppressed	O
upon	O
simultaneous	O
injection	O
of	O
anti	O
-	O
VEGF	O
polyclonal	O
antibodies	O
with	O
the	O
supernatant	O
.	O

Heating	O
and	O
protease	O
treatment	O
of	O
the	O
stimulants	O
reduced	O
the	O
VEGF	O
enhancing	O
levels	O
in	O
Ve	O
and	O
OMP	O
in	O
vitro	O
.	O

These	O
results	O
suggest	O
that	O
Ve	O
and	O
OMP	O
may	O
be	O
crucial	O
heat	O
-	O
labile	O
and	O
protease	O
-	O
sensitive	O
components	O
of	O
periodontal	O
pathogens	O
that	O
enhance	O
VEGF	O
expression	O
.	O

In	O
addition	O
,	O
VEGF	O
might	O
be	O
associated	O
with	O
the	O
etiology	O
of	O
periodontitis	O
in	O
its	O
early	O
stages	O
according	O
to	O
neovascularization	O
stimulated	O
by	O
periodontal	O
pathogens	O
causing	O
swelling	O
and	O
edema	O
.	O

Postoperative	O
progression	O
of	O
pulmonary	O
metastasis	O
in	O
osteosarcoma	O
.	O

Early	O
relapse	O
with	O
distant	O
metastasis	O
often	O
is	O
observed	O
in	O
patients	O
with	O
cancer	O
after	O
resection	O
of	O
the	O
primary	O
tumor	O
.	O

It	O
is	O
considered	O
that	O
resection	O
of	O
the	O
primary	O
tumor	O
induces	O
activation	O
of	O
systemic	O
angiogenesis	O
and	O
enhances	O
progression	O
of	O
remote	O
metastasis	O
.	O

The	O
authors	O
show	O
that	O
resection	O
of	O
the	O
primary	O
osteosarcoma	O
tumor	O
enhances	O
progression	O
of	O
pulmonary	O
metastasis	O
in	O
animal	O
osteosarcoma	O
models	O
.	O

Matrigel	O
plug	O
neovascularization	O
assay	O
revealed	O
that	O
systemic	O
angiogenic	O
activity	O
was	O
elevated	O
after	O
primary	O
tumor	O
removal	O
(	O
tumor	O
intact	O
group	O
,	O
1	O
.	O
61	O
+	O
/	O
-	O
0	O
.	O
21	O
g	O
/	O
dL	O
;	O
tumor	O
removed	O
group	O
,	O
4	O
.	O
92	O
+	O
/	O
-	O
0	O
.	O
35	O
g	O
/	O
dL	O
)	O
.	O

In	O
addition	O
,	O
serum	O
concentration	O
of	O
the	O
angiogenesis	O
inhibitor	O
,	O
endostatin	O
,	O
decreased	O
significantly	O
after	O
primary	O
tumor	O
removal	O
.	O

Treatment	O
with	O
the	O
antiangiogenic	O
reagent	O
TNP	O
-	O
470	O
suppressed	O
postoperative	O
progression	O
of	O
pulmonary	O
metastasis	O
.	O

These	O
results	O
indicate	O
the	O
possibility	O
that	O
activation	O
of	O
angiogenic	O
activity	O
after	O
resection	O
of	O
osteosarcoma	O
tumors	O
enhances	O
progression	O
of	O
pulmonary	O
metastasis	O
.	O

The	O
current	O
data	O
also	O
suggest	O
that	O
administration	O
of	O
antiangiogenic	O
reagents	O
can	O
prevent	O
progression	O
of	O
pulmonary	O
metastasis	O
in	O
osteosarcoma	O
postoperatively	O
.	O

Rural	O
/	O
urban	O
differences	O
in	O
access	O
to	O
and	O
utilization	O
of	O
services	O
among	O
people	O
in	O
Alabama	O
with	O
sickle	O
cell	O
disease	O
.	O

OBJECTIVE	O
:	O

This	O
study	O
examined	O
relationships	O
between	O
socioeconomic	O
factors	O
and	O
the	O
geographic	O
distribution	O
of	O
662	O
cases	O
of	O
sickle	O
cell	O
disease	O
in	O
Alabama	O
in	O
1999	O
-	O
2001	O
.	O

METHODS	O
:	O

Measures	O
of	O
community	O
distress	O
,	O
physical	O
functioning	O
,	O
and	O
medical	O
problems	O
were	O
used	O
in	O
analyzing	O
utilization	O
differences	O
between	O
individuals	O
with	O
sickle	O
cell	O
disease	O
living	O
in	O
urban	O
and	O
rural	O
areas	O
.	O

RESULTS	O
:	O

Utilization	O
of	O
comprehensive	O
sickle	O
cells	O
disease	O
services	O
was	O
lower	O
for	O
individuals	O
with	O
sickle	O
cell	O
disease	O
living	O
in	O
rural	O
areas	O
than	O
for	O
those	O
living	O
in	O
urban	O
areas	O
.	O

Rural	O
clients	O
reported	O
significantly	O
more	O
limitations	O
than	O
urban	O
clients	O
on	O
several	O
measures	O
of	O
physical	O
functioning	O
.	O

The	O
results	O
also	O
suggest	O
that	O
utilization	O
of	O
services	O
was	O
higher	O
for	O
those	O
with	O
more	O
medical	O
problems	O
and	O
those	O
who	O
lived	O
in	O
high	O
distress	O
areas	O
,	O
although	O
these	O
findings	O
did	O
not	O
meet	O
the	O
criterion	O
for	O
statistical	O
significance	O
.	O

CONCLUSIONS	O
:	O

Conclusions	O
based	O
on	O
statistical	O
evidence	O
that	O
geographic	O
location	O
and	O
socioeconomic	O
factors	O
relate	O
to	O
significantly	O
different	O
health	O
care	O
service	O
experience	O
bear	O
important	O
implications	O
for	O
medical	O
and	O
health	O
care	O
support	O
systems	O
,	O
especially	O
on	O
the	O
community	O
level	O
.	O

Arteriogenesis	O
:	O
the	O
development	O
and	O
growth	O
of	O
collateral	O
arteries	O
.	O

In	O
patients	O
with	O
atherosclerotic	O
vascular	O
diseases	O
,	O
collateral	O
vessels	O
bypassing	O
major	O
arterial	O
obstructions	O
have	O
frequently	O
been	O
observed	O
.	O

This	O
may	O
explain	O
why	O
some	O
patients	O
remain	O
without	O
symptoms	O
or	O
signs	O
of	O
ischemia	O
.	O

The	O
term	O
""""	O
arteriogenesis	O
""""	O
was	O
introduced	O
to	O
differentiate	O
the	O
formation	O
of	O
collateral	O
arteries	O
from	O
angiogenesis	O
,	O
which	O
mainly	O
occurs	O
in	O
the	O
ischemic	O
,	O
collateral	O
flow	O
-	O
dependent	O
tissue	O
.	O

Many	O
observations	O
in	O
various	O
animal	O
models	O
and	O
humans	O
support	O
that	O
the	O
remodeling	O
of	O
preexisting	O
collateral	O
vessels	O
is	O
the	O
mechanism	O
of	O
collateral	O
artery	O
formation	O
.	O

This	O
remodeling	O
process	O
seems	O
to	O
be	O
mainly	O
flow	O
-	O
mediated	O
.	O

It	O
involves	O
endothelial	O
cell	O
activation	O
,	O
basal	O
membrane	O
degradation	O
,	O
leukocyte	O
invasion	O
,	O
proliferation	O
of	O
vascular	O
cells	O
,	O
neointima	O
formation	O
(	O
in	O
most	O
species	O
studied	O
)	O
,	O
and	O
changes	O
of	O
the	O
extracellular	O
matrix	O
.	O

The	O
contribution	O
of	O
ischemia	O
to	O
arteriogenesis	O
is	O
still	O
unclear	O
,	O
but	O
arteriogenesis	O
clearly	O
can	O
occur	O
in	O
the	O
absence	O
of	O
any	O
significant	O
ischemia	O
.	O

It	O
is	O
questionable	O
,	O
whether	O
collateral	O
arteries	O
also	O
form	O
de	O
novo	O
in	O
ischemic	O
vascular	O
diseases	O
.	O

A	O
better	O
understanding	O
of	O
the	O
mechanisms	O
of	O
arteriogenesis	O
will	O
be	O
important	O
for	O
the	O
design	O
of	O
more	O
effective	O
strategies	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
ischemic	O
vascular	O
diseases	O
.	O

NF	O
-	O
kappaB	O
/	O
Rel	O
transcriptional	O
pathway	O
:	O
implications	O
in	O
pancreatic	O
cancer	O
.	O

Despite	O
considerable	O
efforts	O
in	O
understanding	O
the	O
cellular	O
mechanisms	O
contributing	O
to	O
pancreatic	O
cancer	O
,	O
the	O
prognosis	O
of	O
this	O
malignant	O
disease	O
is	O
still	O
extremely	O
poor	O
.	O

Although	O
pancreatic	O
cancer	O
is	O
the	O
fifth	O
common	O
cause	O
of	O
cancer	O
death	O
in	O
Western	O
countries	O
,	O
current	O
options	O
in	O
treatment	O
enable	O
a	O
5	O
-	O
yr	O
survival	O
rate	O
for	O
all	O
stages	O
of	O
less	O
than	O
5	O
%	O
.	O

In	O
the	O
face	O
fo	O
the	O
fatal	O
outcome	O
,	O
new	O
approaches	O
to	O
the	O
therapy	O
have	O
been	O
established	O
.	O

Based	O
on	O
its	O
role	O
in	O
malignant	O
transformation	O
,	O
apoptosis	O
,	O
and	O
cell	O
proliferation	O
,	O
the	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
/	O
Rel	O
has	O
gained	O
the	O
attention	O
of	O
many	O
laboratories	O
.	O

This	O
review	O
provides	O
basic	O
information	O
for	O
the	O
understanding	O
of	O
the	O
biology	O
of	O
NF	O
-	O
kappaB	O
and	O
aims	O
at	O
presenting	O
experimental	O
data	O
illustrating	O
the	O
involvement	O
of	O
NF	O
-	O
kappaB	O
/	O
Rel	O
in	O
pancreatic	O
cancer	O
.	O

Sickle	O
cell	O
disease	O
:	O
continuous	O
arterial	O
spin	O
-	O
labeling	O
perfusion	O
MR	O
imaging	O
in	O
children	O
.	O

Cerebral	O
blood	O
flow	O
(	O
CBF	O
)	O
was	O
measured	O
with	O
continuous	O
arterial	O
spin	O
-	O
labeling	O
perfusion	O
magnetic	O
resonance	O
(	O
MR	O
)	O
imaging	O
in	O
14	O
children	O
with	O
sickle	O
cell	O
disease	O
and	O
seven	O
control	O
subjects	O
.	O

Mean	O
CBF	O
values	O
were	O
higher	O
in	O
patients	O
(	O
P	O
<	O
.	O
005	O
)	O
than	O
in	O
control	O
subjects	O
in	O
all	O
cerebral	O
artery	O
territories	O
.	O

Three	O
patients	O
had	O
decreased	O
CBF	O
in	O
right	O
anterior	O
and	O
middle	O
cerebral	O
artery	O
territories	O
compared	O
with	O
CBF	O
on	O
the	O
left	O
,	O
and	O
one	O
patient	O
had	O
a	O
profound	O
decrease	O
in	O
CBF	O
in	O
all	O
three	O
territories	O
in	O
the	O
right	O
hemisphere	O
.	O

Baseline	O
CBF	O
was	O
significantly	O
decreased	O
in	O
territories	O
seen	O
as	O
unaffected	O
on	O
conventional	O
MR	O
images	O
and	O
MR	O
angiograms	O
in	O
four	O
children	O
with	O
sickle	O
cell	O
disease	O
.	O

Bee	O
venom	O
induces	O
apoptosis	O
and	O
inhibits	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
mRNA	O
in	O
human	O
lung	O
cancer	O
cell	O
line	O
NCI	B
-	I
H1299	I
.	O

To	O
investigate	O
whether	O
bee	O
venom	O
(	O
BV	O
)	O
induces	O
apoptosis	O
,	O
the	O
3	O
-	O
(	O
4	O
,	O
5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2	O
,	O
5	O
-	O
diphenyltetrazolium	O
bromide	O
assay	O
,	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
-	O
labeling	O
assay	O
,	O
4	O
,	O
6	O
-	O
diamidino	O
-	O
2	O
-	O
phenylindole	O
staining	O
,	O
flow	O
cytometric	O
analysis	O
,	O
and	O
DNA	O
fragmentation	O
assay	O
were	O
performed	O
on	O
NCI	B
-	I
H1299	I
lung	O
cancer	O
cells	O
treated	O
with	O
BV	O
.	O

Through	O
morphological	O
and	O
biochemical	O
analyses	O
,	O
it	O
was	O
demonstrated	O
that	O
NCI	B
-	I
H1299	I
cells	O
treated	O
with	O
BV	O
exhibit	O
several	O
features	O
of	O
apoptosis	O
.	O

In	O
addition	O
,	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
and	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
immunoassay	O
were	O
performed	O
to	O
verify	O
whether	O
BV	O
possesses	O
an	O
inhibitory	O
effect	O
on	O
the	O
expression	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
and	O
PGE	O
(	O
2	O
)	O
synthesis	O
.	O

Expression	O
of	O
COX	O
-	O
2	O
mRNA	O
and	O
synthesis	O
of	O
PGE	O
(	O
2	O
)	O
were	O
inhibited	O
by	O
BV	O
.	O

These	O
results	O
suggest	O
the	O
possibility	O
that	O
BV	O
may	O
exert	O
an	O
anti	O
-	O
tumor	O
effect	O
on	O
human	O
lung	O
cancer	O
.	O

Prenatal	O
aspects	O
of	O
ascorbic	O
acid	O
metabolism	O
in	O
the	O
albino	O
rat	O
.	O

Transfer	O
of	O
ascorbic	O
acid	O
and	O
/	O
or	O
its	O
derivatives	O
from	O
maternal	O
blood	O
into	O
the	O
fetus	O
was	O
studied	O
during	O
the	O
last	O
week	O
of	O
gestation	O
in	O
the	O
rat	O
.	O

Rats	O
were	O
injected	O
intravenously	O
with	O
[	O
1	O
-	O
14C	O
]	O
-	O
ascorbic	O
acid	O
and	O
the	O
rate	O
of	O
transfer	O
estimated	O
by	O
the	O
concentration	O
and	O
content	O
of	O
label	O
present	O
in	O
placentas	O
and	O
fetuses	O
.	O

At	O
all	O
times	O
studied	O
the	O
concentration	O
of	O
label	O
in	O
the	O
placenta	O
was	O
greater	O
than	O
in	O
the	O
fetus	O
.	O

The	O
highest	O
capacity	O
of	O
the	O
placenta	O
to	O
concentrate	O
label	O
was	O
found	O
on	O
day	O
15	O
decreasing	O
to	O
a	O
low	O
at	O
day	O
19	O
and	O
again	O
increasing	O
up	O
to	O
day	O
21	O
.	O

While	O
in	O
the	O
fetuses	O
,	O
the	O
concentration	O
of	O
label	O
per	O
gram	O
of	O
tissue	O
remained	O
remarkably	O
constant	O
throughout	O
the	O
study	O
.	O

The	O
quantity	O
of	O
labeled	O
compounds	O
transferred	O
into	O
the	O
fetus	O
per	O
gram	O
of	O
placental	O
tissue	O
increased	O
between	O
day	O
15	O
and	O
day	O
21	O
of	O
gestation	O
.	O

Possible	O
role	O
of	O
cyclooxygenase	O
II	O
in	O
the	O
acquisition	O
of	O
ovarian	O
luteal	O
function	O
in	O
rodents	O
.	O

The	O
development	O
of	O
the	O
corpus	O
luteum	O
(	O
CL	O
)	O
,	O
which	O
involves	O
angiogenesis	O
,	O
is	O
essential	O
for	O
the	O
establishment	O
of	O
early	O
pregnancy	O
.	O

We	O
investigated	O
the	O
roles	O
of	O
the	O
prostaglandin	O
synthases	O
cyclooxygenase	O
(	O
COX	O
)	O
I	O
and	O
COX	O
-	O
II	O
in	O
angiogenesis	O
and	O
progesterone	O
production	O
in	O
the	O
newly	O
formed	O
CL	O
,	O
using	O
inhibitors	O
of	O
the	O
COX	O
enzymes	O
and	O
the	O
gonadotropin	O
-	O
induced	O
pseudopregnant	O
rat	O
as	O
a	O
model	O
.	O

Injection	O
of	O
indomethacin	O
,	O
a	O
nonselective	O
COX	O
inhibitor	O
,	O
on	O
the	O
day	O
of	O
ovulation	O
and	O
the	O
following	O
day	O
decreased	O
serum	O
levels	O
of	O
progesterone	O
,	O
as	O
did	O
injection	O
of	O
the	O
selective	O
COX	O
-	O
II	O
inhibitor	O
NS	O
-	O
398	O
.	O

In	O
contrast	O
,	O
a	O
selective	O
COX	O
-	O
I	O
inhibitor	O
,	O
SC	O
-	O
560	O
,	O
had	O
no	O
effect	O
on	O
serum	O
progesterone	O
concentrations	O
.	O

None	O
of	O
the	O
inhibitors	O
had	O
any	O
effect	O
on	O
the	O
weight	O
of	O
the	O
superovulated	O
ovaries	O
or	O
on	O
the	O
synthesis	O
of	O
progesterone	O
by	O
cultured	O
luteal	O
cells	O
.	O

To	O
determine	O
whether	O
changes	O
in	O
angiogenesis	O
are	O
responsible	O
for	O
the	O
decrease	O
in	O
progesterone	O
synthesis	O
,	O
we	O
measured	O
hemoglobin	O
and	O
CD34	O
levels	O
in	O
luteinized	O
ovaries	O
following	O
injection	O
of	O
COX	O
inhibitors	O
and	O
measured	O
the	O
relative	O
frequency	O
of	O
cells	O
positive	O
for	O
platelet	O
-	O
endothelial	O
cell	O
adhesion	O
molecule	O
as	O
a	O
specific	O
marker	O
for	O
endothelial	O
cells	O
.	O

All	O
of	O
these	O
parameters	O
were	O
reduced	O
by	O
the	O
COX	O
-	O
II	O
inhibitors	O
,	O
suggesting	O
that	O
changes	O
in	O
the	O
vasculature	O
are	O
responsible	O
for	O
the	O
decrease	O
in	O
serum	O
progesterone	O
.	O

Histological	O
examination	O
of	O
ovarian	O
corrosion	O
casts	O
indicated	O
that	O
NS	O
-	O
398	O
inhibited	O
the	O
establishment	O
of	O
luteal	O
capillary	O
vessels	O
following	O
the	O
injection	O
of	O
hCG	O
.	O

The	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
activity	O
of	O
COX	O
-	O
II	O
is	O
associated	O
with	O
the	O
formation	O
of	O
functional	O
CL	O
via	O
its	O
stimulation	O
of	O
angiogenesis	O
.	O

Tumor	O
angiogenesis	O
modulates	O
leukocyte	O
-	O
vessel	O
wall	O
interactions	O
in	O
vivo	O
by	O
reducing	O
endothelial	O
adhesion	O
molecule	O
expression	O
.	O

The	O
expression	O
of	O
endothelial	O
cell	O
(	O
EC	O
)	O
adhesion	O
molecules	O
involved	O
in	O
leukocyte	O
-	O
vessel	O
wall	O
interactions	O
is	O
suppressed	O
in	O
malignancies	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
in	O
vivo	O
the	O
regulation	O
of	O
leukocyte	O
-	O
vessel	O
wall	O
interactions	O
by	O
the	O
presence	O
of	O
a	O
tumor	O
.	O

By	O
means	O
of	O
intravital	O
microscopy	O
,	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
stimulated	O
leukocyte	O
-	O
vessel	O
wall	O
interactions	O
were	O
studied	O
in	O
ear	O
skin	O
microvessels	O
of	O
nude	O
mice	O
bearing	O
small	O
human	O
LS174	B
T	I
colon	O
carcinomas	O
and	O
in	O
C57Bl	O
/	O
6	O
mice	O
bearing	O
murine	O
B16F10	B
melanomas	O
.	O

Leukocyte	O
-	O
vessel	O
wall	O
interactions	O
were	O
studied	O
both	O
within	O
and	O
outside	O
small	O
tumors	O
growing	O
in	O
the	O
ear	O
,	O
and	O
in	O
ear	O
microvessels	O
of	O
mice	O
with	O
a	O
large	O
tumor	O
growing	O
on	O
their	O
flank	O
.	O

Tumor	O
-	O
free	O
mice	O
were	O
used	O
as	O
controls	O
.	O

Compared	O
with	O
values	O
measured	O
at	O
the	O
edge	O
of	O
the	O
ear	O
and	O
in	O
the	O
contralateral	O
ear	O
,	O
leukocyte	O
adhesion	O
was	O
found	O
to	O
be	O
diminished	O
significantly	O
in	O
vessels	O
inside	O
the	O
ear	O
tumor	O
in	O
both	O
mouse	O
models	O
.	O

This	O
reduction	O
disappeared	O
with	O
increasing	O
distance	O
from	O
the	O
tumor	O
.	O

Surprisingly	O
,	O
the	O
level	O
of	O
leukocyte	O
adhesion	O
in	O
ear	O
venules	O
of	O
mice	O
with	O
a	O
large	O
flank	O
tumor	O
was	O
also	O
reduced	O
significantly	O
.	O

Leukocyte	O
rolling	O
,	O
i	O
.	O
e	O
.	O
,	O
the	O
step	O
preceding	O
adhesion	O
,	O
was	O
not	O
influenced	O
by	O
the	O
presence	O
of	O
a	O
tumor	O
in	O
nude	O
mice	O
,	O
but	O
was	O
down	O
-	O
regulated	O
in	O
immune	O
-	O
competent	O
C57Bl	O
/	O
6	O
mice	O
.	O

Treatment	O
of	O
mice	O
bearing	O
a	O
small	O
ear	O
tumor	O
with	O
a	O
humanized	O
antivascular	O
endothelial	O
growth	O
factor	O
antibody	O
prevented	O
the	O
down	O
-	O
regulation	O
of	O
leukocyte	O
-	O
vessel	O
wall	O
interactions	O
inside	O
the	O
tumor	O
vessels	O
compared	O
with	O
the	O
nontreated	O
group	O
.	O

Fluorescence	O
-	O
activated	O
cell	O
sorter	O
analysis	O
showed	O
that	O
isolated	O
tumor	O
ECs	O
have	O
suppressed	O
levels	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
as	O
compared	O
with	O
ECs	O
from	O
normal	O
mouse	O
tissues	O
.	O

In	O
cultured	O
b	B
.	I
END5	I
cells	I
the	O
tumor	O
necrosis	O
factor	O
alpha	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
intercellular	O
adhesion	O
molecule	O
1	O
and	O
vascular	O
cell	O
adhesion	O
molecule	O
1	O
was	O
reduced	O
in	O
ECs	O
that	O
were	O
preincubated	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
or	O
vascular	O
endothelial	O
growth	O
factor	O
.	O

The	O
current	O
results	O
may	O
have	O
an	O
impact	O
on	O
the	O
effectiveness	O
of	O
clinical	O
immunotherapeutic	O
treatment	O
protocols	O
,	O
because	O
immune	O
effector	O
cells	O
may	O
not	O
be	O
able	O
to	O
enter	O
tumor	O
tissue	O
.	O

Antiapoptotic	O
effect	O
of	O
coagulation	O
factor	O
VIIa	O
.	O

Binding	O
of	O
factor	O
VIIa	O
(	O
FVIIa	O
)	O
to	O
its	O
cellular	O
receptor	O
tissue	O
factor	O
(	O
TF	O
)	O
was	O
previously	O
shown	O
to	O
induce	O
various	O
intracellular	O
signaling	O
events	O
,	O
which	O
were	O
thought	O
to	O
be	O
responsible	O
for	O
TF	O
-	O
mediated	O
biologic	O
effects	O
,	O
including	O
angiogenesis	O
,	O
tumor	O
metastasis	O
,	O
and	O
restenosis	O
.	O

To	O
understand	O
the	O
mechanisms	O
behind	O
these	O
processes	O
,	O
we	O
have	O
examined	O
the	O
effect	O
of	O
FVIIa	O
on	O
apoptosis	O
.	O

Serum	O
deprivation	O
-	O
induced	O
apoptosis	O
of	O
BHK	B
(	O
+	O
TF	O
)	O
cells	O
was	O
characterized	O
by	O
apoptotic	O
blebs	O
,	O
nuclei	O
with	O
chromatin	O
-	O
condensed	O
bodies	O
,	O
DNA	O
degradation	O
,	O
and	O
activation	O
of	O
caspase	O
3	O
.	O

FVIIa	O
markedly	O
decreased	O
the	O
number	O
of	O
cells	O
with	O
apoptotic	O
morphology	O
and	O
prevented	O
the	O
DNA	O
degradation	O
as	O
measured	O
by	O
means	O
of	O
TdT	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
.	O

The	O
antiapoptotic	O
effect	O
of	O
FVIIa	O
was	O
confirmed	O
by	O
the	O
observation	O
that	O
FVIIa	O
attenuated	O
caspase	O
3	O
activation	O
.	O

FVIIa	O
-	O
induced	O
antiapoptotic	O
effect	O
was	O
dependent	O
on	O
its	O
proteolytic	O
activity	O
and	O
TF	O
but	O
independent	O
of	O
factor	O
Xa	O
and	O
thrombin	O
.	O

FVIIa	O
-	O
induced	O
cell	O
survival	O
correlated	O
with	O
the	O
activation	O
of	O
Akt	O
and	O
was	O
inhibited	O
markedly	O
by	O
the	O
specific	O
PI3	O
-	O
kinase	O
inhibitor	O
,	O
LY294002	O
.	O

Blocking	O
the	O
activation	O
of	O
p44	O
/	O
42	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
by	O
the	O
specific	O
mitogen	O
-	O
induced	O
extracellular	O
kinase	O
(	O
MEK	O
)	O
inhibitor	O
,	O
U0126	O
,	O
impaired	O
modestly	O
the	O
ability	O
of	O
FVIIa	O
to	O
promote	O
cell	O
survival	O
.	O

In	O
conclusion	O
,	O
FVIIa	O
binding	O
to	O
TF	O
provided	O
protection	O
against	O
apoptosis	O
induced	O
by	O
growth	O
factor	O
deprivation	O
,	O
primarily	O
through	O
activation	O
of	O
PI3	O
-	O
kinase	O
/	O
Akt	O
pathway	O
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
p44	O
/	O
42	O
MAPK	O
pathway	O
.	O

Impact	O
of	O
technology	O
on	O
the	O
utilisation	O
of	O
positron	O
emission	O
tomography	O
in	O
lymphoma	O
:	O
current	O
and	O
future	O
perspectives	O
.	O

Positron	O
emission	O
tomography	O
(	O
PET	O
)	O
has	O
now	O
gained	O
a	O
place	O
in	O
the	O
management	O
of	O
patients	O
with	O
cancer	O
,	O
including	O
those	O
with	O
Hodgkin	O
'	O
s	O
disease	O
and	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Restaging	O
studies	O
and	O
those	O
addressing	O
the	O
monitoring	O
of	O
response	O
to	O
treatment	O
are	O
especially	O
in	O
focus	O
.	O

Most	O
of	O
the	O
knowledge	O
gained	O
has	O
been	O
achieved	O
with	O
dedicated	O
BGO	O
-	O
based	O
PET	O
technology	O
,	O
but	O
there	O
are	O
a	O
number	O
of	O
developments	O
that	O
will	O
impact	O
on	O
the	O
use	O
of	O
this	O
metabolic	O
imaging	O
technique	O
in	O
the	O
investigation	O
of	O
patients	O
with	O
lymphoma	O
.	O

The	O
challenges	O
ahead	O
are	O
determined	O
by	O
the	O
need	O
for	O
high	O
-	O
quality	O
whole	O
-	O
body	O
imaging	O
associated	O
with	O
increased	O
patient	O
throughput	O
and	O
the	O
need	O
to	O
investigate	O
the	O
role	O
of	O
new	O
labelled	O
ligands	O
.	O

The	O
latter	O
are	O
likely	O
to	O
yield	O
new	O
insights	O
into	O
tumour	O
cell	O
characterisation	O
,	O
tumour	O
behaviour	O
and	O
tumour	O
outcome	O
assessment	O
.	O

The	O
study	O
of	O
new	O
radiolabelled	O
ligands	O
will	O
impose	O
further	O
demands	O
for	O
rapid	O
dynamic	O
data	O
acquisition	O
and	O
accurate	O
tracer	O
quantification	O
.	O

Current	O
and	O
future	O
developments	O
in	O
PET	O
technology	O
range	O
from	O
the	O
use	O
of	O
new	O
detector	O
materials	O
to	O
different	O
detector	O
geometries	O
and	O
data	O
acquisition	O
modes	O
.	O

The	O
search	O
for	O
alternatives	O
to	O
BGO	O
scintillation	O
materials	O
for	O
PET	O
has	O
led	O
to	O
the	O
development	O
of	O
PET	O
instruments	O
utilising	O
new	O
crystals	O
such	O
as	O
LSO	O
and	O
GSO	O
.	O

The	O
use	O
of	O
these	O
new	O
detectors	O
and	O
the	O
increased	O
sensitivity	O
achieved	O
with	O
3D	O
data	O
acquisitions	O
represent	O
the	O
most	O
significant	O
current	O
developments	O
in	O
the	O
field	O
.	O

With	O
the	O
increasing	O
demands	O
imposed	O
on	O
the	O
clinical	O
utilisation	O
of	O
PET	O
,	O
issues	O
such	O
as	O
study	O
cost	O
and	O
patient	O
throughput	O
will	O
emerge	O
as	O
significant	O
future	O
factors	O
.	O

As	O
a	O
consequence	O
,	O
low	O
-	O
cost	O
units	O
are	O
being	O
offered	O
by	O
the	O
manufacturers	O
through	O
the	O
utilisation	O
of	O
gamma	O
camera	O
-	O
based	O
SPET	O
systems	O
for	O
PET	O
coincidence	O
imaging	O
.	O

Unfortunately	O
,	O
clinical	O
studies	O
in	O
lymphoma	O
and	O
other	O
cancers	O
have	O
already	O
demonstrated	O
the	O
limitations	O
of	O
this	O
technology	O
,	O
with	O
20	O
%	O
of	O
lesions	O
<	O
15	O
mm	O
in	O
size	O
escaping	O
detection	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
recent	O
development	O
of	O
combined	O
PET	O
/	O
CT	O
devices	O
attempts	O
to	O
address	O
the	O
lack	O
of	O
anatomical	O
information	O
inherent	O
with	O
PET	O
images	O
,	O
taking	O
advantage	O
of	O
further	O
improvement	O
in	O
patient	O
throughput	O
and	O
hence	O
cost	O
-	O
effectiveness	O
.	O

Preliminary	O
studies	O
using	O
this	O
multimodality	O
imaging	O
approach	O
have	O
already	O
demonstrated	O
the	O
potential	O
of	O
the	O
technique	O
.	O

Although	O
the	O
potential	O
exists	O
,	O
certain	O
technical	O
issues	O
with	O
PET	O
/	O
CT	O
require	O
refinement	O
of	O
the	O
methodology	O
.	O

Such	O
issues	O
include	O
organ	O
movement	O
(	O
such	O
as	O
respiratory	O
motion	O
)	O
,	O
which	O
strongly	O
influences	O
the	O
image	O
fusion	O
of	O
a	O
rapidly	O
acquired	O
CT	O
scan	O
with	O
the	O
slower	O
acquisition	O
of	O
a	O
PET	O
dataset	O
,	O
and	O
the	O
derivation	O
of	O
CT	O
-	O
based	O
attenuation	O
coefficients	O
in	O
the	O
presence	O
of	O
contrast	O
agents	O
or	O
metallic	O
implants	O
.	O

The	O
application	O
of	O
the	O
technology	O
for	O
radiotherapy	O
planning	O
also	O
poses	O
a	O
number	O
of	O
associated	O
challenges	O
.	O

Finally	O
,	O
the	O
development	O
of	O
dedicated	O
PET	O
systems	O
based	O
on	O
planar	O
detector	O
arrangements	O
with	O
new	O
detector	O
components	O
has	O
the	O
potential	O
to	O
improve	O
clinical	O
throughput	O
by	O
over	O
100	O
%	O
,	O
but	O
clinical	O
trials	O
using	O
such	O
systems	O
have	O
still	O
to	O
be	O
carried	O
out	O
in	O
order	O
to	O
establish	O
the	O
associated	O
whole	O
-	O
body	O
image	O
quality	O
.	O

[	O
Effects	O
of	O
Epstein	O
-	O
Barr	O
virus	O
latent	O
membrane	O
protein	O
1	O
(	O
EBV	O
-	O
LMP1	O
)	O
on	O
related	O
factors	O
of	O
metastasis	O
of	O
nasopharyngeal	O
carcinoma	O
cell	O
line	O
CNE1	B
]	O
.	O

BACKGROUND	O
&	O
#	O
38	O
;	O
OBJECTIVE	O
:	O
It	O
has	O
been	O
proved	O
that	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
latent	O
membrane	O
protein	O
1	O
(	O
EBV	O
-	O
LMP1	O
)	O
can	O
induce	O
the	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
(	O
MMP	O
-	O
9	O
)	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
effect	O
of	O
EBV	O
-	O
LMP1	O
on	O
related	O
factors	O
of	O
metastasis	O
of	O
nasopharyngeal	O
carcinoma	O
cell	O
line	O
CNE1	B
.	O

METHODS	O
:	O
Expression	O
of	O
MMP	O
-	O
9	O
was	O
studied	O
in	O
human	O
NPC	O
cell	O
lines	O
cultured	O
in	O
vitro	O
:	O
CNE1	B
(	O
well	O
differentiated	O
cell	O
line	O
of	O
NPC	O
)	O
and	O
CNE1	B
-	O
GL	O
(	O
CNE1	B
cell	O
line	O
transfected	O
with	O
an	O
eukaryotic	O
LMP1	O
-	O
expression	O
plasmid	O
)	O
by	O
SP	O
immunohistochemistry	O
and	O
Western	O
blot	O
analysis	O
.	O

Cell	O
-	O
matrix	O
adhesion	O
assay	O
was	O
used	O
to	O
study	O
the	O
adhesive	O
ability	O
of	O
CNE1	B
-	O
GL	O
cells	O
.	O

The	O
effects	O
of	O
LMP1	O
on	O
the	O
invasion	O
and	O
migration	O
of	O
CNE1	B
cells	O
were	O
investigated	O
by	O
transwell	O
methods	O
.	O

RESULTS	O
:	O
MMP	O
-	O
9	O
was	O
expressed	O
in	O
both	O
cell	O
lines	O
but	O
the	O
intensity	O
of	O
the	O
staining	O
was	O
different	O
.	O

The	O
positive	O
rates	O
of	O
expression	O
of	O
MMP	O
-	O
9	O
in	O
CNE1	B
and	O
CNE1	B
-	O
GL	O
cells	O
were	O
30	O
.	O
2	O
%	O
and	O
98	O
.	O
2	O
%	O
,	O
respectively	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
increased	O
expression	O
of	O
MMP	O
-	O
9	O
was	O
also	O
shown	O
in	O
CNE1	B
-	O
GL	O
cells	O
by	O
Western	O
blot	O
analysis	O
.	O

Cell	O
-	O
matrix	O
adhesion	O
assay	O
showed	O
that	O
the	O
adhesive	O
ability	O
of	O
CNE1	B
-	O
GL	O
with	O
the	O
matrix	O
(	O
mean	O
A	O
value	O
:	O
1	O
.	O
2508	O
+	O
/	O
-	O
0	O
.	O
0711	O
)	O
was	O
higher	O
than	O
that	O
of	O
CNE1	B
cell	O
(	O
mean	O
A	O
value	O
:	O
0	O
.	O
9519	O
+	O
/	O
-	O
0	O
.	O
068	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Invasion	O
assay	O
and	O
migration	O
assay	O
showed	O
that	O
the	O
invasion	O
and	O
migration	O
of	O
CNE1	B
-	O
GL	O
cell	O
were	O
higher	O
than	O
those	O
of	O
CNE1	B
cells	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSION	O
:	O
The	O
transfection	O
of	O
LMP1	O
can	O
increase	O
the	O
expression	O
of	O
MMP	O
-	O
9	O
in	O
CNE1	B
cells	O
.	O

Abilities	O
of	O
adhesion	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
CNE1	B
cell	O
were	O
induced	O
by	O
LMP1	O
.	O

It	O
is	O
suggested	O
that	O
MMP	O
-	O
9	O
may	O
have	O
a	O
role	O
in	O
the	O
LMP1	O
-	O
induced	O
acceleration	O
of	O
invasion	O
and	O
metastasis	O
of	O
NPC	O
cells	O
.	O

Combined	O
topical	O
fluconazole	O
and	O
corticosteroid	O
treatment	O
for	O
experimental	O
Candida	O
albicans	O
keratomycosis	O
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
most	O
efficient	O
time	O
point	O
and	O
concentration	O
of	O
topical	O
corticosteroids	O
in	O
Candida	O
albicans	O
keratitis	O
treated	O
with	O
fluconazole	O
.	O

METHODS	O
:	O
Corneas	O
of	O
105	O
rabbits	O
were	O
infected	O
with	O
viable	O
yeast	O
cells	O
of	O
C	O
.	O
albicans	O
(	O
2	O
.	O
5	O
x	O
10	O
(	O
5	O
)	O
)	O
.	O

After	O
a	O
48	O
-	O
hour	O
incubation	O
period	O
,	O
seven	O
groups	O
of	O
animals	O
were	O
treated	O
for	O
21	O
days	O
with	O
fluconazole	O
,	O
with	O
group	O
I	O
acting	O
as	O
a	O
control	O
,	O
and	O
groups	O
II	O
to	O
VII	O
receiving	O
adjunct	O
therapy	O
with	O
the	O
corticosteroid	O
prednisolone	O
(	O
5	O
or	O
10	O
times	O
daily	O
;	O
3	O
,	O
9	O
,	O
or	O
15	O
days	O
after	O
infection	O
)	O
.	O

The	O
degree	O
of	O
corneal	O
infiltration	O
,	O
ulceration	O
,	O
corneal	O
clouding	O
,	O
hypopyon	O
,	O
conjunctivitis	O
,	O
neovascularization	O
,	O
and	O
corneal	O
perforation	O
was	O
monitored	O
over	O
a	O
24	O
-	O
day	O
period	O
,	O
as	O
well	O
as	O
recultivation	O
and	O
resistance	O
to	O
fluconazole	O
of	O
the	O
C	O
.	O
albicans	O
pathogen	O
.	O

RESULTS	O
:	O
The	O
control	O
group	O
showed	O
the	O
highest	O
level	O
of	O
corneal	O
clouding	O
and	O
neovascularization	O
.	O

In	O
comparison	O
,	O
by	O
day	O
24	O
,	O
the	O
majority	O
of	O
groups	O
also	O
treated	O
with	O
prednisolone	O
displayed	O
significantly	O
less	O
corneal	O
clouding	O
and	O
neovascularization	O
.	O

An	O
immediate	O
decrease	O
in	O
corneal	O
clouding	O
was	O
observed	O
in	O
groups	O
treated	O
with	O
additional	O
low	O
-	O
or	O
high	O
-	O
dose	O
prednisolone	O
from	O
day	O
9	O
after	O
inoculation	O
.	O

After	O
additional	O
prednisolone	O
treatment	O
from	O
day	O
9	O
or	O
15	O
after	O
inoculation	O
,	O
no	O
significant	O
difference	O
was	O
detected	O
in	O
the	O
recultivation	O
rate	O
of	O
C	O
.	O
albicans	O
compared	O
with	O
the	O
control	O
.	O

Early	O
administration	O
of	O
prednisolone	O
(	O
day	O
3	O
,	O
low	O
and	O
high	O
dose	O
)	O
resulted	O
in	O
the	O
recultivation	O
of	O
significantly	O
more	O
C	O
.	O
albicans	O
.	O

CONCLUSIONS	O
:	O
Fluconazole	O
plus	O
adjunct	O
high	O
-	O
dose	O
prednisolone	O
treatment	O
was	O
most	O
effective	O
when	O
administered	O
9	O
days	O
after	O
infection	O
.	O

The	O
delayed	O
application	O
of	O
corticosteroids	O
after	O
treatment	O
with	O
antimycotic	O
drugs	O
in	O
cases	O
of	O
fungal	O
keratitis	O
is	O
therefore	O
not	O
contraindicated	O
and	O
may	O
be	O
beneficial	O
in	O
patients	O
.	O

Solid	O
tumor	O
therapy	O
:	O
manipulation	O
of	O
the	O
vasculature	O
with	O
TNF	O
.	O

Drug	O
delivery	O
to	O
solid	O
tumors	O
is	O
one	O
of	O
the	O
most	O
challenging	O
aspects	O
in	O
cancer	O
therapy	O
.	O

Whereas	O
agents	O
seem	O
promising	O
in	O
the	O
test	O
tube	O
,	O
clinical	O
trials	O
often	O
fail	O
due	O
to	O
unfavorable	O
pharmacokinetics	O
,	O
poor	O
delivery	O
,	O
low	O
local	O
concentrations	O
,	O
and	O
limited	O
accumulation	O
in	O
the	O
target	O
cell	O
.	O

A	O
major	O
step	O
forwards	O
in	O
the	O
treatment	O
of	O
solid	O
tumors	O
is	O
the	O
recognition	O
of	O
the	O
tumor	O
-	O
associated	O
vasculature	O
as	O
an	O
important	O
target	O
for	O
therapy	O
.	O

Inhibition	O
of	O
tumor	O
vascular	O
development	O
has	O
a	O
direct	O
effect	O
on	O
the	O
growth	O
and	O
progression	O
of	O
the	O
tumor	O
.	O

Destruction	O
of	O
an	O
existing	O
vasculature	O
also	O
directly	O
inflicts	O
serious	O
damage	O
to	O
the	O
tumor	O
cell	O
.	O

Moreover	O
,	O
the	O
tumor	O
vascular	O
bed	O
can	O
be	O
manipulated	O
facilitating	O
enhanced	O
permissiveness	O
of	O
the	O
tumor	O
for	O
administered	O
chemotherapeutics	O
.	O

In	O
this	O
review	O
,	O
we	O
focus	O
on	O
the	O
use	O
of	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
)	O
in	O
local	O
and	O
systemic	O
therapy	O
in	O
conjunction	O
with	O
chemotherapy	O
.	O

In	O
these	O
settings	O
TNF	O
demonstrates	O
potent	O
and	O
selective	O
activity	O
on	O
the	O
tumor	O
vascular	O
bed	O
,	O
which	O
strongly	O
improves	O
tumor	O
response	O
.	O

Truncated	O
galectin	O
-	O
3	O
inhibits	O
tumor	O
growth	O
and	O
metastasis	O
in	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
The	O
goal	O
of	O
this	O
research	O
was	O
to	O
evaluate	O
a	O
potential	O
therapeutic	O
agent	O
for	O
breast	O
cancer	O
based	O
on	O
galectin	O
-	O
3	O
that	O
has	O
been	O
implicated	O
in	O
tumorigenicity	O
and	O
metastasis	O
of	O
breast	O
cancer	O
.	O

The	O
hypothesis	O
was	O
that	O
therapy	O
with	O
NH	O
(	O
2	O
)	O
-	O
terminally	O
truncated	O
form	O
of	O
galectin	O
-	O
3	O
(	O
galectin	O
-	O
3C	O
)	O
will	O
be	O
efficacious	O
for	O
reduction	O
in	O
tumor	O
growth	O
and	O
for	O
inhibition	O
of	O
metastases	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Recombinant	O
human	O
galectin	O
-	O
3	O
was	O
produced	O
in	O
Escherichia	O
coli	O
from	O
which	O
galectin	O
-	O
3C	O
was	O
derived	O
by	O
collagenase	O
enzyme	O
digestion	O
.	O

Toxicity	O
,	O
pharmacokinetic	O
,	O
and	O
organ	O
biodistribution	O
studies	O
were	O
performed	O
in	O
nude	O
mice	O
.	O

For	O
efficacy	O
studies	O
,	O
nude	O
mice	O
bearing	O
orthotopically	O
implanted	O
tumors	O
derived	O
from	O
breast	O
cancer	O
cell	O
line	O
MDA	B
-	I
MB	I
-	I
435	I
were	O
treated	O
with	O
galectin	O
-	O
3C	O
or	O
a	O
vehicle	O
control	O
i	O
.	O
m	O
.	O
twice	O
daily	O
for	O
90	O
days	O
.	O

RESULTS	O
:	O
The	O
maximum	O
tolerated	O
dose	O
of	O
galectin	O
-	O
3C	O
in	O
nude	O
mice	O
was	O
determined	O
to	O
be	O
>	O
125	O
mg	O
/	O
kg	O
without	O
overt	O
adverse	O
effects	O
.	O

The	O
elimination	O
half	O
-	O
life	O
when	O
administered	O
i	O
.	O
m	O
.	O
was	O
found	O
to	O
be	O
3	O
.	O
0	O
h	O
in	O
the	O
serum	O
and	O
4	O
.	O
3	O
h	O
in	O
the	O
cellular	O
fraction	O
of	O
the	O
blood	O
.	O

Organ	O
biodistribution	O
studies	O
revealed	O
that	O
galectin	O
-	O
3C	O
localized	O
in	O
the	O
liver	O
,	O
kidneys	O
,	O
and	O
spleen	O
but	O
not	O
in	O
the	O
heart	O
or	O
lungs	O
.	O

We	O
found	O
that	O
the	O
mean	O
tumor	O
volumes	O
and	O
weights	O
were	O
statistically	O
significantly	O
less	O
in	O
mice	O
treated	O
with	O
galectin	O
-	O
3C	O
compared	O
with	O
control	O
mice	O
,	O
and	O
that	O
fewer	O
numbers	O
of	O
mice	O
exhibited	O
lymph	O
node	O
metastases	O
in	O
the	O
treated	O
group	O
compared	O
with	O
the	O
control	O
group	O
.	O

CONCLUSIONS	O
:	O
Galectin	O
-	O
3C	O
is	O
not	O
overtly	O
toxic	O
,	O
and	O
is	O
efficacious	O
in	O
reducing	O
metastases	O
and	O
tumor	O
volumes	O
and	O
weights	O
in	O
primary	O
tumors	O
in	O
an	O
orthotopic	O
nude	O
mouse	O
model	O
of	O
human	O
breast	O
cancer	O
.	O

[	O
Screening	O
and	O
identification	O
of	O
novel	O
genes	O
involved	O
in	O
biosynthesis	O
of	O
ginsenoside	O
in	O
Panax	O
ginseng	O
plant	O
]	O
.	O

The	O
root	O
of	O
Panax	O
ginseng	O
plant	O
undergoes	O
a	O
specific	O
developmental	O
process	O
to	O
become	O
a	O
biosynthesis	O
and	O
accumulation	O
organ	O
for	O
ginsenosides	O
.	O

To	O
identify	O
and	O
analyze	O
genes	O
involved	O
in	O
the	O
biosynthesis	O
of	O
ginsenoside	O
,	O
suppression	O
subtractive	O
hybridization	O
(	O
SSH	O
)	O
between	O
mRNAs	O
of	O
4	O
-	O
and	O
1	O
-	O
year	O
-	O
old	O
root	O
tissues	O
was	O
performed	O
,	O
and	O
a	O
subtracted	O
cDNA	O
library	O
specific	O
to	O
4	O
-	O
year	O
-	O
old	O
roots	O
was	O
constructed	O
.	O

Forty	O
cDNA	O
clones	O
selected	O
randomly	O
from	O
the	O
subtracted	O
cDNA	O
library	O
were	O
sequenced	O
.	O

Sequence	O
information	O
of	O
all	O
clones	O
was	O
evaluated	O
by	O
Nucleotide	O
Blast	O
analysis	O
in	O
GenBank	O
/	O
DDBJ	O
/	O
EMBL	O
.	O

The	O
results	O
showed	O
that	O
six	O
subtracted	O
cDNA	O
clones	O
represented	O
the	O
novel	O
genes	O
(	O
ESTs	O
)	O
,	O
because	O
no	O
sequence	O
homology	O
with	O
any	O
known	O
sequences	O
was	O
found	O
in	O
the	O
database	O
.	O

Expression	O
in	O
4	O
-	O
year	O
-	O
old	O
P	O
.	O
ginseng	O
root	O
tissues	O
was	O
verified	O
by	O
reverse	O
Northern	O
dot	O
hybridization	O
for	O
the	O
six	O
clones	O
.	O

These	O
six	O
novel	O
genes	O
were	O
named	O
GBR1	O
,	O
GBR2	O
,	O
GBR3	O
,	O
GBR4	O
,	O
GBR5	O
,	O
and	O
GBR6	O
,	O
and	O
their	O
Accession	O
numbers	O
of	O
GenBank	O
are	O
AF485334	O
,	O
AF485335	O
,	O
AF485336	O
,	O
AF485337	O
,	O
AF485332	O
,	O
and	O
AF485333	O
,	O
respectively	O
.	O

Finally	O
,	O
Northern	O
blot	O
analysis	O
and	O
semi	O
-	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
confirmed	O
that	O
these	O
six	O
novel	O
genes	O
were	O
differentially	O
expressed	O
in	O
the	O
defined	O
development	O
stage	O
of	O
P	O
.	O
ginseng	O
plant	O
roots	O
.	O

It	O
is	O
possible	O
that	O
their	O
overexpression	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
ginsenoside	O
biosynthesis	O
.	O

In	O
addition	O
,	O
most	O
of	O
transcripts	O
of	O
all	O
genes	O
could	O
also	O
be	O
detected	O
in	O
other	O
P	O
.	O
ginseng	O
plant	O
tissues	O
such	O
as	O
stem	O
,	O
leaf	O
and	O
seed	O
.	O

Our	O
results	O
provided	O
a	O
basis	O
for	O
obtaining	O
the	O
full	O
-	O
length	O
cDNA	O
sequences	O
of	O
such	O
six	O
novel	O
genes	O
,	O
and	O
for	O
identifying	O
their	O
function	O
involved	O
in	O
the	O
biosynthesis	O
of	O
ginsenoside	O
.	O

The	O
septic	O
abscess	O
wall	O
:	O
a	O
cytokine	O
-	O
generating	O
organ	O
associated	O
with	O
portal	O
venous	O
cytokinemia	O
,	O
hepatic	O
outflow	O
fibrosis	O
,	O
sinusoidal	O
congestion	O
,	O
inflammatory	O
cell	O
sequestration	O
,	O
hepatocellular	O
lipid	O
deposition	O
,	O
and	O
focal	O
cell	O
death	O
.	O

An	O
acute	O
septic	O
inflammatory	O
response	O
with	O
access	O
to	O
the	O
portal	O
circulation	O
was	O
created	O
in	O
a	O
rat	O
model	O
using	O
an	O
intra	O
-	O
abdominal	O
abscess	O
composed	O
of	O
a	O
sterile	O
agar	O
pellet	O
,	O
or	O
one	O
contaminated	O
with	O
102	O
Escherichia	O
coli	O
(	O
E	O
.	O
coli	O
)	O
and	O
109	O
Bacteriodes	O
fragilis	O
(	O
B	O
.	O
fragilis	O
)	O
.	O

After	O
3	O
days	O
postimplantation	O
,	O
a	O
well	O
-	O
formed	O
intra	O
-	O
abdominal	O
abscess	O
occurred	O
whose	O
wall	O
showed	O
IL	O
-	O
6	O
DNA	O
by	O
PCR	O
and	O
IL	O
-	O
6	O
mRNA	O
by	O
in	O
situ	O
hybridization	O
.	O

Portal	O
venous	O
blood	O
draining	O
into	O
the	O
liver	O
from	O
the	O
intra	O
-	O
abdominal	O
abscess	O
had	O
increased	O
levels	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
in	O
both	O
sterile	O
and	O
septic	O
groups	O
compared	O
with	O
a	O
control	O
normal	O
animal	O
group	O
.	O

Increased	O
levels	O
of	O
these	O
cytokines	O
were	O
also	O
found	O
in	O
suprahepatic	O
inferior	O
vena	O
caval	O
blood	O
,	O
but	O
were	O
correlated	O
with	O
the	O
higher	O
portal	O
vein	O
levels	O
,	O
suggesting	O
a	O
gradient	O
from	O
abscess	O
wall	O
to	O
portal	O
vein	O
into	O
the	O
systemic	O
circulation	O
via	O
the	O
liver	O
.	O

Liver	O
histology	O
demonstrated	O
sinusoidal	O
congestion	O
centering	O
on	O
the	O
central	O
vein	O
,	O
growing	O
worse	O
with	O
progression	O
from	O
normal	O
in	O
control	O
,	O
to	O
sterile	O
,	O
to	O
septic	O
.	O

Similarly	O
,	O
the	O
degree	O
of	O
intrahepatic	O
myeloperoxidase	O
-	O
positive	O
inflammatory	O
cell	O
infiltration	O
and	O
hepatocellular	O
lipid	O
deposition	O
and	O
apoptosis	O
also	O
increased	O
from	O
control	O
,	O
to	O
sterile	O
,	O
to	O
septic	O
.	O

Gene	O
expression	O
by	O
in	O
situ	O
hybridization	O
demonstrated	O
a	O
significant	O
increase	O
in	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
cells	O
surrounding	O
the	O
central	O
vein	O
in	O
sterile	O
and	O
septic	O
animals	O
,	O
being	O
greatest	O
in	O
animals	O
with	O
sepsis	O
,	O
associated	O
with	O
an	O
increased	O
deposition	O
of	O
collagen	O
in	O
the	O
central	O
vein	O
area	O
,	O
most	O
prominent	O
in	O
the	O
septic	O
liver	O
.	O

The	O
pericentral	O
vein	O
cells	O
with	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNA	O
increases	O
paralleled	O
the	O
increases	O
in	O
cells	O
containing	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
the	O
abscess	O
walls	O
of	O
sterile	O
and	O
septic	O
animals	O
,	O
respectively	O
.	O

The	O
data	O
suggest	O
that	O
an	O
intra	O
-	O
abdominal	O
abscess	O
,	O
especially	O
when	O
contaminated	O
with	O
gram	O
-	O
negative	O
bacteria	O
,	O
induces	O
mRNA	O
-	O
generated	O
cytokine	O
responses	O
in	O
the	O
abscess	O
wall	O
that	O
are	O
related	O
to	O
increased	O
portal	O
venous	O
levels	O
of	O
the	O
inflammatory	O
cytokines	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
,	O
and	O
IL	O
-	O
6	O
perfusing	O
the	O
liver	O
.	O

These	O
,	O
in	O
turn	O
,	O
induce	O
localized	O
production	O
of	O
IL	O
-	O
6	O
and	O
fibrinogen	O
mRNAs	O
in	O
cells	O
at	O
the	O
central	O
vein	O
area	O
with	O
resultant	O
outflow	O
fibrosis	O
and	O
increased	O
inflammatory	O
cell	O
sequestration	O
within	O
the	O
liver	O
lobular	O
sinuses	O
.	O

This	O
is	O
associated	O
with	O
a	O
generalized	O
inflammatory	O
response	O
and	O
intrahepatic	O
portal	O
sinusoid	O
congestion	O
.	O

There	O
is	O
also	O
increased	O
hepatocellular	O
lipid	O
deposition	O
and	O
apoptosis	O
.	O

Thus	O
,	O
the	O
cytokine	O
production	O
of	O
the	O
abscess	O
wall	O
itself	O
appears	O
to	O
be	O
a	O
major	O
mediator	O
of	O
the	O
septic	O
hepatic	O
response	O
.	O

Prognostic	O
value	O
of	O
p53	O
protein	O
expression	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
in	O
resected	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
esophagus	O
.	O

The	O
most	O
common	O
genetic	O
alterations	O
found	O
in	O
a	O
wide	O
variety	O
of	O
cancers	O
are	O
p53	O
tumor	O
suppressor	O
gene	O
mutations	O
.	O

p53	O
appears	O
to	O
be	O
a	O
nuclear	O
transcription	O
factor	O
that	O
plays	O
a	O
role	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
the	O
maintenance	O
of	O
genetic	O
stability	O
.	O

Angiogenesis	O
is	O
a	O
critical	O
process	O
in	O
solid	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
a	O
recently	O
identified	O
growth	O
factor	O
with	O
significant	O
angiogenic	O
properties	O
,	O
may	O
be	O
a	O
major	O
tumor	O
angiogenesis	O
regulator	O
.	O

Few	O
studies	O
have	O
investigated	O
the	O
association	O
between	O
p53	O
and	O
VEGF	O
expressions	O
and	O
prognosis	O
in	O
esophageal	O
carcinoma	O
.	O

Forty	O
-	O
seven	O
specimens	O
resected	O
from	O
patients	O
with	O
stage	O
II	O
and	O
III	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
of	O
the	O
esophagus	O
were	O
studied	O
using	O
immunohistochemical	O
staining	O
.	O

VEGF	O
and	O
p53	O
expressions	O
were	O
observed	O
in	O
40	O
%	O
and	O
53	O
%	O
of	O
the	O
tumors	O
,	O
respectively	O
.	O

The	O
p53	O
and	O
VEGF	O
staining	O
statuses	O
were	O
coincident	O
in	O
only	O
21	O
%	O
of	O
the	O
tumors	O
,	O
and	O
no	O
significant	O
correlation	O
was	O
found	O
between	O
p53	O
and	O
VEGF	O
statuses	O
.	O

No	O
clinicopathologic	O
factors	O
were	O
significantly	O
correlated	O
with	O
p53	O
or	O
VEGF	O
expression	O
.	O

No	O
significant	O
association	O
between	O
p53	O
and	O
VEGF	O
expressions	O
and	O
poor	O
prognosis	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
p53	O
and	O
VEGF	O
were	O
not	O
correlated	O
with	O
prognosis	O
in	O
patients	O
with	O
stage	O
II	O
and	O
III	O
SCC	O
of	O
the	O
esophagus	O
.	O

Comparison	O
of	O
tissue	O
integration	O
between	O
polyester	O
and	O
polypropylene	O
prostheses	O
in	O
the	O
preperitoneal	O
space	O
.	O

Tissue	O
integration	O
and	O
implant	O
characteristics	O
of	O
various	O
biomaterials	O
commonly	O
used	O
for	O
inguinal	O
hernia	O
repair	O
have	O
not	O
been	O
studied	O
extensively	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
behavior	O
and	O
tissue	O
response	O
between	O
two	O
new	O
polyester	O
prostheses	O
and	O
a	O
commonly	O
used	O
polypropylene	O
(	O
PP	O
)	O
mesh	O
.	O

The	O
polyester	O
prostheses	O
utilized	O
were	O
polyester	O
flat	O
(	O
PF	O
)	O
and	O
polyester	O
soft	O
three	O
-	O
dimensional	O
(	O
PS	O
)	O
;	O
the	O
PP	O
mesh	O
utilized	O
was	O
Marlex	O
.	O

Eight	O
randomly	O
assigned	O
4	O
x	O
4	O
-	O
cm2	O
pieces	O
of	O
two	O
different	O
meshes	O
were	O
fixed	O
in	O
the	O
preperitoneal	O
space	O
with	O
a	O
centrally	O
placed	O
single	O
suture	O
.	O

Gross	O
evaluation	O
included	O
shrinkage	O
and	O
stiffness	O
.	O

Histological	O
evaluation	O
included	O
amount	O
of	O
fibrous	O
and	O
fat	O
encapsulation	O
,	O
connective	O
tissue	O
,	O
foreign	O
-	O
body	O
reaction	O
,	O
neovascularization	O
,	O
hemorrhage	O
,	O
necrosis	O
,	O
and	O
exudate	O
.	O

Evaluations	O
were	O
graded	O
on	O
a	O
zero	O
to	O
four	O
scale	O
.	O

The	O
area	O
and	O
the	O
area	O
ratio	O
were	O
measured	O
using	O
a	O
calibrated	O
micrometer	O
.	O

PP	O
mesh	O
resulted	O
in	O
more	O
fibrous	O
encapsulation	O
and	O
stiffness	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O

PP	O
also	O
resulted	O
in	O
less	O
connective	O
tissue	O
formation	O
and	O
foreign	O
-	O
body	O
reaction	O
than	O
PF	O
and	O
PS	O
prostheses	O
.	O

There	O
was	O
no	O
difference	O
in	O
fat	O
encapsulation	O
,	O
necrosis	O
,	O
hemorrhage	O
,	O
or	O
exudate	O
between	O
prostheses	O
.	O

Both	O
polyester	O
prostheses	O
(	O
PF	O
and	O
PS	O
)	O
have	O
better	O
tissue	O
integration	O
than	O
the	O
PP	O
mesh	O
,	O
as	O
evidenced	O
by	O
the	O
higher	O
amount	O
of	O
connective	O
tissue	O
and	O
lower	O
extent	O
of	O
fibrous	O
encapsulation	O
.	O

Therapeutic	O
targeting	O
of	O
the	O
survivin	O
pathway	O
in	O
cancer	O
:	O
initiation	O
of	O
mitochondrial	O
apoptosis	O
and	O
suppression	O
of	O
tumor	O
-	O
associated	O
angiogenesis	O
.	O

PURPOSE	O
:	O
Molecular	O
antagonists	O
of	O
the	O
inhibitor	O
of	O
apoptosis	O
protein	O
survivin	O
have	O
shown	O
promise	O
as	O
novel	O
anticancer	O
strategies	O
for	O
triggering	O
tumor	O
cell	O
apoptosis	O
,	O
dysregulating	O
mitotic	O
progression	O
,	O
and	O
inhibiting	O
tumor	O
growth	O
in	O
preclinical	O
models	O
.	O

However	O
,	O
how	O
survivin	O
couples	O
to	O
the	O
cell	O
death	O
machinery	O
has	O
remained	O
elusive	O
,	O
and	O
the	O
relevant	O
cellular	O
targets	O
of	O
survivin	O
antagonists	O
have	O
not	O
been	O
completely	O
elucidated	O
.	O

Experimental	O
Design	O
:	O
Human	O
umbilical	O
vein	O
and	O
dermal	O
microvascular	O
endothelial	O
cells	O
were	O
infected	O
with	O
replication	O
-	O
deficient	O
adenoviruses	O
encoding	O
survivin	O
(	O
pAd	O
-	O
Survivin	O
)	O
,	O
green	O
fluorescent	O
protein	O
(	O
pAd	O
-	O
GFP	O
)	O
,	O
or	O
a	O
phosphorylation	O
-	O
defective	O
survivin	O
Thr	O
(	O
34	O
)	O
-	O
-	O
>	O
Ala	O
(	O
pAd	O
-	O
T34A	O
)	O
dominant	O
negative	O
mutant	O
.	O

The	O
effect	O
of	O
wild	O
-	O
type	O
or	O
mutant	O
survivin	O
was	O
investigated	O
on	O
capillary	O
network	O
stability	O
,	O
endothelial	O
cell	O
viability	O
,	O
and	O
caspase	O
activation	O
in	O
vitro	O
and	O
on	O
kinetics	O
of	O
tumor	O
growth	O
and	O
development	O
of	O
angiogenesis	O
in	O
a	O
breast	O
cancer	O
xenograft	O
model	O
in	O
vivo	O
.	O

The	O
cell	O
death	O
pathway	O
initiated	O
by	O
survivin	O
targeting	O
was	O
mapped	O
with	O
respect	O
to	O
cytochrome	O
c	O
release	O
,	O
changes	O
in	O
mitochondrial	O
transmembrane	O
potential	O
,	O
and	O
apoptosome	O
requirements	O
using	O
mouse	O
embryonic	O
fibroblasts	O
deficient	O
in	O
Apaf	O
-	O
1	O
or	O
caspase	O
-	O
9	O
.	O

RESULTS	O
:	O
Adenoviral	O
transduction	O
of	O
endothelial	O
cells	O
with	O
pAd	O
-	O
Survivin	O
inhibited	O
growth	O
factor	O
deprivation	O
-	O
or	O
ceramide	O
-	O
induced	O
apoptosis	O
,	O
reduced	O
caspase	O
-	O
3	O
and	O
-	O
7	O
generation	O
,	O
and	O
stabilized	O
three	O
-	O
dimensional	O
capillary	O
networks	O
in	O
vitro	O
.	O

Conversely	O
,	O
expression	O
of	O
pAd	O
-	O
T34A	O
caused	O
apoptosis	O
in	O
umbilical	O
vein	O
and	O
dermal	O
microvascular	O
endothelial	O
cells	O
and	O
resulted	O
in	O
caspase	O
-	O
3	O
activity	O
.	O

Cell	O
death	O
induced	O
by	O
survivin	O
targeting	O
exhibited	O
the	O
hallmarks	O
of	O
mitochondrial	O
-	O
dependent	O
apoptosis	O
with	O
release	O
of	O
cytochrome	O
c	O
and	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
and	O
was	O
suppressed	O
in	O
Apaf	O
-	O
1	O
or	O
caspase	O
-	O
9	O
knockout	O
mouse	O
embryonic	O
fibroblasts	O
.	O

When	O
injected	O
in	O
human	O
breast	O
cancer	O
xenografts	O
,	O
pAd	O
-	O
T34A	O
inhibited	O
growth	O
of	O
established	O
tumors	O
and	O
triggered	O
tumor	O
cell	O
apoptosis	O
in	O
vivo	O
.	O

This	O
was	O
associated	O
with	O
a	O
approximately	O
60	O
%	O
reduction	O
in	O
tumor	O
-	O
derived	O
blood	O
vessels	O
by	O
quantitative	O
morphometry	O
of	O
CD31	O
-	O
stained	O
tumor	O
areas	O
,	O
and	O
appearance	O
of	O
endothelial	O
cell	O
apoptosis	O
by	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
vivo	O
.	O

CONCLUSIONS	O
:	O
Survivin	O
functions	O
as	O
a	O
novel	O
upstream	O
regulator	O
of	O
mitochondrial	O
-	O
dependent	O
apoptosis	O
,	O
and	O
molecular	O
targeting	O
of	O
this	O
pathway	O
results	O
in	O
anticancer	O
activity	O
via	O
a	O
dual	O
mechanism	O
of	O
induction	O
of	O
tumor	O
cell	O
apoptosis	O
and	O
suppression	O
of	O
angiogenesis	O
.	O

The	O
role	O
of	O
organ	O
vascularization	O
and	O
lipoplex	O
-	O
serum	O
initial	O
contact	O
in	O
intravenous	O
murine	O
lipofection	O
.	O

Following	O
intravenous	O
administration	O
of	O
cationic	O
lipid	O
-	O
DNA	O
complexes	O
(	O
lipoplexes	O
)	O
into	O
mice	O
,	O
transfection	O
(	O
lipofection	O
)	O
occurs	O
predominantly	O
in	O
the	O
lungs	O
.	O

This	O
was	O
attributed	O
to	O
high	O
entrapment	O
of	O
lipoplexes	O
in	O
the	O
extended	O
lung	O
vascular	O
tree	O
.	O

To	O
determine	O
whether	O
lipofection	O
in	O
other	O
organs	O
could	O
be	O
enhanced	O
by	O
increasing	O
the	O
degree	O
of	O
vascularization	O
,	O
we	O
used	O
a	O
transgenic	O
mouse	O
model	O
with	O
tissue	O
-	O
specific	O
angiogenesis	O
in	O
liver	O
.	O

Tail	O
vein	O
injection	O
of	O
N	O
-	O
(	O
1	O
-	O
(	O
2	O
,	O
3	O
-	O
dioleoyloxy	O
)	O
propyl	O
)	O
-	O
N	O
,	O
N	O
,	O
N	O
-	O
trimethylammonium	O
chloride	O
(	O
DOTAP	O
)	O
/	O
cholesterol	O
lipoplexes	O
resulted	O
in	O
increased	O
lipoplex	O
entrapment	O
in	O
hypervascularized	O
liver	O
but	O
did	O
not	O
boost	O
luciferase	O
expression	O
,	O
suggesting	O
that	O
lipoplex	O
delivery	O
is	O
not	O
a	O
sufficient	O
condition	O
for	O
efficient	O
organ	O
lipofection	O
.	O

Because	O
the	O
intravenously	O
injected	O
lipoplexes	O
migrated	O
within	O
seconds	O
to	O
lungs	O
,	O
we	O
checked	O
whether	O
the	O
effects	O
of	O
immediate	O
contact	O
with	O
serum	O
correlate	O
with	O
lung	O
lipofection	O
efficiency	O
of	O
different	O
DOTAP	O
-	O
based	O
formulations	O
.	O

Under	O
conditions	O
mimicking	O
the	O
injection	O
environment	O
,	O
the	O
lipoplex	O
-	O
serum	O
interaction	O
was	O
strongly	O
dependent	O
on	O
helper	O
lipid	O
and	O
ionic	O
strength	O
:	O
lipoplexes	O
prepared	O
in	O
150	O
mM	O
NaCl	O
or	O
lipoplexes	O
with	O
high	O
(	O
greater	O
than	O
33	O
mol	O
%	O
)	O
cholesterol	O
were	O
found	O
to	O
aggregate	O
immediately	O
.	O

This	O
aggregation	O
process	O
was	O
irreversible	O
and	O
was	O
inversely	O
correlated	O
with	O
the	O
percentage	O
of	O
lung	O
cells	O
that	O
took	O
up	O
lipoplexes	O
and	O
with	O
the	O
efficiency	O
of	O
lipofection	O
.	O

No	O
other	O
structural	O
changes	O
in	O
serum	O
were	O
observed	O
for	O
cholesterol	O
-	O
based	O
lipoplexes	O
.	O

Dioleoyl	O
phosphatidylethanolamine	O
-	O
based	O
lipoplexes	O
were	O
found	O
to	O
give	O
low	O
expression	O
,	O
apparently	O
because	O
of	O
an	O
immediate	O
loss	O
of	O
integrity	O
in	O
serum	O
,	O
without	O
lipid	O
-	O
DNA	O
dissociation	O
.	O

Our	O
study	O
suggests	O
that	O
efficient	O
in	O
vivo	O
lipofection	O
is	O
the	O
result	O
of	O
cross	O
-	O
talk	O
between	O
lipoplex	O
composition	O
,	O
interaction	O
with	O
serum	O
,	O
hemodynamics	O
,	O
and	O
target	O
tissue	O
""""	O
susceptibility	O
""""	O
to	O
transfection	O
.	O

Integration	O
of	O
interferon	O
-	O
alpha	O
/	O
beta	O
signalling	O
to	O
p53	O
responses	O
in	O
tumour	O
suppression	O
and	O
antiviral	O
defence	O
.	O

Swift	O
elimination	O
of	O
undesirable	O
cells	O
is	O
an	O
important	O
feature	O
in	O
tumour	O
suppression	O
and	O
immunity	O
.	O

The	O
tumour	O
suppressor	O
p53	O
and	O
interferon	O
-	O
alpha	O
and	O
-	O
beta	O
(	O
IFN	O
-	O
alpha	O
/	O
beta	O
)	O
are	O
essential	O
for	O
the	O
induction	O
of	O
apoptosis	O
in	O
cancerous	O
cells	O
and	O
in	O
antiviral	O
immune	O
responses	O
,	O
respectively	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
interrelationship	O
.	O

Here	O
we	O
show	O
that	O
transcription	O
of	O
the	O
p53	O
gene	O
is	O
induced	O
by	O
IFN	O
-	O
alpha	O
/	O
beta	O
,	O
accompanied	O
by	O
an	O
increase	O
in	O
p53	O
protein	O
level	O
.	O

IFN	O
-	O
alpha	O
/	O
beta	O
signalling	O
itself	O
does	O
not	O
activate	O
p53	O
;	O
rather	O
,	O
it	O
contributes	O
to	O
boosting	O
p53	O
responses	O
to	O
stress	O
signals	O
.	O

We	O
show	O
examples	O
in	O
which	O
p53	O
gene	O
induction	O
by	O
IFN	O
-	O
alpha	O
/	O
beta	O
contributes	O
to	O
tumour	O
suppression	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
p53	O
is	O
activated	O
in	O
virally	O
infected	O
cells	O
to	O
evoke	O
an	O
apoptotic	O
response	O
and	O
that	O
p53	O
is	O
critical	O
for	O
antiviral	O
defence	O
of	O
the	O
host	O
.	O

Our	O
study	O
reveals	O
a	O
hitherto	O
unrecognized	O
link	O
between	O
p53	O
and	O
IFN	O
-	O
alpha	O
/	O
beta	O
in	O
tumour	O
suppression	O
and	O
antiviral	O
immunity	O
,	O
which	O
may	O
have	O
therapeutic	O
implications	O
.	O

Stereoselective	O
synthesis	O
of	O
1	O
-	O
aminoalkanephosphonic	O
acids	O
with	O
two	O
chiral	O
centers	O
and	O
their	O
activity	O
towards	O
leucine	O
aminopeptidase	O
.	O

The	O
stereoselective	O
synthesis	O
of	O
1	O
-	O
amino	O
-	O
2	O
-	O
alkylalkanephosphonic	O
acids	O
,	O
namely	O
,	O
compounds	O
bearing	O
two	O
chiral	O
centers	O
,	O
was	O
achieved	O
by	O
the	O
condensation	O
of	O
hypophosphorous	O
acid	O
salts	O
of	O
(	O
R	O
)	O
(	O
+	O
)	O
or	O
(	O
S	O
)	O
(	O
-	O
)	O
-	O
N	O
-	O
alpha	O
-	O
methylbenzylamine	O
with	O
the	O
appropriate	O
aldehydes	O
in	O
isopropanol	O
.	O

Simultaneous	O
deprotection	O
and	O
oxidation	O
by	O
the	O
action	O
of	O
bromine	O
water	O
provided	O
equimolar	O
mixtures	O
of	O
the	O
RS	O
:	O
RR	O
and	O
SR	O
:	O
SS	O
diastereomers	O
of	O
desired	O
acids	O
.	O

They	O
appeared	O
to	O
act	O
as	O
moderate	O
inhibitors	O
of	O
kidney	O
leucine	O
aminopeptidase	O
with	O
potency	O
dependent	O
on	O
the	O
absolute	O
configuration	O
of	O
both	O
centers	O
of	O
chirality	O
.	O

Proliferative	O
diabetic	O
retinopathy	O
is	O
associated	O
with	O
a	O
low	O
level	O
of	O
the	O
natural	O
ocular	O
anti	O
-	O
angiogenic	O
agent	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
in	O
aqueous	O
humor	O
.	O

a	O
pilot	O
study	O
.	O

Retinopathy	O
is	O
the	O
most	O
common	O
microvascular	O
diabetes	O
complication	O
and	O
represents	O
a	O
major	O
threat	O
to	O
the	O
eyesight	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
address	O
the	O
role	O
of	O
pro	O
-	O
and	O
anti	O
-	O
angiogenic	O
molecules	O
in	O
diabetic	O
retinopathy	O
in	O
the	O
aqueous	O
humor	O
of	O
the	O
eye	O
.	O

Aqueous	O
humor	O
was	O
collected	O
at	O
cataract	O
surgery	O
from	O
19	O
diabetic	O
patients	O
and	O
from	O
13	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normoglycemic	O
controls	O
.	O

Levels	O
of	O
pro	O
-	O
angiogenic	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
angiogenic	O
inhibitor	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
(	O
PEDF	O
)	O
were	O
determined	O
.	O

Angiogenic	O
activity	O
of	O
the	O
aqueous	O
humor	O
was	O
quantified	O
by	O
measuring	O
its	O
effect	O
on	O
the	O
migration	O
of	O
capillary	O
endothelial	O
cells	O
.	O

In	O
the	O
aqueous	O
fluid	O
,	O
VEGF	O
levels	O
were	O
increased	O
in	O
diabetics	O
(	O
mean	O
values	O
:	O
501	O
vs	O
.	O
367	O
pg	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
05	O
)	O
,	O
compared	O
to	O
controls	O
.	O

PEDF	O
was	O
found	O
to	O
be	O
decreased	O
in	O
diabetics	O
(	O
mean	O
values	O
:	O
2080	O
vs	O
.	O
5780	O
ng	O
/	O
ml	O
;	O
p	O
=	O
0	O
.	O
04	O
)	O
compared	O
to	O
controls	O
.	O

In	O
seven	O
diabetic	O
patients	O
with	O
proliferative	O
retinopathy	O
,	O
the	O
most	O
profound	O
finding	O
was	O
a	O
significant	O
decrease	O
of	O
the	O
PEDF	O
level	O
(	O
mean	O
value	O
:	O
237	O
ng	O
/	O
ml	O
)	O
,	O
whereas	O
VEGF	O
levels	O
were	O
comparable	O
to	O
diabetic	O
patients	O
without	O
proliferation	O
(	O
mean	O
value	O
:	O
3153	O
;	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

Angiogenic	O
activity	O
in	O
samples	O
of	O
patients	O
from	O
the	O
control	O
group	O
was	O
generally	O
inhibitory	O
due	O
to	O
PEDF	O
,	O
and	O
inhibition	O
was	O
blocked	O
by	O
neutralizing	O
antibodies	O
to	O
PEDF	O
.	O

Likewise	O
,	O
in	O
diabetics	O
without	O
proliferation	O
,	O
angiogenic	O
activity	O
was	O
also	O
blocked	O
by	O
antibodies	O
to	O
PEDF	O
.	O

We	O
will	O
demonstrate	O
here	O
that	O
the	O
level	O
of	O
the	O
natural	O
ocular	O
anti	O
-	O
angiogenic	O
agent	O
PEDF	O
is	O
inversely	O
associated	O
with	O
proliferative	O
retinopathy	O
.	O

PEDF	O
is	O
an	O
important	O
negative	O
regulator	O
of	O
angiogenic	O
activity	O
of	O
aqueous	O
humor	O
.	O

Our	O
data	O
may	O
have	O
implications	O
for	O
the	O
development	O
of	O
novel	O
regimens	O
for	O
diabetic	O
retinopathy	O
.	O

Expression	O
of	O
osteoprotegerin	O
and	O
RANK	O
ligand	O
in	O
breast	O
cancer	O
bone	O
metastasis	O
.	O

Bone	O
destruction	O
is	O
primarily	O
mediated	O
by	O
osteoclastic	O
bone	O
resorption	O
,	O
and	O
cancer	O
cells	O
stimulate	O
the	O
formation	O
and	O
activation	O
of	O
osteoclasts	O
next	O
to	O
metastatic	O
foci	O
.	O

Accumulating	O
evidences	O
indicate	O
that	O
receptor	O
activator	O
of	O
NF	O
-	O
kB	O
ligand	O
(	O
RANKL	O
)	O
is	O
the	O
ultimate	O
extracellular	O
mediator	O
that	O
stimulates	O
osteoclast	O
differentiation	O
into	O
mature	O
osteoclasts	O
.	O

In	O
contrast	O
,	O
osteoprotegerin	O
(	O
OPG	O
)	O
inhibits	O
osteoclast	O
development	O
.	O

In	O
order	O
to	O
elucidate	O
a	O
mechanism	O
for	O
cancer	O
-	O
induced	O
osteoclastogenesis	O
,	O
cells	O
from	O
a	O
human	O
breast	O
cancer	O
line	O
,	O
MDA	B
-	I
MB	I
-	I
231	I
,	O
were	O
directly	O
co	O
-	O
cultured	O
with	O
ST2	B
,	O
MC3T3	B
-	I
E1	I
,	O
or	O
with	O
primary	O
mouse	O
calvarial	O
cells	O
.	O

Osteoclast	O
-	O
like	O
cells	O
and	O
tartarate	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
activities	O
were	O
then	O
quantitated	O
.	O

We	O
examined	O
these	O
cell	O
lines	O
and	O
samples	O
from	O
breast	O
cancer	O
by	O
RT	O
-	O
PCR	O
for	O
the	O
expressions	O
of	O
OPG	O
and	O
RANKL	O
mRNA	O
.	O

Compared	O
to	O
controls	O
,	O
co	O
-	O
culture	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
cells	O
with	O
stromal	O
or	O
osteoblastic	O
cells	O
induced	O
an	O
increase	O
in	O
number	O
of	O
osteoclasts	O
and	O
TRAP	O
activities	O
.	O

MDA	B
-	I
MB	I
-	I
231	I
cells	O
alone	O
or	O
breast	O
cancer	O
samples	O
did	O
not	O
express	O
RANKL	O
mRNA	O
.	O

However	O
,	O
co	O
-	O
culture	O
of	O
these	O
cancer	O
cells	O
with	O
stromal	O
or	O
osteoblastic	O
cells	O
induced	O
RANKL	O
mRNA	O
expression	O
and	O
decreased	O
OPG	O
mRNA	O
expression	O
.	O

These	O
experiments	O
demonstrate	O
that	O
direct	O
interactions	O
between	O
breast	O
cancer	O
and	O
stromal	O
or	O
osteoblastic	O
cells	O
induce	O
osteoclastogenesis	O
in	O
vitro	O
through	O
modulating	O
RANKL	O
expression	O
.	O

T140	O
analogs	O
as	O
CXCR4	O
antagonists	O
identified	O
as	O
anti	O
-	O
metastatic	O
agents	O
in	O
the	O
treatment	O
of	O
breast	O
cancer	O
.	O

A	O
chemokine	O
receptor	O
,	O
CXCR4	O
,	O
and	O
its	O
endogenous	O
ligand	O
,	O
stromal	O
cell	O
-	O
derived	O
factor	O
-	O
1	O
(	O
SDF	O
-	O
1	O
)	O
,	O
have	O
been	O
recognized	O
to	O
be	O
involved	O
in	O
the	O
metastasis	O
of	O
several	O
types	O
of	O
cancers	O
.	O

T140	O
analogs	O
are	O
peptidic	O
CXCR4	O
antagonists	O
composed	O
of	O
14	O
amino	O
acid	O
residues	O
that	O
were	O
previously	O
developed	O
as	O
anti	O
-	O
HIV	O
agents	O
having	O
inhibitory	O
activity	O
against	O
HIV	O
-	O
entry	O
through	O
its	O
co	O
-	O
receptor	O
,	O
CXCR4	O
.	O

Herein	O
,	O
we	O
report	O
that	O
these	O
compounds	O
effectively	O
inhibited	O
SDF	O
-	O
1	O
-	O
induced	O
migration	O
of	O
human	O
breast	O
cancer	O
cells	O
(	O
MDA	B
-	I
MB	I
-	I
231	I
)	O
,	O
human	O
leukemia	O
T	O
cells	O
(	O
Sup	B
-	I
T1	I
)	O
and	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
at	O
concentrations	O
of	O
10	O
-	O
100	O
nM	O
in	O
vitro	O
.	O

Furthermore	O
,	O
slow	O
release	O
administration	O
by	O
subcutaneous	O
injection	O
using	O
an	O
Alzet	O
osmotic	O
pump	O
of	O
a	O
potent	O
and	O
bio	O
-	O
stable	O
T140	O
analog	O
,	O
4F	O
-	O
benzoyl	O
-	O
TN14003	O
,	O
gave	O
a	O
partial	O
,	O
but	O
statistically	O
significant	O
(	O
P	O
<	O
/	O
=	O
0	O
.	O
05	O
(	O
t	O
-	O
test	O
)	O
)	O
reduction	O
in	O
pulmonary	O
metastasis	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
in	O
SCID	O
mice	O
,	O
even	O
though	O
no	O
attempt	O
was	O
made	O
to	O
inhibit	O
other	O
important	O
targets	O
such	O
as	O
CCR7	O
.	O

These	O
results	O
suggest	O
that	O
T140	O
analogs	O
have	O
potential	O
use	O
for	O
cancer	O
therapy	O
,	O
and	O
that	O
small	O
molecular	O
CXCR4	O
antagonists	O
could	O
potentially	O
replace	O
neutralizing	O
antibodies	O
as	O
anti	O
-	O
metastatic	O
agents	O
for	O
breast	O
cancer	O
.	O

Treatment	O
effects	O
on	O
nigrostriatal	O
projection	O
integrity	O
in	O
partial	O
6	O
-	O
OHDA	O
lesions	O
:	O
comparison	O
of	O
L	O
-	O
DOPA	O
and	O
pramipexole	O
.	O

There	O
is	O
controversy	O
over	O
potential	O
effects	O
of	O
dopaminergic	O
replacement	O
therapies	O
on	O
the	O
partially	O
lesioned	O
nigrostriatal	O
dopaminergic	O
projection	O
.	O

We	O
evaluated	O
indirect	O
(	O
levodopa	O
,	O
L	O
-	O
DOPA	O
)	O
versus	O
direct	O
(	O
pramipexole	O
,	O
PRA	O
)	O
dopaminergic	O
treatment	O
effects	O
on	O
nigrostriatal	O
lesion	O
severity	O
as	O
measured	O
with	O
vesicular	O
monoamine	O
transporter	O
type	O
-	O
2	O
(	O
VMAT2	O
)	O
binding	O
.	O

Prior	O
studies	O
have	O
shown	O
that	O
striatal	O
VMAT2	O
density	O
provides	O
an	O
objective	O
estimate	O
of	O
dopaminergic	O
neuronal	O
integrity	O
,	O
without	O
confounding	O
effects	O
of	O
compensatory	O
regulation	O
.	O

Partial	O
unilateral	O
median	O
forebrain	O
bundle	O
lesions	O
were	O
made	O
by	O
injection	O
of	O
6	O
-	O
hydroxydopamine	O
in	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

Lesion	O
severity	O
was	O
estimated	O
using	O
rotational	O
behavior	O
after	O
injections	O
of	O
apomorphine	O
and	O
amphetamine	O
.	O

Rats	O
were	O
ranked	O
and	O
matched	O
in	O
pairs	O
by	O
rotation	O
and	O
assigned	O
to	O
receive	O
either	O
PRA	O
(	O
1	O
mg	O
/	O
kg	O
/	O
day	O
)	O
or	O
L	O
-	O
DOPA	O
/	O
benserazide	O
(	O
100	O
/	O
25	O
mg	O
/	O
kg	O
/	O
day	O
)	O
ip	O
via	O
osmotic	O
pump	O
.	O

After	O
4	O
weeks	O
of	O
drug	O
treatment	O
,	O
in	O
vitro	O
autoradiography	O
was	O
performed	O
with	O
[	O
(	O
3	O
)	O
H	O
]	O
methoxytetrabenazine	O
to	O
measure	O
striatal	O
VMAT2	O
binding	O
density	O
.	O

Lesion	O
-	O
to	O
-	O
intact	O
VMAT2	O
density	O
correlated	O
with	O
rotation	O
in	O
both	O
treatment	O
groups	O
.	O

There	O
was	O
no	O
treatment	O
effect	O
on	O
VMAT2	O
expression	O
in	O
the	O
partially	O
lesioned	O
striatum	O
and	O
thus	O
no	O
differential	O
effect	O
of	O
indirect	O
versus	O
direct	O
dopamimetic	O
treatment	O
on	O
nigrostriatal	O
integrity	O
.	O

CCL16	O
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	O
endothelial	O
cells	O
.	O

Besides	O
regulating	O
leukocyte	O
trafficking	O
in	O
normal	O
and	O
injured	O
tissues	O
,	O
several	O
chemokines	O
may	O
positively	O
or	O
negatively	O
regulate	O
angiogenesis	O
.	O

Here	O
we	O
report	O
that	O
CCL16	O
activates	O
an	O
angiogenic	O
program	O
in	O
vascular	O
endothelial	O
cells	O
by	O
activating	O
CCR1	O
.	O

CCL16	O
induces	O
dose	O
-	O
dependent	O
random	O
and	O
directional	O
migration	O
of	O
endothelial	O
cells	O
isolated	O
from	O
large	O
vessels	O
and	O
liver	O
capillaries	O
without	O
inducing	O
their	O
proliferation	O
.	O

It	O
also	O
promotes	O
endothelial	O
differentiation	O
into	O
capillary	O
-	O
like	O
structures	O
in	O
an	O
in	O
vitro	O
assay	O
and	O
is	O
angiogenic	O
in	O
the	O
chick	O
chorionallantoic	O
membrane	O
.	O

These	O
angiogenic	O
activities	O
are	O
neutralized	O
by	O
a	O
specific	O
antibody	O
against	O
CCL16	O
.	O

The	O
direct	O
angiogenic	O
activity	O
of	O
CCL16	O
is	O
further	O
amplified	O
by	O
its	O
ability	O
to	O
prime	O
endothelium	O
to	O
a	O
mitogen	O
signal	O
induced	O
by	O
vascular	O
endothelial	O
growth	O
factor	O
A	O
and	O
to	O
raise	O
their	O
basal	O
production	O
of	O
CXCL8	O
and	O
CCL2	O
,	O
2	O
other	O
angiogenic	O
chemokines	O
.	O

BX471	O
(	O
R	O
-	O
N	O
-	O
[	O
5	O
-	O
chloro	O
-	O
2	O
-	O
[	O
2	O
-	O
[	O
4	O
(	O
4	O
-	O
fluorophenyl	O
)	O
methyl	O
]	O
-	O
2	O
-	O
methyl	O
-	O
1	O
-	O
piperazinyl	O
]	O
-	O
2	O
-	O
oxoethoxy	O
]	O
phenyl	O
]	O
urea	O
hydrochloric	O
acid	O
salt	O
)	O
,	O
a	O
CCR1	O
antagonist	O
,	O
inhibits	O
angiogenic	O
properties	O
of	O
CCL16	O
,	O
whereas	O
blocking	O
of	O
CCR8	O
or	O
desensitizing	O
CCR2	O
,	O
which	O
are	O
both	O
well	O
known	O
receptors	O
for	O
CCL16	O
,	O
did	O
not	O
abolish	O
endothelial	O
activation	O
.	O

CCL16	O
may	O
be	O
specifically	O
cross	O
-	O
linked	O
to	O
CCR1	O
expressed	O
on	O
endothelial	O
cells	O
.	O

The	O
largely	O
restricted	O
CCL16	O
expression	O
in	O
the	O
liver	O
suggests	O
that	O
this	O
chemokine	O
may	O
play	O
a	O
role	O
in	O
hepatic	O
vascular	O
formation	O
during	O
development	O
and	O
in	O
angiogenesis	O
associated	O
to	O
hepatic	O
diseases	O
.	O

Simvastatin	O
induces	O
apoptosis	O
of	O
B	O
-	O
CLL	O
cells	O
by	O
activation	O
of	O
mitochondrial	O
caspase	O
9	O
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
Chronic	O
lymphocytic	O
leukemia	O
(	O
CLL	O
)	O
is	O
the	O
most	O
common	O
leukemia	O
in	O
the	O
western	O
world	O
.	O

Despite	O
several	O
advances	O
in	O
therapeutic	O
options	O
,	O
the	O
disease	O
remains	O
incurable	O
.	O

Recently	O
,	O
it	O
was	O
repeatedly	O
demonstrated	O
that	O
statins	O
,	O
competitive	O
inhibitors	O
of	O
3	O
-	O
hydroxy	O
-	O
3	O
-	O
methyl	O
glutaryl	O
coenzyme	O
A	O
(	O
HMG	O
-	O
CoA	O
)	O
reductase	O
,	O
have	O
antineoplastic	O
effects	O
.	O

Therefore	O
we	O
aimed	O
to	O
study	O
the	O
effects	O
of	O
simvastatin	O
(	O
Sim	O
)	O
on	O
malignant	O
B	O
cells	O
derived	O
from	O
patients	O
with	O
CLL	O
and	O
mechanisms	O
of	O
action	O
of	O
the	O
drug	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Purified	O
B	O
-	O
CLL	O
cells	O
from	O
15	O
patients	O
were	O
cultured	O
either	O
alone	O
or	O
with	O
Sim	O
at	O
concentrations	O
of	O
10	O
,	O
50	O
,	O
and	O
100	O
microM	O
.	O

Viability	O
,	O
measured	O
by	O
the	O
activity	O
of	O
mitochondrial	O
dehydrogenases	O
,	O
was	O
reduced	O
significantly	O
in	O
the	O
cells	O
treated	O
with	O
Sim	O
at	O
50	O
and	O
100	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
005	O
)	O
.	O

The	O
level	O
of	O
apoptosis	O
,	O
as	O
measured	O
by	O
annexin	O
binding	O
to	O
exposed	O
phosphatidylserine	O
moieties	O
,	O
increased	O
significantly	O
in	O
the	O
treated	O
cells	O
at	O
concentrations	O
higher	O
than	O
50	O
microM	O
for	O
24	O
hours	O
(	O
p	O
<	O
0	O
.	O
003	O
)	O
.	O

The	O
level	O
of	O
necrosis	O
,	O
as	O
measured	O
by	O
propidium	O
iodide	O
internalization	O
,	O
increased	O
significantly	O
after	O
24	O
hours	O
exposure	O
to	O
Sim	O
at	O
50	O
microM	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
apoptotic	O
cascade	O
was	O
studied	O
by	O
immunoblot	O
analysis	O
of	O
caspases	O
following	O
Sim	O
treatment	O
.	O

These	O
showed	O
cleavage	O
of	O
caspases	O
9	O
,	O
8	O
,	O
and	O
3	O
.	O

Addition	O
of	O
the	O
caspase	O
inhibitor	O
Z	O
-	O
VAD	O
.	O
fmk	O
inhibited	O
caspase	O
8	O
and	O
3	O
significantly	O
but	O
did	O
not	O
affect	O
caspase	O
9	O
.	O

CONCLUSION	O
:	O
Exposure	O
of	O
clonal	O
B	O
lymphocytes	O
from	O
patients	O
with	O
CLL	O
to	O
simvastatin	O
decreases	O
viability	O
significantly	O
by	O
the	O
induction	O
of	O
apoptosis	O
.	O

The	O
apoptosis	O
induced	O
by	O
Sim	O
is	O
probably	O
initiated	O
by	O
the	O
mitochondrial	O
caspase	O
9	O
,	O
which	O
indirectly	O
leads	O
to	O
activation	O
of	O
caspase	O
3	O
and	O
8	O
.	O

[	O
Community	O
intervention	O
on	O
hypertension	O
and	O
stroke	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
evaluate	O
the	O
community	O
-	O
based	O
intervention	O
on	O
reduction	O
of	O
hypertension	O
and	O
stroke	O
in	O
different	O
age	O
groups	O
and	O
subtypes	O
hypertension	O
.	O

METHODS	O
:	O

In	O
6	O
cities	O
,	O
2	O
geographically	O
separated	O
communities	O
with	O
a	O
registered	O
population	O
about	O
10	O
000	O
of	O
each	O
were	O
selected	O
as	O
either	O
intervention	O
or	O
control	O
communities	O
.	O

A	O
cohort	O
containing	O
2	O
700	O
subjects	O
,	O
35	O
years	O
or	O
older	O
,	O
and	O
free	O
of	O
stroke	O
were	O
sampled	O
from	O
each	O
community	O
.	O

The	O
baseline	O
survey	O
was	O
conducted	O
to	O
screen	O
the	O
subjects	O
for	O
intervention	O
.	O

In	O
each	O
city	O
,	O
a	O
program	O
for	O
control	O
of	O
hypertension	O
,	O
heart	O
diseases	O
and	O
diabetes	O
was	O
initiated	O
in	O
the	O
intervention	O
cohort	O
and	O
health	O
education	O
was	O
provided	O
to	O
the	O
whole	O
intervention	O
community	O
.	O

A	O
follow	O
-	O
up	O
survey	O
was	O
conducted	O
3	O
years	O
later	O
.	O

RESULTS	O
:	O

Within	O
3	O
years	O
,	O
the	O
prevalence	O
of	O
hypertension	O
increased	O
in	O
both	O
intervention	O
and	O
control	O
cohorts	O
,	O
as	O
well	O
as	O
in	O
the	O
middle	O
and	O
elderly	O
cohorts	O
,	O
especially	O
in	O
the	O
middle	O
aged	O
in	O
control	O
group	O
.	O

Among	O
hypertensives	O
in	O
the	O
intervention	O
cohort	O
,	O
the	O
rates	O
of	O
awareness	O
,	O
treatment	O
and	O
control	O
of	O
hypertension	O
got	O
improved	O
.	O

The	O
incidence	O
of	O
stroke	O
was	O
29	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
71	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
58	O
-	O
0	O
.	O
87	O
)	O
and	O
mortality	O
of	O
stroke	O
was	O
40	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
60	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
42	O
-	O
0	O
.	O
86	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
the	O
control	O
cohort	O
.	O

The	O
intervention	O
was	O
most	O
effective	O
in	O
reduction	O
of	O
stroke	O
for	O
those	O
with	O
isolated	O
systolic	O
hypertension	O
and	O
combined	O
systolic	O
and	O
diastolic	O
hypertension	O
(	O
All	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Meanwhile	O
,	O
all	O
-	O
cause	O
mortality	O
was	O
11	O
%	O
lower	O
(	O
HR	O
=	O
0	O
.	O
89	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
78	O
-	O
0	O
.	O
99	O
)	O
in	O
the	O
intervention	O
cohort	O
than	O
in	O
the	O
control	O
cohort	O
.	O

CONCLUSION	O
:	O

The	O
community	O
-	O
based	O
intervention	O
was	O
effective	O
in	O
controlling	O
the	O
development	O
of	O
hypertension	O
and	O
stroke	O
,	O
while	O
the	O
elderly	O
people	O
benefit	O
more	O
than	O
the	O
middle	O
aged	O
people	O
from	O
the	O
intervention	O
.	O

Neutrophil	O
function	O
in	O
chronic	O
neutrophilic	O
leukemia	O
:	O
defective	O
respiratory	O
burst	O
in	O
response	O
to	O
phorbol	O
esters	O
.	O

Functional	O
analyses	O
were	O
performed	O
on	O
neutrophils	O
isolated	O
from	O
6	O
patients	O
from	O
two	O
institutions	O
who	O
displayed	O
features	O
of	O
chronic	O
neutrophilic	O
leukemia	O
(	O
CNL	O
)	O
.	O

These	O
neutrophils	O
demonstrated	O
a	O
consistent	O
deficiency	O
(	O
44	O
+	O
/	O
-	O
8	O
%	O
of	O
control	O
values	O
)	O
in	O
superoxide	O
anion	O
(	O
O2	O
-	O
)	O
production	O
in	O
response	O
to	O
the	O
phorbol	O
ester	O
,	O
phorbol	O
myristate	O
acetate	O
(	O
PMA	O
)	O
.	O

O2	O
-	O
production	O
in	O
response	O
to	O
chemotactic	O
peptides	O
was	O
near	O
normal	O
(	O
82	O
.	O
3	O
+	O
/	O
-	O
10	O
.	O
7	O
%	O
of	O
control	O
values	O
)	O
.	O

Bacterial	O
killing	O
was	O
normal	O
in	O
the	O
two	O
patients	O
studied	O
,	O
and	O
chemotaxis	O
was	O
diminished	O
in	O
response	O
to	O
zymosan	O
-	O
activated	O
plasma	O
and	O
to	O
high	O
concentrations	O
of	O
chemotactic	O
peptides	O
in	O
the	O
patients	O
studied	O
.	O

Cytosolic	O
C	O
kinase	O
activity	O
was	O
decreased	O
in	O
one	O
of	O
the	O
two	O
patients	O
studied	O
.	O

These	O
results	O
suggest	O
that	O
a	O
deficient	O
O2	O
-	O
release	O
in	O
response	O
to	O
PMA	O
is	O
a	O
hallmark	O
of	O
neutrophils	O
in	O
CNL	O
and	O
may	O
provide	O
a	O
diagnostic	O
indicator	O
of	O
this	O
condition	O
.	O

In	O
situ	O
alkylation	O
of	O
cysteine	O
residues	O
in	O
a	O
hydrophobic	O
membrane	O
protein	O
immobilized	O
on	O
polyvinylidene	O
difluoride	O
membranes	O
by	O
electroblotting	O
prior	O
to	O
microsequence	O
and	O
amino	O
acid	O
analysis	O
.	O

For	O
identification	O
of	O
cysteine	O
residues	O
on	O
microsequence	O
analysis	O
it	O
is	O
crucial	O
to	O
derivatize	O
the	O
sulfhydryl	O
groups	O
.	O

This	O
reaction	O
requires	O
a	O
desalting	O
step	O
which	O
often	O
represents	O
a	O
major	O
obstacle	O
,	O
especially	O
if	O
the	O
sample	O
consists	O
of	O
limited	O
amounts	O
of	O
a	O
hydrophobic	O
membrane	O
protein	O
.	O

An	O
alkylation	O
procedure	O
is	O
described	O
,	O
allowing	O
efficient	O
derivatization	O
(	O
greater	O
than	O
90	O
%	O
)	O
of	O
cysteines	O
and	O
cystines	O
even	O
in	O
low	O
microgram	O
quantities	O
,	O
as	O
revealed	O
by	O
test	O
analyses	O
with	O
lysozyme	O
and	O
a	O
hydrophobic	O
membrane	O
protein	O
.	O

The	O
modified	O
protein	O
is	O
recovered	O
in	O
high	O
yields	O
in	O
a	O
form	O
suitable	O
for	O
both	O
microsequence	O
analysis	O
and	O
amino	O
acid	O
analysis	O
.	O

The	O
method	O
involves	O
electrophoretic	O
desalting	O
by	O
miniaturized	O
Tricine	O
-	O
sodium	O
dodecyl	O
sulfate	O
-	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
in	O
situ	O
alkylation	O
after	O
electro	O
-	O
transfer	O
onto	O
polyvinylidene	O
difluoride	O
membranes	O
.	O

Precautions	O
against	O
NH2	O
-	O
terminal	O
blocking	O
during	O
sample	O
preparations	O
are	O
provided	O
.	O

The	O
general	O
applicability	O
of	O
the	O
method	O
is	O
illustrated	O
by	O
the	O
structural	O
characterization	O
of	O
the	O
low	O
abundance	O
membrane	O
receptor	O
for	O
human	O
urokinase	O
plasminogen	O
activator	O
.	O

Cloning	O
and	O
characterization	O
of	O
the	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
of	O
a	O
specific	O
Epstein	O
-	O
Barr	O
virus	O
variant	O
derived	O
from	O
the	O
nasopharyngeal	O
carcinoma	O
in	O
the	O
Taiwanese	O
population	O
.	O

A	O
DNA	O
fragment	O
containing	O
Epstein	O
-	O
Barr	O
virus	O
(	O
EBV	O
)	O
terminal	O
fragment	O
sequence	O
was	O
obtained	O
from	O
a	O
genomic	O
library	O
of	O
nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
.	O

One	O
of	O
the	O
clones	O
(	O
clone	O
1510	O
)	O
contained	O
the	O
gene	O
encoding	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
this	O
gene	O
had	O
95	O
%	O
homology	O
with	O
the	O
LMP	O
sequence	O
of	O
the	O
B95	O
-	O
8	O
strain	O
.	O

Among	O
the	O
sequence	O
variations	O
,	O
there	O
was	O
a	O
change	O
from	O
G	O
to	O
T	O
at	O
nucleotide	O
position	O
169	O
,	O
426	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
an	O
XhoI	O
site	O
in	O
exon	O
1	O
of	O
the	O
LMP	O
gene	O
.	O

A	O
pair	O
of	O
primers	O
bracketing	O
the	O
XhoI	O
site	O
were	O
designed	O
to	O
synthesize	O
the	O
EBV	O
DNA	O
fragment	O
from	O
nucleotides	O
169	O
,	O
081	O
-	O
169	O
,	O
577	O
by	O
using	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
then	O
subject	O
to	O
XhoI	O
digestion	O
and	O
to	O
DNA	O
sequencing	O
analysis	O
.	O

This	O
restriction	O
enzyme	O
site	O
polymorphism	O
along	O
with	O
the	O
sequence	O
variations	O
were	O
also	O
observed	O
in	O
50	O
biopsy	O
tissues	O
as	O
well	O
as	O
in	O
the	O
throat	O
washings	O
of	O
6	O
out	O
of	O
20	O
healthy	O
individuals	O
that	O
we	O
examined	O
,	O
indicating	O
that	O
the	O
EBV	O
strain	O
predominantly	O
existing	O
in	O
these	O
biopsy	O
tissues	O
was	O
different	O
from	O
strains	O
of	O
B95	O
-	O
8	O
,	O
Jijoye	O
or	O
nude	O
mouse	O
passaged	O
cells	O
(	O
C15	B
)	O
with	O
an	O
African	O
origin	O
,	O
but	O
closely	O
resembled	O
other	O
nude	O
mouse	O
passaged	O
CAO	B
cells	O
which	O
were	O
originally	O
derived	O
from	O
China	O
.	O

Balb	B
/	I
c	I
3T3	I
cells	O
carrying	O
this	O
NPC	O
-	O
LMP	O
gene	O
showed	O
a	O
transformed	O
cell	O
morphology	O
and	O
were	O
tumorigenic	O
in	O
nude	O
mice	O
.	O

The	O
relationship	O
between	O
this	O
unique	O
type	O
of	O
EBV	O
and	O
NPC	O
has	O
yet	O
to	O
be	O
established	O
.	O

The	O
effect	O
of	O
p	O
-	O
chlorophenylalanine	O
on	O
the	O
pethidine	O
-	O
or	O
methadone	O
-	O
induced	O
decrease	O
in	O
locomotor	O
activity	O
of	O
rats	O
.	O

Either	O
pethidine	O
HCl	O
(	O
50	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
methadone	O
HCl	O
(	O
8	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
produced	O
a	O
prominent	O
decrease	O
in	O
locomotor	O
activity	O
of	O
rats	O
.	O

Pretreatment	O
of	O
rats	O
with	O
p	O
-	O
chlorophenylalanine	O
(	O
p	O
-	O
CPA	O
,	O
320	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
48	O
h	O
before	O
the	O
narcotic	O
injection	O
significantly	O
antagonized	O
the	O
activity	O
-	O
decreasing	O
effects	O
of	O
narcotics	O
.	O

When	O
rats	O
pretreated	O
with	O
p	O
-	O
CPA	O
were	O
given	O
5	O
-	O
hydroxytryptophan	O
(	O
75	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
30	O
min	O
before	O
narcotic	O
administration	O
,	O
the	O
activity	O
-	O
decreasing	O
response	O
to	O
narcotics	O
was	O
restored	O
.	O

Thus	O
,	O
a	O
decrease	O
in	O
locomotor	O
activity	O
induced	O
in	O
rats	O
by	O
either	O
pethidine	O
or	O
methadone	O
is	O
probably	O
mediated	O
by	O
serotonergic	O
mechanisms	O
.	O

Autocrine	O
angiotensin	O
system	O
regulation	O
of	O
bovine	O
aortic	O
endothelial	O
cell	O
migration	O
and	O
plasminogen	O
activator	O
involves	O
modulation	O
of	O
proto	O
-	O
oncogene	O
pp60c	O
-	O
src	O
expression	O
.	O

Rapid	O
endothelial	O
cell	O
migration	O
and	O
inhibition	O
of	O
thrombosis	O
are	O
critical	O
for	O
the	O
resolution	O
of	O
denudation	O
injuries	O
to	O
the	O
vessel	O
wall	O
.	O

Inhibition	O
of	O
the	O
endothelial	O
cell	O
autocrine	O
angiotensin	O
system	O
,	O
with	O
either	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
lisinopril	O
or	O
the	O
angiotensin	O
II	O
receptor	O
antagonist	O
sar1	O
,	O
ile8	O
-	O
angiotensin	O
II	O
,	O
leads	O
to	O
increased	O
endothelial	O
cell	O
migration	O
and	O
urokinase	O
-	O
like	O
plasminogen	O
activator	O
(	O
u	O
-	O
PA	O
)	O
activity	O
(	O
Bell	O
,	O
L	O
.	O
,	O
and	O
J	O
.	O
A	O
.	O
Madri	O
.	O
1990	O
.	O
Am	O
.	O
J	O
.	O
Pathol	O
.	O
137	O
:	O
7	O
-	O
12	O
)	O
.	O

Inhibition	O
of	O
the	O
autocrine	O
angiotensin	O
system	O
with	O
the	O
converting	O
-	O
enzyme	O
inhibitor	O
or	O
the	O
receptor	O
antagonist	O
also	O
leads	O
to	O
increased	O
expression	O
of	O
the	O
proto	O
-	O
oncogene	O
c	O
-	O
src	O
:	O
pp60c	O
-	O
src	O
mRNA	O
increased	O
7	O
-	O
11	O
-	O
fold	O
,	O
c	O
-	O
src	O
protein	O
3	O
-	O
fold	O
,	O
and	O
c	O
-	O
src	O
kinase	O
activity	O
2	O
-	O
3	O
-	O
fold	O
.	O

Endothelial	O
cell	O
expression	O
of	O
c	O
-	O
src	O
was	O
constitutively	O
elevated	O
after	O
stable	O
infection	O
with	O
a	O
retroviral	O
vector	O
containing	O
the	O
c	O
-	O
src	O
coding	O
sequence	O
.	O

Constitutively	O
increased	O
c	O
-	O
src	O
kinase	O
activity	O
reconstituted	O
the	O
increases	O
in	O
migration	O
and	O
u	O
-	O
PA	O
observed	O
with	O
angiotensin	O
system	O
interruption	O
.	O

Antisera	O
to	O
bovine	O
u	O
-	O
PA	O
blocked	O
the	O
increase	O
in	O
migration	O
associated	O
with	O
increased	O
c	O
-	O
src	O
expression	O
.	O

These	O
data	O
suggest	O
that	O
increases	O
in	O
endothelial	O
cell	O
migration	O
and	O
plasminogen	O
activator	O
after	O
angiotensin	O
system	O
inhibition	O
are	O
at	O
least	O
partially	O
pp60c	O
-	O
src	O
mediated	O
.	O

Elevated	O
c	O
-	O
src	O
expression	O
with	O
angiotensin	O
system	O
inhibition	O
may	O
act	O
to	O
enhance	O
intimal	O
wound	O
closure	O
and	O
to	O
reduce	O
luminal	O
thrombogenicity	O
in	O
vivo	O
.	O

Angiogenesis	O
-	O
-	O
biomedical	O
technology	O
.	O

All	O
of	O
these	O
studies	O
show	O
that	O
angiogenesis	O
research	O
can	O
benefit	O
from	O
new	O
biomedical	O
technology	O
tools	O
currently	O
being	O
developed	O
,	O
as	O
well	O
as	O
contribute	O
by	O
providing	O
new	O
technologies	O
that	O
can	O
be	O
used	O
in	O
other	O
areas	O
of	O
medicine	O
.	O

It	O
is	O
hoped	O
that	O
the	O
chapters	O
in	O
this	O
book	O
in	O
this	O
area	O
will	O
provide	O
the	O
reader	O
with	O
an	O
up	O
-	O
to	O
-	O
date	O
appreciation	O
of	O
some	O
of	O
the	O
exciting	O
research	O
that	O
is	O
currently	O
being	O
pursued	O
.	O

Interleukin	O
-	O
1	O
receptor	O
antagonist	O
inhibits	O
ischaemic	O
and	O
excitotoxic	O
neuronal	O
damage	O
in	O
the	O
rat	O
.	O

Interleukin	O
-	O
1	O
(	O
IL	O
-	O
1	O
)	O
synthesis	O
in	O
the	O
brain	O
is	O
stimulated	O
by	O
mechanical	O
injury	O
and	O
IL	O
-	O
1	O
mimics	O
some	O
effects	O
of	O
injury	O
,	O
such	O
as	O
gliosis	O
and	O
neovascularization	O
.	O

We	O
report	O
that	O
neuronal	O
death	O
resulting	O
from	O
focal	O
cerebral	O
ischaemia	O
(	O
middle	O
cerebral	O
artery	O
occlusion	O
,	O
24	O
h	O
)	O
is	O
significantly	O
inhibited	O
(	O
by	O
50	O
%	O
)	O
in	O
rats	O
injected	O
with	O
a	O
recombinant	O
IL	O
-	O
1	O
receptor	O
antagonist	O
(	O
IL	O
-	O
1ra	O
,	O
10	O
micrograms	O
,	O
icv	O
30	O
min	O
before	O
and	O
10	O
min	O
after	O
ischaemia	O
)	O
.	O

Excitotoxic	O
damage	O
due	O
to	O
striatal	O
infusion	O
of	O
an	O
NMDA	O
-	O
receptor	O
agonist	O
(	O
cis	O
-	O
2	O
,	O
4	O
-	O
methanoglutamate	O
)	O
was	O
also	O
markedly	O
inhibited	O
(	O
71	O
%	O
)	O
by	O
injection	O
of	O
the	O
IL	O
-	O
1ra	O
.	O

These	O
data	O
indicate	O
that	O
endogenous	O
IL	O
-	O
1	O
is	O
a	O
mediator	O
of	O
ischaemic	O
and	O
excitotoxic	O
brain	O
damage	O
,	O
and	O
that	O
inhibitors	O
of	O
IL	O
-	O
1	O
action	O
may	O
be	O
of	O
therapeutic	O
value	O
in	O
the	O
treatment	O
of	O
acute	O
or	O
chronic	O
neuronal	O
death	O
.	O

Laser	O
treatment	O
of	O
eccentric	O
leaks	O
in	O
central	O
serous	O
chorioretinopathy	O
resulting	O
in	O
disappearance	O
of	O
untreated	O
juxtafoveal	O
leaks	O
.	O

In	O
central	O
serous	O
chorioretinopathy	O
(	O
CSCR	O
)	O
laser	O
treatment	O
of	O
leaking	O
points	O
close	O
to	O
the	O
macular	O
center	O
should	O
be	O
avoided	O
because	O
of	O
the	O
possibility	O
of	O
producing	O
juxtafoveal	O
scotoma	O
and	O
stimulating	O
choroidal	O
neovascularization	O
.	O

Nine	O
eyes	O
of	O
nine	O
consecutive	O
patients	O
with	O
CSCR	O
had	O
two	O
or	O
more	O
leaking	O
points	O
within	O
a	O
macular	O
detachment	O
,	O
one	O
of	O
which	O
was	O
foveal	O
or	O
near	O
to	O
the	O
fovea	O
.	O

Photocoagulation	O
with	O
green	O
argon	O
laser	O
was	O
performed	O
in	O
all	O
eyes	O
,	O
treating	O
all	O
the	O
leaking	O
points	O
except	O
for	O
the	O
central	O
one	O
.	O

Visual	O
symptoms	O
regressed	O
after	O
treatment	O
,	O
and	O
the	O
serous	O
detachment	O
was	O
resolved	O
10	O
days	O
to	O
4	O
weeks	O
after	O
photocoagulation	O
in	O
all	O
cases	O
.	O

Fluorescein	O
angiography	O
showed	O
no	O
leakage	O
at	O
either	O
the	O
central	O
leakage	O
point	O
or	O
the	O
leakage	O
point	O
that	O
had	O
been	O
treated	O
.	O

These	O
results	O
led	O
us	O
to	O
believe	O
that	O
the	O
central	O
or	O
dependent	O
leak	O
in	O
our	O
cases	O
was	O
not	O
sufficient	O
to	O
maintain	O
the	O
serous	O
detachment	O
by	O
itself	O
.	O

An	O
alternative	O
hypothesis	O
is	O
that	O
the	O
untreated	O
leak	O
did	O
not	O
represent	O
real	O
fluid	O
movement	O
but	O
only	O
diffusion	O
of	O
fluorescein	O
molecules	O
,	O
or	O
a	O
false	O
leak	O
.	O

In	O
cases	O
of	O
CSCR	O
with	O
multiple	O
leaks	O
within	O
a	O
single	O
macular	O
detachment	O
,	O
we	O
believe	O
that	O
a	O
foveal	O
leak	O
may	O
be	O
a	O
dependent	O
or	O
false	O
leak	O
and	O
that	O
direct	O
treatment	O
is	O
not	O
necessary	O
.	O

Transcriptional	O
and	O
post	O
-	O
translation	O
regulation	O
of	O
the	O
Tie1	O
receptor	O
by	O
fluid	O
shear	O
stress	O
changes	O
in	O
vascular	O
endothelial	O
cells	O
.	O

The	O
interaction	O
between	O
the	O
vascular	O
endothelium	O
and	O
hemodynamic	O
forces	O
(	O
and	O
more	O
specifically	O
,	O
fluid	O
shear	O
stress	O
)	O
,	O
induced	O
by	O
the	O
flow	O
of	O
blood	O
,	O
plays	O
a	O
major	O
role	O
in	O
vascular	O
remodeling	O
and	O
in	O
new	O
blood	O
vessels	O
formation	O
via	O
a	O
process	O
termed	O
arteriogenesis	O
.	O

Tie1	O
is	O
an	O
orphan	O
tyrosine	O
kinase	O
receptor	O
expressed	O
almost	O
exclusively	O
in	O
endothelial	O
cells	O
and	O
is	O
required	O
for	O
normal	O
vascular	O
development	O
and	O
maintenance	O
.	O

The	O
present	O
study	O
demonstrates	O
that	O
Tie1	O
expression	O
is	O
rapidly	O
down	O
-	O
regulated	O
in	O
endothelial	O
cells	O
exposed	O
to	O
shear	O
stress	O
,	O
and	O
more	O
so	O
to	O
shear	O
stress	O
changes	O
.	O

This	O
down	O
-	O
regulation	O
is	O
accompanied	O
by	O
a	O
rapid	O
cleavage	O
of	O
Tie1	O
and	O
binding	O
of	O
the	O
cleaved	O
Tie1	O
45	O
kDa	O
endodomain	O
to	O
Tie2	O
.	O

The	O
rapid	O
cleavage	O
of	O
Tie1	O
is	O
followed	O
by	O
a	O
transcriptional	O
down	O
-	O
regulation	O
in	O
response	O
to	O
shear	O
stress	O
.	O

The	O
activity	O
of	O
the	O
Tie1	O
promoter	O
is	O
suppressed	O
by	O
shear	O
stress	O
and	O
by	O
tumor	O
necrosis	O
factor	O
alpha	O
.	O

Shear	O
stress	O
-	O
induced	O
transcriptional	O
suppression	O
of	O
Tie1	O
is	O
mediated	O
by	O
a	O
negative	O
shear	O
stress	O
response	O
element	O
,	O
localized	O
in	O
a	O
region	O
of	O
250	O
bp	O
within	O
the	O
promoter	O
.	O

The	O
rapid	O
down	O
-	O
regulation	O
of	O
Tie1	O
by	O
shear	O
stress	O
changes	O
and	O
its	O
rapid	O
binding	O
to	O
Tie2	O
may	O
be	O
required	O
for	O
destabilization	O
of	O
endothelial	O
cells	O
in	O
order	O
to	O
initiate	O
the	O
process	O
of	O
vascular	O
restructuring	O
.	O

The	O
presence	O
of	O
nitrite	O
during	O
UVA	O
irradiation	O
protects	O
from	O
apoptosis	O
.	O

Nitrite	O
occurs	O
ubiquitously	O
in	O
biological	O
fluids	O
such	O
as	O
blood	O
and	O
sweat	O
,	O
representing	O
an	O
oxidation	O
product	O
of	O
nitric	O
oxide	O
.	O

Nitrite	O
has	O
been	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
effects	O
such	O
as	O
mutagenicity	O
,	O
carcinogenesis	O
,	O
and	O
toxicity	O
.	O

In	O
contrast	O
,	O
here	O
we	O
demonstrate	O
that	O
the	O
presence	O
of	O
nitrite	O
,	O
but	O
not	O
nitrate	O
,	O
during	O
irradiation	O
of	O
endothelial	O
cells	O
in	O
culture	O
exerts	O
a	O
potent	O
and	O
concentration	O
-	O
dependent	O
protection	O
against	O
UVA	O
-	O
induced	O
apoptotic	O
cell	O
death	O
.	O

Protection	O
is	O
half	O
-	O
maximal	O
at	O
a	O
concentration	O
of	O
3	O
mM	O
,	O
and	O
complete	O
rescue	O
is	O
observed	O
at	O
10	O
mM	O
.	O

Nitrite	O
-	O
mediated	O
protection	O
is	O
mediated	O
via	O
inhibition	O
of	O
lipid	O
peroxidation	O
in	O
a	O
similar	O
manner	O
as	O
seen	O
with	O
butylated	O
hydroxytoluene	O
,	O
a	O
known	O
inhibitor	O
of	O
lipid	O
peroxidation	O
.	O

Interestingly	O
,	O
nitrite	O
-	O
mediated	O
protection	O
is	O
completely	O
abolished	O
by	O
coincubation	O
with	O
the	O
NO	O
scavenger	O
cPTIO	O
.	O

Using	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
or	O
Faraday	O
modulation	O
spectroscopy	O
,	O
we	O
directly	O
prove	O
UVA	O
-	O
induced	O
NO	O
formation	O
in	O
solutions	O
containing	O
nitrite	O
.	O

In	O
conclusion	O
,	O
evidence	O
is	O
presented	O
that	O
nitrite	O
represents	O
a	O
protective	O
agent	O
against	O
UVA	O
-	O
induced	O
apoptosis	O
due	O
to	O
photodecomposition	O
of	O
nitrite	O
and	O
subsequent	O
formation	O
of	O
NO	O
.	O

Maternal	O
antenatal	O
anxiety	O
and	O
behavioural	O
/	O
emotional	O
problems	O
in	O
children	O
:	O
a	O
test	O
of	O
a	O
programming	O
hypothesis	O
.	O

BACKGROUND	O
:	O

Previous	O
animal	O
investigations	O
link	O
antenatal	O
stress	O
with	O
a	O
range	O
of	O
persistent	O
behavioural	O
abnormalities	O
in	O
the	O
offspring	O
.	O

The	O
current	O
study	O
examined	O
if	O
the	O
effect	O
was	O
also	O
found	O
in	O
humans	O
through	O
middle	O
childhood	O
.	O

METHODS	O
:	O

The	O
current	O
study	O
is	O
based	O
on	O
the	O
Avon	O
Longitudinal	O
Study	O
of	O
Parents	O
and	O
Children	O
(	O
ALSPAC	O
)	O
,	O
a	O
prospective	O
,	O
community	O
-	O
based	O
study	O
that	O
has	O
followed	O
a	O
cohort	O
of	O
women	O
from	O
pregnancy	O
.	O

Self	O
-	O
report	O
measures	O
of	O
maternal	O
anxiety	O
and	O
depression	O
were	O
assessed	O
at	O
repeated	O
intervals	O
in	O
pregnancy	O
and	O
the	O
postnatal	O
period	O
.	O

Children	O
'	O
s	O
behavioural	O
/	O
emotional	O
problems	O
were	O
assessed	O
by	O
parent	O
report	O
at	O
age	O
47	O
and	O
81	O
months	O
.	O

Information	O
on	O
obstetric	O
and	O
psychosocial	O
factors	O
was	O
obtained	O
at	O
several	O
points	O
in	O
pregnancy	O
and	O
the	O
postnatal	O
period	O
.	O

RESULTS	O
:	O

Children	O
whose	O
mothers	O
experienced	O
high	O
levels	O
of	O
anxiety	O
in	O
late	O
pregnancy	O
exhibited	O
higher	O
rates	O
of	O
behavioural	O
/	O
emotional	O
problems	O
at	O
81	O
months	O
of	O
age	O
after	O
controlling	O
for	O
obstetric	O
risks	O
,	O
psychosocial	O
disadvantage	O
,	O
and	O
postnatal	O
anxiety	O
and	O
depression	O
(	O
for	O
girls	O
,	O
OR	O
=	O
1	O
.	O
91	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
26	O
-	O
2	O
.	O
89	O
;	O
for	O
boys	O
,	O
OR	O
=	O
2	O
.	O
16	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
41	O
-	O
3	O
.	O
30	O
)	O
.	O

Furthermore	O
,	O
the	O
effect	O
at	O
81	O
months	O
was	O
comparable	O
to	O
what	O
was	O
previously	O
obtained	O
at	O
47	O
months	O
,	O
suggesting	O
the	O
kind	O
of	O
persistent	O
effect	O
proposed	O
in	O
the	O
animal	O
literature	O
.	O

CONCLUSIONS	O
:	O

There	O
is	O
evidence	O
that	O
antenatal	O
stress	O
/	O
anxiety	O
has	O
a	O
programming	O
effect	O
on	O
the	O
fetus	O
which	O
lasts	O
at	O
least	O
until	O
middle	O
childhood	O
.	O

Therapeutic	O
angiogenesis	O
:	O
a	O
complex	O
problem	O
requiring	O
a	O
sophisticated	O
approach	O
.	O

Blood	O
and	O
vascular	O
disorders	O
underlie	O
a	O
plethora	O
of	O
pathologic	O
conditions	O
and	O
are	O
the	O
single	O
most	O
frequent	O
cause	O
of	O
human	O
disease	O
.	O

Ischemia	O
,	O
involving	O
restricted	O
blood	O
flow	O
to	O
tissues	O
is	O
the	O
most	O
common	O
consequence	O
of	O
vessel	O
dysfunction	O
resulting	O
in	O
the	O
disruption	O
of	O
oxygen	O
and	O
nutrient	O
delivery	O
and	O
the	O
accumulation	O
of	O
waste	O
metabolites	O
.	O

Cells	O
can	O
not	O
survive	O
extended	O
severe	O
ischemia	O
but	O
may	O
be	O
able	O
to	O
adapt	O
to	O
a	O
moderate	O
condition	O
where	O
diffusion	O
to	O
and	O
from	O
bordering	O
nonischemic	O
regions	O
sustains	O
vital	O
functions	O
.	O

Under	O
this	O
condition	O
,	O
the	O
secondary	O
functions	O
of	O
effected	O
cells	O
are	O
likely	O
to	O
be	O
impaired	O
,	O
and	O
a	O
new	O
metabolic	O
equilibrium	O
is	O
established	O
,	O
determined	O
by	O
the	O
level	O
of	O
cross	O
-	O
diffusion	O
and	O
degree	O
of	O
hypoxia	O
.	O

In	O
tissues	O
with	O
a	O
normally	O
high	O
metabolic	O
turnover	O
such	O
as	O
skeletal	O
and	O
cardiac	O
muscle	O
,	O
even	O
mild	O
ischemia	O
causes	O
hypoxia	O
,	O
acidosis	O
,	O
and	O
depressed	O
function	O
(	O
contractility	O
)	O
and	O
eventually	O
threatens	O
myocyte	O
viability	O
and	O
organ	O
function	O
.	O

Ischemic	O
cardiac	O
muscle	O
is	O
additionally	O
vulnerable	O
because	O
reperfusion	O
is	O
essential	O
for	O
survival	O
but	O
reperfusion	O
itself	O
poses	O
additional	O
stress	O
principally	O
from	O
increased	O
production	O
of	O
free	O
radicals	O
during	O
reoxygenation	O
.	O

The	O
latter	O
effect	O
is	O
called	O
reperfusion	O
injury	O
and	O
can	O
cause	O
as	O
much	O
damage	O
as	O
the	O
ischemia	O
.	O

The	O
treatment	O
possibilities	O
for	O
ischemia	O
-	O
related	O
vascular	O
disease	O
are	O
limited	O
.	O

Lipid	O
/	O
cholesterol	O
-	O
lowering	O
agents	O
,	O
diet	O
and	O
antiplatelet	O
adherence	O
(	O
aspirin	O
)	O
therapy	O
may	O
help	O
slow	O
the	O
progression	O
of	O
vessel	O
disease	O
in	O
some	O
instances	O
;	O
but	O
surgical	O
reconstruction	O
may	O
be	O
the	O
only	O
option	O
in	O
advanced	O
stages	O
,	O
and	O
even	O
this	O
is	O
not	O
always	O
an	O
option	O
.	O

An	O
alternative	O
and	O
rather	O
obvious	O
strategy	O
to	O
treat	O
ischemia	O
is	O
to	O
activate	O
endogenous	O
angiogenic	O
or	O
arteriogenic	O
pathways	O
to	O
stimulate	O
revascularization	O
of	O
the	O
tissue	O
.	O

The	O
feasibility	O
of	O
such	O
a	O
strategy	O
has	O
now	O
been	O
established	O
through	O
the	O
results	O
of	O
studies	O
over	O
the	O
past	O
decade	O
,	O
and	O
a	O
new	O
discipline	O
called	O
therapeutic	O
angiogenesis	O
has	O
emerged	O
.	O

This	O
review	O
focuses	O
on	O
the	O
application	O
of	O
therapeutic	O
angiogenesis	O
for	O
treating	O
ischemic	O
muscle	O
disease	O
and	O
includes	O
a	O
critical	O
evaluation	O
of	O
the	O
parameters	O
and	O
limitations	O
of	O
current	O
procedures	O
.	O

The	O
development	O
of	O
this	O
technology	O
has	O
benefited	O
from	O
its	O
application	O
to	O
both	O
peripheral	O
and	O
coronary	O
artery	O
disease	O
and	O
results	O
from	O
both	O
are	O
reviewed	O
here	O
.	O

Induction	O
of	O
apoptosis	O
in	O
skeletal	O
tissues	O
:	O
phosphate	O
-	O
mediated	O
chick	O
chondrocyte	O
apoptosis	O
is	O
calcium	O
dependent	O
.	O

In	O
an	O
earlier	O
study	O
,	O
we	O
have	O
shown	O
that	O
Pi	O
induced	O
apoptosis	O
of	O
terminally	O
differentiated	O
hypertrophic	O
chondrocytes	O
.	O

To	O
ascertain	O
whether	O
Ca2	O
+	O
modulates	O
Pi	O
-	O
induced	O
cell	O
death	O
,	O
we	O
asked	O
the	O
following	O
two	O
questions	O
:	O
First	O
,	O
can	O
we	O
prevent	O
Pi	O
-	O
induced	O
apoptosis	O
by	O
removing	O
Ca2	O
+	O
from	O
the	O
culture	O
medium	O
;	O
alternatively	O
,	O
can	O
we	O
potentiate	O
cell	O
death	O
by	O
increasing	O
the	O
Ca2	O
+	O
concentration	O
?	O

Second	O
,	O
can	O
we	O
inhibit	O
chondrocyte	O
apoptosis	O
by	O
blocking	O
Pi	O
transport	O
?	O

We	O
also	O
explored	O
the	O
mechanism	O
of	O
apoptosis	O
by	O
evaluating	O
mitochondrial	O
activity	O
and	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
generation	O
in	O
cells	O
treated	O
with	O
the	O
ion	O
pair	O
.	O

We	O
noted	O
that	O
EDTA	O
and	O
EGTA	O
blocked	O
Pi	O
-	O
induced	O
apoptosis	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

While	O
high	O
levels	O
of	O
Ca2	O
+	O
alone	O
had	O
little	O
effect	O
on	O
chondrocyte	O
viability	O
,	O
the	O
cation	O
enhanced	O
Pi	O
-	O
dependent	O
cell	O
death	O
and	O
greatly	O
increased	O
Pi	O
uptake	O
.	O

When	O
Pi	O
transport	O
was	O
blocked	O
,	O
there	O
was	O
complete	O
inhibition	O
of	O
cell	O
killing	O
.	O

The	O
process	O
of	O
cell	O
death	O
was	O
characterized	O
by	O
mitochondrial	O
hyperpolarization	O
;	O
two	O
hours	O
following	O
apoptogen	O
treatment	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
mitochondrial	O
membrane	O
potential	O
.	O

Coincident	O
with	O
the	O
changes	O
in	O
mitochondrial	O
function	O
,	O
there	O
was	O
an	O
increase	O
in	O
intracellular	O
Ca2	O
+	O
that	O
was	O
maintained	O
throughout	O
the	O
experimental	O
period	O
.	O

A	O
raised	O
Ca2	O
+	O
signal	O
was	O
observed	O
in	O
blebs	O
at	O
the	O
cell	O
membrane	O
.	O

Finally	O
,	O
we	O
noted	O
that	O
,	O
75	O
minutes	O
after	O
treatment	O
with	O
the	O
ion	O
pair	O
,	O
there	O
was	O
a	O
six	O
-	O
fold	O
elevation	O
in	O
ROS	O
levels	O
.	O

This	O
increase	O
declined	O
to	O
baseline	O
values	O
after	O
three	O
hours	O
.	O

Based	O
on	O
these	O
observations	O
,	O
we	O
suggest	O
that	O
,	O
at	O
the	O
cartilage	O
mineralization	O
front	O
,	O
an	O
elevation	O
in	O
local	O
environmental	O
Ca2	O
+	O
and	O
Pi	O
concentrations	O
modulates	O
oxidative	O
metabolism	O
,	O
and	O
triggers	O
apoptosis	O
of	O
terminally	O
differentiated	O
chondrocytes	O
.	O

Cell	O
type	O
-	O
specific	O
regulation	O
of	O
angiogenic	O
growth	O
factor	O
gene	O
expression	O
and	O
induction	O
of	O
angiogenesis	O
in	O
nonischemic	O
tissue	O
by	O
a	O
constitutively	O
active	O
form	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
.	O

Understanding	O
molecular	O
mechanisms	O
regulating	O
angiogenesis	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
ischemic	O
disorders	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF	O
-	O
1	O
)	O
activates	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
gene	O
expression	O
in	O
hypoxic	O
/	O
ischemic	O
tissue	O
.	O

In	O
this	O
study	O
we	O
demonstrate	O
that	O
exposure	O
of	O
primary	O
cultures	O
of	O
cardiac	O
and	O
vascular	O
cells	O
to	O
hypoxia	O
or	O
AdCA5	O
,	O
an	O
adenovirus	O
encoding	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	O
-	O
1alpha	O
,	O
modulates	O
the	O
expression	O
of	O
genes	O
encoding	O
the	O
angiogenic	O
factors	O
angiopoietin	O
-	O
1	O
(	O
ANGPT1	O
)	O
,	O
ANGPT2	O
,	O
placental	O
growth	O
factor	O
,	O
and	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
.	O

Loss	O
-	O
of	O
-	O
function	O
effects	O
were	O
also	O
observed	O
in	O
HIF	O
-	O
1alpha	O
-	O
null	O
embryonic	O
stem	O
cells	O
.	O

Depending	O
on	O
the	O
cell	O
type	O
,	O
expression	O
of	O
ANGPT1	O
and	O
ANGPT2	O
was	O
either	O
activated	O
or	O
repressed	O
in	O
response	O
to	O
hypoxia	O
or	O
AdCA5	O
.	O

In	O
all	O
cases	O
,	O
there	O
was	O
complete	O
concordance	O
between	O
the	O
effects	O
of	O
hypoxia	O
and	O
AdCA5	O
.	O

Injection	O
of	O
AdCA5	O
into	O
mouse	O
eyes	O
induced	O
neovascularization	O
in	O
multiple	O
capillary	O
beds	O
,	O
including	O
those	O
not	O
responsive	O
to	O
VEGF	O
alone	O
.	O

Analysis	O
of	O
gene	O
expression	O
revealed	O
increased	O
expression	O
of	O
ANGPT1	O
,	O
ANGPT2	O
,	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
,	O
placental	O
growth	O
factor	O
,	O
and	O
VEGF	O
mRNA	O
in	O
AdCA5	O
-	O
injected	O
eyes	O
.	O

These	O
results	O
indicate	O
that	O
HIF	O
-	O
1	O
functions	O
as	O
a	O
master	O
regulator	O
of	O
angiogenesis	O
by	O
controlling	O
the	O
expression	O
of	O
multiple	O
angiogenic	O
growth	O
factors	O
and	O
that	O
adenovirus	O
-	O
mediated	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
of	O
HIF	O
-	O
1alpha	O
is	O
sufficient	O
to	O
induce	O
angiogenesis	O
in	O
nonischemic	O
tissue	O
of	O
an	O
adult	O
animal	O
.	O

Differential	O
regulation	O
of	O
in	O
vivo	O
angiogenesis	O
by	O
angiotensin	O
II	O
receptors	O
.	O

Angiotensin	O
II	O
(	O
ANG	O
II	O
)	O
,	O
a	O
key	O
regulator	O
of	O
blood	O
pressure	O
and	O
body	O
fluid	O
homeostasis	O
,	O
exerts	O
mitogenic	O
effects	O
on	O
endothelial	O
cells	O
.	O

We	O
therefore	O
hypothesized	O
that	O
ANG	O
II	O
could	O
be	O
a	O
mediator	O
between	O
homeostatic	O
changes	O
within	O
the	O
vascular	O
perfusion	O
bed	O
and	O
growth	O
factor	O
-	O
driven	O
angiogenesis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
applied	O
the	O
alginate	O
implant	O
angiogenesis	O
model	O
in	O
mice	O
with	O
normal	O
ANG	O
II	O
levels	O
,	O
elevated	O
ANG	O
II	O
levels	O
by	O
transgenic	O
overexpression	O
of	O
angiotensinogen	O
(	O
AOGEN	O
)	O
,	O
or	O
in	O
AT2	O
receptor	O
-	O
deficient	O
mice	O
.	O

We	O
demonstrate	O
that	O
a	O
decrease	O
in	O
the	O
amount	O
of	O
circulating	O
ANG	O
II	O
by	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
enalapril	O
or	O
the	O
AT1	O
receptor	O
antagonist	O
losartan	O
induced	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
implying	O
an	O
inhibitory	O
function	O
of	O
ANG	O
II	O
through	O
the	O
AT1	O
receptor	O
.	O

However	O
,	O
the	O
strong	O
increase	O
of	O
angiogenesis	O
in	O
AOGEN	O
-	O
transgenic	O
mice	O
compared	O
with	O
mice	O
with	O
normal	O
ANG	O
II	O
levels	O
suggests	O
additional	O
stimulatory	O
activity	O
.	O

We	O
showed	O
that	O
the	O
ANG	O
II	O
-	O
induced	O
stimulation	O
of	O
angiogenesis	O
is	O
linked	O
to	O
the	O
AT2	O
receptor	O
as	O
an	O
impaired	O
induction	O
of	O
angiogenesis	O
was	O
obtained	O
in	O
AT2	O
receptor	O
knockout	O
mice	O
.	O

These	O
findings	O
provide	O
the	O
first	O
evidence	O
that	O
the	O
AT2	O
receptor	O
mediates	O
a	O
stimulation	O
of	O
in	O
vivo	O
angiogenesis	O
and	O
indicate	O
that	O
ANG	O
II	O
is	O
a	O
humoral	O
regulator	O
of	O
peripheral	O
angiogenesis	O
involving	O
two	O
receptor	O
subtypes	O
with	O
opposing	O
actions	O
.	O

Expression	O
,	O
regulation	O
,	O
and	O
function	O
of	O
IGF	O
-	O
1	O
,	O
IGF	O
-	O
1R	O
,	O
and	O
IGF	O
-	O
1	O
binding	O
proteins	O
in	O
blood	O
vessels	O
.	O

The	O
vascular	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-	O
1	O
system	O
includes	O
the	O
IGFs	O
,	O
the	O
IGF	O
-	O
1	O
receptor	O
(	O
IGF	O
-	O
1R	O
)	O
,	O
and	O
multiple	O
binding	O
proteins	O
.	O

This	O
growth	O
factor	O
system	O
exerts	O
multiple	O
physiologic	O
effects	O
on	O
the	O
vasculature	O
through	O
both	O
endocrine	O
and	O
autocrine	O
/	O
paracrine	O
mechanisms	O
.	O

The	O
effects	O
of	O
IGF	O
-	O
1	O
are	O
mediated	O
principally	O
through	O
the	O
IGF	O
-	O
1R	O
but	O
are	O
modulated	O
by	O
complex	O
interactions	O
with	O
multiple	O
IGF	O
binding	O
proteins	O
that	O
themselves	O
are	O
regulated	O
by	O
phosphorylation	O
,	O
proteolysis	O
,	O
polymerization	O
,	O
and	O
cell	O
or	O
matrix	O
association	O
.	O

During	O
the	O
last	O
decade	O
,	O
a	O
significant	O
body	O
of	O
evidence	O
has	O
accumulated	O
,	O
indicating	O
that	O
expression	O
of	O
the	O
components	O
of	O
the	O
IGF	O
system	O
are	O
regulated	O
by	O
multiple	O
factors	O
,	O
including	O
growth	O
factors	O
,	O
cytokines	O
,	O
lipoproteins	O
,	O
reactive	O
oxygen	O
species	O
,	O
and	O
hemodynamic	O
forces	O
.	O

In	O
addition	O
,	O
cross	O
-	O
talk	O
between	O
the	O
IGF	O
system	O
and	O
other	O
growth	O
factors	O
and	O
integrin	O
receptors	O
has	O
been	O
demonstrated	O
.	O

There	O
is	O
accumulating	O
evidence	O
of	O
a	O
role	O
for	O
IGF	O
-	O
1	O
in	O
multiple	O
vascular	O
pathologies	O
,	O
including	O
atherosclerosis	O
,	O
hypertension	O
,	O
restenosis	O
,	O
angiogenesis	O
,	O
and	O
diabetic	O
vascular	O
disease	O
.	O

This	O
review	O
will	O
discuss	O
the	O
regulation	O
of	O
expression	O
of	O
IGF	O
-	O
1	O
,	O
IGF	O
-	O
1R	O
,	O
and	O
IGF	O
binding	O
proteins	O
in	O
the	O
vasculature	O
and	O
summarize	O
evidence	O
implicating	O
involvement	O
of	O
this	O
system	O
in	O
vascular	O
diseases	O
.	O

Microvascular	O
density	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
immunoreactivity	O
as	O
predictors	O
of	O
regional	O
lymph	O
node	O
metastasis	O
from	O
betel	O
-	O
associated	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

PURPOSE	O
:	O
Neovascularization	O
has	O
profound	O
effects	O
on	O
tumor	O
growth	O
and	O
metastasis	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
mitogen	O
that	O
acts	O
exclusively	O
on	O
endothelial	O
cells	O
.	O

The	O
roles	O
of	O
miscrovascularity	O
density	O
(	O
MVD	O
)	O
and	O
VEGF	O
expression	O
in	O
the	O
progression	O
of	O
oral	O
squamous	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
have	O
been	O
controversial	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
measure	O
the	O
MVD	O
and	O
VEGF	O
expression	O
in	O
a	O
cohort	O
of	O
patients	O
with	O
betel	O
-	O
associated	O
OSCC	O
and	O
to	O
evaluate	O
for	O
possible	O
clinicopathologic	O
correlations	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
paraffin	O
sections	O
from	O
49	O
subjects	O
with	O
OSCC	O
were	O
subjected	O
to	O
immunohistochemical	O
studies	O
to	O
measure	O
the	O
highest	O
MVD	O
(	O
h	O
-	O
MVD	O
)	O
and	O
cytoplasmic	O
immunoreactivity	O
of	O
VEGF	O
.	O

The	O
findings	O
in	O
the	O
tissue	O
samples	O
were	O
analyzed	O
with	O
regard	O
to	O
the	O
patients	O
'	O
risk	O
factors	O
and	O
clinical	O
course	O
.	O

RESULTS	O
:	O
The	O
OSCC	O
samples	O
had	O
an	O
average	O
h	O
-	O
MVD	O
score	O
of	O
27	O
.	O
7	O
/	O
mm	O
(	O
2	O
)	O
.	O

VEGF	O
immunoreactivity	O
was	O
positive	O
in	O
75	O
.	O
5	O
%	O
of	O
samples	O
.	O

Both	O
h	O
-	O
MVD	O
and	O
VEGF	O
immunoreactivity	O
were	O
statistically	O
associated	O
with	O
lymph	O
node	O
metastasis	O
(	O
P	O
=	O
.	O
012	O
and	O
.	O
037	O
,	O
respectively	O
)	O
.	O

A	O
marginally	O
significant	O
association	O
was	O
also	O
noted	O
between	O
the	O
h	O
-	O
MVD	O
and	O
patient	O
survival	O
(	O
P	O
=	O
.	O
056	O
)	O
.	O

The	O
age	O
and	O
oral	O
habits	O
of	O
patients	O
,	O
as	O
well	O
as	O
the	O
tumor	O
site	O
and	O
size	O
,	O
did	O
not	O
appear	O
to	O
be	O
correlated	O
with	O
h	O
-	O
MVD	O
or	O
VEGF	O
immunoreactivity	O
.	O

CONCLUSION	O
:	O
The	O
data	O
suggest	O
that	O
both	O
h	O
-	O
MVD	O
and	O
VEGF	O
immunoreactivity	O
may	O
be	O
useful	O
predictors	O
for	O
the	O
progression	O
of	O
a	O
subset	O
of	O
OSCC	O
associated	O
mostly	O
with	O
betel	O
use	O
.	O

Antiangiogenesis	O
therapy	O
might	O
have	O
a	O
role	O
in	O
reducing	O
regional	O
metastasis	O
.	O

Insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
enhances	O
invasion	O
and	O
induces	O
resistance	O
to	O
apoptosis	O
of	O
colon	O
cancer	O
cells	O
through	O
the	O
Akt	O
/	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
pathway	O
.	O

Colon	O
cancer	O
overexpresses	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF1	O
)	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
receptor	O
(	O
IGF1	O
-	O
R	O
)	O
,	O
as	O
compared	O
with	O
normal	O
or	O
adenomatous	O
mucosa	O
,	O
and	O
it	O
has	O
been	O
postulated	O
that	O
colorectal	O
cancer	O
cells	O
depend	O
on	O
the	O
IGF1	O
/	O
IGF1	O
-	O
R	O
pathway	O
for	O
their	O
growth	O
and	O
progression	O
.	O

In	O
this	O
study	O
,	O
using	O
the	O
human	O
colon	O
cancer	O
cell	O
line	O
HCT116	B
,	O
we	O
find	O
that	O
established	O
HCT116	B
/	O
IGF1	O
-	O
R	O
transfectants	O
exhibit	O
a	O
more	O
aggressive	O
transformed	O
phenotype	O
than	O
the	O
parental	O
cell	O
line	O
,	O
as	O
demonstrated	O
by	O
their	O
higher	O
proliferation	O
rate	O
in	O
response	O
to	O
IGF1	O
,	O
higher	O
degree	O
of	O
anchorage	O
-	O
independent	O
growth	O
,	O
resistance	O
to	O
serum	O
deprivation	O
-	O
induced	O
apoptosis	O
,	O
and	O
higher	O
migratory	O
capability	O
in	O
a	O
monolayer	O
""""	O
wounding	O
assay	O
.	O
""""	O
When	O
injected	O
into	O
nude	O
mice	O
,	O
HCT116	B
/	O
IGF1	O
-	O
R	O
transfectants	O
were	O
highly	O
invasive	O
and	O
produced	O
distant	O
metastases	O
,	O
whereas	O
the	O
parental	O
cell	O
did	O
not	O
.	O

Moreover	O
,	O
the	O
overexpression	O
of	O
IGF1	O
-	O
R	O
in	O
these	O
cells	O
was	O
associated	O
with	O
IGF1	O
-	O
R	O
-	O
induced	O
activation	O
of	O
Akt	O
and	O
up	O
-	O
regulation	O
of	O
the	O
antiapoptotic	O
protein	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
.	O

We	O
also	O
show	O
that	O
Akt	O
pathway	O
mediates	O
IGF1	O
-	O
R	O
-	O
induced	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
expression	O
at	O
transcriptional	O
level	O
.	O

Our	O
data	O
demonstrate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
IGF1	O
-	O
R	O
/	O
Akt	O
/	O
Bcl	O
-	O
x	O
(	O
L	O
)	O
pathway	O
may	O
contribute	O
to	O
a	O
more	O
aggressive	O
malignant	O
phenotype	O
,	O
in	O
a	O
subset	O
of	O
colorectal	O
cancers	O
.	O

Promotion	O
of	O
tumorigenesis	O
by	O
heterozygous	O
disruption	O
of	O
the	O
beclin	O
1	O
autophagy	O
gene	O
.	O

Malignant	O
cells	O
often	O
display	O
defects	O
in	O
autophagy	O
,	O
an	O
evolutionarily	O
conserved	O
pathway	O
for	O
degrading	O
long	O
-	O
lived	O
proteins	O
and	O
cytoplasmic	O
organelles	O
.	O

However	O
,	O
as	O
yet	O
,	O
there	O
is	O
no	O
genetic	O
evidence	O
for	O
a	O
role	O
of	O
autophagy	O
genes	O
in	O
tumor	O
suppression	O
.	O

The	O
beclin	O
1	O
autophagy	O
gene	O
is	O
monoallelically	O
deleted	O
in	O
40	O
-	O
75	O
%	O
of	O
cases	O
of	O
human	O
sporadic	O
breast	O
,	O
ovarian	O
,	O
and	O
prostate	O
cancer	O
.	O

Therefore	O
,	O
we	O
used	O
a	O
targeted	O
mutant	O
mouse	O
model	O
to	O
test	O
the	O
hypothesis	O
that	O
monoallelic	O
deletion	O
of	O
beclin	O
1	O
promotes	O
tumorigenesis	O
.	O

Here	O
we	O
show	O
that	O
heterozygous	O
disruption	O
of	O
beclin	O
1	O
increases	O
the	O
frequency	O
of	O
spontaneous	O
malignancies	O
and	O
accelerates	O
the	O
development	O
of	O
hepatitis	O
B	O
virus	O
-	O
induced	O
premalignant	O
lesions	O
.	O

Molecular	O
analyses	O
of	O
tumors	O
in	O
beclin	O
1	O
heterozygous	O
mice	O
show	O
that	O
the	O
remaining	O
wild	O
-	O
type	O
allele	O
is	O
neither	O
mutated	O
nor	O
silenced	O
.	O

Furthermore	O
,	O
beclin	O
1	O
heterozygous	O
disruption	O
results	O
in	O
increased	O
cellular	O
proliferation	O
and	O
reduced	O
autophagy	O
in	O
vivo	O
.	O

These	O
findings	O
demonstrate	O
that	O
beclin	O
1	O
is	O
a	O
haplo	O
-	O
insufficient	O
tumor	O
-	O
suppressor	O
gene	O
and	O
provide	O
genetic	O
evidence	O
that	O
autophagy	O
is	O
a	O
novel	O
mechanism	O
of	O
cell	O
-	O
growth	O
control	O
and	O
tumor	O
suppression	O
.	O

Thus	O
,	O
mutation	O
of	O
beclin	O
1	O
or	O
other	O
autophagy	O
genes	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
human	O
cancers	O
.	O

Effects	O
of	O
dietary	O
folate	O
on	O
ulcerative	O
colitis	O
-	O
associated	O
colorectal	O
carcinogenesis	O
in	O
the	O
interleukin	O
2	O
-	O
and	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
-	O
deficient	O
mice	O
.	O

Folate	O
supplementation	O
may	O
reduce	O
the	O
risk	O
of	O
colorectal	O
dysplasia	O
and	O
cancer	O
in	O
subjects	O
with	O
chronic	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
.	O

The	O
interleukin	O
(	O
IL	O
)	O
2	O
-	O
and	O
beta	O
(	O
2	O
)	O
-	O
microglobulin	O
(	O
beta	O
(	O
2	O
)	O
m	O
)	O
-	O
deficient	O
(	O
IL	O
-	O
2	O
(	O
null	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
null	O
)	O
)	O
mice	O
spontaneously	O
develop	O
colon	O
cancer	O
in	O
the	O
setting	O
of	O
chronic	O
UC	O
.	O

This	O
study	O
investigated	O
the	O
effects	O
of	O
dietary	O
folate	O
on	O
the	O
development	O
of	O
UC	O
-	O
associated	O
colon	O
cancer	O
in	O
the	O
IL	O
-	O
2	O
(	O
null	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
null	O
)	O
mice	O
.	O

Weaning	O
IL	O
-	O
2	O
(	O
null	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
null	O
)	O
mice	O
were	O
randomized	O
to	O
receive	O
0	O
(	O
deficient	O
;	O
n	O
=	O
40	O
)	O
,	O
2	O
(	O
basal	O
requirement	O
;	O
control	O
;	O
n	O
=	O
46	O
)	O
,	O
or	O
8	O
(	O
supplemented	O
;	O
n	O
=	O
36	O
)	O
mg	O
folate	O
/	O
kg	O
diet	O
for	O
32	O
weeks	O
.	O

At	O
necropsy	O
,	O
all	O
macroscopic	O
colonic	O
tumors	O
were	O
identified	O
and	O
histologically	O
classified	O
as	O
dysplasia	O
or	O
adenocarcinoma	O
.	O

The	O
incidence	O
of	O
high	O
-	O
grade	O
lesions	O
(	O
high	O
-	O
grade	O
dysplasia	O
/	O
carcinoma	O
in	O
situ	O
and	O
invasive	O
adenocarcinoma	O
)	O
in	O
the	O
folate	O
-	O
supplemented	O
group	O
was	O
46	O
%	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
35	O
.	O
3	O
%	O
versus	O
65	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
.	O

The	O
incidence	O
of	O
high	O
-	O
grade	O
lesions	O
in	O
the	O
folate	O
-	O
deficient	O
group	O
was	O
also	O
49	O
%	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
(	O
33	O
.	O
3	O
%	O
versus	O
65	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

The	O
higher	O
mortality	O
rate	O
in	O
the	O
folate	O
-	O
deficient	O
group	O
compared	O
with	O
the	O
other	O
two	O
groups	O
(	O
25	O
%	O
versus	O
6	O
.	O
5	O
%	O
and	O
5	O
.	O
6	O
%	O
,	O
P	O
<	O
0	O
.	O
02	O
)	O
partially	O
accounted	O
for	O
the	O
low	O
incidence	O
of	O
high	O
-	O
grade	O
lesions	O
in	O
this	O
group	O
.	O

These	O
data	O
indicate	O
that	O
dietary	O
folate	O
supplementation	O
at	O
4x	O
the	O
basal	O
dietary	O
requirement	O
significantly	O
suppresses	O
UC	O
-	O
associated	O
colorectal	O
carcinogenesis	O
in	O
the	O
IL	O
-	O
2	O
(	O
null	O
)	O
x	O
beta	O
(	O
2	O
)	O
m	O
(	O
null	O
)	O
mice	O
.	O

These	O
data	O
also	O
suggest	O
that	O
folate	O
deficiency	O
may	O
inhibit	O
colorectal	O
carcinogenesis	O
in	O
chronic	O
UC	O
.	O

However	O
,	O
the	O
high	O
mortality	O
observed	O
in	O
the	O
folate	O
-	O
deficient	O
group	O
precludes	O
a	O
definitive	O
conclusion	O
concerning	O
the	O
effect	O
of	O
folate	O
deficiency	O
on	O
UC	O
-	O
associated	O
colorectal	O
carcinogenesis	O
in	O
this	O
model	O
.	O

[	O
Laboratory	O
diagnostics	O
of	O
Crimean	O
hemorrhagic	O
fever	O
by	O
polymerase	O
chain	O
reaction	O
]	O
.	O

Our	O
group	O
developed	O
,	O
within	O
the	O
present	O
case	O
study	O
,	O
two	O
techniques	O
'	O
variations	O
,	O
i	O
.	O
e	O
.	O
a	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
and	O
nested	O
RT	O
-	O
PCR	O
assays	O
,	O
for	O
the	O
purpose	O
of	O
detecting	O
the	O
Crimean	O
-	O
Congo	O
hemorrhagic	O
fever	O
RNA	O
virus	O
in	O
human	O
samples	O
.	O

The	O
above	O
assays	O
as	O
well	O
as	O
those	O
previously	O
recommended	O
by	O
the	O
Ministry	O
of	O
Health	O
of	O
the	O
Russian	O
Federation	O
were	O
simultaneously	O
used	O
in	O
14	O
clinical	O
samples	O
obtained	O
from	O
patients	O
with	O
Crimean	O
hemorrhagic	O
fever	O
.	O

After	O
assessing	O
the	O
detection	O
accuracy	O
,	O
it	O
was	O
found	O
that	O
the	O
developed	O
-	O
by	O
-	O
us	O
test	O
system	O
displayed	O
the	O
same	O
or	O
even	O
better	O
diagnostic	O
values	O
versus	O
the	O
previously	O
recommended	O
nested	O
RT	O
-	O
PCR	O
and	O
a	O
1000	O
-	O
fold	O
advantage	O
over	O
the	O
previously	O
recommended	O
single	O
-	O
step	O
RT	O
-	O
PCA	O
.	O

The	O
single	O
-	O
step	O
RT	O
-	O
PCR	O
assay	O
variation	O
is	O
always	O
more	O
preferable	O
in	O
sense	O
of	O
technical	O
and	O
economic	O
motivations	O
.	O

Finally	O
,	O
the	O
test	O
system	O
developed	O
by	O
us	O
has	O
every	O
reason	O
to	O
become	O
the	O
method	O
of	O
choice	O
in	O
routine	O
PCR	O
diagnosis	O
of	O
Crimean	O
hemorrhagic	O
fever	O
after	O
all	O
official	O
trials	O
and	O
approvals	O
are	O
duly	O
complied	O
with	O
.	O

Endogenous	O
thyroid	O
hormones	O
modulate	O
pituitary	O
somatotroph	O
differentiation	O
during	O
chicken	O
embryonic	O
development	O
.	O

Growth	O
hormone	O
cell	O
differentiation	O
normally	O
occurs	O
between	O
day	O
14	O
and	O
day	O
16	O
of	O
chicken	O
embryonic	O
development	O
.	O

We	O
reported	O
previously	O
that	O
corticosterone	O
(	O
CORT	O
)	O
could	O
induce	O
somatotroph	O
differentiation	O
in	O
vitro	O
and	O
in	O
vivo	O
and	O
that	O
thyroid	O
hormones	O
could	O
act	O
in	O
combination	O
with	O
CORT	O
to	O
further	O
augment	O
the	O
abundance	O
of	O
somatotrophs	O
in	O
vitro	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
test	O
our	O
hypothesis	O
that	O
endogenous	O
thyroid	O
hormones	O
regulate	O
the	O
abundance	O
of	O
somatotrophs	O
during	O
chicken	O
embryonic	O
development	O
.	O

Plasma	O
samples	O
were	O
collected	O
on	O
embryonic	O
day	O
(	O
e	O
)	O
9	O
-	O
14	O
.	O

We	O
found	O
that	O
plasma	O
CORT	O
and	O
thyroid	O
hormone	O
levels	O
increased	O
progressively	O
in	O
mid	O
-	O
embryogenesis	O
to	O
e	O
13	O
or	O
e	O
14	O
,	O
immediately	O
before	O
normal	O
somatotroph	O
differentiation	O
.	O

Administration	O
of	O
thyroxine	O
(	O
T4	O
)	O
and	O
triiodothyronine	O
(	O
T3	O
)	O
into	O
the	O
albumen	O
of	O
fertile	O
eggs	O
on	O
e	O
11	O
increased	O
somatotroph	O
proportions	O
prematurely	O
on	O
e	O
13	O
in	O
the	O
developing	O
chick	O
embryos	O
in	O
vivo	O
.	O

Furthermore	O
,	O
administration	O
of	O
methimazole	O
,	O
the	O
thyroid	O
hormone	O
synthesis	O
inhibitor	O
,	O
on	O
e	O
9	O
inhibited	O
somatotroph	O
differentiation	O
in	O
vivo	O
,	O
as	O
assessed	O
on	O
e	O
14	O
;	O
this	O
suppression	O
was	O
completely	O
reversed	O
by	O
T3	O
replacement	O
on	O
e	O
11	O
.	O

Since	O
we	O
reported	O
that	O
T3	O
alone	O
was	O
ineffective	O
in	O
vitro	O
,	O
we	O
interpret	O
these	O
findings	O
to	O
indicate	O
that	O
the	O
effects	O
of	O
treatments	O
in	O
vivo	O
were	O
due	O
to	O
interactions	O
with	O
endogenous	O
glucocorticoids	O
.	O

These	O
results	O
indicate	O
that	O
treatment	O
with	O
exogenous	O
thyroid	O
hormones	O
can	O
modulate	O
somatotroph	O
abundance	O
and	O
that	O
endogenous	O
thyroid	O
hormone	O
synthesis	O
likely	O
contributes	O
to	O
normal	O
somatotroph	O
differentiation	O
.	O

Prognostic	O
significance	O
and	O
correlation	O
with	O
survival	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
colon	O
cancer	O
.	O

Bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
receptors	O
type	O
II	O
(	O
RII	O
)	O
in	O
colon	O
carcinomas	O
were	O
studied	O
in	O
a	O
series	O
of	O
113	O
patients	O
,	O
to	O
determine	O
their	O
prognostic	O
significance	O
and	O
to	O
correlate	O
their	O
expression	O
with	O
other	O
prognostic	O
indicators	O
.	O

Bcl	O
-	O
2	O
expression	O
in	O
the	O
tumor	O
cells	O
showed	O
a	O
reverse	O
relation	O
with	O
tumor	O
size	O
(	O
P	O
=	O
0	O
.	O
018	O
)	O
,	O
histological	O
grade	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
stage	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Univariate	O
survival	O
analysis	O
using	O
the	O
log	O
rank	O
test	O
showed	O
that	O
the	O
survival	O
of	O
patients	O
with	O
bcl	O
-	O
2	O
-	O
positive	O
tumors	O
was	O
significantly	O
better	O
than	O
the	O
survival	O
of	O
patients	O
with	O
bcl	O
-	O
2	O
-	O
negative	O
tumors	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

However	O
,	O
when	O
entered	O
into	O
a	O
multivariate	O
analysis	O
model	O
,	O
it	O
was	O
not	O
found	O
to	O
be	O
of	O
independent	O
prognostic	O
significance	O
.	O

TGF	O
-	O
beta	O
RII	O
expression	O
was	O
correlated	O
with	O
stage	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
while	O
no	O
statistically	O
significant	O
correlation	O
was	O
found	O
between	O
TGF	O
-	O
beta	O
RII	O
expression	O
and	O
histological	O
grade	O
or	O
survival	O
.	O

In	O
conclusion	O
,	O
these	O
results	O
provide	O
additional	O
evidence	O
for	O
the	O
role	O
of	O
bcl	O
-	O
2	O
and	O
TGF	O
-	O
beta	O
RII	O
in	O
carcinogenesis	O
of	O
the	O
colon	O
,	O
while	O
they	O
do	O
not	O
support	O
the	O
use	O
of	O
these	O
factors	O
as	O
prognostic	O
markers	O
in	O
patients	O
with	O
colon	O
cancer	O
.	O

Antibiotic	O
-	O
induced	O
persistence	O
of	O
cytotoxic	O
Staphylococcus	O
aureus	O
in	O
non	O
-	O
phagocytic	O
cells	O
.	O

OBJECTIVES	O
:	O

After	O
infection	O
of	O
non	O
-	O
phagocytic	O
cells	O
,	O
some	O
Staphylococcus	O
aureus	O
strains	O
are	O
able	O
to	O
survive	O
and	O
kill	O
their	O
host	O
cells	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
action	O
of	O
various	O
antibiotics	O
on	O
the	O
survival	O
of	O
host	O
cells	O
and	O
/	O
or	O
intracellular	O
S	O
.	O
aureus	O
.	O

METHODS	O
:	O

Murine	O
keratinocyte	O
(	O
PAM212	B
)	O
and	O
fibroblast	O
(	O
mKSA	B
)	O
cell	O
lines	O
were	O
infected	O
with	O
cytotoxic	O
S	O
.	O
aureus	O
and	O
cultured	O
in	O
the	O
presence	O
of	O
various	O
antibiotics	O
at	O
graded	O
concentrations	O
.	O

The	O
viability	O
of	O
host	O
cells	O
was	O
measured	O
24	O
h	O
after	O
infection	O
.	O

To	O
determine	O
the	O
bacterial	O
viability	O
within	O
host	O
cells	O
,	O
cellular	O
lysates	O
were	O
prepared	O
and	O
colony	O
forming	O
units	O
were	O
quantified	O
using	O
a	O
spiral	O
plater	O
.	O

Host	O
cells	O
infected	O
with	O
fluorescein	O
isothiocyanate	O
(	O
FITC	O
)	O
-	O
labelled	O
S	O
.	O
aureus	O
were	O
analysed	O
by	O
flow	O
cytometry	O
and	O
microscopy	O
to	O
determine	O
the	O
subcellular	O
localization	O
S	O
.	O
aureus	O
.	O

RESULTS	O
:	O

Oxacillin	O
,	O
vancomycin	O
,	O
gentamicin	O
,	O
ciprofloxacin	O
and	O
trimethoprim	O
/	O
sulfamethoxazole	O
did	O
not	O
rescue	O
host	O
cells	O
from	O
cell	O
death	O
induced	O
by	O
intracellular	O
S	O
.	O
aureus	O
.	O

In	O
contrast	O
,	O
linezolid	O
,	O
rifampicin	O
,	O
azithromycin	O
,	O
clindamycin	O
,	O
erythromycin	O
and	O
quinupristin	O
/	O
dalfopristin	O
suppressed	O
the	O
cytotoxic	O
action	O
of	O
S	O
.	O
aureus	O
.	O

After	O
withdrawal	O
of	O
antibiotics	O
,	O
intracellular	O
S	O
.	O
aureus	O
regained	O
cytotoxic	O
activity	O
and	O
killed	O
their	O
host	O
cells	O
.	O

Only	O
rifampicin	O
was	O
able	O
to	O
eliminate	O
intracellular	O
S	O
.	O
aureus	O
completely	O
within	O
72	O
h	O
.	O

In	O
contrast	O
,	O
clindamycin	O
,	O
azithromycin	O
and	O
linezolid	O
induced	O
a	O
state	O
of	O
intracellular	O
persistence	O
of	O
viable	O
S	O
.	O
aureus	O
.	O

CONCLUSIONS	O
:	O

Antibiotics	O
commonly	O
used	O
for	O
the	O
management	O
of	O
S	O
.	O
aureus	O
infections	O
appear	O
to	O
create	O
a	O
niche	O
for	O
invasive	O
intracellular	O
S	O
.	O
aureus	O
,	O
which	O
may	O
play	O
an	O
important	O
role	O
for	O
persistence	O
and	O
recurrence	O
of	O
infection	O
.	O

Because	O
of	O
its	O
unique	O
ability	O
to	O
eliminate	O
intracellular	O
S	O
.	O
aureus	O
,	O
rifampicin	O
appears	O
to	O
be	O
valuable	O
for	O
the	O
treatment	O
of	O
invasive	O
S	O
.	O
aureus	O
infections	O
.	O

Expression	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
in	O
colorectal	O
cancer	O
:	O
correlation	O
with	O
cancer	O
metastasis	O
.	O

Recently	O
,	O
overexpression	O
of	O
EphA2	O
,	O
a	O
member	O
of	O
the	O
Eph	O
family	O
of	O
receptor	O
tyrosine	O
kinases	O
,	O
has	O
been	O
reported	O
in	O
several	O
cancers	O
.	O

Reduced	O
expression	O
of	O
E	O
-	O
cadherin	O
,	O
an	O
intercellular	O
adhesion	O
molecule	O
of	O
epithelial	O
cells	O
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
aggressive	O
clinicopathological	O
phenotypes	O
in	O
various	O
cancers	O
.	O

In	O
epithelial	O
cells	O
,	O
EphA2	O
and	O
E	O
-	O
cadherin	O
co	O
-	O
localize	O
to	O
sites	O
of	O
cell	O
-	O
cell	O
contact	O
,	O
and	O
it	O
has	O
been	O
shown	O
that	O
E	O
-	O
cadherin	O
regulates	O
EphA2	O
.	O

This	O
study	O
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
the	O
EphA2	O
and	O
E	O
-	O
cadherin	O
proteins	O
and	O
clinicopathological	O
characteristics	O
,	O
with	O
reference	O
to	O
the	O
expression	O
levels	O
of	O
both	O
EphA2	O
and	O
E	O
-	O
cadherin	O
,	O
in	O
patients	O
with	O
colorectal	O
cancer	O
.	O

We	O
performed	O
immunohistochemical	O
staining	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
with	O
EphA2	O
and	O
E	O
-	O
cadherin	O
monoclonal	O
antibodies	O
in	O
samples	O
from	O
194	O
primary	O
lesions	O
of	O
colorectal	O
cancer	O
.	O

The	O
expression	O
level	O
of	O
EphA2	O
had	O
a	O
statistically	O
significant	O
relationship	O
with	O
liver	O
metastasis	O
,	O
lymphatic	O
vessel	O
invasion	O
and	O
clinical	O
stage	O
(	O
p	O
=	O
0	O
.	O
0477	O
,	O
0	O
.	O
0316	O
and	O
0	O
.	O
0467	O
,	O
respectively	O
)	O
.	O

In	O
addition	O
,	O
the	O
positivity	O
rate	O
of	O
EphA2	O
was	O
significantly	O
higher	O
in	O
primary	O
lesions	O
with	O
lymph	O
node	O
metastasis	O
than	O
in	O
those	O
without	O
metastasis	O
(	O
p	O
=	O
0	O
.	O
0014	O
)	O
.	O

However	O
,	O
the	O
expression	O
level	O
of	O
E	O
-	O
cadherin	O
had	O
an	O
inverse	O
relationship	O
with	O
both	O
differentiation	O
level	O
of	O
the	O
tumor	O
and	O
lymphatic	O
vessel	O
invasion	O
(	O
p	O
=	O
0	O
.	O
0430	O
and	O
0	O
.	O
0320	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
a	O
significant	O
relationship	O
between	O
the	O
expression	O
of	O
EphA2	O
and	O
E	O
-	O
cadherin	O
was	O
observed	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
revealed	O
that	O
the	O
overexpression	O
of	O
EphA2	O
protein	O
in	O
colorectal	O
carcinoma	O
tissue	O
correlates	O
closely	O
with	O
cancer	O
progression	O
and	O
hematogenous	O
and	O
lymphogenous	O
metastasis	O
,	O
suggesting	O
that	O
both	O
EphA2	O
and	O
E	O
-	O
cadherin	O
may	O
play	O
an	O
important	O
role	O
in	O
tumor	O
metastasis	O
in	O
colorectal	O
cancer	O
.	O

Outcomes	O
of	O
cefazolin	O
versus	O
ceftriaxone	O
therapy	O
in	O
treating	O
lower	O
respiratory	O
tract	O
infections	O
in	O
adults	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
whether	O
choice	O
of	O
a	O
first	O
-	O
versus	O
third	O
-	O
generation	O
cephalosporin	O
as	O
initial	O
therapy	O
for	O
lower	O
respiratory	O
tract	O
infections	O
in	O
hospitalized	O
adults	O
affects	O
the	O
course	O
and	O
duration	O
of	O
care	O
,	O
both	O
of	O
which	O
may	O
influence	O
antimicrobial	O
treatment	O
cost	O
.	O

DESIGN	O
:	O

Retrospective	O
analysis	O
of	O
discharge	O
abstracts	O
and	O
hospital	O
pharmacy	O
records	O
.	O

SETTING	O
:	O

Forty	O
-	O
eight	O
US	O
acute	O
-	O
care	O
hospitals	O
.	O

PATIENTS	O
:	O

One	O
thousand	O
ninety	O
-	O
two	O
hospitalized	O
adults	O
(	O
aged	O
>	O
17	O
y	O
)	O
with	O
principal	O
diagnoses	O
of	O
lower	O
respiratory	O
tract	O
infections	O
(	O
DRGs	O
79	O
-	O
80	O
,	O
89	O
-	O
90	O
)	O
.	O

INTERVENTIONS	O
:	O

Cefazolin	O
or	O
ceftriaxone	O
,	O
given	O
as	O
sole	O
antimicrobial	O
therapy	O
for	O
at	O
least	O
one	O
day	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O

(	O
1	O
)	O
The	O
number	O
of	O
patients	O
who	O
received	O
another	O
parenteral	O
antibiotic	O
anytime	O
prior	O
to	O
hospital	O
discharge	O
;	O
(	O
2	O
)	O
the	O
number	O
of	O
days	O
during	O
which	O
patients	O
received	O
any	O
parenteral	O
antibiotic	O
while	O
in	O
the	O
hospital	O
;	O
and	O
(	O
3	O
)	O
the	O
number	O
of	O
days	O
patients	O
remained	O
hospitalized	O
following	O
the	O
start	O
of	O
antibiotic	O
therapy	O
.	O

RESULTS	O
:	O

Patients	O
treated	O
with	O
cefazolin	O
(	O
n	O
=	O
763	O
)	O
were	O
more	O
likely	O
to	O
receive	O
another	O
parenteral	O
antibiotic	O
while	O
in	O
the	O
hospital	O
(	O
30	O
.	O
3	O
vs	O
.	O
20	O
.	O
7	O
percent	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
received	O
more	O
total	O
days	O
of	O
therapy	O
(	O
7	O
.	O
2	O
vs	O
.	O
6	O
.	O
7	O
d	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
than	O
those	O
treated	O
with	O
ceftriaxone	O
(	O
n	O
=	O
329	O
)	O
.	O

Although	O
the	O
time	O
to	O
hospital	O
discharge	O
did	O
not	O
differ	O
in	O
the	O
full	O
sample	O
(	O
9	O
.	O
2	O
d	O
for	O
both	O
groups	O
)	O
,	O
it	O
was	O
greater	O
among	O
those	O
receiving	O
cefazolin	O
(	O
8	O
.	O
6	O
vs	O
.	O
8	O
.	O
0	O
d	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
when	O
patients	O
with	O
lengths	O
of	O
stay	O
exceeding	O
24	O
days	O
were	O
excluded	O
from	O
both	O
groups	O
.	O

CONCLUSIONS	O
:	O

In	O
addition	O
to	O
acquisition	O
cost	O
,	O
differences	O
in	O
course	O
and	O
duration	O
of	O
care	O
should	O
be	O
considered	O
when	O
determining	O
the	O
most	O
cost	O
-	O
effective	O
choice	O
for	O
antimicrobial	O
therapy	O
.	O

Full	O
sequencing	O
analysis	O
of	O
estrogen	O
receptor	O
-	O
alpha	O
gene	O
polymorphism	O
and	O
its	O
association	O
with	O
breast	O
cancer	O
risk	O
.	O

BACKGROUND	O
:	O

The	O
estrogen	O
receptor	O
plays	O
a	O
critical	O
role	O
in	O
breast	O
cancer	O
development	O
and	O
progression	O
.	O

So	O
the	O
genetic	O
polymorphism	O
of	O
ER	O
-	O
alpha	O
gene	O
could	O
affect	O
cancer	O
risk	O
and	O
phenotype	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

We	O
fully	O
sequenced	O
the	O
ER	O
-	O
alpha	O
gene	O
to	O
investigate	O
its	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
100	O
breast	O
cancer	O
patients	O
and	O
100	O
controls	O
.	O

RESULTS	O
:	O

Six	O
novel	O
polymorphism	O
in	O
the	O
control	O
and	O
11	O
in	O
cancer	O
patients	O
were	O
found	O
.	O

The	O
G	O
/	O
G	O
genotype	O
at	O
C975	O
G	O
and	O
A	O
/	O
A	O
genotype	O
at	O
G1782	O
A	O
had	O
a	O
protective	O
effect	O
against	O
breast	O
cancer	O
when	O
compared	O
to	O
other	O
genotypes	O
(	O
OR	O
=	O
0	O
.	O
3	O
and	O
0	O
.	O
3	O
,	O
respectively	O
)	O
.	O

975	O
G	O
allele	O
was	O
associated	O
inversely	O
with	O
the	O
p53	O
expression	O
and	O
positively	O
with	O
the	O
bcl	O
-	O
2	O
expression	O
in	O
cancer	O
with	O
borderline	O
significance	O
.	O

Combining	O
this	O
result	O
with	O
our	O
previous	O
study	O
,	O
these	O
associations	O
became	O
more	O
significant	O
(	O
p	O
=	O
0	O
.	O
005	O
and	O
0	O
.	O
019	O
,	O
respectively	O
)	O
.	O

CONCLUSION	O
:	O

Polymorphisms	O
in	O
ER	O
-	O
alpha	O
gene	O
can	O
affect	O
the	O
breast	O
cancer	O
susceptibility	O
and	O
may	O
be	O
related	O
to	O
other	O
protein	O
expression	O
,	O
such	O
as	O
p53	O
and	O
bcl	O
-	O
2	O
.	O

Effect	O
of	O
antitumor	O
agents	O
on	O
cytotoxicity	O
induction	O
by	O
sodium	O
fluoride	O
.	O

We	O
have	O
recently	O
found	O
that	O
sodium	O
fluoride	O
(	O
NaF	O
)	O
induced	O
apoptotic	O
cell	O
death	O
in	O
tumor	O
cell	O
lines	O
.	O

We	O
investigated	O
here	O
whether	O
6	O
popular	O
antitumor	O
compounds	O
modify	O
the	O
cytotoxic	O
activity	O
of	O
NaF	O
against	O
human	O
squamous	O
cell	O
carcinoma	O
(	O
HSC	B
-	I
2	I
)	O
and	O
human	O
promyelocytic	O
leukemia	O
(	O
HL	B
-	I
60	I
)	O
cell	O
lines	O
.	O

Cytotoxic	O
concentrations	O
of	O
cisplatin	O
,	O
etoposide	O
,	O
doxorubicin	O
or	O
peplomycin	O
(	O
tentatively	O
termed	O
as	O
Group	O
I	O
compounds	O
)	O
,	O
but	O
not	O
methotrexate	O
and	O
5	O
-	O
FU	O
(	O
tentatively	O
termed	O
as	O
Group	O
II	O
compounds	O
)	O
,	O
enhanced	O
the	O
cytotoxic	O
activity	O
of	O
NaF	O
.	O

NaF	O
and	O
Group	O
I	O
compounds	O
induced	O
internucleosomal	O
DNA	O
fragmentation	O
in	O
HL	B
-	I
60	I
cells	O
,	O
whereas	O
Group	O
II	O
compounds	O
were	O
inactive	O
even	O
in	O
the	O
presence	O
of	O
NaF	O
.	O

Most	O
Group	O
I	O
compounds	O
except	O
doxorubicin	O
(	O
which	O
induced	O
DNA	O
fragmentation	O
less	O
effectively	O
than	O
others	O
)	O
activated	O
caspase	O
3	O
more	O
efficiently	O
than	O
Group	O
II	O
compounds	O
.	O

Caspase	O
8	O
(	O
involved	O
in	O
non	O
-	O
mitochondrial	O
extrinsic	O
pathway	O
)	O
and	O
caspase	O
9	O
(	O
involved	O
in	O
mitochondrial	O
intrinsic	O
pathway	O
)	O
were	O
also	O
activated	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
.	O

NaF	O
reduced	O
the	O
glucose	O
consumption	O
at	O
early	O
stage	O
,	O
possibly	O
by	O
inhibition	O
of	O
glycolysis	O
,	O
whereas	O
cisplatin	O
and	O
etoposide	O
reduced	O
the	O
glucose	O
consumption	O
at	O
later	O
stage	O
,	O
suggesting	O
that	O
early	O
decline	O
of	O
glucose	O
consumption	O
is	O
rather	O
specific	O
to	O
NaF	O
.	O

Angiopoietin	O
/	O
tie	O
-	O
2	O
as	O
mediators	O
of	O
angiogenesis	O
:	O
a	O
role	O
in	O
congestive	O
heart	O
failure	O
?	O

Angiogenic	O
factors	O
,	O
in	O
particular	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
the	O
angiopoietins	O
,	O
Ang	O
-	O
1	O
and	O
-	O
2	O
,	O
have	O
recently	O
generated	O
significant	O
interest	O
,	O
especially	O
in	O
oncology	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
also	O
thought	O
to	O
occur	O
in	O
response	O
to	O
ischaemic	O
conditions	O
,	O
which	O
lie	O
at	O
the	O
core	O
of	O
cardiovascular	O
disease	O
states	O
such	O
as	O
coronary	O
artery	O
disease	O
and	O
congestive	O
heart	O
failure	O
.	O

However	O
,	O
current	O
data	O
do	O
not	O
conclusively	O
show	O
evidence	O
of	O
angiogenesis	O
per	O
se	O
in	O
these	O
conditions	O
,	O
despite	O
(	O
for	O
example	O
)	O
the	O
presence	O
of	O
high	O
levels	O
of	O
VEGF	O
and	O
Ang	O
-	O
2	O
.	O

High	O
levels	O
of	O
these	O
angiogenic	O
factors	O
in	O
heart	O
disease	O
also	O
have	O
not	O
translated	O
into	O
clinically	O
significant	O
new	O
vessel	O
formation	O
,	O
as	O
in	O
accelerated	O
cancer	O
growth	O
or	O
proliferative	O
retinopathy	O
.	O

Indeed	O
,	O
we	O
would	O
hypothesize	O
that	O
these	O
angiogenic	O
markers	O
-	O
-	O
especially	O
the	O
angiopoietins	O
-	O
-	O
do	O
not	O
necessarily	O
translate	O
into	O
new	O
vessel	O
formation	O
in	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
,	O
but	O
may	O
well	O
reflect	O
disturbances	O
of	O
endothelial	O
integrity	O
in	O
CHF	O
.	O

Covariance	O
structure	O
analysis	O
:	O
statistical	O
practice	O
,	O
theory	O
,	O
and	O
directions	O
.	O

Although	O
covariance	O
structure	O
analysis	O
is	O
used	O
increasingly	O
to	O
analyze	O
nonexperimental	O
data	O
,	O
important	O
statistical	O
requirements	O
for	O
its	O
proper	O
use	O
are	O
frequently	O
ignored	O
.	O

Valid	O
conclusions	O
about	O
the	O
adequacy	O
of	O
a	O
model	O
as	O
an	O
acceptable	O
representation	O
of	O
data	O
,	O
which	O
are	O
based	O
on	O
goodness	O
-	O
of	O
-	O
fit	O
test	O
statistics	O
and	O
standard	O
errors	O
of	O
parameter	O
estimates	O
,	O
rely	O
on	O
the	O
model	O
estimation	O
procedure	O
being	O
appropriate	O
for	O
the	O
data	O
.	O

Using	O
analogies	O
to	O
linear	O
regression	O
and	O
anova	O
,	O
this	O
review	O
examines	O
conditions	O
under	O
which	O
conclusions	O
drawn	O
from	O
various	O
estimation	O
methods	O
will	O
be	O
correct	O
and	O
the	O
consequences	O
of	O
ignoring	O
these	O
conditions	O
.	O

A	O
distinction	O
is	O
made	O
between	O
estimation	O
methods	O
that	O
are	O
either	O
correctly	O
or	O
incorrectly	O
specified	O
for	O
the	O
distribution	O
of	O
data	O
being	O
analyzed	O
,	O
and	O
it	O
is	O
shown	O
that	O
valid	O
conclusions	O
are	O
possible	O
even	O
under	O
misspecification	O
.	O

A	O
brief	O
example	O
illustrates	O
the	O
ideas	O
.	O

Internet	O
access	O
is	O
given	O
to	O
a	O
computer	O
code	O
for	O
several	O
methods	O
that	O
are	O
not	O
available	O
in	O
programs	O
such	O
as	O
EQS	O
or	O
LISREL	O
.	O

Morphogenesis	O
of	O
embryonic	O
CNS	O
vessels	O
.	O

This	O
chapter	O
focuses	O
on	O
the	O
morphology	O
of	O
blood	O
vessel	O
formation	O
in	O
and	O
around	O
the	O
early	O
central	O
nervous	O
system	O
(	O
CNS	O
,	O
i	O
.	O
e	O
.	O
,	O
brain	O
and	O
spinal	O
cord	O
)	O
of	O
avian	O
embryos	O
.	O

We	O
discuss	O
cell	O
lineages	O
,	O
proliferation	O
and	O
interactions	O
of	O
endothelial	O
cells	O
,	O
pericytes	O
and	O
smooth	O
muscle	O
cells	O
,	O
and	O
macrophages	O
.	O

Due	O
to	O
space	O
limitations	O
,	O
we	O
can	O
not	O
review	O
the	O
molecular	O
control	O
of	O
CNS	O
angiogenesis	O
,	O
but	O
refer	O
the	O
reader	O
to	O
other	O
chapters	O
in	O
this	O
book	O
and	O
to	O
recent	O
publications	O
on	O
the	O
assembly	O
of	O
the	O
vasculature	O
(	O
1	O
,	O
2	O
)	O
.	O

[	O
Correlation	O
between	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
C	O
in	O
tumor	O
-	O
associated	O
macrophages	O
and	O
lymphatic	O
metastasis	O
in	O
oral	O
cancer	O
]	O
.	O

BACKGROUND	O
&	O
#	O
38	O
;	O
OBJECTIVE	O
:	O
Previous	O
study	O
shows	O
that	O
both	O
vascular	O
endothelial	O
growth	O
-	O
C	O
(	O
VEGF	O
-	O
C	O
)	O
and	O
tumor	O
-	O
associated	O
macrophages	O
(	O
TAMs	O
)	O
are	O
related	O
to	O
lymphatic	O
metastasis	O
.	O

This	O
study	O
aimed	O
to	O
explore	O
the	O
correlation	O
between	O
the	O
expression	O
of	O
VEGF	O
-	O
C	O
in	O
TAMs	O
and	O
lymphatic	O
metastasis	O
in	O
human	O
oral	O
squamous	O
-	O
cell	O
carcinoma	O
(	O
OSCC	O
)	O
.	O

METHODS	O
:	O
After	O
immunohistochemical	O
staining	O
,	O
light	O
microscope	O
was	O
used	O
for	O
counting	O
macrophages	O
and	O
automated	O
image	O
analysis	O
quantification	O
was	O
used	O
to	O
determine	O
VEGF	O
-	O
C	O
expression	O
,	O
which	O
was	O
reflected	O
by	O
positive	O
index	O
(	O
PI	O
)	O
.	O

In	O
addition	O
,	O
the	O
double	O
staining	O
was	O
also	O
used	O
to	O
determine	O
VEGF	O
-	O
C	O
expression	O
in	O
TAMs	O
.	O

RESULTS	O
:	O
VEGF	O
-	O
C	O
expression	O
was	O
higher	O
in	O
lymphatic	O
metastasis	O
group	O
(	O
PI	O
=	O
12	O
.	O
169	O
+	O
/	O
-	O
2	O
.	O
778	O
)	O
than	O
in	O
no	O
-	O
metastasis	O
group	O
(	O
PI	O
=	O
8	O
.	O
498	O
+	O
/	O
-	O
2	O
.	O
674	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

TAMs	O
counts	O
was	O
related	O
to	O
VEGF	O
-	O
C	O
expression	O
in	O
OSCC	O
(	O
r	O
=	O
0	O
.	O
370	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
result	O
of	O
double	O
staining	O
indicated	O
that	O
macrophage	O
with	O
positive	O
VEGF	O
-	O
C	O
expression	O
accounted	O
for	O
about	O
22	O
.	O
8	O
%	O
of	O
the	O
total	O
.	O

CONCLUSION	O
:	O
Not	O
only	O
tumor	O
cells	O
but	O
also	O
TAMs	O
secrete	O
the	O
VEGF	O
-	O
C	O
in	O
OSCC	O
,	O
and	O
TAMs	O
may	O
play	O
a	O
major	O
role	O
in	O
peritumoral	O
lymphatic	O
neoangiogenesis	O
and	O
lymphatic	O
metastasis	O
.	O

The	O
candidate	O
tumour	O
suppressor	O
protein	O
ING4	O
regulates	O
brain	O
tumour	O
growth	O
and	O
angiogenesis	O
.	O

Gliomas	O
are	O
the	O
most	O
common	O
primary	O
tumours	O
of	O
the	O
central	O
nervous	O
system	O
,	O
with	O
nearly	O
15	O
,	O
000	O
diagnosed	O
annually	O
in	O
the	O
United	O
States	O
and	O
a	O
lethality	O
approaching	O
80	O
%	O
within	O
the	O
first	O
year	O
of	O
glioblastoma	O
diagnosis	O
.	O

The	O
marked	O
induction	O
of	O
angiogenesis	O
in	O
glioblastomas	O
suggests	O
that	O
it	O
is	O
a	O
necessary	O
part	O
of	O
malignant	O
progression	O
;	O
however	O
,	O
the	O
precise	O
molecular	O
mechanisms	O
underlying	O
the	O
regulation	O
of	O
brain	O
tumour	O
growth	O
and	O
angiogenesis	O
remain	O
unresolved	O
.	O

Here	O
we	O
report	O
that	O
a	O
candidate	O
tumour	O
suppressor	O
gene	O
,	O
ING4	O
,	O
is	O
involved	O
in	O
regulating	O
brain	O
tumour	O
growth	O
and	O
angiogenesis	O
.	O

Expression	O
of	O
ING4	O
is	O
significantly	O
reduced	O
in	O
gliomas	O
as	O
compared	O
with	O
normal	O
human	O
brain	O
tissue	O
,	O
and	O
the	O
extent	O
of	O
reduction	O
correlates	O
with	O
the	O
progression	O
from	O
lower	O
to	O
higher	O
grades	O
of	O
tumours	O
.	O

In	O
mice	O
,	O
xenografts	O
of	O
human	O
glioblastoma	O
U87MG	O
,	O
which	O
has	O
decreased	O
expression	O
of	O
ING4	O
,	O
grow	O
significantly	O
faster	O
and	O
have	O
higher	O
vascular	O
volume	O
fractions	O
than	O
control	O
tumours	O
.	O

We	O
show	O
that	O
ING4	O
physically	O
interacts	O
with	O
p65	O
(	O
RelA	O
)	O
subunit	O
of	O
nuclear	O
factor	O
NF	O
-	O
kappaB	O
,	O
and	O
that	O
ING4	O
regulates	O
brain	O
tumour	O
angiogenesis	O
through	O
transcriptional	O
repression	O
of	O
NF	O
-	O
kappaB	O
-	O
responsive	O
genes	O
.	O

These	O
results	O
indicate	O
that	O
ING4	O
has	O
an	O
important	O
role	O
in	O
brain	O
tumour	O
pathogenesis	O
.	O

Deletion	O
of	O
guanine	O
nucleotide	O
binding	O
protein	O
alpha	O
z	O
subunit	O
in	O
mice	O
induces	O
a	O
gene	O
dose	O
dependent	O
tolerance	O
to	O
morphine	O
.	O

The	O
mechanism	O
underlying	O
the	O
development	O
of	O
tolerance	O
to	O
morphine	O
is	O
still	O
incompletely	O
understood	O
.	O

Morphine	O
binds	O
to	O
opioid	O
receptors	O
,	O
which	O
in	O
turn	O
activates	O
downstream	O
second	O
messenger	O
cascades	O
through	O
heterotrimeric	O
guanine	O
nucleotide	O
binding	O
proteins	O
(	O
G	O
proteins	O
)	O
.	O

In	O
this	O
paper	O
,	O
we	O
show	O
that	O
G	O
(	O
z	O
)	O
,	O
a	O
member	O
of	O
the	O
inhibitory	O
G	O
protein	O
family	O
,	O
plays	O
an	O
important	O
role	O
in	O
mediating	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
after	O
tolerance	O
development	O
.	O

We	O
blocked	O
signaling	O
through	O
the	O
G	O
(	O
z	O
)	O
second	O
messenger	O
cascade	O
by	O
genetic	O
ablation	O
of	O
the	O
alpha	O
subunit	O
of	O
the	O
G	O
protein	O
in	O
mice	O
.	O

The	O
Galpha	O
(	O
z	O
)	O
knockout	O
mouse	O
develops	O
significantly	O
increased	O
tolerance	O
to	O
morphine	O
,	O
which	O
depends	O
on	O
Galpha	O
(	O
z	O
)	O
gene	O
dosage	O
.	O

Further	O
experiments	O
demonstrate	O
that	O
the	O
enhanced	O
morphine	O
tolerance	O
is	O
not	O
caused	O
by	O
pharmacokinetic	O
and	O
behavioural	O
learning	O
mechanisms	O
.	O

The	O
results	O
suggest	O
that	O
G	O
(	O
z	O
)	O
signaling	O
pathways	O
are	O
involved	O
in	O
transducing	O
the	O
analgesic	O
and	O
lethality	O
effects	O
of	O
morphine	O
following	O
chronic	O
morphine	O
treatment	O
.	O

Nuclear	O
translocation	O
of	O
a	O
clusterin	O
isoform	O
is	O
associated	O
with	O
induction	O
of	O
anoikis	O
in	O
SV40	O
-	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
.	O

Clusterin	O
gene	O
expression	O
is	O
potently	O
induced	O
in	O
experimental	O
models	O
in	O
which	O
apoptosis	O
is	O
activated	O
,	O
such	O
as	O
rat	O
prostate	O
involution	O
following	O
castration	O
.	O

Nevertheless	O
,	O
its	O
precise	O
physiological	O
role	O
has	O
not	O
yet	O
been	O
established	O
,	O
and	O
both	O
anti	O
-	O
apoptotic	O
and	O
pro	O
-	O
apoptotic	O
functions	O
have	O
been	O
suggested	O
for	O
this	O
gene	O
.	O

Clusterin	O
expression	O
level	O
depends	O
on	O
cell	O
proliferation	O
state	O
,	O
and	O
we	O
recently	O
showed	O
that	O
its	O
over	O
-	O
expression	O
inhibited	O
cell	O
cycle	O
progression	O
of	O
SV40	O
-	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
PNT2	B
and	O
PNT1a	B
.	O

Here	O
we	O
studied	O
clusterin	O
expression	O
in	O
PNT1a	B
cells	O
subjected	O
to	O
serum	O
-	O
starvation	O
with	O
the	O
aim	O
of	O
defining	O
clusterin	O
early	O
molecular	O
changes	O
following	O
apoptosis	O
induction	O
.	O

Under	O
serum	O
-	O
starvation	O
conditions	O
,	O
decreased	O
growth	O
rate	O
,	O
slow	O
rounding	O
-	O
up	O
of	O
cells	O
,	O
cell	O
detachment	O
,	O
and	O
formation	O
of	O
apoptotic	O
bodies	O
indicative	O
of	O
anoikis	O
(	O
detachment	O
-	O
induced	O
apoptosis	O
)	O
were	O
preceded	O
by	O
significant	O
downregulation	O
of	O
70	O
kDa	O
clusterin	O
precursor	O
and	O
upregulation	O
of	O
45	O
-	O
40	O
kDa	O
isoforms	O
.	O

On	O
the	O
8th	O
day	O
of	O
serum	O
-	O
free	O
culturing	O
,	O
only	O
the	O
higher	O
molecular	O
weight	O
protein	O
-	O
band	O
of	O
about	O
45	O
kDa	O
was	O
clearly	O
induced	O
and	O
accumulated	O
in	O
detached	O
cells	O
and	O
apoptotic	O
bodies	O
in	O
which	O
PARP	O
was	O
activated	O
.	O

Anoikis	O
was	O
preceded	O
by	O
induction	O
and	O
transloction	O
of	O
a	O
45	O
-	O
kDa	O
clusterin	O
isoform	O
to	O
the	O
nucleus	O
.	O

Thus	O
,	O
nuclear	O
targeting	O
of	O
a	O
specific	O
45	O
-	O
kDa	O
isoform	O
of	O
clusterin	O
appeared	O
to	O
be	O
an	O
early	O
and	O
specific	O
molecular	O
signal	O
triggering	O
anoikis	O
-	O
death	O
.	O

Considering	O
also	O
that	O
clusterin	O
is	O
downregulated	O
during	O
prostate	O
cancer	O
onset	O
and	O
progression	O
,	O
and	O
that	O
its	O
upregulation	O
has	O
inhibited	O
DNA	O
synthesis	O
and	O
cell	O
cycle	O
progression	O
of	O
immortalized	O
human	O
prostate	O
epithelial	O
cells	O
,	O
we	O
suggest	O
that	O
clusterin	O
might	O
be	O
a	O
new	O
anti	O
-	O
oncogene	O
in	O
the	O
prostate	O
.	O

TGFbeta1	O
,	O
back	O
to	O
the	O
future	O
:	O
revisiting	O
its	O
role	O
as	O
a	O
transforming	O
growth	O
factor	O
.	O

TGFbeta1	O
was	O
initially	O
identified	O
in	O
culture	O
media	O
from	O
transformed	O
cells	O
as	O
part	O
of	O
a	O
factor	O
that	O
could	O
produce	O
a	O
transformed	O
phenotype	O
in	O
a	O
nontransformed	O
cell	O
line	O
.	O

Subsequently	O
this	O
activity	O
was	O
separated	O
into	O
TGFbeta	O
and	O
TGFalpha	O
an	O
EGF	O
receptor	O
ligand	O
.	O

With	O
the	O
discovery	O
that	O
TGFbeta1	O
was	O
a	O
potent	O
growth	O
inhibitor	O
of	O
epithelial	O
cells	O
,	O
and	O
the	O
identification	O
of	O
inactivating	O
mutations	O
within	O
the	O
TGFbeta1	O
signaling	O
pathway	O
in	O
cancers	O
it	O
became	O
clear	O
that	O
TGFbeta1	O
signaling	O
is	O
a	O
tumor	O
suppressor	O
pathway	O
for	O
early	O
stages	O
of	O
cancer	O
.	O

However	O
many	O
human	O
carcinomas	O
overexpress	O
TGFbeta1	O
and	O
this	O
is	O
associated	O
with	O
poor	O
patient	O
prognosis	O
and	O
increased	O
frequency	O
of	O
metastasis	O
.	O

Similar	O
results	O
have	O
been	O
obtained	O
with	O
tumor	O
cell	O
lines	O
and	O
experimental	O
animal	O
models	O
.	O

Thus	O
stage	O
specific	O
duality	O
of	O
function	O
is	O
the	O
emerging	O
paradigm	O
for	O
the	O
role	O
of	O
TGFbeta1	O
in	O
cancer	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
evidence	O
for	O
TGFbeta1	O
as	O
a	O
tumor	O
promoting	O
and	O
metastasis	O
factor	O
and	O
examine	O
the	O
biological	O
and	O
molecular	O
basis	O
for	O
these	O
effects	O
.	O

It	O
is	O
proposed	O
that	O
the	O
switch	O
from	O
tumor	O
suppressor	O
to	O
oncogene	O
reflects	O
genetic	O
or	O
epigenetic	O
alterations	O
in	O
signaling	O
pathways	O
in	O
tumor	O
cells	O
that	O
alter	O
the	O
readout	O
from	O
the	O
TGFbeta1	O
pathway	O
.	O

Role	O
of	O
thrombin	O
in	O
angiogenesis	O
and	O
tumor	O
progression	O
.	O

Clinical	O
,	O
laboratory	O
,	O
histopathological	O
,	O
and	O
pharmacological	O
evidence	O
support	O
the	O
notion	O
that	O
the	O
coagulation	O
system	O
,	O
which	O
is	O
activated	O
in	O
most	O
cancer	O
patients	O
,	O
plays	O
an	O
important	O
role	O
in	O
tumor	O
biology	O
.	O

Our	O
laboratory	O
has	O
provided	O
evidence	O
that	O
thrombin	O
activates	O
angiogenesis	O
,	O
a	O
process	O
which	O
is	O
essential	O
in	O
tumor	O
growth	O
and	O
metastasis	O
.	O

This	O
event	O
is	O
independent	O
of	O
fibrin	O
formation	O
.	O

At	O
the	O
cellular	O
level	O
many	O
actions	O
of	O
thrombin	O
can	O
contribute	O
to	O
activation	O
of	O
angiogenesis	O
:	O
(	O
1	O
)	O
.	O

Thrombin	O
decreases	O
the	O
ability	O
of	O
endothelial	O
cells	O
to	O
attach	O
to	O
basement	O
membrane	O
proteins	O
.	O

(	O
2	O
)	O
.	O

Thrombin	O
greatly	O
potentiates	O
vascular	O
endothelial	O
growth	O
factor	O
-	O
(	O
VEGF	O
-	O
)	O
induced	O
endothelial	O
cell	O
proliferation	O
.	O

This	O
potentiation	O
is	O
accompanied	O
by	O
up	O
-	O
regulation	O
of	O
the	O
expression	O
of	O
VEGF	O
receptors	O
(	O
kinase	O
insert	O
domain	O
-	O
containing	O
receptor	O
[	O
KDR	O
]	O
and	O
fms	O
-	O
like	O
tyrosine	O
kinase	O
[	O
Flt	O
-	O
1	O
]	O
)	O
.	O

(	O
3	O
)	O
.	O

Thrombin	O
increases	O
the	O
mRNA	O
and	O
protein	O
levels	O
of	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
and	O
serves	O
as	O
a	O
ligand	O
to	O
this	O
receptor	O
.	O

Furthermore	O
,	O
thrombin	O
increases	O
the	O
secretion	O
of	O
VEGF	O
and	O
enhances	O
the	O
expression	O
and	O
protein	O
synthesis	O
of	O
matrix	O
metalloprotease	O
-	O
9	O
and	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
in	O
human	O
prostate	O
cancer	O
PC	B
-	I
3	I
cells	O
.	O

These	O
results	O
could	O
explain	O
the	O
angiogenic	O
and	O
tumor	O
-	O
promoting	O
effect	O
of	O
thrombin	O
and	O
provide	O
the	O
basis	O
for	O
development	O
of	O
thrombin	O
receptor	O
mimetics	O
or	O
antagonists	O
for	O
therapeutic	O
application	O
.	O

Levels	O
of	O
expression	O
of	O
CYR61	O
and	O
CTGF	O
are	O
prognostic	O
for	O
tumor	O
progression	O
and	O
survival	O
of	O
individuals	O
with	O
gliomas	O
.	O

The	O
biological	O
properties	O
of	O
CCN	O
proteins	O
include	O
stimulation	O
of	O
cell	O
proliferation	O
,	O
migration	O
,	O
and	O
adhesion	O
,	O
as	O
well	O
as	O
angiogenesis	O
and	O
tumorigenesis	O
.	O

We	O
quantified	O
CYR61	O
,	O
CTGF	O
,	O
WISP	O
-	O
1	O
,	O
and	O
NOV	O
mRNA	O
expression	O
levels	O
in	O
samples	O
from	O
sixty	O
-	O
six	O
primary	O
gliomas	O
and	O
five	O
normal	O
brain	O
samples	O
using	O
quantitative	O
real	O
-	O
time	O
PCR	O
assay	O
.	O

Statistical	O
analysis	O
was	O
performed	O
to	O
explore	O
the	O
links	O
between	O
expression	O
of	O
the	O
CCN	O
genes	O
and	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Overexpression	O
of	O
CYR61	O
,	O
CTGF	O
,	O
WISP	O
-	O
1	O
,	O
and	O
NOV	O
occurred	O
in	O
48	O
%	O
(	O
32	O
of	O
66	O
)	O
,	O
58	O
%	O
(	O
38	O
of	O
66	O
)	O
,	O
36	O
%	O
(	O
24	O
of	O
66	O
)	O
,	O
and	O
15	O
%	O
(	O
10	O
of	O
66	O
)	O
of	O
primary	O
gliomas	O
,	O
respectively	O
.	O

Interestingly	O
,	O
significant	O
associations	O
were	O
found	O
between	O
CYR61	O
expression	O
versus	O
tumor	O
grade	O
,	O
pathology	O
,	O
gender	O
,	O
and	O
age	O
at	O
diagnosis	O
.	O

Also	O
,	O
a	O
significant	O
correlation	O
existed	O
between	O
CTGF	O
mRNA	O
levels	O
versus	O
tumor	O
grade	O
,	O
gender	O
,	O
and	O
pathology	O
.	O

In	O
contrast	O
to	O
CYR61	O
and	O
CTGF	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
expression	O
of	O
either	O
WISP	O
-	O
1	O
or	O
NOV	O
versus	O
any	O
of	O
the	O
pathological	O
features	O
.	O

Furthermore	O
,	O
Cox	O
regression	O
analysis	O
showed	O
that	O
CYR61	O
and	O
CTGF	O
expression	O
had	O
a	O
significant	O
correlation	O
with	O
patient	O
survival	O
.	O

These	O
results	O
suggest	O
that	O
CYR61	O
and	O
CTGF	O
may	O
play	O
a	O
role	O
in	O
the	O
progression	O
of	O
gliomas	O
;	O
their	O
levels	O
at	O
diagnosis	O
may	O
have	O
prognostic	O
significance	O
;	O
and	O
these	O
proteins	O
might	O
serve	O
as	O
valuable	O
targets	O
for	O
therapeutic	O
intervention	O
.	O

NIH3T3	B
transfectant	O
containing	O
human	O
K	O
-	O
ras	O
oncogene	O
shows	O
enhanced	O
metastatic	O
activity	O
after	O
in	O
vivo	O
tumor	O
growth	O
or	O
co	O
-	O
culture	O
with	O
fibroblasts	O
.	O

A	O
clone	O
of	O
NIH3T3	B
transformant	O
(	O
H	B
-	I
3	I
)	O
,	O
obtained	O
by	O
transfecting	O
genomic	O
DNA	O
of	O
a	O
human	O
colon	O
carcinoma	O
cell	O
line	O
,	O
contains	O
human	O
K	O
-	O
ras	O
oncogene	O
and	O
yields	O
metastatic	O
pulmonary	O
nodules	O
after	O
intravenous	O
injection	O
of	O
the	O
cells	O
into	O
nude	O
mice	O
.	O

This	O
metastatic	O
ability	O
was	O
enhanced	O
remarkably	O
after	O
in	O
vivo	O
tumor	O
growth	O
(	O
subcutaneous	O
tumor	O
formation	O
in	O
nude	O
mice	O
)	O
accompanied	O
by	O
increased	O
mRNA	O
expression	O
and	O
gene	O
amplification	O
of	O
the	O
human	O
-	O
derived	O
K	O
-	O
ras	O
oncogene	O
,	O
while	O
it	O
declined	O
gradually	O
as	O
the	O
passage	O
number	O
increased	O
in	O
vitro	O
,	O
with	O
corresponding	O
decreases	O
of	O
gene	O
amplification	O
and	O
mRNA	O
expression	O
.	O

Six	O
subclones	O
were	O
randomly	O
selected	O
from	O
H	B
-	I
3	I
cells	O
which	O
had	O
been	O
subcultured	O
to	O
passage	O
22	O
.	O

All	O
of	O
the	O
clones	O
in	O
culture	O
showed	O
almost	O
the	O
same	O
low	O
level	O
of	O
metastatic	O
ability	O
and	O
exhibited	O
little	O
K	O
-	O
ras	O
oncogene	O
amplification	O
with	O
correspondingly	O
low	O
mRNA	O
expression	O
.	O

However	O
,	O
after	O
they	O
formed	O
tumors	O
in	O
nude	O
mice	O
,	O
every	O
clone	O
acquired	O
high	O
metastatic	O
ability	O
and	O
the	O
gene	O
amplification	O
increased	O
,	O
with	O
elevated	O
mRNA	O
expression	O
.	O

These	O
experimental	O
facts	O
indicated	O
that	O
acquisition	O
of	O
metastatic	O
ability	O
coupled	O
with	O
the	O
function	O
of	O
K	O
-	O
ras	O
oncogene	O
was	O
conditional	O
in	O
nature	O
,	O
being	O
strongly	O
affected	O
by	O
in	O
vivo	O
tumor	O
circumstances	O
.	O

The	O
low	O
metastatic	O
and	O
G	O
-	O
418	O
-	O
resistant	O
H	B
-	I
3	I
cells	O
were	O
co	O
-	O
cultured	O
with	O
BALB	B
/	I
c3T3	I
fibroblasts	O
for	O
2	O
-	O
4	O
weeks	O
.	O

After	O
removal	O
of	O
fibroblasts	O
by	O
exposure	O
to	O
G	O
-	O
418	O
,	O
the	O
tumor	O
cells	O
exhibited	O
increased	O
metastatic	O
ability	O
and	O
human	O
K	O
-	O
ras	O
oncogene	O
mRNA	O
,	O
suggesting	O
an	O
intimate	O
interaction	O
between	O
H	B
-	I
3	I
cells	O
and	O
fibroblasts	O
influencing	O
the	O
function	O
of	O
transfected	O
human	O
K	O
-	O
ras	O
oncogene	O
.	O

Fibroblasts	O
of	O
the	O
host	O
animal	O
may	O
thus	O
have	O
an	O
important	O
role	O
in	O
generating	O
enhanced	O
metastatic	O
activity	O
of	O
H	B
-	I
3	I
cells	O
.	O

Potent	O
antibacterial	O
activity	O
of	O
Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
with	O
selective	O
action	O
against	O
Helicobacter	O
pylori	O
.	O

Y	O
-	O
754	O
,	O
a	O
novel	O
benzimidazole	O
compound	O
,	O
was	O
investigated	O
for	O
in	O
vitro	O
and	O
in	O
vivo	O
antibacterial	O
activity	O
.	O

Unlike	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
,	O
the	O
compound	O
had	O
no	O
activity	O
against	O
common	O
aerobic	O
and	O
anaerobic	O
bacteria	O
other	O
than	O
Helicobacter	O
pylori	O
.	O

The	O
minimum	O
inhibitory	O
concentration	O
of	O
Y	O
-	O
754	O
against	O
H	O
.	O
pylori	O
,	O
at	O
0	O
.	O
025	O
microg	O
/	O
ml	O
,	O
was	O
nearly	O
equal	O
to	O
that	O
of	O
amoxicillin	O
and	O
clarithromycin	O
.	O

The	O
respective	O
concentrations	O
of	O
Y	O
-	O
754	O
,	O
amoxicillin	O
,	O
clarithromycin	O
,	O
and	O
metronidazole	O
required	O
to	O
inhibit	O
90	O
%	O
of	O
39	O
isolates	O
of	O
H	O
.	O
pylori	O
were	O
0	O
.	O
05	O
,	O
0	O
.	O
39	O
,	O
6	O
.	O
25	O
,	O
and	O
25	O
microg	O
/	O
ml	O
,	O
indicating	O
the	O
potent	O
activity	O
of	O
Y	O
-	O
754	O
,	O
including	O
activity	O
against	O
clarithromycin	O
-	O
and	O
metronidazole	O
-	O
resistant	O
strains	O
.	O

The	O
anti	O
-	O
H	O
.	O
pylori	O
activity	O
of	O
Y	O
-	O
754	O
was	O
potent	O
even	O
at	O
pH	O
5	O
.	O
5	O
and	O
was	O
bactericidal	O
at	O
concentrations	O
of	O
0	O
.	O
1	O
microg	O
/	O
ml	O
and	O
above	O
.	O

Exposure	O
of	O
H	O
.	O
pylori	O
to	O
Y	O
-	O
754	O
did	O
not	O
result	O
in	O
the	O
induction	O
of	O
drug	O
-	O
resistant	O
mutation	O
.	O

Oral	O
administration	O
(	O
10	O
mg	O
/	O
kg	O
twice	O
a	O
day	O
for	O
7	O
days	O
)	O
to	O
Mongolian	O
gerbils	O
infected	O
with	O
strain	O
ATCC	O
43504	O
demonstrated	O
that	O
Y	O
-	O
754	O
was	O
effective	O
in	O
H	O
.	O
pylori	O
eradication	O
and	O
that	O
its	O
eradication	O
efficacy	O
increased	O
in	O
line	O
with	O
the	O
progress	O
of	O
damage	O
to	O
the	O
gastric	O
mucosa	O
caused	O
by	O
H	O
.	O
pylori	O
infection	O
.	O

Y	O
-	O
754	O
was	O
also	O
efficacious	O
in	O
the	O
treatment	O
of	O
infection	O
by	O
the	O
clarithromycin	O
-	O
resistant	O
strain	O
OIT	O
-	O
36	O
.	O

The	O
results	O
obtained	O
lead	O
to	O
the	O
expectation	O
that	O
the	O
new	O
benzimidazole	O
Y	O
-	O
754	O
will	O
,	O
in	O
the	O
near	O
future	O
,	O
be	O
used	O
for	O
H	O
.	O
pylori	O
eradication	O
therapy	O
in	O
peptic	O
ulcer	O
patients	O
.	O

Active	O
respiratory	O
syncytial	O
virus	O
purified	O
by	O
ion	O
-	O
exchange	O
chromatography	O
:	O
characterization	O
of	O
binding	O
and	O
elution	O
requirements	O
.	O

Two	O
viruses	O
,	O
respiratory	O
syncytial	O
virus	O
(	O
RSV	O
)	O
and	O
vesicular	O
stomatitis	O
virus	O
(	O
VSV	O
)	O
were	O
used	O
to	O
evaluate	O
viral	O
purification	O
by	O
an	O
affinity	O
resin	O
column	O
(	O
Matrex	O
Cellufine	O
Sulfate	O
(	O
MCS	O
)	O
;	O
Amicon	O
Division	O
,	O
WR	O
Grace	O
&	O
Co	O
.	O
)	O
.	O

Viable	O
RSV	O
was	O
purified	O
significantly	O
from	O
crude	O
cell	O
lysate	O
by	O
a	O
single	O
pass	O
through	O
a	O
column	O
containing	O
the	O
anionic	O
MCS	O
resin	O
.	O

Most	O
cell	O
protein	O
and	O
albumin	O
eluted	O
from	O
the	O
MCS	O
resin	O
with	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
but	O
RSV	O
eluted	O
at	O
high	O
ionic	O
strength	O
,	O
i	O
.	O
e	O
.	O
,	O
greater	O
than	O
or	O
equal	O
to	O
0	O
.	O
6	O
M	O
NaCl	O
.	O

Further	O
purification	O
was	O
possible	O
by	O
sucrose	O
step	O
gradient	O
centrifugation	O
.	O

The	O
RSV	O
prepared	O
by	O
column	O
purification	O
or	O
by	O
column	O
plus	O
sucrose	O
gradient	O
separation	O
was	O
both	O
intact	O
and	O
infective	O
.	O

RSV	O
and	O
pure	O
samples	O
of	O
VSV	O
were	O
used	O
to	O
optimize	O
ionic	O
strength	O
and	O
salts	O
for	O
elution	O
from	O
the	O
MCS	O
column	O
:	O
0	O
.	O
8	O
M	O
NaCl	O
removed	O
most	O
of	O
the	O
viral	O
protein	O
.	O

The	O
capacity	O
of	O
the	O
MCS	O
gel	O
for	O
RSV	O
or	O
VSV	O
was	O
found	O
to	O
be	O
about	O
0	O
.	O
6	O
-	O
0	O
.	O
8	O
mg	O
viral	O
protein	O
per	O
ml	O
of	O
hydrated	O
resin	O
.	O

Detergent	O
-	O
solubilized	O
viral	O
membrane	O
proteins	O
bound	O
to	O
the	O
MCS	O
resin	O
in	O
0	O
.	O
145	O
M	O
NaCl	O
and	O
eluted	O
with	O
higher	O
salt	O
concentrations	O
.	O

Thus	O
,	O
this	O
resin	O
also	O
may	O
be	O
a	O
useful	O
aid	O
for	O
relatively	O
gentle	O
purification	O
of	O
these	O
proteins	O
.	O

Lactoferrin	O
enhances	O
Fas	O
expression	O
and	O
apoptosis	O
in	O
the	O
colon	O
mucosa	O
of	O
azoxymethane	O
-	O
treated	O
rats	O
.	O

Bovine	O
lactoferrin	O
,	O
a	O
multifunctional	O
glycoprotein	O
,	O
has	O
been	O
shown	O
to	O
strongly	O
inhibit	O
development	O
of	O
azoxymethane	O
(	O
AOM	O
)	O
-	O
induced	O
rat	O
colon	O
tumors	O
.	O

Little	O
,	O
however	O
,	O
is	O
known	O
about	O
the	O
inhibitory	O
mechanisms	O
.	O

We	O
have	O
demonstrated	O
recently	O
that	O
lactoferrin	O
enhances	O
the	O
expression	O
of	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
family	O
,	O
Fas	O
,	O
in	O
the	O
colon	O
mucosa	O
during	O
both	O
early	O
and	O
late	O
stages	O
of	O
carcinogenesis	O
.	O

Thus	O
,	O
Fas	O
could	O
be	O
involved	O
in	O
bovine	O
lactoferrin	O
-	O
mediated	O
inhibition	O
of	O
tumor	O
development	O
.	O

To	O
investigate	O
this	O
possibility	O
,	O
we	O
studied	O
the	O
influence	O
of	O
bovine	O
lactoferrin	O
on	O
Fas	O
-	O
mediated	O
apoptosis	O
with	O
regard	O
to	O
expression	O
of	O
Fas	O
,	O
activation	O
of	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
,	O
and	O
DNA	O
fragmentation	O
in	O
the	O
colon	O
mucosa	O
of	O
AOM	O
-	O
treated	O
rats	O
.	O

Western	O
blot	O
analysis	O
demonstrated	O
a	O
>	O
2	O
.	O
5	O
-	O
fold	O
increase	O
in	O
Fas	O
protein	O
expression	O
,	O
as	O
well	O
as	O
elevation	O
of	O
the	O
active	O
forms	O
of	O
both	O
caspase	O
-	O
8	O
and	O
caspase	O
-	O
3	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
Fas	O
-	O
positive	O
cells	O
and	O
apoptotic	O
cells	O
preferentially	O
within	O
the	O
proximal	O
colon	O
region	O
,	O
clearly	O
at	O
the	O
site	O
of	O
bovine	O
lactoferrin	O
-	O
mediated	O
tumor	O
inhibition	O
.	O

These	O
results	O
suggest	O
that	O
apoptosis	O
caused	O
by	O
elevated	O
expression	O
of	O
Fas	O
is	O
involved	O
in	O
chemoprevention	O
by	O
lactoferrin	O
of	O
colon	O
carcinogenesis	O
.	O

Dynein	O
light	O
chain	O
1	O
,	O
a	O
p21	O
-	O
activated	O
kinase	O
1	O
-	O
interacting	O
substrate	O
,	O
promotes	O
cancerous	O
phenotypes	O
.	O

We	O
identified	O
dynein	O
light	O
chain	O
1	O
(	O
DLC1	O
)	O
as	O
a	O
physiologic	O
substrate	O
of	O
p21	O
-	O
activated	O
kinase	O
1	O
(	O
Pak1	O
)	O
.	O

Pak1	O
-	O
DLC1	O
interaction	O
plays	O
an	O
essential	O
role	O
in	O
cell	O
survival	O
,	O
which	O
depends	O
on	O
Pak1	O
'	O
s	O
phosphorylation	O
of	O
DLC1	O
on	O
Ser88	O
.	O

Pak1	O
associates	O
with	O
the	O
complex	O
of	O
DLC1	O
and	O
BimL	O
,	O
a	O
proapoptotic	O
BH3	O
-	O
only	O
protein	O
,	O
and	O
phosphorylates	O
both	O
proteins	O
.	O

Phosphorylation	O
of	O
BimL	O
by	O
Pak1	O
prevents	O
it	O
from	O
interacting	O
with	O
and	O
inactivation	O
of	O
Bcl	O
-	O
2	O
,	O
an	O
antiapoptotic	O
protein	O
.	O

Overexpression	O
of	O
DLC1	O
but	O
not	O
DLC1	O
-	O
Ser88Ala	O
mutant	O
promotes	O
cancerous	O
properties	O
of	O
breast	O
cancer	O
cells	O
.	O

DLC1	O
protein	O
level	O
is	O
elevated	O
in	O
more	O
than	O
90	O
%	O
of	O
human	O
breast	O
tumors	O
.	O

The	O
regulation	O
of	O
cell	O
survival	O
functions	O
by	O
Pak1	O
-	O
DLC1	O
interaction	O
represents	O
a	O
novel	O
mechanism	O
by	O
which	O
a	O
signaling	O
kinase	O
might	O
regulate	O
the	O
cancerous	O
phenotypes	O
.	O

Novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O

The	O
factors	O
involved	O
in	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
nephrolithiasis	O
are	O
well	O
known	O
.	O

A	O
low	O
urinary	O
pH	O
is	O
the	O
most	O
significant	O
element	O
in	O
the	O
generation	O
of	O
stones	O
,	O
with	O
hyperuricosuria	O
being	O
a	O
less	O
common	O
finding	O
.	O

The	O
underlying	O
mechanism	O
(	O
s	O
)	O
responsible	O
for	O
these	O
disturbances	O
remain	O
poorly	O
characterized	O
.	O

This	O
review	O
summarizes	O
previous	O
knowledge	O
and	O
highlights	O
some	O
recent	O
developments	O
in	O
the	O
pathophysiology	O
of	O
low	O
urine	O
pH	O
and	O
hyperuricosuria	O
.	O

RECENT	O
FINDINGS	O
:	O

Epidemiological	O
and	O
metabolic	O
studies	O
have	O
indicated	O
an	O
association	O
between	O
uric	O
acid	O
nephrolithiasis	O
and	O
insulin	O
resistance	O
.	O

Some	O
potential	O
mechanisms	O
include	O
impaired	O
ammoniagenesis	O
caused	O
by	O
resistance	O
to	O
insulin	O
action	O
in	O
the	O
renal	O
proximal	O
tubule	O
,	O
or	O
substrate	O
competition	O
by	O
free	O
fatty	O
acids	O
.	O

The	O
evaluation	O
of	O
a	O
large	O
Sicilian	O
kindred	O
recently	O
revealed	O
a	O
putative	O
genetic	O
locus	O
linked	O
to	O
uric	O
acid	O
stone	O
disease	O
.	O

The	O
identification	O
of	O
novel	O
complementary	O
DNA	O
has	O
provided	O
an	O
interesting	O
insight	O
into	O
the	O
renal	O
handling	O
of	O
uric	O
acid	O
,	O
including	O
one	O
genetic	O
cause	O
of	O
renal	O
uric	O
acid	O
wasting	O
.	O

SUMMARY	O
:	O

The	O
recognition	O
of	O
metabolic	O
,	O
molecular	O
,	O
and	O
genetic	O
factors	O
that	O
influence	O
urinary	O
pH	O
,	O
and	O
uric	O
acid	O
metabolism	O
and	O
excretion	O
,	O
will	O
provide	O
novel	O
insights	O
into	O
the	O
pathogenesis	O
of	O
uric	O
acid	O
stones	O
,	O
and	O
open	O
the	O
way	O
for	O
new	O
therapeutic	O
strategies	O
.	O

Effects	O
of	O
buffer	O
properties	O
on	O
cyclodextrin	O
glucanotransferase	O
reactions	O
and	O
cyclodextrin	O
production	O
from	O
raw	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	O
.	O

Results	O
from	O
the	O
present	O
study	O
have	O
shown	O
that	O
the	O
ionic	O
species	O
of	O
buffers	O
,	O
pH	O
values	O
and	O
reaction	O
temperature	O
can	O
affect	O
the	O
enzyme	O
unit	O
activities	O
and	O
product	O
specificity	O
of	O
Toruzyme	O
(	O
Novo	O
Nordisk	O
A	O
/	O
S	O
Bagsvaerd	O
,	O
Denmark	O
)	O
CGTase	O
(	O
cyclodextrin	O
glucanotransferase	O
)	O
.	O

Applying	O
a	O
similar	O
reaction	O
environment	O
(	O
acetate	O
buffer	O
,	O
pH	O
6	O
.	O
0	O
;	O
temperature	O
,	O
60	O
degrees	O
C	O
)	O
,	O
the	O
CGTase	O
was	O
found	O
to	O
be	O
capable	O
of	O
producing	O
pre	O
dominantly	O
beta	O
-	O
cyclodextrin	O
from	O
either	O
raw	O
or	O
gelatinized	O
sago	O
(	O
Cycas	O
revoluta	O
)	O
starch	O
.	O

Changing	O
the	O
buffer	O
from	O
acetate	O
to	O
phosphate	O
reduced	O
the	O
yield	O
of	O
beta	O
-	O
cyclodextrin	O
from	O
2	O
.	O
48	O
to	O
1	O
.	O
42	O
mg	O
/	O
ml	O
and	O
also	O
affected	O
the	O
product	O
specificity	O
,	O
where	O
production	O
of	O
both	O
alpha	O
-	O
and	O
beta	O
-	O
cyclodextrins	O
were	O
more	O
pronounced	O
.	O

The	O
decrease	O
in	O
the	O
production	O
of	O
cyclodextrins	O
in	O
phosphate	O
buffer	O
was	O
significant	O
at	O
both	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
.	O

However	O
,	O
changing	O
the	O
buffer	O
to	O
Tris	O
/	O
HCl	O
(	O
pH	O
7	O
.	O
0	O
)	O
showed	O
a	O
significant	O
increase	O
in	O
beta	O
-	O
cyclodextrin	O
production	O
.	O

Increasing	O
the	O
ionic	O
strength	O
of	O
sodium	O
acetate	O
and	O
Tris	O
/	O
HCl	O
buffers	O
at	O
pH	O
6	O
.	O
0	O
and	O
7	O
.	O
0	O
to	O
equivalent	O
ionic	O
strength	O
of	O
phosphate	O
buffers	O
showed	O
no	O
significant	O
effects	O
on	O
cyclodextrin	O
production	O
.	O

Higher	O
yield	O
of	O
cyclodextrins	O
at	O
pH	O
7	O
.	O
0	O
when	O
Tris	O
/	O
HCl	O
was	O
used	O
might	O
be	O
due	O
to	O
the	O
binding	O
of	O
chloride	O
ions	O
at	O
the	O
calcium	O
-	O
binding	O
sites	O
of	O
the	O
CGTase	O
,	O
resulting	O
in	O
the	O
shift	O
of	O
the	O
optimum	O
pH	O
close	O
to	O
physiological	O
environment	O
,	O
leading	O
to	O
an	O
increase	O
in	O
the	O
activities	O
and	O
specificity	O
.	O

Hypothesis	O
:	O
Induced	O
angiogenesis	O
after	O
surgery	O
in	O
premenopausal	O
node	O
-	O
positive	O
breast	O
cancer	O
patients	O
is	O
a	O
major	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	O
works	O
particularly	O
well	O
for	O
those	O
patients	O
.	O

BACKGROUND	O
:	O
We	O
suggest	O
that	O
surgical	O
extirpation	O
of	O
primary	O
breast	O
cancer	O
among	O
other	O
effects	O
accelerates	O
relapse	O
for	O
some	O
premenopausal	O
node	O
-	O
positive	O
patients	O
.	O

These	O
accelerated	O
relapses	O
occur	O
within	O
10	O
months	O
of	O
surgery	O
for	O
untreated	O
patients	O
.	O

The	O
mechanism	O
proposed	O
is	O
a	O
stimulation	O
of	O
angiogenesis	O
for	O
distant	O
dormant	O
micrometastases	O
.	O

This	O
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
mechanisms	O
to	O
explain	O
the	O
mammography	O
paradox	O
for	O
women	O
aged	O
40	O
-	O
49	O
years	O
.	O

We	O
could	O
imagine	O
that	O
it	O
also	O
plays	O
a	O
role	O
in	O
adjuvant	O
chemotherapy	O
effectiveness	O
since	O
,	O
perhaps	O
not	O
coincidentally	O
,	O
this	O
is	O
most	O
beneficial	O
for	O
premenopausal	O
node	O
-	O
positive	O
patients	O
.	O

HYPOTHESIS	O
:	O
We	O
speculate	O
that	O
there	O
is	O
a	O
burst	O
of	O
angiogenesis	O
of	O
distant	O
dormant	O
micrometastases	O
after	O
surgery	O
in	O
approximately	O
20	O
%	O
of	O
premenopausal	O
node	O
-	O
positive	O
patients	O
.	O

We	O
also	O
speculate	O
that	O
this	O
synchronizes	O
them	O
into	O
a	O
temporal	O
highly	O
chemosensitive	O
state	O
and	O
is	O
the	O
underlying	O
reason	O
why	O
adjuvant	O
chemotherapy	O
works	O
particularly	O
well	O
for	O
that	O
patient	O
category	O
.	O

Furthermore	O
,	O
this	O
may	O
explain	O
why	O
cancer	O
in	O
younger	O
patients	O
is	O
more	O
often	O
'	O
aggressive	O
'	O
.	O

TESTING	O
THE	O
HYPOTHESIS	O
:	O
Stimulation	O
of	O
dormant	O
micrometastases	O
by	O
primary	O
tumor	O
removal	O
is	O
known	O
to	O
occur	O
in	O
animal	O
models	O
.	O

However	O
,	O
we	O
need	O
to	O
determine	O
whether	O
it	O
happens	O
in	O
breast	O
cancer	O
.	O

Transient	O
circulating	O
levels	O
of	O
angioactive	O
molecules	O
and	O
serial	O
high	O
-	O
resolution	O
imaging	O
studies	O
of	O
focal	O
angiogenesis	O
might	O
help	O
.	O

IMPLICATIONS	O
:	O
Short	O
-	O
course	O
cytotoxic	O
chemotherapy	O
after	O
surgery	O
has	O
probably	O
reached	O
its	O
zenith	O
,	O
and	O
other	O
strategies	O
,	O
perhaps	O
antiangiogenic	O
methods	O
,	O
are	O
needed	O
to	O
successfully	O
treat	O
more	O
patients	O
.	O

In	O
addition	O
,	O
the	O
hypothesis	O
predicts	O
that	O
early	O
detection	O
,	O
which	O
is	O
designed	O
to	O
find	O
more	O
patients	O
without	O
involved	O
lymph	O
nodes	O
,	O
may	O
not	O
be	O
a	O
synergistic	O
strategy	O
with	O
adjuvant	O
chemotherapy	O
,	O
which	O
works	O
best	O
with	O
positive	O
lymph	O
node	O
patients	O
.	O

Targeting	O
wide	O
-	O
range	O
oncogenic	O
transformation	O
via	O
PU24FCl	O
,	O
a	O
specific	O
inhibitor	O
of	O
tumor	O
Hsp90	O
.	O

Agents	O
that	O
inhibit	O
Hsp90	O
function	O
hold	O
significant	O
promise	O
in	O
cancer	O
therapy	O
.	O

Here	O
we	O
present	O
PU24FCl	O
,	O
a	O
representative	O
of	O
the	O
first	O
class	O
of	O
designed	O
Hsp90	O
inhibitors	O
.	O

By	O
specifically	O
and	O
potently	O
inhibiting	O
tumor	O
Hsp90	O
,	O
PU24FCl	O
exhibits	O
wide	O
-	O
ranging	O
anti	O
-	O
cancer	O
activities	O
that	O
occur	O
at	O
similar	O
doses	O
in	O
all	O
tested	O
tumor	O
types	O
.	O

Normal	O
cells	O
are	O
10	O
-	O
to	O
50	O
-	O
fold	O
more	O
resistant	O
to	O
these	O
effects	O
.	O

Its	O
Hsp90	O
inhibition	O
results	O
in	O
multiple	O
anti	O
-	O
tumor	O
-	O
specific	O
effects	O
,	O
such	O
as	O
degradation	O
of	O
Hsp90	O
-	O
client	O
proteins	O
involved	O
in	O
cell	O
growth	O
,	O
survival	O
,	O
and	O
specific	O
transformation	O
,	O
inhibition	O
of	O
cancer	O
cell	O
growth	O
,	O
delay	O
of	O
cell	O
cycle	O
progression	O
,	O
induction	O
of	O
morphological	O
and	O
functional	O
changes	O
,	O
and	O
apoptosis	O
.	O

In	O
concordance	O
with	O
its	O
higher	O
affinity	O
for	O
tumor	O
Hsp90	O
,	O
in	O
vivo	O
PU24FCl	O
accumulates	O
in	O
tumors	O
while	O
being	O
rapidly	O
cleared	O
from	O
normal	O
tissue	O
.	O

Concentrations	O
achieved	O
in	O
vivo	O
in	O
tumors	O
lead	O
to	O
single	O
-	O
agent	O
anti	O
-	O
tumor	O
activity	O
at	O
non	O
-	O
toxic	O
doses	O
.	O

Multicriteria	O
evaluation	O
of	O
simulated	O
logging	O
scenarios	O
in	O
a	O
tropical	O
rain	O
forest	O
.	O

Forest	O
growth	O
models	O
are	O
useful	O
tools	O
for	O
investigating	O
the	O
long	O
-	O
term	O
impacts	O
of	O
logging	O
.	O

In	O
this	O
paper	O
,	O
the	O
results	O
of	O
the	O
rain	O
forest	O
growth	O
model	O
FORMIND	O
were	O
assessed	O
by	O
a	O
multicriteria	O
decision	O
analysis	O
.	O

The	O
main	O
processes	O
covered	O
by	O
FORMIND	O
include	O
tree	O
growth	O
,	O
mortality	O
,	O
regeneration	O
and	O
competition	O
.	O

Tree	O
growth	O
is	O
calculated	O
based	O
on	O
a	O
carbon	O
balance	O
approach	O
.	O

Trees	O
compete	O
for	O
light	O
and	O
space	O
;	O
dying	O
large	O
trees	O
fall	O
down	O
and	O
create	O
gaps	O
in	O
the	O
forest	O
.	O

Sixty	O
-	O
four	O
different	O
logging	O
scenarios	O
for	O
an	O
initially	O
undisturbed	O
forest	O
stand	O
at	O
Deramakot	O
(	O
Malaysia	O
)	O
were	O
simulated	O
.	O

The	O
scenarios	O
differ	O
regarding	O
the	O
logging	O
cycle	O
,	O
logging	O
method	O
,	O
cutting	O
limit	O
and	O
logging	O
intensity	O
.	O

We	O
characterise	O
the	O
impacts	O
with	O
four	O
criteria	O
describing	O
the	O
yield	O
,	O
canopy	O
opening	O
and	O
changes	O
in	O
species	O
composition	O
.	O

Multicriteria	O
decision	O
analysis	O
was	O
used	O
for	O
the	O
first	O
time	O
to	O
evaluate	O
the	O
scenarios	O
and	O
identify	O
the	O
efficient	O
ones	O
.	O

Our	O
results	O
plainly	O
show	O
that	O
reduced	O
-	O
impact	O
logging	O
scenarios	O
are	O
more	O
'	O
efficient	O
'	O
than	O
the	O
others	O
,	O
since	O
in	O
these	O
scenarios	O
forest	O
damage	O
is	O
minimised	O
without	O
significantly	O
reducing	O
yield	O
.	O

Nevertheless	O
,	O
there	O
is	O
a	O
trade	O
-	O
off	O
between	O
yield	O
and	O
achieving	O
a	O
desired	O
ecological	O
state	O
of	O
logged	O
forest	O
;	O
the	O
ecological	O
state	O
of	O
the	O
logged	O
forests	O
can	O
only	O
be	O
improved	O
by	O
reducing	O
yields	O
and	O
enlarging	O
the	O
logging	O
cycles	O
.	O

Our	O
study	O
also	O
demonstrates	O
that	O
high	O
cutting	O
limits	O
or	O
low	O
logging	O
intensities	O
can	O
not	O
compensate	O
for	O
the	O
high	O
level	O
of	O
damage	O
caused	O
by	O
conventional	O
logging	O
techniques	O
.	O

Rational	O
synthesis	O
of	O
multicyclic	O
bis	O
[	O
2	O
]	O
catenanes	O
.	O

Bis	O
-	O
loop	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
6	O
has	O
been	O
prepared	O
by	O
acylation	O
of	O
the	O
wide	O
-	O
rim	O
calix	O
[	O
4	O
]	O
arene	O
tetraamine	O
1	O
with	O
the	O
activated	O
bis	O
(	O
urethane	O
)	O
8	O
under	O
dilution	O
conditions	O
.	O

Similarly	O
the	O
bis	O
(	O
Boc	O
-	O
protected	O
)	O
tetraamine	O
2	O
is	O
converted	O
into	O
the	O
mono	O
-	O
loop	O
derivative	O
3	O
which	O
after	O
deprotection	O
and	O
acylation	O
gives	O
the	O
bisalkenyl	O
derivative	O
5	O
.	O

In	O
apolar	O
solvents	O
this	O
tetraurea	O
calix	O
[	O
4	O
]	O
arene	O
5	O
forms	O
regioselectively	O
a	O
single	O
hydrogen	O
-	O
bonded	O
homodimer	O
,	O
from	O
which	O
the	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
is	O
formed	O
in	O
49	O
%	O
by	O
a	O
metathesis	O
reaction	O
followed	O
by	O
hydrogenation	O
.	O

Bis	O
-	O
loop	O
derivative	O
6	O
forms	O
no	O
homodimers	O
for	O
steric	O
reasons	O
,	O
but	O
a	O
stoichiometric	O
mixture	O
with	O
the	O
open	O
-	O
chain	O
tetraalkenyl	O
derivative	O
7a	O
contains	O
exclusively	O
the	O
heterodimer	O
.	O

Metathesis	O
and	O
subsequent	O
hydrogenation	O
now	O
yields	O
65	O
%	O
of	O
the	O
pure	O
bis	O
[	O
2	O
]	O
catenane	O
10a	O
which	O
could	O
not	O
be	O
isolated	O
from	O
the	O
complex	O
reaction	O
mixture	O
obtained	O
from	O
the	O
homodimer	O
7a	O
.	O
7a	O
.	O

The	O
chirality	O
of	O
10a	O
(	O
D	O
(	O
2	O
)	O
symmetry	O
)	O
has	O
been	O
verified	O
by	O
optical	O
resolution	O
using	O
HPLC	O
on	O
a	O
chiral	O
stationary	O
phase	O
.	O

Matrix	O
metalloproteinase	O
activity	O
and	O
immunohistochemical	O
profile	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
and	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
during	O
human	O
dermal	O
wound	O
healing	O
.	O

Proteolytic	O
activity	O
is	O
required	O
for	O
the	O
turnover	O
of	O
the	O
extracellular	O
matrix	O
during	O
wound	O
healing	O
.	O

Matrix	O
metalloproteinases	O
can	O
collectively	O
cleave	O
all	O
components	O
of	O
the	O
extracellular	O
matrix	O
,	O
with	O
the	O
endogenous	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
regulating	O
their	O
activity	O
.	O

Breast	O
tissue	O
taken	O
at	O
varying	O
postoperative	O
times	O
(	O
n	O
=	O
92	O
)	O
or	O
during	O
surgery	O
(	O
controls	O
,	O
n	O
=	O
17	O
)	O
,	O
was	O
used	O
to	O
investigate	O
the	O
temporal	O
and	O
spatial	O
activity	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
and	O
tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
during	O
human	O
wound	O
healing	O
.	O

Matrix	O
metalloproteinase	O
activity	O
,	O
determined	O
using	O
a	O
quenched	O
fluorescence	O
substrate	O
assay	O
,	O
increased	O
during	O
early	O
healing	O
(	O
3	O
-	O
8	O
weeks	O
)	O
compared	O
to	O
controls	O
,	O
and	O
then	O
decreased	O
between	O
24	O
and	O
36	O
weeks	O
after	O
surgery	O
(	O
p	O
less	O
than	O
0	O
.	O
05	O
until	O
24	O
weeks	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
test	O
)	O
.	O

Immunohistochemistry	O
scores	O
for	O
matrix	O
metalloproteinase	O
-	O
9	O
expression	O
were	O
significantly	O
elevated	O
compared	O
to	O
controls	O
in	O
scar	O
endothelial	O
cells	O
and	O
fibroblasts	O
from	O
2	O
until	O
12	O
and	O
20	O
weeks	O
,	O
respectively	O
.	O

Matrix	O
metalloproteinase	O
-	O
2	O
staining	O
was	O
observed	O
exclusively	O
in	O
fibroblasts	O
,	O
reaching	O
maximum	O
levels	O
8	O
-	O
12	O
weeks	O
after	O
surgery	O
,	O
decreasing	O
by	O
1	O
.	O
5	O
years	O
but	O
remaining	O
significantly	O
increased	O
.	O

Tissue	O
inhibitor	O
of	O
metalloproteinase	O
-	O
1	O
staining	O
was	O
relatively	O
sparse	O
but	O
was	O
significantly	O
increased	O
until	O
8	O
weeks	O
after	O
surgery	O
.	O

These	O
results	O
show	O
that	O
matrix	O
metalloproteinases	O
are	O
present	O
at	O
elevated	O
levels	O
during	O
early	O
wound	O
healing	O
,	O
when	O
angiogenesis	O
occurs	O
,	O
and	O
suggest	O
that	O
matrix	O
metalloproteinase	O
-	O
9	O
may	O
play	O
a	O
significant	O
role	O
.	O

The	O
later	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
in	O
fibroblasts	O
suggests	O
a	O
role	O
in	O
extracellular	O
matrix	O
remodeling	O
.	O

The	O
learning	O
curve	O
:	O
the	O
advantages	O
and	O
disadvantages	O
in	O
the	O
use	O
of	O
focus	O
groups	O
as	O
a	O
method	O
of	O
data	O
collection	O
.	O

Focus	O
groups	O
are	O
not	O
simply	O
a	O
discussion	O
between	O
people	O
,	O
but	O
are	O
focused	O
interviews	O
exploring	O
interactions	O
between	O
participants	O
.	O

In	O
this	O
paper	O
,	O
Ian	O
Mansell	O
,	O
Glynis	O
Bennett	O
,	O
Ruth	O
Northway	O
,	O
Donna	O
Mead	O
and	O
Laurie	O
Moseley	O
explore	O
the	O
complexities	O
and	O
practicalities	O
of	O
using	O
focus	O
groups	O
in	O
research	O
,	O
with	O
reference	O
to	O
a	O
study	O
of	O
palliative	O
care	O
services	O
.	O

Differential	O
proteomic	O
analysis	O
of	O
human	O
hepatocellular	O
carcinoma	O
cell	O
line	O
metastasis	O
-	O
associated	O
proteins	O
.	O

PURPOSE	O
:	O
The	O
comparative	O
study	O
of	O
differentially	O
expression	O
of	O
protein	O
profiles	O
of	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
with	O
various	O
metastasic	O
potential	O
and	O
screening	O
key	O
molecules	O
related	O
to	O
hepatocellular	O
carcinoma	O
metastasis	O
and	O
recurrence	O
.	O

METHODS	O
:	O
Using	O
two	O
-	O
dimensional	O
electrophoresis	O
and	O
liquid	O
chromatography	O
-	O
electrospray	O
ionization	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
,	O
we	O
analyzed	O
differentially	O
displayed	O
proteomics	O
of	O
human	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
Hep3B	B
,	O
MHCC97L	B
,	O
MHCC97H	B
with	O
different	O
metastasic	O
potential	O
.	O

RESULTS	O
:	O
Approximate	O
1	O
,	O
000	O
protein	O
spots	O
were	O
detected	O
on	O
silver	O
-	O
stained	O
gel	O
by	O
ImageMaster	O
(	O
977	O
+	O
/	O
-	O
113	O
spots	O
in	O
Hep3B	B
,	O
1092	O
+	O
/	O
-	O
40	O
in	O
MHCC97L	B
,	O
and	O
889	O
+	O
/	O
-	O
14	O
in	O
MHCC97H	B
)	O
.	O

Fifty	O
distinct	O
different	O
protein	O
spots	O
were	O
analyzed	O
with	O
online	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
.	O

Only	O
26	O
protein	O
spots	O
had	O
a	O
positive	O
result	O
,	O
including	O
annexin1	O
,	O
S100A4	O
,	O
and	O
so	O
on	O
.	O

In	O
comparison	O
with	O
nonmetastasis	O
Hep3B	B
cell	O
lines	O
,	O
there	O
were	O
16	O
proteins	O
overexpressed	O
in	O
MHCC97H	B
and	O
MHCC97L	B
,	O
10	O
proteins	O
underexpressed	O
in	O
MHCC97H	B
and	O
MHCC97L	B
.	O

Applying	O
cell	O
immunohistochemistry	O
and	O
RT	O
-	O
PCR	O
,	O
we	O
further	O
validated	O
two	O
interesting	O
and	O
different	O
proteins	O
,	O
annexin1	O
and	O
S100A4	O
.	O

CONCLUSION	O
:	O
The	O
protein	O
profile	O
of	O
metastatic	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
displayed	O
obvious	O
differences	O
compared	O
with	O
non	O
-	O
metastatic	O
liver	O
cancer	O
cell	O
lines	O
.	O

The	O
results	O
imply	O
that	O
various	O
different	O
proteins	O
may	O
lead	O
to	O
HCC	O
metastasis	O
together	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
in	O
seizures	O
:	O
a	O
double	O
-	O
edged	O
sword	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
is	O
a	O
vascular	O
growth	O
factor	O
which	O
induces	O
angiogenesis	O
(	O
the	O
development	O
of	O
new	O
blood	O
vessels	O
)	O
,	O
vascular	O
permeability	O
,	O
and	O
inflammation	O
.	O

In	O
brain	O
,	O
receptors	O
for	O
VEGF	O
have	O
been	O
localized	O
to	O
vascular	O
endothelium	O
,	O
neurons	O
,	O
and	O
glia	O
.	O

VEGF	O
is	O
upregulated	O
after	O
hypoxic	O
injury	O
to	O
the	O
brain	O
,	O
which	O
can	O
occur	O
during	O
cerebral	O
ischemia	O
or	O
high	O
-	O
altitude	O
edema	O
,	O
and	O
has	O
been	O
implicated	O
in	O
the	O
blood	O
-	O
brain	O
barrier	O
breakdown	O
associated	O
with	O
these	O
conditions	O
.	O

Given	O
its	O
recently	O
-	O
described	O
role	O
as	O
an	O
inflammatory	O
mediator	O
,	O
VEGF	O
could	O
also	O
contribute	O
to	O
the	O
inflammatory	O
responses	O
observed	O
in	O
cerebral	O
ischemia	O
.	O

After	O
seizures	O
,	O
blood	O
-	O
brain	O
barrier	O
breakdown	O
and	O
inflammation	O
is	O
also	O
observed	O
in	O
brain	O
,	O
albeit	O
on	O
a	O
lower	O
scale	O
than	O
that	O
observed	O
after	O
stroke	O
.	O

Recent	O
evidence	O
has	O
suggested	O
a	O
role	O
for	O
inflammation	O
in	O
seizure	O
disorders	O
.	O

We	O
have	O
described	O
striking	O
increases	O
in	O
VEGF	O
protein	O
in	O
both	O
neurons	O
and	O
glia	O
after	O
pilocarpine	O
-	O
induced	O
status	O
epilepticus	O
in	O
the	O
brain	O
.	O

Increases	O
in	O
VEGF	O
could	O
contribute	O
to	O
the	O
blood	O
-	O
brain	O
barrier	O
breakdown	O
and	O
inflammation	O
observed	O
after	O
seizures	O
.	O

However	O
,	O
VEGF	O
has	O
also	O
been	O
shown	O
to	O
be	O
neuroprotective	O
across	O
several	O
experimental	O
paradigms	O
,	O
and	O
hence	O
could	O
potentially	O
protect	O
vulnerable	O
cells	O
from	O
damage	O
associated	O
with	O
seizures	O
.	O

Therefore	O
,	O
the	O
role	O
of	O
VEGF	O
after	O
seizures	O
could	O
be	O
either	O
protective	O
or	O
destructive	O
.	O

Although	O
only	O
further	O
research	O
will	O
determine	O
the	O
exact	O
nature	O
of	O
VEGF	O
'	O
s	O
role	O
after	O
seizures	O
,	O
preliminary	O
data	O
indicate	O
that	O
VEGF	O
plays	O
a	O
protective	O
role	O
after	O
seizures	O
.	O

Clinical	O
implication	O
of	O
expression	O
of	O
cyclooxygenase	O
-	O
2	O
and	O
peroxisome	O
proliferator	O
activated	O
-	O
receptor	O
gamma	O
in	O
epithelial	O
ovarian	O
tumours	O
.	O

Expression	O
of	O
cyclooxygenase	O
(	O
COX	O
)	O
-	O
2	O
plays	O
a	O
key	O
role	O
in	O
tumorigenesis	O
and	O
development	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPARgamma	O
)	O
has	O
been	O
implicated	O
in	O
the	O
control	O
of	O
COX	O
-	O
2	O
expression	O
in	O
some	O
tissues	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
(	O
1	O
)	O
whether	O
expression	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
is	O
associated	O
with	O
ovarian	O
carcinogenesis	O
and	O
progression	O
of	O
ovarian	O
tumours	O
and	O
(	O
2	O
)	O
whether	O
COX	O
-	O
2	O
expression	O
is	O
controlled	O
through	O
ligand	O
-	O
mediated	O
activation	O
of	O
PPARgamma	O
in	O
ovarian	O
carcinoma	O
cells	O
.	O

For	O
this	O
purpose	O
,	O
the	O
presence	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
was	O
immunohistochemically	O
examined	O
in	O
71	O
epithelial	O
ovarian	O
carcinomas	O
,	O
18	O
borderline	O
tumours	O
and	O
23	O
benign	O
tumours	O
and	O
the	O
levels	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
proteins	O
were	O
determined	O
by	O
enzyme	O
immunoassay	O
in	O
four	O
benign	O
tumours	O
,	O
three	O
borderline	O
tumours	O
and	O
12	O
carcinomas	O
.	O

The	O
frequency	O
of	O
COX	O
-	O
2	O
and	O
PPARgamma	O
detection	O
was	O
significantly	O
increased	O
and	O
decreased	O
as	O
lesions	O
progressed	O
to	O
carcinoma	O
,	O
respectively	O
.	O

The	O
COX	O
-	O
2	O
protein	O
was	O
not	O
detected	O
in	O
the	O
three	O
borderline	O
tumours	O
,	O
whereas	O
PPARgamma	O
protein	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O

COX	O
-	O
2	O
protein	O
was	O
detected	O
in	O
eight	O
of	O
the	O
12	O
carcinomas	O
,	O
whereas	O
PPARgamma	O
protein	O
was	O
detected	O
in	O
only	O
two	O
cases	O
.	O

In	O
addition	O
,	O
PPARgamma	O
protein	O
was	O
not	O
detected	O
in	O
all	O
of	O
the	O
eight	O
carcinomas	O
in	O
which	O
COX	O
-	O
2	O
protein	O
was	O
detected	O
,	O
suggesting	O
that	O
expression	O
of	O
PPARgamma	O
and	O
COX	O
-	O
2	O
was	O
in	O
a	O
reciprocal	O
relationship	O
.	O

Furthermore	O
,	O
in	O
cultured	O
ovarian	O
carcinoma	O
cells	O
,	O
Western	O
blot	O
revealed	O
that	O
PPARgamma	O
and	O
COX	O
-	O
2	O
expression	O
was	O
regulated	O
conversely	O
as	O
a	O
result	O
of	O
stimulation	O
by	O
15	O
-	O
deoxy	O
-	O
Delta	O
(	O
12	O
,	O
14	O
)	O
PGJ	O
(	O
2	O
)	O
(	O
15	O
-	O
PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPARgamma	O
activator	O
.	O

In	O
addition	O
,	O
15d	O
-	O
PGJ	O
(	O
2	O
)	O
suppressed	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
-	O
induced	O
-	O
COX	O
-	O
2	O
expression	O
,	O
confirming	O
the	O
reciprocal	O
correlation	O
between	O
COX	O
-	O
2	O
and	O
PPARgamma	O
.	O

From	O
these	O
results	O
,	O
it	O
was	O
suggested	O
that	O
PPARgamma	O
activation	O
might	O
suppress	O
COX	O
-	O
2	O
expression	O
via	O
the	O
nuclear	O
factor	O
-	O
kappaB	O
pathway	O
in	O
the	O
ovarian	O
carcinoma	O
cells	O
and	O
that	O
low	O
expression	O
of	O
PPARgamma	O
and	O
high	O
expression	O
of	O
COX	O
-	O
2	O
might	O
be	O
involved	O
in	O
carcinogenesis	O
and	O
progression	O
of	O
ovarian	O
tumours	O
.	O

Safety	O
of	O
verteporfin	O
for	O
treatment	O
of	O
subfoveal	O
choroidal	O
neovascular	O
membranes	O
associated	O
with	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

Photodynamic	O
therapy	O
(	O
PDT	O
)	O
is	O
a	O
novel	O
treatment	O
entity	O
that	O
exploits	O
the	O
photophysical	O
properties	O
of	O
various	O
photosensitive	O
chemical	O
entities	O
which	O
,	O
upon	O
light	O
activation	O
,	O
results	O
in	O
targeted	O
photooxidation	O
and	O
subsequent	O
tissue	O
destruction	O
.	O

The	O
antiangiogenic	O
properties	O
of	O
PDT	O
have	O
been	O
adapted	O
for	O
treatment	O
of	O
subfoveal	O
choroidal	O
neovascular	O
membranes	O
due	O
to	O
disease	O
states	O
such	O
as	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
.	O

Historically	O
,	O
PDT	O
has	O
been	O
limited	O
by	O
a	O
lack	O
of	O
suitable	O
photosensitive	O
dyes	O
.	O

However	O
,	O
agents	O
such	O
as	O
verteporfin	O
,	O
a	O
second	O
-	O
generation	O
benzoporphyrin	O
derivative	O
,	O
appear	O
to	O
be	O
free	O
from	O
the	O
extensive	O
phototoxicity	O
that	O
limited	O
the	O
success	O
of	O
previous	O
agents	O
.	O

Verteporfin	O
has	O
a	O
high	O
affinity	O
for	O
choroidal	O
neovascular	O
membranes	O
,	O
typically	O
found	O
with	O
exudative	O
AMD	O
,	O
and	O
upon	O
photoactivation	O
results	O
in	O
targeted	O
microvascular	O
damage	O
and	O
thrombus	O
formation	O
with	O
resultant	O
vessel	O
occlusion	O
.	O

Scrutiny	O
of	O
diagnostic	O
indicators	O
for	O
verteporfin	O
administration	O
,	O
including	O
critical	O
angiographic	O
evaluation	O
of	O
lesion	O
size	O
and	O
visual	O
acuity	O
,	O
is	O
essential	O
to	O
treatment	O
success	O
.	O

Large	O
lesions	O
with	O
relatively	O
good	O
visual	O
acuity	O
(	O
20	O
/	O
50	O
or	O
better	O
)	O
may	O
be	O
at	O
particular	O
risk	O
for	O
marked	O
vision	O
loss	O
following	O
verteporfin	O
administration	O
.	O

Lesion	O
composition	O
also	O
appears	O
to	O
influence	O
visual	O
outcome	O
with	O
verteporfin	O
use	O
.	O

The	O
safety	O
of	O
verteporfin	O
is	O
directly	O
dependent	O
upon	O
the	O
appropriate	O
integration	O
of	O
dosage	O
,	O
infusion	O
and	O
light	O
activation	O
required	O
for	O
a	O
suitable	O
pharmacotherapeutic	O
outcome	O
.	O

When	O
used	O
appropriately	O
,	O
and	O
with	O
adequate	O
patient	O
education	O
regarding	O
photosensitivity	O
,	O
the	O
risk	O
-	O
benefit	O
of	O
verteporfin	O
for	O
the	O
medical	O
treatment	O
of	O
neovascular	O
AMD	O
is	O
favourable	O
.	O

Retrospective	O
case	O
series	O
of	O
juxtafoveal	O
choroidal	O
neovascularization	O
treated	O
with	O
photodynamic	O
therapy	O
with	O
verteporfin	O
.	O

PURPOSE	O
:	O
To	O
describe	O
visual	O
acuity	O
and	O
angiographic	O
outcomes	O
of	O
juxtafoveal	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
treated	O
with	O
photodynamic	O
therapy	O
and	O
verteporfin	O
(	O
PDT	O
)	O
.	O

METHODS	O
:	O
Four	O
hundred	O
eighty	O
-	O
four	O
consecutive	O
eyes	O
of	O
446	O
patients	O
treated	O
with	O
PDT	O
from	O
January	O
1	O
,	O
2001	O
,	O
to	O
June	O
30	O
,	O
2002	O
,	O
were	O
identified	O
from	O
billing	O
records	O
.	O

Fluorescein	O
angiograms	O
were	O
reviewed	O
retrospectively	O
to	O
identify	O
juxtafoveal	O
CNV	O
.	O

Eligible	O
patients	O
had	O
CNV	O
in	O
which	O
the	O
central	O
boundary	O
of	O
the	O
lesion	O
was	O
between	O
1	O
and	O
199	O
microm	O
from	O
the	O
geometric	O
center	O
of	O
the	O
foveal	O
avascular	O
zone	O
(	O
FAZ	O
)	O
.	O

Patient	O
charts	O
were	O
reviewed	O
for	O
visual	O
acuity	O
of	O
the	O
treated	O
eye	O
before	O
PDT	O
and	O
at	O
6	O
-	O
and	O
12	O
-	O
month	O
follow	O
-	O
up	O
examinations	O
.	O

Presence	O
of	O
subfoveal	O
CNV	O
at	O
6	O
and	O
12	O
months	O
of	O
follow	O
-	O
up	O
was	O
determined	O
by	O
review	O
of	O
fluorescein	O
angiograms	O
.	O

A	O
lesion	O
was	O
considered	O
subfoveal	O
if	O
it	O
extended	O
underneath	O
the	O
geometric	O
center	O
of	O
the	O
FAZ	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
eyes	O
had	O
juxtafoveal	O
CNV	O
.	O

Median	O
change	O
in	O
visual	O
acuity	O
both	O
6	O
and	O
12	O
months	O
after	O
the	O
initial	O
PDT	O
was	O
0	O
lines	O
(	O
n	O
=	O
18	O
at	O
6	O
months	O
,	O
range	O
-	O
14	O
to	O
+	O
8	O
lines	O
;	O
n	O
=	O
17	O
at	O
12	O
months	O
,	O
range	O
-	O
18	O
to	O
+	O
7	O
lines	O
)	O
.	O

Eleven	O
lesions	O
progressed	O
to	O
a	O
subfoveal	O
location	O
by	O
12	O
months	O
.	O

Visual	O
acuity	O
in	O
eyes	O
with	O
progressive	O
lesions	O
decreased	O
a	O
median	O
of	O
4	O
lines	O
of	O
vision	O
.	O

CONCLUSIONS	O
:	O
Despite	O
a	O
small	O
sample	O
size	O
and	O
limited	O
length	O
of	O
follow	O
-	O
up	O
,	O
this	O
study	O
shows	O
that	O
visual	O
acuity	O
on	O
average	O
can	O
remain	O
stable	O
for	O
at	O
least	O
12	O
months	O
after	O
PDT	O
of	O
juxtafoveal	O
lesions	O
.	O

Growth	O
through	O
the	O
foveal	O
center	O
still	O
can	O
occur	O
,	O
however	O
,	O
and	O
this	O
can	O
be	O
associated	O
with	O
substantial	O
visual	O
loss	O
.	O

Is	O
there	O
an	O
upper	O
limit	O
of	O
intracranial	O
pressure	O
in	O
patients	O
with	O
severe	O
head	O
injury	O
if	O
cerebral	O
perfusion	O
pressure	O
is	O
maintained	O
?	O

Authors	O
of	O
recent	O
studies	O
have	O
championed	O
the	O
importance	O
of	O
maintaining	O
cerebral	O
perfusion	O
pressure	O
(	O
CPP	O
)	O
to	O
prevent	O
secondary	O
brain	O
injury	O
following	O
traumatic	O
head	O
injury	O
.	O

Data	O
from	O
these	O
studies	O
have	O
provided	O
little	O
information	O
regarding	O
outcome	O
following	O
severe	O
head	O
injury	O
in	O
patients	O
with	O
an	O
intracranial	O
pressure	O
(	O
ICP	O
)	O
greater	O
than	O
40	O
mm	O
Hg	O
,	O
however	O
,	O
in	O
July	O
1997	O
the	O
authors	O
instituted	O
a	O
protocol	O
for	O
the	O
management	O
of	O
severe	O
head	O
injury	O
in	O
patients	O
with	O
a	O
Glasgow	O
Coma	O
Scale	O
score	O
lower	O
than	O
9	O
.	O

The	O
protocol	O
was	O
focused	O
on	O
resuscitation	O
from	O
acidosis	O
,	O
maintenance	O
of	O
a	O
CPP	O
greater	O
than	O
60	O
mm	O
Hg	O
through	O
whatever	O
means	O
necessary	O
as	O
well	O
as	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
mannitol	O
infusion	O
,	O
and	O
ventriculostomy	O
with	O
cerebrospinal	O
fluid	O
drainage	O
for	O
control	O
of	O
ICP	O
.	O

Since	O
the	O
institution	O
of	O
this	O
protocol	O
,	O
nine	O
patients	O
had	O
a	O
sustained	O
ICP	O
greater	O
than	O
40	O
mm	O
Hg	O
for	O
2	O
or	O
more	O
hours	O
,	O
and	O
five	O
of	O
these	O
had	O
an	O
ICP	O
greater	O
than	O
75	O
mm	O
Hg	O
on	O
insertion	O
of	O
the	O
ICP	O
monitor	O
and	O
later	O
experienced	O
herniation	O
and	O
expired	O
within	O
24	O
hours	O
.	O

Because	O
of	O
the	O
severe	O
nature	O
of	O
the	O
injuries	O
demonstrated	O
on	O
computerized	O
tomography	O
scans	O
and	O
their	O
physical	O
examinations	O
,	O
these	O
patients	O
were	O
not	O
aggressively	O
treated	O
under	O
this	O
protocol	O
.	O

The	O
authors	O
vigorously	O
attempted	O
to	O
maintain	O
a	O
CPP	O
greater	O
than	O
60	O
mm	O
Hg	O
with	O
intensive	O
fluid	O
resuscitation	O
and	O
the	O
administration	O
of	O
pressor	O
agents	O
in	O
the	O
four	O
remaining	O
patients	O
who	O
had	O
developed	O
an	O
ICP	O
higher	O
than	O
40	O
mm	O
Hg	O
after	O
placement	O
of	O
the	O
ICP	O
monitor	O
.	O

Two	O
patients	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
40	O
mm	O
Hg	O
for	O
more	O
than	O
36	O
hours	O
,	O
the	O
third	O
patient	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
of	O
50	O
mm	O
Hg	O
for	O
more	O
than	O
36	O
hours	O
,	O
and	O
the	O
fourth	O
patient	O
had	O
an	O
episodic	O
ICP	O
greater	O
than	O
50	O
mm	O
Hg	O
for	O
more	O
than	O
48	O
hours	O
.	O

On	O
discharge	O
,	O
all	O
four	O
patients	O
were	O
able	O
to	O
perform	O
normal	O
activities	O
of	O
daily	O
living	O
with	O
minimal	O
assistance	O
and	O
experience	O
ongoing	O
improvement	O
.	O

Data	O
from	O
this	O
preliminary	O
study	O
indicate	O
that	O
intense	O
,	O
aggressive	O
management	O
of	O
CPP	O
can	O
lead	O
to	O
good	O
neurological	O
outcomes	O
despite	O
extremely	O
high	O
ICP	O
.	O

Aggressive	O
CPP	O
therapy	O
should	O
be	O
performed	O
and	O
maintained	O
even	O
though	O
apparently	O
lethal	O
ICP	O
levels	O
may	O
be	O
present	O
.	O

Further	O
study	O
is	O
needed	O
to	O
support	O
these	O
encouraging	O
results	O
.	O

[	O
Epidemiology	O
of	O
fractures	O
of	O
the	O
proximal	O
femur	O
]	O
.	O

Fractures	O
of	O
the	O
upper	O
end	O
of	O
the	O
femur	O
constitute	O
a	O
major	O
public	O
health	O
problem	O
which	O
,	O
for	O
demographic	O
reasons	O
,	O
will	O
become	O
worse	O
during	O
the	O
next	O
decades	O
.	O

The	O
clinical	O
determination	O
of	O
femoral	O
neck	O
fractures	O
is	O
imperfectly	O
known	O
.	O

Two	O
factors	O
seem	O
to	O
be	O
determinant	O
:	O
bone	O
fragility	O
and	O
fall	O
,	O
but	O
these	O
factors	O
are	O
frequent	O
in	O
the	O
elderly	O
and	O
other	O
factors	O
seem	O
to	O
intervene	O
,	O
notably	O
the	O
modality	O
of	O
the	O
impact	O
and	O
the	O
protection	O
reflexes	O
during	O
the	O
fall	O
.	O

The	O
epidemiology	O
of	O
proximal	O
femur	O
fractures	O
therefore	O
can	O
not	O
be	O
restricted	O
to	O
the	O
diminution	O
of	O
bone	O
mass	O
.	O

Beside	O
age	O
and	O
female	O
sex	O
,	O
the	O
confirmed	O
risk	O
factors	O
for	O
these	O
fractures	O
are	O
:	O
ethnic	O
origin	O
,	O
absence	O
of	O
replacement	O
hormonal	O
therapy	O
in	O
menopausal	O
women	O
,	O
slight	O
build	O
and	O
absorption	O
of	O
certain	O
psychotropic	O
drugs	O
.	O

To	O
be	O
efficient	O
,	O
preventive	O
measures	O
must	O
rest	O
on	O
a	O
better	O
knowledge	O
of	O
the	O
determinant	O
factors	O
.	O

Epidemiological	O
research	O
should	O
develop	O
rationally	O
and	O
aim	O
at	O
identifying	O
more	O
accurate	O
risk	O
factors	O
,	O
taking	O
into	O
account	O
the	O
mechanisms	O
responsible	O
for	O
proximal	O
femur	O
fractures	O
:	O
fall	O
,	O
lack	O
of	O
cushioning	O
and	O
protection	O
during	O
the	O
fall	O
,	O
and	O
bone	O
fragility	O
.	O

Newly	O
recognized	O
syndrome	O
with	O
heminasal	O
aplasia	O
and	O
ocular	O
anomalies	O
or	O
wider	O
spectrum	O
of	O
heminasal	O
aplasia	O
/	O
atypical	O
clefting	O
syndrome	O
?	O

We	O
report	O
on	O
five	O
unrelated	O
Brazilian	O
patients	O
with	O
heminasal	O
aplasia	O
associated	O
with	O
diverses	O
anomalies	O
,	O
including	O
lateral	O
proboscis	O
,	O
and	O
anomalies	O
of	O
the	O
eye	O
and	O
first	O
branchial	O
arch	O
.	O

We	O
suggest	O
that	O
these	O
patients	O
represent	O
different	O
conditions	O
within	O
the	O
spectrum	O
of	O
the	O
heminasal	O
aplasia	O
malformation	O
.	O

Clinical	O
,	O
genetic	O
,	O
and	O
differential	O
diagnosis	O
are	O
discussed	O
.	O

Convergence	O
of	O
p53	O
and	O
TGF	O
-	O
beta	O
signaling	O
networks	O
.	O

p53	O
is	O
a	O
protein	O
with	O
many	O
talents	O
.	O

One	O
of	O
the	O
most	O
fundamental	O
is	O
the	O
ability	O
to	O
act	O
as	O
essential	O
growth	O
checkpoint	O
that	O
protects	O
cells	O
against	O
cellular	O
transformation	O
.	O

p53	O
does	O
so	O
through	O
the	O
induction	O
of	O
genes	O
leading	O
to	O
growth	O
arrest	O
or	O
apoptosis	O
.	O

Most	O
of	O
the	O
studies	O
focusing	O
on	O
the	O
mechanisms	O
of	O
p53	O
activity	O
have	O
been	O
performed	O
in	O
cultured	O
cells	O
upon	O
treatment	O
with	O
well	O
-	O
established	O
p53	O
-	O
activating	O
inputs	O
,	O
such	O
as	O
high	O
doses	O
of	O
radiations	O
,	O
DNA	O
-	O
damaging	O
drugs	O
and	O
activated	O
oncogenes	O
.	O

However	O
,	O
how	O
the	O
tumor	O
suppressive	O
functions	O
of	O
p53	O
become	O
concerted	O
with	O
the	O
extracellular	O
cues	O
arriving	O
at	O
the	O
cell	O
surface	O
during	O
tissue	O
homeostasis	O
,	O
remains	O
largely	O
unknown	O
.	O

Intriguingly	O
,	O
two	O
recent	O
papers	O
have	O
shed	O
new	O
light	O
into	O
this	O
unexplored	O
field	O
,	O
indicating	O
that	O
p53	O
plays	O
a	O
key	O
role	O
in	O
TGF	O
-	O
beta	O
-	O
induced	O
growth	O
arrest	O
and	O
,	O
unexpectedly	O
,	O
in	O
the	O
developmental	O
effects	O
of	O
TGF	O
-	O
beta	O
in	O
early	O
embryos	O
.	O

Here	O
we	O
review	O
and	O
comment	O
on	O
these	O
findings	O
and	O
on	O
their	O
implications	O
for	O
cancer	O
biology	O
.	O

Enhanced	O
IGF	O
-	O
1	O
expression	O
improves	O
smooth	O
muscle	O
cell	O
engraftment	O
after	O
cell	O
transplantation	O
.	O

The	O
functional	O
benefit	O
of	O
cell	O
transplantation	O
after	O
a	O
myocardial	O
infarction	O
is	O
diminished	O
by	O
early	O
cell	O
losses	O
.	O

IGF	O
-	O
1	O
enhances	O
cell	O
proliferation	O
and	O
survival	O
.	O

We	O
hypothesized	O
that	O
IGF	O
-	O
1	O
-	O
transfected	O
smooth	O
muscle	O
cells	O
(	O
SMCs	O
)	O
would	O
enhance	O
cell	O
survival	O
and	O
improve	O
engraftment	O
after	O
cell	O
transplantation	O
.	O

The	O
IGF	O
-	O
1	O
gene	O
was	O
transfected	O
into	O
male	O
SMCs	O
and	O
compared	O
with	O
SMCs	O
transfected	O
with	O
a	O
plasmid	O
vector	O
(	O
vector	O
control	O
)	O
and	O
nontransfected	O
SMCs	O
(	O
cell	O
control	O
)	O
.	O

IGF	O
-	O
1	O
mRNA	O
(	O
n	O
=	O
10	O
/	O
group	O
)	O
and	O
protein	O
levels	O
(	O
n	O
=	O
6	O
/	O
group	O
)	O
were	O
higher	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
at	O
3	O
,	O
7	O
,	O
and	O
14	O
days	O
compared	O
with	O
controls	O
.	O

VEGF	O
was	O
also	O
increased	O
in	O
parallel	O
to	O
enhanced	O
IGF	O
-	O
1	O
expression	O
.	O

IGF	O
-	O
1	O
-	O
transfected	O
cells	O
demonstrated	O
greater	O
cell	O
proliferation	O
,	O
stimulated	O
angiogenesis	O
,	O
and	O
decreased	O
caspase	O
-	O
3	O
activity	O
after	O
simulated	O
ischemia	O
and	O
reperfusion	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
compared	O
with	O
vector	O
or	O
cell	O
controls	O
)	O
.	O

A	O
uniform	O
left	O
ventricular	O
injury	O
was	O
produced	O
in	O
female	O
rats	O
using	O
a	O
cryoprobe	O
.	O

Three	O
weeks	O
later	O
,	O
2	O
x	O
10	O
(	O
6	O
)	O
cells	O
from	O
three	O
groups	O
were	O
implanted	O
into	O
the	O
scar	O
.	O

One	O
week	O
later	O
,	O
IGF	O
-	O
1	O
-	O
transfected	O
SMCs	O
had	O
increased	O
myocardial	O
IGF	O
-	O
1	O
and	O
VEGF	O
levels	O
,	O
increased	O
Bcl2	O
expression	O
,	O
limited	O
cell	O
apoptosis	O
,	O
and	O
enhanced	O
vessel	O
formation	O
in	O
the	O
myocardial	O
scar	O
compared	O
with	O
the	O
two	O
control	O
groups	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
for	O
all	O
groups	O
)	O
.	O

The	O
proportion	O
of	O
SMCs	O
surviving	O
in	O
the	O
implanted	O
region	O
was	O
greater	O
(	O
P	O
less	O
than	O
0	O
.	O
05	O
)	O
in	O
the	O
IGF	O
-	O
1	O
-	O
transfected	O
group	O
than	O
in	O
the	O
vector	O
or	O
cell	O
controls	O
.	O

Gene	O
enhancement	O
with	O
IGF	O
-	O
1	O
improved	O
donor	O
cell	O
proliferation	O
,	O
survival	O
,	O
and	O
engraftment	O
after	O
cell	O
transplantation	O
,	O
perhaps	O
mediated	O
by	O
enhanced	O
angiogenesis	O
and	O
reduced	O
apoptosis	O
.	O

[	O
Altered	O
expression	O
of	O
PTEN	O
gene	O
and	O
LOH	O
of	O
its	O
epigenetic	O
microsatellite	O
in	O
gastric	O
carcinoma	O
]	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
expression	O
of	O
PTEN	O
and	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
of	O
its	O
epigenetic	O
microsatellite	O
in	O
gastric	O
carcinoma	O
and	O
explore	O
their	O
roles	O
in	O
progression	O
of	O
gastric	O
carcinoma	O
.	O

METHODS	O
:	O
LOH	O
of	O
epigenetic	O
microsatellites	O
of	O
PTEN	O
(	O
D10S541	O
,	O
D10S583	O
and	O
D10S1687	O
)	O
in	O
advanced	O
gastric	O
cancer	O
was	O
detected	O
by	O
PCR	O
-	O
SSCP	O
.	O

Expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
in	O
normal	O
gastric	O
mucosa	O
and	O
gastric	O
cancer	O
was	O
evaluated	O
by	O
RT	O
-	O
PCR	O
and	O
SABC	O
immunohistochemistry	O
,	O
respectively	O
.	O

The	O
relationship	O
between	O
expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
and	O
lymph	O
node	O
metastasis	O
or	O
LOH	O
of	O
microsatellites	O
was	O
discussed	O
.	O

RESULTS	O
:	O
LOH	O
of	O
D10S541	O
,	O
D10S583	O
and	O
D10S1687	O
was	O
found	O
in	O
37	O
.	O
5	O
%	O
(	O
21	O
/	O
56	O
)	O
of	O
advanced	O
gastric	O
cancers	O
.	O

The	O
positive	O
rates	O
of	O
PTEN	O
mRNA	O
expression	O
were	O
80	O
.	O
4	O
%	O
(	O
45	O
/	O
56	O
)	O
,	O
45	O
.	O
5	O
%	O
(	O
5	O
/	O
11	O
)	O
and	O
32	O
.	O
1	O
%	O
(	O
18	O
/	O
56	O
)	O
in	O
normal	O
mucosa	O
,	O
early	O
and	O
advanced	O
gastric	O
carcinomas	O
,	O
respectively	O
,	O
while	O
78	O
.	O
6	O
%	O
(	O
44	O
/	O
56	O
)	O
,	O
44	O
.	O
5	O
%	O
(	O
5	O
/	O
11	O
)	O
and	O
28	O
.	O
6	O
%	O
(	O
16	O
/	O
56	O
)	O
at	O
the	O
protein	O
level	O
.	O

PTEN	O
mRNA	O
and	O
protein	O
were	O
less	O
frequently	O
expressed	O
in	O
early	O
and	O
advanced	O
gastric	O
carcinomas	O
than	O
that	O
in	O
normal	O
gastric	O
mucosa	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
positive	O
correlation	O
between	O
PTEN	O
mRNA	O
expression	O
and	O
LOH	O
of	O
microsatellites	O
in	O
advanced	O
gastric	O
carcinomas	O
.	O

PTEN	O
protein	O
expression	O
paralleled	O
with	O
its	O
mRNA	O
expression	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
expression	O
of	O
PTEN	O
mRNA	O
and	O
protein	O
was	O
negatively	O
correlated	O
with	O
lymph	O
node	O
metastasis	O
of	O
advanced	O
gastric	O
carcinomas	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
Down	O
-	O
regulated	O
expression	O
of	O
PTEN	O
gene	O
is	O
found	O
in	O
different	O
stages	O
of	O
gastric	O
carcinoma	O
,	O
and	O
is	O
closely	O
correlated	O
with	O
LOH	O
of	O
its	O
epigenetic	O
microsatellites	O
,	O
which	O
probably	O
is	O
its	O
underlying	O
molecular	O
mechanisms	O
.	O

It	O
suggests	O
that	O
altered	O
PTEN	O
gene	O
contributes	O
to	O
tumorigenesis	O
and	O
progression	O
of	O
gastric	O
carcinomas	O
.	O

Flow	O
dynamics	O
of	O
the	O
internal	O
thoracic	O
and	O
radial	O
artery	O
T	O
-	O
graft	O
.	O

BACKGROUND	O
:	O

Complex	O
use	O
of	O
arterial	O
conduits	O
has	O
resurrected	O
concerns	O
about	O
the	O
adequacy	O
of	O
conduit	O
flow	O
.	O

The	O
T	O
-	O
graft	O
is	O
the	O
extreme	O
example	O
of	O
this	O
trend	O
.	O

Our	O
purpose	O
was	O
to	O
identify	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
and	O
to	O
compare	O
flow	O
capacity	O
with	O
completion	O
coronary	O
flow	O
.	O

METHODS	O
:	O

Between	O
February	O
1999	O
and	O
November	O
2001	O
,	O
372	O
patients	O
underwent	O
total	O
arterial	O
revascularization	O
with	O
the	O
T	O
-	O
graft	O
alone	O
.	O

Intraoperative	O
flows	O
were	O
recorded	O
for	O
each	O
limb	O
of	O
the	O
T	O
-	O
graft	O
before	O
and	O
after	O
distal	O
anastomoses	O
in	O
204	O
patients	O
.	O

Independent	O
predictors	O
of	O
T	O
-	O
graft	O
flow	O
were	O
identified	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O

Free	O
flow	O
for	O
the	O
radial	O
arterial	O
(	O
RA	O
)	O
limb	O
was	O
161	O
+	O
/	O
-	O
81	O
mL	O
/	O
min	O
,	O
the	O
internal	O
thoracic	O
artery	O
(	O
ITA	O
)	O
limb	O
137	O
+	O
/	O
-	O
57	O
mL	O
/	O
min	O
(	O
combined	O
298	O
+	O
/	O
-	O
101	O
mL	O
/	O
min	O
)	O
versus	O
simultaneous	O
limb	O
flow	O
of	O
226	O
+	O
/	O
-	O
84	O
mL	O
/	O
min	O
giving	O
a	O
flow	O
restriction	O
of	O
24	O
%	O
+	O
/	O
-	O
14	O
%	O
.	O

Completion	O
coronary	O
flow	O
was	O
88	O
+	O
/	O
-	O
49	O
mL	O
/	O
min	O
for	O
the	O
RA	O
,	O
60	O
+	O
/	O
-	O
45	O
mL	O
/	O
min	O
for	O
the	O
ITA	O
,	O
and	O
140	O
+	O
/	O
-	O
70	O
mL	O
/	O
min	O
for	O
both	O
limbs	O
simultaneously	O
to	O
give	O
a	O
flow	O
reserve	O
(	O
vs	O
simultaneous	O
free	O
flow	O
)	O
of	O
160	O
%	O
or	O
1	O
.	O
6	O
.	O

Independent	O
predictors	O
of	O
completion	O
RA	O
limb	O
flow	O
are	O
RA	O
proximal	O
diameter	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
number	O
of	O
anastomoses	O
(	O
p	O
=	O
0	O
.	O
018	O
)	O
,	O
and	O
target	O
stenosis	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
.	O

CONCLUSIONS	O
:	O

A	O
flow	O
reserve	O
of	O
1	O
.	O
6	O
compares	O
favorably	O
with	O
an	O
ITA	O
flow	O
reserve	O
of	O
1	O
.	O
8	O
at	O
1	O
-	O
month	O
postoperatively	O
and	O
1	O
.	O
8	O
for	O
both	O
the	O
ITA	O
T	O
-	O
graft	O
and	O
the	O
ITA	O
/	O
RA	O
T	O
-	O
graft	O
at	O
1	O
-	O
week	O
postoperatively	O
as	O
reported	O
by	O
others	O
.	O

Proximal	O
RA	O
diameter	O
and	O
competitive	O
coronary	O
flow	O
influence	O
completion	O
T	O
-	O
graft	O
flow	O
.	O

These	O
data	O
quantitate	O
the	O
limitation	O
of	O
single	O
source	O
inflow	O
of	O
the	O
T	O
-	O
graft	O
configuration	O
and	O
support	O
its	O
continued	O
use	O
.	O

Expression	O
of	O
DCC	O
and	O
netrin	O
-	O
1	O
in	O
normal	O
human	O
endometrium	O
and	O
its	O
implication	O
in	O
endometrial	O
carcinogenesis	O
.	O

OBJECTIVE	O
:	O
Although	O
DCC	O
has	O
been	O
considered	O
as	O
a	O
candidate	O
tumor	O
suppressor	O
,	O
the	O
roles	O
it	O
plays	O
in	O
the	O
uterine	O
endometrium	O
and	O
in	O
the	O
carcinogenic	O
process	O
remains	O
unclear	O
.	O

To	O
define	O
these	O
roles	O
more	O
clearly	O
,	O
we	O
examined	O
the	O
expression	O
of	O
DCC	O
and	O
its	O
ligand	O
,	O
netrin	O
-	O
1	O
,	O
in	O
the	O
normal	O
endometrium	O
and	O
in	O
endometrial	O
cancer	O
.	O

METHODS	O
:	O
The	O
expression	O
of	O
DCC	O
and	O
netrin	O
-	O
1	O
in	O
normal	O
endometrial	O
glands	O
and	O
in	O
cancer	O
cell	O
lines	O
was	O
examined	O
by	O
RT	O
-	O
PCR	O
and	O
immunohistochemistry	O
.	O

The	O
effects	O
of	O
exogenous	O
DCC	O
and	O
netrin	O
-	O
1	O
expression	O
were	O
observed	O
together	O
with	O
the	O
respective	O
expression	O
vector	O
transfection	O
.	O

RESULTS	O
:	O
Endometrial	O
glands	O
in	O
the	O
proliferative	O
and	O
early	O
secretory	O
phase	O
expressed	O
both	O
DCC	O
and	O
netrin	O
-	O
1	O
,	O
but	O
glands	O
in	O
the	O
late	O
-	O
secretory	O
phase	O
tended	O
to	O
silence	O
DCC	O
expression	O
.	O

In	O
addition	O
,	O
all	O
of	O
the	O
endometrial	O
cancer	O
cell	O
lines	O
lost	O
normal	O
DCC	O
expression	O
.	O

Restored	O
DCC	O
expression	O
in	O
the	O
cancer	O
cell	O
lines	O
in	O
the	O
absence	O
of	O
netrin	O
-	O
1	O
induced	O
apoptosis	O
.	O

However	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
presence	O
of	O
netrin	O
-	O
1	O
.	O

CONCLUSION	O
:	O
Our	O
observations	O
suggest	O
that	O
DCC	O
/	O
netrin	O
-	O
1	O
signaling	O
may	O
commit	O
cells	O
to	O
the	O
transition	O
of	O
endometrial	O
gland	O
architecture	O
or	O
function	O
from	O
a	O
proliferating	O
to	O
a	O
secretory	O
phase	O
.	O

In	O
addition	O
,	O
the	O
silencing	O
of	O
DCC	O
expression	O
may	O
contribute	O
to	O
the	O
escape	O
of	O
endometrial	O
cancer	O
cells	O
from	O
a	O
DCC	O
-	O
regulated	O
apoptotic	O
program	O
,	O
thereby	O
promoting	O
malignant	O
phenotypes	O
.	O

Role	O
of	O
osteopontin	O
in	O
adhesion	O
,	O
migration	O
,	O
cell	O
survival	O
and	O
bone	O
remodeling	O
.	O

Osteopontin	O
(	O
OPN	O
)	O
is	O
a	O
secreted	O
adhesive	O
glycophosphoprotein	O
expressed	O
by	O
several	O
cell	O
types	O
.	O

It	O
is	O
normally	O
produced	O
in	O
bone	O
,	O
teeth	O
,	O
kidney	O
and	O
epithelial	O
lining	O
tissues	O
and	O
is	O
found	O
in	O
plasma	O
and	O
breast	O
milk	O
.	O

It	O
is	O
involved	O
in	O
a	O
number	O
of	O
physiologic	O
and	O
pathologic	O
events	O
including	O
angiogenesis	O
,	O
apoptosis	O
,	O
inflammation	O
,	O
wound	O
healing	O
and	O
tumor	O
metastasis	O
.	O

In	O
this	O
review	O
focus	O
will	O
be	O
on	O
OPN	O
in	O
bone	O
and	O
its	O
role	O
in	O
adhesion	O
,	O
migration	O
and	O
cell	O
survival	O
.	O

These	O
aspects	O
of	O
OPN	O
biology	O
are	O
important	O
in	O
tumorigenesis	O
.	O

Neurologic	O
diagnosis	O
and	O
treatment	O
in	O
patients	O
with	O
computed	O
tomography	O
and	O
nasal	O
endoscopy	O
negative	O
facial	O
pain	O
.	O

OBJECTIVE	O
:	O

To	O
determine	O
the	O
helpfulness	O
of	O
specialist	O
neurology	O
referral	O
for	O
patients	O
with	O
facial	O
pain	O
,	O
a	O
normal	O
sinus	O
computed	O
tomography	O
(	O
CT	O
)	O
scan	O
,	O
and	O
normal	O
nasal	O
endoscopy	O
findings	O
.	O

STUDY	O
DESIGN	O
:	O

Prospective	O
identification	O
of	O
patients	O
and	O
analysis	O
of	O
data	O
approved	O
by	O
the	O
Institutional	O
Review	O
Board	O
.	O

METHODS	O
:	O

The	O
data	O
of	O
104	O
consecutive	O
patients	O
presenting	O
with	O
facial	O
pain	O
,	O
a	O
normal	O
sinus	O
CT	O
scan	O
,	O
and	O
normal	O
nasal	O
endoscopy	O
findings	O
were	O
reviewed	O
.	O

The	O
patients	O
presented	O
to	O
a	O
single	O
rhinologist	O
in	O
a	O
tertiary	O
care	O
institution	O
.	O

All	O
patients	O
were	O
referred	O
for	O
specialist	O
neurologic	O
evaluation	O
and	O
potential	O
treatment	O
.	O

Further	O
information	O
was	O
obtained	O
from	O
a	O
patient	O
survey	O
.	O

RESULTS	O
:	O

Of	O
the	O
104	O
patients	O
,	O
81	O
were	O
women	O
and	O
23	O
were	O
men	O
.	O

The	O
average	O
age	O
was	O
46	O
years	O
(	O
range	O
,	O
22	O
-	O
85	O
)	O
.	O

Fifty	O
-	O
six	O
had	O
clear	O
CT	O
scans	O
,	O
48	O
had	O
minimal	O
change	O
,	O
and	O
all	O
had	O
negative	O
endoscopies	O
.	O

Twenty	O
-	O
nine	O
had	O
previous	O
unsuccessful	O
sinus	O
surgery	O
.	O

The	O
average	O
follow	O
-	O
up	O
period	O
was	O
10	O
.	O
5	O
months	O
.	O

Forty	O
of	O
75	O
patients	O
seeing	O
a	O
neurologist	O
were	O
seen	O
on	O
multiple	O
occasions	O
.	O

Four	O
percent	O
of	O
patients	O
seen	O
by	O
a	O
neurologist	O
had	O
an	O
unsuspected	O
serious	O
intracranial	O
diagnosis	O
.	O

The	O
most	O
common	O
diagnoses	O
were	O
migraine	O
(	O
37	O
%	O
)	O
,	O
rebound	O
headache	O
(	O
17	O
%	O
)	O
,	O
chronic	O
daily	O
headache	O
(	O
17	O
%	O
)	O
,	O
and	O
obstructive	O
sleep	O
apnea	O
(	O
16	O
%	O
)	O
.	O

Overall	O
,	O
58	O
%	O
improved	O
on	O
medical	O
therapy	O
;	O
60	O
%	O
of	O
those	O
with	O
a	O
clear	O
CT	O
scan	O
improved	O
,	O
and	O
53	O
%	O
of	O
those	O
with	O
minimal	O
change	O
on	O
CT	O
scan	O
improved	O
(	O
P	O
=	O
.	O
749	O
)	O
.	O

CONCLUSIONS	O
:	O

Facial	O
pain	O
remains	O
a	O
difficult	O
symptom	O
to	O
diagnose	O
and	O
treat	O
in	O
rhinologic	O
practice	O
.	O

Patients	O
often	O
undergo	O
surgery	O
without	O
help	O
.	O

Most	O
patients	O
with	O
facial	O
pain	O
,	O
a	O
normal	O
sinus	O
CT	O
scan	O
,	O
and	O
normal	O
endoscopy	O
findings	O
benefit	O
from	O
neurologic	O
consultation	O
.	O

Serious	O
intracranial	O
pathologic	O
conditions	O
can	O
be	O
excluded	O
and	O
diagnosis	O
-	O
specific	O
pharmacogenetic	O
therapy	O
instituted	O
with	O
improvement	O
in	O
more	O
than	O
50	O
%	O
.	O

[	O
Glaucoma	O
and	O
ocular	O
ischemic	O
syndrome	O
-	O
-	O
case	O
report	O
]	O

PURPOSE	O
:	O
Ocular	O
ischemic	O
syndrome	O
(	O
OIS	O
)	O
is	O
often	O
poorly	O
diagnosed	O
and	O
treated	O
as	O
primary	O
open	O
angle	O
glaucoma	O
or	O
later	O
on	O
,	O
as	O
neovascular	O
glaucoma	O
.	O

We	O
present	O
a	O
54	O
year	O
old	O
male	O
,	O
treated	O
topical	O
since	O
23	O
years	O
for	O
glaucoma	O
and	O
sent	O
to	O
our	O
clinic	O
for	O
trabeculectomy	O
because	O
of	O
rapid	O
worsening	O
of	O
vision	O
on	O
right	O
eye	O
with	O
bilateral	O
total	O
excavation	O
of	O
optic	O
disc	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
Observational	O
case	O
report	O
.	O

RESULTS	O
:	O
Because	O
of	O
typical	O
signs	O
of	O
IOS	O
(	O
iris	O
neovascularization	O
,	O
mid	O
-	O
peripheral	O
dot	O
and	O
blot	O
hemorrhages	O
in	O
both	O
eyes	O
,	O
narrowed	O
arterioles	O
in	O
right	O
eye	O
,	O
following	O
examinations	O
were	O
performed	O
:	O
Doppler	O
ultrasonography	O
of	O
carotid	O
arteries	O
,	O
digital	O
subtractional	O
angiography	O
of	O
the	O
carotid	O
vessels	O
and	O
magnetic	O
resonance	O
angiography	O
.	O

The	O
examinations	O
showed	O
occlusion	O
of	O
the	O
right	O
common	O
carotid	O
artery	O
and	O
with	O
80	O
%	O
stenosis	O
of	O
the	O
left	O
common	O
carotid	O
artery	O
,	O
occlusion	O
of	O
abdominal	O
aorta	O
.	O

After	O
phacoemulsification	O
with	O
implantation	O
of	O
intraocular	O
lens	O
because	O
of	O
rapid	O
intumescence	O
cataract	O
in	O
the	O
right	O
eye	O
,	O
and	O
endarterectomy	O
of	O
left	O
external	O
carotid	O
artery	O
,	O
the	O
neovascularization	O
of	O
the	O
iris	O
regressed	O
in	O
both	O
eyes	O
.	O

CONCLUSION	O
:	O
In	O
case	O
of	O
iris	O
neovascularization	O
or	O
mid	O
-	O
peripheral	O
hemorrhages	O
the	O
Doppler	O
sonography	O
of	O
carotid	O
arteries	O
should	O
be	O
performed	O
.	O

Quick	O
cooperation	O
between	O
ophthalmologist	O
,	O
radiologist	O
and	O
vascular	O
surgeon	O
following	O
endarterectomy	O
seems	O
to	O
stop	O
progressing	O
changes	O
of	O
ocular	O
ischemic	O
syndrome	O
.	O

Structural	O
evolution	O
in	O
cationic	O
micelles	O
upon	O
incorporation	O
of	O
a	O
polar	O
organic	O
dopant	O
.	O

Micelles	O
of	O
cetyltrimethylammonium	O
bromide	O
(	O
CTAB	O
)	O
,	O
when	O
doped	O
with	O
increasing	O
levels	O
of	O
4	O
-	O
ethylphenol	O
,	O
show	O
microstructural	O
transitions	O
from	O
spherical	O
micelles	O
to	O
elongated	O
wormlike	O
micelles	O
,	O
disks	O
,	O
and	O
subsequently	O
to	O
globular	O
and	O
then	O
to	O
tubular	O
vesicles	O
.	O

Wormlike	O
micelles	O
are	O
observed	O
at	O
a	O
dopant	O
-	O
to	O
-	O
CTAB	O
molar	O
ratio	O
of	O
1	O
:	O
3	O
.	O

At	O
higher	O
dopant	O
ratios	O
(	O
1	O
:	O
1	O
)	O
,	O
globular	O
vesicles	O
are	O
observed	O
which	O
transition	O
to	O
tubular	O
vesicles	O
when	O
the	O
dopant	O
becomes	O
the	O
predominant	O
species	O
at	O
a	O
ratio	O
of	O
3	O
:	O
1	O
.	O

These	O
transitions	O
are	O
reflected	O
in	O
small	O
-	O
angle	O
neutron	O
scattering	O
analysis	O
and	O
,	O
interestingly	O
,	O
can	O
be	O
directly	O
observed	O
through	O
cryo	O
-	O
transmission	O
electron	O
microscopy	O
.	O

The	O
para	O
-	O
substituted	O
phenol	O
is	O
interfacially	O
active	O
and	O
modulates	O
interfacial	O
curvature	O
of	O
the	O
micelles	O
.	O

The	O
observations	O
of	O
microstructure	O
modifications	O
have	O
relevance	O
to	O
the	O
synthesis	O
of	O
mesoporous	O
materials	O
using	O
CTAB	O
as	O
the	O
template	O
.	O

Thiazole	O
orange	O
positive	O
platelets	O
in	O
a	O
dog	O
with	O
Evans	O
'	O
syndrome	O
.	O

We	O
examined	O
transition	O
for	O
the	O
percentage	O
of	O
reticulated	O
platelets	O
(	O
RP	O
%	O
)	O
and	O
platelet	O
count	O
in	O
a	O
canine	O
case	O
of	O
Evans	O
'	O
syndrome	O
.	O

The	O
result	O
demonstrated	O
that	O
measurement	O
of	O
the	O
RP	O
%	O
can	O
be	O
useful	O
in	O
evaluating	O
platelet	O
production	O
in	O
the	O
bone	O
marrow	O
and	O
response	O
to	O
treatment	O
.	O

Granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
and	O
interleukin	O
-	O
3	O
enhance	O
the	O
incorporation	O
of	O
cytosine	O
arabinoside	O
into	O
the	O
DNA	O
of	O
leukemic	O
blasts	O
and	O
the	O
cytotoxic	O
effect	O
on	O
clonogenic	O
cells	O
from	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

In	O
the	O
present	O
study	O
the	O
effects	O
of	O
the	O
48	O
-	O
hour	O
administration	O
of	O
granulocyte	O
-	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
GM	O
-	O
CSF	O
)	O
(	O
100	O
U	O
/	O
mL	O
)	O
or	O
interleukin	O
-	O
3	O
(	O
IL	O
-	O
3	O
)	O
(	O
100	O
U	O
/	O
mL	O
)	O
on	O
the	O
proliferative	O
activity	O
of	O
leukemic	O
cells	O
and	O
on	O
the	O
intracellular	O
metabolism	O
and	O
cytotoxic	O
efficacy	O
of	O
a	O
subsequent	O
12	O
-	O
hour	O
application	O
of	O
cytosine	O
arabinoside	O
(	O
ara	O
-	O
C	O
)	O
at	O
doses	O
of	O
0	O
.	O
1	O
,	O
1	O
.	O
0	O
,	O
10	O
.	O
0	O
,	O
and	O
100	O
.	O
0	O
mumol	O
/	O
L	O
were	O
evaluated	O
on	O
bone	O
marrow	O
cells	O
from	O
17	O
patients	O
with	O
acute	O
myeloid	O
leukemia	O
.	O

After	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
,	O
a	O
1	O
.	O
2	O
-	O
to	O
2	O
.	O
4	O
-	O
fold	O
increase	O
in	O
S	O
-	O
phase	O
cells	O
was	O
observed	O
in	O
nine	O
of	O
14	O
GM	O
-	O
CSF	O
and	O
seven	O
of	O
11	O
IL	O
-	O
3	O
cases	O
.	O

3H	O
-	O
Cytosine	O
arabinoside	O
incorporation	O
into	O
the	O
DNA	O
was	O
enhanced	O
1	O
.	O
33	O
-	O
to	O
18	O
.	O
3	O
-	O
fold	O
over	O
respective	O
controls	O
in	O
14	O
of	O
17	O
patients	O
.	O

While	O
in	O
control	O
specimens	O
are	O
ara	O
-	O
C	O
dose	O
-	O
dependent	O
increase	O
in	O
3H	O
-	O
ara	O
-	O
C	O
uptake	O
was	O
accompanied	O
by	O
a	O
corresponding	O
rise	O
in	O
intracellular	O
ara	O
-	O
C	O
-	O
5	O
'	O
triphosphate	O
(	O
ara	O
-	O
CTP	O
)	O
levels	O
,	O
ara	O
-	O
CTP	O
concentrations	O
were	O
not	O
increased	O
after	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
exposure	O
,	O
resulting	O
in	O
a	O
higher	O
ara	O
-	O
C	O
to	O
ara	O
-	O
CTP	O
ratio	O
over	O
controls	O
.	O

This	O
finding	O
may	O
be	O
explained	O
by	O
a	O
stimulatory	O
effect	O
of	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
3	O
on	O
ara	O
-	O
C	O
phosphorylating	O
enzymes	O
and	O
a	O
more	O
rapid	O
incorporation	O
of	O
ara	O
-	O
CTP	O
into	O
the	O
DNA	O
of	O
leukemic	O
blasts	O
.	O

These	O
effects	O
translated	O
into	O
a	O
2	O
.	O
2	O
-	O
to	O
229	O
.	O
0	O
-	O
fold	O
increase	O
in	O
the	O
cytotoxic	O
activity	O
of	O
ara	O
-	O
C	O
against	O
clonogenic	O
leukemic	O
cells	O
after	O
GM	O
-	O
CSF	O
or	O
IL	O
-	O
3	O
pretreatment	O
.	O

Hence	O
,	O
GM	O
-	O
CSF	O
and	O
IL	O
-	O
3	O
enhance	O
the	O
intracellular	O
metabolism	O
of	O
ara	O
-	O
C	O
and	O
its	O
incorporation	O
into	O
the	O
DNA	O
of	O
leukemic	O
cells	O
leading	O
to	O
a	O
higher	O
antileukemic	O
activity	O
of	O
ara	O
-	O
C	O
on	O
clonogenic	O
leukemic	O
cells	O
(	O
CFU	O
-	O
L	O
)	O
.	O

Oxidation	O
in	O
rheumatoid	O
arthritis	O
.	O

Oxygen	O
metabolism	O
has	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
rheumatoid	O
arthritis	O
.	O

Reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
produced	O
in	O
the	O
course	O
of	O
cellular	O
oxidative	O
phosphorylation	O
,	O
and	O
by	O
activated	O
phagocytic	O
cells	O
during	O
oxidative	O
bursts	O
,	O
exceed	O
the	O
physiological	O
buffering	O
capacity	O
and	O
result	O
in	O
oxidative	O
stress	O
.	O

The	O
excessive	O
production	O
of	O
ROS	O
can	O
damage	O
protein	O
,	O
lipids	O
,	O
nucleic	O
acids	O
,	O
and	O
matrix	O
components	O
.	O

They	O
also	O
serve	O
as	O
important	O
intracellular	O
signaling	O
molecules	O
that	O
amplify	O
the	O
synovial	O
inflammatory	O
-	O
proliferative	O
response	O
.	O

Repetitive	O
cycles	O
of	O
hypoxia	O
and	O
reoxygenation	O
associated	O
with	O
changes	O
in	O
synovial	O
perfusion	O
are	O
postulated	O
to	O
activate	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
and	O
nuclear	O
factor	O
-	O
kappaB	O
,	O
two	O
key	O
transcription	O
factors	O
that	O
are	O
regulated	O
by	O
changes	O
in	O
cellular	O
oxygenation	O
and	O
cytokine	O
stimulation	O
,	O
and	O
that	O
in	O
turn	O
orchestrate	O
the	O
expression	O
of	O
a	O
spectrum	O
of	O
genes	O
critical	O
to	O
the	O
persistence	O
of	O
synovitis	O
.	O

An	O
understanding	O
of	O
the	O
complex	O
interactions	O
involved	O
in	O
these	O
pathways	O
might	O
allow	O
the	O
development	O
of	O
novel	O
therapeutic	O
strategies	O
for	O
rheumatoid	O
arthritis	O
.	O

Human	O
cytomegalovirus	O
5	O
-	O
kilobase	O
immediate	O
-	O
early	O
RNA	O
is	O
a	O
stable	O
intron	O
.	O

Immediate	O
-	O
early	O
viral	O
gene	O
products	O
of	O
human	O
cytomegalovirus	O
(	O
HCMV	O
)	O
are	O
derived	O
from	O
several	O
genomic	O
loci	O
and	O
largely	O
serve	O
to	O
establish	O
a	O
cellular	O
environment	O
conducive	O
to	O
viral	O
replication	O
.	O

We	O
have	O
further	O
examined	O
an	O
unusual	O
immediate	O
-	O
early	O
transcript	O
known	O
as	O
the	O
5	O
-	O
kb	O
RNA	O
,	O
concluding	O
that	O
it	O
is	O
a	O
stable	O
intron	O
encoded	O
by	O
HCMV	O
.	O

The	O
5	O
-	O
kb	O
RNA	O
is	O
highly	O
AT	O
rich	O
in	O
sequence	O
and	O
lacks	O
open	O
reading	O
frames	O
likely	O
to	O
be	O
translated	O
into	O
protein	O
.	O

We	O
confirmed	O
the	O
absence	O
of	O
polyadenylation	O
of	O
the	O
transcript	O
and	O
showed	O
that	O
it	O
is	O
primarily	O
nuclear	O
localized	O
during	O
viral	O
infection	O
.	O

We	O
mapped	O
the	O
5	O
'	O
end	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
to	O
a	O
consensus	O
splice	O
donor	O
site	O
and	O
localized	O
the	O
3	O
'	O
end	O
in	O
the	O
vicinity	O
of	O
a	O
splice	O
acceptor	O
site	O
.	O

In	O
transfection	O
studies	O
,	O
we	O
showed	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
can	O
be	O
spliced	O
from	O
a	O
heterologous	O
primary	O
transcript	O
.	O

Using	O
bacterial	O
artificial	O
chromosome	O
technology	O
,	O
we	O
constructed	O
a	O
viral	O
recombinant	O
containing	O
a	O
mutation	O
in	O
the	O
5	O
'	O
splice	O
donor	O
site	O
that	O
defines	O
the	O
5	O
'	O
end	O
of	O
the	O
RNA	O
and	O
found	O
that	O
this	O
mutation	O
eliminates	O
expression	O
of	O
the	O
5	O
-	O
kb	O
RNA	O
during	O
viral	O
infection	O
.	O

This	O
mutant	O
grows	O
in	O
human	O
fibroblasts	O
without	O
complementation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
support	O
the	O
conclusion	O
that	O
the	O
5	O
-	O
kb	O
RNA	O
is	O
a	O
stable	O
intron	O
expressed	O
by	O
HCMV	O
.	O

Silencing	O
of	O
monocarboxylate	O
transporters	O
via	O
small	O
interfering	O
ribonucleic	O
acid	O
inhibits	O
glycolysis	O
and	O
induces	O
cell	O
death	O
in	O
malignant	O
glioma	O
:	O
an	O
in	O
vitro	O
study	O
.	O

OBJECTIVE	O
:	O
Dependence	O
on	O
glycolysis	O
is	O
a	O
hallmark	O
of	O
malignant	O
tumors	O
.	O

As	O
a	O
consequence	O
,	O
these	O
tumors	O
generate	O
more	O
lactate	O
,	O
which	O
is	O
effluxed	O
from	O
cells	O
by	O
monocarboxylate	O
transporters	O
(	O
MCTs	O
)	O
.	O

We	O
hypothesized	O
that	O
1	O
)	O
MCT	O
expression	O
in	O
malignant	O
tumors	O
may	O
differ	O
from	O
normal	O
tissue	O
in	O
quantity	O
,	O
isoform	O
,	O
or	O
both	O
;	O
and	O
2	O
)	O
silencing	O
MCT	O
expression	O
would	O
induce	O
intracellular	O
acidification	O
,	O
resulting	O
in	O
decreased	O
proliferation	O
and	O
/	O
or	O
increased	O
cell	O
death	O
.	O

METHODS	O
:	O
We	O
quantified	O
expression	O
of	O
MCT	O
isoforms	O
in	O
human	O
glioblastoma	O
multiforme	O
and	O
glioma	O
-	O
derived	O
cells	O
lines	O
by	O
Western	O
blot	O
analysis	O
.	O

MCTs	O
that	O
were	O
abundant	O
or	O
specific	O
to	O
glioma	O
then	O
were	O
targeted	O
in	O
the	O
model	O
U	B
-	I
87	I
MG	O
glioma	O
cell	O
line	O
via	O
small	O
interfering	O
ribonucleic	O
acid	O
-	O
mediated	O
gene	O
silencing	O
and	O
tested	O
for	O
inhibition	O
of	O
lactate	O
efflux	O
,	O
intracellular	O
pH	O
changes	O
,	O
reduced	O
proliferation	O
,	O
and	O
/	O
or	O
induction	O
of	O
cell	O
death	O
.	O

RESULTS	O
:	O
MCT	O
1	O
and	O
2	O
were	O
the	O
primary	O
isoforms	O
expressed	O
in	O
human	O
glioblastoma	O
multiforme	O
and	O
glioma	O
-	O
derived	O
cell	O
lines	O
.	O

In	O
contrast	O
,	O
MCT	O
3	O
was	O
the	O
predominantly	O
expressed	O
isoform	O
in	O
normal	O
brain	O
.	O

Small	O
interfering	O
ribonucleic	O
acid	O
specific	O
for	O
MCT	O
1	O
and	O
2	O
reduced	O
expression	O
of	O
these	O
isoforms	O
in	O
U	B
-	I
87	I
MG	I
cells	O
to	O
barely	O
detectable	O
levels	O
and	O
reduced	O
lactate	O
efflux	O
by	O
30	O
%	O
individually	O
and	O
85	O
%	O
in	O
combination	O
,	O
with	O
a	O
concomitant	O
decrease	O
of	O
intracellular	O
pH	O
by	O
0	O
.	O
6	O
units	O
(	O
a	O
fourfold	O
increase	O
in	O
intracellular	O
H	O
(	O
+	O
)	O
)	O
.	O

Prolonged	O
silencing	O
of	O
both	O
MCTs	O
reduced	O
viability	O
by	O
75	O
%	O
individually	O
and	O
92	O
%	O
in	O
combination	O
,	O
as	O
measured	O
by	O
both	O
phenotypic	O
and	O
flow	O
cytometric	O
analyses	O
.	O

CONCLUSION	O
:	O
MCT	O
targeting	O
significantly	O
reduced	O
the	O
viability	O
of	O
U	B
-	I
87	I
MG	I
cells	O
mediated	O
by	O
both	O
apoptosis	O
and	O
necrosis	O
.	O

This	O
indicates	O
that	O
the	O
strategy	O
may	O
be	O
a	O
useful	O
therapeutic	O
avenue	O
for	O
treatment	O
of	O
patients	O
with	O
malignant	O
glioma	O
.	O

Hypoxia	O
-	O
responsive	O
element	O
-	O
mediated	O
soluble	O
Tie2	O
vector	O
exhibits	O
an	O
anti	O
-	O
angiogenic	O
activity	O
in	O
vitro	O
under	O
hypoxic	O
condition	O
.	O

Hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
is	O
one	O
of	O
the	O
key	O
mammalian	O
transcription	O
factors	O
and	O
shows	O
increased	O
levels	O
in	O
both	O
protein	O
stability	O
and	O
intrinsic	O
transcriptional	O
activity	O
during	O
low	O
oxygen	O
tension	O
.	O

Hypoxia	O
-	O
activated	O
functional	O
HIF	O
-	O
1	O
protein	O
binds	O
to	O
hypoxia	O
-	O
responsive	O
elements	O
(	O
HRE	O
)	O
in	O
the	O
enhancers	O
of	O
several	O
genes	O
including	O
VEGF	O
,	O
the	O
major	O
player	O
in	O
angiogenesis	O
,	O
and	O
initiates	O
their	O
mRNA	O
expression	O
.	O

The	O
molecular	O
mechanisms	O
regulating	O
the	O
gene	O
expression	O
under	O
hypoxic	O
conditions	O
could	O
increase	O
the	O
therapeutic	O
window	O
of	O
tumor	O
-	O
specific	O
delivery	O
systems	O
.	O

In	O
this	O
study	O
,	O
to	O
examine	O
hypoxia	O
-	O
specific	O
production	O
of	O
anti	O
-	O
angiogenic	O
therapeutic	O
gene	O
,	O
we	O
constructed	O
5	O
copies	O
of	O
HRE	O
(	O
5xHRE	O
)	O
of	O
human	O
VEGF	O
linked	O
to	O
soluble	O
Tie2	O
(	O
sTie2	O
)	O
driven	O
by	O
minimal	O
SV40	O
promoter	O
(	O
5xHRE	O
/	O
SV40	O
/	O
sTie2	O
)	O
.	O

Our	O
data	O
showed	O
that	O
under	O
hypoxia	O
the	O
secreted	O
sTie2	O
selectively	O
inhibited	O
tube	O
formation	O
and	O
migration	O
capacities	O
of	O
endothelial	O
cells	O
in	O
vitro	O
.	O

Hence	O
,	O
we	O
propose	O
that	O
the	O
vector	O
system	O
,	O
5xHRE	O
/	O
SV40	O
/	O
sTie2	O
,	O
might	O
be	O
a	O
useful	O
tool	O
for	O
down	O
-	O
regulating	O
tumor	O
angiogenesis	O
under	O
hypoxic	O
condition	O
.	O

Glucocorticoid	O
receptor	O
-	O
induced	O
MAPK	O
phosphatase	O
-	O
1	O
(	O
MPK	O
-	O
1	O
)	O
expression	O
inhibits	O
paclitaxel	O
-	O
associated	O
MAPK	O
activation	O
and	O
contributes	O
to	O
breast	O
cancer	O
cell	O
survival	O
.	O

Glucocorticoid	O
receptor	O
(	O
GR	O
)	O
activation	O
has	O
recently	O
been	O
shown	O
to	O
inhibit	O
apoptosis	O
in	O
breast	O
epithelial	O
cells	O
.	O

We	O
have	O
previously	O
described	O
a	O
group	O
of	O
genes	O
that	O
is	O
rapidly	O
up	O
-	O
regulated	O
in	O
these	O
cells	O
following	O
dexamethasone	O
(	O
Dex	O
)	O
treatment	O
.	O

In	O
an	O
effort	O
to	O
dissect	O
the	O
mechanisms	O
of	O
GR	O
-	O
mediated	O
breast	O
epithelial	O
cell	O
survival	O
,	O
we	O
now	O
examine	O
the	O
molecular	O
events	O
downstream	O
of	O
GR	O
activation	O
.	O

Here	O
we	O
show	O
that	O
GR	O
activation	O
leads	O
to	O
both	O
the	O
rapid	O
induction	O
of	O
MAPK	O
phosphatase	O
-	O
1	O
(	O
MKP	O
-	O
1	O
)	O
mRNA	O
and	O
its	O
sustained	O
expression	O
.	O

Induction	O
of	O
the	O
MKP	O
-	O
1	O
protein	O
in	O
the	O
MCF10A	B
-	O
Myc	O
and	O
MDA	B
-	I
MB	I
-	I
231	I
breast	O
epithelial	O
cell	O
lines	O
was	O
also	O
seen	O
.	O

Paclitaxel	O
treatment	O
resulted	O
in	O
MAPK	O
activation	O
and	O
apoptosis	O
of	O
MDA	B
-	I
MB	I
-	I
231	I
breast	O
cancer	O
cells	O
,	O
and	O
both	O
processes	O
were	O
inhibited	O
by	O
Dex	O
pretreatment	O
.	O

Furthermore	O
,	O
induction	O
of	O
MKP	O
-	O
1	O
correlated	O
with	O
the	O
inhibition	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
activity	O
,	O
whereas	O
p38	O
activity	O
was	O
minimally	O
affected	O
.	O

Blocking	O
Dex	O
-	O
induced	O
MKP	O
-	O
1	O
induction	O
using	O
small	O
interfering	O
RNA	O
increased	O
ERK1	O
/	O
2	O
and	O
JNK	O
phosphorylation	O
and	O
decreased	O
cell	O
survival	O
.	O

ERK1	O
/	O
2	O
and	O
JNK	O
inactivation	O
was	O
associated	O
with	O
Ets	O
-	O
like	O
transcription	O
factor	O
-	O
1	O
(	O
ELK	O
-	O
1	O
)	O
dephosphorylation	O
.	O

To	O
explore	O
the	O
gene	O
expression	O
changes	O
that	O
occur	O
downstream	O
of	O
ELK	O
-	O
1	O
dephosphorylation	O
,	O
we	O
used	O
a	O
combination	O
of	O
temporal	O
gene	O
expression	O
data	O
and	O
promoter	O
element	O
analyses	O
.	O

This	O
approach	O
revealed	O
a	O
previously	O
unrecognized	O
transcriptional	O
target	O
of	O
ELK	O
-	O
1	O
,	O
the	O
human	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
.	O

We	O
verified	O
the	O
predicted	O
ELK	O
-	O
1	O
-	O
-	O
>	O
tPA	O
transcriptional	O
regulatory	O
relationship	O
using	O
a	O
luciferase	O
reporter	O
assay	O
.	O

We	O
conclude	O
that	O
GR	O
-	O
mediated	O
MAPK	O
inactivation	O
contributes	O
to	O
cell	O
survival	O
and	O
that	O
the	O
potential	O
transcriptional	O
targets	O
of	O
this	O
inhibition	O
can	O
be	O
identified	O
from	O
large	O
scale	O
gene	O
array	O
analysis	O
.	O

Proteome	O
analysis	O
of	O
NIH3T3	B
cells	O
transformed	O
by	O
activated	O
Galpha12	O
:	O
regulation	O
of	O
leukemia	O
-	O
associated	O
protein	O
SET	O
.	O

Galpha	O
(	O
12	O
)	O
,	O
the	O
alpha	O
-	O
subunit	O
of	O
the	O
G12	O
family	O
of	O
heterotrimeric	O
G	O
proteins	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
neoplastic	O
transformation	O
.	O

GTPase	O
-	O
deficient	O
,	O
constitutively	O
activated	O
mutant	O
of	O
Galpha	O
(	O
12	O
)	O
(	O
Galpha	O
(	O
12	O
)	O
Q229L	O
or	O
Galpha	O
(	O
12	O
)	O
QL	O
)	O
has	O
been	O
previously	O
shown	O
to	O
induce	O
oncogenic	O
transformation	O
of	O
NIH3T3	B
cells	O
promoting	O
serum	O
-	O
and	O
anchorage	O
-	O
independent	O
growth	O
.	O

Reduced	O
growth	O
-	O
factor	O
dependent	O
,	O
autonomous	O
cell	O
growth	O
forms	O
a	O
critical	O
defining	O
point	O
at	O
which	O
a	O
normal	O
cell	O
turns	O
into	O
an	O
oncogenic	O
one	O
.	O

To	O
identify	O
the	O
underlying	O
mechanism	O
involved	O
in	O
such	O
growth	O
-	O
factor	O
/	O
serum	O
independent	O
growth	O
of	O
Galpha	O
(	O
12	O
)	O
QL	O
-	O
transformed	O
NIH3T3	B
,	O
we	O
carried	O
out	O
a	O
two	O
-	O
dimensional	O
differential	O
proteome	O
analysis	O
of	O
Galpha	O
(	O
12	O
)	O
QL	O
-	O
transformed	O
NIH3T3	B
cells	O
and	O
cells	O
expressing	O
vector	O
control	O
.	O

This	O
analysis	O
revealed	O
a	O
total	O
of	O
22	O
protein	O
-	O
spots	O
whose	O
expression	O
was	O
altered	O
by	O
more	O
than	O
3	O
-	O
folds	O
.	O

Two	O
of	O
these	O
spots	O
were	O
identified	O
by	O
MALDI	O
-	O
MS	O
analysis	O
as	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
and	O
myeloid	O
-	O
leukemia	O
-	O
associated	O
SET	O
protein	O
.	O

The	O
increased	O
expressions	O
of	O
these	O
proteins	O
in	O
Galpha	O
(	O
12	O
)	O
QL	O
cells	O
were	O
validated	O
by	O
immunoblot	O
analysis	O
.	O

Furthermore	O
,	O
transient	O
transfection	O
studies	O
with	O
NIH3T3	B
cells	O
indicated	O
that	O
the	O
expression	O
of	O
activated	O
Galpha	O
(	O
12	O
)	O
readily	O
increased	O
the	O
expression	O
of	O
SET	O
protein	O
by	O
24	O
h	O
.	O

As	O
SET	O
has	O
been	O
previously	O
reported	O
to	O
be	O
an	O
inhibitor	O
of	O
phosphatase	O
PP2A	O
,	O
the	O
nuclear	O
phosphatase	O
activity	O
was	O
monitored	O
in	O
cells	O
expressing	O
activated	O
Galpha	O
(	O
12	O
)	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
nuclear	O
phosphatase	O
activity	O
is	O
inhibited	O
by	O
greater	O
than	O
50	O
%	O
in	O
Galpha	O
(	O
12	O
)	O
QL	O
cells	O
compared	O
to	O
vector	O
control	O
cells	O
.	O

Thus	O
,	O
our	O
results	O
from	O
differential	O
proteome	O
analysis	O
presented	O
here	O
report	O
for	O
the	O
first	O
time	O
a	O
role	O
for	O
SET	O
in	O
Galpha	O
(	O
12	O
)	O
-	O
mediated	O
signaling	O
pathways	O
and	O
a	O
role	O
for	O
Galpha	O
(	O
12	O
)	O
in	O
the	O
regulation	O
of	O
the	O
leukemia	O
-	O
associated	O
SET	O
-	O
protein	O
expression	O
.	O

TBX21	O
:	O
a	O
functional	O
variant	O
predicts	O
improvement	O
in	O
asthma	O
with	O
the	O
use	O
of	O
inhaled	O
corticosteroids	O
.	O

TBX21	O
encodes	O
for	O
the	O
transcription	O
factor	O
T	O
-	O
bet	O
(	O
T	O
-	O
box	O
expressed	O
in	O
T	O
cells	O
)	O
,	O
which	O
influences	O
naive	O
T	O
lymphocyte	O
development	O
and	O
has	O
been	O
implicated	O
in	O
asthma	O
pathogenesis	O
.	O

Specifically	O
,	O
the	O
T	O
-	O
bet	O
knockout	O
mouse	O
spontaneously	O
develops	O
airway	O
hyperresponsiveness	O
and	O
other	O
changes	O
consistent	O
with	O
asthma	O
.	O

Because	O
airway	O
responsiveness	O
is	O
moderated	O
by	O
the	O
use	O
of	O
inhaled	O
corticosteroids	O
in	O
asthma	O
,	O
it	O
is	O
conceivable	O
that	O
genetic	O
variation	O
in	O
TBX21	O
may	O
alter	O
asthma	O
phenotypes	O
in	O
a	O
treatment	O
-	O
specific	O
fashion	O
.	O

Here	O
we	O
demonstrate	O
that	O
the	O
nonsynonymous	O
variation	O
in	O
TBX21	O
coding	O
for	O
replacement	O
of	O
histidine	O
33	O
with	O
glutamine	O
is	O
associated	O
with	O
significant	O
improvement	O
in	O
the	O
PC	O
(	O
20	O
)	O
(	O
a	O
measure	O
of	O
airway	O
responsiveness	O
)	O
of	O
asthmatic	O
children	O
in	O
a	O
large	O
clinical	O
trial	O
spanning	O
4	O
years	O
.	O

We	O
note	O
that	O
this	O
increase	O
occurs	O
only	O
in	O
the	O
children	O
randomized	O
to	O
inhaled	O
corticosteroids	O
and	O
that	O
it	O
dramatically	O
enhances	O
the	O
overall	O
improvement	O
in	O
PC	O
(	O
20	O
)	O
associated	O
with	O
inhaled	O
corticosteroid	O
usage	O
.	O

The	O
average	O
PC	O
(	O
20	O
)	O
at	O
trial	O
end	O
for	O
subjects	O
on	O
inhaled	O
corticosteroids	O
possessing	O
a	O
variant	O
allele	O
was	O
in	O
the	O
normal	O
range	O
for	O
nonasthmatics	O
.	O

In	O
cellular	O
models	O
,	O
we	O
show	O
that	O
the	O
TBX21	O
variant	O
increases	O
T	O
helper	O
1	O
and	O
decreases	O
T	O
helper	O
2	O
cytokine	O
expression	O
comparably	O
with	O
wild	O
type	O
.	O

TBX21	O
may	O
thus	O
be	O
an	O
important	O
determinant	O
pharmacogenetic	O
response	O
to	O
the	O
therapy	O
of	O
asthma	O
with	O
inhaled	O
corticosteroids	O
.	O

Matrix	O
metalloproteinase	O
/	O
tissue	O
inhibitors	O
of	O
matrix	O
metalloproteinase	O
phenotype	O
identifies	O
poor	O
prognosis	O
colorectal	O
cancers	O
.	O

PURPOSE	O
:	O
The	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
are	O
a	O
family	O
of	O
proteolytic	O
enzymes	O
involved	O
in	O
tumor	O
invasion	O
;	O
several	O
individual	O
members	O
of	O
which	O
have	O
been	O
implicated	O
in	O
tumor	O
prognosis	O
.	O

These	O
enzymes	O
and	O
their	O
physiologic	O
inhibitors	O
,	O
the	O
tissue	O
inhibitors	O
of	O
matrix	O
metalloproteinases	O
(	O
TIMPs	O
)	O
,	O
act	O
in	O
a	O
coordinated	O
manner	O
to	O
form	O
an	O
integrated	O
system	O
.	O

Therefore	O
,	O
to	O
understand	O
their	O
role	O
in	O
tumor	O
invasion	O
,	O
it	O
is	O
necessary	O
to	O
evaluate	O
them	O
collectively	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
In	O
this	O
study	O
all	O
of	O
the	O
major	O
members	O
of	O
the	O
matrix	O
metalloproteinase	O
(	O
MMP	O
-	O
1	O
,	O
MMP	O
-	O
2	O
,	O
MMP	O
-	O
3	O
,	O
MMP	O
-	O
7	O
,	O
MMP	O
-	O
9	O
,	O
MMP	O
-	O
13	O
,	O
MT1	O
-	O
MMP	O
and	O
MT2	O
-	O
MMP	O
)	O
/	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
(	O
TIMP	O
-	O
1	O
,	O
TIMP	O
-	O
2	O
,	O
and	O
TIMP	O
-	O
3	O
)	O
system	O
have	O
been	O
investigated	O
by	O
immunohistochemistry	O
in	O
a	O
series	O
(	O
n	O
=	O
90	O
)	O
of	O
stage	O
III	O
(	O
Dukes	O
'	O
C	O
)	O
colorectal	O
cancers	O
.	O

An	O
immunohistochemical	O
score	O
based	O
on	O
the	O
intensity	O
of	O
immunoreactivity	O
and	O
proportion	O
of	O
immunoreactive	O
cells	O
was	O
established	O
for	O
each	O
MMP	O
and	O
TIMP	O
.	O

RESULTS	O
:	O
The	O
MMP	O
/	O
TIMP	O
profile	O
defined	O
by	O
hierarchical	O
cluster	O
analysis	O
of	O
the	O
immunohistochemical	O
score	O
identifies	O
a	O
distinct	O
group	O
of	O
colorectal	O
cancers	O
with	O
poor	O
prognosis	O
(	O
log	O
-	O
rank	O
test	O
,	O
12	O
.	O
22	O
,	O
P	O
=	O
0	O
.	O
0005	O
)	O
.	O

The	O
median	O
survival	O
time	O
of	O
patients	O
in	O
this	O
survival	O
group	O
was	O
18	O
months	O
compared	O
with	O
a	O
median	O
survival	O
of	O
49	O
months	O
in	O
the	O
""""	O
good	O
""""	O
survival	O
group	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
this	O
profile	O
was	O
independently	O
the	O
most	O
significant	O
prognostic	O
factor	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
has	O
identified	O
that	O
the	O
MMP	O
/	O
TIMP	O
profile	O
is	O
an	O
independent	O
indicator	O
of	O
poor	O
prognosis	O
in	O
colorectal	O
cancer	O
.	O

2	O
-	O
methoxyestradiol	O
inhibits	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
,	O
tumor	O
growth	O
,	O
and	O
angiogenesis	O
and	O
augments	O
paclitaxel	O
efficacy	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

PURPOSE	O
:	O
Head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
have	O
been	O
reported	O
to	O
overexpress	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1alpha	O
,	O
a	O
transcription	O
factor	O
that	O
promotes	O
expression	O
of	O
angiogenesis	O
factors	O
and	O
resistance	O
to	O
programmed	O
and	O
therapy	O
-	O
induced	O
cell	O
death	O
.	O

2	O
-	O
Methoxyestradiol	O
(	O
2ME2	O
)	O
is	O
a	O
natural	O
compound	O
with	O
HIF	O
-	O
1alpha	O
inhibitory	O
activity	O
that	O
is	O
currently	O
being	O
evaluated	O
in	O
phase	O
1	O
and	O
2	O
clinical	O
trials	O
for	O
advanced	O
solid	O
tumors	O
and	O
multiple	O
myeloma	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
evaluate	O
the	O
effects	O
of	O
2ME2	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
2ME2	O
alone	O
and	O
in	O
combination	O
with	O
paclitaxel	O
,	O
an	O
active	O
agent	O
in	O
recurrent	O
or	O
advanced	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

RESULTS	O
:	O
2ME2	O
exhibited	O
antiproliferative	O
and	O
cytotoxic	O
effects	O
in	O
a	O
panel	O
of	O
five	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
cell	O
lines	O
in	O
the	O
0	O
.	O
5	O
to	O
10	O
micromol	O
/	O
L	O
range	O
,	O
including	O
induction	O
of	O
G2	O
-	O
M	O
blockade	O
,	O
caspase	O
-	O
3	O
/	O
7	O
activation	O
,	O
and	O
apoptosis	O
at	O
48	O
hours	O
.	O

2ME2	O
resulted	O
in	O
decreased	O
nuclear	O
HIF	O
-	O
1alpha	O
-	O
binding	O
activity	O
and	O
affected	O
the	O
expression	O
of	O
downstream	O
genes	O
,	O
such	O
as	O
bid	O
,	O
a	O
proapoptotic	O
bcl	O
-	O
2	O
family	O
member	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
a	O
proangiogenic	O
cytokine	O
.	O

The	O
up	O
-	O
regulation	O
of	O
Bid	O
(	O
57	O
.	O
5	O
%	O
at	O
12	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
and	O
inhibition	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
secretion	O
(	O
57	O
.	O
7	O
%	O
at	O
24	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
015	O
;	O
and	O
50	O
.	O
3	O
%	O
at	O
48	O
hours	O
,	O
P	O
less	O
than	O
0	O
.	O
0006	O
)	O
could	O
be	O
partially	O
attributed	O
to	O
the	O
effects	O
on	O
HIF	O
-	O
1alpha	O
,	O
because	O
HIF	O
-	O
1alpha	O
small	O
interfering	O
RNAs	O
produced	O
similar	O
effects	O
.	O

Finally	O
,	O
in	O
vivo	O
,	O
in	O
a	O
xenograft	O
model	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
using	O
UM	B
-	I
SCC	I
-	I
11A	I
cells	O
,	O
2ME2	O
exhibited	O
antitumor	O
and	O
antiangiogenic	O
activity	O
,	O
as	O
measured	O
by	O
CD31	O
immunostaining	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
provide	O
support	O
for	O
the	O
use	O
of	O
2ME2	O
in	O
combination	O
with	O
paclitaxel	O
for	O
the	O
treatment	O
of	O
recurrent	O
or	O
advanced	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
.	O

HIF	O
-	O
2alpha	O
expression	O
in	O
human	O
fetal	O
paraganglia	O
and	O
neuroblastoma	O
:	O
relation	O
to	O
sympathetic	O
differentiation	O
,	O
glucose	O
deficiency	O
,	O
and	O
hypoxia	O
.	O

Solid	O
tumors	O
are	O
frequently	O
necrotic	O
and	O
hypoxic	O
due	O
to	O
poor	O
vascularization	O
.	O

Tumor	O
cells	O
adapt	O
to	O
hypoxia	O
by	O
modulating	O
their	O
phenotype	O
.	O

Key	O
players	O
in	O
this	O
process	O
are	O
the	O
hypoxia	O
-	O
inducible	O
factors	O
(	O
HIF	O
-	O
1alpha	O
to	O
3alpha	O
)	O
.	O

HIFs	O
are	O
also	O
expressed	O
during	O
normal	O
development	O
;	O
for	O
example	O
,	O
HIF	O
-	O
2alpha	O
is	O
specifically	O
expressed	O
and	O
appears	O
to	O
be	O
involved	O
in	O
the	O
development	O
of	O
the	O
murine	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
HIF	O
-	O
2alpha	O
protein	O
is	O
selectively	O
present	O
in	O
human	O
fetal	O
week	O
8	O
.	O
5	O
SNS	O
paraganglia	O
.	O

Neuroblastoma	O
is	O
derived	O
from	O
SNS	O
precursors	O
.	O

In	O
a	O
subset	O
of	O
neuroblastomas	O
,	O
a	O
spontaneous	O
neuronal	O
to	O
neuroendocrine	O
differentiation	O
occurs	O
in	O
areas	O
adjacent	O
to	O
necrotic	O
zones	O
.	O

As	O
HIF	O
-	O
2alpha	O
activity	O
has	O
been	O
associated	O
not	O
only	O
with	O
hypoxic	O
but	O
also	O
with	O
hypoglycemic	O
conditions	O
,	O
we	O
have	O
investigated	O
putative	O
effects	O
of	O
hypoxia	O
,	O
glucose	O
depletion	O
,	O
and	O
HIF	O
-	O
2alpha	O
on	O
the	O
neuroblastoma	O
phenotype	O
.	O

HIF	O
-	O
2alpha	O
was	O
detected	O
in	O
hypoxic	O
and	O
in	O
well	O
-	O
oxygenized	O
neuroblastoma	O
cells	O
and	O
tissue	O
,	O
presumably	O
reflecting	O
their	O
embryonic	O
features	O
.	O

With	O
regard	O
to	O
differentiation	O
,	O
hypoxic	O
cells	O
lost	O
their	O
neuronal	O
/	O
neuroendocrine	O
features	O
and	O
gained	O
marker	O
gene	O
expression	O
associated	O
with	O
an	O
immature	O
,	O
neural	O
crest	O
-	O
like	O
phenotype	O
.	O

Low	O
glucose	O
potentiated	O
the	O
effect	O
of	O
hypoxia	O
.	O

These	O
findings	O
suggest	O
that	O
poorly	O
vascularized	O
neuroblastomas	O
become	O
immature	O
and	O
maintain	O
a	O
more	O
aggressive	O
phenotype	O
,	O
which	O
possibly	O
could	O
involve	O
a	O
sustained	O
stabilization	O
and	O
activation	O
of	O
HIF	O
-	O
2alpha	O
.	O

Reduced	O
prognostic	O
power	O
of	O
ventricular	O
late	O
potentials	O
in	O
post	O
-	O
infarction	O
patients	O
of	O
the	O
reperfusion	O
era	O
.	O

AIMS	O
:	O

To	O
test	O
the	O
prognostic	O
value	O
of	O
ventricular	O
late	O
potentials	O
(	O
LPs	O
)	O
in	O
a	O
large	O
cohort	O
of	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

1800	O
consecutive	O
survivors	O
of	O
acute	O
myocardial	O
infarction	O
in	O
sinus	O
rhythm	O
and	O
under	O
76	O
years	O
of	O
age	O
were	O
enrolled	O
.	O

Many	O
(	O
99	O
%	O
)	O
of	O
the	O
patients	O
received	O
reperfusion	O
/	O
revascularization	O
therapy	O
(	O
91	O
%	O
percutaneous	O
coronary	O
intervention	O
)	O
and	O
up	O
-	O
to	O
-	O
date	O
pharmacological	O
treatment	O
(	O
99	O
%	O
aspirin	O
,	O
93	O
%	O
beta	O
-	O
blockers	O
,	O
90	O
%	O
ACE	O
-	O
inhibitors	O
,	O
and	O
85	O
%	O
statins	O
)	O
.	O

LPs	O
were	O
calculated	O
in	O
968	O
patients	O
and	O
found	O
to	O
be	O
present	O
in	O
90	O
(	O
9	O
.	O
3	O
%	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
composite	O
of	O
cardiac	O
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O

The	O
secondary	O
endpoint	O
was	O
the	O
composite	O
of	O
sudden	O
cardiac	O
death	O
and	O
serious	O
arrhythmic	O
events	O
.	O

During	O
follow	O
-	O
up	O
(	O
median	O
34	O
months	O
)	O
,	O
26	O
patients	O
reached	O
the	O
primary	O
endpoint	O
.	O

The	O
presence	O
of	O
LPs	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
primary	O
endpoint	O
in	O
univariable	O
or	O
multivariable	O
analysis	O
.	O

In	O
contrast	O
,	O
low	O
(	O
<	O
or	O
=	O
30	O
%	O
)	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
hazard	O
ratio	O
9	O
.	O
6	O
,	O
95	O
%	O
confidence	O
interval	O
4	O
.	O
1	O
-	O
22	O
.	O
4	O
)	O
,	O
heart	O
rate	O
turbulence	O
category	O
2	O
(	O
7	O
.	O
5	O
,	O
2	O
.	O
4	O
-	O
23	O
.	O
9	O
)	O
and	O
category	O
1	O
(	O
5	O
.	O
3	O
,	O
1	O
.	O
9	O
-	O
14	O
.	O
9	O
)	O
were	O
significant	O
predictors	O
in	O
both	O
univariable	O
and	O
multivariable	O
analysis	O
.	O

CONCLUSION	O
:	O

Ventricular	O
LPs	O
are	O
of	O
limited	O
use	O
for	O
risk	O
stratification	O
in	O
unselected	O
post	O
-	O
infarction	O
patients	O
in	O
the	O
modern	O
reperfusion	O
era	O
.	O

Expression	O
and	O
purification	O
of	O
the	O
catalytic	O
domain	O
of	O
human	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
for	O
inhibitor	O
screening	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
an	O
endothelial	O
cell	O
-	O
specific	O
mitogen	O
,	O
can	O
act	O
in	O
tumor	O
-	O
induced	O
angiogenesis	O
by	O
binding	O
to	O
specific	O
receptors	O
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
.	O

One	O
such	O
receptor	O
,	O
VEGFR	O
-	O
2	O
/	O
KDR	O
,	O
plays	O
a	O
key	O
role	O
in	O
VEGF	O
-	O
induced	O
angiogenesis	O
.	O

Here	O
,	O
we	O
expressed	O
the	O
catalytic	O
domain	O
of	O
VEGFR	O
-	O
2	O
as	O
a	O
soluble	O
active	O
kinase	O
using	O
Bac	O
-	O
to	O
-	O
Bac	O
expression	O
system	O
,	O
and	O
investigated	O
correlations	O
between	O
VEGFR	O
-	O
2	O
activity	O
and	O
enzyme	O
concentration	O
,	O
ATP	O
concentration	O
,	O
substrate	O
concentration	O
and	O
divalent	O
cation	O
type	O
.	O

We	O
used	O
these	O
data	O
to	O
establish	O
a	O
convenient	O
,	O
effective	O
and	O
non	O
-	O
radioactive	O
ELISA	O
screening	O
technique	O
for	O
the	O
identification	O
and	O
evaluation	O
of	O
potential	O
inhibitors	O
for	O
VEGFR	O
-	O
2	O
kinase	O
.	O

We	O
screened	O
200	O
RTK	O
target	O
-	O
based	O
compounds	O
and	O
identified	O
one	O
(	O
TKI	O
-	O
31	O
)	O
that	O
potently	O
inhibited	O
VEGFR	O
-	O
2	O
kinase	O
activity	O
(	O
IC50	O
=	O
0	O
.	O
596	O
microM	O
)	O
.	O

Treatment	O
of	O
NIH3T3	B
/	O
KDR	O
cells	O
with	O
TKI	O
-	O
31	O
blocked	O
VEGF	O
-	O
induced	O
phosphorylation	O
of	O
KDR	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
TKI	O
-	O
31	O
dose	O
-	O
dependently	O
suppressed	O
HUVEC	O
tube	O
formation	O
.	O

Thus	O
,	O
we	O
herein	O
report	O
a	O
novel	O
,	O
efficient	O
method	O
for	O
identifying	O
VEGFR	O
-	O
2	O
kinase	O
inhibitors	O
and	O
introduce	O
one	O
,	O
TKI	O
-	O
31	O
,	O
that	O
may	O
prove	O
to	O
be	O
a	O
useful	O
new	O
angiogenesis	O
inhibitor	O
.	O

An	O
evaluation	O
of	O
low	O
molecular	O
weight	O
heparin	O
and	O
hyperbaric	O
oxygen	O
treatment	O
in	O
the	O
prevention	O
of	O
intra	O
-	O
abdominal	O
adhesions	O
and	O
wound	O
healing	O
.	O

BACKGROUND	O
:	O
Abdominal	O
surgery	O
can	O
lead	O
to	O
intra	O
-	O
abdominal	O
adhesions	O
with	O
significant	O
morbidity	O
and	O
mortality	O
.	O

To	O
prevent	O
adhesions	O
,	O
an	O
experimental	O
study	O
was	O
planned	O
to	O
designate	O
the	O
effects	O
of	O
low	O
molecular	O
weight	O
(	O
LMW	O
)	O
heparins	O
and	O
hyperbaric	O
oxygen	O
(	O
HBO	O
)	O
therapy	O
both	O
on	O
the	O
formation	O
of	O
adhesions	O
and	O
wound	O
healing	O
.	O

METHODS	O
:	O
Thirty	O
-	O
eight	O
Wistar	O
albino	O
rats	O
underwent	O
laparotomy	O
to	O
cause	O
intra	O
-	O
abdominal	O
adhesions	O
by	O
mechanical	O
abrasion	O
of	O
the	O
cecum	O
and	O
ethanol	O
application	O
.	O

The	O
rats	O
were	O
divided	O
into	O
4	O
groups	O
.	O

In	O
the	O
control	O
group	O
(	O
group	O
1	O
)	O
no	O
further	O
management	O
was	O
undertaken	O
.	O

Group	O
2	O
was	O
treated	O
by	O
Enoxaparine	O
Na	O
,	O
group	O
3	O
received	O
HBO	O
therapy	O
,	O
and	O
group	O
4	O
was	O
given	O
both	O
enoxaparine	O
Na	O
and	O
HBO	O
treatment	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
statistically	O
significant	O
difference	O
between	O
the	O
control	O
and	O
enoxaparine	O
Na	O
groups	O
regarding	O
adhesions	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
between	O
groups	O
1	O
and	O
4	O
and	O
between	O
groups	O
1	O
and	O
3	O
regarding	O
the	O
hydroxyproline	O
content	O
of	O
the	O
abdominal	O
wounds	O
.	O

In	O
the	O
pathologic	O
analysis	O
of	O
the	O
abdominal	O
wounds	O
,	O
there	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
any	O
of	O
the	O
groups	O
,	O
including	O
the	O
control	O
group	O
,	O
regarding	O
inflammation	O
.	O

Statistically	O
significant	O
differences	O
were	O
observed	O
regarding	O
angiogenesis	O
between	O
the	O
control	O
group	O
and	O
groups	O
3	O
and	O
4	O
.	O

There	O
was	O
also	O
a	O
statistically	O
significant	O
difference	O
regarding	O
fibrosis	O
between	O
groups	O
1	O
and	O
4	O
.	O

CONCLUSIONS	O
:	O
Enoxaparine	O
Na	O
decreased	O
intra	O
-	O
abdominal	O
adhesions	O
,	O
and	O
HBO	O
therapy	O
had	O
no	O
beneficial	O
effect	O
on	O
adhesions	O
.	O

Enoxaparine	O
Na	O
had	O
no	O
harmful	O
effects	O
on	O
wound	O
healing	O
,	O
and	O
HBO	O
therapy	O
increased	O
the	O
process	O
of	O
wound	O
healing	O
.	O

Novel	O
biological	O
agents	O
for	O
the	O
treatment	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
.	O

Hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
is	O
an	O
inevitable	O
evolution	O
of	O
prostate	O
carcinogenesis	O
,	O
through	O
which	O
the	O
normal	O
dependence	O
on	O
hormones	O
for	O
growth	O
and	O
survival	O
is	O
bypassed	O
.	O

Although	O
advances	O
in	O
terms	O
of	O
symptoms	O
palliation	O
and	O
quality	O
of	O
life	O
improvement	O
have	O
been	O
addressed	O
with	O
current	O
treatment	O
options	O
,	O
innovative	O
approaches	O
are	O
needed	O
to	O
improve	O
survival	O
rates	O
.	O

A	O
thorough	O
understanding	O
of	O
HRPC	O
-	O
associated	O
molecular	O
pathways	O
and	O
mechanisms	O
of	O
resistance	O
are	O
a	O
prerequisite	O
for	O
novel	O
potential	O
therapeutic	O
interventions	O
.	O

Preclinical	O
and	O
early	O
clinical	O
studies	O
are	O
ongoing	O
to	O
evaluate	O
new	O
therapies	O
that	O
target	O
specific	O
molecular	O
entities	O
.	O

Agents	O
under	O
development	O
include	O
growth	O
factor	O
receptor	O
inhibitors	O
,	O
small	O
molecules	O
targeting	O
signal	O
transduction	O
pathways	O
,	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
regulators	O
,	O
angiogenesis	O
and	O
metastasis	O
inhibitors	O
,	O
differentiation	O
agents	O
,	O
telomerase	O
inactivators	O
,	O
and	O
epigenetic	O
therapeutics	O
.	O

Incorporation	O
of	O
these	O
agents	O
into	O
existing	O
treatment	O
regimens	O
will	O
guide	O
us	O
in	O
the	O
development	O
of	O
a	O
multidisciplinary	O
treatment	O
strategy	O
of	O
HRPC	O
.	O

This	O
article	O
critically	O
reviews	O
published	O
data	O
on	O
new	O
biological	O
agents	O
that	O
are	O
being	O
tested	O
in	O
HRPC	O
clinical	O
trials	O
,	O
highlights	O
ongoing	O
research	O
and	O
considers	O
the	O
future	O
perspectives	O
of	O
this	O
new	O
class	O
of	O
agents	O
.	O

Role	O
of	O
thrombogenic	O
factors	O
in	O
the	O
development	O
of	O
atherosclerosis	O
.	O

Hemostatic	O
factors	O
play	O
a	O
crucial	O
role	O
in	O
generating	O
thrombotic	O
plugs	O
at	O
sites	O
of	O
vascular	O
damage	O
(	O
atherothrombosis	O
)	O
.	O

However	O
,	O
whether	O
hemostatic	O
factors	O
contribute	O
directly	O
or	O
indirectly	O
to	O
the	O
pathogenesis	O
of	O
atherosclerosis	O
remains	O
uncertain	O
.	O

Autopsy	O
studies	O
have	O
revealed	O
that	O
intimal	O
thickening	O
represents	O
the	O
first	O
stage	O
of	O
atherosclerosis	O
and	O
that	O
lipid	O
-	O
rich	O
plaque	O
arises	O
from	O
such	O
lesions	O
.	O

Several	O
factors	O
contribute	O
to	O
the	O
start	O
of	O
intimal	O
thickening	O
.	O

Platelets	O
release	O
several	O
growth	O
factors	O
and	O
bioactive	O
agents	O
that	O
play	O
a	O
central	O
role	O
in	O
development	O
of	O
not	O
only	O
thrombus	O
but	O
also	O
of	O
intimal	O
thickening	O
.	O

We	O
have	O
been	O
investigating	O
which	O
coagulation	O
factors	O
simultaneously	O
,	O
or	O
subsequently	O
with	O
platelet	O
aggregation	O
,	O
participate	O
in	O
thrombus	O
formation	O
.	O

Tissue	O
factor	O
(	O
TF	O
)	O
is	O
an	O
essential	O
initiator	O
of	O
blood	O
coagulation	O
that	O
is	O
expressed	O
in	O
various	O
stages	O
of	O
atherosclerotic	O
lesions	O
in	O
humans	O
and	O
other	O
animals	O
.	O

Factors	O
including	O
thrombin	O
and	O
fibrin	O
,	O
which	O
are	O
downstream	O
of	O
the	O
coagulation	O
cascade	O
activated	O
by	O
TF	O
,	O
also	O
contribute	O
to	O
atherosclerosis	O
.	O

TF	O
is	O
involved	O
in	O
cell	O
migration	O
,	O
embryogenesis	O
and	O
angiogenesis	O
.	O

Thus	O
TF	O
,	O
in	O
addition	O
to	O
factors	O
downstream	O
of	O
the	O
coagulation	O
cascade	O
and	O
the	O
protease	O
-	O
activated	O
receptor	O
2	O
activation	O
system	O
,	O
would	O
be	O
a	O
multifactorial	O
regulator	O
of	O
atherogenesis	O
.	O

Investigating	O
the	O
causes	O
of	O
low	O
birth	O
weight	O
in	O
contrasting	O
ovine	O
paradigms	O
.	O

Intrauterine	O
growth	O
restriction	O
(	O
IUGR	O
)	O
still	O
accounts	O
for	O
a	O
large	O
incidence	O
of	O
infant	O
mortality	O
and	O
morbidity	O
worldwide	O
.	O

Many	O
of	O
the	O
circulatory	O
and	O
transport	O
properties	O
of	O
the	O
sheep	O
placenta	O
are	O
similar	O
to	O
those	O
of	O
the	O
human	O
placenta	O
and	O
as	O
such	O
,	O
the	O
pregnant	O
sheep	O
offers	O
an	O
excellent	O
model	O
in	O
which	O
to	O
study	O
the	O
development	O
of	O
IUGR	O
.	O

Two	O
natural	O
models	O
of	O
ovine	O
IUGR	O
are	O
those	O
of	O
hyperthermic	O
exposure	O
during	O
pregnancy	O
,	O
and	O
adolescent	O
overfeeding	O
,	O
also	O
during	O
pregnancy	O
.	O

Both	O
models	O
yield	O
significantly	O
reduced	O
placental	O
weights	O
and	O
an	O
asymmetrically	O
growth	O
-	O
restricted	O
fetus	O
,	O
and	O
display	O
altered	O
maternal	O
hormone	O
concentrations	O
,	O
indicative	O
of	O
an	O
impaired	O
trophoblast	O
capacity	O
.	O

Additionally	O
,	O
impaired	O
placental	O
angiogenesis	O
and	O
uteroplacental	O
blood	O
flow	O
appears	O
to	O
be	O
an	O
early	O
defect	O
in	O
both	O
the	O
hyperthermic	O
and	O
adolescent	O
paradigms	O
.	O

The	O
effects	O
of	O
these	O
alterations	O
in	O
placental	O
functional	O
development	O
appear	O
to	O
be	O
irreversible	O
.	O

IUGR	O
fetuses	O
are	O
both	O
hypoxic	O
and	O
hypoglycaemic	O
,	O
and	O
have	O
reduced	O
insulin	O
and	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
,	O
and	O
elevated	O
concentrations	O
of	O
lactate	O
.	O

However	O
,	O
fetal	O
utilization	O
of	O
oxygen	O
and	O
glucose	O
,	O
on	O
a	O
weight	O
basis	O
,	O
remain	O
constant	O
compared	O
with	O
control	O
pregnancies	O
.	O

Maintained	O
utilization	O
of	O
these	O
substrates	O
,	O
in	O
a	O
substrate	O
-	O
deficient	O
environment	O
,	O
suggests	O
increased	O
sensitivities	O
to	O
metabolic	O
signals	O
,	O
which	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
metabolic	O
diseases	O
in	O
later	O
adult	O
life	O
.	O

Angiogenin	O
is	O
up	O
-	O
regulated	O
in	O
the	O
nucleus	O
and	O
cytoplasm	O
in	O
human	O
primary	O
breast	O
carcinoma	O
and	O
is	O
associated	O
with	O
markers	O
of	O
hypoxia	O
but	O
not	O
survival	O
.	O

Angiogenin	O
,	O
a	O
14	O
.	O
2	O
kD	O
polypeptide	O
that	O
was	O
originally	O
noted	O
for	O
its	O
angiogenic	O
activity	O
,	O
is	O
now	O
increasingly	O
recognized	O
to	O
have	O
a	O
multiplicity	O
of	O
biological	O
roles	O
in	O
both	O
physiological	O
and	O
pathological	O
conditions	O
.	O

In	O
breast	O
cancer	O
,	O
there	O
are	O
conflicting	O
studies	O
questioning	O
the	O
role	O
of	O
angiogenin	O
.	O

Here	O
,	O
the	O
pattern	O
of	O
expression	O
of	O
angiogenin	O
during	O
the	O
transition	O
from	O
normal	O
breast	O
tissue	O
to	O
ductal	O
carcinoma	O
in	O
situ	O
and	O
invasive	O
carcinoma	O
is	O
reported	O
together	O
with	O
the	O
correlates	O
between	O
the	O
level	O
of	O
angiogenin	O
in	O
239	O
invasive	O
carcinomas	O
and	O
standard	O
clinicopathological	O
parameters	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
(	O
HIF	O
)	O
-	O
1	O
alpha	O
and	O
the	O
HIF	O
-	O
1	O
alpha	O
target	O
gene	O
DEC	O
-	O
1	O
.	O

This	O
study	O
shows	O
that	O
angiogenin	O
expression	O
is	O
up	O
-	O
regulated	O
in	O
the	O
cytoplasmic	O
and	O
nuclear	O
compartments	O
in	O
in	O
situ	O
carcinoma	O
and	O
invasive	O
carcinoma	O
compared	O
with	O
normal	O
breast	O
tissue	O
and	O
that	O
angiogenin	O
expression	O
in	O
invasive	O
carcinomas	O
is	O
significantly	O
positively	O
associated	O
with	O
high	O
tumour	O
grade	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
positive	O
oestrogen	O
receptor	O
(	O
ER	O
)	O
status	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
HIF	O
-	O
1	O
alpha	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
DEC	O
1	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
with	O
patient	O
age	O
(	O
p	O
=	O
0	O
.	O
8	O
)	O
,	O
tumour	O
size	O
(	O
p	O
=	O
0	O
.	O
25	O
)	O
,	O
lymph	O
node	O
status	O
(	O
p	O
=	O
0	O
.	O
69	O
)	O
,	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
p	O
=	O
0	O
.	O
56	O
)	O
or	O
microvessel	O
density	O
(	O
p	O
=	O
0	O
.	O
32	O
)	O
.	O

No	O
difference	O
in	O
relapse	O
-	O
free	O
(	O
p	O
=	O
0	O
.	O
26	O
)	O
or	O
overall	O
(	O
p	O
=	O
0	O
.	O
63	O
)	O
survival	O
was	O
observed	O
in	O
patients	O
stratified	O
by	O
angiogenin	O
expression	O
.	O

This	O
study	O
suggests	O
that	O
angiogenin	O
may	O
be	O
important	O
in	O
breast	O
cancer	O
progression	O
and	O
that	O
,	O
through	O
its	O
relationship	O
with	O
ER	O
,	O
it	O
may	O
be	O
a	O
target	O
for	O
tamoxifen	O
.	O

Hereditary	O
paraganglioma	O
/	O
pheochromocytoma	O
and	O
inherited	O
succinate	O
dehydrogenase	O
deficiency	O
.	O

Mitochondrial	O
complex	O
II	O
,	O
or	O
succinate	O
dehydrogenase	O
,	O
is	O
a	O
key	O
enzymatic	O
complex	O
involved	O
in	O
both	O
the	O
tricarboxylic	O
acid	O
(	O
TCA	O
)	O
cycle	O
and	O
oxidative	O
phosphorylation	O
as	O
part	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
.	O

Germline	O
succinate	O
dehydrogenase	O
subunit	O
A	O
(	O
SDHA	O
)	O
mutations	O
have	O
been	O
reported	O
in	O
a	O
few	O
patients	O
with	O
a	O
classical	O
mitochondrial	O
neurodegenerative	O
disease	O
.	O

Mutations	O
in	O
the	O
genes	O
encoding	O
the	O
three	O
other	O
succinate	O
dehydrogenase	O
subunits	O
(	O
SDHB	O
,	O
SDHC	O
and	O
SDHD	O
)	O
have	O
been	O
identified	O
in	O
patients	O
affected	O
by	O
familial	O
or	O
'	O
apparently	O
sporadic	O
'	O
paraganglioma	O
and	O
/	O
or	O
pheochromocytoma	O
,	O
an	O
autosomal	O
inherited	O
cancer	O
-	O
susceptibility	O
syndrome	O
.	O

These	O
discoveries	O
have	O
dramatically	O
changed	O
the	O
work	O
-	O
up	O
and	O
genetic	O
counseling	O
of	O
patients	O
and	O
families	O
with	O
paragangliomas	O
and	O
/	O
or	O
pheochromocytomas	O
.	O

The	O
subsequent	O
identification	O
of	O
germline	O
mutations	O
in	O
the	O
gene	O
encoding	O
fumarase	O
-	O
-	O
another	O
TCA	O
cycle	O
enzyme	O
-	O
-	O
in	O
a	O
new	O
hereditary	O
form	O
of	O
susceptibility	O
to	O
renal	O
,	O
uterine	O
and	O
cutaneous	O
tumors	O
has	O
highlighted	O
the	O
potential	O
role	O
of	O
the	O
TCA	O
cycle	O
and	O
,	O
more	O
generally	O
,	O
of	O
the	O
mitochondria	O
in	O
cancer	O
.	O

[	O
Uncommon	O
etiology	O
of	O
gastrointestinal	O
bleeding	O
:	O
duodenal	O
metastases	O
from	O
renal	O
cell	O
carcinoma	O
]	O
.	O

Because	O
of	O
its	O
unpredictable	O
behavior	O
,	O
renal	O
cell	O
carcinoma	O
is	O
one	O
of	O
the	O
most	O
controversial	O
neoplasms	O
.	O

On	O
the	O
one	O
hand	O
,	O
patients	O
frequently	O
show	O
metastases	O
at	O
diagnosis	O
because	O
of	O
its	O
slight	O
manifestations	O
,	O
while	O
on	O
the	O
other	O
,	O
the	O
neoplasm	O
can	O
remain	O
stable	O
after	O
nephrectomy	O
and	O
can	O
then	O
metastasize	O
many	O
years	O
later	O
.	O

When	O
this	O
happens	O
,	O
the	O
metastases	O
usually	O
involve	O
more	O
than	O
2	O
organs	O
.	O

The	O
most	O
frequent	O
sites	O
of	O
metastases	O
are	O
the	O
lung	O
and	O
lymph	O
nodes	O
,	O
followed	O
by	O
the	O
bones	O
and	O
liver	O
,	O
while	O
duodenal	O
involvement	O
is	O
rare	O
.	O

Indeed	O
,	O
intestinal	O
metastases	O
are	O
found	O
in	O
only	O
2	O
%	O
of	O
autopsies	O
and	O
of	O
these	O
,	O
renal	O
cell	O
carcinoma	O
metastases	O
account	O
for	O
7	O
.	O
1	O
%	O
.	O

We	O
present	O
a	O
case	O
of	O
a	O
solitary	O
late	O
recurrence	O
presenting	O
as	O
upper	O
gastrointestinal	O
bleeding	O
19	O
years	O
after	O
nephrectomy	O
for	O
clear	O
cell	O
renal	O
carcinoma	O
.	O

Mouse	O
p10	O
,	O
an	O
alternative	O
spliced	O
form	O
of	O
p15INK4b	O
,	O
inhibits	O
cell	O
cycle	O
progression	O
and	O
malignant	O
transformation	O
.	O

The	O
INK4	O
family	O
of	O
proteins	O
negatively	O
regulates	O
cell	O
cycle	O
progression	O
at	O
the	O
G	O
(	O
1	O
)	O
-	O
S	O
transition	O
by	O
inhibiting	O
cyclin	O
-	O
dependent	O
kinases	O
.	O

Two	O
of	O
these	O
cell	O
cycle	O
inhibitors	O
,	O
p16	O
(	O
INK4A	O
)	O
and	O
p15	O
(	O
INK4B	O
)	O
,	O
have	O
tumor	O
suppressor	O
activities	O
and	O
are	O
inactivated	O
in	O
human	O
cancer	O
.	O

Interestingly	O
,	O
both	O
INK4	O
genes	O
express	O
alternative	O
splicing	O
variants	O
.	O

In	O
addition	O
to	O
p16	O
(	O
INK4A	O
)	O
,	O
the	O
INK4A	O
locus	O
encodes	O
a	O
splice	O
variant	O
,	O
termed	O
p12	O
-	O
-	O
specifically	O
expressed	O
in	O
human	O
pancreas	O
-	O
-	O
and	O
ARF	O
,	O
a	O
protein	O
encoded	O
by	O
an	O
alternative	O
reading	O
frame	O
that	O
acts	O
as	O
a	O
tumor	O
suppressor	O
through	O
the	O
p53	O
pathway	O
.	O

Similarly	O
,	O
the	O
human	O
INK4B	O
locus	O
encodes	O
the	O
p15	O
(	O
INK4B	O
)	O
tumor	O
suppressor	O
and	O
one	O
alternatively	O
spliced	O
form	O
,	O
termed	O
as	O
p10	O
.	O

We	O
show	O
here	O
that	O
p10	O
,	O
which	O
arises	O
from	O
the	O
use	O
of	O
an	O
alternative	O
splice	O
donor	O
site	O
within	O
intron	O
1	O
,	O
is	O
conserved	O
in	O
the	O
mouse	O
genome	O
and	O
is	O
widely	O
expressed	O
in	O
mouse	O
tissues	O
.	O

Similarly	O
to	O
mouse	O
p15	O
(	O
INK4B	O
)	O
,	O
p10	O
expression	O
is	O
also	O
induced	O
by	O
oncogenic	O
insults	O
and	O
transforming	O
growth	O
factor	O
-	O
beta	O
treatment	O
and	O
acts	O
as	O
a	O
cell	O
cycle	O
inhibitor	O
.	O

Importantly	O
,	O
we	O
show	O
that	O
mouse	O
p10	O
is	O
able	O
to	O
induce	O
cell	O
cycle	O
arrest	O
in	O
a	O
p53	O
-	O
dependent	O
manner	O
.	O

We	O
also	O
show	O
that	O
mouse	O
p10	O
is	O
able	O
to	O
inhibit	O
foci	O
formation	O
and	O
anchorage	O
-	O
independent	O
growth	O
in	O
wild	O
-	O
type	O
mouse	O
embryonic	O
fibroblasts	O
,	O
and	O
that	O
these	O
antitransforming	O
properties	O
of	O
mouse	O
p10	O
are	O
also	O
p53	O
-	O
dependent	O
.	O

These	O
results	O
indicate	O
that	O
the	O
INK4B	O
locus	O
,	O
similarly	O
to	O
INK4A	O
-	O
ARF	O
,	O
harbors	O
two	O
different	O
splicing	O
variants	O
that	O
can	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
both	O
the	O
p53	O
and	O
retinoblastoma	O
pathways	O
,	O
the	O
two	O
major	O
molecular	O
pathways	O
in	O
tumor	O
suppression	O
.	O

p53	O
mutation	O
heterogeneity	O
in	O
cancer	O
.	O

The	O
p53	O
gene	O
is	O
inactivated	O
in	O
about	O
50	O
%	O
of	O
human	O
cancers	O
and	O
the	O
p53	O
protein	O
is	O
an	O
essential	O
component	O
of	O
the	O
cell	O
response	O
induced	O
by	O
genotoxic	O
stresses	O
such	O
as	O
those	O
generated	O
by	O
radiotherapy	O
or	O
chemotherapy	O
.	O

It	O
is	O
therefore	O
highly	O
likely	O
that	O
these	O
alterations	O
are	O
an	O
important	O
component	O
in	O
tumor	O
resistance	O
to	O
therapy	O
.	O

The	O
particular	O
characteristics	O
of	O
these	O
alterations	O
,	O
80	O
%	O
of	O
which	O
are	O
missense	O
mutations	O
leading	O
to	O
functionally	O
heterogeneous	O
proteins	O
,	O
make	O
p53	O
a	O
unique	O
gene	O
in	O
the	O
class	O
of	O
tumor	O
suppressor	O
genes	O
.	O

A	O
considerable	O
number	O
of	O
mutant	O
p53	O
proteins	O
probably	O
have	O
an	O
oncogenic	O
activity	O
per	O
se	O
and	O
therefore	O
actively	O
participate	O
in	O
cell	O
transformation	O
.	O

The	O
fact	O
that	O
the	O
apoptotic	O
and	O
antiproliferative	O
functions	O
of	O
p53	O
can	O
be	O
dissociated	O
in	O
certain	O
mutants	O
also	O
suggests	O
another	O
level	O
of	O
complexity	O
in	O
the	O
relationships	O
between	O
p53	O
inactivation	O
and	O
neoplasia	O
.	O

Rofecoxib	O
as	O
adjunctive	O
therapy	O
for	O
haemophilic	O
arthropathy	O
.	O

Joint	O
haemorrhage	O
and	O
subsequent	O
haemophilic	O
arthropathy	O
are	O
significant	O
complications	O
in	O
haemophilia	O
.	O

The	O
pathophysiology	O
involves	O
inflammation	O
and	O
angiogenesis	O
.	O

Cyclooxygenase	O
-	O
2	O
(	O
COX	O
-	O
2	O
)	O
inhibitors	O
are	O
anti	O
-	O
inflammatory	O
agents	O
,	O
which	O
have	O
potent	O
anti	O
-	O
inflammatory	O
,	O
anti	O
-	O
angiogenic	O
and	O
analgesic	O
properties	O
yet	O
do	O
not	O
affect	O
platelet	O
function	O
in	O
the	O
manner	O
of	O
traditional	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

These	O
properties	O
make	O
such	O
agents	O
potentially	O
useful	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
.	O

There	O
is	O
only	O
one	O
prior	O
report	O
describing	O
rofecoxib	O
treatment	O
in	O
a	O
single	O
haemophilia	O
patient	O
.	O

Our	O
objectives	O
were	O
to	O
determine	O
the	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	O
in	O
treating	O
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joints	O
and	O
pain	O
.	O

We	O
conducted	O
a	O
retrospective	O
medical	O
record	O
review	O
of	O
patients	O
treated	O
with	O
rofecoxib	O
for	O
acute	O
haemarthrosis	O
,	O
chronic	O
synovitis	O
,	O
target	O
joint	O
or	O
pain	O
.	O

The	O
safety	O
and	O
efficacy	O
of	O
rofecoxib	O
treatment	O
were	O
determined	O
based	O
on	O
subjective	O
patient	O
reports	O
and	O
physical	O
examinations	O
during	O
follow	O
-	O
up	O
clinic	O
visits	O
.	O

A	O
total	O
of	O
28	O
patients	O
between	O
3	O
and	O
37	O
years	O
of	O
age	O
were	O
treated	O
for	O
a	O
total	O
of	O
42	O
courses	O
of	O
rofecoxib	O
treatment	O
.	O

All	O
courses	O
were	O
evaluated	O
for	O
safety	O
and	O
31	O
for	O
efficacy	O
.	O

Rofecoxib	O
was	O
used	O
for	O
eight	O
acute	O
haemarthrosis	O
,	O
four	O
target	O
joints	O
,	O
seven	O
cases	O
of	O
synovitis	O
and	O
12	O
episodes	O
of	O
pain	O
.	O

Efficacy	O
was	O
demonstrated	O
particularly	O
for	O
chronic	O
synovitis	O
and	O
pain	O
and	O
no	O
serious	O
adverse	O
events	O
occurred	O
.	O

This	O
is	O
the	O
largest	O
study	O
to	O
date	O
evaluating	O
COX	O
-	O
2	O
inhibitors	O
as	O
adjunctive	O
therapy	O
in	O
haemophilia	O
and	O
suggests	O
that	O
these	O
agents	O
may	O
be	O
an	O
important	O
adjunctive	O
therapy	O
in	O
the	O
management	O
of	O
haemophilia	O
.	O

Sox9	O
neural	O
crest	O
determinant	O
gene	O
controls	O
patterning	O
and	O
closure	O
of	O
the	O
posterior	O
frontal	O
cranial	O
suture	O
.	O

Cranial	O
suture	O
development	O
involves	O
a	O
complex	O
interaction	O
of	O
genes	O
and	O
tissues	O
derived	O
from	O
neural	O
crest	O
cells	O
(	O
NCC	O
)	O
and	O
paraxial	O
mesoderm	O
.	O

In	O
mice	O
,	O
the	O
posterior	O
frontal	O
(	O
PF	O
)	O
suture	O
closes	O
during	O
the	O
first	O
month	O
of	O
life	O
while	O
other	O
sutures	O
remain	O
patent	O
throughout	O
the	O
life	O
of	O
the	O
animal	O
.	O

Given	O
the	O
unique	O
NCC	O
origin	O
of	O
PF	O
suture	O
complex	O
(	O
analogous	O
to	O
metopic	O
suture	O
in	O
humans	O
)	O
,	O
we	O
performed	O
quantitative	O
real	O
-	O
time	O
PCR	O
and	O
immunohistochemistry	O
to	O
study	O
the	O
expression	O
pattern	O
of	O
the	O
NCC	O
determinant	O
gene	O
Sox9	O
and	O
select	O
markers	O
of	O
extracellular	O
matrix	O
.	O

Our	O
results	O
indicated	O
a	O
unique	O
up	O
-	O
regulated	O
expression	O
of	O
Sox9	O
,	O
a	O
regulator	O
of	O
chondrogenesis	O
,	O
during	O
initiation	O
of	O
PF	O
suture	O
closure	O
,	O
along	O
with	O
the	O
expression	O
of	O
specific	O
cartilage	O
markers	O
(	O
Type	O
II	O
Collagen	O
and	O
Type	O
X	O
Collagen	O
)	O
,	O
as	O
well	O
as	O
cartilage	O
tissue	O
formation	O
in	O
the	O
PF	O
suture	O
.	O

This	O
process	O
was	O
followed	O
by	O
expression	O
of	O
bone	O
markers	O
(	O
Type	O
I	O
Collagen	O
and	O
Osteocalcin	O
)	O
,	O
suggesting	O
endochondral	O
ossification	O
.	O

Moreover	O
,	O
we	O
studied	O
the	O
effect	O
of	O
haploinsufficiency	O
of	O
the	O
NCC	O
determinant	O
gene	O
Sox9	O
in	O
the	O
NCC	O
derived	O
PF	O
suture	O
complex	O
.	O

A	O
decrease	O
in	O
dosage	O
of	O
Sox9	O
by	O
haploinsufficiency	O
in	O
NCC	O
-	O
derived	O
tissues	O
resulted	O
in	O
delayed	O
PF	O
suture	O
closure	O
.	O

These	O
results	O
demonstrate	O
a	O
unique	O
development	O
of	O
the	O
PF	O
suture	O
complex	O
and	O
the	O
role	O
of	O
Sox9	O
as	O
an	O
important	O
contributor	O
to	O
timely	O
and	O
proper	O
closure	O
of	O
the	O
PF	O
suture	O
through	O
endochondral	O
ossification	O
.	O

Bcl	O
-	O
2	O
decreases	O
cell	O
proliferation	O
and	O
promotes	O
accumulation	O
of	O
cells	O
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
in	O
human	O
ovarian	O
carcinoma	O
cells	O
.	O

OBJECTIVES	O
:	O

The	O
Bcl	O
-	O
2	O
protein	O
is	O
an	O
important	O
regulator	O
of	O
the	O
apoptotic	O
cascade	O
and	O
promotes	O
cell	O
survival	O
.	O

Bcl	O
-	O
2	O
can	O
also	O
delay	O
entry	O
into	O
the	O
cell	O
cycle	O
from	O
quiescence	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
two	O
isogenic	O
human	O
ovarian	O
carcinoma	O
cell	O
lines	O
,	O
which	O
expressed	O
differential	O
levels	O
of	O
Bcl	O
-	O
2	O
proteins	O
,	O
to	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
may	O
regulate	O
the	O
growth	O
rates	O
of	O
adenocarcinoma	O
cells	O
.	O

METHODS	O
:	O

The	O
growth	O
rates	O
of	O
two	O
isogenic	O
ovarian	O
cancer	O
cell	O
lines	O
were	O
determined	O
by	O
XTT	O
assays	O
and	O
flow	O
cytometry	O
combined	O
with	O
PI	O
staining	O
.	O

Bcl	O
-	O
2	O
-	O
overexpressing	O
SKOV3	B
cells	O
were	O
modified	O
to	O
express	O
a	O
doxycycline	O
-	O
inducible	O
anti	O
-	O
Bcl	O
-	O
2	O
single	O
-	O
chain	O
antibody	O
and	O
the	O
effects	O
of	O
Bcl	O
-	O
2	O
protein	O
inhibition	O
on	O
cell	O
proliferation	O
and	O
apoptosis	O
were	O
assessed	O
.	O

RESULTS	O
:	O

We	O
demonstrate	O
that	O
Bcl	O
-	O
2	O
promotes	O
the	O
accumulation	O
of	O
proliferating	O
carcinoma	O
cells	O
in	O
S	O
phase	O
.	O

The	O
Bcl	O
-	O
2	O
-	O
overexpressing	O
SKOV3	B
cell	O
line	O
proliferates	O
markedly	O
faster	O
and	O
shows	O
delayed	O
progression	O
to	O
G2	O
M	O
phase	O
compared	O
to	O
its	O
low	O
Bcl	O
-	O
2	O
-	O
expressing	O
counterpart	O
SKOV3	B
.	I
ip1	I
cell	O
line	O
.	O

Single	O
-	O
chain	O
antibody	O
-	O
mediated	O
inhibition	O
of	O
Bcl	O
-	O
2	O
in	O
SKOV3	B
cells	O
was	O
associated	O
with	O
increased	O
growth	O
rates	O
and	O
more	O
rapid	O
cell	O
cycle	O
progression	O
.	O

Treatment	O
with	O
cisplatin	O
resulted	O
in	O
more	O
cells	O
accumulating	O
in	O
S	O
phase	O
in	O
Bcl	O
-	O
2	O
-	O
overexpressing	O
SKOV3	B
cells	O
,	O
while	O
the	O
inhibition	O
of	O
Bcl	O
-	O
2	O
abolished	O
delayed	O
entry	O
into	O
G2	O
M	O
phase	O
without	O
affecting	O
cisplatin	O
-	O
induced	O
apoptosis	O
.	O

CONCLUSIONS	O
:	O

Our	O
results	O
suggest	O
that	O
,	O
in	O
ovarian	O
cancer	O
cells	O
,	O
Bcl	O
-	O
2	O
delays	O
cell	O
cycle	O
progression	O
by	O
promoting	O
accumulation	O
of	O
cells	O
in	O
S	O
phase	O
without	O
affecting	O
the	O
rate	O
of	O
apoptosis	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
its	O
known	O
role	O
at	O
the	O
G0	O
/	O
G1	O
checkpoint	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Bcl	O
-	O
2	O
also	O
regulates	O
the	O
S	O
phase	O
.	O

Treatment	O
of	O
transplanted	O
CT26	B
tumour	O
with	O
dendritic	O
cell	O
vaccine	O
in	O
combination	O
with	O
blockade	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
and	O
CTLA	O
-	O
4	O
.	O

We	O
investigated	O
the	O
anti	O
CT26	B
tumour	O
effect	O
of	O
dendritic	O
cell	O
based	O
vaccination	O
with	O
the	O
MuLV	O
gp70	O
envelope	O
protein	O
-	O
derived	O
peptides	O
AH1	O
and	O
p320	O
-	O
333	O
.	O

Vaccination	O
lead	O
to	O
generation	O
of	O
AH1	O
specific	O
cytotoxic	O
lymphocytes	O
(	O
CTL	O
)	O
and	O
some	O
decrease	O
in	O
tumour	O
growth	O
of	O
simultaneously	O
inoculated	O
CT26	B
cells	O
.	O

After	O
combination	O
with	O
an	O
antibody	O
against	O
VEGF	O
receptor	O
2	O
(	O
DC101	O
)	O
,	O
a	O
significant	O
increase	O
in	O
survival	O
of	O
the	O
tumour	O
cell	O
recipients	O
was	O
observed	O
.	O

Also	O
,	O
monotherapy	O
with	O
an	O
antibody	O
against	O
CTLA	O
-	O
4	O
(	O
9H10	O
)	O
,	O
led	O
to	O
approximately	O
100	O
%	O
survival	O
of	O
tumour	O
cell	O
recipients	O
.	O

However	O
,	O
effective	O
treatment	O
of	O
mice	O
with	O
already	O
established	O
tumours	O
was	O
only	O
obtained	O
after	O
combination	O
of	O
vaccination	O
,	O
DC101	O
and	O
9H10	O
treatment	O
in	O
which	O
setting	O
80	O
%	O
of	O
the	O
mice	O
rejected	O
their	O
tumours	O
.	O

Randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
on	O
the	O
effect	O
of	O
zoledronic	O
acid	O
on	O
the	O
prevention	O
of	O
bone	O
metastases	O
in	O
patients	O
with	O
recurrent	O
solid	O
tumors	O
that	O
did	O
not	O
present	O
with	O
bone	O
metastases	O
at	O
baseline	O
.	O

OBJECTIVES	O
:	O
Bisphosphonates	O
have	O
been	O
used	O
successfully	O
in	O
the	O
treatment	O
of	O
hypercalcemia	O
and	O
to	O
reduce	O
skeletal	O
-	O
related	O
complications	O
of	O
bone	O
metastases	O
.	O

Recent	O
in	O
vitro	O
and	O
in	O
vivo	O
evidence	O
suggest	O
that	O
they	O
may	O
also	O
have	O
direct	O
antitumor	O
effects	O
via	O
induction	O
of	O
apoptosis	O
,	O
inhibition	O
of	O
the	O
invasive	O
potential	O
of	O
tumor	O
cell	O
lines	O
in	O
vitro	O
,	O
inhibition	O
of	O
angiogenesis	O
,	O
and	O
reduction	O
in	O
tumor	O
growth	O
indirectly	O
via	O
effects	O
on	O
accessory	O
cells	O
.	O

This	O
is	O
a	O
randomized	O
,	O
open	O
label	O
,	O
prospective	O
study	O
that	O
examined	O
the	O
effect	O
of	O
preventive	O
zoledronic	O
acid	O
treatment	O
on	O
the	O
development	O
of	O
bone	O
metastases	O
in	O
patients	O
with	O
recurrent	O
solid	O
tumors	O
,	O
without	O
bone	O
metastases	O
at	O
the	O
time	O
of	O
randomization	O
.	O

METHODS	O
:	O
Forty	O
patients	O
with	O
recurrent	O
or	O
metastatic	O
advanced	O
cancer	O
,	O
without	O
bone	O
metastases	O
,	O
were	O
randomized	O
into	O
the	O
trial	O
to	O
either	O
receive	O
zoledronic	O
acid	O
or	O
no	O
treatment	O
.	O

Patients	O
were	O
followed	O
up	O
until	O
bone	O
metastases	O
were	O
established	O
.	O

RESULTS	O
:	O
The	O
percentage	O
of	O
patients	O
being	O
bone	O
metastases	O
free	O
at	O
12	O
mo	O
was	O
60	O
%	O
in	O
the	O
zoledronic	O
acid	O
and	O
10	O
%	O
in	O
the	O
control	O
group	O
(	O
p	O
less	O
than	O
0	O
.	O
0005	O
)	O
,	O
while	O
the	O
percentages	O
at	O
18	O
mo	O
were	O
20	O
%	O
and	O
5	O
%	O
respectively	O
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
have	O
shown	O
that	O
bisphosphonates	O
as	O
adjuvant	O
treatment	O
might	O
be	O
useful	O
for	O
the	O
prevention	O
of	O
bone	O
metastases	O
;	O
however	O
,	O
there	O
is	O
need	O
for	O
blinded	O
randomized	O
data	O
before	O
such	O
an	O
approach	O
would	O
be	O
confirmed	O
.	O

In	O
the	O
meantime	O
preventive	O
use	O
of	O
bisphosphonates	O
in	O
patients	O
without	O
any	O
bone	O
metastases	O
should	O
not	O
be	O
used	O
outside	O
the	O
scope	O
of	O
a	O
clinical	O
trial	O
.	O

VEGF	O
-	O
targeted	O
therapy	O
:	O
therapeutic	O
potential	O
and	O
recent	O
advances	O
.	O

After	O
over	O
30	O
years	O
of	O
theorizing	O
,	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
as	O
anticancer	O
therapy	O
has	O
finally	O
moved	O
from	O
the	O
realm	O
of	O
research	O
to	O
reality	O
.	O

Normal	O
adult	O
vasculature	O
is	O
generally	O
quiescent	O
in	O
nature	O
,	O
with	O
endothelial	O
cells	O
dividing	O
approximately	O
every	O
10	O
years	O
.	O

In	O
contrast	O
,	O
the	O
growth	O
of	O
tumors	O
requires	O
constant	O
vascular	O
growth	O
and	O
remodeling	O
in	O
order	O
for	O
solid	O
tumors	O
to	O
grow	O
beyond	O
1	O
-	O
2	O
mm	O
(	O
3	O
)	O
in	O
size	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
its	O
receptors	O
are	O
key	O
regulators	O
of	O
the	O
process	O
of	O
angiogenesis	O
,	O
which	O
makes	O
them	O
attractive	O
therapeutic	O
targets	O
.	O

A	O
multitude	O
of	O
VEGF	O
-	O
targeted	O
inhibitory	O
agents	O
are	O
currently	O
being	O
investigated	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

This	O
review	O
article	O
focuses	O
on	O
recent	O
developments	O
in	O
the	O
use	O
of	O
angiogenesis	O
inhibitors	O
for	O
the	O
treatment	O
of	O
breast	O
,	O
lung	O
,	O
and	O
colorectal	O
cancers	O
.	O

Thalidomide	O
and	O
angiostatin	O
inhibit	O
tumor	O
growth	O
in	O
a	O
murine	O
xenograft	O
model	O
of	O
human	O
cervical	O
cancer	O
.	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
impact	O
of	O
thalidomide	O
and	O
angiostatin	O
on	O
tumor	O
growth	O
,	O
angiogenesis	O
,	O
and	O
apoptosis	O
in	O
a	O
xenograft	O
model	O
of	O
cervical	O
cancer	O
.	O

METHODS	O
:	O
Human	O
umbilical	O
endothelial	O
cells	O
were	O
treated	O
with	O
angiostatin	O
or	O
thalidomide	O
and	O
bFGF	O
-	O
induced	O
proliferation	O
was	O
assessed	O
with	O
the	O
MTT	O
assay	O
.	O

Human	O
cervical	O
cancer	O
cells	O
(	O
CaSki	B
and	O
SiHa	B
)	O
were	O
injected	O
into	O
the	O
flanks	O
of	O
nude	O
mice	O
.	O

After	O
tumors	O
developed	O
,	O
mice	O
were	O
treated	O
with	O
angiostatin	O
20	O
mg	O
/	O
kg	O
/	O
day	O
or	O
thalidomide	O
200	O
mg	O
/	O
kg	O
/	O
day	O
for	O
30	O
days	O
.	O

Fractional	O
tumor	O
growth	O
was	O
determined	O
and	O
immunohistochemical	O
analysis	O
of	O
tumors	O
was	O
used	O
to	O
determine	O
degree	O
of	O
angiogenesis	O
.	O

TUNEL	O
assay	O
was	O
used	O
to	O
assess	O
apoptosis	O
.	O

RESULTS	O
:	O
Angiostatin	O
inhibited	O
endothelial	O
cell	O
proliferation	O
by	O
50	O
-	O
60	O
%	O
.	O

Thalidomide	O
had	O
no	O
direct	O
effect	O
on	O
endothelial	O
cells	O
.	O

Angiostatin	O
and	O
thalidomide	O
both	O
inhibited	O
tumor	O
growth	O
by	O
about	O
55	O
%	O
.	O

We	O
found	O
no	O
additive	O
or	O
synergistic	O
effect	O
when	O
the	O
two	O
agents	O
were	O
combined	O
.	O

Both	O
agents	O
inhibited	O
angiogenesis	O
and	O
induced	O
apoptosis	O
when	O
compared	O
to	O
tumors	O
from	O
control	O
animals	O
.	O

CONCLUSIONS	O
:	O
Angiostatin	O
and	O
thalidomide	O
inhibit	O
tumor	O
growth	O
,	O
angiogenesis	O
,	O
and	O
induce	O
apoptosis	O
in	O
this	O
xenograft	O
model	O
of	O
cervical	O
cancer	O
.	O

MDM2	O
as	O
a	O
predictor	O
of	O
prostate	O
carcinoma	O
outcome	O
:	O
an	O
analysis	O
of	O
Radiation	O
Therapy	O
Oncology	O
Group	O
Protocol	O
8610	O
.	O

BACKGROUND	O
:	O
The	O
MDM2	O
oncoprotein	O
promotes	O
p53	O
degradation	O
via	O
ubiquitin	O
,	O
establishing	O
negative	O
feedback	O
control	O
of	O
p53	O
and	O
consequently	O
affecting	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
.	O

The	O
authors	O
evaluated	O
the	O
association	O
between	O
MDM2	O
expression	O
and	O
local	O
failure	O
,	O
distant	O
metastasis	O
(	O
DM	O
)	O
,	O
cause	O
-	O
specific	O
mortality	O
,	O
and	O
overall	O
mortality	O
in	O
men	O
treated	O
in	O
Radiation	O
Therapy	O
Oncology	O
Group	O
8610	O
with	O
radiotherapy	O
,	O
with	O
or	O
without	O
androgen	O
deprivation	O
.	O

METHODS	O
:	O
Of	O
the	O
456	O
eligible	O
and	O
analyzable	O
patients	O
(	O
parent	O
cohort	O
)	O
,	O
adequate	O
archival	O
diagnostic	O
tissue	O
specimens	O
from	O
108	O
patients	O
were	O
available	O
for	O
MDM2	O
analysis	O
(	O
MDM2	O
cohort	O
)	O
.	O

Cox	O
proportional	O
hazards	O
multivariate	O
analysis	O
(	O
MVA	O
)	O
was	O
used	O
to	O
determine	O
the	O
relation	O
of	O
MDM2	O
to	O
the	O
endpoints	O
.	O

MDM2	O
overexpression	O
was	O
manually	O
classified	O
as	O
>	O
5	O
%	O
nuclear	O
staining	O
.	O

An	O
image	O
analysis	O
system	O
was	O
also	O
used	O
to	O
quantify	O
the	O
proportion	O
of	O
tumor	O
nuclei	O
with	O
MDM2	O
staining	O
(	O
ACIS	O
index	O
)	O
and	O
staining	O
intensity	O
.	O

RESULTS	O
:	O
Overexpression	O
of	O
MDM2	O
by	O
manual	O
counts	O
was	O
seen	O
in	O
44	O
%	O
(	O
n	O
=	O
47	O
)	O
of	O
the	O
patients	O
.	O

In	O
the	O
manual	O
count	O
analysis	O
,	O
there	O
was	O
no	O
significant	O
relation	O
between	O
MDM2	O
overexpression	O
and	O
outcome	O
.	O

The	O
ACIS	O
index	O
,	O
using	O
a	O
cutoff	O
point	O
defined	O
by	O
the	O
median	O
value	O
,	O
<	O
or	O
=	O
3	O
%	O
versus	O
>	O
3	O
%	O
,	O
was	O
related	O
to	O
5	O
-	O
year	O
DM	O
rates	O
in	O
univariate	O
analyses	O
(	O
32	O
.	O
6	O
%	O
vs	O
.	O
45	O
.	O
8	O
%	O
;	O
P	O
=	O
0	O
.	O
057	O
)	O
and	O
MVA	O
(	O
P	O
=	O
0	O
.	O
06	O
)	O
.	O

The	O
intensity	O
of	O
MDM2	O
staining	O
was	O
not	O
significant	O
.	O

CONCLUSIONS	O
:	O
MDM2	O
expression	O
quantified	O
by	O
image	O
analysis	O
was	O
weakly	O
associated	O
with	O
DM	O
.	O

The	O
cohort	O
examined	O
was	O
relatively	O
small	O
and	O
with	O
larger	O
patient	O
numbers	O
,	O
MDM2	O
overexpression	O
may	O
emerge	O
as	O
a	O
more	O
significant	O
covariate	O
.	O

Therapeutic	O
Electromagnetic	O
Field	O
(	O
TEMF	O
)	O
and	O
gamma	O
irradiation	O
on	O
human	O
breast	O
cancer	O
xenograft	O
growth	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
a	O
rectified	O
semi	O
-	O
sinewave	O
signal	O
(	O
15	O
mT	O
amplitude	O
,	O
120	O
pulses	O
per	O
second	O
,	O
EMF	O
Therapeutics	O
,	O
Inc	O
.	O
)	O
(	O
TEMF	O
)	O
alone	O
and	O
in	O
combination	O
with	O
gamma	O
irradiation	O
(	O
IR	O
)	O
therapy	O
in	O
nude	O
mice	O
bearing	O
a	O
human	O
MDA	B
MB231	I
breast	O
cancer	O
xenograft	O
were	O
tested	O
.	O

Green	O
fluorescence	O
protein	O
transfected	O
cancer	O
cells	O
were	O
injected	O
into	O
the	O
mammary	O
fat	O
pad	O
of	O
young	O
female	O
mice	O
.	O

Six	O
weeks	O
later	O
,	O
mice	O
were	O
randomly	O
divided	O
into	O
four	O
treatment	O
groups	O
:	O
untreated	O
controls	O
;	O
10	O
minute	O
daily	O
TEMF	O
;	O
200	O
cGy	O
of	O
IR	O
every	O
other	O
day	O
(	O
total	O
800	O
cGy	O
)	O
;	O
IR	O
plus	O
daily	O
TEMF	O
.	O

Some	O
mice	O
in	O
each	O
group	O
were	O
euthanized	O
24	O
hours	O
after	O
the	O
end	O
of	O
IR	O
.	O

TEMF	O
treatment	O
continued	O
for	O
3	O
additional	O
weeks	O
.	O

Tumor	O
sections	O
were	O
stained	O
for	O
:	O
endothelial	O
cells	O
with	O
CD31	O
and	O
PAS	O
or	O
hypoxia	O
inducible	O
factor	O
1alpha	O
(	O
HIF	O
)	O
.	O

RESULTS	O
:	O
Most	O
tumors	O
less	O
than	O
35	O
mm3	O
were	O
white	O
but	O
tumors	O
greater	O
than	O
35	O
mm3	O
were	O
pink	O
and	O
had	O
a	O
vascularized	O
capsule	O
.	O

The	O
cortex	O
within	O
100	O
microns	O
of	O
the	O
capsule	O
had	O
little	O
vascularization	O
.	O

Blood	O
vessels	O
,	O
capillaries	O
,	O
and	O
endothelial	O
pseudopods	O
were	O
found	O
at	O
greater	O
than	O
100	O
microns	O
from	O
the	O
capsule	O
(	O
subcortex	O
)	O
.	O

Tumors	O
greater	O
than	O
35	O
mm3	O
treated	O
with	O
IR	O
24	O
hours	O
previously	O
or	O
with	O
TEMF	O
had	O
decreased	O
blood	O
vessels	O
in	O
the	O
subcortex	O
and	O
more	O
endothelial	O
pseudopods	O
projecting	O
into	O
hypoxic	O
,	O
HIF	O
positive	O
areas	O
than	O
tumors	O
from	O
the	O
control	O
group	O
.	O

Mice	O
that	O
received	O
either	O
IR	O
or	O
TEMF	O
had	O
significantly	O
fewer	O
lung	O
metastatic	O
sites	O
and	O
slower	O
tumor	O
growth	O
than	O
did	O
untreated	O
mice	O
.	O

No	O
harmful	O
side	O
effects	O
were	O
attributed	O
to	O
TEMF	O
.	O

CONCLUSION	O
:	O
TEMF	O
therapy	O
provided	O
a	O
safe	O
means	O
for	O
retarding	O
tumor	O
vascularization	O
,	O
growth	O
and	O
metastasis	O
.	O

Thrombospondins	O
,	O
metallo	O
proteases	O
and	O
thrombospondin	O
receptors	O
messenger	O
RNA	O
and	O
protein	O
expression	O
in	O
different	O
tumour	O
sublines	O
of	O
the	O
Dunning	O
prostate	O
cancer	O
model	O
.	O

Thrombospondin	O
is	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	O
and	O
might	O
therefore	O
be	O
important	O
in	O
controlling	O
tumour	O
growth	O
.	O

TSP	O
interacts	O
with	O
a	O
number	O
of	O
proteases	O
and	O
receptors	O
and	O
in	O
this	O
way	O
inhibits	O
stimulation	O
of	O
angiogenesis	O
.	O

An	O
earlier	O
study	O
showed	O
that	O
thrombospondin	O
is	O
expressed	O
in	O
benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
and	O
high	O
-	O
grade	O
prostatic	O
intraepithelial	O
neoplasia	O
(	O
PIN	O
)	O
but	O
is	O
absent	O
in	O
prostate	O
cancer	O
.	O

The	O
present	O
study	O
was	O
therefore	O
designed	O
to	O
evaluate	O
the	O
expression	O
of	O
thrombospondin	O
1	O
and	O
2	O
(	O
TSP	O
-	O
1	O
,	O
TSP	O
-	O
2	O
)	O
,	O
TSP	O
receptors	O
CD36	O
and	O
CD47	O
,	O
and	O
matrix	O
-	O
metalloproteases	O
2	O
and	O
9	O
(	O
MMP	O
-	O
,	O
MMP	O
-	O
9	O
)	O
in	O
a	O
rat	O
prostate	O
cancer	O
model	O
.	O

By	O
using	O
immunohistochemistry	O
,	O
Western	O
blot	O
,	O
and	O
real	O
-	O
time	O
PCR	O
the	O
expression	O
patterns	O
of	O
TSP	O
-	O
1	O
,	O
TSP	O
-	O
2	O
,	O
CD36	O
,	O
CD47	O
,	O
MMP	O
-	O
2	O
,	O
and	O
MMP	O
-	O
9	O
were	O
investigated	O
in	O
normal	O
rat	O
prostate	O
tissue	O
and	O
five	O
malignant	O
Dunning	O
sublines	O
tissue	O
.	O

TSP	O
-	O
1	O
mRNA	O
levels	O
were	O
decreased	O
in	O
all	O
tumours	O
compared	O
with	O
normal	O
prostate	O
.	O

However	O
,	O
there	O
was	O
no	O
difference	O
in	O
expression	O
of	O
TSP	O
-	O
2	O
and	O
CD36	O
mRNA	O
in	O
these	O
samples	O
.	O

MMP	O
-	O
2	O
was	O
increased	O
with	O
malignancy	O
,	O
but	O
no	O
expression	O
of	O
MMP	O
-	O
9	O
was	O
seen	O
.	O

The	O
CD47	O
receptor	O
did	O
slightly	O
increase	O
with	O
malignancy	O
except	O
for	O
H3327	O
.	O

The	O
results	O
showed	O
that	O
thrombospondin	O
is	O
expressed	O
in	O
normal	O
prostate	O
but	O
not	O
in	O
prostate	O
tumours	O
in	O
a	O
rat	O
model	O
.	O

Simultaneously	O
,	O
MMP	O
-	O
2	O
expression	O
increases	O
with	O
malignancy	O
.	O

Bovine	O
papillomavirus	O
E7	O
transformation	O
function	O
correlates	O
with	O
cellular	O
p600	O
protein	O
binding	O
.	O

The	O
E7	O
oncoprotein	O
of	O
bovine	O
papillomavirus	O
type	O
1	O
(	O
BPV	O
-	O
1	O
)	O
is	O
required	O
for	O
the	O
full	O
transformation	O
activity	O
of	O
the	O
virus	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
E7	O
contributes	O
to	O
cellular	O
transformation	O
is	O
unknown	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
used	O
the	O
proteomic	O
approach	O
of	O
tandem	O
affinity	O
purification	O
to	O
identify	O
cellular	O
proteins	O
that	O
are	O
in	O
complex	O
with	O
E7	O
,	O
and	O
identified	O
the	O
600	O
-	O
kDa	O
protein	O
,	O
p600	O
,	O
as	O
a	O
binding	O
partner	O
of	O
E7	O
.	O

The	O
ability	O
of	O
E7	O
to	O
complex	O
with	O
p600	O
correlated	O
with	O
its	O
ability	O
to	O
enhance	O
anchorage	O
independence	O
of	O
BPV	O
-	O
1	O
E6	O
-	O
expressing	O
cells	O
.	O

Furthermore	O
,	O
E7	O
mutant	O
proteins	O
impaired	O
in	O
their	O
ability	O
to	O
bind	O
p600	O
were	O
transformation	O
defective	O
.	O

Additionally	O
,	O
knockdown	O
of	O
p600	O
reduced	O
transformation	O
of	O
cells	O
expressing	O
both	O
BPV	O
-	O
1	O
E6	O
and	O
E7	O
,	O
as	O
well	O
as	O
E6	O
alone	O
,	O
suggesting	O
that	O
the	O
ability	O
of	O
E7	O
to	O
transformed	O
cells	O
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
through	O
its	O
ability	O
to	O
bind	O
p600	O
.	O

These	O
data	O
complement	O
work	O
that	O
shows	O
that	O
HPV16	O
E7	O
also	O
interacts	O
with	O
p600	O
,	O
and	O
that	O
this	O
interaction	O
correlates	O
with	O
the	O
ability	O
of	O
HPV16	O
E7	O
to	O
transform	O
cells	O
.	O

These	O
studies	O
thus	O
identify	O
p600	O
as	O
a	O
shared	O
target	O
of	O
the	O
E7	O
proteins	O
of	O
multiple	O
papillomaviruses	O
.	O

Experimental	O
investigation	O
of	O
equibiaxial	O
extension	O
and	O
breakup	O
of	O
drops	O
in	O
a	O
molten	O
two	O
-	O
phase	O
polymer	O
blend	O
.	O

We	O
experimentally	O
investigate	O
the	O
breakup	O
of	O
an	O
equibiaxially	O
elongated	O
polystyrene	O
(	O
PS	O
)	O
drop	O
in	O
a	O
poly	O
(	O
methyl	O
methacrylate	O
)	O
(	O
PMMA	O
)	O
matrix	O
during	O
relaxation	O
after	O
melt	O
elongation	O
.	O

In	O
equibiaxial	O
elongation	O
,	O
the	O
initially	O
spherical	O
PS	O
drop	O
is	O
deformed	O
into	O
an	O
ellipsoidal	O
disclike	O
shape	O
for	O
our	O
test	O
parameters	O
.	O

Using	O
a	O
hotstage	O
in	O
combination	O
with	O
a	O
light	O
microscope	O
,	O
we	O
observe	O
the	O
evolution	O
of	O
the	O
drop	O
shape	O
during	O
relaxation	O
.	O

In	O
the	O
initial	O
stage	O
of	O
relaxation	O
,	O
fingers	O
and	O
holes	O
are	O
formed	O
.	O

The	O
holes	O
are	O
located	O
preferentially	O
near	O
the	O
rim	O
of	O
the	O
drop	O
.	O

The	O
number	O
and	O
the	O
size	O
of	O
the	O
holes	O
increase	O
with	O
time	O
such	O
that	O
the	O
elongated	O
PS	O
drop	O
attains	O
a	O
complex	O
shape	O
during	O
relaxation	O
.	O

The	O
fingers	O
form	O
bulbous	O
ends	O
which	O
separate	O
from	O
the	O
fingers	O
.	O

We	O
discuss	O
the	O
dynamics	O
of	O
this	O
breakup	O
process	O
by	O
taking	O
into	O
account	O
the	O
interfacial	O
energy	O
between	O
PS	O
and	O
PMMA	O
.	O

Our	O
analysis	O
shows	O
that	O
a	O
very	O
large	O
number	O
of	O
small	O
PS	O
droplets	O
can	O
be	O
generated	O
by	O
the	O
sequential	O
breakup	O
of	O
the	O
elongated	O
PS	O
drop	O
.	O

Molecular	O
requirements	O
for	O
epithelial	O
-	O
mesenchymal	O
transition	O
during	O
tumor	O
progression	O
.	O

Epithelial	O
-	O
mesenchymal	O
transitions	O
(	O
EMTs	O
)	O
occur	O
as	O
key	O
steps	O
during	O
embryonic	O
morphogenesis	O
,	O
and	O
are	O
now	O
implicated	O
in	O
the	O
progression	O
of	O
primary	O
tumors	O
towards	O
metastases	O
.	O

Recent	O
advances	O
have	O
fostered	O
a	O
more	O
detailed	O
understanding	O
of	O
molecular	O
mechanisms	O
and	O
networks	O
governing	O
EMT	O
in	O
tumor	O
progression	O
.	O

Besides	O
TGFbeta	O
and	O
RTK	O
/	O
Ras	O
signaling	O
,	O
autocrine	O
factors	O
and	O
Wnt	O
-	O
,	O
Notch	O
-	O
,	O
Hedgehog	O
-	O
and	O
NF	O
-	O
kappaB	O
-	O
dependent	O
pathways	O
were	O
found	O
to	O
contribute	O
to	O
EMT	O
.	O

Repression	O
of	O
E	O
-	O
cadherin	O
by	O
transcriptional	O
regulators	O
such	O
as	O
Snail	O
or	O
Twist	O
emerges	O
as	O
one	O
critical	O
step	O
driving	O
EMT	O
,	O
and	O
this	O
stage	O
is	O
currently	O
being	O
molecularly	O
linked	O
with	O
many	O
of	O
the	O
new	O
players	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
EMT	O
plays	O
a	O
specific	O
role	O
in	O
the	O
migration	O
of	O
cells	O
from	O
a	O
primary	O
tumor	O
into	O
the	O
circulation	O
and	O
may	O
provide	O
a	O
rationale	O
for	O
developing	O
more	O
effective	O
cancer	O
therapies	O
.	O

A	O
novel	O
conotoxin	O
from	O
Conus	O
delessertii	O
with	O
posttranslationally	O
modified	O
lysine	O
residues	O
.	O

A	O
major	O
peptide	O
,	O
de13a	O
from	O
the	O
crude	O
venom	O
of	O
Conus	O
delessertii	O
collected	O
in	O
the	O
Yucatan	O
Channel	O
,	O
Mexico	O
,	O
was	O
purified	O
.	O

The	O
peptide	O
had	O
a	O
high	O
content	O
of	O
posttranslationally	O
modified	O
amino	O
acids	O
,	O
including	O
6	O
-	O
bromotryptophan	O
and	O
a	O
nonstandard	O
amino	O
acid	O
that	O
proved	O
to	O
be	O
5	O
-	O
hydroxylysine	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
5	O
-	O
hydroxylysine	O
residues	O
in	O
conotoxins	O
.	O

The	O
sequence	O
analysis	O
,	O
together	O
with	O
cDNA	O
cloning	O
and	O
a	O
mass	O
determination	O
(	O
monoisotopic	O
mass	O
of	O
3486	O
.	O
76	O
Da	O
)	O
,	O
established	O
that	O
the	O
mature	O
toxin	O
has	O
the	O
sequence	O
DCOTSCOTTCANGWECCKGYOCVNKACSGCTH	O
,	O
where	O
O	O
is	O
4	O
-	O
hydroxyproline	O
,	O
W	O
6	O
-	O
bromotryptophan	O
,	O
and	O
K	O
5	O
-	O
hydroxylysine	O
,	O
the	O
asterisk	O
represents	O
the	O
amidated	O
C	O
-	O
terminus	O
,	O
and	O
the	O
calculated	O
monoisotopic	O
mass	O
is	O
3487	O
.	O
09	O
Da	O
.	O

The	O
eight	O
Cys	O
residues	O
are	O
arranged	O
in	O
a	O
pattern	O
(	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
-	O
C	O
)	O
not	O
described	O
previously	O
in	O
conotoxins	O
.	O

This	O
arrangement	O
,	O
for	O
which	O
we	O
propose	O
the	O
designation	O
of	O
framework	O
#	O
13	O
or	O
XIII	O
,	O
differs	O
from	O
the	O
ones	O
(	O
C	O
-	O
C	O
-	O
CC	O
-	O
CC	O
-	O
C	O
-	O
C	O
and	O
C	O
-	O
C	O
-	O
C	O
-	O
C	O
-	O
CC	O
-	O
C	O
-	O
C	O
)	O
present	O
in	O
other	O
conotoxins	O
which	O
also	O
contain	O
eight	O
Cys	O
residues	O
.	O

This	O
peptide	O
thus	O
defines	O
a	O
novel	O
class	O
of	O
conotoxins	O
,	O
with	O
a	O
new	O
posttranslational	O
modification	O
not	O
previously	O
found	O
in	O
other	O
Conus	O
peptide	O
families	O
.	O

Management	O
of	O
extremity	O
trauma	O
and	O
related	O
infections	O
occurring	O
in	O
the	O
aquatic	O
environment	O
.	O

Wounds	O
sustained	O
in	O
oceans	O
,	O
lakes	O
,	O
and	O
streams	O
are	O
exposed	O
to	O
a	O
milieu	O
of	O
bacteria	O
rarely	O
encountered	O
in	O
typical	O
land	O
-	O
based	O
injuries	O
.	O

These	O
include	O
Vibrio	O
species	O
,	O
Aeromonas	O
hydrophila	O
,	O
Pseudomonas	O
and	O
Plesiomonas	O
species	O
,	O
Erysipelothrix	O
rhusiopathiae	O
,	O
Mycobacterium	O
marinum	O
,	O
and	O
other	O
microbes	O
.	O

Failure	O
to	O
recognize	O
and	O
treat	O
these	O
less	O
common	O
pathogens	O
in	O
a	O
timely	O
manner	O
may	O
result	O
in	O
significant	O
morbidity	O
or	O
death	O
.	O

Initial	O
antibiotic	O
therapy	O
should	O
address	O
common	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
aquatic	O
bacteria	O
,	O
depending	O
on	O
the	O
environment	O
.	O

Trauma	O
occurring	O
in	O
brackish	O
or	O
salt	O
water	O
should	O
be	O
treated	O
with	O
doxycycline	O
and	O
ceftazidime	O
,	O
or	O
a	O
fluoroquinolone	O
(	O
eg	O
,	O
ciprofloxacin	O
or	O
levofloxacin	O
)	O
.	O

Freshwater	O
wounds	O
should	O
be	O
managed	O
with	O
ciprofloxacin	O
,	O
levofloxacin	O
,	O
or	O
a	O
third	O
-	O
or	O
fourth	O
-	O
generation	O
cephalosporin	O
(	O
eg	O
,	O
ceftazidime	O
)	O
.	O

Injuries	O
sustained	O
in	O
a	O
marine	O
or	O
freshwater	O
environment	O
may	O
result	O
from	O
bites	O
or	O
venomous	O
stings	O
of	O
aquatic	O
organisms	O
as	O
well	O
as	O
from	O
accidental	O
trauma	O
.	O

Musculoskeletal	O
trauma	O
caused	O
by	O
venomous	O
underwater	O
species	O
(	O
eg	O
,	O
stingrays	O
,	O
stinging	O
fish	O
,	O
sea	O
urchins	O
,	O
and	O
coral	O
)	O
requires	O
immediate	O
neutralization	O
of	O
the	O
heat	O
-	O
labile	O
toxin	O
with	O
immersion	O
in	O
nonscalding	O
water	O
for	O
30	O
to	O
90	O
minutes	O
.	O

Appropriate	O
management	O
of	O
aquatic	O
wounds	O
requires	O
recognition	O
of	O
the	O
mechanism	O
of	O
injury	O
,	O
neutralization	O
of	O
venom	O
,	O
antibiotic	O
administration	O
,	O
radiographic	O
assessment	O
,	O
surgical	O
debridement	O
with	O
irrigation	O
,	O
wound	O
cultures	O
,	O
and	O
structural	O
repair	O
or	O
amputation	O
as	O
indicated	O
by	O
the	O
severity	O
of	O
the	O
injury	O
.	O

Minimal	O
contribution	O
of	O
marrow	O
-	O
derived	O
endothelial	O
precursors	O
to	O
tumor	O
vasculature	O
.	O

During	O
embryogenesis	O
,	O
vascular	O
and	O
hemopoietic	O
cells	O
originate	O
from	O
a	O
common	O
precursor	O
,	O
the	O
hemangioblast	O
.	O

Recent	O
evidence	O
suggests	O
the	O
existence	O
of	O
endothelial	O
precursors	O
in	O
adult	O
bone	O
marrow	O
cells	O
,	O
but	O
it	O
is	O
unclear	O
whether	O
those	O
precursors	O
have	O
a	O
role	O
in	O
tumor	O
neovascularization	O
.	O

In	O
this	O
report	O
,	O
we	O
demonstrate	O
that	O
murine	O
bone	O
marrow	O
contains	O
endothelial	O
progenitors	O
,	O
which	O
arise	O
from	O
a	O
cell	O
with	O
self	O
-	O
renewing	O
capacity	O
,	O
and	O
can	O
integrate	O
into	O
tumor	O
microvasculature	O
,	O
albeit	O
at	O
a	O
very	O
low	O
frequency	O
.	O

A	O
transgenic	O
double	O
-	O
reporter	O
strategy	O
allowed	O
us	O
to	O
demonstrate	O
definitively	O
that	O
tumor	O
bone	O
marrow	O
-	O
derived	O
endothelial	O
cells	O
arise	O
by	O
transdifferentiation	O
of	O
marrow	O
progenitors	O
rather	O
than	O
by	O
cell	O
fusion	O
.	O

Single	O
cell	O
transplants	O
showed	O
that	O
a	O
common	O
precursor	O
contributes	O
to	O
both	O
the	O
hemopoietic	O
and	O
endothelial	O
lineages	O
,	O
thus	O
demonstrating	O
the	O
presence	O
of	O
an	O
adult	O
hemangioblast	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
increased	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
-	O
A	O
secretion	O
by	O
tumor	O
cells	O
,	O
as	O
well	O
as	O
activation	O
of	O
VEGF	O
receptor	O
-	O
2	O
in	O
bone	O
marrow	O
cells	O
does	O
not	O
alter	O
the	O
mobilization	O
and	O
incorporation	O
of	O
marrow	O
-	O
derived	O
endothelial	O
progenitors	O
into	O
tumor	O
vasculature	O
.	O

Finally	O
,	O
in	O
human	O
umbilical	O
cord	O
blood	O
cells	O
,	O
we	O
show	O
that	O
endothelial	O
precursors	O
make	O
up	O
only	O
approximately	O
1	O
in	O
10	O
(	O
7	O
)	O
mononuclear	O
cells	O
but	O
are	O
highly	O
enriched	O
in	O
the	O
CD133	O
+	O
cell	O
population	O
.	O

By	O
ruling	O
out	O
cell	O
fusion	O
,	O
we	O
clearly	O
demonstrate	O
the	O
existence	O
of	O
an	O
adult	O
hemangioblast	O
,	O
but	O
the	O
differentiation	O
of	O
marrow	O
stem	O
cells	O
toward	O
the	O
endothelial	O
lineage	O
is	O
an	O
extremely	O
rare	O
event	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
VEGF	O
-	O
A	O
stimulation	O
of	O
hemopoietic	O
cells	O
does	O
not	O
significantly	O
alter	O
this	O
process	O
.	O

Impaired	O
coronary	O
collateral	O
vessel	O
development	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
.	O

BACKGROUND	O
:	O
Diabetic	O
patients	O
have	O
been	O
reported	O
to	O
have	O
impaired	O
coronary	O
collateral	O
vessel	O
growth	O
,	O
although	O
they	O
have	O
excessive	O
neovascularization	O
in	O
the	O
retina	O
.	O

HYPOTHESIS	O
:	O
This	O
study	O
was	O
designed	O
to	O
compare	O
coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
in	O
patients	O
with	O
proliferative	O
diabetic	O
retinopathy	O
(	O
PDR	O
)	O
with	O
that	O
in	O
patients	O
without	O
DR	O
.	O

METHODS	O
:	O
Ninety	O
diabetic	O
patients	O
with	O
chronic	O
total	O
occlusion	O
in	O
at	O
least	O
one	O
major	O
epicardial	O
coronary	O
artery	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Groups	O
1	O
and	O
2	O
consisted	O
of	O
48	O
patients	O
without	O
DR	O
and	O
42	O
patients	O
with	O
PDR	O
,	O
respectively	O
.	O

Coronary	O
collateral	O
circulation	O
(	O
CCC	O
)	O
was	O
analyzed	O
according	O
to	O
the	O
Rentrop	O
system	O
.	O

Each	O
group	O
was	O
also	O
divided	O
into	O
two	O
subgroups	O
according	O
to	O
poor	O
and	O
good	O
CCC	O
.	O

Serum	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
levels	O
were	O
measured	O
using	O
the	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
kit	O
.	O

RESULTS	O
:	O
The	O
mean	O
Rentrop	O
collateral	O
score	O
was	O
higher	O
in	O
Group	O
1	O
than	O
in	O
Group	O
2	O
(	O
2	O
.	O
39	O
+	O
/	O
-	O
1	O
.	O
07	O
vs	O
.	O
1	O
.	O
76	O
+	O
/	O
-	O
0	O
.	O
76	O
,	O
respectively	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

When	O
the	O
two	O
groups	O
were	O
compared	O
with	O
respect	O
to	O
poor	O
and	O
good	O
CCC	O
,	O
poor	O
CCC	O
was	O
higher	O
in	O
patients	O
with	O
PDR	O
(	O
64	O
vs	O
.	O
36	O
%	O
,	O
respectively	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Serum	O
VEGF	O
levels	O
were	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
(	O
219	O
+	O
/	O
-	O
99	O
vs	O
.	O
139	O
+	O
/	O
-	O
98	O
pg	O
/	O
ml	O
,	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
;	O
however	O
,	O
patients	O
with	O
poor	O
and	O
good	O
CCC	O
had	O
similar	O
VEGF	O
levels	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
shown	O
that	O
patients	O
with	O
PDR	O
have	O
a	O
lower	O
coronary	O
collateral	O
score	O
than	O
patients	O
without	O
DR	O
.	O

Also	O
,	O
serum	O
VEGF	O
was	O
significantly	O
higher	O
in	O
patients	O
with	O
PDR	O
than	O
in	O
those	O
without	O
DR	O
.	O

These	O
findings	O
have	O
suggested	O
that	O
diabetes	O
mellitus	O
may	O
have	O
a	O
different	O
action	O
on	O
retinal	O
and	O
coronary	O
circulation	O
.	O

Enhancement	O
of	O
skin	O
permeation	O
of	O
ketotifen	O
by	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
of	O
the	O
drug	O
.	O

Pressure	O
sensitive	O
adhesive	O
(	O
PSA	O
)	O
matrices	O
containing	O
amorphous	O
ketotifen	O
were	O
prepared	O
and	O
evaluated	O
for	O
enhanced	O
skin	O
permeability	O
of	O
the	O
drug	O
.	O

A	O
solvent	O
casting	O
method	O
using	O
silicone	O
-	O
typed	O
PSA	O
was	O
employed	O
,	O
and	O
n	O
-	O
hexane	O
,	O
an	O
original	O
solvent	O
for	O
the	O
PSA	O
and	O
one	O
more	O
solvent	O
,	O
dichloromethane	O
,	O
tetrahydrofuran	O
,	O
acetone	O
,	O
ethyl	O
acetate	O
or	O
toluene	O
,	O
were	O
used	O
for	O
complete	O
dissolution	O
of	O
ketotifen	O
and	O
high	O
dispersion	O
in	O
an	O
amorphous	O
state	O
of	O
the	O
drug	O
.	O

Presence	O
of	O
the	O
amorphous	O
form	O
was	O
judged	O
based	O
on	O
the	O
in	O
vitro	O
drug	O
release	O
rate	O
from	O
the	O
matrix	O
.	O

As	O
a	O
result	O
,	O
dichloromethane	O
and	O
tetrahudrofuran	O
were	O
selected	O
as	O
appropriate	O
dilution	O
solvents	O
.	O

In	O
vitro	O
permeation	O
experiments	O
through	O
excised	O
hairless	O
mouse	O
skin	O
revealed	O
that	O
the	O
steady	O
-	O
state	O
flux	O
from	O
the	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
was	O
about	O
five	O
times	O
greater	O
than	O
that	O
of	O
the	O
crystalline	O
ketotifen	O
-	O
dispersed	O
matrices	O
,	O
and	O
that	O
the	O
enhancement	O
ratio	O
was	O
in	O
good	O
agreement	O
with	O
the	O
solubility	O
ratio	O
of	O
the	O
amorphous	O
to	O
crystalline	O
form	O
of	O
the	O
drug	O
.	O

Comparison	O
of	O
the	O
skin	O
permeation	O
profiles	O
of	O
amorphous	O
ketotifen	O
-	O
dispersed	O
matrices	O
between	O
two	O
different	O
drug	O
contents	O
suggested	O
that	O
the	O
steady	O
-	O
state	O
flux	O
was	O
not	O
influenced	O
by	O
the	O
drug	O
content	O
.	O

In	O
addition	O
,	O
at	O
both	O
drug	O
contents	O
,	O
the	O
period	O
of	O
the	O
steady	O
-	O
state	O
permeation	O
coincided	O
with	O
the	O
time	O
until	O
the	O
amorphous	O
drug	O
was	O
depleted	O
from	O
the	O
matrix	O
.	O

These	O
results	O
suggest	O
that	O
the	O
increase	O
in	O
skin	O
permeation	O
of	O
ketotifen	O
from	O
PSA	O
matrix	O
was	O
due	O
to	O
the	O
supersaturation	O
generated	O
by	O
amorphous	O
form	O
,	O
and	O
that	O
the	O
amorphous	O
form	O
was	O
stable	O
during	O
the	O
application	O
period	O
.	O

Polybrominated	O
diphenyl	O
ethers	O
in	O
indoor	O
dust	O
in	O
Ottawa	O
,	O
Canada	O
:	O
implications	O
for	O
sources	O
and	O
exposure	O
.	O

Polybrominated	O
diphenyl	O
ethers	O
(	O
PBDEs	O
)	O
are	O
widely	O
used	O
as	O
additive	O
flame	O
retardants	O
in	O
plastics	O
,	O
soft	O
furnishings	O
,	O
electrical	O
and	O
electronic	O
equipment	O
,	O
and	O
insulation	O
in	O
the	O
indoor	O
environment	O
,	O
and	O
may	O
be	O
released	O
indoors	O
via	O
volatilization	O
or	O
as	O
dusts	O
.	O

The	O
penta	O
-	O
and	O
octa	O
-	O
brominated	O
mixes	O
are	O
now	O
banned	O
in	O
most	O
parts	O
of	O
Europe	O
,	O
and	O
phasing	O
out	O
of	O
their	O
use	O
has	O
recently	O
begun	O
in	O
North	O
America	O
.	O

This	O
study	O
follows	O
a	O
previous	O
investigation	O
into	O
indoor	O
air	O
levels	O
of	O
PBDEs	O
.	O

House	O
dust	O
was	O
analyzed	O
from	O
the	O
family	O
vacuum	O
cleaners	O
of	O
68	O
of	O
the	O
same	O
74	O
randomly	O
selected	O
homes	O
,	O
in	O
Ottawa	O
,	O
Canada	O
during	O
the	O
winter	O
of	O
2002	O
-	O
2003	O
.	O

PBDEs	O
,	O
comprising	O
on	O
average	O
42	O
%	O
BDE	O
-	O
209	O
,	O
were	O
found	O
in	O
all	O
samples	O
.	O

The	O
levels	O
were	O
log	O
-	O
normally	O
distributed	O
with	O
a	O
geometric	O
mean	O
sigmaPBDE	O
of	O
2000	O
ng	O
g	O
(	O
-	O
1	O
)	O
,	O
and	O
a	O
median	O
of	O
1800	O
ng	O
g	O
(	O
-	O
1	O
)	O
dust	O
.	O

The	O
levels	O
in	O
dust	O
did	O
not	O
correlate	O
with	O
questionnaire	O
information	O
on	O
house	O
characteristics	O
.	O

Correlations	O
were	O
found	O
between	O
pentamix	O
congener	O
levels	O
in	O
dust	O
and	O
in	O
air	O
from	O
the	O
same	O
homes	O
,	O
but	O
not	O
for	O
congeners	O
of	O
the	O
more	O
highly	O
brominated	O
mixes	O
.	O

Exposure	O
scenarios	O
are	O
presented	O
for	O
mean	O
and	O
high	O
dust	O
ingestion	O
rates	O
,	O
and	O
compared	O
against	O
exposures	O
from	O
other	O
pathways	O
,	O
for	O
both	O
adults	O
and	O
toddlers	O
(	O
6	O
months	O
-	O
2	O
years	O
)	O
.	O

Assuming	O
a	O
mean	O
dust	O
ingestion	O
rate	O
and	O
median	O
dust	O
and	O
air	O
concentrations	O
,	O
adults	O
would	O
be	O
exposed	O
to	O
ca	O
.	O

7	O
.	O
5	O
ng	O
sigmaPBDE	O
d	O
(	O
-	O
1	O
)	O
via	O
the	O
dust	O
ingestion	O
pathway	O
,	O
which	O
represents	O
approximately	O
14	O
%	O
of	O
total	O
daily	O
exposure	O
when	O
compared	O
to	O
diet	O
(	O
82	O
%	O
)	O
and	O
inhalation	O
(	O
4	O
%	O
)	O
.	O

However	O
,	O
for	O
toddlers	O
the	O
equivalent	O
intakes	O
would	O
be	O
99	O
ng	O
d	O
(	O
-	O
1	O
)	O
,	O
representing	O
80	O
%	O
of	O
their	O
daily	O
PBDE	O
exposure	O
.	O

At	O
high	O
dust	O
ingestion	O
rates	O
these	O
values	O
increase	O
to	O
180	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
80	O
%	O
daily	O
intake	O
)	O
for	O
adults	O
and	O
360	O
ng	O
d	O
(	O
-	O
1	O
)	O
(	O
89	O
%	O
daily	O
intake	O
)	O
for	O
toddlers	O
.	O

The	O
data	O
give	O
a	O
clearer	O
picture	O
of	O
sources	O
of	O
PBDE	O
exposure	O
in	O
the	O
home	O
environment	O
and	O
suggest	O
that	O
dust	O
could	O
be	O
a	O
significant	O
exposure	O
pathway	O
for	O
some	O
individuals	O
,	O
particularly	O
children	O
.	O

The	O
threshold	O
level	O
of	O
adenomatous	O
polyposis	O
coli	O
protein	O
for	O
mouse	O
intestinal	O
tumorigenesis	O
.	O

The	O
adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
gene	O
,	O
whose	O
mutations	O
are	O
responsible	O
for	O
familial	O
adenomatous	O
polyposis	O
,	O
is	O
a	O
major	O
negative	O
controller	O
of	O
the	O
Wnt	O
/	O
beta	O
-	O
catenin	O
pathway	O
.	O

To	O
investigate	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
APC	O
protein	O
in	O
suppressing	O
intestinal	O
tumorigenesis	O
,	O
we	O
constructed	O
mutant	O
mice	O
carrying	O
hypomorphic	O
Apc	O
alleles	O
Apc	O
(	O
neoR	O
)	O
and	O
Apc	O
(	O
neoF	O
)	O
whose	O
expression	O
levels	O
were	O
reduced	O
to	O
20	O
%	O
and	O
10	O
%	O
of	O
the	O
wild	O
type	O
,	O
respectively	O
.	O

Although	O
both	O
hypomorphic	O
heterozygotes	O
developed	O
intestinal	O
polyps	O
,	O
tumor	O
multiplicities	O
were	O
much	O
lower	O
than	O
that	O
in	O
Apc	O
(	O
Delta716	O
)	O
mice	O
,	O
heterozygotes	O
of	O
an	O
Apc	O
null	O
allele	O
.	O

Like	O
in	O
Apc	O
(	O
Delta716	O
)	O
mice	O
,	O
loss	O
of	O
the	O
wild	O
-	O
type	O
Apc	O
allele	O
was	O
confirmed	O
for	O
all	O
polyps	O
examined	O
in	O
the	O
Apc	O
(	O
neoR	O
)	O
and	O
Apc	O
(	O
neoF	O
)	O
mice	O
.	O

In	O
the	O
embryonic	O
stem	O
cells	O
homozygous	O
for	O
these	O
hypomorphic	O
Apc	O
alleles	O
,	O
the	O
level	O
of	O
the	O
APC	O
protein	O
was	O
inversely	O
correlated	O
with	O
both	O
the	O
beta	O
-	O
catenin	O
accumulation	O
and	O
beta	O
-	O
catenin	O
/	O
T	O
-	O
cell	O
factor	O
transcriptional	O
activity	O
.	O

These	O
results	O
suggest	O
that	O
the	O
reduced	O
APC	O
protein	O
level	O
increases	O
intestinal	O
polyp	O
multiplicity	O
through	O
quantitative	O
stimulation	O
of	O
the	O
beta	O
-	O
catenin	O
/	O
T	O
-	O
cell	O
factor	O
transcription	O
.	O

We	O
further	O
estimated	O
the	O
threshold	O
of	O
APC	O
protein	O
level	O
that	O
forms	O
one	O
polyp	O
per	O
mouse	O
as	O
approximately	O
15	O
%	O
of	O
the	O
wild	O
type	O
.	O

These	O
results	O
also	O
suggest	O
therapeutic	O
implications	O
concerning	O
Wnt	O
signaling	O
inhibitors	O
.	O

Pathogenesis	O
of	O
thrombosis	O
in	O
essential	O
thrombocythemia	O
and	O
polycythemia	O
vera	O
:	O
the	O
role	O
of	O
neutrophils	O
.	O

Thrombotic	O
complications	O
are	O
frequently	O
observed	O
in	O
patients	O
with	O
polycythemia	O
vera	O
(	O
PV	O
)	O
and	O
essential	O
thrombocythemia	O
(	O
ET	O
)	O
.	O

Abnormalities	O
of	O
red	O
blood	O
cells	O
and	O
platelets	O
arising	O
from	O
the	O
clonal	O
rearrangement	O
of	O
hematopoietic	O
cells	O
have	O
been	O
considered	O
,	O
although	O
causal	O
relationships	O
between	O
any	O
of	O
these	O
specific	O
abnormalities	O
and	O
thrombosis	O
have	O
not	O
been	O
clearly	O
established	O
.	O

The	O
involvement	O
of	O
neutrophils	O
and	O
macrophages	O
,	O
which	O
participate	O
in	O
thrombosis	O
and	O
hemostasis	O
,	O
has	O
been	O
insufficiently	O
explored	O
in	O
PV	O
and	O
ET	O
.	O

Persistent	O
activation	O
of	O
circulating	O
neutrophils	O
was	O
recently	O
demonstrated	O
in	O
ET	O
and	O
PV	O
patients	O
,	O
in	O
parallel	O
with	O
an	O
increase	O
in	O
plasma	O
concentrations	O
of	O
endothelial	O
damage	O
-	O
derived	O
and	O
prothrombotic	O
substances	O
.	O

Other	O
studies	O
have	O
explored	O
whether	O
the	O
augmentation	O
of	O
adhesion	O
of	O
neutrophils	O
may	O
affect	O
neutrophil	O
/	O
platelet	O
interaction	O
since	O
a	O
significant	O
increase	O
in	O
circulating	O
neutrophil	O
/	O
platelet	O
aggregates	O
is	O
found	O
in	O
ET	O
and	O
PV	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
of	O
the	O
pathogenesis	O
of	O
thrombosis	O
in	O
PV	O
and	O
ET	O
,	O
with	O
emphasis	O
on	O
the	O
role	O
of	O
neutrophils	O
in	O
hemostasis	O
and	O
their	O
possible	O
involvement	O
in	O
the	O
mechanisms	O
of	O
the	O
acquired	O
thrombophilia	O
of	O
these	O
patients	O
.	O

Available	O
data	O
suggest	O
that	O
these	O
hemostatic	O
markers	O
deserve	O
to	O
be	O
included	O
in	O
prospective	O
clinical	O
studies	O
aimed	O
at	O
identifying	O
their	O
predictive	O
role	O
in	O
the	O
vascular	O
complications	O
of	O
patients	O
with	O
ET	O
and	O
PV	O
.	O

The	O
merits	O
of	O
vascular	O
targeting	O
for	O
gynecologic	O
malignancies	O
.	O

Neovascularization	O
is	O
an	O
early	O
and	O
critical	O
step	O
in	O
tumor	O
development	O
and	O
progression	O
.	O

Tumor	O
vessels	O
are	O
distinct	O
from	O
their	O
normal	O
counterparts	O
morphologically	O
as	O
well	O
as	O
at	O
a	O
molecular	O
level	O
.	O

Recent	O
studies	O
on	O
factors	O
involved	O
in	O
tumor	O
vascular	O
development	O
have	O
identified	O
new	O
therapeutic	O
targets	O
for	O
inhibiting	O
tumor	O
neovascularization	O
and	O
thus	O
tumor	O
progression	O
.	O

However	O
,	O
the	O
process	O
of	O
tumor	O
blood	O
vessel	O
formation	O
is	O
complex	O
,	O
and	O
each	O
tumor	O
exhibits	O
unique	O
features	O
in	O
its	O
vasculature	O
.	O

An	O
understanding	O
of	O
the	O
relative	O
contribution	O
of	O
various	O
pathways	O
in	O
the	O
development	O
of	O
tumor	O
vasculature	O
is	O
critical	O
for	O
developing	O
effective	O
and	O
selective	O
therapeutic	O
approaches	O
.	O

Several	O
such	O
agents	O
are	O
currently	O
in	O
clinical	O
trials	O
,	O
and	O
many	O
others	O
are	O
under	O
development	O
.	O

In	O
this	O
review	O
,	O
the	O
mechanisms	O
and	O
factors	O
involved	O
in	O
tumor	O
blood	O
vessel	O
formation	O
are	O
discussed	O
.	O

In	O
addition	O
,	O
selected	O
novel	O
classes	O
of	O
antivascular	O
therapies	O
,	O
including	O
those	O
targeting	O
tumor	O
endothelial	O
cells	O
and	O
other	O
components	O
of	O
the	O
tumor	O
vasculature	O
,	O
are	O
summarized	O
.	O

Normal	O
and	O
transforming	O
functions	O
of	O
RUNX1	O
:	O
a	O
perspective	O
.	O

Converging	O
studies	O
from	O
many	O
investigators	O
indicate	O
that	O
RUNX1	O
has	O
a	O
critical	O
role	O
in	O
the	O
correct	O
maintenance	O
of	O
essential	O
cellular	O
functions	O
during	O
embryonic	O
development	O
and	O
after	O
birth	O
.	O

The	O
discovery	O
that	O
this	O
gene	O
is	O
also	O
frequently	O
mutated	O
in	O
human	O
leukemia	O
has	O
increased	O
the	O
interest	O
in	O
the	O
role	O
that	O
RUNX1	O
plays	O
in	O
both	O
normal	O
and	O
transforming	O
pathways	O
.	O

Here	O
,	O
we	O
provide	O
an	O
overview	O
of	O
the	O
many	O
roles	O
of	O
RUNX1	O
in	O
hematopoietic	O
self	O
-	O
renewal	O
and	O
differentiation	O
and	O
summarize	O
the	O
information	O
that	O
is	O
currently	O
available	O
on	O
the	O
many	O
mechanisms	O
of	O
RUNX1	O
deregulation	O
in	O
human	O
leukemia	O
.	O

Sensitivity	O
variation	O
in	O
two	O
-	O
center	O
holographic	O
recording	O
.	O

An	O
experimental	O
study	O
of	O
variation	O
of	O
sensitivity	O
with	O
recording	O
and	O
sensitizing	O
intensities	O
in	O
two	O
-	O
center	O
recording	O
is	O
presented	O
.	O

The	O
experimental	O
results	O
are	O
in	O
good	O
agreement	O
with	O
the	O
theoretical	O
predictions	O
.	O

It	O
is	O
shown	O
experimentally	O
,	O
for	O
what	O
is	O
to	O
our	O
knowledge	O
the	O
first	O
time	O
,	O
that	O
the	O
sensitivity	O
is	O
a	O
function	O
of	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
and	O
not	O
the	O
absolute	O
intensities	O
.	O

Also	O
,	O
the	O
ratio	O
of	O
recording	O
to	O
sensitizing	O
intensities	O
should	O
be	O
small	O
to	O
obtain	O
high	O
sensitivity	O
values	O
.	O

We	O
also	O
report	O
the	O
highest	O
sensitivity	O
(	O
S	O
=	O
0	O
.	O
15	O
cm	O
/	O
J	O
)	O
that	O
has	O
been	O
achieved	O
to	O
date	O
for	O
a	O
LiNbO3	O
:	O
Fe	O
:	O
Mn	O
crystal	O
.	O

Domain	O
5	O
of	O
cleaved	O
high	O
molecular	O
weight	O
kininogen	O
inhibits	O
endothelial	O
cell	O
migration	O
through	O
Akt	O
.	O

Domain	O
5	O
(	O
D5	O
)	O
of	O
cleaved	O
high	O
molecular	O
weight	O
kininogen	O
(	O
HKa	O
)	O
inhibits	O
angiogenesis	O
in	O
vivo	O
and	O
endothelial	O
cell	O
migration	O
in	O
vitro	O
,	O
but	O
the	O
cell	O
signaling	O
pathways	O
involved	O
in	O
HKa	O
and	O
D5	O
inhibition	O
of	O
endothelial	O
cell	O
migration	O
are	O
incompletely	O
delineated	O
.	O

This	O
study	O
examines	O
the	O
mechanism	O
of	O
HKa	O
and	O
D5	O
inhibition	O
of	O
two	O
potent	O
stimulators	O
of	O
endothelial	O
cell	O
migration	O
,	O
sphingosine	O
1	O
-	O
phosphate	O
(	O
S1P	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
that	O
act	O
through	O
the	O
P13	O
-	O
kinase	O
-	O
Akt	O
signaling	O
pathway	O
.	O

HKa	O
and	O
D5	O
inhibit	O
bovine	O
pulmonary	O
artery	O
endothelial	O
cell	O
(	O
BPAE	O
)	O
or	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
chemotaxis	O
in	O
the	O
modified	O
-	O
Boyden	O
chamber	O
in	O
response	O
toVEGF	O
or	O
S1P	O
.	O

The	O
inhibition	O
of	O
migration	O
by	O
HKa	O
is	O
reversed	O
by	O
antibodies	O
to	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O
receptor	O
.	O

Both	O
HKa	O
and	O
D5	O
decrease	O
the	O
speed	O
of	O
BPAE	O
cell	O
migration	O
and	O
alter	O
the	O
morphology	O
in	O
live	O
,	O
time	O
-	O
lapse	O
microscopy	O
after	O
stimulation	O
with	O
S1P	O
or	O
VEGF	O
.	O

HKa	O
and	O
D5	O
reduce	O
the	O
localization	O
of	O
paxillin	O
to	O
the	O
focal	O
adhesions	O
after	O
S1P	O
and	O
VEGF	O
stimulation	O
.	O

To	O
better	O
understand	O
the	O
intracellular	O
signaling	O
pathways	O
,	O
we	O
examined	O
the	O
effect	O
of	O
HKa	O
on	O
the	O
phosphorylation	O
of	O
Akt	O
and	O
its	O
downstream	O
effector	O
,	O
GSK	O
-	O
3alpha	O
HKa	O
and	O
D5	O
inhibit	O
phosphorylation	O
of	O
Akt	O
and	O
GSK	O
-	O
3alpha	O
after	O
stimulation	O
withVEGF	O
and	O
S1P	O
.	O

Inhibitors	O
of	O
Akt	O
and	O
P13	O
-	O
kinase	O
,	O
the	O
upstream	O
activator	O
of	O
Akt	O
,	O
block	O
endothelial	O
cell	O
migration	O
and	O
disrupt	O
paxillin	O
localization	O
to	O
the	O
focal	O
adhesions	O
after	O
stimulation	O
with	O
VEGF	O
and	O
S1P	O
.	O

Therefore	O
we	O
suggest	O
that	O
HKa	O
through	O
its	O
D5	O
domain	O
alters	O
P13	O
-	O
kinase	O
-	O
Akt	O
signaling	O
to	O
inhibit	O
endothelial	O
cell	O
migration	O
through	O
alterations	O
in	O
the	O
focal	O
adhesions	O
.	O

Histopathological	O
development	O
of	O
gastric	O
tumors	O
induced	O
by	O
N	O
-	O
methyl	O
-	O
N	O
'	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
in	O
rats	O
.	O

The	O
development	O
of	O
carcinoma	O
was	O
examined	O
in	O
male	O
Wistar	O
rats	O
(	O
n	O
=	O
120	O
)	O
exposed	O
to	O
N	O
-	O
methyl	O
-	O
N	O
'	O
-	O
nitro	O
-	O
N	O
-	O
nitrosoguanidine	O
(	O
MNNG	O
)	O
in	O
the	O
drinking	O
water	O
(	O
83	O
micrograms	O
/	O
ml	O
)	O
for	O
16	O
weeks	O
.	O

After	O
MNNG	O
administration	O
,	O
rats	O
were	O
investigated	O
by	O
endoscopic	O
observation	O
,	O
visualization	O
of	O
microvascular	O
structure	O
,	O
and	O
estimation	O
of	O
lectin	O
binding	O
sites	O
.	O

Changes	O
of	O
bile	O
reflux	O
to	O
the	O
stomach	O
was	O
observed	O
endoscopically	O
at	O
24	O
weeks	O
as	O
well	O
as	O
the	O
development	O
of	O
gastric	O
mucosal	O
erosions	O
.	O

Protruding	O
and	O
expansive	O
ulcerating	O
carcinomas	O
developed	O
at	O
36	O
weeks	O
and	O
had	O
a	O
microvascular	O
pattern	O
similar	O
to	O
that	O
of	O
human	O
adenocarcinoma	O
.	O

Estimation	O
of	O
lectin	O
binding	O
site	O
and	O
pattern	O
was	O
useful	O
to	O
evaluate	O
the	O
malignant	O
potential	O
of	O
cell	O
proliferation	O
.	O

We	O
postulate	O
that	O
endoscopic	O
observation	O
is	O
valuable	O
in	O
investigating	O
the	O
development	O
of	O
gastric	O
carcinoma	O
,	O
and	O
microvascular	O
structure	O
and	O
lectin	O
binding	O
pattern	O
may	O
be	O
useful	O
to	O
demonstrate	O
the	O
mechanism	O
of	O
growth	O
of	O
gastric	O
carcinoma	O
.	O

Effect	O
of	O
thalidomide	O
affecting	O
VEGF	O
secretion	O
,	O
cell	O
migration	O
,	O
adhesion	O
and	O
capillary	O
tube	O
formation	O
of	O
human	O
endothelial	O
EA	B
.	I
hy	I
926	I
cells	O
.	O

Angiogenesis	O
,	O
new	O
blood	O
vessel	O
formation	O
,	O
is	O
a	O
multistep	O
process	O
,	O
precisely	O
regulated	O
by	O
pro	O
-	O
angiogenic	O
cytokines	O
,	O
which	O
stimulate	O
endothelial	O
cells	O
to	O
migrate	O
,	O
proliferate	O
and	O
differentiate	O
to	O
form	O
new	O
capillary	O
microvessels	O
.	O

Excessive	O
vascular	O
development	O
and	O
blood	O
vessel	O
remodeling	O
appears	O
in	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
diabetic	O
retinopathy	O
and	O
solid	O
tumors	O
formation	O
.	O

Thalidomide	O
[	O
alpha	O
-	O
(	O
N	O
-	O
phthalimido	O
)	O
-	O
glutarimide	O
]	O
is	O
known	O
to	O
be	O
a	O
potent	O
inhibitor	O
of	O
angiogenesis	O
,	O
but	O
the	O
mechanism	O
of	O
its	O
inhibitory	O
action	O
remains	O
unclear	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
influence	O
of	O
thalidomide	O
on	O
the	O
several	O
steps	O
of	O
angiogenesis	O
,	O
using	O
in	O
vitro	O
models	O
.	O

We	O
have	O
evaluated	O
the	O
effect	O
of	O
thalidomide	O
on	O
VEGF	O
secretion	O
,	O
cell	O
migration	O
,	O
adhesion	O
as	O
well	O
as	O
in	O
capillary	O
formation	O
of	O
human	O
endothelial	O
cell	O
line	O
EA	B
.	I
hy	I
926	I
.	O

Thalidomide	O
at	O
the	O
concentrations	O
of	O
0	O
.	O
01	O
microM	O
and	O
10	O
microM	O
inhibited	O
VEGF	O
secretion	O
into	O
supernatants	O
,	O
decreased	O
the	O
number	O
of	O
formed	O
capillary	O
tubes	O
and	O
increased	O
cell	O
adhesion	O
to	O
collagen	O
.	O

Administration	O
of	O
thalidomide	O
at	O
the	O
concentration	O
of	O
0	O
.	O
01	O
microM	O
increased	O
cell	O
migration	O
,	O
while	O
at	O
10	O
microM	O
,	O
it	O
decreased	O
cell	O
migration	O
.	O

Thalidomide	O
in	O
concentrations	O
from	O
0	O
.	O
1	O
microM	O
to	O
10	O
microM	O
did	O
not	O
change	O
cell	O
proliferation	O
of	O
72	O
-	O
h	O
cell	O
cultures	O
.	O

We	O
conclude	O
that	O
anti	O
-	O
angiogenic	O
action	O
of	O
thalidomide	O
is	O
due	O
to	O
direct	O
inhibitory	O
action	O
on	O
VEGF	O
secretion	O
and	O
capillary	O
microvessel	O
formation	O
as	O
well	O
as	O
immunomodulatory	O
influence	O
on	O
EA	O
.	O
hy	O
926	O
cells	O
migration	O
and	O
adhesion	O
.	O

VEGFR1	O
-	O
positive	O
haematopoietic	O
bone	O
marrow	O
progenitors	O
initiate	O
the	O
pre	O
-	O
metastatic	O
niche	O
.	O

The	O
cellular	O
and	O
molecular	O
mechanisms	O
by	O
which	O
a	O
tumour	O
cell	O
undergoes	O
metastasis	O
to	O
a	O
predetermined	O
location	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
demonstrate	O
that	O
bone	O
marrow	O
-	O
derived	O
haematopoietic	O
progenitor	O
cells	O
that	O
express	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
1	O
(	O
VEGFR1	O
;	O
also	O
known	O
as	O
Flt1	O
)	O
home	O
to	O
tumour	O
-	O
specific	O
pre	O
-	O
metastatic	O
sites	O
and	O
form	O
cellular	O
clusters	O
before	O
the	O
arrival	O
of	O
tumour	O
cells	O
.	O

Preventing	O
VEGFR1	O
function	O
using	O
antibodies	O
or	O
by	O
the	O
removal	O
of	O
VEGFR1	O
(	O
+	O
)	O
cells	O
from	O
the	O
bone	O
marrow	O
of	O
wild	O
-	O
type	O
mice	O
abrogates	O
the	O
formation	O
of	O
these	O
pre	O
-	O
metastatic	O
clusters	O
and	O
prevents	O
tumour	O
metastasis	O
,	O
whereas	O
reconstitution	O
with	O
selected	O
Id3	O
(	O
inhibitor	O
of	O
differentiation	O
3	O
)	O
-	O
competent	O
VEGFR1	O
+	O
cells	O
establishes	O
cluster	O
formation	O
and	O
tumour	O
metastasis	O
in	O
Id3	O
knockout	O
mice	O
.	O

We	O
also	O
show	O
that	O
VEGFR1	O
+	O
cells	O
express	O
VLA	O
-	O
4	O
(	O
also	O
known	O
as	O
integrin	O
alpha4beta1	O
)	O
,	O
and	O
that	O
tumour	O
-	O
specific	O
growth	O
factors	O
upregulate	O
fibronectin	O
-	O
-	O
a	O
VLA	O
-	O
4	O
ligand	O
-	O
-	O
in	O
resident	O
fibroblasts	O
,	O
providing	O
a	O
permissive	O
niche	O
for	O
incoming	O
tumour	O
cells	O
.	O

Conditioned	O
media	O
obtained	O
from	O
distinct	O
tumour	O
types	O
with	O
unique	O
patterns	O
of	O
metastatic	O
spread	O
redirected	O
fibronectin	O
expression	O
and	O
cluster	O
formation	O
,	O
thereby	O
transforming	O
the	O
metastatic	O
profile	O
.	O

These	O
findings	O
demonstrate	O
a	O
requirement	O
for	O
VEGFR1	O
+	O
haematopoietic	O
progenitors	O
in	O
the	O
regulation	O
of	O
metastasis	O
,	O
and	O
suggest	O
that	O
expression	O
patterns	O
of	O
fibronectin	O
and	O
VEGFR1	O
+	O
VLA	O
-	O
4	O
+	O
clusters	O
dictate	O
organ	O
-	O
specific	O
tumour	O
spread	O
.	O

Regulation	O
of	O
skin	O
microvasculature	O
angiogenesis	O
,	O
cell	O
migration	O
,	O
and	O
permeability	O
by	O
a	O
specific	O
inhibitor	O
of	O
PKCalpha	O
.	O

Activation	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
induces	O
phenotypic	O
changes	O
in	O
the	O
morphology	O
of	O
microvascular	O
endothelial	O
cells	O
that	O
affect	O
major	O
functions	O
of	O
the	O
microvasculature	O
.	O

These	O
functions	O
include	O
the	O
first	O
stages	O
of	O
sprouting	O
in	O
angiogenesis	O
,	O
cell	O
migration	O
following	O
wounding	O
,	O
and	O
vascular	O
permeability	O
.	O

The	O
specific	O
isoform	O
(	O
s	O
)	O
of	O
PKC	O
responsible	O
for	O
each	O
of	O
these	O
changes	O
has	O
not	O
been	O
previously	O
identified	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
two	O
inflammatory	O
agents	O
,	O
IL	O
-	O
1beta	O
and	O
phorbol	O
myristic	O
acetate	O
,	O
to	O
activate	O
PKC	O
isozymes	O
and	O
specific	O
inhibitors	O
of	O
PKCalpha	O
(	O
Go6976	O
)	O
and	O
PKCbeta	O
(	O
hispidin	O
)	O
to	O
distinguish	O
how	O
each	O
of	O
these	O
isoform	O
(	O
s	O
)	O
controls	O
angiogenesis	O
,	O
wound	O
healing	O
,	O
and	O
permeability	O
.	O

In	O
all	O
cases	O
,	O
only	O
inhibition	O
of	O
PKCalpha	O
inhibited	O
each	O
of	O
these	O
functions	O
when	O
compared	O
to	O
the	O
inhibition	O
of	O
PKCbeta	O
.	O

Additional	O
analysis	O
of	O
the	O
mechanism	O
of	O
action	O
of	O
Go6976	O
(	O
RT	O
-	O
PCR	O
,	O
Western	O
blots	O
,	O
and	O
immunohistochemistry	O
)	O
of	O
the	O
changes	O
in	O
the	O
phosphorylated	O
and	O
nonphosphorylated	O
forms	O
of	O
PKCalpha	O
in	O
the	O
cell	O
membrane	O
and	O
cytoplasm	O
confirmed	O
the	O
specificity	O
of	O
PKCalpha	O
inhibition	O
by	O
Go6976	O
.	O

These	O
studies	O
therefore	O
indicate	O
a	O
specific	O
and	O
a	O
regulatory	O
role	O
of	O
the	O
PKCalpha	O
isoform	O
in	O
three	O
major	O
endothelial	O
cell	O
functions	O
that	O
are	O
important	O
in	O
the	O
maintenance	O
of	O
microvascular	O
homeostasis	O
.	O

Recent	O
advances	O
in	O
minisatellite	O
biology	O
.	O

Highly	O
polymorphic	O
tandemly	O
repeated	O
'	O
minisatellite	O
'	O
loci	O
are	O
very	O
abundant	O
in	O
the	O
human	O
genome	O
,	O
and	O
of	O
considerable	O
utility	O
in	O
human	O
genetic	O
analysis	O
.	O

This	O
review	O
describes	O
the	O
use	O
of	O
an	O
ordered	O
-	O
array	O
Charomid	O
library	O
in	O
the	O
systematic	O
and	O
efficient	O
cloning	O
of	O
these	O
regions	O
,	O
and	O
in	O
the	O
analysis	O
of	O
the	O
relative	O
overlap	O
between	O
the	O
different	O
probes	O
used	O
to	O
screen	O
for	O
hypervariable	O
loci	O
.	O

Recent	O
work	O
on	O
the	O
process	O
of	O
mutation	O
leading	O
to	O
the	O
generation	O
of	O
new	O
-	O
length	O
alleles	O
is	O
also	O
discussed	O
,	O
including	O
the	O
observation	O
that	O
at	O
least	O
some	O
mutations	O
may	O
be	O
due	O
to	O
unequal	O
exchanges	O
.	O

The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
G	O
protein	O
-	O
coupled	O
receptor	O
as	O
a	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

The	O
Kaposi	O
'	O
s	O
sarcoma	O
-	O
associated	O
herpesvirus	O
(	O
KSHV	O
)	O
encodes	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
(	O
vGPCR	O
)	O
that	O
has	O
been	O
implicated	O
in	O
the	O
initiation	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
,	O
identifying	O
vGPCR	O
as	O
an	O
attractive	O
target	O
for	O
preventing	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

However	O
,	O
as	O
only	O
a	O
fraction	O
of	O
cells	O
in	O
advanced	O
Kaposi	O
'	O
s	O
sarcoma	O
lesions	O
express	O
vGPCR	O
,	O
it	O
is	O
unclear	O
whether	O
this	O
unique	O
viral	O
oncogene	O
contributes	O
to	O
Kaposi	O
'	O
s	O
sarcoma	O
progression	O
.	O

We	O
therefore	O
set	O
out	O
to	O
determine	O
whether	O
the	O
few	O
cells	O
that	O
express	O
vGPCR	O
in	O
established	O
tumors	O
represent	O
an	O
appropriate	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
preexisting	O
Kaposi	O
'	O
s	O
sarcoma	O
.	O

To	O
this	O
end	O
,	O
we	O
generated	O
endothelial	O
cell	O
lines	O
stably	O
expressing	O
vGPCR	O
or	O
key	O
KSHV	O
latently	O
expressed	O
proteins	O
(	O
vCyclin	O
,	O
vFlip	O
,	O
and	O
LANA1	O
)	O
.	O

The	O
endothelial	O
cell	O
line	O
expressing	O
vGPCR	O
was	O
rendered	O
sensitive	O
to	O
treatment	O
with	O
the	O
nucleoside	O
analogue	O
ganciclovir	O
by	O
using	O
a	O
bicistronic	O
construct	O
coexpressing	O
the	O
herpes	O
simplex	O
virus	O
1	O
thymidine	O
kinase	O
.	O

S	O
.	O
c	O
.	O
injection	O
into	O
nude	O
mice	O
with	O
mixed	O
-	O
cell	O
populations	O
formed	O
tumors	O
that	O
approximate	O
the	O
ratio	O
of	O
vGPCR	O
-	O
expressing	O
and	O
KSHV	O
latent	O
gene	O
-	O
expressing	O
cells	O
.	O

These	O
mice	O
were	O
then	O
treated	O
with	O
ganciclovir	O
to	O
specifically	O
target	O
only	O
the	O
vGPCR	O
-	O
expressing	O
cells	O
.	O

Surprisingly	O
,	O
despite	O
the	O
expression	O
of	O
KSHV	O
latent	O
genes	O
in	O
the	O
vast	O
majority	O
of	O
tumor	O
cells	O
,	O
specifically	O
targeting	O
only	O
the	O
few	O
vGPCR	O
-	O
expressing	O
cells	O
in	O
established	O
tumors	O
resulted	O
in	O
tumor	O
regression	O
.	O

Moreover	O
,	O
we	O
observed	O
an	O
increase	O
in	O
apoptosis	O
of	O
latent	O
gene	O
-	O
expressing	O
cells	O
after	O
the	O
pharmacologic	O
deletion	O
of	O
the	O
vGPCR	O
-	O
expressing	O
cells	O
.	O

These	O
findings	O
indicate	O
that	O
vGPCR	O
may	O
play	O
a	O
key	O
role	O
in	O
Kaposi	O
'	O
s	O
sarcoma	O
progression	O
and	O
provide	O
experimental	O
justification	O
for	O
developing	O
molecular	O
-	O
based	O
therapies	O
specifically	O
targeting	O
vGPCR	O
and	O
its	O
effectors	O
for	O
the	O
treatment	O
of	O
Kaposi	O
'	O
s	O
sarcoma	O
patients	O
.	O

The	O
differential	O
regulation	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
p63	O
-	O
positive	O
breast	O
carcinomas	O
.	O

p63	O
,	O
a	O
p53	O
homologue	O
,	O
is	O
a	O
myoepithelial	O
cell	O
marker	O
in	O
the	O
normal	O
mammary	O
gland	O
but	O
p63	O
-	O
positive	O
neoplastic	O
cells	O
may	O
be	O
found	O
in	O
up	O
to	O
11	O
%	O
of	O
invasive	O
breast	O
carcinomas	O
.	O

This	O
study	O
aims	O
to	O
verify	O
the	O
relationship	O
between	O
p63	O
expression	O
and	O
several	O
clinicopathological	O
features	O
and	O
tumor	O
markers	O
of	O
clinical	O
significance	O
in	O
breast	O
pathology	O
including	O
key	O
regulators	O
of	O
the	O
cell	O
cycle	O
,	O
oncogenes	O
,	O
apoptosis	O
-	O
related	O
proteins	O
,	O
metalloproteinases	O
and	O
their	O
inhibitors	O
.	O

Immunohistochemistry	O
with	O
27	O
primary	O
antibodies	O
was	O
performed	O
in	O
100	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
samples	O
of	O
invasive	O
ductal	O
carcinomas	O
.	O

p63	O
-	O
positive	O
cells	O
were	O
found	O
in	O
16	O
%	O
of	O
carcinomas	O
.	O

p63	O
-	O
positive	O
carcinomas	O
were	O
poorly	O
differentiated	O
,	O
hormone	O
receptor	O
-	O
negative	O
neoplasms	O
with	O
a	O
high	O
proliferation	O
rate	O
.	O

p63	O
also	O
correlated	O
with	O
advanced	O
pathological	O
stage	O
,	O
tumor	O
size	O
,	O
and	O
the	O
expression	O
of	O
human	O
telomerase	O
reverse	O
transcriptase	O
(	O
hTERT	O
)	O
,	O
tissue	O
inhibitor	O
of	O
matrix	O
metalloproteinase	O
1	O
(	O
TIMP1	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

The	O
expression	O
of	O
TIMP1	O
suggests	O
that	O
the	O
anti	O
-	O
proteolytic	O
stimuli	O
may	O
be	O
preponderant	O
in	O
p63	O
-	O
positive	O
carcinomas	O
.	O

hTERT	O
activity	O
is	O
associated	O
with	O
nodal	O
metastases	O
and	O
cellular	O
proliferation	O
.	O

VEGF	O
regulates	O
angiogenesis	O
,	O
which	O
is	O
also	O
a	O
fundamental	O
event	O
in	O
the	O
process	O
of	O
tumor	O
growth	O
and	O
metastatic	O
dissemination	O
.	O

Thus	O
,	O
the	O
differential	O
regulation	O
of	O
hTERT	O
and	O
VEGF	O
in	O
p63	O
-	O
positive	O
breast	O
carcinomas	O
may	O
contribute	O
to	O
the	O
clinically	O
more	O
aggressive	O
behavior	O
of	O
these	O
neoplasms	O
.	O

Mechanisms	O
of	O
pericyte	O
recruitment	O
in	O
tumour	O
angiogenesis	O
:	O
a	O
new	O
role	O
for	O
metalloproteinases	O
.	O

Pericytes	O
occur	O
in	O
tumour	O
blood	O
vessels	O
and	O
are	O
critical	O
for	O
the	O
development	O
of	O
a	O
functional	O
vascular	O
network	O
.	O

Targeting	O
tumour	O
pericytes	O
is	O
a	O
promising	O
anti	O
-	O
angiogenic	O
therapy	O
but	O
requires	O
identifying	O
the	O
mechanisms	O
of	O
their	O
recruitment	O
in	O
tumour	O
and	O
addressing	O
whether	O
these	O
mechanisms	O
can	O
be	O
selectively	O
harnessed	O
.	O

Among	O
the	O
pathways	O
involved	O
in	O
pericyte	O
recruitment	O
during	O
embryonic	O
development	O
,	O
the	O
contribution	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
B	O
and	O
sphingosine	O
1	O
-	O
phosphate	O
is	O
confirmed	O
in	O
tumour	O
angiogenesis	O
.	O

The	O
effect	O
of	O
angiopoietin	O
1	O
depends	O
on	O
the	O
tumour	O
model	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta1	O
enhances	O
tumour	O
vascularization	O
and	O
microvessel	O
maturation	O
.	O

Recent	O
reports	O
suggest	O
a	O
participation	O
of	O
matrix	O
metalloproteinases	O
(	O
MMP	O
)	O
in	O
tumour	O
pericyte	O
recruitment	O
that	O
is	O
consistent	O
with	O
the	O
effect	O
of	O
certain	O
MMPs	O
in	O
the	O
development	O
of	O
microvasculature	O
in	O
embryonic	O
development	O
and	O
in	O
in	O
vitro	O
models	O
of	O
vascular	O
remodelling	O
.	O

Here	O
,	O
we	O
discuss	O
the	O
possibility	O
for	O
MMPs	O
to	O
contribute	O
to	O
pericyte	O
recruitment	O
at	O
six	O
levels	O
:	O
(	O
1	O
)	O
direct	O
promotion	O
of	O
pericyte	O
invasion	O
by	O
extracellular	O
matrix	O
degradation	O
;	O
(	O
2	O
)	O
stimulation	O
of	O
pericyte	O
proliferation	O
and	O
protection	O
against	O
apoptosis	O
by	O
modification	O
of	O
the	O
ECM	O
;	O
(	O
3	O
)	O
activation	O
of	O
pericytes	O
through	O
the	O
release	O
of	O
growth	O
factor	O
bound	O
to	O
the	O
ECM	O
;	O
(	O
4	O
)	O
transactivation	O
of	O
angiogenic	O
cell	O
surface	O
receptor	O
;	O
(	O
5	O
)	O
propagation	O
of	O
angiogenic	O
signalling	O
as	O
cofactor	O
;	O
and	O
(	O
6	O
)	O
recruitment	O
of	O
bone	O
marrow	O
-	O
derived	O
stem	O
cells	O
.	O

Regulation	O
of	O
tumor	O
angiogenesis	O
by	O
thrombospondin	O
-	O
1	O
.	O

Angiogenesis	O
plays	O
a	O
critical	O
role	O
in	O
the	O
growth	O
and	O
metastasis	O
of	O
tumors	O
.	O

Thrombospondin	O
-	O
1	O
(	O
TSP	O
-	O
1	O
)	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
,	O
and	O
down	O
-	O
regulation	O
of	O
TSP	O
-	O
1	O
has	O
been	O
suggested	O
to	O
alter	O
tumor	O
growth	O
by	O
modulating	O
angiogenesis	O
in	O
a	O
variety	O
of	O
tumor	O
types	O
.	O

Expression	O
of	O
TSP	O
-	O
1	O
is	O
up	O
-	O
regulated	O
by	O
the	O
tumor	O
suppressor	O
gene	O
,	O
p53	O
,	O
and	O
down	O
-	O
regulated	O
by	O
oncogenes	O
such	O
as	O
Myc	O
and	O
Ras	O
.	O

TSP	O
-	O
1	O
inhibits	O
angiogenesis	O
by	O
inhibiting	O
endothelial	O
cell	O
migration	O
and	O
proliferation	O
and	O
by	O
inducing	O
apoptosis	O
.	O

In	O
addition	O
,	O
activation	O
of	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
by	O
TSP	O
-	O
1	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
tumor	O
progression	O
.	O

An	O
understanding	O
of	O
the	O
molecular	O
basis	O
of	O
TSP	O
-	O
1	O
-	O
mediated	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	O
progression	O
will	O
aid	O
in	O
the	O
development	O
of	O
novel	O
therapeutics	O
for	O
the	O
treatment	O
of	O
cancer	O
.	O

Regulation	O
of	O
the	O
composition	O
of	O
the	O
extracellular	O
matrix	O
by	O
low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
:	O
activities	O
based	O
on	O
regulation	O
of	O
mRNA	O
expression	O
.	O

Low	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
-	O
1	O
(	O
LRP	O
-	O
1	O
)	O
is	O
a	O
catabolic	O
receptor	O
for	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
structural	O
proteins	O
and	O
for	O
proteins	O
that	O
bind	O
to	O
ECM	O
.	O

LRP	O
-	O
1	O
also	O
is	O
implicated	O
in	O
integrin	O
maturation	O
.	O

In	O
this	O
study	O
,	O
we	O
applied	O
a	O
proteomics	O
strategy	O
to	O
identify	O
novel	O
proteins	O
involved	O
in	O
ECM	O
modeling	O
that	O
are	O
regulated	O
by	O
LRP	O
-	O
1	O
.	O

We	O
show	O
that	O
LRP	O
-	O
1	O
deficiency	O
in	O
murine	O
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
is	O
associated	O
with	O
increased	O
levels	O
of	O
type	O
III	O
collagen	O
and	O
pigment	O
epithelium	O
-	O
derived	O
factor	O
,	O
which	O
accumulate	O
in	O
the	O
substratum	O
surrounding	O
cells	O
.	O

The	O
collagen	O
receptor	O
,	O
uPAR	O
-	O
AP	O
/	O
Endo	O
-	O
180	O
,	O
is	O
also	O
increased	O
in	O
LRP	O
-	O
1	O
-	O
deficient	O
MEFs	O
.	O

Human	O
LRP	O
-	O
1	O
reversed	O
the	O
changes	O
in	O
protein	O
expression	O
associated	O
with	O
LRP	O
-	O
1	O
deficiency	O
;	O
however	O
,	O
the	O
endocytic	O
activity	O
of	O
LRP	O
-	O
1	O
was	O
not	O
involved	O
.	O

Instead	O
,	O
regulation	O
occurred	O
at	O
the	O
mRNA	O
level	O
.	O

Inhibition	O
of	O
c	O
-	O
Jun	O
amino	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
blocked	O
type	O
III	O
collagen	O
expression	O
in	O
LRP	O
-	O
1	O
-	O
deficient	O
MEFs	O
,	O
suggesting	O
regulation	O
of	O
JNK	O
activity	O
as	O
a	O
mechanism	O
by	O
which	O
LRP	O
-	O
1	O
controls	O
mRNA	O
expression	O
.	O

The	O
ability	O
of	O
LRP	O
-	O
1	O
to	O
regulate	O
expression	O
of	O
the	O
factors	O
identified	O
here	O
suggests	O
a	O
role	O
for	O
LRP	O
-	O
1	O
in	O
determining	O
blood	O
vessel	O
structure	O
and	O
in	O
angiogenesis	O
.	O

Involvement	O
of	O
de	O
novo	O
ceramide	O
synthesis	O
in	O
radiocontrast	O
-	O
induced	O
renal	O
tubular	O
cell	O
injury	O
.	O

We	O
reported	O
previously	O
that	O
various	O
radiocontrast	O
media	O
cause	O
apoptosis	O
in	O
porcine	O
proximal	O
tubular	O
(	O
LLC	O
-	O
PK	O
(	O
1	O
)	O
)	O
cells	O
,	O
in	O
which	O
reduction	O
in	O
B	O
-	O
cell	O
lymphoma	O
(	O
Bcl	O
)	O
-	O
2	O
expression	O
and	O
caspase	O
-	O
3	O
activation	O
are	O
implicated	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
a	O
role	O
for	O
ceramide	O
in	O
radiocontrast	O
media	O
-	O
induced	O
apoptosis	O
in	O
renal	O
tubular	O
cells	O
.	O

LLC	O
-	O
PK	O
(	O
1	O
)	O
cells	O
were	O
exposed	O
to	O
radiocontrast	O
media	O
for	O
30	O
min	O
,	O
followed	O
by	O
incubation	O
for	O
24	O
h	O
in	O
normal	O
medium	O
.	O

Cell	O
viability	O
was	O
assessed	O
by	O
2	O
-	O
(	O
2	O
-	O
methoxy	O
-	O
4	O
-	O
nitrophenyl	O
)	O
-	O
3	O
-	O
(	O
4	O
-	O
nitrophenyl	O
)	O
-	O
5	O
-	O
(	O
2	O
,	O
4	O
-	O
disulfophenyl	O
)	O
-	O
2H	O
-	O
tetrazolium	O
monosodium	O
salt	O
assay	O
,	O
while	O
apoptosis	O
was	O
determined	O
by	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	O
nick	O
end	O
labeling	O
stain	O
.	O

Immunofluorescent	O
stains	O
were	O
performed	O
using	O
antibodies	O
against	O
phosphorylated	O
Akt	O
(	O
pAkt	O
)	O
and	O
cAMP	O
response	O
element	O
binding	O
protein	O
(	O
CREB	O
)	O
(	O
pCREB	O
)	O
,	O
and	O
ceramide	O
.	O

The	O
mRNA	O
expression	O
and	O
protein	O
content	O
of	O
Bcl	O
-	O
2	O
were	O
determined	O
by	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
and	O
enzyme	O
immunoassay	O
,	O
respectively	O
.	O

In	O
vivo	O
model	O
of	O
contrast	O
-	O
induced	O
renal	O
injury	O
was	O
induced	O
in	O
mice	O
with	O
unilateral	O
renal	O
occlusion	O
.	O

The	O
cell	O
injury	O
induced	O
by	O
the	O
nonionic	O
radiocontrast	O
medium	O
ioversol	O
was	O
reversed	O
by	O
inhibiting	O
de	O
novo	O
ceramide	O
synthesis	O
with	O
fumonisin	O
B	O
(	O
1	O
)	O
(	O
FB	O
(	O
1	O
)	O
)	O
and	O
L	O
-	O
cycloserine	O
,	O
but	O
not	O
by	O
suppressing	O
sphingomyelin	O
breakdown	O
with	O
D609	O
.	O

FB	O
(	O
1	O
)	O
reversed	O
ioversol	O
-	O
induced	O
decrease	O
in	O
the	O
immunoreactivities	O
of	O
pAkt	O
and	O
pCREB	O
,	O
reduction	O
in	O
Bcl	O
-	O
2	O
expression	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Like	O
ioversol	O
,	O
C2	O
ceramide	O
and	O
the	O
Akt	O
inhibitor	O
Src	O
homology	O
-	O
6	O
induced	O
apoptosis	O
by	O
reducing	O
pAkt	O
and	O
pCREB	O
-	O
like	O
immunoreactivities	O
,	O
lowering	O
Bcl	O
-	O
2	O
expression	O
and	O
enhancing	O
caspase	O
-	O
3	O
activity	O
.	O

Indeed	O
,	O
various	O
radiocontrast	O
media	O
,	O
excluding	O
iodixanol	O
which	O
showed	O
the	O
least	O
nephrotoxicity	O
,	O
enhanced	O
ceramide	O
-	O
like	O
immunoreactivity	O
.	O

The	O
role	O
for	O
de	O
novo	O
ceramide	O
synthesis	O
was	O
also	O
shown	O
in	O
the	O
in	O
vivo	O
model	O
of	O
radiocontrast	O
nephropathy	O
.	O

We	O
demonstrated	O
here	O
for	O
the	O
first	O
time	O
that	O
the	O
enhancement	O
of	O
de	O
novo	O
ceramide	O
synthesis	O
contributes	O
to	O
radiocontrast	O
nephropathy	O
.	O

Decrease	O
in	O
c	O
-	O
Myc	O
activity	O
enhances	O
cancer	O
cell	O
sensitivity	O
to	O
vinblastine	O
.	O

The	O
c	O
-	O
myc	O
oncogene	O
encodes	O
for	O
a	O
transcriptional	O
factor	O
involved	O
in	O
many	O
cellular	O
processes	O
such	O
as	O
proliferation	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

According	O
to	O
these	O
different	O
functions	O
,	O
the	O
role	O
of	O
c	O
-	O
Myc	O
protein	O
in	O
cellular	O
sensitivity	O
to	O
anti	O
-	O
cancer	O
drugs	O
is	O
controversial	O
.	O

We	O
defined	O
the	O
role	O
of	O
c	O
-	O
Myc	O
in	O
cancer	O
cell	O
sensitivity	O
to	O
vinblastine	O
(	O
VLB	O
)	O
using	O
human	O
colon	O
cancer	O
cells	O
:	O
LoVo	B
wild	O
-	O
type	O
or	O
transfected	O
with	O
a	O
plasmid	O
containing	O
the	O
human	O
c	O
-	O
myc	O
gene	O
in	O
antisense	O
orientation	O
(	O
LoVo	B
-	O
mycANS	O
)	O
.	O

Analysis	O
of	O
VLB	O
cytotoxicity	O
demonstrated	O
a	O
3	O
-	O
fold	O
increase	O
in	O
VLB	O
sensitivity	O
in	O
LoVo	B
-	O
mycANS	O
cells	O
.	O

Comparison	O
between	O
cells	O
revealed	O
different	O
apoptosis	O
kinetics	O
:	O
accumulation	O
of	O
cells	O
in	O
sub	O
-	O
G1	O
phase	O
and	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
cleavage	O
occurred	O
earlier	O
in	O
LoVo	B
-	O
mycANS	O
.	O

Then	O
,	O
we	O
demonstrated	O
a	O
mitochondrial	O
membrane	O
potential	O
disruption	O
followed	O
by	O
cytochrome	O
c	O
release	O
that	O
indicates	O
the	O
involvement	O
of	O
mitochondria	O
in	O
this	O
apoptotic	O
signaling	O
pathway	O
.	O

This	O
earlier	O
apoptosis	O
was	O
accompanied	O
by	O
a	O
Bcl	O
-	O
2	O
decrease	O
and	O
a	O
p53	O
increase	O
.	O

In	O
conclusion	O
,	O
the	O
decrease	O
in	O
c	O
-	O
Myc	O
expression	O
enhanced	O
the	O
VLB	O
sensitivity	O
,	O
triggering	O
earlier	O
apoptosis	O
through	O
induction	O
of	O
the	O
intrinsic	O
pathway	O
.	O

Thus	O
,	O
c	O
-	O
myc	O
induction	O
is	O
a	O
resistance	O
factor	O
and	O
our	O
findings	O
suggest	O
that	O
tumors	O
carrying	O
low	O
levels	O
of	O
c	O
-	O
Myc	O
protein	O
could	O
be	O
more	O
responsive	O
to	O
vinca	O
alkaloids	O
treatment	O
.	O

Moreover	O
,	O
the	O
downregulation	O
of	O
c	O
-	O
myc	O
oncogene	O
by	O
an	O
antisense	O
strategy	O
might	O
represent	O
a	O
useful	O
goal	O
for	O
improving	O
the	O
efficacy	O
of	O
this	O
anti	O
-	O
neoplastic	O
drug	O
family	O
.	O

Sensitization	O
to	O
gimatecan	O
-	O
induced	O
apoptosis	O
by	O
tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
in	O
prostate	O
carcinoma	O
cells	O
.	O

Since	O
the	O
intrinsic	O
resistance	O
of	O
prostate	O
carcinoma	O
likely	O
reflects	O
a	O
low	O
susceptibility	O
to	O
drug	O
-	O
induced	O
apoptosis	O
,	O
in	O
this	O
study	O
we	O
explored	O
the	O
possibility	O
of	O
sensitizing	O
prostate	O
carcinoma	O
cells	O
to	O
apoptosis	O
by	O
combination	O
of	O
TRAIL	O
with	O
camptothecins	O
.	O

Indeed	O
,	O
these	O
agents	O
are	O
known	O
to	O
activate	O
different	O
pathways	O
of	O
apoptosis	O
.	O

Topotecan	O
-	O
and	O
gimatecan	O
induced	O
moderate	O
up	O
-	O
regulation	O
of	O
TRAIL	O
-	O
R1	O
and	O
-	O
R2	O
which	O
resulted	O
in	O
a	O
different	O
cell	O
response	O
to	O
the	O
combination	O
in	O
androgen	O
-	O
independent	O
cells	O
(	O
DU	B
-	I
145	I
and	O
PC	B
-	I
3	I
)	O
.	O

In	O
DU	B
-	I
145	I
cells	O
apoptosis	O
was	O
increased	O
by	O
lower	O
TRAIL	O
concentrations	O
and	O
was	O
earlier	O
than	O
in	O
PC	B
-	I
3	I
cells	O
,	O
as	O
shown	O
using	O
Annexin	O
V	O
-	O
binding	O
assay	O
.	O

The	O
relative	O
resistance	O
of	O
PC	B
-	I
3	I
cells	O
to	O
drug	O
-	O
induced	O
apoptosis	O
was	O
associated	O
with	O
constitutive	O
Akt	O
activation	O
,	O
higher	O
levels	O
of	O
cFLIP	O
-	O
L	O
and	O
Bcl	O
-	O
2	O
,	O
and	O
lower	O
levels	O
of	O
Bax	O
.	O

The	O
different	O
expression	O
/	O
activation	O
of	O
apoptosis	O
-	O
related	O
factors	O
appears	O
to	O
influence	O
the	O
sensitization	O
of	O
prostate	O
carcinoma	O
cells	O
by	O
TRAIL	O
.	O

Potentiation	O
of	O
camptothecin	O
-	O
induced	O
apoptosis	O
by	O
TRAIL	O
appears	O
dependent	O
on	O
cooperation	O
between	O
extrinsic	O
and	O
intrinsic	O
pathways	O
,	O
as	O
documented	O
by	O
loss	O
of	O
the	O
sensitization	O
to	O
apoptosis	O
following	O
reduction	O
of	O
caspase	O
8	O
after	O
small	O
interfering	O
RNA	O
transfection	O
.	O

The	O
efficacy	O
of	O
the	O
approach	O
may	O
be	O
critically	O
dependent	O
on	O
the	O
intrinsic	O
susceptibility	O
to	O
apoptosis	O
of	O
different	O
tumors	O
.	O

These	O
observations	O
support	O
that	O
the	O
activation	O
of	O
multiple	O
signals	O
could	O
enhance	O
apoptotic	O
response	O
and	O
suggest	O
the	O
therapeutic	O
interest	O
of	O
the	O
TRAIL	O
/	O
camptothecin	O
combination	O
.	O

c	O
-	O
Met	O
expression	O
is	O
regulated	O
by	O
Mitf	O
in	O
the	O
melanocyte	O
lineage	O
.	O

Hepatocyte	O
growth	O
factor	O
(	O
HGF	O
)	O
/	O
c	O
-	O
Met	O
signaling	O
is	O
thought	O
to	O
be	O
a	O
key	O
pathway	O
in	O
both	O
melanocyte	O
development	O
and	O
melanoma	O
metastasis	O
.	O

Here	O
,	O
HGF	O
stimulation	O
of	O
melanocytes	O
was	O
seen	O
to	O
up	O
-	O
regulate	O
c	O
-	O
Met	O
expression	O
.	O

In	O
an	O
effort	O
to	O
decipher	O
the	O
mechanism	O
by	O
which	O
HGF	O
up	O
-	O
regulates	O
its	O
receptor	O
,	O
we	O
found	O
that	O
c	O
-	O
Met	O
is	O
a	O
direct	O
transcriptional	O
target	O
of	O
Mitf	O
.	O

This	O
was	O
confirmed	O
with	O
chromatin	O
immunoprecipitation	O
experiments	O
of	O
the	O
human	O
c	O
-	O
Met	O
promoter	O
,	O
as	O
well	O
as	O
by	O
the	O
ability	O
of	O
adenovirally	O
expressed	O
Mitf	O
to	O
modulate	O
endogenous	O
c	O
-	O
Met	O
protein	O
levels	O
in	O
melanocytes	O
.	O

Disruption	O
of	O
Mitf	O
blocked	O
HGF	O
-	O
dependent	O
increases	O
in	O
endogenous	O
c	O
-	O
Met	O
message	O
and	O
protein	O
levels	O
,	O
indicating	O
that	O
HGF	O
regulates	O
its	O
own	O
receptor	O
levels	O
via	O
Mitf	O
.	O

Finally	O
,	O
dominant	O
-	O
negative	O
inhibition	O
of	O
Mitf	O
resulted	O
in	O
profound	O
resistance	O
of	O
melanocytes	O
and	O
melanoma	O
cells	O
to	O
HGF	O
-	O
dependent	O
matrix	O
invasion	O
,	O
suggesting	O
a	O
physiologic	O
role	O
for	O
this	O
pathway	O
in	O
melanocytic	O
development	O
and	O
melanoma	O
.	O

L	O
-	O
Carnitine	O
ameliorates	O
methotrexate	O
-	O
induced	O
oxidative	O
organ	O
injury	O
and	O
inhibits	O
leukocyte	O
death	O
.	O

Methotrexate	O
(	O
MTX	O
)	O
,	O
a	O
folic	O
acid	O
antagonist	O
widely	O
used	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
tumors	O
and	O
inflammatory	O
diseases	O
,	O
affects	O
normal	O
tissues	O
that	O
have	O
a	O
high	O
rate	O
of	O
proliferation	O
,	O
including	O
the	O
hematopoietic	O
cells	O
of	O
the	O
bone	O
marrow	O
and	O
the	O
gastrointestinal	O
mucosal	O
cells	O
.	O

To	O
elucidate	O
the	O
role	O
of	O
free	O
radicals	O
and	O
leukocytes	O
in	O
MTX	O
-	O
induced	O
oxidative	O
organ	O
damage	O
and	O
the	O
putative	O
protective	O
effect	O
of	O
L	O
-	O
carnitine	O
(	O
L	O
-	O
Car	O
)	O
,	O
Wistar	O
albino	O
rats	O
were	O
administered	O
a	O
single	O
dose	O
of	O
MTX	O
(	O
20	O
mg	O
/	O
kg	O
)	O
followed	O
by	O
either	O
saline	O
or	O
L	O
-	O
Car	O
(	O
500	O
mg	O
/	O
kg	O
)	O
for	O
5	O
days	O
.	O

After	O
decapitation	O
of	O
the	O
rats	O
,	O
trunk	O
blood	O
was	O
obtained	O
,	O
and	O
the	O
ileum	O
,	O
liver	O
,	O
and	O
kidney	O
were	O
removed	O
for	O
histological	O
examination	O
and	O
for	O
the	O
measurement	O
of	O
malondialdehyde	O
(	O
MDA	O
)	O
and	O
glutathione	O
(	O
GSH	O
)	O
levels	O
,	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
,	O
and	O
collagen	O
content	O
.	O

Our	O
results	O
showed	O
that	O
MTX	O
administration	O
increased	O
the	O
MDA	O
and	O
MPO	O
activities	O
and	O
collagen	O
content	O
and	O
decreased	O
GSH	O
levels	O
in	O
all	O
tissues	O
,	O
while	O
these	O
alterations	O
were	O
reversed	O
in	O
L	O
-	O
Car	O
-	O
treated	O
group	O
.	O

The	O
elevated	O
serum	O
TNF	O
-	O
alpha	O
level	O
observed	O
following	O
MTX	O
treatment	O
was	O
depressed	O
with	O
L	O
-	O
Car	O
.	O

The	O
oxidative	O
burst	O
of	O
neutrophils	O
stimulated	O
by	O
Annexin	O
V	O
was	O
reduced	O
in	O
the	O
saline	O
-	O
treated	O
MTX	O
group	O
,	O
while	O
L	O
-	O
Car	O
abolished	O
this	O
inhibition	O
.	O

Similarly	O
,	O
flow	O
cytometric	O
measurements	O
revealed	O
that	O
leukocyte	O
apoptosis	O
was	O
increased	O
in	O
MTX	O
-	O
treated	O
animals	O
,	O
while	O
L	O
-	O
Car	O
reversed	O
these	O
effects	O
.	O

Severe	O
degeneration	O
of	O
the	O
intestinal	O
mucosa	O
,	O
liver	O
parenchyma	O
,	O
and	O
glomerular	O
and	O
tubular	O
epithelium	O
observed	O
in	O
the	O
saline	O
-	O
treated	O
MTX	O
group	O
was	O
improved	O
by	O
L	O
-	O
Car	O
treatment	O
.	O

These	O
results	O
suggest	O
that	O
L	O
-	O
Car	O
,	O
possibly	O
via	O
its	O
free	O
radical	O
scavenging	O
and	O
antioxidant	O
properties	O
,	O
ameliorates	O
MTX	O
-	O
induced	O
oxidative	O
organ	O
injury	O
and	O
inhibits	O
leukocyte	O
apoptosis	O
.	O

Thus	O
,	O
supplementation	O
with	O
L	O
-	O
Carnitine	O
as	O
an	O
adjuvant	O
therapy	O
may	O
be	O
promising	O
in	O
alleviating	O
the	O
systemic	O
side	O
-	O
effects	O
of	O
chemotherapeutics	O
.	O

Pericytes	O
limit	O
tumor	O
cell	O
metastasis	O
.	O

Previously	O
we	O
observed	O
that	O
neural	O
cell	O
adhesion	O
molecule	O
(	O
NCAM	O
)	O
deficiency	O
in	O
beta	O
tumor	O
cells	O
facilitates	O
metastasis	O
into	O
distant	O
organs	O
and	O
local	O
lymph	O
nodes	O
.	O

Here	O
,	O
we	O
show	O
that	O
NCAM	O
-	O
deficient	O
beta	O
cell	O
tumors	O
grew	O
leaky	O
blood	O
vessels	O
with	O
perturbed	O
pericyte	O
-	O
endothelial	O
cell	O
-	O
cell	O
interactions	O
and	O
deficient	O
perivascular	O
deposition	O
of	O
ECM	O
components	O
.	O

Conversely	O
,	O
tumor	O
cell	O
expression	O
of	O
NCAM	O
in	O
a	O
fibrosarcoma	O
model	O
(	O
T241	O
)	O
improved	O
pericyte	O
recruitment	O
and	O
increased	O
perivascular	O
deposition	O
of	O
ECM	O
molecules	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
NCAM	O
may	O
limit	O
tumor	O
cell	O
metastasis	O
by	O
stabilizing	O
the	O
microvessel	O
wall	O
.	O

To	O
directly	O
address	O
whether	O
pericyte	O
dysfunction	O
increases	O
the	O
metastatic	O
potential	O
of	O
solid	O
tumors	O
,	O
we	O
studied	O
beta	O
cell	O
tumorigenesis	O
in	O
primary	O
pericyte	O
-	O
deficient	O
Pdgfb	O
(	O
ret	O
/	O
ret	O
)	O
mice	O
.	O

This	O
resulted	O
in	O
beta	O
tumor	O
cell	O
metastases	O
in	O
distant	O
organs	O
and	O
local	O
lymph	O
nodes	O
,	O
demonstrating	O
a	O
role	O
for	O
pericytes	O
in	O
limiting	O
tumor	O
cell	O
metastasis	O
.	O

These	O
data	O
support	O
a	O
new	O
model	O
for	O
how	O
tumor	O
cells	O
trigger	O
metastasis	O
by	O
perturbing	O
pericyte	O
-	O
endothelial	O
cell	O
-	O
cell	O
interactions	O
.	O

NF	O
-	O
kappaB	O
and	O
IKK	O
as	O
therapeutic	O
targets	O
in	O
cancer	O
.	O

The	O
transcription	O
factor	O
NF	O
-	O
kappaB	O
and	O
associated	O
regulatory	O
factors	O
(	O
including	O
IkappaB	O
kinase	O
subunits	O
and	O
the	O
IkappaB	O
family	O
member	O
Bcl	O
-	O
3	O
)	O
are	O
strongly	O
implicated	O
in	O
a	O
variety	O
of	O
hematologic	O
and	O
solid	O
tumor	O
malignancies	O
.	O

A	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
cancer	O
cells	O
appears	O
to	O
involve	O
regulation	O
of	O
cell	O
proliferation	O
,	O
control	O
of	O
apoptosis	O
,	O
promotion	O
of	O
angiogenesis	O
,	O
and	O
stimulation	O
of	O
invasion	O
/	O
metastasis	O
.	O

Consistent	O
with	O
a	O
role	O
for	O
NF	O
-	O
kappaB	O
in	O
oncogenesis	O
are	O
observations	O
that	O
inhibition	O
of	O
NF	O
-	O
kappaB	O
alone	O
or	O
in	O
combination	O
with	O
cancer	O
therapies	O
leads	O
to	O
tumor	O
cell	O
death	O
or	O
growth	O
inhibition	O
.	O

However	O
,	O
other	O
experimental	O
data	O
indicate	O
that	O
NF	O
-	O
kappaB	O
can	O
play	O
a	O
tumor	O
suppressor	O
role	O
in	O
certain	O
settings	O
and	O
that	O
it	O
can	O
be	O
important	O
in	O
promoting	O
an	O
apoptotic	O
signal	O
downstream	O
of	O
certain	O
cancer	O
therapy	O
regimens	O
.	O

In	O
order	O
to	O
appropriately	O
move	O
NF	O
-	O
kappaB	O
inhibitors	O
in	O
the	O
clinic	O
,	O
thorough	O
approaches	O
must	O
be	O
initiated	O
to	O
determine	O
the	O
molecular	O
mechanisms	O
that	O
dictate	O
the	O
complexity	O
of	O
oncologic	O
and	O
therapeutic	O
outcomes	O
that	O
are	O
controlled	O
by	O
NF	O
-	O
kappaB	O
.	O

Runx2	O
and	O
MYC	O
collaborate	O
in	O
lymphoma	O
development	O
by	O
suppressing	O
apoptotic	O
and	O
growth	O
arrest	O
pathways	O
in	O
vivo	O
.	O

Members	O
of	O
the	O
Runx	O
and	O
MYC	O
families	O
have	O
been	O
implicated	O
as	O
collaborating	O
oncogenes	O
.	O

The	O
mechanism	O
of	O
this	O
potent	O
collaboration	O
is	O
elucidated	O
in	O
this	O
study	O
of	O
Runx2	O
/	O
MYC	O
mice	O
.	O

As	O
shown	O
previously	O
,	O
ectopic	O
expression	O
of	O
Runx2	O
in	O
the	O
thymus	O
leads	O
to	O
a	O
preneoplastic	O
state	O
defined	O
by	O
an	O
accumulation	O
of	O
cells	O
with	O
an	O
immature	O
phenotype	O
and	O
a	O
low	O
proliferative	O
rate	O
.	O

We	O
now	O
show	O
that	O
c	O
-	O
MYC	O
overexpression	O
is	O
sufficient	O
to	O
rescue	O
proliferation	O
and	O
to	O
release	O
the	O
differentiation	O
block	O
imposed	O
by	O
Runx2	O
.	O

Analysis	O
of	O
Runx2	O
-	O
expressing	O
lymphomas	O
reveals	O
a	O
consistently	O
low	O
rate	O
of	O
apoptosis	O
,	O
in	O
contrast	O
to	O
lymphomas	O
of	O
MYC	O
mice	O
which	O
are	O
often	O
highly	O
apoptotic	O
.	O

The	O
low	O
apoptosis	O
phenotype	O
is	O
dominant	O
in	O
Runx2	O
/	O
MYC	O
tumors	O
,	O
indicating	O
that	O
Runx2	O
confers	O
a	O
potent	O
survival	O
advantage	O
to	O
MYC	O
-	O
expressing	O
tumor	O
cells	O
.	O

The	O
role	O
of	O
the	O
p53	O
pathway	O
in	O
Runx2	O
/	O
MYC	O
tumors	O
was	O
explored	O
on	O
a	O
p53	O
heterozygote	O
background	O
.	O

Surprisingly	O
,	O
functional	O
p53	O
was	O
retained	O
in	O
vivo	O
,	O
even	O
after	O
transplantation	O
,	O
whereas	O
explanted	O
tumor	O
cells	O
displayed	O
rapid	O
allele	O
loss	O
in	O
vitro	O
.	O

Our	O
results	O
show	O
that	O
Runx2	O
and	O
MYC	O
overcome	O
distinct	O
""""	O
fail	O
-	O
safe	O
""""	O
responses	O
and	O
that	O
their	O
selection	O
as	O
collaborating	O
genes	O
is	O
due	O
to	O
their	O
ability	O
to	O
neutralize	O
each	O
other	O
'	O
s	O
negative	O
growth	O
effect	O
.	O

Furthermore	O
,	O
the	O
Runx2	O
/	O
MYC	O
combination	O
overcomes	O
the	O
requirement	O
for	O
genetic	O
inactivation	O
of	O
the	O
p53	O
pathway	O
in	O
vivo	O
.	O

Inhibition	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
by	O
rapamycin	O
increases	O
chemosensitivity	O
of	O
CaSki	B
cells	O
to	O
paclitaxel	O
.	O

Paclitaxel	O
,	O
a	O
potent	O
anti	O
-	O
neoplastic	O
agent	O
,	O
has	O
been	O
found	O
to	O
be	O
effective	O
against	O
several	O
tumours	O
,	O
including	O
cervical	O
cancer	O
.	O

However	O
,	O
the	O
exact	O
mechanism	O
underlying	O
the	O
cytotoxic	O
effects	O
of	O
pacitaxel	O
,	O
especially	O
in	O
the	O
survival	O
-	O
signalling	O
pathway	O
,	O
is	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
molecular	O
pathway	O
of	O
the	O
cytotoxic	O
effect	O
of	O
paclitaxel	O
in	O
human	O
cervical	O
cancer	O
cell	O
lines	O
.	O

Four	O
human	O
cervical	O
cancer	O
cell	O
lines	O
were	O
treated	O
for	O
24	O
h	O
with	O
various	O
concentration	O
of	O
paclitaxel	O
,	O
and	O
the	O
sensitivity	O
was	O
analysed	O
by	O
an	O
MTT	O
assay	O
.	O

The	O
cell	O
cycle	O
progression	O
and	O
sub	O
-	O
G1	O
population	O
were	O
analysed	O
by	O
flow	O
cytometry	O
.	O

Apoptosis	O
was	O
further	O
measured	O
by	O
DNA	O
fragmentation	O
and	O
microscope	O
examination	O
.	O

The	O
protein	O
expression	O
was	O
determined	O
by	O
Western	O
blot	O
analysis	O
.	O

Our	O
results	O
showed	O
that	O
HeLa	B
cells	O
demonstrated	O
the	O
highest	O
sensitivity	O
to	O
paclitaxel	O
,	O
whereas	O
CaSki	B
cells	O
showed	O
the	O
lowest	O
.	O

In	O
cervical	O
cancer	O
cells	O
,	O
paclitaxel	O
induced	O
apoptosis	O
through	O
an	O
intrinsic	O
pathway	O
with	O
prior	O
G2	O
/	O
M	O
arrest	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
paclitaxel	O
downregulated	O
the	O
phosphorylation	O
of	O
Akt	O
in	O
both	O
HeLa	B
and	O
CaSki	B
cells	O
.	O

Interestingly	O
,	O
in	O
CaSki	B
cells	O
,	O
which	O
were	O
more	O
suggestive	O
of	O
a	O
resistant	O
phenotype	O
,	O
paclitaxel	O
induced	O
the	O
activation	O
of	O
mTOR	O
as	O
a	O
downstream	O
target	O
of	O
Akt	O
.	O

Pre	O
-	O
treatment	O
with	O
rapamycin	O
inhibited	O
activation	O
of	O
mTOR	O
signalling	O
and	O
significantly	O
enhanced	O
the	O
sensitivity	O
of	O
CaSki	B
cells	O
to	O
paclitaxel	O
by	O
increasing	O
apoptotic	O
cell	O
death	O
.	O

This	O
effect	O
was	O
mediated	O
,	O
at	O
least	O
partly	O
,	O
through	O
caspase	O
activation	O
.	O

Overall	O
,	O
paclitaxel	O
exerts	O
its	O
anti	O
-	O
tumour	O
effects	O
on	O
cervical	O
cancer	O
cells	O
by	O
inducing	O
apoptosis	O
through	O
intrinsic	O
pathway	O
,	O
and	O
rapamycin	O
targeted	O
to	O
mTOR	O
can	O
sensitise	O
paclitaxel	O
-	O
resistant	O
cervical	O
cancer	O
cells	O
.	O

Circulating	O
endothelial	O
cells	O
in	O
malignant	O
disease	O
.	O

Cancer	O
is	O
a	O
disease	O
largely	O
dependent	O
on	O
neoangiogenesis	O
.	O

Cancer	O
neoangiogenesis	O
is	O
often	O
disordered	O
and	O
abnormal	O
,	O
with	O
evidence	O
of	O
coexisting	O
vascular	O
endothelial	O
dysfunction	O
.	O

A	O
novel	O
method	O
of	O
assessing	O
vascular	O
endothelial	O
function	O
in	O
cancer	O
is	O
via	O
the	O
quantification	O
of	O
circulating	O
endothelial	O
cells	O
(	O
CEC	O
)	O
.	O

Unusual	O
in	O
healthy	O
individuals	O
,	O
their	O
presence	O
in	O
elevated	O
numbers	O
often	O
indicates	O
substantial	O
vascular	O
endothelial	O
perturbation	O
.	O

Another	O
interesting	O
cell	O
type	O
is	O
the	O
endothelial	O
progenitor	O
cell	O
(	O
EPC	O
)	O
,	O
whose	O
numbers	O
increase	O
in	O
the	O
presence	O
of	O
vascular	O
damage	O
.	O

Recent	O
research	O
suggests	O
that	O
EPCs	O
have	O
an	O
important	O
role	O
in	O
tumor	O
vasculogenesis	O
.	O

Another	O
marker	O
being	O
investigated	O
in	O
the	O
context	O
of	O
vascular	O
dysfunction	O
and	O
coagulopathy	O
is	O
the	O
endothelial	O
microparticle	O
(	O
EMP	O
)	O
.	O

Thus	O
,	O
CECs	O
,	O
EPCs	O
and	O
EMPs	O
may	O
represent	O
potentially	O
novel	O
methods	O
for	O
evaluating	O
the	O
vascular	O
status	O
of	O
cancer	O
patients	O
.	O

This	O
review	O
will	O
summarize	O
the	O
current	O
position	O
of	O
CECs	O
,	O
EPCs	O
and	O
EMPs	O
in	O
cell	O
biology	O
terms	O
,	O
with	O
particular	O
emphasis	O
on	O
their	O
relationship	O
to	O
malignant	O
disease	O
.	O

Targeting	O
PIM	O
kinases	O
impairs	O
survival	O
of	O
hematopoietic	O
cells	O
transformed	O
by	O
kinase	O
inhibitor	O
-	O
sensitive	O
and	O
kinase	O
inhibitor	O
-	O
resistant	O
forms	O
of	O
Fms	O
-	O
like	O
tyrosine	O
kinase	O
3	O
and	O
BCR	O
/	O
ABL	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
activation	O
of	O
the	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5	O
(	O
STAT5	O
)	O
plays	O
an	O
essential	O
role	O
in	O
leukemogenesis	O
mediated	O
through	O
constitutive	O
activated	O
protein	O
tyrosine	O
kinases	O
(	O
PTK	O
)	O
.	O

Because	O
PIM	O
-	O
1	O
is	O
a	O
STAT5	O
target	O
gene	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
family	O
of	O
PIM	O
serine	O
/	O
threonine	O
kinases	O
(	O
PIM	O
-	O
1	O
to	O
PIM	O
-	O
3	O
)	O
in	O
PTK	O
-	O
mediated	O
transformation	O
of	O
hematopoietic	O
cells	O
.	O

Ba	B
/	I
F3	I
cells	O
transformed	O
to	O
growth	O
factor	O
independence	O
by	O
various	O
oncogenic	O
PTKs	O
(	O
TEL	O
/	O
JAK2	O
,	O
TEL	O
/	O
TRKC	O
,	O
TEL	O
/	O
ABL	O
,	O
BCR	O
/	O
ABL	O
,	O
FLT3	O
-	O
ITD	O
,	O
and	O
H4	O
/	O
PDGFbetaR	O
)	O
show	O
abundant	O
expression	O
of	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
.	O

Suppression	O
of	O
PIM	O
-	O
1	O
activity	O
had	O
a	O
negligible	O
effect	O
on	O
transformation	O
.	O

In	O
contrast	O
,	O
expression	O
of	O
kinase	O
-	O
dead	O
PIM	O
-	O
2	O
mutant	O
(	O
PIM	O
-	O
2KD	O
)	O
led	O
to	O
a	O
rapid	O
decline	O
of	O
survival	O
in	O
Ba	B
/	I
F3	I
cells	O
transformed	O
by	O
FLT3	O
-	O
ITD	O
but	O
not	O
by	O
other	O
oncogenic	O
PTKs	O
tested	O
.	O

Coexpression	O
of	O
PIM	O
-	O
1KD	O
and	O
PIM	O
-	O
2KD	O
abrogated	O
growth	O
factor	O
-	O
independent	O
growth	O
of	O
Ba	B
/	I
F3	I
transformed	O
by	O
several	O
PTKs	O
,	O
including	O
BCR	O
/	O
ABL	O
.	O

Targeted	O
down	O
-	O
regulation	O
of	O
PIM	O
-	O
2	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
selectively	O
abrogated	O
survival	O
of	O
Ba	B
/	I
F3	I
cells	O
transformed	O
by	O
various	O
Fms	O
-	O
like	O
tyrosine	O
kinase	O
3	O
(	O
FLT3	O
)	O
-	O
activating	O
mutants	O
[	O
internal	O
tandem	O
duplication	O
(	O
ITD	O
)	O
and	O
kinase	O
domain	O
]	O
and	O
attenuated	O
growth	O
of	O
human	O
cell	O
lines	O
containing	O
FLT3	O
mutations	O
.	O

Interestingly	O
,	O
cells	O
transformed	O
by	O
FLT3	O
and	O
BCR	O
/	O
ABL	O
mutations	O
that	O
confer	O
resistance	O
to	O
small	O
-	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
were	O
still	O
sensitive	O
to	O
knockdown	O
of	O
PIM	O
-	O
2	O
,	O
or	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
by	O
RNAi	O
.	O

Our	O
observations	O
indicate	O
that	O
combined	O
inactivation	O
of	O
PIM	O
-	O
1	O
and	O
PIM	O
-	O
2	O
interferes	O
with	O
oncogenic	O
PTKs	O
and	O
suggest	O
that	O
PIMs	O
are	O
alternative	O
therapeutic	O
targets	O
in	O
PTK	O
-	O
mediated	O
leukemia	O
.	O

Targeting	O
the	O
PIM	O
kinase	O
family	O
could	O
provide	O
a	O
new	O
avenue	O
to	O
overcome	O
resistance	O
against	O
small	O
-	O
molecule	O
tyrosine	O
kinase	O
inhibitors	O
.	O

Complications	O
after	O
plate	O
fixation	O
of	O
phalangeal	O
fractures	O
.	O

PURPOSE	O
:	O

To	O
assess	O
the	O
complications	O
after	O
plate	O
fixation	O
of	O
phalangeal	O
fractures	O
,	O
their	O
correlation	O
with	O
the	O
type	O
of	O
injury	O
,	O
and	O
the	O
outcome	O
.	O

METHODS	O
:	O

We	O
retrospectively	O
reviewed	O
the	O
clinical	O
records	O
and	O
the	O
x	O
-	O
rays	O
of	O
54	O
consecutive	O
patients	O
with	O
64	O
phalangeal	O
fractures	O
treated	O
by	O
open	O
reduction	O
and	O
plate	O
fixation	O
with	O
regard	O
to	O
fracture	O
healing	O
,	O
plate	O
loosening	O
or	O
failure	O
,	O
infection	O
,	O
complex	O
regional	O
pain	O
syndrome	O
,	O
pain	O
,	O
return	O
to	O
work	O
,	O
and	O
range	O
of	O
motion	O
.	O

RESULTS	O
:	O

In	O
31	O
out	O
of	O
54	O
patients	O
(	O
57	O
%	O
)	O
and	O
33	O
out	O
of	O
64	O
fractures	O
(	O
52	O
%	O
)	O
,	O
one	O
or	O
more	O
major	O
complications	O
occurred	O
.	O

Stiffness	O
(	O
definition	O
is	O
composite	O
range	O
of	O
motion	O
of	O
metaphalangeal	O
,	O
proximal	O
interphalangeal	O
,	O
and	O
distal	O
interphalangeal	O
joints	O
added	O
together	O
equaling	O
<	O
180	O
degrees	O
)	O
contributed	O
the	O
highest	O
number	O
(	O
22	O
patients	O
,	O
24	O
fractures	O
)	O
.	O

The	O
complication	O
rates	O
were	O
not	O
different	O
whether	O
the	O
fracture	O
was	O
open	O
or	O
closed	O
,	O
if	O
it	O
was	O
located	O
in	O
the	O
proximal	O
or	O
middle	O
phalanx	O
,	O
the	O
presence	O
or	O
absence	O
of	O
an	O
associated	O
soft	O
tissue	O
lesion	O
,	O
and	O
the	O
patient	O
'	O
s	O
occupation	O
.	O

CONCLUSIONS	O
:	O

In	O
spite	O
of	O
early	O
mobilization	O
,	O
stiffness	O
is	O
the	O
most	O
frequent	O
complication	O
after	O
open	O
reduction	O
and	O
plate	O
fixation	O
of	O
phalangeal	O
fractures	O
.	O

The	O
undue	O
amount	O
of	O
scarring	O
and	O
adhesion	O
may	O
arise	O
from	O
the	O
implant	O
itself	O
or	O
the	O
difficulty	O
in	O
finding	O
the	O
perfect	O
mixture	O
between	O
the	O
minimal	O
surgical	O
invasiveness	O
and	O
a	O
sufficient	O
restoration	O
of	O
skeletal	O
stability	O
.	O

Otherwise	O
,	O
plate	O
fixation	O
of	O
unstable	O
and	O
complex	O
phalangeal	O
fractures	O
proved	O
efficient	O
and	O
reliable	O
,	O
although	O
not	O
free	O
of	O
potential	O
problems	O
.	O

A	O
potential	O
role	O
for	O
the	O
Src	O
-	O
like	O
adapter	O
protein	O
SLAP	O
-	O
2	O
in	O
signaling	O
by	O
the	O
colony	O
stimulating	O
factor	O
-	O
1	O
receptor	O
.	O

The	O
development	O
of	O
macrophages	O
from	O
myeloid	O
progenitor	O
cells	O
is	O
primarily	O
controlled	O
by	O
the	O
growth	O
factor	O
colony	O
stimulating	O
factor	O
-	O
1	O
(	O
CSF	O
-	O
1	O
)	O
and	O
its	O
cognate	O
receptor	O
,	O
a	O
transmembrane	O
tyrosine	O
kinase	O
encoded	O
by	O
the	O
c	O
-	O
Fms	O
proto	O
-	O
oncogene	O
.	O

The	O
CSF	O
-	O
1	O
receptor	O
exerts	O
its	O
biological	O
effects	O
on	O
cells	O
via	O
a	O
range	O
of	O
signaling	O
proteins	O
including	O
Erk1	O
/	O
2	O
and	O
Akt	O
.	O

Here	O
we	O
have	O
investigated	O
the	O
potential	O
involvement	O
of	O
the	O
Src	O
-	O
like	O
adapter	O
protein	O
(	O
SLAP	O
-	O
2	O
)	O
in	O
signaling	O
by	O
the	O
CSF	O
-	O
1	O
receptor	O
in	O
mouse	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
.	O

RT	O
-	O
PCR	O
analysis	O
revealed	O
constitutive	O
expression	O
of	O
the	O
SLAP	O
-	O
2	O
gene	O
in	O
bone	O
marrow	O
macrophages	O
.	O

Surprisingly	O
,	O
co	O
-	O
immunoprecipitation	O
and	O
GST	O
binding	O
experiments	O
demonstrated	O
that	O
the	O
CSF	O
-	O
1	O
receptor	O
could	O
bind	O
to	O
SLAP	O
-	O
2	O
in	O
a	O
ligand	O
-	O
independent	O
manner	O
.	O

Furthermore	O
,	O
the	O
binding	O
of	O
SLAP	O
-	O
2	O
to	O
the	O
CSF	O
-	O
1	O
receptor	O
involved	O
multiple	O
domains	O
of	O
SLAP	O
-	O
2	O
.	O

SLAP	O
-	O
2	O
also	O
bound	O
c	O
-	O
Cbl	O
,	O
with	O
the	O
interaction	O
being	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
unique	O
C	O
-	O
terminal	O
domain	O
of	O
SLAP	O
-	O
2	O
.	O

Overexpression	O
of	O
SLAP	O
-	O
2	O
in	O
bone	O
marrow	O
macrophages	O
partially	O
suppressed	O
the	O
CSF	O
-	O
1	O
-	O
induced	O
tyrosine	O
phosphorylation	O
and	O
/	O
or	O
expression	O
level	O
of	O
a	O
approximately	O
80	O
kDa	O
protein	O
without	O
affecting	O
CSF	O
-	O
1	O
-	O
induced	O
global	O
tyrosine	O
phosphorylation	O
,	O
or	O
activation	O
of	O
Akt	O
or	O
Erk1	O
/	O
2	O
.	O

Significantly	O
,	O
CSF	O
-	O
1	O
stimulation	O
induced	O
serine	O
phosphorylation	O
of	O
SLAP	O
-	O
2	O
.	O

Pharmacologic	O
inhibition	O
of	O
specific	O
protein	O
kinases	O
revealed	O
that	O
CSF	O
-	O
1	O
-	O
induced	O
phosphorylation	O
of	O
SLAP	O
-	O
2	O
was	O
dependent	O
on	O
JNK	O
activity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
SLAP	O
-	O
2	O
could	O
potentially	O
be	O
involved	O
in	O
signaling	O
by	O
the	O
CSF	O
-	O
1	O
receptor	O
.	O

The	O
ictal	O
bradycardia	O
syndrome	O
:	O
localization	O
and	O
lateralization	O
.	O

PURPOSE	O
:	O

Previous	O
studies	O
have	O
established	O
the	O
importance	O
of	O
the	O
insular	O
cortex	O
and	O
temporal	O
lobe	O
in	O
cardiovascular	O
autonomic	O
modulation	O
.	O

Some	O
investigators	O
,	O
based	O
on	O
the	O
results	O
of	O
cortical	O
stimulation	O
response	O
,	O
functional	O
imaging	O
,	O
EEG	O
recordings	O
of	O
seizures	O
,	O
and	O
lesional	O
studies	O
,	O
have	O
suggested	O
that	O
cardiac	O
sympathetic	O
and	O
parasympathetic	O
function	O
may	O
be	O
lateralized	O
,	O
with	O
sympathetic	O
representation	O
lateralized	O
to	O
the	O
right	O
insula	O
,	O
and	O
parasympathetic	O
,	O
to	O
the	O
left	O
.	O

These	O
studies	O
have	O
suggested	O
that	O
ictal	O
bradycardia	O
is	O
most	O
commonly	O
a	O
manifestation	O
of	O
activation	O
of	O
the	O
left	O
temporal	O
and	O
insular	O
cortex	O
.	O

However	O
,	O
the	O
evidence	O
for	O
this	O
is	O
inconsistent	O
.	O

We	O
sought	O
to	O
assess	O
critically	O
the	O
predictable	O
value	O
of	O
ictal	O
bradycardia	O
for	O
seizure	O
localization	O
and	O
lateralization	O
.	O

METHODS	O
:	O

In	O
this	O
study	O
,	O
we	O
reviewed	O
the	O
localization	O
of	O
seizure	O
activity	O
in	O
13	O
consecutive	O
patients	O
with	O
ictal	O
bradycardia	O
diagnosed	O
during	O
prolonged	O
video	O
-	O
EEG	O
monitoring	O
at	O
Mayo	O
Clinic	O
Rochester	O
.	O

The	O
localization	O
of	O
electrographic	O
seizure	O
activity	O
at	O
seizure	O
onset	O
and	O
bradycardia	O
onset	O
was	O
identified	O
in	O
all	O
patients	O
.	O

In	O
addition	O
,	O
we	O
performed	O
a	O
comprehensive	O
review	O
of	O
the	O
ictal	O
bradycardia	O
literature	O
focusing	O
on	O
localization	O
of	O
seizure	O
activity	O
in	O
ictal	O
bradycardia	O
cases	O
.	O

RESULTS	O
:	O

All	O
occurrences	O
of	O
ictal	O
bradycardia	O
in	O
the	O
13	O
identified	O
patients	O
were	O
associated	O
with	O
temporal	O
lobe	O
-	O
onset	O
seizures	O
.	O

However	O
,	O
no	O
consistent	O
lateralization	O
of	O
seizure	O
activity	O
was	O
found	O
at	O
onset	O
of	O
seizure	O
activity	O
or	O
at	O
onset	O
of	O
bradycardia	O
in	O
this	O
population	O
.	O

Seizure	O
activity	O
was	O
bilateral	O
at	O
bradycardia	O
onset	O
in	O
nine	O
of	O
13	O
patients	O
.	O

The	O
results	O
from	O
the	O
literature	O
review	O
also	O
showed	O
that	O
a	O
predominance	O
of	O
patients	O
had	O
bilateral	O
activity	O
at	O
bradycardia	O
onset	O
;	O
however	O
,	O
more	O
of	O
the	O
ictal	O
bradycardia	O
cases	O
from	O
the	O
literature	O
had	O
left	O
hemispheric	O
localization	O
of	O
seizure	O
onset	O
.	O

CONCLUSIONS	O
:	O

Ictal	O
bradycardia	O
most	O
often	O
occurs	O
in	O
association	O
with	O
bilateral	O
hemispheric	O
seizure	O
activity	O
and	O
is	O
not	O
a	O
consistent	O
lateralizing	O
sign	O
in	O
localizing	O
seizure	O
onset	O
.	O

Our	O
data	O
do	O
not	O
support	O
the	O
existence	O
of	O
a	O
strictly	O
unilateral	O
parasympathetic	O
cardiomotor	O
representation	O
in	O
the	O
left	O
hemisphere	O
,	O
as	O
has	O
been	O
suggested	O
.	O

Ectopic	O
localization	O
of	O
mitochondrial	O
ATP	O
synthase	O
:	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
intervention	O
?	O

A	O
receptor	O
for	O
angiostatin	O
was	O
identified	O
on	O
the	O
surface	O
of	O
endothelial	O
cells	O
as	O
F	O
(	O
1	O
)	O
-	O
F	O
(	O
0	O
)	O
ATP	O
synthase	O
(	O
Moser	O
et	O
al	O
.	O
,	O
1999	O
)	O
.	O

Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U	O
.	O
S	O
.	O
A	O
.	O

96	O
,	O
2811	O
-	O
2816	O
.	O

This	O
ectopic	O
ATP	O
synthase	O
catalyzes	O
ATP	O
synthesis	O
and	O
is	O
inhibited	O
by	O
angiostatin	O
over	O
a	O
wide	O
pH	O
range	O
.	O

Endothelial	O
cells	O
grown	O
at	O
normal	O
pH	O
suffer	O
no	O
ill	O
effects	O
from	O
this	O
angiostatin	O
-	O
mediated	O
inhibition	O
of	O
ATP	O
synthase	O
,	O
whereas	O
endothelial	O
cells	O
grown	O
at	O
low	O
,	O
tumor	O
-	O
like	O
extracellular	O
pH	O
can	O
not	O
maintain	O
a	O
normal	O
intracellular	O
pH	O
and	O
die	O
.	O

Angiostatin	O
inhibits	O
both	O
ATP	O
synthesis	O
and	O
ATP	O
hydrolysis	O
(	O
Moser	O
et	O
al	O
.	O
,	O
2001	O
)	O
and	O
interferes	O
with	O
intracellular	O
pH	O
regulation	O
(	O
Wahl	O
and	O
Grant	O
,	O
2002	O
;	O
Wahl	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

Although	O
angiostatin	O
administered	O
intravenously	O
is	O
cleared	O
from	O
the	O
circulation	O
in	O
a	O
matter	O
of	O
minutes	O
,	O
angiostatin	O
-	O
mimetics	O
that	O
are	O
more	O
stable	O
have	O
potential	O
for	O
clinical	O
application	O
.	O

An	O
angiostatin	O
-	O
mimetic	O
activity	O
has	O
recently	O
been	O
observed	O
using	O
a	O
polyclonal	O
antibody	O
against	O
the	O
beta	O
catalytic	O
subunit	O
of	O
ATP	O
synthase	O
.	O

In	O
order	O
to	O
explore	O
the	O
mechanism	O
of	O
action	O
of	O
angiostatin	O
and	O
its	O
mimetics	O
,	O
further	O
work	O
needs	O
to	O
be	O
done	O
to	O
evaluate	O
clinical	O
applicability	O
,	O
specificity	O
,	O
and	O
contraindications	O
for	O
this	O
class	O
of	O
therapeutics	O
.	O

Hepatitis	O
B	O
virus	O
integration	O
event	O
in	O
human	O
chromosome	O
17p	O
near	O
the	O
p53	O
gene	O
identifies	O
the	O
region	O
of	O
the	O
chromosome	O
commonly	O
deleted	O
in	O
virus	O
-	O
positive	O
hepatocellular	O
carcinomas	O
.	O

The	O
development	O
of	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
presumably	O
occurs	O
in	O
multiple	O
steps	O
and	O
is	O
influenced	O
by	O
numerous	O
factors	O
.	O

Hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
is	O
strongly	O
associated	O
with	O
the	O
development	O
of	O
HCC	O
in	O
people	O
chronically	O
infected	O
with	O
the	O
virus	O
,	O
but	O
the	O
mechanism	O
of	O
viral	O
involvement	O
remains	O
unclear	O
.	O

One	O
possibility	O
is	O
that	O
the	O
gross	O
chromosomal	O
alterations	O
frequently	O
observed	O
in	O
HCC	O
DNA	O
at	O
the	O
site	O
of	O
HBV	O
integration	O
may	O
alter	O
the	O
expression	O
of	O
important	O
nearby	O
cellular	O
genes	O
.	O

We	O
previously	O
reported	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
HBV	O
insert	O
from	O
a	O
Chinese	O
HCC	O
.	O

The	O
viral	O
insert	O
mapped	O
to	O
chromosome	O
17p11	O
.	O
2	O
-	O
12	O
,	O
and	O
cellular	O
sequences	O
were	O
duplicated	O
at	O
the	O
site	O
of	O
viral	O
integration	O
.	O

In	O
the	O
present	O
study	O
a	O
DNA	O
probe	O
derived	O
from	O
cellular	O
DNA	O
sequences	O
adjacent	O
to	O
the	O
previously	O
characterized	O
HBV	O
insert	O
was	O
used	O
to	O
analyze	O
a	O
set	O
of	O
19	O
matched	O
normal	O
liver	O
and	O
HBV	O
-	O
positive	O
hepatoma	O
samples	O
obtained	O
from	O
the	O
same	O
region	O
of	O
China	O
,	O
near	O
Shanghai	O
.	O

Tumor	O
-	O
specific	O
DNA	O
changes	O
were	O
detected	O
in	O
two	O
additional	O
HCCs	O
,	O
suggesting	O
that	O
the	O
small	O
region	O
of	O
chromosome	O
17p	O
defined	O
by	O
the	O
flanking	O
cell	O
DNA	O
probe	O
is	O
commonly	O
altered	O
in	O
hepatomas	O
.	O

Restriction	O
fragment	O
length	O
polymorphism	O
studies	O
demonstrated	O
that	O
the	O
loss	O
of	O
one	O
copy	O
of	O
portions	O
of	O
chromosome	O
17	O
occurred	O
in	O
10	O
(	O
53	O
%	O
)	O
of	O
the	O
19	O
patients	O
.	O

The	O
loss	O
of	O
one	O
allele	O
of	O
the	O
p53	O
gene	O
(	O
located	O
on	O
chromosome	O
17p13	O
)	O
occurred	O
in	O
at	O
least	O
6	O
(	O
60	O
%	O
)	O
of	O
the	O
10	O
patients	O
who	O
were	O
heterozygous	O
at	O
the	O
p53	O
locus	O
.	O

As	O
the	O
p53	O
gene	O
is	O
known	O
to	O
possess	O
tumor	O
suppressor	O
activity	O
,	O
the	O
functional	O
loss	O
of	O
this	O
gene	O
may	O
be	O
a	O
significant	O
step	O
in	O
the	O
development	O
of	O
a	O
subset	O
of	O
HCCs	O
.	O

High	O
levels	O
of	O
allele	O
loss	O
also	O
were	O
detected	O
for	O
chromosomes	O
8q	O
(	O
4	O
of	O
9	O
;	O
44	O
%	O
)	O
and	O
16p	O
(	O
5	O
of	O
6	O
;	O
83	O
%	O
)	O
and	O
may	O
indicate	O
the	O
presence	O
of	O
additional	O
cellular	O
genes	O
whose	O
functional	O
loss	O
is	O
important	O
in	O
the	O
development	O
of	O
HCCs	O
.	O

GDP	O
and	O
AGE	O
receptors	O
:	O
mechanisms	O
of	O
peritoneal	O
damage	O
.	O

Long	O
-	O
term	O
peritoneal	O
dialysis	O
(	O
PD	O
)	O
is	O
limited	O
by	O
morphological	O
changes	O
of	O
the	O
peritoneal	O
membrane	O
.	O

Structural	O
changes	O
were	O
promoted	O
by	O
toxicity	O
of	O
glucose	O
degradation	O
products	O
(	O
GDPs	O
)	O
which	O
are	O
generated	O
during	O
heat	O
sterilization	O
in	O
peritoneal	O
dialysis	O
fluids	O
(	O
PDFs	O
)	O
.	O

Besides	O
their	O
direct	O
toxicity	O
GDPs	O
promote	O
formation	O
of	O
advanced	O
glycation	O
endproducts	O
(	O
AGEs	O
)	O
.	O

RAGE	O
(	O
receptor	O
for	O
AGE	O
)	O
is	O
the	O
best	O
characterized	O
signal	O
transduction	O
receptor	O
for	O
AGEs	O
and	O
is	O
expressed	O
on	O
mesothelial	O
cells	O
.	O

The	O
effects	O
of	O
PDFs	O
with	O
different	O
amounts	O
of	O
GDPs	O
were	O
compared	O
on	O
morphological	O
changes	O
in	O
the	O
peritoneal	O
membrane	O
in	O
a	O
RAGE	O
-	O
/	O
-	O
mouse	O
model	O
.	O

It	O
could	O
be	O
demonstrated	O
that	O
RAGE	O
plays	O
a	O
pivotal	O
role	O
in	O
structural	O
damage	O
(	O
e	O
.	O
g	O
.	O
inflammation	O
,	O
neoangiogenesis	O
and	O
fibrosis	O
)	O
of	O
the	O
peritoneal	O
membrane	O
.	O

Further	O
investigations	O
of	O
this	O
pathway	O
with	O
regard	O
to	O
preventing	O
peritoneal	O
fibrosis	O
should	O
be	O
performed	O
to	O
maintain	O
the	O
integrity	O
of	O
the	O
peritoneal	O
membrane	O
in	O
peritoneal	O
dialysis	O
patients	O
.	O

Hyperfibrinogenemia	O
is	O
associated	O
with	O
lymphatic	O
as	O
well	O
as	O
hematogenous	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	O
gastric	O
cancer	O
.	O

BACKGROUND	O
:	O
Abnormal	O
hemostasis	O
in	O
cancer	O
patients	O
has	O
previously	O
been	O
described	O
,	O
however	O
the	O
correlation	O
between	O
the	O
plasma	O
fibrinogen	O
level	O
and	O
cancer	O
metastasis	O
and	O
prognosis	O
has	O
not	O
been	O
reported	O
in	O
a	O
large	O
-	O
scale	O
clinical	O
study	O
.	O

METHODS	O
:	O
Preoperative	O
plasma	O
fibrinogen	O
levels	O
were	O
retrospectively	O
examined	O
in	O
405	O
patients	O
who	O
underwent	O
surgery	O
for	O
advanced	O
gastric	O
cancer	O
.	O

The	O
association	O
of	O
fibrinogen	O
levels	O
with	O
clinical	O
/	O
pathological	O
findings	O
and	O
clinical	O
outcome	O
was	O
evaluated	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
positive	O
correlation	O
between	O
plasma	O
fibrinogen	O
levels	O
and	O
the	O
depth	O
of	O
invasion	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Hyperfibrinogenemia	O
(	O
>	O
310	O
mg	O
/	O
dl	O
)	O
was	O
independently	O
associated	O
with	O
lymph	O
node	O
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
342	O
,	O
P	O
=	O
0	O
.	O
0032	O
)	O
and	O
liver	O
(	O
Odds	O
Ratio	O
;	O
2	O
.	O
933	O
,	O
P	O
=	O
0	O
.	O
0147	O
)	O
metastasis	O
,	O
not	O
with	O
peritoneal	O
metastasis	O
in	O
this	O
series	O
.	O

Patients	O
with	O
hyperfibrinogenemia	O
showed	O
worse	O
clinical	O
outcome	O
in	O
T2	O
gastric	O
cancer	O
,	O
however	O
,	O
there	O
was	O
no	O
correlation	O
of	O
plasma	O
fibrinogen	O
level	O
with	O
prognosis	O
in	O
T3	O
/	O
T4	O
gastric	O
cancer	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
might	O
support	O
the	O
idea	O
that	O
hyperfibrinogenemia	O
can	O
augment	O
lymphatic	O
and	O
hematogeneous	O
metastasis	O
of	O
advanced	O
gastric	O
cancer	O
,	O
which	O
is	O
major	O
determinant	O
of	O
the	O
prognosis	O
in	O
T2	O
gastric	O
cancer	O
.	O

Therefore	O
,	O
in	O
the	O
situation	O
without	O
peritoneal	O
involvement	O
,	O
hyperfibrinogenemia	O
is	O
a	O
useful	O
biomarker	O
to	O
predict	O
the	O
possible	O
metastasis	O
and	O
worse	O
clinical	O
outcome	O
in	O
T2	O
gastric	O
cancer	O
.	O

Alteration	O
of	O
homeobox	O
gene	O
expression	O
by	O
N	O
-	O
ras	O
transformation	O
of	O
PA	B
-	I
1	I
human	O
teratocarcinoma	O
cells	O
.	O

We	O
used	O
a	O
series	O
of	O
cell	O
clones	O
from	O
a	O
human	O
teratocarcinoma	O
cell	O
line	O
,	O
PA	B
-	I
1	I
,	O
to	O
study	O
the	O
effect	O
of	O
transformation	O
by	O
an	O
activated	O
N	O
-	O
ras	O
oncogene	O
on	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
retinoic	O
acid	O
(	O
RA	O
)	O
-	O
induced	O
differentiation	O
and	O
growth	O
regulation	O
.	O

Recently	O
,	O
it	O
has	O
been	O
shown	O
that	O
expression	O
of	O
human	O
HOX	O
2	O
genes	O
is	O
sequentially	O
activated	O
by	O
RA	O
beginning	O
from	O
Hox	O
2	O
.	O
9	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
HOX	O
2	O
cluster	O
(	O
A	O
.	O
Simeone	O
,	O
D	O
.	O
Acampora	O
,	O
L	O
.	O
Arcioni	O
,	O
P	O
.	O
W	O
.	O
Andrews	O
,	O
E	O
.	O
Boncinelli	O
,	O
and	O
F	O
.	O
Mavilio	O
,	O
Nature	O
[	O
London	O
]	O
346	O
:	O
763	O
-	O
766	O
,	O
1990	O
)	O
.	O

We	O
now	O
report	O
that	O
six	O
different	O
genes	O
of	O
the	O
cluster	O
HOX	O
1	O
are	O
sequentially	O
induced	O
by	O
RA	O
in	O
a	O
similar	O
temporal	O
pattern	O
,	O
beginning	O
with	O
genes	O
at	O
the	O
3	O
'	O
end	O
of	O
the	O
cluster	O
.	O

However	O
,	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cell	O
clones	O
,	O
RA	O
-	O
induced	O
expression	O
of	O
these	O
homeobox	O
genes	O
is	O
delayed	O
.	O

Hox	O
1	O
.	O
4	O
and	O
Hox	O
1	O
.	O
3	O
,	O
genes	O
abundantly	O
induced	O
in	O
nontransformed	O
clones	O
after	O
3	O
days	O
of	O
RA	O
treatment	O
,	O
are	O
expressed	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	O
only	O
after	O
10	O
days	O
of	O
RA	O
treatment	O
.	O

At	O
this	O
time	O
,	O
the	O
cells	O
'	O
growth	O
is	O
arrested	O
at	O
very	O
high	O
density	O
,	O
and	O
no	O
differentiated	O
morphologic	O
characteristics	O
are	O
observed	O
.	O

Constitutive	O
expression	O
of	O
a	O
transfected	O
Hox	O
1	O
.	O
4	O
gene	O
under	O
the	O
control	O
of	O
a	O
simian	O
virus	O
40	O
promotor	O
leads	O
to	O
differentiated	O
cell	O
morphology	O
similar	O
to	O
that	O
of	O
the	O
RA	O
-	O
induced	O
phenotype	O
and	O
restores	O
the	O
growth	O
-	O
inhibitory	O
effects	O
of	O
RA	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	O
.	O

These	O
observations	O
provide	O
evidence	O
that	O
enhanced	O
proliferation	O
in	O
N	O
-	O
ras	O
-	O
transformed	O
cells	O
compromises	O
teratocarcinoma	O
cell	O
differentiation	O
by	O
a	O
mechanism	O
that	O
transiently	O
suppresses	O
homeobox	O
gene	O
induction	O
and	O
implies	O
a	O
central	O
role	O
for	O
homeobox	O
genes	O
in	O
RA	O
-	O
induced	O
cell	O
differentiation	O
.	O

We	O
conclude	O
that	O
stimulation	O
of	O
a	O
putative	O
growth	O
factor	O
signal	O
pathway	O
,	O
associated	O
with	O
ras	O
-	O
induced	O
proliferation	O
,	O
transiently	O
suppresses	O
the	O
induction	O
of	O
transcription	O
factors	O
functionally	O
involved	O
in	O
cell	O
growth	O
and	O
differentiation	O
.	O

Dendrimer	O
-	O
templated	O
Fe	O
nanoparticles	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
by	O
plasma	O
-	O
enhanced	O
CVD	O
.	O

A	O
fourth	O
-	O
generation	O
(	O
G4	O
)	O
poly	O
(	O
amidoamine	O
)	O
(	O
PAMAM	O
)	O
dendrimer	O
(	O
G4	O
-	O
NH2	O
)	O
has	O
been	O
used	O
as	O
a	O
template	O
to	O
deliver	O
nearly	O
monodispersed	O
catalyst	O
nanoparticles	O
to	O
SiO2	O
/	O
Si	O
,	O
Ti	O
/	O
Si	O
,	O
sapphire	O
,	O
and	O
porous	O
anodic	O
alumina	O
(	O
PAA	O
)	O
substrates	O
.	O

Fe2O3	O
nanoparticles	O
obtained	O
after	O
calcination	O
of	O
the	O
immobilized	O
Fe3	O
+	O
/	O
G4	O
-	O
NH2	O
composite	O
served	O
as	O
catalytic	O
""""	O
seeds	O
""""	O
for	O
the	O
growth	O
of	O
single	O
-	O
wall	O
carbon	O
nanotubes	O
(	O
SWNTs	O
)	O
by	O
microwave	O
plasma	O
-	O
enhanced	O
CVD	O
(	O
PECVD	O
)	O
.	O

To	O
surmount	O
the	O
difficulty	O
associated	O
with	O
SWNT	O
growth	O
via	O
PECVD	O
,	O
reaction	O
conditions	O
that	O
promote	O
the	O
stabilization	O
of	O
Fe	O
nanoparticles	O
,	O
resulting	O
in	O
enhanced	O
SWNT	O
selectivity	O
and	O
quality	O
,	O
have	O
been	O
identified	O
.	O

In	O
particular	O
,	O
in	O
situ	O
annealing	O
of	O
Fe	O
catalyst	O
in	O
an	O
N2	O
atmosphere	O
was	O
found	O
to	O
improve	O
SWNT	O
selectivity	O
and	O
quality	O
.	O

H2	O
prereduction	O
at	O
900	O
degrees	O
C	O
for	O
5	O
min	O
was	O
also	O
found	O
to	O
enhance	O
SWNT	O
selectivity	O
and	O
quality	O
for	O
SiO2	O
/	O
Si	O
supported	O
catalyst	O
,	O
albeit	O
of	O
lower	O
quality	O
for	O
sapphire	O
supported	O
catalyst	O
.	O

The	O
application	O
of	O
positive	O
dc	O
bias	O
voltage	O
(	O
+	O
200	O
V	O
)	O
during	O
SWNT	O
growth	O
was	O
shown	O
to	O
be	O
very	O
effective	O
in	O
removing	O
amorphous	O
carbon	O
impurities	O
while	O
enhancing	O
graphitization	O
,	O
SWNT	O
selectivity	O
,	O
and	O
vertical	O
alignment	O
.	O

The	O
results	O
of	O
this	O
study	O
should	O
promote	O
the	O
use	O
of	O
exposed	O
Fe	O
nanoparticles	O
supported	O
on	O
different	O
substrates	O
for	O
the	O
growth	O
of	O
high	O
-	O
quality	O
SWNTs	O
by	O
PECVD	O
.	O

Fluoro	O
-	O
Jade	O
B	O
staining	O
following	O
zymosan	O
microinjection	O
into	O
the	O
spinal	O
cord	O
white	O
matter	O
.	O

1	O
.	O

The	O
fluorescein	O
derivate	O
Fluoro	O
-	O
Jade	O
B	O
(	O
FJB	O
)	O
,	O
which	O
primarily	O
labels	O
dead	O
or	O
dying	O
neurons	O
,	O
was	O
used	O
to	O
study	O
the	O
acute	O
focal	O
inflammation	O
in	O
the	O
spinal	O
cord	O
white	O
matter	O
.	O

Inflammation	O
was	O
induced	O
by	O
microinjection	O
of	O
the	O
yeast	O
particulate	O
zymosan	O
to	O
evaluate	O
the	O
biological	O
effects	O
of	O
intraspinal	O
macrophages	O
activation	O
without	O
the	O
confounding	O
effects	O
of	O
physical	O
trauma	O
.	O

2	O
.	O

A	O
single	O
bolus	O
of	O
zymosan	O
(	O
Sigma	O
,	O
75	O
nL	O
)	O
was	O
stereotaxically	O
injected	O
at	O
the	O
thoracic	O
level	O
into	O
the	O
lateral	O
white	O
matter	O
of	O
rat	O
spinal	O
cord	O
.	O

A	O
standard	O
Fluoro	O
-	O
Jade	O
B	O
staining	O
protocol	O
was	O
applied	O
to	O
spinal	O
cord	O
sections	O
at	O
6	O
,	O
12	O
,	O
24	O
h	O
and	O
2	O
,	O
4	O
days	O
postinjection	O
.	O

Neutral	O
Red	O
,	O
NADPH	O
-	O
diaphorase	O
,	O
Iba1	O
-	O
IR	O
,	O
and	O
DAPI	O
staining	O
protocols	O
accomplished	O
examination	O
of	O
the	O
cells	O
participating	O
in	O
the	O
acute	O
inflammatory	O
response	O
.	O

3	O
.	O

Zymosan	O
caused	O
formation	O
of	O
clearly	O
delineated	O
inflammation	O
lesions	O
localized	O
in	O
the	O
lateral	O
white	O
matter	O
of	O
the	O
spinal	O
cord	O
.	O

Fluoro	O
-	O
Jade	O
B	O
stained	O
cells	O
in	O
the	O
area	O
of	O
inflammation	O
were	O
not	O
observed	O
at	O
12	O
h	O
postinjection	O
while	O
mild	O
FJB	O
staining	O
appeared	O
at	O
24	O
h	O
and	O
intense	O
staining	O
was	O
observed	O
at	O
2	O
and	O
4	O
days	O
postinjection	O
.	O

4	O
.	O

This	O
study	O
shows	O
that	O
the	O
acute	O
response	O
to	O
zymosan	O
-	O
induced	O
inflammation	O
in	O
the	O
rat	O
spinal	O
cord	O
white	O
matter	O
causes	O
a	O
gradual	O
appearance	O
of	O
phagocytic	O
microglia	O
/	O
macrophages	O
and	O
delayed	O
FJB	O
staining	O
of	O
the	O
inflammatory	O
cells	O
.	O

5	O
.	O

FJB	O
,	O
a	O
reliable	O
marker	O
of	O
dying	O
neurons	O
,	O
is	O
a	O
more	O
universal	O
agent	O
than	O
formerly	O
believed	O
.	O

One	O
possible	O
explanation	O
for	O
the	O
gradual	O
appearance	O
of	O
FJB	O
-	O
stained	O
cells	O
in	O
the	O
area	O
of	O
inflammation	O
is	O
that	O
specific	O
time	O
is	O
required	O
for	O
sufficient	O
levels	O
of	O
proteins	O
and	O
/	O
or	O
myelin	O
debris	O
of	O
axonal	O
origin	O
to	O
appear	O
in	O
the	O
cytoplasm	O
of	O
phagocytic	O
microglia	O
/	O
macrophages	O
.	O

Prostate	O
-	O
specific	O
membrane	O
antigen	O
regulates	O
angiogenesis	O
by	O
modulating	O
integrin	O
signal	O
transduction	O
.	O

The	O
transmembrane	O
peptidase	O
prostate	O
-	O
specific	O
membrane	O
antigen	O
(	O
PSMA	O
)	O
is	O
universally	O
upregulated	O
in	O
the	O
vasculature	O
of	O
solid	O
tumors	O
,	O
but	O
its	O
functional	O
role	O
in	O
tumor	O
angiogenesis	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
we	O
show	O
that	O
angiogenesis	O
is	O
severely	O
impaired	O
in	O
PSMA	O
-	O
null	O
animals	O
and	O
that	O
this	O
angiogenic	O
defect	O
occurs	O
at	O
the	O
level	O
of	O
endothelial	O
cell	O
invasion	O
through	O
the	O
extracellular	O
matrix	O
barrier	O
.	O

Because	O
proteolytic	O
degradation	O
of	O
the	O
extracellular	O
matrix	O
is	O
a	O
critical	O
component	O
of	O
endothelial	O
invasion	O
in	O
angiogenesis	O
,	O
it	O
is	O
logical	O
to	O
assume	O
that	O
PSMA	O
participates	O
in	O
matrix	O
degradation	O
.	O

However	O
,	O
we	O
demonstrate	O
a	O
novel	O
and	O
more	O
complex	O
role	O
for	O
PSMA	O
in	O
angiogenesis	O
,	O
where	O
it	O
is	O
a	O
principal	O
component	O
of	O
a	O
regulatory	O
loop	O
that	O
is	O
tightly	O
modulating	O
laminin	O
-	O
specific	O
integrin	O
signaling	O
and	O
GTPase	O
-	O
dependent	O
,	O
p21	O
-	O
activated	O
kinase	O
1	O
(	O
PAK	O
-	O
1	O
)	O
activity	O
.	O

We	O
show	O
that	O
PSMA	O
inhibition	O
,	O
knockdown	O
,	O
or	O
deficiency	O
decreases	O
endothelial	O
cell	O
invasion	O
in	O
vitro	O
via	O
integrin	O
and	O
PAK	O
,	O
thus	O
abrogating	O
angiogenesis	O
.	O

Interestingly	O
,	O
the	O
neutralization	O
of	O
beta	O
(	O
1	O
)	O
or	O
the	O
inactivation	O
of	O
PAK	O
increases	O
PSMA	O
activity	O
,	O
suggesting	O
that	O
they	O
negatively	O
regulate	O
PSMA	O
.	O

This	O
negative	O
regulation	O
is	O
mediated	O
by	O
the	O
cytoskeleton	O
as	O
the	O
disruption	O
of	O
interactions	O
between	O
the	O
PSMA	O
cytoplasmic	O
tail	O
and	O
the	O
anchor	O
protein	O
filamin	O
A	O
decreases	O
PSMA	O
activity	O
,	O
integrin	O
function	O
,	O
and	O
PAK	O
activation	O
.	O

Finally	O
,	O
the	O
inhibition	O
of	O
PAK	O
activation	O
enhances	O
the	O
PSMA	O
/	O
filamin	O
A	O
interaction	O
and	O
,	O
thus	O
,	O
boosts	O
PSMA	O
activity	O
.	O

These	O
data	O
imply	O
that	O
PSMA	O
participates	O
in	O
an	O
autoregulatory	O
loop	O
,	O
wherein	O
active	O
PSMA	O
facilitates	O
integrin	O
signaling	O
and	O
PAK	O
activation	O
,	O
leading	O
to	O
both	O
productive	O
invasion	O
and	O
downregulation	O
of	O
integrin	O
beta	O
(	O
1	O
)	O
signaling	O
via	O
reduced	O
PSMA	O
activity	O
.	O

Therefore	O
,	O
we	O
have	O
identified	O
a	O
novel	O
role	O
for	O
PSMA	O
as	O
a	O
true	O
molecular	O
interface	O
,	O
integrating	O
both	O
extracellular	O
and	O
intracellular	O
signals	O
during	O
angiogenesis	O
.	O

Defective	O
expression	O
of	O
HRK	O
is	O
associated	O
with	O
promoter	O
methylation	O
in	O
primary	O
central	O
nervous	O
system	O
lymphomas	O
.	O

OBJECTIVES	O
:	O
Recently	O
,	O
it	O
has	O
been	O
reported	O
that	O
expression	O
of	O
the	O
HRK	O
gene	O
was	O
significantly	O
reduced	O
by	O
hypermethylation	O
in	O
astrocytic	O
tumors	O
.	O

Our	O
aim	O
is	O
to	O
verify	O
the	O
alterations	O
in	O
the	O
HRK	O
gene	O
in	O
primary	O
central	O
nervous	O
system	O
lymphomas	O
(	O
PCNSLs	O
)	O
.	O

METHODS	O
:	O
We	O
analyzed	O
the	O
hypermethylation	O
status	O
and	O
expression	O
of	O
the	O
gene	O
and	O
12q13	O
.	O
1	O
loss	O
of	O
heterozygosity	O
in	O
31	O
PCNSLs	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
13	O
PCNSLs	O
(	O
31	O
%	O
)	O
demonstrated	O
hypermethylation	O
in	O
either	O
the	O
promoter	O
or	O
exon	O
1	O
;	O
loss	O
of	O
HRK	O
expression	O
was	O
immunohistochemically	O
observed	O
in	O
9	O
tumors	O
and	O
was	O
significantly	O
associated	O
with	O
promoter	O
methylation	O
.	O

In	O
addition	O
,	O
higher	O
apoptotic	O
counts	O
were	O
associated	O
with	O
HRK	O
positivity	O
.	O

PCNSLs	O
with	O
HRK	O
methylation	O
also	O
showed	O
methylation	O
of	O
multiple	O
genes	O
,	O
such	O
as	O
p14ARF	O
,	O
p16INK4a	O
,	O
RB1	O
,	O
p27Kip1	O
and	O
O6	O
-	O
MGMT	O
.	O

Patients	O
with	O
tumors	O
demonstrating	O
concurrent	O
methylation	O
of	O
more	O
than	O
half	O
of	O
their	O
genes	O
demonstrated	O
significantly	O
poorer	O
survival	O
and	O
earlier	O
recurrence	O
.	O

Hypermethylation	O
of	O
the	O
HRK	O
promoter	O
alone	O
was	O
not	O
associated	O
with	O
overall	O
outcome	O
,	O
but	O
relapse	O
-	O
free	O
survival	O
was	O
significantly	O
shorter	O
.	O

CONCLUSIONS	O
:	O
Our	O
findings	O
suggest	O
that	O
transcriptional	O
repression	O
of	O
HRK	O
is	O
caused	O
by	O
promoter	O
hypermethylation	O
in	O
PCNSL	O
,	O
and	O
that	O
the	O
loss	O
of	O
HRK	O
associated	O
with	O
the	O
methylation	O
profile	O
of	O
other	O
genes	O
is	O
a	O
potential	O
step	O
in	O
the	O
modulation	O
of	O
cellular	O
death	O
by	O
apoptosis	O
during	O
PCNSL	O
tumorigenesis	O
.	O

Changes	O
of	O
lymphocyte	O
subsets	O
in	O
leukemia	O
patients	O
who	O
received	O
allogenic	O
bone	O
marrow	O
transplantation	O
.	O

Proportional	O
changes	O
of	O
lymphocyte	O
subsets	O
in	O
the	O
peripheral	O
blood	O
were	O
monitored	O
by	O
two	O
-	O
color	O
flow	O
-	O
cytometry	O
in	O
seven	O
leukemia	O
patients	O
who	O
had	O
received	O
allogenic	O
bone	O
marrow	O
transplantation	O
(	O
BMT	O
)	O
.	O

Lymphocyte	O
counts	O
,	O
and	O
proportions	O
of	O
T	O
and	O
B	O
-	O
cells	O
returned	O
to	O
normal	O
ranges	O
between	O
the	O
2nd	O
and	O
12th	O
months	O
after	O
BMT	O
.	O

Activated	O
T	O
-	O
cells	O
prominently	O
increased	O
after	O
BMT	O
,	O
and	O
the	O
values	O
gradually	O
returned	O
toward	O
normal	O
.	O

As	O
to	O
lymphocyte	O
subsets	O
,	O
the	O
proportions	O
of	O
CD	O
4	O
+	O
cells	O
had	O
remained	O
low	O
,	O
while	O
those	O
of	O
CD	O
8	O
+	O
cells	O
high	O
for	O
a	O
whole	O
observation	O
period	O
after	O
BMT	O
.	O

The	O
changes	O
of	O
CD	O
4	O
+	O
cells	O
were	O
caused	O
by	O
the	O
decrease	O
of	O
suppressor	O
-	O
inducer	O
T	O
-	O
cells	O
(	O
CD	O
4	O
+	O
Leu	O
8	O
+	O
)	O
.	O

High	O
proportion	O
of	O
CD	O
8	O
+	O
cells	O
was	O
mainly	O
associated	O
with	O
increased	O
suppressor	O
T	O
-	O
cells	O
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O

Among	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
highly	O
active	O
NK	O
cells	O
(	O
CD	O
16	O
+	O
CD	O
57	O
-	O
)	O
markedly	O
increased	O
shortly	O
after	O
BMT	O
,	O
and	O
gradually	O
returned	O
to	O
normal	O
.	O

CD	O
16	O
-	O
CD	O
57	O
+	O
NK	O
cells	O
increased	O
beyond	O
normal	O
ranges	O
after	O
the	O
2nd	O
month	O
.	O

The	O
incidence	O
or	O
degree	O
of	O
acute	O
and	O
chronic	O
graft	O
-	O
versus	O
-	O
host	O
diseases	O
(	O
GVHD	O
)	O
did	O
not	O
correlate	O
with	O
the	O
changes	O
of	O
any	O
lymphocyte	O
subsets	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
increase	O
of	O
activated	O
T	O
-	O
cells	O
shortly	O
after	O
BMT	O
reflects	O
lymphocyte	O
reconstitution	O
.	O

The	O
prolonged	O
immune	O
deficiency	O
after	O
BMT	O
might	O
be	O
related	O
to	O
either	O
deficient	O
expression	O
of	O
homing	O
receptor	O
(	O
Leu	O
8	O
antigen	O
)	O
on	O
CD	O
4	O
+	O
cells	O
or	O
increased	O
suppressor	O
T	O
-	O
cells	O
(	O
CD	O
8	O
+	O
CD	O
11	O
+	O
)	O
.	O

In	O
addition	O
,	O
the	O
early	O
increase	O
of	O
NK	O
cells	O
after	O
BMT	O
may	O
compensate	O
for	O
the	O
immune	O
deficiency	O
in	O
BMT	O
patients	O
.	O

Fluoroscopically	O
guided	O
cervical	O
prolotherapy	O
for	O
instability	O
with	O
blinded	O
pre	O
and	O
post	O
radiographic	O
reading	O
.	O

BACKGROUND	O
:	O

Several	O
authors	O
have	O
postulated	O
that	O
cervical	O
instability	O
is	O
a	O
major	O
cause	O
of	O
traumatic	O
spinal	O
pain	O
.	O

OBJECTIVE	O
:	O

The	O
purpose	O
of	O
this	O
prospective	O
case	O
series	O
study	O
(	O
n	O
=	O
6	O
)	O
was	O
to	O
determine	O
if	O
proliferant	O
injections	O
have	O
an	O
effect	O
on	O
cervical	O
translation	O
as	O
measured	O
by	O
a	O
blinded	O
reader	O
.	O

DESIGN	O
:	O

This	O
study	O
was	O
a	O
prospective	O
case	O
series	O
.	O

Study	O
participants	O
were	O
selected	O
from	O
patients	O
seen	O
for	O
the	O
primary	O
complaint	O
of	O
Motor	O
Vehicle	O
Collision	O
related	O
neck	O
pain	O
in	O
a	O
private	O
sub	O
-	O
specialty	O
pain	O
clinic	O
.	O

METHODS	O
:	O

Flexion	O
and	O
extension	O
views	O
were	O
obtained	O
by	O
standard	O
radiographs	O
taken	O
with	O
a	O
C	O
-	O
Arm	O
fluoroscope	O
under	O
Valium	O
sedation	O
.	O

Patients	O
with	O
more	O
than	O
2	O
.	O
7	O
mm	O
of	O
absolute	O
cervical	O
translation	O
and	O
at	O
least	O
50	O
%	O
reduction	O
of	O
cervical	O
and	O
referred	O
pain	O
with	O
a	O
two	O
day	O
rigid	O
cervical	O
immobilization	O
test	O
were	O
admitted	O
into	O
the	O
study	O
.	O

Participants	O
underwent	O
3	O
prolotherapy	O
injections	O
at	O
all	O
sites	O
that	O
demonstrated	O
translation	O
.	O

The	O
difference	O
in	O
means	O
between	O
pre	O
-	O
test	O
and	O
post	O
-	O
test	O
measurements	O
(	O
flexion	O
translation	O
,	O
extension	O
translation	O
,	O
and	O
pain	O
VAS	O
scores	O
)	O
were	O
assessed	O
by	O
a	O
Wilcoxon	O
signed	O
ranks	O
test	O
(	O
alpha	O
=	O
0	O
.	O
05	O
)	O
.	O

RESULTS	O
:	O

The	O
mean	O
post	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
3	O
.	O
83	O
,	O
SD	O
=	O
2	O
.	O
3	O
,	O
t	O
=	O
2	O
.	O
889	O
)	O
was	O
significantly	O
less	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
than	O
the	O
mean	O
pre	O
-	O
test	O
VAS	O
score	O
(	O
M	O
=	O
5	O
.	O
75	O
,	O
SD	O
=	O
1	O
.	O
94	O
)	O
.	O

The	O
correlation	O
between	O
difference	O
in	O
mean	O
extension	O
at	O
C2	O
-	O
3	O
and	O
C5	O
-	O
6	O
and	O
difference	O
in	O
mean	O
extension	O
was	O
significant	O
(	O
rho	O
=	O
0	O
.	O
89	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
85	O
,	O
p	O
=	O
0	O
.	O
03	O
respectively	O
)	O
.	O

Difference	O
in	O
mean	O
flexion	O
at	O
C3	O
-	O
4	O
and	O
C4	O
-	O
5	O
was	O
significantly	O
correlated	O
with	O
difference	O
in	O
mean	O
flexion	O
(	O
rho	O
=	O
0	O
.	O
88	O
,	O
p	O
=	O
0	O
.	O
02	O
and	O
rho	O
=	O
0	O
.	O
941	O
,	O
p	O
<	O
0	O
.	O
01	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O

The	O
results	O
of	O
this	O
study	O
demonstrate	O
statistically	O
significant	O
correlations	O
between	O
proliferant	O
injections	O
,	O
a	O
reduction	O
of	O
both	O
cervical	O
flexion	O
and	O
extension	O
translation	O
,	O
as	O
well	O
as	O
a	O
reduction	O
in	O
pain	O
VAS	O
score	O
.	O

Since	O
patients	O
with	O
traumatic	O
cervical	O
instability	O
have	O
few	O
viable	O
treatment	O
options	O
other	O
than	O
surgical	O
fusion	O
,	O
cervical	O
proliferant	O
injections	O
under	O
C	O
-	O
Arm	O
fluoroscope	O
may	O
be	O
a	O
viable	O
treatment	O
option	O
.	O

Differential	O
mechanisms	O
of	O
radiosensitization	O
by	O
2	O
-	O
deoxy	O
-	O
D	O
-	O
glucose	O
in	O
the	O
monolayers	O
and	O
multicellular	O
spheroids	O
of	O
a	O
human	O
glioma	O
cell	O
line	O
.	O

In	O
vitro	O
studies	O
using	O
monolayer	O
cultures	O
of	O
human	O
tumor	O
cell	O
lines	O
have	O
shown	O
that	O
2	O
-	O
DG	O
selectively	O
inhibits	O
energy	O
-	O
dependent	O
DNA	O
repair	O
and	O
cellular	O
recovery	O
processes	O
in	O
cancer	O
cells	O
.	O

However	O
,	O
monolayer	O
cultures	O
differ	O
greatly	O
from	O
the	O
complex	O
environmental	O
conditions	O
generated	O
in	O
solid	O
tumors	O
that	O
develop	O
inhomogeneous	O
hypoxic	O
and	O
necrotic	O
regions	O
.	O

In	O
contrast	O
,	O
multicellular	O
spheroids	O
mimic	O
heterogeneous	O
cellular	O
behavior	O
and	O
the	O
consequent	O
functional	O
characteristics	O
of	O
in	O
vivo	O
solid	O
tumors	O
,	O
and	O
serve	O
as	O
important	O
in	O
vitro	O
model	O
to	O
investigate	O
tumor	O
biology	O
and	O
responses	O
to	O
potential	O
therapeutic	O
agents	O
.	O

The	O
present	O
study	O
compares	O
the	O
radiomodification	O
by	O
2	O
-	O
DG	O
in	O
monolayer	O
cultures	O
and	O
spheroids	O
of	O
a	O
human	O
glioma	O
cell	O
line	O
(	O
BMG	B
-	I
1	I
)	O
to	O
gain	O
insight	O
into	O
the	O
effects	O
in	O
solid	O
tumors	O
.	O

In	O
spheroids	O
,	O
the	O
glucose	O
consumption	O
(	O
2	O
.	O
1	O
p	O
mole	O
/	O
cell	O
/	O
h	O
)	O
and	O
lactate	O
production	O
(	O
3	O
.	O
67	O
p	O
mole	O
/	O
cell	O
/	O
h	O
)	O
was	O
nearly	O
2	O
-	O
3	O
fold	O
higher	O
than	O
in	O
monolayer	O
cells	O
(	O
0	O
.	O
83	O
and	O
1	O
.	O
43	O
p	O
mole	O
/	O
cell	O
/	O
h	O
respectively	O
)	O
.	O

Presence	O
of	O
2	O
-	O
DG	O
(	O
5	O
mM	O
)	O
for	O
2	O
-	O
4	O
h	O
inhibited	O
the	O
glucose	O
usage	O
and	O
lactate	O
production	O
by	O
70	O
%	O
in	O
spheroids	O
,	O
while	O
a	O
35	O
%	O
reduction	O
was	O
observed	O
in	O
monolayer	O
cells	O
.	O

Under	O
these	O
conditions	O
,	O
2	O
-	O
DG	O
drastically	O
enhanced	O
the	O
radiation	O
-	O
induced	O
cell	O
death	O
of	O
spheroids	O
(	O
by	O
2	O
-	O
3	O
folds	O
)	O
;	O
while	O
a	O
40	O
%	O
increase	O
was	O
observed	O
in	O
monolayer	O
cells	O
.	O

Radiosensitization	O
by	O
2	O
-	O
DG	O
in	O
monolayer	O
cells	O
was	O
primarily	O
due	O
to	O
an	O
increase	O
in	O
mitotic	O
death	O
(	O
23	O
%	O
)	O
linked	O
to	O
cytogenetic	O
damage	O
(	O
micronuclei	O
)	O
,	O
whereas	O
a	O
profound	O
induction	O
of	O
apoptosis	O
(	O
40	O
%	O
)	O
accounted	O
for	O
the	O
sensitization	O
in	O
spheroids	O
.	O

Although	O
the	O
Bcl	O
-	O
2	O
and	O
Bax	O
levels	O
were	O
significantly	O
higher	O
in	O
spheroids	O
,	O
Bcl	O
-	O
2	O
/	O
Bax	O
ratio	O
was	O
similar	O
in	O
monolayers	O
and	O
spheroids	O
.	O

Comet	O
assay	O
revealed	O
a	O
late	O
onset	O
of	O
DNA	O
breaks	O
in	O
the	O
presence	O
of	O
2	O
-	O
DG	O
following	O
irradiation	O
only	O
in	O
spheroids	O
,	O
which	O
corroborated	O
well	O
with	O
the	O
late	O
onset	O
of	O
oxidative	O
stress	O
.	O

2	O
-	O
DG	O
did	O
not	O
induce	O
a	O
significant	O
cell	O
cycle	O
delay	O
in	O
monolayers	O
,	O
while	O
a	O
transient	O
G	O
(	O
2	O
)	O
delay	O
was	O
apparent	O
in	O
spheroids	O
.	O

Heparin	O
immobilized	O
porous	O
PLGA	O
microspheres	O
for	O
angiogenic	O
growth	O
factor	O
delivery	O
.	O

PURPOSE	O
:	O
Heparin	O
immobilized	O
porous	O
poly	O
(	O
D	O
,	O
L	O
-	O
lactic	O
-	O
co	O
-	O
glycolic	O
acid	O
)	O
(	O
PLGA	O
)	O
microspheres	O
were	O
prepared	O
for	O
sustained	O
release	O
of	O
basic	O
fibroblast	O
growth	O
factor	O
(	O
bFGF	O
)	O
to	O
induce	O
angiogenesis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Porous	O
PLGA	O
microspheres	O
having	O
primary	O
amine	O
groups	O
on	O
the	O
surface	O
were	O
prepared	O
using	O
an	O
oil	O
-	O
in	O
-	O
water	O
(	O
O	O
/	O
W	O
)	O
single	O
emulsion	O
method	O
using	O
Pluronic	O
F	O
-	O
127	O
as	O
an	O
extractable	O
porogen	O
.	O

Heparin	O
was	O
surface	O
immobilized	O
via	O
covalent	O
conjugation	O
.	O

bFGF	O
was	O
loaded	O
into	O
the	O
heparin	O
functionalized	O
(	O
PLGA	O
-	O
heparin	O
)	O
microspheres	O
by	O
a	O
simple	O
dipping	O
method	O
.	O

The	O
bFGF	O
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
were	O
tested	O
for	O
in	O
vitro	O
release	O
and	O
in	O
vivo	O
angiogenic	O
activity	O
.	O

RESULTS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
-	O
porous	O
structure	O
were	O
formed	O
.	O

The	O
amount	O
of	O
conjugated	O
amine	O
group	O
onto	O
the	O
microspheres	O
was	O
1	O
.	O
93	O
+	O
/	O
-	O
0	O
.	O
01	O
nmol	O
/	O
mg	O
-	O
microspheres	O
,	O
while	O
the	O
amount	O
of	O
heparin	O
was	O
95	O
.	O
8	O
pmol	O
/	O
mg	O
-	O
microspheres	O
.	O

PLGA	O
-	O
heparin	O
microspheres	O
released	O
out	O
bFGF	O
in	O
a	O
more	O
sustained	O
manner	O
with	O
a	O
smaller	O
extent	O
of	O
initial	O
burst	O
than	O
PLGA	O
microspheres	O
,	O
indicating	O
that	O
surface	O
immobilized	O
heparin	O
controlled	O
the	O
release	O
rate	O
of	O
bFGF	O
.	O

Subcutaneous	O
implantation	O
of	O
bFGF	O
loaded	O
PLGA	O
-	O
heparin	O
microspheres	O
in	O
mice	O
significantly	O
induced	O
the	O
formation	O
of	O
new	O
vascular	O
microvessels	O
.	O

CONCLUSIONS	O
:	O
PLGA	O
microspheres	O
with	O
an	O
open	O
porous	O
structure	O
allowed	O
significant	O
amount	O
of	O
heparin	O
immobilization	O
and	O
bFGF	O
loading	O
.	O

bFGF	O
loaded	O
PLGA	O
-	O
HP	O
microspheres	O
showed	O
sustained	O
release	O
profiles	O
of	O
bFGF	O
in	O
vitro	O
,	O
demonstrating	O
reversible	O
and	O
specific	O
binding	O
of	O
bFGF	O
to	O
immobilized	O
heparin	O
.	O

They	O
also	O
induced	O
local	O
angiogenesis	O
in	O
vivo	O
in	O
an	O
animal	O
model	O
.	O

[	O
Autologous	O
bone	O
marrow	O
stem	O
cell	O
or	O
peripheral	O
blood	O
endothelial	O
progenitor	O
cell	O
therapy	O
in	O
patients	O
with	O
peripheral	O
limb	O
ischaemia	O
]	O

No	O
effective	O
medical	O
therapies	O
have	O
been	O
developed	O
sofar	O
to	O
enhance	O
blood	O
flow	O
in	O
the	O
legs	O
of	O
patients	O
with	O
peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
.	O

For	O
patients	O
with	O
limb	O
threatening	O
ischaemia	O
the	O
only	O
option	O
for	O
relief	O
of	O
rest	O
pain	O
or	O
gangraena	O
is	O
amputation	O
.	O

There	O
is	O
evidence	O
in	O
experimental	O
and	O
clinical	O
studies	O
that	O
adult	O
bone	O
marrow	O
-	O
derived	O
stem	O
cells	O
and	O
endothelial	O
progenitor	O
cells	O
participate	O
in	O
the	O
development	O
of	O
new	O
blood	O
vessels	O
,	O
called	O
neoangiogenesis	O
or	O
neovascularization	O
.	O

Clinical	O
results	O
induced	O
by	O
autologous	O
bone	O
marrow	O
stem	O
cells	O
or	O
angiogenic	O
growth	O
/	O
differentiation	O
factors	O
in	O
end	O
-	O
stage	O
patients	O
with	O
PAD	O
are	O
summarized	O
.	O

Considering	O
the	O
relatively	O
few	O
number	O
of	O
patients	O
treated	O
by	O
angiogenic	O
therapy	O
,	O
the	O
interpretation	O
of	O
clinical	O
results	O
needs	O
cautiousness	O
.	O

Formation	O
of	O
new	O
bone	O
during	O
vertical	O
distraction	O
osteogenesis	O
of	O
the	O
human	O
mandible	O
is	O
related	O
to	O
the	O
presence	O
of	O
blood	O
vessels	O
.	O

We	O
examined	O
the	O
effect	O
of	O
distraction	O
rate	O
on	O
blood	O
vessel	O
growth	O
in	O
intramembraneous	O
ossification	O
after	O
vertical	O
distraction	O
osteogenesis	O
in	O
the	O
human	O
mandible	O
.	O

Six	O
edentulous	O
patients	O
(	O
aged	O
60	O
+	O
/	O
-	O
9	O
years	O
)	O
with	O
a	O
severely	O
atrophic	O
mandible	O
underwent	O
bone	O
augmentation	O
with	O
distraction	O
osteogenesis	O
.	O

Two	O
distraction	O
rates	O
(	O
0	O
.	O
5	O
and	O
1	O
mm	O
/	O
day	O
)	O
were	O
compared	O
and	O
for	O
each	O
group	O
three	O
patients	O
were	O
analyzed	O
.	O

Vascular	O
histomorphometry	O
was	O
carried	O
out	O
in	O
two	O
different	O
areas	O
in	O
the	O
distraction	O
gap	O
:	O
(	O
1	O
)	O
in	O
the	O
first	O
and	O
(	O
2	O
)	O
in	O
the	O
second	O
1	O
mm	O
area	O
from	O
the	O
osteotomy	O
line	O
,	O
representing	O
the	O
oldest	O
and	O
younger	O
new	O
-	O
bone	O
area	O
,	O
respectively	O
.	O

Correlation	O
analysis	O
was	O
performed	O
between	O
blood	O
vessel	O
parameters	O
and	O
the	O
amount	O
of	O
new	O
bone	O
formed	O
during	O
distraction	O
.	O

Histological	O
analysis	O
demonstrated	O
the	O
presence	O
of	O
blood	O
vessels	O
throughout	O
the	O
soft	O
connective	O
tissue	O
in	O
the	O
distraction	O
gap	O
.	O

The	O
volume	O
density	O
of	O
blood	O
vessels	O
between	O
the	O
two	O
investigated	O
areas	O
was	O
significantly	O
lower	O
in	O
the	O
1	O
mm	O
/	O
day	O
groups	O
,	O
suggesting	O
a	O
delay	O
in	O
angiogenesis	O
in	O
this	O
group	O
of	O
patients	O
.	O

A	O
positive	O
correlation	O
between	O
blood	O
vessel	O
volume	O
and	O
bone	O
volume	O
density	O
was	O
found	O
in	O
the	O
younger	O
new	O
-	O
bone	O
area	O
but	O
not	O
in	O
the	O
oldest	O
new	O
-	O
bone	O
area	O
.	O

This	O
correlation	O
was	O
due	O
to	O
a	O
higher	O
number	O
of	O
blood	O
vessels	O
rather	O
than	O
to	O
a	O
larger	O
size	O
of	O
the	O
blood	O
vessels	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
lower	O
blood	O
vessel	O
density	O
found	O
in	O
the	O
patients	O
with	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
may	O
be	O
related	O
to	O
disruption	O
of	O
angiogenesis	O
in	O
the	O
soft	O
connective	O
tissue	O
of	O
the	O
gap	O
or	O
to	O
a	O
less	O
optimal	O
mechanical	O
stimulation	O
of	O
cells	O
involved	O
in	O
angiogenesis	O
.	O

This	O
probably	O
results	O
in	O
the	O
slower	O
rate	O
of	O
osteogenesis	O
seen	O
at	O
the	O
1	O
mm	O
/	O
day	O
distraction	O
rate	O
compared	O
with	O
the	O
0	O
.	O
5	O
mm	O
/	O
day	O
distraction	O
rate	O
.	O

The	O
data	O
support	O
the	O
concept	O
that	O
a	O
positive	O
relationship	O
exists	O
between	O
the	O
density	O
of	O
blood	O
vessels	O
and	O
the	O
formation	O
of	O
bone	O
.	O

For	O
distraction	O
of	O
the	O
human	O
mandible	O
in	O
elderly	O
patients	O
,	O
a	O
distraction	O
rate	O
of	O
0	O
.	O
5	O
mm	O
/	O
day	O
seems	O
beneficial	O
.	O

[	O
The	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
.	O
A	O
comparison	O
of	O
two	O
diagnostic	O
instruments	O
]	O
.	O

OBJECTIVES	O
:	O

In	O
order	O
to	O
analyse	O
the	O
prevalence	O
of	O
ADHD	O
and	O
attention	O
problems	O
in	O
preschool	O
-	O
aged	O
children	O
,	O
mothers	O
were	O
asked	O
to	O
rate	O
their	O
children	O
using	O
two	O
measuring	O
instruments	O
.	O

METHODS	O
:	O

The	O
analysis	O
is	O
part	O
of	O
a	O
prospective	O
,	O
randomised	O
control	O
study	O
of	O
N	O
=	O
280	O
children	O
aged	O
three	O
to	O
six	O
years	O
,	O
whose	O
mothers	O
rated	O
them	O
using	O
the	O
Child	O
Behaviour	O
Checklist	O
/	O
CBCL	O
1	O
1	O
/	O
2	O
-	O
5	O
and	O
the	O
Parent	O
Rating	O
Scale	O
for	O
Attention	O
-	O
Deficit	O
Hyperactivity	O
Disorder	O
(	O
ADHD	O
)	O
.	O

RESULTS	O
:	O

The	O
prevalence	O
rates	O
ranged	O
from	O
2	O
.	O
7	O
%	O
to	O
9	O
.	O
9	O
%	O
.	O

There	O
was	O
no	O
significant	O
gender	O
effect	O
in	O
this	O
age	O
group	O
.	O

CONCLUSIONS	O
:	O

The	O
study	O
delivers	O
initial	O
findings	O
and	O
provides	O
support	O
for	O
decisions	O
to	O
implement	O
in	O
Germany	O
new	O
assessment	O
methods	O
for	O
preschool	O
-	O
aged	O
children	O
with	O
ADHD	O
or	O
hyperkinetic	O
syndrome	O
.	O

Finally	O
,	O
the	O
different	O
rates	O
of	O
prevalence	O
and	O
the	O
implications	O
of	O
the	O
findings	O
for	O
epidemiology	O
and	O
the	O
prevention	O
of	O
ADHD	O
and	O
attention	O
problems	O
among	O
preschool	O
-	O
aged	O
children	O
are	O
discussed	O
.	O

The	O
role	O
of	O
syndecans	O
in	O
disease	O
and	O
wound	O
healing	O
.	O

Syndecans	O
are	O
a	O
family	O
of	O
transmembrane	O
heparan	O
sulfate	O
proteoglycans	O
widely	O
expressed	O
in	O
both	O
developing	O
and	O
adult	O
tissues	O
.	O

Until	O
recently	O
,	O
their	O
role	O
in	O
pathogenesis	O
was	O
largely	O
unexplored	O
.	O

In	O
this	O
review	O
,	O
we	O
discuss	O
the	O
reported	O
involvement	O
of	O
syndecans	O
in	O
human	O
cancers	O
,	O
infectious	O
diseases	O
,	O
obesity	O
,	O
wound	O
healing	O
and	O
angiogenesis	O
.	O

In	O
some	O
cancers	O
,	O
syndecan	O
expression	O
has	O
been	O
shown	O
to	O
regulate	O
tumor	O
cell	O
function	O
(	O
e	O
.	O
g	O
.	O
proliferation	O
,	O
adhesion	O
,	O
and	O
motility	O
)	O
and	O
serve	O
as	O
a	O
prognostic	O
marker	O
for	O
tumor	O
progression	O
and	O
patient	O
survival	O
.	O

The	O
ectodomains	O
and	O
heparan	O
sulfate	O
glycosaminoglycan	O
chains	O
of	O
syndecans	O
can	O
also	O
act	O
as	O
receptors	O
/	O
co	O
-	O
receptors	O
for	O
some	O
bacterial	O
and	O
viral	O
pathogens	O
,	O
mediating	O
infection	O
.	O

In	O
addition	O
,	O
syndecans	O
bind	O
to	O
obesity	O
-	O
related	O
factors	O
and	O
regulate	O
their	O
signaling	O
,	O
in	O
turn	O
modulating	O
food	O
consumption	O
and	O
weight	O
balance	O
.	O

In	O
vivo	O
animal	O
models	O
of	O
tissue	O
injury	O
and	O
in	O
vitro	O
data	O
also	O
implicate	O
syndecans	O
in	O
processes	O
necessary	O
for	O
wound	O
healing	O
,	O
including	O
fibroblast	O
and	O
endothelial	O
proliferation	O
,	O
cell	O
motility	O
,	O
angiogenesis	O
,	O
and	O
extracellular	O
matrix	O
organization	O
.	O

These	O
new	O
insights	O
into	O
the	O
involvement	O
of	O
syndecans	O
in	O
disease	O
and	O
tissue	O
repair	O
coupled	O
with	O
the	O
emergence	O
of	O
syndecan	O
-	O
specific	O
molecular	O
tools	O
may	O
lead	O
to	O
novel	O
therapies	O
for	O
a	O
variety	O
of	O
human	O
diseases	O
.	O

High	O
-	O
Dose	O
celecoxib	O
and	O
metronomic	O
""""	O
low	O
-	O
dose	O
""""	O
cyclophosphamide	O
is	O
an	O
effective	O
and	O
safe	O
therapy	O
in	O
patients	O
with	O
relapsed	O
and	O
refractory	O
aggressive	O
histology	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

PURPOSE	O
:	O
Angiogenesis	O
is	O
increased	O
in	O
aggressive	O
histology	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
and	O
may	O
be	O
a	O
target	O
with	O
selective	O
cyclooxygenase	O
-	O
2	O
inhibition	O
and	O
metronomic	O
chemotherapy	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
assessed	O
response	O
,	O
toxicity	O
,	O
and	O
biomarkers	O
of	O
angiogenesis	O
to	O
low	O
-	O
dose	O
cyclophosphamide	O
(	O
50	O
mg	O
p	O
.	O
o	O
.	O
o	O
.	O
d	O
.	O
)	O
and	O
high	O
-	O
dose	O
celecoxib	O
(	O
400	O
mg	O
p	O
.	O
o	O
.	O
b	O
.	O
i	O
.	O
d	O
.	O
)	O
in	O
adult	O
patients	O
with	O
relapsed	O
or	O
refractory	O
aggressive	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
in	O
a	O
multicenter	O
phase	O
II	O
prospective	O
study	O
.	O

RESULTS	O
:	O
Thirty	O
-	O
two	O
of	O
35	O
patients	O
(	O
median	O
age	O
,	O
62	O
years	O
)	O
are	O
evaluable	O
for	O
response	O
.	O

Patients	O
had	O
primarily	O
relapsed	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
(	O
63	O
%	O
)	O
were	O
heavily	O
pretreated	O
(	O
median	O
of	O
three	O
regimens	O
)	O
and	O
high	O
risk	O
(	O
79	O
%	O
international	O
prognostic	O
index	O
,	O
greater	O
than	O
or	O
=	O
2	O
)	O
and	O
34	O
%	O
were	O
relapsed	O
after	O
autologous	O
stem	O
cell	O
transplant	O
.	O

With	O
a	O
median	O
follow	O
-	O
up	O
of	O
8	O
.	O
4	O
months	O
,	O
the	O
overall	O
best	O
response	O
rate	O
is	O
37	O
%	O
(	O
2	O
complete	O
clinical	O
response	O
/	O
complete	O
clinical	O
response	O
unconfirmed	O
and	O
9	O
partial	O
response	O
)	O
,	O
with	O
22	O
%	O
achieving	O
stable	O
disease	O
.	O

Median	O
overall	O
and	O
progression	O
-	O
free	O
survivals	O
are	O
14	O
.	O
4	O
and	O
4	O
.	O
7	O
months	O
,	O
respectively	O
.	O

The	O
median	O
response	O
duration	O
was	O
8	O
.	O
2	O
months	O
.	O

The	O
most	O
common	O
toxicity	O
was	O
skin	O
rash	O
(	O
40	O
%	O
)	O
;	O
myelosuppression	O
and	O
gastrointestinal	O
side	O
effects	O
were	O
uncommon	O
.	O

Three	O
patients	O
developed	O
deep	O
vein	O
thromboses	O
and	O
two	O
heavily	O
pretreated	O
patients	O
developed	O
treatment	O
-	O
related	O
acute	O
myelogenous	O
leukemia	O
or	O
myelodysplasia	O
after	O
3	O
.	O
7	O
and	O
12	O
months	O
of	O
therapy	O
.	O

Circulating	O
endothelial	O
cells	O
and	O
their	O
precursors	O
declined	O
and	O
remained	O
low	O
in	O
responders	O
,	O
whereas	O
plasma	O
vascular	O
endothelial	O
growth	O
factor	O
trended	O
to	O
decline	O
in	O
responding	O
patients	O
but	O
increase	O
in	O
nonresponders	O
.	O

Trough	O
celecoxib	O
levels	O
achieved	O
targeted	O
""""	O
antiangiogenic	O
""""	O
levels	O
.	O

CONCLUSIONS	O
:	O
Low	O
-	O
dose	O
cyclophosphamide	O
and	O
high	O
-	O
dose	O
celecoxib	O
is	O
well	O
tolerated	O
and	O
active	O
in	O
pretreated	O
aggressive	O
non	O
-	O
Hodgkin	O
'	O
s	O
lymphoma	O
.	O

Close	O
surveillance	O
for	O
arterial	O
and	O
venous	O
thrombotic	O
events	O
is	O
recommended	O
.	O

The	O
decline	O
in	O
circulating	O
endothelial	O
cells	O
and	O
their	O
precursors	O
suggests	O
that	O
this	O
combination	O
may	O
be	O
working	O
by	O
inhibiting	O
angiogenesis	O
but	O
should	O
be	O
validated	O
in	O
a	O
larger	O
patient	O
sample	O
.	O

Structure	O
of	O
the	O
genetic	O
code	O
suggested	O
by	O
the	O
hydropathy	O
correlation	O
between	O
anticodons	O
and	O
amino	O
acid	O
residues	O
.	O

The	O
correlation	O
between	O
hydropathies	O
of	O
anticodons	O
and	O
amino	O
acids	O
,	O
detected	O
by	O
other	O
authors	O
utilizing	O
scales	O
of	O
amino	O
acid	O
molecules	O
in	O
solution	O
,	O
was	O
improved	O
with	O
the	O
utilization	O
of	O
scales	O
of	O
amino	O
acid	O
residues	O
in	O
proteins	O
.	O

Three	O
partitions	O
were	O
discerned	O
in	O
the	O
correlation	O
plot	O
with	O
the	O
principal	O
dinucleotides	O
of	O
anticodons	O
(	O
pDiN	O
,	O
excluding	O
the	O
wobble	O
position	O
)	O
.	O

(	O
a	O
)	O
The	O
set	O
of	O
outliers	O
of	O
the	O
correlation	O
:	O
Gly	O
-	O
CC	O
,	O
Pro	O
-	O
GG	O
,	O
Ser	O
-	O
GA	O
and	O
Ser	O
-	O
CU	O
.	O

The	O
amino	O
acids	O
are	O
consistently	O
small	O
,	O
hydro	O
-	O
apathetic	O
,	O
stabilizers	O
of	O
protein	O
N	O
-	O
ends	O
,	O
preferred	O
in	O
aperiodic	O
protein	O
conformations	O
and	O
belong	O
to	O
synthetases	O
class	O
II	O
.	O

The	O
pDiN	O
sequences	O
are	O
representative	O
of	O
the	O
homogeneous	O
sector	O
(	O
triplets	O
NRR	O
and	O
NYY	O
)	O
,	O
distinguished	O
from	O
the	O
mixed	O
sector	O
(	O
triplets	O
NRY	O
and	O
NYR	O
)	O
,	O
that	O
depict	O
a	O
70	O
%	O
correspondence	O
to	O
the	O
synthetases	O
class	O
II	O
and	O
I	O
,	O
respectively	O
.	O

The	O
triplet	O
pairs	O
proposed	O
to	O
be	O
responsible	O
for	O
the	O
coherence	O
in	O
the	O
set	O
of	O
outliers	O
are	O
of	O
the	O
palindromic	O
kind	O
,	O
where	O
the	O
lateral	O
bases	O
are	O
the	O
same	O
,	O
CCC	O
:	O
GGG	O
and	O
AGA	O
:	O
UCU	O
.	O

This	O
suggests	O
that	O
UCU	O
previously	O
belonged	O
to	O
Ser	O
,	O
adding	O
to	O
other	O
indications	O
that	O
the	O
attribution	O
of	O
Arg	O
to	O
YCU	O
was	O
due	O
to	O
an	O
expansion	O
of	O
the	O
Arg	O
-	O
tRNA	O
synthetase	O
specificity	O
.	O

The	O
other	O
attributions	O
produced	O
two	O
correlation	O
sets	O
.	O

(	O
b	O
)	O
One	O
corresponds	O
to	O
the	O
remaining	O
pDiN	O
of	O
the	O
homogeneous	O
sector	O
,	O
containing	O
both	O
synthetase	O
classes	O
;	O
its	O
regression	O
line	O
overlapped	O
the	O
one	O
formed	O
by	O
the	O
remaining	O
attributions	O
to	O
class	O
II	O
.	O

(	O
c	O
)	O
The	O
other	O
contains	O
the	O
pDiN	O
of	O
the	O
mixed	O
sector	O
and	O
produced	O
steeper	O
slopes	O
,	O
especially	O
with	O
the	O
class	O
I	O
attributions	O
.	O

It	O
is	O
suggested	O
that	O
the	O
correlation	O
was	O
established	O
when	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
synthetases	O
became	O
progressively	O
enriched	O
and	O
that	O
the	O
set	O
of	O
outliers	O
were	O
the	O
earliest	O
to	O
have	O
been	O
fixed	O
.	O

Photodynamic	O
therapy	O
with	O
verteporfin	O
for	O
subfoveal	O
choroidal	O
neovascularization	O
secondary	O
to	O
pathologic	O
myopia	O
:	O
long	O
-	O
term	O
study	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
safety	O
and	O
effectiveness	O
of	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
with	O
verteporfin	O
for	O
subfoveal	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
secondary	O
to	O
pathologic	O
myopia	O
(	O
PM	O
)	O
.	O

METHODS	O
:	O
Sixty	O
-	O
two	O
patients	O
(	O
62	O
eyes	O
)	O
with	O
PM	O
underwent	O
PDT	O
according	O
to	O
the	O
guidelines	O
of	O
the	O
Verteporfin	O
in	O
Photodynamic	O
Therapy	O
Study	O
.	O

Clinical	O
evaluations	O
performed	O
at	O
all	O
study	O
visits	O
included	O
measurement	O
of	O
best	O
-	O
corrected	O
Snellen	O
visual	O
acuity	O
,	O
slit	O
-	O
lamp	O
biomicroscopy	O
,	O
and	O
fundus	O
fluorescein	O
angiography	O
.	O

Patients	O
were	O
followed	O
up	O
at	O
1	O
month	O
and	O
3	O
months	O
after	O
treatment	O
and	O
thereafter	O
at	O
3	O
-	O
month	O
intervals	O
.	O

RESULTS	O
:	O
The	O
final	O
visual	O
acuity	O
of	O
the	O
study	O
patients	O
,	O
after	O
a	O
median	O
follow	O
-	O
up	O
of	O
31	O
months	O
,	O
improved	O
by	O
greater	O
than	O
or	O
=	O
1	O
Snellen	O
lines	O
in	O
8	O
patients	O
(	O
13	O
%	O
)	O
,	O
deteriorated	O
in	O
20	O
(	O
32	O
%	O
)	O
,	O
and	O
remained	O
stable	O
in	O
34	O
(	O
55	O
%	O
)	O
.	O

The	O
baseline	O
visual	O
acuity	O
was	O
similar	O
in	O
the	O
various	O
study	O
groups	O
.	O

The	O
final	O
mean	O
visual	O
acuity	O
in	O
group	O
A	O
(	O
55	O
years	O
of	O
age	O
or	O
younger	O
)	O
was	O
20	O
/	O
80	O
and	O
significantly	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
better	O
than	O
that	O
(	O
20	O
/	O
138	O
)	O
in	O
group	O
B	O
(	O
older	O
than	O
55	O
years	O
of	O
age	O
)	O
.	O

The	O
mean	O
final	O
visual	O
acuity	O
in	O
eyes	O
with	O
higher	O
refractive	O
error	O
at	O
baseline	O
(	O
greater	O
than	O
-	O
17	O
diopters	O
)	O
was	O
significantly	O
better	O
(	O
P	O
=	O
0	O
.	O
014	O
)	O
than	O
that	O
in	O
eyes	O
with	O
lower	O
refractive	O
error	O
(	O
-	O
6	O
to	O
-	O
10	O
diopters	O
)	O
.	O

CNV	O
size	O
did	O
not	O
affect	O
visual	O
outcomes	O
.	O

CONCLUSION	O
:	O
PDT	O
preserves	O
vision	O
in	O
patients	O
with	O
CNV	O
associated	O
with	O
PM	O
.	O

Younger	O
patients	O
and	O
eyes	O
with	O
higher	O
refractive	O
error	O
appear	O
more	O
likely	O
to	O
benefit	O
from	O
PDT	O
with	O
verteporfin	O
.	O

Medical	O
adherence	O
and	O
childhood	O
chronic	O
illness	O
:	O
family	O
daily	O
management	O
skills	O
and	O
emotional	O
climate	O
as	O
emerging	O
contributors	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O

To	O
describe	O
recent	O
research	O
that	O
examines	O
family	O
factors	O
that	O
promote	O
or	O
derail	O
adherence	O
to	O
medical	O
regimens	O
for	O
children	O
with	O
chronic	O
health	O
conditions	O
,	O
primarily	O
asthma	O
,	O
diabetes	O
,	O
and	O
cystic	O
fibrosis	O
.	O

From	O
the	O
past	O
2	O
years	O
,	O
eight	O
correlational	O
studies	O
were	O
identified	O
which	O
specifically	O
examined	O
the	O
links	O
between	O
family	O
management	O
strategies	O
,	O
family	O
climate	O
and	O
medical	O
adherence	O
.	O

RECENT	O
FINDINGS	O
:	O

Findings	O
from	O
the	O
studies	O
suggest	O
that	O
team	O
-	O
based	O
management	O
strategies	O
and	O
cohesive	O
family	O
climate	O
promote	O
adherence	O
to	O
medical	O
treatments	O
over	O
time	O
.	O

Family	O
interactions	O
that	O
are	O
characterized	O
by	O
conflict	O
and	O
disengagement	O
tend	O
to	O
disrupt	O
adherence	O
and	O
inevitably	O
cause	O
a	O
decline	O
in	O
child	O
health	O
.	O

Moreover	O
,	O
these	O
findings	O
seem	O
to	O
be	O
moderated	O
by	O
child	O
age	O
in	O
that	O
poorer	O
adherence	O
often	O
occurs	O
when	O
a	O
child	O
reaches	O
adolescence	O
and	O
is	O
searching	O
for	O
greater	O
autonomy	O
.	O

SUMMARY	O
:	O

Future	O
research	O
should	O
consider	O
the	O
challenges	O
in	O
measuring	O
medical	O
adherence	O
in	O
the	O
family	O
context	O
as	O
well	O
as	O
incorporating	O
more	O
naturalistic	O
studies	O
of	O
family	O
interactions	O
.	O

Randomized	O
controlled	O
trials	O
using	O
family	O
-	O
based	O
interventions	O
may	O
consider	O
focusing	O
on	O
medical	O
adherence	O
as	O
an	O
important	O
mediator	O
between	O
family	O
process	O
and	O
child	O
health	O
outcomes	O
.	O

C	O
/	O
EBPbeta	O
is	O
over	O
-	O
expressed	O
in	O
gastric	O
carcinogenesis	O
and	O
is	O
associated	O
with	O
COX	O
-	O
2	O
expression	O
.	O

The	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
beta	O
(	O
C	O
/	O
EBPbeta	O
)	O
transcription	O
factor	O
has	O
been	O
associated	O
with	O
several	O
cancer	O
models	O
.	O

In	O
this	O
study	O
,	O
the	O
expression	O
of	O
C	O
/	O
EBPbeta	O
was	O
analysed	O
in	O
a	O
series	O
of	O
90	O
gastric	O
carcinomas	O
(	O
GCs	O
)	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
C	O
/	O
EBPbeta	O
on	O
COX	O
-	O
2	O
expression	O
.	O

In	O
normal	O
gastric	O
mucosa	O
,	O
C	O
/	O
EBPbeta	O
expression	O
was	O
restricted	O
to	O
cells	O
in	O
the	O
proliferative	O
zone	O
.	O

In	O
intestinal	O
metaplasia	O
,	O
dysplasia	O
,	O
and	O
GC	O
of	O
the	O
intestinal	O
and	O
atypical	O
subtypes	O
,	O
C	O
/	O
EBPbeta	O
was	O
over	O
-	O
expressed	O
(	O
p	O
<	O
0	O
.	O
0001	O
,	O
for	O
the	O
association	O
with	O
histological	O
type	O
)	O
.	O

C	O
/	O
EBPbeta	O
and	O
Ki67	O
,	O
a	O
marker	O
of	O
cell	O
proliferation	O
,	O
were	O
also	O
co	O
-	O
expressed	O
in	O
primary	O
GC	O
.	O

We	O
also	O
observed	O
an	O
overlap	O
between	O
C	O
/	O
EBPbeta	O
and	O
COX	O
-	O
2	O
expression	O
in	O
GC	O
.	O

Using	O
GC	O
cell	O
lines	O
we	O
show	O
that	O
C	O
/	O
EBPbeta	O
can	O
regulate	O
the	O
expression	O
of	O
endogenous	O
COX	O
-	O
2	O
and	O
transactivate	O
the	O
promoter	O
of	O
the	O
COX	O
-	O
2	O
gene	O
,	O
depending	O
on	O
its	O
methylation	O
status	O
.	O

These	O
results	O
suggest	O
that	O
C	O
/	O
EBPbeta	O
may	O
be	O
a	O
marker	O
of	O
neoplastic	O
transformation	O
and	O
also	O
play	O
an	O
active	O
role	O
in	O
gastric	O
tumourigenesis	O
by	O
regulating	O
COX	O
-	O
2	O
expression	O
.	O

Neoplastic	O
transformation	O
of	O
ciliary	O
body	O
epithelium	O
is	O
associated	O
with	O
loss	O
of	O
opticin	O
expression	O
.	O

BACKGROUND	O
:	O
Opticin	O
is	O
a	O
recently	O
discovered	O
glycoprotein	O
present	O
predominantly	O
in	O
the	O
vitreous	O
humour	O
.	O

It	O
is	O
synthesised	O
and	O
secreted	O
by	O
the	O
ciliary	O
body	O
epithelium	O
(	O
CBE	O
)	O
from	O
the	O
initiation	O
of	O
CBE	O
development	O
in	O
the	O
embryo	O
,	O
and	O
production	O
continues	O
throughout	O
life	O
.	O

AIM	O
:	O
To	O
determine	O
whether	O
a	O
variety	O
of	O
ciliary	O
body	O
tumours	O
synthesise	O
opticin	O
to	O
characterise	O
further	O
its	O
role	O
in	O
ciliary	O
body	O
health	O
and	O
disease	O
.	O

METHODS	O
:	O
Immunohistochemistry	O
was	O
used	O
to	O
determine	O
the	O
distribution	O
of	O
opticin	O
in	O
normal	O
human	O
CBE	O
,	O
and	O
in	O
hyperplastic	O
and	O
neoplastic	O
CBE	O
lesions	O
.	O

RESULTS	O
:	O
Opticin	O
was	O
immunolocalised	O
to	O
the	O
basal	O
cell	O
surface	O
and	O
basement	O
membrane	O
material	O
of	O
the	O
non	O
-	O
pigmented	O
CBE	O
in	O
nine	O
donor	O
eyes	O
as	O
well	O
as	O
four	O
hyperplastic	O
lesions	O
of	O
the	O
CBE	O
(	O
Fuchs	O
'	O
s	O
adenoma	O
)	O
.	O

By	O
contrast	O
,	O
none	O
of	O
eight	O
neoplastic	O
lesions	O
(	O
two	O
adenoma	O
and	O
six	O
adenocarcinoma	O
)	O
of	O
CBE	O
stained	O
for	O
opticin	O
.	O

CONCLUSION	O
:	O
The	O
present	O
series	O
supports	O
the	O
theory	O
that	O
opticin	O
is	O
produced	O
by	O
the	O
non	O
-	O
pigmented	O
CBE	O
throughout	O
adult	O
life	O
.	O

Loss	O
of	O
opticin	O
expression	O
by	O
this	O
tissue	O
is	O
associated	O
with	O
and	O
could	O
contribute	O
towards	O
neoplastic	O
transformation	O
.	O

Imaging	O
tumor	O
angiogenesis	O
.	O

Since	O
the	O
discovery	O
of	O
vascular	O
-	O
specific	O
growth	O
factors	O
with	O
angiogenic	O
activity	O
,	O
there	O
has	O
been	O
a	O
significant	O
effort	O
to	O
develop	O
cancer	O
drugs	O
that	O
restrict	O
tumorigenesis	O
by	O
targeting	O
the	O
blood	O
supply	O
.	O

In	O
this	O
issue	O
of	O
the	O
JCI	O
,	O
Mancuso	O
et	O
al	O
.	O
use	O
mouse	O
models	O
to	O
better	O
understand	O
the	O
plasticity	O
of	O
the	O
tumor	O
vasculature	O
in	O
the	O
face	O
of	O
antiangiogenic	O
therapy	O
(	O
see	O
the	O
related	O
article	O
beginning	O
on	O
page	O
2610	O
)	O
.	O

They	O
describe	O
a	O
rapid	O
regrowth	O
of	O
the	O
tumor	O
vasculature	O
following	O
withdrawal	O
of	O
VEGFR	O
inhibitors	O
,	O
emphasizing	O
the	O
importance	O
of	O
fully	O
understanding	O
the	O
function	O
of	O
these	O
and	O
similar	O
treatments	O
used	O
in	O
the	O
clinic	O
at	O
the	O
cellular	O
and	O
molecular	O
level	O
.	O

Collagen	O
-	O
poly	O
glycolic	O
acid	O
hybrid	O
matrix	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
accelerated	O
angiogenesis	O
and	O
granulation	O
tissue	O
formation	O
in	O
diabetic	O
mice	O
.	O

Because	O
poor	O
skin	O
wound	O
healing	O
associated	O
with	O
diabetes	O
is	O
thought	O
to	O
be	O
partly	O
a	O
result	O
from	O
impaired	O
angiogenesis	O
,	O
treatments	O
that	O
improve	O
angiogenesis	O
could	O
have	O
important	O
clinical	O
applications	O
.	O

We	O
herein	O
report	O
the	O
effects	O
of	O
novel	O
developed	O
material	O
,	O
collagen	O
-	O
poly	O
glycolic	O
acid	O
fiber	O
hybrid	O
matrix	O
,	O
being	O
used	O
together	O
with	O
basic	O
fibroblast	O
growth	O
factor	O
to	O
promote	O
wound	O
healing	O
of	O
full	O
-	O
thickness	O
skin	O
defects	O
on	O
the	O
back	O
of	O
type	O
2	O
diabetic	O
Lepr	O
(	O
db	O
)	O
mice	O
.	O

Our	O
data	O
indicates	O
that	O
this	O
therapeutic	O
approach	O
markedly	O
promotes	O
angiogenesis	O
and	O
granulation	O
tissue	O
formation	O
in	O
comparison	O
with	O
other	O
conditions	O
14	O
days	O
after	O
wounding	O
.	O

Hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
Glycyrrhiza	O
glabra	O
(	O
Linn	O
)	O
in	O
rats	O
.	O

The	O
hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
Glycyrrhiza	O
glabra	O
(	O
GG	O
)	O
root	O
powder	O
were	O
examined	O
in	O
hypercholesterolaemic	O
male	O
albino	O
rats	O
.	O

A	O
4	O
-	O
week	O
administration	O
of	O
GG	O
root	O
powder	O
(	O
5	O
and	O
10	O
gm	O
%	O
in	O
diet	O
)	O
to	O
hypercholesterolaemic	O
rats	O
resulted	O
in	O
significant	O
reduction	O
in	O
plasma	O
,	O
hepatic	O
total	O
lipids	O
,	O
cholesterol	O
,	O
triglycerides	O
and	O
plasma	O
low	O
-	O
density	O
lipoprotein	O
and	O
VLDL	O
-	O
cholesterol	O
accompanied	O
by	O
significant	O
increases	O
in	O
HDL	O
-	O
cholesterol	O
levels	O
.	O

Furthermore	O
,	O
significant	O
increases	O
in	O
fecal	O
cholesterol	O
,	O
neutral	O
sterols	O
and	O
bile	O
acid	O
excretion	O
along	O
with	O
an	O
increase	O
in	O
hepatic	O
HMG	O
-	O
CoA	O
reductase	O
activity	O
and	O
bile	O
acid	O
production	O
were	O
observed	O
in	O
these	O
animals	O
.	O

The	O
root	O
powder	O
administration	O
to	O
hypercholesterolaemic	O
rats	O
also	O
decreased	O
hepatic	O
lipid	O
peroxidation	O
with	O
a	O
concomitant	O
increase	O
in	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
and	O
catalase	O
activities	O
and	O
total	O
ascorbic	O
acid	O
content	O
.	O

Thus	O
,	O
the	O
hypocholesterolaemic	O
and	O
antioxidant	O
effects	O
of	O
GG	O
root	O
appeared	O
to	O
be	O
mediated	O
via	O
(	O
i	O
)	O
accelerated	O
cholesterol	O
,	O
neutral	O
sterol	O
and	O
bile	O
acid	O
elimination	O
through	O
fecal	O
matter	O
with	O
an	O
increased	O
hepatic	O
bile	O
acid	O
production	O
and	O
(	O
ii	O
)	O
improving	O
the	O
activities	O
of	O
hepatic	O
SOD	O
,	O
catalase	O
and	O
increasing	O
the	O
ascorbic	O
acid	O
content	O
.	O

The	O
normo	O
-	O
cholesterolaemic	O
animals	O
when	O
fed	O
with	O
GG	O
root	O
powder	O
at	O
10	O
gm	O
%	O
level	O
,	O
registered	O
a	O
significant	O
decline	O
in	O
plasma	O
lipid	O
profiles	O
and	O
an	O
increase	O
in	O
HDL	O
-	O
cholesterol	O
content	O
.	O

The	O
antioxidant	O
status	O
of	O
these	O
animals	O
also	O
was	O
improved	O
upon	O
treatment	O
.	O

Multicentre	O
study	O
on	O
peri	O
-	O
and	O
postoperative	O
central	O
venous	O
oxygen	O
saturation	O
in	O
high	O
-	O
risk	O
surgical	O
patients	O
.	O

INTRODUCTION	O
:	O

Low	O
central	O
venous	O
oxygen	O
saturation	O
(	O
ScvO2	O
)	O
has	O
been	O
associated	O
with	O
increased	O
risk	O
of	O
postoperative	O
complications	O
in	O
high	O
-	O
risk	O
surgery	O
.	O

Whether	O
this	O
association	O
is	O
centre	O
-	O
specific	O
or	O
more	O
generalisable	O
is	O
not	O
known	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
peri	O
-	O
and	O
postoperative	O
ScvO2	O
and	O
outcome	O
in	O
high	O
-	O
risk	O
surgical	O
patients	O
in	O
a	O
multicentre	O
setting	O
.	O

METHODS	O
:	O

Three	O
large	O
European	O
university	O
hospitals	O
(	O
two	O
in	O
Finland	O
,	O
one	O
in	O
Switzerland	O
)	O
participated	O
.	O

In	O
60	O
patients	O
with	O
intra	O
-	O
abdominal	O
surgery	O
lasting	O
more	O
than	O
90	O
minutes	O
,	O
the	O
presence	O
of	O
at	O
least	O
two	O
of	O
Shoemaker	O
'	O
s	O
criteria	O
,	O
and	O
ASA	O
(	O
American	O
Society	O
of	O
Anesthesiologists	O
)	O
class	O
greater	O
than	O
2	O
,	O
ScvO2	O
was	O
determined	O
preoperatively	O
and	O
at	O
two	O
hour	O
intervals	O
during	O
the	O
operation	O
until	O
12	O
hours	O
postoperatively	O
.	O

Hospital	O
length	O
of	O
stay	O
(	O
LOS	O
)	O
mortality	O
,	O
and	O
predefined	O
postoperative	O
complications	O
were	O
recorded	O
.	O

RESULTS	O
:	O

The	O
age	O
of	O
the	O
patients	O
was	O
72	O
+	O
/	O
-	O
10	O
years	O
(	O
mean	O
+	O
/	O
-	O
standard	O
deviation	O
)	O
,	O
and	O
simplified	O
acute	O
physiology	O
score	O
(	O
SAPS	O
II	O
)	O
was	O
32	O
+	O
/	O
-	O
12	O
.	O

Hospital	O
LOS	O
was	O
10	O
.	O
5	O
(	O
8	O
to	O
14	O
)	O
days	O
,	O
and	O
28	O
-	O
day	O
hospital	O
mortality	O
was	O
10	O
.	O
0	O
%	O
.	O

Preoperative	O
ScvO2	O
decreased	O
from	O
77	O
%	O
+	O
/	O
-	O
10	O
%	O
to	O
70	O
%	O
+	O
/	O
-	O
11	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
immediately	O
after	O
surgery	O
and	O
remained	O
unchanged	O
12	O
hours	O
later	O
.	O

A	O
total	O
of	O
67	O
postoperative	O
complications	O
were	O
recorded	O
in	O
32	O
patients	O
.	O

After	O
multivariate	O
analysis	O
,	O
mean	O
ScvO2	O
value	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1	O
.	O
23	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
01	O
to	O
1	O
.	O
50	O
]	O
,	O
p	O
=	O
0	O
.	O
037	O
)	O
,	O
hospital	O
LOS	O
(	O
OR	O
0	O
.	O
75	O
[	O
95	O
%	O
CI	O
0	O
.	O
59	O
to	O
0	O
.	O
94	O
]	O
,	O
p	O
=	O
0	O
.	O
012	O
)	O
,	O
and	O
SAPS	O
II	O
(	O
OR	O
0	O
.	O
90	O
[	O
95	O
%	O
CI	O
0	O
.	O
82	O
to	O
0	O
.	O
99	O
]	O
,	O
p	O
=	O
0	O
.	O
029	O
)	O
were	O
independently	O
associated	O
with	O
postoperative	O
complications	O
.	O

The	O
optimal	O
value	O
of	O
mean	O
ScvO2	O
to	O
discriminate	O
between	O
patients	O
who	O
did	O
or	O
did	O
not	O
develop	O
complications	O
was	O
73	O
%	O
(	O
sensitivity	O
72	O
%	O
,	O
specificity	O
61	O
%	O
)	O
.	O

CONCLUSION	O
:	O

Low	O
ScvO2	O
perioperatively	O
is	O
related	O
to	O
increased	O
risk	O
of	O
postoperative	O
complications	O
in	O
high	O
-	O
risk	O
surgery	O
.	O

This	O
warrants	O
trials	O
with	O
goal	O
-	O
directed	O
therapy	O
using	O
ScvO2	O
as	O
a	O
target	O
in	O
high	O
-	O
risk	O
surgery	O
patients	O
.	O

Carcinogenesis	O
and	O
transcriptional	O
regulation	O
through	O
Maf	O
recognition	O
elements	O
.	O

Many	O
studies	O
on	O
carcinogenesis	O
carried	O
out	O
early	O
in	O
the	O
last	O
century	O
are	O
united	O
on	O
the	O
consensus	O
that	O
cancer	O
is	O
a	O
genetic	O
disease	O
.	O

Cancer	O
cells	O
typically	O
display	O
gene	O
dysfunction	O
and	O
endogenous	O
or	O
exogenous	O
insults	O
resulting	O
in	O
gene	O
dysfunction	O
are	O
often	O
carcinogenic	O
.	O

Recent	O
advances	O
in	O
stem	O
cell	O
biology	O
added	O
the	O
new	O
concept	O
that	O
cancer	O
originates	O
from	O
a	O
single	O
cancer	O
-	O
initiating	O
cell	O
.	O

To	O
understand	O
the	O
molecular	O
basis	O
of	O
carcinogenesis	O
from	O
the	O
beginning	O
to	O
the	O
full	O
acquirement	O
of	O
malignancy	O
,	O
factors	O
concerned	O
with	O
carcinogenesis	O
were	O
categorized	O
into	O
three	O
groups	O
:	O
those	O
guarding	O
and	O
stabilizing	O
genomes	O
,	O
those	O
regulating	O
cell	O
proliferation	O
,	O
and	O
those	O
conferring	O
resistance	O
to	O
various	O
micro	O
-	O
environmental	O
stresses	O
.	O

One	O
example	O
of	O
particular	O
interest	O
is	O
the	O
Keap1	O
-	O
Nrf2	O
system	O
since	O
,	O
according	O
to	O
recent	O
studies	O
,	O
it	O
has	O
turned	O
out	O
to	O
be	O
ambivalent	O
.	O

Nrf2	O
heterodimerizes	O
with	O
small	O
Maf	O
protein	O
to	O
strongly	O
activate	O
transcription	O
through	O
the	O
Maf	O
recognition	O
element	O
(	O
MARE	O
)	O
and	O
Keap1	O
is	O
an	O
inhibitory	O
regulator	O
of	O
Nrf2	O
.	O

The	O
genes	O
regulated	O
by	O
Nrf2	O
are	O
very	O
important	O
for	O
cellular	O
protection	O
of	O
the	O
genome	O
from	O
xenobiotic	O
and	O
oxidative	O
stresses	O
and	O
,	O
consequently	O
,	O
for	O
preventing	O
carcinogenesis	O
.	O

This	O
implies	O
that	O
enhancing	O
Nrf2	O
activity	O
is	O
a	O
promising	O
method	O
for	O
thwarting	O
cancer	O
.	O

On	O
the	O
contrary	O
,	O
the	O
constitutive	O
activation	O
of	O
Nrf2	O
due	O
to	O
mutations	O
in	O
the	O
keap1	O
gene	O
is	O
characteristically	O
observed	O
in	O
lung	O
cancer	O
cells	O
,	O
suggesting	O
that	O
induced	O
expression	O
of	O
Nrf2	O
target	O
genes	O
favors	O
the	O
prevalence	O
of	O
cancer	O
cells	O
.	O

Lysophosphatidic	O
acid	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
,	O
which	O
are	O
negatively	O
involved	O
in	O
lysophosphatidic	O
acid	O
-	O
induced	O
cell	O
invasion	O
.	O

Ovarian	O
cancer	O
is	O
a	O
highly	O
metastatic	O
disease	O
.	O

Lysophosphatidic	O
acid	O
(	O
LPA	O
)	O
levels	O
are	O
elevated	O
in	O
ascites	O
from	O
ovarian	O
cancer	O
patients	O
,	O
but	O
its	O
potential	O
role	O
in	O
ovarian	O
cancer	O
metastasis	O
has	O
just	O
begun	O
to	O
be	O
revealed	O
.	O

In	O
this	O
work	O
,	O
we	O
show	O
that	O
LPA	O
stimulates	O
invasion	O
of	O
primary	O
ovarian	O
cancer	O
cells	O
,	O
but	O
not	O
ovarian	O
epithelial	O
or	O
borderline	O
ovarian	O
tumor	O
cells	O
,	O
although	O
these	O
benign	O
cells	O
indeed	O
respond	O
to	O
LPA	O
in	O
cell	O
migration	O
.	O

We	O
have	O
found	O
that	O
LPA	O
downregulates	O
tissue	O
inhibitor	O
of	O
metalloproteinases	O
(	O
TIMPs	O
)	O
.	O

TIMP2	O
and	O
TIMP3	O
play	O
functional	O
role	O
in	O
LPA	O
-	O
induced	O
invasion	O
as	O
negative	O
regulators	O
.	O

G	O
(	O
i	O
)	O
protein	O
,	O
phosphatidylinositol	O
-	O
3	O
kinase	O
(	O
PI3	O
K	O
)	O
,	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
,	O
cytosolic	O
phospholipase	O
A	O
(	O
2	O
)	O
and	O
urokinase	O
type	O
plasminogen	O
activator	O
(	O
uPA	O
)	O
are	O
required	O
for	O
LPA	O
-	O
induced	O
cells	O
invasion	O
.	O

TIMP3	O
may	O
affect	O
two	O
independent	O
downstream	O
targets	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
and	O
p38	O
MAPK	O
.	O

In	O
vivo	O
,	O
LPA	O
stimulates	O
tumor	O
metastasis	O
in	O
an	O
orthotopic	O
ovarian	O
tumor	O
model	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
a	O
PI3	O
K	O
inhibitor	O
,	O
LY294002	O
.	O

In	O
summary	O
,	O
LPA	O
is	O
likely	O
a	O
key	O
component	O
for	O
promoting	O
ovarian	O
metastasis	O
in	O
vivo	O
.	O

LPA	O
downregulates	O
TIMP3	O
,	O
which	O
may	O
have	O
targets	O
other	O
than	O
metalloproteinases	O
.	O

Our	O
in	O
vivo	O
metastasis	O
mouse	O
model	O
is	O
useful	O
for	O
studying	O
the	O
efficacy	O
of	O
therapeutic	O
regimes	O
of	O
ovarian	O
cancer	O
.	O

p18Ink4c	O
,	O
but	O
not	O
p27Kip1	O
,	O
collaborates	O
with	O
Men1	O
to	O
suppress	O
neuroendocrine	O
organ	O
tumors	O
.	O

Mutant	O
mice	O
lacking	O
both	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
inhibitors	O
p18	O
(	O
Ink4c	O
)	O
and	O
p27	O
(	O
Kip1	O
)	O
develop	O
a	O
tumor	O
spectrum	O
reminiscent	O
of	O
human	O
multiple	O
endocrine	O
neoplasia	O
(	O
MEN	O
)	O
syndromes	O
.	O

To	O
determine	O
how	O
p18	O
and	O
p27	O
genetically	O
interact	O
with	O
Men1	O
,	O
the	O
tumor	O
suppressor	O
gene	O
mutated	O
in	O
familial	O
MEN1	O
,	O
we	O
characterized	O
p18	O
-	O
Men1	O
and	O
p27	O
-	O
Men1	O
double	O
mutant	O
mice	O
.	O

Compared	O
with	O
their	O
corresponding	O
single	O
mutant	O
littermates	O
,	O
the	O
p18	O
(	O
-	O
/	O
-	O
)	O
;	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
develop	O
tumors	O
at	O
an	O
accelerated	O
rate	O
and	O
with	O
an	O
increased	O
incidence	O
in	O
the	O
pituitary	O
,	O
thyroid	O
,	O
parathyroid	O
,	O
and	O
pancreas	O
.	O

In	O
the	O
pituitary	O
and	O
pancreatic	O
islets	O
,	O
phosphorylation	O
of	O
the	O
retinoblastoma	O
(	O
Rb	O
)	O
protein	O
at	O
both	O
CDK2	O
and	O
CDK4	O
/	O
6	O
sites	O
was	O
increased	O
in	O
p18	O
(	O
-	O
/	O
-	O
)	O
and	O
Men1	O
(	O
+	O
/	O
-	O
)	O
cells	O
and	O
was	O
further	O
increased	O
in	O
p18	O
(	O
-	O
/	O
-	O
)	O
;	O
Men1	O
(	O
+	O
/	O
-	O
)	O
cells	O
.	O

The	O
remaining	O
wild	O
-	O
type	O
Men1	O
allele	O
was	O
lost	O
in	O
most	O
tumors	O
from	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
but	O
was	O
retained	O
in	O
most	O
tumors	O
from	O
p18	O
(	O
-	O
/	O
-	O
)	O
;	O
Men1	O
(	O
+	O
/	O
-	O
)	O
mice	O
.	O

Combined	O
mutations	O
of	O
p27	O
(	O
-	O
/	O
-	O
)	O
and	O
Men1	O
(	O
+	O
/	O
-	O
)	O
,	O
in	O
contrast	O
,	O
did	O
not	O
exhibit	O
noticeable	O
synergistic	O
stimulation	O
of	O
Rb	O
kinase	O
activity	O
,	O
cell	O
proliferation	O
,	O
and	O
tumor	O
growth	O
.	O

These	O
results	O
demonstrate	O
that	O
functional	O
collaboration	O
exists	O
between	O
p18	O
and	O
Men1	O
and	O
suggest	O
that	O
Men1	O
may	O
regulate	O
additional	O
factor	O
(	O
s	O
)	O
that	O
interact	O
with	O
p18	O
and	O
p27	O
differently	O
.	O

[	O
Treatment	O
of	O
squamous	O
intraepithelial	O
lesion	O
of	O
type	O
CIN2	O
et	O
CIN3	O
with	O
laser	O
CO2	O
vaporization	O
:	O
retrospective	O
study	O
of	O
52	O
cases	O
]	O
.	O

OBJECTIVES	O
:	O

This	O
study	O
was	O
carried	O
out	O
over	O
an	O
8	O
-	O
year	O
period	O
in	O
order	O
to	O
evaluate	O
the	O
long	O
-	O
term	O
effectiveness	O
of	O
laser	O
CO2	O
vaporization	O
in	O
the	O
treatment	O
of	O
squamous	O
intraepithelial	O
lesion	O
of	O
type	O
CIN2	O
and	O
CIN3	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O

A	O
retrospective	O
study	O
of	O
52	O
cases	O
of	O
cervical	O
lesions	O
of	O
type	O
CIN2	O
and	O
CIN3	O
treated	O
in	O
first	O
intention	O
by	O
laser	O
CO2	O
vaporization	O
was	O
carried	O
out	O
at	O
the	O
hospital	O
Jeanne	O
-	O
de	O
-	O
Flandre	O
in	O
CHRU	O
of	O
Lille	O
from	O
1996	O
to	O
2003	O
.	O

This	O
treatment	O
was	O
performed	O
on	O
only	O
high	O
-	O
grade	O
exo	O
-	O
cervical	O
lesions	O
,	O
of	O
small	O
size	O
(	O
<	O
2cm2	O
)	O
,	O
after	O
a	O
complete	O
colposcopic	O
examination	O
.	O

RESULTS	O
:	O

Fifty	O
-	O
two	O
patients	O
were	O
treated	O
by	O
first	O
-	O
intention	O
laser	O
vaporization	O
only	O
.	O

Mean	O
age	O
was	O
29	O
.	O
4	O
years	O
and	O
51	O
.	O
9	O
%	O
were	O
nulliparous	O
.	O

At	O
the	O
first	O
cyto	O
-	O
colposcopic	O
control	O
,	O
there	O
were	O
17	O
persistent	O
lesions	O
(	O
32	O
.	O
7	O
%	O
)	O
.	O

Among	O
the	O
35	O
patients	O
without	O
persistent	O
lesion	O
,	O
29	O
achieved	O
cure	O
(	O
absence	O
of	O
recurrence	O
)	O
,	O
4	O
presented	O
a	O
recurrence	O
and	O
2	O
were	O
lost	O
to	O
follow	O
-	O
up	O
.	O

CONCLUSION	O
:	O

The	O
current	O
data	O
of	O
the	O
literature	O
concerning	O
the	O
treatment	O
by	O
laser	O
CO2	O
vaporization	O
authorize	O
application	O
of	O
this	O
method	O
for	O
certain	O
high	O
-	O
grade	O
exocervical	O
lesions	O
after	O
a	O
complete	O
colposcopic	O
examination	O
.	O

This	O
type	O
of	O
treatment	O
remains	O
less	O
aggressive	O
than	O
a	O
surgical	O
treatment	O
.	O

The	O
high	O
rate	O
of	O
residual	O
lesions	O
in	O
particular	O
in	O
the	O
event	O
of	O
CIN3	O
can	O
be	O
due	O
to	O
an	O
incomplete	O
destruction	O
of	O
the	O
lesion	O
.	O

Patients	O
should	O
thus	O
be	O
advised	O
that	O
monitoring	O
is	O
an	O
integral	O
part	O
of	O
the	O
treatment	O
.	O

Laser	O
vaporization	O
could	O
be	O
limited	O
to	O
CIN1	O
and	O
CIN2	O
lesions	O
.	O

Punica	O
granatum	O
(	O
pomegranate	O
)	O
and	O
its	O
potential	O
for	O
prevention	O
and	O
treatment	O
of	O
inflammation	O
and	O
cancer	O
.	O

The	O
last	O
7	O
years	O
have	O
seen	O
over	O
seven	O
times	O
as	O
many	O
publications	O
indexed	O
by	O
Medline	O
dealing	O
with	O
pomegranate	O
and	O
Punica	O
granatum	O
than	O
in	O
all	O
the	O
years	O
preceding	O
them	O
.	O

Because	O
of	O
this	O
,	O
and	O
the	O
virtual	O
explosion	O
of	O
interest	O
in	O
pomegranate	O
as	O
a	O
medicinal	O
and	O
nutritional	O
product	O
that	O
has	O
followed	O
,	O
this	O
review	O
is	O
accordingly	O
launched	O
.	O

The	O
pomegranate	O
tree	O
,	O
Punica	O
granatum	O
,	O
especially	O
its	O
fruit	O
,	O
possesses	O
a	O
vast	O
ethnomedical	O
history	O
and	O
represents	O
a	O
phytochemical	O
reservoir	O
of	O
heuristic	O
medicinal	O
value	O
.	O

The	O
tree	O
/	O
fruit	O
can	O
be	O
divided	O
into	O
several	O
anatomical	O
compartments	O
:	O
(	O
1	O
)	O
seed	O
,	O
(	O
2	O
)	O
juice	O
,	O
(	O
3	O
)	O
peel	O
,	O
(	O
4	O
)	O
leaf	O
,	O
(	O
5	O
)	O
flower	O
,	O
(	O
6	O
)	O
bark	O
,	O
and	O
(	O
7	O
)	O
roots	O
,	O
each	O
of	O
which	O
has	O
interesting	O
pharmacologic	O
activity	O
.	O

Juice	O
and	O
peels	O
,	O
for	O
example	O
,	O
possess	O
potent	O
antioxidant	O
properties	O
,	O
while	O
juice	O
,	O
peel	O
and	O
oil	O
are	O
all	O
weakly	O
estrogenic	O
and	O
heuristically	O
of	O
interest	O
for	O
the	O
treatment	O
of	O
menopausal	O
symptoms	O
and	O
sequellae	O
.	O

The	O
use	O
of	O
juice	O
,	O
peel	O
and	O
oil	O
have	O
also	O
been	O
shown	O
to	O
possess	O
anticancer	O
activities	O
,	O
including	O
interference	O
with	O
tumor	O
cell	O
proliferation	O
,	O
cell	O
cycle	O
,	O
invasion	O
and	O
angiogenesis	O
.	O

These	O
may	O
be	O
associated	O
with	O
plant	O
based	O
anti	O
-	O
inflammatory	O
effects	O
,	O
The	O
phytochemistry	O
and	O
pharmacological	O
actions	O
of	O
all	O
Punica	O
granatum	O
components	O
suggest	O
a	O
wide	O
range	O
of	O
clinical	O
applications	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
,	O
as	O
well	O
as	O
other	O
diseases	O
where	O
chronic	O
inflammation	O
is	O
believed	O
to	O
play	O
an	O
essential	O
etiologic	O
role	O
.	O

Angiotensin	O
II	O
induces	O
soluble	O
fms	O
-	O
Like	O
tyrosine	O
kinase	O
-	O
1	O
release	O
via	O
calcineurin	O
signaling	O
pathway	O
in	O
pregnancy	O
.	O

Maternal	O
endothelial	O
dysfunction	O
in	O
preeclampsia	O
is	O
associated	O
with	O
increased	O
soluble	O
fms	O
-	O
like	O
tyrosine	O
kinase	O
-	O
1	O
(	O
sFlt	O
-	O
1	O
)	O
,	O
a	O
circulating	O
antagonist	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
placental	O
growth	O
factor	O
.	O

Angiotensin	O
II	O
(	O
Ang	O
II	O
)	O
is	O
a	O
potent	O
vasoconstrictor	O
that	O
increases	O
concomitant	O
with	O
sFlt	O
-	O
1	O
during	O
pregnancy	O
.	O

Therefore	O
,	O
we	O
speculated	O
that	O
Ang	O
II	O
may	O
promote	O
the	O
expression	O
of	O
sFlt	O
-	O
1	O
in	O
pregnancy	O
.	O

Here	O
we	O
report	O
that	O
infusion	O
of	O
Ang	O
II	O
significantly	O
increases	O
circulating	O
levels	O
of	O
sFlt	O
-	O
1	O
in	O
pregnant	O
mice	O
,	O
thereby	O
demonstrating	O
that	O
Ang	O
II	O
is	O
a	O
regulator	O
of	O
sFlt	O
-	O
1	O
secretion	O
in	O
vivo	O
.	O

Furthermore	O
,	O
Ang	O
II	O
stimulated	O
sFlt	O
-	O
1	O
production	O
in	O
a	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manner	O
from	O
human	O
villous	O
explants	O
and	O
cultured	O
trophoblasts	O
but	O
not	O
from	O
endothelial	O
cells	O
,	O
suggesting	O
that	O
trophoblasts	O
are	O
the	O
primary	O
source	O
of	O
sFlt	O
-	O
1	O
during	O
pregnancy	O
.	O

As	O
expected	O
,	O
Ang	O
II	O
-	O
induced	O
sFlt	O
-	O
1	O
secretion	O
resulted	O
in	O
the	O
inhibition	O
of	O
endothelial	O
cell	O
migration	O
and	O
in	O
vitro	O
tube	O
formation	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
with	O
losartan	O
,	O
small	O
interfering	O
RNA	O
specific	O
for	O
calcineurin	O
and	O
FK506	O
demonstrated	O
that	O
Ang	O
II	O
-	O
mediated	O
sFlt	O
-	O
1	O
release	O
was	O
via	O
Ang	O
II	O
type	O
1	O
receptor	O
activation	O
and	O
calcineurin	O
signaling	O
,	O
respectively	O
.	O

These	O
findings	O
reveal	O
a	O
previously	O
unrecognized	O
regulatory	O
role	O
for	O
Ang	O
II	O
on	O
sFlt	O
-	O
1	O
expression	O
in	O
murine	O
and	O
human	O
pregnancy	O
and	O
suggest	O
that	O
elevated	O
sFlt	O
-	O
1	O
levels	O
in	O
preeclampsia	O
may	O
be	O
caused	O
by	O
a	O
dysregulation	O
of	O
the	O
local	O
renin	O
/	O
angiotensin	O
system	O
.	O

p21	O
delays	O
tumor	O
onset	O
by	O
preservation	O
of	O
chromosomal	O
stability	O
.	O

The	O
p53	O
protein	O
suppresses	O
tumorigenesis	O
by	O
initiating	O
cellular	O
functions	O
such	O
as	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
in	O
response	O
to	O
DNA	O
damage	O
.	O

A	O
p53	O
mutant	O
,	O
p53R172P	O
,	O
which	O
is	O
deficient	O
for	O
apoptosis	O
but	O
retains	O
a	O
partial	O
cell	O
cycle	O
arrest	O
function	O
,	O
delays	O
tumor	O
onset	O
in	O
mice	O
.	O

Remarkably	O
,	O
lymphomas	O
arising	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
(	O
encoding	O
p53R172P	O
)	O
retain	O
stable	O
genomes	O
.	O

Given	O
the	O
dominant	O
role	O
of	O
p21	O
in	O
p53	O
cell	O
cycle	O
control	O
,	O
we	O
crossed	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
onto	O
a	O
p21	O
-	O
null	O
background	O
to	O
determine	O
whether	O
p21	O
was	O
required	O
for	O
maintaining	O
chromosomal	O
stability	O
and	O
delaying	O
tumor	O
onset	O
.	O

Loss	O
of	O
p21	O
completely	O
abolished	O
the	O
cell	O
cycle	O
arrest	O
function	O
of	O
p53R172P	O
and	O
accelerated	O
tumor	O
onset	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
mice	O
.	O

Cytogenetic	O
examination	O
of	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
p21	O
(	O
-	O
/	O
-	O
)	O
sarcomas	O
and	O
lymphomas	O
revealed	O
aneuploidy	O
and	O
chromosomal	O
aberrations	O
that	O
were	O
absent	O
in	O
Trp53	O
(	O
515C	O
/	O
515C	O
)	O
malignancies	O
.	O

Thus	O
,	O
p21	O
coupled	O
p53	O
-	O
dependent	O
checkpoint	O
control	O
and	O
preservation	O
of	O
chromosomal	O
stability	O
,	O
and	O
cooperated	O
with	O
apoptosis	O
in	O
suppressing	O
tumor	O
onset	O
in	O
mice	O
.	O

Role	O
of	O
the	O
fibrinolytic	O
and	O
matrix	O
metalloproteinase	O
systems	O
in	O
development	O
of	O
adipose	O
tissue	O
.	O

Obesity	O
is	O
a	O
common	O
disorder	O
and	O
related	O
diseases	O
such	O
as	O
diabetes	O
,	O
atherosclerosis	O
,	O
hypertension	O
,	O
cardiovascular	O
disease	O
and	O
cancer	O
are	O
a	O
major	O
cause	O
of	O
mortality	O
and	O
morbidity	O
in	O
Western	O
-	O
type	O
societies	O
.	O

Development	O
of	O
obesity	O
is	O
associated	O
with	O
extensive	O
modifications	O
in	O
adipose	O
tissue	O
involving	O
adipogenesis	O
,	O
angiogenesis	O
and	O
extracellular	O
matrix	O
proteolysis	O
.	O

The	O
fibrinolytic	O
(	O
plasminogen	O
/	O
plasmin	O
)	O
and	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
systems	O
cooperate	O
in	O
these	O
processes	O
.	O

A	O
nutritionally	O
induced	O
obesity	O
model	O
in	O
transgenic	O
mice	O
has	O
been	O
used	O
extensively	O
to	O
study	O
the	O
role	O
of	O
the	O
fibrinolytic	O
and	O
MMP	O
systems	O
in	O
the	O
development	O
of	O
obesity	O
.	O

These	O
studies	O
support	O
a	O
role	O
of	O
both	O
systems	O
in	O
adipogenesis	O
and	O
obesity	O
;	O
the	O
role	O
of	O
specific	O
members	O
of	O
these	O
families	O
,	O
however	O
,	O
remains	O
to	O
be	O
determined	O
.	O

Recombinant	O
human	O
prothrombin	O
kringle	O
-	O
2	O
inhibits	O
B16F10	B
melanoma	O
metastasis	O
through	O
inhibition	O
of	O
neovascularization	O
and	O
reduction	O
of	O
matrix	O
metalloproteinase	O
expression	O
.	O

Angiogenesis	O
,	O
a	O
multi	O
-	O
step	O
process	O
which	O
involves	O
endothelial	O
cell	O
proliferation	O
,	O
adhesion	O
,	O
migration	O
,	O
and	O
basement	O
membrane	O
(	O
BM	O
)	O
degradation	O
,	O
is	O
essential	O
for	O
tumor	O
metastasis	O
.	O

Here	O
we	O
show	O
that	O
recombinant	O
human	O
prothrombin	O
kringle	O
-	O
2	O
(	O
rk	O
-	O
2	O
)	O
inhibited	O
bovine	O
capillary	O
endothelial	O
cell	O
migration	O
with	O
an	O
IC	O
(	O
50	O
)	O
(	O
concentration	O
for	O
half	O
maximal	O
inhibition	O
)	O
of	O
38	O
nM	O
and	O
inhibited	O
adhesion	O
to	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
proteins	O
.	O

Because	O
tumor	O
metastasis	O
requires	O
angiogenesis	O
,	O
we	O
examined	O
whether	O
rk	O
-	O
2	O
could	O
inhibit	O
metastases	O
induced	O
by	O
injection	O
of	O
B16F10	B
melanoma	O
cells	O
into	O
mice	O
.	O

The	O
results	O
revealed	O
that	O
the	O
metastatic	O
tumors	O
in	O
mouse	O
lung	O
were	O
markedly	O
decreased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
acute	O
lung	O
injury	O
induced	O
by	O
B16F10	B
melanoma	O
metastasis	O
was	O
diminished	O
by	O
systemic	O
rk	O
-	O
2	O
treatment	O
.	O

In	O
immunohistochemical	O
analysis	O
,	O
rk	O
-	O
2	O
reduced	O
expression	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
which	O
is	O
a	O
potent	O
angiogenic	O
activator	O
and	O
neovascularization	O
in	O
the	O
mouse	O
lung	O
.	O

Also	O
,	O
rk	O
-	O
2	O
diminished	O
the	O
expression	O
of	O
matrix	O
metalloproteinase	O
-	O
2	O
and	O
-	O
9	O
in	O
the	O
mouse	O
lung	O
which	O
induces	O
tumor	O
metastasis	O
and	O
angiogenesis	O
.	O

These	O
data	O
suggest	O
that	O
inhibition	O
of	O
B16F10	B
melanoma	O
metastasis	O
by	O
rk	O
-	O
2	O
was	O
caused	O
by	O
inhibition	O
of	O
neovascularization	O
and	O
reduction	O
of	O
matrix	O
metalloproteinase	O
expression	O
.	O

Extracellular	O
matrix	O
as	O
a	O
bioactive	O
material	O
for	O
soft	O
tissue	O
reconstruction	O
.	O

The	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
directs	O
all	O
phases	O
of	O
healing	O
following	O
trauma	O
or	O
disease	O
and	O
is	O
therefore	O
a	O
natural	O
source	O
of	O
prosthetic	O
mesh	O
material	O
that	O
can	O
be	O
used	O
strategically	O
to	O
induce	O
the	O
repair	O
and	O
restoration	O
of	O
soft	O
tissues	O
following	O
surgery	O
.	O

Biomaterials	O
such	O
as	O
Surgisis	O
(	O
Cook	O
Biotech	O
Incorporated	O
,	O
West	O
Lafayette	O
,	O
IN	O
,	O
USA	O
)	O
,	O
which	O
are	O
derived	O
from	O
natural	O
ECM	O
,	O
provide	O
the	O
extracellular	O
components	O
necessary	O
to	O
direct	O
the	O
healing	O
response	O
,	O
allow	O
for	O
the	O
proliferation	O
of	O
new	O
,	O
healthy	O
tissue	O
and	O
restore	O
tissue	O
integrity	O
to	O
the	O
damaged	O
site	O
.	O

The	O
3	O
-	O
D	O
organization	O
of	O
these	O
extracellular	O
components	O
distinguishes	O
the	O
Surgisis	O
mesh	O
from	O
synthetic	O
materials	O
and	O
is	O
associated	O
with	O
constructive	O
tissue	O
remodelling	O
instead	O
of	O
scar	O
tissue	O
.	O

Common	O
features	O
of	O
this	O
ECM	O
-	O
assisted	O
tissue	O
remodelling	O
include	O
angiogenesis	O
,	O
recruitment	O
of	O
circulating	O
progenitor	O
cells	O
and	O
constructive	O
remodelling	O
of	O
damaged	O
tissue	O
structures	O
.	O

The	O
tissue	O
response	O
to	O
this	O
biologic	O
mesh	O
is	O
discussed	O
in	O
the	O
context	O
of	O
recent	O
reports	O
on	O
clinical	O
hernia	O
repair	O
.	O

Activation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
through	O
reactive	O
oxygen	O
species	O
mediates	O
20	O
-	O
hydroxyeicosatetraenoic	O
acid	O
-	O
induced	O
endothelial	O
cell	O
proliferation	O
.	O

20	O
-	O
Hydroxyeicosatetraenoic	O
acid	O
(	O
20	O
-	O
HETE	O
)	O
is	O
formed	O
by	O
the	O
omega	O
-	O
hydroxylation	O
of	O
arachidonic	O
acid	O
by	O
cytochrome	O
P450	O
4A	O
and	O
4F	O
enzymes	O
,	O
and	O
it	O
induces	O
angiogenic	O
responses	O
in	O
vivo	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
20	O
-	O
HETE	O
increases	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
via	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
,	O
we	O
studied	O
the	O
effects	O
of	O
WIT003	O
[	O
20	O
-	O
hydroxyeicosa	O
-	O
5	O
(	O
Z	O
)	O
,	O
14	O
(	O
Z	O
)	O
-	O
dienoic	O
acid	O
]	O
,	O
a	O
20	O
-	O
HETE	O
analog	O
on	O
human	O
macrovascular	O
or	O
microvascular	O
EC	O
.	O

WIT003	O
,	O
as	O
well	O
as	O
pure	O
20	O
-	O
HETE	O
,	O
stimulated	O
EC	O
proliferation	O
by	O
approximately	O
40	O
%	O
.	O

These	O
proliferative	O
effects	O
were	O
accompanied	O
by	O
increased	O
VEGF	O
expression	O
and	O
release	O
that	O
were	O
observed	O
as	O
early	O
as	O
4	O
h	O
after	O
20	O
-	O
HETE	O
agonist	O
addition	O
.	O

This	O
was	O
accompanied	O
by	O
increased	O
phosphorylation	O
of	O
the	O
VEGF	O
receptor	O
2	O
.	O

The	O
proliferative	O
effects	O
of	O
20	O
-	O
HETE	O
were	O
markedly	O
inhibited	O
by	O
a	O
VEGF	O
-	O
neutralizing	O
antibody	O
.	O

Polyethylene	O
glycol	O
-	O
superoxide	O
dismutase	O
(	O
PEG	O
-	O
SOD	O
)	O
markedly	O
inhibited	O
both	O
the	O
increases	O
in	O
VEGF	O
expression	O
and	O
the	O
proliferative	O
effects	O
of	O
20	O
-	O
HETE	O
.	O

In	O
contrast	O
,	O
administration	O
of	O
the	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
inhibitor	O
apocynin	O
had	O
no	O
effect	O
to	O
the	O
proliferative	O
response	O
to	O
20	O
-	O
HETE	O
.	O

The	O
20	O
-	O
HETE	O
agonist	O
markedly	O
increased	O
superoxide	O
formation	O
as	O
reflected	O
by	O
an	O
increase	O
in	O
dihydroethidium	O
staining	O
of	O
EC	O
,	O
and	O
this	O
increase	O
was	O
inhibited	O
by	O
PEG	O
-	O
SOD	O
but	O
not	O
by	O
apocynin	O
.	O

20	O
-	O
HETE	O
also	O
increased	O
the	O
phosphorylation	O
of	O
p42	O
/	O
p44	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
in	O
EC	O
,	O
whereas	O
an	O
inhibitor	O
of	O
MAPK	O
[	O
U0126	O
,	O
1	O
,	O
4	O
-	O
diamino	O
-	O
2	O
,	O
3	O
-	O
dicyano	O
-	O
1	O
,	O
4	O
-	O
bis	O
(	O
2	O
-	O
aminophenylthio	O
)	O
butadiene	O
]	O
suppressed	O
the	O
proliferative	O
and	O
the	O
VEGF	O
changes	O
but	O
not	O
the	O
pro	O
-	O
oxidant	O
effects	O
of	O
20	O
-	O
HETE	O
.	O

These	O
data	O
suggest	O
that	O
20	O
-	O
HETE	O
stimulates	O
superoxide	O
formation	O
by	O
pathways	O
other	O
than	O
apocynin	O
-	O
sensitive	O
NAD	O
(	O
P	O
)	O
H	O
oxidase	O
,	O
thereby	O
activating	O
MAPK	O
and	O
then	O
enhancing	O
VEGF	O
synthesis	O
that	O
drives	O
EC	O
proliferation	O
.	O

Thus	O
,	O
20	O
-	O
HETE	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
EC	O
functions	O
,	O
such	O
as	O
angiogenesis	O
.	O

Relationship	O
of	O
cellular	O
immunity	O
,	O
cytokines	O
and	O
CRP	O
with	O
clinical	O
course	O
in	O
breast	O
cancer	O
patients	O
with	O
endocrine	O
-	O
dependent	O
distant	O
metastases	O
treated	O
with	O
immunotherapy	O
.	O

We	O
have	O
reported	O
important	O
benefits	O
and	O
survival	O
with	O
an	O
immunotherapy	O
schedule	O
in	O
patients	O
with	O
endocrine	O
-	O
dependent	O
breast	O
cancer	O
and	O
distant	O
metastases	O
.	O

Here	O
clinical	O
outcome	O
is	O
updated	O
and	O
its	O
correlation	O
with	O
new	O
immunological	O
data	O
is	O
shown	O
.	O

In	O
32	O
evaluated	O
breast	O
cancer	O
patients	O
with	O
endocrine	O
-	O
dependent	O
distant	O
metastases	O
treated	O
with	O
a	O
new	O
immunotherapy	O
schedule	O
(	O
cyclic	O
administration	O
of	O
beta	O
-	O
interferon	O
and	O
interleukin	O
-	O
2	O
)	O
,	O
cellular	O
immunity	O
,	O
cytokines	O
and	O
CRP	O
were	O
related	O
to	O
the	O
clinical	O
course	O
.	O

Estimated	O
and	O
true	O
5	O
-	O
10	O
year	O
overall	O
survival	O
rates	O
from	O
first	O
line	O
antiestrogen	O
and	O
distant	O
metastases	O
were	O
higher	O
than	O
previously	O
reported	O
in	O
a	O
similar	O
population	O
.	O

Interleukin	O
-	O
2	O
administration	O
was	O
followed	O
by	O
a	O
significant	O
increase	O
in	O
total	O
lymphocytes	O
,	O
CD4	O
+	O
,	O
CD8	O
+	O
,	O
CD16	O
+	O
56	O
+	O
(	O
NK	O
)	O
cells	O
,	O
IL	O
-	O
6	O
,	O
IL	O
-	O
12	O
,	O
and	O
CRP	O
(	O
from	O
P	O
<	O
0	O
.	O
04	O
to	O
P	O
<	O
0	O
.	O
000	O
)	O
but	O
no	O
change	O
in	O
IL	O
-	O
10	O
and	O
TGFbeta1	O
during	O
clinical	O
benefit	O
.	O

During	O
progressive	O
disease	O
no	O
change	O
was	O
observed	O
in	O
the	O
former	O
parameters	O
,	O
concomitant	O
with	O
a	O
significant	O
increase	O
in	O
IL	O
-	O
10	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
and	O
a	O
significant	O
decrease	O
in	O
TGFbeta1	O
(	O
P	O
=	O
0	O
.	O
023	O
)	O
.	O

These	O
findings	O
confirm	O
that	O
cellular	O
immunity	O
is	O
significantly	O
stimulated	O
by	O
IL	O
-	O
2	O
only	O
during	O
clinical	O
benefit	O
.	O

Furthermore	O
,	O
these	O
results	O
demonstrate	O
that	O
different	O
changes	O
of	O
proinflammatory	O
cytokines	O
,	O
CRP	O
and	O
inhibiting	O
factors	O
are	O
consistent	O
with	O
associated	O
clinical	O
benefit	O
or	O
with	O
disease	O
progression	O
,	O
respectively	O
.	O

Trib1	O
and	O
Evi1	O
cooperate	O
with	O
Hoxa	O
and	O
Meis1	O
in	O
myeloid	O
leukemogenesis	O
.	O

Cooperative	O
activation	O
of	O
Meis1	O
and	O
Hoxa9	O
perturbs	O
myeloid	O
differentiation	O
and	O
eventually	O
leads	O
myeloid	O
progenitors	O
to	O
leukemia	O
,	O
yet	O
it	O
remains	O
to	O
be	O
clarified	O
what	O
kinds	O
of	O
subsequent	O
molecular	O
processes	O
are	O
required	O
for	O
development	O
of	O
overt	O
leukemia	O
.	O

To	O
understand	O
the	O
molecular	O
pathway	O
in	O
Hoxa9	O
/	O
Meis1	O
-	O
induced	O
leukemogenesis	O
,	O
retroviral	O
insertional	O
mutagenesis	O
was	O
applied	O
using	O
retrovirus	O
-	O
mediated	O
gene	O
transfer	O
.	O

The	O
mice	O
that	O
received	O
Hoxa9	O
/	O
Meis1	O
-	O
transduced	O
bone	O
marrow	O
cells	O
developed	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
,	O
and	O
Trib1	O
,	O
Evi1	O
,	O
Ahi1	O
,	O
Raralpha	O
,	O
Pitpnb	O
,	O
and	O
AK039950	O
were	O
identified	O
as	O
candidate	O
cooperative	O
genes	O
located	O
near	O
common	O
retroviral	O
integration	O
sites	O
.	O

Trib1	O
and	O
Evi1	O
were	O
up	O
-	O
regulated	O
due	O
to	O
retroviral	O
insertions	O
,	O
and	O
coexpression	O
of	O
these	O
genes	O
significantly	O
accelerated	O
the	O
onset	O
of	O
Hoxa9	O
/	O
Meis1	O
-	O
induced	O
AML	O
,	O
suggesting	O
that	O
Trib1	O
and	O
Evi1	O
are	O
the	O
key	O
collaborators	O
.	O

Furthermore	O
,	O
Trib1	O
by	O
itself	O
is	O
a	O
novel	O
myeloid	O
oncogene	O
,	O
enhancing	O
phosphorylation	O
of	O
ERK	O
,	O
resulting	O
in	O
inhibition	O
of	O
apoptosis	O
.	O

These	O
results	O
demonstrate	O
the	O
importance	O
of	O
specific	O
oncogene	O
interaction	O
in	O
myeloid	O
leukemogenesis	O
.	O

Pro	O
/	O
antioxidant	O
status	O
and	O
AP	O
-	O
1	O
transcription	O
factor	O
in	O
murine	O
skin	O
following	O
topical	O
exposure	O
to	O
cumene	O
hydroperoxide	O
.	O

Organic	O
peroxides	O
,	O
widely	O
used	O
in	O
the	O
chemical	O
and	O
pharmaceutical	O
industries	O
,	O
can	O
act	O
as	O
skin	O
tumor	O
promoters	O
and	O
cause	O
epidermal	O
hyperplasia	O
.	O

They	O
are	O
also	O
known	O
to	O
trigger	O
free	O
radical	O
generation	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
effect	O
of	O
cumene	O
hydroperoxide	O
(	O
Cum	O
-	O
OOH	O
)	O
on	O
the	O
induction	O
of	O
activator	O
protein	O
-	O
1	O
(	O
AP	O
-	O
1	O
)	O
,	O
which	O
is	O
linked	O
to	O
the	O
expression	O
of	O
genes	O
regulating	O
cell	O
proliferation	O
,	O
growth	O
and	O
transformation	O
.	O

Previously	O
,	O
we	O
reported	O
that	O
topical	O
exposure	O
to	O
Cum	O
-	O
OOH	O
caused	O
formation	O
of	O
free	O
radicals	O
and	O
oxidative	O
stress	O
in	O
the	O
skin	O
of	O
vitamin	O
E	O
-	O
deficient	O
mice	O
.	O

The	O
present	O
study	O
used	O
JB6	O
P	O
+	O
mouse	O
epidermal	O
cells	O
and	O
AP	O
-	O
1	O
-	O
luciferase	O
reporter	O
transgenic	O
mice	O
to	O
identify	O
whether	O
exposure	O
to	O
Cum	O
-	O
OOH	O
caused	O
activation	O
of	O
AP	O
-	O
1	O
,	O
oxidative	O
stress	O
,	O
depletion	O
of	O
antioxidants	O
and	O
tumor	O
formation	O
during	O
two	O
-	O
stage	O
carcinogenesis	O
.	O

In	O
vitro	O
studies	O
found	O
that	O
exposure	O
to	O
Cum	O
-	O
OOH	O
reduced	O
the	O
level	O
of	O
glutathione	O
(	O
GSH	O
)	O
in	O
mouse	O
epidermal	O
cells	O
(	O
JB6	O
P	O
+	O
)	O
and	O
caused	O
the	O
induction	O
of	O
AP	O
-	O
1	O
.	O

Mice	O
primed	O
with	O
dimethyl	O
-	O
benz	O
[	O
a	O
]	O
anthracene	O
(	O
DMBA	O
)	O
were	O
topically	O
exposed	O
to	O
Cum	O
-	O
OOH	O
(	O
82	O
.	O
6	O
micromol	O
)	O
or	O
the	O
positive	O
control	O
,	O
12	O
-	O
O	O
-	O
tetradecanoylphorbol	O
-	O
13	O
-	O
acetate	O
(	O
TPA	O
,	O
17	O
nmol	O
)	O
,	O
twice	O
weekly	O
for	O
29	O
weeks	O
.	O

Activation	O
of	O
AP	O
-	O
1	O
in	O
skin	O
was	O
detected	O
as	O
early	O
as	O
2	O
weeks	O
following	O
Cum	O
-	O
OOH	O
or	O
TPA	O
exposure	O
.	O

No	O
AP	O
-	O
1	O
expression	O
was	O
found	O
19	O
weeks	O
after	O
initiation	O
.	O

Papilloma	O
formation	O
was	O
observed	O
in	O
both	O
the	O
DMBA	O
-	O
TPA	O
-	O
and	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
exposed	O
animals	O
,	O
whereas	O
skin	O
carcinomas	O
were	O
found	O
only	O
in	O
the	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
treated	O
mice	O
.	O

A	O
greater	O
accumulation	O
of	O
peroxidative	O
products	O
(	O
thiobarbituric	O
acid	O
-	O
reactive	O
substances	O
)	O
,	O
inflammation	O
and	O
decreased	O
levels	O
of	O
GSH	O
and	O
total	O
antioxidant	O
reserves	O
were	O
also	O
observed	O
in	O
the	O
skin	O
of	O
DMBA	O
-	O
Cum	O
-	O
OOH	O
-	O
exposed	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
Cum	O
-	O
OOH	O
-	O
induced	O
carcinogenesis	O
is	O
accompanied	O
by	O
increased	O
AP	O
-	O
1	O
activation	O
and	O
changes	O
in	O
antioxidant	O
status	O
.	O

Segmental	O
atrial	O
contraction	O
in	O
patients	O
restored	O
to	O
sinus	O
rhythm	O
after	O
cardioversion	O
for	O
chronic	O
atrial	O
fibrillation	O
:	O
a	O
colour	O
Doppler	O
tissue	O
imaging	O
study	O
.	O

AIMS	O
:	O

There	O
is	O
little	O
known	O
about	O
segmental	O
atrial	O
function	O
in	O
patients	O
with	O
atrial	O
arrhythmias	O
.	O

We	O
evaluated	O
segmental	O
atrial	O
contractility	O
using	O
colour	O
Doppler	O
tissue	O
imaging	O
(	O
CDTI	O
)	O
in	O
patients	O
with	O
chronic	O
atrial	O
fibrillation	O
(	O
CAF	O
)	O
who	O
were	O
successfully	O
restored	O
and	O
maintained	O
in	O
sinus	O
rhythm	O
(	O
SR	O
)	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O

We	O
compared	O
the	O
segmental	O
atrial	O
contractility	O
in	O
39	O
CAF	O
patients	O
who	O
were	O
successfully	O
cardioverted	O
and	O
maintained	O
in	O
SR	O
for	O
6	O
months	O
.	O

Follow	O
up	O
echocardiograms	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
week	O
,	O
1	O
month	O
and	O
6	O
months	O
and	O
compared	O
to	O
a	O
normal	O
age	O
matched	O
cohort	O
(	O
n	O
=	O
34	O
)	O
.	O

Using	O
CDTI	O
,	O
mean	O
peak	O
velocities	O
of	O
atrial	O
contraction	O
were	O
measured	O
from	O
annular	O
,	O
mid	O
and	O
superior	O
segments	O
of	O
lateral	O
and	O
septal	O
walls	O
of	O
the	O
left	O
atrium	O
and	O
right	O
atrium	O
in	O
the	O
apical	O
four	O
-	O
chamber	O
view	O
.	O

Segmental	O
velocities	O
from	O
the	O
posterior	O
and	O
anterior	O
walls	O
of	O
the	O
left	O
atrium	O
were	O
measured	O
from	O
the	O
apical	O
two	O
-	O
chamber	O
view	O
.	O

Segmental	O
left	O
atrial	O
velocities	O
improved	O
over	O
time	O
in	O
the	O
CAF	O
group	O
,	O
with	O
the	O
majority	O
of	O
the	O
recovery	O
occurring	O
in	O
the	O
first	O
month	O
,	O
but	O
failed	O
to	O
normalise	O
even	O
at	O
6	O
months	O
.	O

In	O
comparison	O
,	O
the	O
right	O
atrial	O
velocities	O
in	O
the	O
AF	O
group	O
had	O
normalised	O
at	O
1	O
month	O
.	O

CONCLUSION	O
:	O

Patients	O
with	O
CAF	O
have	O
persistent	O
segmental	O
left	O
atrial	O
dysfunction	O
even	O
6	O
months	O
after	O
restoration	O
and	O
maintenance	O
of	O
SR	O
,	O
though	O
right	O
atrial	O
velocities	O
appear	O
to	O
normalise	O
.	O

This	O
differential	O
recovery	O
indicates	O
that	O
left	O
atrial	O
function	O
remains	O
subnormal	O
in	O
patients	O
with	O
CAF	O
despite	O
maintenance	O
of	O
SR	O
,	O
suggesting	O
underlying	O
atrial	O
myopathy	O
or	O
fibrosis	O
as	O
a	O
consequence	O
of	O
CAF	O
.	O

[	O
Study	O
on	O
the	O
expression	O
of	O
angiogenesis	O
and	O
spontaneous	O
apoptosis	O
and	O
their	O
relevance	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
]	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
relationship	O
among	O
angiogenesis	O
,	O
spontaneous	O
apoptosis	O
and	O
clinicopathological	O
parameters	O
in	O
laryngeal	O
squamous	O
cell	O
carcinoma	O
(	O
LSCC	O
)	O
.	O

METHOD	O
:	O
The	O
intratumor	O
microvessel	O
density	O
(	O
IMVD	O
)	O
,	O
apoptotic	O
index	O
(	O
AI	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
were	O
detected	O
by	O
immunohistochemistry	O
SABC	O
and	O
terminal	O
uridine	O
deoxynucleotidyl	O
transferase	O
mediated	O
nick	O
end	O
labeling	O
(	O
TUNEL	O
)	O
methods	O
in34	O
LSCC	O
patients	O
.	O

RESULT	O
:	O
The	O
average	O
IMVD	O
was	O
(	O
21	O
.	O
50	O
+	O
/	O
-	O
8	O
.	O
87	O
)	O
,	O
and	O
median	O
of	O
AI	O
was	O
1	O
.	O
15	O
%	O
.	O

The	O
average	O
IMVD	O
in	O
positive	O
and	O
negative	O
cervical	O
lymphatic	O
metastasis	O
was	O
(	O
26	O
.	O
33	O
+	O
/	O
-	O
9	O
.	O
70	O
)	O
and	O
(	O
17	O
.	O
68	O
+	O
/	O
-	O
6	O
.	O
06	O
)	O
respectively	O
,	O
and	O
the	O
IMVD	O
with	O
positive	O
lymphatic	O
metastasis	O
tumors	O
was	O
statistical	O
significantly	O
higher	O
than	O
those	O
with	O
negative	O
cervical	O
lymphatic	O
metastasis	O
tumors	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

The	O
average	O
IMVD	O
had	O
statistical	O
difference	O
in	O
histological	O
grading	O
(	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
,	O
and	O
analysis	O
by	O
one	O
to	O
one	O
,	O
the	O
average	O
IMVD	O
had	O
statistical	O
difference	O
between	O
high	O
and	O
median	O
grading	O
.	O

Expression	O
of	O
VEGF	O
had	O
a	O
significantly	O
positive	O
correlation	O
with	O
IMVD	O
(	O
r	O
=	O
0	O
.	O
51	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Statistical	O
analysis	O
revealed	O
a	O
significantly	O
inverse	O
correlation	O
between	O
AI	O
and	O
IMVD	O
(	O
r	O
=	O
-	O
0	O
.	O
53	O
,	O
P	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

We	O
failed	O
to	O
find	O
the	O
statistical	O
difference	O
between	O
IMVD	O
and	O
tumor	O
T	O
-	O
stage	O
in	O
LSCC	O
.	O

CONCLUSION	O
:	O
IMVD	O
may	O
be	O
an	O
important	O
indicator	O
to	O
predict	O
cervical	O
lymphatic	O
metastasis	O
in	O
LSCC	O
.	O

VEGF	O
might	O
be	O
an	O
important	O
angiogenic	O
factor	O
,	O
and	O
could	O
promote	O
tumor	O
angiogenesis	O
in	O
LSCC	O
.	O

Tumor	O
angiogenesis	O
might	O
contribute	O
to	O
tumor	O
malignant	O
progression	O
by	O
inhibiting	O
spontaneous	O
apoptosis	O
in	O
LSCC	O
.	O

Hyperforin	O
blocks	O
neutrophil	O
activation	O
of	O
matrix	O
metalloproteinase	O
-	O
9	O
,	O
motility	O
and	O
recruitment	O
,	O
and	O
restrains	O
inflammation	O
-	O
triggered	O
angiogenesis	O
and	O
lung	O
fibrosis	O
.	O

Hyperforin	O
(	O
Hyp	O
)	O
,	O
a	O
polyphenol	O
-	O
derivative	O
of	O
St	O
.	O

John	O
'	O
s	O
wort	O
(	O
Hypericum	O
perforatum	O
)	O
,	O
has	O
emerged	O
as	O
key	O
player	O
not	O
only	O
in	O
the	O
antidepressant	O
activity	O
of	O
the	O
plant	O
but	O
also	O
as	O
an	O
inhibitor	O
of	O
bacteria	O
lymphocyte	O
and	O
tumor	O
cell	O
proliferation	O
,	O
and	O
matrix	O
proteinases	O
.	O

We	O
tested	O
whether	O
as	O
well	O
as	O
inhibiting	O
leukocyte	O
elastase	O
(	O
LE	O
)	O
activity	O
,	O
Hyp	O
might	O
be	O
effective	O
in	O
containing	O
both	O
polymorphonuclear	O
neutrophil	O
(	O
PMN	O
)	O
leukocyte	O
recruitment	O
and	O
unfavorable	O
eventual	O
tissue	O
responses	O
.	O

The	O
results	O
show	O
that	O
,	O
without	O
affecting	O
in	O
vitro	O
human	O
PMN	O
viability	O
and	O
chemokine	O
-	O
receptor	O
expression	O
,	O
Hyp	O
(	O
as	O
stable	O
dicyclohexylammonium	O
salt	O
)	O
was	O
able	O
to	O
inhibit	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
their	O
chemotaxis	O
and	O
chemoinvasion	O
(	O
IC50	O
=	O
1	O
microM	O
for	O
both	O
)	O
;	O
this	O
effect	O
was	O
associated	O
with	O
a	O
reduced	O
expression	O
of	O
the	O
adhesion	O
molecule	O
CD11b	O
by	O
formyl	O
-	O
Met	O
-	O
Leu	O
-	O
Phe	O
-	O
stimulated	O
neutrophils	O
and	O
block	O
of	O
LE	O
-	O
triggered	O
activation	O
of	O
the	O
gelatinase	O
matrix	O
metalloproteinase	O
-	O
9	O
.	O

PMN	O
-	O
triggered	O
angiogenesis	O
is	O
also	O
blocked	O
by	O
both	O
local	O
injection	O
and	O
daily	O
i	O
.	O
p	O
.	O
administration	O
of	O
the	O
Hyp	O
salt	O
in	O
an	O
interleukin	O
-	O
8	O
-	O
induced	O
murine	O
model	O
.	O

Furthermore	O
,	O
i	O
.	O
p	O
.	O
treatment	O
with	O
Hyp	O
reduces	O
acute	O
PMN	O
recruitment	O
and	O
enhances	O
resolution	O
in	O
a	O
pulmonary	O
bleomycin	O
-	O
induced	O
inflammation	O
model	O
,	O
significantly	O
reducing	O
consequent	O
fibrosis	O
.	O

These	O
results	O
indicate	O
that	O
Hyp	O
is	O
a	O
powerful	O
anti	O
-	O
inflammatory	O
compound	O
with	O
therapeutic	O
potential	O
,	O
and	O
they	O
elucidate	O
mechanistic	O
keys	O
.	O

New	O
vectors	O
and	O
strategies	O
for	O
cardiovascular	O
gene	O
therapy	O
.	O

Cardiovascular	O
diseases	O
are	O
the	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
both	O
men	O
and	O
women	O
in	O
industrially	O
developed	O
countries	O
.	O

These	O
disorders	O
may	O
result	O
from	O
impaired	O
angiogenesis	O
,	O
particularly	O
in	O
response	O
to	O
hypoxia	O
.	O

Despite	O
many	O
limitations	O
,	O
gene	O
therapy	O
is	O
still	O
emerging	O
as	O
a	O
potential	O
alternative	O
for	O
patients	O
who	O
are	O
not	O
candidates	O
for	O
traditional	O
revascularization	O
procedures	O
,	O
like	O
angioplasty	O
or	O
vein	O
grafts	O
.	O

This	O
review	O
focuses	O
on	O
recent	O
approaches	O
in	O
the	O
development	O
of	O
new	O
gene	O
delivery	O
vectors	O
,	O
with	O
great	O
respect	O
to	O
newly	O
discovered	O
AAV	O
serotypes	O
and	O
their	O
modified	O
forms	O
.	O

Moreover	O
,	O
some	O
new	O
cardiovascular	O
gene	O
therapy	O
strategies	O
have	O
been	O
highlighted	O
,	O
such	O
as	O
combination	O
of	O
different	O
angiogenic	O
growth	O
factors	O
or	O
simultaneous	O
application	O
of	O
genes	O
and	O
progenitor	O
cells	O
in	O
order	O
to	O
obtain	O
stable	O
and	O
functional	O
blood	O
vessels	O
in	O
ischemic	O
tissue	O
.	O

Impaired	O
apoptosis	O
of	O
pulmonary	O
endothelial	O
cells	O
is	O
associated	O
with	O
intimal	O
proliferation	O
and	O
irreversibility	O
of	O
pulmonary	O
hypertension	O
in	O
congenital	O
heart	O
disease	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
sought	O
to	O
assess	O
the	O
cellular	O
and	O
histologic	O
basis	O
of	O
irreversible	O
pulmonary	O
hypertension	O
(	O
PHT	O
)	O
in	O
the	O
clinical	O
setting	O
of	O
congenital	O
heart	O
disease	O
(	O
CHD	O
)	O
.	O

BACKGROUND	O
:	O
Although	O
many	O
children	O
with	O
CHD	O
develop	O
pulmonary	O
vascular	O
disease	O
,	O
it	O
is	O
unclear	O
why	O
this	O
complication	O
is	O
reversible	O
after	O
complete	O
repair	O
in	O
some	O
cases	O
but	O
irreversible	O
in	O
others	O
.	O

Because	O
failure	O
of	O
endothelial	O
cell	O
apoptosis	O
might	O
lead	O
to	O
intimal	O
proliferation	O
and	O
lack	O
of	O
reversibility	O
of	O
PHT	O
,	O
we	O
investigated	O
this	O
and	O
other	O
key	O
markers	O
of	O
vasoactivity	O
and	O
angiogenesis	O
in	O
subjects	O
with	O
PHT	O
and	O
CHD	O
.	O

METHODS	O
:	O
We	O
assessed	O
antiapoptotic	O
and	O
proapoptotic	O
markers	O
in	O
vascular	O
and	O
perivascular	O
cells	O
in	O
lung	O
biopsy	O
samples	O
from	O
18	O
patients	O
with	O
CHD	O
,	O
7	O
with	O
reversible	O
and	O
11	O
with	O
irreversible	O
PHT	O
,	O
and	O
6	O
control	O
patients	O
.	O

Immunostaining	O
for	O
endothelial	O
nitric	O
oxide	O
synthase	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
and	O
CD34	O
(	O
markers	O
of	O
vasoactivity	O
and	O
neoangiogenesis	O
)	O
was	O
also	O
performed	O
.	O

RESULTS	O
:	O
The	O
antiapoptotic	O
protein	O
Bcl	O
-	O
2	O
was	O
highly	O
expressed	O
by	O
pulmonary	O
endothelial	O
cells	O
in	O
all	O
cases	O
of	O
irreversible	O
PHT	O
but	O
in	O
no	O
cases	O
of	O
reversible	O
PHT	O
,	O
nor	O
in	O
control	O
patients	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Intimal	O
proliferation	O
was	O
present	O
in	O
10	O
of	O
11	O
irreversible	O
PHT	O
cases	O
,	O
but	O
never	O
observed	O
in	O
reversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

Similarly	O
,	O
perivascular	O
inflammatory	O
T	O
-	O
cells	O
expressed	O
more	O
antiapoptotic	O
proteins	O
in	O
irreversible	O
PHT	O
(	O
p	O
less	O
than	O
0	O
.	O
01	O
)	O
.	O

Irreversible	O
PHT	O
cases	O
were	O
also	O
more	O
likely	O
to	O
show	O
compensatory	O
upregulation	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
new	O
small	O
vessel	O
formation	O
at	O
the	O
sites	O
of	O
native	O
vessel	O
stenosis	O
or	O
occlusion	O
(	O
p	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
Irreversible	O
PHT	O
is	O
strongly	O
associated	O
with	O
impaired	O
endothelial	O
cell	O
apoptosis	O
and	O
antiapoptotic	O
signaling	O
from	O
perivascular	O
inflammatory	O
cells	O
.	O

These	O
changes	O
are	O
associated	O
with	O
intimal	O
proliferation	O
and	O
vessel	O
narrowing	O
,	O
and	O
thereby	O
may	O
contribute	O
to	O
clinical	O
outcomes	O
associated	O
with	O
pulmonary	O
hypertension	O
.	O

Inhibition	O
of	O
Dll4	O
-	O
mediated	O
signaling	O
induces	O
proliferation	O
of	O
immature	O
vessels	O
and	O
results	O
in	O
poor	O
tissue	O
perfusion	O
.	O

Vascular	O
development	O
is	O
dependent	O
on	O
various	O
growth	O
factors	O
and	O
certain	O
modifiers	O
critical	O
for	O
providing	O
arterial	O
or	O
venous	O
identity	O
,	O
interaction	O
with	O
the	O
surrounding	O
stroma	O
and	O
tissues	O
,	O
hierarchic	O
network	O
formation	O
,	O
and	O
recruitment	O
of	O
pericytes	O
.	O

Notch	O
receptors	O
and	O
ligands	O
(	O
Jagged	O
and	O
Delta	O
-	O
like	O
)	O
play	O
a	O
critical	O
role	O
in	O
this	O
process	O
in	O
addition	O
to	O
VEGF	O
.	O

Dll4	O
is	O
one	O
of	O
the	O
Notch	O
ligands	O
that	O
regulates	O
arterial	O
specification	O
and	O
maturation	O
events	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
have	O
shown	O
that	O
loss	O
of	O
function	O
by	O
either	O
targeted	O
allele	O
deletion	O
or	O
use	O
of	O
a	O
soluble	O
form	O
of	O
Dll4	O
extracellular	O
domain	O
leads	O
to	O
inhibition	O
of	O
Notch	O
signaling	O
,	O
resulting	O
in	O
increased	O
vascular	O
proliferation	O
but	O
defective	O
maturation	O
.	O

Newly	O
forming	O
vessels	O
have	O
thin	O
caliber	O
,	O
a	O
markedly	O
reduced	O
vessel	O
lumen	O
,	O
markedly	O
reduced	O
pericyte	O
recruitment	O
,	O
and	O
deficient	O
vascular	O
perfusion	O
.	O

sDll4	O
similarly	O
induced	O
defective	O
vascular	O
response	O
in	O
tumor	O
implants	O
leading	O
to	O
reduced	O
tumor	O
growth	O
.	O

Interference	O
with	O
Dll4	O
-	O
Notch	O
signaling	O
may	O
be	O
particularly	O
desirable	O
in	O
tumors	O
that	O
have	O
highly	O
induced	O
Dll4	O
-	O
Notch	O
pathway	O
.	O

[	O
Diagnostic	O
value	O
of	O
DNA	O
,	O
RNA	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
examination	O
in	O
malignant	O
pleural	O
effusions	O
by	O
flow	O
cytometry	O
]	O
.	O

OBJECTIVE	O
:	O

To	O
study	O
the	O
diagnostic	O
value	O
of	O
DNA	O
,	O
RNA	O
and	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
examination	O
in	O
malignant	O
effusion	O
by	O
multiparametric	O
flow	O
cytometry	O
,	O
and	O
therefore	O
to	O
provide	O
proof	O
for	O
clinical	O
application	O
.	O

METHODS	O
:	O

Forty	O
seven	O
patients	O
with	O
pleural	O
effusions	O
in	O
our	O
hospital	O
from	O
August	O
2003	O
to	O
February	O
2004	O
were	O
divided	O
into	O
two	O
groups	O
:	O
19	O
suffering	O
from	O
benign	O
pleural	O
effusions	O
and	O
28	O
from	O
malignant	O
effusions	O
confirmed	O
by	O
pathologic	O
examination	O
.	O

The	O
cells	O
for	O
diagnosis	O
were	O
divided	O
into	O
four	O
groups	O
stained	O
by	O
PI	O
(	O
Propidium	O
-	O
iodide	O
)	O
,	O
PY	O
(	O
Pyronin	O
)	O
,	O
PCNA	O
-	O
FITC	O
and	O
PCNA	O
-	O
mouse	O
-	O
alpha	O
-	O
2a	O
.	O

The	O
specimens	O
were	O
analyzed	O
by	O
a	O
flow	O
cytometer	O
(	O
FacS	O
Caliber	O
,	O
Becton	O
Dickinson	O
)	O
.	O

The	O
sensitivity	O
and	O
the	O
specificity	O
of	O
each	O
examination	O
and	O
combined	O
examination	O
were	O
calculated	O
by	O
statistic	O
software	O
SPSS	O
13	O
.	O
0	O
.	O

RESULTS	O
:	O

(	O
1	O
)	O
The	O
expression	O
of	O
DI	O
,	O
RI	O
,	O
and	O
PI	O
in	O
benign	O
pleural	O
effusion	O
was	O
1	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
06	O
,	O
10	O
.	O
03	O
+	O
/	O
-	O
0	O
.	O
54	O
,	O
and	O
(	O
4	O
.	O
86	O
+	O
/	O
-	O
0	O
.	O
72	O
)	O
%	O
,	O
respectively	O
,	O
and	O
those	O
in	O
malignant	O
ones	O
was	O
1	O
.	O
26	O
+	O
/	O
-	O
0	O
.	O
17	O
,	O
11	O
.	O
65	O
+	O
/	O
-	O
1	O
.	O
45	O
,	O
and	O
(	O
11	O
.	O
97	O
+	O
/	O
-	O
1	O
.	O
50	O
)	O
%	O
,	O
respectively	O
,	O
the	O
difference	O
being	O
statistically	O
significant	O
.	O

The	O
cutoff	O
value	O
of	O
DI	O
,	O
RI	O
and	O
PI	O
was	O
1	O
.	O
10	O
%	O
,	O
10	O
.	O
75	O
%	O
and	O
4	O
.	O
56	O
%	O
,	O
and	O
the	O
sensitivity	O
of	O
DI	O
examination	O
was	O
89	O
.	O
3	O
%	O
,	O
78	O
.	O
6	O
%	O
,	O
75	O
.	O
0	O
%	O
,	O
and	O
the	O
specificity	O
was	O
89	O
.	O
5	O
%	O
,	O
98	O
.	O
5	O
%	O
,	O
84	O
.	O
2	O
%	O
,	O
respectively	O
.	O

(	O
2	O
)	O
In	O
6	O
cases	O
suffering	O
from	O
malignant	O
pleural	O
effusions	O
,	O
RI	O
was	O
positive	O
but	O
DI	O
was	O
negative	O
,	O
indicating	O
that	O
DI	O
combined	O
with	O
RI	O
examination	O
was	O
better	O
than	O
DI	O
examination	O
alone	O
.	O

(	O
3	O
)	O
In	O
5	O
cases	O
suffering	O
from	O
malignant	O
pleural	O
effusions	O
confirmed	O
by	O
tissue	O
examination	O
,	O
the	O
cytology	O
was	O
negative	O
,	O
but	O
the	O
result	O
of	O
DI	O
and	O
RI	O
was	O
abnormal	O
,	O
indicating	O
that	O
flow	O
cytometry	O
was	O
complementary	O
to	O
pathologic	O
examination	O
.	O

(	O
4	O
)	O
The	O
sensitivity	O
of	O
DI	O
+	O
RI	O
,	O
DI	O
+	O
PI	O
,	O
RI	O
+	O
PI	O
and	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
was	O
98	O
.	O
2	O
%	O
,	O
89	O
.	O
3	O
%	O
,	O
89	O
.	O
3	O
%	O
,	O
92	O
.	O
9	O
%	O
;	O
the	O
specificity	O
was	O
84	O
.	O
2	O
%	O
,	O
89	O
.	O
5	O
%	O
,	O
84	O
.	O
2	O
%	O
,	O
94	O
.	O
2	O
%	O
respectively	O
.	O

The	O
results	O
demonstrated	O
that	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
was	O
the	O
best	O
,	O
which	O
showed	O
the	O
least	O
false	O
negative	O
and	O
false	O
positive	O
results	O
.	O

The	O
sensitivity	O
of	O
DI	O
+	O
RI	O
combined	O
examination	O
was	O
98	O
.	O
2	O
%	O
,	O
but	O
the	O
specificity	O
was	O
84	O
.	O
2	O
%	O
,	O
the	O
false	O
positive	O
rate	O
being	O
higher	O
than	O
DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
.	O

In	O
none	O
of	O
the	O
benign	O
pleural	O
effusions	O
was	O
the	O
DI	O
+	O
RI	O
+	O
PI	O
higher	O
than	O
the	O
cutoff	O
value	O
,	O
suggesting	O
that	O
combined	O
examination	O
can	O
exclude	O
benign	O
pleural	O
effusions	O
.	O

CONCLUSIONS	O
:	O

DNA	O
,	O
RNA	O
and	O
PCNA	O
examinations	O
by	O
flow	O
cytometry	O
are	O
of	O
value	O
in	O
the	O
diagnosis	O
of	O
malignant	O
effusion	O
,	O
especially	O
for	O
cases	O
which	O
can	O
not	O
be	O
diagnosed	O
by	O
cytological	O
examination	O
.	O

DI	O
+	O
RI	O
+	O
PI	O
combined	O
examination	O
showed	O
better	O
results	O
with	O
the	O
lowest	O
false	O
negative	O
and	O
false	O
positive	O
rates	O
.	O

Schizophrenia	O
:	O
a	O
common	O
disease	O
caused	O
by	O
multiple	O
rare	O
alleles	O
.	O

Schizophrenia	O
is	O
widely	O
held	O
to	O
stem	O
from	O
the	O
combined	O
effects	O
of	O
multiple	O
common	O
polymorphisms	O
,	O
each	O
with	O
a	O
small	O
impact	O
on	O
disease	O
risk	O
.	O

We	O
suggest	O
an	O
alternative	O
view	O
:	O
that	O
schizophrenia	O
is	O
highly	O
heterogeneous	O
genetically	O
and	O
that	O
many	O
predisposing	O
mutations	O
are	O
highly	O
penetrant	O
and	O
individually	O
rare	O
,	O
even	O
specific	O
to	O
single	O
cases	O
or	O
families	O
.	O

This	O
""""	O
common	O
disease	O
-	O
-	O
rare	O
alleles	O
""""	O
hypothesis	O
is	O
supported	O
by	O
recent	O
findings	O
in	O
human	O
genomics	O
and	O
by	O
allelic	O
and	O
locus	O
heterogeneity	O
for	O
other	O
complex	O
traits	O
.	O

We	O
review	O
the	O
implications	O
of	O
this	O
model	O
for	O
gene	O
discovery	O
research	O
in	O
schizophrenia	O
.	O

SWAP	O
-	O
70	O
is	O
required	O
for	O
oncogenic	O
transformation	O
by	O
v	O
-	O
Src	O
in	O
mouse	O
embryo	O
fibroblasts	O
.	O

SWAP	O
-	O
70	O
is	O
a	O
phosphatidylinositol	O
trisphosphate	O
(	O
PtdIns	O
(	O
3	O
,	O
4	O
,	O
5	O
)	O
P	O
(	O
3	O
)	O
)	O
binding	O
protein	O
,	O
which	O
acts	O
in	O
F	O
-	O
actin	O
rearrangement	O
.	O

The	O
role	O
of	O
SWAP	O
-	O
70	O
in	O
oncogenic	O
transformation	O
of	O
mouse	O
embryo	O
fibroblasts	O
(	O
MEFs	O
)	O
by	O
v	O
-	O
Src	O
was	O
examined	O
by	O
use	O
of	O
MEFs	O
defective	O
in	O
SWAP	O
-	O
70	O
.	O

v	O
-	O
Src	O
morphologically	O
transformed	O
MEFs	O
lacking	O
SWAP	O
-	O
70	O
,	O
but	O
growth	O
of	O
the	O
transformed	O
cells	O
in	O
culture	O
was	O
slower	O
than	O
that	O
of	O
cells	O
supplemented	O
with	O
exogenous	O
SWAP	O
-	O
70	O
.	O

The	O
v	O
-	O
Src	O
-	O
transformed	O
MEFs	O
deficient	O
in	O
SWAP	O
-	O
70	O
were	O
unable	O
to	O
grow	O
in	O
soft	O
agar	O
while	O
those	O
expressing	O
SWAP70	O
readily	O
formed	O
colonies	O
,	O
suggesting	O
that	O
SWAP	O
-	O
70	O
is	O
required	O
for	O
anchorage	O
independent	O
growth	O
of	O
v	O
-	O
Src	O
transformed	O
MEFs	O
.	O

When	O
transplanted	O
in	O
nude	O
mice	O
,	O
tumors	O
formed	O
by	O
the	O
v	O
-	O
Src	O
transformed	O
SWAP	O
-	O
70	O
(	O
-	O
/	O
-	O
)	O
MEFs	O
were	O
smaller	O
than	O
those	O
formed	O
by	O
cells	O
expressing	O
exogenous	O
SWAP	O
-	O
70	O
.	O

These	O
results	O
suggest	O
that	O
SWAP	O
-	O
70	O
may	O
be	O
required	O
for	O
oncogenic	O
transformation	O
and	O
contributes	O
to	O
cell	O
growth	O
in	O
MEFs	O
transformed	O
by	O
v	O
-	O
Src	O
.	O

Tsg101	O
is	O
upregulated	O
in	O
a	O
subset	O
of	O
invasive	O
human	O
breast	O
cancers	O
and	O
its	O
targeted	O
overexpression	O
in	O
transgenic	O
mice	O
reveals	O
weak	O
oncogenic	O
properties	O
for	O
mammary	O
cancer	O
initiation	O
.	O

Previous	O
studies	O
reported	O
that	O
the	O
Tumor	O
Susceptibility	O
Gene	O
101	O
(	O
TSG101	O
)	O
is	O
upregulated	O
in	O
selected	O
human	O
malignancies	O
,	O
and	O
the	O
expression	O
of	O
exogenous	O
Tsg101	O
was	O
suggested	O
to	O
transform	O
immortalized	O
fibroblasts	O
in	O
culture	O
.	O

To	O
date	O
,	O
the	O
potential	O
oncogenic	O
properties	O
of	O
Tsg101	O
have	O
not	O
been	O
examined	O
in	O
vivo	O
owing	O
to	O
the	O
lack	O
of	O
appropriate	O
model	O
systems	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
Tsg101	O
is	O
highly	O
expressed	O
in	O
a	O
subset	O
of	O
invasive	O
human	O
breast	O
cancers	O
.	O

Based	O
on	O
this	O
observation	O
,	O
we	O
generated	O
the	O
first	O
transgenic	O
mouse	O
model	O
with	O
a	O
targeted	O
overexpression	O
of	O
Tsg101	O
in	O
the	O
developing	O
mammary	O
gland	O
to	O
test	O
whether	O
exogenous	O
Tsg101	O
is	O
capable	O
of	O
initiating	O
tumorigenesis	O
.	O

Normal	O
functionality	O
of	O
exogenous	O
Tsg101	O
was	O
tested	O
by	O
rescuing	O
the	O
survival	O
of	O
Tsg101	O
-	O
deficient	O
mammary	O
epithelial	O
cells	O
in	O
conditional	O
knockout	O
mice	O
.	O

The	O
overexpression	O
of	O
Tsg101	O
resulted	O
in	O
increased	O
phosphorylation	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
and	O
downstream	O
activation	O
of	O
MAP	O
kinases	O
.	O

Despite	O
an	O
increase	O
in	O
the	O
activation	O
of	O
these	O
signal	O
transducers	O
,	O
the	O
mammary	O
gland	O
of	O
females	O
expressing	O
exogenous	O
Tsg101	O
developed	O
normally	O
throughout	O
the	O
reproductive	O
cycle	O
.	O

In	O
aging	O
females	O
,	O
the	O
overexpression	O
of	O
Tsg101	O
seemed	O
to	O
increase	O
the	O
susceptibility	O
of	O
mammary	O
epithelia	O
toward	O
malignant	O
transformation	O
.	O

However	O
,	O
owing	O
to	O
the	O
long	O
latency	O
of	O
tumor	O
formation	O
and	O
the	O
sporadic	O
occurrence	O
of	O
bona	O
fide	O
mammary	O
cancers	O
,	O
we	O
conclude	O
that	O
the	O
Tsg101	O
protein	O
has	O
only	O
weak	O
oncogenic	O
properties	O
.	O

Instead	O
of	O
cancer	O
initiation	O
,	O
it	O
is	O
therefore	O
likely	O
that	O
Tsg101	O
plays	O
a	O
more	O
predominant	O
role	O
in	O
the	O
progression	O
of	O
a	O
subset	O
of	O
spontaneously	O
arising	O
breast	O
cancers	O
.	O

Expression	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
in	O
primary	O
tumors	O
and	O
lymph	O
node	O
metastases	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Disturbances	O
in	O
expression	O
of	O
apoptosis	O
-	O
associated	O
proteins	O
take	O
part	O
in	O
the	O
development	O
and	O
progression	O
of	O
many	O
human	O
malignancies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
the	O
assessment	O
of	O
correlations	O
among	O
proteins	O
involved	O
in	O
apoptosis	O
-	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
-	O
as	O
well	O
as	O
relationships	O
of	O
these	O
proteins	O
with	O
selected	O
clinicopathological	O
features	O
in	O
oral	O
squamous	O
cell	O
carcinoma	O
.	O

Consequently	O
,	O
we	O
examined	O
by	O
immunohistochemistry	O
,	O
using	O
the	O
avidin	O
-	O
biotin	O
-	O
peroxidase	O
method	O
,	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
expression	O
in	O
56	O
samples	O
of	O
primary	O
oral	O
squamous	O
cell	O
carcinoma	O
and	O
in	O
22	O
matched	O
pairs	O
of	O
primary	O
and	O
metastatic	O
tumors	O
.	O

The	O
evaluation	O
of	O
immunostaining	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
was	O
analyzed	O
in	O
10	O
different	O
tumor	O
fields	O
,	O
and	O
the	O
mean	O
percentage	O
of	O
tumor	O
cells	O
with	O
positive	O
staining	O
was	O
evaluated	O
.	O

The	O
significance	O
of	O
the	O
associations	O
was	O
determined	O
using	O
Spearman	O
correlation	O
analysis	O
and	O
the	O
chi	O
-	O
square	O
test	O
.	O

We	O
found	O
positive	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
immunostaining	O
in	O
44	O
.	O
6	O
%	O
,	O
28	O
.	O
6	O
%	O
,	O
and	O
58	O
.	O
9	O
%	O
of	O
the	O
studied	O
primary	O
tumors	O
and	O
in	O
63	O
.	O
6	O
%	O
,	O
45	O
.	O
5	O
%	O
,	O
and	O
72	O
.	O
7	O
%	O
of	O
lymph	O
node	O
metastases	O
,	O
respectively	O
.	O

Analysis	O
of	O
associations	O
among	O
studied	O
proteins	O
revealed	O
positive	O
correlation	O
between	O
Bcl	O
-	O
xL	O
and	O
Bax	O
in	O
primary	O
tumors	O
(	O
P	O
<	O
0	O
.	O
03	O
,	O
r	O
=	O
0	O
.	O
307	O
)	O
.	O

Statistically	O
significant	O
relationship	O
between	O
p53	O
expression	O
in	O
primary	O
oral	O
cancers	O
and	O
its	O
expression	O
in	O
lymph	O
node	O
metastases	O
(	O
P	O
<	O
0	O
.	O
02	O
)	O
as	O
well	O
as	O
increased	O
expression	O
of	O
Bcl	O
-	O
xL	O
,	O
Bax	O
,	O
and	O
p53	O
in	O
metastatic	O
sites	O
compared	O
with	O
primary	O
tumors	O
could	O
indicate	O
an	O
association	O
of	O
these	O
proteins	O
with	O
oral	O
cancer	O
progression	O
and	O
development	O
of	O
metastases	O
.	O

Moreover	O
,	O
we	O
suppose	O
that	O
knowledge	O
about	O
heterogeneity	O
between	O
primary	O
and	O
metastatic	O
tumor	O
might	O
help	O
to	O
understand	O
mechanisms	O
of	O
oral	O
cancer	O
progression	O
.	O

Mechanisms	O
for	O
the	O
magnolol	O
-	O
induced	O
cell	O
death	O
of	O
CGTH	O
W	O
-	O
2	O
thyroid	O
carcinoma	O
cells	O
.	O

Magnolol	O
,	O
a	O
substance	O
purified	O
from	O
the	O
bark	O
of	O
Magnolia	O
officialis	O
,	O
inhibits	O
cell	O
proliferation	O
and	O
induces	O
apoptosis	O
in	O
a	O
variety	O
of	O
cancer	O
cells	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
study	O
the	O
effects	O
of	O
magnolol	O
on	O
CGTH	O
W	O
-	O
2	O
thyroid	O
carcinoma	O
cells	O
.	O

After	O
24	O
h	O
treatment	O
with	O
80	O
microM	O
magnolol	O
in	O
serum	O
-	O
containing	O
medium	O
,	O
about	O
50	O
%	O
of	O
the	O
cells	O
exhibited	O
apoptotic	O
features	O
and	O
20	O
%	O
necrotic	O
features	O
.	O

Cytochrome	O
-	O
c	O
staining	O
was	O
diffused	O
in	O
the	O
cytoplasm	O
of	O
the	O
apoptotic	O
cells	O
,	O
but	O
restricted	O
to	O
the	O
mitochondria	O
in	O
control	O
cells	O
.	O

Western	O
blot	O
analyses	O
showed	O
an	O
increase	O
in	O
levels	O
of	O
activated	O
caspases	O
(	O
caspase	O
-	O
3	O
and	O
-	O
7	O
)	O
and	O
of	O
cleaved	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
by	O
magnolol	O
.	O

Concomitantly	O
,	O
immunostaining	O
for	O
apoptosis	O
inducing	O
factor	O
(	O
AIF	O
)	O
showed	O
a	O
time	O
-	O
dependent	O
translocation	O
from	O
the	O
mitochondria	O
to	O
the	O
nucleus	O
.	O

Inhibition	O
of	O
either	O
PARP	O
or	O
caspase	O
activity	O
blocked	O
magnolol	O
-	O
induced	O
apoptosis	O
,	O
supporting	O
the	O
involvement	O
of	O
the	O
caspases	O
and	O
PARP	O
.	O

In	O
addition	O
,	O
magnolol	O
activated	O
phosphatase	O
and	O
tensin	O
homolog	O
deleted	O
on	O
chromosome	O
10	O
(	O
PTEN	O
)	O
and	O
inactivated	O
Akt	O
by	O
decreasing	O
levels	O
of	O
phosphorylated	O
PTEN	O
and	O
phosphorylated	O
Akt	O
.	O

These	O
data	O
suggest	O
that	O
magnolol	O
promoted	O
apoptosis	O
probably	O
by	O
alleviating	O
the	O
inhibitory	O
effect	O
of	O
Akt	O
on	O
caspase	O
9	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
PARP	O
activity	O
,	O
but	O
not	O
of	O
caspase	O
activity	O
,	O
completely	O
prevented	O
magnolol	O
-	O
induced	O
necrosis	O
,	O
suggesting	O
the	O
notion	O
that	O
it	O
might	O
be	O
caused	O
by	O
depletion	O
of	O
intracellular	O
ATP	O
levels	O
due	O
to	O
PARP	O
activation	O
.	O

These	O
results	O
show	O
that	O
magnolol	O
initiates	O
apoptosis	O
via	O
the	O
cytochrome	O
-	O
c	O
/	O
caspase	O
3	O
/	O
PARP	O
/	O
AIF	O
and	O
PTEN	O
/	O
Akt	O
/	O
caspase	O
9	O
/	O
PARP	O
pathways	O
and	O
necrosis	O
via	O
PARP	O
activation	O
.	O

[	O
Anomalous	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
from	O
the	O
left	O
sinus	O
of	O
Valsalva	O
:	O
case	O
report	O
and	O
literature	O
review	O
]	O
.	O

We	O
describe	O
the	O
case	O
of	O
a	O
patient	O
in	O
whom	O
evaluation	O
of	O
effort	O
angina	O
revealed	O
a	O
tight	O
stenosis	O
of	O
a	O
right	O
coronary	O
artery	O
anomalously	O
arising	O
from	O
the	O
left	O
sinus	O
of	O
Valsalva	O
,	O
which	O
was	O
successfully	O
treated	O
by	O
stent	O
implantation	O
.	O

The	O
abnormal	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
from	O
the	O
left	O
aortic	O
sinus	O
coursing	O
between	O
the	O
aorta	O
and	O
the	O
pulmonary	O
trunk	O
is	O
a	O
rare	O
congenital	O
anomaly	O
.	O

It	O
may	O
remain	O
asymptomatic	O
,	O
but	O
can	O
also	O
cause	O
major	O
cardiac	O
events	O
,	O
even	O
in	O
the	O
absence	O
of	O
coronary	O
atherosclerosis	O
.	O

We	O
discuss	O
the	O
clinical	O
importance	O
of	O
this	O
anomaly	O
and	O
review	O
the	O
literature	O
concerning	O
current	O
views	O
and	O
therapy	O
.	O

The	O
cancer	O
cell	O
'	O
s	O
""""	O
power	O
plants	O
""""	O
as	O
promising	O
therapeutic	O
targets	O
:	O
an	O
overview	O
.	O

This	O
introductory	O
article	O
to	O
the	O
review	O
series	O
entitled	O
""""	O
The	O
Cancer	O
Cell	O
'	O
s	O
Power	O
Plants	O
as	O
Promising	O
Therapeutic	O
Targets	O
""""	O
is	O
written	O
while	O
more	O
than	O
20	O
million	O
people	O
suffer	O
from	O
cancer	O
.	O

It	O
summarizes	O
strategies	O
to	O
destroy	O
or	O
prevent	O
cancers	O
by	O
targeting	O
their	O
energy	O
production	O
factories	O
,	O
i	O
.	O
e	O
.	O
,	O
""""	O
power	O
plants	O
.	O
""""	O
All	O
nucleated	O
animal	O
/	O
human	O
cells	O
have	O
two	O
types	O
of	O
power	O
plants	O
,	O
i	O
.	O
e	O
.	O
,	O
systems	O
that	O
make	O
the	O
""""	O
high	O
energy	O
""""	O
compound	O
ATP	O
from	O
ADP	O
and	O
P	O
(	O
i	O
)	O
.	O

One	O
type	O
is	O
""""	O
glycolysis	O
,	O
""""	O
the	O
other	O
the	O
""""	O
mitochondria	O
.	O
""""	O
In	O
contrast	O
to	O
most	O
normal	O
cells	O
where	O
the	O
mitochondria	O
are	O
the	O
major	O
ATP	O
producers	O
(	O
>	O
90	O
%	O
)	O
in	O
fueling	O
growth	O
,	O
human	O
cancers	O
detected	O
via	O
Positron	O
Emission	O
Tomography	O
(	O
PET	O
)	O
rely	O
on	O
both	O
types	O
of	O
power	O
plants	O
.	O

In	O
such	O
cancers	O
,	O
glycolysis	O
may	O
contribute	O
nearly	O
half	O
the	O
ATP	O
even	O
in	O
the	O
presence	O
of	O
oxygen	O
(	O
""""	O
Warburg	O
effect	O
""""	O
)	O
.	O

Based	O
solely	O
on	O
cell	O
energetics	O
,	O
this	O
presents	O
a	O
challenge	O
to	O
identify	O
curative	O
agents	O
that	O
destroy	O
only	O
cancer	O
cells	O
as	O
they	O
must	O
destroy	O
both	O
of	O
their	O
power	O
plants	O
causing	O
""""	O
necrotic	O
cell	O
death	O
""""	O
and	O
leave	O
normal	O
cells	O
alone	O
.	O

One	O
such	O
agent	O
,	O
3	O
-	O
bromopyruvate	O
(	O
3	O
-	O
BrPA	O
)	O
,	O
a	O
lactic	O
acid	O
analog	O
,	O
has	O
been	O
shown	O
to	O
inhibit	O
both	O
glycolytic	O
and	O
mitochondrial	O
ATP	O
production	O
in	O
rapidly	O
growing	O
cancers	O
(	O
Ko	O
et	O
al	O
.	O
,	O
Cancer	O
Letts	O
.	O
,	O
173	O
,	O
83	O
-	O
91	O
,	O
2001	O
)	O
,	O
leave	O
normal	O
cells	O
alone	O
,	O
and	O
eradicate	O
advanced	O
cancers	O
(	O
19	O
of	O
19	O
)	O
in	O
a	O
rodent	O
model	O
(	O
Ko	O
et	O
al	O
.	O
,	O
Biochem	O
.	O
Biophys	O
.	O
Res	O
.	O
Commun	O
.	O
,	O
324	O
,	O
269	O
-	O
275	O
,	O
2004	O
)	O
.	O

A	O
second	O
approach	O
is	O
to	O
induce	O
only	O
cancer	O
cells	O
to	O
undergo	O
""""	O
apoptotic	O
cell	O
death	O
.	O
""""	O
Here	O
,	O
mitochondria	O
release	O
cell	O
death	O
inducing	O
factors	O
(	O
e	O
.	O
g	O
.	O
,	O
cytochrome	O
c	O
)	O
.	O

In	O
a	O
third	O
approach	O
,	O
cancer	O
cells	O
are	O
induced	O
to	O
die	O
by	O
both	O
apoptotic	O
and	O
necrotic	O
events	O
.	O

In	O
summary	O
,	O
much	O
effort	O
is	O
being	O
focused	O
on	O
identifying	O
agents	O
that	O
induce	O
""""	O
necrotic	O
,	O
""""	O
""""	O
apoptotic	O
""""	O
or	O
apoptotic	O
plus	O
necrotic	O
cell	O
death	O
only	O
in	O
cancer	O
cells	O
.	O

Regardless	O
how	O
death	O
is	O
inflicted	O
,	O
every	O
cancer	O
cell	O
must	O
die	O
,	O
be	O
it	O
fast	O
or	O
slow	O
.	O

Determination	O
of	O
eprosartan	O
in	O
human	O
plasma	O
and	O
urine	O
by	O
LC	O
/	O
MS	O
/	O
MS	O
.	O

A	O
protein	O
precipitation	O
,	O
liquid	O
chromatography	O
/	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
/	O
MS	O
/	O
MS	O
)	O
method	O
has	O
been	O
developed	O
and	O
validated	O
for	O
the	O
determination	O
of	O
eprosartan	O
in	O
human	O
plasma	O
and	O
urine	O
.	O

The	O
solvent	O
system	O
also	O
served	O
as	O
a	O
protein	O
precipitation	O
reagent	O
.	O

The	O
chromatographic	O
separation	O
was	O
achieved	O
on	O
a	O
CAPCELL	O
PAK	O
C18	O
column	O
(	O
50	O
mmx2	O
.	O
0	O
mm	O
,	O
5	O
microm	O
,	O
Shiseido	O
)	O
.	O

A	O
mobile	O
phase	O
was	O
consisted	O
of	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
water	O
and	O
0	O
.	O
5	O
%	O
formic	O
acid	O
in	O
acetonitrile	O
(	O
72	O
:	O
28	O
)	O
.	O

Detection	O
was	O
by	O
positive	O
ion	O
electrospray	O
tandem	O
mass	O
spectrometry	O
on	O
a	O
Sciex	O
API3000	O
.	O

The	O
standard	O
curves	O
,	O
which	O
ranged	O
from	O
5	O
to	O
2000	O
ng	O
/	O
mL	O
in	O
human	O
plasma	O
and	O
from	O
0	O
.	O
25	O
to	O
50	O
microg	O
/	O
mL	O
in	O
urine	O
,	O
were	O
fitted	O
to	O
a	O
1	O
/	O
x	O
weighted	O
quadratic	O
regression	O
model	O
.	O

The	O
method	O
proved	O
to	O
be	O
accurate	O
,	O
specific	O
and	O
sensitive	O
enough	O
to	O
be	O
successfully	O
applied	O
to	O
a	O
pharmacokinetic	O
study	O
.	O

The	O
relationship	O
between	O
brain	O
activity	O
and	O
peak	O
grip	O
force	O
is	O
modulated	O
by	O
corticospinal	O
system	O
integrity	O
after	O
subcortical	O
stroke	O
.	O

In	O
healthy	O
human	O
subjects	O
,	O
the	O
relative	O
contribution	O
of	O
cortical	O
regions	O
to	O
motor	O
performance	O
varies	O
with	O
the	O
task	O
parameters	O
.	O

Additionally	O
,	O
after	O
stroke	O
,	O
recruitment	O
of	O
cortical	O
areas	O
during	O
a	O
simple	O
motor	O
task	O
varies	O
with	O
corticospinal	O
system	O
integrity	O
.	O

We	O
investigated	O
whether	O
the	O
pattern	O
of	O
motor	O
system	O
recruitment	O
in	O
a	O
task	O
involving	O
increasingly	O
forceful	O
hand	O
grips	O
is	O
influenced	O
by	O
the	O
degree	O
of	O
corticospinal	O
system	O
damage	O
.	O

Nine	O
chronic	O
subcortical	O
stroke	O
patients	O
and	O
nine	O
age	O
-	O
matched	O
controls	O
underwent	O
functional	O
magnetic	O
brain	O
imaging	O
whilst	O
performing	O
repetitive	O
isometric	O
hand	O
grips	O
.	O

Target	O
grip	O
forces	O
were	O
varied	O
between	O
15	O
%	O
and	O
45	O
%	O
of	O
individual	O
maximum	O
grip	O
force	O
.	O

Corticospinal	O
system	O
functional	O
integrity	O
was	O
assessed	O
with	O
transcranial	O
magnetic	O
stimulation	O
.	O

Averaged	O
across	O
all	O
forces	O
,	O
there	O
was	O
more	O
task	O
-	O
related	O
activation	O
compared	O
with	O
rest	O
in	O
the	O
secondary	O
motor	O
areas	O
of	O
patients	O
with	O
greater	O
corticospinal	O
system	O
damage	O
,	O
confirming	O
previous	O
reports	O
.	O

However	O
,	O
here	O
we	O
were	O
primarily	O
interested	O
in	O
regional	O
brain	O
activation	O
,	O
which	O
covaried	O
with	O
the	O
amount	O
of	O
force	O
generated	O
,	O
implying	O
a	O
prominent	O
executive	O
role	O
in	O
force	O
production	O
.	O

We	O
found	O
that	O
in	O
control	O
subjects	O
and	O
patients	O
with	O
lesser	O
corticospinal	O
system	O
damage	O
,	O
signal	O
change	O
increased	O
linearly	O
with	O
increasing	O
force	O
output	O
in	O
contralateral	O
primary	O
motor	O
cortex	O
,	O
supplementary	O
motor	O
area	O
and	O
ipsilateral	O
cerebellum	O
.	O

In	O
contrast	O
,	O
in	O
patients	O
with	O
greater	O
corticospinal	O
system	O
damage	O
,	O
force	O
-	O
related	O
signal	O
changes	O
were	O
seen	O
mainly	O
in	O
contralesional	O
dorsolateral	O
premotor	O
cortex	O
,	O
bilateral	O
ventrolateral	O
premotor	O
cortices	O
and	O
contralesional	O
cerebellum	O
,	O
but	O
not	O
ipsilesional	O
primary	O
motor	O
cortex	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
premotor	O
cortices	O
might	O
play	O
a	O
new	O
and	O
functionally	O
relevant	O
role	O
in	O
controlling	O
force	O
production	O
in	O
patients	O
with	O
more	O
severe	O
corticospinal	O
system	O
disruption	O
.	O

Antimicrobial	O
prophylaxis	O
in	O
vaginal	O
gynecologic	O
surgery	O
:	O
a	O
prospective	O
randomized	O
study	O
comparing	O
amoxicillin	O
-	O
clavulanic	O
acid	O
with	O
cefazolin	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
,	O
randomized	O
study	O
was	O
to	O
compare	O
amoxicillin	O
-	O
clavulanic	O
acid	O
with	O
cefazolin	O
as	O
ultra	O
-	O
short	O
term	O
prophylaxis	O
in	O
vaginal	O
gynecologic	O
surgery	O
.	O

It	O
was	O
conducted	O
at	O
the	O
Department	O
of	O
Obstetrics	O
and	O
Gynecology	O
,	O
University	O
of	O
Bari	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
receive	O
amoxicillin	O
-	O
clavulanic	O
acid	O
(	O
2	O
.	O
2	O
g	O
)	O
[	O
Group	O
A	O
]	O
or	O
cefazolin	O
(	O
2	O
g	O
)	O
[	O
Group	O
B	O
]	O
as	O
a	O
single	O
dose	O
30	O
minutes	O
before	O
surgery	O
.	O

Each	O
patient	O
was	O
assessed	O
daily	O
until	O
discharge	O
to	O
evidence	O
febrile	O
status	O
and	O
the	O
presence	O
of	O
infections	O
at	O
the	O
operative	O
site	O
,	O
urinary	O
tract	O
and	O
respiratory	O
tract	O
.	O

In	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
(	O
Group	O
A	O
)	O
and	O
cefazolin	O
(	O
Group	O
B	O
)	O
groups	O
,	O
overall	O
88	O
and	O
90	O
patients	O
,	O
respectively	O
,	O
were	O
evaluable	O
for	O
prophylactic	O
efficacy	O
at	O
hospital	O
discharge	O
.	O

Infectious	O
complications	O
were	O
infrequent	O
in	O
both	O
arms	O
,	O
with	O
febrile	O
morbidity	O
occurring	O
in	O
4	O
(	O
4	O
.	O
5	O
%	O
)	O
and	O
16	O
(	O
8	O
.	O
9	O
%	O
)	O
patients	O
respectively	O
in	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
and	O
cefazolin	O
groups	O
(	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Urinary	O
tract	O
infections	O
were	O
higher	O
but	O
not	O
significantly	O
in	O
the	O
amoxicillin	O
-	O
clavulanic	O
acid	O
group	O
(	O
6	O
.	O
8	O
%	O
versus	O
4	O
.	O
4	O
%	O
)	O
,	O
whereas	O
asymptomatic	O
bacteriuria	O
was	O
detected	O
in	O
2	O
.	O
2	O
%	O
of	O
the	O
patients	O
in	O
both	O
groups	O
.	O

There	O
was	O
no	O
respiratory	O
tract	O
infection	O
or	O
septic	O
death	O
in	O
either	O
group	O
.	O

It	O
is	O
concluded	O
that	O
ultra	O
-	O
short	O
term	O
prophylaxis	O
with	O
both	O
amoxicillin	O
-	O
clavulanic	O
acid	O
and	O
cefazolin	O
is	O
safe	O
and	O
effective	O
in	O
elective	O
vaginal	O
gynecologic	O
surgery	O
.	O

Pathological	O
animal	O
models	O
in	O
the	O
experimental	O
evaluation	O
of	O
tumour	O
microvasculature	O
with	O
magnetic	O
resonance	O
imaging	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
applications	O
of	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
,	O
and	O
in	O
particular	O
,	O
dynamic	O
contrast	O
-	O
enhanced	O
MRI	O
(	O
DCE	O
-	O
MRI	O
)	O
,	O
in	O
the	O
assessment	O
of	O
tumour	O
microvasculature	O
by	O
means	O
of	O
animal	O
tumour	O
models	O
evaluated	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
two	O
MRI	O
exams	O
were	O
performed	O
with	O
intravascular	O
contrast	O
media	O
in	O
21	O
rats	O
:	O
tumours	O
were	O
induced	O
by	O
subcutaneous	O
injection	O
of	O
colon	O
carcinoma	O
cells	O
in	O
7	O
rats	O
and	O
mammary	O
adenocarcinoma	O
cells	O
in	O
14	O
rats	O
.	O

Perfusion	O
and	O
permeability	O
parameters	O
of	O
the	O
implanted	O
tumours	O
were	O
evaluated	O
by	O
using	O
two	O
contrast	O
media	O
(	O
B22956	O
/	O
1	O
and	O
Gd	O
-	O
DTPA37	O
-	O
albumin	O
)	O
to	O
establish	O
response	O
to	O
treatment	O
with	O
two	O
different	O
antiangiogenic	O
drugs	O
(	O
tamoxifen	O
and	O
SU6668	O
)	O
.	O

These	O
parameters	O
were	O
correlated	O
with	O
histology	O
to	O
obtain	O
a	O
radiological	O
-	O
histological	O
map	O
of	O
tumour	O
microvasculature	O
.	O

RESULTS	O
:	O
DCE	O
-	O
MRI	O
revealed	O
greater	O
enhancement	O
in	O
the	O
peripheral	O
area	O
than	O
in	O
the	O
central	O
area	O
in	O
all	O
the	O
examined	O
animal	O
models	O
.	O

In	O
the	O
mammary	O
carcinoma	O
experiment	O
,	O
vascular	O
permeability	O
measured	O
by	O
means	O
of	O
B22956	O
/	O
1	O
in	O
the	O
animals	O
treated	O
with	O
the	O
antiangiogenic	O
drug	O
(	O
0	O
.	O
0043317	O
+	O
/	O
-	O
0	O
.	O
0040418	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
was	O
significantly	O
less	O
than	O
in	O
untreated	O
animals	O
(	O
0	O
.	O
0090460	O
+	O
/	O
-	O
0	O
.	O
0043680	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
with	O
Gd	O
-	O
DTPA	O
-	O
albumin	O
(	O
13	O
.	O
14	O
+	O
/	O
-	O
13	O
.	O
94	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
treated	O
animals	O
and	O
18	O
.	O
07	O
+	O
/	O
-	O
11	O
.	O
92	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
in	O
untreated	O
animals	O
)	O
.	O

In	O
the	O
colon	O
carcinoma	O
experiment	O
,	O
mean	O
permeability	O
and	O
perfusion	O
decreased	O
by	O
51	O
%	O
(	O
from	O
5	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
2	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
8	O
ml	O
/	O
100	O
ml	O
)	O
and	O
59	O
%	O
(	O
from	O
0	O
.	O
00165	O
+	O
/	O
-	O
5	O
.	O
1	O
to	O
0	O
.	O
0067	O
+	O
/	O
-	O
4	O
.	O
8	O
ml	O
/	O
min	O
(	O
-	O
1	O
)	O
/	O
ml	O
(	O
-	O
1	O
)	O
of	O
tissue	O
)	O
,	O
respectively	O
,	O
in	O
all	O
animals	O
after	O
antiangiogenic	O
drug	O
administration	O
.	O

CONCLUSIONS	O
:	O
DCE	O
-	O
MRI	O
permits	O
a	O
noninvasive	O
evaluation	O
of	O
tumour	O
microcirculation	O
and	O
in	O
particular	O
of	O
its	O
dynamic	O
characteristics	O
and	O
vascularity	O
before	O
and	O
after	O
antiangiogenic	O
treatment	O
.	O

An	O
antibody	O
directed	O
against	O
PDGF	O
receptor	O
beta	O
enhances	O
the	O
antitumor	O
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
an	O
anti	O
-	O
VEGF	O
receptor	O
2	O
antibody	O
.	O

Platelet	O
-	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and	O
its	O
receptors	O
(	O
PDGFR	O
)	O
play	O
important	O
roles	O
in	O
tumorigenesis	O
through	O
stimulating	O
tumor	O
growth	O
and	O
promoting	O
angiogenesis	O
via	O
enhancing	O
pericyte	O
recruitment	O
and	O
vessel	O
maturation	O
.	O

Here	O
we	O
produced	O
a	O
neutralizing	O
antibody	O
,	O
1B3	O
,	O
directed	O
against	O
mouse	O
PDGFRbeta	O
.	O

1B3	O
binds	O
to	O
PDGFRbeta	O
with	O
high	O
affinity	O
(	O
9x10	O
(	O
-	O
11	O
)	O
M	O
)	O
and	O
blocks	O
PDGF	O
-	O
BB	O
from	O
binding	O
to	O
the	O
receptor	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
approximately	O
1	O
.	O
2	O
nM	O
.	O

The	O
antibody	O
also	O
blocks	O
ligand	O
-	O
stimulated	O
activation	O
of	O
PDGFRbeta	O
and	O
downstream	O
signaling	O
molecules	O
,	O
including	O
Akt	O
and	O
MAPK	O
p42	O
/	O
44	O
,	O
in	O
tumor	O
cells	O
.	O

In	O
animal	O
studies	O
,	O
1B3	O
significantly	O
enhanced	O
the	O
antitumor	O
and	O
the	O
anti	O
-	O
angiogenic	O
activities	O
of	O
DC101	O
,	O
an	O
antibody	O
directed	O
against	O
mouse	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
,	O
in	O
a	O
pancreatic	O
(	O
BxPC	B
-	I
3	I
)	O
and	O
a	O
non	O
-	O
small	O
cell	O
lung	O
(	O
NCI	B
-	I
H460	I
)	O
tumor	O
xenograft	O
models	O
.	O

Treatment	O
with	O
the	O
combination	O
of	O
1B3	O
and	O
DC101	O
in	O
BxPC	B
-	I
3	I
xenograft	O
-	O
bearing	O
mice	O
resulted	O
in	O
tumor	O
regression	O
in	O
58	O
%	O
of	O
mice	O
compared	O
to	O
that	O
in	O
18	O
%	O
of	O
mice	O
treated	O
with	O
DC101	O
alone	O
.	O

Taken	O
together	O
,	O
these	O
results	O
lend	O
great	O
support	O
to	O
use	O
PDGFRbeta	O
antagonists	O
in	O
combinations	O
with	O
other	O
antitumor	O
and	O
/	O
or	O
anti	O
-	O
angiogenic	O
agents	O
in	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
cancers	O
.	O

[	O
Synthetic	O
fragments	O
of	O
the	O
NS1	O
protein	O
of	O
the	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
exhibiting	O
a	O
protective	O
effect	O
]	O
.	O

Potentially	O
immunoactive	O
regions	O
of	O
the	O
NS1	O
nonstructural	O
protein	O
of	O
the	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
that	O
can	O
stimulate	O
the	O
antibody	O
formation	O
in	O
vivo	O
and	O
protect	O
animals	O
from	O
this	O
disease	O
were	O
chosen	O
on	O
the	O
basis	O
of	O
theoretical	O
calculations	O
.	O

Eleven	O
16	O
-	O
to	O
27	O
-	O
aa	O
peptides	O
containing	O
the	O
chosen	O
regions	O
were	O
synthesized	O
.	O

The	O
ability	O
of	O
the	O
free	O
peptides	O
(	O
without	O
any	O
high	O
-	O
molecular	O
-	O
mass	O
carrier	O
)	O
to	O
stimulate	O
the	O
production	O
of	O
antipeptide	O
antibodies	O
in	O
mice	O
of	O
three	O
lines	O
and	O
ensure	O
the	O
formation	O
of	O
protective	O
immunity	O
was	O
studied	O
.	O

Most	O
of	O
these	O
peptides	O
were	O
shown	O
to	O
exhibit	O
the	O
immunogenic	O
activity	O
in	O
a	O
free	O
state	O
.	O

Five	O
fragments	O
that	O
can	O
protect	O
mice	O
from	O
the	O
infection	O
by	O
a	O
lethal	O
dose	O
of	O
tick	O
-	O
borne	O
encephalitis	O
virus	O
were	O
found	O
.	O

In	O
vivo	O
p53	O
response	O
and	O
immune	O
reaction	O
underlie	O
highly	O
effective	O
low	O
-	O
dose	O
radiotherapy	O
in	O
follicular	O
lymphoma	O
.	O

Very	O
low	O
-	O
dose	O
irradiation	O
(	O
2	O
x	O
2	O
Gy	O
)	O
is	O
a	O
new	O
,	O
effective	O
,	O
and	O
safe	O
local	O
treatment	O
for	O
follicular	O
lymphoma	O
.	O

To	O
understand	O
the	O
biologic	O
mechanisms	O
of	O
this	O
extremely	O
effective	O
response	O
,	O
we	O
compared	O
by	O
microarray	O
the	O
gene	O
-	O
expression	O
profile	O
of	O
patients	O
'	O
biopsies	O
taken	O
before	O
and	O
after	O
radiation	O
.	O

In	O
all	O
patients	O
,	O
a	O
major	O
and	O
consistent	O
induction	O
of	O
p53	O
target	O
genes	O
was	O
seen	O
.	O

p53	O
targets	O
involved	O
in	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
showed	O
the	O
same	O
mode	O
of	O
regulation	O
,	O
indicating	O
that	O
,	O
in	O
vivo	O
,	O
both	O
are	O
activated	O
simultaneously	O
.	O

p53	O
up	O
-	O
regulation	O
and	O
p53	O
-	O
mediated	O
proliferation	O
arrest	O
and	O
apoptosis	O
were	O
substantiated	O
using	O
immunohistochemistry	O
,	O
with	O
activation	O
of	O
both	O
the	O
intrinsic	O
and	O
the	O
extrinsic	O
apoptotic	O
pathways	O
.	O

The	O
other	O
induced	O
genes	O
revealed	O
a	O
whole	O
set	O
of	O
biologically	O
meaningful	O
genes	O
related	O
to	O
macrophage	O
activation	O
and	O
TH1	O
immune	O
response	O
.	O

Immunohistochemical	O
analysis	O
suggested	O
a	O
specific	O
activation	O
or	O
differentiation	O
of	O
resident	O
macrophages	O
by	O
apoptotic	O
cells	O
.	O

These	O
biologic	O
insights	O
are	O
important	O
arguments	O
to	O
advocate	O
the	O
use	O
of	O
low	O
-	O
dose	O
radiotherapy	O
as	O
an	O
effective	O
palliative	O
treatment	O
for	O
follicular	O
lymphoma	O
.	O

Moreover	O
,	O
this	O
study	O
is	O
the	O
first	O
in	O
vivo	O
report	O
of	O
the	O
radiation	O
-	O
induced	O
p53	O
apoptotic	O
response	O
in	O
patients	O
and	O
suggests	O
that	O
this	O
apoptotic	O
response	O
is	O
not	O
immunologically	O
silent	O
.	O

Caffeine	O
inhibits	O
adenosine	O
-	O
induced	O
accumulation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
,	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
and	O
interleukin	O
-	O
8	O
expression	O
in	O
hypoxic	O
human	O
colon	O
cancer	O
cells	O
.	O

Frequent	O
coffee	O
consumption	O
has	O
been	O
associated	O
with	O
a	O
reduced	O
risk	O
of	O
colorectal	O
cancer	O
in	O
a	O
number	O
of	O
case	O
-	O
control	O
studies	O
.	O

Coffee	O
is	O
a	O
leading	O
source	O
of	O
methylxanthines	O
,	O
such	O
as	O
caffeine	O
.	O

The	O
induction	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
interleukin	O
-	O
8	O
(	O
IL	O
-	O
8	O
)	O
is	O
an	O
essential	O
feature	O
of	O
tumor	O
angiogenesis	O
,	O
and	O
the	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1	O
(	O
HIF	O
-	O
1	O
)	O
transcription	O
factor	O
is	O
known	O
to	O
be	O
a	O
key	O
regulator	O
of	O
this	O
process	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
caffeine	O
on	O
HIF	O
-	O
1	O
protein	O
accumulation	O
and	O
on	O
VEGF	O
and	O
IL	O
-	O
8	O
expression	O
in	O
the	O
human	O
colon	O
cancer	O
cell	O
line	O
HT29	B
under	O
hypoxic	O
conditions	O
.	O

Our	O
results	O
show	O
that	O
caffeine	O
significantly	O
inhibits	O
adenosine	O
-	O
induced	O
HIF	O
-	O
1alpha	O
protein	O
accumulation	O
in	O
cancer	O
cells	O
.	O

We	O
show	O
that	O
HIF	O
-	O
1alpha	O
and	O
VEGF	O
are	O
increased	O
through	O
A3	O
adenosine	O
receptor	O
stimulation	O
,	O
whereas	O
the	O
effects	O
on	O
IL	O
-	O
8	O
are	O
mediated	O
via	O
the	O
A2B	O
subtype	O
.	O

Pretreatment	O
of	O
cells	O
with	O
caffeine	O
significantly	O
reduces	O
adenosine	O
-	O
induced	O
VEGF	O
promoter	O
activity	O
and	O
VEGF	O
and	O
IL	O
-	O
8	O
expression	O
.	O

The	O
mechanism	O
of	O
caffeine	O
seems	O
to	O
involve	O
the	O
inhibition	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
p38	O
,	O
and	O
Akt	O
,	O
leading	O
to	O
a	O
marked	O
decrease	O
in	O
adenosine	O
-	O
induced	O
HIF	O
-	O
1alpha	O
accumulation	O
,	O
VEGF	O
transcriptional	O
activation	O
,	O
and	O
VEGF	O
and	O
IL	O
-	O
8	O
protein	O
accumulation	O
.	O

From	O
a	O
functional	O
perspective	O
,	O
we	O
observe	O
that	O
caffeine	O
also	O
significantly	O
inhibits	O
the	O
A3	O
receptor	O
-	O
stimulated	O
cell	O
migration	O
of	O
colon	O
cancer	O
cells	O
.	O

Conditioned	O
media	O
prepared	O
from	O
colon	O
cells	O
treated	O
with	O
an	O
adenosine	O
analog	O
increased	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
migration	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
adenosine	O
could	O
modulate	O
the	O
migration	O
of	O
colon	O
cancer	O
cells	O
by	O
an	O
HIF	O
-	O
1alpha	O
/	O
VEGF	O
/	O
IL	O
-	O
8	O
-	O
dependent	O
mechanism	O
and	O
that	O
caffeine	O
has	O
the	O
potential	O
to	O
inhibit	O
colon	O
cancer	O
cell	O
growth	O
.	O

Angiogenesis	O
in	O
the	O
caprine	O
caruncles	O
in	O
non	O
-	O
pregnant	O
and	O
pregnant	O
normal	O
and	O
swainsonine	O
-	O
treated	O
does	O
.	O

Microvascular	O
corrosion	O
casts	O
of	O
caruncles	O
from	O
non	O
-	O
pregnant	O
and	O
pregnant	O
doe	O
goats	O
at	O
4	O
,	O
7	O
,	O
10	O
,	O
13	O
,	O
16	O
,	O
and	O
18	O
weeks	O
were	O
examined	O
with	O
scanning	O
electron	O
microscopy	O
.	O

The	O
internal	O
convex	O
surface	O
of	O
the	O
caruncles	O
of	O
non	O
-	O
pregnant	O
does	O
was	O
covered	O
with	O
capillary	O
meshes	O
of	O
regular	O
diameter	O
and	O
form	O
,	O
without	O
crypts	O
.	O

As	O
pregnancy	O
advanced	O
the	O
complexity	O
of	O
the	O
vasculature	O
increased	O
:	O
at	O
4	O
weeks	O
the	O
surface	O
showed	O
a	O
pattern	O
of	O
ridges	O
separated	O
by	O
troughs	O
.	O

At	O
later	O
stages	O
,	O
branches	O
of	O
radial	O
arteries	O
penetrated	O
the	O
periphery	O
forming	O
an	O
extensive	O
mesh	O
of	O
capillaries	O
on	O
the	O
concave	O
surface	O
.	O

Capillary	O
diameters	O
increased	O
significantly	O
during	O
pregnancy	O
,	O
especially	O
after	O
4	O
weeks	O
,	O
when	O
large	O
flattened	O
sinusoids	O
formed	O
.	O

These	O
sinusoids	O
had	O
a	O
great	O
deal	O
of	O
surface	O
area	O
for	O
potential	O
contact	O
with	O
the	O
fetal	O
component	O
.	O

The	O
caprine	O
placenta	O
is	O
usually	O
considered	O
to	O
have	O
increased	O
interhemal	O
distance	O
compared	O
with	O
endotheliochorial	O
and	O
hemochorial	O
types	O
:	O
our	O
results	O
suggest	O
that	O
the	O
very	O
extensive	O
development	O
of	O
sinusoids	O
and	O
crypts	O
may	O
compensate	O
for	O
any	O
negative	O
consequences	O
of	O
the	O
placental	O
architecture	O
.	O

Placental	O
angiogenesis	O
,	O
which	O
is	O
physiologically	O
normal	O
,	O
may	O
serve	O
as	O
a	O
general	O
model	O
of	O
this	O
process	O
in	O
other	O
circumstances	O
,	O
such	O
as	O
tumor	O
.	O

The	O
effect	O
of	O
swainsonine	O
(	O
active	O
compound	O
of	O
locoweed	O
and	O
a	O
potential	O
anticancer	O
drug	O
)	O
on	O
vascular	O
development	O
showed	O
no	O
differences	O
in	O
sinusoidal	O
diameters	O
at	O
7	O
weeks	O
,	O
but	O
a	O
decrease	O
in	O
capillary	O
density	O
was	O
noted	O
.	O

Swainsonine	O
caused	O
a	O
great	O
distortion	O
to	O
the	O
vasculature	O
at	O
18	O
weeks	O
.	O

The	O
effects	O
of	O
this	O
compound	O
on	O
the	O
vascular	O
development	O
lend	O
credibility	O
to	O
its	O
potential	O
as	O
an	O
anticancer	O
agent	O
.	O

Stress	O
and	O
psychological	O
distress	O
among	O
SARS	O
survivors	O
1	O
year	O
after	O
the	O
outbreak	O
.	O

OBJECTIVE	O
:	O

Our	O
study	O
examined	O
the	O
stress	O
level	O
and	O
psychological	O
distress	O
of	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
survivors	O
1	O
year	O
after	O
the	O
outbreak	O
.	O

METHOD	O
:	O

During	O
the	O
SARS	O
outbreak	O
in	O
2003	O
,	O
we	O
used	O
the	O
10	O
-	O
item	O
Perceived	O
Stress	O
Scale	O
(	O
PSS	O
-	O
10	O
)	O
to	O
assess	O
SARS	O
survivors	O
treated	O
in	O
2	O
major	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
49	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
30	O
)	O
.	O

We	O
invited	O
SARS	O
survivors	O
from	O
the	O
same	O
hospitals	O
(	O
non	O
-	O
health	O
care	O
workers	O
,	O
n	O
=	O
63	O
;	O
health	O
care	O
workers	O
,	O
n	O
=	O
33	O
)	O
to	O
complete	O
the	O
PSS	O
-	O
10	O
again	O
in	O
2004	O
.	O

At	O
that	O
time	O
,	O
they	O
were	O
also	O
asked	O
to	O
complete	O
the	O
General	O
Health	O
Questionnaire	O
(	O
GHQ	O
-	O
12	O
)	O
and	O
measures	O
of	O
depression	O
,	O
anxiety	O
,	O
and	O
posttraumatic	O
symptoms	O
.	O

PSS	O
-	O
10	O
scores	O
were	O
also	O
obtained	O
from	O
matched	O
community	O
control	O
subjects	O
during	O
the	O
outbreak	O
(	O
n	O
=	O
145	O
)	O
and	O
again	O
in	O
2004	O
(	O
n	O
=	O
112	O
)	O
.	O

RESULTS	O
:	O

SARS	O
survivors	O
had	O
higher	O
stress	O
levels	O
during	O
the	O
outbreak	O
,	O
compared	O
with	O
control	O
subjects	O
(	O
PSS	O
-	O
10	O
scores	O
=	O
19	O
.	O
8	O
and	O
17	O
.	O
9	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
this	O
persisted	O
1	O
year	O
later	O
(	O
PSS	O
-	O
10	O
scores	O
=	O
19	O
.	O
9	O
and	O
17	O
.	O
3	O
,	O
respectively	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
without	O
signs	O
of	O
decrease	O
.	O

In	O
2004	O
,	O
SARS	O
survivors	O
also	O
showed	O
worrying	O
levels	O
of	O
depression	O
,	O
anxiety	O
,	O
and	O
posttraumatic	O
symptoms	O
.	O

An	O
alarming	O
proportion	O
(	O
64	O
%	O
)	O
scored	O
above	O
the	O
GHQ	O
-	O
12	O
cut	O
-	O
off	O
that	O
suggests	O
psychiatric	O
morbidity	O
.	O

During	O
the	O
outbreak	O
,	O
health	O
care	O
worker	O
SARS	O
survivors	O
had	O
stress	O
levels	O
similar	O
to	O
those	O
of	O
non	O
-	O
health	O
care	O
workers	O
,	O
but	O
health	O
care	O
workers	O
showed	O
significantly	O
higher	O
stress	O
levels	O
in	O
2004	O
(	O
PSS	O
-	O
10	O
score	O
=	O
22	O
.	O
8	O
,	O
compared	O
with	O
PSS	O
-	O
10	O
score	O
=	O
18	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
had	O
higher	O
depression	O
,	O
anxiety	O
,	O
posttraumatic	O
symptoms	O
,	O
and	O
GHQ	O
-	O
12	O
scores	O
.	O

CONCLUSIONS	O
:	O

One	O
year	O
after	O
the	O
outbreak	O
,	O
SARS	O
survivors	O
still	O
had	O
elevated	O
stress	O
levels	O
and	O
worrying	O
levels	O
of	O
psychological	O
distress	O
.	O

The	O
situation	O
of	O
health	O
care	O
worker	O
SARS	O
survivors	O
is	O
particularly	O
worrying	O
.	O

The	O
long	O
-	O
term	O
psychological	O
implications	O
of	O
infectious	O
diseases	O
should	O
not	O
be	O
ignored	O
.	O

Mental	O
health	O
services	O
could	O
play	O
an	O
important	O
role	O
in	O
rehabilitation	O
.	O

High	O
-	O
grade	O
clear	O
cell	O
renal	O
cell	O
carcinoma	O
has	O
a	O
higher	O
angiogenic	O
activity	O
than	O
low	O
-	O
grade	O
renal	O
cell	O
carcinoma	O
based	O
on	O
histomorphological	O
quantification	O
and	O
qRT	O
-	O
PCR	O
mRNA	O
expression	O
profile	O
.	O

Clear	O
cell	O
renal	O
cell	O
carcinoma	O
(	O
CC	O
-	O
RCC	O
)	O
is	O
a	O
highly	O
vascularised	O
tumour	O
and	O
is	O
therefore	O
an	O
attractive	O
disease	O
to	O
study	O
angiogenesis	O
and	O
to	O
test	O
novel	O
angiogenesis	O
inhibitors	O
in	O
early	O
clinical	O
development	O
.	O

Endothelial	O
cell	O
proliferation	O
plays	O
a	O
pivotal	O
role	O
in	O
the	O
process	O
of	O
angiogenesis	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
angiogenesis	O
parameters	O
in	O
low	O
nuclear	O
grade	O
(	O
n	O
=	O
87	O
)	O
vs	O
high	O
nuclear	O
grade	O
CC	O
-	O
RCC	O
(	O
n	O
=	O
63	O
)	O
.	O

A	O
panel	O
of	O
antibodies	O
was	O
used	O
for	O
immunohistochemistry	O
:	O
CD34	O
/	O
Ki	O
-	O
67	O
,	O
carbonic	O
anhydrase	O
IX	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
-	O
1alpha	O
(	O
HIF	O
-	O
1alpha	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

Vessel	O
density	O
(	O
MVD	O
-	O
microvessel	O
density	O
)	O
,	O
endothelial	O
cell	O
proliferation	O
fraction	O
(	O
ECP	O
%	O
)	O
and	O
tumour	O
cell	O
proliferation	O
fraction	O
(	O
TCP	O
%	O
)	O
were	O
assessed	O
.	O

mRNA	O
expression	O
levels	O
of	O
angiogenesis	O
stimulators	O
and	O
inhibitors	O
were	O
determined	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

High	O
-	O
grade	O
CC	O
-	O
RCC	O
showed	O
a	O
higher	O
ECP	O
%	O
(	O
P	O
=	O
0	O
.	O
049	O
)	O
,	O
a	O
higher	O
TCP	O
%	O
(	O
P	O
=	O
0	O
.	O
009	O
)	O
,	O
a	O
higher	O
VEGF	O
protein	O
expression	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
a	O
lower	O
MVD	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
a	O
lower	O
HIF	O
-	O
1alpha	O
protein	O
expression	O
(	O
P	O
=	O
0	O
.	O
002	O
)	O
than	O
low	O
-	O
grade	O
CC	O
-	O
RCC	O
.	O

Growth	O
factor	O
mRNA	O
expression	O
analyses	O
revealed	O
a	O
higher	O
expression	O
of	O
angiopoietin	O
2	O
in	O
low	O
-	O
grade	O
CC	O
-	O
RCC	O
.	O

Microvessel	O
density	O
and	O
ECP	O
%	O
were	O
inversely	O
correlated	O
(	O
Rho	O
=	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

Because	O
of	O
the	O
imperfect	O
association	O
of	O
nuclear	O
grade	O
and	O
ECP	O
%	O
or	O
MVD	O
,	O
CC	O
-	O
RCC	O
was	O
also	O
grouped	O
based	O
on	O
low	O
/	O
high	O
MVD	O
and	O
ECP	O
%	O
.	O

This	O
analysis	O
revealed	O
a	O
higher	O
expression	O
of	O
vessel	O
maturation	O
and	O
stabilisation	O
factors	O
(	O
placental	O
growth	O
factor	O
,	O
PDGFB1	O
,	O
angiopoietin	O
1	O
)	O
in	O
CC	O
-	O
RCC	O
with	O
high	O
MVD	O
,	O
a	O
group	O
of	O
CC	O
-	O
RCC	O
highly	O
enriched	O
in	O
low	O
nuclear	O
grade	O
CC	O
-	O
RCC	O
,	O
with	O
low	O
ECP	O
%	O
.	O

Our	O
results	O
suggest	O
heterogeneity	O
in	O
angiogenic	O
activity	O
and	O
vessel	O
maturation	O
of	O
CC	O
-	O
RCC	O
,	O
to	O
a	O
large	O
extent	O
linked	O
to	O
nuclear	O
grade	O
,	O
and	O
,	O
with	O
probable	O
therapeutic	O
implications	O
.	O

Characterization	O
of	O
transferrin	O
glycoforms	O
in	O
human	O
serum	O
by	O
CE	O
-	O
UV	O
and	O
CE	O
-	O
ESI	O
-	O
MS	O
.	O

Human	O
transferrin	O
(	O
Tf	O
)	O
is	O
a	O
model	O
glycoprotein	O
for	O
congenital	O
disorders	O
of	O
glycosylation	O
(	O
CDG	O
)	O
diagnosis	O
.	O

In	O
the	O
last	O
few	O
years	O
,	O
new	O
CE	O
-	O
UV	O
methods	O
for	O
intact	O
Tf	O
glycoforms	O
analysis	O
have	O
been	O
developed	O
using	O
nonvolatile	O
BGEs	O
and	O
organic	O
modifiers	O
.	O

However	O
,	O
the	O
use	O
of	O
these	O
BGEs	O
does	O
not	O
allow	O
the	O
coupling	O
of	O
these	O
procedures	O
with	O
electrospray	O
MS	O
(	O
ESI	O
-	O
MS	O
)	O
.	O

In	O
this	O
study	O
,	O
a	O
new	O
CE	O
-	O
UV	O
separation	O
method	O
of	O
Tf	O
glycoforms	O
is	O
developed	O
,	O
using	O
a	O
double	O
-	O
layer	O
stable	O
coating	O
and	O
a	O
volatile	O
BGE	O
based	O
on	O
ammonium	O
acetate	O
.	O

The	O
separation	O
method	O
is	O
optimized	O
using	O
standard	O
Tf	O
and	O
their	O
potential	O
is	O
demonstrated	O
applying	O
the	O
method	O
to	O
the	O
analysis	O
of	O
sera	O
Tf	O
from	O
healthy	O
individuals	O
and	O
CDG	O
patients	O
.	O

The	O
CE	O
-	O
UV	O
separation	O
method	O
has	O
been	O
coupled	O
to	O
ESI	O
-	O
MS	O
detection	O
.	O

Main	O
parameters	O
such	O
as	O
sheath	O
liquid	O
composition	O
are	O
optimized	O
in	O
order	O
to	O
obtain	O
a	O
good	O
sensitivity	O
.	O

The	O
CE	O
-	O
ESI	O
-	O
MS	O
method	O
has	O
also	O
been	O
used	O
in	O
serum	O
samples	O
obtaining	O
the	O
separation	O
of	O
the	O
different	O
proteins	O
present	O
in	O
serum	O
and	O
partial	O
separation	O
of	O
Tf	O
glycoforms	O
.	O

Different	O
mass	O
spectra	O
and	O
deconvoluted	O
molecular	O
masses	O
were	O
obtained	O
for	O
each	O
sialoform	O
,	O
allowing	O
unequivocal	O
glycoform	O
identification	O
.	O

Medical	O
therapy	O
for	O
intermittent	O
claudication	O
.	O

Medical	O
therapy	O
to	O
improve	O
symptoms	O
,	O
stabilise	O
the	O
underlying	O
vascular	O
disease	O
and	O
improve	O
lower	O
limb	O
outcomes	O
is	O
an	O
important	O
and	O
effective	O
adjunct	O
to	O
lifestyle	O
modification	O
and	O
surgical	O
or	O
endovascular	O
interventions	O
in	O
patients	O
with	O
IC	O
.	O

Randomised	O
placebo	O
controlled	O
trials	O
have	O
shown	O
that	O
the	O
phosphodiesterase	O
III	O
inhibitor	O
cilostazol	O
100	O
mg	O
bid	O
improves	O
pain	O
-	O
free	O
and	O
maximum	O
walking	O
distance	O
,	O
as	O
well	O
as	O
quality	O
of	O
life	O
,	O
in	O
a	O
range	O
of	O
patients	O
with	O
intermittent	O
claudication	O
in	O
whom	O
there	O
is	O
no	O
evidence	O
of	O
tissue	O
necrosis	O
or	O
rest	O
pain	O
.	O

This	O
review	O
summarises	O
the	O
evidence	O
from	O
8	O
pivotal	O
trials	O
of	O
cilostazol	O
involving	O
over	O
2000	O
patients	O
with	O
intermittent	O
claudication	O
treated	O
for	O
up	O
to	O
6	O
months	O
.	O

There	O
is	O
comparatively	O
less	O
evidence	O
to	O
support	O
the	O
use	O
of	O
other	O
treatment	O
modalities	O
for	O
relief	O
of	O
symptoms	O
in	O
intermittent	O
claudication	O
,	O
but	O
there	O
is	O
considerable	O
interest	O
in	O
therapeutic	O
angiogenesis	O
to	O
promote	O
new	O
vessel	O
formation	O
and	O
enhance	O
collateralisation	O
of	O
the	O
lower	O
limb	O
using	O
recombinant	O
growth	O
factor	O
proteins	O
or	O
gene	O
transfer	O
strategies	O
.	O

The	O
rationale	O
for	O
therapeutic	O
angiogenesis	O
is	O
discussed	O
,	O
together	O
with	O
the	O
most	O
recent	O
results	O
from	O
randomised	O
trials	O
in	O
patients	O
with	O
peripheral	O
arterial	O
disease	O
.	O

Deletion	O
of	O
Tip30	O
leads	O
to	O
rapid	O
immortalization	O
of	O
murine	O
mammary	O
epithelial	O
cells	O
and	O
ductal	O
hyperplasia	O
in	O
the	O
mammary	O
gland	O
.	O

Transformation	O
of	O
mammary	O
epithelial	O
cells	O
(	O
MECs	O
)	O
from	O
the	O
normal	O
to	O
the	O
neoplastic	O
stage	O
requires	O
the	O
dysregulation	O
of	O
tumor	O
suppressor	O
genes	O
and	O
proto	O
-	O
oncogenes	O
.	O

Tip30	O
is	O
a	O
tumor	O
suppressor	O
that	O
can	O
inhibit	O
estrogen	O
receptor	O
-	O
mediated	O
transcription	O
in	O
MECs	O
,	O
but	O
its	O
role	O
in	O
MEC	O
proliferation	O
remains	O
unknown	O
.	O

Here	O
,	O
we	O
show	O
that	O
deleting	O
the	O
Tip30	O
gene	O
leads	O
to	O
ductal	O
hyperplasia	O
in	O
mouse	O
mammary	O
glands	O
early	O
in	O
life	O
and	O
extensive	O
mammary	O
hyperplasia	O
with	O
age	O
.	O

Tip30	O
(	O
-	O
/	O
-	O
)	O
mammary	O
glands	O
transplanted	O
into	O
wild	O
-	O
type	O
mammary	O
fat	O
pads	O
also	O
display	O
mammary	O
trees	O
with	O
extensive	O
ductal	O
hyperplasia	O
.	O

Strikingly	O
,	O
Tip30	O
deletion	O
promotes	O
proliferation	O
of	O
primary	O
MECs	O
and	O
results	O
in	O
rapid	O
immortalization	O
of	O
MECs	O
in	O
vitro	O
relative	O
to	O
wild	O
-	O
type	O
cells	O
.	O

Gene	O
array	O
analysis	O
identified	O
significant	O
increases	O
in	O
the	O
expression	O
of	O
mammary	O
epithelial	O
growth	O
factors	O
Wisp2	O
and	O
Igf	O
-	O
1	O
in	O
Tip30	O
(	O
-	O
/	O
-	O
)	O
cells	O
.	O

Knockdown	O
of	O
either	O
Wisp2	O
or	O
Igf	O
-	O
1	O
using	O
short	O
interfering	O
RNA	O
dramatically	O
inhibited	O
proliferation	O
of	O
Tip30	O
(	O
-	O
/	O
-	O
)	O
cells	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
Tip30	O
is	O
an	O
intrinsic	O
and	O
negative	O
regulator	O
of	O
MEC	O
proliferation	O
partly	O
through	O
the	O
inhibition	O
of	O
Wisp2	O
and	O
Igf	O
-	O
1	O
expression	O
,	O
and	O
its	O
absence	O
in	O
the	O
mammary	O
gland	O
may	O
predispose	O
MECs	O
to	O
neoplastic	O
transformation	O
.	O

Long	O
-	O
term	O
immunosuppression	O
in	O
burned	O
patients	O
assessed	O
by	O
in	O
vitro	O
neutrophil	O
oxidative	O
burst	O
(	O
Phagoburst	O
)	O
.	O

OBJECTIVE	O
:	O

To	O
assess	O
the	O
duration	O
and	O
magnitude	O
of	O
immunosuppression	O
induced	O
by	O
burns	O
as	O
measured	O
by	O
the	O
neutrophil	O
oxidative	O
burst	O
in	O
vitro	O
.	O

DESIGN	O
:	O

Prospective	O
exploratory	O
cohort	O
study	O
.	O

SETTING	O
:	O

Tertiary	O
referral	O
unit	O
,	O
University	O
Hospital	O
,	O
Linkoping	O
,	O
Sweden	O
(	O
National	O
Burn	O
Unit	O
)	O
.	O

PATIENTS	O
AND	O
HEALTHY	O
VOLUNTEERS	O
(	O
CONTROLS	O
)	O
:	O
Twenty	O
-	O
eight	O
subjects	O
consecutively	O
admitted	O
to	O
the	O
Burn	O
Unit	O
.	O

The	O
mean	O
total	O
burn	O
surface	O
area	O
(	O
TBSA	O
%	O
)	O
was	O
36	O
(	O
range	O
13	O
-	O
87	O
)	O
and	O
mean	O
age	O
44	O
years	O
(	O
range	O
14	O
-	O
89	O
)	O
.	O

Patients	O
'	O
data	O
were	O
collected	O
prospectively	O
in	O
the	O
burn	O
unit	O
,	O
which	O
also	O
included	O
sequential	O
organ	O
failure	O
assessment	O
(	O
SOFA	O
)	O
score	O
.	O

INTERVENTIONS	O
:	O

None	O
.	O

MEASUREMENTS	O
AND	O
RESULTS	O
:	O

To	O
assess	O
the	O
changes	O
in	O
the	O
oxidative	O
capacity	O
of	O
neutrophils	O
after	O
the	O
burn	O
,	O
blood	O
samples	O
for	O
the	O
Phagoburst	O
analysis	O
were	O
taken	O
on	O
admission	O
and	O
at	O
least	O
once	O
every	O
second	O
week	O
for	O
the	O
duration	O
of	O
stay	O
in	O
hospital	O
and	O
thereafter	O
monthly	O
up	O
to	O
12	O
months	O
after	O
the	O
burn	O
.	O

Neutrophils	O
were	O
stimulated	O
in	O
vitro	O
by	O
Escherichia	O
coli	O
,	O
phorbol	O
12	O
-	O
phorbol	O
myristate	O
13	O
-	O
acetate	O
(	O
PMA	O
)	O
,	O
and	O
peptide	O
N	O
-	O
formyl	O
-	O
Met	O
-	O
Leu	O
-	O
Phe	O
(	O
fMLP	O
)	O
.	O

Oxidative	O
burst	O
was	O
measured	O
by	O
flow	O
cytometry	O
.	O

Oxidative	O
capacity	O
of	O
the	O
neutrophils	O
decreased	O
similarly	O
for	O
all	O
three	O
stimulants	O
:	O
there	O
was	O
a	O
pathological	O
decrease	O
shortly	O
after	O
admission	O
,	O
with	O
the	O
lowest	O
value	O
occurring	O
between	O
days	O
7	O
and	O
10	O
,	O
followed	O
by	O
a	O
gradual	O
recovery	O
during	O
the	O
ensuing	O
months	O
.	O

Full	O
recovery	O
(	O
to	O
the	O
values	O
of	O
the	O
controls	O
)	O
was	O
seen	O
first	O
3	O
.	O
5	O
months	O
after	O
the	O
burn	O
.	O

Using	O
multiple	O
regression	O
,	O
we	O
found	O
that	O
only	O
age	O
and	O
time	O
since	O
the	O
burn	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
affected	O
the	O
oxidative	O
burst	O
.	O

White	O
cell	O
count	O
(	O
WCC	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
values	O
returned	O
to	O
reference	O
ranges	O
long	O
before	O
the	O
oxidative	O
burst	O
.	O

CONCLUSIONS	O
:	O

This	O
study	O
provides	O
evidence	O
that	O
immunosuppression	O
in	O
those	O
injured	O
by	O
burns	O
,	O
as	O
assessed	O
by	O
the	O
in	O
vitro	O
oxidative	O
burst	O
of	O
neutrophils	O
,	O
remains	O
long	O
after	O
the	O
event	O
of	O
the	O
burn	O
(	O
up	O
to	O
3	O
.	O
5	O
months	O
after	O
burn	O
)	O
.	O

Absence	O
of	O
correlations	O
to	O
TBSA	O
%	O
,	O
FTB	O
%	O
,	O
blood	O
transfusion	O
,	O
opiates	O
provided	O
,	O
and	O
multiple	O
organ	O
failure	O
score	O
and	O
laboratory	O
infection	O
variables	O
together	O
with	O
the	O
finding	O
that	O
decreased	O
oxidative	O
burst	O
was	O
uniform	O
after	O
the	O
injury	O
,	O
suggesting	O
that	O
this	O
immunosuppression	O
is	O
primarily	O
due	O
to	O
the	O
general	O
metabolic	O
response	O
rather	O
than	O
recurring	O
infections	O
.	O

A	O
pivotal	O
role	O
for	O
p53	O
:	O
balancing	O
aerobic	O
respiration	O
and	O
glycolysis	O
.	O

The	O
genetic	O
basis	O
of	O
increased	O
glycolytic	O
activity	O
observed	O
in	O
cancer	O
cells	O
is	O
likely	O
to	O
be	O
the	O
result	O
of	O
complex	O
interactions	O
of	O
multiple	O
regulatory	O
pathways	O
.	O

Here	O
we	O
review	O
the	O
recent	O
evidence	O
of	O
a	O
simple	O
genetic	O
mechanism	O
by	O
which	O
tumor	O
suppressor	O
p53	O
regulates	O
mitochondrial	O
respiration	O
with	O
secondary	O
changes	O
in	O
glycolysis	O
that	O
are	O
reminiscent	O
of	O
the	O
Warburg	O
effect	O
.	O

The	O
biological	O
significance	O
of	O
this	O
regulation	O
of	O
the	O
two	O
major	O
pathways	O
of	O
energy	O
generation	O
by	O
p53	O
remains	O
to	O
be	O
seen	O
.	O

The	O
contribution	O
of	O
Harold	O
F	O
.	O
Dvorak	O
to	O
the	O
study	O
of	O
tumor	O
angiogenesis	O
and	O
stroma	O
generation	O
mechanisms	O
.	O

In	O
1983	O
,	O
Harold	O
Dvorak	O
and	O
his	O
colleagues	O
were	O
the	O
first	O
to	O
show	O
that	O
tumor	O
cells	O
secreted	O
vascular	O
permeability	O
factor	O
(	O
VPF	O
)	O
and	O
that	O
a	O
blocking	O
antibody	O
to	O
VPF	O
could	O
prevent	O
the	O
edema	O
and	O
fluid	O
accumulation	O
that	O
is	O
characteristic	O
of	O
human	O
cancers	O
.	O

In	O
1986	O
,	O
Dvorak	O
went	O
on	O
to	O
demonstrate	O
that	O
VPF	O
was	O
secreted	O
by	O
a	O
variety	O
of	O
human	O
tumor	O
cell	O
lines	O
and	O
proposed	O
that	O
VPF	O
was	O
in	O
part	O
responsible	O
for	O
the	O
abnormal	O
vasculature	O
seen	O
in	O
human	O
tumors	O
.	O

As	O
a	O
result	O
,	O
he	O
and	O
other	O
investigators	O
demonstrated	O
that	O
VPF	O
was	O
capable	O
of	O
stimulating	O
endothelial	O
cell	O
growth	O
and	O
angiogenesis	O
.	O

These	O
fundamental	O
discoveries	O
led	O
to	O
additional	O
research	O
conducted	O
by	O
Napoleone	O
Ferrara	O
and	O
his	O
laboratory	O
,	O
confirming	O
the	O
cloning	O
of	O
VPF	O
and	O
renaming	O
the	O
protein	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

In	O
1986	O
,	O
Dvorak	O
proposed	O
that	O
by	O
secreting	O
VPF	O
,	O
tumors	O
induce	O
angiogenesis	O
by	O
turning	O
on	O
the	O
wound	O
healing	O
response	O
.	O

He	O
noted	O
that	O
wounds	O
,	O
like	O
tumors	O
,	O
secrete	O
VPF	O
,	O
causing	O
blood	O
vessels	O
to	O
leak	O
plasma	O
fibrinogen	O
,	O
which	O
stimulates	O
blood	O
vessel	O
growth	O
and	O
provides	O
a	O
matrix	O
on	O
which	O
they	O
can	O
spread	O
.	O

Unlike	O
wounds	O
,	O
however	O
,	O
that	O
turn	O
off	O
VPF	O
production	O
after	O
healing	O
,	O
tumors	O
did	O
not	O
turn	O
off	O
their	O
VPF	O
production	O
and	O
instead	O
continued	O
to	O
make	O
large	O
amounts	O
of	O
VPF	O
,	O
allowing	O
malignant	O
cells	O
to	O
continue	O
to	O
induce	O
new	O
blood	O
vessels	O
and	O
so	O
to	O
grow	O
and	O
spread	O
.	O

Thus	O
,	O
tumors	O
behave	O
like	O
wounds	O
that	O
fail	O
to	O
heal	O
.	O

This	O
work	O
is	O
again	O
extremely	O
significant	O
for	O
patients	O
worldwide	O
,	O
as	O
Dvorak	O
'	O
s	O
scientific	O
research	O
is	O
leading	O
his	O
colleagues	O
all	O
over	O
the	O
world	O
to	O
examine	O
how	O
to	O
treat	O
a	O
tumor	O
through	O
its	O
blood	O
supply	O
.	O

Modulating	O
metastasis	O
by	O
a	O
lymphangiogenic	O
switch	O
in	O
prostate	O
cancer	O
.	O

Prostate	O
cancer	O
dissemination	O
is	O
difficult	O
to	O
detect	O
in	O
the	O
clinic	O
,	O
and	O
few	O
treatment	O
options	O
exist	O
for	O
patients	O
with	O
advanced	O
-	O
stage	O
disease	O
.	O

Our	O
aim	O
was	O
to	O
investigate	O
the	O
role	O
of	O
tumor	O
lymphangiogenesis	O
during	O
metastasis	O
.	O

Further	O
,	O
we	O
implemented	O
a	O
noninvasive	O
molecular	O
imaging	O
technique	O
to	O
facilitate	O
the	O
assessment	O
of	O
the	O
metastatic	O
process	O
.	O

The	O
metastatic	O
potentials	O
of	O
several	O
human	O
prostate	O
cancer	O
xenograft	O
models	O
,	O
LAPC	B
-	I
4	I
,	O
LAPC	B
-	I
9	I
,	O
PC3	B
and	O
CWR22Rv	B
-	I
1	I
were	O
compared	O
.	O

The	O
cells	O
were	O
labeled	O
with	O
luciferase	O
,	O
a	O
bioluminescence	O
imaging	O
reporter	O
gene	O
,	O
to	O
enable	O
optical	O
imaging	O
.	O

After	O
tumor	O
implantation	O
the	O
animals	O
were	O
examined	O
weekly	O
during	O
several	O
months	O
for	O
the	O
appearance	O
of	O
metastases	O
.	O

Metastatic	O
lesions	O
were	O
confirmed	O
by	O
immunohistochemistry	O
.	O

Additionally	O
,	O
the	O
angiogenic	O
and	O
lymphangiogenic	O
profiles	O
of	O
the	O
tumors	O
were	O
characterized	O
.	O

To	O
confirm	O
the	O
role	O
of	O
lymphangiogenesis	O
in	O
mediating	O
metastasis	O
,	O
the	O
low	O
-	O
metastatic	O
LAPC	B
-	I
9	I
tumor	O
cells	O
were	O
engineered	O
to	O
overexpress	O
VEGF	O
-	O
C	O
,	O
and	O
the	O
development	O
of	O
metastases	O
was	O
evaluated	O
.	O

Our	O
results	O
show	O
CWR22Rv	B
-	I
1	I
and	O
PC3	B
tumor	O
cell	O
lines	O
to	O
be	O
more	O
metastatic	O
than	O
LAPC	B
-	I
4	I
,	O
which	O
in	O
turn	O
disseminates	O
more	O
readily	O
than	O
LAPC	B
-	I
9	I
.	O

The	O
difference	O
in	O
metastatic	O
potential	O
correlated	O
with	O
the	O
endogenous	O
production	O
levels	O
of	O
lymphangiogenic	O
growth	O
factor	O
VEGF	O
-	O
C	O
and	O
the	O
presence	O
of	O
tumor	O
lymphatics	O
.	O

In	O
agreement	O
,	O
induced	O
overexpression	O
of	O
VEGF	O
-	O
C	O
in	O
LAPC	B
-	I
9	I
enhanced	O
tumor	O
lymphangiogenesis	O
leading	O
to	O
the	O
development	O
of	O
metastatic	O
lesions	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
,	O
based	O
on	O
a	O
molecular	O
imaging	O
approach	O
for	O
semiquantitative	O
detection	O
of	O
micrometastases	O
,	O
point	O
to	O
an	O
important	O
role	O
of	O
tumor	O
lymphatics	O
in	O
the	O
metastatic	O
process	O
of	O
human	O
prostate	O
cancer	O
.	O

In	O
particular	O
,	O
VEGF	O
-	O
C	O
seems	O
to	O
play	O
a	O
key	O
role	O
in	O
prostate	O
cancer	O
metastasis	O
.	O

Quantitative	O
sequencing	O
of	O
complex	O
mixtures	O
of	O
heterochitooligosaccharides	O
by	O
vMALDI	O
-	O
linear	O
ion	O
trap	O
mass	O
spectrometry	O
.	O

Heterochitooligosaccharides	O
possess	O
interesting	O
biological	O
properties	O
.	O

Isobaric	O
mixtures	O
of	O
such	O
linear	O
heterochitooligosaccharides	O
can	O
be	O
obtained	O
by	O
chemical	O
or	O
enzymatic	O
degradation	O
of	O
chitosan	O
.	O

However	O
,	O
the	O
separation	O
of	O
such	O
mixtures	O
is	O
a	O
challenging	O
analytical	O
problem	O
which	O
is	O
so	O
far	O
unresolved	O
.	O

It	O
is	O
shown	O
that	O
these	O
isobaric	O
mixtures	O
can	O
be	O
sequenced	O
and	O
quantified	O
simultaneously	O
using	O
standard	O
derivatization	O
and	O
multistage	O
tandem	O
mass	O
spectrometric	O
techniques	O
.	O

A	O
linear	O
ion	O
trap	O
mass	O
spectrometer	O
equipped	O
with	O
a	O
vacuum	O
matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
(	O
vMALDI	O
)	O
source	O
is	O
used	O
to	O
perform	O
MS2	O
as	O
well	O
as	O
MS3	O
experiments	O
.	O

Selective	O
activation	O
of	O
mast	O
cells	O
in	O
rheumatoid	O
synovial	O
tissue	O
results	O
in	O
production	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
.	O

OBJECTIVES	O
AND	O
DESIGN	O
:	O

To	O
study	O
the	O
consequences	O
of	O
mast	O
cell	O
activation	O
in	O
human	O
synovial	O
tissue	O
.	O

METHODS	O
:	O

Synovial	O
tissue	O
was	O
obtained	O
from	O
18	O
RA	O
patients	O
and	O
mast	O
cells	O
was	O
selectively	O
activated	O
in	O
synovial	O
tissue	O
explant	O
cultures	O
.	O

Expression	O
of	O
TNF	O
-	O
alpha	O
,	O
IL	O
-	O
1beta	O
and	O
IL	O
-	O
1Ra	O
were	O
determined	O
and	O
tissue	O
distribution	O
of	O
IL	O
-	O
1beta	O
was	O
studied	O
.	O

RESULTS	O
:	O

Compared	O
to	O
untreated	O
synovia	O
,	O
selective	O
activation	O
of	O
synovial	O
mast	O
cells	O
increased	O
significantly	O
the	O
production	O
of	O
TNF	O
-	O
alpha	O
(	O
0	O
.	O
49	O
+	O
/	O
-	O
0	O
.	O
88	O
vs	O
.	O
4	O
.	O
56	O
+	O
/	O
-	O
3	O
.	O
18	O
pg	O
/	O
mg	O
wet	O
tissue	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
IL	O
-	O
1beta	O
(	O
0	O
.	O
058	O
+	O
/	O
-	O
0	O
.	O
032	O
vs	O
.	O
2	O
.	O
55	O
+	O
/	O
-	O
1	O
.	O
98	O
pg	O
/	O
mg	O
wet	O
tissue	O
,	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O

The	O
expression	O
of	O
TNF	O
-	O
alpha	O
and	O
IL	O
-	O
1beta	O
mRNA	O
increased	O
significantly	O
(	O
19	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
13	O
-	O
fold	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
,	O
respectively	O
)	O
.	O

Mast	O
cell	O
activation	O
induced	O
IL	O
-	O
1beta	O
expression	O
in	O
particular	O
in	O
nearby	O
CD68	O
positive	O
synovial	O
macrophages	O
.	O

Secretion	O
of	O
IL	O
-	O
1Ra	O
was	O
also	O
increased	O
but	O
to	O
a	O
lesser	O
degree	O
than	O
that	O
of	O
IL	O
-	O
1beta	O
.	O

CONCLUSIONS	O
:	O

Synovial	O
mast	O
cells	O
produce	O
proinflammmatory	O
cytokines	O
and	O
may	O
thus	O
contribute	O
to	O
the	O
inflammation	O
in	O
RA	O
.	O

An	O
assay	O
to	O
measure	O
angiogenesis	O
in	O
human	O
fat	O
tissue	O
.	O

BACKGROUND	O
:	O
Inhibition	O
of	O
angiogenesis	O
reverses	O
rodent	O
obesity	O
.	O

A	O
validated	O
assay	O
in	O
human	O
fat	O
tissue	O
is	O
needed	O
to	O
study	O
the	O
role	O
of	O
angiogenesis	O
in	O
human	O
obesity	O
.	O

METHODS	O
:	O
Human	O
fat	O
tissue	O
fragments	O
from	O
surgery	O
were	O
placed	O
in	O
96	O
-	O
well	O
plates	O
,	O
embedded	O
in	O
fibrin	O
thrombin	O
clot	O
and	O
overlaid	O
with	O
cell	O
culture	O
media	O
containing	O
20	O
%	O
fetal	O
bovine	O
serum	O
.	O

After	O
15	O
days	O
,	O
the	O
clots	O
were	O
examined	O
by	O
histology	O
and	O
electron	O
microscopy	O
.	O

The	O
effect	O
of	O
taxol	O
,	O
cobalt	O
chloride	O
and	O
a	O
heparin	O
-	O
steroid	O
combination	O
was	O
tested	O
in	O
the	O
fat	O
tissue	O
assay	O
and	O
compared	O
to	O
the	O
validated	O
human	O
placental	O
vein	O
angiogenesis	O
model	O
(	O
HPVAM	O
)	O
.	O

RESULTS	O
:	O
Blood	O
vessels	O
initiated	O
growth	O
and	O
elongated	O
from	O
the	O
fat	O
tissue	O
fragments	O
over	O
15	O
days	O
.	O

Presence	O
of	O
blood	O
vessels	O
was	O
confirmed	O
with	O
histology	O
and	O
electron	O
microscopy	O
.	O

Taxol	O
at	O
10	O
(	O
-	O
6	O
)	O
and	O
10	O
(	O
-	O
7	O
)	O
M	O
completely	O
inhibited	O
angiogenesis	O
,	O
while	O
Taxol	O
10	O
(	O
-	O
8	O
)	O
and	O
10	O
(	O
-	O
9	O
)	O
M	O
and	O
the	O
heparin	O
-	O
steroid	O
partially	O
inhibited	O
angiogenesis	O
.	O

The	O
response	O
to	O
taxol	O
and	O
heparin	O
-	O
steroid	O
was	O
similar	O
to	O
that	O
of	O
the	O
HPVAM	O
,	O
a	O
validated	O
angiogenesis	O
assay	O
.	O

Cobalt	O
chloride	O
,	O
a	O
stimulator	O
of	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
stimulated	O
angiogenesis	O
initiation	O
at	O
10	O
(	O
-	O
9	O
)	O
M	O
in	O
fat	O
tissue	O
and	O
the	O
HPVAM	O
,	O
but	O
at	O
10	O
(	O
-	O
10	O
)	O
M	O
blood	O
vessel	O
growth	O
was	O
stimulated	O
only	O
in	O
the	O
fat	O
assay	O
.	O

CONCLUSION	O
:	O
This	O
angiogenesis	O
assay	O
based	O
on	O
human	O
fat	O
tissue	O
uses	O
three	O
-	O
dimensionally	O
intact	O
human	O
tissue	O
.	O

The	O
vessels	O
are	O
derived	O
from	O
quiescient	O
vessels	O
within	O
the	O
fat	O
.	O

These	O
properties	O
allow	O
the	O
angiogenic	O
switch	O
to	O
be	O
evaluated	O
in	O
an	O
in	O
vitro	O
setting	O
.	O

The	O
angiogenic	O
response	O
of	O
fat	O
tissue	O
is	O
not	O
identical	O
to	O
placental	O
tissue	O
.	O

This	O
assay	O
allows	O
exploration	O
of	O
angiogenesis	O
in	O
fat	O
tissue	O
.	O

Rapid	O
mixing	O
between	O
old	O
and	O
new	O
C	O
pools	O
in	O
the	O
canopy	O
of	O
mature	O
forest	O
trees	O
.	O

Stable	O
C	O
isotope	O
signals	O
in	O
plant	O
tissues	O
became	O
a	O
key	O
tool	O
in	O
explaining	O
growth	O
responses	O
to	O
the	O
environment	O
.	O

The	O
technique	O
is	O
based	O
on	O
the	O
fundamental	O
assumption	O
that	O
the	O
isotopic	O
composition	O
of	O
a	O
given	O
unit	O
of	O
tissue	O
(	O
e	O
.	O
g	O
.	O
a	O
tree	O
ring	O
)	O
reflects	O
the	O
specific	O
C	O
uptake	O
conditions	O
in	O
the	O
leaf	O
at	O
a	O
given	O
time	O
.	O

Beyond	O
the	O
methodological	O
implications	O
of	O
any	O
deviation	O
from	O
this	O
assumption	O
,	O
it	O
is	O
of	O
physiological	O
interest	O
whether	O
new	O
C	O
is	O
transferred	O
directly	O
from	O
sources	O
(	O
a	O
photosynthesizing	O
leaf	O
)	O
to	O
structural	O
sinks	O
(	O
e	O
.	O
g	O
.	O
adjacent	O
stem	O
tissue	O
)	O
,	O
or	O
inherently	O
passes	O
through	O
existing	O
(	O
mobile	O
)	O
C	O
pools	O
,	O
which	O
may	O
be	O
of	O
variable	O
(	O
older	O
)	O
age	O
.	O

Here	O
,	O
we	O
explore	O
the	O
fate	O
of	O
(	O
13	O
)	O
C	O
-	O
labelled	O
photosynthates	O
in	O
the	O
crowns	O
of	O
a	O
30	O
-	O
35	O
m	O
tall	O
,	O
mixed	O
forest	O
using	O
a	O
canopy	O
crane	O
.	O

In	O
all	O
nine	O
study	O
species	O
labelled	O
C	O
reached	O
woody	O
tissue	O
within	O
2	O
-	O
9	O
h	O
after	O
labelling	O
.	O

Four	O
months	O
later	O
,	O
very	O
small	O
signals	O
were	O
left	O
in	O
branch	O
wood	O
of	O
Tilia	O
suggesting	O
that	O
low	O
mixing	O
of	O
new	O
,	O
labelled	O
C	O
with	O
old	O
C	O
had	O
taken	O
place	O
.	O

In	O
contrast	O
,	O
signals	O
in	O
Fagus	O
and	O
Quercus	O
had	O
increased	O
,	O
indicating	O
more	O
intense	O
mixing	O
.	O

This	O
species	O
-	O
specific	O
mixing	O
of	O
new	O
with	O
old	O
C	O
pools	O
is	O
likely	O
to	O
mask	O
year	O
-	O
or	O
season	O
-	O
specific	O
linkages	O
between	O
tree	O
ring	O
formation	O
and	O
climate	O
and	O
has	O
considerable	O
implications	O
for	O
climate	O
reconstruction	O
using	O
stable	O
isotopes	O
as	O
proxies	O
for	O
past	O
climatic	O
conditions	O
.	O

Adaptive	O
landscapes	O
and	O
emergent	O
phenotypes	O
:	O
why	O
do	O
cancers	O
have	O
high	O
glycolysis	O
?	O

Investigating	O
the	O
causes	O
of	O
increased	O
aerobic	O
glycolysis	O
in	O
tumors	O
(	O
Warburg	O
Effect	O
)	O
has	O
gone	O
in	O
and	O
out	O
of	O
fashion	O
many	O
times	O
since	O
it	O
was	O
first	O
described	O
almost	O
a	O
century	O
ago	O
.	O

The	O
field	O
is	O
currently	O
in	O
ascendance	O
due	O
to	O
two	O
factors	O
.	O

Over	O
a	O
million	O
FDG	O
-	O
PET	O
studies	O
have	O
unequivocally	O
identified	O
increased	O
glucose	O
uptake	O
as	O
a	O
hallmark	O
of	O
metastatic	O
cancer	O
in	O
humans	O
.	O

These	O
observations	O
,	O
combined	O
with	O
new	O
molecular	O
insights	O
with	O
HIF	O
-	O
1alpha	O
and	O
c	O
-	O
myc	O
,	O
have	O
rekindled	O
an	O
interest	O
in	O
this	O
important	O
phenotype	O
.	O

A	O
preponderance	O
of	O
work	O
has	O
been	O
focused	O
on	O
the	O
molecular	O
mechanisms	O
underlying	O
this	O
effect	O
,	O
with	O
the	O
expectation	O
that	O
a	O
mechanistic	O
understanding	O
may	O
lead	O
to	O
novel	O
therapeutic	O
approaches	O
.	O

There	O
is	O
also	O
an	O
implicit	O
assumption	O
that	O
a	O
mechanistic	O
understanding	O
,	O
although	O
fundamentally	O
reductionist	O
,	O
will	O
nonetheless	O
lead	O
to	O
a	O
more	O
profound	O
teleological	O
understanding	O
of	O
the	O
need	O
for	O
altered	O
metabolism	O
in	O
invasive	O
cancers	O
.	O

In	O
this	O
communication	O
,	O
we	O
describe	O
an	O
alternative	O
approach	O
that	O
begins	O
with	O
teleology	O
;	O
i	O
.	O
e	O
.	O
adaptive	O
landscapes	O
and	O
selection	O
pressures	O
that	O
promote	O
emergence	O
of	O
aerobic	O
glycolysis	O
during	O
the	O
somatic	O
evolution	O
of	O
invasive	O
cancer	O
.	O

Mathematical	O
models	O
and	O
empirical	O
observations	O
are	O
used	O
to	O
define	O
the	O
adaptive	O
advantage	O
of	O
aerobic	O
glycolysis	O
that	O
would	O
explain	O
its	O
remarkable	O
prevalence	O
in	O
human	O
cancers	O
.	O

These	O
studies	O
have	O
led	O
to	O
the	O
hypothesis	O
that	O
increased	O
consumption	O
of	O
glucose	O
in	O
metastatic	O
lesions	O
is	O
not	O
used	O
for	O
substantial	O
energy	O
production	O
via	O
Embden	O
-	O
Meyerhoff	O
glycolysis	O
,	O
but	O
rather	O
for	O
production	O
of	O
acid	O
,	O
which	O
gives	O
the	O
cancer	O
cells	O
a	O
competitive	O
advantage	O
for	O
invasion	O
.	O

Alternative	O
hypotheses	O
,	O
wherein	O
the	O
glucose	O
is	O
used	O
for	O
generation	O
of	O
reducing	O
equivalents	O
(	O
NADPH	O
)	O
or	O
anabolic	O
precursors	O
(	O
ribose	O
)	O
are	O
also	O
discussed	O
.	O

Neurohypophyseal	O
granulomatous	O
germinoma	O
invading	O
the	O
right	O
cavernous	O
sinus	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

We	O
encountered	O
a	O
rare	O
case	O
of	O
neurohypophyseal	O
germinoma	O
with	O
a	O
prominent	O
granulomatous	O
reaction	O
,	O
which	O
invaded	O
the	O
right	O
cavernous	O
sinus	O
.	O

The	O
neuroimaging	O
and	O
histopathology	O
features	O
in	O
this	O
case	O
were	O
unique	O
,	O
distinguishing	O
it	O
from	O
other	O
types	O
of	O
suprasellar	O
lesions	O
.	O

A	O
13	O
-	O
year	O
-	O
old	O
boy	O
presented	O
with	O
loss	O
of	O
appetite	O
and	O
polyuria	O
;	O
both	O
symptoms	O
were	O
present	O
for	O
1	O
year	O
,	O
and	O
headache	O
,	O
general	O
fatigue	O
and	O
blurred	O
vision	O
present	O
for	O
the	O
prior	O
2	O
months	O
.	O

On	O
admission	O
,	O
neurological	O
examination	O
indicated	O
bitemporal	O
hemianopsia	O
and	O
optic	O
atrophy	O
.	O

Endocrinological	O
exam	O
showed	O
panhypopituitarism	O
.	O

Tumor	O
markers	O
such	O
as	O
alpha	O
-	O
fetoprotein	O
,	O
human	O
growth	O
hormone	O
,	O
carcinoembryonic	O
antigen	O
,	O
and	O
placental	O
alkaline	O
phosphatase	O
were	O
negative	O
.	O

Brain	O
CT	O
revealed	O
a	O
suprasellar	O
tumor	O
with	O
calcification	O
.	O

MR	O
T	O
(	O
1	O
)	O
-	O
weighted	O
and	O
T	O
(	O
2	O
)	O
-	O
weighted	O
images	O
showed	O
the	O
tumor	O
to	O
be	O
isointense	O
to	O
normal	O
brain	O
parenchyma	O
and	O
to	O
be	O
enhanced	O
densely	O
.	O

The	O
tumor	O
also	O
involved	O
the	O
right	O
cavernous	O
sinus	O
,	O
so	O
that	O
a	O
biopsy	O
was	O
performed	O
by	O
the	O
transsphenoidal	O
approach	O
.	O

On	O
pathologic	O
examination	O
of	O
the	O
specimen	O
,	O
typical	O
large	O
tumor	O
cells	O
with	O
lymphocytic	O
cell	O
infiltration	O
and	O
prominent	O
granulomatous	O
reaction	O
were	O
observed	O
.	O

Neurohypophyseal	O
granulomatous	O
germinoma	O
was	O
diagnosed	O
.	O

Radiotherapy	O
was	O
performed	O
with	O
a	O
total	O
dose	O
of	O
51	O
Gy	O
and	O
the	O
tumor	O
shrank	O
remarkably	O
.	O

The	O
patient	O
returned	O
to	O
school	O
under	O
hormone	O
replacement	O
therapy	O
.	O

Melissoidesin	O
G	O
,	O
a	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
induces	O
leukemic	O
-	O
cell	O
apoptosis	O
through	O
induction	O
of	O
redox	O
imbalance	O
and	O
exhibits	O
synergy	O
with	O
other	O
anticancer	O
agents	O
.	O

Melissoidesin	O
G	O
(	O
MOG	O
)	O
is	O
a	O
new	O
diterpenoid	O
purified	O
from	O
Isodon	O
melissoides	O
,	O
a	O
plant	O
used	O
in	O
Chinese	O
traditional	O
medicine	O
as	O
antitumor	O
and	O
anti	O
-	O
inflammatory	O
agents	O
.	O

In	O
our	O
study	O
,	O
MOG	O
was	O
shown	O
to	O
specifically	O
inhibit	O
the	O
growth	O
of	O
human	O
leukemia	O
cell	O
lines	O
and	O
primary	O
acute	O
myeloid	O
leukemia	O
(	O
AML	O
)	O
blasts	O
via	O
induction	O
of	O
apoptosis	O
,	O
with	O
the	O
evidence	O
of	O
mitochondrial	O
DeltaPsim	O
loss	O
,	O
reactive	O
oxygen	O
species	O
production	O
,	O
caspases	O
activation	O
and	O
nuclear	O
fragmentation	O
.	O

Furthermore	O
,	O
it	O
was	O
shown	O
that	O
thiol	O
-	O
containing	O
antioxidants	O
completely	O
blocked	O
MOG	O
-	O
induced	O
mitochondrial	O
DeltaPsim	O
loss	O
and	O
subsequent	O
cell	O
apoptosis	O
,	O
while	O
the	O
inhibition	O
of	O
apoptosis	O
by	O
benzyloxy	O
-	O
carbonyl	O
-	O
Val	O
-	O
Ala	O
-	O
Asp	O
-	O
fluoromethylketone	O
only	O
partially	O
attenuated	O
mitochondrial	O
DeltaPsim	O
loss	O
,	O
indicating	O
that	O
MOG	O
-	O
induced	O
redox	O
imbalance	O
is	O
an	O
early	O
event	O
upstream	O
to	O
mitochondrial	O
DeltaPsim	O
loss	O
and	O
caspase	O
-	O
3	O
activation	O
.	O

Consistently	O
,	O
it	O
was	O
found	O
that	O
MOG	O
rapidly	O
decreased	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
content	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
significance	O
of	O
GSH	O
depletion	O
in	O
MOG	O
-	O
induced	O
apoptosis	O
was	O
further	O
supported	O
by	O
the	O
protective	O
effects	O
of	O
tert	O
-	O
butylhydroquinone	O
(	O
tBHQ	O
)	O
and	O
the	O
facilitative	O
effects	O
of	O
DL	O
-	O
buthionine	O
(	O
S	O
,	O
R	O
)	O
-	O
sulfoximine	O
(	O
BSO	O
)	O
.	O

Furthermore	O
,	O
it	O
was	O
showed	O
that	O
GSH	O
depletion	O
induced	O
by	O
MOG	O
rendered	O
some	O
leukemia	O
cell	O
lines	O
more	O
sensitive	O
to	O
arsenic	O
trioxide	O
(	O
As2O3	O
)	O
,	O
doxorubicin	O
or	O
cisplatin	O
.	O

Additionally	O
,	O
the	O
synergistic	O
apoptotic	O
effects	O
of	O
MOG	O
with	O
As2O3	O
were	O
detected	O
in	O
HL	B
-	I
60	I
and	O
primary	O
AML	O
cells	O
,	O
but	O
not	O
in	O
normal	O
cells	O
,	O
suggesting	O
the	O
selective	O
toxicity	O
of	O
their	O
combination	O
to	O
the	O
malignant	O
cells	O
.	O

Together	O
,	O
we	O
proposed	O
that	O
MOG	O
alone	O
or	O
administered	O
with	O
other	O
anticancer	O
agents	O
may	O
provide	O
a	O
novel	O
therapeutic	O
strategy	O
for	O
leukemia	O
.	O

Subcellular	O
localisation	O
of	O
BAG	O
-	O
1	O
and	O
its	O
regulation	O
of	O
vitamin	O
D	O
receptor	O
-	O
mediated	O
transactivation	O
and	O
involucrin	O
expression	O
in	O
oral	O
keratinocytes	O
:	O
implications	O
for	O
oral	O
carcinogenesis	O
.	O

In	O
oral	O
cancers	O
,	O
cytoplasmic	O
BAG	O
-	O
1	O
overexpression	O
is	O
a	O
marker	O
of	O
poor	O
prognosis	O
.	O

BAG	O
-	O
1	O
regulates	O
cellular	O
growth	O
,	O
differentiation	O
and	O
survival	O
through	O
interactions	O
with	O
diverse	O
proteins	O
,	O
including	O
the	O
vitamin	O
D	O
receptor	O
(	O
VDR	O
)	O
,	O
a	O
key	O
regulator	O
of	O
keratinocyte	O
growth	O
and	O
differentiation	O
.	O

BAG	O
-	O
1	O
is	O
expressed	O
ubiquitously	O
in	O
human	O
cells	O
as	O
three	O
major	O
isoforms	O
of	O
50	O
kDa	O
(	O
BAG	O
-	O
1L	O
)	O
,	O
46	O
kDa	O
(	O
BAG	O
-	O
1	O
M	O
)	O
and	O
36	O
kDa	O
(	O
BAG	O
-	O
1S	O
)	O
from	O
a	O
single	O
mRNA	O
.	O

In	O
oral	O
keratinocytes	O
BAG	O
-	O
1L	O
,	O
but	O
not	O
BAG	O
-	O
1	O
M	O
and	O
BAG	O
-	O
1S	O
,	O
enhanced	O
VDR	O
transactivation	O
in	O
response	O
to	O
1alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

BAG	O
-	O
1L	O
was	O
nucleoplasmic	O
and	O
nucleolar	O
,	O
whereas	O
BAG	O
-	O
1S	O
and	O
BAG	O
-	O
1	O
M	O
were	O
cytoplasmic	O
and	O
nucleoplasmic	O
in	O
localisation	O
.	O

Having	O
identified	O
the	O
nucleolar	O
localisation	O
sequence	O
in	O
BAG	O
-	O
1L	O
,	O
we	O
showed	O
that	O
mutation	O
of	O
this	O
sequence	O
did	O
not	O
prevent	O
BAG	O
-	O
1L	O
from	O
potentiating	O
VDR	O
activity	O
.	O

BAG	O
-	O
1L	O
also	O
potentiated	O
transactivation	O
of	O
known	O
vitamin	O
-	O
D	O
-	O
responsive	O
gene	O
promoters	O
,	O
osteocalcin	O
and	O
24	O
-	O
hydroxylase	O
,	O
and	O
enhanced	O
VDR	O
-	O
dependent	O
transcription	O
and	O
protein	O
expression	O
of	O
the	O
keratinocyte	O
differentiation	O
marker	O
,	O
involucrin	O
.	O

These	O
results	O
demonstrate	O
endogenous	O
gene	O
regulation	O
by	O
BAG	O
-	O
1L	O
by	O
potentiating	O
nuclear	O
hormone	O
receptor	O
function	O
and	O
suggest	O
a	O
role	O
for	O
BAG	O
-	O
1L	O
in	O
24	O
-	O
hydroxylase	O
regulation	O
of	O
vitamin	O
D	O
metabolism	O
and	O
the	O
cellular	O
response	O
of	O
oral	O
keratinocytes	O
to	O
1alpha	O
,	O
25	O
-	O
dihydroxyvitamin	O
D3	O
.	O

By	O
contrast	O
to	O
the	O
cytoplasmic	O
BAG	O
-	O
1	O
isoforms	O
,	O
BAG	O
-	O
1L	O
may	O
act	O
to	O
suppress	O
tumorigenesis	O
.	O

Hedgehog	O
signaling	O
in	O
the	O
murine	O
melanoma	O
microenvironment	O
.	O

The	O
Hedgehog	O
intercellular	O
signaling	O
pathway	O
regulates	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

This	O
pathway	O
has	O
been	O
implicated	O
to	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
cancer	O
and	O
in	O
embryonic	O
blood	O
vessel	O
development	O
.	O

In	O
the	O
current	O
study	O
,	O
Hedgehog	O
signaling	O
in	O
tumor	O
related	O
vasculature	O
and	O
microenvironment	O
was	O
examined	O
using	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
and	O
B16F0	B
(	O
murine	O
melanoma	O
)	O
tumors	O
models	O
.	O

Use	O
of	O
exogenous	O
Sonic	O
hedgehog	O
(	O
Shh	O
)	O
peptide	O
significantly	O
increased	O
BrdU	O
incorporation	O
in	O
endothelial	O
cells	O
in	O
vitro	O
by	O
a	O
factor	O
of	O
2	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
.	O

The	O
Hedgehog	O
pathway	O
antagonist	O
cyclopamine	O
effectively	O
reduced	O
Shh	O
-	O
induced	O
proliferation	O
to	O
control	O
levels	O
.	O

To	O
study	O
Hedgehog	O
signaling	O
in	O
vivo	O
a	O
hind	O
limb	O
tumor	O
model	O
with	O
the	O
B16F0	B
cell	O
line	O
was	O
used	O
.	O

Treatment	O
with	O
25	O
mg	O
/	O
kg	O
cyclopamine	O
significantly	O
attenuated	O
BrdU	O
incorporation	O
in	O
tumor	O
cells	O
threefold	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
,	O
in	O
tumor	O
related	O
endothelial	O
cells	O
threefold	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
and	O
delayed	O
tumor	O
growth	O
by	O
4	O
days	O
.	O

Immunohistochemistry	O
revealed	O
that	O
the	O
Hedgehog	O
receptor	O
Patched	O
was	O
localized	O
to	O
the	O
tumor	O
stroma	O
and	O
that	O
B16F0	B
cells	O
expressed	O
Shh	O
peptide	O
.	O

Furthermore	O
,	O
mouse	O
embryonic	O
fibroblasts	O
required	O
the	O
presence	O
of	O
B16F0	B
cells	O
to	O
express	O
Patched	O
in	O
a	O
co	O
-	O
culture	O
assay	O
system	O
.	O

These	O
studies	O
indicate	O
that	O
Shh	O
peptide	O
produced	O
by	O
melanoma	O
cells	O
induces	O
Patched	O
expression	O
in	O
fibroblasts	O
.	O

To	O
study	O
tumor	O
related	O
angiogenesis	O
a	O
vascular	O
window	O
model	O
was	O
used	O
to	O
monitor	O
tumor	O
vascularity	O
.	O

Treatment	O
with	O
cyclopamine	O
significantly	O
attenuated	O
vascular	O
formation	O
by	O
a	O
factor	O
of	O
2	O
.	O
5	O
(	O
P	O
less	O
than	O
0	O
.	O
001	O
)	O
and	O
altered	O
vascular	O
morphology	O
.	O

Furthermore	O
,	O
cyclopamine	O
reduced	O
tumor	O
blood	O
vessel	O
permeability	O
to	O
FITC	O
labeled	O
dextran	O
while	O
having	O
no	O
effect	O
on	O
normal	O
blood	O
vessels	O
.	O

These	O
studies	O
suggest	O
that	O
Hedgehog	O
signaling	O
regulates	O
melanoma	O
related	O
vascular	O
formation	O
and	O
function	O
.	O

Expression	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
,	O
transforming	O
growth	O
factor	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
in	O
relationship	O
to	O
malignant	O
transformation	O
of	O
pleomorphic	O
adenoma	O
.	O

CONCLUSION	O
:	O
Quantitative	O
assessment	O
is	O
more	O
sensitive	O
as	O
a	O
measure	O
of	O
cellular	O
protein	O
content	O
as	O
compared	O
with	O
standard	O
optical	O
density	O
measurements	O
.	O

The	O
data	O
support	O
the	O
hypothesis	O
that	O
increased	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
and	O
transforming	O
growth	O
factor	O
(	O
TGF	O
)	O
-	O
alpha	O
expression	O
is	O
associated	O
with	O
early	O
events	O
in	O
malignant	O
transformation	O
of	O
pleomorphic	O
adenoma	O
(	O
PA	O
)	O
.	O

OBJECTIVE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
attempted	O
to	O
identify	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
expression	O
and	O
Ki	O
-	O
67	O
index	O
in	O
carcinoma	O
ex	O
-	O
pleomorphic	O
adenoma	O
(	O
Ca	O
ex	O
-	O
PA	O
)	O
and	O
PA	O
.	O

We	O
also	O
compared	O
the	O
presence	O
of	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
index	O
with	O
clinical	O
data	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
tissues	O
were	O
stained	O
with	O
monoclonal	O
antibodies	O
to	O
EGFR	O
,	O
TGF	O
-	O
alpha	O
and	O
Ki	O
-	O
67	O
.	O

The	O
results	O
were	O
analysed	O
using	O
quantitative	O
immunohistochemical	O
analysis	O
.	O

We	O
also	O
analysed	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
clinical	O
parameters	O
and	O
the	O
histological	O
classification	O
of	O
the	O
carcinomatous	O
component	O
.	O

RESULTS	O
:	O
As	O
regards	O
the	O
association	O
of	O
patients	O
'	O
prognosis	O
with	O
EGFR	O
staining	O
and	O
Ki	O
-	O
67	O
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
patients	O
who	O
died	O
or	O
had	O
residual	O
disease	O
compared	O
with	O
patients	O
who	O
were	O
alive	O
without	O
disease	O
.	O

In	O
the	O
immunohistochemical	O
analysis	O
of	O
EGFR	O
and	O
TGF	O
-	O
alpha	O
and	O
Ki67	O
index	O
,	O
a	O
significant	O
increase	O
was	O
observed	O
in	O
Ca	O
ex	O
-	O
PA	O
,	O
especially	O
with	O
adenocarcinoma	O
,	O
compared	O
with	O
PA	O
and	O
sialadenitis	O
.	O

Transporters	O
,	O
enzymes	O
,	O
and	O
enalapril	O
removal	O
in	O
a	O
rat	O
(	O
CC531	B
-	O
induced	O
)	O
liver	O
metastatic	O
model	O
.	O

Temporal	O
changes	O
in	O
physiological	O
spaces	O
,	O
protein	O
expression	O
of	O
transporters	O
and	O
enzymes	O
,	O
and	O
enalapril	O
removal	O
were	O
appraised	O
in	O
the	O
metastatic	O
liver	O
tumor	O
model	O
developed	O
from	O
male	O
Wag	O
/	O
Rij	O
rats	O
after	O
the	O
intraportal	O
injection	O
of	O
CC531	B
colon	O
adenocarcinoma	O
cells	O
;	O
sham	O
-	O
operated	O
preparations	O
received	O
PBS	O
.	O

Liver	O
tissue	O
spaces	O
,	O
investigated	O
with	O
multiple	O
indicator	O
dilution	O
technique	O
in	O
liver	O
perfusion	O
studies	O
,	O
were	O
unchanged	O
at	O
week	O
3	O
after	O
tumor	O
induction	O
.	O

At	O
week	O
4	O
,	O
however	O
,	O
the	O
sinusoidal	O
blood	O
volume	O
and	O
albumin	O
Disse	O
space	O
in	O
tumor	O
-	O
bearing	O
livers	O
were	O
slightly	O
lower	O
compared	O
with	O
those	O
of	O
shams	O
.	O

Increased	O
levels	O
of	O
the	O
canalicular	O
ATP	O
transporters	O
,	O
P	O
-	O
glycoprotein	O
,	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
2	O
(	O
Mrp2	O
)	O
,	O
and	O
bile	O
salt	O
export	O
pump	O
(	O
Bsep	O
)	O
at	O
week	O
2	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
unchanged	O
levels	O
of	O
Ntcp	O
,	O
Oatp1a1	O
,	O
Oatp1a4	O
,	O
and	O
Mct2	O
,	O
but	O
decreased	O
levels	O
of	O
cytochrome	O
P450	O
3a2	O
(	O
Cyp3a2	O
)	O
and	O
glutathione	O
S	O
-	O
transferase	O
(	O
Gst4	O
-	O
4	O
)	O
at	O
week	O
4	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
peritumor	O
vs	O
.	O
sham	O
-	O
operated	O
liver	O
tissues	O
with	O
Western	O
blotting	O
.	O

The	O
steady	O
-	O
state	O
extraction	O
ratio	O
of	O
enalapril	O
,	O
a	O
substrate	O
that	O
enters	O
the	O
liver	O
rapidly	O
via	O
Oatp1a1	O
and	O
primarily	O
undergoes	O
metabolism	O
by	O
the	O
carboxylesterases	O
,	O
was	O
unaffected	O
by	O
liver	O
metastasis	O
at	O
week	O
4	O
regardless	O
of	O
its	O
delivery	O
via	O
the	O
portal	O
vein	O
or	O
hepatic	O
artery	O
into	O
the	O
perfused	O
liver	O
preparations	O
.	O

Wnt	O
signaling	O
,	O
stem	O
cells	O
,	O
and	O
the	O
cellular	O
origin	O
of	O
breast	O
cancer	O
.	O

The	O
breast	O
epithelium	O
comprises	O
cells	O
at	O
different	O
stages	O
of	O
differentiation	O
,	O
including	O
stem	O
cells	O
,	O
progenitor	O
cells	O
,	O
and	O
more	O
differentiated	O
epithelial	O
and	O
myoepithelial	O
cells	O
.	O

Wnt	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
stem	O
/	O
progenitor	O
cells	O
in	O
the	O
mammary	O
gland	O
as	O
well	O
as	O
other	O
tissue	O
compartments	O
.	O

Furthermore	O
,	O
there	O
is	O
strong	O
evidence	O
suggesting	O
that	O
aberrant	O
activation	O
of	O
Wnt	O
signaling	O
induces	O
mammary	O
tumors	O
from	O
stem	O
/	O
progenitor	O
cells	O
,	O
and	O
that	O
Wnt	O
exerts	O
its	O
oncogenic	O
effects	O
through	O
LRP5	O
/	O
6	O
-	O
mediated	O
activation	O
of	O
beta	O
-	O
catenin	O
and	O
mTOR	O
pathways	O
.	O

Recent	O
studies	O
using	O
avian	O
retrovirus	O
-	O
mediated	O
introduction	O
of	O
oncogenes	O
into	O
a	O
small	O
subset	O
of	O
somatic	O
mammary	O
cells	O
suggest	O
that	O
polyoma	O
middle	O
T	O
antigen	O
(	O
PyMT	O
)	O
may	O
also	O
preferentially	O
transform	O
stem	O
/	O
progenitor	O
cells	O
.	O

These	O
observations	O
suggest	O
that	O
stem	O
/	O
progenitor	O
cells	O
in	O
the	O
mammary	O
gland	O
may	O
be	O
especially	O
susceptible	O
to	O
oncogenic	O
transformation	O
.	O

Whether	O
more	O
differentiated	O
cells	O
may	O
also	O
be	O
transformed	O
by	O
particular	O
oncogenes	O
is	O
actively	O
debated	O
;	O
it	O
is	O
presently	O
unclear	O
whether	O
stem	O
cells	O
or	O
differentiated	O
mammary	O
cells	O
are	O
more	O
susceptible	O
to	O
transformation	O
by	O
individual	O
oncogenes	O
.	O

Better	O
stem	O
cell	O
and	O
progenitor	O
cell	O
markers	O
as	O
well	O
as	O
the	O
ability	O
to	O
specifically	O
target	O
oncogenes	O
into	O
different	O
mammary	O
cell	O
types	O
will	O
be	O
needed	O
to	O
determine	O
the	O
spectrum	O
of	O
oncogene	O
transformation	O
for	O
stem	O
cells	O
versus	O
more	O
differentiated	O
cells	O
.	O

CX3CR1	O
-	O
dependent	O
subretinal	O
microglia	O
cell	O
accumulation	O
is	O
associated	O
with	O
cardinal	O
features	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

The	O
role	O
of	O
retinal	O
microglial	O
cells	O
(	O
MCs	O
)	O
in	O
age	O
-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
is	O
unclear	O
.	O

Here	O
we	O
demonstrated	O
that	O
all	O
retinal	O
MCs	O
express	O
CX3C	O
chemokine	O
receptor	O
1	O
(	O
CX3CR1	O
)	O
and	O
that	O
homozygosity	O
for	O
the	O
CX3CR1	O
M280	O
allele	O
,	O
which	O
is	O
associated	O
with	O
impaired	O
cell	O
migration	O
,	O
increases	O
the	O
risk	O
of	O
AMD	O
.	O

In	O
humans	O
with	O
AMD	O
,	O
MCs	O
accumulated	O
in	O
the	O
subretinal	O
space	O
at	O
sites	O
of	O
retinal	O
degeneration	O
and	O
choroidal	O
neovascularization	O
(	O
CNV	O
)	O
.	O

In	O
CX3CR1	O
-	O
deficient	O
mice	O
,	O
MCs	O
accumulated	O
subretinally	O
with	O
age	O
and	O
albino	O
background	O
and	O
after	O
laser	O
impact	O
preceding	O
retinal	O
degeneration	O
.	O

Raising	O
the	O
albino	O
mice	O
in	O
the	O
dark	O
prevented	O
both	O
events	O
.	O

The	O
appearance	O
of	O
lipid	O
-	O
bloated	O
subretinal	O
MCs	O
was	O
drusen	O
-	O
like	O
on	O
funduscopy	O
of	O
senescent	O
mice	O
,	O
and	O
CX3CR1	O
-	O
dependent	O
MC	O
accumulation	O
was	O
associated	O
with	O
an	O
exacerbation	O
of	O
experimental	O
CNV	O
.	O

These	O
results	O
show	O
that	O
CX3CR1	O
-	O
dependent	O
accumulation	O
of	O
subretinal	O
MCs	O
evokes	O
cardinal	O
features	O
of	O
AMD	O
.	O

These	O
findings	O
reveal	O
what	O
we	O
believe	O
to	O
be	O
a	O
novel	O
pathogenic	O
process	O
with	O
important	O
implications	O
for	O
the	O
development	O
of	O
new	O
therapies	O
for	O
AMD	O
.	O

Ovarian	O
cancers	O
overexpress	O
the	O
antimicrobial	O
protein	O
hCAP	O
-	O
18	O
and	O
its	O
derivative	O
LL	O
-	O
37	O
increases	O
ovarian	O
cancer	O
cell	O
proliferation	O
and	O
invasion	O
.	O

The	O
role	O
of	O
the	O
pro	O
-	O
inflammatory	O
peptide	O
,	O
LL	O
-	O
37	O
,	O
and	O
its	O
pro	O
-	O
form	O
,	O
human	O
cationic	O
antimicrobial	O
protein	O
18	O
(	O
hCAP	O
-	O
18	O
)	O
,	O
in	O
cancer	O
development	O
and	O
progression	O
is	O
poorly	O
understood	O
.	O

In	O
damaged	O
and	O
inflamed	O
tissue	O
,	O
LL	O
-	O
37	O
functions	O
as	O
a	O
chemoattractant	O
,	O
mitogen	O
and	O
pro	O
-	O
angiogenic	O
factor	O
suggesting	O
that	O
the	O
peptide	O
may	O
potentiate	O
tumor	O
progression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
characterize	O
the	O
distribution	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
in	O
normal	O
and	O
cancerous	O
ovarian	O
tissue	O
and	O
to	O
examine	O
the	O
effects	O
of	O
LL	O
-	O
37	O
on	O
ovarian	O
cancer	O
cells	O
.	O

Expression	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
was	O
localized	O
to	O
immune	O
and	O
granulosa	O
cells	O
of	O
normal	O
ovarian	O
tissue	O
.	O

By	O
contrast	O
,	O
ovarian	O
tumors	O
displayed	O
significantly	O
higher	O
levels	O
of	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
where	O
expression	O
was	O
observed	O
in	O
tumor	O
and	O
stromal	O
cells	O
.	O

Protein	O
expression	O
was	O
statistically	O
compared	O
to	O
the	O
degree	O
of	O
immune	O
cell	O
infiltration	O
and	O
microvessel	O
density	O
in	O
epithelial	O
-	O
derived	O
ovarian	O
tumors	O
and	O
a	O
significant	O
correlation	O
was	O
observed	O
for	O
both	O
.	O

It	O
was	O
demonstrated	O
that	O
ovarian	O
tumor	O
tissue	O
lysates	O
and	O
ovarian	O
cancer	O
cell	O
lines	O
express	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
.	O

Treatment	O
of	O
ovarian	O
cancer	O
cell	O
lines	O
with	O
recombinant	O
LL	O
-	O
37	O
stimulated	O
proliferation	O
,	O
chemotaxis	O
,	O
invasion	O
and	O
matrix	O
metalloproteinase	O
expression	O
.	O

These	O
data	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
hCAP	O
-	O
18	O
/	O
LL	O
-	O
37	O
is	O
significantly	O
overexpressed	O
in	O
ovarian	O
tumors	O
and	O
suggest	O
LL	O
-	O
37	O
may	O
contribute	O
to	O
ovarian	O
tumorigenesis	O
through	O
direct	O
stimulation	O
of	O
tumor	O
cells	O
,	O
initiation	O
of	O
angiogenesis	O
and	O
recruitment	O
of	O
immune	O
cells	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
of	O
the	O
existing	O
relationship	O
between	O
pro	O
-	O
inflammatory	O
molecules	O
and	O
ovarian	O
cancer	O
progression	O
.	O

Conditional	O
deletion	O
of	O
Smad1	O
and	O
Smad5	O
in	O
somatic	O
cells	O
of	O
male	O
and	O
female	O
gonads	O
leads	O
to	O
metastatic	O
tumor	O
development	O
in	O
mice	O
.	O

The	O
transforming	O
growth	O
factor	O
beta	O
(	O
TGFbeta	O
)	O
family	O
has	O
critical	O
roles	O
in	O
the	O
regulation	O
of	O
fertility	O
.	O

In	O
addition	O
,	O
the	O
pathogenesis	O
of	O
some	O
human	O
cancers	O
is	O
attributed	O
to	O
misregulation	O
of	O
TGFbeta	O
function	O
and	O
SMAD2	O
or	O
SMAD4	O
mutations	O
.	O

There	O
are	O
limited	O
mouse	O
models	O
for	O
the	O
BMP	O
signaling	O
SMADs	O
(	O
BR	O
-	O
SMADs	O
)	O
1	O
,	O
5	O
,	O
and	O
8	O
because	O
of	O
embryonic	O
lethality	O
and	O
suspected	O
genetic	O
redundancy	O
.	O

Using	O
tissue	O
-	O
specific	O
ablation	O
in	O
mice	O
,	O
we	O
deleted	O
the	O
BR	O
-	O
SMADs	O
from	O
somatic	O
cells	O
of	O
ovaries	O
and	O
testes	O
.	O

Single	O
conditional	O
knockouts	O
for	O
Smad1	O
or	O
Smad5	O
or	O
mice	O
homozygous	O
null	O
for	O
Smad8	O
are	O
viable	O
and	O
fertile	O
.	O

Female	O
double	O
Smad1	O
Smad5	O
and	O
triple	O
Smad1	O
Smad5	O
Smad8	O
conditional	O
knockout	O
mice	O
become	O
infertile	O
and	O
develop	O
metastatic	O
granulosa	O
cell	O
tumors	O
.	O

Male	O
double	O
Smad1	O
Smad5	O
conditional	O
knockout	O
mice	O
are	O
fertile	O
but	O
demonstrate	O
metastatic	O
testicular	O
tumor	O
development	O
.	O

Microarray	O
analysis	O
indicated	O
significant	O
alterations	O
in	O
expression	O
of	O
genes	O
related	O
to	O
the	O
TGFbeta	O
pathway	O
,	O
as	O
well	O
as	O
genes	O
involved	O
in	O
infertility	O
and	O
extracellular	O
matrix	O
production	O
.	O

These	O
data	O
strongly	O
implicate	O
the	O
BR	O
-	O
SMADs	O
as	O
part	O
of	O
a	O
critical	O
developmental	O
pathway	O
in	O
ovaries	O
and	O
testis	O
that	O
,	O
when	O
disrupted	O
,	O
leads	O
to	O
malignant	O
transformation	O
.	O

Role	O
of	O
telomeres	O
in	O
vascular	O
senescence	O
.	O

Telomeres	O
are	O
DNA	O
regions	O
composed	O
of	O
TTAGGG	O
repeats	O
that	O
are	O
located	O
at	O
the	O
ends	O
of	O
chromosomes	O
.	O

Specific	O
proteins	O
associate	O
with	O
the	O
telomeres	O
and	O
form	O
non	O
-	O
nucleosomal	O
DNA	O
-	O
protein	O
complexes	O
that	O
serve	O
as	O
protective	O
caps	O
for	O
the	O
chromosome	O
ends	O
.	O

There	O
is	O
accumulating	O
evidence	O
that	O
progressive	O
telomere	O
shortening	O
is	O
closely	O
related	O
to	O
cardiovascular	O
disease	O
.	O

For	O
example	O
,	O
vascular	O
cell	O
senescence	O
has	O
been	O
reported	O
to	O
occur	O
in	O
human	O
atherosclerotic	O
lesions	O
and	O
this	O
change	O
is	O
associated	O
with	O
telomere	O
shortening	O
.	O

Impairment	O
of	O
telomere	O
integrity	O
causes	O
vascular	O
dysfunction	O
,	O
which	O
is	O
prevented	O
by	O
the	O
activation	O
of	O
telomerase	O
.	O

Mice	O
with	O
short	O
telomeres	O
develop	O
hypertension	O
and	O
exhibit	O
impaired	O
neovascularization	O
.	O

Short	O
telomeres	O
have	O
also	O
been	O
reported	O
in	O
the	O
leukocytes	O
of	O
patients	O
with	O
cardiovascular	O
disease	O
or	O
various	O
cardiovascular	O
risk	O
factors	O
.	O

Although	O
it	O
remains	O
unclear	O
whether	O
short	O
telomeres	O
directly	O
cause	O
cardiovascular	O
disease	O
,	O
manipulation	O
of	O
telomere	O
function	O
is	O
potentially	O
an	O
attractive	O
strategy	O
for	O
the	O
treatment	O
of	O
vascular	O
senescence	O
.	O

Ectopic	O
decorin	O
expression	O
up	O
-	O
regulates	O
VEGF	O
expression	O
in	O
mouse	O
cerebral	O
endothelial	O
cells	O
via	O
activation	O
of	O
the	O
transcription	O
factors	O
Sp1	O
,	O
HIF1alpha	O
,	O
and	O
Stat3	O
.	O

We	O
demonstrate	O
that	O
a	O
proteoglycan	O
decorin	O
(	O
DCN	O
)	O
up	O
-	O
regulates	O
the	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
with	O
activation	O
of	O
VEGF	O
regulating	O
transcription	O
factors	O
Sp1	O
,	O
hypoxia	O
-	O
inducible	O
factor	O
1alpha	O
(	O
HIF1alpha	O
)	O
,	O
and	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
3	O
(	O
Stat3	O
)	O
via	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
1	O
/	O
2	O
(	O
ERK1	O
/	O
2	O
)	O
,	O
and	O
protein	O
kinase	O
B	O
(	O
AKT	O
)	O
pathways	O
in	O
DCN	O
transfected	O
mouse	O
cerebral	O
endothelial	O
(	O
MCE	O
)	O
cells	O
.	O

Treatment	O
with	O
pharmacological	O
inhibitors	O
and	O
small	O
interfering	O
RNAs	O
reveal	O
that	O
induction	O
and	O
activation	O
of	O
Sp1	O
,	O
HIF1alpha	O
,	O
and	O
Stat3	O
facilitate	O
their	O
nuclear	O
localization	O
and	O
binding	O
to	O
their	O
specific	O
motifs	O
of	O
the	O
VEGF	O
promoter	O
and	O
induce	O
VEGF	O
expression	O
via	O
two	O
independent	O
pathways	O
,	O
DCN	O
/	O
EGFR	O
/	O
phosphoinositide	O
-	O
3	O
kinase	O
/	O
AKT	O
and	O
DCN	O
/	O
EGFR	O
/	O
ERK1	O
/	O
2	O
,	O
respectively	O
,	O
in	O
DCN	O
synthesizing	O
MCE	O
cells	O
.	O

The	O
cell	O
type	O
specific	O
glycosylation	O
protects	O
Sp1	O
and	O
HIF1alpha	O
from	O
proteosome	O
degradation	O
and	O
plays	O
an	O
important	O
and	O
novel	O
role	O
in	O
the	O
regulation	O
of	O
VEGF	O
in	O
DCN	O
transfected	O
MCE	O
cells	O
.	O

Induction	O
of	O
gelatinases	O
(	O
matrix	O
metalloproteinase	O
2	O
and	O
9	O
)	O
,	O
the	O
serine	O
protease	O
tissue	O
plasminogen	O
activator	O
and	O
plasmin	O
by	O
DCN	O
transfection	O
in	O
MCE	O
cells	O
leads	O
to	O
extracellular	O
proteolysis	O
and	O
to	O
release	O
of	O
matrix	O
-	O
bound	O
VEGF	O
and	O
activation	O
of	O
angiogenesis	O
.	O

In	O
this	O
study	O
,	O
we	O
demonstrate	O
that	O
two	O
independent	O
downstream	O
signal	O
pathways	O
,	O
DCN	O
/	O
EGFR	O
/	O
ERK1	O
/	O
2	O
and	O
DCN	O
/	O
EGFR	O
/	O
phosphoinositide	O
-	O
3	O
kinase	O
/	O
AKT	O
,	O
mediate	O
up	O
-	O
regulation	O
and	O
activation	O
of	O
transcription	O
factors	O
of	O
VEGF	O
such	O
as	O
HIF1alpha	O
,	O
Stat3	O
,	O
and	O
Sp1	O
and	O
increase	O
VEGF	O
transcription	O
and	O
angiogenesis	O
in	O
MCE	O
cells	O
.	O

Melanoma	O
/	O
skin	O
cancer	O
screening	O
clinics	O
:	O
experiences	O
in	O
The	O
Netherlands	O
.	O

In	O
1989	O
and	O
1990	O
we	O
conducted	O
two	O
free	O
melanoma	O
/	O
skin	O
screening	O
clinics	O
in	O
Oss	O
and	O
Arnhem	O
in	O
the	O
Netherlands	O
.	O

The	O
study	O
was	O
carried	O
out	O
along	O
the	O
lines	O
of	O
the	O
recent	O
campaigns	O
supported	O
by	O
the	O
American	O
Academy	O
of	O
Dermatology	O
.	O

Of	O
2564	O
persons	O
screened	O
,	O
53	O
had	O
melanoma	O
or	O
nonmelanoma	O
skin	O
cancer	O
(	O
2	O
.	O
1	O
%	O
)	O
.	O

Compliance	O
with	O
follow	O
-	O
up	O
for	O
persons	O
with	O
suspected	O
melanoma	O
/	O
skin	O
cancer	O
was	O
adequate	O
(	O
93	O
of	O
103	O
;	O
90	O
.	O
3	O
%	O
)	O
.	O

M	O
.	O
leprae	O
-	O
and	O
BCG	O
-	O
induced	O
chemiluminescence	O
response	O
of	O
monocytes	O
from	O
leprosy	O
patients	O
and	O
healthy	O
subjects	O
:	O
effects	O
of	O
gamma	O
-	O
interferon	O
and	O
GM	O
-	O
CSF	O
.	O

Mycobacterium	O
leprae	O
,	O
in	O
contrast	O
to	O
BCG	O
,	O
failed	O
to	O
trigger	O
any	O
chemiluminescence	O
(	O
CL	O
)	O
response	O
in	O
mononuclear	O
cells	O
from	O
either	O
leprosy	O
patients	O
or	O
healthy	O
subjects	O
,	O
a	O
deficit	O
not	O
reversed	O
by	O
either	O
interferon	O
-	O
gamma	O
or	O
GM	O
-	O
CSF	O
.	O

Chemiluminescence	O
responses	O
induced	O
without	O
mycobacteria	O
or	O
with	O
BCG	O
were	O
found	O
to	O
be	O
lower	O
in	O
leprosy	O
patients	O
than	O
in	O
controls	O
.	O

M	O
.	O
leprae	O
were	O
also	O
less	O
well	O
phagocytosed	O
than	O
BCG	O
.	O

However	O
,	O
there	O
was	O
a	O
significant	O
difference	O
in	O
phagocytosis	O
between	O
healthy	O
and	O
tuberculoid	O
leprosy	O
subjects	O
.	O

Phagocytosis	O
was	O
not	O
altered	O
by	O
the	O
addition	O
of	O
either	O
lymphokine	O
,	O
and	O
no	O
major	O
differences	O
between	O
healthy	O
subjects	O
and	O
patients	O
were	O
observed	O
.	O

Preincubating	O
mononuclear	O
cells	O
with	O
anti	O
-	O
mycobacteria	O
antibodies	O
(	O
lepromatous	O
patients	O
'	O
sera	O
)	O
did	O
not	O
increase	O
the	O
CL	O
response	O
nor	O
the	O
phagocytosis	O
of	O
M	O
.	O
leprae	O
or	O
BCG	O
.	O

[	O
Clinical	O
significance	O
of	O
interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
as	O
a	O
prognostic	O
factor	O
of	O
cancer	O
disease	O
]	O

Interleukin	O
-	O
6	O
(	O
IL	O
-	O
6	O
)	O
is	O
proinflammatory	O
cytokine	O
that	O
produces	O
multifunctional	O
effects	O
.	O

It	O
is	O
also	O
involved	O
in	O
the	O
regulation	O
of	O
immune	O
reactions	O
,	O
hematopoiesis	O
and	O
inflammatory	O
state	O
.	O

Interleukin	O
-	O
6	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
tumor	O
progression	O
including	O
inhibition	O
of	O
cancer	O
cells	O
apoptosis	O
and	O
stimulation	O
of	O
angiogenesis	O
.	O

Anti	O
-	O
IL	O
-	O
6	O
therapy	O
is	O
a	O
new	O
strategy	O
in	O
the	O
inflammatory	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O

Clinical	O
studies	O
have	O
shown	O
elevated	O
serum	O
IL	O
-	O
6	O
concentrations	O
in	O
patients	O
with	O
endometrial	O
cancer	O
,	O
non	O
-	O
small	O
cell	O
lung	O
carcinoma	O
,	O
colorectal	O
cancer	O
,	O
renal	O
cell	O
carcinoma	O
,	O
breast	O
and	O
ovarian	O
cancer	O
.	O

Serum	O
IL	O
-	O
6	O
levels	O
correlate	O
with	O
tumor	O
stage	O
,	O
and	O
survival	O
of	O
patients	O
.	O

In	O
this	O
article	O
we	O
have	O
focused	O
on	O
a	O
role	O
of	O
IL	O
-	O
6	O
as	O
a	O
prognostic	O
factor	O
in	O
several	O
malignancies	O
such	O
as	O
colorectal	O
cancer	O
,	O
breast	O
cancer	O
,	O
gastric	O
cancer	O
and	O
pancreatic	O
cancer	O
.	O

Tumor	O
microenvironment	O
,	O
a	O
dangerous	O
society	O
leading	O
to	O
cancer	O
metastasis	O
.	O

From	O
mechanisms	O
to	O
therapy	O
and	O
prevention	O
.	O

Cancer	O
is	O
no	O
longer	O
considered	O
by	O
scientists	O
just	O
a	O
jumble	O
of	O
mutated	O
cells	O
.	O

To	O
grow	O
,	O
invade	O
and	O
metastasize	O
,	O
a	O
treacherous	O
society	O
between	O
cancer	O
and	O
host	O
cells	O
must	O
be	O
formed	O
,	O
and	O
this	O
association	O
provides	O
novel	O
and	O
effective	O
clinical	O
targets	O
for	O
cancer	O
control	O
and	O
prevention	O
.	O

This	O
collection	O
of	O
reviews	O
at	O
the	O
front	O
-	O
edge	O
of	O
scientific	O
knowledge	O
focuses	O
on	O
host	O
-	O
tumor	O
cell	O
interactions	O
,	O
the	O
disastrous	O
consequences	O
they	O
can	O
produce	O
and	O
approaches	O
the	O
ways	O
to	O
break	O
up	O
these	O
cellular	O
conspiracies	O
,	O
to	O
leave	O
the	O
tumor	O
cells	O
unattended	O
and	O
vulnerable	O
.	O

Effects	O
of	O
spironolactone	O
on	O
corneal	O
allograft	O
survival	O
in	O
the	O
rat	O
.	O

PURPOSE	O
:	O
Spironolactone	O
has	O
recently	O
been	O
shown	O
to	O
have	O
suppressive	O
effects	O
on	O
several	O
immunoactive	O
and	O
proinflammatory	O
cytokines	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
spironolactone	O
on	O
the	O
prevention	O
of	O
corneal	O
allograft	O
rejection	O
in	O
a	O
MHC	O
class	O
I	O
/	O
II	O
mismatch	O
rat	O
corneal	O
transplant	O
model	O
.	O

METHODS	O
:	O
Grafted	O
animals	O
for	O
corneal	O
survival	O
analysis	O
were	O
assigned	O
to	O
receive	O
either	O
spironolactone	O
suspension	O
(	O
orally	O
,	O
100	O
mg	O
/	O
kg	O
/	O
day	O
,	O
n	O
=	O
7	O
)	O
,	O
phosphate	O
-	O
buffered	O
saline	O
(	O
PBS	O
,	O
orally	O
,	O
same	O
volume	O
as	O
spironolactone	O
,	O
n	O
=	O
9	O
)	O
or	O
remained	O
untreated	O
(	O
n	O
=	O
16	O
)	O
.	O

Additional	O
grafted	O
rats	O
treated	O
with	O
spironolactone	O
(	O
n	O
=	O
6	O
)	O
or	O
PBS	O
(	O
n	O
=	O
8	O
)	O
were	O
sacrificed	O
on	O
day	O
12	O
for	O
quantitative	O
RT	O
-	O
PCR	O
analysis	O
for	O
mechanistic	O
studies	O
.	O

RESULTS	O
:	O
Mean	O
(	O
+	O
/	O
-	O
SEM	O
)	O
graft	O
survival	O
was	O
significantly	O
prolonged	O
in	O
animals	O
receiving	O
spironolactone	O
(	O
14	O
.	O
9	O
+	O
/	O
-	O
2	O
.	O
0	O
days	O
)	O
compared	O
with	O
both	O
PBS	O
-	O
treated	O
(	O
12	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
days	O
,	O
p	O
=	O
0	O
.	O
007	O
)	O
and	O
untreated	O
controls	O
(	O
13	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
0	O
days	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

We	O
found	O
a	O
decrease	O
in	O
corneal	O
neovascularization	O
in	O
spironolactone	O
-	O
treated	O
rats	O
compared	O
with	O
the	O
PBS	O
-	O
treated	O
group	O
,	O
although	O
the	O
difference	O
was	O
not	O
statistically	O
significant	O
.	O

Spironolactone	O
affected	O
both	O
systemic	O
(	O
down	O
-	O
regulation	O
of	O
CD25	O
+	O
cells	O
in	O
spleen	O
)	O
and	O
local	O
immune	O
response	O
(	O
up	O
-	O
regulation	O
of	O
IL	O
-	O
10	O
in	O
cornea	O
)	O
.	O

CONCLUSION	O
:	O
We	O
present	O
initial	O
results	O
demonstrating	O
anti	O
-	O
inflammatory	O
effects	O
of	O
spironolactone	O
.	O

FAS	O
-	O
1377	O
G	O
/	O
A	O
polymorphism	O
and	O
the	O
risk	O
of	O
lymph	O
node	O
metastasis	O
in	O
cervical	O
cancer	O
.	O

Single	O
-	O
nucleotide	O
polymorphisms	O
of	O
the	O
FAS	O
-	O
1377	O
G	O
/	O
A	O
,	O
FAS	O
-	O
670A	O
/	O
G	O
,	O
and	O
FASL	O
-	O
844	O
T	O
/	O
C	O
genes	O
may	O
alter	O
transcriptional	O
activity	O
of	O
these	O
genes	O
.	O

Recent	O
evidence	O
suggests	O
an	O
association	O
of	O
these	O
polymorphisms	O
with	O
an	O
increased	O
risk	O
of	O
cervical	O
cancer	O
,	O
so	O
we	O
explored	O
this	O
relationship	O
.	O

Genotypes	O
of	O
155	O
patients	O
with	O
cervical	O
cancer	O
and	O
160	O
healthy	O
control	O
subjects	O
were	O
determined	O
using	O
polymerase	O
chain	O
reaction	O
-	O
based	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
.	O

Associations	O
with	O
cancer	O
risk	O
were	O
estimated	O
using	O
two	O
-	O
sided	O
logistic	O
regression	O
.	O

We	O
observed	O
a	O
significantly	O
increased	O
risk	O
of	O
lymph	O
node	O
metastasis	O
associated	O
with	O
the	O
FAS	O
-	O
1377	O
GA	O
or	O
AA	O
polymorphism	O
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
4	O
.	O
16	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
1	O
.	O
10	O
to	O
15	O
.	O
74	O
;	O
P	O
=	O
0	O
.	O
036	O
]	O
.	O

In	O
addition	O
,	O
the	O
FAS	O
-	O
670AG	O
or	O
GG	O
genotype	O
showed	O
an	O
increased	O
incidence	O
of	O
node	O
metastasis	O
,	O
but	O
these	O
findings	O
were	O
not	O
statistically	O
significant	O
(	O
OR	O
=	O
3	O
.	O
67	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
96	O
-	O
14	O
.	O
00	O
,	O
P	O
=	O
0	O
.	O
059	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
an	O
increased	O
risk	O
of	O
cervical	O
cancer	O
and	O
polymorphisms	O
of	O
the	O
death	O
pathway	O
genes	O
FAS	O
and	O
FASL	O
.	O

None	O
of	O
the	O
polymorphisms	O
were	O
associated	O
with	O
risk	O
of	O
advanced	O
stage	O
or	O
histologic	O
subtype	O
of	O
cervical	O
cancer	O
.	O

In	O
conclusion	O
,	O
FAS	O
-	O
1377	O
G	O
-	O
-	O
>	O
A	O
polymorphism	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lymph	O
node	O
metastasis	O
in	O
Korean	O
cervical	O
cancer	O
patients	O
.	O

Detection	O
of	O
lymphovascular	O
invasion	O
in	O
early	O
breast	O
cancer	O
by	O
D2	O
-	O
40	O
(	O
podoplanin	O
)	O
:	O
a	O
clinically	O
useful	O
predictor	O
for	O
axillary	O
lymph	O
node	O
metastases	O
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
use	O
of	O
D2	O
-	O
40	O
for	O
the	O
detection	O
of	O
lymphovascular	O
invasion	O
(	O
LVI	O
)	O
in	O
node	O
positive	O
and	O
negative	O
early	O
breast	O
cancer	O
.	O

LVI	O
is	O
associated	O
with	O
axillary	O
lymph	O
node	O
metastases	O
(	O
ALNM	O
)	O
and	O
a	O
long	O
-	O
term	O
prognostic	O
factor	O
.	O

A	O
precise	O
identification	O
of	O
LVI	O
would	O
have	O
a	O
strong	O
clinical	O
impact	O
for	O
breast	O
cancer	O
patients	O
.	O

METHODS	O
:	O
Immunohistochemical	O
staining	O
with	O
D2	O
-	O
40	O
and	O
CD34	O
was	O
performed	O
on	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
sections	O
of	O
254	O
invasive	O
breast	O
tumors	O
of	O
247	O
patients	O
with	O
node	O
negative	O
and	O
node	O
positive	O
early	O
breast	O
cancer	O
.	O

All	O
slides	O
were	O
screened	O
for	O
the	O
presence	O
of	O
LVI	O
.	O

Correlation	O
with	O
clinico	O
-	O
pathological	O
factors	O
including	O
LVI	O
as	O
retrieved	O
by	O
routine	O
haematoxylin	O
and	O
eosin	O
(	O
H	O
.	O
E	O
.	O
)	O
stained	O
sections	O
and	O
the	O
eligibility	O
for	O
the	O
prediction	O
of	O
ALNM	O
was	O
assessed	O
.	O

RESULTS	O
:	O
Using	O
the	O
D2	O
-	O
40	O
antibody	O
for	O
immunostaining	O
,	O
our	O
results	O
demonstrate	O
a	O
significant	O
higher	O
detection	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
of	O
LVI	O
as	O
compared	O
with	O
routine	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	O
cancer	O
.	O

LVI	O
was	O
correctly	O
identified	O
by	O
D2	O
-	O
40	O
(	O
D2	O
-	O
40	O
+	O
)	O
in	O
70	O
out	O
of	O
254	O
tumors	O
(	O
28	O
%	O
)	O
as	O
compared	O
to	O
40	O
tumors	O
(	O
16	O
%	O
)	O
by	O
routine	O
HE	O
staining	O
(	O
HE	O
+	O
)	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
age	O
,	O
t	O
-	O
stage	O
,	O
nodal	O
status	O
,	O
grading	O
and	O
hormonreceptor	O
-	O
status	O
.	O

Correlation	O
between	O
D2	O
-	O
40	O
+	O
LVI	O
and	O
menopausal	O
-	O
status	O
,	O
HER2	O
-	O
status	O
and	O
histological	O
type	O
was	O
not	O
significant	O
,	O
while	O
there	O
was	O
a	O
significant	O
correlation	O
of	O
D2	O
-	O
40	O
and	O
so	O
called	O
""""	O
triple	O
negative	O
""""	O
tumors	O
(	O
ER	O
/	O
PR	O
and	O
HER2neu	O
-	O
negative	O
)	O
.	O

In	O
a	O
multivariate	O
analysis	O
D2	O
-	O
40	O
+	O
was	O
the	O
strongest	O
predictor	O
for	O
ALNM	O
with	O
an	O
odds	O
ratio	O
of	O
3	O
.	O
489	O
and	O
a	O
P	O
-	O
value	O
of	O
P	O
=	O
0	O
.	O
0003	O
,	O
followed	O
only	O
by	O
T	O
-	O
stage	O
and	O
grading	O
with	O
odds	O
ratios	O
of	O
3	O
.	O
167	O
and	O
1	O
.	O
953	O
and	O
P	O
-	O
values	O
P	O
=	O
0	O
.	O
0003	O
and	O
P	O
=	O
0	O
.	O
0352	O
.	O

CONCLUSION	O
:	O
Immunostaining	O
with	O
D2	O
-	O
40	O
significantly	O
increased	O
the	O
frequency	O
of	O
detection	O
of	O
lymphatic	O
invasion	O
compared	O
to	O
conventional	O
H	O
.	O
E	O
.	O
-	O
staining	O
in	O
early	O
breast	O
cancer	O
.	O

As	O
LVI	O
is	O
a	O
strong	O
predictive	O
and	O
prognostic	O
marker	O
,	O
the	O
monoclonal	O
antibody	O
D2	O
-	O
40	O
has	O
the	O
potential	O
to	O
play	O
a	O
significant	O
role	O
in	O
pathological	O
routine	O
workup	O
of	O
breast	O
tumors	O
.	O

Further	O
prospective	O
studies	O
are	O
needed	O
to	O
prove	O
the	O
clinical	O
impact	O
of	O
D2	O
-	O
40	O
.	O

Expression	O
of	O
CDK4	O
or	O
CDK2	O
in	O
mouse	O
oral	O
cavity	O
is	O
retained	O
in	O
adult	O
pituitary	O
with	O
distinct	O
effects	O
on	O
tumorigenesis	O
.	O

The	O
keratin	O
5	O
(	O
K5	O
)	O
promoter	O
drives	O
transgenic	O
expression	O
to	O
the	O
basal	O
cell	O
layer	O
of	O
stratified	O
epithelia	O
.	O

Surprisingly	O
,	O
analysis	O
of	O
K5CDK4	O
and	O
K5CDK2	O
transgenic	O
mouse	O
embryos	O
showed	O
CDK4	O
and	O
CDK2	O
expression	O
not	O
only	O
in	O
the	O
expected	O
tissues	O
,	O
but	O
also	O
in	O
the	O
adenohypophysis	O
.	O

This	O
organ	O
is	O
derived	O
from	O
an	O
upwards	O
growth	O
of	O
the	O
primitive	O
oropharynx	O
,	O
a	O
K5	O
-	O
expressing	O
tissue	O
.	O

We	O
show	O
that	O
transgenic	O
expression	O
of	O
CDKs	O
in	O
the	O
embryonic	O
oral	O
ectoderm	O
is	O
specifically	O
retained	O
in	O
undifferentiated	O
cells	O
from	O
the	O
pars	O
intermedia	O
of	O
the	O
adenohypophysis	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
K5CDK4	O
mice	O
show	O
a	O
decreased	O
number	O
of	O
pituitary	O
stem	O
cells	O
,	O
even	O
though	O
CDK4	O
is	O
not	O
expressed	O
in	O
the	O
stem	O
cells	O
but	O
in	O
transit	O
-	O
amplifying	O
(	O
TA	O
)	O
-	O
like	O
cells	O
.	O

Interestingly	O
,	O
CDK4	O
-	O
expressing	O
cells	O
,	O
but	O
not	O
CDK2	O
-	O
expressing	O
cells	O
,	O
strongly	O
synergize	O
with	O
lack	O
of	O
p27	O
(	O
Kip1	O
)	O
to	O
generate	O
pituitary	O
carcinomas	O
that	O
appear	O
with	O
shortened	O
latency	O
and	O
are	O
drastically	O
more	O
aggressive	O
than	O
those	O
arising	O
in	O
p27	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Thus	O
,	O
we	O
show	O
that	O
deregulation	O
of	O
CDK	O
expression	O
in	O
the	O
primitive	O
oral	O
epithelium	O
plays	O
a	O
unique	O
function	O
,	O
providing	O
a	O
selective	O
advantage	O
that	O
gives	O
rise	O
to	O
transgene	O
-	O
positive	O
TA	O
-	O
like	O
pituitary	O
cells	O
.	O

Furthermore	O
,	O
retention	O
of	O
CDK4	O
in	O
these	O
TA	O
-	O
like	O
pituitary	O
cells	O
synergizes	O
with	O
loss	O
of	O
p27	O
(	O
Kip1	O
)	O
to	O
induce	O
pituitary	O
adenocarcinomas	O
.	O

This	O
model	O
suggests	O
that	O
forced	O
expression	O
of	O
CDK4	O
sensitizes	O
cells	O
and	O
synergizes	O
with	O
a	O
second	O
change	O
resulting	O
in	O
tumor	O
development	O
.	O

[	O
Photodynamic	O
therapy	O
in	O
severe	O
chronic	O
central	O
serous	O
chorioretinopaty	O
]	O

OBJECTIVE	O
:	O
To	O
determine	O
the	O
efficacy	O
of	O
Photodynamic	O
Therapy	O
(	O
PDT	O
)	O
in	O
chronic	O
Central	O
Serous	O
Chorioretinopathy	O
(	O
CSC	O
)	O
.	O

METHODS	O
:	O
Patients	O
diagnosed	O
with	O
chronic	O
CSC	O
,	O
with	O
clinical	O
evidence	O
of	O
activity	O
and	O
treated	O
with	O
Photodynamic	O
Therapy	O
,	O
are	O
included	O
in	O
this	O
report	O
.	O

All	O
were	O
assessed	O
by	O
a	O
complete	O
ophthalmological	O
examination	O
,	O
including	O
assessment	O
of	O
the	O
best	O
corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
using	O
an	O
ETDRS	O
chart	O
,	O
fluorescein	O
and	O
indocyanine	O
angiography	O
and	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
.	O

The	O
main	O
objective	O
of	O
the	O
study	O
was	O
to	O
determine	O
the	O
mean	O
visual	O
acuity	O
change	O
.	O

RESULTS	O
:	O
11	O
eyes	O
of	O
11	O
patients	O
were	O
included	O
in	O
the	O
study	O
,	O
which	O
had	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
11	O
months	O
.	O

The	O
mean	O
BCVA	O
increased	O
from	O
20	O
/	O
76	O
to	O
20	O
/	O
64	O
.	O

35	O
%	O
of	O
eyes	O
improved	O
their	O
BCVA	O
by	O
2	O
lines	O
or	O
more	O
,	O
45	O
%	O
remained	O
stable	O
and	O
18	O
%	O
lost	O
2	O
lines	O
or	O
more	O
.	O

Choroidal	O
hyperpermeability	O
was	O
reduced	O
in	O
every	O
case	O
.	O

Neurosensorial	O
retinal	O
detachment	O
decreased	O
in	O
80	O
%	O
of	O
cases	O
.	O

Only	O
one	O
eye	O
received	O
a	O
second	O
PDT	O
treatment	O
due	O
to	O
choroidal	O
neovascularization	O
.	O

An	O
increase	O
of	O
atrophy	O
over	O
the	O
Retinal	O
Pigment	O
Epithelium	O
(	O
RPE	O
)	O
was	O
observed	O
in	O
another	O
patient	O
.	O

CONCLUSIONS	O
:	O
PDT	O
can	O
reduce	O
the	O
clinical	O
signs	O
of	O
activity	O
,	O
such	O
as	O
choroidal	O
hyperpermeability	O
or	O
neurosensorial	O
retinal	O
detachment	O
,	O
in	O
patients	O
affected	O
by	O
chronic	O
CSC	O
.	O

However	O
,	O
the	O
increase	O
in	O
visual	O
acuity	O
is	O
variable	O
,	O
probably	O
due	O
to	O
the	O
extent	O
of	O
RPE	O
damage	O
.	O

N	O
-	O
myc	O
augments	O
death	O
and	O
attenuates	O
protective	O
effects	O
of	O
Bcl	O
-	O
2	O
in	O
trophically	O
stressed	O
neuroblastoma	O
cells	O
.	O

N	O
-	O
myc	O
has	O
proapoptotic	O
functions	O
,	O
yet	O
it	O
acts	O
as	O
an	O
oncogene	O
in	O
neuroblastoma	O
.	O

Thus	O
,	O
antiapoptotic	O
mechanisms	O
have	O
to	O
be	O
operative	O
in	O
neuroblastoma	O
cells	O
that	O
antagonize	O
the	O
proapoptotic	O
effects	O
of	O
N	O
-	O
myc	O
.	O

We	O
conditionally	O
activated	O
N	O
-	O
myc	O
in	O
SH	B
-	I
EP	I
neuroblastoma	O
cells	O
subjected	O
to	O
the	O
trophic	O
stress	O
of	O
serum	O
or	O
nutrient	O
deprivation	O
while	O
changing	O
the	O
expression	O
of	O
Bcl	O
-	O
2	O
,	O
survivin	O
and	O
FLIP	O
(	O
L	O
)	O
,	O
antiapoptotic	O
molecules	O
often	O
overexpressed	O
in	O
poor	O
prognosis	O
neuroblastomas	O
.	O

Bcl	O
-	O
2	O
protected	O
SH	B
-	I
EP	I
cells	O
from	O
death	O
during	O
nutritional	O
deprivation	O
by	O
activating	O
energetically	O
advantageous	O
oxidative	O
phosphorylation	O
.	O

N	O
-	O
myc	O
overrode	O
the	O
metabolic	O
protection	O
provided	O
by	O
Bcl	O
-	O
2	O
-	O
induced	O
oxidative	O
phosphorylation	O
by	O
reestablishing	O
the	O
glycolytic	O
phenotype	O
and	O
attenuated	O
the	O
antiapoptotic	O
effect	O
of	O
Bcl	O
-	O
2	O
during	O
metabolic	O
stress	O
.	O

Survivin	O
partially	O
antagonized	O
the	O
growth	O
suppressive	O
function	O
of	O
N	O
-	O
myc	O
in	O
SH	B
-	I
EP	I
neuroblastoma	O
cells	O
during	O
serum	O
deprivation	O
whereas	O
FLIP	O
(	O
L	O
)	O
did	O
not	O
.	O

These	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
functions	O
of	O
N	O
-	O
myc	O
in	O
neuroblastoma	O
cells	O
.	O

Angiopoietin	O
-	O
1	O
prevents	O
VEGF	O
-	O
induced	O
endothelial	O
permeability	O
by	O
sequestering	O
Src	O
through	O
mDia	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
Angiopoietin	O
1	O
(	O
Ang1	O
)	O
are	O
both	O
potent	O
proangiogenic	O
factors	O
,	O
but	O
,	O
whereas	O
VEGF	O
causes	O
vascular	O
permeability	O
,	O
Ang1	O
stabilizes	O
blood	O
vessels	O
and	O
protects	O
them	O
from	O
VEGF	O
-	O
induced	O
plasma	O
leakage	O
.	O

The	O
antivascular	O
permeability	O
mechanisms	O
deployed	O
by	O
Ang1	O
are	O
still	O
undefined	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
Ang1	O
halts	O
the	O
ability	O
of	O
VEGF	O
to	O
induce	O
the	O
phosphorylation	O
-	O
dependent	O
redistribution	O
of	O
the	O
adhesion	O
molecule	O
VE	O
-	O
cadherin	O
,	O
thereby	O
rescuing	O
the	O
endothelial	O
barrier	O
function	O
.	O

Ang1	O
inhibits	O
the	O
activation	O
of	O
Src	O
by	O
VEGF	O
,	O
the	O
most	O
upstream	O
component	O
of	O
the	O
pathway	O
linking	O
VEGF	O
receptors	O
to	O
VE	O
-	O
cadherin	O
internalization	O
.	O

Indeed	O
,	O
Ang1	O
promotes	O
the	O
activation	O
of	O
mDia	O
through	O
RhoA	O
,	O
resulting	O
in	O
the	O
association	O
of	O
mDia	O
with	O
Src	O
.	O

This	O
ultimately	O
deprives	O
VEGF	O
receptors	O
of	O
an	O
essential	O
molecule	O
required	O
for	O
promoting	O
the	O
disruption	O
of	O
endothelial	O
cell	O
-	O
cell	O
contacts	O
and	O
paracellular	O
permeability	O
.	O

RUNX1	O
DNA	O
-	O
binding	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
cryptic	O
fusions	O
in	O
BCR	O
-	O
ABL	O
+	O
leukemias	O
are	O
frequently	O
associated	O
with	O
secondary	O
trisomy	O
21	O
and	O
may	O
contribute	O
to	O
clonal	O
evolution	O
and	O
imatinib	O
resistance	O
.	O

Acquired	O
molecular	O
abnormalities	O
(	O
mutations	O
or	O
chromosomal	O
translocations	O
)	O
of	O
the	O
RUNX1	O
transcription	O
factor	O
gene	O
are	O
frequent	O
in	O
acute	O
myeloblastic	O
leukemias	O
(	O
AMLs	O
)	O
and	O
in	O
therapy	O
-	O
related	O
myelodysplastic	O
syndromes	O
,	O
but	O
rarely	O
in	O
acute	O
lymphoblastic	O
leukemias	O
(	O
ALLs	O
)	O
and	O
chronic	O
myelogenous	O
leukemias	O
(	O
CMLs	O
)	O
.	O

Among	O
18	O
BCR	O
-	O
ABL	O
+	O
leukemias	O
presenting	O
acquired	O
trisomy	O
of	O
chromosome	O
21	O
,	O
we	O
report	O
a	O
high	O
frequency	O
(	O
33	O
%	O
)	O
of	O
recurrent	O
point	O
mutations	O
(	O
4	O
in	O
myeloid	O
blast	O
crisis	O
[	O
BC	O
]	O
CML	O
and	O
one	O
in	O
chronic	O
phase	O
CML	O
)	O
within	O
the	O
DNA	O
-	O
binding	O
region	O
of	O
RUNX1	O
.	O

We	O
did	O
not	O
found	O
any	O
mutation	O
in	O
de	O
novo	O
BCR	O
-	O
ABL	O
+	O
ALLs	O
or	O
lymphoid	O
BC	O
CML	O
.	O

Emergence	O
of	O
the	O
RUNX1	O
mutations	O
was	O
detected	O
at	O
diagnosis	O
or	O
before	O
the	O
acquisition	O
of	O
trisomy	O
21	O
during	O
disease	O
progression	O
.	O

In	O
addition	O
,	O
we	O
also	O
report	O
a	O
high	O
frequency	O
of	O
cryptic	O
chromosomal	O
RUNX1	O
translocation	O
to	O
a	O
novel	O
recently	O
described	O
gene	O
partner	O
,	O
PRDM16	O
on	O
chromosome	O
1p36	O
,	O
for	O
3	O
(	O
21	O
.	O
4	O
%	O
)	O
of	O
14	O
investigated	O
patients	O
:	O
2	O
myeloid	O
BC	O
CMLs	O
and	O
,	O
for	O
the	O
first	O
time	O
,	O
1	O
therapy	O
-	O
related	O
BCR	O
-	O
ABL	O
+	O
ALL	O
.	O

Two	O
patients	O
presented	O
both	O
RUNX1	O
mutations	O
and	O
RUNX1	O
-	O
PRDM16	O
fusion	O
.	O

These	O
events	O
are	O
associated	O
with	O
a	O
short	O
survival	O
and	O
support	O
the	O
concept	O
of	O
a	O
cooperative	O
effect	O
of	O
BCR	O
-	O
ABL	O
with	O
molecular	O
RUNX1	O
abnormalities	O
on	O
the	O
differentiation	O
arrest	O
phenotype	O
observed	O
during	O
progression	O
of	O
CML	O
and	O
in	O
BCR	O
-	O
ABL	O
+	O
ALL	O
.	O

A	O
new	O
autosomal	O
dominant	O
vascular	O
retinopathy	O
syndrome	O
.	O

We	O
describe	O
a	O
new	O
syndrome	O
with	O
autosomal	O
dominant	O
transmission	O
whose	O
most	O
striking	O
feature	O
is	O
vascular	O
retinopathy	O
.	O

The	O
retinopathy	O
is	O
often	O
associated	O
with	O
migraine	O
,	O
Raynaud	O
'	O
s	O
phenomenon	O
and	O
mental	O
changes	O
,	O
mainly	O
forgetfulness	O
,	O
aggression	O
and	O
depression	O
.	O

To	O
define	O
this	O
syndrome	O
we	O
collected	O
medical	O
data	O
on	O
110	O
family	O
members	O
.	O

General	O
ophthalmological	O
examination	O
and	O
fluorescein	O
angiography	O
were	O
performed	O
in	O
61	O
persons	O
.	O

The	O
retinopathy	O
,	O
as	O
diagnosed	O
in	O
22	O
persons	O
,	O
is	O
characterized	O
by	O
central	O
and	O
peripheral	O
microangiopathy	O
,	O
areas	O
of	O
capillary	O
non	O
-	O
perfusion	O
,	O
haemorrhages	O
,	O
cotton	O
wool	O
spots	O
and	O
,	O
in	O
a	O
more	O
advanced	O
stage	O
,	O
occlusion	O
of	O
large	O
retinal	O
vessels	O
,	O
which	O
can	O
induce	O
a	O
neovascular	O
response	O
.	O

A	O
vascular	O
occlusive	O
disorder	O
may	O
be	O
the	O
common	O
aetiological	O
factor	O
of	O
the	O
various	O
manifestation	O
of	O
this	O
syndrome	O
.	O

The	O
element	O
effect	O
and	O
nucleophilicity	O
in	O
nucleophilic	O
aromatic	O
photosubstitution	O
(	O
SN2Ar	O
*	O
)	O
.	O

Local	O
atom	O
effects	O
as	O
mechanistic	O
probes	O
of	O
very	O
fast	O
reactions	O
.	O

Photoreactions	O
of	O
4	O
-	O
nitroanisole	O
and	O
the	O
2	O
-	O
halo	O
-	O
4	O
-	O
nitroanisoles	O
(	O
halogen	O
=	O
F	O
,	O
Cl	O
,	O
Br	O
,	O
and	O
I	O
)	O
with	O
the	O
nucleophiles	O
hydroxide	O
ion	O
and	O
pyridine	O
have	O
been	O
investigated	O
quantitatively	O
to	O
extend	O
the	O
findings	O
recently	O
communicated	O
for	O
cyanide	O
ion	O
.	O

The	O
halonitroanisoles	O
on	O
excitation	O
form	O
triplet	O
pi	O
,	O
pi	O
*	O
states	O
,	O
which	O
undergo	O
substitution	O
of	O
the	O
halogen	O
by	O
nucleophiles	O
.	O

Chemical	O
yields	O
of	O
photoproducts	O
,	O
Stern	O
-	O
Volmer	O
kinetic	O
plots	O
,	O
triplet	O
lifetimes	O
,	O
and	O
triplet	O
yields	O
are	O
reported	O
for	O
the	O
five	O
compounds	O
with	O
the	O
three	O
nucleophiles	O
.	O

Following	O
a	O
standard	O
kinetic	O
treatment	O
,	O
73	O
rate	O
constants	O
are	O
determined	O
for	O
elementary	O
reactions	O
of	O
the	O
triplets	O
including	O
quenching	O
and	O
various	O
nucleophilic	O
addition	O
processes	O
.	O

The	O
photoadditions	O
are	O
roughly	O
14	O
orders	O
of	O
magnitude	O
faster	O
than	O
thermal	O
counterparts	O
.	O

Rate	O
constants	O
for	O
attack	O
at	O
the	O
fluorine	O
-	O
bearing	O
carbon	O
of	O
triplet	O
2	O
-	O
fluoro	O
-	O
4	O
-	O
nitroanisole	O
are	O
2	O
.	O
9	O
x	O
10	O
(	O
9	O
)	O
,	O
1	O
.	O
3	O
x	O
10	O
(	O
9	O
)	O
,	O
and	O
6	O
.	O
3	O
x	O
10	O
(	O
8	O
)	O
M	O
(	O
-	O
1	O
)	O
s	O
(	O
-	O
1	O
)	O
for	O
cyanide	O
ion	O
,	O
hydroxide	O
ion	O
,	O
and	O
pyridine	O
,	O
respectively	O
.	O

The	O
relative	O
rates	O
for	O
attack	O
at	O
the	O
halogen	O
-	O
bearing	O
carbons	O
for	O
F	O
/	O
Cl	O
/	O
Br	O
/	O
I	O
are	O
27	O
:	O
1	O
.	O
9	O
:	O
1	O
.	O
9	O
:	O
1	O
(	O
cyanide	O
ion	O
)	O
,	O
29	O
:	O
2	O
.	O
6	O
:	O
2	O
.	O
4	O
:	O
1	O
(	O
hydroxide	O
ion	O
)	O
,	O
and	O
39	O
:	O
3	O
.	O
9	O
:	O
3	O
.	O
5	O
:	O
1	O
(	O
pyridine	O
)	O
,	O
respectively	O
.	O

The	O
relative	O
nucleophilicities	O
vary	O
somewhat	O
with	O
the	O
attack	O
site	O
;	O
they	O
are	O
about	O
5	O
:	O
2	O
:	O
1	O
for	O
cyanide	O
ion	O
,	O
hydroxide	O
ion	O
,	O
and	O
pyridine	O
for	O
attack	O
at	O
the	O
halogen	O
-	O
bearing	O
carbons	O
.	O

The	O
trend	O
of	O
the	O
element	O
effect	O
opposes	O
that	O
of	O
aliphatic	O
substitution	O
and	O
elimination	O
but	O
is	O
similar	O
in	O
size	O
and	O
parallel	O
to	O
that	O
of	O
thermal	O
nucleophilic	O
aromatic	O
substitution	O
.	O

Relative	O
nucleophilicities	O
in	O
the	O
photoreactions	O
are	O
also	O
similar	O
to	O
those	O
of	O
comparable	O
but	O
vastly	O
slower	O
thermal	O
reactions	O
.	O

The	O
findings	O
imply	O
that	O
the	O
efficiency	O
-	O
determining	O
step	O
of	O
the	O
halogen	O
photosubstitution	O
is	O
simple	O
formation	O
of	O
a	O
sigma	O
-	O
complex	O
through	O
electron	O
-	O
paired	O
bonding	O
within	O
the	O
triplet	O
manifold	O
.	O

Suppression	O
of	O
lung	O
tumor	O
growth	O
and	O
metastasis	O
in	O
mice	O
by	O
adeno	O
-	O
associated	O
virus	O
-	O
mediated	O
expression	O
of	O
vasostatin	O
.	O

PURPOSE	O
:	O
Angiogenesis	O
inhibitors	O
have	O
strong	O
therapeutic	O
potential	O
as	O
antitumor	O
agents	O
in	O
suppressing	O
tumor	O
growth	O
and	O
metastatic	O
progression	O
.	O

Vasostatin	O
,	O
the	O
N	O
-	O
terminal	O
domain	O
of	O
calreticulin	O
,	O
is	O
a	O
potent	O
angiogenesis	O
inhibitor	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
effectiveness	O
of	O
vasostatin	O
delivered	O
by	O
recombinant	O
pseudotype	O
adeno	O
-	O
associated	O
virus	O
2	O
/	O
5	O
(	O
rAAV2	O
/	O
5	O
-	O
VAS	O
)	O
as	O
a	O
gene	O
therapy	O
approach	O
for	O
lung	O
cancer	O
treatment	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
We	O
used	O
rAAV2	O
/	O
5	O
to	O
deliver	O
vasostatin	O
intratumorally	O
or	O
systemically	O
in	O
different	O
mouse	O
lung	O
tumor	O
models	O
-	O
-	O
subcutaneous	O
,	O
orthotopic	O
xenograft	O
,	O
and	O
spontaneous	O
metastasis	O
lung	O
tumor	O
models	O
.	O

The	O
therapeutic	O
efficacy	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
was	O
determined	O
by	O
monitoring	O
tumor	O
volume	O
,	O
survival	O
rate	O
,	O
and	O
degree	O
of	O
neovascularization	O
after	O
treatment	O
in	O
these	O
models	O
.	O

RESULTS	O
:	O
Mice	O
bearing	O
subcutaneous	O
tumor	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
pretreated	O
Lewis	O
lung	O
carcinoma	O
cells	O
showed	O
>	O
50	O
%	O
reduction	O
in	O
primary	O
tumor	O
volume	O
and	O
reduced	O
spontaneous	O
pulmonary	O
metastases	O
.	O

The	O
tumor	O
-	O
suppressive	O
action	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
in	O
subcutaneous	O
human	O
lung	O
tumor	O
A549	B
xenograft	O
correlated	O
with	O
a	O
reduced	O
number	O
of	O
capillary	O
vessels	O
in	O
tumors	O
.	O

In	O
the	O
orthotopic	O
xenograft	O
model	O
,	O
rAAV2	O
/	O
5	O
-	O
VAS	O
suppressed	O
metastasis	O
of	O
A549	B
tumors	O
to	O
mediastinal	O
lymph	O
nodes	O
and	O
contralateral	O
lung	O
.	O

Furthermore	O
,	O
treatment	O
of	O
immunocompetent	O
mice	O
in	O
the	O
spontaneous	O
lung	O
metastases	O
model	O
with	O
rAAV2	O
/	O
5	O
-	O
VAS	O
after	O
primary	O
tumor	O
excision	O
prolonged	O
their	O
median	O
survival	O
from	O
21	O
to	O
51	O
.	O
5	O
days	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
the	O
effectiveness	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
as	O
an	O
angiogenesis	O
inhibitor	O
in	O
suppressing	O
tumor	O
growth	O
during	O
different	O
stages	O
of	O
tumor	O
progression	O
,	O
validating	O
the	O
application	O
of	O
rAAV2	O
/	O
5	O
-	O
VAS	O
gene	O
therapy	O
in	O
treatment	O
against	O
lung	O
cancer	O
.	O

Survivin	O
expression	O
in	O
breast	O
carcinoma	O
:	O
correlation	O
with	O
apoptosis	O
and	O
prognosis	O
.	O

BACKGROUND	O
:	O
Survivin	O
is	O
a	O
novel	O
inhibitor	O
of	O
apoptosis	O
commonly	O
detected	O
in	O
tissues	O
during	O
fetal	O
development	O
and	O
in	O
cancer	O
,	O
but	O
not	O
usually	O
in	O
normal	O
tissues	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
expression	O
of	O
this	O
protein	O
may	O
be	O
of	O
prognostic	O
significance	O
in	O
gastric	O
,	O
colorectal	O
,	O
and	O
bladder	O
carcinomas	O
.	O

We	O
assessed	O
survivin	O
expression	O
in	O
breast	O
carcinomas	O
correlating	O
results	O
with	O
expression	O
of	O
other	O
antiapoptotic	O
(	O
bcl	O
-	O
2	O
,	O
bcl	O
-	O
x	O
)	O
and	O
proapoptotic	O
(	O
bax	O
)	O
markers	O
,	O
with	O
prognostic	O
parameters	O
,	O
and	O
with	O
prognosis	O
.	O

DESIGN	O
:	O
Paraffin	O
-	O
embedded	O
sections	O
of	O
37	O
breast	O
carcinomas	O
were	O
immunostained	O
for	O
survivin	O
,	O
bcl	O
-	O
2	O
,	O
bcl	O
-	O
x	O
,	O
and	O
bax	O
.	O

Expression	O
was	O
evaluated	O
in	O
normal	O
breast	O
tissue	O
and	O
carcinoma	O
,	O
nuclei	O
and	O
cytoplasm	O
,	O
as	O
intensity	O
(	O
0	O
to	O
3	O
+	O
)	O
,	O
and	O
percentage	O
of	O
positive	O
cells	O
.	O

RESULTS	O
:	O
Survivin	O
expression	O
was	O
noted	O
in	O
30	O
(	O
81	O
%	O
)	O
of	O
breast	O
carcinomas	O
,	O
and	O
in	O
normal	O
breast	O
tissue	O
,	O
in	O
nuclei	O
,	O
and	O
cytoplasm	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
(	O
P	O
=	O
0	O
.	O
022	O
)	O
between	O
survivin	O
and	O
bcl	O
-	O
x	O
expression	O
;	O
survivin	O
and	O
bcl	O
-	O
x	O
tended	O
to	O
correlate	O
with	O
overall	O
survival	O
(	O
P	O
=	O
0	O
.	O
072	O
and	O
0	O
.	O
075	O
,	O
respectively	O
)	O
,	O
but	O
not	O
with	O
disease	O
-	O
free	O
survival	O
(	O
P	O
=	O
0	O
.	O
19	O
and	O
0	O
.	O
18	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
correlation	O
of	O
survivin	O
with	O
bcl	O
-	O
2	O
or	O
bax	O
expression	O
,	O
or	O
with	O
other	O
prognostic	O
parameters	O
(	O
age	O
,	O
tumor	O
size	O
,	O
histologic	O
type	O
,	O
histologic	O
grade	O
,	O
nodal	O
status	O
,	O
and	O
tumor	O
stage	O
)	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSION	O
:	O
The	O
majority	O
(	O
81	O
%	O
)	O
of	O
breast	O
carcinomas	O
show	O
survivin	O
expression	O
which	O
correlates	O
with	O
bcl	O
-	O
x	O
,	O
another	O
antiapoptotic	O
marker	O
,	O
and	O
both	O
markers	O
tend	O
to	O
correlate	O
with	O
prognosis	O
.	O

Radiation	O
retinopathy	O
is	O
treatable	O
with	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
bevacizumab	O
(	O
Avastin	O
)	O
.	O

PURPOSE	O
:	O
To	O
report	O
on	O
bevacizumab	O
treatment	O
for	O
radiation	O
retinopathy	O
affecting	O
the	O
macula	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Twenty	O
-	O
one	O
patients	O
with	O
radiation	O
retinopathy	O
(	O
edema	O
,	O
hemorrhages	O
,	O
capillary	O
dropout	O
,	O
and	O
neovascularization	O
)	O
and	O
a	O
subjective	O
or	O
objective	O
loss	O
of	O
vision	O
were	O
treated	O
.	O

Treatment	O
involved	O
intravitreal	O
injection	O
of	O
bevacizumab	O
(	O
1	O
.	O
25	O
mg	O
in	O
0	O
.	O
05	O
mL	O
)	O
every	O
6	O
-	O
12	O
weeks	O
.	O

Treatment	O
was	O
discontinued	O
at	O
patient	O
request	O
or	O
if	O
there	O
was	O
no	O
measurable	O
response	O
to	O
therapy	O
.	O

Main	O
outcome	O
measures	O
included	O
best	O
corrected	O
visual	O
acuity	O
,	O
ophthalmic	O
examination	O
,	O
retinal	O
photography	O
,	O
and	O
angiography	O
.	O

RESULTS	O
:	O
Bevacizumab	O
treatment	O
was	O
followed	O
by	O
reductions	O
in	O
retinal	O
hemorrhage	O
,	O
exudation	O
,	O
and	O
edema	O
.	O

Visual	O
acuities	O
were	O
stable	O
or	O
improved	O
in	O
86	O
%	O
(	O
n	O
=	O
18	O
)	O
.	O

Three	O
patients	O
discontinued	O
therapy	O
.	O

Each	O
was	O
legally	O
blind	O
before	O
treatment	O
(	O
n	O
=	O
1	O
)	O
,	O
experienced	O
little	O
to	O
no	O
subjective	O
improvement	O
(	O
n	O
=	O
2	O
)	O
,	O
or	O
was	O
poorly	O
compliant	O
(	O
n	O
=	O
2	O
)	O
.	O

Three	O
patients	O
(	O
14	O
%	O
)	O
regained	O
2	O
or	O
more	O
lines	O
of	O
visual	O
acuity	O
.	O

No	O
ocular	O
or	O
systemic	O
bevacizumab	O
-	O
related	O
side	O
effects	O
were	O
observed	O
.	O

CONCLUSIONS	O
:	O
Intravitreal	O
bevacizumab	O
can	O
be	O
used	O
to	O
treat	O
radiation	O
retinopathy	O
.	O

In	O
most	O
cases	O
treatment	O
was	O
associated	O
with	O
decreased	O
vascular	O
leakage	O
,	O
stabilization	O
,	O
or	O
improved	O
vision	O
.	O

An	O
anti	O
-	O
vascular	O
endothelial	O
growth	O
factor	O
strategy	O
may	O
reduce	O
tissue	O
damage	O
associated	O
with	O
radiation	O
vasculopathy	O
and	O
neuropathy	O
.	O

Mitogen	O
-	O
activated	O
protein	O
kinase	O
kinase	O
signaling	O
promotes	O
growth	O
and	O
vascularization	O
of	O
fibrosarcoma	O
.	O

We	O
hypothesized	O
that	O
signaling	O
through	O
multiple	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
kinase	O
(	O
MKK	O
)	O
pathways	O
is	O
essential	O
for	O
the	O
growth	O
and	O
vascularization	O
of	O
soft	O
-	O
tissue	O
sarcomas	O
,	O
which	O
are	O
malignant	O
tumors	O
derived	O
from	O
mesenchymal	O
tissues	O
.	O

We	O
tested	O
this	O
using	O
HT	B
-	I
1080	I
,	O
NCI	B
,	O
and	O
Shac	B
fibrosarcoma	O
-	O
derived	O
cell	O
lines	O
and	O
anthrax	O
lethal	O
toxin	O
(	O
LeTx	O
)	O
,	O
a	O
bacterial	O
toxin	O
that	O
inactivates	O
MKKs	O
.	O

Western	O
blots	O
confirmed	O
that	O
LeTx	O
treatment	O
reduced	O
the	O
levels	O
of	O
phosphorylated	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
p38	O
MAPK	O
in	O
vitro	O
.	O

Although	O
short	O
treatments	O
with	O
LeTx	O
only	O
modestly	O
affected	O
cell	O
proliferation	O
,	O
sustained	O
treatment	O
markedly	O
reduced	O
cell	O
numbers	O
.	O

LeTx	O
also	O
substantially	O
inhibited	O
the	O
extracellular	O
release	O
of	O
angioproliferative	O
factors	O
including	O
vascular	O
endothelial	O
growth	O
factor	O
,	O
interleukin	O
-	O
8	O
,	O
and	O
basic	O
fibroblast	O
growth	O
factor	O
.	O

Similar	O
results	O
were	O
obtained	O
with	O
cell	O
lines	O
derived	O
from	O
malignant	O
fibrous	O
histiocytomas	O
,	O
leiomyosarcomas	O
,	O
and	O
liposarcomas	O
.	O

In	O
vivo	O
,	O
LeTx	O
decreased	O
MAPK	O
activity	O
and	O
blocked	O
fibrosarcoma	O
growth	O
.	O

Growth	O
inhibition	O
correlated	O
with	O
decreased	O
cellular	O
proliferation	O
and	O
extensive	O
necrosis	O
,	O
and	O
it	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
tumor	O
mean	O
vessel	O
density	O
as	O
well	O
as	O
a	O
reduction	O
in	O
serum	O
expression	O
of	O
angioproliferative	O
cytokines	O
.	O

Vital	O
imaging	O
using	O
high	O
-	O
resolution	O
ultrasound	O
enhanced	O
with	O
contrast	O
microbubbles	O
revealed	O
that	O
the	O
effects	O
of	O
LeTx	O
on	O
tumor	O
perfusion	O
were	O
remarkably	O
rapid	O
(	O
less	O
than	O
24	O
h	O
)	O
and	O
resulted	O
in	O
a	O
marked	O
reduction	O
of	O
perfusion	O
within	O
the	O
tumor	O
but	O
not	O
in	O
nontumor	O
tissues	O
.	O

These	O
results	O
are	O
consistent	O
with	O
our	O
initial	O
hypothesis	O
and	O
lead	O
us	O
to	O
propose	O
that	O
MKK	O
inhibition	O
by	O
LeTx	O
is	O
a	O
broadly	O
effective	O
strategy	O
for	O
targeting	O
neovascularization	O
in	O
fibrosarcomas	O
and	O
other	O
similar	O
proliferative	O
lesions	O
.	O

Impact	O
of	O
dexamethasone	O
-	O
induced	O
immunosuppression	O
on	O
the	O
duration	O
and	O
level	O
of	O
shedding	O
of	O
Escherichia	O
coli	O
O157	O
:	O
H7	O
in	O
calves	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
immunosuppression	O
plays	O
a	O
role	O
in	O
the	O
level	O
and	O
duration	O
of	O
fecal	O
shedding	O
of	O
Escherichia	O
coli	O
O157	O
.	O

Immunosuppression	O
was	O
induced	O
in	O
calves	O
by	O
administering	O
dexamethasone	O
.	O

Six	O
1	O
-	O
week	O
-	O
old	O
Holstein	O
bull	O
calves	O
were	O
injected	O
intramuscularly	O
with	O
dexamethasone	O
and	O
orally	O
inoculated	O
with	O
10	O
(	O
9	O
)	O
CFU	O
of	O
a	O
mixture	O
of	O
three	O
nalidixic	O
-	O
acid	O
resistant	O
strains	O
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
.	O

Five	O
1	O
-	O
week	O
-	O
old	O
Holstein	O
bull	O
calves	O
that	O
were	O
given	O
the	O
same	O
oral	O
inoculation	O
of	O
E	O
.	O
coli	O
O157	O
:	O
H7	O
,	O
but	O
not	O
the	O
dexamethasone	O
injections	O
,	O
served	O
as	O
controls	O
.	O

All	O
calves	O
were	O
examined	O
daily	O
and	O
fecal	O
samples	O
were	O
collected	O
three	O
times	O
a	O
week	O
for	O
detection	O
and	O
enumeration	O
of	O
the	O
nalidixic	O
-	O
acid	O
resistant	O
E	O
.	O
coli	O
O157	O
.	O

Four	O
weeks	O
after	O
the	O
last	O
calf	O
stopped	O
shedding	O
,	O
all	O
calves	O
were	O
necropsied	O
and	O
samples	O
from	O
the	O
gastrointestinal	O
tract	O
were	O
taken	O
for	O
the	O
detection	O
of	O
the	O
nalidixic	O
-	O
acid	O
resistant	O
E	O
.	O
coli	O
O157	O
.	O

Dexamethasone	O
-	O
injected	O
calves	O
shed	O
at	O
higher	O
levels	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
on	O
days	O
4	O
and	O
7	O
postinoculation	O
,	O
but	O
not	O
thereafter	O
.	O

None	O
of	O
the	O
samples	O
collected	O
at	O
necropsy	O
were	O
positive	O
for	O
E	O
.	O
coli	O
O157	O
.	O

Data	O
from	O
this	O
study	O
suggest	O
that	O
there	O
may	O
be	O
a	O
time	O
-	O
dependent	O
relationship	O
between	O
dexamethasone	O
immunosuppression	O
and	O
the	O
fecal	O
concentration	O
of	O
E	O
.	O
coli	O
O157	O
but	O
that	O
transient	O
immunosuppression	O
does	O
not	O
appear	O
to	O
prolong	O
shedding	O
of	O
E	O
.	O
coli	O
O157	O
.	O

A	O
novel	O
putative	O
tyrosine	O
kinase	O
receptor	O
with	O
oncogenic	O
potential	O
.	O

We	O
have	O
detected	O
transforming	O
activity	O
by	O
a	O
tumorigenicity	O
assay	O
using	O
NIH3T3	B
cells	O
transfected	O
with	O
DNA	O
from	O
a	O
chronic	O
myeloproliferative	O
disorder	O
patient	O
.	O

Here	O
,	O
we	O
report	O
the	O
cDNA	O
cloning	O
of	O
the	O
corresponding	O
oncogene	O
,	O
designated	O
UFO	O
,	O
in	O
allusion	O
to	O
the	O
as	O
yet	O
unidentified	O
function	O
of	O
its	O
protein	O
.	O

Nucleotide	O
sequence	O
analysis	O
of	O
a	O
3116bp	O
cDNA	O
clone	O
revealed	O
a	O
2682	O
-	O
bp	O
-	O
long	O
open	O
reading	O
frame	O
capable	O
of	O
directing	O
the	O
synthesis	O
of	O
a	O
894	O
amino	O
acid	O
polypeptide	O
.	O

The	O
predicted	O
UFO	O
protein	O
exhibits	O
characteristic	O
features	O
of	O
a	O
transmembrane	O
receptor	O
with	O
associated	O
tyrosine	O
kinase	O
activity	O
.	O

The	O
UFO	O
proto	O
-	O
oncogene	O
maps	O
to	O
human	O
chromosome	O
19q13	O
.	O
1	O
and	O
is	O
transcribed	O
into	O
two	O
5	O
.	O
0	O
kb	O
and	O
3	O
.	O
2	O
kb	O
mRNAs	O
in	O
human	O
bone	O
marrow	O
and	O
human	O
tumor	O
cell	O
lines	O
.	O

The	O
UFO	O
locus	O
is	O
evolutionarily	O
conserved	O
between	O
vertebrate	O
species	O
.	O

A	O
4	O
.	O
0	O
kb	O
mRNA	O
of	O
the	O
murine	O
UFO	O
homolog	O
is	O
expressed	O
in	O
a	O
variety	O
of	O
different	O
mouse	O
tissues	O
.	O

We	O
thus	O
have	O
identified	O
a	O
novel	O
element	O
of	O
the	O
complex	O
signaling	O
network	O
involved	O
in	O
the	O
control	O
of	O
cell	O
proliferation	O
and	O
differentiation	O
.	O

Functional	O
significance	O
of	O
VEGF	O
-	O
a	O
in	O
human	O
ovarian	O
carcinoma	O
:	O
role	O
in	O
vasculogenic	O
mimicry	O
.	O

Ovarian	O
cancer	O
is	O
a	O
silent	O
killer	O
,	O
and	O
shows	O
early	O
extensive	O
tumor	O
invasion	O
and	O
peritoneal	O
metastasis	O
.	O

The	O
microcirculation	O
of	O
most	O
tumors	O
includes	O
cooperation	O
of	O
pre	O
-	O
existing	O
vessels	O
,	O
intussusceptive	O
microvascular	O
growth	O
,	O
postnatal	O
vasculogenesis	O
,	O
glomeruloid	O
angiogenesis	O
and	O
vasculogenic	O
mimicry	O
(	O
VM	O
)	O
.	O

VM	O
is	O
critical	O
for	O
a	O
tumor	O
blood	O
supply	O
and	O
is	O
asscociated	O
with	O
aggressive	O
features	O
and	O
metastasis	O
.	O

Our	O
studies	O
highlight	O
the	O
plasticity	O
of	O
aggressive	O
human	O
ovarian	O
carcinoma	O
cells	O
and	O
call	O
into	O
question	O
the	O
underlying	O
significance	O
of	O
their	O
ability	O
to	O
form	O
VM	O
in	O
vitro	O
induced	O
by	O
VEGF	O
-	O
a	O
.	O

These	O
studies	O
also	O
show	O
their	O
clinicalpathological	O
features	O
of	O
the	O
cancers	O
with	O
human	O
Paraffin	O
-	O
embedded	O
tumor	O
tissue	O
samples	O
.	O

Results	O
show	O
that	O
the	O
process	O
:	O
VEGF	O
-	O
a	O
-	O
-	O
greater	O
than	O
EphA2	O
-	O
-	O
greater	O
than	O
MMPs	O
-	O
-	O
greater	O
than	O
VM	O
is	O
the	O
main	O
pathway	O
for	O
VM	O
formation	O
and	O
VEGF	O
-	O
a	O
appears	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
formation	O
of	O
VM	O
based	O
on	O
our	O
in	O
vitro	O
assays	O
and	O
clinical	O
immunohistochemical	O
analyses	O
.	O

VM	O
-	O
targeting	O
strategies	O
for	O
ovarian	O
cancer	O
include	O
anti	O
-	O
VEGF	O
-	O
a	O
treatment	O
,	O
knocking	O
down	O
the	O
EphA2	O
gene	O
and	O
using	O
antibodies	O
against	O
human	O
MMPs	O
if	O
the	O
tumor	O
is	O
VM	O
positive	O
.	O

This	O
strategy	O
may	O
be	O
of	O
significant	O
value	O
in	O
laying	O
the	O
foundation	O
for	O
a	O
more	O
explicit	O
anti	O
-	O
tumor	O
angiogenesis	O
therapy	O
.	O

Proteomic	O
comparison	O
of	O
nasopharyngeal	O
cancer	O
cell	O
lines	O
C666	B
-	I
1	I
and	O
NP69	B
identifies	O
down	O
-	O
regulation	O
of	O
annexin	O
II	O
and	O
beta2	O
-	O
tubulin	O
for	O
nasopharyngeal	O
carcinoma	O
.	O

CONTEXT	O
:	O
Nasopharyngeal	O
carcinoma	O
(	O
NPC	O
)	O
,	O
common	O
in	O
southern	O
China	O
and	O
North	O
Africa	O
,	O
has	O
a	O
complex	O
etiology	O
involving	O
interplay	O
between	O
viral	O
,	O
environmental	O
,	O
and	O
hereditary	O
factors	O
and	O
is	O
almost	O
constantly	O
associated	O
with	O
the	O
Epstein	O
-	O
Barr	O
virus	O
.	O

Since	O
the	O
prognosis	O
of	O
locally	O
advanced	O
and	O
metastatic	O
diseases	O
is	O
poor	O
,	O
increased	O
understanding	O
of	O
the	O
pathogenesis	O
of	O
NPC	O
would	O
be	O
important	O
for	O
discovering	O
novel	O
markers	O
for	O
patients	O
'	O
management	O
.	O

OBJECTIVES	O
:	O
To	O
compare	O
the	O
proteomic	O
expression	O
profile	O
between	O
an	O
Epstein	O
-	O
Barr	O
virus	O
-	O
associated	O
NPC	O
cell	O
line	O
(	O
C666	B
-	I
1	I
)	O
and	O
a	O
normal	O
NP	O
cell	O
line	O
(	O
NP69	B
)	O
.	O

The	O
proteins	O
with	O
differential	O
expression	O
were	O
analyzed	O
in	O
40	O
undifferentiated	O
NPC	O
paraffin	O
-	O
embedded	O
specimens	O
.	O

DESIGN	O
:	O
Differentially	O
expressed	O
proteins	O
discovered	O
between	O
the	O
two	O
cell	O
lines	O
were	O
identified	O
by	O
mass	O
spectrometry	O
.	O

After	O
confirmation	O
by	O
immunocytochemical	O
staining	O
,	O
their	O
expression	O
in	O
patient	O
samples	O
was	O
measured	O
using	O
40	O
pairs	O
of	O
undifferentiated	O
NPCs	O
together	O
with	O
their	O
adjacent	O
normal	O
epithelia	O
.	O

RESULTS	O
:	O
Proteomic	O
findings	O
indicated	O
that	O
adenosine	O
triphosphate	O
synthase	O
alpha	O
chain	O
was	O
up	O
-	O
regulated	O
,	O
whereas	O
annexin	O
II	O
,	O
annexin	O
V	O
,	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
,	O
and	O
profilin	O
1	O
were	O
down	O
-	O
regulated	O
.	O

After	O
confirming	O
the	O
results	O
in	O
agar	O
-	O
processed	O
cell	O
lines	O
,	O
annexin	O
II	O
and	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
expression	O
were	O
found	O
to	O
be	O
lower	O
in	O
tumor	O
cells	O
than	O
in	O
adjacent	O
normal	O
epithelial	O
cells	O
in	O
100	O
%	O
and	O
90	O
%	O
of	O
the	O
patients	O
'	O
specimens	O
,	O
respectively	O
.	O

Finally	O
,	O
annexin	O
II	O
down	O
-	O
regulation	O
was	O
positively	O
associated	O
with	O
lymph	O
node	O
metastasis	O
,	O
suggesting	O
that	O
it	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
NPC	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
suggest	O
that	O
annexin	O
II	O
and	O
beta	O
(	O
2	O
)	O
-	O
tubulin	O
down	O
-	O
regulation	O
is	O
important	O
in	O
NPC	O
formation	O
and	O
may	O
represent	O
potential	O
targets	O
for	O
further	O
investigations	O
.	O

A	O
practical	O
interface	O
for	O
microfluidics	O
and	O
nanoelectrospray	O
mass	O
spectrometry	O
.	O

We	O
report	O
a	O
new	O
method	O
for	O
fabricating	O
nanospray	O
ionization	O
tips	O
for	O
MS	O
,	O
formed	O
from	O
glass	O
substrates	O
and	O
the	O
inert	O
polymer	O
,	O
parylene	O
-	O
C	O
.	O

Using	O
a	O
single	O
photolithography	O
step	O
,	O
the	O
emitters	O
are	O
formed	O
contiguously	O
with	O
microchannels	O
,	O
such	O
that	O
no	O
dead	O
volumes	O
are	O
observed	O
.	O

In	O
addition	O
,	O
because	O
the	O
devices	O
are	O
very	O
thin	O
(	O
approximately	O
0	O
.	O
3	O
mm	O
)	O
and	O
the	O
tips	O
are	O
formed	O
at	O
rectangular	O
corners	O
,	O
the	O
Taylor	O
cone	O
volumes	O
are	O
small	O
,	O
which	O
makes	O
the	O
method	O
attractive	O
for	O
future	O
integration	O
with	O
microfluidic	O
separations	O
.	O

Device	O
performance	O
was	O
demonstrated	O
by	O
evaluating	O
diverse	O
analytes	O
,	O
ranging	O
from	O
synthetic	O
polymers	O
,	O
to	O
peptides	O
,	O
to	O
nucleic	O
acids	O
.	O

For	O
all	O
analytes	O
,	O
performance	O
was	O
similar	O
to	O
that	O
of	O
conventional	O
emitters	O
(	O
pulled	O
-	O
glass	O
capillaries	O
and	O
the	O
Agilent	O
HPLC	O
Chip	O
)	O
with	O
the	O
advantage	O
of	O
rapid	O
,	O
batch	O
fabrication	O
of	O
identical	O
devices	O
.	O

A	O
novel	O
role	O
of	O
thrombospondin	O
-	O
1	O
in	O
cervical	O
carcinogenesis	O
:	O
inhibit	O
stroma	O
reaction	O
by	O
inhibiting	O
activated	O
fibroblasts	O
from	O
invading	O
cancer	O
.	O

Thrombospondin	O
(	O
TSP	O
)	O
-	O
1	O
,	O
a	O
potent	O
angiogenesis	O
inhibitor	O
,	O
has	O
been	O
shown	O
to	O
exert	O
different	O
biological	O
functions	O
on	O
various	O
cell	O
types	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
role	O
of	O
TSP	O
-	O
1	O
in	O
tumor	O
-	O
stroma	O
reaction	O
,	O
which	O
is	O
mainly	O
characterized	O
by	O
fibroblast	O
activation	O
to	O
create	O
a	O
permissive	O
microenvironment	O
for	O
tumor	O
progression	O
.	O

Immunohistochemistry	O
examinations	O
in	O
the	O
human	O
surgical	O
specimens	O
have	O
shown	O
that	O
a	O
downregulation	O
of	O
TSP	O
-	O
1	O
during	O
the	O
progression	O
of	O
cervical	O
carcinogenesis	O
was	O
accompanied	O
by	O
an	O
emergence	O
in	O
the	O
upregulation	O
of	O
stroma	O
markers	O
,	O
alpha	O
-	O
smooth	O
muscle	O
actin	O
(	O
alpha	O
-	O
SMA	O
)	O
and	O
desmin	O
.	O

Transfection	O
of	O
SiHa	B
cervical	O
cancer	O
cells	O
with	O
a	O
plasmid	O
expressing	O
the	O
TSP	O
-	O
1	O
protein	O
exhibited	O
antiangiogenic	O
activity	O
in	O
vitro	O
and	O
resulted	O
in	O
reduced	O
tumor	O
growth	O
in	O
severe	O
combined	O
immunodeficiency	O
(	O
SCID	O
)	O
mice	O
,	O
which	O
was	O
accompanied	O
by	O
a	O
decrease	O
in	O
tumor	O
vascularization	O
and	O
lower	O
expressions	O
of	O
alpha	O
-	O
SMA	O
and	O
desmin	O
than	O
those	O
in	O
the	O
vector	O
controls	O
.	O

Transfection	O
with	O
TSP	O
-	O
1	O
and	O
purified	O
TSP	O
-	O
1	O
added	O
to	O
NIH3T3	B
cells	O
did	O
not	O
alter	O
the	O
protein	O
levels	O
of	O
alpha	O
-	O
SMA	O
and	O
desmin	O
but	O
significantly	O
inhibited	O
matrix	O
metalloprotease	O
-	O
2	O
activity	O
.	O

Transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
beta	O
)	O
,	O
a	O
major	O
factor	O
in	O
the	O
activation	O
of	O
fibroblasts	O
,	O
increased	O
alpha	O
-	O
SMA	O
and	O
desmin	O
expression	O
and	O
the	O
ability	O
of	O
cell	O
migration	O
and	O
invasion	O
in	O
NIH3T3	B
cells	O
.	O

The	O
increased	O
migration	O
ability	O
and	O
the	O
invasive	O
ability	O
into	O
tumor	O
cluster	O
of	O
TGF	O
-	O
beta	O
-	O
treated	O
NIH3T3	B
cells	O
were	O
dose	O
dependently	O
inhibited	O
by	O
TSP	O
-	O
1	O
.	O

In	O
contrast	O
,	O
ectopic	O
TSP	O
-	O
1	O
expression	O
in	O
SiHa	B
cells	O
has	O
little	O
effect	O
on	O
the	O
invasive	O
ability	O
of	O
the	O
NIH3T3	B
cells	O
.	O

Together	O
,	O
our	O
findings	O
demonstrate	O
a	O
novel	O
role	O
of	O
TSP	O
-	O
1	O
to	O
inhibit	O
tumor	O
-	O
stroma	O
reaction	O
that	O
could	O
be	O
attributed	O
to	O
the	O
blockage	O
of	O
activated	O
fibroblasts	O
from	O
invading	O
cancer	O
cells	O
.	O

Targeting	O
a	O
tumor	O
-	O
specific	O
laminin	O
domain	O
critical	O
for	O
human	O
carcinogenesis	O
.	O

Laminin	O
-	O
332	O
is	O
critical	O
for	O
squamous	O
cell	O
carcinoma	O
(	O
SCC	O
)	O
tumorigenesis	O
,	O
but	O
targeting	O
it	O
for	O
cancer	O
therapy	O
has	O
been	O
unachievable	O
due	O
to	O
key	O
role	O
of	O
laminin	O
-	O
332	O
in	O
promoting	O
tissue	O
integrity	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
portion	O
of	O
laminin	O
-	O
332	O
,	O
termed	O
G45	O
,	O
which	O
is	O
proteolytically	O
removed	O
and	O
absent	O
in	O
normal	O
tissues	O
,	O
is	O
prominently	O
expressed	O
in	O
most	O
human	O
SCC	B
tumors	O
and	O
plays	O
an	O
important	O
role	O
in	O
human	O
SCC	O
tumorigenesis	O
.	O

Primary	O
human	O
keratinocytes	O
lacking	O
G45	O
(	O
DeltaG45	O
)	O
showed	O
alterations	O
of	O
basal	O
receptor	O
organization	O
,	O
impaired	O
matrix	O
deposition	O
,	O
and	O
increased	O
migration	O
.	O

After	O
SCC	O
transformation	O
,	O
the	O
absence	O
of	O
G45	O
domain	O
in	O
DeltaG45	O
cells	O
was	O
associated	O
with	O
deficient	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
and	O
phosphotidylinositol	O
3	O
-	O
kinase	O
(	O
PI3	O
K	O
)	O
pathway	O
activation	O
,	O
impaired	O
invasion	O
,	O
deficient	O
metalloproteinase	O
activity	O
,	O
and	O
absent	O
tumorgenicity	O
in	O
vivo	O
.	O

Expression	O
of	O
G45	O
or	O
activated	O
PI3	O
K	O
subunit	O
in	O
DeltaG45	O
cells	O
reversed	O
these	O
abnormalities	O
.	O

G45	O
antibody	O
treatment	O
induced	O
SCC	O
tumor	O
apoptosis	O
,	O
decreased	O
SCC	O
tumor	O
proliferation	O
,	O
and	O
markedly	O
impaired	O
human	O
SCC	O
tumorigenesis	O
in	O
vivo	O
without	O
affecting	O
normal	O
tissue	O
adhesion	O
.	O

These	O
results	O
show	O
a	O
remarkable	O
selectivity	O
of	O
expression	O
and	O
function	O
for	O
laminin	O
-	O
332	O
G45	O
in	O
human	O
SCC	O
tumorigenesis	O
and	O
implicate	O
it	O
as	O
a	O
specific	O
target	O
for	O
anticancer	O
therapy	O
.	O

MMTV	O
-	O
cre	O
-	O
mediated	O
fur	O
inactivation	O
concomitant	O
with	O
PLAG1	O
proto	O
-	O
oncogene	O
activation	O
delays	O
salivary	O
gland	O
tumorigenesis	O
in	O
mice	O
.	O

Proprotein	O
convertases	O
are	O
serine	O
endoproteases	O
implicated	O
in	O
the	O
proteolytic	O
processing	O
of	O
a	O
large	O
variety	O
of	O
regulatory	O
proteins	O
.	O

An	O
important	O
role	O
of	O
proprotein	O
convertases	O
in	O
tumorigenic	O
processes	O
has	O
been	O
suggested	O
by	O
various	O
studies	O
.	O

In	O
this	O
study	O
,	O
the	O
role	O
of	O
the	O
proprotein	O
convertase	O
furin	O
in	O
PLAG1	O
proto	O
-	O
oncogene	O
-	O
induced	O
salivary	O
gland	O
tumorigenesis	O
was	O
investigated	O
.	O

PLAG1	O
overexpression	O
in	O
salivary	O
glands	O
has	O
previously	O
been	O
shown	O
to	O
result	O
in	O
salivary	O
gland	O
tumors	O
in	O
100	O
%	O
of	O
mice	O
within	O
5	O
weeks	O
after	O
birth	O
.	O

MMTV	O
-	O
cre	O
-	O
mediated	O
inactivation	O
of	O
fur	O
without	O
over	O
-	O
expression	O
of	O
PLAG1	O
caused	O
smaller	O
but	O
histologically	O
normal	O
salivary	O
glands	O
.	O

Moreover	O
,	O
the	O
lymph	O
nodes	O
close	O
to	O
the	O
salivary	O
glands	O
were	O
enlarged	O
,	O
and	O
histology	O
showed	O
that	O
they	O
had	O
activated	O
follicles	O
.	O

When	O
genetic	O
ablation	O
of	O
1	O
or	O
2	O
alleles	O
of	O
fur	O
and	O
overexpression	O
of	O
the	O
PLAG1	O
transgene	O
were	O
simultaneously	O
achieved	O
,	O
a	O
significant	O
delay	O
in	O
tumorigenesis	O
was	O
observed	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
an	O
important	O
role	O
for	O
furin	O
in	O
PLAG1	O
-	O
induced	O
salivary	O
gland	O
tumorigenesis	O
in	O
mice	O
.	O

Isotype	O
-	O
specific	O
inhibitors	O
of	O
the	O
glycolytic	O
key	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
moderately	O
decelerate	O
tumor	O
cell	O
proliferation	O
.	O

Tumor	O
cells	O
express	O
the	O
glycolytic	O
regulator	O
pyruvate	O
kinase	O
subtype	O
M2	O
(	O
M2	O
-	O
PK	O
)	O
,	O
which	O
can	O
occur	O
in	O
a	O
tetrameric	O
form	O
with	O
high	O
affinity	O
to	O
its	O
substrate	O
phosphoenolpyruvate	O
(	O
PEP	O
)	O
and	O
a	O
dimeric	O
form	O
with	O
a	O
low	O
PEP	O
affinity	O
.	O

The	O
transition	O
between	O
both	O
conformations	O
contributes	O
to	O
the	O
control	O
of	O
glycolysis	O
and	O
is	O
important	O
for	O
tumor	O
cell	O
proliferation	O
and	O
survival	O
.	O

Here	O
we	O
targeted	O
M2	O
-	O
PK	O
by	O
synthetic	O
peptide	O
aptamers	O
,	O
which	O
specifically	O
bind	O
to	O
M2	O
-	O
PK	O
and	O
shift	O
the	O
isoenzyme	O
into	O
its	O
low	O
affinity	O
dimeric	O
conformation	O
.	O

The	O
aptamer	O
-	O
induced	O
dimerization	O
and	O
inactivation	O
of	O
M2	O
-	O
PK	O
led	O
to	O
a	O
significant	O
decrease	O
in	O
the	O
PK	O
mass	O
-	O
action	O
ratio	O
as	O
well	O
as	O
ATP	O
:	O
ADP	O
ratio	O
in	O
the	O
target	O
cells	O
.	O

Furthermore	O
,	O
the	O
expression	O
of	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
moderately	O
reduced	O
the	O
growth	O
of	O
immortalized	O
NIH3T3	B
cell	O
populations	O
by	O
decelerating	O
cell	O
proliferation	O
,	O
but	O
without	O
affecting	O
apoptotic	O
cell	O
death	O
.	O

Moreover	O
,	O
the	O
M2	O
-	O
PK	O
-	O
binding	O
peptide	O
aptamers	O
also	O
reduced	O
the	O
proliferation	O
rate	O
of	O
human	O
U	B
-	I
2	I
OS	O
osteosarcoma	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
developed	O
the	O
first	O
specific	O
inhibitors	O
of	O
the	O
pyruvate	O
kinase	O
isoenzyme	O
type	O
M2	O
and	O
present	O
evidence	O
that	O
these	O
inhibitors	O
moderately	O
decelerate	O
tumor	O
cell	O
proliferation	O
.	O

Sciatic	O
nerve	O
repair	O
by	O
microgrooved	O
nerve	O
conduits	O
made	O
of	O
chitosan	O
-	O
gold	O
nanocomposites	O
.	O

BACKGROUND	O
:	O

To	O
better	O
direct	O
the	O
repair	O
of	O
peripheral	O
nerve	O
after	O
injury	O
,	O
an	O
implant	O
consisting	O
of	O
a	O
multicomponent	O
micropatterned	O
conduit	O
seeded	O
with	O
NSC	B
was	O
designed	O
.	O

METHODS	O
:	O

The	O
mechanical	O
properties	O
of	O
the	O
chi	O
-	O
Au	O
nanocomposites	O
were	O
tested	O
.	O

In	O
vitro	O
,	O
the	O
effect	O
of	O
chi	O
-	O
Au	O
on	O
cell	O
behavior	O
(	O
NSC	B
and	O
glial	O
cell	O
line	O
C6	B
)	O
and	O
the	O
influence	O
of	O
micropattern	O
on	O
cell	O
alignment	O
were	O
evaluated	O
.	O

In	O
vivo	O
,	O
the	O
micropatterned	O
conduits	O
with	O
/	O
without	O
the	O
preseeded	O
NSC	B
were	O
implanted	O
to	O
bridge	O
a	O
10	O
-	O
mm	O
-	O
long	O
defect	O
of	O
the	O
sciatic	O
nerve	O
in	O
9	O
male	O
Sprague	O
-	O
Dawley	O
rats	O
.	O

The	O
repair	O
outcome	O
was	O
investigated	O
6	O
weeks	O
after	O
the	O
surgery	O
.	O

RESULTS	O
:	O

Based	O
on	O
the	O
dynamic	O
modulus	O
,	O
chitosan	O
with	O
50	O
ppm	O
or	O
more	O
gold	O
was	O
a	O
stronger	O
material	O
than	O
others	O
.	O

In	O
vitro	O
,	O
gold	O
at	O
25	O
or	O
50	O
ppm	O
led	O
to	O
better	O
cell	O
performance	O
for	O
NSC	B
;	O
and	O
gold	O
at	O
50	O
ppm	O
gave	O
better	O
cell	O
performance	O
for	O
C6	B
.	O

On	O
the	O
microgrooved	O
substrate	O
,	O
the	O
NSC	B
had	O
elongated	O
processes	O
oriented	O
parallel	O
to	O
the	O
grooves	O
,	O
whereas	O
the	O
NSC	B
on	O
the	O
nonpatterned	O
surfaces	O
did	O
not	O
exhibit	O
a	O
particular	O
bias	O
in	O
alignment	O
.	O

In	O
vivo	O
,	O
the	O
number	O
of	O
regenerated	O
axons	O
,	O
the	O
regenerated	O
area	O
,	O
and	O
the	O
number	O
of	O
blood	O
vessels	O
were	O
significantly	O
higher	O
in	O
the	O
NSC	B
-	O
preseeded	O
conduit	O
.	O

CONCLUSION	O
:	O

Modification	O
of	O
the	O
chitosan	O
matrix	O
by	O
gold	O
nanoparticles	O
not	O
only	O
provides	O
the	O
mechanical	O
strength	O
but	O
also	O
affects	O
the	O
cellular	O
response	O
.	O

The	O
preliminary	O
in	O
vivo	O
data	O
demonstrated	O
that	O
the	O
biodegradable	O
micropatterned	O
conduits	O
preseeded	O
with	O
NSC	B
provided	O
a	O
combination	O
of	O
physical	O
and	O
biological	O
guidance	O
cues	O
for	O
regenerating	O
axons	O
at	O
the	O
cellular	O
level	O
and	O
offered	O
a	O
better	O
alternative	O
for	O
repairing	O
sciatic	O
nerve	O
transactions	O
.	O

[	O
Parotid	O
gland	O
'	O
s	O
tumors	O
in	O
children	O
]	O
.	O

The	O
tumors	O
of	O
the	O
salivary	O
glands	O
are	O
infrequent	O
in	O
children	O
,	O
and	O
parotid	O
gland	O
is	O
involved	O
in	O
80	O
%	O
of	O
them	O
.	O

When	O
a	O
salivary	O
gland	O
tumor	O
is	O
present	O
,	O
the	O
chance	O
of	O
malignancy	O
is	O
greater	O
in	O
the	O
child	O
than	O
in	O
the	O
adult	O
.	O

We	O
reviewed	O
8	O
cases	O
identified	O
in	O
patients	O
aged	O
14	O
years	O
and	O
younger	O
in	O
our	O
hospital	O
,	O
analyzing	O
its	O
antecedents	O
,	O
signs	O
and	O
symptoms	O
,	O
histological	O
features	O
,	O
diagnosis	O
,	O
treatment	O
and	O
evolution	O
.	O

All	O
the	O
patients	O
displayed	O
preauricular	O
painless	O
,	O
non	O
-	O
inflammatory	O
and	O
slow	O
-	O
growing	O
masses	O
to	O
an	O
age	O
between	O
10	O
months	O
and	O
14	O
years	O
.	O

Four	O
or	O
them	O
were	O
pleomorphic	O
adenomas	O
,	O
two	O
haemangiomas	O
,	O
one	O
epidermal	O
cysts	O
and	O
one	O
myoepithelial	O
carcinoma	O
.	O

We	O
emphasize	O
the	O
exceptional	O
nature	O
of	O
the	O
carcinoma	O
for	O
its	O
rareness	O
and	O
for	O
the	O
high	O
degree	O
of	O
malignancy	O
expressed	O
.	O

We	O
made	O
a	O
fine	O
needle	O
aspiration	O
biopsy	O
in	O
four	O
cases	O
but	O
they	O
were	O
conclusive	O
only	O
in	O
three	O
.	O

All	O
were	O
treated	O
by	O
surgical	O
resection	O
of	O
the	O
tumour	O
except	O
for	O
the	O
myoepithelial	O
carcinoma	O
and	O
the	O
recurrent	O
pleomorphic	O
adenoma	O
that	O
were	O
treated	O
by	O
total	O
parotidectomy	O
.	O

The	O
malignant	O
tumours	O
of	O
the	O
parotid	O
gland	O
are	O
clinically	O
indistinguishable	O
of	O
the	O
benign	O
ones	O
,	O
thus	O
when	O
any	O
palpable	O
mass	O
appears	O
in	O
the	O
zone	O
of	O
the	O
parotid	O
gland	O
,	O
an	O
accurate	O
diagnosis	O
should	O
be	O
made	O
without	O
delay	O
.	O

The	O
treatment	O
of	O
choice	O
is	O
the	O
surgical	O
excision	O
with	O
wide	O
margins	O
,	O
being	O
other	O
adjuvant	O
treatments	O
less	O
useful	O
to	O
this	O
age	O
than	O
in	O
the	O
adult	O
age	O
.	O

